<SEC-DOCUMENT>0001193125-24-273671.txt : 20241210
<SEC-HEADER>0001193125-24-273671.hdr.sgml : 20241210
<ACCEPTANCE-DATETIME>20241210061312
ACCESSION NUMBER:		0001193125-24-273671
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		122
FILED AS OF DATE:		20241210
DATE AS OF CHANGE:		20241210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALLURION TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001964979
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283701
		FILM NUMBER:		241537052

	BUSINESS ADDRESS:	
		STREET 1:		11 HURON DR STE 200
		CITY:			NATICK
		STATE:			MA
		ZIP:			01760
		BUSINESS PHONE:		508-647-4000

	MAIL ADDRESS:	
		STREET 1:		11 HURON DR STE 200
		CITY:			NATICK
		STATE:			MA
		ZIP:			01760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALLURION TECHNOLOGIES HOLDINGS, INC.
		DATE OF NAME CHANGE:	20230207
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d915839ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:alur="http://www.allurion.com/20240930" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To09_30_2024" id="ixv-39978">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="hidden127678485" contextRef="P01_01_2024To09_30_2024">0001964979</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden127678532" contextRef="P01_01_2024To09_30_2024">MA</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden127678533" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">MA</ix:nonNumeric><ix:footnote id="FN_485645" xml:lang="en-US">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information.</ix:footnote></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alur-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="P01_01_2024To09_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2023To02_15_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-15</xbrli:startDate> <xbrli:endDate>2023-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_29_2024To08_29_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-29</xbrli:startDate> <xbrli:endDate>2024-08-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtApril012013Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesAOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:OtherCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:OtherCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCCommonStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCCommonStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EarnOutSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesAOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDTwoPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDThreePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_DoNotExpireMemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:DoNotExpireMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_StockOptionPlan2020MemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersDMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersDMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ESsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CLsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShippingAndHandlingMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alur:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PipeInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ESsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CLsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandNineteenTermLoanAndSuccessFeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ShippingAndHandlingMembersrtProductOrServiceAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EarliestTaxYearMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LatestTaxYearTwoThousandFortyTwoMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:LatestTaxYearTwoThousandFortyTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_EarliestTaxYearMemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LatestTaxYearMemberusgaapTaxPeriodAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alur:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_FortressTermLoanMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:PipeSubscriptionAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoAdditionalSharesLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoSharesAndBackstopShareLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:NewAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:HVLTerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:GaurContributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorContributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RSUForfeitureAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_01_2023_MinimumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:NewAllurionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-02-09</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-09</xbrli:startDate> <xbrli:endDate>2023-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-09</xbrli:startDate> <xbrli:endDate>2023-02-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PipeInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RtwAndFortressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteHoldersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthSponsorSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SideLetterTerminationSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:LegacyAllurionEquityholdersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:PipeSubscriptionAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermLoanFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:UntilMarch312024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:FromApril12024ToJune302024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:FromJuly12024ToSeptember302024Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:OnOctober12024AndThereafterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-08-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To08_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_02_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_02_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-05-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-02</xbrli:startDate> <xbrli:endDate>2023-05-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-05-02</xbrli:startDate> <xbrli:endDate>2023-05-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-18</xbrli:startDate> <xbrli:endDate>2023-12-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommitmentSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-18</xbrli:startDate> <xbrli:endDate>2023-12-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-18</xbrli:startDate> <xbrli:endDate>2023-12-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:LnmpJpbcInvestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:KkgEnterprisesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:RemusGroupManagementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alur:HunterVenturesLimitedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-15</xbrli:startDate> <xbrli:endDate>2023-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:BenoitChardonConsultingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:TerminationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-12</xbrli:startDate> <xbrli:endDate>2023-12-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2022To12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To02_28_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-01</xbrli:startDate> <xbrli:endDate>2023-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_14_2024_MaximumMembersrtRangeAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-14</xbrli:startDate> <xbrli:endDate>2024-04-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_14_2024To04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-14</xbrli:startDate> <xbrli:endDate>2024-04-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-16</xbrli:startDate> <xbrli:endDate>2024-04-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_16_2024To04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteAgreementWithRtwMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-16</xbrli:startDate> <xbrli:endDate>2024-04-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:BenoitChardonConsultingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-09-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2023To10_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-01</xbrli:startDate> <xbrli:endDate>2023-10-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJuly012024Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_EarnOutSharesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_ConvertibleNotesMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_GBsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ESsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AUsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ITsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CLsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingDueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FRsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ESsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_GBsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandNineteenTermLoanAndSuccessFeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapShortTermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RTWParticipationInPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingDueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_AUsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_ITsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_USsrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-04-01</xbrli:startDate> <xbrli:endDate>2023-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-22</xbrli:startDate> <xbrli:endDate>2024-10-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-22</xbrli:startDate> <xbrli:endDate>2024-10-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteAgreementWithRtwMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To04_16_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-04-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2026-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_30_2026To12_30_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-12-30</xbrli:startDate> <xbrli:endDate>2026-12-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_30_2026To12_30_2026_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-12-30</xbrli:startDate> <xbrli:endDate>2026-12-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2026To12_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-12-31</xbrli:startDate> <xbrli:endDate>2026-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2027To01_01_2027_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2027-01-01</xbrli:startDate> <xbrli:endDate>2027-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2027To01_01_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2027-01-01</xbrli:startDate> <xbrli:endDate>2027-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_02_2027To01_02_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2027-01-02</xbrli:startDate> <xbrli:endDate>2027-01-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-04-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_28_2024To06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-28</xbrli:startDate> <xbrli:endDate>2024-06-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-28</xbrli:startDate> <xbrli:endDate>2024-06-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-28</xbrli:startDate> <xbrli:endDate>2024-06-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-06-28</xbrli:startDate> <xbrli:endDate>2024-06-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-01</xbrli:startDate> <xbrli:endDate>2024-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-07-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-07-05</xbrli:startDate> <xbrli:endDate>2024-07-05</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-07-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2024To04_30_2024_NatickAndHudsonMembersrtStatementGeographicalAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-04-01</xbrli:startDate> <xbrli:endDate>2024-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_29_2024To08_29_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-08-29</xbrli:startDate> <xbrli:endDate>2024-08-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_29_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-08-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_30_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">alur:RestructuringPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-06</xbrli:startDate> <xbrli:endDate>2024-11-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001964979</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft"> <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR"> <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month"> <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Country"> <xbrli:measure>alur:Country</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Days"> <xbrli:measure>alur:Days</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Employees"> <xbrli:measure>alur:Employees</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_TradingDay"> <xbrli:measure>alur:TradingDay</xbrli:measure> </xbrli:unit><ix:relationship fromRefs="Fact_127680422" toRefs="FN_485645"/><ix:relationship fromRefs="Fact_127680423" toRefs="FN_485645"/><ix:relationship fromRefs="Fact_127680424" toRefs="FN_485645"/><ix:relationship fromRefs="Fact_127680425" toRefs="FN_485645"/></ix:resources></ix:header></div><div style="-sec-ix-hidden:hidden127678485;display:inline;"></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">As filed with the Securities and Exchange Commission on December&#160;9, 2024. </div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Registration </div>No.&#160;333-&#8195;&#8195;&#8195; </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">UNITED STATES </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;display:inline;">Washington, D.C. 20549 </div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2024To09_30_2024" id="ixv-47345">S-1</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;display:inline;">REGISTRATION STATEMENT </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 20pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 20pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To09_30_2024" id="ixv-47346">ALLURION TECHNOLOGIES, INC.</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 8pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 32%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 32%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:stateprovnameen" id="ixv-47347">Delaware</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2024To09_30_2024" id="ixv-47348">3841</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2024To09_30_2024" id="ixv-47349">92-2182207</ix:nonNumeric></div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(State or other jurisdiction of</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">incorporation or organization)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Primary Standard Industrial</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Classification Code Number)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(I.R.S. Employer</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">Identification No.)</div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To09_30_2024" id="ixv-47350">11 Huron Drive</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To09_30_2024" id="ixv-47351">Natick</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden127678532;display:inline;">MA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To09_30_2024" id="ixv-47352">01760</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To09_30_2024" id="ixv-47353">508</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To09_30_2024" id="ixv-47354">647-4000</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47355">Shantanu Gaur</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Chief Executive Officer </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Allurion Technologies, Inc. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47356">11 Huron Drive</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47357">Natick</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden127678533;display:inline;">MA</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47358">01760</ix:nonNumeric> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Telephone: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47359">508</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-47360">647-4000</ix:nonNumeric></div> </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 34%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 32%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 32%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Danielle M. Lauzon</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Jeffrey A. Letalien</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Paul R. Rosie</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Goodwin Procter LLP</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">100 Northern Avenue</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Boston, MA 02210</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">570-1000</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: top;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Brendan Gibbons</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Chief Legal Officer</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Allurion Technologies, Inc.</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">11 Huron Drive</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">Natick, MA 01760</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(508) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">647-4000</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Charles Phillips</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">Ellenoff Grossman &amp; Schole LLP</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">1345 Avenue of the Americas</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">New York, NY 10105</div><div style="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman;font-weight:bold;text-align:center">(212) 370-1300</div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: From time to time after this Registration Statement becomes effective. </div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:&#8194;&#9746; </div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div></div></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">12b-2</div> of the Exchange Act. </div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 9pt; border-collapse: collapse;text-indent: 0px;">
<tr>
<td style="width: 15%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 61%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 19%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 1%; vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="width: 2%;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Large&#160;accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#9744;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#9744;</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:entityfilercategoryen" id="ixv-47361">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Smaller&#160;reporting&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:boolballotbox" id="ixv-47362">&#9746;</ix:nonNumeric></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td colspan="2" style="height: 1.5pt;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Emerging&#160;growth&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:boolballotbox" id="ixv-47363">&#9746;</ix:nonNumeric></div></td></tr></table><div style="clear:both;max-height:0pt;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:boolballotbox" id="ixv-47364">&#9744;</ix:nonNumeric> </div></div></div><div style="font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="text-align: center;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 1pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;display:inline;">The registrant (the &#8220;Registrant&#8221;) hereby amends this registration statement (this &#8220;Registration Statement&#8221;) on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be issued until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and does not constitute the solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED DECEMBER 9, 2024 </span></span></p> <p style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g01a03.jpg" alt="LOGO" style="width:2.30731in;height:0.471732in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman;font-weight:bold;text-align:center">ALLURION TECHNOLOGIES, INC. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to &#8195;&#8195;&#8195;&#8195; Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Warrants to Purchase up to &#8195;&#8195;&#8195;&#8195;&#160;Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pre-Funded Warrants to Purchase up to &#8195;&#8195;&#8195;&#8195; Shares of Common Stock </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195; Shares of Common Stock Underlying the Common Warrants </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195; Shares of Common Stock Underlying the Pre-Funded Warrants </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">We are offering up to $&#8195;&#8195;&#8195;&#8195; of shares of our common stock, or a pre-funded warrant in lieu thereof, and new warrants to purchase up to an aggregate of &#8195;&#8195;&#8195;&#8195; shares of our common stock (the &#8220;common warrants&#8221;). This prospectus also relates to the offering of the shares of our common stock issuable upon the exercise of such warrants. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">The shares of common stock and the accompanying common warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Each purchaser of one share of our common stock will receive one common warrant per share of common stock purchased thereby. Each common warrant may be exercised for one share of our common stock. The common warrants will be immediately exercisable upon issuance at an exercise price of $&#8195;&#8195;&#8195;&#8195;&#160;per share and will expire five years from the date of issuance, subject to certain limitations described herein. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">We are also offering to each purchaser whose purchase of shares of our common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately following consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants to purchase shares of common stock in lieu of shares of common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant will equal the price per share of common stock being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The pre-funded warrants and common warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. This prospectus also covers the shares of common stock issuable from time to time upon the exercise of the pre-funded warrants and common warrants. For each pre-funded warrant that we sell, the number of shares of our common stock that we are offering will be decreased on a one-for-one basis. The pre-funded and common warrants will not be listed on the NYSE and are not expected to trade in any market, however we anticipate that the shares of our common stock to be issued upon exercise of the pre-funded and common warrants will trade on the NYSE. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">We have retained Roth Capital Partners, LLC to act as our exclusive placement agent for this offering. We have agreed to pay the placement agent the placement agent fees set forth in the table below, which assumes that we sell all of the securities we are offering and to provide certain other compensation to the placement agent. The placement agent is not required to arrange for the sale of any specific number or dollar amount of securities but will use reasonable best efforts to arrange for the sale of the securities. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above and throughout this prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">The securities will be offered at a fixed price and are expected to be issued in a single closing. The offering will terminate on &#8195;&#8195;&#8195;&#8195;, unless (i)&#160;the closing occurs prior thereto or (ii)&#160;we decide to terminate the offering prior thereto (which we may do at any time in our discretion). Investors purchasing securities offered hereby will have the option to execute a securities purchase agreement with us. We expect that the closing of the offering will occur one trading day after we price the securities offered hereby. When we price the securities, we will simultaneously enter into securities purchase agreements relating to the offering with those investors who so choose. The offering will settle delivery versus payment (&#8220;DVP&#8221;)/receipt versus payment (&#8220;RVP&#8221;). That is, on the closing date, we will issue the shares of our common stock directly to the account(s) at the placement agent identified by each purchaser; upon receipt of such shares, the placement agent shall promptly electronically deliver such shares to the applicable purchaser, and payment therefor shall be made by the placement agent (or its clearing firm) by wire transfer to us. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">Our common stock is listed on the New York Stock Exchange (&#8220;NYSE&#8221;) under the symbol &#8220;ALUR&#8221;, and the last reported sale price of our common stock on the NYSE on December&#160;6, 2024 was $0.37. Our existing public warrants (the &#8220;Public Warrants&#8221;) are listed on the NYSE under the symbol &#8220;ALUR WS,&#8221; and the last reported sale price of the Public Warrants on the NYSE on December&#160;6, 2024 was $0.035 per warrant. Our July 2024 Public Warrants (as defined herein) have an exercise price of $1.20 per warrant. Neither the pre-funded warrants nor the common warrants offered as part of this offering have the same terms and conditions as our Public Warrants or July 2024 Public Warrants. The actual number of securities, and the combined public offering price per share of common stock and the accompanying common warrants (and pre-funded warrants), and the exercise price for the accompanying common warrants will be as determined between us, the placement agent and investors at the time of pricing, and may be at a discount to the current market price of our common stock and the Public Warrants. Therefore, the recent market prices used throughout this prospectus may not be indicative of the actual public offering price of the shares of common stock and accompanying common warrants offered hereunder. Currently, there is no public market for the pre-funded warrants and common warrants offered hereunder. In addition, we do not intend to apply for a listing of the pre-funded warrants or common warrants on the NYSE or any other national securities exchange or nationally recognized trading system. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; under the federal securities laws and are subject to reduced public company reporting requirements. See &#8220;<span style="font-style:italic">Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company</span>.&#8221; </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:56%"/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:6.5pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Per Share and<br/>Accompanying<br/>Common<br/>Warrant</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Per&#160;Pre-Funded</span><br/>Warrant and<br/>Accompanying</span><br/><span style="font-weight:bold">Common<br/>Warrant</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Public offering price</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Placement agent&#8217;s fees<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Proceeds to Allurion Technologies, Inc. before expenses<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman;text-align:left">We have retained Roth Capital Partners, LLC to act as our exclusive placement agent for this offering. We have agreed to pay the placement agent the placement agent fee set forth in the table above, which assumes that we sell all of the securities we are offering. The placement agent is not required to arrange for the sale of any specific number or dollar amount of securities but will use reasonable best efforts to arrange for the sale of the securities. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:3%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman;text-align:left">Does not include the proceeds from the exercise of the pre-funded warrants or common warrants in cash, if any. Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman">We expect to deliver the securities against payment on or about &#8195;&#8195;&#8195;&#8195;, 2024, subject to satisfaction of customary closing conditions. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman;font-weight:bold">Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in &#8220;<a href="#tx915839_5">Risk Factors</a>&#8221; beginning on page 13 of this prospectus. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:7.5pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Placement Agent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Roth Capital Partners </p> <p style="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195;, 2024 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="4"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_4">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_6">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_7">MARKET PRICE AND DIVIDEND INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_8">CAPITALIZATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_9">DILUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_10">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_11">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_12">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_13">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_14">DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_15">PRINCIPAL STOCKHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">156</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_17">DESCRIPTION OF SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_18">DESCRIPTION OF SECURITIES WE ARE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_19">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_20">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_21">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_22">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_23">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">186</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx915839_24">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus, and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. Neither we nor the placement agent have authorized anyone to provide you with information that is different from, or in addition to, that contained in this prospectus, any amendment or supplement to this prospectus and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the placement agent take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. Our business, financial condition, results of operations and prospects may have changed since that date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the placement agent have taken any action that would permit this offering, or possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus applicable to that jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or will be filed as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references herein to &#8220;Allurion,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to the business and operations of Legacy Allurion (as defined below) and its consolidated subsidiaries prior to consummation of the Business Combination (as defined below) and to New Allurion (as defined below) and its consolidated subsidiaries following the consummation of the Business Combination. &#8220;Legacy Allurion&#8221; refers to Allurion Technologies, LLC, which was previously known as Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc.) prior to the consummation of the Business Combination. &#8220;New Allurion&#8221; refers to Allurion Technologies, Inc., which was previously known as Allurion Technologies Holdings, Inc. prior to the consummation of the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the <sup style="font-size:75%; vertical-align:top">&#174;</sup> or <sup style="font-size:75%; vertical-align:top">&#8482;</sup> symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements in this prospectus may constitute &#8220;forward-looking statements&#8221; within the meaning of the U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. These <span style="white-space:nowrap">forward-looking</span> statements include, but are not limited to, statements regarding the plans, strategies and prospects, both business and financial, of Allurion. These statements are based on the beliefs and assumptions of our management. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;forecasts,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;future,&#8221; &#8220;seeks,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;propose,&#8221; &#8220;scheduled,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; or similar expressions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements in this prospectus include, but are not limited to, statements about our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">realize the benefits expected from the business combination (the &#8220;Business Combination&#8221;) between Allurion and Compute Health Acquisition Corp. (&#8220;Compute Health&#8221;) pursuant to that certain Business Combination Agreement, dated as of February&#160;9, 2023 (as amended, the &#8220;Business Combination Agreement&#8221;), by and among Allurion, Legacy Allurion, Compute Health, Compute Health Corp., (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully defend litigation that may be instituted by or against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage various conflicts of interest that could arise among us or our affiliates, investors, directors, and officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully manage our cash and cash equivalents and any anticipated proceeds from this offering or the Chardan Equity Facility (as defined herein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain the listing of our securities on the NYSE, and the potential liquidity and trading of such securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve the benefits of the collaboration with Medtronic plc (&#8220;Medtronic&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acquire sufficient sources of funding if and when needed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain key employees, officers, and directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implement and achieve business plans, forecasts, and other expectations, including any financial projections provided to PIPE Investors (as defined herein) in connection with the Business Combination, the Purchasers in connection with the Notes (each as defined herein), and the investors in any offering hereunder, and identify and realize additional opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage risks associated with our management having limited experience operating as a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercialize current and future products and services and create sufficient demand among health care providers and patients for such products, including the recent launch of our compounded <span style="white-space:nowrap">GLP-1</span> program and achieving the expected benefits of such program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete current and future preclinical studies and clinical trials of the swallowable, Procedureless<sup style="font-size:75%; vertical-align:top">TM</sup> intragastric balloon for weight loss developed by us (the &#8220;Allurion Balloon&#8221;) and any other future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain market acceptance of the Allurion Balloon as safe and effective; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effectively sell existing and future products through distribution arrangements with distributors and/or successfully adopt a direct sales force as part of a hybrid sales model that includes both distributors and a direct sales effort; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete remediation programs to resume sales of the Allurion Balloon in France and any other country that suspends sales of our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely collect accounts receivable from our customers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain regulatory approval or clearance in the United States and certain <span style="white-space:nowrap">non-U.S.</span> jurisdictions for current and future products and maintain previously obtained approvals and/or clearances in those jurisdictions where products and services are currently offered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">accurately forecast customer demand and manufacture sufficient quantities of products that patients and health care providers request; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully compete in the highly competitive and rapidly changing regulated industries in which we operate, and effectively address changes in such industries, including changes in competitors&#8217; products and services and changes in the laws and regulations that affect us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully manage any future international expansion of our business and navigate business, regulatory, political, operational, financial, and economic risks associated with doing business internationally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully manage any future growth or contraction in our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">contract with third-party suppliers and providers and monitor their ability to perform adequately under those arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">comply with applicable legal and regulatory obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain and maintain intellectual property protection for our products and technologies and acquire or license (on commercially reasonable terms) intellectual property from third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sell products, and use proprietary technologies, without infringing, misappropriating, or otherwise violating the proprietary rights or intellectual property of third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage the impact of any significant acquisitions, dispositions, and other similar or material transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implement and maintain effective internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage the effects of natural disasters, terrorist attacks, the spread and/or abatement of infectious diseases such as <span style="white-space:nowrap">COVID-19,</span> and the occurrence of other events beyond our reasonable control, including with respect to potential operational disruptions, labor disruptions, increased costs, and impacts to demand related thereto, on our ability to implement business plans, forecasts, and other expectations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based the forward-looking statements contained in this prospectus primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, assumptions and other factors described in the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 14 and elsewhere in this prospectus. These risks are not exhaustive. Other sections of this prospectus include additional factors that could adversely impact our business and financial performance. Moreover, we operate in very competitive and rapidly changing environments. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following summary highlights information contained elsewhere in this prospectus. It does not contain all the information you should consider before investing in our securities. You should read this entire prospectus carefully, including the sections entitled &#8220;Risk Factors,&#8221; &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Where You Can Find More Information,&#8221; and our consolidated financial statements and related notes included elsewhere in this prospectus, before making an investment decision. In this prospectus, unless the context requires otherwise, all references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Allurion,&#8221; the &#8220;Registrant,&#8221; and the &#8220;Company&#8221; refer to Allurion Technologies, Inc. and its consolidated subsidiaries. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dedicated to ending obesity by creating a <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> weight loss platform to treat the estimated two billion people globally who are overweight. Our platform, the Allurion Program (the &#8220;Allurion Program&#8221;), features the world&#8217;s first and only swallowable, Procedureless<sup style="font-size:75%; vertical-align:top">&#8482;</sup> intragastric balloon for weight loss (the &#8220;Allurion Balloon&#8221;) and offers access to artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a behavior change program, secure messaging and video telehealth that are delivered by the Allurion Virtual Care Suite (&#8220;VCS&#8221;). Over 150,000 patients have already been treated commercially with the Allurion Balloon in over 50 countries globally outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon is swallowed as a capsule under the guidance of a health care provider without surgery, endoscopy, or anesthesia. The placement takes approximately 15 minutes during an outpatient visit (though times may vary across different outpatient offices). We believe the proprietary technologies that differentiate the Allurion Balloon enable improved safety and efficacy outcomes. In a prospective, <span style="white-space:nowrap">non-randomized,</span> open-label, registry trial, the Allurion Balloon demonstrated low device or procedure related rates of serious adverse events, which we believe compare favorably to that of our competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The VCS is comprised of the following tools to support patients&#8217; weight loss experience, which we believe benefit both patients and health care providers: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For Allurion Program patients: Every current Allurion Program patient receives an Allurion Connected Scale (&#8220;Allurion Connected Scale&#8221;) and access to our mobile app (&#8220;App&#8221;), which integrates data from the Allurion Connected Scale to conveniently monitor weight, body fat, activity, sleep, and several other critical metrics. The App can also enable secure messaging and video telehealth with the patient&#8217;s care team and can deliver content from Allurion&#8217;s behavior change program - a library of 100 weight loss actions related to diet, nutrition, mental health, sleep, goal setting, and a number of other topics -directly to the patient. The App is available in 15 languages. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For Allurion Program providers: Every Allurion Program provider receives access to our clinic dashboard (&#8220;Allurion Insights&#8221;), which provides <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> remote patient monitoring powered by the Allurion Iris AI platform, which leverages machine learning to deliver key insights and streamline workflow. Allurion Insights offers real-time access to patient data and <span style="white-space:nowrap">AI-powered</span> analytics, 1:1 video telehealth and secure messaging directly to the patient&#8217;s App, note functionality to keep track of patient encounters, and clinic-wide metrics that provide a snapshot of the clinic&#8217;s overall performance. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its use by Allurion Balloon patients, we believe the VCS can potentially be a platform for optimal long-term <span style="white-space:nowrap">follow-up</span> after other medical and surgical weight loss interventions in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, VCS includes a Treatment Tracking and <span style="white-space:nowrap">Clinic-Led</span> Onboarding feature that enables seamless onboarding and management of patients undergoing one or multiple weight loss treatments including gastric </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
balloons such as the Allurion Balloon, surgery, or medications. In addition, in connection with our collaboration with Medtronic, we expect to develop bundled offerings that incorporate the VCS to onboard and manage Medtronic&#8217;s patients. Further, in April 2024, we launched the VCS in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, we launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with our <span style="white-space:nowrap">AI-native</span> platform to promote long-term weight maintenance, virtual access to dieticians, and the Allurion Connected Scale that measures not just weight but muscle and bone mass. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Allurion Program products are currently sold in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region. AllurionMeds is currently only available in the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restructuring Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2024, our board of directors (&#8220;Board&#8221;) approved a restructuring plan to reduce operating costs and better align our workforce with the needs of our business. The majority of the restructuring plan is expected to be completed in the fourth quarter of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the restructuring plan, we anticipate reducing our workforce by approximately 113 roles (approximately 50% of our workforce). In connection with the restructuring plan, we estimate that we will incur <span style="white-space:nowrap">one-time</span> aggregate restructuring charges of approximately $3.5&#160;million, which will be recorded primarily in the fourth quarter of 2024, related to severance payments and other employee-related costs. The cash payments related to the personnel-related restructuring will be paid primarily during the first quarter of 2025. The charges that we expect to incur in connection with the workforce reduction are subject to a number of assumptions, and actual results may differ materially. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Revenue Interest Financing Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced, on February&#160;9, 2023, Allurion Technologies, LLC (&#8220;Allurion Opco&#8221;), a Delaware limited liability company and wholly-owned subsidiary of the Company, entered into the Original RIFA (as defined herein), with RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd. (as transferees of the investors initially party to the Original RIFA). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced and in connection with the Original RIFA, the Company, Allurion Opco, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. (as transferee from RTW Biotech Opportunities Ltd. (formerly known as RTW Venture Fund Limited)) (in each case, together with their successors and permitted assigns, the &#8220;Additional RIFA Investors&#8221;) entered into the RTW Side Letter (as modified by that Amended and Restated Letter Agreement, dated as of May&#160;2, 2023, that certain Assignment Agreement, dated as of July&#160;28, 2023, that certain Assignment Agreement, dated as of April&#160;9, 2024, and that certain First Amendment to Amended and Restated Letter Agreement, dated as of April&#160;14, 2024, the &#8220;Amended and Restated RTW Side Letter&#8221;). The Amended and Restated RTW Side Letter provided, among other things, that the Additional RIFA Investors may make a single election in certain circumstances to convert up to $7,500,000 of the purchase price (the &#8220;Conversion Amount&#8221;) that the Additional RIFA Investors paid for certain shares of our common stock, into an amount of financing provided by the Additional RIFA Investors to Allurion Opco pursuant to an additional revenue interest financing agreement with Allurion Opco (the &#8220;Investment Conversion&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated RTW Side Letter, on October&#160;22, 2024, the Additional RIFA Investors notified us of their election to exercise the Investment Conversion in full. Accordingly, on October&#160;30, </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2024, we and the Additional RIFA Investors entered into the additional Revenue Interest Financing Agreement (the &#8220;Additional Revenue Interest Financing Agreement&#8221;). The Additional Revenue Interest Financing Agreement has substantially identical terms and conditions as the Original RIFA, except that the amount of financing provided by the Additional RIFA Investors to Allurion Opco under the Additional Revenue Interest Financing Agreement is equal to the Conversion Amount. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. If any of these risks actually occur, our business, financial condition and results of operations would likely be materially adversely affected. You should carefully consider all the information contained in this prospectus before making a decision to invest in our securities. In particular, you should consider the risk factors described under &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page 14. Some of these risks related to our business, operations, financial performance and industry, as well as this offering and our securities, are summarized below. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We expect to incur losses for the foreseeable future, our ability to achieve and maintain profitability depends on the commercial success of the Allurion Balloon, and we expect our revenues to continue to be driven primarily by sales of the Allurion Balloon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history and may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The failure of the Allurion Balloon or our new compounded <span style="white-space:nowrap">GLP-1</span> program to achieve and maintain market acceptance could result in achieving sales or profitability below our expectations, which would cause our business, financial condition, and operating results to be materially and adversely affected. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is no guarantee that the FDA or <span style="white-space:nowrap">non-U.S.</span> regulatory agencies will grant approval or clearance for our current or future products, and failure to obtain regulatory approvals or clearances in the United States and other international jurisdictions, or revocation of approvals or clearances in those jurisdictions, will prevent us from marketing our products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Allurion Balloon is not currently approved for commercial sale in the United States. Obtaining such approval is costly and time consuming, and we may not obtain the regulatory approval required to sell the Allurion Balloon in the U.S. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The weight loss and obesity-management industries are highly competitive. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our competitors are able to develop and market products, whether medical devices or otherwise, that are safer, more effective, easier to use, or more readily adopted by patients and health care providers, our commercial opportunities will be reduced or eliminated. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Continued international expansion of our business will expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business internationally. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We depend on a limited number of single source suppliers to manufacture components, <span style="white-space:nowrap">sub-assemblies,</span> and materials, which makes us vulnerable to supply shortages and price fluctuations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval process is expensive, time consuming, and uncertain, and may prevent us from obtaining approvals for the commercialization of the Allurion Balloon or other products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Even if we receive regulatory approval for the Allurion Balloon, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If patients using our products experience adverse events or other undesirable side effects, regulatory authorities could withdraw or modify our regulatory approvals, which would adversely affect our reputation and commercial prospects and/or result in other significant negative consequences. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The medical device industry is characterized by patent litigation and we could become subject to adversarial proceedings or litigation that could be costly, result in the diversion of management&#8217;s time and efforts, result in a loss of our intellectual property, require us to pay damages, or prevent us from marketing our existing or future products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are not able to obtain and maintain intellectual property protection for our products and technologies, if the scope of our patents is not sufficiently broad or our patents are invalidated, or if competitors gain broader patent protection, we may not be able to effectively maintain our market leading technology position. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred net operating losses in the past and expect to incur net operating losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may need additional funds to support our operations, and such funding may not be available to us on acceptable terms, or at all, which would force us to delay, reduce, or suspend our planned development and commercialization efforts. Raising additional capital may subject us to unfavorable terms, cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our products and technologies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We receive the majority of our revenue from sales to health care providers and other third-party distributors, and the failure to collect receivables from them could adversely affect our financial position and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our share price may be volatile, and purchasers of our securities could incur substantial losses. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">You will experience immediate and substantial dilution as a result of this offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Implications of Being an Emerging Growth Company and a Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933 (&#8220;Securities Act&#8221;), as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a <span style="white-space:nowrap">non-binding</span> advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended, the &#8220;Exchange Act&#8221;) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparability of our financial </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statements with another public company that is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the effectiveness of the registration statement filed in connection with our Business Combination, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.00&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of this status, we have taken advantage of reduced reporting requirements in this prospectus. In particular, in this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K,</span> which allows us to take advantage of certain exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section&#160;404. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of the shares of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June&#160;30, and (ii)&#160;our annual revenue exceeded $100&#160;million during such completed fiscal year or the market value of the shares of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Company Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on January&#160;25, 2023. The mailing address of our principal executive office is 11 Huron Drive, Natick, MA 01760, and the telephone number is (508) <span style="white-space:nowrap">647-4000.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The SEC maintains an Internet website at <span style="font-style:italic">www.sec.gov</span> that contains reports, proxy and information statements and other information about issuers, like us, that file electronically with the SEC. We also maintain a website at <span style="font-style:italic">www.allurion.com</span>. We make available, free of charge, on our investor relations website at <span style="font-style:italic">investors.allurion.com</span>, our Annual Reports on Form <span style="white-space:nowrap">10-K,</span> Quarterly Reports on Form <span style="white-space:nowrap">10-Q,</span> Current Reports on Form <span style="white-space:nowrap">8-K</span> and amendments to these reports as soon as reasonably practicable after electronically filing or furnishing those reports to the SEC. Information contained on or accessible through our website is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses in this prospectus is an inactive textual reference only. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_4">THE OFFERING </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of common stock offered by us </p></td>
<td>Up to &#8195;&#8195;&#8195;&#8195; shares. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common warrants offered by us </p></td>
<td>Common warrants to purchase up to &#8195;&#8195;&#8195;&#8195; shares of our common stock. Each common warrant will have an exercise price of $&#8195;&#8195;&#8195; per share of common stock, will be immediately exercisable upon issuance and will expire on the fifth anniversary of the original issuance date. See &#8220;<span style="font-style:italic">Description of Securities We Are Offering&#8212;Common Warrants.</span>&#8221; </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Pre-funded warrants offered by us </p></td>
<td>We are also offering to those purchasers, if any, whose purchase of the common stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or at the election of the purchaser, 9.99%) of our outstanding common stock immediately following consummation of this offering, the opportunity to purchase, if they so choose, pre-funded warrants in lieu of the common stock that would otherwise result in ownership in excess of 4.99% (or 9.99%, as applicable) of our outstanding common stock. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The pre-funded warrants and common warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of our common stock to be outstanding immediately after this offering </p></td>
<td>Up to &#8195;&#8195;&#8195;&#8195; shares, assuming no sale of any pre-funded warrants and no exercise of any common warrants sold in this offering. If the common warrants are exercised in full, there would be an additional &#8195;&#8195;&#8195;&#8195; shares of common stock outstanding. To the extent pre-funded warrants are sold, the number of shares of common stock sold in this offering will be reduced on a one-for-one basis. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Reasonable best efforts offering </p></td>
<td>We have agreed to issue and sell the securities offered hereby to the purchasers through the placement agent. The placement agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; beginning on page 180 of this prospectus. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </p></td>
<td> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195;&#8195; million, based on an assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant, which is the last reported sales price of our common stock on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2024, and after deducting estimated placement agent fees and estimated offering expenses payable by us, assuming no sale of pre-funded warrants and no proceeds from the exercise of common warrants. If the common warrants are exercised for cash in full, we would receive an additional $&#8195;&#8195;&#8195; of proceeds </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr>
<td style="width:38%">&#160;</td>
<td align="left" style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
therefrom. We intend to use any net proceeds of this offering, together with our existing cash and cash equivalents, to fund our commercial sales, research and development, and for working capital and other general corporate purposes. Pending other uses, we may invest the net proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether any net proceeds so invested will yield a favorable return. Because this is a best efforts offering with no minimum amount as a condition to closing, we may not sell all or any of the securities offered hereby. As a result, we may receive significantly less in net proceeds than we currently estimate. See &#8220;<span style="font-style:italic">Use of Proceeds</span>.&#8221; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Listing </p></td>
<td>Our shares of common stock are listed on the NYSE under the symbol &#8220;ALUR.&#8221; Currently, there is no public market for the pre-funded warrants or common warrants. We do not intend to list the pre-funded warrants or common warrants on the NYSE or any other national securities exchange or nationally recognized trading system. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>Any investment in our securities involves a high degree of risk. You should carefully consider the information set forth under &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and our consolidated financial statements and related notes appearing elsewhere in this prospectus before investing in our securities. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 64,797,259 shares of our common stock outstanding as of December&#160;6, 2024, and excludes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">18,759,554 shares of common stock issuable upon the exercise of our existing publicly traded warrants to purchase shares of common stock outstanding as of December&#160;6, 2024, with an exercise price of $8.10 per share (the &#8220;Public Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">364,578&#160;shares of common stock issuable upon the exercise of existing warrants to purchase shares of common stock outstanding as of December&#160;6, 2024, with a weighted average exercise price of $5.64 per share (the &#8220;Rollover Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,567,484 shares of common stock issuable upon the exercise of existing warrants issued by the Company pursuant to an underwriting agreement with Jefferies LLC and TD Securities (USA) LLC, dated June&#160;28, 2024, with an exercise price of $1.20 per share (the &#8220;July 2024 Public Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,260,159 shares of Series A <span style="white-space:nowrap">non-voting</span> convertible preferred stock, par value $0.0001 per share (&#8220;Series A Preferred Stock&#8221;) and 2,260,159 private placement warrants to purchase shares of common stock (the &#8220;Private Placement Warrants&#8221;), with an exercise price of $1.20 per share, issued pursuant to the subscription agreement, dated June&#160;28, 2024, by and among the Company and RTW (the &#8220;Subscription Agreement&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,717,316&#160;shares of common stock issuable upon exercise of options outstanding as of December&#160;6, 2024, with a weighted-average exercise price of $2.32 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,588,093&#160;shares of common stock issuable upon the vesting of restricted stock units outstanding as of December&#160;6, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">6,478,717&#160;shares of common stock available for future issuance as of December&#160;6, 2024 under the Allurion Technologies, Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;); </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,226,122 shares of common stock available for future issuance as of December&#160;6, 2024 under the Allurion Technologies, Inc. 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">60,691,007 shares of common stock that may become issuable upon the conversion of the Notes (as defined below) pursuant to the Amended Note Purchase Agreement (as defined below) if the First Stockholder Approval (as defined below) is obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">8,442,601&#160;shares of common stock available for future issuance under the Purchase Agreement with Chardan as of December&#160;6, 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">9,000,000 shares of common stock that may be issued pursuant to the earnout provisions of the Business Combination Agreement (&#8220;Contingency Shares&#8221;) reserved for issuance upon triggering events for such Contingency Shares. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, all information in this prospectus assumes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no exercise of any of the common warrants issued and sold in this offering; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no issuance of shares of common stock under the Purchase Agreement with Chardan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no issuance of the Contingency Shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no exercise of the outstanding existing warrants and options or vesting of the outstanding restricted stock units described above, in each case, after December&#160;6, 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the exercise for cash of all pre-funded warrants issued in this offering. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before you decide to invest in our securities, you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, results of operations and financial condition would likely be materially and adversely affected. In these circumstances, the market price of our securities could decline, and you may lose part or all of your investment. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to the Development and Commercialization of Our Products </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We expect to incur losses for the foreseeable future, our ability to achieve and maintain profitability depends on the commercial success of the Allurion Balloon, and we expect our revenues to continue to be driven primarily by sales of the Allurion Balloon. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses to date and expect to continue to incur losses for the foreseeable future. Sales of the Allurion Balloon and related accessories, which have occurred outside of the U.S. because we have not yet obtained the regulatory approval required to sell our products within the U.S., accounted for substantially all of our revenues for the years ended December&#160;31, 2023 and 2022 and the nine months ended September&#160;30, 2024 and 2023, and we expect our revenues to continue to be driven primarily by sales of the Allurion Balloon. In order to achieve and sustain profitability, our revenues from sales of the Allurion Balloon will need to grow beyond the levels we have achieved in the past. If health care providers and/or patients do not perceive our products to be competitive in features, efficacy and safety when compared to other products in the market, or if demand for the Allurion Balloon or for weight loss procedures and programs in general decreases, we may fail to achieve sales levels that provide for future profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to successfully market the Allurion Balloon and our other current and future product and service offerings depends on numerous factors, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">outcomes of current and future clinical trials of, and trials involving, the Allurion Balloon; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance of the Allurion Balloon as safe and effective by patients, caregivers and the medical community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an acceptable safety profile of the Allurion Balloon in markets where we have obtained regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to successfully complete the remediation programs to resume sales of the Allurion Balloon in France and any other country that suspends sales of our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether key thought leaders in the medical community accept that such clinical trials are sufficiently meaningful to influence their or their patients&#8217; choices of product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintenance of our existing regulatory approvals and expansion of the geographies in which we have regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercially viable processes at a scale sufficient to meet anticipated demand at an adequate cost of manufacturing, and that are compliant with ISO 13485 Quality Management System requirements and/or good manufacturing practice requirements, as set forth in the FDA&#8217;s QSR and other international regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our success in educating health care providers and patients about the benefits, administration and use of the Allurion Balloon; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> for the Allurion Balloon and/or Allurion VCS in the absence of coverage and reimbursement for such treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our internal sales and marketing organization and the sales forces of our distributors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continued demand for weight loss using balloon products, which may be adversely affected by events involving our products or those of our competitors, among other things. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of these factors are beyond our control. For example, on August&#160;6, 2024, we announced that the Agence Nationale de S&#233;curit&#233; du M&#233;dicament (&#8220;ANSM&#8221;) suspended sales of the Allurion Balloon in France, and that we are withdrawing the Allurion Balloon from the French market, pending implementation of a remediation plan to reduce certain risks associated with the advertising, <span style="white-space:nowrap">follow-up</span> program, and adverse events for the Allurion Balloon. There is no guarantee that we will be able to successfully implement a remediation plan to the satisfaction of ANSM and we could be delayed or prevented from resuming sales of the Allurion Balloon in France. In addition, a withdrawal from the market in one country may have a negative effect on the regulatory approval process and ability to sell and commercialize the Allurion Balloon in other countries, and on the market acceptance of the Allurion Balloon. Any of these events may have an adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to continue to commercialize the Allurion Balloon and our other current and future products and services, or are unable to obtain a distributor or partner to commercialize them, we may not be able to produce any incremental revenues related to the Allurion Balloon and our other current and future products and services. This would result in an adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon has been marketed in countries outside of the United States since 2016, and as such, we have a limited operating history upon which to evaluate our business and forecast our future revenue and operating results. In assessing our business prospects, you should consider the various risks and difficulties frequently encountered by companies early in their commercialization in competitive markets, particularly companies that develop and sell medical devices. These risks include our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implement and execute our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expand and improve the productivity of our direct sales force, distributors and marketing programs to grow sales of our existing and proposed products and services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increase awareness of our brand and build loyalty among health care providers and patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manage growth and expanding operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">respond effectively to competitive pressures and developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enhance our existing products and develop new products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain regulatory approval or clearance to enhance our existing products and commercialize new products, including any label expansions for use of our products in adolescents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">respond to changing regulations associated with medical devices across all geographies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perform clinical trials with respect to our existing products and any new products, including products under development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract, retain and motivate qualified personnel in various areas of our business; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain and maintain coverage and adequate levels of reimbursement for our products. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to our limited operating history, we may not have the institutional knowledge or experience to be able to effectively address these and other risks that we may face. In addition, we may not be able to develop insights into trends that could emerge and negatively affect our business and may fail to respond effectively to those trends. As a result of these or other risks, we may not be able to execute key components of our business strategy, and our business, financial condition and operating results may suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not expect that health care providers or patients will receive third-party reimbursement for treatment with our products. As a result, we expect that our success will depend on the ability and willingness of health care providers to adopt <span style="white-space:nowrap">self-pay</span> practice management infrastructure and of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> for treatment with our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain elective treatments, such as an intragastric balloon, are typically not covered by insurance. Accordingly, we do not expect that any third-party payors will cover or reimburse health care providers or patients for the Allurion Program. As a result, we expect that our success will depend on the ability and willingness of health care providers that may not have historically operated a <span style="white-space:nowrap">self-pay</span> practice to adopt the policies and procedures needed to successfully operate such a practice. Our sales and marketing efforts have historically targeted bariatric surgeons, gastroenterologists, plastic surgeons and other health care providers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although many of these health care providers are accustomed to selling <span style="white-space:nowrap">cash-pay</span> services in their practices, some are primarily accustomed to providing services that are reimbursed by third-party payors. As a result, these health care providers may need to augment their administrative staff and billing procedures to address the logistics of a <span style="white-space:nowrap">self-pay</span> practice. If health care providers are unable or unwilling to make such changes, adoption of our products may be slower than anticipated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will also depend on the ability and willingness of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> for treatment with our products. Adverse changes in the economy, including from heightened inflation, higher interest rates, and geopolitical conflicts such as the Russia-Ukraine war and the Israel-Hamas war, may cause consumers to reassess their spending choices and reduce the demand for elective treatments and could have an adverse effect on consumer spending. This shift could have an adverse effect on our revenues and operating results. In addition, the operations of the medical device distributors upon whom we rely to sell our products may be negatively impacted by any such adverse economic changes. If our distributors are unable to maintain their operations and effectively market and sell our products, our results of operations and business may suffer. Furthermore, consumer preferences and trends may shift due to a variety of factors, including changes in demographic and social trends, public health initiatives and product innovations, which may reduce consumer demand for our products. The decision by a patient to elect to undergo treatment with the Allurion Balloon may be influenced by a number of additional factors, such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of any sales and marketing programs, including <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> marketing efforts, that we, or any third parties we engage, undertake; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which health care providers offer the Allurion Balloon to their patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which the Allurion Balloon satisfies patient expectations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost, safety, comfort, tolerability, ease of use, and effectiveness of the Allurion Program as compared to other treatments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general consumer confidence, which may be impacted by economic and political conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial performance will be materially harmed if we cannot generate significant customer demand for the Allurion Balloon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in coverage and reimbursement for obesity treatments and procedures could affect the adoption of the Allurion Program and our future revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, intragastric balloon products are not reimbursed by third-party payors, although a very limited number of balloon procedures have recently been subject to reimbursement in the U.K. market. We do not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently plan on submitting any requests to any third-party payor for coverage or billing codes specific to our products other than our partnership with the National Health Service in the United Kingdom. However, payors may change their coverage and reimbursement policies for intragastric balloon products as a category and/or for other obesity treatments and procedures, and these changes could negatively impact our business. For example, healthcare reform legislation or regulation that may be proposed or enacted in the future that results in a favorable change in coverage and reimbursement for competitive products and procedures in weight loss and obesity could also negatively impact adoption of our products and our future revenues, and our business could be harmed as we would be at an economic disadvantage when competing for customers. For more information, see section entitled &#8220;<span style="font-style:italic"> Business - Government Regulation - Other U.S. Healthcare Laws - Coverage, Reimbursement and Healthcare Reform</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The failure of the Allurion Balloon to achieve and maintain market acceptance could result in us achieving sales below our expectations, which would cause our business, financial condition and operating results to be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current business and growth strategy is highly dependent on the Allurion Balloon achieving and maintaining market acceptance. In order for us to sell our products to healthcare providers and, ultimately, weight loss patients, we must convince them that our products are an attractive alternative to competitive treatments for patients who are obese and overweight, including traditional pharmaceutical therapies and more aggressive bariatric surgical treatments, such as gastric bypass and sleeve gastrectomy. Market acceptance and adoption of the Allurion Balloon depends on educating health care providers on its safe and appropriate use, as well as the cost, safety, comfort, tolerability, ease of use, and effectiveness of the Allurion Program compared to other treatments. If we are not successful in convincing existing and potential customers of the benefits of our product, or if we are not able to achieve the support of health care providers for our product, our sales may decline or we may achieve sales below our expectations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance of our products could be negatively impacted by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of patients to pay <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> for the Allurion Program in the absence of coverage and reimbursement for such program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure of our products to achieve and maintain wide acceptance among patients who are obese and overweight, their health care providers, third-party payors and key opinion leaders in the weight loss treatment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of evidence supporting the safety, <span style="white-space:nowrap"><span style="white-space:nowrap">ease-of-use</span></span> or other perceived benefits of the Allurion Balloon over competitive products or other currently available weight loss treatment alternatives; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perceived risks or uncertainties, or actual adverse events or other undesirable side effects, associated with the use of our gastric balloons, or components thereof, or of similar products or technologies of our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any adverse legal action, including products liability litigation, against us or our competitors relating to the Allurion Balloon or similar products or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the withdrawal or modification of any regulatory approvals for our products (including the withdrawal of the Allurion Balloon from the French market in August 2024); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical studies relating to the Allurion Balloon or similar competitive products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the rapid evolution of technology and treatment options within our industry may cause consumers to delay the purchase of our products in anticipation of advancements or breakthroughs, or the perception that advancements or breakthroughs could occur, in our products or the products offered by our competitors. It is also possible that consumers interested in purchasing any of our future products currently under development may delay the purchase of one of our current products. In addition, customers may delay their purchasing decisions, or health care providers may refrain from providing our products, as a result of a global pandemic or unfavorable changes in general economic conditions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Allurion Balloon, or any other therapy or product that we may develop, does not achieve and maintain widespread market acceptance, we may fail to achieve sales consistent with our projections, in which case our business, financial condition and operating results could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A substantial proportion of our sales are through third-party distributors, and we do not have direct control over the efforts these distributors may use to sell our products. If our relationships with these distributors deteriorate, or if these distributors fail to sell our products or engage in activities that harm our reputation, or fail to adhere to medical device regulations, our financial results may be negatively affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, our sales model has been to sell primarily through distributors rather than through our own sales force, but recently we have begun to transition certain territories to both a direct sales model and a hybrid sales model that includes both distributors and a direct sales effort. We believe that our reliance on distributors improves the economics of our business, as we do not carry the high fixed costs of a large direct sales force in many of the countries in which the Allurion Balloon is commercially available. If we are unable to maintain or enter into such distribution arrangements on acceptable terms, or at all, we may not be able to successfully commercialize our products in certain countries. Furthermore, distributors can choose the level of effort that they apply to selling our products relative to others in their portfolio. The selection, training, and compensation of distributors&#8217; sales personnel are within the distributor&#8217;s control rather than our own and may vary significantly in quality from distributor to distributor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, although our contract terms require our distributors to comply with all applicable laws regarding the sale of our products, including anti-competition, anti-money laundering, sanctions laws and FDA and other health care regulations, we may not be able to ensure proper compliance. If our distributors fail to effectively market and sell our products in full compliance with applicable laws, our results of operations and business may suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In certain large markets, we engage in direct sales efforts. We may fail to maintain and develop our direct sales force, and our revenues and financial outcomes could suffer as a result. Furthermore, our direct sales personnel may not effectively sell our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We engage in direct sales efforts in over 20 countries. We have hired and will need to retain and motivate a significant number of sales and marketing personnel in order to support our anticipated growth in these and other new countries. There is significant competition for quality personnel experienced in such activities, including from companies with greater financial resources than ours. If we are not successful in our efforts to continue recruiting, retaining, and motivating such personnel, we may not be able to increase our revenues, or we may increase our expenses in greater measure than our revenues, negatively impacting our operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also working on creating a direct sales structure and strategy in certain markets. We are working to put in place the correct legal and business structure to comply with taxation and operational requirements. These structures may not ultimately be implemented or, if implemented, be successful or effective and may not be able to increase our revenues or improve our gross margins. In addition, our expenses or <span style="white-space:nowrap">tax-related</span> costs may increase in greater measure than our revenues, negatively impacting our operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our sales force may operate independently with limited <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> oversight from management. They may engage in sales practices that increase certain risks to our business, including the risk of scrutiny from regulatory authorities and the risk that we violate anti-corruption regulations in one or more countries. These and other independent actions may result in unexpected costs, news that might impair our reputation or revenues, litigation in various jurisdictions, and/or sanctions. Any of these could impair the trading price of our common stock and adversely impact our results. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The effectiveness and safety of the Allurion Balloon depends critically on our ability to educate health care providers on its safe and proper use. If we are unable to do so, we may not achieve our expected growth and may be subject to risks and liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to educating health care providers on the clinical benefits of the Allurion Balloon, we must also train health care providers on the safe and appropriate use of the Allurion Balloon. If we are unable to provide an adequate training program with respect to the Allurion Balloon, product misuse may occur that could lead to serious adverse events. Many health care providers may be unfamiliar with such treatments or find it more complex than competitive products or alternative treatments. As such, there is a learning process involved for health care providers to become proficient in the use of our products and it may take several procedures for a health care provider to be able to use the Allurion Balloon comfortably. In addition, it is also critical for health care providers to be educated and trained on best practices in order to achieve optimal results, including patient selection and eligibility criteria, as well as complementary methods of use such as diet or behavioral modification programs. Convincing health care providers to dedicate the time and energy necessary for adequate training is challenging, and we cannot assure you that we will be successful in these efforts. This training process may also take longer than we expect. In the event that health care providers are not properly trained in the use of the Allurion Balloon, they may misuse or ineffectively use our products for the treatment of patients. As a result, patients may experience adverse events or not be able to enjoy the benefits of our program or achieve the weight loss outcomes they expect, leading to dissatisfaction and market rejection of our products. In addition, misuse of our products in any stage of the treatment may result in, among other things, patient injury, adverse side effects, negative publicity or lawsuits against us. Any of these events could have an adverse effect on our business and reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The misuse or <span style="white-space:nowrap">off-label</span> use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations and sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon has been approved or cleared by regulatory authorities in the countries in which we sell it or in which we conduct our operations for specific indications. We do not promote the Allurion Balloon for uses outside of approved or cleared indications for use, known as <span style="white-space:nowrap">&#8220;off-label</span> uses.&#8221; We cannot, however, prevent a health care provider from using our product <span style="white-space:nowrap">off-label,</span> when in the health care provider&#8217;s independent professional medical judgment he or she deems it appropriate. There may be increased risk of injury to patients if health care providers attempt to use our product <span style="white-space:nowrap">off-label.</span> Furthermore, the use of our product for indications other than those approved or cleared by regulatory authorities may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health care providers may also misuse our products, use improper techniques, ignore or disregard product warnings, contraindications or other information provided in training materials or product labeling, fail to obtain adequate training, fail to inform patients of the risks associated with procedures that utilize our product or fail to solicit sufficient information from patients regarding their health status or medical histories, any of which may potentially lead to injury and an increased risk of product liability claims. If our product is misused or used with improper techniques or insufficient information, we may become subject to costly litigation by our health care providers or their patients. Moreover, if patients fail to disclose medical conditions or to follow the <span style="white-space:nowrap">pre-</span> and post-placement instructions, medication program, and dietary guidelines in connection with their treatment with the Allurion Balloon, there is the risk of injury. Such patients may also fail to achieve their desired results, which could harm our image in the marketplace. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no guarantee that the FDA or <span style="white-space:nowrap">non-U.S.</span> regulatory agencies will grant approval or clearance for our current or future products, including the Allurion Balloon. Failure to obtain regulatory approvals or clearances in the United States and other international jurisdictions, or revocation of approvals or clearances in those jurisdictions, will prevent us from marketing our products in such jurisdictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek regulatory approval or clearance of our current and future products in the United States and certain <span style="white-space:nowrap">non-U.S.</span> jurisdictions. We have obtained a CE Mark for the Allurion Balloon and are therefore authorized to sell in the EU; however, in order to market in regions such as the United States, the Asia Pacific region and many other jurisdictions, we must obtain separate regulatory approvals or clearances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The procedures for approval vary among countries and can involve additional clinical testing, and the time required to obtain approval or clearance may differ from that required to obtain the CE Mark or FDA approval. As a result of the United Kingdom leaving the EU, since January&#160;1, 2021, the regulatory framework and regimes for medical devices in the United Kingdom and the EU have diverged. In particular, a new UKCA Mark was introduced for medical devices placed on the Great Britain market (which includes England, Scotland and Wales), and Northern Ireland adopted a hybrid approach as a result of the divergence in accordance with the Northern Ireland Protocol. Of note, on June&#160;30, 2023, the UK Government introduced legislation, confirming that, subject to certain conditions, general medical devices compliant with the MDD with a valid declaration and CE mark can be placed on the Great Britain market up until the sooner of the expiry of the CE certificate or June&#160;30, 2028, and general medical devices compliant with the Medical Device Regulation (&#8220;MDR&#8221;) with a valid declaration and CE mark can be placed on the Great Britain market up until June&#160;30, 2030. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, clinical studies or manufacturing processes conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more international regulatory authorities does not ensure approval by regulatory authorities in other countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. An international regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not obtain regulatory approvals on a timely basis, if at all. We may not be able to submit for regulatory approvals or clearances and even if we submit we may not receive necessary approvals or clearances to commercialize our products in any market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval or clearance for the sale of a product, we may be required to conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our planned products in human patients. Preclinical studies and clinical trials can be expensive, difficult to design and implement, can take many years to complete, and are uncertain as to outcome. A failure of one or more of our trials could occur at any stage of testing. In connection with the initiation of a clinical trial in the U.S., we filed an investigational device exemption (&#8220;IDE&#8221;) application, which was approved by the FDA in 2016. After we conducted that trial and submitted a premarket approval (&#8220;PMA&#8221;) application to the FDA, in 2020, the FDA requested additional data. Therefore, we withdrew the PMA application and in 2021 submitted an IDE application for our AUDACITY trial, which the FDA approved in 2021. We are currently conducting that clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous unforeseen events during, or as a result of, preclinical and clinical trials could occur, which would delay or prevent our ability to receive regulatory approval or commercialize the Allurion Balloon or any of our future products, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preclinical studies and clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional studies or abandon product development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, or patients may drop out of these clinical studies at a higher rate than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of preclinical studies and clinical trials may be greater than we anticipate; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we might suspend or terminate clinical trials of our products for various reasons, including a finding that our products have unanticipated serious side effects or other unexpected characteristics, or that the trial subjects are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators may not approve our proposed clinical development plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or independent institutional review boards (&#8220;IRBs&#8221;) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or IRBs may require that we, or our investigators, suspend or terminate clinical studies for various reasons, including <span style="white-space:nowrap">non-compliance</span> with regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators in countries where our products are currently marketed may require that we suspend commercial distribution if there is <span style="white-space:nowrap">non-compliance</span> with regulatory requirements or safety concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supply or quality of our products or other materials necessary to conduct clinical studies of our products may be insufficient or inadequate; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the enactment of new regulatory requirements in the EU under the MDR effective since May&#160;26, 2021 may make approval times longer and standards more difficult to pass. In particular, manufacturers are required to: (i)&#160;assign a unique device identification (&#8220;UDI&#8221;) to a medical device before it is placed on the EU market in order to improve traceability of the medical device; and (ii)&#160;register themselves, the medical device and the UDI, among other things, with a new European medical device database. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any future collaboration or distribution partner are required to conduct additional clinical trials or other testing of the Allurion Balloon or any future products, those clinical studies or other testing may not be successfully completed. If the results of these studies or tests are not positive, or are only modestly positive or if they raise safety concerns, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed in obtaining marketing approvals for the Allurion Balloon or our future products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not obtain marketing approval at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications that are not as broad as desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have a product removed from the market after obtaining marketing approval; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to restrictions on how the product is distributed or used. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approvals or clearances in a jurisdiction, our products may be removed from the market due to a variety of factors, including adverse events, recalls, suspension of regulatory clearance to sell, or other factors. For example, on August&#160;6, 2024, we announced that ANSM has suspended sales of the Allurion Balloon in France, and we are withdrawing the Allurion Balloon from the French market, pending implementation of a remediation plan to reduce certain risks associated with the advertising, <span style="white-space:nowrap">follow-up</span> program, and adverse events for the Allurion Balloon. There is no guarantee that we will be able to successfully implement a remediation plan to the satisfaction of ANSM and we could be delayed or prevented from resuming sales of the Allurion Balloon in France. A withdrawal from the market in one country may have a negative effect on the regulatory approval process and ability to sell and commercialize the Allurion Balloon in other countries, and on the market acceptance of the Allurion Balloon in other countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we launched the Allurion Balloon commercially in January 2016 and have placed over 150,000 units to date in various countries outside the U.S., we do not have as much post-market surveillance data as our competitors and may not have clearly identified all possible or actual risks of our products. Furthermore, if our clinical trials do not produce patient data that compares favorably with products that are already on the market, health care providers and patients may opt not to use our products, and our business would suffer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays to our clinical trials or approvals. </p> <p style="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant clinical trial delays also could allow our competitors to bring products to market before we do, which would impair our ability to commercialize our products and harm our business and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Allurion Balloon is not currently approved for commercial sale in the United States. Obtaining such approval is costly and time consuming, and we may not obtain the regulatory approval required to sell our products in the U.S. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any future collaboration or distributor partner, can commercialize the Allurion Balloon in the U.S. without first obtaining regulatory approval from the FDA. Extensive preclinical and clinical testing is required to support FDA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA approval process is expensive and will take at least several years to complete, and FDA approval may never be obtained. We must also demonstrate that our manufacturing facilities, processes and controls are adequate to support FDA approval and that our clinical investigators complied with good clinical practices in the conduct of the Allurion Balloon clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has substantial discretion in the approval process. Despite the time and expense exerted, failure may occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials. The FDA can delay, limit, or deny approval of a product for many reasons, including, but not limited, to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a product may not be deemed to be safe and effective; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may not find the data from clinical trials and preclinical studies sufficient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the opportunity for bias in the clinical trials as a result of the open-label design may not be adequately handled and may cause our trial to fail; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may not approve suppliers&#8217; processes or facilities; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may change its approval policies or adopt new regulations. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Allurion Balloon or our future products fail to demonstrate safety and efficacy in further clinical trials that may be required for FDA approval, or do not gain regulatory approval, our business and results of operations will be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we expect that the initial FDA approval of the Allurion Balloon, if obtained, will be subject to a lengthy and expensive <span style="white-space:nowrap">follow-up</span> period, during which we must monitor patients enrolled in clinical studies and collect data on their safety outcomes. Even if FDA approval is obtained, the FDA has authority to impose post-market approval conditions, which can include (i)&#160;restrictions on the device&#8217;s sale, distribution, or use, (ii)&#160;continuing evaluation of the device&#8217;s safety and efficacy, (iii)&#160;additional warning/hazard labeling requirements, (iv)&#160;significant record management, (v)&#160;periodic reporting requirements, and (vi)&#160;any other requirements the FDA determines necessary to provide reasonable assurance of the device&#8217;s safety and effectiveness. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Completion of this <span style="white-space:nowrap">follow-up</span> trial, in a manner which results in data sufficient to maintain FDA approval, is subject to multiple risks, many of which are outside of our control. These include, but are not limited to, our ability to fund the ongoing trial from our operations or via additional fundraising; trial participants&#8217; willingness and ability to return for <span style="white-space:nowrap">follow-up</span> trial visits; and maintenance of a suitable trial database over a long period of time. Even if completed and appropriately evaluated, the trial <span style="white-space:nowrap">follow-up</span> may reveal safety or other issues that impact the approved labeling, or may result in withdrawal of the Allurion Balloon from the marketplace in the U.S. or elsewhere. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if clinical trials demonstrate acceptable safety and efficacy for the Allurion Balloon in some patient populations, the FDA or similar regulatory authorities outside the U.S. may not approve the marketing of the Allurion Balloon or may approve it with restrictions on the label, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible the FDA or similar regulatory authorities may not consider the results of our clinical trials to be sufficient for approval of the Allurion Balloon for our desired indications for use. Moreover, even if the FDA or other regulatory authorities approve the marketing of the Allurion Balloon, the approval may include additional restrictions on the label that could make the Allurion Balloon less attractive to health care providers and patients compared to other products that may be approved for broader indications, which could limit potential sales of the Allurion Balloon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to obtain FDA or other regulatory approval of the Allurion Balloon, or if the approval is narrower than what we seek, it could impair our ability to realize value from the Allurion Balloon, and therefore may have a material adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The results of preclinical studies and earlier clinical trials may not be predictive of the results of later preclinical studies and clinical trials, and the results of our current and future clinical trials may not satisfy the requirements of the FDA or other comparable regulatory authorities. If we cannot replicate the positive results from our preclinical studies or earlier clinical trials of the Allurion Balloon in our current or future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our current or future product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to demonstrate with sufficient valid scientific evidence through well-controlled clinical trials, that our product candidates are safe and effective for their intended uses before we can seek marketing approvals for their commercial sale. Positive results from our preclinical studies of the Allurion Balloon, and any positive results we may obtain from our early clinical trials of our current or future product candidates, may not necessarily be predictive of the results from subsequent preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies or any clinical trials of the Allurion Balloon according to our current development timeline, the positive results from such preclinical studies and clinical trials of the Allurion Balloon may not be replicated in subsequent preclinical studies or clinical trial results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, several of our past, planned and ongoing clinical trials utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. <span style="white-space:nowrap">Open-label</span> clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a sham procedure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies in the pharmaceutical, biotechnology and medical device industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain approval from the FDA or a comparable foreign regulatory authority. If we fail to produce positive results in our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
planned preclinical studies or clinical trials of the Allurion Balloon, the development timeline and regulatory approval and commercialization prospects for the Allurion Balloon, and, correspondingly, our business and financial prospects, would be materially adversely affected. Thus, even if the results from our initial research and preclinical activities appear positive, we do not know whether subsequent clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market the Allurion Balloon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Commercial success of the Allurion Balloon in the United States or elsewhere depends on our ability to accurately forecast customer demand and manufacture sufficient quantities of product that patients and health care providers request, and to manage inventory effectively. The failure to do so could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing of the Allurion Balloon requires capital expenditures and a highly-skilled workforce. There is a significant lead time to build and certify a new manufacturing facility. Although we believe our current facilities will give us adequate manufacturing capacity to meet demand for at least the next two years, we have, in the past, been unable to fill all incoming orders to meet growing demand. If we obtain FDA approval, we intend to rely on our existing manufacturing facilities to supply products in the U.S. If demand increases faster than we expect, or if we are unable to produce the quantity of goods that we expect with our current facilities, we may not be able to grow revenue at an optimal rate. There may be other negative effects from supply shortages, including loss of our reputation in the marketplace and a negative impact on our relationships with our distributors, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the other hand, if demand for our products declines, or if market supply surpasses demand, we may not be able to reduce manufacturing expenses or overhead costs proportionately. We have invested significantly in our manufacturing capacity. If an increase in supply outpaces the increase in market demand, or if demand decreases, the resulting oversupply could adversely impact our sales and result in the underutilization of our manufacturing capacity, higher inventory carrying costs and associated working capital, changes in revenue mix, and/or price erosion, any of which would lower our margins and adversely impact our financial results, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business depends on maintaining our brand, reputation, and ongoing demand for our products and services, and a significant reduction in sentiment or demand could affect our results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on awareness and the reputation of our brand, which depends on factors such as the safety and quality of our products, our communication activities, including marketing and education efforts, customer acquisition and retention strategies, and our management of our heath care provider and patient experience. Maintaining, promoting and positioning our brand is important to expanding our customer base. This will depend largely on the success of our education and marketing efforts and our ability to provide a consistent, high-quality experience to health care providers and patients. If we do not successfully continue our education and marketing efforts, particularly to health care systems and large institutions, or if existing users decrease their level of engagement, our revenue, financial results and business may be significantly harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A decrease in customer retention, growth or engagement with our products may have a material and adverse impact on our revenue, business, financial condition and results of operations. Any number of factors could negatively affect customer retention, growth and engagement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">customers increasingly engaging with competing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to maintain high quality products, including any failure to introduce new and improved products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to continue to develop or maintain applications for mobile devices that customers find engaging, that work with a variety of mobile operating systems and networks and that achieve a high level of market acceptance; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in customer sentiment about the safety, quality or usefulness of our products, including concerns related to privacy and data sharing, security or other factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to manage and prioritize information to ensure customers are presented with content that is engaging, useful and relevant to them; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse changes in our products that are mandated by legislation or regulatory agencies, both in the United States and internationally; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">technical or other problems preventing us from delivering products in a rapid and reliable manner or otherwise affecting the user experience. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to make substantial investments in the areas of education and marketing in order to maintain and enhance our brand and awareness of our products. Ineffective marketing, negative publicity, significant discounts by our competitors, product defects, serious adverse events and related liability litigation, failure to obtain regulatory approval or clearance for our products, counterfeit products, unfair labor practices and failure to protect our intellectual property rights are some of the potential threats to the strength of our business. We may need to make substantial expenditures to mitigate the impact of such threats. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that maintaining and enhancing awareness of our products and brand in the countries in which we currently sell our products and in new countries where we have limited awareness or brand recognition is important to expanding our customer base. As such, our growth will depend on the further development and commercialization of our current products, and marketing authorization of our future products. If we are unable to increase awareness of our products or enhance the strength of our brand in the countries in which we currently sell our products and in new countries in a timely manner, then our growth strategy could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Business and Industry </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The weight loss and obesity management industries are highly competitive. We also compete with companies that make weight loss drugs and other weight loss solutions outside the medical device industry, including compounded drugs. If our competitors are able to develop and market products that are safer, more effective, easier to use or more readily adopted by patients and health care providers, our commercial opportunities will be reduced or eliminated. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weight loss and obesity management industries are highly competitive, subject to rapid change and significantly affected by new product introductions, results of clinical research, corporate combinations, actions by regulatory bodies, changes by public and private payers and other factors relating to our industry. We compete both with companies that offer medical devices as a weight loss therapy as well as companies that make weight loss drugs and other weight loss solutions outside the medical device industry. Because of the market opportunity and the high growth potential of the <span style="white-space:nowrap">non-surgical</span> device market for weight loss and obesity, in particular recent pharmaceutical therapies known as <span style="white-space:nowrap">GLP-1s,</span> competitors and potential competitors have historically dedicated, and will continue to dedicate, significant resources to aggressively develop and commercialize their products. Any one of these factors could reduce the demand for our devices or services or require substantial resources and expenditures for research, design and development to avoid technological or market obsolescence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the U.S., we compete with a variety of local and regional competitive intragastric balloon manufacturers including SC MedSil, Medicone and Spatz Laboratories. In the U.S., there are three manufacturers with an intragastric balloon approved by the FDA at this time: Boston Scientific Corporation, ReShape Lifesciences, Inc. and Spatz FGIA Inc. All of these balloons require endoscopy and anesthesia for placement and/or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also compete against the manufacturers of pharmaceuticals that are directed at treating weight loss, such as NovoNordisk A/S, Eli Lilly&#160;&amp; Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, we launched AllurionMeds, a program which combines <span style="white-space:nowrap">GLP-1</span> drugs with our <span style="white-space:nowrap">AI-native</span> platform. AllurionMeds will compete against other branded <span style="white-space:nowrap">GLP-1</span> drugs and will face direct competition with those drugs and the existence of these products may limit the market size for AllurionMeds. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time, these or other competitors may introduce new or alternative products that compete directly or indirectly with our products and services. They may also develop and patent products and processes earlier than we can or obtain regulatory clearance or approvals before we are able to obtain required approvals, which could impair our ability to develop and commercialize similar products or services. If clinical outcomes of procedures performed with our competitors&#8217; products are, or are perceived to be, superior to the outcomes of treatments performed with our products, sales of our products could be negatively affected and our business, results of operations and financial condition could suffer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend on our ability to enhance our current products and technologies and develop or acquire and market new products and technologies to keep pace with technological developments and evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements or new devices that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely basis, may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, or their parent companies, have significantly greater financial and other resources than we do, as well as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">well-established reputations and name recognition with key opinion leaders and health care provider networks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an established base of long-time customers with strong brand loyalty; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">products supported by long-term data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">longer operating histories; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significantly larger installed bases and distributors and established distribution channels; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater existing market share in the obesity and weight management market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broader product offerings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater ability to cross-sell products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to offer rebates or bundle products to offer higher discounts or incentives; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more experience in conducting research and development, manufacturing, performing clinical trials and obtaining regulatory approvals or clearances. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We might have insufficient financial resources to improve existing devices, advance technologies, develop new devices, and market them at competitive prices. Technological advances by one or more competitors or future entrants into the field may result in our current devices becoming <span style="white-space:nowrap">non-competitive</span> or obsolete, which may decrease revenues and profits and adversely affect our business and results of operations. Competition with these companies could result in significant price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations. In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or products that could effectively compete with our existing and future products, which may cause our revenues to decline and harm our business. In addition, many of our competitors are well-established manufacturers with significant resources and may engage in aggressive marketing tactics. Competitors may also possess the ability to commercialize additional lines of products, bundle products or offer higher discounts and incentives to customers in order to gain a competitive advantage. If the prices of competing products are lowered as a result, we may not be able to compete effectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Continued international expansion of our business will expose us to business, regulatory, political, operational, financial and economic risks associated with doing business internationally. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Allurion Program products are registered to be sold in over 50 countries, and we operate subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia and Mexico. Our business strategy contemplates continued international expansion in key markets, including partnering with medical device distributors and introducing the Allurion Balloon and other products outside the U.S. The sale and shipment of our products internationally, as well as the purchase of components from international sources, subjects us to potential trade, export, import and customs, and economic sanctions regulations and laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <span style="white-space:nowrap">non-compliance.</span> Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export or import privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. Also, the failure to comply with applicable legal and regulatory obligations could result in the disruption of our shipping and sales activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, several of the countries in which we sell our products or conduct our operations are, to some degree, subject to political, economic or social instability. Doing business in other countries outside the U.S. involves a number of other risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with the free zone regime regulations under which the manufacturing sites operate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different regulatory requirements for device approvals in international markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, conflicting and changing laws and regulations such as tariffs and tax laws, export and import restrictions, employment laws, and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential failure by us or our distributors to obtain and/or maintain regulatory approvals for the sale or use of our products in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in managing global operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">logistics and regulations associated with shipping products, including infrastructure conditions and transportation delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limits on our ability to penetrate international markets if our distributors do not execute successfully; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governmental price controls, differing reimbursement regimes and other market regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced protection for intellectual property rights, or lack of them in certain jurisdictions, forcing more reliance on our trade secrets, if available; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">economic weakness, political and economic instability, including wars, terrorism and political unrest (such as attacks on commercial ships by Houthi rebels), outbreak of disease, boycotts, curtailment of trade and other business restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to comply with the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), including its books and records provisions and its anti-bribery provisions, by maintaining accurate information and control over sales activities and distributors&#8217; activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unexpected changes in tariffs, trade barriers and regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with tax, employment, immigration and labor laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">taxes, including withholding of payroll taxes; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">workforce uncertainty in countries where labor unrest is more common than in the U.S.; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business and shipping interruptions resulting from natural or other disasters including earthquakes, volcanic activity, hurricanes, floods and fires. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could harm our future international expansion and operations and, consequently, have an adverse effect on our financial condition, results of operations and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on a limited number of single source suppliers to manufacture our components, <span style="white-space:nowrap">sub-assemblies</span> and materials, which makes us vulnerable to supply shortages and price fluctuations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on single source suppliers for some of the components, <span style="white-space:nowrap">sub-assemblies</span> and materials for our products. These components, <span style="white-space:nowrap">sub-assemblies</span> and materials are critical and, for certain items, there are relatively few alternative sources of supply. These single source suppliers may be unwilling or unable to supply the necessary materials and components reliably and at the levels we anticipate or that are required by the market. We also have two suppliers with which we do not maintain a formal contractual relationship. We typically have at least a six-month supply of the materials provided by each of these suppliers but we cannot guarantee that we could find an alternative before our inventory ran out and therefore the loss of these relationships could cause a substantial disruption to our business. We would also have little to no recourse if one of these two suppliers became unwilling or unable to continue to supply materials. While our suppliers have generally met our demand for their products and services on a timely basis in the past, we cannot guarantee that they will in the future be able to meet our demand for their products, either because of an increase in the level of such demand, acts of nature, the nature of our agreements with those suppliers or our relative importance to them as a customer. Our suppliers may decide in the future to discontinue or reduce the level of business they conduct with us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not qualified or obtained necessary regulatory approvals for additional suppliers for some of these components, <span style="white-space:nowrap">sub-assemblies</span> and materials, but we do carry a significant inventory of these items ourselves. While we believe that alternative sources of supply or sterilization may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers or providers would be able to provide the quantity and quality of components, materials and sterilization that we would need to manufacture and ship our products if our existing suppliers and providers were unable to satisfy our requirements. To utilize other sources, we would need to identify and qualify new providers to our quality standards and obtain any additional regulatory approvals required to change providers, which could result in manufacturing delays and increase our expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our dependence on third parties subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of supply or sterilization resulting from modifications to, or discontinuation of, a third party&#8217;s operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in product shipments resulting from uncorrected defects, reliability issues or a third party&#8217;s failure to produce components or complete sterilizations that consistently meet our quality specifications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">price fluctuations due to a lack of long-term supply arrangements with our third parties for key components or sterilization requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain adequate supply or services in a timely manner or on commercially reasonable terms; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulty identifying and qualifying alternative third parties for the supply of components; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability of third parties to comply with applicable provisions of the FDA&#8217;s QSR, or other applicable laws or regulations enforced by the FDA, foreign and state regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to ensure the quality of products manufactured or sterilization conducted by third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production delays related to the evaluation and testing of products and services from alternative third parties and corresponding regulatory qualifications; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in delivery by our suppliers and service providers. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we require our third-party suppliers and providers to supply us with components and services that meet our specifications and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that these third parties will not always act consistently with our best interests, and may not always supply components or provide services that meet our requirements or in a timely manner. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Negative publicity, product defects and any resulting litigation concerning our products or our competitors&#8217; products could harm our reputation and reduce demand for the Allurion Balloon, either of which could negatively impact our financial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responses of potential patients, health care providers, the media, legislative and regulatory bodies and others to information about complications or alleged complications of our products, or products liability litigation against us or our competitors, could result in negative publicity and could materially reduce market acceptance of our products. These responses or any investigations and potential resulting negative publicity may have a material adverse effect on our business and reputation and negatively impact our financial condition, results of operations or the market price of our common stock. In addition, significant negative publicity could result in an increased number of product liability claims against us. On August&#160;6, 2024, the ANSM has suspended sales of the Allurion Balloon in France due to adverse events, and we withdrew the Allurion Balloon from the French market, pending implementation of a remediation plan. There is no guarantee that we will be able to successfully implement a remediation plan to the satisfaction of ANSM and we could be delayed or prevented from resuming sales of the Allurion Balloon in France. A withdrawal from the market in in France and the risks identified by ANSM could negatively affect the market acceptance of the Allurion Balloon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on our senior management team and the loss of one or more key employees or an inability to attract and retain highly skilled employees could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success largely depends upon the continued services of our executive management team and key employees and the loss of one or more of our executive officers or key employees could harm us and directly impact our financial results. Although we have entered into employment agreements with some of our executive officers and key employees, each of them may terminate their employment with us at any time. Changes in our executive management team resulting from the hiring or departure of executives could disrupt our business. For example, on November&#160;7, 2024, Christopher Geberth, our former Chief Financial Officer, notified us of his decision to resign effective as of November&#160;13, 2024, to pursue other interests. These types of changes in our management team could cause retention and morale concerns among current employees, as well as operational risks. In addition, our Chief Executive Officer, Shantanu Gaur, has been with us since inception and has been instrumental in building operational capabilities, raising capital and guiding product development and regulatory strategy. If Dr.&#160;Gaur was no longer working at our company, our industry credibility and operational capabilities would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To execute our growth plan, we must attract and retain highly qualified personnel. Competition for skilled personnel is intense, especially for engineers with high levels of experience in designing and developing medical devices and for sales executives. We have, from time to time, experienced, and we expect to continue to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience, difficulty in hiring and retaining employees with appropriate qualifications. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize medical devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies with which we compete for experienced personnel have greater resources than we have. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived value of our stock awards declines, either because we are a public company or otherwise, it may harm our ability to recruit and retain highly skilled employees. In addition, we invest significant time and expense in training our employees, which increases their value to competitors who may seek to recruit them. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may acquire other businesses or form joint ventures or make investments in other companies or technologies in the future. If we are not successful in integrating these businesses, as well as identifying and controlling risks associated with the past operations of these businesses, we may incur significant costs, receive penalties or other sanctions from various regulatory agencies, and/or incur significant diversions of management time and attention. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our business growth will be enhanced if we continually seek opportunities to enhance and broaden our product offerings. As part of our business strategy, we may pursue acquisitions or licenses of assets, or acquisitions of businesses. We also may pursue strategic alliances and joint ventures that leverage our core technology and industry experience to expand our product offerings or sales and distribution resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could have an adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company may also disrupt ongoing operations and require management resources that would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a negative effect on our results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, license, strategic alliance or joint venture. To finance such a transaction, we may choose to issue our common stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our common stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings, royalty or debt financings. Additional funds may not be available on terms that are favorable to us, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know whether we will be able to successfully integrate any acquired business, product or technology. The success of any given acquisition may depend on our ability to retain any key employees related thereto, and we may not be successful at retaining or integrating such key personnel. Integrating any business, product or technology we acquire could be expensive and time-consuming, disrupt our ongoing business, impact our liquidity, and/or distract our management. If we are unable to integrate any acquired businesses, products or technologies effectively, our business may suffer. Whether as a result of unsuccessful integration, unanticipated </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
costs, including those associated with assumed liabilities and indemnification obligations, negative accounting impact, or other factors, we may not realize the economic benefits we anticipate from acquisitions. In addition, any amortization or charges resulting from the costs of acquisitions could increase our expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If changes in the economy and/or consumer spending, consumer preference and other trends reduce consumer demand for our products, our sales and profitability would suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the risks arising from adverse changes in general economic and market conditions. Certain elective procedures, including those for weight loss, are typically not covered by insurance. Adverse changes in the economy may cause consumers to reassess their spending choices, which could have an adverse effect on consumer spending, reduce the demand for these procedures, and therefore have an adverse effect on our revenues. Furthermore, consumer preferences and trends may shift due to a variety of factors, including changes in demographic and social trends, public health initiatives and product innovations, which may reduce consumer demand for our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our overall performance depends, in part, on worldwide economic conditions. In recent quarters, we have observed increased economic uncertainty in the U.S. and abroad. Impacts of such economic weakness include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">falling overall demand for goods and services, leading to reduced profitability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced credit availability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">higher borrowing costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced liquidity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">volatility in credit, equity and foreign exchange markets; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">bankruptcies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These developments could lead to supply chain disruption, inflation, higher interest rates, and uncertainty about business continuity, which may adversely affect our business and our results of operations. As our customers react to global economic conditions and the potential for a global recession, we may see them reduce spending on our products and take additional precautionary measures to limit or delay expenditures and preserve capital and liquidity. Reductions in spending on our products, delays in purchasing decisions, failure to complete the Allurion Program, and inability to attract new customers, as well as pressure for extended billing terms or pricing discounts, would limit our ability to grow our business and negatively affect our operating results and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in our business and operations have placed, and may continue to place, significant demands on our management team and infrastructure. If we fail to manage these demands effectively, we may be unable to execute our business plan, maintain high levels of customer and patient satisfaction, or address competitive challenges adequately. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business, headcount, and operations have grown, in the United States and abroad, since our inception, and we anticipate operational changes in the future as we enhance our product development efforts and refine our marketing and distribution strategies. While we expect to continue to grow headcount and operations over the long-term, in January 2024 we announced a restructuring plan designed to more closely align our cost structure with near-term revenue expectations, improve our capital structure, and accelerate the path to profitability. The January 2024 plan anticipated a total reduction of approximately 30% of our global workforce as of December 2023. Additionally, on November&#160;6, 2024, the Board approved a restructuring plan to reduce operating costs and better align its workforce with the needs of our business. The majority of the November 2024 restructuring plan is expected to be completed in the fourth quarter of 2024. Under the November 2024 restructuring plan, we anticipate reducing our workforce by approximately 113 roles (approximately 50% of the total workforce). We may be unable to manage effectively the changes to the business and potential disruption occasioned by such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reductions. The implementation of our restructuring efforts, including the impact of a leaner organization, may result in delays in delivering our products and services, declines in customer and patient satisfaction, loss of customers, or difficulties in executing new strategies such as new sales and marketing strategies. We may experience employee attrition, decreased employee morale, and difficulty recruiting and retaining new employees in the future, all of which will require the time and attention of our management team. In addition, our ability to complete the restructuring plans and achieve the anticipated benefits from the plans within the expected time frame, or at all, are subject to successful execution of management&#8217;s estimates and assumptions and may vary materially from our expectations, including as a result of factors that are beyond our control. If we do not realize the expected benefits of the restructuring plans on a timely basis, or at all, our business, results of operations and financial condition could be adversely affected. Furthermore, following completion of the restructuring plans, our business may not be more efficient or flexible than prior to implementation. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reductions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, should demand for our products and services significantly increase, including as a result of regulatory approvals in the United States and elsewhere, we may need to increase the number of our employees and the scope of our operations, particularly in the areas of regulatory affairs and sales and marketing. We also intend, now and in the future, to continue to improve our operational, financial and management controls and reporting systems and procedures, which may require additional personnel and capital investments and will increase our costs. Such business growth could place a strain on our existing administrative and operational infrastructure, and we may not be able to make improvements to our personnel infrastructure in an efficient or timely manner, or at all. In addition, we may discover deficiencies in existing systems and controls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some new personnel likely would be operating in countries outside the jurisdiction of our corporate headquarters, which adds additional complexity, and may require us to expand our facilities. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Managing personnel across a global enterprise requires expertise and resources and places a strain on our management, administrative and financial infrastructure. Our failure to effectively manage change and accomplish any of these tasks could delay the execution of our business plans or disrupt our operations, and prevent us from growing successfully. We may also be exposed or subject to additional unforeseen or undisclosed liabilities as well as increased levels of indebtedness. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to substantial warranty or product liability claims or other litigation in the ordinary course of business that may adversely affect our business, financial condition and operating results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the sale of the Allurion Balloon and any products in clinical trials. The marketing, sale and use, misuse or <span style="white-space:nowrap">off-label</span> use of the Allurion Balloon and our other current and future products could lead to the filing of product liability claims against us if someone alleges that our products failed to perform as designed or caused significant adverse events in patients. We may also be subject to liability for a misunderstanding of, or inappropriate reliance upon, the information we provide. If we cannot successfully defend ourselves against claims that the Allurion Balloon or our other current or future products caused injuries, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for any products we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of patients from clinical trials or cancellation of trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant costs to defend the related litigation and distraction to our management team; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to plaintiffs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize any products that we may develop. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently hold $5.0&#160;million in product liability insurance coverage, which may not be adequate to cover all liabilities we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any future collaboration agreements (including with respect to product distribution or commercialization) we may enter into with respect to our current or future products may place the development or commercialization of such products outside our control, or may otherwise be on terms unfavorable to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into additional collaboration agreements with third parties with respect to our current or future products, including for distribution or commercialization in or outside the U.S. Our likely collaborators for any distribution, marketing, licensing or other collaboration arrangements include large and <span style="white-space:nowrap">mid-size</span> medical device and diagnostic companies, regional and national medical device and diagnostic companies, and distribution or group purchasing organizations. We will have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our products. Our ability to generate revenue from these arrangements will depend in part on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct certain components of our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which could interfere with or delay our ability to get regulatory approval or commercialize our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to perform various functions for our clinical trials. Our reliance on third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. We remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the International Council for Harmonization and the FDA require us to comply with standards, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of patients in clinical trials are protected. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, regulatory approvals for our planned products and will not be able to, or may be delayed in our efforts to, successfully commercialize our planned products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The failure of third parties to meet their contractual, regulatory, and other obligations could adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on suppliers, vendors, outsourcing partners, consultants, alliance partners and other third parties to research, develop, manufacture and commercialize our products and manage certain parts of our business. Using these third parties poses a number of risks, such as: (i)&#160;they may not perform to our standards or legal requirements; (ii)&#160;they may not produce reliable results; (iii)&#160;they may not perform in a timely manner; (iv)&#160;they may not maintain confidentiality of our proprietary information; (v)&#160;disputes may arise with respect to ownership of rights to technology developed with our partners; and (vi)&#160;disagreements could cause delays in, or termination of, the research, development or commercialization of our products or result in litigation or arbitration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, some third parties are located in markets subject to political and social risk, corruption, infrastructure problems and natural disasters, in addition to country-specific privacy and data security risk given current legal and regulatory environments. Failure of third parties to meet their contractual, regulatory, and other obligations may materially affect our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have significant exposure to the economic and political situations in emerging market countries, and developments in these countries could materially impact our financial results, or our business more generally. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the countries in which our products are sold are emerging markets. Our global growth strategy contemplates the expansion of our existing sales activities in Latin America, the Middle East, Africa and the Asia-Pacific region. Our exposure to emerging markets has increased in recent years, as have the number and importance of our distributor arrangements. Economic and political developments in the emerging markets, including economic crises, currency inflation, or political instability, have had in the past, and may have in the future, a material adverse effect on our financial condition and results of operations. Moreover, as these markets continue to grow, competitors may seek to enter these markets and existing market participants will likely try to aggressively protect or increase their market shares. Increased competition may result in price reductions, reduced margins and our inability to gain or hold market share, which could have an adverse effect on our financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Increasing scrutiny and changing expectations from investors with respect to our environmental, social and governance practices may impose additional costs on us or expose us to reputational or other risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors have increased their emphasis on the environmental, social and governance (&#8220;ESG&#8221;) practices of companies across all industries, including the environmental impact of operations and human capital management. Certain stockholders use third-party benchmarks or scores to measure a company&#8217;s ESG practices and decide whether to invest in its common stock or engage with the company to require changes to its practices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with investor expectations and standards, which are evolving and vary considerably, or the perception that we have not responded appropriately to the growing concern for ESG issues, could result in reputational harm to our business and could have an adverse effect on us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval process is expensive, time consuming and uncertain, and may prevent us from obtaining approvals for the commercialization of the Allurion Balloon or our planned products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of medical devices are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries, where regulations differ from country to country. Our products are registered to be sold in over 50 countries, but we are not permitted to market our products in the U.S. until we receive the requisite approval or clearance from the FDA; we have not received such FDA approval to date. In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning or untitled letters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">civil or criminal penalties and fines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension of any ongoing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">voluntary or mandatory product recalls and publicity requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal to accept or approve applications for marketing approval of new devices or supplements to approved applications filed by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on operations, including costly new manufacturing requirements; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seizure or detention of our products or import bans. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to receiving approval to commercialize any of our products in the U.S. or abroad, we may be required to demonstrate with substantial evidence from preclinical and well-controlled clinical trials, to the satisfaction of the FDA or other regulatory authorities abroad, that such products are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our products are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering any of our products to humans may produce undesirable side effects, which could interrupt, delay or cause suspension of clinical trials of our planned products and result in the FDA or other regulatory authorities denying approval of our products for any or all targeted indications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory approval from the FDA is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense exerted, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. For example, we previously conducted a clinical trial on the Allurion Balloon and submitted a PMA application based on data from that trial. When the FDA requested additional data, we withdrew the PMA application and sought FDA approval to conduct our AUDACITY trial, which the FDA granted in 2021. We are currently conducting that clinical trial. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product, the indication that the product is designed to address and the regulations applicable to any particular product. The FDA can delay, limit or deny approval of a planned product for many reasons, including, but not limited to, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a planned product or one or more of its features may not be deemed safe or effective; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may not find the data from preclinical studies and clinical trials sufficient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA might not approve our manufacturing or our third-party supplier&#8217;s processes or facilities; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA may change its approval policies or adopt new regulations. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Allurion Balloon or any of our other products fail to demonstrate safety and efficacy in preclinical studies and clinical trials or do not gain requisite regulatory approval, our business and results of operations will likely be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inadequate funding for the FDA, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which could adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Upon receipt of regulatory approval to market the Allurion Balloon in a given jurisdiction, we are (or will be) subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a regulatory approval is obtained, the approved product and its manufacturer are subject to continual review by regulatory authorities (including, if applicable, the FDA). Our <span style="white-space:nowrap">non-U.S.</span> regulatory approvals for the Allurion Balloon, as well as any future regulatory approval that we receive for the Allurion Balloon or for any of our other products, may be subject to limitations on the indicated uses for which the product may be marketed. Future approvals may contain requirements for potentially costly post-marketing <span style="white-space:nowrap">follow-up</span> trials to monitor the safety and efficacy of the approved product. In addition, we are subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities with regard to the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for our products. In addition, we are required to comply with regulations regarding the manufacture of the Allurion Balloon, which include requirements related to quality control and quality assurance as well as the corresponding maintenance of records and documentation. Further, regulatory authorities must inspect these manufacturing facilities and determine they are in compliance with FDA good manufacturing practice requirements as set forth in the QSR before the products can be approved. These facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the QSR and similar regulations. If we or a third party discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If patients using our products experience adverse events or other undesirable side effects, regulatory authorities could withdraw or modify our regulatory approvals, which would adversely affect our reputation and commercial prospects and/or result in other significant negative consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by the Allurion Balloon could cause us, the FDA or other applicable regulatory authorities to interrupt, delay or halt clinical trials, and could result in more restrictive labeling than originally required, cause the FDA or other regulatory authorities to subsequently withdraw or modify our PMA, if we obtain approval, or other regulatory approvals, or result in the delay or denial of regulatory approval by regulatory authorities. For example, we suspended sales of the Allurion Balloon in France following a request by the ANSM, due to, among other things, adverse events linked to gastrointestinal complications. In addition, in the 1980s and early 1990s, the FDA required post-market safety and efficacy data be collected on an earlier version of an intragastric balloon after patients suffered severe side effects and complications with the device, which ultimately resulted in the withdrawal of the PMA approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, we had sold over 150,000 units of the Allurion Balloon in international markets. In our commercial experience, the serious adverse event (&#8220;SAE&#8221;) rate has been less than 0.2% and has been similar to the SAE profile reported in the literature. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to demonstrate that any adverse events are not related to our product, the FDA or other regulatory authorities could order us to cease further development of, require more restrictive indications for use and/or additional warnings, precautions and/or contraindications in the labeling than originally required, or delay or deny approval of any of our products. Even if we are able to do so, such event(s) could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our products, the commercial prospects of such product may be harmed and our ability to generate product revenues from our product may be delayed or eliminated. Any of these occurrences may harm our ability to develop other products, and may harm our business, financial condition and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we or others may later identify undesirable side effects caused by the product (or any other similar product), resulting in potentially significant consequences, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw or limit their approval of the product; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, such as a contraindication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to correct or remove the product from the marketplace or decide to conduct a voluntary recall; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may decide to alert physicians through customer notifications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may use publicity such as a press release to alert our customers and the public of the issue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">health care providers and patients may be dissatisfied, seek refunds and refuse to use our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for injury caused to individuals using our product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the Allurion Balloon and could substantially increase the costs of commercializing our product and significantly impact our ability to successfully commercialize our product and generate product sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Health care reform measures could hinder or prevent our planned products&#8217; commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the health care system in ways that could affect our future revenue and future profitability and the future revenue and future profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation, that could result in significant changes to the health care system, some of which are intended to contain or reduce the costs of medical products and services. For example, one of the most significant health care reform measures in decades, ACA, was enacted in 2010. The ACA contains a number of provisions, including those governing enrollment in federal health care programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government health care programs and will result in the development of new programs. For more information, see section entitled &#8220;<span style="font-style:italic">Business - Government Regulation - Other U.S. Healthcare Laws - Coverage, Reimbursement and Healthcare Reform.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial and Congressional challenges to certain aspects of the ACA, as well as executive efforts to repeal or replace certain aspects of the ACA. The Tax Cuts and Jobs Act passed in 2017 included a provision that would repeal one of the primary pillars of the law, the ACA&#8217;s individual mandate penalty, which essentially assessed a monetary penalty or fine on certain individuals who fail to maintain qualifying health coverage for all or part of a year. The U.S. Congress may consider other legislation to repeal or replace elements of the ACA on a <span style="white-space:nowrap"><span style="white-space:nowrap">provision-by-provision</span></span> basis. We cannot assure you that the ACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to health care reform will affect our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the impact that such actions against the ACA or other health care reform under the Biden administration will have on our business, and there is uncertainty as to what health care programs and regulations may be implemented or changed at the federal and/or state level in the U.S., or the effect of any future legislation or regulation. However, it is possible that such initiatives could have an adverse effect on our ability to obtain approval and/or successfully commercialize products in the U.S. in the future. For example, any changes that reduce, or impede the ability to obtain, reimbursement for the type of products we intend to commercialize in the U.S. (or our products more specifically, if approved) or reduce medical procedure volumes could adversely affect our business plan to introduce our products in the U.S. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 and subsequent legislation resulted in reductions to Medicare payments </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to providers of up to 2% per fiscal year to 2031 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers, cancer centers and other treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether any additional legislative changes will affect our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of health care. The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from our products and product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop future product candidates. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the demand for our product(s) and product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to set a price that we believe is fair for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to generate revenue and achieve or maintain profitability; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of capital. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be adversely affected by a disruption to our contractual relationships for the provision of telehealth services. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate practice of medicine doctrine <span style="white-space:nowrap">prohibits&#160;non-licensed</span> individuals from practicing medicine, including by employing physicians or other licensed professionals to provide clinical services, directing the clinical practice of physicians and clinical professionals, or holding an ownership interest in an entity that employs or contracts with physicians and other licensed professionals. Certain jurisdictions also prohibit licensed professionals from splitting professional fees with <span style="white-space:nowrap">non-licensed</span> professionals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through our Virtual Care Suite platform, our customers gain access to one or more licensed health care providers for telehealth consultations. We contract with third parties who maintain a separate clinical environment through which customers can access telehealth consultations, and we contract with additional groups that employ or contract with licensed health care providers to deliver telehealth services and consultations in the same clinical environment (collectively, the &#8220;<span style="text-decoration:underline">Contracted Telehealth Groups</span>&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contractual arrangements are structured to comply with applicable law and to help ensure providers delivering telehealth services to our customers retain exclusive authority for the provision of telehealth services and exercise independent professional judgment in performing weight-loss consults, supervising nurse practitioners and physician assistants, and writing prescriptions for patients, as applicable. We cannot guarantee that government entities or courts would determine our approach is consistent with the corporate practice of medicine, fee splitting laws, or other laws governing the delivery of clinical services via telehealth. Furthermore, the foregoing laws, and the enforcement landscape, are subject to change based upon political, regulatory, and other influences. If our arrangements for the delivery of telehealth services on the platform are deemed to be unlawful, providers accessing our platform could be subject to penalties (e.g., fines or license suspension), which could discourage providers from entering arrangements with the Contracted Telehealth Groups and delivering services to our customers. Such enforcement actions could result in lawsuits by providers&#8212;against the Contracted Telehealth Groups or us&#8212;and could require us to restructure or terminate our arrangements with Contracted Telehealth Groups. These consequences, along with any other disputes that may arise with the Contracted Telehealth Groups related to the delivery of telehealth services to our customers, could impair our ability to offer telehealth services on our platform and materially affect our business, financial condition, and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our and the Contracted Telehealth Groups&#8217; activities are subject to laws governing the provision of telehealth services, which could be subject to changes that result in additional operational complexity or increase costs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Contracted Telehealth Groups and their providers are subject to laws governing the provision of telehealth services and the delivery of professional healthcare services more broadly. For example, some states limit the modality through which telehealth services are delivered, such as requiring synchronous (i.e. &#8220;live&#8221;) communication or curtailing asynchronous <span style="white-space:nowrap"><span style="white-space:nowrap">(or&#160;&#8220;store-and-forward&#8221;)&#160;communication</span></span> for certain telehealth services (e.g., prescribing certain types of medications). Although our contractual arrangements with the Contracted Telehealth Groups are structured to comply with laws governing the provision of telehealth services, these laws are evolving at a rapid pace and are subject to changing political, regulatory, and other influences. Due to the rapidly evolving regulatory climate, we cannot assure that our contractual arrangements and telehealth activities, if challenged, will be deemed compliant, nor can we assure that a new or existing law will not be implemented, enforced, or changed, with little or no notice, in manner that requires us to modify our business model at a material expense. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Evolving government regulations and enforcement activities may require increased costs or adversely affect our results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our contractual arrangements are structured to comply with all applicable material laws, but, due to the uncertain regulatory environment and enforcement discretion, government regulators or enforcement agencies may determine that we or our Contracted Telehealth Groups are in violation of their laws and regulations. If we must remedy such violations, we or the Contracted Telehealth Groups may be required to modify business operations and services in a manner that undermines our ability to retain or acquire new customers, or we&#8212;or our Contracted Telehealth Groups&#8212;may be subject to fines or other burdensome enforcement actions that may result in our termination of operations in certain jurisdictions. If so, our revenue may decline and our business, financial condition, and results of operations could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the laws applicable to our operations are subject to change or reinterpretation, and continued compliance may require us to change our practices at significant expense. Additional expenses may increase future overhead, which could have a material adverse effect on our results of operations. Additionally, modifications to our platform and the products, services and solutions we offer may require us to comply with additional laws and regulations, obtain necessary licenses or certifications, or materially alter our operations&#8212;any of which may require incurring significant expenses to ensure compliance. The failure to adequately comply with these future laws and regulations may delay or possibly prevent our products or services from being offered to customers, which could have a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to comply with laws applicable to the use, disclosure, and processing of personally identifiable information could result in significant liability or reputational harm and, in turn, a material adverse effect on our customers, providers, and revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of health information and other types of personal data or personally identifiable information (&#8220;PII&#8221;). We believe that, because of our current operations and the fact that we do not submit claims to third-party payors for reimbursement, we are not a covered entity or a business associate that acts on behalf of a covered entity under the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;). Nonetheless, numerous other federal, state, and foreign laws protect the confidentiality, privacy, availability, integrity and security of health information and other types of PII. These laws are subject to change or differing interpretations, and new laws regarding privacy, data protection, and information security may be enacted in the future. This complex and evolving landscape could expose us&#8212;and the Contracted Telehealth Groups and their providers&#8212;to additional expense, adverse publicity, and liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the collection, use, storage, disclosure, transfer, or other processing of personal data (including health data) (i) regarding individuals in the EEA or the UK, and/or (ii) carried out in the context of the activities </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our establishment in the EEA or the UK, is subject to the EU General Data Protection Regulation (&#8220;EU GDPR&#8221;), and the EU GDPR as it forms part of the laws of the United Kingdom post-Brexit (the &#8220;UK GDPR&#8221;, together with the EU GDPR referred to as &#8220;GDPR&#8221;), as well as other national data protection legislation in force in relevant Member States. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring consent of individuals in certain circumstances, additional disclosures to individuals, safeguards to protect the security and confidentiality of personal data, limiting retention periods for personal data, increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data, creating mandatory data breach notification requirements, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA or the UK, including the United States, and permits data protection authorities to impose large penalties, including potential fines of up to &#8364;20&#160;million (17.5&#160;million GBP) or 4% of annual global revenue, whichever is greater. The GDPR further provides individuals with various rights in respect of their personal data, including rights of access, erasure, portability, rectification, restriction and objection. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented data privacy and security measures, as well as consent practices, in an effort to comply with applicable laws and regulations relating to data privacy and security, some health information and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, and it is possible that laws, rules, and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit health information and other PII or confidential information to us. A finding of noncompliance could result in penalties, orders requiring modification to our data privacy and security practices, or criminal charges, which could adversely affect our business. Moreover, changes in these laws could result in substantial expenses or require us to materially change our operations in a manner adverse to our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a privacy policy available to customers that describes how we handle health information or other PII. Statements in our privacy policy could be subject to claims of deceptive practices by federal or state regulatory authorities or private parties, which could lead to significant legal expenses, divert our management&#8217;s attention from our operations, and seriously harm our business and our financial results. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations and policies that are applicable to us may limit customers&#8217; use and adoption of, and reduce the overall demand for, our platform. Any of the foregoing consequences could have a material adverse impact on our business and our financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be affected negatively by increased public scrutiny, regulatory enforcement, or changes in law with respect to online privacy and security. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Practices regarding the registration, collection, processing, storage, sharing, disclosure, use and security of personal and other information by companies offering online services like our platform have recently come under increased public scrutiny and regulatory enforcement. The regulatory landscape applicable to internet privacy and security is evolving rapidly and requires careful monitoring to remain in compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, comprehensive state privacy laws, such as the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which became effective on January&#160;1, 2020, and which, as of January&#160;1, 2023, was modified significantly by the California Privacy Rights Act require, among other things, requires covered companies to provide new disclosures to California consumers and afford such consumers new abilities to <span style="white-space:nowrap">opt-out</span> of certain sales of personal information. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how such laws are interpreted and the types of personal information that we handle. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar legislation has been proposed or adopted in many other states. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. There are also states that are specifically regulating health information. For example, Washington state recently passed a health privacy law that, as of June&#160;30, 2024, regulates the collection and sharing of health information. This law also has a private right of action, which further increases the relevant compliance risk collecting the health information of Washington residents. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states have passed laws that regulate biometric data specifically. These various privacy and security laws may impact our business activities, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we may likely become subject, if enacted. Aspects of these new and emerging state privacy laws and regulations, as well as their interpretation and enforcement, are dynamic and evolving. These laws and regulations each require particular assessment for compliance, and we may be required to modify our practices in an effort to comply with them, which may impact demand for our offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, the UK government has announced plans to reform the data protection legal framework in the UK in its Data Use and Access Bill. This lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of European personal information and our privacy and data security compliance programs and could require us to implement different compliance measures for the UK and the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there is a significant change to applicable laws, regulations, or industry standards or practices regarding the storage, use, or disclosure of data our customers or providers share with us, or regarding the manner in which the express or implied consent of customers or providers for such collection, analysis and disclosure is obtained., we may be required to modify the design of our websites, mobile applications, solutions, features, or our privacy policies, and we may be limited in our ability to develop new offerings, functionalities or features. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our AllurionMeds program offers patients access to compounded semaglutide. Compounded drugs, including compounded semaglutide, have been subject to increased scrutiny by FDA, state governmental agencies, and other third-parties, and may expose us to a variety of risks that could result in an adverse impact on our business or reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed and market a program, AllurionMeds, which offers patients access to compounded injectable semaglutide, a <span style="white-space:nowrap">GLP-1</span> prescription medication, that is prescribed by the patient&#8217;s practitioner. The compounded semaglutide is prepared by a third-party 503B outsourcing facility (&#8220;Semaglutide Compounding Facility&#8221;) and dispensed via a state-licensed pharmacy. 503B outsourcing facilities are regulated by the FDA and are required to comply with certain FDA requirements, including current good manufacturing practice requirements, product labeling requirements, restrictions on compounding drugs that are essentially a copy of an <span style="white-space:nowrap">FDA-approved</span> drug, and restrictions on compounding from bulk drug substances. 503B outsourcing facilities are also subject to analogous state laws and regulations. 503B outsourcing facilities have experienced both facility and product quality issues and have been subject to increased scrutiny by the FDA and state governmental agencies. If the Semaglutide Compounding Facility or any of its compounded products do not comply with applicable regulatory requirements or if there are quality issues with compounded semaglutide, FDA or state governmental agencies could pursue regulatory or enforcement action against the Semaglutide Compounding Facility, which could interrupt or halt the facility&#8217;s operations. Any such action could impact the ability of the Semaglutide Compounding Facility to supply compounded semaglutide, which could have an adverse effect on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our business. Additionally, if we are found to have manufactured, distributed, marketed, sold, or labeled any products in violation of applicable regulatory requirements, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. Certain 503B outsourcing facilities have been subject to negative media coverage, governmental inquiries and actions, and litigation in recent years, including with respect to compounded <span style="white-space:nowrap">GLP-1s.&#160;For</span> example, manufacturers of branded <span style="white-space:nowrap">GLP-1</span> medications have brought lawsuits against 503B outsourcing facilities offering compounded <span style="white-space:nowrap">GLP-1s</span> as well as the prescribers of such medications, including telehealth providers. Any negative media coverage, governmental inquiries or actions, or litigation against us or the Semaglutide Compounding Facility could have an adverse effect on our reputation or business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">503B outsourcing facilities are permitted to compound from bulk drug substances if the product appears on FDA&#8217;s drug shortage list.&#160;Semaglutide injection has been listed on the FDA drug shortage list since August 2022. If the shortage is resolved and semaglutide is removed from the FDA drug shortage list, 503B outsourcing facilities, including the Semaglutide Compounding Facility, will be restricted in their ability to compound semaglutide. Additionally, on October&#160;22, 2024, Novo Nordisk submitted a nomination for semaglutide to be included on FDA&#8217;s list of drug products that present demonstrable difficulties for compounding. If added to this list, 503B outsourcing facilities would be prohibited from producing compounded semaglutide, even if semaglutide is on the drug shortage list. If any of these events occurs, we cannot guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all, due to a variety of factors outside our control, including supply chain, intellectual property, regulatory and resource allocation matters. If our ability to offer these products is constrained in the future, supply may be limited, the price of these offerings may increase significantly, which could decrease new customer demand, cause existing customers to cancel their subscriptions, and reduce our revenues and/or gross profit, which could harm our brand, reputation, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with health care regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even though we do not and will not control referrals of health care services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state health care laws and regulations pertaining to fraud and abuse and patients&#8217; rights may be applicable to our business. If we are approved by the FDA to market our products in the U.S., we could be subject to health care fraud and abuse, transparency, and patient privacy regulation by both the federal government and the states in which we conduct our business. For more information, see section entitled &#8220;<span style="font-style:italic">Business - Government Regulation - Other U.S. Healthcare Laws</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar regulations would also apply to our business in countries where we have direct sales operations where there are different regulations at European and national levels. There is a high degree of complication in complying with the different levels of regulation and the singular differences in the different countries and markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in Medicare, Medicaid and other federal health care programs, additional reporting and government oversight, if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <span style="white-space:nowrap">non-compliance</span> with these laws and the curtailment or restructuring of our operations. Any such penalties or curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal, state or international privacy, security and fraud laws may prove costly. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained the authorization to distribute our products in regions/countries through the certification of our quality system by the corresponding regulatory entities. Failing to demonstrate that our quality system is in place and consistently and systematically ensures compliance with regulations from such regions/countries might imply losing the certifications and as such, the rights to freely distribute the products which would adversely impact our revenue and reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have not historically maintained a compliance policy relating to U.S. or foreign economic sanctions, export controls or anti-corruption laws and regulations, and failure to comply with these regimes creates the potential for significant liabilities, penalties and reputational harm. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not historically maintained a compliance policy relating to U.S. economic sanctions, export controls or anti-corruption laws and regulations. Failure to comply with such laws and regulations creates the potential for significant liabilities, penalties and reputational harm. We are subject to a number of laws and regulations governing commercial activities with and payments and contributions to third parties, including restrictions imposed by the FCPA, as well as trade sanctions and export control laws administered by the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control (&#8220;OFAC&#8221;), the U.S. Department of Commerce and the U.S. Department of State. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCPA, among other things, prohibits bribery of foreign governments and their officials and political parties and requires U.S. public companies to keep books and records that accurately and fairly reflect those companies&#8217; transactions. OFAC, the U.S. Department of Commerce and the U.S. Department of State administer and enforce various export control laws and regulations and economic sanctions based on U.S. foreign policy and national security goals against targeted foreign states, organizations and individuals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar laws in <span style="white-space:nowrap">non-U.S.</span> jurisdictions, such as UK sanctions, EU sanctions or the U.K. Bribery Act, as well as other applicable anti-bribery, anti-corruption, anti-money laundering, sanctions or export control laws, may also impose stricter or more onerous requirements than U.S. economic sanctions, export controls, and <span style="white-space:nowrap">anti-corruption</span> laws and regulations, and implementing compliance measures may disrupt our business or cause us to incur significantly more costs. Different laws may also contain conflicting provisions, making compliance more difficult. If we fail to comply with these laws and regulations, we could be exposed to claims for damages, civil or criminal financial penalties, reputational harm, incarceration of our employees, restrictions on our operations and other liabilities, which could materially and adversely affect our business, results of operations and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented policies and procedures designed to promote compliance by us and our personnel with the FCPA and other anti-corruption laws, they may not be effective in all instances to prevent violations. Any determination that we have violated the FCPA or other applicable anti-corruption, sanctions or export control laws could subject us to, among other things, civil and criminal penalties, material fines, profit disgorgement, injunctions on future conduct, securities litigation and a general loss of investor confidence, any one of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or <span style="white-space:nowrap">non-performance</span> by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events involving limited liquidity, defaults, <span style="white-space:nowrap">non-performance</span> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. On March&#160;10, March&#160;12, and May&#160;1, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank (&#8220;SVB&#8221;), Signature Bank, and First Republic Bank, respectively, after each bank was unable to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue its operations. We are unable to predict the extent or nature of the impacts of the failures of SVB, Signature Bank and First Republic Bank and related circumstances at this time. Similarly, we cannot predict the impact that the high market volatility and instability of the banking sector more broadly could have on economic activity and our business in particular. The failure of other banks and financial institutions and measures taken, or not taken, by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be affected by regulatory responses to climate-related issues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biden Administration has made climate change and the limitation of greenhouse gas (&#8220;GHG&#8221;) emissions one of its primary objectives. Several states and other geographic regions in the United States have also adopted legislation and regulations to reduce emissions of GHGs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;6, 2024, the SEC finalized new rules for public companies that will require extensive <span style="white-space:nowrap">climate-related</span> disclosures and significant analysis of the impact of climate-related issues on our business strategy, results of operations, and financial condition (the &#8220;SEC Climate Disclosure Rules&#8221;). The new rules will require us to disclose our material climate-related risks and opportunities, GHG emissions inventory, climate-related targets and goals, and financial impacts of physical and transition risks. As a result of the SEC Climate Disclosure Rules, our legal, accounting, and other compliance expenses may increase significantly, and compliance efforts may divert management time and attention. We may also be exposed to legal or regulatory action or claims as a result of these new regulations. All of these risks could have a material adverse effect on our business, financial position, and/or stock price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The medical device industry is characterized by patent litigation and we could become subject to adversarial proceedings or litigation that could be costly, result in the diversion of management&#8217;s time and efforts, result in a loss of our intellectual property, require us to pay damages or prevent us from marketing our existing or future products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent litigation and other adversarial proceedings are prevalent in the medical device and diagnostic sectors. Our commercial success depends in part upon our ability and that of our distributors, contract </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers, and suppliers to manufacture, market, and sell our planned products, and to use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights or intellectual property of third parties. We have been, and in the future may become, party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology. Third parties may assert infringement claims against us based on existing or future intellectual property rights, or may assert that our patents are invalid or unenforceable. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that we may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. Medical device and diagnostic industries have produced a significant number of patents and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts and administrative agencies, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that the relevant product or methods of using the product either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, and we may not have sufficient resources to bring these actions to a successful conclusion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third-party to continue developing and marketing our products and technology. We may also elect to enter into such a license in order to settle pending or threatened litigation. However, we may not be able to obtain any required license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us, and could require us to pay significant royalties and other fees. We could be forced, including by court order, to cease commercializing the infringing technology or product if we are found to infringe a third party&#8217;s intellectual property rights. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our planned products in commercially important territories, or force us to cease some of our business operations, which could harm our business. Many of our employees were previously employed at, and many of our current advisors and consultants are employed by, universities or other biotechnology, medical device or pharmaceutical companies, including our competitors or potential competitors. Although we instruct our employees, advisors and consultants not to, and otherwise endeavor to ensure that they do not, use or disclose the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, we may be subject to claims that we, or these service providers, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such service providers&#8217; current or former employer or other third party. These and other claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our business to the infringement claims discussed above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful in defending against intellectual property claims, litigation or other legal proceedings relating to such claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of litigation or other intellectual property related proceedings could have a material adverse effect on our ability to compete in the marketplace. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents or future patents. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations in our intellectual property agreements, we could lose intellectual property rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party, and expect to become party in the future, to certain intellectual property agreements that impose various obligations on us. If we fail to comply with these obligations, any licensor may have the right to terminate such agreements, in which event we may not be able to develop and market any product that is covered by such agreements. Termination of such agreements, or reduction or elimination of our rights under such agreements, may result in our having to negotiate new or reinstated arrangements on less favorable terms, or our not having sufficient intellectual property rights to operate our business. The occurrence of such events could harm our business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks described elsewhere in this prospectus pertaining to our intellectual property rights also apply to any intellectual property rights that we may license, and any failure by us or any future licensor to obtain, maintain, defend and enforce these rights could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are not able to obtain and maintain intellectual property protection for our products and technologies, or if the scope of our patents is not sufficiently broad, or our patents are invalidated, we may not be able to effectively maintain our market leading technology position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;29, 2024, we owned or had rights to 19 issued and five pending patents in the United States related to various aspects of the Allurion Balloon such as a swallowable, self-deflating and naturally passing gastric balloon, improvements to the fill and release valves therein, methods for deploying and releasing a gastric balloon within the body, and next generation fill and release valves. In addition, we had 39 issued and five patents pending outside of the United States. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and in other countries with respect to our proprietary technology and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of medical device and diagnostic companies generally is highly uncertain and involves complex legal and factual questions which are dependent upon the current legal and intellectual property context, extant legal precedent and interpretations of the law by individuals, and for which certain legal principles remain unresolved. In recent years, patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of the patent rights we rely on are highly uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Pending and future patent applications may not result in patents being issued at all, may not result in patents being issued in a manner which protect our technology or products, or may not result in patents being issued which effectively prevent others from </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercializing competitive technologies and products. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&#160;16, 2013, in the U.S., the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If third parties have filed prior patent applications on inventions claimed in our patents or applications that were filed on or before March&#160;15, 2013, an interference proceeding in the U.S. can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such prior applications after March&#160;15, 2013, a derivation proceeding in the U.S. can be initiated by such third parties to determine whether our invention was derived from theirs. The determination that a patent application or patent claim meets all the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO, or by a court or other trier of fact in the U.S., or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our owned (jointly or fully) or <span style="white-space:nowrap">licensed-in</span> patents or patent applications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that any invention that is the subject of our patent applications, whether <span style="white-space:nowrap">licensed-in</span> or owned jointly or completely by us, will be found to be patentable, including over our own prior art publications or patent literature, or any such that application will result in an issued patent. We cannot make assurances as to the scope of any claims that may issue from our pending and future patent applications or to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the U.S. or foreign jurisdictions. Any such challenge, if successful, could limit patent protection for our technology and products and/or materially harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the patent applications we rely on issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a <span style="white-space:nowrap">non-infringing</span> manner. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and the patents we rely on may be challenged in the courts or patent offices in the U.S. and abroad. There is no assurance that all the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be subject to a third-party submission of prior art to the USPTO or to other patent offices around the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alternately or additionally, we may become involved in post-grant review procedures, oppositions, derivation proceedings, ex parte <span style="white-space:nowrap">re-examinations,</span> inter partes review, supplemental examinations, or interference proceedings or challenges in district court, in the U.S. or in various foreign patent offices, including both national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to protect our business. Patents that may be issued or <span style="white-space:nowrap">in-licensed</span> may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage. An adverse determination in any such challenge may result in loss of the patent or in patent application or patent claims being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction of the scope of one or more claims of the patent or patent application, any of which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As another example, a European Unified Patent Court (&#8220;UPC&#8221;) has entered into force on June&#160;1, 2023. The UPC is a common patent court to hear patent infringement and revocation proceedings effective for member states of the European Union (&#8220;EU&#8221;). This could enable third parties to seek revocation of any of our European patents or <span style="white-space:nowrap">licensed-in</span> European patents in a single proceeding at the UPC rather than through multiple proceedings in each of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the jurisdictions in which any such European patent is validated. Any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce our European patents, whether owned or <span style="white-space:nowrap">licensed-in,</span> or defend the validity thereof. We, or any future licensor, may decide to opt out our European patents and patent applications from the UPC. If certain formalities and requirements are not met, however, these European patents and patent applications could be challenged for <span style="white-space:nowrap">non-compliance</span> and brought under the jurisdiction of the UPC. We cannot be certain that our owned (jointly or fully) or <span style="white-space:nowrap">licensed-in</span> European patents or European patent applications will avoid falling under the jurisdiction of the UPC, if we, or any future licensor, decide to opt out of the UPC. Our competitors, who may have greater resources and may have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our technologies and products. Given the amount of time required for the development, testing and regulatory review of new planned products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of the patents we rely on or narrow the scope of our patent protection. The laws of other countries may not protect our rights to the same extent as the laws of the U.S. For example, patent laws in various jurisdictions, including jurisdictions covering significant commercial markets, such as the European Patent Office, China and Japan, restrict the patentability of methods of treatment of the human body more than U.S. law does. Our inability to protect our innovations could have a material adverse effect on our ability to generate revenue. There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns. Countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing products. Countries other than the U.S. may, under certain circumstances, force us to grant a license under our patents to a competitor, thus allowing the competitor to compete with us in that jurisdiction or forcing us to lower the price of our product in that jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s) claims will have sufficient scope to protect all of our planned products, provide us with commercially viable patent protection or provide us with any competitive advantages; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if our pending applications issue as patents, they may be challenged by third parties as invalid or unenforceable under U.S. or foreign laws; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not successfully commercialize all of our planned products, if approved, before our relevant patents expire; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not be the first to make the inventions covered by each of our patents and pending patent applications; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies or products that are separately patentable. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that we are unable to obtain and maintain patent protection for our technologies or product, or in the event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of any future products. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, tradenames and brand names to distinguish our products from the products of our competitors, and have registered or applied to register these trademarks. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources towards advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or <span style="white-space:nowrap">know-how,</span> or are in breach of <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreements with our competitors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, <span style="white-space:nowrap">non-disclosure</span> and <span style="white-space:nowrap">non-competition</span> agreements in connection with such employment. Although we instruct our employees and consultants not to, and otherwise endeavor to ensure that they do not, use or disclose the intellectual property, proprietary information, <span style="white-space:nowrap">know-how</span> or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information of such employers or competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or essential to our products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our products. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our products, which could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose us to litigation and have a significant adverse effect on our prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Determinations of inventorship can be subjective. While we undertake to accurately identify correct inventorship of inventions made on our behalf by our employees, consultants and contractors, an employee, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consultant or contractor may disagree with our determination of inventorship and assert a claim of inventorship. Any disagreement over inventorship could result in our being forced to defend our determination of inventorship in a legal action, which could result in substantial costs and be a distraction to our senior management and scientific personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we typically require employees, consultants and contractors who may develop intellectual property on our behalf to execute agreements assigning such intellectual property to us, we may be unsuccessful in obtaining execution of assignment agreements with each party who in fact develops intellectual property that we regard as our own. If we are unsuccessful in obtaining assignment agreements from an employee, consultant or contractor who develops intellectual property on our behalf, the employee, consultant or contractor may later claim ownership of the invention. Any disagreement over ownership of intellectual property could result in our losing ownership, or exclusive ownership, of the contested intellectual property, paying monetary damages and/ or being enjoined from clinical testing, manufacturing and marketing of the affected product candidate(s). Even if we are successful in defending against such claims, a dispute could result in substantial costs and be a distraction to our senior management and scientific personnel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in legal proceedings to protect or enforce our intellectual property rights, which could be expensive, time consuming, or unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate the patents we rely on, or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims that we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property rights, or that our intellectual property rights are invalid. In an infringement proceeding, a court may decide that a patent we are asserting is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the patents we are asserting do not cover the technology in question. With respect to a counterclaim of invalidity, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. An adverse result in any litigation proceeding could put one or more patents at risk of being invalidated or interpreted narrowly, or prevent us from stopping the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. If any of our patents are found invalid or unenforceable, or construed narrowly, our ability to stop the other party from launching a competitive product would be materially impaired. Further, such adverse outcomes could limit our ability to assert those patents against future competitors. Loss of patent protection would have a material adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement of any of our patents by a competitive product, a court may decide not to grant an injunction against further infringing activity, thus allowing the competitive product to continue to be marketed by the competitor. It is difficult to obtain an injunction in U.S. litigation and a court could decide that the competitor should instead pay us a &#8220;reasonable royalty&#8221; as determined by the court, and/or other monetary damages. A reasonable royalty or other monetary damages may or may not be an adequate remedy. Loss of exclusivity and/or competition from a related product would have a material adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation often involves significant amounts of public disclosures. Such disclosures could have a materially adverse impact on our competitive position or our stock prices. During any litigation, we would be required to produce voluminous records related to our patents and our research and development activities in a process called discovery. The discovery process may result in the disclosure of some of our confidential information. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation is inherently expensive, and the outcome is often uncertain. Any litigation likely would substantially increase our operating losses and reduce our resources available for development activities. Further, we may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. As a result, we may conclude that even if a competitor is infringing any of our patents, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of us or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <span style="white-space:nowrap">non-litigious</span> action or solution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with an infringement litigation, third parties may also be able to challenge the validity of our patents before administrative bodies in the U.S. or abroad. Such mechanisms include <span style="white-space:nowrap">re-examination,</span> post grant review and equivalent proceedings in foreign jurisdictions, e.g., opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our products, potentially negatively impacting any concurrent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference or derivation proceedings provoked by third parties or brought by the USPTO or any other patent authority may be necessary to determine the priority of inventions or other matters of inventorship with respect to patents and patent applications. In addition to challenges during litigation, third parties can challenge the validity of our patents in the U.S. using post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent filed March&#160;16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to March&#160;16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with an effective filing date of March&#160;16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas inter partes review proceedings can only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we or any future licensors or collaborators will be successful in defending the patent, which may result in a loss of the challenged patent right to us. We may become involved in proceedings, including oppositions, interferences, derivation proceedings inter partes reviews, patent nullification proceedings, or <span style="white-space:nowrap">re-examinations,</span> challenging our patent rights or the patent rights of others, and the outcome of any such proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, important patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Our business also could be harmed if a prevailing party does not offer us a license on commercially reasonable terms, if any license is offered at all. Litigation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may also become involved in disputes with others regarding the ownership of intellectual property rights. If we are unable to resolve these disputes, we could lose valuable intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical or management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the market price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, harming our business and competitive position. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our patented technology and products, we rely upon confidential proprietary information, including trade secrets, unpatented <span style="white-space:nowrap">know-how,</span> technology and other proprietary information, to develop and maintain our competitive position. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in the market. Although we have taken steps to protect our confidential proprietary information, in part, by confidentiality agreements with our employees and our collaborators, consultants, vendors and advisors, we cannot provide assurances that all such agreements have been duly executed. Third parties may still obtain this information or may come upon this or similar information independently, and we cannot be certain that our trade secrets and other confidential information will not be disclosed or that competitors will not otherwise gain access to our trade secrets, or that technology relevant to our business will not be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees, consultants, collaborators, vendors or advisors that are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could be disclosed, misappropriated or otherwise become known or be independently discovered by our competitors. In addition, intellectual property laws in foreign countries may not protect trade secrets and confidential information to the same extent as the laws of the U.S. If we are unable to prevent disclosure of the intellectual property related to our technologies to third parties, we may not be able to establish or maintain a competitive advantage in our market, which would harm our ability to protect our rights and have an adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect or enforce our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on all of our planned products throughout the world may be prohibitively expensive to us. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, laws of some countries outside of the U.S. and Europe do not afford intellectual property protection to the same extent as the laws of the U.S. and Europe. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the U.S. and Europe or from selling or importing products made from our inventions in and into the U.S. or other jurisdictions. Consequently, competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the U.S. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in international jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Further, such proceedings could put our patents (in that or other jurisdictions) at risk of being invalidated, held unenforceable or interpreted narrowly; put our pending patent applications at risk of not issuing; and provoke third parties to assert claims </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, we cannot ensure that we will be able to initiate or maintain the same level or quality of patent protection in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the U.S., the U.S. Congress is responsible for passing laws establishing patentability standards, and, as with any laws, implementation is left to federal agencies and the federal courts based on their interpretations of the laws. In the U.S., interpretation of patent standards can vary significantly within the USPTO, and across the various federal courts, including the U.S. Supreme Court. Recently, the U.S. Supreme Court has ruled on several patent cases, generally limiting the types of inventions that can be patented. Further, there are open questions regarding interpretation of patentability standards that the U.S. Supreme Court has yet to decisively address. Absent clear guidance from the U.S. Supreme Court, the USPTO has become increasingly conservative in its interpretation of patent laws and standards. Similar tensions between government administrations and judicial interpretation of patent laws in other jurisdictions may resulting in changes to the scope or validity of our patents in such jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to increasing uncertainty with regard to our ability to obtain patents in the future, the legal landscape in the U.S. and outside the U.S. has created uncertainty with respect to the value of patents. Depending on any actions by applicable legislating bodies, and future decisions by the entities implementing such laws, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents or applications will be due to be paid by us to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents or applications. The USPTO and various <span style="white-space:nowrap">non-U.S.</span> governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. Though we use commercially reasonable efforts to comply with all applicable maintenance requirements, we may fail to do so on occasion. In many cases, such an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <span style="white-space:nowrap">non-compliance,</span> whether intentional or not, can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to use our technologies and this circumstance would have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to acquire or license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third party may hold intellectual property, including patent rights, that we may determine are important or necessary to the development of our technology and products. In addition, it may be necessary for us to use the patented or proprietary technology of one or more third parties to commercialize our current and future products. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we determine to license or acquire third-party intellectual property and we are unable to acquire such intellectual property outright, or obtain licenses to such intellectual property from such third parties when needed or on commercially reasonable terms, our ability to commercialize our products at such time would likely be delayed or we may have to abandon development of that product or program and our business and financial condition could suffer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we <span style="white-space:nowrap">in-license</span> additional technologies or products in the future, we might become dependent on proprietary rights from third parties with respect to those technologies or products. Any termination of such licenses could result in the loss of significant rights and would cause material adverse harm to our ability to develop and commercialize any product subject to such licenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and any future licensors regarding intellectual property subject to a license agreement. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product(s). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we may determine to <span style="white-space:nowrap">in-license,</span> and any failure by us or any future licensors to obtain, maintain, defend and enforce such rights could have an adverse effect on our business. In some cases we may not have control over the prosecution, maintenance or enforcement of the patents that we determine to license, and may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and potential future licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Allurion VCS and other products or services contain third-party open source software components. Certain use of such open source components with our proprietary software could adversely affect our ability to charge fees for, or otherwise protect the value of, our offerings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion VCS and our other products and services contain software licensed to us by third-party authors under &#8220;open source&#8221; licenses. Use of such software may entail greater risks than use of <span style="white-space:nowrap">non-open</span> source <span style="white-space:nowrap">third-party</span> commercial software, as open source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. Although we seek to monitor our use of open source software to avoid such consequences and to comply with the terms thereof, the terms of many open source licenses have not been interpreted by U.S. or foreign courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to provide or distribute our platform. If we are held to have breached the terms of an open source software license, we could face liability which may result in an injunction against providing our offering, or be required to seek costly licenses from third parties to continue providing our offerings on terms that are not economically feasible, to <span style="white-space:nowrap">re-engineer</span> our platform, to discontinue or delay the provision of our offerings if <span style="white-space:nowrap">re-engineering</span> could not be accomplished on a timely basis or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those used by third parties which we rely on, may fail or suffer security breaches. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems, or those used by third parties which we rely on, are vulnerable to damage from computer viruses and unauthorized access, malware, natural disasters, fire, terrorism, war, telecommunication failures, electrical failures, cyber-attacks or <span style="white-space:nowrap">cyber-intrusions</span> over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. Although our information security program is in compliance with the global ISO 27001:2013 standards, it does not yet fully comply with all of the additions and changes in the updated ISO 27001:2022 version of the standards, which we anticipate complying with prior to the required transition date of October&#160;31, 2025 to maintain ISO 27001 security certification. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our security measures are breached, whether due to failure to comply with the ISO 27001:2022 version of the standards or otherwise, or if design flaws in our software or information systems are exposed and exploited, and, as a result, a third party obtains unauthorized access to any of our or our customer&#8217;s data, our relationships with our customers and distributors may be damaged, and we could incur significant liability and reputational harm. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. While we have not experienced any such material system failure or security breach to our knowledge to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of data from completed, ongoing or future trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our current and future products could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on internet infrastructure, bandwidth providers, third-party computer hardware and software and other third parties for providing services to our customers and patients, and any failure or interruption in the services provided by these third parties could expose us to litigation and negatively impact our relationships with customers and patients, adversely affecting our operating results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to deliver our internet-based services depends on the development and maintenance of the infrastructure of the internet by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity, bandwidth capacity and security. Our services are designed to operate without interruption. However, we may experience future interruptions and delays in services and availability from time to time. In the event of a catastrophic event with respect to one or more of our systems, we may experience an extended period of system unavailability, which could negatively impact our relationship with clients and members. To operate without interruption, both we and our service providers must guard against: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">damage from fire, power loss, natural disasters and other force of nature events outside our control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">communications failures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">software and hardware errors, failures, and crashes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">security breaches, computer viruses, hacking, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks, and similar disruptive problems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other potential interruptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely on software licensed from third parties in order to offer our services. These licenses are generally commercially available on varying terms. However, it is possible that this software may not continue to be available on commercially reasonable terms, or at all. Any loss of the right to use any of this software could result in delays in the provisioning of our services until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated. Furthermore, our use of additional or alternative third-party software would require us to enter into license agreements with third parties, and integration of our software with new third-party software may require significant work and require substantial investment of our time and resources. Also, any undetected errors or defects in third-party software could prevent the deployment or impair the functionality of our software, delay new updates or enhancements to our platform, result in a failure of our platform, and injure our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to adequately protect personal information in compliance with evolving legal requirements could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information and personally identifiable information. We collect this kind of information on our customers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for purposes of servicing potential warranty claims and for post-marketing safety vigilance. Data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of state, federal and international laws protecting the privacy and security of health information and personal data. As part of the American Recovery and Reinvestment Act 2009 (&#8220;ARRA&#8221;), the U.S. Congress amended the privacy and security provisions of HIPAA. HIPAA imposes limitations on the use and disclosure of an individual&#8217;s protected health information by certain health care providers, health care clearinghouses, and health insurance plans, collectively referred to as covered entities, that involve the creation, use, maintenance or disclosure of protected health information. The HIPAA amendments also impose compliance obligations and corresponding penalties for <span style="white-space:nowrap">non-compliance</span> on individuals and entities that provide services to health care providers and other covered entities, collectively referred to as business associates. Most recently, on December&#160;10, 2020, HHS issued a Notice of Proposed Rulemaking (the public comment period to which was further extended in March 2021) which, if finalized, would make changes to some of HIPAA&#8217;s regulatory requirements, which would impact us, to the extent we are a business associate. ARRA also significantly increased the penalties for improper use or disclosure of an individual&#8217;s protected health information under HIPAA and extended enforcement authority to state attorneys general. The amendments also create notification requirements for individuals whose protected health information has been inappropriately accessed or disclosed, notification requirements to federal regulators and in some cases, notification to local and national media. Notification is not required under HIPAA if the health information that is improperly used or disclosed is deemed secured in accordance with encryption or other standards developed by HHS. Most states have laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the protected health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure ongoing protection of personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&#160;5(a) of the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many foreign countries and governmental bodies, including the EU, Canada, Australia and other relevant jurisdictions, have laws and regulations concerning the collection and use of personal or sensitive data obtained from their residents or by businesses operating within their jurisdiction. For example, the European Commission adopted the General Data Protection Regulation (&#8220;GDPR&#8221;), effective on May&#160;25, 2018, that supersedes previous EU data protection legislation, imposes more stringent EU data protection requirements and provides for greater penalties for <span style="white-space:nowrap">non-compliance.</span> The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in connection with the offering goods or services to individuals in the EU or the monitoring of their behavior. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, following the United Kingdom&#8217;s exit from the EU on January&#160;31, 2020, the GDPR ceased to apply in the United Kingdom at the end of the transition period on December&#160;31, 2020. However, as of January&#160;1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into United Kingdom law (referred to as the UK GDPR). The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. In this prospectus, &#8220;GDPR&#8221; refers to both the EU and the UK GDPR, unless specified otherwise. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breach notification requirements and onerous new obligations on services providers. <span style="white-space:nowrap">Non-compliance</span> with the GDPR can trigger steep fines of up to &#8364;20&#160;million (&#163;17.5 million) or 4% of total worldwide annual revenues, whichever is higher. Given the breadth and depth of changes in data protection obligations, meeting the GDPR&#8217;s requirements requires time, resources and a review of the technology and systems currently in use against the GDPR&#8217;s requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EU Member States have adopted national laws to implement the EU GDPR, which may partially deviate from the EU GDPR, and the competent authorities in the EU Member States may interpret GDPR obligations slightly differently from country to country, such that we do not expect to operate in a uniform legal landscape in the EU with respect to data protection laws. In addition, the UK has announced plans to reform the UK data protection regime. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR imposes strict rules on the transfer of personal data out of the European Economic Area (&#8220;EEA&#8221;), or the United Kingdom to third countries, including the U.S. On June&#160;4, 2021, the European Commission issued new forms of standard contractual clauses for data transfers from controllers or processors in the EEA, or otherwise subject to the GDPR, to controllers or processors established outside the EEA, and not subject to the GDPR. The new forms of standard contractual clauses have replaced the standard contractual clauses that were adopted previously under the Data Protection Directive. The UK is not subject to the European Commission&#8217;s new standard contractual clauses but has published its own transfer mechanism, the International Data Transfer Agreement, which enables transfers from the UK. We will be required to transition to the new forms of standard contractual clauses and doing so will require significant effort and cost. Although the United Kingdom is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the United Kingdom as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EEA to the United Kingdom remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the United Kingdom to countries not regarded by the United Kingdom as providing adequate protection. The United Kingdom government has confirmed that personal data transfers from the United Kingdom to the EEA remain free flowing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be at risk of enforcement actions taken by certain EU or UK data protection authorities until such point in time that we may be able to ensure that all transfers of personal data to us from the EEA or the United Kingdom are conducted in compliance with all applicable regulatory obligations, the guidance of data protection authorities and evolving best practices. We may find it necessary to establish systems to maintain personal data originating from the EU/UK in the EEA or the United Kingdom (as applicable), which may involve substantial expense and may cause us to need to divert resources from other aspects of our business, all of which may adversely affect our business. Our failure to comply with applicable laws and regulations, or to protect such data, could result in enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by <span style="white-space:nowrap">end-customers</span> and other affected individuals, damage to our reputation and loss of goodwill, any of which could harm on our operations, financial performance, and business. Evolving and changing definitions of personal data and personal information, within the European Union, the United Kingdom, the U.S., and elsewhere, may limit or inhibit our ability to operate or expand our business, including limiting strategic partnerships that may involve the sharing of data. Moreover, if the relevant laws and regulations change, or are interpreted and applied in a manner that is inconsistent with our data practices or the operation of our products, we may need to expend resources in order to change our business operations, data practices, or the manner in which our products operate. Even the perception of privacy concerns, whether or not valid, may harm our reputation and inhibit adoption of our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is the risk that the limits we obtained for our cyber liability insurance may not cover the total loss experienced in the event of a data security incident, including the financial loss, legal costs, and business and reputational harm, particularly if there is an interruption to our systems. Additionally, there is the risk of a data privacy or security incident by an employee, which may expose us to liability. If personal information of our customers or employees is misappropriated, our reputation with our customers and employees may be injured resulting in loss of business and/or morale, and we may incur costs to remediate possible injury to our customers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and employees or be required to pay fines or take other action with respect to judicial or regulatory actions arising out of such incidents. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are not able to satisfy data protection, security, privacy, and other government- and industry-specific requirements, our business could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of data protection, security, privacy and other <span style="white-space:nowrap">government-and</span> industry-specific requirements, including those that require companies to notify individuals of data security incidents involving certain types of personal data. Security compromises experienced by other companies, by our customers or by us may lead to public disclosures, which could harm our reputation, erode customer confidence in the effectiveness of our security measures, and negatively impact our other products and our ability to attract new customers. As we expand into new regions, we will need to comply with new requirements. If we cannot comply or if we incur a violation in one or more of these requirements, our growth could be adversely impacted, and we could incur significant liability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incorporated, and plan to incorporate in the future, artificial intelligence, or AI, into some of our products. This technology is new and developing and may present risks that could affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incorporated, and plan to incorporate in the future, AI, including large language models (such as GPT), machine learning, and predictive analytics into our products under a platform which we call Allurion Iris. Coach Iris is part of the Allurion Iris AI platform, which leverages large learning models to help patients during their weight loss journey by providing 24/7 virtual coaching. AI is a new and emerging technology that is in its early stages of commercial use, particularly within the medical device industry. If any of our products that incorporate AI have perceived or actual negative impacts on the clinicians or patients who use them, we may experience brand or reputational harm, competitive harm or legal liability. The rapid evolution of AI may also require the application of significant resources to develop, test and maintain our products and services that incorporate AI in order to help ensure that it is implemented in a socially responsible manner, to minimize any real or perceived unintended harmful impacts. In addition, AI is subject to a complex and evolving regulatory landscape, including data protection, privacy, and potentially other laws and different jurisdictions have taken and may take in the future varying approaches to regulating AI. Compliance with these laws and regulations can be complex, costly and time-consuming, and there is a risk of regulatory enforcement actions or litigation if we fail to comply with these requirements. As regulations evolve, we may have to alter our business practices or products in order to comply with regulatory requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred net operating losses in the past and expect to incur net operating losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net operating losses since our inception, and we continue to incur significant research and development, general and administrative, and sales and marketing expenses related to our operations. We do not expect to be profitable in 2024, and in future years we expect to incur significant sales and marketing expenses to expand our business and clinical research expenses related to, among other things, the AUDACITY trial for the Allurion Balloon in the U.S. Investment in medical device product development, particularly clinical trials, is highly speculative. It entails substantial upfront capital expenditures and significant risk that any potential planned product will fail to demonstrate adequate safety or effectiveness. We expect to generate significant operating losses for the foreseeable future. As of September&#160;30, 2024 and December&#160;31, 2023, we had an accumulated deficit of $218.4&#160;million and $212.8&#160;million, respectively. Based on our recurring losses and expectations to incur significant expenses and negative cash flow for the foreseeable future, the need to raise additional capital to finance our future operations, we have concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the consolidated financial statements for the quarter ended September&#160;30, 2024 are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our future financial results will depend primarily on our success in launching, selling and supporting the Allurion Balloon and other products that are part of our weight loss platform. This will require us </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be successful in a range of activities, including manufacturing, marketing, and selling the Allurion Balloon. We may not succeed in these activities and may never generate revenue that is sufficient to be profitable in the future. Even if we are profitable, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, diversify our planned products, market our current and future products, or continue our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, we issued an aggregate principal amount of $48&#160;million of Notes due April&#160;16, 2031. The interest rate is fixed at 6.00% per annum and is payable quarterly in cash or, at our option, in kind for the first three years. In addition, upon consummation of the Business Combination, we received an investment of $40&#160;million from RTW in exchange for future royalty payments pursuant to the Revenue Interest Financing; we are also required to make royalty payments on an additional $7.5&#160;million under the Additional RIFA. We may also incur additional indebtedness to meet future financing needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to make scheduled payments of debt principal and interest on our existing or future indebtedness, or to refinance our indebtedness, and to pay our royalty obligations, depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our debt, including the Amended Note Purchase Agreement, contains certain financial covenants relating to minimum liquidity and minimum revenue requirements. We have received waivers of minimum liquidity and minimum revenue requirements under debt arrangements in the past, and there is no guarantee that we will not need to obtain waivers of financial covenants in the future or that, should we require them, we would be able to obtain such waiver on terms favorable to the Company, or at all. To the extent that we are unable to continue to comply with such ongoing minimum liquidity and revenue requirements, including as a result of any weakness in our business or macroeconomic trends, and are unable to procure additional waivers from RTW or other lenders in the future, such lenders may pursue a number of actions, including declaring us in breach of our covenants, requiring conditions to cure such breaches and/or exercising foreclosure remedies. Any or all of these actions may materially impact our working capital, and our business may not continue to generate sufficient cash flows from operations to fund operations, service our debt, and satisfy our royalty payment obligations. If we are unable to generate such cash flows, we may be required to adopt one or more alternatives, such as raising additional capital on terms that may be unfavorable, selling assets or portions of our business, or ceasing operations. Our ability to refinance our existing or any future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our indebtedness owed to RTW is collateralized by substantially all of our assets and subject to customary financial and operating covenants limiting our ability to, among other things, incur additional indebtedness, change our material line of business, modify our organizational documents, create liens, sell assets, or prepay other indebtedness. These covenants may make it difficult to operate our business. We are also subject to standard event of default provisions under the Revenue Interest Financing Agreement, Additional RIFA and the Amended Note Purchase Agreement, that, if triggered, would allow the debt to be accelerated, which could significantly deplete our cash resources, cause us to raise additional capital at unfavorable terms, require us to sell portions of our business or result in us becoming insolvent. The existing collateral pledged to RTW, and the covenants to which we are bound, may (i)&#160;prevent us from being able to secure additional debt or equity financing on favorable terms, or at all, or to pursue business opportunities, including potential acquisitions, (ii)&#160;heighten our vulnerability to downturns in our business, industry or the economy in general, (iii)&#160;limit our ability to adjust to changing market conditions, and (iv)&#160;place us at a competitive disadvantage compared to our competitors who have greater capital resources. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need additional funds to support our operations, and such funding may not be available to us on acceptable terms, or at all, which would force us to delay, reduce or suspend our planned development and commercialization efforts. Raising additional capital may subject us to unfavorable terms, cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our products and technologies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since our inception, and we expect to incur significant expenses in connection with our planned clinical research, development and product commercialization efforts. If our available cash resources and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, we may seek to sell equity or convertible debt securities, to obtain another form of third-party funding, or to enter into other debt financing. Any failure to raise the funds necessary to support our operations may force us to delay, reduce or suspend our planned clinical trials, research and development programs, or other commercialization efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through strategic collaborations or partnerships, or marketing, distribution, royalty or licensing arrangements with third parties, we may be required to do so at an earlier stage than would otherwise be ideal and/or may have to limit valuable rights to our intellectual property, technologies, products, or future revenue streams, or grant licenses or other rights on terms that are not favorable to us. Furthermore, any additional fundraising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect our ability to develop and commercialize our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We receive the majority of our revenue from sales to health care providers and other third-party distributors, and the failure to collect receivables from them could adversely affect our financial position and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We receive the majority of our revenue from sales to health care providers and other third-party distributors. We extend credit to our customers for a significant portion of our sales and receivables from our customers are not secured by any type of collateral. We are therefore subject to the risk that our customers may not pay for the products they have purchased, pay at a slower rate than we have historically experienced, or may seek extended payment terms, which may, in turn, result in delays in our cash collection and increases in our accounts receivable. Our customers may encounter cash flow or operating difficulties, which may reduce their demand for our products or delay their payments to us, thereby increasing our accounts receivable turnover days, or increasing the risk that they may default on their payment obligations. These risks are heightened during periods of global or industry-specific economic downturn or uncertainty and during periods of rising interest rates. Our liquidity and cash flows from operations may be adversely affected if we are unable to settle our accounts receivable on a timely basis, if our accounts receivable cycles or collection periods lengthen or if we encounter a material increase in defaults of payment of our accounts receivable or repayments of amounts we have extended to our customers on credit. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of our financial statements requires us to make estimates and assumptions affecting the reported amounts of our assets, liabilities, revenues, expenses and earnings. If these estimates or assumptions are incorrect, it could have a material adverse effect on our results of operations or financial condition. We have identified several accounting policies as being critical to the fair presentation of our financial condition and results of operations because they involve major aspects of our business and require us to make judgments about </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matters that are inherently uncertain. These policies are described under the section entitled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>&#8221; and should be considered in conjunction with our audited consolidated financial statements and notes thereto included elsewhere in this prospectus. The implementation of new accounting requirements or other changes to GAAP, could have a material adverse effect on our reported results of operations and financial condition. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below our expectations and the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to this Offering and Ownership of Our Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">You will experience immediate and substantial dilution as a result of this offering. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You will incur immediate and substantial dilution as a result of this offering. Based on the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the last reported sales price of our common stock on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2024, and accompanying common warrant (and assuming no sale of any pre-funded warrants, no exercise of the common warrants being offered in this offering and that the common warrants are classified as and accounted for as equity), purchasers of common stock (or pre-funded warrants in lieu of common stock) and common warrants in this offering will experience immediate dilution of $&#8195;&#8195;&#8195;&#8195; per share in net tangible book value of the common stock. Moreover, in the past, we issued options and warrants to acquire common stock at prices significantly below the public offering price. To the extent these outstanding options and warrants are ultimately exercised, investors purchasing securities in this offering will sustain further dilution. In addition, the Notes are convertible into shares of our common stock upon the terms and conditions set forth in the Amended Note Purchase Agreement based on a conversion rate of 617.2840 shares of common stock per $1,000 principal amount of Notes (equivalent to a conversion price of approximately $1.62 per share). Further, as of November&#160;29, 2024, we had up to $99.5&#160;million in shares available for issuance and sale under a ChEF Purchase Agreement, dated as of December&#160;18, 2023, with Chardan Capital Markets LLC (the &#8220;Purchase Agreement&#8221;). Sales under the Purchase Agreement are subject to a remaining cap of 9,039,534&#160;shares, based on 19.99% of our outstanding shares of common stock on the execution date of the Purchase Agreement, unless approved by stockholders or individual issuances are considered above market under the rules of the NYSE. See the section entitled &#8220;<span style="font-style:italic">Dilution</span>&#8221; for a more detailed description of the dilution to new investors in the offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">There is no established public market for the pre-funded warrants or common warrants being offered in this offering. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we cannot predict the extent to which investor interest in Allurion will lead to the development of an active trading market in our pre-funded warrants or common warrants or how liquid that market might become. Without an active market, the liquidity of the pre-funded warrants or common warrants will be limited. We do not intend to list the pre-funded warrants or common warrants on the NYSE or any national securities exchange or nationally recognized trading system. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Holders of pre-funded warrants or common warrants purchased in this offering will have no rights as common stockholders until such holders exercise their pre-funded warrants or common warrants and acquire our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until holders of pre-funded warrants or common warrants acquire shares of our common stock upon exercise thereof, holders of pre-funded warrants or warrants will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of the pre-funded warrants or common warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The common warrants may never be in the money, and they may expire worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may receive up to an aggregate of approximately $&#8195;&#8195;&#8195;&#8195; million from the cash exercise of the common warrants we are offering. The exercise price of each of the common warrants is $&#8195;&#8195;&#8195;&#8195; per warrant. However, the last reported sale price of our common stock on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2024 was $&#8195;&#8195;&#8195;&#8195;. The likelihood that holders of common warrants will exercise their warrants, and therefore any amount of cash proceeds that we may receive, is dependent upon the trading price of our common stock. If the trading price for our common stock continues to be less than $&#8195;&#8195;&#8195;&#8195; per share, we do not expect holders to exercise their common warrants. There is no guarantee that the common warrants will be in the money prior to their expiration and, as such, the common warrants may expire worthless. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have considerable discretion in the application of the net proceeds of this offering, including for any of the purposes described in the section entitled &#8220;<span style="font-style:italic">Use of Proceeds</span>,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. As a result, investors will be relying upon management&#8217;s judgment with only limited information about our specific intentions for the use of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no required minimum number of securities or dollar amount that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount and proceeds to us are not presently determinable and may be substantially less than the maximum amount set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional funds, which may not be available or available on terms acceptable to us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to rights and remedies available to all purchasers in this offering under federal and state securities law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including, but not limited to: (i) timely delivery of shares; (ii) agreement to not issue any shares or securities convertible into shares for a period of ninety days from closing of the offering, subject to certain exceptions; and (iii)&#160;indemnification for breach of contract. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our share price may be volatile, and purchasers of our securities could incur substantial losses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price is likely to be volatile. The securities markets in general, and the market for biotechnology and medical device companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. You may not be able to resell your shares at an attractive price due to a number of factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to successfully commercialize, and realize revenues from sales of, the Allurion Balloon; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of competitive products or technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of clinical trials of the Allurion Balloon or other current or future products or those of our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introductions and announcements of new products by us (such as AllurionMeds), our commercialization partners, or our competitors, and the timing of these introductions or announcements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing processes or sales and marketing terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variations in our financial results or those of companies that are perceived to be similar to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our efforts to acquire or <span style="white-space:nowrap">in-license</span> additional products or planned products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments concerning our collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments concerning our ability to bring our manufacturing processes to scale in a cost-effective manner; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability or inability to raise additional capital and the terms on which we raise it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of health care payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions in the medical device, pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated changes in earnings estimates or changes in securities analyst recommendations regarding our common stock, other comparable companies or our industry generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">guidance or projections, if any, that we provide to the public, any changes in this guidance or projections or our failure to meet this guidance or projections; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">comments by securities analysts or other third parties, including blogs, articles, message boards and social and other media; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">large stockholders exiting their position in our common stock or an increase or decrease in the short interest in our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative public perception of us, our competitors, or our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic and political conditions such as recessions, interest rates, fuel prices, trade wars, pandemics (such as <span style="white-space:nowrap">COVID-19),</span> currency fluctuations, geopolitical conflicts and acts of war or terrorism; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effects of natural disasters, terrorist attacks and the spread and/or abatement of infectious diseases, including with respect to potential operational disruptions, labor disruptions, increased costs, and impacts to demand related thereto; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the other risks described in this &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; section. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These broad market and industry factors may harm the market price of our securities, regardless of our operating performance. Stock markets in general and our stock price in particular have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies and our Company. For example, from January&#160;1, 2024 to December&#160;1, 2024, the closing price per share of our common stock on the NYSE ranged from as low as $0.3430 to as high as $3.70 and daily trading volume ranged from approximately 3,914 to 63,488,900 shares. During such period, we did not experience any material changes in our financial condition or results of operations that would explain such price volatility or trading volume. Investors that purchase shares of our common stock in this offering may lose their investments if the price of our common stock subsequently declines. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could adversely affect our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not intend to pay cash dividends for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in our current or future credit agreements and financing instruments, business prospects and such other factors as our board of directors deems relevant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of our common stock, or the perception that future sales may occur, may cause the market price of our common stock to decline, regardless of our operating performance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market, including the resale of shares held by various holders of our securities registered for resale, could occur at any time (after the expiration of any applicable <span style="white-space:nowrap">lock-up</span> period). These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&#160;18, 2023, we entered into the Purchase Agreement with Chardan Capital Markets (&#8220;Chardan&#8221;) related to a &#8220;ChEF,&#8221; Chardan&#8217;s committed equity facility (the &#8220;Chardan Equity Facility&#8221;). Pursuant to the Purchase Agreement, Chardan shall purchase from us up to $100.0&#160;million of shares of our common stock, upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement. As of September&#160;30, 2024, we have sold 143,234 shares of our Common Stock to Chardan as Purchase Shares (as defined in the Chardan Purchase Agreement) under the Chardan Purchase Agreement, for aggregate net cash proceeds to us of approximately $0.4&#160;million. Additional shares of our common stock under the Purchase Agreement may be sold by us to Chardan at our discretion from time to time. Sales of shares of our common stock under the Purchase Agreement in the future may cause the trading price of shares of our common stock to decrease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The resale, or expected or potential resale, of a substantial number of shares of our common stock in the public market could adversely affect the market price for our common stock and make it more difficult for stockholders to sell their holdings at times and prices that they determine are appropriate. Furthermore, we expect that, because there is a large number of shares of our common stock registered pursuant to various resale registration statements, the selling securityholders thereunder will continue to offer the securities covered thereby for a significant period of time, the precise duration of which cannot be predicted. Accordingly, the adverse market and price pressures resulting from an offering pursuant to the effective resale registration statements may continue for an extended period of time. Sales of a substantial number of such shares in the public market could adversely affect the market price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a significant portion of the shares of our common stock registered for resale were purchased by securityholders pursuant to investments in Legacy Allurion that date from 2013 onwards at prices </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considerably below the current market price of our common stock. The sale of such shares would result in the securityholders realizing a significant gain even if other securityholders experience a negative rate of return. For example, holders of Legacy Allurion common stock, many of whom purchased their shares pursuant to investments in Legacy Allurion that date from 2013 through the closing of the Business Combination, paid, on average, an effective purchase price of approximately $0.22 for each share of our common stock they received in connection with the Business Combination. Even if our trading price is significantly below $7.04, the offering price for the units offered in Compute Health&#8217;s initial public offering (&#8220;IPO&#8221;) after giving effect to the applicable exchange ratio of 1.420455 pursuant to the Business Combination Agreement (the &#8220;CPUH Exchange Ratio&#8221;), certain of the securityholders, including such holders of Legacy Allurion common stock, may still have an incentive to sell shares of our common stock because they purchased the shares at prices lower than the public investors or the current trading price of our common stock. For example, based on the closing price of our common stock of $0.61 as of September 30, 2024, such holders of Legacy Allurion common stock would experience a potential profit, on average, of up to approximately $0.39 per share, or approximately $2.1&#160;million in the aggregate upon the sale of all such shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales and issuances of our common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner as determined from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could adversely affect our business, results of operations, and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are subject to the reporting requirements of the Exchange Act, the listing standards of the NYSE, and other applicable securities rules and regulations. We expect that the requirements of these rules and regulations will continue to increase our legal, accounting and financial compliance costs, make some activities more difficult, time-consuming and costly, and place significant strain on our personnel, systems and resources. For example, the Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and results of operations. As a result of the complexity involved in complying with the rules and regulations applicable to public companies, our management&#8217;s attention may be diverted from other business concerns, which could harm our business, results of operations and financial condition. Although we have already hired additional employees to assist us in complying with these requirements, we may need to hire more employees in the future or engage outside consultants, which will increase our operating expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest substantial resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from business operations to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that being a public company and these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of disclosure of information in the filings required of a public company, our business and financial condition will become more visible, which may result in an increased risk of threatened or actual litigation, including by competitors and other third parties. If such claims are successful, our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in our favor, these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business, results of operations, and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain parties have the right to nominate directors to our board of directors, and their interests may conflict with ours or yours in the future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our Investor Rights and <span style="white-space:nowrap">Lock-up</span> Agreement, dated August&#160;1, 2023, by and among us, Compute Health Sponsor LLC (the &#8220;Sponsor&#8221;), certain Legacy Allurion stockholders and certain other parties (the &#8220;Investor Rights Agreement&#8221;), the following persons have the following nomination rights with respect to our board of directors: (i)&#160;one director and one independent director to be nominated by Shantanu Gaur; (ii)&#160;one director and one independent director to be nominated by Remus Group Management, LLC and its affiliates (&#8220;Remus Capital&#8221;); (iii) one director to be nominated by the Sponsor; and (iv)&#160;two independent directors to be nominated by Allurion (one of whom shall be designated by RTW until such time as all obligations under the Revenue Interest Financing Agreement or any additional revenue interest financing agreement have been satisfied by Allurion). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in September 2024, we appointed Keith Johns to our Board, in satisfaction of certain obligations to RTW set forth in the Amended Note Purchase Agreement </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the foregoing, Shantanu Gaur, Remus Capital, the Sponsor and RTW or their respective nominees to our Board collectively have the ability to control the appointment of our management, the entering into of mergers, sales of substantially all or all of our assets and other extraordinary transactions, and influence amendments to our amended and restated certificate of incorporation (&#8220;Charter&#8221;) and bylaws (&#8220;Bylaws&#8221;). In any of these matters, the interests of the parties to the Investor Rights Agreement with the right to nominate directors may differ from or conflict with your interests. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, this control over the nomination of directors to our Board may also adversely affect the trading price for our common stock to the extent investors perceive disadvantages in owning stock of a company with these corporate governance provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; within the meaning of the Securities Act, and we intend to take advantage of certain exemptions from disclosure requirements available to emerging growth companies and/or smaller reporting companies, which could make our securities less attractive to investors and may make it more difficult to compare our performance with that of other public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (&#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act (&#8220;Section&#160;404&#8221;), reduced disclosure obligations regarding executive compensation in their periodic reports and proxy statements, and exemptions from the requirements of holding a <span style="white-space:nowrap">non-binding</span> advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparability of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K,</span> which allows us to take advantage of certain exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&#160;404 and reduced disclosure obligations regarding executive compensation in this prospectus and in our periodic reports and proxy statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of the shares of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June&#160;30, and (ii)&#160;our annual revenue exceeded $100&#160;million during such completed fiscal year or the market value of the shares of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be subject to securities class action litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in the price of our common stock, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and results of operations and divert management&#8217;s attention and resources from our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have previously identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future. If we fail to remediate a material weakness or if we otherwise fail to establish and maintain effective control over financial reporting, it may adversely affect our ability to accurately and timely report our financial results, and may adversely affect investor confidence and business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements as of and for the years ended December&#160;31, 2023 and 2022, we identified material weaknesses in our internal control over financial reporting that we are currently working to remediate, which relate to: (a)&#160;insufficient segregation of duties in the financial statement close process; (b)&#160;a lack of sufficient levels of staff with public company and technical accounting experience to maintain proper control activities and perform risk assessment and monitoring activities; and (c)&#160;insufficient information systems controls, including access and change management controls. We have concluded that these material weaknesses in our internal control over financial reporting occurred because we do not have the necessary business processes, personnel and related internal controls to operate in a manner to satisfy the accounting and financial reporting timeline requirements of a public company. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on designing and implementing effective internal controls measures to improve our evaluation of disclosure controls and procedures, including internal control over financial reporting, and remediating the material weaknesses. We have taken steps to remediate including consulting with experts on technical accounting matters and in the preparation of our financial statements. We have also hired additional senior level experienced staff with public company experience and upgraded our enterprise resource planning system to SAP in August of 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we cannot assure you that the measures we are taking to remediate the material weaknesses will prevent or avoid potential future material weaknesses. Further, additional weaknesses in our disclosure controls and internal controls over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such a case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to the listing requirements of the NYSE, investors may lose confidence in our financial reporting and our stock price may decline as a result. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock may decrease. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of designing and implementing our internal controls over financial reporting, which will be time-consuming, costly and complicated. We have identified gaps in our internal control environment in the past and cannot provide assurances that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. If we identify additional material weaknesses in our internal control over financial reporting, if we are unable to comply with the requirements of Section&#160;404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or, once required, if our independent registered public accounting firm is unable to attest that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decrease. We could also become subject to stockholder or other third-party litigation as well as investigations by the NYSE, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to raise additional capital in order to execute our business plan and to respond to changing market conditions, which additional capital may not be available on terms acceptable to us, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will need to raise additional capital by issuing equity, debt, or a combination of the two, in order to respond to market timing delays, technological advancements, competition, competitive technologies, customer demands, business opportunities, potential acquisitions, unforeseen circumstances, or other reasons. In order to further business relationships with current or potential customers or partners, we may issue equity or <span style="white-space:nowrap">equity-linked</span> securities to such customers or partners. Despite the need for additional capital, we may not be able to timely secure additional debt or equity financing on favorable terms, or at all, especially given current market conditions where raising additional capital has proven particularly challenging. If we raise additional capital through the issuance of equity or convertible debt or other equity-linked securities, or if we issue equity or equity-linked securities to current or potential customers to further our business relationships, our existing stockholders would likely experience dilution, which may be significant. Any debt financing obtained by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital or to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing on terms satisfactory to us, when we require it, our ability to continue to support our business and to respond to business challenges could be significantly limited. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, under current SEC regulations, if our public float is less than $75&#160;million, and for so long as our public float remains less than $75&#160;million, the amount we can raise through primary public offerings of securities in any twelve-month period using shelf registration statements on Form <span style="white-space:nowrap">S-3</span> is limited to an aggregate of <span style="white-space:nowrap">one-third</span> of our public float, which is referred to as the &#8220;baby shelf&#8221; rules. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As&#160;of the date of this prospectus, our public float is below $75&#160;million. As such, we will be limited by the&#160;baby shelf&#160;rules until such time as our public float exceeds $75&#160;million, which means we only have the capacity to sell shares up to <span style="white-space:nowrap">one-third</span> of our public float under shelf registration statements on Form <span style="white-space:nowrap">S-3</span> in any twelve-month period. If our public float decreases, the number of securities we may sell under our Form <span style="white-space:nowrap">S-3</span> shelf registration statement will also decrease. We will remain constrained by the&#160;baby shelf&#160;rules under our Form <span style="white-space:nowrap">S-3</span> shelf registration statement until such time as our public float exceeds $75&#160;million, at which time, the number of securities we may sell under a Form <span style="white-space:nowrap">S-3</span> registration statement will no longer be limited by the&#160;baby shelf&#160;rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are not in compliance with the NYSE&#8217;s minimum share price requirement or its minimum market capitalization standard and thus are at risk of the NYSE delisting shares of our common stock, which would have an adverse impact on the trading volume, liquidity and market price of shares of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2024, we received a letter from NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of our common stock had closed below $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. Pursuant to Rule 802.01C of the NYSE Listed Company Manual, a company will be considered to be below compliance standards if the average closing price of a security fell below $1.00 over a period of 30 consecutive trading days. A company can regain compliance with the minimum share price requirement at any time during the <span style="white-space:nowrap">six-month</span> cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 <span style="white-space:nowrap">trading-day</span> period ending on the last trading day of that month. In the event that at the expiration of the <span style="white-space:nowrap">six-month</span> cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 <span style="white-space:nowrap">trading-day</span> period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement. On November&#160;8, 2024, we filed a definitive proxy statement on Schedule 14A for our 2024 annual stockholder meeting (the &#8220;2024 Proxy Statement&#8217;) and included a proposal for stockholders to consider and vote upon an amendment to our Charter to combine the outstanding shares of common stock into a lesser number of outstanding shares (the &#8220;Reverse Stock Split&#8221;). Our primary objective in effectuating the Reverse Stock Split is to raise the trading price of our common stock to meet the NYSE&#8217;s minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2024, we received a notice from the NYSE notifying us that as of August&#160;29, 2024, we are not in compliance with the continued listing standard set forth in Section&#160;802.01B of the NYSE&#8217;s Listed Company Manual (the &#8220;Minimum Market Capitalization Standard&#8221;) because our average market capitalization was less than $50.0&#160;million over the consecutive 30 <span style="white-space:nowrap">trading-day</span> period ended August&#160;29, 2024 and our last reported stockholders&#8217; equity as of August&#160;29, 2024 was less than $50.0&#160;million. In accordance with applicable NYSE procedures, within 45 days of receipt of the notice, we submitted a plan to the NYSE advising it of outlining measures that would bring us into conformity with the Minimum Market Capitalization Standard within 18 months of receipt of the notice (the &#8220;Cure Period&#8221;). The NYSE will evaluate the plan and determine whether the Company has made a reasonable demonstration of its ability to come into conformity with the relevant listing standards within the Cure Period. If the NYSE accepts our plan, the NYSE will review us on a quarterly basis to confirm compliance with the plan. If our plan is not accepted, we fail to comply with the plan or we do not meet the Minimum Market Capitalization Standard at the end of the Cure Period, we will be subject to NYSE&#8217;s prompt initiation of suspension and delisting procedures. We submitted a business plan to the NYSE demonstrating our ability to regain compliance with the NYSE&#8217;s rules. The NYSE has accepted the plan and as a result, we are subject to quarterly monitoring for compliance with the business plan and our common stock will continue to trade on the NYSE during the period, subject to our compliance with other NYSE continued listing requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will be able to cure these deficiencies or comply with other NYSE continued listing standards. A delisting of shares of our common stock from the NYSE could negatively impact us as it </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would likely reduce the liquidity and market price of shares of our common stock, reduce the number of investors willing to hold or acquire shares of our common stock, and negatively impact our ability to access equity markets and obtain financing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market may not develop or be sustained. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our securities may be highly volatile or may decline regardless of our operating performance. An active public market for our securities may not develop or be sustained. We cannot predict the extent to which investor interest in Allurion will lead to the development of an active trading market in our common stock or how liquid that market might become. If an active market does not develop or is not sustained, or if we fail to satisfy the continued listing standards of the NYSE for any reason and our securities are delisted, it may be difficult for you to sell your securities at the time you wish to sell them, at a price that is attractive to you, or at all. An inactive trading market may also impair our ability to both raise capital by selling shares of capital stock, attract and motivate employees through equity incentive awards and acquire other companies, products or technologies by using shares of capital stock as consideration. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2024, we received a letter from NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of our common stock had closed below $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. We cannot assure you that we will be able to cure this deficiency or comply with other NYSE continued listing standards. A delisting of shares of our common stock from the NYSE could negatively impact us as it would likely reduce the liquidity and market price of shares of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We submitted a business plan to the NYSE demonstrating our ability to regain compliance with the NYSE&#8217;s rules. The NYSE has accepted the plan and as a result, the Company is subject to quarterly monitoring for compliance with the business plan and our common stock will continue to trade on the NYSE during the period, subject to our compliance with other NYSE continued listing requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our common stock share price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. If few or no securities or industry analysts cover us, the trading price for our common stock would likely be negatively impacted. If one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, our share price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our share price would likely decline. If one or more of these analysts cease coverage of Allurion or fail to publish reports on us regularly, demand for our common stock could decrease, which might cause our share price and trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provisions in our Charter and Bylaws could make an acquisition of Allurion more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our Charter and Bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our board of directors is divided into three classes with staggered three-year terms which may delay or prevent a change of our management or a change in control; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our board of directors has the right to elect directors to fill a vacancy created by the expansion of our board of directors or the resignation, death, or removal of a director, which will prevent stockholders from being able to fill vacancies on our board of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our stockholders are not able to act by written consent, and as a result, a holder, or holders, controlling a majority of our shares are not be able to take certain actions other than at annual stockholders&#8217; meetings or special stockholders&#8217; meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our Charter does not allow cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">amendments of our Charter and Bylaws require the approval of stockholders holding 66 2/3% of our outstanding voting shares (unless amended by our board of directors); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our stockholders are required to provide advance notice and additional disclosures in order to nominate individuals for election to our board of directors or to propose matters that can be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of Allurion; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our board of directors is able to issue, without stockholder approval, preferred shares with voting or other rights or preferences that could impede the success of any attempt to acquire us. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales of shares of our common stock may cause the market price of our common stock to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of our common stock intend to sell shares, could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the Sponsor and certain Legacy Allurion stockholders have signed the Investor Rights Agreement which contains <span style="white-space:nowrap">lock-up</span> restrictions for a period of either 18 months or 12 months following the consummation of the Business Combination, as applicable, and certain other Legacy Allurion stockholders are subject to similar <span style="white-space:nowrap">lock-up</span> restrictions pursuant to our Bylaws, the <span style="white-space:nowrap">lock-up</span> restrictions shall not apply to: (a)&#160;any shares of our common stock purchased pursuant to the PIPE Subscription Agreements (as defined below), (b) 100 shares of our common stock held by each Investor (as defined in the Investor Rights Agreement), (c) shares issued to the Sponsor in the loans made by the Sponsor to Compute Health, which balance was $3.7&#160;million at the time of the Business Combination, was converted into 525,568 shares of Allurion common stock (the &#8220;Sponsor Loan Equity Issuance&#8221;), (d) certain incremental shares of PIPE Investors who are Legacy Allurion stockholders or holders of convertible unsecured promissory notes issued by Legacy Allurion pursuant to that certain (i)&#160;Convertible Note Purchase Agreement, dated December&#160;22, 2021, by and among Legacy Allurion and the investors listed on Exhibit A thereto, (ii)&#160;Convertible Note Purchase Agreement, dated February&#160;15, 2023, by and among Legacy Allurion and the investors listed on Exhibit A thereto and (iii)&#160;Convertible Note Purchase Agreement, dated June&#160;14, 2023, by and among Legacy Allurion and the investors listed on Exhibit A thereto (collectively, &#8220;Legacy Allurion Convertible Notes&#8221;), or shares issued upon conversion of the convertible notes issued between February 2023 and August 2023 (&#8220;2023 Convertible Notes&#8221;), (e) the Backstop Shares or the shares of our common stock issued to each of HVL, RTW and Fortress Credit Corp. (&#8220;Fortress&#8221;), and such shares of our common stock will be freely tradeable subject to federal securities laws and other applicable rules and regulations. In addition, the lock-up restrictions pertaining to this offering described in the section entitled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; will expire 90 days from the date of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective purchase prices at which certain independent directors of Compute Health, certain Legacy Allurion stockholders, the PIPE Investors, RTW, a Fortress affiliate and HVL acquired their shares of our common stock are generally substantially less than the IPO price of $7.04 per share, after giving effect to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CPUH Exchange Ratio. Consequently, such stockholders may realize a positive rate of return on the sale of their shares of common stock even if the market price per share of our common stock is below $7.04 per share. While some of our securityholders may experience a positive rate of return based on the current trading price, public securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices they paid and the trading price at the time of sale and may instead experience a negative rate of return on their investment. On December 6, 2024, the last quoted sale price for our common stock as reported on the NYSE was $0.37&#160;per share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, these securityholders may have an incentive to sell their shares of our common stock even if the trading price is below the price paid by investors in Compute Health&#8217;s IPO, which could cause the market price of our common stock to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&#160;18, 2023, we entered into the Purchase Agreement with Chardan related to the Chardan Equity Facility. Pursuant to the Purchase Agreement, Chardan shall purchase from us up to $100.0&#160;million of shares of our common stock, upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common stock that may be issued under the Purchase Agreement may be sold by us to Chardan at our discretion from time to time. The purchase price for shares of our common stock that we may sell to Chardan under the Purchase Agreement will fluctuate based on the trading price of shares of our common stock. As a result, investors who purchase shares from Chardan at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Chardan as a result of future sales made by us to Chardan at prices lower than the prices such investors paid for their shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on market liquidity at the time, sales of shares of our common stock may cause the trading price of shares of our common stock to decrease. We generally have the right to control the timing and amount of any future sales of shares of our common stock to Chardan. Additional sales of shares of our common stock, if any, to Chardan will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Chardan all, some or none of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares of our common stock to Chardan, after Chardan has acquired shares of our common stock, Chardan may resell all, some or none of such shares of our common stock at any time or from time to time in its discretion. Therefore, sales to Chardan by us could result in substantial dilution to the interests of other holders of shares of our common stock. In addition, if we sell a substantial number of shares of our common stock to Chardan under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares of our common Stock or the mere existence of our arrangement with Chardan may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable NYSE rules, in no event may we issue to Chardan shares of our common stock representing more than the lower of the 19.99% voting power threshold and the 19.99% share and share equivalent thresholds referenced in Section&#160;312.03(c) of the NYSE Listed Company Manual, unless we obtain prior stockholder approval or if such approval is not required in accordance with the applicable NYSE rules. In addition, Chardan is not obligated to buy any common stock under the Purchase Agreement if such shares, when aggregated with all other common stock then beneficially owned by Chardan and its affiliates (as calculated pursuant to Section&#160;13(d) of the Exchange Act and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder), would result in Chardan beneficially owning common stock in excess of 4.99% of our outstanding voting power or shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2024, we entered into the Amended Note Purchase Agreement, pursuant to which we issued and sold $48&#160;million of Notes to the Purchasers. The actual number of shares of our common stock that may be issued upon conversion of the Notes will vary depending on the then-current conversion price of the Notes sold, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not to exceed 479,196 shares of common stock, or 1% of the number of shares of the common stock outstanding as of April&#160;14, 2024, unless we obtain approval of our stockholders for such securities issuance (the &#8220;First Stockholder Approval&#8221;), in accordance with the applicable stock exchange rules. Therefore, the Amended Note Purchase Agreement provides that unless and until the requisite First Stockholder Approval is obtained, we will not deliver common stock upon conversion of the Notes in excess of 1% of the number of shares of the common stock outstanding as of April&#160;14, 2024. Under the Amended Note Purchase Agreement, we are required to include a proposal in our definitive proxy statement on Schedule 14A seeking the First Stockholder Approval no later than December&#160;31, 2025. If we do not obtain the First Stockholder Approval at such meeting, we are required to call a special meeting of stockholders each <span style="white-space:nowrap">90-day</span> period thereafter at least two times, and thereafter at each subsequent annual meeting until the First Stockholder Approval is obtained or the Notes are no longer outstanding; provided, that shares of common stock issued upon conversion of the Notes prior to obtaining the First Stockholder Approval shall not be entitled to vote in favor of the First Stockholder Approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also in July 2024, concurrently with the Offering, we consummated the Private Placement of an aggregate of 2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants to RTW, at a purchase price of $1.20 per share and warrant. The actual number of shares of our common stock that may be issued upon conversion of the Series A Preferred Stock and exercise of the Private Placement Warrants shall not exceed 479,683 shares of common stock, or 1% of the number of shares of the common stock outstanding as of June&#160;28, 2024, unless we obtain the approval of our stockholders for such securities issuance (the &#8220;Second Stockholder Approval&#8221;), in accordance with the applicable stock exchange rules. Following the date upon which we obtain the Second Stockholder Approval for the issuance of the underlying common stock, which we have agreed to obtain as set forth in the Subscription Agreement, each share of Series A Preferred Stock shall automatically convert into one share of common stock (or <span style="white-space:nowrap">pre-funded</span> warrants), subject to adjustment;<span style="font-style:italic"> provided,</span><span style="font-style:italic"></span><span style="font-style:italic"> however</span>, that in no event shall the Series&#160;A Preferred Stock be converted into a number of shares of common stock exceeding 9.99% of the total number of shares of common stock outstanding. In addition, the Private Placement Warrants are not exercisable prior to the Second Stockholder Approval and thereafter are immediately exercisable at an exercise price of $1.20 and will expire five years from the date of issuance, subject to certain limitations. A holder of&#160;Private Placement Warrants may not exercise the Private Placement Warrant if such holder, together with its affiliates, would beneficially own more than 4.99% (or, upon election by a holder prior to the issuance of the Private Placement Warrants, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;8, 2024, we filed the 2024 Proxy Statement for our 2024 annual stockholder meeting and included proposals for the First Stockholder Approval and Second Stockholder Approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described above, there are no <span style="white-space:nowrap">lock-up,</span> beneficial ownership or stock exchange restrictions that would prevent the foregoing stockholders from selling some or all of their common stock subject to compliance with applicable rules and regulations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our existing warrants are exercisable for common stock, the exercise of which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, there were outstanding: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">13,206,720 Public Warrants to purchase an aggregate of 18,759,554 shares of common stock at an exercise price of $8.10 per share, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">403,658 Rollover Warrants to purchase an aggregate of 403,658 shares of common stock at exercise prices ranging from $0.02 per share to $12.14 per share, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the July 2024 Public Warrants to purchase an aggregate of 16,567,484 shares of common stock at an exercise price of $1.20 per share, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Private Placement Warrants to purchase an aggregate of 2,260,159 shares of common stock at an exercise price of $1.20 per share. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent such existing warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our common stock, the impact of which increases as the value of our stock price increases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our pre-funded warrants and common warrants being issued in this offering will be exercisable for common stock, the exercise of which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering common warrants to purchase up to &#8195;&#8195;&#8195;&#8195; shares of our common stock at an exercise price of $&#8195;&#8195;&#8195;&#8195; per share in this offering. We are also offering to each purchaser whose purchase of shares of our common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding shares of common stock immediately following consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants to purchase shares of common stock in lieu of shares of common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant will equal the price per share of common stock being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001 per share. To the extent such warrants are exercised, additional shares of our common stock will be issued, which will result in dilution to the holders of our common stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect the market price of our common stock, the impact of which increases as the value of our stock price increases. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our existing warrants may not be exercised at all and we may not receive any cash proceeds from the exercise of such warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the significant number of redemptions of Compute Health Class&#160;A common stock in connection with the Business Combination, there was a significantly lower number of shares of Compute Health Class&#160;A common stock that converted into shares of our common stock in connection with the Business Combination. As a result, the shares of our common stock previously registered for resale (a substantial portion of which may not be resold until the expiration of the applicable <span style="white-space:nowrap">lock-up</span> period) are anticipated to constitute a considerable percentage of our public float. Additionally, a significant portion of the shares of our common stock registered for resale were purchased by securityholders pursuant to investments in Legacy Allurion that date from 2013 through the closing of the Business Combination at prices considerably below the current market price of our common stock. This discrepancy in purchase prices may have an impact on the market perception of our common stock&#8217;s value and could increase the volatility of the market price of our common stock or result in a significant decline in the public trading price of our common stock. The registration of these shares for resale creates the possibility of a significant increase in the supply of our common stock in the market. The increased supply, coupled with the potential disparity in purchase prices, may lead to heightened selling pressure, which could negatively affect the public trading price of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise prices of the existing warrants, in certain circumstances, may be higher than the prevailing market price of our underlying common stock and the cash proceeds to us associated with the exercise of such warrants are contingent upon our stock price. The value of our common stock may fluctuate and may not exceed the exercise price of the existing warrants at any given time. As of the date of this prospectus, all of our Public Warrants, each of which has an exercise price of $8.10 per share, and July 2024 Public Warrants, each of which has an exercise price of $1.20 per share, are &#8220;out of the money,&#8221; meaning the exercise price is higher than the market price of our common stock. As of September 30, 2024, 22,303 Rollover Warrants have been exercised. Of the 403,658 Rollover Warrants outstanding as of September&#160;30, 2024, 274,580 of such warrants (55,729 of which have an exercise price of $1.05, 9,779 of which have an exercise price of $1.13, 44,272 of which have an exercise price of $2.43, 130,053 of which have an exercise price of $6.73, and 90,476 of which have an exercise price of $12.14) are &#8220;out of the money.&#8221; Holders of such &#8220;out of the money&#8221; warrants are not likely to exercise such warrants. There can be no assurance that such warrants will be in the money prior to their respective expiration dates, and therefore, we may not receive any cash proceeds from the exercise of such warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our common warrants may not be exercised at all and we may not receive any cash proceeds from the exercise of such warrants. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The value of our common stock may fluctuate and may not exceed the exercise price of the new warrants offered hereby at any given time. The exercise price of the common warrants, $&#8195;&#8195;&#8195;&#8195;, is a &#8195;&#8195;&#8195;&#8195;% premium to the closing price of our common stock on the date of this prospectus. Accordingly, such common warrants are currently &#8220;out of the money.&#8221; Holders of &#8220;out of the money&#8221; warrants, or warrants for which the exercise price is higher than the market price of our common stock, are not likely to exercise such warrants. There can be no assurance that such warrants will be in the money prior to their respective expiration dates, or that such warrants will be exercised at all and, therefore, we may not receive any cash proceeds from the exercise of such warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our existing warrants are accounted for as liabilities and the changes in value of such warrants could have a material effect on, or cause volatility in, our financial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, we assumed Public Warrants to purchase up to 18,759,696 shares of our common stock (which were originally issued as warrants to purchase shares of Compute Health Class&#160;A common stock in connection with Compute Health&#8217;s IPO) and Rollover Warrants to purchase up to 403,658 shares of our common stock (which were originally issued as warrants to purchase shares of Legacy Allurion Common Stock and Legacy Allurion Preferred Stock). We evaluated the accounting treatment of such warrants and determined to classify certain of such warrants as liabilities measured at fair value. The fair value of such warrants is remeasured on a quarterly basis with changes in the estimated fair value recorded in Other (expense) income on the consolidated statement of operations and comprehensive loss. Due to the recurring fair value measurement, we expect that we will recognize <span style="white-space:nowrap">non-cash</span> gains or losses on such warrants each reporting period and that the amount of such gains or losses could materially impact or cause volatility in our financial results. For example, upon consummation of the Business Combination, the total value of the liability associated with the Public Warrants was $13.8&#160;million measured at fair value based on the Public Warrant quoted price. However, at September 30, 2024, the fair value of the liability associated with the Public Warrants was determined to be $0.5&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our <span style="white-space:nowrap">Earn-Out</span> Shares are accounted for as liabilities and the changes in value of such shares could have a material effect on, or cause volatility in, our financial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, holders of Legacy Allurion common stock and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive additional shares of our common stock (the <span style="white-space:nowrap">&#8220;Earn-Out</span> Shares&#8221;) upon the achievement of certain <span style="white-space:nowrap">earn-out</span> targets. We evaluated the accounting treatment of our <span style="white-space:nowrap">Earn-Out</span> Shares and determined to classify such shares as liabilities measured at fair value. The fair value of such shares is remeasured on a quarterly basis over the <span style="white-space:nowrap">earn-out</span> period with changes in the estimated fair value recorded in other income (expense) on the consolidated statement of operations and comprehensive loss. Due to the recurring fair value measurement, we expect that we will recognize <span style="white-space:nowrap">non-cash</span> gains or losses on our <span style="white-space:nowrap">Earn-Out</span> Shares each reporting period and that the amount of such gains or losses could materially impact or cause volatility in our financial results. For example, upon consummation of the Business Combination, the fair value of the liability associated with the <span style="white-space:nowrap">Earn-Out</span> Shares was initially valued and recorded as $53.0&#160;million. However, at September&#160;30, 2024, the fair value of the liability associated with the <span style="white-space:nowrap">Earn-Out</span> Shares was determined to be $1.9&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The provisions of our Bylaws requiring exclusive forum in the Court of Chancery of the State of Delaware and the federal district courts of the United States for certain types of lawsuits may have the effect of discouraging lawsuits against our directors and officers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provide that, to the fullest extent permitted by law, and unless we consent in writing to the selection of an alternative forum, the Court of Chancery (the &#8220;Chancery Court&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district court for the District of Delaware </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other state courts of the State of Delaware) and any appellate court thereof will be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL, our Charter or our Bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers jurisdiction on the Chancery Court of the State of Delaware, or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine; provided, however, that the preceding clauses (i)&#160;through (iv) will not apply to any causes of action arising under the Securities Act or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our Bylaws as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such Securities Act claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, the Exchange Act, or the respective rules and regulations promulgated thereunder; however, there is uncertainty as to whether a court would enforce such provision, and investors cannot waive compliance with federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may limit or increase the difficultly in a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors and officers, or may increase the cost for such stockholder to bring a claim, both of which may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_6">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from the issuance and sale of shares of our common stock (or <span style="white-space:nowrap">pre-funded</span> warrants in lieu of common stock) and accompanying common or warrants in this offering, as applicable, will be approximately $&#8195;&#8195;&#8195;&#8195; million, based on the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant, which is the last reported sales price of our common stock on the NYSE on&#8195;&#8195;&#8195;&#8195;, 2024, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting estimated placement agent fees and estimated offering expenses payable by us. However, because this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. If all of the pre-funded warrants or common warrants sold in this offering were to be exercised at their exercise price in cash, we would receive additional gross proceeds of approximately $&#8195;&#8195;&#8195;&#8195;&#160;million. Based on the assumed public offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $&#8195;&#8195;&#8195;&#8195;&#160;million, $&#8195;&#8195;&#8195;&#8195;&#160;million, and $&#8195;&#8195;&#8195;&#8195;&#160;million, respectively, assuming no sale of any pre-funded warrants or exercise of any common warrants, and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund commercial sales, research and development, and for working capital and other general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe our existing cash and cash equivalents, together with the net proceeds from this offering, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant would increase (decrease) the net proceeds to us from this offering by approximately $&#8195;&#8195;&#8195;&#8195;&#160;million, assuming that the number of shares and accompanying common warrants offered by us, as set forth on the cover page of this prospectus, remains the same, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, each 1.0&#160;million share increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us by approximately $&#8195;&#8195;&#8195;&#8195;&#160;million, assuming the public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant, remains the same, and after deducting the estimated placement agent fees and estimated offering expenses payable by us, assuming no sale of any pre-funded warrants or exercise of any common warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates exclude the proceeds, if any, from the exercise of common warrants offered hereby. If all of the common warrants offered hereby were to be exercised in cash at the exercise price, we would receive additional gross proceeds of approximately $&#8195;&#8195;&#8195;&#8195;&#160;million. We cannot predict when or if these common warrants will be exercised. It is possible that these common warrants may expire and may never be exercised. Additionally, these common warrants contain a cashless exercise provision that permit exercise of such common warrants on a cashless basis at any time when there is no effective registration statement under the Securities Act covering the issuance of the underlying shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We cannot predict with certainty all the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development efforts, the status of and results from clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates or strategic opportunities that become available to us, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may invest the net proceeds from this offering in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether any proceeds so invested will yield a favorable return. Our management will retain broad discretion in the application of the net proceeds we receive from this offering, and investors will be relying on the judgment of our management regarding the application of the net proceeds. See the subsection entitled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to This Offering and Ownership of Our Securities&#8212;We will have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_7">MARKET PRICE AND DIVIDEND INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Price </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock and Public Warrants are listed on the NYSE under the symbols &#8220;ALUR&#8221; and &#8220;ALUR WS,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing price of our common stock and our Public Warrants as reported on the NYSE on December&#160;6, 2024 was $0.37 per share and $0.035 per Public Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there is no public market for the pre-funded warrants or common warrants offered hereunder. We do not intend to list the pre-funded warrants or common warrants on the NYSE or any other national securities exchange or nationally recognized trading system. We cannot predict the extent to which investor interest in Allurion will lead to the development of an active trading market in such warrants or how liquid that market might become. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;6, 2024, there were 252 holders of record of our common stock and one holder of record of our Public Warrants. The number of holders of record does not include for example a substantially greater number of &#8220;street name&#8221; holders or beneficial holders whose shares are held of record by banks, brokers and other financial institutions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any cash dividends will be within the discretion of our Board at such time. Our ability to pay dividends may also be restricted by the terms of any future credit agreement, or any of our or our subsidiaries&#8217; future debt, or preferred equity securities. See the subsection entitled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to Our Financial Condition and Capital Requirements&#8212;We have a significant amount of debt, which may affect our ability to operate our business and secure additional financing in the future</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_8">CAPITALIZATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and capitalization as of September&#160;30, 2024 on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an actual basis; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a pro forma basis, giving effect to the issuance and sale of $&#8195;&#8195;&#8195;&#8195; shares of our common stock (or <span style="white-space:nowrap">pre-funded</span> warrants in lieu of common stock) and accompanying common warrants in this offering at an assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share, which is the last reported sales price of our common stock on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2024, and accompanying common warrant, assuming no sale of any pre-funded warrants or exercise of any common warrants after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma information set forth in the table below is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined at pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following table in conjunction with the section titled &#8220;Use of Proceeds&#8221; in this prospectus and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes thereto included in this registration statement of which this prospectus forms a part for the three and nine months ended September&#160;30, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">AS&#160;OF&#160;SEPTEMBER&#160;30,&#160;2024</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">ACTUAL</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">PRO&#160;FORMA(1)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">(In thousands, except share<br/>and&#160;per share data)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of term loan, net of discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue Interest Financing liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Convertible Notes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value: 100,000,000 authorized, 2,260,159 shares issued and outstanding, actual; 100,000,000 shares authorized, &#8195;&#8195;&#8195;&#8195; shares issued and outstanding, pro forma, as adjusted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; equity (deficit):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value: 1,000,000,000 shares authorized, 64,369,381 shares issued and outstanding, actual; 1,000,000,000 shares authorized, &#8195;&#8195;&#8195;&#8195; shares issued and outstanding, pro forma, as adjusted;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(218,379</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity (deficit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(64,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each $1.00 increase or decrease in the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant would increase or decrease the as adjusted amount of each of cash and cash equivalents, additional <span style="white-space:nowrap">paid-in</span> capital, total stockholders&#8217; equity and total capitalization by $&#8195;&#8195;&#8195;&#8195;&#160;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting estimated placement agent fees and estimated offering expenses payable by us. Similarly, each increase or decrease of 1.0&#160;million in </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
the number of shares offered by us would increase or decrease the pro forma amount of each of cash and cash equivalents, additional <span style="white-space:nowrap">paid-in</span> capital, total stockholders&#8217; equity and total capitalization by $&#8195;&#8195;&#8195;&#8195;&#160;million, assuming no change in the assumed public offering price per share and accompanying common warrant, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting estimated placement agent fees and estimated offering expenses payable by us. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock, pro forma in the table above, is based on an aggregate of 64,369,381 shares of our common stock outstanding as of September&#160;30, 2024 and excludes the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">18,759,554 shares of common stock issuable upon the exercise of Public Warrants outstanding as of September&#160;30, 2024, with an exercise price of $8.10 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">403,658 shares of common stock issuable upon the exercise of the Rollover Warrants outstanding as of September&#160;30, 2024, with a weighted average exercise price of $5.33 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,567,484 shares of common stock issuable upon the exercise of the July 2024 Public Warrants, with an exercise price of $1.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants, with an exercise price of $1.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">7,108,316 shares of our common stock issuable upon the exercise of stock options outstanding as of September&#160;30, 2024 under the 2023 Plan at a weighted-average exercise price of $2.28 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">530,778 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of September&#160;30, 2024 under the 2023 Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">8,174,364 shares of our common stock reserved for future issuance pursuant to future awards under our 2023 Plan, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the 2023 Plan, as of September&#160;30, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,226,122 shares of our common stock reserved for future issuance, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the 2023 ESPP, as of September&#160;30, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">60,691,007 shares of common stock that may become issuable upon the conversion of the Notes pursuant to the Amended Note Purchase Agreement if the First Stockholder Approval is obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">9,339,234 shares of common stock available for future issuance under the Purchase Agreement with Chardan as of September&#160;30, 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">9,000,000 Contingency Shares reserved for issuance upon triggering events for such Contingency Shares. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_9">DILUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the public offering price per share of common stock and accompanying common warrant and the pro forma net tangible book value per share of common stock immediately after this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of September&#160;30, 2024 was $(63.8) million, or $(0.99) per share of common stock. Our historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities. Historical net tangible book value per share of common stock represents historical net tangible book value divided by an aggregate of shares of our common stock outstanding as of September&#160;30, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the issuance and sale of our common stock (or pre-funded warrants in lieu of common stock) and common warrants in this offering at an assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant, which is the last reported sales price of our common stock on the NYSE on &#8195;&#8195;&#8195;&#8195;, 2024, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting the estimated placement agent fees and estimated offering expenses payable by us, our pro forma net tangible book value as of September&#160;30, 2024 would have been $(&#8195;&#8195;&#8195;&#8195;) million, or $(&#8195;&#8195;&#8195;&#8195;) per share of common stock. This represents an immediate increase in pro forma net tangible book value per share of $&#8195;&#8195;&#8195;&#8195; to existing stockholders and immediate dilution of $&#8195;&#8195;&#8195;&#8195; in pro forma net tangible book value per share to new investors purchasing shares of common stock (or pre-funded warrants in lieu of common stock) and accompanying common warrants in this offering. Dilution per share to new investors is determined by subtracting pro forma net tangible book value per share of common stock after this offering from the assumed public offering price per share and accompanying common warrant paid by new investors. The following table illustrates this dilution on a per share basis: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share and accompanying common warrant</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value (deficit) per share as of September&#160;30, 2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.99)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value (deficit) per share immediately after this offering</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(&#8195;&#8195;)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the actual public offering price and other terms of this offering determined at pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase in the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; per share and accompanying common warrant would increase our pro forma net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195; and dilution per share to new investors purchasing shares of common stock in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, that no exercise of any common warrants issued in this offering, and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 decrease in the assumed public offering price of $&#8195;&#8195;&#8195;&#8195; would decrease our pro forma net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195; and dilution per share to new investors purchasing shares of common stock in this offering by $(&#8195;&#8195;&#8195;&#8195;), assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, assuming no sale of any pre-funded warrants or exercise of any common warrants and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An increase of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase our pro forma net tangible book value per share after this offering by $&#8195;&#8195;&#8195;&#8195; and decrease the dilution per share to new investors purchasing shares of common stock and accompanying common warrants in this offering by $(&#8195;&#8195;&#8195;&#8195;), assuming no change in the assumed public offering price per share and accompanying common warrant, no sale of any pre-funded warrants or exercise of any common warrants and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would decrease our pro forma net tangible book value per share after this offering by $(&#8195;&#8195;&#8195;&#8195;) and increase the dilution per share to new investors purchasing shares of common stock (or pre-funded warrants in lieu of common stock) and accompanying common warrants in this offering by $&#8195;&#8195;&#8195;&#8195;, assuming no change in the assumed public offering price per share and accompanying common warrant, no sale of any pre-funded warrants or exercise of any common warrants, and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations (other than the historical net tangible book value calculation) are based on an aggregate of 64,369,381&#160;shares of our common stock outstanding as of September&#160;30, 2024 and excludes the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">18,759,554 shares of common stock issuable upon the exercise of our existing publicly traded warrants to purchase shares of common stock outstanding as of September&#160;30, 2024, with an exercise price of $8.10 per share (the &#8220;Public Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">403,658 shares of common stock issuable upon the exercise of existing warrants to purchase shares of common stock outstanding as of September&#160;30, 2024, with a weighted average exercise price of $5.33 per share (the &#8220;Rollover Warrants&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,567,484 shares of common stock issuable upon the exercise of the July 2024 Public Warrants, with an exercise price of $1.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants, with an exercise price of $1.20 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">7,108,316 shares of common stock issuable upon exercise of options outstanding as of September&#160;30, 2024, with a weighted-average exercise price of $2.28 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">530,778 shares of common stock issuable upon the vesting of restricted stock units outstanding as of September&#160;30, 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">8,174,364 shares of common stock available for future issuance as of September&#160;30, 2024 under the Allurion Technologies, Inc. 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">2,226,122 shares of common stock available for future issuance as of September&#160;30, 2024 under the Allurion Technologies, Inc. 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">60,691,007 shares of common stock that may become issuable upon the conversion of the Notes pursuant to the Amended Note Purchase Agreement if the First Stockholder Approval is obtained; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">9,339,234 shares of common stock available for future issuance under the Purchase Agreement with Chardan as of September&#160;30, 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">9,000,000 shares of common stock that may be issued pursuant to the earnout provisions of the Business Combination Agreement (&#8220;Contingency Shares&#8221;) reserved for issuance upon triggering events for such Contingency Shares. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_10">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless the context otherwise requires, all references in this section to the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refer to the business of Legacy Allurion and its subsidiaries prior to the consummation of the Business Combination and to Allurion (formerly known as Allurion Technologies Holdings, Inc.) and its subsidiaries after giving effect to the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company is dedicated to ending obesity by creating a <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> weight loss platform to treat the estimated two billion people globally who are overweight. Our platform, the Allurion Program (the &#8220;Allurion Program&#8221;), features the world&#8217;s first and only swallowable, Procedureless<sup style="font-size:75%; vertical-align:top">TM</sup> intragastric balloon for weight loss (the &#8220;Allurion Balloon&#8221;) and offers access to artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a behavior change program, secure messaging and video telehealth that are delivered by the Allurion Virtual Care Suite (&#8220;VCS&#8221;). Over 150,000 patients have already been treated commercially with the Allurion Balloon in over 50 countries outside of the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon is swallowed as a capsule under the guidance of a health care provider without surgery, endoscopy, or anesthesia. The placement takes approximately 15 minutes during an outpatient visit (though times may vary across different outpatient offices). We believe the proprietary technologies that differentiate the Allurion Balloon enable improved safety and efficacy outcomes. In a prospective, <span style="white-space:nowrap">non-randomized,</span> open-label, registry trial, the Allurion Balloon demonstrated significant weight loss and low device- or procedure-related rates of serious adverse events, both of which results we believe compare favorably to that of our competitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The VCS is comprised of the following tools to support patients&#8217; weight loss experience, which we believe benefit both patients and health care providers: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For Allurion Program patients: Every current Allurion Program patient receives an Allurion Connected Scale (&#8220;Allurion Connected Scale&#8221;) and access to our mobile app (&#8220;App&#8221;), which integrates data from the Allurion Connected Scale, to conveniently monitor weight, body fat, activity, sleep, and several other critical metrics. The App can also enable secure messaging and video telehealth with the patient&#8217;s care team and can deliver content from Allurion&#8217;s behavior change program&#8212;a library of 100 weight loss actions related to diet, nutrition, mental health, sleep, goal setting, and a number of other topics-directly to the patient. The App also provides access to Coach Iris, a generative <span style="white-space:nowrap">AI-powered</span> health coach designed to enhance outcomes with the Allurion Program, offer <span style="white-space:nowrap">always-on</span> support, education and motivation, and maximize clinical efficiency. The App is available in 15 languages. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For Allurion Program providers: Every Allurion Program provider receives access to our clinic dashboard (&#8220;Allurion Insights&#8221;), which provides <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> remote patient monitoring powered by the Allurion Iris AI platform, which leverages machine learning to deliver key insights and streamline workflow. Allurion Insights offers real-time access to patient data and <span style="white-space:nowrap">AI-powered</span> analytics, 1:1 video telehealth and secure messaging directly to the patient&#8217;s App, note functionality to keep track of patient encounters, and clinic-wide metrics that provide a snapshot of the clinic&#8217;s overall performance. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its use by Allurion Balloon patients, we believe the VCS can potentially be a platform for optimal long-term <span style="white-space:nowrap">follow-up</span> after other medical and surgical weight loss interventions in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, VCS includes a Treatment Tracking and <span style="white-space:nowrap">Clinic-Led</span> Onboarding feature that enables seamless onboarding and management of patients undergoing one or multiple weight loss treatments, including gastric balloons such as the Allurion Balloon, surgery, or medications. In addition, in connection with our collaboration with Medtronic plc, we expect to develop bundled offerings that incorporate the VCS to onboard and manage Medtronic&#8217;s patients. Further, in April 2024, we launched the VCS in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, we launched AllurionMeds, a unique offering to patients that combines affordable and accessible weight loss medications with our <span style="white-space:nowrap">AI-native</span> platform to promote long-term weight maintenance, virtual access to dieticians and the Allurion Connected Scale that measures not just weight but muscle and bone mass. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2021, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved the investigational device exemption (the &#8220;IDE&#8221;), for our AUDACITY trial, a <span style="white-space:nowrap">48-week,</span> prospective, randomized, open-label trial, in the United States. Enrollment in the AUDACITY trial is complete, with 550 patients in the trial across 17 sites in the United States, the first of which was treated in July 2022. The results of the trial are expected by <span style="white-space:nowrap">year-end</span> 2024, and, if positive, are expected to support a premarket approval (the &#8220;PMA&#8221;) to the FDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a broad portfolio of intellectual property related to our medical device, the Allurion Balloon, and our supporting technology platform, the VCS. We believe this intellectual property, combined with proprietary manufacturing processes and the regulatory approvals we have successfully obtained outside of the United States, provides us with a strong market position. As of November&#160;29, 2024, we owned or had rights to 19 issued and five pending patents in the United States related to various aspects of our Allurion Balloon such as a swallowable, self-deflating and naturally passing gastric balloon, improvements to the fill and release valves therein, methods for deploying and releasing a gastric balloon within the body, and next generation fill and release valves. In addition, as of November&#160;29, 2024, we had 39 issued and five patents pending outside of the United States. We intend to continue to expand our intellectual property portfolio and invest in protecting new innovations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, most of our revenues have been generated from sales of the Allurion Balloon. We began selling the Allurion Balloon in Europe in January 2016 and to date have launched in over 50 countries outside of the United States. We currently sell our products either via our direct sales force or, in certain countries, distributors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Market Opportunity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the World Health Organization (&#8220;WHO&#8221;), over two billion people around the world are overweight and by 2030, one billion people globally will have obesity, defined as a body mass index (&#8220;BMI&#8221;) of 30 or greater. Likewise, according to WHO, the number of obese adults worldwide has nearly tripled since 1975. The global obesity treatment market is expected to be $54&#160;billion by 2030. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, according to WHO, obesity is the leading cause of chronic diseases worldwide and leads to a higher risk of cardiovascular disease, type 2 diabetes, infertility, liver disease, and certain cancers. According to McKinsey, the annual global economic impact of obesity is estimated to be over $2 trillion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect the rates of obesity to rise globally as access to calorie-rich foods increases and lifestyles become increasingly sedentary, especially among adolescents. According to WHO, the prevalence of obesity in children and adolescents has increased <span style="white-space:nowrap">10-fold</span> in the past four decades and will fuel higher rates of adult obesity in the decades to come. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant medical and economic burden that obesity poses, there remains a significant unmet need for safer, more effective, and more consumer-centric treatments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on a market research study we conducted with 9,800 consumers in eight countries, where we assessed each participant&#8217;s weight, income level, and interest in various weight loss alternatives, we estimate that 4.3% of the population eligible for the Allurion Balloon and interested in treatment would consider the Allurion Program as a treatment for obesity. Furthermore, based on our market research, we estimate that 3% of the adult U.S. population, or approximately 10&#160;million adults, would consider the Allurion Program as a weight loss treatment. We believe this is an $18&#160;billion total addressable market in the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Current Therapeutic Interventions Used in Weight Loss </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current treatment alternatives for patients who are obese and overweight begin with lifestyle modification, such as diet and exercise. If this course of treatment fails to produce the desired results, as is often the case, physicians may prescribe pharmaceutical therapies, and in patients with more severe obesity, physicians may pursue aggressive bariatric surgical treatments, such as gastric bypass and sleeve gastrectomy. These approaches are associated with concerns around safety, permanence, lifestyle impact, ease of use, cost and compliance issues, as well as the significant weight <span style="white-space:nowrap">re-gain</span> associated with such approaches that have limited their adoption. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Lifestyle Modification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lifestyle modification, which includes diet, exercise and behavior modification delivered either <span style="white-space:nowrap">in-person</span> or digitally, is usually prescribed as an initial treatment for a patient who is obese or overweight. However, lifestyle modification alone has generally been ineffective in producing sustainable weight loss in patients with obesity due to poor adherence over an extended period. Many studies have shown that a significant majority of dieters will regain lost weight and many will gain more than they originally lost. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pharmaceutical Therapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical therapy often represents a first option in the treatment of patients with obesity who have failed to achieve weight loss goals through lifestyle modifications alone. Pharmaceutical therapies can have limited effectiveness due to <span style="white-space:nowrap">non-adherence</span> and, in most cases, need to be taken for life. In addition, more recent pharmaceutical therapies, commonly known as <span style="white-space:nowrap">GLP-1s,</span> require once weekly injections and impose significant financial costs on the patient. Since these drugs are absorbed into the bloodstream, they have been shown to pose significant safety risks and negative systemic side effects, such as adverse gastrointestinal, cardiovascular and central nervous system issues, some of which are serious or life threatening. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Bariatric Surgery </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bariatric surgery is a treatment option generally reserved for cases of severe obesity in patients with a BMI greater than 40. Each year, approximately 580,000 people undergo bariatric surgery worldwide. The most common forms of bariatric surgery, gastric bypass and sleeve gastrectomy, promote weight loss by surgically restricting the stomach&#8217;s capacity and outlet size. Gastric bypass also affects weight loss by restricting the body&#8217;s ability to absorb nutrients. These procedures are highly invasive, inherently risky in a high BMI population, expensive for the patient, and irreversible. Moreover, patients cite fear of complications as the primary reason to not pursue bariatric surgery. Only one percent of patients who qualify for bariatric surgery actually get it. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bariatric surgery patients are generally required to make significant postoperative lifestyle changes, including strict dietary changes, vitamin supplementation and long-term medical <span style="white-space:nowrap">follow-up</span> programs. Side effects of bariatric surgery include a high rate of <span style="white-space:nowrap">re-operation,</span> nausea, vomiting, dumping syndrome, dehydration, and even death. Moreover, up to 25% of patients undergoing bariatric surgery will regain all of the weight previously lost as a result of the surgery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Recently Developed Treatment Alternatives </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the shortcomings and limitations of existing treatment alternatives, new medical procedures have recently been introduced. Endoscopic balloon therapy involves an endoscopic procedure with anesthesia to implant a balloon in the stomach that leads to satiety, followed by another endoscopic procedure with anesthesia several months later to remove the balloon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe high costs, procedural complexity, poor consumer experiences, lack of ongoing patient support and <span style="white-space:nowrap">follow-up,</span> and the risk of serious side effects have limited the adoption of endoscopic balloon therapy: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">1.</span> <span style="font-weight:bold">Rate of SAEs.</span> In the ReShape Lifesciences, Inc. pivotal clinical trial for its ReShape Integrated Duo Balloon System, 31 device- or procedure-related serious adverse events were reported in 20 patients, resulting in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a serious adverse event (&#8220;SAE&#8221;) rate of approximately 7.5%. Similarly, in the Apollo Endosurgery, Inc. pivotal clinical trial for its ORBERA Intragastric Balloon System, 17 SAEs were reported in 16 patients, resulting in an SAE rate of approximately 10%. In both trials, there were multiple SAEs related to the endoscopy and anesthesia required for placement and removal of the balloons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">2.</span> <span style="font-weight:bold">Lack of comfort and tolerability.</span> The ReShape Duo Balloon and ORBERA Balloon are manufactured from thick silicone containing rigid components. We believe that the materials used in these balloons can lead to discomfort, trauma to the stomach lining, and growth of bacteria and fungi on the balloon surface. Intolerance rates in endoscopic balloons requiring the balloons to be removed were approximately <span style="white-space:nowrap">14-17%,</span> compared with approximately <span style="white-space:nowrap">1-3%</span> for the Allurion Balloon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">3.</span> <span style="font-weight:bold">Limited ability to provide progressive and sustained weight loss.</span> For patients receiving balloon treatment in the ReShape Duo Balloon pivotal trial, the mean weight loss at 24 weeks was just 14.3 pounds. Furthermore, the average treatment subject in ReShape&#8217;s pivotal trial with weight loss at 24 weeks regained 40% of the weight loss at 48 weeks, resulting in a mean weight loss of 9.9 pounds at 48 weeks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">4.</span> <span style="font-weight:bold">Inconvenient placement procedure.</span> The placement procedures for the ReShape Duo Balloon and the ORBERA Balloon require both the device placement and the device removal to be performed in an endoscopic procedure using anesthesia. The patient cannot immediately return to normal activities and must be placed under medical observation for at least a few hours until cleared to go home. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Platform </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Allurion Program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Program features the Allurion Balloon and offers access to the VCS, a cutting-edge digital therapeutic that combines <span style="white-space:nowrap">AI-powered</span> remote patient monitoring tools with a behavior change program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Allurion Balloon </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon is a first of its kind, Procedureless<sup style="font-size:75%; vertical-align:top">TM</sup> intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). Once the capsule is in the stomach, a delivery catheter is used to fill the Allurion Balloon with approximately 550 milliliters of filling fluid. Approximately four months later, a patented time-activated ReleaseValve<sup style="font-size:75%; vertical-align:top">&#8482;</sup> opens and allows the balloon to empty and pass out of the body naturally, although in rare cases, endoscopic or surgical intervention may be required for removal. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g81a01.jpg" alt="LOGO" style="width:5.96317in;height:3.05333in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon is designed to help reduce a patient&#8217;s food intake by taking up space in the stomach and slowing the rate at which the stomach empties. By the time the Allurion Balloon passes, patients develop new food preferences, including smaller portion sizes, which we believe leads to maintainable, long-lasting results. We believe our clinical studies support that the Allurion Balloon can be swallowed, filled, and passed, and provide short and long-term therapeutic benefit while minimizing risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon is comprised of several novel and innovative features that differentiate it from previous intragastric balloons and enable it to be swallowed and then naturally passed, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Dissolvable capsule.</span> We designed the capsule to be large enough to accommodate the folded balloon, yet small enough to be swallowed. The capsule is titrated to optimize dissolution timing. If the capsule dissolves too quickly, the balloon could be prematurely released before entering the stomach, and if too slowly, the patient and physician are inconvenienced by having to wait longer to fill the balloon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Balloon film.</span> Our film is made from a polyether polyurethane that was specifically chosen to be extrudable into a film thin enough to fit into a capsule and pass through the gastrointestinal tract yet impervious to the chemical environment and mechanical forces of the stomach. The film is biocompatible, cost-effective to extrude and manufacture, and puncture resistant, all while being smooth and atraumatic to the gastrointestinal lining. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Balloon valves.</span> Our Allurion Balloon contains two valves: a fill valve and ReleaseValve<sup style="font-size:75%; vertical-align:top">&#8482;</sup>. The valves are constructed from polyurethane film and, unlike valves used in other intragastric balloons, there are no rigid parts. This design ensures that the valves are atraumatic to the stomach lining and can pass through the gastrointestinal tract without obstructing. Both valves are small and flexible so that they can be folded to fit inside the capsule. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The fill valve is designed to reseal after the delivery catheter is removed. It also contains a radiopaque marker so that the Allurion Balloon can be visualized on <span style="white-space:nowrap">x-ray.</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The ReleaseValve<sup style="font-size:75%; vertical-align:top">&#8482;</sup> is constructed from a degradable polymer that faces the inside of the Balloon. Once the degradable polymer is fully degraded, the ReleaseValve<sup style="font-size:75%; vertical-align:top">&#8482;</sup> opens, the Allurion Balloon empties and then passes through the gastrointestinal tract to be excreted. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Delivery catheter.</span> Our delivery catheter is designed to quickly fill the Allurion Balloon. It is small, flexible, and smooth in order to minimize any potential discomfort to the patient during balloon placement. In addition, the catheter contains length markings to measure transit through the esophagus and into the stomach and is radiopaque to facilitate visualization on <span style="white-space:nowrap">x-ray.</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Allurion Virtual Care Suite </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The VCS is a cutting-edge digital therapeutic that combines <span style="white-space:nowrap">AI-powered</span> remote patient monitoring tools with a behavior change program. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g82a01.jpg" alt="LOGO" style="width:3.07667in;height:1.77667in"/>
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The VCS is comprised of tools to support patients&#8217; weight loss experience, which we believe benefit both patients and health care providers: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For patients, the App integrates data from the Allurion Connected Scale, smart watches and other wearables and trackers to conveniently monitor weight, body fat, activity, sleep, and several other critical metrics. The App also enables secure messaging and video telehealth with the patient&#8217;s care team and delivers content from our behavior change <span style="white-space:nowrap">program-a</span> library of 100 weight loss actions developed by our team of behavior change experts related to diet, nutrition, mental health, sleep, goal setting, and a number of other topics-directly to the patient. The App also provides access to Coach Iris, a generative <span style="white-space:nowrap">AI-powered</span> health coach designed to enhance outcomes with the Allurion Program, offer <span style="white-space:nowrap">always-on</span> support, education and motivation, and maximize clinical efficiency. The App is available in 15 languages. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g83a01.jpg" alt="LOGO" style="width:6.30556in;height:3.15278in"/>
 </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For health care providers, Allurion Insights provides <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> remote patient monitoring powered by the Allurion Iris AI platform, which leverages machine learning to deliver key insights and streamline workflow. Allurion Insights includes a feature called Success Predictor which uses a machine learning algorithm to predict which patients are on track to succeed with their weight loss goals and which patients are not on track. Allurion Insights offers real-time access to patient data and <span style="white-space:nowrap">AI-powered</span> analytics, 1:1 video telehealth and secure messaging directly to the patient&#8217;s App, note functionality to keep track of patient encounters, and clinic-wide metrics that provide a snapshot of the clinic&#8217;s overall performance. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g83a02.jpg" alt="LOGO" style="width:6.12333in;height:2.41in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its use by Allurion Balloon patients, we believe the VCS can potentially be a platform for optimal long-term follow up after other medical and surgical weight loss interventions in the future. In June 2022, we incorporated a Treatment Tracking and <span style="white-space:nowrap">Clinic-Led</span> Onboarding feature into the VCS, which enables seamless onboarding and management of patients undergoing one or multiple weight loss treatments including gastric balloons such as the Allurion Balloon, surgery, or medications. In addition, in connection with our collaboration with Medtronic, we expect to develop bundled offerings that incorporate the VCS to onboard and manage Medtronic&#8217;s patients. Further, in April 2024, we launched the VCS in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Allurion Program Trials </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Balloon has demonstrated favorable short and long-term results for weight loss and resolution of <span style="white-space:nowrap">co-morbidities</span> in multiple trials, with few adverse events. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a prospective, <span style="white-space:nowrap">non-randomized,</span> open-label, registry trial of 1,770 patients, Allurion Balloon patients lost 14% of total body weight or 30 pounds on average after just four months. In another trial of 509 patients, average weight loss was 13.9% of total body weight at four months and 13.3% of total body weight at one year after balloon passage, representing a 96% maintenance of total body weight loss. In a third trial of 42 patients treated with a second balloon, average total body weight loss was 23%. In a study of 5,003 patients treated with the Allurion Program, patients lost an average of 14% after 4 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a trial of 232 Allurion Balloon patients who maintained ongoing lifestyle modification after balloon passage, average weight loss was 17% of total body weight at one year; In another trial of 522 Allurion Balloon patients, 96% of weight loss was maintained one year after removal of the Allurion Balloon. In a trial of 181 patients that combined Allurion Balloon treatment with a <span style="white-space:nowrap">GLP-1</span> weight loss drug, the first multi-center trial of balloon and drug combination therapy demonstrating significant synergies, average weight loss was 19% of total body weight at eight months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a trial of 518 patients (225 with type 2 diabetes and 293 with <span style="white-space:nowrap">pre-diabetes)</span> treated with the Allurion Program, those with type 2 diabetes reduced their hemoglobin A1c (HbA1c) on average by 1.6 points, or 23%, and those with <span style="white-space:nowrap">pre-diabetes</span> reduced their HbA1c by 0.8 points, or 14%. In a separate trial of 115 patients treated with the Allurion Balloon, <span style="white-space:nowrap">co-morbidities</span> were reduced meaningfully&#8212;56% resolution of Type 2 diabetes, 59% resolution of hypertension, and 58% resolution of obstructive sleep apnea. When combined with <span style="white-space:nowrap">GLP-1</span> drugs, patients showed 17.6% weight-loss on average after four months. A separate trial of 42 patients showed that after two sequential balloons, 26% percent of patients achieved weigh loss of 30% or more. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA approved the IDE for our AUDACITY trial, a <span style="white-space:nowrap">48-week,</span> prospective, randomized, open-label trial comparing the Allurion Balloon to moderate intensity lifestyle intervention. We received approval of the IDE </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from the FDA in November 2021 to initiate the AUDACITY clinical trial in the United States. The first patient was treated in July 2022. During the third quarter of 2023, we completed the enrollment of 550 patients in the trial across 17 sites in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subjects in the treatment arm will be eligible for up to two Allurion Balloons. <span style="white-space:nowrap">Co-primary</span> endpoints of the trial include a 50% responder rate, defined as greater than 5.0% of total body weight loss, at 48 weeks following balloon placement, and a 3.0% total body weight loss superiority margin at 48 weeks. The results of the trial, if positive, are expected to support a PMA application to the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prior ENLIGHTEN Trial </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AUDACITY&#8217;s trial design reflects the FDA&#8217;s updated recommendations for weight loss devices and builds upon the ENLIGHTEN trial, our prior IDE trial which was conducted in 2018-2019. The ENLIGHTEN trial featured a sham-controlled design with one balloon cycle. The Allurion Balloon met the <span style="white-space:nowrap">co-primary</span> endpoint related to responder rate but failed to meet the <span style="white-space:nowrap">co-primary</span> endpoint on superiority margin due to sham overperformance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, the FDA issued a White Paper on Weight Loss Devices after safety issues were encountered with other weight loss balloons (ReShape and ORBERA) on the market. The FDA&#8217;s updated guidance for clinical trials for weight loss balloons required increased efficacy and increased the minimum treatment duration to 6 months with a preference for <span style="white-space:nowrap">one-year</span> outcomes. We designed the AUDACITY trial in collaboration with the FDA in 2021 to address these new criteria. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that AUDACITY improves upon ENLIGHTEN given the open-label trial design (i.e., no sham), utilization of multiple balloon cycles, and alignment with the FDA&#8217;s updated guidance on intragastric balloons for weight loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">French Regulatory Decision </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2024, it was announced that the Agence Nationale de S&#233;curit&#233; du M&#233;dicament (&#8220;ANSM&#8221;), the French regulatory authority, has suspended sales of the Allurion Balloon in France, and we withdrew the device from the French market. We submitted and have implemented a remediation plan to reduce certain risks associated with the advertising, <span style="white-space:nowrap">follow-up</span> program, and adverse events for the Allurion Balloon.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we disagree with ANSM&#8217;s decision, we are fully cooperating and are in active dialogue with the agency regarding our remediation program prioritizing changes related to its advertising strategy, <span style="white-space:nowrap">follow-up</span> program and training programs to address ANSM&#8217;s concerns. We are committed to continuing our engagement with ANSM to identify a path that will enable us to resume the commercialization of the Allurion Balloon in France.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Business Model </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">business-to-business-to-consumer</span></span></span></span> business model creates an economic benefit for all key stakeholders. Health care providers may benefit from providing the Allurion Program because it addresses a significant unmet need for their patients and is designed to not require time-consuming surgery, endoscopy, or anesthesia. Moreover, we can provide our product to health care providers who have historically not been able to provide cash pay weight loss procedures, because the Allurion Balloon does not require endoscopy or anesthesia for placement and hence there are fewer restrictions on the type of doctor that can use the Allurion Balloon versus other balloons. Patients may benefit because placement procedures do not require invasive surgery, endoscopy, or anesthesia and hence may reduce the overall cost and inconvenience of getting treated. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our platform addresses the following limitations of current weight loss treatments: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Poor patient and health care provider experience.</span> Many other weight-loss innovations lack remote patient monitoring or behavior modification. By combining a therapeutic medical device with remote patient monitoring and behavior modification, we believe we can improve both the patient and provider experiences. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">More complex safety profile.</span> Weight loss treatments that require surgery, endoscopy, or anesthesia may result in SAEs that limit adoption. These invasive procedures are inherently risky in a high BMI population, especially where patients must undergo anesthesia. The Allurion Balloon has been observed to result in fewer SAEs when compared to other balloons. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Poor economics.</span> <span style="white-space:nowrap">All-in</span> costs for <span style="white-space:nowrap">cash-pay</span> bariatric surgery can cost patients approximately $14,000 <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> on average and up to approximately $33,000 with limited insurance coverage. Weight loss drugs can cost patients as much as $1,000 per month, and weight loss is dependent on patients continuing to use the drugs for life. By removing endoscopy and anesthesia from the placement and removal (except in rare cases) of the Allurion Balloon, we believe that the Allurion Program is significantly more affordable for patients than the alternatives while maintaining attractive health care provider economics. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Limited channels.</span> We believe most health care providers lack the necessary infrastructure and training to deliver a comprehensive weight-loss platform. Moreover, interventions that require surgery, endoscopy or anesthesia must be performed by gastroenterologists or surgeons, many of whom are not weight-loss specialists. We believe that the Allurion Program can be delivered by a much wider group of health care providers across multiple specialties. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Flawed <span style="white-space:nowrap"><span style="white-space:nowrap">go-to-market</span></span> strategy.</span> We believe other weight-loss companies have deployed strategies which fail to embrace <span style="white-space:nowrap">modern-day</span> digital advertising and account training techniques. We believe that the strategies we have developed to acquire leads, increase conversion through the funnel, and educate providers significantly improve the scalability of our business compared to the competition. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g86a01.jpg" alt="LOGO" style="width:4.70333in;height:2.42667in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Competitive Strengths </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed the Allurion Program to overcome the limitations of other weight loss treatments, including the other intragastric balloons. Based on our commercial experience in over 150,000 patients, we believe that the Allurion Program provides considerable advantages to patients and providers: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Consumer-centric, Procedureless</span></span><span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">TM</sup></span></span><span style="font-weight:bold"><span style="font-style:italic"> technology with favorable safety profile. </span></span>The Allurion Balloon does not require surgery, endoscopy, or anesthesia for placement; in rare cases, endoscopic or surgical intervention </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be required for removal. We believe this results in a safer, easier, faster, and more convenient patient experience at a lower cost and a device that can be administered by a wide array of providers. Though the Allurion Balloon has not been compared in <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> trials with other liquid-filled intragastric balloons, Allurion has reported a lower device or procedure-related SAE rate than competing intragastric balloons, with considerably better weight loss results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">More than just a balloon: an <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> weight management platform powered by AI and data.</span></span> The Allurion Program features a uniquely designed medical device and offers access to a clinically-proven behavior change program and <span style="white-space:nowrap">AI-powered</span> remote patient monitoring through the VCS. We believe this holistic approach can improve outcomes for patients, streamline provider workflow, enable <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> weight management, and open the door to a life-long relationship with the patient. Further, we believe that the ongoing stream of data we receive on patient outcomes and provider productivity will enable us to enhance the capabilities of our AI platform and further expand our data moat. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g87a01.jpg" alt="LOGO" style="width:6.30556in;height:3.49291in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Life-changing clinical outcomes that are fast yet durable.</span></span> On average, Allurion Program patients lose 14% of their total body weight (approximately 14kg or 30lbs) over just four months and sustain 96% of that weight loss at one year. We have also observed similarly significant effects on obesity-related <span style="white-space:nowrap">co-morbidities</span> like type 2 diabetes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Attractive economics for patients and providers.</span></span> By eliminating endoscopy and anesthesia from balloon placement and removal, we believe that we have made our weight loss product more affordable to the patient and more lucrative for the provider compared to the competition. Health care providers can treat patients with a high- margin device in just a <span style="white-space:nowrap">15-minute</span> office visit, which when compared to devices that require hospital stays, significantly improves profitability per hour. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Broad patent portfolio and proprietary manufacturing capabilities. </span></span>We have a broad portfolio of intellectual property-including 58 issued patents protecting our products as of November&#160;29, 2024, which we believe, when combined with our proprietary manufacturing processes and <span style="white-space:nowrap">know-how,</span> leads to a significant competitive moat. Currently, the Allurion Balloon is manufactured and assembled <span style="white-space:nowrap">in-house</span> using components and <span style="white-space:nowrap">sub-assemblies</span> at our facilities in Natick, Massachusetts, which further enhances our ability to maintain high levels of quality and protect manufacturing trade secrets that we have developed since inception. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Proven management team with expansive industry experience.</span></span> Our executive team consists of seasoned medical device and digital health professionals with deep industry experience and expertise, who have led and managed high-growth private and public companies that have introduced and commercialized multiple new products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Growth Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective is to become the world&#8217;s leading weight loss treatment provider and fulfill our mission to end obesity. The key elements to our strategy are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Broaden our Global Presence. </span>The Allurion Program is currently sold in over 50 countries around the world. In these existing markets, we employ a multi-faceted marketing strategy that includes online advertising, <span style="white-space:nowrap">co-op</span> marketing campaigns, and professional education programs. This approach enables us to engage with and educate patients and providers, increase the awareness and credibility of our program, provide qualified leads to our accounts, and increase the productivity of our providers. We intend to invest strategically in our existing markets and leverage the commercial strategies we have deployed successfully thus far to drive procedure and revenue growth by increasing the productivity of existing accounts and opening new, high-potential accounts. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Launch the Allurion Program in New Markets, including the U.S.</span> The addressable market for the Allurion Balloon in the United States is currently over $10&#160;billion. To commercialize in the United States, we are conducting our <span style="white-space:nowrap">FDA-approved</span> clinical trial, AUDACITY. We expect readout data for this trial by <span style="white-space:nowrap">year-end</span> 2024, which, if positive, will support our PMA submission to the FDA. In addition to the United States, we anticipate expanding in new, key markets in the future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Scale and Monetize VCS.</span> The Allurion Program is an <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> weight management platform powered by AI and data through the VCS. Currently, providers report that the VCS is driving increased productivity, improved outcomes, and higher patient engagement during the balloon phase. We have also expanded the sale of the VCS in a Software as a Service model, including the launch of the VCS in the United States, to be used in clinics for their patients before and after balloon therapy to drive even better short and long-term outcomes. In addition, VCS can be a stand-alone opportunity that can be used by patients undergoing other weight loss interventions, including the use of <span style="white-space:nowrap">GLP-1s.</span> We believe this opportunity to be complimentary to, not just competitive with, other weight loss interventions that can be a key to our growth. 45% of our providers believed that other anti-obesity medications boosted awareness and/or interest in the Allurion Balloon. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand label, advance product pipeline, and strengthen weight loss platform.</span> We plan to leverage our proprietary product technology and research and development expertise to expand our current label, if approved, into adolescents and a lower BMI population. We also plan to develop products for weight loss that improve clinical outcomes, increase ease of use, and reduce costs. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Strengthen Gross Margin and Improve Profitability.</span> Our gross margin was 78% in the year ended December&#160;31, 2023, and we believe that we can continue to increase our gross margin through increased sales volume and production efficiencies and from scaling the VCS software. In addition, we have implemented a number of operational efficiency initiatives to improve our profitability, reducing expected cash used in operating activities. With this expected continued improvement in profitability, we expect to be able to make key, strategic investments in our initiatives to drive growth. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed, manufactured, and commercialized the world&#8217;s first and only swallowable, Procedureless<sup style="font-size:75%; vertical-align:top">TM</sup> gastric balloon for weight loss, which we offer as part of our Allurion Program, a multi-faceted weight loss platform. Weight-loss treatments range from behavioral modification, to drugs and medical devices, and surgery. Outside the U.S., we compete with a variety of local and regional competitive intragastric balloon </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers including SC MedSil, Medicone and Spatz Laboratories. In the U.S., there are three manufacturers with an intragastric balloon approved by the FDA at this time: Boston Scientific Corporation, Inc., ReShape Lifesciences, Inc. and Spatz FGIA Inc. All of these balloons require endoscopy and anesthesia for placement and/or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also compete against the manufacturers of pharmaceuticals that are directed at treating weight loss, such as Novo Nordisk A/S, Eli Lilly&#160;&amp; Co., Roche Holding AG, GlaxoSmithKline plc, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the principal competitive factors in our market include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by health care providers and patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">published rates of safety and efficacy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reliability and high-quality performance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effectiveness at controlling <span style="white-space:nowrap">co-morbidities</span> such as diabetes and hypertension; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">invasiveness and the inherent reversibility of the procedure or device; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost and average selling price of products and relative rates of reimbursement, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effective marketing, training, education, sales and distribution; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">technological leadership and superiority; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">speed of product innovation and time to market. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, or their parent companies, are larger than we are, and they may enjoy several competitive advantages over us, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">stronger name recognition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">existing relationships with health care professionals, customers and third-party payers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">established distribution networks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant experience in research and development, manufacturing, preclinical testing, clinical trials, obtaining regulatory approvals, obtaining reimbursement and marketing approved products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater financial, sales and marketing, and manufacturing resources. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we cannot assure you that we will be able to compete effectively against these companies or their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a broad portfolio of intellectual property related to our medical device, the Allurion Balloon, and our supporting technology platform, the VCS. We believe this intellectual property, combined with proprietary manufacturing processes and the regulatory approvals we have successfully obtained in over 50 countries outside of the United States, provides us with a strong market position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;29, 2024, we owned or had rights to 19 issued patents and five pending patent applications in the U.S. related to various aspects of our Allurion Balloon, such as a swallowable, self-deflating and naturally passing gastric balloon, improvements to the fill and release valves therein, methods for deploying and releasing a gastric balloon within the body, and next generation fill and release valves. In addition, outside of the United </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States we had 39 issued and five patents pending that generally parallel the U.S. portfolio in 17 countries as of November&#160;29, 2024. We are not currently licensing any patents. Allurion owns and possesses all right, title and interest in and to each patent and patent application noted herein free and clear of all liens, other than any liens granted to RTW pursuant to our royalty arrangements and Amended Note Purchase Agreement with RTW. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our issued patents are expected to expire at various times between February&#160;21, 2033 and November&#160;27, 2040. The following table sets forth a summary of our patents and patent applications, including where patent applications have been filed, the exemplary subject matter being pursed in the applications, and expected expiration dates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:20%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Family<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Jurisdictions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Patent/Application&#160;&amp;<br/>Status</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exemplary Subject<br/>Matter and Scope</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Australia; Brazil; Canada; China; Europe; Israel; India; Japan; South Korea; Mexico; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted European patent validated in Germany; Spain; France; United Kingdom; Ireland; Italy; granted Australia; Brazil; Canada; China; Israel; India; Japan; South Korea; Mexico; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Medical devices for temporary implantation within the body, such as a gastric space, and methods for temporarily occupying a space in the body, such as a gastric space</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2033</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Ingestible Delivery Systems and methods</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2033</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Australia; Brazil; China; Europe; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted European patent validated in France; United Kingdom; Ireland; granted Australia; Brazil; China; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Medical devices for temporary implantation within the body, such as a gastric space, and methods for temporarily occupying a space in the body, such as a gastric space; improved fill valves for use with the medical devices</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2033, 2036</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">European Patent Convention; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pending patent applications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Medical devices for temporary implantation within the body, such as a gastric space, and methods for temporarily occupying a space in the body, such as a gastric</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2033, 2036</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:20%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:17%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Family<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Jurisdictions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Patent/Application&#160;&amp;<br/>Status</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exemplary Subject<br/>Matter and Scope</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Expiration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Type</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">space; improved fill valves for use with the medical devices</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Automatic-Sealing Balloon- Filling Catheter Systems and methods of use</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2039</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Europe; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pending patent applications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Automatic-Sealing Balloon- Filling Catheter Systems and methods of use</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2039</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">China; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted China; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Binary fluid control valve systems</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2039</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Europe; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pending patent applications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Binary fluid control valve systems</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2039</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">6</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Granted</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Enhanced Fluid Delivery System</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2040</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">China; United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pending patent applications</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Fluid Delivery Catheter</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2041</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center">8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Pending patent application</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Automatic-Sealing Balloon- Filling Catheter Systems and methods of use</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">2043</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Utility</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are protecting three Allurion-related trademarks in three classes: medical devices (the balloon), downloadable software and digital scale (the mobile app), and medical services (provided by our physicians). As of November&#160;29, 2024, we have 65 registered trademarks among 14 jurisdictions (which jurisdictions include the 27 member states of the European Union). It is our intention to maintain these registrations indefinitely and to expand the number of jurisdictions in which we have registered trademarks as deemed necessary to protect our freedom to use the marks and/or block competitors in additional markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also hold registrations to the &#8220;Elipse&#8221; trademark in three classes in four jurisdictions; it is our intention to allow these registrations to lapse at the end of their current terms as we are no longer identified by this trademark. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to pursuing patents on our products, we have taken steps to protect our intellectual property and proprietary technology by entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants, corporate partners, and, when needed, our advisors. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure. Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. In addition, we intend to expand our international operations, and effective patent, copyright, trademark and trade secret protection may not be available or may be limited in foreign countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the medical device industry is characterized by the existence of a large number of patents and frequent allegations and related litigation regarding patent and other intellectual property rights. Third parties, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including our competitor companies, may assert patent, copyright, trademark and other intellectual property rights against us, our partners or our customers. Our standard license and other agreements may obligate us to indemnify our partners and customers against such claims. We could incur substantial costs and diversion of the attention of our management and technical personnel in defending against any such claims. Successful claims of infringement of a valid patent by a third party could prevent us from selling or distributing our products or performing certain services, require us to expend time and resources to develop <span style="white-space:nowrap">non-infringing</span> products, or force us to pay substantial damages (including treble damages if we are found to have willfully infringed patents), royalties or other fees. We cannot assure you that we do not currently infringe, or that we will not in the future infringe, upon any third-party patents or other proprietary rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to expand our intellectual property portfolio and invest in protecting new innovations developed in our pipeline programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Third-party open source software components. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion VCS and our other products and services contain software licensed to us by third-party authors under &#8220;open source&#8221; licenses. Use of such software may entail greater risks than use of <span style="white-space:nowrap">non-open</span> source third-party commercial software, as open source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. Although we seek to monitor our use of open source software to avoid such consequences and to comply with the terms thereof, the terms of many open source licenses have not been interpreted by U.S. or foreign courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to provide or distribute our platform. Although we try to mitigate the risk of our use of open source software by managing software development with an information security program that is in compliance with the global standard International Organization for standardization (&#8220;ISO&#8221;) 27001:2013, our information security program does not yet comply fully with all of the additions and changes in the updated ISO 27001:2022 version of the standard. We anticipate transitioning to compliance with the ISO 27001:2022 version of the standard prior to the required transition date of October&#160;31, 2025. Using an automated static code analysis tool, we regularly examine all VCS software code, as well as included open source code, for security vulnerabilities, code quality, as well as open source licensing that is in alignment with our software distribution requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sales and Marketing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently sell our products either through our direct sales force, or in certain countries, through distributors. As of November&#160;29, 2024, our sales and marketing organization consisted of approximately 74 employees and consultants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our sales personnel are equipped with a suite of resources including extensive <span style="white-space:nowrap">in-depth</span> training, marketing resource tools, and access to a robust schedule of education events. In the regions where we have distributors, we provide clinical training and support to build positive relationships with physicians and clinics and to position our product in the marketplace as a premium product with consequent premium pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ a multi-faceted marketing strategy focused on social media engagement with patient success stories, conferences, advertisements and education. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing Capabilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Balloons are manufactured <span style="white-space:nowrap">in-house</span> using components and <span style="white-space:nowrap">sub-assemblies</span> at our 10,000 square foot, ISO 13485 certified manufacturing facility in Natick, Massachusetts. We rely on suppliers for the extruded film to manufacture our Allurion Balloon and suppliers for stylets, filler kits, accessories, and scales. All critical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
component suppliers undergo strict quality system audits and component inspections to ensure they meet our quality standards. All suppliers and materials must be qualified prior to being approved for manufacturing activities. Our suppliers have no contractual obligations to supply us with components, and we are not contractually obligated to purchase such components from any of our suppliers. Order quantities and lead times for components purchased from our suppliers are based on our forecasts derived from anticipated future demand. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lead times for components may vary significantly depending on the size of the order, time required to fabricate and test the components, specific supplier requirements and current market demand for the components and <span style="white-space:nowrap">sub-assemblies.</span> However, some of these components are critical to our products and there are relatively few alternative sources of supply. To date, we have not experienced significant delays in obtaining any of our components or <span style="white-space:nowrap">sub-assemblies.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered with the FDA as a medical device manufacturer and the Center for Devices and Radiological Health. We and our component suppliers manufacture our products in compliance with the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;) in 21 CFR part 820 of the FDCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to periodic inspections and audits by various international regulatory and notified bodies, and we believe our past performance in these audits reflects the strength of our quality system and production and process controls. We consider this to be a key element of our risk management and business continuity strategies and a competitive advantage as we have full control of the product life-cycle. Our <span style="white-space:nowrap">in-house</span> manufacturing team included 11 employees at November&#160;29, 2024. We believe our manufacturing experience, <span style="white-space:nowrap">know-how,</span> and process-related trade secrets are a competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we will need to increase our manufacturing capabilities over time in order to satisfy any increased demand for our balloon system, and we have no experience manufacturing our balloon system in such quantities. If we are unable to keep up with demand for our balloon system, our revenue could be impaired, market acceptance for our balloon system could be harmed and our customers might instead purchase our competitors&#8217; products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare industry, and thus our business as a medical device company, is subject to extensive federal, state, local and foreign regulation. Some of the pertinent laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. In addition, these laws and their interpretations are subject to change. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulatory System for Medical Devices in the United States </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless an exemption applies, each new or significantly modified medical device a company seeks to commercially distribute in the United States will require a premarket notification to the FDA requesting permission for commercial distribution under Section&#160;510(k) of the FDCA, also referred to as a 510(k) clearance, a de novo classification request, or approval from the FDA of a PMA application. Our Allurion Balloon will require approval from the FDA of a PMA application. The 510(k) clearance, de novo classification request and PMA processes can be resource intensive, expensive and lengthy, and require payment of significant user fees, unless an exemption is available. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Device Classification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II or Class&#160;III&#8212;depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&#160;I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as General Controls, which require compliance with the applicable portions of the QSR facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and <span style="white-space:nowrap">non-misleading</span> labeling and promotional materials. Some Class&#160;I devices, also called Class&#160;I reserved devices, also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class&#160;I products are exempt from the premarket notification requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&#160;II devices are those that are subject to the General Controls, and Special Controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These Special Controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class&#160;II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class&#160;II devices is accomplished through the 510(k) premarket notification process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&#160;III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class&#160;III devices cannot be reasonably assured solely by the General Controls and Special Controls described above. Therefore, these devices are subject to the PMA application process, described below, which is generally more costly and time consuming than the 510(k) process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The Investigational Device Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, absent certain limited exceptions, human clinical trials intended to support 510(k) clearance, de novo classification, or PMA approval require an IDE application. Some types of trials considered to present <span style="white-space:nowrap">&#8220;non-significant</span> risk&#8221; are deemed to have an approved IDE once certain requirements are addressed, and investigational review board (&#8220;IRB&#8221;) approval is obtained. If the device presents a &#8220;significant risk&#8221; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The IDE application must be approved in advance by the FDA for a specified number of subjects. The FDA also may issue a conditional approval, in which case the trial may be conducted subject to the FDA&#8217;s conditions, which the sponsor must address in order to conduct the trial as originally requested. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the trial protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. There can be no assurance that submission of an IDE application will result in the ability to commence clinical trials, and although the FDA&#8217;s approval of an IDE application allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and efficacy, even if the trial meets its intended success criteria, unless the sponsor has obtained a binding protocol agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of trial sponsors and trial investigators. Clinical trials must further comply with the FDA&#8217;s good clinical practice regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. Clinical trial investigators must disclose certain financial interests to clinical trial sponsors. The commencement or completion of any clinical trial may be delayed or halted, including from the FDA imposing a clinical hold on a trial, or be inadequate to support approval of a PMA application, de novo classification or clearance of a 510(k), for numerous reasons. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The 510(k) Clearance Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 510(k) process, the manufacturer must submit to the FDA a premarket notification 90 days before it seeks to commercially distribute its device, demonstrating that the device is &#8220;substantially equivalent,&#8221; as defined in the statute, to a legally marketed predicate device. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May&#160;28, 1976 <span style="white-space:nowrap">(pre-amendments</span> device) and for which a PMA is not required, a device that has been reclassified from Class&#160;III to Class&#160;II or I, or a device that was previously found substantially equivalent through the 510(k) process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be &#8220;substantially equivalent,&#8221; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) premarket notification. If it is accepted for filing, the FDA begins a substantive review. As a practical matter, clearance often takes longer than 90 days, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that the device is not &#8220;substantially equivalent&#8221; to a predicate device, or if the device is automatically classified into Class&#160;III, the device sponsor must then fulfill the much more rigorous premarketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. A manufacturer can also submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After a device receives 510(k) clearance, any modification, including modification to or deviation from design, manufacturing processes, materials, packaging and sterilization that could significantly affect the device&#8217;s safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application or de novo classification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications are accomplished by a <span style="white-space:nowrap"><span style="white-space:nowrap">letter-to-file</span></span> in which the manufacturer documents the change in an internal <span style="white-space:nowrap"><span style="white-space:nowrap">letter-to-file.</span></span> The <span style="white-space:nowrap"><span style="white-space:nowrap">letter-to-file</span></span> is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer&#8217;s determination regarding whether a new premarket submission is required for the modification of an existing device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite PMA application(s). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The PMA Approval Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the PMA application process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#8217;s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding device design and development, preclinical study and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device trials. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA, by statute and by regulation, has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee&#8217;s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years, but may take significantly longer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains several conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA&#8217;s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support any changes from the device covered by the approved PMA application and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In approving a PMA application, as a condition of approval, the FDA may also require some form of post-approval trial or post-market surveillance, whereby the applicant conducts a <span style="white-space:nowrap">follow-up</span> trial or follows certain patient groups for several years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer-term safety and effectiveness data for the device. The FDA may also require post-market surveillance for certain devices cleared under a 510(k) notification, such as implants or life-supporting or life-sustaining devices used outside a device user facility. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pervasive and Continuing FDA Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA permits a device to enter commercial distribution, numerous regulatory requirements continue to apply. These include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">labeling regulations, unique device identification requirements and FDA prohibitions against the promotion of products for uncleared, unapproved or <span style="white-space:nowrap">off-label</span> uses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">advertising and promotion requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on sale, distribution or use of a device; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PMA annual reporting requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">PMA approval or clearance of a 510(k) for product modifications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">medical device reporting (&#8220;MDR&#8221;) regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">medical device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an order of repair, replacement or refund; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">device tracking requirements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our manufacturing processes are required to comply with the applicable portions of the FDA&#8217;s QSR that covers the methods and the facilities and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation, and servicing of finished devices intended for human use. In February 2024, the FDA issued the Quality Management System Regulation Final Rule to amend the QSR, incorporating by reference the international standard for medical device quality management systems set by the ISO, ISO 13485:2016. The rule will become effective on February&#160;2, 2026. Until then, manufacturers are required to comply with the QSR. We actively maintain compliance with the FDA&#8217;s QSR, and the European Union&#8217;s Quality Management Systems requirements, ISO 13485:2016. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since February 2017, the FDA has issued three separate letters to health care providers warning of SAEs, including deaths, which are specific to liquid-filled intragastric balloons. We are aware of the filing of additional reports of SAEs, including deaths, associated with liquid-filled balloons since the issuance of the FDA letters to health care providers. While the advisory letters were specific to liquid-filled intragastric balloons and not the Allurion Balloon, these letters could create negative perceptions of the entire gastric balloon category, which may cause negative consequences for us including requiring additional warnings, precautions and/or contraindications in the labeling, delaying or denying approval of our products, or possible review or withdrawal of any approval that we may obtain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has broad post-market and regulatory enforcement powers. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">warning or untitled letters, fines, injunctions, consent decrees and civil penalties; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated expenditures, repair, replacement, refunds, recall or seizure of products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operating restrictions, partial suspension or total shutdown of production; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA&#8217;s refusal of requests for 510(k) clearance, de novo classification or premarket approval of new products, new intended uses or modifications to existing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA&#8217;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawing premarket approvals that have already been granted or reclassifying our devices; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">criminal prosecution. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Healthcare Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is regulated by laws pertaining to healthcare fraud and abuse, including anti-kickback laws and false claims laws, and other healthcare laws. Violations of these laws are punishable by significant administrative, criminal and civil penalties, including damages, disgorgement, monetary fines, possible exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, imprisonment, and integrity oversight and reporting obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Kickback Statute </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing, recommending, purchasing, leasing, ordering, or arranging for, a good or service for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including payments to physicians or other providers, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments and providing anything of value at less than fair market value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. These exceptions and safe harbors exist for various types of arrangements, including certain investment interests, leases, personal service arrangements, discounts and management contracts. The failure of a particular activity to comply with all requirements of an applicable safe harbor regulation does not mean that the activity violates the federal Anti-Kickback Statute or that prosecution will be pursued. Instead, the legality of the arrangement will be evaluated on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis based on a cumulative review of all of the relevant facts and circumstances. Activities and business arrangements that do not fully satisfy each applicable exception or safe harbor may result in increased scrutiny by government enforcement authorities such as the Office of the Inspector General. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221;) to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the renumeration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the ACA codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (&#8220;FCA&#8221;) (discussed below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, certain states have adopted prohibitions similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not only by government healthcare programs such as the Medicare and Medicaid programs, and do not include comparable exceptions and/or safe harbors to those provided by the federal Anti-Kickback Statute. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Federal False Claims Act </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FCA prohibits, among other things, knowingly filing or causing the filing of a false claim or the knowing use of false statements to obtain payment from the federal government. A claim that is filed pursuant to an unlawful kickback may be a false claim under this law and, in a number of cases, manufacturers of medical products have entered into settlements based on FCA allegations that their financial relationships with customers &#8220;caused&#8221; these customers to submit false claims. When an entity is determined to have violated the FCA, it may be required to pay up to three times the actual damages sustained by the government, <span style="font-style:italic">plus </span>mandatory civil penalties for each separate false claim. Private individuals can file suits under the FCA on behalf of the government. These lawsuits are known as &#8220;qui tam&#8221; actions, and the individuals bringing such suits, sometimes known as &#8220;relators&#8221; or, more commonly, &#8220;whistleblowers,&#8221; may share in any amounts paid by the entity to the government in fines or settlement. Since complaints related to &#8220;qui tam&#8221; actions are initially filed under seal, the action may be pending for some time before a defendant is even aware of such action. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">HIPAA </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) created new federal crimes, including healthcare fraud and false statements relating to healthcare matters. HIPAA prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payers. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from government-sponsored programs. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A violation of this statute is a felony and may result in fines or imprisonment. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), also protects the security and privacy of individually identifiable health information maintained or transmitted by certain healthcare providers, health plans and healthcare clearinghouses and their business associates. HIPAA restricts the use and disclosure of patient health information, including patient records. Although we believe that HIPAA does not apply directly to us, most of our customers have significant obligations under HIPAA, and we intend to cooperate with customers and others to ensure compliance with HIPAA with respect to patient information. HITECH created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. Failure to comply with HIPAA obligations can result in civil fines and/or criminal penalties. Some states have also enacted rigorous laws or regulations protecting the security and privacy of patient information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transparency Reporting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the U.S. Congress enacted the ACA. The U.S. Physician Payments Sunshine Act, which is part of the ACA, requires manufacturers of drugs, biologics, devices and medical supplies that are subject to (or used in procedures subject to) Medicare and Medicaid reimbursement to record payments and transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain <span style="white-space:nowrap">non-physician</span> healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals as well as ownership and investment interests held by physicians and their immediate family members and to report this data to the Centers for Medicare&#160;&amp; Medicaid Services, for public disclosure. Failure to report may result in civil or criminal fines and/or penalties. Similar reporting requirements have also been enacted in several states, and an increasing number of countries worldwide either have adopted or are considering similar laws requiring transparency of interactions with healthcare professionals. In addition to reporting, some states </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as Massachusetts and Vermont impose a ban or limit the ability of medical device and pharmaceutical manufacturers providing certain items of value or payments to physicians or other healthcare practitioners licensed in these states. In recent years, the federal government and several states have enacted legislation requiring biotechnology, pharmaceutical and medical device companies to establish marketing compliance programs and file periodic reports on sales, marketing and other activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Analogous State and Foreign Laws and Regulations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by <span style="white-space:nowrap">non-governmental</span> payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Coverage, Reimbursement and Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients in the U.S. and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their healthcare treatment. Accordingly, market acceptance of our products is dependent on the extent to which third-party coverage and reimbursement is available from third-party payors, which can differ significantly from payor to payor and may change from time to time. Further, from time to time, typically on an annual basis, payment amounts are updated and revised by third-party payors. In cases where the cost of certain of our products are recovered by the healthcare provider as part of the payment for performing a procedure and not separately reimbursed or paid directly by the patient, these updates could directly impact the demand for our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a covered benefit under its health plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">safe, effective and medically necessary; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appropriate for the specific patient; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effective; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">neither experimental nor investigational. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All third-party payors, whether governmental or commercial and whether inside the U.S. or outside, are developing increasingly sophisticated methods of controlling healthcare costs. These cost-control methods include prospective payment systems, bundled payment models, capitated arrangements, group purchasing, benefit redesign, <span style="white-space:nowrap">pre-authorization</span> processes and requirements for second opinions prior to procedures. These cost-control methods also potentially limit the amount that healthcare providers may be willing to pay for our products. Therefore, coverage or reimbursement for medical devices may decrease in the future. In addition, consolidation in the healthcare industry could lead to demands for price concessions, which may impact our ability to sell our products at prices necessary to support our current business strategies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal and state governments in the U.S. and outside the U.S. may enact legislation to modify the healthcare system, which may result in increased government price controls, additional regulatory mandates and other measures designed to constrain medical costs. These reform measures may limit the amounts that federal and state governments will pay for healthcare products and services, and also indirectly affect the amounts that private payors are willing to pay. The pricing pressure resulting from healthcare cost containment and reimbursement changes could decrease demand for our products, the prices that customers are willing to pay and the frequency of use of our products, which could have an adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to U.S. regulations, we are subject to a variety of foreign government regulations applicable to medical devices, medicinal products and combination products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Regulation of Medical Devices in the European Union </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The European Union (&#8220;EU&#8221;), has adopted specific directives and regulations regulating the design, manufacture, clinical investigation, conformity assessment, labeling and adverse event reporting for medical devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until May&#160;25, 2021, medical devices were regulated by the Council Directive 93/42/EEC, or Medical Devices Directive (&#8220;MDD&#8221;), which has been repealed and replaced by Regulation (EU) No 2017/745, or MDR. There is a transition period during which certificates issued under the Medical Devices Directive remain valid; however, when such certificates expire (or, if earlier, by May&#160;26, 2024), the devices must be certified under the new regime set forth in the Medical Devices Regulation. An extension for devices transitioning to the EU Medical Devices Regulation has been changed from May&#160;26, 2024 to May&#160;26, 2026 for class III implantable custom-made devices and December&#160;31, 2027 for class III and implantable class IIb devices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Medical Devices Directive </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Medical Devices Directive, or MDD, all medical devices placed on the market in the EU must meet the relevant essential requirements laid down in Annex I to the Medical Devices Directive, including the requirement that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performance intended by the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards applicable to medical devices and there are additionally harmonized standards relating to the design and manufacture of medical devices which are not mandatory but, if complied with, indicate that the device satisfies the applicable element of the essential requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To demonstrate compliance with the essential requirements laid down in Annex I to the Medical Devices Directive, medical device manufacturers must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification with respect to risk. As a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. Except for <span style="white-space:nowrap">low-risk</span> medical devices (Class I <span style="white-space:nowrap">non-sterile,</span> <span style="white-space:nowrap">non-measuring</span> devices), where the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to sterility or metrology), a conformity assessment procedure requires the intervention of a notified body. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. A notified body would typically audit and examine a product&#8217;s technical dossiers and the manufacturers&#8217; quality system. If satisfied that the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relevant product conforms to the relevant essential requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on the market throughout the EU. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Medical Devices Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;5, 2017, MDR was adopted with the aim of ensuring better protection of public health and patient safety. Unlike the MDD, the MDR is directly applicable in EU member states without the need for member states to implement into national law. This aims at increasing harmonization across the EU. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MDR became effective on May&#160;26, 2021. The new Regulation follows the same process of conformity assessment, certificates of conformity and applying a CE mark to devices before they can be placed on the market. However, among other things, the MDR: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strengthens the rules on placing devices on the market (e.g. reclassification of certain devices and wider scope than the MDD) and reinforces surveillance once they are available; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishes explicit provisions on manufacturers&#8217; responsibilities for the <span style="white-space:nowrap">follow-up</span> of the quality, performance and safety of devices placed on the market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishes explicit provisions on importers&#8217; and distributors&#8217; obligations and responsibilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposes an obligation to identify a responsible person who is ultimately responsible for all aspects of compliance with the requirements of the new regulation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">improves the traceability of medical devices throughout the supply chain to the <span style="white-space:nowrap">end-user</span> or patient through the introduction of a unique identification number (&#8220;UDI&#8221;) to increase the ability of manufacturers and regulatory authorities to trace specific devices through the supply chain and to facilitate the prompt and efficient recall of medical devices that have been found to present a safety risk; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sets up a European medical device database (&#8220;Eudamed&#8221;) to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo a clinical evaluation consultation procedure by experts before they are placed on the market. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Devices lawfully placed on the market pursuant to the Medical Devices Directive prior to May&#160;26, 2021 may generally continue to be made available on the market or put into service until May&#160;26, 2025, provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the Medical Devices Regulation, in particular the obligations described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MDR requires that before placing a device, other than a custom-made device, on the market, manufacturers (as well as other economic operators such as authorized representatives and importers) must register by submitting identification information to Eudamed, unless they have already registered. The information to be submitted by manufacturers (and authorized representatives) also includes the name, address and contact details of the person or persons responsible for regulatory compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MDR also requires that before placing a device, other than a custom-made device, on the market, manufacturers must assign a unique identifier to the device and provide it along with other core data to the UDI database. These new requirements aim at ensuring better identification and traceability of the devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers are responsible for entering the necessary data on Eudamed, which includes the UDI database, and for keeping it up to date. Eudamed is not yet fully functional, however the European Commission </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is aiming to have a fully functional version of the Eudamed medical device database available in the fourth quarter of 2027. The Medical Device Coordination Group has published guidance on administrative practices for manufacturers until Eudamed is fully functional. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All manufacturers placing medical devices on the market in the EU must also comply with the EU medical device vigilance system, which has been reinforced by the MDR. Under this system, serious incidents and Field Safety Corrective Actions must be reported to the relevant authorities of the EU member states. These reports will have to be submitted through Eudamed&#8212;once functional&#8212;and aim to ensure that, in addition to reporting to the relevant authorities of the EU member states, other actors such as the economic operators in the supply chain will also be informed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the new requirements, manufacturers (and authorized representatives) must have available within their organization at least one person responsible for regulatory compliance (&#8220;PRRC&#8221;), who possesses the requisite expertise in the field of medical devices. The PRRC is responsible for compliance with post-market surveillance and vigilance requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned EU rules are generally applicable in the European Economic Area, which consists of the 27 EU Member States <span style="font-style:italic">plus </span>Norway, Liechtenstein and Iceland. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Brexit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the United Kingdom leaving the EU, since January&#160;1, 2021, the regulatory framework and regimes for medical devices in the United Kingdom and the EU have diverged. In particular, a new UKCA Mark was introduced for medical devices placed on the Great Britain market (which includes England, Scotland and Wales). Northern Ireland has adopted a hybrid approach as a result of the divergence in accordance with the Northern Ireland Protocol. Manufactures can continue placing CE marked medical devices on the Great Britain market until June&#160;30, 2024. From July&#160;1, 2024, transitional arrangements will apply for CE and UKCA marked medical devices placed on the Great Britain market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Environmental Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The costs and effects of our compliance with applicable environmental laws during fiscal years 2022 and 2023 and the nine months ended September&#160;30, 2024 were, and historically have been, immaterial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Human Capital Resources </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&#160;29, 2024, we had 148 employees, 146 of whom were full-time, consisting of clinical, research and development, operations, regulatory and quality, sales, marketing, technology, finance, business analytics and human resources. This included 62 employees located in the United States. From time to time, we also engage contractors, consultants and temporary employees to support our operations. None of the U.S. employees are subject to collective bargaining agreements or represented by a labor union, however, our employees in France are subject to a collective bargaining agreement. We consider our relationship with our employees to be good. On November&#160;6, 2024, the Company&#8217;s board of directors approved a restructuring plan to reduce operating costs and better align its workforce with the needs of its business. Under the restructuring plan, the Company is reducing its workforce by approximately 113 roles (approximately 50%). The majority of the restructuring is expected to be completed in the fourth quarter of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate&#160;&amp; Available Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on January&#160;25, 2023. The mailing address of our principal executive office is 11 Huron Drive, Natick, MA 01760, and the telephone number is (508) <span style="white-space:nowrap">647-4000.</span> Our website address is https://allurion.com/. Further corporate governance information, including our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Code of Conduct, Corporate Governance Guidelines and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available on our investor relations website under the heading &#8220;Governance Documents.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), maintains an Internet site that contains current and periodic reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC at www.sec.gov. Additional information about our filings can also be obtained at our website at www.investors.allurion.com under &#8220;Financials&#8212;SEC Filings.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make available free of charge on our website our Annual Reports on Form 10K, Quarterly Reports on Form 10Q, Current Reports on Form <span style="white-space:nowrap">8-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The contents of our website are not a part of this prospectus and should not be considered to be a part of, or incorporated into, this prospectus or any of our other securities filings unless specifically incorporated herein or therein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_11">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis includes information that our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The discussion and analysis should be read together with the consolidated financial statements as of and for the three and nine months ended September&#160;30, 2024 and September&#160;30, 2023, and for the years ended December&#160;31, 2023 and December&#160;31, 2022 that are included in this prospectus. This discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the sections titled &#8220;Cautionary Statement Regarding Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; in this prospectus. For purposes of this section, all references in this discussion and analysis to &#8220;Allurion,&#8221; the &#8220;Company&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; refers to the business and operations of Allurion and its consolidated subsidiaries following the consummation of the Business Combination and to Legacy Allurion and its consolidated subsidiaries prior to the consummation of the Business Combination. &#8220;Legacy Allurion&#8221; refers to Allurion Technologies, LLC, which was previously known as Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc.) prior to the consummation of the Business Combination.</span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion is a leading medical device company that is focused on creating a <span style="white-space:nowrap"><span style="white-space:nowrap">best-in-class</span></span> weight loss platform to treat obese and overweight patients. Our platform, the Allurion Program (the &#8220;Allurion Program&#8221;), features the world&#8217;s first and only swallowable, procedure-less intragastric balloon for weight loss (the &#8220;Allurion Balloon&#8221;) and offers artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging and video telehealth that are delivered by the Allurion Virtual Care Suite (&#8220;VCS&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary intragastric balloon, the Allurion Balloon, is swallowed as a capsule under the guidance of a health care provider without surgery, endoscopy, or anesthesia for placement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion VCS is comprised of tools to support patients&#8217; weight loss experience, which we believe benefit both patients and health care providers: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Allurion Program patients: Every current Allurion Program patient receives an Allurion Connected Scale (&#8220;Allurion Connected Scale&#8221;) and access to our mobile app (the &#8220;App&#8221;), which integrates data from the Allurion Connected Scale to conveniently monitor weight, body fat, activity, sleep, and several other critical metrics. The App can also enable secure messaging and video telehealth with the patient&#8217;s care team and can deliver content from Allurion&#8217;s proprietary behavior change <span style="white-space:nowrap">program-a</span> library of 100 weight loss actions related to diet, nutrition, mental health, sleep, goal setting, and a number of other topics-directly to the patient. The App is available in 15 languages. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Allurion Program providers: Our clinic dashboard (&#8220;Allurion Insights&#8221;) provides <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> remote patient monitoring powered by the Allurion Iris AI platform, which leverages machine learning to deliver key insights related to patient tracking data. Allurion Insights offers real-time access to patient data and <span style="white-space:nowrap">AI-powered</span> analytics, note functionality to keep track of patient encounters, and clinic-wide metrics that provide a snapshot of the clinic&#8217;s overall performance. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its use by Allurion Balloon patients, we believe the Allurion VCS can potentially be a platform for optimal long-term follow up after other medical and surgical weight loss interventions in the future. For example, in June 2022, we incorporated a Treatment Tracking and <span style="white-space:nowrap">Clinic-Led</span> Onboarding feature into the Allurion VCS, which enables seamless onboarding and management of patients undergoing one or multiple weight loss treatments, including gastric balloons such as the Allurion Balloon, surgery, or medications. In addition, in connection with our collaboration with Medtronic plc (&#8220;Medtronic&#8221;), we may incorporate the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Allurion VCS in onboarding and managing Medtronic&#8217;s patients. Further, in April 2024, the Company launched the Allurion VCS in the United States for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products are currently sold in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region. The U.S. Food and Drug Administration (&#8220;FDA&#8221;) has approved the investigational device exemption (&#8220;IDE&#8221;), for Allurion&#8217;s AUDACITY clinical trial, a <span style="white-space:nowrap">48-week,</span> prospective, randomized, open-label trial. We received approval of the IDE from the FDA in November 2021 to initiate the AUDACITY clinical trial in the United States. The first patient in the trial was treated in July 2022. During the third quarter of 2023, we completed the enrollment of 550 patients in the trial across 17 sites in the United States and the last patient in the trial was treated in September 2024. The results of the trial are expected to support a premarket approval submission to the FDA.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses. Our ability to generate revenue and achieve cost improvements sufficient to achieve profitability will depend on the successful further development and commercialization of our products and receipt and maintenance of regulatory approvals. We generated revenue of $26.5&#160;million and $45.2&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, and incurred a net loss of $5.6&#160;million and $61.4&#160;million for those same periods, respectively. We expect to continue to incur net losses for the foreseeable future as we focus on obtaining regulatory approvals for our products in new markets, reinstating regulatory approvals, refining our sales and marketing strategies, and continuing research and development efforts to further enhance our existing products. Further, following the closing of the Business Combination described below in &#8220;Recent Developments,&#8221; we have incurred, and expect to continue to incur, additional costs associated with operating as a public company. As a result, we will need additional funding for expenses related to our operating activities, including selling, marketing, general and administrative expenses and research and development expenses.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with obtaining and maintaining regulatory approval, market acceptance of our products, product development and enhancement, and commercialization, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Until such time, if ever, as we can generate substantial revenue sufficient to achieve profitability, we expect to finance our operations through a combination of equity offerings and debt financings. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations. See the subsections titled&#8212;&#8220;<span style="font-style:italic">Liquidity and Capital Resources</span>&#8221; and &#8220;<span style="font-style:italic">Recent Developments</span>&#8221; below.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combination Agreement</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#8220;Legacy Allurion&#8221;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#8220;Business Combination Agreement&#8221;) with Compute Health Acquisition Corp. (&#8220;CPUH&#8221; or &#8220;Compute Health&#8221;), Compute Health Corp. (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#8220;Closing Date&#8221;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#8220;CPUH Merger&#8221;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#8220;CPUH Merger Effective Time&#8221;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#8220;Intermediate Merger&#8221; and the time at which the Intermediate Merger became </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective, the &#8220;Intermediate Merger Effective Time&#8221;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#8220;Final Merger&#8221; and, collectively with the CPUH Merger and the Intermediate Merger, the &#8220;Mergers&#8221;, and together with all other transactions contemplated by the Business Combination Agreement, the &#8220;Business Combination&#8221;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#8220;Final Merger Effective Time&#8221;). Shares of Allurion&#8217;s Common Stock (defined below) began trading on the NYSE under the ticker symbol &#8220;ALUR&#8221; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#8217;s business operations continued as our business operations.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#8220;acquired&#8221; company for financial reporting purposes and Legacy Allurion was the accounting &#8220;acquirer&#8221;. Accordingly, the Business Combination was treated as the equivalent of our company issuing stock for the net assets of Compute Health, accompanied by a recapitalization. Our net assets and the net assets of Compute Health are stated at historical costs, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#8217;s common stock, $0.0001 par value per share (&#8220;Allurion Common Stock&#8221; or the &#8220;Company&#8217;s Common Stock&#8221;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#8217;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the &#8220;Exchange Ratio&#8221;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the condensed consolidated financial statements have changed. Refer to Note 3, <span style="font-style:italic">Business Combination</span> in the notes to our unaudited interim condensed consolidated financial statements for further discussion regarding the closing of the Business Combination with Compute Health. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Note Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April 14, 2024, Allurion, RTW Investments, LP (together with its affiliates, &#8220;RTW&#8221;), as agent for the purchasers (the &#8220;Purchasers&#8221;) party thereto from time to time (RTW in such capacity, the &#8220;Principal Purchaser&#8221;), and Acquiom Agency Services LLC (&#8220;Acquiom&#8221;), as collateral agent for the Purchasers and the Principal Purchaser, entered into a Note Purchase Agreement (the&#160;&#8220;Original Note Purchase Agreement&#8221;). Subsequently, on April&#160;16, 2024, the Company, the Principal Purchaser, the Purchasers and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the &#8220;Amendment&#8221;; the Original Note Purchase Agreement, as amended by the Amendment, the &#8220;Amended Note Purchase Agreement&#8221;).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $48&#160;million aggregate principal amount of convertible senior secured notes (the &#8220;Notes&#8221;) to the Purchasers in a private placement transaction. The Company used the proceeds from the issuance of the Notes to refinance its outstanding obligations under the Credit Agreement and Guaranty, dated as of August&#160;1, 2023 (as amended by Amendment No.&#160;1 to the Credit Agreement and Guaranty, dated as of December&#160;29, 2023, the &#8220;Fortress Credit Agreement&#8221;) by and among Allurion, Allurion Opco, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto in full and to pay fees and expenses in connection therewith and in connection with the transactions contemplated by the Amended Note Purchase Agreement. The Company has terminated and repaid in full the outstanding borrowings and other obligations under the Fortress Credit Agreement.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes bear interest at the annual rate of 6.0%, which interest is payable quarterly in cash or, at the Company&#8217;s option, in kind for the first three years. The maturity date for the Notes is April&#160;16, 2031. The Notes </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are guaranteed by Allurion Technologies, LLC, a Delaware limited liability company and wholly-owned subsidiary of the Company (&#8220;Allurion Opco&#8221;), and certain other current and future subsidiaries of the Company, and are secured by substantially all the assets of the Company and the guarantors.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes are convertible into shares of the Company&#8217;s Common Stock, at a Purchaser&#8217;s election at any time after the earliest of (i)&#160;the date on which Stockholder Approval (as defined below) is obtained, (ii)&#160;December&#160;31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Amended Note Purchase Agreement), and (iv)&#160;the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on a conversion rate of 617.2840 shares of common stock per $1,000 principal amount of Notes (equivalent to a conversion price of approximately $1.62 per share, which represents a 35% premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $15,000,000 (the &#8220;Next Equity Financing&#8221;). On July&#160;1, 2024, we consummated the Public Offering, as described elsewhere in this prospectus, which constituted a Next Equity Financing. Because the conversion price was reset in connection with the Next Equity Financing to a price below the NYSE&#8217;s &#8220;Minimum Price&#8221; (as such term is defined in Section&#160;312.03 of the NYSE Listed Company Manual), the Amended Note Purchase Agreement provides that unless and until requisite approval of the Company&#8217;s stockholders is obtained (&#8220;Stockholder Approval&#8221;), the Company will not deliver Common Stock upon conversion of the Notes in excess of 1% of the number of shares of the Company&#8217;s Common Stock outstanding as of April&#160;14, 2024. The Company is required to include a proposal in its definitive proxy statement on Schedule 14A seeking Stockholder Approval no later than December&#160;31, 2025. If the Company does not obtain Stockholder Approval at such meeting, it shall call a special meeting of stockholders each <span style="white-space:nowrap">90-day</span> period thereafter at least two times, and thereafter at each subsequent annual meeting until Stockholder Approval is obtained or the Notes are no longer outstanding; provided, that shares of Common Stock issued upon conversion of the Notes prior to obtaining Stockholder Approval shall not be entitled to vote in favor of Stockholder Approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment to Revenue Interest Financing Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2024, the Revenue Interest Financing Agreement (the &#8220;Original RIFA&#8221;) was amended pursuant to the Omnibus Amendment (the &#8220;RIFA Amendment&#8221;) by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned subsidiary of the Company, the Original RIFA Investors (as defined therein) and RTW, to reflect certain modifications agreed between the parties thereto in connection with the Purchasers&#8217; purchase of the Notes and the refinancing of the Fortress Credit Agreement. Among other things, the RIFA Amendment waived the existing event of default under the Original RIFA, increased the rate of revenue interest payments to be paid to RTW on all current and future products and digital solutions developed and to be developed by the Company (the &#8220;Royalty Rate&#8221;) for net sales less than or equal to $100&#160;million prior to December&#160;31, 2026 from 6% to 12%, and increased the Royalty Rate on net sales less than or equal to $100&#160;million on or after January&#160;1, 2027 from 10% to 12%, subject to the terms and conditions of the RIFA Amendment.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated RTW Side Letter, on October&#160;22, 2024, the Additional RIFA Investors notified us of their election to exercise the Investment Conversion in full. Accordingly, on October&#160;30, 2024, we and the Additional RIFA Investors entered into the additional Revenue Interest Financing Agreement (the &#8220;Additional Revenue Interest Financing Agreement&#8221;). The Additional Revenue Interest Financing Agreement has substantially identical terms and conditions as the Original RIFA, except that the amount of financing provided by the Additional RIFA Investors to Allurion Opco under the Additional Revenue Interest Financing Agreement is equal to the Conversion Amount. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment to RTW Side Letter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2024, we, Allurion Opco, Compute Health, Merger Sub II, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. (as transferee from RTW Biotech </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Opportunities Ltd. (formerly known as RTW Venture Fund Limited)) (in each case, together with their successors and permitted assigns, the &#8220;Additional RIFA Investors&#8221;) entered into the First Amendment to Amended and Restated Letter Agreement (the &#8220;RTW Side Letter Amendment&#8221;) to reflect certain modifications to the Amended and Restated RTW Side Letter in connection with the Purchasers&#8217; purchase of the Notes. The RTW Side Letter Amendment provides, among other things, that the Additional RIFA Investors may make a single election in certain circumstances to convert up to $7,500,000 of the purchase price that the Additional RIFA Investors paid for certain equity interests in the Company into an amount of financing provided by the Additional RIFA Investors to Allurion Opco pursuant to an additional revenue interest financing agreement with Allurion Opco, which election was made effective October&#160;30, 2024 as described above.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of Fortress Term Loan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, we terminated and repaid in full all outstanding borrowings and fees under the Fortress Credit Agreement, dated as of August&#160;1, 2023 (as amended by the Fortress Amendment, dated as of December&#160;29, 2023), by and among the Company, Allurion Opco, the subsidiary guarantors from time to time party thereto, the lenders from time to time party thereto (the &#8220;Lenders&#8221;&#160;and each, a &#8220;Lender&#8221;) and Fortress Credit Corp., as administrative agent for the Lenders, including the release of all guarantees and liens related thereto.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Offering </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC and TD Securities (USA) LLC, as representative of the several underwriters (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 14,406,508 shares of the Company&#8217;s Common Stock and warrants (&#8220;July 2024 Public Warrants&#8221;) to purchase up to 14,406,508 shares of the Company&#8217;s Common Stock at an offering price of $1.20 per share and accompanying warrant (the &#8220;Public Offering&#8221;). Pursuant to the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 2,160,976 shares of Common Stock (the &#8220;Share Overallotment&#8221;) and/or 2,160,976 July 2024 Public Warrants at the public offering price. The Public Offering closed on July&#160;1, 2024 with net proceeds received of $15.2&#160;million after deducting underwriting discounts of $1.0&#160;million and offering costs of $1.0&#160;million. Additionally, on July&#160;1, 2024, the Underwriters exercised the option with respect to the July 2024 Public Warrants in full, which resulted in the issuance of an additional 2,160,976 July 2024 Public Warrants at the closing. Further, the Underwriters exercised a portion of the option with respect to the Common Stock on July&#160;5, 2024 for net proceeds of $2.2&#160;million, which resulted in the issuance of 1,927,265 shares of the Company&#8217;s Common Stock at an offering price of $1.20 per share.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 28, 2024, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with RTW, pursuant to which the Company agreed to sell to RTW 2,260,159 shares of a newly created series of preferred stock, the Series A <span style="white-space:nowrap">non-voting</span> convertible preferred stock, par value $0.0001 per share (&#8220;Series A Preferred Stock&#8221;), and 2,260,159 private placement warrants (&#8220;Private Placement Warrants&#8221;) to purchase Common Stock, equal to the per share Public Offering price for the shares of Common Stock and July 2024 Public Warrants in the Public Offering (the &#8220;Private Placement&#8221;). The Private Placement closed on July&#160;1, 2024 with net proceeds received of $2.5&#160;million after deducting offering costs of $0.2&#160;million.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">French Regulatory Decision </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2024, it was announced that the Agence Nationale de S&#233;curit&#233; du M&#233;dicament (&#8220;ANSM&#8221;), the French regulatory authority, has suspended sales of the Allurion Balloon in France, and the Company withdrew the device from the French market. The Company submitted and has implemented a remediation plan to reduce certain risks associated with the advertising, <span style="white-space:nowrap">follow-up</span> program, and adverse events for the Allurion Balloon.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Company disagrees with ANSM&#8217;s decision, it is fully cooperating and in active dialogue with the agency regarding the Company&#8217;s remediation program prioritizing changes related to its advertising strategy, <span style="white-space:nowrap">follow-up</span> program and training programs to address ANSM&#8217;s concerns. The Company is committed to continuing its engagement with ANSM to identify a path that will enable the Company to resume the commercialization of the Allurion Balloon in France.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">NYSE Continued Listing Standards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2024, we received a letter from NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#8217;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the <span style="white-space:nowrap">six-month</span> cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 <span style="white-space:nowrap">trading-day</span> period ending on the last trading day of that month. In the event that at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 <span style="white-space:nowrap">trading-day</span> period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2024, we received written notice from the NYSE that we are not in compliance with the continued listing standard set forth in Section&#160;802.01B of the NYSE&#8217;s Listed Company Manual because the average market capitalization of the Company was less than $50.0&#160;million over the consecutive 30 <span style="white-space:nowrap">trading-day</span> period ended August&#160;29, 2024 and the Company&#8217;s last reported stockholders&#8217; equity as of August&#160;29, 2024 was less than $50.0 million. In accordance with applicable NYSE procedures, we submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice. We submitted a business plan to the NYSE demonstrating our ability to regain compliance with the NYSE&#8217;s rules. The NYSE has accepted the plan and as a result, the Company is subject to quarterly monitoring for compliance with the business plan and our common stock will continue to trade on the NYSE during the period, subject to our compliance with other NYSE continued listing requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restructuring Plan </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2024, our board of directors (&#8220;Board&#8221;) approved a restructuring plan to reduce operating costs and better align our workforce with the needs of our business. The majority of the restructuring is expected to be completed in the fourth quarter of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the restructuring plan, we anticipate reducing our workforce by approximately 113 roles (approximately 50% of our workforce). In connection with the restructuring plan, we estimate that wet will incur <span style="white-space:nowrap">one-time</span> aggregate restructuring charges of approximately $3.5&#160;million, which will be recorded primarily in the fourth quarter of 2024, related to severance payments and other employee-related costs. The cash payments related to the personnel-related restructuring will be paid primarily during the first quarter of 2025. The charges that we expect to incur in connection with the workforce reduction are subject to a number of assumptions, and actual results may differ materially. We may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Key Factors Affecting Our Operating Results</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our performance and future success depend on many factors that present significant opportunities but also pose risks and challenges, including those discussed below and under the heading &#8220;Risk Factors&#8221; above. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Market Acceptance</span>. The growth of our business depends on our ability to gain broader acceptance of our current products by continuing to make health care providers aware of the benefits of our products to generate increased demand and frequency of use, and thus increase our sales. Our ability to grow our business will also depend on our ability to expand our customer base in existing or new target markets. Although we have increased the number of patients treated with our products through our established relationships and focused sales efforts, we cannot provide assurance that our efforts will continue to increase the use of our products. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Regulatory approval and timing and efficiency of new product introductions</span>. We must successfully obtain timely approvals, maintain regulatory approval, successfully implement any remediation programs required by regulators to resume sales of the Allurion Balloon, and introduce new products that gain acceptance with health care providers. For our sales to grow, we will also need to obtain regulatory approval of our existing product and any new products or modifications/enhancements to our existing products in the markets that we operate in and new markets as applicable. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Sales force size and effectiveness. </span>The speed at which newly hired salespeople become effective can impact our revenue growth or our costs incurred in anticipation of such growth. We intend to continue to improve and increase performance in our sales and marketing organization, and expand our international programs to help facilitate further adoption of our products as well as broaden awareness of our products to new customers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Product and geographic mix; timing. </span>Our financial results, including our gross margins, may fluctuate from period to period based on the timing of orders, fluctuations in foreign currency exchange rates and the number of available selling days in a particular period, which can be impacted by a number of factors, such as holidays or days of severe inclement weather in a particular geography, the mix of products sold and the geographic mix of where products are sold. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating Segments</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate our business in a single segment and as one reporting unit, which is how our chief operating decision maker (&#8220;CODM&#8221;), our chief executive officer, reviews financial performance and allocates resources. The CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since we operate as one operating segment, all required financial segment information can be found in the consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Our Results of Operations</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive revenue from the sale of the Allurion Balloon to customers, which are either distributors or health care providers. The Allurion Balloon is the foundation of the Allurion Program, a holistic weight loss program that offers patients the opportunity to receive, and clinic and other health care providers the ability to deliver, behavior change assistance through their use of our remote patient support and monitoring tools. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists primarily of costs that are closely correlated or directly related to the delivery of our products, including material costs, labor costs, and depreciation expense for fixed assets.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sales and Marketing Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses consist primarily of salaries and related expenses (including commissions) for our sales and marketing personnel. Marketing programs consist of advertising, training events, brand building, product marketing activities and shipping costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist of costs associated with performing research and development activities such as registering our products in various jurisdictions and performing clinical trials. These costs include salaries and benefits, stock-based compensation, <span style="white-space:nowrap">non-capitalizable</span> software development costs, product development costs, materials and supplies, clinical trial activities, registration expenses, depreciation of equipment and other outside services.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, information technology, finance and accounting, human resources and other administrative functions. General and administrative expenses also include legal fees relating to corporate matters; professional fees paid for accounting, auditing, consulting and tax services; insurance costs; travel expenses; office and information technology costs; and facilities, depreciation and other expenses related to general and administrative activities, which include direct or allocated expenses for rent and maintenance of facilities and utilities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income (Expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of interest expense associated with outstanding borrowings under our debt obligations as well as the amortization of debt issuance costs and discounts associated with such borrowings.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Warrants</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of warrants consists of the expense recognized upon the mark to market of our warrant liabilities.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Debt</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of debt consists of the expense recognized upon the mark to market of our convertible debt.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Revenue Interest Financing and PIPE Conversion Option </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of Revenue Interest Financing and PIPE Conversion Option consists of the expense recognized upon the mark to market of the Revenue Interest Financing with RTW and the issuance and mark to market of the PIPE Conversion Option. See Note 10, <span style="font-style:italic">Fair Value Measurements </span>for further information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of <span style="white-space:nowrap">Earn-out</span> Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of <span style="white-space:nowrap">earn-out</span> liabilities consists of the gain or loss recognized upon mark to market of the contingent <span style="white-space:nowrap">earn-out</span> consideration. See Note 10, <span style="font-style:italic">Fair Value Measurements </span>for further information. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Loss on extinguishment of debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss on extinguishment of debt consists of the loss recognized upon the termination of our 2021 Term Loan and Fortress Term Loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination of convertible note side letters</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The termination of convertible note side letters consists of the expense recognized related to the convertible note prepayment penalty and recognition of the PubCo Share liability and Base PubCo and Backstop Share liability.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income, net</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net consists of interest earned on our invested cash balances, which primarily consist of deposit accounts and money market funds, foreign currency transaction gains and losses and expense associated with our Success Fee derivative liability and Fortress Term Loan derivative liability. See Note 10, <span style="font-style:italic">Fair Value Measurements, </span>for further information.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Three and Nine Months Ended September&#160;30, 2024 and 2023 (unaudited)</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the three and nine months ended September&#160;30, 2024 and 2023 (in thousands):</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Three Months Ended September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nine Months Ended September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,833</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,976</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,616</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,857</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,097</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(18,067</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,979</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,376</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,043</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,899</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,657</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,911</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(24,670</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,407</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36,354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,341</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(26,154</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,813</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(33,083</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53,340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,586</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,331</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,067</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,703</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,008</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,771</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of Revenue Interest Financing and PIPE conversion option</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(11,104</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,040</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,064</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,608</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,040</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,568</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of <span style="white-space:nowrap">earn-out</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,713</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,784</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of convertible note side letters</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,466</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,598</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">757</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,152</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,997</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,935</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,596</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(61,337</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(69</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(34</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(210</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(90</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(120</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(61,427</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue decreased $12.8&#160;million, or 71%, to $5.4&#160;million and decreased $18.7&#160;million, or 41%, to $26.5&#160;million for the three and nine months ended September&#160;30, 2024, respectively, compared to the same periods in 2023. The decrease in revenue was primarily the result of decreased gastric balloon units sold due to macroeconomic headwinds in certain markets leading to lower <span style="white-space:nowrap">re-order</span> rates as distributors and certain accounts adjusted their inventory levels. Additionally, in August 2024, ANSM suspended sales of the Allurion balloon in France, resulting in a $1.2&#160;million reduction to revenue for customer returns of the Allurion Balloon. The decrease in revenue was also attributable to selling less or no product to certain distributors and accounts to manage our credit risk.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue decreased $2.0&#160;million, or 47%, to $2.3&#160;million for the three months ended September&#160;30, 2024, and decreased $2.6&#160;million, or 26%, to $7.5&#160;million for the nine months ended September&#160;30, 2024 compared to the same periods in 2023. The decrease in cost of revenue was a direct result of decreased gastric balloon units sold, partially offset by an increase in manufacturing expense, as less labor and overhead was absorbed due to lower production volumes.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gross Profit</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit decreased $10.9&#160;million, or 78%, to $3.1&#160;million for the three months ended September&#160;30, 2024, and decreased $16.1&#160;million, or 46%, to $19.0&#160;million for the nine months ended September&#160;30, 2024 compared to the same periods in 2023. The decrease in gross profit was primarily the result of an increase in our manufacturing expense, as less labor and overhead was absorbed due to lower production volumes, as well as a decrease in revenue and sales volume of our gastric balloon system. Additionally, in August 2024, ANSM suspended sales of the Allurion balloon in France, resulting in a $1.2&#160;million reduction to revenue for customer returns of the Allurion Balloon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales and Marketing Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses decreased $8.8&#160;million, or 63%, to $5.2&#160;million for the three months ended September&#160;30, 2024, compared to the same period in 2023. The decrease in sales and marketing expenses was the result of a $5.3&#160;million decrease in marketing expenditures driven by a reorganization of our selling and marketing spend focusing on more efficient channels and geographies, a $1.9&#160;million decrease in shipping and logistics expenses, a $1.3&#160;million decrease in salaries and related benefits, a $0.2&#160;million decrease in meeting expenses, and a $0.1&#160;million decrease in travel expenses.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses decreased $18.1&#160;million, or 50%, to $18.0&#160;million for the nine months ended September&#160;30, 2024, as compared to the same period in 2023. The decrease in sales and marketing expenses was the result of a $9.8&#160;million decrease in marketing spend, a $3.4&#160;million decrease in shipping and logistics expenses, a $2.8&#160;million decrease in salaries, related benefits, and consulting costs, a $1.1&#160;million decrease in meeting expenses, and a $0.6&#160;million decrease in travel expenses.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased $4.0&#160;million, or 55%, to $3.2&#160;million for the three months ended September&#160;30, 2024, compared to the same period in 2023. The decrease in research and development expenses was primarily the result of a $2.4&#160;million decrease in costs related to the AUDACITY clinical trial as it nears completion, a $1.0&#160;million decrease attributable to salaries and related benefit costs due to lower headcount, and a $0.4&#160;million decrease in outside consulting costs.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses decreased $8.4&#160;million, or 39%, to $13.2&#160;million for the nine months ended September&#160;30, 2024, compared to the same period in 2023. The decrease in research and development expenses was primarily the result of a $4.8&#160;million decrease in costs related to the AUDACITY clinical trial as it nears completion, a $2.4&#160;million decrease attributable to salaries and related benefit costs due to lower headcount, and a $0.9&#160;million decrease in outside consulting costs. We expect research and development expenses to continue to decrease in 2024 as our AUDACITY trial progresses toward completion.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased $11.9&#160;million, or 63%, to $7.0&#160;million for the three months ended September&#160;30, 2024, compared to the same period in 2023. The decrease in general and administrative expenses was primarily the result of a $4.6&#160;million decrease in stock based compensation as the prior period consisted of a $4.9&#160;million <span style="white-space:nowrap">one-time</span> charge as a result of the Business Combination, a $3.4&#160;million decrease in insurance expense as the prior period consisted of a $3.6&#160;million <span style="white-space:nowrap">one-time</span> insurance charge related to the Business Combination, a $1.8&#160;million decrease attributable to salaries, benefits, and related costs, a $1.0&#160;million decrease in bad debt expense, and a $0.8&#160;million decrease in legal and professional fees, primarily driven by $1.2&#160;million in <span style="white-space:nowrap">one-time</span> charges in the prior period related to the Business Combination.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses decreased $9.9&#160;million, or 32%, to $20.7&#160;million for the nine months ended September&#160;30, 2024, compared to the same period in 2023. The decrease in general and administrative expenses was primarily the result of a $4.1&#160;million decrease in stock based compensation as the prior period consisted of a $4.9&#160;million <span style="white-space:nowrap">one-time</span> charge as a result of the Business Combination, a $3.9&#160;million decrease in bad debt expense, a $2.9&#160;million decrease in insurance expense as the prior period consisted of a $3.6&#160;million <span style="white-space:nowrap">one-time</span> insurance charge related to the Business Combination, partially offset by an increase in director and officer insurance in the current year, and a $0.6&#160;million decrease attributable to salaries, benefits, and related costs. These decreases were partially offset by $1.7&#160;million of legal and professional fees, driven by $1.4&#160;million of <span style="white-space:nowrap">one-time</span> legal fees in connection with the Amended Note Purchase Agreement with RTW and $0.9&#160;million of offering costs expensed as part of the Public Offering and Private Placement in July 2024.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other income (expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense decreased $2.6&#160;million, or 100%, to zero for the three months ended September&#160;30, 2024 and $5.1&#160;million, or 69%, to $2.3&#160;million for the nine months ended September&#160;30, 2024, compared to the same periods in 2023. The decrease in interest expense was due the termination of our Fortress Term Loan in April 2024, as well as a reduction in principal of our Fortress Term Loan as compared to our 2021 Term Loan during the comparable nine month period.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Warrants&#160; </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $9.7&#160;million gain and $14.2&#160;million gain attributable to the change in fair value of warrants for the three and nine months ended September&#160;30, 2024, respectively, compared to the same periods in 2023, were due to mark to market fluctuations in our warrant liabilities due to the decline in value of our Common Stock during the periods, as well as the issuance of the July 2024 Public Warrants and Private Placement Warrants on July&#160;1, 2024, for which there were no comparable mark to market fluctuations in the prior period.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Debt&#160; </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1.8&#160;million and $10.0&#160;million gain attributable to the change in fair value of debt for each of the three and nine months ended September&#160;30, 2024, compared to the same periods in 2023, was due to mark to market fluctuations in our convertible debt.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of Revenue Interest Financing and PIPE Conversion Option</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $11.1&#160;million loss attributable to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option for the three months ended September&#160;30, 2024, compared to the same period in 2023, was primarily due to a $6.7&#160;million loss related to the change in fair value of the Revenue Interest Financing and a $4.4&#160;million loss on PIPE Conversion Option primarily driven by a decrease in the discount rate. The $9.6&#160;million loss attributable to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option for the nine months ended September&#160;30, 2024, compared to the same period in 2023, was primarily due to a $5.4&#160;million loss related to the change in fair value in the Revenue Interest Financing from December&#160;31, 2023 to September&#160;30, 2024 and a $4.3&#160;million loss in the change in fair value of the PIPE Conversion Option from December&#160;31, 2023 to September&#160;30, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Change in Fair Value of <span style="white-space:nowrap">Earn-Out</span> Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $2.3&#160;million gain attributable to the change in the fair value of <span style="white-space:nowrap">earn-out</span> liabilities for the three months ended September&#160;30, 2024 and the $22.1&#160;million gain attributable to the change in the fair value of the <span style="white-space:nowrap">earn-out</span> liabilities for the nine months ended September&#160;30, 2024 were due to the decrease in the Company&#8217;s stock price from December&#160;31, 2023 to September&#160;30, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss on extinguishment of debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt decreased $3.9&#160;million, or 100%, to zero for the three months ended September&#160;30, 2024, compared to the same period in 2023. The decrease was due to a $3.9&#160;million loss on the extinguishment of the 2021 Term Loan with Runway during the comparable period. Loss on extinguishment of debt increased $4.8&#160;million, or 122%, to $8.7&#160;million for the nine months ended September&#160;30, 2024, compared to the same period in 2023. This increase was due to the $8.7&#160;million loss on extinguishment of our Fortress Term Loan in April 2024, compared to the $3.9&#160;million loss on the extinguishment of our 2021 Term Loan with Runway in August 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Termination of convertible note side letters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Termination of convertible note side letters decreased $9.5&#160;million, or 100%, to zero for the three months ended September&#160;30, 2024 and $17.6&#160;million, or 100%, to zero for the nine months ended September&#160;30, 2024, compared to the same periods in 2023. The decreases were primarily due to changes in the PubCo Share Liability, Base PubCo Shares and Backstop Shares liabilities driven by the use of the full backstop during the comparable periods for which there were no comparable liabilities in the current period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income, Net</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in Other income, net for the three months ended September&#160;30, 2024 compared to the same period in 2023 was a gain of $0.4&#160;million attributable to a $0.4&#160;million gain related to fluctuations in exchange rates of foreign currencies. The change in Other income, net for the nine months ended September&#160;30, 2024 compared to the same period in 2023 was a gain of $1.8&#160;million, primarily driven by the $2.1&#160;million <span style="white-space:nowrap">write-off</span> of the term loan derivative liability to zero in connection with the termination of the Fortress Term Loan and a $1.1&#160;million gain in interest income, partially offset by a $1.1&#160;million loss related to the Amended Note Purchase Agreement.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Provision for Income Taxes</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a provision for income taxes of $0.1&#160;million and $0.2&#160;million for the three and nine months ended September&#160;30, 2024, respectively. These provisions for income taxes are due to net income in certain foreign jurisdictions.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Years Ended December&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the years ended December&#160;31, 2023 and 2022 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:73%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years Ended December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">53,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,515</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,229</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales and marketing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,548</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,839</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(79,078</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32,010</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,068</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,566</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,426</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,364</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(821</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of Revenue Interest Financing and PIPE conversion option</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value of <span style="white-space:nowrap">earn-out</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination of convertible note side letters</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,598</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,598</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on extinguishment of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(643</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(344</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(299</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,265</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,591</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(37,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,742</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(264</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(143</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(121</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(80,607</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(37,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,863</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue decreased $10.7&#160;million, or 17%, to $53.5&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The decrease in revenue was primarily the result of a delay in closing of the Business Combination, which led to decreased investment in certain markets, leading to temporarily lower <span style="white-space:nowrap">re-order</span> rates as distributors and certain accounts adjusted their inventory levels during the second half of 2023. The decrease in revenue was also attributable to selling less or no product to certain distributors and accounts to manage our credit risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue decreased $1.5&#160;million, or 11%, to $12.0&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The decrease in cost of revenue was primarily a direct result of decreased gastric balloons sold. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gross Profit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gross profit decreased $9.2&#160;million, or 18%, to $41.5&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The decrease in gross profit was primarily the result of fewer gastric balloons sold, an increase in our direct manufacturing costs and a higher percentage of sales in lower-margin geographies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sales and Marketing Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales and marketing expenses decreased $3.5&#160;million, or 7%, to $46.9&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The decrease in sales and marketing expenses was primarily the result of a $3.9&#160;million decrease in marketing spend driven by our decision to delay investment in sales and marketing while completing the Business Combination with Compute Health, and a $1.8&#160;million decrease related to changes in our distribution model, which were partially offset by a $2.3&#160;million increase attributable to salaries and related benefit costs due to higher headcount. We expect sales and marketing costs to decrease in 2024 as we have implemented cost reduction initiatives, including a reduction in force, and shift our focus of selling and marketing spend on more efficient channels and geographies. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased $10.7&#160;million, or 63%, to $27.7&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The increase in research and development expenses was the result of an increase of $9.8&#160;million in costs related to the AUDACITY clinical trial, and a $0.9&#160;million increase attributable to salaries due to higher headcount to support new product development and clinical trials. We expect research and development expenses to decrease in 2024 as our AUDACITY trial nears completion. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased $30.6&#160;million, or 199%, to $46.0&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The increase in general and administrative expenses was primarily the result of a $12.0&#160;million increase in accounts receivable reserves resulting primarily from challenges entering new markets and transitioning certain markets from a distributor model to a direct model, a $7.8&#160;million increase in stock-based compensation, including $4.9&#160;million of <span style="white-space:nowrap">one-time</span> charges as a result of the Business Combination, a $3.6&#160;million increase in insurance expense as a result of the Business Combination, a $4.5&#160;million increase in professional, legal, and consulting fees, including $1.7&#160;million of <span style="white-space:nowrap">one-time</span> charges as a result of the Business Combination, and a $2.2&#160;million increase attributable to salaries and related benefit costs due to higher headcount. We expect general and administrative expenses to decrease in 2024, as we have implemented cost reduction initiatives. Further, we had incurred a significant increase in accounting, audit, legal, regulatory, compliance, and investor and public relations expenses associated with the Business Combination for the year ended December&#160;31, 2023. We also incurred significant bad debts expense in 2023 which is not expected to recur. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other expense (income) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense increased $6.1&#160;million, or 139%, to $10.6&#160;million for the year ended December&#160;31, 2023, compared to the same period in 2022. The increase in interest expense was primarily due to a $4.9&#160;million increase in interest expense associated with our Fortress Term Loan signed in August 2023, a $0.8&#160;million increase in interest on our 2021 Term Loan, and a $0.5&#160;million increase in interest expense associated with our 2023 convertible notes that were converted into shares of our Common Stock at the closing of the Business Combination in August 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Warrants</span><span style="font-weight:bold"><span style="font-style:italic">&#160;</span></span><span style="font-style:italic"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of warrants for the year ended December&#160;31, 2023 compared to the same period in 2022 was a gain of $9.2&#160;million, primarily driven by a $7.8&#160;million gain attributable to the change in fair value of the CPUH public warrants and a $0.5&#160;million gain attributable to the change in fair value of our private warrants due to the decline in value of our common and preferred stock during those periods. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $3.8&#160;million loss attributable to the change in fair value of debt for the year ended December&#160;31, 2023 was driven by mark to market fluctuations in our convertible debt as a result of the closing of the Business Combination and automatic conversion of the notes to our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of Revenue Interest Financing and PIPE Conversion Option </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $2.2&#160;million loss attributable to the change in fair value of Revenue Interest Financing and PIPE conversion option for the year ended December&#160;31, 2023 was primarily due to the initial recognition of the PIPE Conversion Option of $3.3&#160;million on August&#160;1, 2023 and an additional $2.3&#160;million loss in the fair value from August&#160;1, 2023 to December&#160;31, 2023 due to a decrease in the Company&#8217;s stock price during that period. This expense was partially offset by a $3.4&#160;million gain in the fair value in the Revenue Interest Financing from when the liability was established on August&#160;1, 2023 to December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Fair Value of <span style="white-space:nowrap">Earn-Out</span> Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $29.1&#160;million gain attributable to the change in the fair value of <span style="white-space:nowrap">earn-out</span> liabilities for the year ended December&#160;31, 2023 was due to the decrease in our stock price between the establishment of the liability on August&#160;1, 2023 and December&#160;31, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination of convertible note side letters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $17.6&#160;million loss attributable to the termination of convertible note side letters for the year ended December&#160;31, 2023 was primarily due to a $13.4&#160;million loss related to the Base PubCo Shares and Backstop Shares (each as defined in our consolidated financial statements included elsewhere in this prospectus) liabilities driven by the use of the full backstop, a $2.7&#160;million loss on the PubCo Additional Shares liability, and a $1.5&#160;million prepayment penalty related to the repayment of the Company&#8217;s Legacy Allurion convertible note with HVL. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Loss on Extinguishment of Debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $3.9&#160;million loss on extinguishment of debt for the year ended December&#160;31, 2023 was due to the loss on extinguishment of debt related to the repayment of our 2021 Term Loan in connection with the entrance into the Fortress Term Loan on August&#160;1, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other (Expense) Income, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in Other (expense) income, net for the year ended December&#160;31, 2023 compared to the same period in 2022 was $0.3&#160;million of expense, primarily driven by interest expense of $1.7&#160;million due to the establishment of the Fortress Term Loan derivative liability and mark to market fluctuations of the 2019 Term Loan Success Fee derivative liability. This was partially offset by $1.2&#160;million of interest income during the period. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Provision for Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded a provision for income taxes of $0.3 million and $0.1 million for the years ended December&#160;31, 2023 and 2022, respectively. These provisions for income taxes are due to net income in certain foreign jurisdictions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have primarily obtained cash to fund our operations through the sale of Allurion preferred stock and common stock, issuance of term loans, royalty arrangements, and issuance of convertible </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
debt instruments. As of September&#160;30, 2024, we had $28.7&#160;million in cash and cash equivalents. We incurred a net loss of $5.6&#160;million and $61.4&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively. We incurred cash outflows from operating activities of $29.0&#160;million and $43.1&#160;million during the nine months ended September&#160;30, 2024 and 2023, respectively. As of September&#160;30, 2024, we had an accumulated deficit of $218.4&#160;million. As of December 31, 2023, we had $38.0 million in cash and cash equivalents. We incurred net losses of $80.6 million and $37.7 million for the years ended December 31, 2023 and 2022, respectively. We incurred cash outflows from operating activities of $64.0 million and $47.0 million during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $212.8 million. We expect to continue to generate significant operating losses for the foreseeable future.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the emergence of competing innovative weight loss experiences and other adverse marketing developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and extent of our sales and marketing and research and development expenditures; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any investments or acquisitions we may choose to pursue in the future. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue for the nine months ended September&#160;30, 2024 was $26.5&#160;million, which represented a quarter-over-quarter decrease of 41%. The decrease in revenue was primarily the result of lower <span style="white-space:nowrap">re-order</span> rates as distributors and certain accounts adjusted their inventory levels. The decrease in revenue was also attributable to selling less or no product to certain distributors and accounts to manage our credit risk. Additionally, in August 2024, ANSM suspended sales of the Allurion balloon in France, resulting in a reduction to revenue for customer returns of the Allurion Balloon. Our revenue for the year ended December&#160;31, 2023 was $53.5&#160;million, which represented a year-over-year decrease of 17%. The decline in revenue was primarily the result of a delay in closing of the Business Combination, which led to decreased investment in certain markets leading to temporarily lower re-order rates as distributors and certain accounts adjusted their inventory levels during the second half of 2023. The decrease in revenue was also attributable to selling less or no product to certain distributors and accounts to manage our credit risk. If our current cash and anticipated revenue and resulting cash flows from operations are insufficient to satisfy our liquidity requirements, due to increased expenditures, lower demand for or sales of our gastric balloon system, the occurrence of other events or the realization of the risks described under the heading &#8220;Risk Factors,&#8221; we may be required to raise additional capital through the issuances of public or private equity or debt financing or other capital sources earlier than expected.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time as we can generate sufficient revenue to fund operations, we expect to use proceeds from the issuance of equity, debt financings, or other capital transactions to fund our operations and satisfy our liquidity requirements. We may be unable to increase our revenue, successfully complete remediation programs to resume sales of the Allurion Balloon, raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to increase our revenue, successfully complete remediation programs to resume sales of the Allurion Balloon, raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue our operations or the development and commercialization of one or more of our product candidates and other strategic initiatives. Based on our recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and the potential need to raise additional capital to finance our future operations and debt service payments, we have concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the consolidated financial statements included in this registration statement of which this prospectus forms a part are issued. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing Arrangements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Public Offering and Concurrent Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;1, 2024, we received $15.2&#160;million in net proceeds from the issuance of 14,406,508 shares of common stock and 16,567,484 July 2024 Public Warrants and $2.5&#160;million in net proceeds from the sale and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of 2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants in the Private Placement, in each case at an offering price of $1.20 per share and accompanying warrant. On July&#160;5, 2024, the Underwriters partially exercised their option to purchase an additional 1,927,265 shares of Common Stock for additional net proceeds of $2.2&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Note Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, we received $48&#160;million in gross proceeds from the Amended Note Purchase Agreement with RTW, which proceeds were used to repay all outstanding principal, accrued and unpaid interest and other obligations with respect to the Fortress Term Loan.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, $48.0&#160;million of the RTW Convertible Notes remains outstanding and is included in convertible notes payable, net of discounts on our consolidated balance sheets. See Note 8, <span style="font-style:italic">Debt</span>, in the notes to our unaudited interim condensed consolidated financial statements for the three and nine months ended September&#160;30, 2024 and 2023 included within this registration statement of which this prospectus forms a part for additional details regarding the RTW Convertible Notes.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chardan Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;18, 2023, we entered into the Purchase Agreement with Chardan. Pursuant to the Purchase Agreement, we have the right from time to time at our option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of our Common Stock, and (ii)&#160;the Exchange Cap, subject to certain conditions.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, we have received $0.4&#160;million in net proceeds from sales of shares of our Common Stock pursuant to the Purchase Agreement with Chardan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue Interest Financing Agreement</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, we received $40.0&#160;million in proceeds from the Revenue Interest Financing Agreement with RTW, which matures in December&#160;2030. We entered into the Revenue Interest Financing Agreement on February&#160;9, 2023 and received the proceeds at the closing of the Business Combination. On April&#160;14, 2024, the Revenue Interest Financing Agreement was amended to, among other things, increase the rate of revenue interest payments to be paid to RTW. The Revenue Interest Financing Agreement is included in Revenue Interest Financing liability on our consolidated balance sheet as of September&#160;30, 2024. See Note 9, <span style="font-style:italic">Revenue Interest Financing, Side Letter, and PIPE Conversion Option </span>in the notes to our unaudited interim condensed consolidated financial statements for the three and nine months ended September&#160;30, 2024 and 2023 included within this registration statement of which this prospectus forms a part for additional details regarding the Revenue Interest Financing Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of common stock of the Company representing $7.5&#160;million in consideration for an additional Revenue&#160;Interest Financing Agreement. Accordingly, on October&#160;30, 2024, the Company and the funds affiliated with RTW entered into the Additional Revenue Interest Financing Agreement.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material Cash Requirements for Known Contractual and Other Obligations</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Leases</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into various <span style="white-space:nowrap">non-cancellable</span> operating leases for our corporate office, manufacturing facilities, research and development labs, management office space and certain equipment. The leases have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
varying terms expiring between 2025 and 2028. See Note 16, <span style="font-style:italic">Commitments and Contingencies </span>of the notes to our unaudited interim condensed consolidated financial statements for the three and nine months ended September&#160;30, 2024 and 2023 for additional details related to our noncancelable operating leases.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">RTW Convertible Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, we received $48&#160;million in gross proceeds from the Amended Note Purchase Agreement with RTW, which proceeds were used to repay all outstanding principal, accrued and unpaid interest and other obligations with respect to the Fortress Term Loan.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue Interest Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received $40.0&#160;million in proceeds from the Revenue Interest Financing Agreement with RTW on August&#160;1, 2023. In exchange, we are obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at certain specified rates. On April&#160;14, 2024, the Revenue Interest Financing Agreement was amended to, among other things, increase the rate of revenue interest payments to be paid to RTW for net sales less than or equal to $100&#160;million prior to December&#160;31, 2026 from 6% to 12%, and increase the royalty rate on net sales less than or equal to $100&#160;million on or after January&#160;1, 2027 from 10% to 12%.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, we must make a cash payment in an amount sufficient to catch RTW up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December&#160;31, 2030, we must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, on October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of common stock of the Company representing $7,500,000 in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October&#160;30, 2024, the Company and the funds affiliated with RTW entered into the Additional Revenue Interest Financing Agreement. The Additional Revenue Interest Financing Agreement has substantially identical terms and conditions as the RIFA Amendment, except that the amount of financing provided under the Additional Revenue Interest Financing Agreement is equal to the conversion amount of $7.5&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Costs</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are continuing to invest in our U.S. FDA AUDACITY clinical trial and have entered into contractual obligations with each clinical trial site. Each contract shall continue until the completion of the trial at that site, which is approximately 48 weeks from the start of each contract. Our clinical trial costs are dependent on, among other things, the size, number, and length of our clinical trial. We also incur research and development costs related to the enhancement of our existing products.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Capital Requirements</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into agreements in the normal course of business with various vendors, which are generally cancelable upon notice. Payments due upon cancellation typically consist only of payments for services provided or expenses incurred, including <span style="white-space:nowrap">non-cancelable</span> obligations of service providers, up to the date of cancellation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of cash flows for the periods presented:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Nine Months Ended<br/>September&#160;30,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Years Ended<br/>December 31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">(In thousands)</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(29,026</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(43,111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(63,982</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46,981</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(611</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,208</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,606</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,550</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,394</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents, and restricted cash</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,376</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,994</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Cash Used in Operating Activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nine Months Ended September&#160;30, 2024 and 2023</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2024, operating activities used $29.0&#160;million of cash, resulting in a net loss of $5.6&#160;million, <span style="white-space:nowrap">non-cash</span> income of $23.0&#160;million, and net cash used from changes in our operating assets and liabilities of $0.4&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-cash</span> income consisted of $22.1&#160;million of income related to the change in fair value of our <span style="white-space:nowrap">earn-out</span> liabilities, $14.2&#160;million of mark to market adjustments related to our warrant liabilities, $10.0&#160;million of income related to the change in fair value of our convertible debt, $2.5&#160;million of interest paid on debt recorded at fair value, and $1.9&#160;million of income related to the change in fair value of our term loan derivative liability. This <span style="white-space:nowrap">non-cash</span> income was partially offset by a $9.6&#160;million loss on the change in fair value of our Revenue Interest Financing and PIPE Conversion Option, an $8.7&#160;million loss on the extinguishment of our Fortress Term Loan, $2.2&#160;million of stock-based compensation expense, $1.5&#160;million of <span style="white-space:nowrap">non-cash</span> interest expense, $1.4&#160;million of debt issuance costs associated with debt at fair value, a $1.1&#160;million provision for uncollectible accounts, a $1.1&#160;million provision for inventory, $0.9&#160;million of issuance costs associated with warrants recorded at fair value, $0.8&#160;million of depreciation and amortization expense, and $0.6&#160;million of <span style="white-space:nowrap">non-cash</span> lease expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by changes in our operating assets and liabilities consisted of a $7.2&#160;million decrease in accounts receivable, a $0.6&#160;million decrease in inventory, and a $0.7&#160;million decrease in prepaid expenses, other current and long-term assets, partially offset by a net $8.4&#160;million decrease in accounts payable, accrued expenses and other current liabilities and a $0.6&#160;million decrease in our lease liabilities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in accounts receivable was the result of an increase in cash collections and decrease in revenue. The decrease in inventory was primarily related to a decrease in finished goods and work in progress. The decrease in prepaid expenses, other current and long-term assets was primarily related to a decrease in prepaid inventory and payroll deposits. The net decrease in accounts payable, accrued expenses and other current liabilities was primarily related to decreased expenses and timing of payments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2023, operating activities used $43.1&#160;million of cash, resulting from a net loss of $61.4&#160;million, partially offset by net cash provided by changes in our operating assets and liabilities of $3.4&#160;million and <span style="white-space:nowrap">non-cash</span> charges of $14.9&#160;million.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-cash</span> charges consisted of $16.1&#160;million for termination of convertible note side letters, $6.3&#160;million of stock-based compensation expense, a $5.0&#160;million provision for uncollectible accounts, $3.9&#160;million loss on extinguishment of debt for our 2021 Term Loan, $3.8&#160;million related to the change in fair value of our convertible debt, $2.0&#160;million related to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option, $1.1&#160;million of <span style="white-space:nowrap">non-cash</span> interest expense primarily related to the accretion of debt discount </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with our outstanding debt arrangements, a $0.7&#160;million provision for inventory, $0.6&#160;million of lease expense, $0.6&#160;million of depreciation and amortization expense, and $0.3&#160;million of unrealized loss on foreign exchange. These charges were partially offset by $24.3&#160;million of income related to the change in fair value of our <span style="white-space:nowrap">earn-out</span> liabilities and $2.4&#160;million of mark to market adjustments related to our warrant and derivative liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by changes in our operating assets and liabilities consisted of a net $8.4&#160;million increase in accounts payable, accrued expenses and other current liabilities and a $0.4&#160;million decrease in prepaid expenses, other current and long-term assets, partially offset by a $3.9&#160;million increase in accounts receivable, a $0.9&#160;million increase in inventory and a $0.6&#160;million decrease in operating lease liabilities.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net increase in accounts payable, accrued expenses and other current liabilities was primarily related to increased expenses as well as timing of payments. The increase in accounts receivable was primarily related to the timing of cash collections. The decrease in prepaid expenses, other current and long-term assets was primarily related to the settlement of deferred deal costs related to the Business Combination. The increase in inventory was primarily related to an increase in work in progress and raw materials.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Years Ended December&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, operating activities used $64.0&#160;million of cash, resulting from a net loss of $80.6&#160;million, partially offset by net cash provided by changes in our operating assets and liabilities of $0.2&#160;million and <span style="white-space:nowrap">non-cash</span> charges of $16.4&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-cash</span> charges consisted of $16.1&#160;million for termination of convertible note side letters, a $12.7&#160;million provision for uncollectible accounts, $8.4&#160;million of stock-based compensation expense, a $3.9&#160;million loss on extinguishment of debt for our 2021 Term Loan, $3.8&#160;million related to the change in fair value of our convertible debt, $2.2&#160;million related to the change in fair value of the Revenue Interest Financing and PIPE Conversion Option, $2.1&#160;million of <span style="white-space:nowrap">non-cash</span> interest expense primarily related to the amortization of debt discount associated with our outstanding debt arrangements, $1.7&#160;million of mark to market adjustments related to our derivative liabilities, $1.2&#160;million of debt issuance costs associated with the Revenue Interest Financing, $0.8&#160;million of lease expense, and $0.7&#160;million of depreciation and amortization expense. These charges were partially offset by $29.1&#160;million of income related to the change in fair value of our <span style="white-space:nowrap">earn-out</span> liabilities, $8.4&#160;million of mark to market adjustments related to our warrant liabilities, and $1.1&#160;million of interest paid on debt recorded at fair value. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by changes in our operating assets and liabilities consisted of a net $5.7&#160;million increase in accounts payable, accrued expenses and other current liabilities and a $0.3&#160;million decrease in prepaid expenses, other current and long-term assets, partially offset by a $3.7&#160;million increase in inventory, a $1.3&#160;million increase in accounts receivable, and a $0.8&#160;million decrease in lease liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net increase in accounts payable, accrued expenses and other current liabilities was primarily related to increased expenses as well as timing of payments. The increase in accounts receivable was primarily related to the timing of cash collections. The decrease in prepaid expenses, other current and long-term assets was primarily related to the settlement of deferred deal costs related to the Business Combination. The increase in inventory was primarily related to an increase in work in progress and raw materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, operating activities used $47.0&#160;million of cash, resulting from a net loss of $37.7&#160;million and net cash used by changes in our operating assets and liabilities of $13.8&#160;million, offset by <span style="white-space:nowrap">non-cash</span> charges of $4.6&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-cash</span> charges primarily consisted of $2.0&#160;million of depreciation and amortization expense and <span style="white-space:nowrap">non-cash</span> lease expense, $1.0&#160;million of interest expense primarily related to the accretion of debt discount associated with our outstanding debt arrangements, a $0.8&#160;million change in fair value of warrant liabilities, a $0.4&#160;million of stock-based compensation expense and a $0.4&#160;million provision for uncollectible accounts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used by changes in our operating assets and liabilities consisted of a $22.8&#160;million increase in accounts receivable, a $1.2&#160;million increase in inventory, a $0.7&#160;million decrease in operating lease liabilities and a $0.6&#160;million increase in prepaid expenses, other current assets and long-term assets, partially offset by a net $11.5&#160;million increase in accounts payable, accrued expenses and other current liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in accounts receivable was primarily related to growth in sales. The increase in prepaid expenses and other current assets was primarily related to increases in prepaid inventory and additional software subscription costs. The increase in inventory was primarily related to an increase in finished goods and raw materials. The decrease in lease liabilities was primarily due to payment of rent for our leased property. The net increase in accounts payable, accrued expenses and other current liabilities was primarily related to an increase in sales and marketing and general and administrative expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Cash Used in Investing Activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nine Months Ended September&#160;30, 2024 and 2023</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2024 and September&#160;30, 2023, cash used in investing activities was $0.6&#160;million and $1.2&#160;million, respectively, consisting of purchases of property and equipment.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Years Ended December&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2023 and December&#160;31, 2022, cash used in investing activities was $1.6&#160;million, consisting of purchases of property and equipment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Cash Provided by Financing Activities</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nine Months Ended September&#160;30, 2024 and 2023</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2024, cash provided by financing activities was $20.3&#160;million, consisting of $48.0&#160;million in proceeds from the issuance of convertible notes, $18.2&#160;million in net proceeds from the Public Offering, $2.7&#160;million in net proceeds from the Private Placement, and $0.4&#160;million of proceeds from our equity line financing, partially offset by $47.7&#160;million repayment of the Fortress Term Loan and a $1.4&#160;million payment of debt issuance costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&#160;30, 2023, cash provided by financing activities was $116.4&#160;million, consisting of $62.1&#160;million of proceeds from the Business Combination, net of transaction costs, $57.6&#160;million from the issuance of our Fortress Term Loan net of debt issuance costs, $38.8&#160;million from the issuance of our Revenue Interest Financing Agreement with RTW net of issuance costs, $28.7&#160;million from the issuance of our 2023 Convertible Notes, net of issuance costs, partially offset by the $57.7&#160;million repayment of our 2021 Term Loan, $10.8&#160;million repayment of our 2023 Convertible Notes and $2.5&#160;million of repayment of a promissory note assumed from Compute Health in the Business Combination.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Years Ended December&#160;31, 2023 and 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2023, cash provided by financing activities was $96.0&#160;million, consisting of $61.7&#160;million of proceeds from the Business Combination, net of transaction costs, $57.6&#160;million from the issuance of our Fortress Term Loan net of debt issuance costs, $38.8&#160;million from the issuance of our Revenue Interest Financing Agreement with RTW net of issuance costs, and $28.7&#160;million from the issuance of our 2023 Convertible Notes, net of issuance costs, partially offset by the $57.7&#160;million repayment of our 2021 Term Loan, $20.0&#160;million repayment of our Fortress Term Loan, $10.8&#160;million repayment of our 2023 Convertible Notes and $2.5&#160;million repayment of a promissory note assumed from Compute Health in the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, cash provided by financing activities was $30.5&#160;million, consisting of $29.6&#160;million from the issuance of our 2021 Term Loan, net of issuance costs, $1.1&#160;million from the issuance of our 2022 Convertible Notes, net of issuance costs and $0.1&#160;million from the exercise of stock options, partially offset by $0.3&#160;million payment of deferred financing costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in more detail in Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies</span>, to our audited consolidated financial statements included in the registration statement of which this prospectus forms a part, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for revenue in accordance with Accounting Standards Update (&#8220;ASU&#8221;) <span style="white-space:nowrap">No.&#160;2014-09,</span> <span style="font-style:italic">Revenue from Contracts with Customers</span> (&#8220;Topic 606&#8221; or &#8220;ASC 606&#8221;). In accordance with ASC 606, we recognize revenue when control of our products is transferred to our customers in an amount that reflects the consideration we expect to receive in exchange for those products. Our revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is generated primarily from the sale of our gastric balloon system, which includes the Allurion Balloon and related accessories. We have provided customers purchasing the Allurion Balloon with an implied license for access to our Allurion VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#8217;s contracts. As such, it has been deemed an immaterial promise in the context of the contract, and we do not consider the license as a separate performance obligation. In the future, if and when Allurion VCS services are determined to be a performance obligation, we expect the associated consideration will be deferred and recognized over the license period.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell our products directly to customers through our direct sales personnel and indirectly through independent distributors. For distributor sales, we sell our products to our distributors, who subsequently resell the products to health care providers, among others. For direct sales, our products are sold directly to our customers, which are typically health care providers. Generally, customer contracts contain Free on Board or <span style="white-space:nowrap">Ex-Works</span> shipping point incoterms. We recognize revenue when the customer obtains control of our product, which typically occurs upon shipment, in return for agreed-upon, fixed-price consideration.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, from time to time, we offer certain incentives to our customers, which are recorded as a reduction of revenue in the period the related product revenue is recognized. Any discounts we offer are outlined in our customer agreements. Payments to the customer for a distinct good or service that reasonably estimates the fair value of the distinct benefit received, such as marketing programs and shipping and logistics services, are recorded as a selling and marketing expense.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our payment terms are consistent with prevailing practice in the respective markets in which we do business, which are not affected by contingent events that could impact the transaction price. Our contracts with customers do not provide general rights of return unless certain product quality standards are not met.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Valuation of <span style="white-space:nowrap">Earn-Out</span> Liabilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, holders of Legacy Allurion common stock and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive additional shares of our Common Stock (the <span style="white-space:nowrap">&#8220;Earn-Out</span> Shares&#8221;) upon the achievement of certain <span style="white-space:nowrap">earn-out</span> targets. As the contingent <span style="white-space:nowrap">earn-out</span> consideration contains a settlement provision that precludes it from being indexed to our stock, it is classified as a liability under ASC 480, as defined in Note 2, <span style="font-style:italic">Summary of Significant Accounting Policies</span>. The fair value of contingent <span style="white-space:nowrap">earn-out</span> consideration is estimated as of the acquisition date at the present value of the expected contingent payments using a Monte Carlo Simulation Method. This method utilizes a combination of observable (Level 2) and unobservable (Level 3) inputs, which include the trading price and volatility of the underlying common stock, expected term, risk-free interest rates, and expected date of a qualifying event. The determination of the fair value of these financial instruments is complex and highly&#160;judgmental due to the significant estimation required. In particular, the fair value estimate is sensitive to certain assumptions, such as the volatility of underlying shares.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the estimated fair value of the contingent <span style="white-space:nowrap">earn-out</span> consideration are recorded in Other income (expense) in the condensed consolidated statements of operations and are reflected in the period in which they are identified. Changes in the estimated fair value of the continent <span style="white-space:nowrap">earn-out</span> consideration may materially impact or cause volatility in our operating results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Valuation of Revenue Interest Financing and PIPE Conversion Option </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, we entered into the Revenue Interest Financing Agreement with RTW, under which the Company received $40.0&#160;million upfront. In exchange, we are obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries until December&#160;31, 2030. We account for the Revenue Interest Financing Agreement under the fair value option election of ASC 825, <span style="font-style:italic">Financial Instruments</span>. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument containing embedded features wherein the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing is calculated using a discounted cash flow method under the income approach utilizing future revenue projections and a discount rate. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering into the Revenue Interest Financing, we and RTW entered into the Amended and Restated RTW Side Letter under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE subscription into an additional revenue interest financing by forfeiting a number of shares of our Common Stock acquired by the RTW in its PIPE Investment. We account for this PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, <span style="font-style:italic">Derivatives and Hedging</span>. The fair value of the PIPE Conversion Option is measured using a MCSM using a combination of observable (Level 2) and unobservable (Level 3) inputs, which include the number of shares convertible, the stock price of the underlying common stock, volatility, risk-free rates, and expected term. The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the condensed consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other income (expense) in the condensed consolidated statements of operations.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Valuation of RTW Convertible Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into the Amended Note Purchase Agreement with RTW on April&#160;16, 2024, under which the Company issued and sold $48.0&#160;million aggregate principal amount of convertible senior secured notes. We account for the RTW Convertible Notes under the FVO election of ASC 825, as the Amended Note Purchase Agreement is a financial instrument containing embedded features where the entire financial instrument is measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes is measured using a discounted cash flow method under the income approach with a MCSM used to determine the simulated stock price at each payment date and event that may trigger conversion of the RTW Convertible Notes. The fair value is measured using a combination of observable (Level 2) and unobservable (Level 3) inputs, which include probabilities of various conversion scenarios, volatility, estimated market yields, and expected term. The determination of the fair value of the RTW Convertible Notes is complex and highly judgmental due to the significant estimation required.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the estimated fair value of the RTW Convertible Notes are recorded in Other income (expense) in the condensed consolidated statement of operations and are reflected in the period in which they are identified.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Determination of Fair Value of Legacy Allurion Preferred Stock, Common Stock and Warrants</span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated fair value of our Legacy Allurion shares has been determined by the Legacy Allurion board of directors, with input from management, considering the most recently available third-party valuations then available and the Legacy Allurion board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant. These factors included, but were not limited to:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prices at which we sold shares of Legacy Allurion preferred stock and the superior rights and preferences of the Legacy Allurion preferred stock relative to the Legacy Allurion common stock at the time of each grant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our stage of development and business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">external market conditions and trends affecting our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our financial position, including cash on hand, and our historical and forecasted performance and operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of an active public market for our Common Stock and our preferred stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the likelihood of achieving a liquidity event, such as an initial public offering, deSPAC transaction, or sale of our company in light of prevailing market conditions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the analysis of initial public offerings or other financing transactions and market performance of comparable companies in the industry. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the underlying Legacy Allurion preferred stock, common stock, and warrants was determined by the Legacy Allurion board of directors until we were listed on the NYSE on August&#160;2, 2023. The fair value of the Legacy Allurion shares is utilized in the determination of stock-based compensation expense, common stock warrant liability expense, preferred stock recorded at fair value and the convertible notes conversion price. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Allurion preferred stock issued in 2021 and Legacy Allurion Convertible Notes converted in 2021 could be materially different. Significantly different assumptions or estimates could also impact the fair value of the Legacy Allurion Stock Options and stock-based compensation and fair value of the Legacy Allurion warrants, but these have not been material to date.</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2, <span style="font-style:italic">Summary of Significant of Accounting Policies</span> in the accompanying notes to the consolidated financial statements included this registration statement of which this prospectus forms a part for a description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company and Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i)&#160;we are no longer an emerging growth company or (ii)&#160;we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K,</span> which allows us to take advantage of certain exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&#160;404. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of the shares of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June&#160;30, and (ii)&#160;our annual revenue exceeded $100&#160;million during such completed fiscal year or the market value of the shares of our Common Stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June 30. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_12">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors, Executive Officers and Corporate Governance. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding our directors and executive officers, including their ages, as of December&#160;9, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:46%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Position</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dr.&#160;Shantanu Gaur</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">38</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Krishna Gupta</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">37</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Co-Chairman</span> and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dr.&#160;Omar Ishrak</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">69</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><span style="white-space:nowrap">Co-Chairman</span> and Lead-Independent Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Michael Davin</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">66</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Douglas Hudson</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">55</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Keith Johns</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">60</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Nicholas Lewin</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">47</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Milena Alberti-Perez</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">51</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold"><span style="font-style:italic">Executive Officers</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Dr.&#160;Ram Chuttani</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">65</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Brendan Gibbons</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">49</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Legal Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Ojas Buch</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="center">52</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Operating Officer</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dr.</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;Shantanu Gaur </span></span>has served as our Chief Executive Officer and as a member of our board of directors (the &#8220;Board of Directors&#8221; or &#8220;Board&#8221;) since September 2009. Dr.&#160;Gaur founded Allurion in 2009 while at Harvard Medical School. Dr.&#160;Gaur graduated summa cum laude with a B.S. in Biology from Harvard College and with an M.D. from Harvard Medical School, where he was a Paul Revere Frothingham Scholar and Paul&#160;&amp; Daisy Soros Fellow. Dr.&#160;Gaur is qualified to serve on our Board of Directors because of his experience founding Allurion and serving as our Chief Executive Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Krishna Gupta </span></span>has served as a member of our Board of Directors since January 2017. He is the founder of REMUS Capital and Romulus Capital (collectively referred to herein as &#8220;REMUS Capital&#8221;), technology-focused venture capital firms he initially founded in 2008. Mr.&#160;Gupta serves as a director on the boards of several privately held companies, including: Ceres Imaging, Inc., which provides computer vision-analytics in agriculture; Cogito Corporation, which provides voice artificial intelligence (&#8220;AI&#8221;) for large enterprises; Cohealo, Inc., which provides equipment sharing services for health systems; Spotta Ltd., which develops smart insect and pest monitoring solutions; and ZeroCater, Inc., which provides catering technology for enterprises. He was the first investor in Ginger, which was a leader in mental health software and merged with Headspace, Inc. Mr.&#160;Gupta has also served as a member of the board of directors of Presto Automation, Inc. (Nasdaq: PRST) since 2017, where he served as chairman of the board from September 2022 to March 2024. Prior to REMUS Capital, Mr.&#160;Gupta held roles at McKinsey&#160;&amp; Company, a management consulting firm, and JPMorgan Chase&#160;&amp; Co., an investment banking firm, where he advised several Fortune 100 clients on technology M&amp;A deals. Mr.&#160;Gupta holds B.S. degrees in materials science and engineering, as well as in management sciences, both from the Massachusetts Institute of Technology. Mr.&#160;Gupta is qualified to serve on our Board of Directors due to his experience investing in technology and healthcare businesses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dr.</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;Omar Ishrak</span></span> has served as a member of our Board of Directors since August 2023, and previously served as chairman of the board of directors of Compute Health Acquisition Corp. (formerly NYSE: CPUH) (&#8220;Compute Health&#8221;) from October 2020 to August 2023. Dr.&#160;Ishrak also serves on the board of directors at Intel Corporation (Nasdaq: INTC), where he served as independent chairman of the board from January 2020 to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
January 2023. Dr.&#160;Ishrak has also served on the board of directors of Amgen, Inc. (Nasdaq: AMGN) since July 2021, of Cargill, Inc., a private company, where he has served since January 2021, and of Insightec, Ltd., a private company, where he has served since May 2022. Dr.&#160;Ishrak was the chief executive officer of Medtronic plc (Nasdaq: MDT) from June 2011 to April 2020 and served as executive chairman and chairman of the board of directors until he stepped down in December 2020. Prior to joining Medtronic, Dr.&#160;Ishrak was the president and chief executive officer of GE Healthcare Systems. Earlier in his career, Dr.&#160;Ishrak amassed 13 years of technology development and business management experience, holding leadership positions at Diasonics Vingmed Ultrasound Ltd., and various product development and engineering positions at Philips Ultrasound Inc. He was inducted into the American Institute for Medical and Biological Engineering College of Fellows in 2016 and was elected to the National Academy of Engineering in 2020. Dr.&#160;Ishrak serves on the board of directors of the Cleveland Clinic, a nonprofit academic medical center. He is also a member of the Board of Trustees of the Asia Society, a leading educational organization dedicated to promoting mutual understanding and strengthening partnerships among peoples, leaders, and institutions of Asia and the United States in a global context. In addition, he is member of the Minnesota Public Radio Board of Trustees. He earned a B.S. degree and Ph.D. in electrical engineering from the University of London, King&#8217;s College. He is also a fellow of King&#8217;s College. Dr.&#160;Ishrak is qualified to serve on our Board of Directors based on his extensive experience on boards of various healthcare and technology companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Michael Davin </span></span>has served as a member of our Board of Directors since October 2017. Mr.&#160;Davin has also served as a director of several privately-held companies, including: Follica, Inc. since December 2020, Amsel Medical Corporation since August 2020, Cynosure, LLC since January 2020, and Inkbit Corporation since June 2018. Previously, Mr.&#160;Davin served as chairman, president, and chief executive officer of Cynosure Inc. (formerly Nasdaq: CYNO), from 2003 until March 2017, when it was acquired by Hologic Inc. Mr.&#160;Davin received his B.S. and B.A. from Southern New Hampshire University. Mr.&#160;Davin is qualified to serve on our Board of Directors due to his experience as a director of health care and technology companies, as well as his familiarity with Allurion as a director. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Douglas Hudson </span></span>has served as a member of our Board of Directors since August 2023. Mr.&#160;Hudson has also served as the founder, chief executive officer and a director of Noho Dental, Inc. since July 2018, and as a director of Modern Age since October 2020. Previously, Mr.&#160;Hudson served on the board of directors of Relode.com, LLC from 2017 until August 2022. Mr.&#160;Hudson also served as the founder and chief executive officer of SmileDirectClub Inc. (formerly Nasdaq: SDC) from 2013 to 2017, and as chairman and chief executive officer of Simplex Healthcare from 2007 until 2013, when it was acquired by Arriva Medical LLC. Earlier in his career, Mr.&#160;Hudson served as founder, chief executive officer and director of HearingPlanet, Inc. from 1999 until 2007. Mr.&#160;Hudson received his B.S. in organizational behavior from Eckerd College and his M.B.A. from Vanderbilt University, and he completed the executive education programs at Harvard Business School. Mr.&#160;Hudson is qualified to serve on our Board of Directors due to his experience as an entrepreneur and an executive of health care companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Keith Johns</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span>&#160;has served as a member of our Board since September 2024. Mr.&#160;Johns has also served as Chief Operating Officer of Adipo Therapeutics, LLC since September 2023, and as President of KJ Consulting LLC since March 2023. Previously, Mr.&#160;Johns served in various roles of increasing responsibility at Eli Lilly&#160;&amp; Company (NYSE: LLY) (&#8220;Eli Lilly&#8221;) during his over twenty-year tenure at Eli Lily, most recently as Senior Vice&#160;President of Global Marketing and Alliance Management for the Diabetes and Obesity Business Unit from October 2022 to December 2022. Mr.&#160;Johns holds a bachelor&#8217;s degree in hydrogeology from the University of South Carolina and a M.B.A. from the University of North Carolina&#8217;s Kenan-Flagler Business School. Mr.&#160;Johns is qualified to serve on our Board due to his experience as an executive of a large healthcare company and his expertise in the obesity management space. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Nicholas Lewin </span></span>has served as a member of our Board of Directors since August 2023. Mr.&#160;Lewin has also served as a director of Establishment Labs Holding, Inc. (Nasdaq: ESTA) since September 2015, and as its chairman since December 2017. He has been a managing member and head of investments at Crown Predator </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Holdings LLC since 2008 and has been a private investor since 2000. Mr.&#160;Lewin has also served as a director of Cutera Inc. (Nasdaq: CUTR) since May 2023, as a director of FaZe Holding Inc. (Nasdaq: FAZE) since July 2022, and as a director of Halo Maritime Defense Systems, a private company, since 2007. Mr.&#160;Lewin holds a bachelor&#8217;s degree in political science from Johns Hopkins University. Mr.&#160;Lewin is qualified to serve on our Board of Directors due to his experience as an investor in, and director of, innovative companies, including health care and medical device companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Milena Alberti-Perez</span></span> has served on our Board of Directors since March 2024. Ms.&#160;Alberti-Perez has also served on the board of directors of Digimarc Corporation (Nasdaq: DMRC) since February 2022, where she serves as the chair of the audit committee and as a member of the compensation and talent management committee. She was most recently the chief financial officer of Getty Images, Inc., the world&#8217;s leading visual content company, from December 2020 to January 2022. Prior to her work with Getty, in 2020, she served as the chief financial officer of MediaMath, Inc., a demand-side platform for programmatic marketing and advertising. Ms.&#160;Alberti-Perez worked in a variety of financial and publishing roles from 2001 to 2017 at Penguin Random House LLC, the world&#8217;s largest book publisher, serving as the Global and US chief financial officer of Penguin Random House LLC from 2015 to 2017 and, as management, served as a <span style="white-space:nowrap">non-voting</span> member of its board of directors and its audit committee. Ms.&#160;Alberti-Perez also worked in financial analyst and research roles at Lehman Brothers Holdings Inc. and Morgan Stanley. She also currently serves on several private company boards of directors, including RBmedia and Overdrive, Inc., and has previously served on the private company boards of Companhia das Letras and Flatworld/Sagence Group, Inc. She has served on <span style="white-space:nowrap"><span style="white-space:nowrap">not-for-profit</span></span> boards of directors, including The University of Pennsylvania Executive Fund, Jumpstart, and the Wild Bird Fund. Ms.&#160;Alberti-Perez holds a B.A. from The University of Pennsylvania, with Distinction in Economics and minors in Math and Latin American Studies. She received her Master&#8217;s degree in Business Administration, with Distinction, from the Harvard Business School. Ms.&#160;Alberti-Perez is qualified to serve on our Board of Directors due to her experience as a chief financial officer and as a director at various public companies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dr.</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;Ram Chuttani</span></span> has served as our Chief Medical Officer since November 2017 and is a founder of Allurion. Prior to joining us, Dr.&#160;Chuttani was the Director of Endoscopy and Chief, Interventional Gastroenterology at Beth Israel Deaconess Medical Center and was on the faculty of Harvard Medical School for 20 years. Dr.&#160;Chuttani holds a M.B. and a B.S. in medicine from Maulana Azad Medical College. Dr.&#160;Chuttani is internationally recognized as a leader in digestive disease care and has pioneered several innovative endoscopic treatments. He <span style="white-space:nowrap">co-invented</span> an endoscopic treatment for gastroesophageal reflux disease and <span style="white-space:nowrap">co-developed</span> a novel treatment for obesity. He has published over 100 original scientific articles, in addition to several reviews and book chapters. He has lectured on, and demonstrated, novel and advanced endoscopic procedure at innumerable international conferences and workshops all over the world. Dr.&#160;Chuttani completed a residency at Norwalk Hospital, Yale University School of Medicine in Internal Medicine in 1987, and a fellowship in gastroenterology at Harvard Medical School in 1990. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Brendan Gibbons </span></span>has served as our Chief Legal Officer and Secretary since January 2024. Prior to joining Allurion, Mr.&#160;Gibbons served as a chief legal officer at several public companies. From December 2017 to December 2021, he served as executive vice president, chief legal officer, and corporate secretary for Acushnet Company (NYSE: GOLF), the world&#8217;s largest golf ball, club, footwear and gear company. From 2014 to 2017, Mr.&#160;Gibbons was senior vice president, general counsel and corporate secretary at Wolverine Worldwide, Inc. (NYSE: WWW), a leading international footwear and apparel company. From 2004 to 2013, Mr.&#160;Gibbons was senior vice president of legal and corporate affairs, general counsel and secretary at Carter&#8217;s, Inc. (NYSE: CRI), the world&#8217;s largest baby and young children&#8217;s apparel and accessory company. Mr.&#160;Gibbons began his career at Ropes&#160;&amp; Gray LLP. He received his B.A., <span style="font-style:italic">magna cum laude</span>, from The University of Pennsylvania and his J.D., <span style="font-style:italic">magna cum laude</span>, from Boston College Law School. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Ojas Buch </span></span>has served as our Chief Operating Officer since June 2024. Prior to this role, he was the President&#8212;Americas at PENTAX Medical from April 2021 to July 2023, a division of HOYA Corporation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(NYSE: HOCPY). PENTAX Medical specializes in endoscopic imaging solutions for Gastroenterology and Otolaryngology. From March 2015 to March 2021, Mr.&#160;Buch held the position of Vice President of Connected Care division of Koninklijke Philips NV (NYSE: PHG) (Philips), a global leader in diversified medical equipment. Mr.&#160;Buch brings over 25 years of extensive experience in the medical device industry. Before joining Philips, he held various leadership roles at CareFusion Corporation, St. Jude Medical, Inc. and GE Healthcare Technologies, Inc. He earned his B.S. in BioMedical Engineering from the University of Bombay and a M.S. in BioMedical Engineering from the University of Akron. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among our directors and executive officers. There is no arrangement or understanding between any of our directors or executive officers and any other person or persons pursuant to which he or she was or is to be selected as a director or an executive officer. There are no material legal proceedings to which any of our directors or executive officers is a party adverse to us or any of our subsidiaries or in which any such person has a material interest adverse to us or any of our subsidiaries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that good corporate governance is important to ensure that our Company is managed for the long-term benefit of our stockholders. We periodically review our corporate governance policies and practices and compare them to those suggested by various authorities in corporate governance and the practices of other public companies. As a result, we have adopted policies and procedures that we believe are in the best interests of our Company and our stockholders. Key information regarding our corporate governance initiatives can be found on our corporate website at https://investors.allurion.com under &#8220;Governance Documents,&#8221; including our Corporate Governance Guidelines, our Code of Business Conduct and Ethics (our &#8220;Code of Conduct&#8221;), and the charters for the committees of our Board, described below. Information contained on, or that can be accessed through, our website is not incorporated by reference into and does not form a part of this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Governance Guidelines </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate governance guidelines assist our Board in the exercise of its duties and responsibilities and to serve the best interests of our company and our stockholders. These guidelines, which provide a framework for the conduct of Board business, provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least a majority of the members of the Board of Directors shall be independent directors as defined by NYSE rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the independent directors shall meet at least quarterly, and at other times at the request of any independent director, in executive session; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">directors shall have full and free access to management and, as necessary and appropriate, independent advisors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least annually, the Nominating and Corporate Governance Committee (the &#8220;Nominating and Corporate Governance Committee&#8221;) oversees a self-evaluation by the Board to assess the effectiveness of the Board of Directors and its committees. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for managing or supervising the management of our business and affairs. This includes appointing our Chief Executive Officer, advising management on strategic issues, approving our business and other plans, and monitoring our performance against those plans and against our operating and capital budgets. In addition, our Board also receives and considers recommendations from its various committees with respect to matters such as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the compensation of our executive officers and directors; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">criteria for Board and committee membership; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons to be nominated for election as members of the Board and to each of the committees of the Board of Directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">matters relating to our corporate governance, including to our Code of Conduct and Corporate Governance Guidelines. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Composition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors is comprised of seven directors, divided into three classes with staggered three-year terms. The three classes are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;I directors: Krishna Gupta, Dr.&#160;Shantanu Gaur, and Nicholas Lewin, whose terms will expire at the annual meeting of stockholders to be held in 2024; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;II directors: Omar Ishrak and Larson Douglas Hudson, whose terms will expire at the annual meeting of stockholders to be held in 2025; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Class&#160;III directors: Michael Davin, Keith Johns and Milena Alberti-Perez, whose terms will expire at the annual meeting of stockholders to be held in 2026. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors in a particular class will be elected for three-year terms at the annual meeting of stockholders in the year in which their terms expire. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Each director&#8217;s term continues until the election and qualification of his or her successor, or the earlier of his or her death, resignation or removal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Investor Rights Agreement, the following persons have the following nomination rights with respect to our Board of Directors, subject to the limitations set forth in the Investor Rights Agreement: </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) one director and one independent director nominated by Dr.&#160;Shantanu Gaur, which are currently Dr.&#160;Gaur and Michael Davin; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) one director and one independent director nominated by Remus Group Management, LLC, which are currently Krishna Gupta and Larson Douglas Hudson; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) one director nominated by Compute Health Sponsor LLC, which is currently Omar Ishrak; and (iv)&#160;two independent directors nominated by Allurion, one of which shall be designated by RTW , which are currently Milena Alberti-Perez and Nicholas Lewin, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in September 2024, we appointed Keith Johns to our Board, in satisfaction of certain obligations to RTW set forth in the Amended Note Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our organizational documents provide that only our Board of Directors can fill vacant directorships, including newly created seats. Any additional directorships resulting from an increase in the authorized number of directors would be distributed pro rata among the three classes so that, as nearly as possible, each class would consist of <span style="white-space:nowrap">one-third</span> of the authorized number of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Diversity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines provide that diversity of background and experience should be considered in determining director candidates as well as other factors such as a candidate&#8217;s character, judgment, skills, education, expertise, and absence of conflicts of interest. Based on our commitment to diversity, our Corporate Governance Guidelines require that the Nominating and Corporate Governance Committee include in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its initial list of director candidates for consideration in filling any vacancy on our Board of Directors at least one or more qualified candidates who reflect diverse backgrounds, including diversity of gender and race or ethnicity. However, we do not have a formal policy concerning the diversity of the Board of Directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our priority in the selection of directors is identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, their knowledge of our business and understanding of the competitive landscape in which we operate, and their adherence to high ethical standards. Although we do not have a formal diversity policy and do not follow any ratio or formula with respect to diversity in order to determine the appropriate composition of the Board of Directors, the Nominating and Corporate Governance Committee and the Board of Directors are committed to creating a board of directors that promotes our strategic objectives and fulfills its responsibilities to our stockholders, and they consider diversity of gender, race, national origin, education, professional experience, and differences in viewpoints and skills when evaluating proposed director candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Committees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The Board of Directors may establish other committees to facilitate the management of our business. The Board of Directors and its committees set schedules for meeting throughout the year and can also hold special meetings and act by written consent from time to time, as appropriate. The Board of Directors has delegated various responsibilities and authority to its committees as generally described below. The committees regularly report on their activities and actions to the full Board. Members will serve on these committees until their resignation or until otherwise determined by the Board of Directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Audit Committee </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Audit Committee include Milena Alberti-Perez (Chair), Omar Ishrak, and Michael Davin each of whom can read and understand fundamental financial statements. The Board of Directors has concluded each member of the Audit Committee is independent under the rules and regulations of the SEC and the listing standards of the NYSE applicable to Audit Committee members. Each of Milena Alberti-Perez and Michael Davin qualify as an audit committee financial expert within the meaning of SEC regulations and meet the financial literacy requirements of the NYSE. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee assists the Board of Directors with its oversight of the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the integrity of our financial statements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our compliance with legal and regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the qualifications, independence, and performance of our independent registered public accounting firm; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design and implementation of our internal audit function, and our risk assessment and risk management activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee also is responsible for reviewing and discussing with management the adequacy and effectiveness of our disclosure controls and procedures, and it discusses with management and our independent registered public accounting firm the annual audit plan, the scope and timing of audit activities and the results of the audit, including significant findings. The Audit Committee also reviews our financial statements quarterly. As appropriate, the Audit Committee may initiate inquiries into certain aspects of our financial affairs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the Audit Committee is responsible for establishing and overseeing procedures for the receipt, retention, and treatment of any complaints regarding accounting, internal accounting controls, or auditing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
matters, as well as for the confidential and anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters. In addition, the Audit Committee has direct responsibility for the appointment, compensation, retention, and oversight of the work of our independent registered public accounting firm. This includes sole authority to approve the hiring and discharging of our independent registered public accounting firm, all audit engagement terms and fees, and all permissible <span style="white-space:nowrap">non-audit</span> engagements with the independent auditor. Finally, the Audit Committee reviews and oversees all related-person transactions in accordance with our policies and procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of the NYSE. A copy of the charter of our Audit Committee is available on our website at https://investors.allurion.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Compensation Committee </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Compensation Committee include Michael Davin (Chair), Nicholas Lewin, and Larson Douglas Hudson. The Board of Directors has concluded each member of the Compensation Committee is considered independent under the rules and regulations of the SEC and the listing standards of the NYSE applicable to Compensation Committee members. The primary objective of the Compensation Committee is to develop and implement compensation policies and plans that ensure the attraction and retention of key management personnel, the motivation of management to achieve our goals and strategies, and the alignment of management&#8217;s interests with the long-term interests of our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee&#8217;s responsibilities include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating our Chief Executive Officer&#8217;s performance against established goals and objectives, and determining and approving the Chief Executive Officer&#8217;s compensation (including long-term incentives) based on such evaluation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, approving, and determining the compensation of our executive officers other than the CEO and, at the discretion of the committee, other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to the Board of Directors the compensation of our <span style="white-space:nowrap">non-employee</span> directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations to the Board of Directors with regard to incentive-based compensation plans and the policies and procedures for awards thereunder, including making grants pursuant to such plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving a peer group of companies to be used for benchmarking executive compensation programs and practices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the administration of all incentive compensation and equity-based plans for employees; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administering our Compensation Recovery Policy, discussed in the section entitled &#8220;<span style="font-style:italic">Compensation Recovery Policy</span>&#8221; below. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards of the NYSE. A copy of the charter of our Compensation Committee is available on our website at https://investors.allurion.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="text-decoration:underline">Nominating and Corporate Governance Committee </span></span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Nominating and Corporate Governance Committee include Larson Douglas Hudson (Chair), Omar Ishrak, and Krishna Gupta. The Board of Directors has concluded each member of the Nominating and Corporate Governance Committee is considered independent under the rules and regulations of the SEC and the listing standards of the NYSE. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee assists the Board of Directors with its identification and evaluation of individuals qualified to become members of the Board of Directors (including those recommended by stockholders), consistent with criteria approved by the Board of Directors, and recommends that the Board select the director nominees for election at annual stockholder meetings. The Nominating and Corporate Governance Committee also develops and recommends to the Board of Directors a set of corporate governance guidelines, monitors compliance with our Code of Conduct, and oversees the evaluation of the Board of Directors, its committees and management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee&#8217;s responsibilities include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and recommending to the Board of Directors criteria for Board of Directors and committee membership, and establishing policies and processes to evaluate nominees&#8212;including those of stockholders - against such criteria; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, evaluating, and making recommendations to our Board of Directors regarding nominees for election to the Board and its committees, including to fill vacancies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluating the performance of our Board of Directors, our committees, and of individual directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering and making recommendations to our Board of Directors regarding the composition of our Board and its committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing an annual evaluation of our Board of Directors and its committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to the Board of Directors corporate governance guidelines and periodically reviewing those guidelines and recommending any changes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and overseeing an orientation program for new directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring compliance with our Code of Conduct and investigating any alleged breach or violation of the Code of Conduct; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and assessing the adequacy of the Corporate Governance Guidelines and the Code of Conduct and recommending any changes to the Board of Directors for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee operates under a written charter that satisfies the applicable listing standards of the NYSE. A copy of the charter of our Nominating and Corporate Governance Committee is available on our website at https://investors.allurion.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Qualifications </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, our Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to serve as directors, consistent with criteria approved by our Board, and recommending to the Board qualified individuals to be nominated for election as directors at each annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In identifying prospective director candidates, the Nominating and Corporate Governance Committee may consider all facts and circumstances that it deems appropriate or advisable, including, among other things, the skills of the prospective candidate, such candidate&#8217;s depth and breadth of business experience or other background characteristics, such candidate&#8217;s independence, and the needs of the Board. At a minimum, the Nominating and Corporate Governance Committee must be satisfied that each recommended nominee meets the following minimum qualifications: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) relevant experience and expertise to enable the candidate to be able to offer germane advice and guidance to management; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) proven achievement and competence in the candidate&#8217;s field; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the ability to exercise sound business judgment; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) an understanding of the fiduciary responsibilities required of a director; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) commitment to devoting time and energy to our affairs; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) a diverse personal background, perspective, and experience; and (vii)&#160;commitment to vigorously represent the long-term interests of our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to any other standards the Nominating and Corporate Governance Committee deems appropriate from time to time for the overall structure and composition of the Board, the Nominating and Corporate Governance Committee may consider whether the candidate, if elected, assists in achieving a mix of Board members that represents a diversity of background and experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board and Committee Meetings Attendance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2023, following the closing of the Business Combination on August&#160;1, 2023, the Board met five times, the Audit Committee met three times, the Compensation Committee met five times and acted by written consent once, and the Nominating and Corporate Governance Committee met one time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2023, following the closing of the Business Combination, each member of the Board attended in person or participated in 75% or more of the aggregate of (i)&#160;the total number of meetings of the Board (held during the period for which such person has been a director) and (ii)&#160;the total number of meetings held by all committees of the Board on which such person served (during the periods that such person served). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Attendance at Annual Meeting of Stockholders </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors are encouraged to attend the annual meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Policy on Insider Trading, Pledging, and Hedging </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Insider Trading Policy prohibits our directors (including <span style="white-space:nowrap">non-employee</span> directors), officers, employees, consultants, and their &#8220;affiliated persons&#8221; (as defined in our Insider Trading Policy) from engaging in the following transactions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading in our securities, whether for their own account or for the account of another, while in the possession of material, nonpublic information about us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disclosing material, nonpublic information about us to others who may trade on the basis of that information (&#8220;tipping&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selling any of our securities that they do not own at the time of the sale (referred to as a &#8220;short sale&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">buying or selling puts, calls, other derivative securities of our securities, or any derivative securities that provide the economic equivalent of ownership of any of our securities or an opportunity, direct or indirect, to profit from any change in the value of our securities or engaging in any other hedging transaction with respect to our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">using our securities as collateral in a margin account; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pledging our securities as collateral for a loan (or modifying an existing pledge). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Recovery Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In light of the SEC&#8217;s adoption of final clawback rules in October 2022 and the NYSE&#8217;s adoption of final listing standards consistent with the SEC rules in June 2023, we adopted a Compensation Recovery Policy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective as of October&#160;2, 2023. If we are required to prepare an accounting restatement due to material <span style="white-space:nowrap">non-compliance</span> with any financial reporting requirements under applicable securities laws, the Compensation Recovery Policy requires (subject to certain limited exceptions described in the policy and permitted by the final clawback rules) that we recover erroneously awarded compensation received by any current or former executive officer in the three fiscal years prior to the date we were required to restate our financial statements that is in excess of the amount that would have been received based on the restated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee Interlocks and Insider Participation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2023, the members of our Compensation Committee included Michael Davin, Nicholas Lewin, and Douglas Hudson. None of the members of our Compensation Committee has ever been an officer or employee of our Company, or had any other relationship requiring disclosure herein. None of our executive officers serve, or have served during the last fiscal year, as a member of the board of directors or compensation committee of any other entity that has or has had one or more executive officers serving as a member of our Board of Directors or Compensation Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Code of Conduct </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted our Code of Conduct, which applies to all of our directors, officers, employees, consultants, and certain designated agents in connection with their work for us. The full text of our Code of Conduct is posted on our website at https://investors.allurion.com. We intend to disclose future amendments to, or waivers of, our Code of Conduct, as and to the extent required by SEC regulations, at the same location on our website identified herein or in public filings. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Board Leadership Structure and Board&#8217;s Role in Risk Oversight </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Omar Ishrak and Krishna Gupta are <span style="white-space:nowrap">co-chairmen</span> of the Board, and Dr.&#160;Ishrak is our lead independent director. Our <span style="white-space:nowrap">co-chairmen</span> preside at all meetings of our Board. Currently, the role of the <span style="white-space:nowrap">co-chairmen</span> of the Board is separated from the role of Chief Executive Officer. Separating these positions allows our Chief Executive Officer to focus on our <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business, while allowing the <span style="white-space:nowrap">co-chairmen</span> to lead the Board in its fundamental role of providing advice to and independent oversight of management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has not adopted a position description for the <span style="white-space:nowrap">co-chairmen.</span> However, there is a shared understanding on the Board of the <span style="white-space:nowrap">co-chairmen&#8217;s</span> responsibilities. The <span style="white-space:nowrap">co-chairmen&#8217;s</span> primary role is to provide leadership to the Board and its committees, including chairing meetings in a manner that facilitates open discussions and expressions of competing views. The <span style="white-space:nowrap">co-chairmen</span> are also responsible for, among other things, assisting the Board in obtaining information required for the performance of its duties, retaining appropriately qualified and independent advisors as needed, working with the Board to support board development and to ensure a proper committee structure is in place, providing a link between the Board and management, and acting in an advisory capacity to the Chief Executive Officer in all matters concerning the interests and management of Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board recognizes the time, effort, and energy that the Chief Executive Officer must devote to his position in the current business environment, as well as the commitment required to serve as the chairman of the Board. Our Board also believes this leadership structure ensures a greater role for the <span style="white-space:nowrap">non-management</span> directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and how well a business manages risk can ultimately determine the business&#8217; success. As a medical device manufacturer, we face a number of risks, including risks related to patient safety, our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management is responsible for the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> management of risks we face, while our Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management. In the Board&#8217;s risk oversight role, our Board has the responsibility to oversee that the risk management processes designed and implemented by management are adequate and functioning as designed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The role of the Board in overseeing the management of our risks is conducted primarily through committees of the Board, as disclosed in the descriptions of each of the committees above and in the charters of each of the committees. The full Board (or the appropriate committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full Board during the committee reports portion of the next Board of Directors meeting. This process enables the Board and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Enterprise Risk Management Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In support of our risk management strategy, we have adopted an Enterprise Risk Management Policy (the &#8220;ERM Policy&#8221;). The ERM Policy governs our risk management practices and establishes responsibilities and processes for the identification, classification, analysis, treatment/mitigation, prevention and governance of all risks to us - defined as anything that could reasonably be expected to have a material adverse impact on the achievement of our strategic objectives and operational goals. The goal of the ERM Policy is to ensure that risks and related exposures are aligned with our strategic objectives, as well as risk tolerances set by the Board. The ERM policy is implemented through a framework guided by internal key principles as well as those outlined by the Committee of Sponsoring Organizations of the Treadway Commission. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_13">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">We have opted to comply with the executive compensation disclosure rules applicable to &#8220;smaller reporting companies&#8221; and &#8220;emerging growth companies&#8221; as such terms are defined in the rules promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). As a result of the Business Combination completed on August&#160;1, 2023, share amounts presented for periods prior to the Business Combination have been retroactively converted by application of the exchange ratio of 0.9780. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the compensation awarded to, earned by, or paid to Allurion&#8217;s chief executive officer and two other most highly compensated executive officers who were serving as executive officers as of December&#160;31, 2023 (our &#8220;Named Executive Officers&#8221; or &#8220;NEOs&#8221;). Our Named Executive Officers for the fiscal year ended December&#160;31, 2023 were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Shantanu Gaur, M.D., our Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Christopher Geberth, our former Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Benoit Chardon, our former Chief Commercial Officer. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2023 Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding the compensation awarded to, earned by or paid to our NEOs for services rendered during the fiscal years ended December&#160;31, 2023 and December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Bonus&#160;($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Awards<br/>($)(2)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-equity</span><br/>Incentive Plan<br/>Compensation<br/>($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)<sup style="font-size:75%; vertical-align:top">(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Shantanu Gaur</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">354,875&#160;</td>
<td style="white-space:nowrap;vertical-align:top">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">296,751</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9,600</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">661,226</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">295,000</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2,605,904</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">79,761</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9,100</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2,989,765</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Geberth</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Former Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">280,650&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">(5)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">255,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">542,592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">319,087</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">844,510</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">83,760</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">6,100</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">1,253,457</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top" rowspan="2"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benoit Chardon<sup style="font-size:75%; vertical-align:top">(6)</sup></p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Former Chief Commercial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2023</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">176,676&#160;</td>
<td style="white-space:nowrap;vertical-align:top">(7)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">280,037</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">37,026</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">367,778</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">861,517</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">358,153</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">9,389</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">291,450</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top" align="right">658,992</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reported in this column include the following amounts: (i)&#160;for Dr.&#160;Gaur, a $200,000 bonus in connection with our Business Combination, and a $96,751 retention bonus, (ii)&#160;for Mr.&#160;Geberth, a $150,000 bonus in connection with our Business Combination, and a $105,342, and (iii)&#160;for Mr.&#160;Chardon, a $280,037 retention bonus. Retention bonuses represent incentive awards made to executives for their continued employment through a target date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts shown reflect the grant date fair value of stock options granted during such fiscal year, calculated in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, excluding any estimates of forfeitures related to service-based vesting conditions. For information regarding assumptions underlying the valuation of equity awards, see Note 14 to our consolidated financial statements included in this prospectus. The amounts reported in this column reflect the accounting cost for the option awards, and do not correspond to the actual economic value that may be recognized by holders upon the vesting or exercise of the applicable awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Dr.&#160;Gaur and Mr.&#160;Geberth, amounts reflect performance-based cash bonuses. For Mr.&#160;Chardon, amount reflects commissions earned as a member of our commercial team. See &#8220;Narrative to the Summary Compensation <span style="white-space:nowrap">Table&#8212;Non-equity</span> Incentive Plan Compensation&#8221; below for a description of the material terms pursuant to which this compensation was awarded. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For the 2023 fiscal year, amounts reported in this column include the following amounts: (i) for Dr. Gaur, $3,000 in payments in lieu of medical coverage, and $6,600 of 401(k) plan employer contributions, (ii) for </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Mr. Geberth, $6,600 of 401(k) plan employer contributions, and (iii)&#160;for Mr.&#160;Chardon, a &#8364;156,740 termination fee and &#8364;183,260 paid pursuant to a settlement agreement. For the 2022 fiscal year, amounts reported in this column include the following: (i)&#160;for Dr.&#160;Gaur, $3,000 in payments in lieu of medical coverage, and $6,100 of 401(k) plan employer contributions, and (ii)&#160;for Mr.&#160;Geberth, $6,100 of 401(k) plan employer contributions. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To preserve our cash prior to the Business Combination, Dr.&#160;Gaur&#8217;s and Mr.&#160;Geberth&#8217;s annual base salary was reduced to $36,000 from April&#160;15, 2023 to July&#160;31, 2023, and Mr.&#160;Chardon&#8217;s consulting fees were adjusted from January&#160;1, 2023 to July&#160;31, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Mr.&#160;Chardon, amounts reported in the &#8220;Salary&#8221;, &#8220;Bonus&#8221; and &#8220;All Other Compensation&#8221; columns have been converted to USD at an exchange rate of 1 Euro to 1.0817 USD, which represents the average annual exchange rate published by the Federal Reserve Bank for 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount represents annual base consulting fees of &#8364;340,000. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Narrative to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Base Salaries </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use base salaries to recognize the experience, skills, knowledge, and responsibilities required of all our employees, including our Named Executive Officers. Base salaries are reviewed annually and adjusted from time to time to align salaries with market levels after taking into account individual responsibilities, performance, and experience. For the year ended December&#160;31, 2023, the annual base salaries for each of Dr.&#160;Gaur and Mr.&#160;Geberth were initially $303,850 and $328,660, respectively, and were reduced to $36,000 from April&#160;15, 2023 to July&#160;31, 2023 in order to preserve our cash prior to the consummation of the Business Combination. Effective as of the closing of the Business Combination, the annual base salaries of Dr.&#160;Gaur and Mr.&#160;Geberth were increased to $620,000 and $425,000, respectively. For the year ended December&#160;31, 2023, Mr.&#160;Chardon was paid base annual consulting fees equal to &#8364;340,000. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-equity</span> Incentive Plan Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Gaur is eligible to earn a performance-based annual cash bonus based on achievement of <span style="white-space:nowrap">pre-established</span> company and individual performance criteria established by our Board of Directors or Compensation Committee in their discretion. For 2023, the target annual bonus for Dr.&#160;Gaur was initially equal to 30% of annual base salary, and was increased to 80% of Dr.&#160;Gaur&#8217;s annual base salary in connection with the closing of the Business Combination. No annual performance bonuses were paid for fiscal 2023. Mr.&#160;Geberth was eligible to earn quarterly commission compensation based on achievement of specified company performance criteria established by our Board or Directors in its discretion. For 2023, Mr.&#160;Geberth&#8217;s target annual bonus was initially equal to 30% of his annual base salary but was increased to 50% of Dr.&#160;Gaur&#8217;s annual base salary in connection with the closing of the Business Combination. No annual performance bonuses were paid for fiscal 2023. Mr.&#160;Chardon was eligible to earn quarterly commission compensation based on achievement of specified company performance criteria established by our Board or Directors in its discretion. For 2023, Mr.&#160;Chardon&#8217;s target commission compensation was equal to 40% of his annual base consulting fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives with our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Independent Compensation Consultant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing and setting the compensation of our Named Executive Officers, the Compensation Committee has engaged Pearl Meyer&#160;&amp; Partner LLC (&#8220;Pearl Meyer&#8221;) as its independent compensation consultant. Pearl </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Meyer advises the Compensation Committee on best practices in executive compensation and provides the Compensation Committee with market data in an effort to ensure our compensation program is competitive and designed to attract, retain, and incentivize our Named Executive Officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment Arrangements with our Named Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the closing of the Business Combination, we entered into new employment agreements with each of Dr.&#160;Gaur and Mr.&#160;Geberth and a new corporate officer agreement with Mr.&#160;Chardon, which set forth the terms and conditions of each executive&#8217;s employment or consulting relationship. The new agreements superseded and replaced each NEO&#8217;s prior employment or consulting arrangement and provided for specified payments and benefits in connection with a termination of the NEO&#8217;s employment or consulting relationship in certain circumstances. Our goal in providing these severance payments and benefits is to offer sufficient cash continuity protection such that the NEOs will focus their full time and attention on the requirements of the business rather than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the NEOs, rather than negotiating severance at the time that a NEO&#8217;s employment or other service relationship terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate to encourage our NEOs to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally. The material terms of each NEO&#8217;s employment or consulting arrangements are summarized below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Dr.&#160;Shantanu Gaur </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment agreement with Dr.&#160;Gaur, effective August&#160;1, 2023, pursuant to which we employ Dr.&#160;Gaur as our Chief Executive Officer on an &#8220;at will&#8221; basis. Dr.&#160;Gaur&#8217;s employment agreement provides that his initial annual base salary is $620,000, and is subject to periodic review by our Board or Compensation Committee. In addition, the employment agreement provides that Dr.&#160;Gaur is eligible to receive annual cash bonuses, which the target annual amount shall be 80% of his annual base salary. Dr.&#160;Gaur is also eligible to participate in the employee benefit plans generally available to our employees, subject to the terms of such plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a termination of Dr.&#160;Gaur&#8217;s employment by Allurion without &#8220;cause&#8221; (as defined in his employment agreement) or by his resignation for &#8220;good reason&#8221; (as defined in his employment agreement), subject to Dr.&#160;Gaur&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a separation agreement containing, among other things, a release of claims in favor of Allurion and its affiliates, Dr.&#160;Gaur will be entitled to receive (i)&#160;base salary continuation for 12 months following his termination date, and (ii)&#160;subject to Dr.&#160;Gaur&#8217;s election to receive continued health benefits under COBRA, payment of the full cost of such continuation coverage plus any administration fee until the earliest of (A) 12 months following termination; (B)&#160;the date he becomes eligible for group medical plan benefits under any other employer&#8217;s group medical plan; or (C)&#160;the expiration of Dr.&#160;Gaur&#8217;s COBRA health continuation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in lieu of the payments and benefits described above, in the event that Dr.&#160;Gaur&#8217;s employment is terminated by us without &#8220;cause&#8221; or by him for &#8220;good reason,&#8221; in each case, within three months prior to or 12 months following a &#8220;sale event&#8221; (as defined in our 2023 Stock Option and Incentive Plan, or &#8220;2023 Plan&#8221;), and subject to Dr.&#160;Gaur&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a separation agreement containing, among other things, a release of claims in favor of Allurion and its affiliates, Dr.&#160;Gaur will be entitled to receive (i)&#160;an amount in cash equal to 1.5 times the sum of (x)&#160;Dr.&#160;Gaur&#8217;s then-current base salary (or, his base salary in effect immediately prior to the sale event, if higher) and (y)&#160;Dr.&#160;Gaur&#8217;s target annual bonus for the then-current year (or, his target annual bonus in effect immediately prior to the sale event, if higher); (ii) full acceleration of vesting of all outstanding time-based equity awards held by Dr.&#160;Gaur; and (iii)&#160;subject to Dr.&#160;Gaur&#8217;s election to receive continued health benefits under COBRA, payment of the full cost of such continuation coverage plus any administration fee until the earliest of (A) 18 months following termination; (B)&#160;the date he becomes eligible for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
group medical plan benefits under any other employer&#8217;s group medical plan; or (C)&#160;the expiration of Dr.&#160;Gaur&#8217;s COBRA health continuation period. The cash severance payable to Dr.&#160;Gaur upon a termination of employment is generally payable in lump sum within 60 days following the date of termination, subject to limited exceptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employment Agreement with Mr.&#160;Christopher Geberth </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an employment agreement with Mr.&#160;Geberth effective August&#160;1, 2023, which provides that his initial annual base salary is $425,000, and is subject to periodic review by our Board or Compensation Committee. In addition, the employment agreement provides that Mr.&#160;Geberth is eligible to receive annual cash bonuses, which target annual amount shall be 50% of his annual base salary. Mr.&#160;Geberth is also eligible to participate in the employee benefit plans generally available to our employees, subject to the terms of such plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a termination of Mr.&#160;Geberth&#8217;s employment by Allurion without &#8220;cause&#8221; (as defined in his employment agreement) or by his resignation for &#8220;good reason&#8221; (as defined in his employment agreement), subject to Mr.&#160;Geberth&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a separation agreement containing, among other things, a release of claims in favor of Allurion and its affiliates, Mr.&#160;Geberth will be entitled to receive (i)&#160;base salary continuation for nine months following his termination date, and (ii)&#160;subject to Mr.&#160;Geberth&#8217;s election to receive continued health benefits under COBRA, payment of the full cost of such continuation coverage plus any administration fee until the earliest of (A) 12 months following termination; (B)&#160;the date he becomes eligible for group medical plan benefits under any other employer&#8217;s group medical plan; or (C)&#160;the expiration of Mr.&#160;Geberth&#8217;s COBRA health continuation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in lieu of the payments and benefits described above, in the event that Mr.&#160;Geberth&#8217;s employment is terminated by us without &#8220;cause&#8221; or by him for &#8220;good reason,&#8221; in each case, within three months prior to or 12 months following a &#8220;sale event&#8221; (as defined in our 2023 Plan), and subject to Mr.&#160;Geberth&#8217;s execution and <span style="white-space:nowrap">non-revocation</span> of a separation agreement containing, among other things, a release of claims in favor of Allurion and its affiliates, Mr.&#160;Geberth will be entitled to receive (i)&#160;an amount in cash equal to 1.0 times the sum of (x)&#160;Mr.&#160;Geberth&#8217;s then-current base salary (or, his base salary in effect immediately prior to the sale event, if higher) and (y)&#160;Mr.&#160;Geberth&#8217;s target annual bonus for the then-current year (or, his target annual bonus in effect immediately prior to the sale event, if higher); (ii) full acceleration of vesting of all outstanding time-based equity awards held by Mr.&#160;Geberth; and (iii)&#160;subject to Mr.&#160;Geberth&#8217;s election to receive continued health benefits under COBRA, payment of the full cost of such continuation coverage plus any administration fee until the earliest of (A) 12 months following termination; (B)&#160;the date he becomes eligible for group medical plan benefits under any other employer&#8217;s group medical plan; or (C)&#160;the expiration of Mr.&#160;Geberth&#8217;s COBRA health continuation period. The cash severance payable to Mr.&#160;Geberth upon a termination of employment is generally payable in lump sum within 60 days following the date of termination, subject to limited exceptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination Agreement and Settlement Agreement with Mr.&#160;Benoit Chardon </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of September&#160;1, 2023, we entered into a corporate officer agreement with Mr.&#160;Chardon and Benoit Chardon Consulting, a French socie&#180;te&#180; a&#8217;responsabilite&#180; limite&#180;e that was solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC agreed to serve as Managing Director of Allurion France, a French socie&#180;te&#180; par actions simplifie&#180;e and wholly-owned subsidiary of Allurion (&#8220;Allurion France&#8221;). The corporate officer agreement provided that BCC would receive base consulting fees of &#8364;28,333.33 per month and additional variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance goal attainment as defined each year by Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate officer agreement was terminated as of December&#160;31, 2023, pursuant to a Termination Agreement (as defined herein), which provided for payment to BCC of a <span style="white-space:nowrap">lump-sum</span> termination fee of &#8364;156,740. Additionally, in connection with his departure, we entered into a settlement agreement with Mr.&#160;Chardon, pursuant to which we agreed to pay Mr.&#160;Chardon &#8364;183,260, which amount was used by Mr.&#160;Chardon in payment of the exercise price of his vested options. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at 2023 Fiscal Year End </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of our NEOs as of December&#160;31, 2023: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:29%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting<br/>Commencement<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>(Exercisable)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>(Unexercisable)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Exercise<br/>Price&#160;($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Shantanu Gaur</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/03/2017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">171,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/02/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/05/2020&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/04/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/20/2022&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/08/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">536,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">429,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Geberth</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/11/2021&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11/16/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">94,234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">02/10/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/07/2021&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">38,203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/06/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/20/2022&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/08/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173,807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139,045</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benoit Chardon</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/05/2020&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">510 </td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">03/04/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/31/2020&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">07/01/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,279&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/07/2021&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,734&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/06/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/07/2020&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/01/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,641&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/06/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reported have been adjusted to reflect the closing of the Business Combination. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests in 48 equal monthly installments following the vesting commencement date, subject to the executive&#8217;s continuing service relationship on each vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests with respect to 25% of the shares on the first anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments thereafter, subject to the executive&#8217;s continuing service relationship on each vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vests in 36 equal monthly installments beginning on the last date of each <span style="white-space:nowrap">one-month</span> period following the vesting commencement date, subject to the executive&#8217;s continuing service relationship on each vesting date. Upon the consummation of the Business Combination, <span style="white-space:nowrap">one-third</span> of the then unvested shares subject to the option accelerated and vested. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each of Mr.&#160;Chardon&#8217;s unvested option awards terminated on December&#160;31, 2023 in connection with his departure. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Narrative Disclosure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Employee Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Named Executive Officers who are employees are eligible to participate in our welfare benefit plans, including medical, dental, vision, basic life and accidental death&#160;&amp; dismemberment, and short-term and long- term disability insurance benefits, in each case on the same basis as all of our other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">401(k) Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion participates in the ADP TotalSource Retirement Savings Plan (the &#8220;401(k) Plan&#8221;), which provides eligible U.S. employees (including our Named Executive Officers who are employees) with an opportunity to save for retirement on a tax advantaged basis. Under the 401(k) Plan, eligible employees may defer eligible compensation subject to applicable annual contribution limits imposed by the Internal Code of 1986, as amended (the &#8220;Code&#8221;). Allurion&#8217;s employees&#8217; contributions are allocated to each participant&#8217;s individual account and employees may begin participating after an initial 90 day waiting period. Under the provisions of the 401(k) Plan, Allurion makes 2% matching contributions and may make discretionary <span style="white-space:nowrap">non-matching</span> contributions, as determined by our Board. The 401(k) Plan is intended to be qualified under Section&#160;401(a) of the Code with the 401(k) Plan&#8217;s related trust intended to be tax exempt under Section&#160;501(a) of the Code. As a <span style="white-space:nowrap">tax-qualified</span> retirement plan, contributions to the 401(k) Plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_14">DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the compensation awarded to, earned by, or paid to Allurion&#8217;s <span style="white-space:nowrap">non-employee</span> directors for service on our Board during the year ended December&#160;31, 2023. Dr.&#160;Gaur, who is our Chief Executive Officer, also served on our Board, but did not receive any additional compensation for his service as a director and therefore is not included in the table below. Dr.&#160;Gaur&#8217;s compensation for his service, as our Chief Executive Officer, is set forth above under &#8220;<span style="font-style:italic">Executive Compensation&#8212;Summary Compensation Table.</span>&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:41%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees&#160;Earned&#160;or<br/>Paid&#160;in&#160;Cash&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">RSU<br/>Awards&#160;($)<sup style="font-size:75%; vertical-align:top">(1)(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">Awards&#160;($)<sup style="font-size:75%; vertical-align:top">(2)(4)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br/>Compensation&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Ishrak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">239,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Krishna Gupta</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">539,583&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">734,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Davin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">340,558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Hudson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas Lewin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">195,415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217,290</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts shown reflect the grant date fair value of restricted stock units granted in 2023, calculated in accordance with FASB ASC Topic 718, excluding any estimates of forfeitures related to service-based vesting conditions. For information regarding assumptions underlying the valuation of equity awards, see Note 14 to our consolidated financial statements included in this prospectus. The amounts reported in this column reflect the accounting cost for the restricted stock unit awards, and do not correspond to the actual economic value that may be recognized by holders upon the vesting or settlement of the applicable awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts shown reflect the grant date fair value of stock options granted in 2023, calculated in accordance with FASB ASC Topic 718, excluding any estimates of forfeitures related to service-based vesting conditions. For information regarding assumptions underlying the valuation of equity awards, see Note 14 to our consolidated financial statements included in this prospectus. The amounts reported in this column reflect the accounting cost for the option awards, and do not correspond to the actual economic value that may be recognized by holders upon the vesting or exercise of the applicable awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount shown for Mr.&#160;Gupta includes $500,000 of fees paid to KKG Enterprises and Remus Group Management (as defined below); Mr.&#160;Gupta is an affiliate of both. Refer to the section entitled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions&#8212;Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC</span>&#8221; below for further information. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The following table provides information regarding the number of shares of our common stock underlying stock options and restricted stock units held by our <span style="white-space:nowrap">non-employee</span> directors that were outstanding as of December&#160;31, 2023: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:52%"/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">RSU&#160;Awards<br/>Outstanding&#160;at&#160;2023<br/>Year&#160;End&#160;(number&#160;of<br/>shares)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option&#160;Awards<br/>Outstanding&#160;at&#160;2023<br/>Year End (number<br/>of shares)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Ishrak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Krishna Gupta</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">462,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Davin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Hudson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas Lewin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount reflects outstanding stock options awarded to Mr.&#160;Davin in his capacity as a <span style="white-space:nowrap">non-employee</span> director, all of which are vested. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of August 2023, our Board adopted a <span style="white-space:nowrap">non-employee</span> director compensation policy (the &#8220;Director Compensation Policy&#8221;) designed to enable us to attract and retain, on a long-term basis, highly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualified <span style="white-space:nowrap">non-employee</span> directors. Under the policy, our <span style="white-space:nowrap">non-employee</span> directors are eligible to receive cash retainers (which are payable quarterly in arrears and prorated for partial years of service) and equity awards as set forth below. In addition, we reimburse <span style="white-space:nowrap">non-employee</span> directors for all reasonable <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in attending meetings of our Board or committees. We do not pay additional compensation for attending individual meetings of our Board. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:85%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Retainer for Board Membership</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Annual Retainer for <span style="white-space:nowrap">Non-Executive</span> Chair</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Annual Retainer for Committee Membership</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Chairperson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee Member (other than Chairperson)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Chairperson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee Member (other than Chairperson)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Chairperson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee Member (other than Chairperson)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Initial Award</span>: The Director Compensation policy provides that each <span style="white-space:nowrap">non-employee</span> director serving on our Board on August&#160;1, 2023 and each new <span style="white-space:nowrap">non-employee</span> director later elected or appointed to our Board will be granted an initial, <span style="white-space:nowrap">one-time</span> restricted stock unit award with a value of $225,000 that will vest in equal annual installments over three years, subject to continued service as a director through each vesting date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Award</span>: On the date of each annual meeting of stockholders, each continuing <span style="white-space:nowrap">non-employee</span> director (excluding any <span style="white-space:nowrap">non-employee</span> director that was initially elected or appointed to our Board within six months prior to such annual meeting) will receive an annual restricted stock unit award with a value of $150,000 that will vest in full on the earlier of the first anniversary of the date of grant and the date of the next annual meeting of stockholders, subject to continued service as a director through such vesting date unless the Board determines otherwise. The vesting of all outstanding initial restricted stock unit awards and annual restricted stock unit awards held by <span style="white-space:nowrap">non-employee</span> directors will fully accelerate upon a &#8220;sale event&#8221; (as defined in our 2023 Plan). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the size of each restricted stock unit award, the Director Compensation Policy defines &#8220;value&#8221; as the product of (A)&#160;the average closing market price on the NYSE (or such other market on which our common stock is then principally listed) of one share of our common stock over the trailing <span style="white-space:nowrap">30-day</span> period ending on the last day of the month immediately prior to the month of the grant date, and (B)&#160;the aggregate number of shares of our common stock underlying such award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&#160;18, 2017, the board of directors of Legacy Allurion granted Mr.&#160;Davin an option to purchase 90,000 shares of Legacy Allurion common stock under our 2010 Plan (as defined below), which was converted into an option to purchase 88,019 shares of common stock upon consummation of the Business Combination and which was fully vested as of October&#160;18, 2021. On March&#160;5, 2020, the board of directors of Legacy Allurion granted Mr.&#160;Davin an option to purchase 45,000 shares of Legacy Allurion common stock under our 2010 Plan, which was converted into an option to purchase 44,009 shares of common stock upon consummation of the Business Combination, and which vested with respect to twenty-five percent (25%) of the shares underlying such option on the <span style="white-space:nowrap">one-year</span> anniversary of the date of grant, and then vested in 36 equally monthly installments thereafter. Finally, on December&#160;7, 2021, the board of directors of Legacy Allurion granted Mr.&#160;Davin an option to purchase 30,000 shares of Legacy Allurion common stock under our 2020 Plan (as defined below), which was converted into an option to purchase 29,339 shares of common stock upon consummation of the Business Combination, and which vested in equal monthly installments over two years. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_15">PRINCIPAL STOCKHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of shares of our common stock, as of December&#160;6, 2024, in each case, by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person who is known to us to be the beneficial owner of more than 5% of the issued and outstanding shares of our common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors and named executive officers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options, restricted stock units, and warrants that are currently exercisable or releasable or exercisable or releasable within 60 days. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all shares of voting shares beneficially owned by them. Unless otherwise noted, the business address of each of those listed in the table is c/o Allurion Technologies, Inc., 11 Huron Drive, Natick, MA 01760. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of the shares of our common stock is based on 64,797,259 shares of our common stock issued and outstanding as of December&#160;6, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owner</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br/>Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br/>Ownership</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shantanu Gaur<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,539,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Krishna Gupta<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,915,659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Ishrak<sup style="font-size:75%; vertical-align:top">(3)(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,972,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Geberth<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427,914</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benoit Chardon<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">199,183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Davin<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">241,632</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Larson Doug Hudson<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas Lewin<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milena Alberti-Perez</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Keith B. Johns II</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Current Directors and Executive Officers as a Group (Eleven Persons)<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14,612,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Five Percent Holders:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armistice Capital Master Fund Ltd. <sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,806,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leavitt Equity Partners III. L.P. <sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,166,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Romulus Growth Allurion L.P.<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,151,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omar Ishrak<sup style="font-size:75%; vertical-align:top">(3)(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,972,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,666,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compute Health Sponsor LLC<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean Nehme<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joshua Fink<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i)&#160;1,003,090 shares of common stock held by The Shantanu K. Gaur Revocable Trust Of 2021, of which Shantanu K. Gaur and Neha Gaur serve as trustees, (ii)&#160;547,679 shares of common stock held by The Gaur Family Irrevocable Trust Of 2021, of which Steven M. Burke, Esq. and Neha Gaur serve as trustees and which Ms.&#160;Gaur has voting and dispositive control, and (iii)&#160;988,765 shares of common stock issuable upon exercise of options within 60 days of December&#160;6, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 3,124,244 shares of common stock held by Romulus Growth Allurion L.P., (ii) 72,953 shares of common stock held by Romulus Capital I, L.P., (iii) 73,349 shares of common stock issuable upon exercise of a warrant held by Romulus Capital I, L.P., (iv) 881,300 shares of common stock held by Romulus Allurion Special Opportunity L.P., (v) 538,101 shares of common stock held by Samin Capital LLC, (vi) 939,285 shares of common stock held by Krishna Gupta, and (vii) 286,427 shares of common stock issuable upon vesting of restricted stock units held by Krishna Gupta within 60 days of December&#160;6, 2024. Krishna Gupta is the general partner of Romulus Allurion Special Opportunity L.P., Romulus Growth Allurion L.P., and Romulus Capital I, L.P., and the manager of Samin Capital LLC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 710,228 shares held by Omar&#160;&amp; Helen Ishrak Living Trust and (ii) 3,262,711 shares held by the Sponsor. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 427,914 shares of common stock issuable upon exercise of options within 60 days of December&#160;6, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 199,183 shares of common stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 65,187 shares of common stock, (ii) 161,367 shares of common stock issuable upon exercise of options within 60 days of December 6, 2024, and (iii) 15,078 shares of common stock issuable upon vesting of restricted stock units held by Michael Davin within 60 days of December 6, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 15,078 shares of common stock issuable upon vesting of restricted stock units held by Larson Douglas Hudson within 60 days of December 6, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 15,078 shares of common stock issuable upon vesting of restricted stock units held by Nicholas Lewin within 60 days of December 6, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See footnotes 1 through 8 above. Also includes (i) 1,662,896 shares of common stock held by Ram Chuttani, (ii)&#160;185,817 shares of common stock issuable upon exercise of options within 60 days of December&#160;6, 2024, held by Ram Chuttani, and (iii) 63,451 shares of common stock issuable upon exercise of options within 60 days of December 6, 2024, held by Brendan Gibbons. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Beneficial ownership is based in part on a Schedule 13G filed jointly on November&#160;14, 2024 with the SEC by Armistice Capital, LLC and Steven Boyd, and consists of 7,806,000 shares of common stock beneficially owned by Armistice Capital Master Fund Ltd. Armistice Capital, LLC, in its capacity as the investment manager of Armistice Capital Master Fund Ltd., and pursuant to an Investment Manager Agreement, has voting and investment power over the shares held by Armistice Capital Master Fund Ltd. Mr.&#160;Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own such securities. Armistice Capital Master Fund Ltd. disclaims beneficial ownership of the shares held by it, except to the extend of its pecuniary interest therein. The address and principal office of such entities and individual is 510 Madison Avenue, 7th Floor, New York, NY 10022. </p></td></tr></table> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(11) Consists of 4,166,666 shares of common stock held by Leavitt Equity Partners III, L.P. </p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 3,124,244 shares of common stock held by Romulus Growth Allurion L.P., (ii) 72,953 shares of common stock held directly by Romulus Capital I, L.P. and 73,349 shares of common stock issuable upon exercise of a warrant held by Romulus Capital I, L.P., and (iii) 881,300 shares of common stock held by Romulus Allurion Special Opportunity L.P. Krishna Gupta is the general partner of Romulus Allurion Special Opportunity L.P., Romulus Growth Allurion L.P., and Romulus Capital I, L.P. The address of each of the entities is 151 Tremont Street, Suite 6F, Boston, MA 02111. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Beneficial ownership is as of October&#160;22, 2024, based solely on a Schedule 13D/A filed jointly on October&#160;24, 2024 with the SEC by RTW and Roderick Wong, M.D. Consists of 3,666,589 shares of common stock beneficially owned by RTW, including 479,196 shares of common stock underlying the Notes issuable to certain RTW entities and RTW, as agent to the Purchasers and 239,824 shares of common stock issuable upon the exercise of July 2024 Public Warrants. RTW, in its capacity as the investment manager of those certain RTW entities, has the power to vote and the power to direct the disposition of the shares held by RTW. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr.&#160;Wong disclaims beneficial ownership of the shares held by RTW, except to the extent of his pecuniary interest therein. The address and principal office of RTW is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr.&#160;Wong and each of the RTW entities is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York, NY 10014. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 3,262,711 shares of common stock held by the Sponsor. The Sponsor is managed by each of Drs. Nehm&#233; and Ishrak and Mr.&#160;Fink. As a result of the foregoing, each of Drs. Nehm&#233; and Ishrak and Mr.&#160;Fink may be deemed to beneficially own shares held by the Sponsor. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the compensation agreements and other arrangements described under &#8220;<span style="font-style:italic">Executive Compensation</span>&#8221; and &#8220;<span style="font-style:italic">Director Compensation</span>&#8221; in this prospectus and the transactions described below, since January&#160;1, 2023, there has not been and there is not currently proposed any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of our total assets at year end for the last two completed fiscal years) and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PIPE Investment </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain investors (&#8220;PIPE Investors&#8221;) related to Legacy Allurion entered into PIPE subscription agreements (&#8220;PIPE Subscription Agreements&#8221;) with Compute Health and us, pursuant to which they subscribed for shares of our common stock in connection with a private placement. The PIPE Investors made a private investment in the aggregate amount of $37.9&#160;million on the terms and conditions set forth in the PIPE Subscription Agreements. Such PIPE Investors who participated in the PIPE Investment include Michael Davin (30,824 shares), who is one of our directors, Omar Ishrak (710,228 shares), who is one of our directors, and RTW (2,130,681 shares), who has the right to designate an independent director nominee to be elected by our stockholders and a Board observer. See the &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Developments&#8212;PIPE Investment</span>&#8221; for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gaur Contribution Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the Shantanu K. Gaur Revocable Trust of 2021 (the &#8220;Gaur Trust&#8221;) and we entered into the Gaur Contribution Agreement, pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust agreed to contribute, as a contribution of capital, 79,232 shares of our common stock (the &#8220;Gaur Trust Contributed Shares&#8221;). The Gaur Trust&#8217;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination between us and Compute Health and the transactions contemplated thereby. See the subsection entitled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Developments&#8212;Gaur Contribution Agreement</span>&#8221; for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">RSU Forfeiture Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Krishna Gupta, a member of our Board of Directors, entered into the RSU Forfeiture Agreement, pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit 79,232 restricted stock units (the &#8220;Forfeited RSUs&#8221;). The Forfeited RSUs were terminated and cancelled without consideration therefor immediately following the consummation of the transactions contemplated by the Business Combination Agreement between Allurion and Compute Health and other parties thereto, dated as of February&#160;9, 2023, as amended from time to time. See &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Developments&#8212;RSU Forfeiture Agreement</span>&#8221; for additional information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2023 Convertible Note Incremental Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, we sold a $13&#160;million convertible bridge note (the &#8220;HVL Bridge Note&#8221;) to Hunter Ventures Limited (&#8220;HVL&#8221;) and entered into a side letter agreement with HVL (the &#8220;HVL Side Letter&#8221;), who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a member of our Board of Directors; in addition, entities affiliated with him hold more than 5% of our outstanding capital stock) (the &#8220;Initial Financing&#8221;). In connection with the refinancing of the Initial Financing, we entered into a Termination Agreement with HVL, pursuant to which the HVL Side Letter was terminated, effective as of May&#160;2, 2023 (the &#8220;HVL Termination Agreement&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The HVL Termination Agreement provided us, upon the terms and subject to the conditions set forth therein, the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under the HVL Bridge Note, including by way of (a)&#160;a $2&#160;million prepayment, $1.5&#160;million of which was deemed a prepayment penalty and (b)&#160;immediately prior to the consummation of the Business Combination, an additional payment of at least $6&#160;million under the HVL Bridge Note by way of (i)&#160;payment in cash by us and/or (ii)&#160;the sale and transfer of all or any portion of the HVL Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the HVL Termination Agreement, upon the terms and subject to the conditions set forth therein, we agreed to issue to HVL 387,696 additional shares of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about the 2023 Convertible Note Incremental Financing and the HVL Bridge Note, see the subsection entitled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of&#8212;2023 Convertible Note Incremental Financing.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Interest Financing Agreement, RTW Side Letter and PIPE Conversion Option </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, we entered into the Original RIFA with certain entities that engaged RTW, pursuant to which, at the closing of the Business Combination, we assumed all obligations of Legacy Allurion under the Original RIFA and RTW paid us an aggregate of $40.0&#160;million (the &#8220;Investment Amount&#8221;). In exchange for the Investment Amount, we will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2024, the Original RIFA was amended pursuant to the RIFA Amendment to reflect certain modifications agreed between the parties thereto in connection with the Amended Note Purchase Agreement and the refinancing of the Fortress Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with our entry into the RIFA Amendment, we, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into the RTW Side Letter under which RTW may elect to exercise the PIPE Conversion Option. Refer to Note 9, Revenue Interest Financing, Side Letter, and PIPE Conversion Option, in the notes to our annual consolidated financial statements for the years ended December&#160;31, 2023 and 2022 included elsewhere in this prospectus for further discussion on the Revenue Interest Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the parties amended and restated the RTW Side Letter in connection with the Backstop Agreement, pursuant to which, among other things, Allurion issued 250,000 shares of common stock to RTW immediately prior to the Intermediate Merger Effective Time. On April&#160;14, 2024, the parties entered into the RTW Side Letter Amendment to reflect certain modifications to the Amended and Restated RTW Side Letter in connection with the Amended Note Purchase Agreement. The RTW Side Letter Amendment provides, among other things, that RTW may make a single election in certain circumstances to convert up to $7,500,000 of the purchase price that RTW paid for certain equity interests in Allurion into an amount of financing provided by RTW to Allurion pursuant to an additional revenue interest financing agreement with Legacy Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated RTW Side Letter, on October&#160;22, 2024, the Additional RIFA Investors notified us of their election to exercise the Investment Conversion in full. Accordingly, on October&#160;30, 2024, we and the Additional RIFA Investors entered into the additional Revenue Interest Financing Agreement (the &#8220;Additional Revenue Interest Financing Agreement&#8221;). The Additional Revenue Interest Financing Agreement has substantially identical terms and conditions as the Original RIFA, except that the amount of financing provided by the Additional RIFA Investors to Allurion Opco under the Additional Revenue Interest Financing Agreement is equal to the Conversion Amount. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amended Note Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, on April&#160;16, 2024, we issued and sold $48&#160;million of Notes to RTW in a private placement. Until the Notes are converted or repaid in full, RTW will be entitled to designate one representative who will serve as a <span style="white-space:nowrap">non-voting</span> board observer to the Board. In addition, in September 2024, we appointed Keith Johns to our Board, in satisfaction of certain obligations to RTW set forth in the Amended Note Purchase Agreement. For more information about the Amended Note Purchase Agreement, see the subsection entitled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of <span style="white-space:nowrap">Operations-RTW</span> Note Purchase Agreement</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Offering and Private Placement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Underwriting Agreement, on July&#160;1, 2024, we issued and sold 14,406,508 shares of our common stock and 14,406,508 July 2024 Public Warrants at an offering price of $1.20 per share and accompanying warrant. RTW purchased 239,842 shares of common stock and warrants to purchase 239,842 shares of common stock in the Offering, for an aggregate purchase price of $0.3&#160;million. On July&#160;5, 2024, the Underwriters partially exercised their over-allotment option to purchase an additional 1,927,265 shares of common stock, generating additional gross proceeds of approximately $2.3&#160;million to us, before deducting the Underwriters&#8217; discounts and commissions and estimated offering expenses payable by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the Underwriting Agreement, we issued and sold 2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $2.7&#160;million, at an offering price of $1.20 per share of Series A Preferred Stock and accompanying Private Placement Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information about the Offering and Private Placement, see the subsection entitled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Public Offering and Concurrent Private Placement</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investment by Former Chief Commercial Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;24, 2023, Legacy Allurion sold a $200,000 Bridge Note to its former Chief Commercial Officer, Benoit Chardon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investor Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the closing of the Business Combination, we entered into the Investor Rights Agreement. For more information about the Investor Rights Agreement, see the section entitled &#8220;<span style="font-style:italic">Description of Securities&#8212;Investor Rights Agreement.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, we entered into consulting agreements with KKG Enterprises, LLC (&#8220;KKG Enterprises&#8221;) and Remus Group Management, LLC (&#8220;Remus Group Management&#8221;) to assist us in building out our AI platform, augment our AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to board-related work by Krishna Gupta, who is a member of our Board of Directors, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder. The agreements included payments of $0.2&#160;million to KKG Enterprises and $0.3&#160;million to Remus Group Management, and were terminated in June 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Allurion Middle East Medical Instruments Trading, LLC </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Middle East Medical Instruments Trading, LLC (&#8220;Allurion Middle East&#8221;) is Allurion&#8217;s subsidiary in the United Arab Emirates (the &#8220;UAE&#8221;). Per the law of the UAE, the majority owner of a UAE limited liability </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company must be a UAE entity. Pursuant to the Second Restated Memorandum of Association of Allurion Middle East Medical Instruments Trading (the &#8220;MoA&#8221;), Shuraa Management&#160;&amp; Consultancy LLC is a 51% owner of Allurion Middle East; Allurion owns the remaining 49%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Middle East was established to carry on the business of medical, surgical equipment, and instruments trading in the Middle East on behalf of Allurion. Allurion Middle East is permitted to enter into agreements and act as an agent on Allurion&#8217;s behalf. Allurion Middle East&#8217;s capital is AED 300,000 divided into 300 <span style="white-space:nowrap">non-divisible</span> shares, par value AED 1,000. The capital is fully paid in cash and divided as follows: Shuraa Management&#160;&amp; Consultancy LLC received 153 shares at a value of AED 153,000 and holds 51% in capital. Allurion holds 147 shares for a value of AED 147,000 and holds 49% in capital. New shares may be issued at any time to increase capital or by transferring the available reserve to share capital by a resolution of the board. Shares are assignable. Under the MoA, transfers are not permitted where they would reduce the UAE national partner&#8217;s hold in the capital below 51% unless the number of partners is reduced to below 2 or increased to above 50. Profits from Allurion Middle East are distributed 20% to Shuraa Management and Consultancy LLC and 80% to Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;2, 2022, Allurion Middle East entered into a <span style="white-space:nowrap">one-year</span> lease agreement with Shuraa Business Centre Branch (&#8220;SBCB&#8221;), an affiliate of Shuraa Management&#160;&amp; Consultancy LLC. On August&#160;29, 2022, Allurion Middle East entered into a second <span style="white-space:nowrap">one-year</span> lease agreement with SBCB. Under each lease, Allurion Middle East pays to SBCB AED 41,500 and AED 35,000 per year, respectively, plus a AED 3,000 refundable security deposit and 5% VAT. These leases automatically renew after one year as agreed to by the parties. On February&#160;2, 2024, Allurion Middle East entered into a <span style="white-space:nowrap">six-month</span> lease agreement with SBCB in lieu of the second annual renewal of its <span style="white-space:nowrap">one-year</span> lease agreement entered into on February&#160;2, 2022. Cancellation of these contracts is not permitted until the seventh month and requires a two month notice period. Standard indemnity provisions exist. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Officer Agreement and Termination Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of September&#160;1, 2023, we entered into a corporate officer agreement with Benoit Chardon, then our Chief Commercial Officer, and Benoit Chardon Consulting, a French soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e that is solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC served as Managing Director of Allurion France. The corporate officer agreement provided that BCC would receive base consulting fees of &#8364;28,333.33 per month and additional variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance goal attainment defined each year by Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, Mr.&#160;Chardon, BCC and Allurion France entered into a Termination Agreement (the &#8220;Termination Agreement&#8221;), pursuant to which the parties agreed to terminate the Corporate Officer Agreement by and among BCC, Mr.&#160;Chardon and Allurion France. By virtue of the Termination Agreement, the parties mutually agreed to terminate the Corporate Officer Agreement as of December&#160;31, 2023 (the &#8220;Departure Date&#8221;). Pursuant to the Termination Agreement, BCC resigned from its duties as managing director of Allurion France effective as of the Departure Date and Allurion paid BCC all amounts due to it under the Corporate Officer Agreement for monthly consulting fees through the Departure Date and its variable compensation due for the third quarter of 2023. In addition, Allurion paid BCC a <span style="white-space:nowrap">lump-sum</span> termination fee of &#8364;156,740. The Termination Agreement contains a mutual release and <span style="white-space:nowrap">non-disparagement</span> provision as well as a <span style="white-space:nowrap">non-solicitation</span> provision by BCC in favor of Allurion France. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Paris Lease Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LNMP JPBC Investment, a French entity, was the lessor under the 56 Rue des Petites Ecuries, Paris Lease (the &#8220;56 Rue des Petites Ecuries Lease&#8221;), pursuant to which we leased certain space for company purposes. LNMP JPBC Investment is partially owned by Benoit Chardon, our former Chief Commercial Officer. Under the 56 Rue des Petites Ecuries Lease, Allurion paid monthly rent of &#8364;9,284. The 56 Rue des Petites Ecuries Lease had a three year term, which began in August 2022, and was renewable by agreement between Allurion and LNMP JPBC Investment. This lease was terminated in February 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indemnification Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into indemnification agreements with our directors and executive officers. The indemnification agreements and our Charter and Bylaws require us to indemnify our directors and executive officers to the fullest extent permitted by law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officer and Director Compensation Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the sections entitled &#8220;<span style="font-style:italic">Executive Compensation</span>&#8221; and &#8220;<span style="font-style:italic">Director Compensation</span>&#8221; above for information regarding compensation arrangements with our executive officers and directors, which include, among other things, employment, termination of employment and change in control arrangements, stock awards and certain other benefits. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Person Transaction Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;Related Person Transaction&#8221; is any transaction in which Allurion or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest. A &#8220;Related Person&#8221; means: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any person who is, or at any time during the applicable period was, one of Allurion&#8217;s executive officers or a member of our Board of Directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any person who is known by Allurion to be the beneficial owner of more than 5% of our voting stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, <span style="white-space:nowrap"><span style="white-space:nowrap">mother-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">father-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">son-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">daughter-in-law,</span></span> <span style="white-space:nowrap"><span style="white-space:nowrap">brother-in-law</span></span> or <span style="white-space:nowrap"><span style="white-space:nowrap">sister-in-law</span></span> or any other person (other than a tenant or employee) sharing the household of such related person of a director, executive officer or a beneficial owner of more than 5% of our voting stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have policies and procedures designed to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, the Audit Committee will have the responsibility to review related person transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors has determined that each member of the Board of Directors, other than Dr.&#160;Gaur, qualifies as independent, as defined under the listing standards of the NYSE. In addition, our Board of Directors has determined that each of the members of the Audit, Nominating and Corporate Governance, and Compensation Committees is independent in accordance with the rules of the NYSE and, in, the case of the members of the Audit Committee, the rules of the SEC. In determining the independence of its members, the Board of Directors considered all the facts and circumstances it deemed relevant in determining their independence, including, but not limited to, the director&#8217;s commercial, industrial, banking, consulting, legal, accounting, charitable, and familial relationships. We are subject to the rules of the SEC and NYSE relating to the memberships, qualifications, and operations of the Audit Committee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_17">DESCRIPTION OF SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following description summarizes certain important terms of our capital stock as of the date of this prospectus as specified in our Charter and Bylaws. Because the following description is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this section entitled &#8220;Description of Securities,&#8221; you should refer to the Charter, the Bylaws, and the Certificate of Designations of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &#8220;Certificate of Designations&#8221;) which are included as exhibits to the registration statement of which this prospectus is a part, and to the applicable provisions of Delaware law. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following description does not summarize the terms of the warrants offered in this offering. For a description summarizing the important terms of the warrants, please refer to the section entitled &#8220;Description of Securities we are Offering&#8221; herein. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter authorizes the issuance of 1.1&#160;billion shares, consisting of 1&#160;billion shares of common stock, $0.0001 par value per share, and 100&#160;million shares of Preferred Stock, $0.0001 par value. As of December 6, 2024, there were 64,797,259 shares of our common stock outstanding, and 2,260,159 shares of Series A Preferred Stock outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides the following with respect to the rights, powers, preferences and privileges of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting Power </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of Preferred Stock, the holders of our common stock will possess all voting power for the election of Allurion&#8217;s directors and all other matters requiring stockholder action. Holders of our common stock will be entitled to one vote per share on matters to be voted on by stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock will be entitled to receive such dividends, if any, as may be declared from time to time by our Board in its discretion out of funds legally available therefor. We do not intend to pay cash dividends in the foreseeable future. Any payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions. In no event will any stock dividends or stock splits or combinations of stock be declared or made on our common stock unless all shares of our common stock at the time outstanding are treated equally and identically. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation, Dissolution and Winding Up </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our voluntary or involuntary liquidation, dissolution or <span style="white-space:nowrap">winding-up,</span> our net assets will be distributed pro rata to the holders of our common stock, subject to the rights of the holders of Preferred Stock, if any. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preemptive or Other Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no sinking fund provisions applicable to our common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides that shares of Preferred Stock may be issued from time to time in one or more series. Our Board is authorized to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series of Preferred Stock and any qualifications, limitations and restrictions thereof. Our Board is able to, without stockholder approval, issue Preferred Stock with voting and other rights that could adversely affect the voting power and other rights of the holders of our common stock and could have anti-takeover effects. The ability of our Board to issue Preferred Stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Allurion or the removal of existing management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Series A Preferred Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, we filed a Certificate of Designations of Preferences, Rights and Limitations of <span style="white-space:nowrap">Series&#160;A&#160;Non-Voting&#160;Convertible</span> Preferred Stock (the &#8220;Certificate of Designations&#8221;) with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the Series A Preferred Stock, and designating 2,260,159 shares of preferred stock as Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General</span>. Each share of Series A Preferred Stock has a stated value of $1.20 per share and, when issued, each share of Series A Preferred Stock is fully paid <span style="white-space:nowrap">and&#160;non-assessable.&#160;With</span> respect to the payment of dividends, distributions and payments upon the liquidation, dissolution and winding up of Allurion, the Series A Preferred Stock will rank on parity with the common stock and junior to any other preferred stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Voting.</span>&#160;Holders of shares of the Series A Preferred Stock shall have no voting rights on any Allurion matter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dividends</span>. Holders of the Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(on&#160;an&#160;as-if-converted-to-common-stock&#160;basis)&#160;to</span></span></span></span> and in the same form as dividends actually paid on shares of the common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Liquidation</span>. In the event of any Liquidation (as defined in the Certificate of Designations), our assets shall be distributed among the holders of the shares of Series A Preferred Stock and common stock pro rata based on the number of shares held by each such holder <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(on&#160;an&#160;as-if-converted-to-common-stock&#160;basis).</span></span></span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Conversion</span>. Following the date upon which we obtain the Second Stockholder Approval for the issuance of the underlying common stock, which we have agreed to obtain as set forth in the Subscription Agreement, each share of Series A Preferred Stock shall automatically convert into one share of common stock (or <span style="white-space:nowrap">pre-funded</span> warrants), subject to adjustment;<span style="font-style:italic">&#160;provided</span>,<span style="font-style:italic">&#160;however</span>, that in no event shall the Series&#160;A Preferred Stock be converted into a number of shares of common stock exceeding 9.99% of the total number of shares of common stock outstanding. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Mandatory Redemption.</span>&#160;We will be required to redeem the shares of Series A Preferred Stock at a price per share equal to the volume weighted average price of the common stock during the 20 trading day period ending on the trading day immediately prior to such redemption if the shares of Series A Preferred Stock remain outstanding on December&#160;31, 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant entitles the registered holder to purchase 1.420455 shares of our common stock at a price of $8.10 per share, subject to adjustment as discussed below, at any time commencing on the date that is 30 days after the completion of the Business Combination. Pursuant to the Warrant Agreement, a Public </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrant holder may exercise its Public Warrants only for a whole number of shares of common stock. This means that only a whole Public Warrant may be exercised at any given time by a Public Warrant holder. The Public Warrants will expire seven years after the completion of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Public Warrants when the price per share of our common stock equals or exceeds $12.67 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not less than all of the Public Warrants may be redeemed for cash or for shares of common stock after a date that is ninety (90)&#160;days after Closing Date of the Business Combination. Once the Public Warrants become exercisable, we may redeem the outstanding Public Warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per Public Warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon a minimum of 30 days&#8217; prior written notice of redemption to each Public Warrant holder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of our common stock equals or exceeds $12.67 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a Public Warrant as described under the heading &#8220;- Anti-dilution adjustments&#8221;) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending three trading days before we send the notice of redemption to the Public Warrant holders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not redeem the Public Warrants as described above unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants is then effective and a current prospectus relating to those shares of common stock is available throughout the <span style="white-space:nowrap">30-day</span> redemption period. If and when the Public Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Public Warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the Public Warrants, each Public Warrant holder will be entitled to exercise his, her or its Public Warrant prior to the scheduled redemption date. Any such exercise would not be done on a &#8220;cashless&#8221; basis and would require the exercising Public Warrant holder to pay the exercise price for each Public Warrant being exercised. However, the price of the common stock may fall below the $12.67 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a Public Warrant as described under the heading &#8220;- Anti-dilution Adjustments&#8221;) as well as the $8.10 (for whole shares) Public Warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption of Public Warrants when the price per share of common stock equals or exceeds $7.04 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the Public Warrants become exercisable, we may redeem the outstanding Public Warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at $0.10 per Public Warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their Public Warrants on a cashless basis prior to redemption and receive that number of shares of common stock to be determined by reference to the table below, based on the redemption date and the &#8220;fair market value&#8221; (as defined below) of our common stock except as otherwise described below; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of our common stock equals or exceeds $7.04 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a Public Warrant as described under the heading &#8220;-<span style="font-style:italic"> Anti-dilution adjustments</span>&#8221;) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending three trading days before we send the notice of redemption to the Public Warrant holders. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on the date the notice of redemption is given until the Public Warrants are redeemed or exercised, holders may elect to exercise their Public Warrants on a cashless basis. The numbers in the table below represent the number of shares of common stock that a Public Warrant holder will receive upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the &#8220;fair market value&#8221; of our common stock on the corresponding redemption date (assuming holders elect to exercise their Public Warrants and such Public Warrants are not redeemed for $0.10 per Public Warrant), determined for these purposes based on the volume-weighted average price of the common stock during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of Public Warrants, and the number of months that the corresponding redemption date precedes the expiration date of the Public Warrants, each as set forth in the table below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide our Public Warrant holders with the final fair market value no later than one business day after the <span style="white-space:nowrap">10-day</span> trading period described above ends. The stock prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a Public Warrant or the exercise price of a Public Warrant is adjusted as set forth under the heading &#8220;Anti-dilution Adjustments&#8221; below. If the number of shares issuable upon exercise of a Public Warrant is adjusted, the adjusted stock prices in the column headings will equal the stock prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Public Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Public Warrant as so adjusted. The number of shares in the table below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a Public Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the exercise price of a Public Warrant is adjusted, (a)&#160;in the case of an adjustment pursuant to the fifth paragraph under the heading &#8220;Anti-dilution Adjustments&#8221; below, the adjusted share prices in the column headings will equal the unadjusted share price multiplied by a fraction, the numerator of which is the higher of the market value and the newly issued price as set forth under the heading &#8220;Anti-dilution Adjustments&#8221; and the denominator of which is $10.00 and (b)&#160;in the case of an adjustment pursuant to the second paragraph under the heading &#8220;Anti-dilution Adjustments&#8221; below, the adjusted share prices in the column headings will equal the unadjusted share price less the decrease in the exercise price of a Public Warrant pursuant to such exercise price adjustment. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="34" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Redemption Fair Market Value of shares of common stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Redemption Date (period to expiration of<br/>Public Warrants)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8804;<span style="font-weight:bold"></span><span style="font-weight:bold">$4.96</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$5.45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$5.95</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$6.45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$6.94</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$7.44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$7.93</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$8.43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8805;<span style="font-weight:bold"></span><span style="font-weight:bold">$8.93</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">84 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.506</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">81 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">78 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">72 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.419</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.438</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">69 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.468</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">66 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">63 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.428</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.479</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.492</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.503</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.369</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.420</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.441</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.490</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.488</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.385</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.405</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.451</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.469</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.486</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.420</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.443</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.355</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.414</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.498</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.401</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="34" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Redemption Fair Market Value of shares of common stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Redemption Date (period to expiration of<br/>Public Warrants)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8804;<span style="font-weight:bold"></span><span style="font-weight:bold">$4.96</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$5.45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$5.95</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$6.45</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$6.94</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$7.44</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$7.93</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$8.43</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8805;<span style="font-weight:bold"></span><span style="font-weight:bold">$8.93</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.416</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.296</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.374</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.408</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.491</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.279</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.425</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.458</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.487</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.376</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.415</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.162</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.262</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.404</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.435</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.046</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0 months</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.399</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.513</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of shares of common stock to be issued for each Public Warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or <span style="white-space:nowrap">366-day</span> year, as applicable. For example, if the volume weighted average price of our common stock during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Public Warrants is $5.45 per share, and at such time there are 57 months until the expiration of the Public Warrants, holders may choose to, in connection with this redemption feature, exercise their Public Warrants for 0.396 shares of common stock for each whole Public Warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume weighted average price of our common stock during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Public Warrants is $5.70 per share, and at such time there are 58 months until the expiration of the Public Warrants, holders may choose to, in connection with this redemption feature, exercise their Public Warrants for 0.410 shares of common stock for each whole Public Warrant. In no event will the Public Warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.513 shares of common stock per Public Warrant (subject to adjustment). Finally, as reflected in the table above, if the Public Warrants are out of the money and about to expire, they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, we can redeem the Public Warrants when our common stock is trading at a price starting at $7.04, which is below the exercise price of $8.10, because it will provide certainty with respect to our capital structure and cash position while providing Public Warrant holders with the opportunity to exercise their Public Warrants on a cashless basis for the applicable number of shares. If we choose to redeem the Public Warrants when our common stock is trading at a price below the exercise price of the Public Warrants, this could result in the Public Warrant holders receiving fewer common stock than they would have received if they had chosen to wait to exercise their Public Warrants for common stock if and when such common stock was trading at a price higher than the exercise price of $8.10. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest whole number of the number of common stock to be issued to the holder. If, at the time of redemption, the Public Warrants are exercisable for a security other than the shares of common stock pursuant to the Warrant Agreement (for instance, if we are not the surviving company in our initial business combination), the Public Warrants may be exercised for such security. At such time as the Public Warrants become exercisable for a security other than the common stock, the company (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon exercise of the Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Redemption Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a Public Warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such Public Warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the Public Warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the shares of common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Anti-Dilution Adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of common stock is increased by a stock capitalization or share dividend payable in shares of common stock, or by a <span style="white-space:nowrap">split-up</span> of shares of common stock or other similar event, then, on the effective date of such stock dividend, <span style="white-space:nowrap">split-up</span> or similar event, the number of shares of common stock issuable on exercise of each Public Warrant will be increased in proportion to such increase in the outstanding shares of common stock. A rights offering made to all, or substantially all, holders of common stock entitling holders to purchase shares of common stock at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a stock dividend of a number of shares of common stock equal to the product of (i)&#160;the number of shares of common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for common stock) and (ii)&#160;one (1) minus the quotient of (x)&#160;the price per share of common stock paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for common stock, in determining the price payable for common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) &#8220;historical fair market value&#8221; means the volume weighted average price of common stock as reported during the ten (10)&#160;trading day period ending on the trading day prior to the first date on which the shares of common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we, at any time while the Public Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to all or substantially all of the holders of the common stock on account of such common stock (or other securities into which the Public Warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the common stock during the <span style="white-space:nowrap">365-day</span> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of shares of common stock issuable on exercise of each Public Warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c)&#160;to satisfy the redemption rights of the holders of common stock in connection with a proposed initial business combination, (d)&#160;to satisfy the redemption rights of the holders of common stock in connection with a stockholder vote to amend our amended and restated certificate of incorporation (A)&#160;to modify the substance or timing of our obligation to provide holders of our common stock the right to have their shares redeemed in connection with our initial business combination or to allow redemption in connection with our initial business combination or to redeem 100% of our public shares if we do not complete our initial business combination within 24 months from the closing of the initial public offering or (B)&#160;with respect to any other provisions relating to stockholders&#8217; rights or <span style="white-space:nowrap">pre-initial</span> business combination activity, or (e)&#160;in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the Public Warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of common stock in respect of such event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of our common stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of common stock or other similar event, then, on the effective date </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of common stock issuable on exercise of each Public Warrant will be decreased in proportion to such decrease in outstanding shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of common stock purchasable upon the exercise of the Public Warrants is adjusted, as described above, the Public Warrant exercise price will be adjusted by multiplying the Public Warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of common stock purchasable upon the exercise of the Public Warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of common stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding shares of common stock (other than those described above or that solely affects the par value of such shares of common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the Public Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Public Warrants and in lieu of the shares of our common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Public Warrants would have received if such holder had exercised their Public Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of common stock in such a transaction is payable in the form of common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Public Warrant properly exercises the Public Warrant within thirty (30)&#160;days following public disclosure of such transaction, the Public Warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes Public Warrant Value (as defined in the Warrant Agreement) of the Public Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of such exercise price reduction is to provide additional value to holders of the Public Warrants when an extraordinary transaction occurs during the exercise period of the Public Warrants pursuant to which the holders of the Public Warrants otherwise do not receive the full potential value of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants were issued in registered form under the Warrant Agreement between Continental Stock Transfer&#160;&amp; Trust Company, as Public Warrant agent, and us. The Warrant Agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, and that all other modifications or amendments will require the vote or written consent of the holders of at least 50% of the then outstanding Public Warrants. You should review a copy of the Warrant Agreement, as amended, which is filed as an exhibit to the registration statement of which this prospectus is a part, for a complete description of the terms and conditions applicable to the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Public Warrants being exercised. The Public Warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their Public Warrants and receive common stock. After the issuance of common stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the Public Warrants. If, upon exercise of the Public Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the number of shares of common stock to be issued to the Public Warrant holder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">July 2024 Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of certain terms and provisions of the July 2024 Public Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of the July 2024 Public Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Duration and Exercise Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each July 2024 Public Warrant has an initial exercise price of $1.20 per share. The July 2024 Public Warrants are immediately exercisable and expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The July 2024 Public Warrants were issued separately from the common stock and may be transferred separately immediately thereafter. Each purchaser of one share of our common stock in the Offering received one July 2024 Public Warrant per share of common stock purchased thereby. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercisability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The July 2024 Public Warrants are exercisable, at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. A holder (together with its affiliates) may not exercise any portion of the July 2024 Public Warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s July 2024 Public Warrants. No fractional shares of common stock will be issued in connection with the exercise of a July 2024 Public Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, a July 2024 Public Warrant may be transferred at the option of the holder upon surrender of the July 2024 Public Warrant together with the appropriate instruments of transfer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exchange Listing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not listed, and do not intend to list, the July 2024 Public Warrants on the NYSE or any other securities exchange or nationally recognized trading system. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Right as a Stockholder </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the July 2024 Public Warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the July 2024 Public Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their July 2024 Public Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private placement warrants that were sold in the concurrent private placement shall have substantially the same terms as the warrants being offered in this offering. See the section entitled &#8220;Description of Securities we are Offering&#8221; for a description of the warrants being offered in this offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investor Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, we and the Investors entered into the Investor Rights Agreement. Pursuant to the Investor Rights Agreement, upon the terms and subject to the conditions set forth therein, each Investor was granted certain registration rights with respect to his, her, or its shares of our common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor Rights Agreement restricts the ability of certain Investors to transfer all or a portion of their respective shares of our common stock (or any securities convertible into or exercisable or exchangeable for shares of our common stock), subject to certain permitted transfers, for a period of either 18 months or 12 months following the Closing Date, as applicable. The foregoing <span style="white-space:nowrap">lock-up</span> restrictions do not apply to: (a)&#160;any shares of our common stock purchased pursuant to the PIPE Subscription Agreements, (b) 100 shares of our common stock held by each Investor, (c)&#160;shares issued to the Sponsor in the Sponsor Loan Equity Issuance, (d)&#160;certain incremental shares of PIPE Investors who were existing Allurion Stockholders or existing holders of Allurion Convertible Notes or shares issued upon conversion of securities issued in the Incremental Financing and (e)&#160;the Backstop Shares, the Sponsor Contributed Shares, the Gaur Trust Contributed Shares or the shares of our common stock issued to each of HVL, RTW, Fortress and the other holders of Bridge Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to the Investor Rights Agreement, upon the terms and subject to the conditions set forth therein, the Board (as defined below) shall consist of seven directors, a majority of which shall be &#8220;independent&#8221; directors for purposes of NYSE rules, and the following persons have the following nomination rights with respect to our Board, subject to the limitations set forth in the Investor Rights Agreement: (i)&#160;one director and one independent director nominated by Shantanu Gaur; (ii)&#160;one director and one independent director nominated by Remus Capital; (iii)&#160;one director nominated by the Sponsor; and (iv)&#160;two independent directors nominated by Allurion (one of which shall be designated by RTW). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Investor Rights Agreement will terminate upon the earlier of (i)&#160;the seventh anniversary of the Closing Date, (ii)&#160;a Change of Control (as defined in the Business Combination Agreement) or (iii)&#160;the date as of which there shall be no registrable securities outstanding; provided, that with respect to any Investor, such Investor will have no rights under the Investor Rights Agreement and all of our obligations to such Investor shall terminate upon the earlier of (x)&#160;the date at least one year after the Closing Date that such Investor ceases to hold at least one percent of the registrable securities outstanding on the Closing Date or (y)&#160;if such Investor is a one of our directors or executive officers, the date such Investor no longer serves as one of our directors or an executive officers. Notwithstanding the foregoing, (a)&#160;the piggy-back registration rights provided for in the Investor Rights Agreement shall terminate no later than the third anniversary of the Closing Date and (b)&#160;the obligations regarding the nomination of directors shall survive until the earlier of a termination of the Investor Rights Agreement in accordance with clauses (i)&#160;or (ii) above or with respect to any one Investor, at such time as such Investor is no longer entitled to nominate a director to our Board under the terms of the Investor Rights Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PIPE Subscription Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PIPE Subscription Agreements also provide that no later than 45 calendar days after the closing date of the Business Combination (the &#8220;Closing Date&#8221;), we will file a registration statement covering the resale of the PIPE Shares and to use our commercially reasonable efforts to have such registration statement declared </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective as soon as practicable after the filing thereof but no later than the earlier of (i) 90 calendar days after the Closing Date (or 120 calendar days after the Closing Date if the SEC notifies us that it will &#8220;review&#8221; such registration statement) and (ii)&#160;the 10th business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that such Resale Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Chardan Registration Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chardan Registration Rights Agreement provides for the registration of the offer and sale of the shares of our common stock issuable pursuant to the Chardan Purchase Agreement on a resale registration statement on Form <span style="white-space:nowrap">S-1.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amended Note Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, we issued and sold $48&#160;million of Notes to RTW in a private placement. Until the Notes are converted or repaid in full, RTW will be entitled to designate one representative who will serve as a <span style="white-space:nowrap">non-voting</span> board observer to the Board. In addition, in September 2023, we appointed Keith Johns to our Board, in satisfaction of certain obligations to RTW set forth in the Amended Note Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Note Purchase Agreement also provides that in no event later than 45 days after April&#160;16, 2024, we must file with the SEC a registration statement covering the resale of the full amount of the shares of common stock underlying the notes sold under the Amended Note Purchase Agreement. We must use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable, but in no event later than the date which shall be either (a)&#160;in the event that the SEC does not review such registration statement, 90 days after April&#160;16, 2024, or (b)&#160;in the event that the SEC reviews such registration statement, 120 days after the April&#160;16, 2024 (but in any event, no later than three business days following the SEC indicating that it has no further comments on the registration statement). Such resale registration statement was declared effective by the SEC on October&#160;7, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Subscription Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, we entered into the Subscription Agreement with funds affiliated with RTW, pursuant to which we sold to RTW 2,260,159 shares of Series A Preferred Stock and 2,260,159 Private Placement Warrants, for an aggregate purchase price of approximately $2.7&#160;million at a purchase price of $1.20 per share of Series A Preferred Stock and accompanying Private Placement Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Subscription Agreement provides that in no event later than 45 days after July&#160;1, 2024, we must file with the SEC a registration statement covering the resale of the full amount of the shares of common stock underlying the Notes sold under the Amended Note Purchase Agreement. We must use commercially reasonable efforts to have such registration statement declared effective by the SEC as soon as practicable, but in no event later than the date which shall be either (a)&#160;in the event that the SEC does not review such registration statement, 90 days after July&#160;1, 2024, or (b)&#160;in the event that the SEC reviews such registration statement, 120 days after the July&#160;1, 2024 (but in any event, no later than three business days following the SEC indicating that it has no further comments on the registration statement). Such resale registration statement was declared effective by the SEC on October&#160;7, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Provisions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Allurion Charter and Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other things, our Charter and Bylaws (as amended from time to time): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">permit our Board to issue up to 100&#160;million shares of Preferred Stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that the number of directors may be changed only by resolution of our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least 66 2/3% of all of our then- outstanding shares of the capital stock entitled to vote generally at an election of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that all vacancies, subject to the rights of any series of Preferred Stock, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that special meetings of stockholders may only be called by our Board pursuant to a resolution adopted by a majority of our Board, by the chairman of our Board or by the chief executive officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that our Board will be divided into three classes of directors, with the directors serving staggered three-year terms (see the section entitled &#8220;<span style="font-style:italic">Management</span>&#8221;), therefore making it more difficult for stockholders to change the composition of the board of directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of our common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The combination of these provisions will make it more difficult for the existing stockholders to replace our Board as well as for another party to obtain control of Allurion by replacing our Board. Because our Board will have the power to retain and discharge its officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated Preferred Stock will make it possible for our Board to issue Preferred Stock with voting or other rights or preferences that could impede the success of any attempt to change the control of Allurion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to enhance the likelihood of continued stability in the composition of our Board and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain Anti-Takeover Provisions of Delaware Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the DGCL. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an affiliate of an interested stockholder; or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;business combination&#8221; includes a merger or sale of more than 10% of a corporation&#8217;s assets. However, the above provisions of Section&#160;203 would not apply if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relevant board of directors approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of the corporation&#8217;s voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or subsequent to the date of the transaction, the initial business combination is approved by the board of directors and authorized at a meeting of the corporation&#8217;s stockholders, and not by written consent, by an affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of delaying, deferring, or preventing changes in control of Allurion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exclusive Forum </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides that, unless we consent in writing to the selection of an alternative forum, the Chancery Court of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction the federal district court for the District of Delaware or other state courts of the State of Delaware) and any appellate court thereof shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (1)&#160;any derivative action, suit or proceeding brought on our behalf; (2)&#160;any action, suit or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, stockholders or employees of ours or our stockholders; (3)&#160;any action, suit or proceeding asserting a claim against us arising pursuant to any provision of the DGCL, our Bylaws or our Charter (as either may be amended from time to time); or (4)&#160;any action, suit or proceeding asserting a claim against us or any current or former director, officer or stockholder governed by the internal affairs doctrine. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. If any such foreign action is filed in a court other than the courts in the State of Delaware in the name of any stockholder, such stockholder shall be deemed to have consented to (a)&#160;the personal jurisdiction of the state and federal courts in the State of Delaware in connection with any action brought in any such court to enforce such actions and (b)&#160;having service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the foreign action as agent for such stockholder. Our Charter also provides that any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our Charter is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This choice of forum provision has important consequences for our stockholders. These provisions may limit or increase the difficultly of a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors and officers, or may increase the associated costs for such stockholder to bring a claim, both of which may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm its business, results of operations, and financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Warrant Agent </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Transfer Agent for our common stock and the warrant agent for our Public Warrants is Continental Stock Transfer&#160;&amp; Trust Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing of our Common Stock and Public Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock and Public Warrants are listed on the NYSE under the symbols &#8220;ALUR&#8221; and &#8220;ALUR WS,&#8221; respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_18">DESCRIPTION OF SECURITIES WE ARE OFFERING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the common stock, pre-funded warrants and common warrants being offered in this offering. The following description is subject in all respects to the provisions contained in instruments governing the applicable security. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material terms and provisions of our common stock and each other class of our securities that qualifies or limits our common stock are described in the section entitled &#8220;<span style="font-style:italic">Description of Securities</span>&#8221; beginning on page&#160;158 of this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of certain terms and provisions of the common warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the common warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of common warrant for a complete description of the terms and conditions of the common warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Form </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a warrant agency agreement between us and Continental Stock Transfer &amp; Trust Company, as warrant agent, the common warrants will be issued in book-entry form and shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company (&#8220;DTC&#8221;), and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Duration and Exercise Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each common warrant offered hereby will have an initial exercise price per share equal to $&#8195;&#8195;&#8195;&#160;per share (representing&#160;&#8195;&#8195;&#8195;% of the public offering price). The common warrants will be immediately exercisable upon issuance and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The common warrants will be issued separately from the common stock and may be transferred separately immediately thereafter. Each purchaser of one share of our common stock (or pre-funded warrants in lieu of common stock) in this offering will receive one common warrant per share of common stock (or pre-funded warrant in lieu of common stock) purchased thereby. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercisability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cashless Exercise </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities Act is not then effective or available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price and subject to the nominal value of the shares being paid up as described below, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares determined according to a formula set forth in the common warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fundamental Transaction </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a fundamental transaction, as described in the common warrants and generally including (i) our merger or consolidation with or into another person, (ii) the sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of our assets, (iii) any purchase offer, tender offer or exchange offer pursuant to which holders of our common stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of our outstanding common stock or 50% or more of the voting power of our common equity, (iv) any reclassification, reorganization or recapitalization of our shares of common stock or any compulsory share exchange or (v) any stock or share purchase agreement or other business combination with another person or group of persons whereby such other person or group acquires 50% or more of our outstanding shares of common stock or 50% or more of the voting power of our common equity, the holders will be entitled to receive the number of shares of the common stock for which the warrant is exercisable immediately prior to the occurrence of such fundamental transaction on a net exercise basis. Notwithstanding the foregoing, in the event of a fundamental transaction, the holders of the common warrants have the right to require us or a successor entity to redeem the common warrants for cash in the amount of the Black Scholes Value (as defined in each common warrant) of the unexercised portion of the common warrants concurrently with or within 30 days following the consummation of a fundamental transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant together with the appropriate instruments of transfer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exchange Listing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to list the common warrants on the NYSE or any other securities exchange or nationally recognized trading system. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Right as a Stockholder </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the common warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the common warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their common warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Pre-Funded Warrants</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain terms and provisions of the pre-funded warrants offered hereby in lieu of shares of common stock. This summary is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Duration and Exercise Price</span>. Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.0001. The pre-funded warrants will be immediately exercisable and may be exercised at any time. There is no expiration date for the pre-funded warrants. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercisability</span>. The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% (or at the election of the holder prior to the issuance of any pre- funded warrants, 9.99%) of the outstanding shares of common stock immediately after exercise. Any holder may increase such percentage to any percentage not in excess of 9.99% upon at least 61 days&#8217; prior notice to us. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares of common stock, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price of such pre-funded warrant or round up to the next whole share. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cashless Exercise</span>. In lieu of making the cash payment of the aggregate exercise price otherwise contemplated to be made to us upon such exercise, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fundamental Transaction</span>. In the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding shares of common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding shares of common stock, the holders of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability</span>. Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Exchange Listing</span>. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Rights as a Stockholder</span>. Except as otherwise provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders of our common stock, including any voting rights. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_19">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our shares of common stock and the acquisition, ownership, exercise, expiration or disposition of the pre-funded warrants and warrants, which, together with our shares of common stock, we refer to in this section as our securities. This discussion applies only to our securities that are held as capital assets for U.S. federal income tax purposes and is applicable only to holders who are receiving our securities in this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is a summary only and does not describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including but not limited to the alternative minimum tax, the Medicare tax on certain investment income and the different consequences (such as the effects of Section&#160;451 of the Code) that may apply if you are subject to special rules that apply to certain types of investors, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">financial institutions or financial services entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governments or agencies or instrumentalities thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the U.S.; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons that actually or constructively own five percent or more of our voting shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders subject to a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting with respect to our securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our securities as part of a &#8220;straddle,&#8221; hedge, integrated transaction or similar transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. holders (as defined below) whose functional currency is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">partnerships or other pass-through entities for U.S. federal income tax purposes and any beneficial owners of such entities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> entities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or <span style="white-space:nowrap">non-U.S.</span> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not sought, and will not seek, a ruling from the IRS as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You are urged to consult your tax advisor with respect to the application of U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or foreign jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our securities through such entities. If a partnership (or other entity or arrangement classified as a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partnership or other pass-through entity for United States federal income tax purposes) is the beneficial owner of our securities, the United States federal income tax treatment of a partner or member in the partnership or other pass-through entity generally will depend on the status of the partner or member and the activities of the partnership or other pass-through entity. If you are a partner or member of a partnership or other pass-through entity holding our securities, we urge you to consult your tax advisor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES. EACH PROSPECTIVE INVESTOR IN OUR SECURITIES IS URGED TO CONSULT ITS TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY UNITED STATES FEDERAL <span style="white-space:nowrap">NON-INCOME,</span> STATE, LOCAL, AND <span style="white-space:nowrap">NON-U.S.</span> TAX LAWS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Treatment of Pre-Funded Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is not entirely free from doubt, a pre-funded warrant should be treated as a share of our common stock for U.S. federal income tax purposes and a holder of pre-funded warrants should generally be taxed in the same manner as a holder of such shares, as described below. Accordingly, no gain or loss should be recognized upon the exercise of a pre-funded warrant and, upon exercise, the holding period of a pre-funded warrant should carry over to the share received. Similarly, the tax basis of the pre-funded warrant should carry over to the share received upon exercise, increased by the exercise price of $0.0001 per share. If a pre-funded warrant expires without being exercised, the holder should recognize a capital loss in an amount equal to such holder&#8217;s tax basis in the pre-funded warrant. This loss will be long-term capital loss if, at the time of the expiration, the holder&#8217;s holding period in the pre-funded warrant is more than one year. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our characterization is not binding on the IRS, and the IRS may treat our pre-funded warrants as warrants to acquire shares of our common stock. In that case, the amount and character of your gain with respect to an investment in our pre-funded warrants could be materially different than the discussion set forth below. Accordingly, each holder should consult his, her or its tax advisor regarding the risks associated with the acquisition of pre-funded warrants pursuant to this offering (including potential alternative characterizations). The balance of this discussion generally assumes that a pre-funded warrant is treated as a share of our common stock for U.S. federal income tax purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section applies to you if you are a &#8220;U.S. holder.&#8221; A U.S. holder is a beneficial owner of our shares of common stock who or that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust, if (i)&#160;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&#160;it has a valid election in effect under Treasury Regulations to be treated as a U.S. person. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Distributions</span>. If we pay distributions in cash or other property (other than certain distributions of our stock or rights to acquire our stock) to U.S. holders of shares of our common stock, such distributions </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. holder&#8217;s adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the common stock and will be treated as described under &#8220;<span style="font-style:italic">U.S. holders&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of our securities</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. holder that is a taxable corporation generally will qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S. holder may constitute &#8220;qualified dividends&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the holding period requirements are not satisfied, then a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> holders may be subject to tax on such dividend at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&#160;305 of the Code, an adjustment to the number of shares of common stock that will be issued on the exercise of the warrants, or an adjustment to the exercise price of the warrants, may be treated as a constructive distribution to a U.S. holder of the warrants if, for example, and to the extent that, such adjustment has the effect of increasing such U.S. holder&#8217;s proportionate interest in our &#8220;earnings and profits&#8221; or assets, depending on the circumstances of such adjustment. For example, such an adjustment to compensate for a distribution of cash or other property to our stockholders would generally be treated as a constructive distribution to a U.S. holder of the warrants. Adjustments to the exercise price of a warrant made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution of the interest of the holders of the warrants should generally not result in a constructive distribution. Any constructive distributions would generally be subject to the tax treatment described in the two immediately preceding paragraphs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of our securities</span>. Upon a sale or other taxable disposition of our common stock, a U.S. holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. holder&#8217;s adjusted tax basis in the common stock. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. holder&#8217;s holding period for the common stock so disposed of exceeds one year. If the holding period requirements are not satisfied, any gain on a sale or taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at regular ordinary income tax rates. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. holders will be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, the amount of gain or loss recognized by a U.S. holder is an amount equal to the difference between (i)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&#160;the U.S. holder&#8217;s adjusted tax basis in its common stock so disposed of. A U.S. holder&#8217;s adjusted tax basis in its common stock generally will equal the U.S. holder&#8217;s acquisition cost for the common stock less any prior distributions treated as a return of capital with respect to such common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For U.S. federal income tax purposes, gain or loss realized on the sale or other taxable disposition of a warrant (other than by exercise) generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. holder held the warrant for more than one year at the time of the sale or other disposition. The amount of the gain or loss will equal the difference between the U.S. holder&#8217;s tax basis in the warrant disposed of and the amount realized on the disposition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a U.S. holder will not be required to recognize income, gain or loss upon the exercise of a warrant by payment of the exercise price, except to the extent of cash paid to such U.S. holder in lieu of a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fractional share. A U.S. holder&#8217;s tax basis in a share of common stock received upon exercise will be equal to the sum of (1)&#160;the U.S. holder&#8217;s tax basis in the warrant and (2)&#160;the exercise price of the warrant. A U.S. holder&#8217;s holding period in the stock received upon exercise will commence on the day or the day after such U.S. holder exercises the warrant. No discussion is provided herein regarding the U.S. federal income tax treatment on the exercise of a warrant on a cashless basis, and U.S. holders are urged to consult their tax advisors as to the exercise of a warrant on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a warrant expires without being exercised, a U.S. holder will recognize a capital loss in an amount equal to such U.S. holder&#8217;s tax basis in the warrant. This loss will be long-term capital loss if, at the time of the expiration, the U.S. holder&#8217;s holding period in the warrant is more than one year. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Information Reporting and Backup Withholding</span>. In general, information reporting requirements may apply to dividends paid to a U.S. holder and to the proceeds of the sale or other disposition of our shares of common stock, unless the U.S. holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn Any amounts withheld under the backup withholding rules generally should be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-U.S.</span> holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section applies to you if you are a <span style="white-space:nowrap">&#8220;Non-U.S.</span> holder.&#8221; As used herein, the term <span style="white-space:nowrap">&#8220;Non-U.S.</span> holder&#8221; means a beneficial owner of our common stock who or that is for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a <span style="white-space:nowrap">non-resident</span> alien individual (other than certain former citizens and residents of the U.S. subject to U.S. tax as expatriates); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a foreign corporation; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate or trust that is not a U.S. holder; </p></td></tr></table> <p style="margin-top:11pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but generally does not include an individual who is present in the U.S. for 183 days or more in the taxable year of disposition. If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities. </p> <p style="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Taxation of Distributions</span>. In general, any distributions we make to a <span style="white-space:nowrap">Non-U.S.</span> holder of shares of our common stock, or on our warrants (including a constructive distribution as discussed above under &#8220;<span style="font-style:italic">U.S. holders&#8212;Taxation of Distributions</span>&#8221;), to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E).</span></span> Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s adjusted tax basis in its shares of our common stock or warrants, as applicable, and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the common stock or warrant, as applicable, which will be treated as described under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> holders&#8212;Gain on Sale, Taxable Exchange or Other Taxable Disposition of our securities</span>&#8221; below. </p> <p style="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding tax does not apply to dividends paid to a <span style="white-space:nowrap">Non-U.S.</span> holder who provides a Form <span style="white-space:nowrap">W-8ECI,</span> certifying that the dividends are effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s conduct of a trade or business within the United States. Instead, such effectively connected dividends will be subject to regular U.S. income tax </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as if the <span style="white-space:nowrap">Non-U.S.</span> holder were a U.S. resident, subject to an applicable income tax treaty providing otherwise. A <span style="white-space:nowrap">Non-U.S.</span> corporation receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax&#8221; imposed at a rate of 30% (or a lower treaty rate). </p> <p style="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a <span style="white-space:nowrap">Non-U.S.</span> holder will not be required to recognize income, gain or loss upon the exercise of a warrant by payment of the exercise price, except to the extent of cash paid in lieu of a fractional share. However, no discussion is provided herein regarding the U.S. federal income tax treatment on the exercise of a warrant on a cashless basis, and <span style="white-space:nowrap">Non-U.S.</span> holders are urged to consult their tax advisors as to the exercise of a warrant on a cashless basis. </p> <p style="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a warrant expires without being exercised, a <span style="white-space:nowrap">Non-U.S.</span> holder that is engaged in a U.S. trade or business to which any income from the warrant would be effectively connected or who is present in the United States for a period or periods aggregating 183 days or more during the calendar year in which the expiration occurs (and certain other conditions are met) will recognize a capital loss in an amount equal to such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s tax basis in the warrant. </p> <p style="margin-top:11pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Sale, Taxable Exchange or Other Taxable Disposition of our securities</span>. A <span style="white-space:nowrap">Non-U.S.</span> holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our common stock or our warrants, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> holder within the United States (and, under certain income tax treaties, is attributable to a United States permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> holder); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">Non-U.S.</span> holder held our common stock or warrants, and, (A)&#160;in the case where shares of our common stock are regularly traded on an established securities market, the <span style="white-space:nowrap">Non-U.S.</span> holder has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s holding period for the shares of our common stock , and (B)&#160;in the case of our warrants, either (a)(i) shares of our common stock are &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on an established securities market, such as the NYSE, (ii)&#160;our warrants are not considered regularly traded on an established securities market and (iii)&#160;the <span style="white-space:nowrap">Non-U.S.</span> Holder does not own, actually or constructively, warrants with a fair market value greater than the fair market value of 5% of the shares of our common stock, determined as of the date that such <span style="white-space:nowrap">Non-U.S.</span> Holder acquired its warrants, or (b)(i) our warrants are considered regularly traded on an established securities market, and (ii)&#160;the <span style="white-space:nowrap">Non-U.S.</span> Holder owns or owned, actually and constructively, 5% or less of our warrants throughout the five-year period ending on the date of the sale or exchange. There can be no assurance that our common stock or warrants will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless an applicable treaty provides otherwise, gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">Non-U.S.</span> holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">Non-U.S.</span> holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower treaty rate). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the second bullet point above applies to a <span style="white-space:nowrap">Non-U.S.</span> holder, gain recognized by such holder on the sale, exchange or other disposition of shares of our securities will be subject to tax at generally applicable U.S. federal income tax rates, and a buyer of such securities may be required to withhold U.S. federal income tax at a rate of 15% of the amount realized upon the disposition. We expect not to be classified as a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes. However, such determination is factual in nature and subject to change and no assurance can be provided as to whether we will be a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes in the future. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Information Reporting and Backup Withholding</span>. Information returns will be filed with the IRS in connection with payments of dividends on our securities or constructive dividends on warrants and the proceeds from a sale or other disposition of our shares of common stock or warrants. A <span style="white-space:nowrap">Non-U.S.</span> holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty will generally satisfy the certification requirements necessary to avoid the backup withholding as well. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">Non-U.S.</span> holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">FATCA Withholding Taxes</span>. Sections 1471 through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) generally impose withholding at a rate of 30% in certain circumstances on dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, securities (including shares of our common stock) which are held by or through certain foreign financial institutions (including investment funds), unless any such institution (i)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (ii)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which shares of our common stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our securities held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends in respect of our securities. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including shares of our common stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_20">PLAN OF DISTRIBUTION </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Roth Capital Partners, LLC has agreed to act as our exclusive placement agent in connection with this offering on a reasonable best efforts basis subject to the terms and conditions of the placement agency agreement dated &#8195;&#8195;, 2024. The placement agent is not purchasing or selling any of the securities offered by this prospectus, nor is it required to arrange for the purchase and sale of any specific number or dollar amount of such securities, other than to use its reasonable &#8220;best efforts&#8221; to arrange for the sale of such securities by us. Therefore, we may not sell all of the securities being offered pursuant to this prospectus. The securities will be offered at a fixed price and are expected to be issued in a single closing. We will enter into a securities purchase agreement directly with certain investors, at the investor&#8217;s option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will terminate no later than &#8195;&#8195;, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. We will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about &#8195;&#8195;, 2024, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Fees and Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to pay the placement agent an aggregate fee equal to seven percent (7%) of the purchase price paid by all purchasers in this offering. In addition, we have agreed to reimburse the placement agent for its legal fees in an amount up to $100,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the total expenses of this offering paid or payable by us, exclusive of the placement agent fee, will be approximately $&#8195;&#8195;. After deducting the fees due to the placement agent and our estimated expenses in connection with this offering, we expect the net proceeds from this offering will be approximately $&#8195;&#8195; million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total cash fees we will pay to the placement agent in connection with the sale of the securities pursuant to this prospectus. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:67%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Per Share of</span><br/><span style="font-weight:bold">Common<br/>Stock and<br/>Accompanying<br/>Common<br/>Warrant</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Per Pre-<br/>Funded</span><br/><span style="font-weight:bold">Warrant and<br/>Accompanying<br/>Common<br/>Warrant</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Placement agent fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds before expenses to us<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8195;&#8195;&#8195;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">We have agreed to pay to the placement agent a cash fee equal to seven percent (7%) of the aggregate gross proceeds raised in this offering. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Does not include proceeds from the exercise of the pre-funded warrants or common warrants, if any. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Tail Fee </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also agreed to pay the placement agent a tail fee equal to the compensation in this offering, if any investor who was introduced to us by the placement agent or who had discussions or negotiations regarding a transaction with us during the term of the placement agent&#8217;s engagement provides us with capital in any offering of our securities during the engagement period of the placement agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Indemnification </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the placement agent and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the placement agent may be required to make in respect thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Lock-Up Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and each of our directors and officers and certain stockholders have agreed with the placement agent to be subject to a period of ninety days following the closing of this offering. During the applicable lock-up period, we and such individuals agreed, subject to specified exceptions, not to sell or transfer any shares of common stock or securities convertible into, or exchangeable or exercisable for, common stock. Specifically, we and such individuals agreed, in part, subject to certain exceptions, not to: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of common stock or securities convertible into or exercisable or exchangeable for common stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of common stock; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any of our securities. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Continental Stock Transfer &amp; Trust Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Determination of Offering Price </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is currently listed on the NYSE under the symbol &#8220;ALUR.&#8221; On December&#160;6, 2024, the reported closing price per share of our common stock was $0.37. The final public offering price will be determined between us, the placement agent and the investors in the offering, and may be at a discount to the current market price of our common stock. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final public offering price. There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect such markets to develop. In addition, we do not intend to apply for a listing of the pre-funded warrants or common warrants on any national securities exchange or other nationally recognized trading system. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Regulation M </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the placement agent acting as principal. Under these rules and regulations, the placement agents: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may not engage in any stabilization activity in connection with our securities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Electronic Distribution </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on a website maintained by the placement agent and the placement agent may distribute prospectuses electronically. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the placement agent and should not be relied upon by investors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Discretionary Accounts </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Activities and Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The placement agent and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The placement agent and certain of its affiliates may in the future perform various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses, but have performed no such services for us or our affiliates prior to this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of its various business activities, the placement agent and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for its own account and for the accounts of its customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the placement agent or its affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The placement agent and its affiliates may hedge such exposure by entering into transactions that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The placement agent and certain of its affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_21">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP, Boston, Massachusetts, has passed upon the validity of the shares of our common stock and warrants offered by this prospectus and certain other legal matters related to this prospectus. Ellenoff Grossman&#160;&amp; Schole LLP, New York, New York, is acting as counsel for the placement agent in connection with this offering. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_22">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Allurion Technologies, Inc. as of December&#160;31, 2023 and 2022, and for each of the two years in the period ended December&#160;31, 2023, included in this prospectus have been audited by Deloitte&#160;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx915839_23">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <span style="white-space:nowrap">S-1,</span> including exhibits, under the Securities Act with respect to the shares of our common stock and accompanying warrants offered by this prospectus. This prospectus constitutes only a part of the registration statement. Some items are contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or document referred to are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at <span style="font-style:italic">www.sec.gov. </span>We also maintain a website at <span style="font-style:italic">investors.allurion.com. </span>Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. Information contained on our website is not a part of or incorporated by reference into this prospectus and the inclusion of our website and investor relations website addresses in this prospectus is an inactive textual reference only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" id="hidden127681918" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" id="hidden127681919" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" id="hidden127682685" contextRef="PAsOn09_30_2024">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" id="hidden127682686" contextRef="PAsOn12_31_2023">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127680782" contextRef="P01_01_2022To12_31_2022">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127680783" contextRef="P01_01_2023To12_31_2023">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127680849" contextRef="P01_01_2023To09_30_2023">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127680850" contextRef="P01_01_2024To09_30_2024">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127681126" contextRef="P07_01_2023To09_30_2023">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="hidden127681127" contextRef="P07_01_2024To09_30_2024">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="hidden127680941" contextRef="PAsOn09_30_2024_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="hidden127682050" contextRef="PAsOn03_31_2024_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="hidden127680787" contextRef="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF">0.5</ix:nonFraction><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="hidden127682683" contextRef="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF">0.5</ix:nonFraction><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="hidden127682954" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3">895000</ix:nonFraction><ix:nonNumeric name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="hidden127682733" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alur-20240930.xsd"/></ix:references></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="tx915839_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; margin: 0px auto; border: 0px currentColor; border-image: none; width: 100%; font-family: Times New Roman; font-size: 10pt; border-collapse: collapse;">
<tr>
<td style="width: 95%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Audited Consolidated Financial Statements as of December&#160;31, 2023</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/>
<td style="vertical-align: bottom;"/></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_1">Report of Independent Registered Public Accounting Firm (PCAOB ID: 34)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_2">Consolidated Balance Sheets as of December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_3">Consolidated Statements of Operations for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_4">Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_5">Consolidated Statements of Stockholders&#8217; Deficit for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_6">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2023 and 2022</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_7">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">F-8</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Interim Unaudited Financial Statements as of September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_8">Unaudited Condensed Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_9">Unaudited Condensed Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_10">Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-53</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_11">Unaudited Condensed Consolidated Statements of Stockholders&#8217; Deficit</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_12">Unaudited Condensed Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-56</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin915839_13">Notes to Unaudited Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;text-align:right;">F-58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin915839_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the stockholders and the Board of Directors of Allurion Technologies, Inc. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of Allurion Technologies, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; deficit, and cash flows, for each of the two years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2023, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has experienced recurring losses from operations, recurring negative operating cash flows and may be unable to remain in compliance with certain financial covenants required under its term loan, that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Boston, Massachusetts </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March&#160;26, 2024 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have served as the Company&#8217;s auditor since 2016. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153); clear: both;"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div><div id="fin915839_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands) </div></div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47385">38,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47386">7,685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net of allowance of doubtful accounts of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47387">12,671</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47388">741</ix:nonFraction>, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47389">18,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47390">29,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47391">6,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47392">3,865</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47393">2,414</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47394">2,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47395">64,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47396">43,383</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47397">3,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47398">2,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47399">3,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47400">2,899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47401">505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47402">2,706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47403">71,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47404">51,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47405">10,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47406">5,809</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47407">38,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47408">53,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47409">908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47410">905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47411">15,495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47412">15,793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47413">65,425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47414">75,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible notes payable, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47415">3,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47416">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenueInterestFinancingLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47417">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47418">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47419">2,306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47420">2,163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47421">8,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47422">2,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47423">142,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47424">83,684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and Contingencies (Note 16)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-47425"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true" id="ixv-47426"/></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; deficit:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47427"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47428">0.0001</ix:nonFraction></ix:nonFraction> par value &#8212; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47429"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47430">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2023; and <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47431"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47432"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47433"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47434">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47435">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-47436">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47437"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47438">0.0001</ix:nonFraction></ix:nonFraction> par value &#8212; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47439"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47440">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2023; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47441"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47442">47,688,096</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47443"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47444">27,079,856</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023 and 2022, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47445">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47446">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47447">143,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47448">99,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47449">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47450">212,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47451">132,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47452">70,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47453">32,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47454">71,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47455">51,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3</div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin915839_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands, except per share amounts) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47456">53,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47457">64,211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47458">11,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47459">13,485</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47460">41,497</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47461">50,726</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47462">46,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47463">50,405</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47464">27,694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47465">16,966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47466">46,024</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47467">15,365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47468">120,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47469">82,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47470">79,078</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47471">32,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47472">10,566</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47473">4,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47474">8,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47475">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47476">3,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of Revenue Interest Financing and PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47477">2,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47478">29,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Termination of convertible note side letters</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47479">17,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47480">3,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47481">643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47482">344</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47483">1,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47484">5,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47485">80,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47486">37,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47487">264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47488">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47489">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47490">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared preferred dividends</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47491">1,697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47492">2,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47493">82,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47494">40,651</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47495"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47496">2.31</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47497"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-47498">1.51</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47499"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47500">35,581,656</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47501"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-47502">26,918,484</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-4 </div></div></div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin915839_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;text-indent: 0px;display:inline;"></div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47503">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47504">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing due to change in credit risk</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47505">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47506">81,307</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47507">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5</div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin915839_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:45%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common Sock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47508">26,807,365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47509">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47510">99,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47511">94,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47512">4,837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47513">128,567</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47514">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47515">128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47516">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47517">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Legacy Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> convertible preferred stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47518">5,611</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47519">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47520">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Legacy Series B convertible preferred stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47521">1,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47522">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2022To12_31_2022_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47523">4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsShares" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47524">137,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47525">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47526">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47527">27,079,856</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47528">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47529">99,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47530">132,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47531">32,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47532">298,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47533">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47534">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series B convertible preferred stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47535">8,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47536">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47537">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> convertible preferred stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47538">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47539">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47540">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reverse recapitalization, net of transaction costs (Note 3)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47541">13,735,872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47542">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47543">58,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47544">58,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of warrant liabilities in connection with the Merger (Note 3)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47545">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47546">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with vesting of RSU awards</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47547">918,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the conversion of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47548">3,301,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47549">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47550">25,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47551">25,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities (Note&#160;3)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47552">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47553">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification of Legacy Allurion <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;display:inline;">liabilitiy</div> classified warrants to equity classification</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47554">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47555">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47556">2,287,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodValueDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47557">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodValueDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47558">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47559">21,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47560">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47561">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47562">8,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47563">8,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for commitment shares for equity line financing (Note 12)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47564">35,511</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47565">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47566">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47567">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47568">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47569">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47570">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47571">47,688,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47572">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47573">143,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47574">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47575">212,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47576">70,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6</div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin915839_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2023&#8195;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8195;2022&#8195;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47577">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47578">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashLeaseExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47579">824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47580">1,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47581">746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47582">895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47583">8,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47584">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47585">12,675</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47586">436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized exchange gain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47587">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47588">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47589">1,399</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfWarrantLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47590">8,364</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangeInFairValueOfWarrantLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47591">820</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of derivative liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47592">1,730</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47593">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47594">3,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing and PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47595">2,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47596">29,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid on debt recorded at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:InterestPaidOnDebtRecordedAtFairValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47597">1,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashInterestExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47598">2,083</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashInterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47599">953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> termination of convertible note side letters</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashTerminationOfConvertibleNoteSideLetters" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47600">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47601">3,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> issuance of common stock for commitment shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashIssuanceOfCommonStockForCommitmentShares" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47602">123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt issuance costs associated with debt recorded at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47603">1,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47604">1,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47605">22,817</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47606">3,705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47607">1,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses, other current and long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47608">285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47609">577</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47610">789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47611">733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47612">4,664</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47613">3,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47614">1,057</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47615">8,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47616">63,982</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47617">46,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47618">1,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47619">1,550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47620">1,606</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47621">1,550</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of convertible notes - net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47622">28,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47623">1,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from term loan - net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47624">59,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47625">29,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47626">3,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47627">262</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromBusinessCombinationNetOfTransactionCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47628">61,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromRevenueInterestFinancing" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47629">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of 2021 Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47630">57,659</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To12_31_2023_FortressTermLoanMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47631">20,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of promissory note assumed in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47632">2,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from option and warrant exercises</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromOptionAndWarrantExercises" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47633">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromOptionAndWarrantExercises" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47634">132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47635">10,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of deferred financing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:PaymentOfDeferredFinancingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47636">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47637">95,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47638">30,537</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase (decrease) in cash and cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47639">30,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47640">17,994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47641">8,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47642">26,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47643">38,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47644">8,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of cash flow information</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47645">8,035</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47646">3,476</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental cash flow information on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> investing and financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of property and equipment included in accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47647">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47648">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of warrants in connection with financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfWarrantsInConnectionWithFinancing" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47649">834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred financing costs in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47650">580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47651">1,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of assumed warrant liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RecognitionOfAssumedWarrantLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47652">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RecognitionOfEarnOutLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47653">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon conversion of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47654">25,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing through OCI</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47655">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7</div> </div></div></div><div></div></div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div></div></div> <div id="fin915839_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">(dollars in thousands, except per share amounts) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="background: none;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679735" id="ixv-16276">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-weight:bold;display:inline;">1.</div></td>
<td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Organization and Basis of Presentation </div></td></tr></table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Technologies, Inc. (&#8220;Allurion&#8221; or the &#8220;Company&#8221;) is a <div style="letter-spacing: 0px; top: 0px;display:inline;">vertically </div>integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion Balloon. The Allurion Balloon is the world&#8217;s first and only swallowable, procedure-less intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement or removal. Allurion sells the Allurion Balloon and related hardware accessories through distributors or directly to health care providers. The Company currently also provides, free of charge, artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#8220;VCS&#8221;) and, collectively with the Allurion Balloon referred to as the &#8220;Allurion Program&#8221;. Allurion currently markets the Allurion Program in over <ix:nonFraction name="alur:NumberOfCountriesInWhichEntityMarketsTheProgram" contextRef="PAsOn12_31_2023" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47656">50</ix:nonFraction> countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, Hong Kong, the United Kingdom, Italy, Spain, Australia and Mexico. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#8220;Legacy Allurion&#8221;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.), entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#8220;Business Combination Agreement&#8221;) with Compute Health Acquisition Corp. (&#8220;CPUH&#8221; or &#8220;Compute Health&#8221;), Compute Health Corp. (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#8220;Closing Date&#8221;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#8220;CPUH Merger&#8221;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#8220;CPUH Merger Effective Time&#8221;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#8220;Intermediate Merger&#8221; and the time at which the Intermediate Merger became effective, the &#8220;Intermediate Merger Effective Time&#8221;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#8220;Final Merger&#8221; and, collectively with the CPUH Merger and the Intermediate Merger, the &#8220;Mergers&#8221;, and together with all other transactions contemplated by the Business Combination Agreement, the &#8220;Business Combination&#8221;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#8220;Final Merger Effective Time&#8221;). Allurion shares began trading on the New York Stock Exchange (&#8220;NYSE&#8221;) under the ticker symbol &#8220;ALUR&#8221; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#8217;s business operations continued as our business operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America. Under this method of accounting, Compute Health was treated as the &#8220;acquired&#8221; company for financial reporting purposes and Legacy Allurion was the accounting &#8220;acquirer&#8221;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of </div> <ix:exclude> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8</div> </ix:exclude> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679735" continuedAt="TextSelectionAppend_127679735_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679735_1" continuedAt="TextSelectionAppend_127679735_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679735_2" continuedAt="TextSelectionAppend_127679735_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679735_3" continuedAt="TextSelectionAppend_127679735_4"><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#8217;s common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47657">0.0001</ix:nonFraction> par value per share (&#8220;Allurion Common Stock&#8221; or the &#8220;Company&#8217;s Common Stock&#8221;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#8217;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately <ix:nonFraction name="alur:BusinessCombinationCommonStockExchangeRatio" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-47658">0.9780</ix:nonFraction> (the &#8220;Exchange Ratio&#8221;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the consolidated financial statements have changed. Refer to Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for further discussion regarding the closing of the Business Combination with Compute Health. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references to the &#8220;Company&#8221;, &#8220;our&#8221;, and &#8220;Allurion&#8221; refer to the consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#8220;Legacy Allurion&#8221; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company&#8217;s equity structure has been restated in prior periods to reflect the number of shares of the Allurion Common Stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47659">0.0001</ix:nonFraction> par value per share, issued to Legacy Allurion stockholders. As such, the shares and corresponding capital amounts presented in the consolidated balance sheet and consolidated statement of redeemable convertible preferred stock and stockholders&#8217; deficit have been retroactively restated as shares reflecting the Exchange Ratio established in the Business Combination. All then-existing Legacy Allurion redeemable convertible preferred stock and Legacy Allurion convertible preferred stock were converted into shares of Allurion Common Stock at the closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include Allurion; and its consolidated subsidiaries, Allurion France SAS, and Allurion Middle East, LLC, which were both incorporated in 2017; Allurion Hong Kong Ltd., which was incorporated in 2019; Allurion UK Ltd., which was incorporated in 2021; Allurion Italy, Srl, Allurion Spain, Srl, Allurion Australia Pty Ltd. and Allurion Mexico S. de R.L de C.V, which were incorporated in 2022; and Allurion Technologies, LLC, which was incorporated in 2023. The Company&#8217;s operations are located in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region, and it operates in one business segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. Gains (losses) from remeasurement of $<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47660">0.1</ix:nonFraction>&#160;million and $(<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47661">0.7</ix:nonFraction>) million for the years ended December&#160;31, 2023 and 2022, respectively, are recorded in the statements of operations and comprehensive loss within other expense, net. The Company translates the foreign functional currency financial <div style="letter-spacing: 0px; top: 0px;display:inline;">statements </div>to U.S.&#160;dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"><ix:exclude>&#160;</ix:exclude></div></ix:continuation><ix:continuation id="TextSelectionAppend_127679735_4" continuedAt="TextSelectionAppend_127679735_5"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-9</div> </ix:exclude></ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_127679735_5" continuedAt="TextSelectionAppend_127679735_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679735_6" continuedAt="TextSelectionAppend_127679735_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679735_7" continuedAt="TextSelectionAppend_127679735_8"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679735_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">equity transactions. The effects of foreign currency translation adjustments were immaterial for the years ended December&#160;31, 2023 and 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred recurring losses since inception and anticipates net losses and negative operating cash flows for the near future and may be unable to remain in compliance with certain financial covenants required under the Fortress Term Loan. Through December&#160;31, 2023, the Company has funded its operations primarily with proceeds from the sale of its convertible preferred stock, issuance of convertible notes, issuance of term loans and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including net losses of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47663">80.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47664">37.7</ix:nonFraction>&#160;million and cash outflows from operating activities of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47665">64.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47666">47.0</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. As of <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47667">212.8</ix:nonFraction>&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations and debt service payments, and the potential of being unable to remain in compliance with certain financial covenants under the Fortress Term Loan, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Due to the substantial doubt about the Company&#8217;s ability to continue operating as a going concern for twelve months from the issuance date of these financial statements and the liquidity and revenue covenant clauses within the Fortress Term Loan, the amounts due as of December&#160;31, 2023, have been classified as current liabilities in the consolidated financial statements. The lender under the Fortress Term Loan has not invoked the material adverse change clause and the Company has met the liquidity covenant as of the date of issuance of these financial statements. </div></ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679738" id="ixv-16356">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of Significant Accounting Policies </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16365"> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679796" id="ixv-16371"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reclassification of Prior Year Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude></div> </ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679796" continuedAt="TextSelectionAppend_127679796_1"><ix:continuation id="TextSelection_127679738" continuedAt="TextSelectionAppend_127679738_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_1" continuedAt="TextSelectionAppend_127679738_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_2" continuedAt="TextSelectionAppend_127679738_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_3" continuedAt="TextSelectionAppend_127679738_4"><ix:continuation id="TextSelectionAppend_127679796_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consolidated statement of <div style="letter-spacing: 0px; top: 0px;display:inline;">operations </div>and comprehensive loss for the year ended December&#160;31, 2022 to present the change in fair value of derivative liabilities as part of Other income (expense), net, and to present the change in fair value of warrants as its own line item. The change in fair value of derivative liabilities was a separate line item in prior years and the change in fair value of warrants was part of Other income (expense), net in prior years. </div></ix:continuation><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16396"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47670"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47671"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47672"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47673">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenue for the years ended December&#160;31, 2023 and 2022 or accounts receivable, net balance as of December&#160;31, 2023 and 2022. <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679833" id="ixv-47674">The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </ix:nonNumeric></div> <ix:continuation id="TextSelection_127679833"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:59%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts&#160;Receivable</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47675">10</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47676">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47677">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer C</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47678">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersDMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47679">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679801" id="ixv-16547"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2022, the Company adopted ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset and a current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> lease liability as applicable, in the consolidated balance sheets if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having an original term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will either renew or not cancel the lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#8217;s incremental borrowing rate. The </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div> <ix:continuation id="TextSelection_127679801" continuedAt="TextSelectionAppend_127679801_1"><ix:continuation id="TextSelectionAppend_127679738_4" continuedAt="TextSelectionAppend_127679738_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679738_5" continuedAt="TextSelectionAppend_127679738_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_6" continuedAt="TextSelectionAppend_127679738_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_7" continuedAt="TextSelectionAppend_127679738_8"><ix:continuation id="TextSelectionAppend_127679801_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#8217;s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of the lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Non</div>-lease</div> components include costs that do not provide a right to use a leased asset but instead provide a service, such as maintenance costs. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. </div></ix:continuation><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16586"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash consists of amounts held in bank savings and checking accounts. Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds. The Company&#8217;s restricted cash consists of cash that the Company is contractually obligated to maintain and deposits of cash collateral held in accordance with the terms of various corporate credit cards. Restricted cash is included within other long-term assets on the consolidated balance sheets. <ix:nonNumeric name="alur:ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679834" id="ixv-47682">A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): </ix:nonNumeric></div> <ix:continuation id="TextSelection_127679834"><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47683">38,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47684">7,685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in <div style="-sec-ix-hidden:hidden127681918;display:inline;"><div style="-sec-ix-hidden:hidden127681919;display:inline;">other long-term assets</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47685">384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47686">338</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47687">38,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47688">8,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16687"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in a single operating and reportable segment. Operating segments are defined as components of an enterprise for which discrete financial information is available and is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) in order to make decisions regarding resource allocation and performance assessment. The Company has determined that its CODM is its Chief Executive Officer. The Company&#8217;s CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since the Company operates as one operating segment, all required financial segment information can be found in the consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s products include the Allurion Balloon and related accessories. See Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue </div></div>below<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for financial information about sales in geographic areas. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679804" id="ixv-16698"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying value of the Company&#8217;s financial instruments such as cash and cash equivalents, accounts payable, and accrued expenses approximate their fair values due to their short-term maturity. The carrying value of the Company&#8217;s term loan approximates its fair value as the interest rate and other terms are that which are currently available to the Company. The Company&#8217;s </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_127679804" continuedAt="TextSelectionAppend_127679804_1"><ix:continuation id="TextSelectionAppend_127679738_8" continuedAt="TextSelectionAppend_127679738_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_9" continuedAt="TextSelectionAppend_127679738_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_10" continuedAt="TextSelectionAppend_127679738_11"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_11" continuedAt="TextSelectionAppend_127679738_12"><ix:continuation id="TextSelectionAppend_127679804_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">assets and liabilities recorded at fair value have been categorized based upon a fair value hierarchy, which is distinguished between observable and unobservable inputs in accordance with authoritative accounting guidance: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that the observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16733"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, which include the costs of material, labor, and overhead, are stated at the lower of cost or net realizable value, with cost generally computed using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> first out method. Estimated losses from obsolete and slow-moving inventories are recorded to reduce inventory values to their estimated net realizable value and are charged to cost of sales. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in a recovery in carrying value. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16740"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include computers, laboratory equipment, machinery, and leasehold improvements. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated on a straight-line basis over the shorter of the estimated life or the lease term. Expenditures for repairs and maintenance are expensed as incurred. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:InternalUseSoftwarePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16746"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Internal-Use</div> Software </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Software development costs consist of certain consulting costs and compensation expenses for employees who devote time to the development projects of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software, as well as certain upgrades and enhancements that are expected to result in enhanced functionality. The Company amortizes these development costs over the estimated useful life, which is determined based on our best estimate of the useful life of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software after considering factors such as continuous developments in the technology, obsolescence, and anticipated life of the service offering before significant upgrades. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined the amount of internal software costs to be capitalized based on the amount of time spent by our developers on projects in the application stage of development. There is judgment in estimating the time allocated to a particular project in the application stage. A significant change in the time spent on each project could have a material impact on the amount capitalized and related amortization expense in subsequent periods. As of December&#160;31, 2023 and 2022, capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software was immaterial. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16757"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </div></ix:nonNumeric> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_127679738_12" continuedAt="TextSelectionAppend_127679738_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679738_13" continuedAt="TextSelectionAppend_127679738_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_14" continuedAt="TextSelectionAppend_127679738_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_15" continuedAt="TextSelectionAppend_127679738_16"><ix:nonNumeric name="alur:DebtIssuanceCostsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16781"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt Issuance Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company defers costs directly associated with acquiring third-party financing. Fees incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. Fees incurred in connection with a modification are deferred and amortized as a component of interest expense over the remaining life of the loan if due to the creditor. Third-party fees incurred in connection with a <div style="letter-spacing: 0px; top: 0px;display:inline;">modification </div>are expensed as incurred. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16788"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the Business Combination. The Company deferred offering costs classified as a long-term asset until the closing or termination of the transaction. At the closing of the Business Combination, these costs were recorded in stockholders&#8217; deficit as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. Deferred offering costs are included in other long-term assets. As of December&#160;31, 2023 and 2022, there were <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2023_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-47692">zero</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47693">2.3</ix:nonFraction>&#160;million of deferred offering costs recorded within other long-term assets on the consolidated balance sheet, respectively. </div> </ix:nonNumeric><ix:nonNumeric name="alur:WarrantsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16795"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity </div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;ASC&#160;480-10&#8221;),</div> then in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock </div></div>(&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40&#8221;).</div> Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or are warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;480-10,</div> the Company assesses the requirements under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40</div> or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16814"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its convertible instruments and other contracts, including warrants, to determine if those contracts or embedded components of those contracts are required to be accounted for as derivatives, either in whole or in part. If an embedded derivative is bifurcated from a debt host contract, changes in the fair value of the bifurcated derivative are recorded in the accompanying consolidated statements of operations. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679813" id="ixv-16820"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the convertible notes issued between February 2023 and August 2023 (the &#8220;2023 Convertible Notes&#8221;) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The convertible notes accounted for under the FVO election were each debt host financial instruments containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the convertible notes were </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_127679813" continuedAt="TextSelectionAppend_127679813_1"><ix:continuation id="TextSelectionAppend_127679738_16" continuedAt="TextSelectionAppend_127679738_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_17" continuedAt="TextSelectionAppend_127679738_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_18" continuedAt="TextSelectionAppend_127679738_19"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_19" continuedAt="TextSelectionAppend_127679738_20"><ix:continuation id="TextSelectionAppend_127679813_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded as a component of Other (expense) income in the consolidated statements of operations. As a result of electing the FVO, direct costs and fees related to the 2023 Convertible Notes were expensed as incurred. The convertible notes issued in 2020, 2021 and 2022 are accounted for as disclosed in Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>. In connection with the closing of the Business Combination on August&#160;1, 2023, a portion of the 2023 convertible notes was repaid, with the remaining balance converted to shares of our Common Stock. </div></ix:continuation><ix:nonNumeric name="alur:EarnoutLiabilityPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16848"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain holders of Legacy Allurion common <div style="letter-spacing: 0px; top: 0px;display:inline;">stock </div>and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive up to <ix:nonFraction name="alur:BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" contextRef="P08_01_2023To08_01_2023_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47696">9,000,000</ix:nonFraction> additional shares of Allurion Common Stock (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Earn-Out</div> Shares&#8221;) upon the achievement of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> targets. The contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration contains a settlement provision that in the event of a change in control, the number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares issued may vary. This settlement provision precludes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liability from being indexed to the Company&#8217;s Common Stock as a change in control event is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">fixed-for-fixed</div></div> forward or option on equity shares. As such, it is classified as a liability under ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity </div></div>(&#8220;ASC 480&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration is remeasured on a quarterly basis over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> period with changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration recorded in Other (expense) income in the consolidated statements of operations, and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration may materially impact or cause volatility in our operating results. </div> </ix:nonNumeric><ix:nonNumeric name="alur:RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679816" id="ixv-16870"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a revenue interest financing agreement, dated as of February&#160;9, 2023 (the &#8220;Revenue Interest Financing Agreement&#8221;) with certain entities that have engaged RTW Investments, LP as investment manager (collectively, &#8220;RTW&#8221;), under which the Company received $<ix:nonFraction name="alur:ProceedsFromRevenueInterestFinancing" contextRef="P08_01_2023To08_01_2023_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47697">40.0</ix:nonFraction>&#160;million upfront (the &#8220;Revenue Interest Financing&#8221;). In exchange, the Company is obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to <ix:nonFraction name="alur:PercentageOfAnnualNetSales" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47698">6.0</ix:nonFraction>% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to <ix:nonFraction name="alur:RemittanceOfRevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47699">10.0</ix:nonFraction>% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for the Revenue Interest Financing Agreement under the fair value option election of ASC 825. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument that contains embedded features. The embedded features include requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events, a change in royalty rates upon the occurrence of certain contingent events, and the Company&#8217;s ability to prepay the Revenue Interest Financing. As the Company has elected the FVO, these embedded features would not meet the criteria for bifurcation and separate accounting as the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis on each reporting period date. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering in the Revenue Interest Financing, the Company and RTW entered into the RTW side letter under which RTW may elect to convert up to $<ix:nonFraction name="us-gaap:RevenuesNetOfInterestExpense" contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47700">7.5</ix:nonFraction>&#160;million of its initial PIPE (as </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div> <ix:continuation id="TextSelection_127679816" continuedAt="TextSelectionAppend_127679816_1"><ix:continuation id="TextSelectionAppend_127679738_20" continuedAt="TextSelectionAppend_127679738_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679738_21" continuedAt="TextSelectionAppend_127679738_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_22" continuedAt="TextSelectionAppend_127679738_23"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_23" continuedAt="TextSelectionAppend_127679738_24"><ix:continuation id="TextSelectionAppend_127679816_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">defined in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div>below) subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by the PIPE subscription (the &#8220;PIPE Conversion Option&#8221;). The Company accounts for the PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;). The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other (expense) income in the consolidated statements of operations. </div></ix:continuation><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16903"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable are unsecured and are carried at net realizable value, including an allowance for doubtful accounts. Trade credit is generally extended on a short-term basis; trade receivables do not bear interest, although a finance charge may be applied to such receivables that are past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors that may affect a customer&#8217;s ability to pay, such as historical expense, credit quality, <div style="letter-spacing: 0px; top: 0px;display:inline;">the </div>age of the account receivable balances, and current economic conditions. Amounts determined to be uncollectible are charged or written off against the allowance. </div> <ix:nonNumeric name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-16910"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity in the allowance for doubtful accounts: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2023&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2022&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47703">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47704">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47705">12,675</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47706">436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Uncollectible accounts written off</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47707">745</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47708">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47709">12,671</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47710">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679818" id="ixv-17015"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers </div></div>(&#8220;Topic 606&#8221; or &#8220;ASC 606&#8221;). In general, the Company&#8217;s sales contracts fall under its standard sales agreement whereby control transfers to the customer upon shipment, satisfying the performance obligations of the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when control of its products is transferred to customers at an amount that reflects the consideration it expects to receive in exchange for those products. The Company&#8217;s revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a good or service to the customer, meaning that such customer has the ability to use and obtain the benefit of the good or service. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has provided customers purchasing the Allurion Balloon with an implied license for access to its VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#8217;s contracts. Further, the customer contracts and related purchase orders do not include nor specify rights or obligations associated with the VCS software. Based on this assessment, the Company determined the implied license to be immaterial in the context of the contract with customers purchasing the Allurion Balloon, and as such did not allocate any value to the implied VCS license. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_127679818" continuedAt="TextSelectionAppend_127679818_1"><ix:continuation id="TextSelectionAppend_127679738_24" continuedAt="TextSelectionAppend_127679738_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_25" continuedAt="TextSelectionAppend_127679738_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_26" continuedAt="TextSelectionAppend_127679738_27"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_27" continuedAt="TextSelectionAppend_127679738_28"><ix:continuation id="TextSelectionAppend_127679818_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from sales of its Allurion Balloon to distributors and health care providers. Customers <div style="letter-spacing: 0px; top: 0px;display:inline;">typically </div>purchase the Allurion Balloon, including the gastric balloon and related accessories together, although customers can purchase the gastric balloon and its accessories separately. Therefore, each component of the Allurion Balloon and accessories represents a distinct performance obligation and is separately identifiable. In arrangements with multiple performance obligations, the transaction price is allocated to each performance obligation using the relative standalone selling price. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account internally approved pricing guidelines and market conditions. Revenue is generally recognized upon shipment of the product because at that point, the customer obtains control of the product and has the ability to direct the use and obtain the benefit of the product. Components of the Allurion Balloon are typically shipped to the customer together, resulting in the performance obligations in the contract being satisfied at the same time. Components shipped separately are recognized upon shipment at their relative standalone selling price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue at the transaction price, which reflects the consideration it believes it is entitled to receive. Transaction price includes estimates of variable consideration for promotions and prompt pay discounts, which are recorded as a reduction of transaction price in the period the related product revenue is recognized. The Company may also make payments to customers for marketing programs. Payments to customers for a distinct good or service that reasonably estimate the fair value of the distinct benefit received, such as marketing programs, are recorded as a marketing expense on the consolidated statement of operations and comprehensive loss. Shipping and logistics costs inclusive of these payments to customers and other costs included in sales and marketing expense for the years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To12_31_2023_ShippingAndHandlingMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47712">3.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2022To12_31_2022_ShippingAndHandlingMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47713">3.6</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses incremental costs of obtaining a contract, such as sales commissions, when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company&#8217;s consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the sales tax practical expedient; therefore, sales and other taxes assessed by a governmental authority that are collected concurrently with revenue-producing activities are excluded from the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the significant financing component practical expedient, which allows management to not assess whether the contract has a significant financing component in circumstances where, at contract inception, the expected contract duration is less than one year. </div></ix:continuation><ix:nonNumeric name="us-gaap:StandardProductWarrantyPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17049"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Warranty </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not provide general rights of return of products sold to its customers. However, the Company does provide for rights of exchange to its distributors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">end-use</div> customers for products that fail to conform to the Company&#8217;s specifications for a limited time following delivery. These performance specifications include that the Allurion Balloon (i)&#160;is successfully filled upon initial placement when used according to the instructions for use provided by the Company and/or (ii)&#160;remains in the patient&#8217;s <div style="letter-spacing: 0px; top: 0px;display:inline;">body </div>for 90 days or more once placed. Customers may exchange product within 30 calendar days if they discover product nonconformities through a reasonable inspection and within 30 calendar days after discovery of any hidden or latent product nonconformities that could not have been discovered by a reasonable inspection. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These instances of nonconformity have been immaterial, and the Company&#8217;s management expects instances of nonconformity to be extremely rare. </div> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_127679738_28" continuedAt="TextSelectionAppend_127679738_29"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679738_29" continuedAt="TextSelectionAppend_127679738_30"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_30" continuedAt="TextSelectionAppend_127679738_31"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_31" continuedAt="TextSelectionAppend_127679738_32"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17076"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses research and development costs as incurred. Research and development expenses consist of costs associated with performing research and development activities, including salaries and benefits, stock-based compensation, product development costs, materials and supplies, clinical trial activities, depreciation of equipment, and contract and other outside services. Payments for activities that are provided by outside vendors are based upon the terms of the individual arrangements with each vendor. Costs of certain of these activities are expensed based upon an evaluation of the progress to completion of specific tasks and actual costs incurred, using information provided to the Company by its vendors. As payments for these activities may differ from the pattern of costs actually incurred, additional costs are reflected in the consolidated financial statements as prepaid or accrued research and development expenses. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17082"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advertising and Marketing Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses advertising and marketing costs as incurred. Advertising and marketing expenses are included in sales and marketing operating expenses. Advertising and marketing costs for the years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47715">10.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47716">16.0</ix:nonFraction>&#160;million, respectively. </div> </ix:nonNumeric><ix:nonNumeric name="alur:IntellectualPropertyProsecutionCostsPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17088"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Intellectual Property Prosecution Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurs registration and prosecution costs related to its intellectual property. The related costs are expensed as incurred and are classified as a component of general and administrative expenses. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17094"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for net operating loss and tax credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines whether a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-47717"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-47718">no</ix:nonFraction></ix:nonFraction>t identified any uncertain tax positions for which reserves would be required. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679824" id="ixv-17101"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method to compute basic and diluted net loss per share attributable to common stockholders, when shares meet the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders less the cumulative undeclared dividend by the weighted average number of common shares outstanding for the period. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div><ix:continuation id="TextSelection_127679824" continuedAt="TextSelectionAppend_127679824_1"><ix:continuation id="TextSelectionAppend_127679738_32" continuedAt="TextSelectionAppend_127679738_33"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_33" continuedAt="TextSelectionAppend_127679738_34"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_34" continuedAt="TextSelectionAppend_127679738_35"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_35" continuedAt="TextSelectionAppend_127679738_36"><ix:continuation id="TextSelectionAppend_127679824_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Legacy Allurion Series D convertible preferred stock were contractually entitled to receive a cumulative dividend, whether or not declared, and therefore, Legacy Allurion Series D convertible preferred stocks were participating securities. The holders of all other redeemable and convertible preferred stock were not entitled to cumulative dividends. The preferred equity holders were also not contractually required to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination with Compute Health, the Company&#8217;s equity in previous periods has been retroactively adjusted to the earliest period presented to reflect the equivalent number of shares of Allurion Common Stock issued to the Company&#8217;s stockholders in connection with the Business Combination. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Business Combination. See Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>, for details of the Business Combination. </div></ix:continuation><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17133"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense for awards based on the grant-date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The Company accounts for awards issued to nonemployees under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2018-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (&#8220;Topic 718&#8221;): Improvements to Nonemployee Share-Based Payment Accounting</div></div>, with the measurement date for nonemployee awards being the date of grant. The fair value of stock options is calculated using the Black-Scholes option-pricing model. The fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is based on the fair market value of common stock at the date of grant. The Company records forfeitures as they occur. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17142"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, comprehensive loss consists of net loss and other comprehensive loss, which includes changes in the fair value attributable to instrument-specific credit risk related to the Revenue Interest Financing with RTW. There were no differences between net loss and comprehensive loss presented in the statements of operations and comprehensive loss for the year ended December&#160;31, 2022. </div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679829" id="ixv-17148"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses: <div style="letter-spacing: 0px; top: 0px;display:inline;">Measurement </div>of Credit Losses on Financial Instruments (Topic 326)</div></div>. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets such as available for sale debt securities, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-47720">adopted</ix:nonNumeric> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> effective <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:date-monthname-day-year-en" id="ixv-47721">January 1, 2023</ix:nonNumeric> under the prospective transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-47722">did not</ix:nonNumeric> have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div> <ix:continuation id="TextSelection_127679829" continuedAt="TextSelectionAppend_127679829_1"><ix:continuation id="TextSelectionAppend_127679738_36" continuedAt="TextSelectionAppend_127679738_37"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679738_37" continuedAt="TextSelectionAppend_127679738_38"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679738_38" continuedAt="TextSelectionAppend_127679738_39"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679738_39"><ix:continuation id="TextSelectionAppend_127679829_1"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</div></div>, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The Company does not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> to have a material impact on its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</div></div> which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which require public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div></ix:continuation></ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679742" id="ixv-17200">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Business Combination </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately <ix:nonFraction name="alur:BusinessCombinationCommonStockExchangeRatio" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-47724">0.9780</ix:nonFraction>, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Allurion Common Stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio (&#8220;Rollover Option&#8221;), (d) each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#8220;Rollover Warrant&#8221;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#8220;Sponsor&#8221;) to CPUH, which balance was $<ix:nonFraction name="alur:SponsorLoanExcessAmount" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47725">3.7</ix:nonFraction>&#160;million at the time of the Business Combination (the &#8220;Sponsor Loan Excess&#8221;), was converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47726">525,568</ix:nonFraction> shares of Allurion Common Stock (the &#8220;Sponsor Loan Equity Issuance&#8221;). For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47727">1.420455</ix:nonFraction> </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude></div> </ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_127679742" continuedAt="TextSelectionAppend_127679742_1"><div></div></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_127679742_1" continuedAt="TextSelectionAppend_127679742_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_2" continuedAt="TextSelectionAppend_127679742_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_3" continuedAt="TextSelectionAppend_127679742_4"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679742_4" continuedAt="TextSelectionAppend_127679742_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shares of Allurion Common Stock. Additionally, the Company assumed <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47730">13,206,922</ix:nonFraction> outstanding public warrants to purchase an aggregate <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P08_01_2023To08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47731">18,759,838</ix:nonFraction> shares of Allurion Common Stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47732">8.10</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company incurred approximately $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47733">22.7</ix:nonFraction>&#160;million of transaction costs, consisting of legal and other professional fees, $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47734">15.2</ix:nonFraction>&#160;million of which were recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital as a reduction of proceeds, $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47735">2.5</ix:nonFraction>&#160;million of which were recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47736">5.0</ix:nonFraction>&#160;million of which were recorded as an expense in general and administrative expenses on the consolidated statement of operations and comprehensive loss. Of the $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P08_01_2023To08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47737">5.0</ix:nonFraction>&#160;million recorded as expense, $<ix:nonFraction name="alur:BusinessCombinationOneTimeInsurancePayment" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47738">3.6</ix:nonFraction>&#160;million relates to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $<ix:nonFraction name="alur:DirectCostsAndFees" contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47739">1.2</ix:nonFraction>&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW. </div><ix:nonNumeric name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17237"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47740">38,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47741">37,922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47742">76,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:BusinessCombinationTransactionCostPaid" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47743">14,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NetProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47744">61,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:WarrantLiabilitiesAssumed" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47745">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:RepaymentOfNoteAssumedInBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47746">2,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:BusinessAcquisitionAccruedTransactionCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47747">580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:BusinessCombinationNetOfTransactionCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47748">44,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Net proceeds from the Business Combination, less the repayment of note assumed in the Business Combination, less the accrued transaction costs at December&#160;31, 2023 are presented net in the consolidated statements of stockholders deficit within line &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221;. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The warrant liabilities assumed are presented separately from the &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221; line within the consolidated statements of stockholders deficit. </div></td></tr></table> </ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679841" id="ixv-17361"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47749">27,897,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47750">5,165,698</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47751">5,386,695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47752">1,900,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47753">3,301,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47754">3,262,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47755">387,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47756">47,301,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stockholders, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur <div style="letter-spacing: 0px; top: 0px;display:inline;">Contributed </div>Shares (as defined below). </div></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude></div></ix:nonNumeric></ix:continuation> </div></div> <ix:continuation id="TextSelection_127679841" continuedAt="TextSelectionAppend_127679841_1"><ix:continuation id="TextSelectionAppend_127679742_5" continuedAt="TextSelectionAppend_127679742_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679742_6" continuedAt="TextSelectionAppend_127679742_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_7" continuedAt="TextSelectionAppend_127679742_8"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679742_8" continuedAt="TextSelectionAppend_127679742_9"><ix:continuation id="TextSelectionAppend_127679841_1">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table></ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023 (the &#8220;PIPE Subscription Agreements&#8221;), with certain accredited investors and qualified institutional buyers (the &#8220;PIPE Investors&#8221;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47758">5,386,695</ix:nonFraction> shares of Allurion Common Stock at a purchase price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47759">7.04</ix:nonFraction> per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47760">37.9</ix:nonFraction>&#160;million, following the CPUH Merger Effective Time (the &#8220;PIPE Investment&#8221;). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement with RTW. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $<ix:nonFraction name="alur:ProceedsFromRevenueInterestFinancing" contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47761">40.0</ix:nonFraction>&#160;million (the &#8220;Investment Amount&#8221;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to <ix:nonFraction name="alur:PercentageOfAnnualNetSales" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-47762">6.0</ix:nonFraction>% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to <ix:nonFraction name="alur:RemittanceOfRevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-47763">10.0</ix:nonFraction>% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the Company entering in the Revenue Interest Financing, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#8220;RTW Side Letter&#8221;) on February&#160;9, 2023 under which RTW may elect to convert up to $<ix:nonFraction name="alur:ConversionOfPipeSubscriptionToRevenueInterestFinance" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47764">7.5</ix:nonFraction>&#160;million of its initial PIPE subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion common stock acquired by its PIPE Investment. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#8220;Amended and Restated RTW Side Letter&#8221;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47765">250,000</ix:nonFraction> shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Credit Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#8220;Fortress Term Loan&#8221;) pursuant to a credit agreement and guaranty, dated as of August&#160;1, 2023 (the &#8220;Fortress Credit Agreement&#8221;), with Fortress Credit Corp. (&#8220;Fortress&#8221;), as administrative agent for the lenders party thereto from time to time (the &#8220;Lenders&#8221;). Under the terms of the Fortress Term Loan, we borrowed $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-47766">60.0</ix:nonFraction>&#160;million which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement, Allurion issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47767">950,000</ix:nonFraction> shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for further discussion on the Fortress Term Loan. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_127679742_9" continuedAt="TextSelectionAppend_127679742_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_10" continuedAt="TextSelectionAppend_127679742_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_11" continuedAt="TextSelectionAppend_127679742_12"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679742_12" continuedAt="TextSelectionAppend_127679742_13"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Backstop Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#8220;Backstop Purchasers&#8221;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#8220;HVL&#8221;) entered into the backstop agreement (the &#8220;Backstop Agreement&#8221;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing (a)&#160;each Backstop Purchaser purchased $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47769">2</ix:nonFraction>&#160;million of the aggregate principal amount outstanding of HVL&#8217;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47770">2</ix:nonFraction>&#160;million each and (d)&#160;Allurion issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47771">700,000</ix:nonFraction> shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion around the Backstop Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">HVL Termination Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#8220;HVL Termination Agreement&#8221;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#8217;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47772">387,696</ix:nonFraction> shares of Allurion Common Stock. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion regarding the HVL Termination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gaur Contribution Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#8220;Gaur Trust&#8221;) and Allurion entered into a contribution agreement (the &#8220;Gaur Contribution Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, <ix:nonFraction name="alur:ContributionOfCapitalByJointVenturePartner" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47773">79,232</ix:nonFraction> shares of Allurion Common Stock (the &#8220;Gaur Trust Contributed Shares&#8221;). The Gaur Trust&#8217;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">RSU Forfeiture Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Krishna Gupta, a member of our Board of Directors, entered into a letter agreement with Legacy Allurion (the &#8220;RSU Forfeiture Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47774">79,232</ix:nonFraction> restricted stock units of Allurion (the &#8220;Forfeited RSUs&#8221;). The Forfeited RSUs were terminated and cancelled without consideration therefore immediately following the closing of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Contribution Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#8220;Sponsor Contribution Agreement&#8221;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, <ix:nonFraction name="alur:ContributionOfCapitalByJointVenturePartner" contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47775">161,379</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock (&#8220;Sponsor Contributed Shares&#8221;). The Sponsor&#8217;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion entered into a support agreement (the &#8220;Sponsor Support Agreement&#8221;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude></div></ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_127679742_13" continuedAt="TextSelectionAppend_127679742_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679742_14" continuedAt="TextSelectionAppend_127679742_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679742_15" continuedAt="TextSelectionAppend_127679742_16"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679742_16"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Sponsor&#8217;s <ix:nonFraction name="alur:RecapitalizationOfCommonStock" contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47778">21,442,500</ix:nonFraction> shares of Compute Health Class&#160;B Common Stock, and all <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47779">12,833,333</ix:nonFraction> of the Sponsor&#8217;s warrants to purchase shares of Class&#160;A Common Stock, into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47780">2,088,327</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement (the &#8220;Additional Class&#160;B Holders&#8221;) recapitalized his or her <ix:nonFraction name="alur:RecapitalizationOfAdditionalShares" contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47781">30,000</ix:nonFraction> shares of Compute Health Class&#160;B Common Stock into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47782">21,120</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock (the &#8220;CPUH Recapitalization&#8221;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47783">1.420455</ix:nonFraction> (the &#8220;CPUH Exchange Ratio&#8221;). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion of Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $<ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47784">21.8</ix:nonFraction>&#160;million were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47785">3,301,222</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital (&#8220;APIC&#8221;) of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47786">25.6</ix:nonFraction>&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further information on the Company&#8217;s convertible notes. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants and Warrant Amendment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company assumed <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47787">13,206,922</ix:nonFraction> outstanding Public Warrants (defined below) to purchase an aggregate <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P08_01_2023To08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47788">18,759,838</ix:nonFraction> shares of Allurion Common Stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47789">8.10</ix:nonFraction> per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47790">13.8</ix:nonFraction>&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-share</div> settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capital Stock and Stockholders&#8217; Deficit</div></div> and Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the Public Warrants and Warrant Amendment. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the shares price achieves certain targets. The Company accounts for the potential issuance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares as a contingent consideration arrangement, which was initially valued and recorded at $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47791">53.0</ix:nonFraction>&#160;million. See Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679745" id="ixv-17604">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue </div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17613"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is domiciled and is summarized by geographic area as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47792">5,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47793">6,032</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47794">5,494</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47795">4,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_ESsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47796">4,618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ESsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47797">6,852</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_CLsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47798">2,708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_CLsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47799">5,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47800">35,078</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47801">42,240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47802">53,467</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47803">64,211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_127679745" continuedAt="TextSelectionAppend_127679745_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679745_1" continuedAt="TextSelectionAppend_127679745_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679745_2" continuedAt="TextSelectionAppend_127679745_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679745_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2023To12_31_2023_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-47805">no</ix:nonFraction> revenue generated in the United States. For the year ended December&#160;31, 2023, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47806">13.3</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47807">four</ix:nonFraction> countries included within All other countries in the table above, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47808">25</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47809">5</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47810">9</ix:nonFraction>%</div> of the total. The remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47811">55</ix:nonFraction> other countries included within All other countries. For the year ended December&#160;31, 2022, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47812">16.0</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-47813">four</ix:nonFraction> countries included within All other countries, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47814">25</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47815">6</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47816">7</ix:nonFraction>%</div> of the total. Remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47817">50</ix:nonFraction> other countries included within All other countries. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17759">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventory </div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17768"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47818">3,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47819">2,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47820">967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47821">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47822">1,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47823">1,556</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47824">6,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47825">3,865</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is stated net of less than $<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47826">0.1</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-47827">zero</ix:nonFraction> for the provision of excess and obsolete inventory as of December&#160;31, 2023 and 2022, respectively. </div> </ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17875">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and Equipment, net </div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-17884"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:22%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimates Useful Life<br/> (in Years)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-47828">3</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47829">618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47830">575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47831">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47832">1,822</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-47833">5</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47834">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47835">251</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-47836">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-47837">5</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47838">2,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47839">2,002</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47840">5,745</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47841">4,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Less accumulated depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47842">3,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47843">2,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Construction in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ConstructionInProgress" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47844">1,195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ConstructionInProgress" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47845">583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47846">3,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47847">2,382</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfDepreciationExpenseTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18110"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47848">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47849">0.9</ix:nonFraction>&#160;million for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023 and 2022, respectively, recorded as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47850">367</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47851">568</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47852">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47853">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47854">138</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47855">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47856">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2022To12_31_2022_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47857">57</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47858">746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-hidden:hidden127682954;display:inline;">875</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-25</div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </div> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18240">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accrued Expenses and Other Current Liabilities </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18249"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributor fees and marketing reimbursements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DistributorFeesAndMarketingReimbursements" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47859">2,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DistributorFeesAndMarketingReimbursements" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47860">6,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47861">1,687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47862">3,453</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedClinicalTrialsAndResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47863">3,694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedClinicalTrialsAndResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47864">228</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47865">1,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47866">481</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47867">1,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47868">2,105</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47869">489</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StandardProductWarrantyAccrualCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47870">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StandardProductWarrantyAccrualCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47871">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedRestructuringCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47872">655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47873">3,966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47874">2,641</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47875">15,495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47876">15,793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with strategic initiatives implemented during the period ended December&#160;31, 2023, the Company&#8217;s management approved and initiated plans to reduce its cost structure. The Company recorded $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47877">1.0</ix:nonFraction>&#160;million of restructuring charges during the year ended December&#160;31, 2023, of which $<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47878">0.4</ix:nonFraction>&#160;million has been paid as of December&#160;31, 2023. The restructuring charges are included in operating expenses in the statement of operations. Substantially all of this charge represents the severance cost of terminated employees. </div></ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679758" id="ixv-18422">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Debt </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18431"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consisted of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47879">43,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021 Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47880">55,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47881">3,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47882">43,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47883">58,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:LoanAccretion" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47884">148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:LoanAccretion" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47885">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47886">38,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47887">53,360</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47888">4,605</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-47889">1,853</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47890">3,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the fair value for the Company&#8217;s Fortress Term Loan and 2021 Term Loan approximated the respective carrying amounts. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Term Loans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Term Loan </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company entered into a loan and security agreement (as amended, the &#8220;2021 Term Loan&#8221; and the &#8220;2021 Term Loan Agreement&#8221;) with Runway Growth Credit Fund, Inc. (&#8220;Runway&#8221;) that provided initial cash proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P03_01_2021To03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47891">15.0</ix:nonFraction>&#160;million, all of which was drawn down in March 2021 and provided for additional borrowings of up to $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-47892">10.0</ix:nonFraction>&#160;million, in $<ix:nonFraction name="alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" contextRef="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47893">5.0</ix:nonFraction>&#160;million increments, based upon the achievement of certain revenue thresholds within specified time periods, as defined in the 2021 Term Loan Agreement. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679758" continuedAt="TextSelectionAppend_127679758_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_1" continuedAt="TextSelectionAppend_127679758_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_2" continuedAt="TextSelectionAppend_127679758_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679758_3" continuedAt="TextSelectionAppend_127679758_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the 2021 Term Loan Agreement was amended (the &#8220;Amendment&#8221;) to extend the maturity date of the 2021 Term Loan to <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-47895">December 30, 2025</ix:nonNumeric> and provide for an additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47896">20.0</ix:nonFraction>&#160;million of borrowings, of which $<ix:nonFraction name="alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47897">15.0</ix:nonFraction>&#160;million (the &#8220;Term C Loan&#8221;) was available based upon the achievement of certain revenue thresholds within specified time periods as defined in 2021 Term Loan Agreement as amended. The agreement provided for equal monthly principal payments to commence on <ix:nonNumeric name="us-gaap:LineOfCreditFacilityDateOfFirstRequiredPayment1" contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-47898">December 30, 2024</ix:nonNumeric> such that the borrowed principal amounts would be repaid in full on December&#160;30, 2025. However, if certain revenue thresholds were achieved prior to April&#160;15, 2023, the borrowed principal amounts would be repaid in full on December&#160;30, 2025. The revenue thresholds were achieved in June 2022. In connection with the 2021 Term Loan, the Company paid issuance costs of $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47899">0.7</ix:nonFraction>&#160;million which were amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company issued warrants exercisable for <ix:nonFraction name="alur:ExercisableWarrantsIssuedAsConsideration" contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47900">132,979</ix:nonFraction> shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $<ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47901"><ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47902">0.3</ix:nonFraction></ix:nonFraction>&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheet as of December&#160;31, 2023 and 2022 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47903">130,053</ix:nonFraction> shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and financial covenant. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things: (1)&#160;<ix:nonNumeric name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" contextRef="P01_01_2023To12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" id="ixv-18637">change the interest rate to the higher of the prime rate or <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47904">3.25</ix:nonFraction>% <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">plus </div></div>the applicable margin of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="7" scale="-2" format="ixt:num-dot-decimal" id="ixv-47905">6.44186</ix:nonFraction>%,</ix:nonNumeric> (2) extend the maturity date of its outstanding term loans from December&#160;30, 2025 to <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-47906">December 30, 2026</ix:nonNumeric>, and (3)&#160;increase additional borrowing up to $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-47907">15.0</ix:nonFraction>&#160;million (the &#8220;Term D Loan&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During June through September of 2022, the Company drew an additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47908">15.0</ix:nonFraction>&#160;million of the Term C Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. In connection with the Term C Loan under the 2021 Term Loan, the Company paid issuance costs of $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47909">0.3</ix:nonFraction>&#160;million, which were amortized over the remaining life of the loan. Upon the additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47910">15.0</ix:nonFraction>&#160;million draw on the Term C Loan, warrants exercisable for <ix:nonFraction name="alur:ExercisableWarrantsIssuedAsConsideration" contextRef="P06_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47911">44,220</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were issued. In 2022, the Company recorded a warrant liability of $<ix:nonFraction name="alur:WarrantLiability" contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47912">0.4</ix:nonFraction>&#160;million in connection with the Term C Loan on the consolidated balance sheets. In September 2022, in connection with the amendment of the 2021 Term Loan, the Company committed to issue warrants exercisable for an additional <ix:nonFraction name="alur:ExercisableWarrantsIssuedAsConsideration" contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47913">44,220</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock if the Company drew on the entire Term D Loan. The fair value of these warrants was determined to be $<ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47914"><ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47915">0.4</ix:nonFraction></ix:nonFraction>&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of December&#160;31, 2023 and 2022 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, the warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47916">88,440</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were converted into warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47917">90,476</ix:nonFraction> shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During October through December of 2022, the Company drew an additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47918">15.0</ix:nonFraction>&#160;million of the Term D Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47919">58.0</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="alur:RepaymentOfPrincipal" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47920">55.0</ix:nonFraction>&#160;million repayment of principal, a $<ix:nonFraction name="alur:PrepaymentFee" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47921">1.1</ix:nonFraction>&#160;million prepayment fee, and a $<ix:nonFraction name="alur:FinalPaymentFee" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47922">1.6</ix:nonFraction>&#160;million final payment fee. The prepayment fee was calculated as <ix:nonFraction name="alur:PrepaymentFeePercentage" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47923">2</ix:nonFraction>% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as <ix:nonFraction name="alur:FinalPaymentFeePercentage" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47924">3</ix:nonFraction>% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $<ix:nonFraction name="alur:OriginalFinalPayment" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47925">0.1</ix:nonFraction>&#160;million. The Company recorded a $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-47926">3.9</ix:nonFraction>&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2023 related to the 2021 Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47927">5.0</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47928">4.7</ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47929">0.1</ix:nonFraction>&#160;million amortization of debt discount, $<ix:nonFraction name="alur:AmortizationOfTheWarrant" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47930">0.1</ix:nonFraction>&#160;million <div style="letter-spacing: 0px; top: 0px;display:inline;">amortization </div>of warrant, and $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47931">0.1</ix:nonFraction>&#160;million term loan accretion. Interest expense for the year ended December&#160;31, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-27</ix:exclude></div></ix:continuation></div></div> </div><ix:continuation id="TextSelectionAppend_127679758_4" continuedAt="TextSelectionAppend_127679758_5"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_127679758_5" continuedAt="TextSelectionAppend_127679758_6"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div></div></ix:continuation></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679758_6" continuedAt="TextSelectionAppend_127679758_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2022 was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47934">4.3</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47935">3.8</ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47936">0.2</ix:nonFraction>&#160;million amortization of debt discount, $<ix:nonFraction name="alur:AmortizationOfTheWarrant" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47937">0.1</ix:nonFraction>&#160;million amortization of warrant, and $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47938">0.2</ix:nonFraction>&#160;million term loan accretion.&#8195; </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47939">60</ix:nonFraction>&#160;million. <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis" id="ixv-47940">The Fortress Term Loan has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-47941">June 30, 2027</ix:nonNumeric> and accrues interest per annum at a rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47942">6.44</ix:nonFraction>% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47943">3.0</ix:nonFraction>%, which interest is payable in arrears on a monthly basis. An exit payment equal to <ix:nonFraction name="alur:DebtInstrumentExitPaymentPercentage" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47944">3.0</ix:nonFraction>% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) is due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.</ix:nonNumeric> The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47945">2.5</ix:nonFraction>&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#8220;Fortress Amendment&#8221;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47946">12.5</ix:nonFraction>&#160;million to $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47947">33.5</ix:nonFraction>&#160;million until March&#160;31, 2024, $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47948">23.5</ix:nonFraction>&#160;million from April&#160;1, 2024 to June 30, 2024, $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47949">16.9</ix:nonFraction>&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47950">12.5</ix:nonFraction>&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provides that at any time after March&#160;31, 2024, each lender will have the right to convert a portion of the outstanding principal amount, not to exceed the lender&#8217;s proportionate share of a maximum of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47951">20.0</ix:nonFraction>&#160;million in aggregate outstanding principal amount, into shares of Common Stock of the Company at a conversion price based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> volume weighted average price (&#8220;VWAP&#8221;) of the Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#8217;s conversion right (the &#8220;Fortress Conversion Option&#8221;). As part of the Fortress Amendment, the Company prepaid $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47952">20.0</ix:nonFraction>&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47953">3.1</ix:nonFraction>&#160;million of fees were incurred and considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in-kind</div></div> and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees will be amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470. In connection with the modification and related prepayment, the Company wrote off $<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47954">0.8</ix:nonFraction>&#160;million of the unamortized debt issuance costs which was recorded within Interest expense on the consolidated statement of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fortress Credit Agreement contains certain financial reporting and other covenants, including the maintenance of a minimum liquidity amount and maintenance of minimum product revenues over trailing twelve-month periods. Upon the occurrence of an event of default, the Lenders may declare all outstanding obligations immediately due and payable as well as increase the interest rate <ix:nonFraction name="alur:DebtInstrumentInterestRateIncreaseEventOfDefault" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47955">3.0</ix:nonFraction>% above the rate that is otherwise applicable. The Company has determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern (see Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>) and there is a risk that it may not meet its covenants under the Fortress Term Loan in the future. Therefore, the amounts due as of December&#160;31, 2023 have been classified as a current liability in the consolidated financial statements. The Company is in compliance with all covenants as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of <ix:nonFraction name="alur:DebtInstrumentDefaultInterestRate" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-47956">3</ix:nonFraction>% which will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#8220;Term Loan Derivative Liability&#8221;) that is required to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-remeasured</div> at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679758_7" continuedAt="TextSelectionAppend_127679758_8"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_8" continuedAt="TextSelectionAppend_127679758_9"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_9" continuedAt="TextSelectionAppend_127679758_10"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679758_10" continuedAt="TextSelectionAppend_127679758_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">derivative was determined to be immaterial. The fair value of the Term Loan Derivative Liability was $<ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47959">1.9</ix:nonFraction>&#160;million as of December&#160;31, 2023, with a corresponding recognition of Other income (expense), net in the consolidated statement of operations. The Company classified the Term Loan Derivative Liability as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> liability within Other liabilities on the balance sheet as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense from August&#160;1, 2023 through December&#160;31, 2023 related to the Fortress Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47960">4.1</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">million</div>, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47961">3.8</ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47962">0.2</ix:nonFraction>&#160;million amortization of the debt discount, and term loan accretion of $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47963">0.1</ix:nonFraction>&#160;million. The average interest rate of the Fortress Term Loan during the year ended December&#160;31, 2023 was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-47964">14.94</ix:nonFraction>%. </div><ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18702"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scheduled future maturities of the Fortress Term Loan for years subsequent to December&#160;31, 2023 are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47965">8,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47966">34,121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-47967">43,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Convertible Notes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company entered into a convertible note agreement with an investor for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47968">2.0</ix:nonFraction>&#160;million with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-47969">5.0</ix:nonFraction>% per annum (the &#8220;2021 Convertible Notes&#8221;) and a maturity date <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-47970">36 months</ix:nonNumeric> from the date of issuance unless previously converted pursuant to their terms of the agreement. <ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-47971">No</ix:nonFraction> issuance costs were incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#8220;deSPAC&#8221;) transaction, closing of a qualified financing, or closing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> financing, all of the outstanding principal and interest would automatically convert into common shares or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $<ix:nonFraction name="alur:ConversionDividedByCappedConversionPrice" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47972">600.0</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2021 Convertible Notes was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47973"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47974">0.1</ix:nonFraction></ix:nonFraction>&#160;million, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47975">133,617</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47976">2.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2022 Convertible Notes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, the Company entered into a convertible note agreement with investors for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47977">1.1</ix:nonFraction>&#160;million with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-47978">5.0</ix:nonFraction>% per annum (the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes mature <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-47979">36 months</ix:nonNumeric> from the issuance date unless previously converted pursuant to their terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2022 Convertible Notes was less than $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47980">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47981">0.2</ix:nonFraction>&#160;million, respectively, consisting entirely of contractual interest. Interest expense </div> </ix:continuation><ix:continuation id="TextSelectionAppend_127679758_11" continuedAt="TextSelectionAppend_127679758_12"><ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-29</div> </ix:exclude></ix:continuation></div></div> <ix:continuation id="TextSelectionAppend_127679758_12" continuedAt="TextSelectionAppend_127679758_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679758_13" continuedAt="TextSelectionAppend_127679758_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_14" continuedAt="TextSelectionAppend_127679758_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679758_15" continuedAt="TextSelectionAppend_127679758_16"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">related to the 2022 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47982">83,216</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47983">1.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of the 2023 Convertible Notes to certain investors for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47984">28.7</ix:nonFraction>&#160;million, with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-47985">7.0</ix:nonFraction>% per annum. The 2023 Convertible Notes provided that they would mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-47986">December 31, 2026</ix:nonNumeric> unless previously converted pursuant to the terms of their agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $<ix:nonFraction name="alur:ConversionDividedByDiscountedCappedConversionPrice" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47987">217.3</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. Additionally, the 2023 Convertible Notes provide that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into common shares or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $<ix:nonFraction name="alur:CappedPrice" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47988">260.0</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2023 related to the 2023 Convertible Notes was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47989">0.5</ix:nonFraction>&#160;million, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023 the Company entered into termination agreements (the &#8220;Termination Agreements&#8221;) with respect to side letters entered into with certain holders of Legacy Allurion Convertible Notes. With respect to the Termination Agreement with one of the side letter holders (the &#8220;Side Letter Holder&#8221;), the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under the 2023 Convertible Note (the &#8220;Side Letter Holder Bridge Note&#8221;), including by way of (a)&#160;a $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47990">2</ix:nonFraction>&#160;million payment in cash by the Company to the Side Letter Holder on May&#160;<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47991">2</ix:nonFraction>, 2023, $<ix:nonFraction name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47992">1.5</ix:nonFraction>&#160;million of which is deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $<ix:nonFraction name="alur:RepaymentOfPrincipal" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47993">0.5</ix:nonFraction>&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_MinimumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-47994">6</ix:nonFraction>&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the Side Letter Holder Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the Side Letter Holder Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Termination Agreement executed with the Side Letter Holder, the Company agreed to issue to the Side Letter Holder a number of shares of Allurion Common Stock (&#8220;PubCo Additional Shares&#8221;) </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679758_16" continuedAt="TextSelectionAppend_127679758_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_17" continuedAt="TextSelectionAppend_127679758_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679758_18" continuedAt="TextSelectionAppend_127679758_19"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679758_19"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">equal to (a)&#160;the outstanding principal and accrued interest under the Side Letter Holder Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $<ix:nonFraction name="alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-47997">5.00</ix:nonFraction>, plus (b) <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-47998">300,000</ix:nonFraction> shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the PubCo Additional Shares are issued. A $<ix:nonFraction name="alur:DeferredLiabilityForIssuanceOfAdditionalShares" contextRef="PAsOn05_02_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-47999">3.4</ix:nonFraction>&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the consolidated balance sheet and the related expense recorded through Other income (expense) on the consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2023. On August&#160;1, 2023, upon closing of the Business Combination, the Side Letter Holder was issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48000">387,696</ix:nonFraction> PubCo Additional Shares with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48001">2.7</ix:nonFraction>&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further on May&#160;2, 2023, RTW and Fortress (the &#8220;Backstop Purchasers&#8221;) entered into the Backstop Agreement with the Company, Legacy Allurion and the Side Letter Holder. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any Side Letter Holder Bridge Notes remain outstanding prior to the consummation of the Business Combination, such Backstop Purchaser will, at the closing of the Business Combination, purchase up to $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48002">2.0</ix:nonFraction>&#160;million of the Side Letter Holder Bridge Notes from the Side Letter Holder in exchange for shares of Allurion Common Stock (the &#8220;Base PubCo Shares&#8221;, &#8220;Backstop Shares&#8221; and &#8220;Conditional Additional PubCo Shares&#8221;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares are issued. A $<ix:nonFraction name="alur:DeferredLiabilityForIssuanceOfAdditionalShares" contextRef="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48003">3.3</ix:nonFraction>&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the consolidated balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and the Backstop Agreement, the Backstop Purchasers were each issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48004">950,000</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48005">13.4</ix:nonFraction>&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48006">6.3</ix:nonFraction>&#160;million of the Side Letter Holder Bridge Note, leaving a principal balance of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48007">6.3</ix:nonFraction>&#160;million. Each Backstop Purchaser then purchased $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48008">2.0</ix:nonFraction>&#160;million principal amount of the outstanding portion of the Side Letter Holder Bridge Note, Allurion canceled the existing Side Letter Holder Bridge Note and issued a new convertible note to the Side Letter Holder for the remaining balance together with all unpaid interest accrued since the date of issuance of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48009">2.7</ix:nonFraction>&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48010">2.0</ix:nonFraction>&#160;million each and Allurion issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48011">700,000</ix:nonFraction> shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48012">3,084,389</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48013">22.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679761" id="ixv-18817">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of $<ix:nonFraction name="alur:RevenuesInterestFinancingLiability" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48014">40.0</ix:nonFraction>&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to <ix:nonFraction name="alur:PercentageOfAnnualNetSales" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48015">6.0</ix:nonFraction>% of annual net sales prior to December&#160;31, 2026. On or after January&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">1</div>, 2027, the Company will remit revenue interest payments at a rate up to <ix:nonFraction name="alur:RemittanceOfRevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48016">10.0</ix:nonFraction>% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-31</ix:exclude></div> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_127679761" continuedAt="TextSelectionAppend_127679761_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679761_1" continuedAt="TextSelectionAppend_127679761_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679761_2" continuedAt="TextSelectionAppend_127679761_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679761_3" continuedAt="TextSelectionAppend_127679761_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">up to <ix:nonFraction name="alur:CashPaymentsPercentage" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48019">100</ix:nonFraction>% of the Investment Amount. If RTW has not received revenue interest payments equal to at least <ix:nonFraction name="alur:RevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48020">240</ix:nonFraction>% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to <ix:nonFraction name="alur:CashPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48021">240</ix:nonFraction>% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of <ix:nonFraction name="alur:RevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48022">260</ix:nonFraction>% of the Investment Amount (the &#8220;Hard Cap&#8221;). In addition, prior to December&#160;31, 2025, the Company may prepay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-specified</div> payment amount (the &#8220;Prepayment Amount&#8221;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to <ix:nonFraction name="alur:PrePaymentsPercentage" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48023">165</ix:nonFraction>% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and <div style="letter-spacing: 0px; top: 0px;display:inline;">separate </div>accounting. The Revenue Interest Financing is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. For the year ended December&#160;31, 2023, the Company recorded a $<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancing" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48024">3.4</ix:nonFraction>&#160;million gain and a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-48025">0.7</ix:nonFraction>&#160;million loss through the consolidated statements of operations and other comprehensive loss, respectively. In connection with the issuance of the Investment Amount, we paid $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48026">1.2</ix:nonFraction>&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election. As of December&#160;31, 2023, the Company has made $<ix:nonFraction name="alur:RoyaltyPayments" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48027">1.1</ix:nonFraction>&#160;million in royalty payments to RTW. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the Revenue Interest Financing and PIPE Subscription Agreement (as discussed in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>), on February&#160;9, 2023, Legacy Allurion entered into the RTW Side Letter with RTW, subsequently amended on May&#160;2, 2023. The Amended and Restated RTW Side Letter amended and restated the existing RTW Side Letter in its entirety, in order to reflect that any conditional additional shares issuable to RTW would be calculated net of any Backstop Shares issuable to RTW under the Backstop Agreement. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for discussion around the additional shares issued to RTW in connection with the Amended and Restated RTW Side Letter and Backstop Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $<ix:nonFraction name="alur:VolumeWeightedAveragePricePerShare" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48028">7.04</ix:nonFraction> for the average of <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_Days" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48029">20</ix:nonFraction> trading days within any <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_Days" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48030">30</ix:nonFraction> trading day period (&#8220;Stock Price Drop&#8221;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48031">10.00</ix:nonFraction> per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $<ix:nonFraction name="alur:ConversionOfPipeSubscriptionToRevenueInterestFinance" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48032">7.5</ix:nonFraction>&#160;million of its initial PIPE subscription into additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE subscription. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48033">3.3</ix:nonFraction>&#160;million within Other liabilities on the consolidated balance sheet with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other <div style="letter-spacing: 0px; top: 0px;display:inline;">income </div>(expense). </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-32</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679761_4" continuedAt="TextSelectionAppend_127679761_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679761_5" continuedAt="TextSelectionAppend_127679761_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679761_6" continuedAt="TextSelectionAppend_127679761_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679761_7"><ix:nonNumeric name="alur:ComponentsOfRevenueInterestFinancingTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-18873"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s Revenue Interest Financing consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenuesInterestFinancingLiability" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48035">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48036">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Royalty payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:RoyaltyPayments" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48037">1,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Change in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfDebt" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48038">2,708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenueInterestFinancingLiabilityNoncurrent" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48039">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679765" id="ixv-18959">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127681647" id="ixv-18968"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48040">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48041">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48042">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48043">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48044">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48045">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48046">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48047">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48048">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48049">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48050">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48051">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48052">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48053">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48054">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48055">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48056">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48057">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48058">74,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48059">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48060">68,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-33</ix:exclude></div> </ix:nonNumeric></ix:nonNumeric></div></div> <ix:continuation id="TextSelection_127681647" continuedAt="TextSelectionAppend_127681647_1"><ix:continuation id="TextSelection_127679765" continuedAt="TextSelectionAppend_127679765_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679765_1" continuedAt="TextSelectionAppend_127679765_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_2" continuedAt="TextSelectionAppend_127679765_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679765_3" continuedAt="TextSelectionAppend_127679765_4"><ix:continuation id="TextSelectionAppend_127681647_1">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48062">4,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48063">4,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48064">4,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48065">4,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48066">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48067">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48068">303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48069">303</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48070">82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48071">82</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48072">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48073">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48074">684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48075">684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative Liability-Success Fee</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48076">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48077">180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48078">707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48079">707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48080">2,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48081">2,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination on August&#160;1, 2023, the <div style="letter-spacing: 0px; top: 0px;display:inline;">Company </div>recorded a liability for Public Warrants to purchase the Company&#8217;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as of December&#160;31, 2023 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48082">0.45</ix:nonFraction>, which is a Level&#160;1 input. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-34</ix:exclude></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_127679765_4" continuedAt="TextSelectionAppend_127679765_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_5" continuedAt="TextSelectionAppend_127679765_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_6" continuedAt="TextSelectionAppend_127679765_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679765_7" continuedAt="TextSelectionAppend_127679765_8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Warrants </div></div></div></div><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-19818"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the warrants within Level&#160;3 of the hierarchy as the fair value is derived <div style="letter-spacing: 0px; top: 0px;display:inline;">using </div>the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (level 3) inputs. See table below for the assumptions used in the pricing model: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48084">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48085">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48086">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48087">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48088">7.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48089">3.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48090">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48091">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48092">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48093">3.69</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48094">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48095">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48096">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48097">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48098">7.25</ix:nonNumeric></div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48099">8.71</ix:nonNumeric></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48100">4.42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48101">1.90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48102">6.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48103">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48104">0.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48105">4.41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48106">2.38</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48107">6.91</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48108">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48109">2.00</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48110">4.11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48111">0.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48112">4.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48113">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48114">4.00</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48115">3.92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48116">6.58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48117">7.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48118">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48119">8.20</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48120">3.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48121">1.02</ix:nonFraction><div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>-&#160;<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48122">1.10</ix:nonFraction></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48123">4.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48124">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48125">4.6</ix:nonNumeric></div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48126">4.7</ix:nonNumeric></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48127">3.88</ix:nonFraction></div>-<div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48128">3.92</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48129">11.87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48130">11.31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48131">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48132">8.2</ix:nonNumeric></div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-48133">9.7</ix:nonNumeric></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expected dividend yield for all calculations is <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48134"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48135">0.00</ix:nonFraction></ix:nonFraction>%. </div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-20150"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the years ended December&#160;31, 2023 and 2022 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:48%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48136">510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48137">231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48138">741</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48139">834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48140">834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680782;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48141">456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48142">365</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48143">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48144">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48145">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48146">1,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48147">596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48148">2,373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680783;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48149">720</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48150">172</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48151">548</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48152">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48153">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48154">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48155">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48156">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48157">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48158">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48159">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-35</ix:exclude></div></ix:continuation> </div></div> </div><ix:continuation id="TextSelectionAppend_127679765_8" continuedAt="TextSelectionAppend_127679765_9"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_127679765_9" continuedAt="TextSelectionAppend_127679765_10"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></div></div></ix:continuation></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679765_10" continuedAt="TextSelectionAppend_127679765_11"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2019 Term Loan Success Fee Derivative Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The derivative liability for the success fee associated with Legacy Allurion&#8217;s November 2019 loan and security agreement with Western Alliance Bank (the &#8220;2019 Term Loan&#8221; and such fee, the &#8220;Success Fee&#8221;) was recorded at fair value as of December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within <ix:nonNumeric name="alur:FairValueAssumptionsOfLiquidityEventTerm" contextRef="P01_01_2023To12_31_2023_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-48161">four years</ix:nonNumeric> from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the notes, using the share price at conversion ($<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48162">7.04</ix:nonFraction> per share). Upon the conversion of the notes, the convertible note liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">PubCo Additional Shares Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PubCo Additional Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, <div style="letter-spacing: 0px; top: 0px;display:inline;">just </div>prior to the close of the Business Combination, using the number of shares issued at the close of the Business Combination of <ix:nonFraction name="alur:FairValueOfEstimatedNumberOfShares" contextRef="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48163">387,696</ix:nonFraction> and an estimated price of shares at settlement of $<ix:nonFraction name="alur:FairValueOfEstimatedPriceOfShares" contextRef="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48164">7.04</ix:nonFraction>. Upon the issuance of shares, the PubCo Additional Shares liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Base PubCo Shares and Backstop Shares Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Base PubCo Shares and Backstop Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, just prior to the close of the Business Combination, using the number of shares for each Backstop Purchaser at the close of the Business Combination of <ix:nonFraction name="alur:FairValueOfEstimatedNumberOfShares" contextRef="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48165">950,000</ix:nonFraction> and an estimated price of shares at settlement of $<ix:nonFraction name="alur:FairValueOfEstimatedPriceOfShares" contextRef="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48166">7.04</ix:nonFraction>. Upon the issuance of shares, the Base PubCo Shares and Backstop Shares liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing was accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of December&#160;31, 2023 using a discounted cash flow (&#8220;DCF&#8221;) method under the income approach utilizing future revenue projections and a discount rate of <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48167">24.4</ix:nonFraction>%. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" escape="true" id="ixv-20430"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method using the number of shares convertible of <ix:nonFraction name="alur:FairValueOfEstimatedNumberOfShares" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48168">1,065,341</ix:nonFraction> and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48169">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48170">4.46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-48171">1.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48172">82.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> </ix:continuation><ix:continuation id="TextSelectionAppend_127679765_11" continuedAt="TextSelectionAppend_127679765_12"><ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-36</div> </ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679765_12" continuedAt="TextSelectionAppend_127679765_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_13" continuedAt="TextSelectionAppend_127679765_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_14" continuedAt="TextSelectionAppend_127679765_15"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679765_15" continuedAt="TextSelectionAppend_127679765_16"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion <div style="letter-spacing: 0px; top: 0px;display:inline;">Common </div>Stock, with the change in fair value recognized in Change in the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities in the consolidated statement of operations. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" escape="true" continuedAt="TextSelection_127681652" id="ixv-20502">The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> shares was determined using a Monte Carlo Simulation Method using the following assumptions at the valuation date: </ix:nonNumeric></div><ix:continuation id="TextSelection_127681652"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48173">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48174">3.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-48175">4.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48176">87.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Term Loan Derivative Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan Derivative Liability associated with the Fortress Term Loan was recorded at fair value as of December&#160;31, 2023 using a DCF model that includes default interest payments expected to be made based on future revenue projections and cash flow assumptions and a discount rate of <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48177">24.4</ix:nonFraction>%. </div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" escape="true" id="ixv-20554"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, PubCo Additional Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, and Term Loan Derivative Liability categorized with Level&#160;3 inputs for the years ended December&#160;31, 2023 and 2022 were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48178">159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48179">159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48180">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48181">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48182">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48183">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48184">28,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48185">3,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48186">3,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48187">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48188">3,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48189">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48190">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48191">133,609</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48192">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48193">3,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48194">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48195">10,106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48196">3,408</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48197">2,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48198">29,050</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48199">17,147</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48200">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48201">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48202">10,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48203">1,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48204">11,842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48205">21,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48206">2,728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48207">13,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48208">37,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48209">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48210">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48211">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48212">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48213">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48214">67,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, PubCo <div style="letter-spacing: 0px; top: 0px;display:inline;">Additional </div>Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> liability, and Term Loan Derivative Liability at each period is recorded as a component of Other (expense) income in the consolidated statements of operations, with the exception of the change in fair value associated with the change in credit risk related to the Revenue Interest Financing which is recorded as a component of other comprehensive loss. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-37</ix:exclude></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_127679765_16" continuedAt="TextSelectionAppend_127679765_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679765_17" continuedAt="TextSelectionAppend_127679765_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679765_18" continuedAt="TextSelectionAppend_127679765_19"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679765_19"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Assets and Liabilities Not Carried at Fair Value </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Fortress term loan is carried at amortized cost. The fair value of the Fortress term loan was estimated to be $<ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48216">43.2</ix:nonFraction>&#160;million on December&#160;31, 2023. The fair value was determined using a discounted cash flow approach. We classified the fair value disclosures for the Fortress Term Loan within level 3 of the fair value hierarchy because the fair value is derived using a significant unobservable input, which includes a discount rate. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679768" id="ixv-21288">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21297"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of net loss before income taxes are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48217">81,259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48218">38,267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48219">916</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48220">666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48221">80,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48222">37,601</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21391"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation between the effective tax rate and the statutory federal income tax rate for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">D</div></div></div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div>c</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;">m</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">b</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div>e</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">r</div></div></div>&#160;31, 2023 and 2022 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48223">21.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48224">21.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48225">7.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48226">6.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of financial instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48227">3.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48228">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48229">0.4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48230">1.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48231">30.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48232">29.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48233">0.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48234">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48235">0.4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48236">0.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48237">0.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-48238">0.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21579"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. federal and state net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48239">36,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48240">25,051</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">start-up</div> and research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48241">10,868</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48242">5,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48243">2,275</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48244">1,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48245">3,918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48246">659</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48247">838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DeferredTaxAssetsDepreciation" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48248">203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DeferredTaxAssetsDepreciation" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48249">236</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bad debt reserve</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48250">3,461</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48251">2,145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48252">994</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48253">59,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48254">34,276</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48255">57,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48256">33,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48257">1,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48258">792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48259">623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48260">792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other deferred tax liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48261">1,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48262">1,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48263">792</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48264">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48265">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-38</ix:exclude></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679768" continuedAt="TextSelectionAppend_127679768_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679768_1" continuedAt="TextSelectionAppend_127679768_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679768_2" continuedAt="TextSelectionAppend_127679768_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679768_3" continuedAt="TextSelectionAppend_127679768_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48267">0.3</ix:nonFraction>&#160;million during the year ended December&#160;31, 2023 due to foreign operating income. The Company recorded $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48268">0.1</ix:nonFraction>&#160;million of income tax expense during the year ended December&#160;31, 2022. The Company maintains a valuation allowance for the full amount of the net United States deferred tax assets, as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased for the years ended December&#160;31, 2023 and 2022 by approximately $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48269">24.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48270">10.9</ix:nonFraction>&#160;million, respectively, due to an increase in deferred tax assets having a full valuation allowance primarily due to the operating losses incurred, capitalized research and development expenses and tax credits generated. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48271">132.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48272">131.7</ix:nonFraction>&#160;million of federal and state NOL carryforwards, respectively. Of the federal NOL carryforwards, $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48273">12.8</ix:nonFraction>&#160;million expire between <ix:nonNumeric name="alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_EarliestTaxYearMemberusgaapTaxPeriodAxis" id="ixv-48274">2030</ix:nonNumeric> and <ix:nonNumeric name="alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LatestTaxYearMemberusgaapTaxPeriodAxis" id="ixv-48275">2037</ix:nonNumeric> and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_DoNotExpireMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48276">119.5</ix:nonFraction>&#160;million do not expire. The state NOL carryforwards expire between <ix:nonNumeric name="alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_EarliestTaxYearMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-48277">2030</ix:nonNumeric> and <ix:nonNumeric name="alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_LatestTaxYearTwoThousandFortyTwoMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-48278">2042</ix:nonNumeric>. As of December&#160;31, 2023, the Company had $<ix:nonFraction name="alur:TaxCreditCarryForwardsResearchAndDevelopment" contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48279">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="alur:TaxCreditCarryForwardsResearchAndDevelopment" contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48280">0.9</ix:nonFraction>&#160;million of federal and state research and development tax credits, which expire beginning in <ix:nonNumeric name="alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-48281">2031</ix:nonNumeric> and <ix:nonNumeric name="alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" id="ixv-48282">2028</ix:nonNumeric>, respectively. </div><ix:nonNumeric name="us-gaap:SummaryOfValuationAllowanceTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-21865"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to the Company&#8217;s valuation allowance are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48283">33,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48284">22,579</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions charged to net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48285">24,501</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48286">10,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48287">57,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48288">33,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of the future tax benefits from these assets is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize net operating loss and research and development credit carryforwards in the future. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to US federal income tax, state income tax in Massachusetts, and income tax in certain foreign jurisdictions. The Company&#8217;s historical income taxes in foreign jurisdictions have been immaterial to the consolidated financial statements. The Company is not currently under examination by the Internal Revenue Service (&#8220;IRS&#8221;) or any other jurisdictions for any tax years; however, all tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the U.S. IRS or other authorities if they have, or will be, used in a future period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the unremitted earnings of the Company&#8217;s foreign subsidiaries are immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interpretive guidance on the accounting for global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-taxed</div> income (&#8220;GILTI&#8221;) states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. The Company made the accounting policy election to recognize GILTI as a period expense. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-39</ix:exclude></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_127679768_4" continuedAt="TextSelectionAppend_127679768_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679768_5" continuedAt="TextSelectionAppend_127679768_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679768_6" continuedAt="TextSelectionAppend_127679768_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679768_7"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48290"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48291">no</ix:nonFraction></ix:nonFraction>t recorded a tax liability for any uncertain tax positions. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. There are <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48292"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-48293">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties as of December&#160;31, 2023 and 2022. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679770" id="ixv-21985">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Capital Stock and Stockholders&#8217; Deficit </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion certificate of incorporation authorizes the issuance of up to <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48294">100,000,000</ix:nonFraction> shares of Allurion preferred stock. As of December&#160;31, 2023, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48295">no</ix:nonFraction> shares of Allurion preferred stock were outstanding. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Preferred Equity </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Legacy Allurion preferred stock was retroactively adjusted, converted into common stock at the Exchange Ratio, and reclassified to permanent equity as a result of the reverse recapitalization. As of December&#160;31, 2023, there is no Legacy Allurion preferred stock authorized, issued, or outstanding. <ix:nonNumeric name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127681683" id="ixv-48296">The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts):</ix:nonNumeric> </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:continuation id="TextSelection_127681683" continuedAt="TextSelectionAppend_127681683_1">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Authorized (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Issued&#160;and<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48297">2,276,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48298">2,276,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48299">1,542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48300">1,513,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48301">1,486,048</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48302">2,842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series B Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48303">2,298,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48304">2,245,515</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48305">5,253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48306">8,113,616</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48307">7,927,446</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48308">39,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48309">1,684,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48310">842,283</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48311">9,614</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48312">3,644,616</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48313">3,644,616</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48314">24,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48315">1,498,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48316">1,498,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48317">14,789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48318">21,029,888</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48319">19,921,042</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48320">97,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:PreferredStockVotingRights" contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" id="ixv-48321">The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors</ix:nonNumeric>, and the Legacy Allurion <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" id="ixv-48322">common stockholders were entitled to elect four members of the Board of Directors.</ix:nonNumeric> </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Legacy Allurion preferred stock participated in dividends with Legacy Allurion common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis when declared by the Board of Directors. The Legacy Allurion preferred stockholders were entitled to receive dividends, when and if declared, on a pro rata pari passu basis according to the number of shares of Legacy Allurion common stock held by such holder. The Legacy Allurion Series D preferred stockholders were also entitled to a cumulative dividend that accrues at the rate of <ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="P01_01_2023To12_31_2023_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48323">6</ix:nonFraction>% per annum. The dividend accrued on a daily basis from and including the issuance date of such shares, whether or not declared. Through the date of the Business Combination, <ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-48324">no</ix:nonFraction> dividends had been declared. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">winding-up</div> of Legacy Allurion, before any payment were to be made to the holders of common stock, the holders of shares of Legacy Allurion </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-40</ix:exclude></div> </ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_127679770" continuedAt="TextSelectionAppend_127679770_1"><div></div></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_127679770_1" continuedAt="TextSelectionAppend_127679770_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679770_2" continuedAt="TextSelectionAppend_127679770_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679770_3" continuedAt="TextSelectionAppend_127679770_4"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679770_4" continuedAt="TextSelectionAppend_127679770_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">preferred stock then outstanding were entitled to be paid out of the funds and assets available for distribution to Legacy Allurion&#8217;s stockholders, on a pari passu basis, an amount per share equal to (i)&#160;the Legacy Allurion Series A, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> Series B and Series C preferred stock, a per share liquidation preference equal to $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48327">1.092</ix:nonFraction>, $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48328">2.850</ix:nonFraction>, $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48329">3.563</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48330">4.935</ix:nonFraction>, respectively, plus any accruing dividends accrued but unpaid, whether or not declared and (ii)&#160;the Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> preferred stock, a per share liquidation preference equal to $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48331">17.809</ix:nonFraction>, $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48332">9.338</ix:nonFraction>, and $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48333">15.137</ix:nonFraction>, respectively, plus any accruing dividends accrued but unpaid, whether or not declared provided, that, if Legacy Allurion achieved a revenue milestone of $<ix:nonFraction name="alur:RevenueRecognitionMilestoneMethodOfRecognizedRevenue" contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48334">65.0</ix:nonFraction>&#160;million in a trailing twelve month period (the &#8220;Milestone&#8221;), then in lieu of the foregoing, the holders of the Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> Preferred Stock were entitled to receive an amount per share equal to $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48335">11.8725</ix:nonFraction>, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48336">6.2256</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48337">10.0916</ix:nonFraction>, respectively, plus any accruing dividends accrued but unpaid, whether or not declared (collectively, the &#8220;Preferred Stock Preference&#8221;). After payment of the Preferred Stock Preference, the funds and assets available for distribution to Legacy Allurion&#8217;s stockholders, if any, would be initially distributed on a pro rata basis to the holders of common stock in Legacy Allurion in proportion to the number of shares of common stock held at an amount per share equal to <ix:nonFraction name="alur:PercentageOfSharesOfCommonStockHeld" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48338">150</ix:nonFraction>% of the Original Issue Price of the Legacy Allurion Series A Preferred Stock ($<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal" id="ixv-48339">1.092</ix:nonFraction>), plus any dividends declared but unpaid thereon (the &#8220;First Catchup Amount&#8221;). Any remaining funds and assets available for distribution to Legacy Allurion stockholders, if any, after the First Catchup Amount would then be distributed on a pro rata basis to the holders of common stock and preferred stock in proportion to the number of shares of common stock or preferred stock held. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis" id="ixv-48340">Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series&#8217; applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock.</ix:nonNumeric> </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Legacy Allurion Series A, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> Series B, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> preferred stock were not entitled to any redemption rights, other than those under their liquidation rights discussed above. Upon the election of the holders of a majority of shares of the Legacy Allurion Series C preferred stock, up to <ix:nonFraction name="alur:PercentageOfPreferredStockRedeemableShares" contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-48341">50</ix:nonFraction>% of the outstanding shares of Legacy Allurion Series C preferred stock were redeemable at a price equal to <ix:nonFraction name="alur:PreferredStockRedemptionValueToPrice" contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-48342">1.5</ix:nonFraction> times the original issuance price, plus all declared, but unpaid dividends thereon, on a pro rata basis in an equal semiannual portion, after January&#160;17, 2022. The Legacy Allurion Series C contingent redemption upon a deemed liquidation event resulted in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Common Equity </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion certificate of incorporation authorizes the issuance of up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48343">1,000,000,000</ix:nonFraction> shares of Allurion Common Stock. As of December&#160;31, 2023 and 2022, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48344">47,688,096</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48345">27,079,856</ix:nonFraction> shares of common stock were outstanding, respectively, after retrospectively adjusting for the effect of the reverse recapitalization. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-41</ix:exclude></div></ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_127679770_5" continuedAt="TextSelectionAppend_127679770_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679770_6" continuedAt="TextSelectionAppend_127679770_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679770_7" continuedAt="TextSelectionAppend_127679770_8"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div></div></div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679770_8" continuedAt="TextSelectionAppend_127679770_9"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_127681683_1" continuedAt="TextSelectionAppend_127681683_2">The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of December&#160;31, 2023, is as follows:</ix:continuation> </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:continuation id="TextSelectionAppend_127681683_2">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48348">3,886,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48349">643,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48350">138,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48351">264,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_PublicWarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48352">18,759,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_EarnOutSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48353">9,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48354">32,693,169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants to Purchase Common Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127681684" id="ixv-48355">As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48356">403,658</ix:nonFraction> such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. </ix:nonNumeric></div> <ix:continuation id="TextSelection_127681684"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td style="width:38%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12/1/2014</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48357">0.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48358">44,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48359">2.44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3/30/2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48360">7.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48361">130,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48362">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/15/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48363">8.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48364">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48365">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/4/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48366">8.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48367">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48368">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1/17/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48369">3.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48370">73,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48371">0.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8/3/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48372">3.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48373">9,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48374">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/8/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48375">3.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48376">28,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48377">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/19/2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48378">4.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48379">17,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48380">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/25/2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48381">5.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48382">8,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48383">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48384">403,658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">4/1/2013</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48385">0.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48386">16,557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48387">1.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48388">1.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series B Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48389">60,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48390">2.44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48391">8.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series C Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48392">130,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48393">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48394">9.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48395">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48396">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48397">9.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48398">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48399">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48400">4.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48401">73,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48402">0.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48403">4.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48404">9,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48405">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48406">4.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48407">28,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48408">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48409">5.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48410">17,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48411">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-48412">6.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48413">8,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48414">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48415">436,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table> </ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-42</ix:exclude></div></ix:continuation> </div></div><ix:continuation id="TextSelectionAppend_127679770_9" continuedAt="TextSelectionAppend_127679770_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679770_10" continuedAt="TextSelectionAppend_127679770_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679770_11" continuedAt="TextSelectionAppend_127679770_12"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679770_12"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Compute Health&#8217;s initial public offering, it sold units at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48417">10.00</ix:nonFraction> per unit, which consisted of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48418">one</ix:nonFraction> share of Class&#160;A Common Stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48419">0.0001</ix:nonFraction> par value, of Compute Health (&#8220;Class A Common Stock&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden127680787;display:inline;">one-half</div></div> of a redeemable warrant (each a &#8220;Public Warrant&#8221;) that entitled the holders the right to purchase <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48420">one</ix:nonFraction> share of Class&#160;A Common Stock of CPUH at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48421">11.50</ix:nonFraction> per share. On July&#160;26, 2023, Compute Health&#8217;s Public Warrant holders approved an amendment (the &#8220;Warrant Amendment&#8221;) to the warrant agreement that governed all Compute Health&#8217;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="6" scale="0" format="ixt:num-dot-decimal" id="ixv-48422">1.420455</ix:nonFraction> shares of the Company&#8217;s Common Stock, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48423">0.0001</ix:nonFraction> per share, at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48424">8.10</ix:nonFraction> per share and each Compute Health Public Warrant was exchanged for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-48425">0.6125</ix:nonFraction> Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for cash at a price of $<ix:nonFraction name="alur:WarrantsRedumptionPricePerShare" contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48426">0.01</ix:nonFraction> per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48427">12.67</ix:nonFraction> per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $<ix:nonFraction name="alur:WarrantsRedumptionPricePerShare" contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48428">0.10</ix:nonFraction> per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48429">7.04</ix:nonFraction> per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#8220;Redemption Fair Market Value&#8221;) of the shares of the Company&#8217;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#8217;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of December&#160;31, 2023, the Company has not redeemed any of the outstanding Public Warrants. As of December&#160;31, 2023, there were <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48430">13,206,922</ix:nonFraction> outstanding Public Warrants exercisable for <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48431">18,759,838</ix:nonFraction> shares of Allurion Common Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Chardan Equity Facility </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), each with Chardan Capital Markets (&#8220;Chardan&#8221;) related to a &#8220;ChEF,&#8221; Chardan&#8217;s committed equity facility (the &#8220;Chardan Equity Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48432">100,000,000</ix:nonFraction> in aggregate gross purchase price of newly issued shares of the Company&#8217;s Common Stock, and (ii) <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48433">9,482,468</ix:nonFraction> shares of Common Stock, which number of shares is equal to <ix:nonFraction name="alur:PercentageOfCommonStockSharesOutstanding" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48434">19.99</ix:nonFraction>% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;). In consideration for Chardan&#8217;s entry into the Purchase Agreement, Allurion agreed to issue to Chardan <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48435">35,511</ix:nonFraction> shares of Allurion Common Stock (the &#8220;Commitment Shares&#8221;). The Company recorded $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48436">0.1</ix:nonFraction>&#160;million to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and $<ix:nonFraction name="alur:ExpenseOfIssuanceOfCommitmentShares" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48437">0.1</ix:nonFraction>&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $<ix:nonFraction name="alur:StructuringFeePayable" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48438">0.1</ix:nonFraction>&#160;million related to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> structuring fee (the &#8220;Structuring Fee&#8221;) immediately following commencement. As of December&#160;31, 2023, the Company had <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2023To12_31_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48439">no</ix:nonFraction>t sold any shares of Common Stock to Chardan in connection with the Purchase Agreement. </div></ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-43</div> </div></div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </div></div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23058">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Net Loss per Share </div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23067"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share was calculated as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48440">80,607</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48441">37,744</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared dividends to participating securities (Legacy Series D convertible preferred stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48442">1,697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48443">2,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48444">82,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48445">40,651</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted weighted-average common stock outstanding</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48446">35,581,656</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48447">26,918,484</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders, basic and diluted (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_127680424"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_127680422">2.31</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_127680425"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="Fact_127680423">1.51</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information. </div> </td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127681680" id="ixv-48452">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </ix:nonNumeric></div> <ix:continuation id="TextSelection_127681680"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48453">3,886,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48454">4,301,960</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48455">643,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48456">1,415,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48457">138,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48458">297,854</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48459">264,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48460">138,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48461">18,759,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48462">9,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible notes (as converted to common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48463">171,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48464">32,693,169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48465">6,325,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation></ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679776" id="ixv-23390">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Based Compensation </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Incentive Plans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2010 Stock Option Plan (the &#8220;2010 Plan&#8221;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. On December&#160;11, 2020, the Company&#8217;s Board of Directors adopted the 2020 Stock Option Plan (the &#8220;2020 Plan&#8221;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-44</ix:exclude></div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_127679776" continuedAt="TextSelectionAppend_127679776_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679776_1" continuedAt="TextSelectionAppend_127679776_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679776_2" continuedAt="TextSelectionAppend_127679776_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679776_3" continuedAt="TextSelectionAppend_127679776_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;), which provides for the award of stock options (both incentive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified),</div> stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48467">7,822,700</ix:nonFraction> shares of Allurion Common Stock were initially reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by <ix:nonFraction name="alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" contextRef="P01_01_2023To12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48468">5</ix:nonFraction>% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the Compensation Committee. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, <ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" contextRef="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48469">4,529,673</ix:nonFraction> options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2022, <ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" contextRef="PAsOn12_31_2022_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48470">5,717,072</ix:nonFraction> options and RSUs were issued and outstanding under the 2010 Plan and 2020 Plan. The stock options generally vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-48471">four-year</ix:nonNumeric> period and expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-48472">10 years</ix:nonNumeric> from the date of grant. </div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23423"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the consolidated statement of operations and comprehensive loss was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48473">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general, and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48474">8,198</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48475">400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48476">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48477">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48478">8,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48479">437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23532"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the year ended December&#160;31, 2023: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:59%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48480">4,301,968</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48481">2.35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-48482">7.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48483">9,437</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48484">257,683</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48485">5.41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48486">375,051</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48487">2.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48488">298,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48489">1.15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48490">3,886,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48491">2.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-48492">6.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48493">5,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercisable at December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48494">2,735,884</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48495">2.23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-48496">6.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48497">4,812</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to stock option awards during the year ended December&#160;31, 2023 was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48498">2.7</ix:nonFraction>&#160;million. As of December&#160;31, 2023, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2023_StockOptionPlan2020MemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48499">2.5</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2020 Plan, which is expected to be recognized over a weighted-average vesting term of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-48500">2.1</ix:nonNumeric> years. The weighted average grant-date fair value of the stock option awards granted during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48501">3.98</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48502">2.36</ix:nonFraction> per option, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-45</ix:exclude></div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_127679776_4" continuedAt="TextSelectionAppend_127679776_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679776_5" continuedAt="TextSelectionAppend_127679776_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679776_6" continuedAt="TextSelectionAppend_127679776_7"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679776_7" continuedAt="TextSelectionAppend_127679776_8"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#8217;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies which are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted- average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-23794"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option-pricing model are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8194;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48504">85.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48505">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48506">4.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-48507">3.56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-48508">5.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear" id="ixv-48509">5.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company issued RSUs under the 2020 Plan to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation </div></div>and Note 3<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">, Business Combination </div></div>above for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2023To12_31_2023_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48510">62.5</ix:nonFraction>% of the RSUs awarded vested. Thereafter, the remaining <ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48511">37.5</ix:nonFraction>% of the RSUs vest monthly over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-48512">two years</ix:nonNumeric>. In October 2023, the Company issued additional RSUs to Board of Director members with annual vesting over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P10_01_2023To10_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-48513">three years</ix:nonNumeric>. All RSUs are subject to forfeiture if the grantee&#8217;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127681675" id="ixv-48514">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the year ended December&#160;31, 2023: </ix:nonNumeric></div> <ix:continuation id="TextSelection_127681675"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant<br/> Date&#160;Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48515">1,415,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48516">4.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48517">226,175</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48518">4.32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48519">79,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48520">4.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48521">918,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48522">4.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December 31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48523">643,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48524">4.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to RSUs for the year ended December&#160;31, 2023 was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48525">5.7</ix:nonFraction>&#160;million. As of December&#160;31, 2023, there were $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48526">1.7</ix:nonFraction>&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-48527">2.0</ix:nonNumeric> years. The weighted average grant-date fair value of time-vested restricted stock units granted during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48528">4.32</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48529">4.51</ix:nonFraction> per share, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-46</ix:exclude></div></ix:continuation> </div> </div> </div> <ix:continuation id="TextSelectionAppend_127679776_8" continuedAt="TextSelectionAppend_127679776_9"><div></div></ix:continuation> </div> <div> <div style="line-height:normal;display: inline;"> <ix:continuation id="TextSelectionAppend_127679776_9" continuedAt="TextSelectionAppend_127679776_10"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679776_10" continuedAt="TextSelectionAppend_127679776_11"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679776_11" continuedAt="TextSelectionAppend_127679776_12"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679776_12"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#8217;s Common Stock through payroll deductions at a price equal to <ix:nonFraction name="alur:PercentageOfPriceLowerOfFairValueMarketValue" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48531">85</ix:nonFraction>% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#8217;s payroll deductions under the 2023 ESPP are limited to <ix:nonFraction name="alur:PercentageOfEmployeesCompensationToPayrollDeductions" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48532">15</ix:nonFraction>% of the employee&#8217;s compensation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48533">1,422,309</ix:nonFraction> shares of the Company&#8217;s Common Stock were initially reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 ESPP will automatically increase each January&#160;<ix:nonFraction name="alur:PercentageOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48534">1</ix:nonFraction>, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48535">1,600,000</ix:nonFraction> shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of December&#160;31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-48536">no</ix:nonFraction> shares have been issued under the 2023 ESPP. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24032">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Employee Benefit Plan </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contribution. During the years ended December&#160;31, 2023 and 2022, the Company&#8217;s matching contributions to the plan were $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-48537"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-48538">0.1</ix:nonFraction></ix:nonFraction>&#160;million. </div> </ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679781" id="ixv-24043">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseDescription" contextRef="P01_01_2023To12_31_2023" id="ixv-48539">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.</ix:nonNumeric> As a result of these amendments, the leases in Natick and Hudson will now expire between <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48540"><ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P02_01_2023To02_28_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48541">June 2024</ix:nonNumeric></ix:nonNumeric> and <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48542"><ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48543">March 2028</ix:nonNumeric></ix:nonNumeric>, and additional operating lease assets obtained in exchange for lease obligations were $<ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48544">0.9</ix:nonFraction>&#160;million. As of December&#160;31, 2023, the Company was a party to seven different leases for office, manufacturing, and laboratory space under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> office leases in three cities. These leases total approximately <ix:nonFraction name="us-gaap:AreaOfLand" contextRef="PAsOn12_31_2023" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48545">51,000</ix:nonFraction> square feet and will expire between <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48546">June 2024</ix:nonNumeric> and <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-48547">March 2028</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2023To12_31_2023" id="ixv-24059">The Company has a <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="P01_01_2023To12_31_2023" format="ixt:fixed-true" id="ixv-48548">right to extend</ix:nonNumeric> certain of these leases for periods between <div style="-sec-ix-hidden:hidden127682050;display:inline;">three</div> and <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-48549">five years</ix:nonNumeric>.</ix:nonNumeric> The Company also holds immaterial leases related to vehicles and office equipment. Under its leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of ROU assets and lease liabilities are included in the consolidated balance sheets. The short-term portion of the Company&#8217;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the consolidated balance sh<div style="letter-spacing: 0px; top: 0px;display:inline;">e</div>ets. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <ix:exclude> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-47</div> </ix:exclude></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_127679781" continuedAt="TextSelectionAppend_127679781_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679781_1" continuedAt="TextSelectionAppend_127679781_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679781_2" continuedAt="TextSelectionAppend_127679781_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation></div> </div> </div> <div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679781_3"><div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Aggregate Lease Information </div></div></div><ix:nonNumeric name="alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24084"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48550">1,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48551">918</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48552">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48553">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48554">187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48555">191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48556">1,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48557">807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48558">936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48559">1,677</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24167"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48560">1,173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48561">1,114</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48562">737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48563">645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48564">108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48565">3,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48566">563</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingAndFinanceLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48567">3,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:OperatingAndFinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48568">908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:OperatingAndFinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48569">2,306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24280"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:85%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-48570">3.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear" id="ixv-48571">3.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48572">9.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-48573">9.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not received any material product liability claims. While product defects and adverse patient reactions associated with the Allurion Balloon have occurred, and are expected to continue to occur, the Company does not have a history of product defects or adverse patient reactions that the Company&#8217;s management believes would give rise to a material product liability claim. Furthermore, the Company has obtained insurance related to potential product liability claims. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Litigation and Claims </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of December&#160;31, 2023 and 2022, the Company has <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-48574"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-48575">no</ix:nonFraction></ix:nonFraction>t recorded accruals for potential losses related to any existing or pending litigation or claims as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div> </ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-48</div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24346">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Geographic Information </div></div></td></tr></table> <ix:nonNumeric name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" id="ixv-24355"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48576">5,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2022_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48577">3,999</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48578">1,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2022_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48579">1,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48580">6,391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48581">5,281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue</div></div> for information on revenue by geography. </div></ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2023To12_31_2023" escape="true" continuedAt="TextSelection_127679789" id="ixv-24464">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Related-party Transactions </div></div></td></tr></table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lease Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#8217;s then-Trade Marketing Director was the signor of this lease for LNMP JPBS Invest. Additionally, the Company&#8217;s Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48582">0.1</ix:nonFraction>&#160;million per year. The lease commenced <ix:nonNumeric name="alur:OperatingLeaseCommencementDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-48583">August 1, 2022</ix:nonNumeric> and was to end on <ix:nonNumeric name="alur:OperatingLeaseEndDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-48584">July 31, 2025</ix:nonNumeric>. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">arm&#8217;s-length.</div> This lease was terminated in <ix:nonNumeric name="alur:LesseeOperatingLeaseTerminatedDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-year-en" id="ixv-48585">February 2024</ix:nonNumeric>. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#8220;KKG Enterprises&#8221;) and Remus Group Management, LLC (&#8220;Remus Group Management&#8221;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $<ix:nonFraction name="alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48586">0.2</ix:nonFraction>&#160;million to KKG Enterprises and $<ix:nonFraction name="alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48587">0.3</ix:nonFraction>&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on <ix:nonNumeric name="alur:AgreementsTerminationDate" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-48588">June 20, 2023</ix:nonNumeric>. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Note with Hunter Ventures Limited </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, Allurion sold $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-48589">13</ix:nonFraction>&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than <ix:nonFraction name="alur:PercentageOfOutstandingCapitalStock" contextRef="P02_15_2023To02_15_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-48590">5</ix:nonFraction>% of our outstanding Common Stock). Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for additional information regarding the 2023 Convertible Notes. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Consulting Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion, entered into a new corporate officer agreement with the Company&#8217;s Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e which is solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The new corporate officer agreement provided that BCC would receive base consulting fees of &#8364;<ix:nonFraction name="alur:RelatedPartyTransactionConsultingFees" contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_EUR" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-48591">28,333.33</ix:nonFraction> per month and additional </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-49</ix:exclude></div> </ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679789" continuedAt="TextSelectionAppend_127679789_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679789_1" continuedAt="TextSelectionAppend_127679789_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679789_2" continuedAt="TextSelectionAppend_127679789_3"><ix:exclude> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents<br/></a></div> </ix:exclude></ix:continuation></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679789_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on <ix:nonNumeric name="alur:AgreementsTerminationDate" contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-48594">December 12, 2023</ix:nonNumeric> by virtue of the termination agreement described below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Termination Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion, entered into a termination agreement with the Company&#8217;s Chief Commercial Officer, Benoit Chardon and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC will resign from its duties as managing director of Allurion France effective December&#160;31, 2023 and Allurion France will pay BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion France will pay BCC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lump-sum</div> termination fee of $<ix:nonFraction name="alur:RelatedPartyTransactionTerminationFees" contextRef="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-48595">0.2</ix:nonFraction>&#160;million. </div> </ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-50</div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%"/> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin915839_8" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(dollars in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48596">28,654</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48597">38,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net of allowance of doubtful accounts of $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48598">8,243</ix:nonFraction> and <br/> $<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48599">12,671</ix:nonFraction>, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48600">9,935</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48601">18,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48602">4,568</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48603">6,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48604">1,672</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48605">2,414</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48606">44,829</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48607">64,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48608">3,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48609">3,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48610">2,283</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48611">3,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48612">507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48613">505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48614">50,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48615">71,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities, Redeemable Convertible Preferred Stock, and Stockholders&#8217; Deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48616">10,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48617">10,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48618">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48619">38,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current portion of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48620">878</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48621">908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48622">7,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48623">15,495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48624">19,244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48625">65,425</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48626">7,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48627">6,765</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenueInterestFinancingLiabilityNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48628">38,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RevenueInterestFinancingLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48629">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48630">1,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48631">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible notes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48632">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48633">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48634">1,578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48635">2,306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48636">9,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48637">7,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48638">114,510</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48639">142,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and Contingencies (Note 16)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-48640"/></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-48641"/></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Redeemable Convertible Preferred Stock (Note 12):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A redeemable convertible preferred stock, $<ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn09_30_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48642"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48643">0.0001</ix:nonFraction></ix:nonFraction> par value&#8212; <ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48644"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48645">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2024; and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48646"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48647">2,260,159</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48648"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-48649">zero</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48650">979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-48651">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; deficit:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48652"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48653">0.0001</ix:nonFraction></ix:nonFraction> par value&#8212;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48654"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48655">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2024; and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48656"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48657">64,369,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48658"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48659">47,688,096</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30, 2024 and December&#160;31, 2023, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48660">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48661">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48662">150,692</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48663">143,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive income (loss)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48664">2,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48665">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48666">218,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48667">212,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48668">64,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48669">70,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities, redeemable convertible preferred stock, and stockholders&#8217; deficit</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48670">50,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48671">71,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-51 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin915839_9" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(dollars in thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:54%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48672">5,367</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48673">18,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48674">26,519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48675">45,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48676">2,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48677">4,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48678">7,549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48679">10,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross profit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48680">3,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48681">13,968</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48682">18,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48683">35,067</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48684">5,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48685">13,989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48686">18,060</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48687">36,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48688">3,212</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48689">7,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48690">13,247</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48691">21,623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48692">7,043</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48693">18,942</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48694">20,746</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48695">30,657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48696">15,452</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48697">40,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48698">52,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48699">88,407</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48700">12,341</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48701">26,154</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48702">33,083</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48703">53,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48704">2,586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48705">2,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48706">7,331</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48707">9,703</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48708">3,868</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48709">14,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48710">2,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangesInFairValueOfDebt" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48711">1,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfDebt" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48712">6,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangesInFairValueOfDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48713">10,020</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48714">3,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of Revenue Interest Financing and PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48715">11,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48716">2,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48717">9,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48718">2,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48719">2,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48720">24,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48721">22,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48722">24,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48723">3,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48724">8,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48725">3,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Termination of convertible note side letters</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48726">9,466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48727">17,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48728">757</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48729">389</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48730">1,928</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48731">133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48732">3,406</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48733">4,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48734">27,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48735">7,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48736">8,935</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48737">21,596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48738">5,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48739">61,337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48740">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48741">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48742">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48743">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48744">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48745">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48746">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48747">61,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared preferred dividends</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48748">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48749">1,697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common shareholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48750">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48751">21,885</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48752">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48753">63,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48754"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48755">0.14</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48756"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48757">0.54</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48758"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48759">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48760"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-48761">2.00</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48762"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48763">64,086,265</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48764"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48765">40,335,457</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48766"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48767">53,310,214</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48768"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-48769">31,558,538</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-52 </div></div></div></div><div></div></div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin915839_10" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(dollars in thousands, except per share amounts) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48770">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48771">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48772">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48773">61,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing due to change in credit risk</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P07_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48774">5,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48775">600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of RTW Convertible Notes due to change in credit risk</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48776">3,070</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48777">2,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive Loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48778">134</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48779">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48780">1,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48781">61,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-53 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="fin915839_11" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(dollars in thousands) </div></div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> Paid-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">in Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive<br/> Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of January&#160;1, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48782">27,079,856</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48783">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48784">99,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48785">132,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48786">32,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48787">15,376</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48788">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48789">20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48790">3,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48791">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48792">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48793">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48794">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48795">17,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48796">17,801</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of March&#160;31, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48797">27,098,786</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48798">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48799">100,333</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48800">149,993</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48801">49,657</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48802">27,626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48803">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48804">28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Legacy convertible preferred stock for the exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48805">492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48806">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48807">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48808">401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48809">401</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48810">21,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2023To06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48811">21,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of June&#160;30, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48812">27,126,904</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48813">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48814">100,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48815">171,989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48816">71,218</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48817">77,214</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48818">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48819">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Legacy convertible preferred stock for the exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48820">4,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48821">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48822">60</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reverse recapitalization, net of transaction costs (Note 3)</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48823">13,735,872</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48824">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48825">58,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48826">58,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of warrant liabilities in connection with the Merger (Note&#160;3)</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48827">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48828">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with vesting of RSU awards</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48829">906,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the conversion of convertible notes</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48830">3,301,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48831">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48832">25,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48833">25,570</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities (Note 3)</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48834">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48835">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reclassification of Legacy Allurion liability classified warrants to equity classification</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48836">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48837">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48838">2,287,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodValueDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48839">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:StockIssuedDuringPeriodValueDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48840">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsShares" contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48841">20,506</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48842">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48843">42</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48844">5,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48845">5,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48846">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48847">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance as of September&#160;30, 2023</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48848">47,460,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48849">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48850">140,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48851">193,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48852">52,756</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr> </table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-54 </div> </div> </div> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Preferred Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> Paid-</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">in Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive<br/> Loss</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Balance as of January&#160;1, 2024</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48853">47,688,096</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48854">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48855">143,007</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48856">700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48857">212,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48858">70,487</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48859">4,646</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48860">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48861">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsShares" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48862">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock from equity line financing (Note 12)</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48863">143,234</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48864">378</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48865">378</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with vesting of RSU awards</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48866">62,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48867">552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48868">552</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2024To03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48869">2,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48870">2,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48871">5,586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48872">5,586</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Balance as of March&#160;31, 2024</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48873">47,898,737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48874">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48875">143,946</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48876">2,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48877">207,213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48878">66,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48879">11,491</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48880">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2024To06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48881">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with vesting of RSU awards</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48882">62,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsShares" contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48883">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48884">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount" contextRef="P04_01_2024To06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48885">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48886">805</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2024To06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48887">805</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P04_01_2024To06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48888">3,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P04_01_2024To06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48889">3,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2024To06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48890">2,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2024To06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48891">2,162</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Balance as of June&#160;30, 2024</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48892">47,972,989</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48893">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48894">144,768</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48895">5,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48896">209,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48897">70,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock for the exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with vesting of RSU awards</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48898">62,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48899">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48900">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of preferred stock in connection with Private Placement, net of issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48901">2,260,159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48902">979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock in connection with Public Offering, net of issuance costs</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48903">16,333,773</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48904">2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48905">5,064</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48906">5,066</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2024To09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48907">8,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48908">8,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48909">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48910">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;">Balance as of September&#160;30, 2024</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48911">2,260,159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48912">979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-48913">64,369,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48914">7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48915">150,692</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48916">2,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48917">218,379</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48918">64,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-55 </div> </div> </div> </div> <div></div> </div> <div> <div style="line-height:normal;display: inline;"> <div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div> <hr style="color:#999999;height:3px;width:100%;clear:both"/> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </div> </div> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin915839_12" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(dollars in thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:86%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48919">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48920">61,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashLeaseExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48921">561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashLeaseExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48922">618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48923">778</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48924">558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48925">2,217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48926">6,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48927">1,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48928">4,953</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unrealized exchange (gain) or loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48929">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48930">253</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48931">1,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48932">743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of warrant liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfWarrantLiabilities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48933">14,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfWarrantLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48934">2,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of derivative liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48935">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48936">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing and PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48937">9,608</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48938">2,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48939">22,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueAdjustmentOfEarnOutLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48940">24,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid on debt recorded at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:InterestPaidOnDebtRecordedAtFairValue" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48941">2,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueAdjustmentOfDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48942"><ix:nonFraction name="alur:FairValueAdjustmentOfDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48943">10,020</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueAdjustmentOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48944"><ix:nonFraction name="alur:FairValueAdjustmentOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48945">3,751</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt issuance costs associated with debt recorded at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48946">1,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48947">1,210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashInterestExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48948">1,464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashInterestExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48949">1,117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> termination of convertible note side letters</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NonCashTerminationOfConvertibleNoteSideLetters" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48950">16,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48951">3,929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on term loan extinguishment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48952">8,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance costs associated with warrants recorded at fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AmortizationOfIssuanceCostsAssociatedWithWarrants" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48953">942</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48954">7,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48955">3,883</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48956">551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48957">899</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses, other current and long-term assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48958">747</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48959">409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48960">593</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48961">617</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48962">578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48963">3,492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48964">7,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48965">4,879</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48966">29,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48967">43,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48968">611</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48969">1,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48970">611</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48971">1,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing Activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48972">48,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48973">28,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Fortress Term Loan&#8212;net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromLongTermLinesOfCredit" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48974">59,780</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromBusinessCombinationNetOfTransactionCosts" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48975">62,078</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromRevenueInterestFinancing" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48976">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from option and warrant exercises</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromOptionAndWarrantExercises" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48977">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromOptionAndWarrantExercises" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48978">195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from equity line financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ProceedsFromEquityLineFinancing" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48979">378</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48980">10,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Private Placement, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48981">2,685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from Public Offering, net of issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48982">18,249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48983">1,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48984">3,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of 2021 Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48985">57,659</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of promissory note assumed in Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48986">2,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayment of Fortress term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48987">47,720</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48988">20,261</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48989">116,394</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (decrease) increase in cash and cash equivalents and restricted cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-48990">9,376</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48991">72,075</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48992">38,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48993">8,023</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48994">29,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48995">80,098</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure of cash flow information</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48996">2,672</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48997">5,022</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental cash flow information on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cash</div> investing and financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchase of property and equipment included in accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48998">270</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred financing costs in accounts payable and accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-48999">1,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49000">1,006</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of assumed warrant liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RecognitionOfAssumedWarrantLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49001">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:RecognitionOfEarnOutLiabilities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49002">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock upon conversion of convertible notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49003">25,569</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of Revenue Interest Financing through other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49004">600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of RTW Convertible Notes through other comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ChangeInFairValueOfRtwConvertibleNotesThroughOci" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49005">2,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-56 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES </div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49006">28,654</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49007">38,037</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in <div style="-sec-ix-hidden:hidden127682685;display:inline;"><div style="-sec-ix-hidden:hidden127682686;display:inline;">other long-term assets</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49008">391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49009">384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49010">29,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49011">38,421</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-57 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679736" id="ixv-29665">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td id="fin915839_13" style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Basis of Presentation </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Technologies, Inc. (&#8220;Allurion&#8221; or the &#8220;Company&#8221;) is a vertically integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#8482;</div> Balloon. The Allurion Balloon is the world&#8217;s first and only swallowable, procedureless<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#8482;</div> intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement. Allurion sells the Allurion Balloon and connected scale through distributors or directly to health care providers. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also offers tiered access to artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#8220;VCS&#8221;) and, collectively with the Allurion Balloon, referred to as the &#8220;Allurion Program&#8221;. The base tier of the VCS is free of charge to those purchasing the Allurion Balloon, as well as customers looking for a weight-loss management platform for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. More full-scale versions of the VCS are available to health care providers on an upgrade basis. Allurion currently markets the Allurion Program in over <ix:nonFraction name="alur:NumberOfCountriesInWhichEntityMarketsTheProgram" contextRef="PAsOn09_30_2024" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49012">50</ix:nonFraction> countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia and Mexico. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Business Combination Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#8220;Legacy Allurion&#8221;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#8220;Business Combination Agreement&#8221;) with Compute Health Acquisition Corp. (&#8220;CPUH&#8221; or &#8220;Compute Health&#8221;), Compute Health Corp. (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#8220;Closing Date&#8221;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#8220;CPUH Merger&#8221;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#8220;CPUH Merger Effective Time&#8221;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#8220;Intermediate Merger&#8221; and the time at which the Intermediate Merger became effective, the &#8220;Intermediate Merger Effective Time&#8221;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#8220;Final Merger&#8221; and, collectively with the CPUH Merger and the Intermediate Merger, the &#8220;Mergers&#8221;, and together with all other transactions contemplated by the Business Combination Agreement, the &#8220;Business Combination&#8221;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#8220;Final Merger Effective Time&#8221;). Shares of Allurion&#8217;s Common Stock (defined below) began trading on the New York Stock Exchange (&#8220;NYSE&#8221;) under the ticker symbol &#8220;ALUR&#8221; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#8217;s business operations continued as our business operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Under this method of accounting, Compute Health was treated as the &#8220;acquired&#8221; company for financial reporting purposes and Legacy Allurion was the accounting &#8220;acquirer&#8221;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-58</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679736" continuedAt="TextSelectionAppend_127679736_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679736_1" continuedAt="TextSelectionAppend_127679736_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679736_2" continuedAt="TextSelectionAppend_127679736_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679736_3" continuedAt="TextSelectionAppend_127679736_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#8217;s common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49015">0.0001</ix:nonFraction> par value per share (&#8220;Common Stock,&#8221; &#8220;Allurion Common Stock&#8221; or the &#8220;Company&#8217;s Common Stock&#8221;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#8217;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately <ix:nonFraction name="alur:BusinessCombinationCommonStockExchangeRatio" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-49016">0.9780</ix:nonFraction> (the &#8220;Exchange Ratio&#8221;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the condensed consolidated financial statements have changed. Refer to Note&#160;3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div> for further discussion regarding the closing of the Business Combination with <div style="display:inline;">Compute </div>Health. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references in this prospectus to the &#8220;Company&#8221;, &#8220;our&#8221;, and &#8220;Allurion&#8221; refer to the condensed consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#8220;Legacy Allurion&#8221; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). They should be read in conjunction with our audited financial statements as of and for the year ended December&#160;31, 2023 included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> as amended (&#8220;Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K&#8221;).</div> The financial statements as of September&#160;30, 2024 and for the three and nine months ended September&#160;30, 2024 and 2023 presented in this report are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. A gain from remeasurement of less than $<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49017">0.1</ix:nonFraction>&#160;million and a loss from remeasurement of s$<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49018">0.3</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, and a gain from remeasurement of $<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49019">0.4</ix:nonFraction>&#160;million and loss from remeasurement of $<ix:nonFraction name="us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49020">0.3</ix:nonFraction>&#160;million for the three months ended September&#160;30, 2024 and 2023, respectively, are recorded in the statements of operations within Other income, net. The Company translates the foreign functional currency financial statements to U.S. dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments were immaterial for the three and nine months ended September&#160;30, 2024 and 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the interim condensed consolidated financial statements are issued. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-59</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679736_4" continuedAt="TextSelectionAppend_127679736_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679736_5" continuedAt="TextSelectionAppend_127679736_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679736_6" continuedAt="TextSelectionAppend_127679736_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679736_7"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred recurring losses since inception, anticipates net losses and negative operating cash flows for the near future, and may be unable to remain in compliance with certain financial covenants required under its credit facilities. Through September&#160;30, 2024, the Company has funded its operations primarily with proceeds from the sale of its Common Stock, convertible preferred stock, issuance of convertible notes, issuance of term loans, and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including losses from operations of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49022">33.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49023">53.3</ix:nonFraction>&#160;million and cash outflows from operating activities of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49024">29.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49025">43.1</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively. As of September&#160;30, 2024, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49026">218.4</ix:nonFraction>&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and the potential of being unable to remain in compliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679739" id="ixv-29740">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of Significant Accounting Policies </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no significant changes, except as described below, to the significant accounting policies disclosed in Note 2 of the &#8220;Notes to Consolidated Financial Statements&#8221; to the consolidated audited financial statements as of and for the year ended December&#160;31, 2023 included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> </div><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-29751"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-29756"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the RTW Convertible Notes (defined below) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The RTW Convertible Notes accounted for under the FVO election was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the RTW Convertible Notes were recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the RTW Convertible Notes were expensed as incurred. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-60</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679739" continuedAt="TextSelectionAppend_127679739_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679739_1" continuedAt="TextSelectionAppend_127679739_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679739_2" continuedAt="TextSelectionAppend_127679739_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679739_3" continuedAt="TextSelectionAppend_127679739_4"><ix:nonNumeric name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-29779"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Reclassification of Prior Year Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustment has been made to the condensed consolidated balance sheet as of December&#160;31, 2023, to present the Legacy Allurion common stock warrant liabilities as part of the Warrant liabilities line item. These amounts were part of the Other liabilities line item in prior years. </div></ix:nonNumeric><ix:nonNumeric name="alur:MezzanineEquityPolicyTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-29784"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Mezzanine Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mezzanine equity represents the Series A Preferred Stock (defined below) issued by the Company. The shares of Series A Preferred Stock are redeemable at a determinable price on a fixed date, which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. Refer to Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock and Stockholder&#8217;s Deficit,</div></div> for additional information regarding the Series A Preferred Stock. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-29791"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49028"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49029"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49030"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49031"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49032"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49033">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenue for the three and nine months ended September&#160;30, 2024 and 2023 or accounts receivable, net balance as of September&#160;30, 2024 and December&#160;31, 2023. <ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679832" id="ixv-49034">The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </ix:nonNumeric></div><ix:continuation id="TextSelection_127679832"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49035">18</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49036">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49037">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49038">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49039">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49040">11</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679830" id="ixv-29954"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity, </div></div>which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The Company <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-49041">adopted</ix:nonNumeric> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> effective <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:date-monthname-day-year-en" id="ixv-49042">January 1, 2024</ix:nonNumeric> under the modified retrospective method of transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true" id="ixv-49043">did not</ix:nonNumeric> have an impact on the Company&#8217;s condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-61</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_127679830" continuedAt="TextSelectionAppend_127679830_1"><ix:continuation id="TextSelectionAppend_127679739_4" continuedAt="TextSelectionAppend_127679739_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679739_5" continuedAt="TextSelectionAppend_127679739_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679739_6" continuedAt="TextSelectionAppend_127679739_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679739_7"><ix:continuation id="TextSelectionAppend_127679830_1"><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div></ix:continuation></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679741" id="ixv-29997">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Business Combination </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately <ix:nonFraction name="alur:BusinessCombinationCommonStockExchangeRatio" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-49045">0.9780</ix:nonFraction>, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Legacy Allurion common stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio, (d)&#160;each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#8220;Rollover Warrant&#8221;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#8220;Sponsor&#8221;) to CPUH, which balance was $<ix:nonFraction name="alur:SponsorLoanExcessAmount" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49046">3.7</ix:nonFraction>&#160;million at the time of the Business Combination, were converted into <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49047">525,568</ix:nonFraction> shares of Allurion Common Stock. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49048">1.420455</ix:nonFraction> shares of Allurion Common Stock. Additionally, the Company assumed <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49049">13,206,922</ix:nonFraction> outstanding public warrants to purchase an aggregate <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P08_01_2023To08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49050">18,759,838</ix:nonFraction>&#160;shares of Allurion Common Stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49051">8.10</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company incurred approximately $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49052">22.7</ix:nonFraction>&#160;million of transaction costs, consisting of legal and other professional fees, of which $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49053">15.2</ix:nonFraction>&#160;million was recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital as a reduction of proceeds, $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49054">2.5</ix:nonFraction>&#160;million was recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49055">5.0</ix:nonFraction>&#160;million was recorded as an expense in general and administrative expenses on the condensed consolidated statement of operations and comprehensive </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-62</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679741" continuedAt="TextSelectionAppend_127679741_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_1" continuedAt="TextSelectionAppend_127679741_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_2" continuedAt="TextSelectionAppend_127679741_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679741_3" continuedAt="TextSelectionAppend_127679741_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">loss. Of the $<ix:nonFraction name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49058">5.0</ix:nonFraction>&#160;million recorded as general and administrative expenses, $<ix:nonFraction name="alur:BusinessCombinationOneTimeInsurancePayment" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49059">3.6</ix:nonFraction>&#160;million relates to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $<ix:nonFraction name="alur:DirectCostsAndFees" contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49060">1.2</ix:nonFraction>&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW (as defined below). </div><ix:nonNumeric name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30031"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49061">38,395</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49062">37,922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:GrossProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49063">76,317</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:BusinessCombinationTransactionCostPaid" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49064">14,665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:NetProceedsFromBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49065">61,652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:WarrantLiabilitiesAssumed" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49066">13,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:RepaymentOfNoteAssumedInBusinessCombination" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49067">2,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:BusinessAcquisitionAccruedTransactionCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49068">580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:BusinessCombinationNetOfTransactionCosts" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49069">44,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30144"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49070">27,897,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49071">5,165,698</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49072">5,386,695</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49073">1,900,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49074">3,301,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49075">3,262,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49076">387,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49077">47,301,409</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Trust Contributed Shares. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">PIPE Investment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023, with certain accredited investors and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-63</ix:exclude> </div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_127679741_4" continuedAt="TextSelectionAppend_127679741_5"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_127679741_5" continuedAt="TextSelectionAppend_127679741_6"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679741_6" continuedAt="TextSelectionAppend_127679741_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">qualified institutional buyers (the &#8220;PIPE Investors&#8221;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49080">5,386,695</ix:nonFraction> shares of Allurion Common Stock at a purchase price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49081">7.04</ix:nonFraction> per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49082">37.9</ix:nonFraction>&#160;million, following the CPUH Merger Effective Time (the &#8220;PIPE Investment&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement (the &#8220;Revenue Interest Financing Agreement&#8221;) with certain entities that engaged RTW Investments, LP (together with its affiliates, &#8220;RTW&#8221;) as investment manager. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $<ix:nonFraction name="alur:ProceedsFromRevenueInterestFinancing" contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49083">40.0</ix:nonFraction>&#160;million (the &#8220;Investment Amount&#8221;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to <ix:nonFraction name="alur:PercentageOfAnnualNetSales" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49084">6.0</ix:nonFraction>% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to <ix:nonFraction name="alur:RemittanceOfRevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49085">10.0</ix:nonFraction>% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. The Revenue Interest Financing Agreement was amended pursuant to the RIFA Amendment (as defined below) on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the Company entering into the Revenue Interest Financing Agreement, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#8220;RTW Side Letter&#8221;) on February&#160;9, 2023 under which RTW may elect to convert up to $<ix:nonFraction name="alur:ConversionOfPipeInvestmentToRevenueInterestFinance" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49086">7.5</ix:nonFraction>&#160;million of its initial PIPE Investment into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by its PIPE Investment. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#8220;Amended and Restated RTW Side Letter&#8221;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49087">250,000</ix:nonFraction> shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender <ix:nonFraction name="alur:NumberOfSurrenderSharesOfCommonStock" contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49088">749,998</ix:nonFraction> shares of Common Stock of the Company representing $<ix:nonFraction name="alur:SurrenderCommonStockValue" contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49089">7.5</ix:nonFraction>&#160;million in consideration for the New RIFA (as defined below). Refer to Note 19, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>, below for further discussion on the RTW conversion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Fortress Credit Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#8220;Fortress Term Loan&#8221;) pursuant to a Credit Agreement and Guaranty, dated as of August&#160;1, 2023 (the &#8220;Fortress Credit Agreement&#8221;), with Fortress Credit Corp. (&#8220;Fortress&#8221;), as administrative agent for the lenders party thereto from time to time (the &#8220;Lenders&#8221;). Under the terms of the Fortress Term Loan, we borrowed $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49090">60.0</ix:nonFraction>&#160;million, which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement (as defined below), Allurion issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49091">950,000</ix:nonFraction> shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for further discussion on the Fortress Term Loan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-64</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679741_7" continuedAt="TextSelectionAppend_127679741_8"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_8" continuedAt="TextSelectionAppend_127679741_9"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_9" continuedAt="TextSelectionAppend_127679741_10"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679741_10" continuedAt="TextSelectionAppend_127679741_11"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Backstop Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#8220;Backstop Purchasers&#8221;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#8220;HVL&#8221;) entered into the backstop agreement (the &#8220;Backstop Agreement&#8221;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing, (a)&#160;each Backstop Purchaser purchased $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49093">2</ix:nonFraction>&#160;million of the aggregate principal amount outstanding of HVL&#8217;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49094">2</ix:nonFraction>&#160;million each and (d)&#160;Allurion issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49095">700,000</ix:nonFraction> shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion around the Backstop Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">HVL Termination Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#8220;HVL Termination Agreement&#8221;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#8217;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49096">387,696</ix:nonFraction> shares of Allurion Common Stock. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion regarding the HVL Termination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Gaur Contribution Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#8220;Gaur Trust&#8221;) and Allurion entered into a contribution agreement (the &#8220;Gaur Contribution Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, <ix:nonFraction name="alur:ContributionOfCapitalByJointVenturePartner" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49097">79,232</ix:nonFraction> shares of Allurion Common Stock (the &#8220;Gaur Trust Contributed Shares&#8221;). The Gaur Trust&#8217;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RSU Forfeiture Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Krishna Gupta, a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221; or &#8220;Board of Directors&#8221;), entered into a letter agreement with Legacy Allurion (the &#8220;RSU Forfeiture Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49098">79,232</ix:nonFraction> restricted stock units of Allurion (the &#8220;Forfeited RSUs&#8221;). The Forfeited RSUs were terminated and cancelled without consideration therefor immediately following the closing of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Sponsor Contribution Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#8220;Sponsor Contribution Agreement&#8221;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, <ix:nonFraction name="alur:ContributionOfCapitalByJointVenturePartner" contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49099">161,379</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock (&#8220;Sponsor Contributed Shares&#8221;). The Sponsor&#8217;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Sponsor Support Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion entered into a support agreement (the &#8220;Sponsor Support Agreement&#8221;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-65</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679741_11" continuedAt="TextSelectionAppend_127679741_12"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_12" continuedAt="TextSelectionAppend_127679741_13"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679741_13" continuedAt="TextSelectionAppend_127679741_14"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679741_14"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Sponsor&#8217;s <ix:nonFraction name="alur:RecapitalizationOfCommonStock" contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49102">21,442,500</ix:nonFraction> shares of Compute Health Class&#160;B Common Stock, and all <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49103">12,833,333</ix:nonFraction> of the Sponsor&#8217;s warrants to purchase shares of Class&#160;A Common Stock, into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49104">2,088,327</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement recapitalized his or her <ix:nonFraction name="alur:RecapitalizationOfAdditionalShares" contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49105">30,000</ix:nonFraction> shares of Compute Health Class&#160;B Common Stock into <ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49106">21,120</ix:nonFraction> shares of Compute Health Class&#160;A Common Stock (the &#8220;CPUH Recapitalization&#8221;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49107">1.420455</ix:nonFraction> (the &#8220;CPUH Exchange Ratio&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $<ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49108">21.8</ix:nonFraction>&#160;million were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49109">3,301,222</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital (&#8220;APIC&#8221;) of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49110">25.6</ix:nonFraction>&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further information on the Company&#8217;s convertible notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Public Warrants and Warrant Amendment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company assumed <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49111">13,206,922</ix:nonFraction> outstanding public warrants (the &#8220;Public Warrants&#8221;) to purchase an aggregate <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P08_01_2023To08_01_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49112">18,759,838</ix:nonFraction> shares of Allurion Common Stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49113">8.10</ix:nonFraction> per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49114">13.8</ix:nonFraction>&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-share</div> settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock and Stockholders Deficit</div></div> and Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the Public Warrants and Warrant Amendment. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the share price achieves certain targets (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Earn-Out</div> Shares&#8221;). The Company accounts for the potential issuance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares as a contingent consideration arrangement, which was initially valued and recorded at $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="PAsOn08_01_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49115">53.0</ix:nonFraction>&#160;million. See Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679744" id="ixv-30385">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue </div></div></td></tr></table><ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679843" id="ixv-30394"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49116">966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49117">3,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024_AUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49118">543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_AUsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49119">979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Italy</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024_ITsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49120">511</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_ITsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49121">626</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_CLsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49122">1,956</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49123">3,347</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49124">11,122</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49125">5,367</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49126">18,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-66</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679744" continuedAt="TextSelectionAppend_127679744_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679744_1" continuedAt="TextSelectionAppend_127679744_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679744_2" continuedAt="TextSelectionAppend_127679744_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679744_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49128">1.8</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49129">five</ix:nonFraction> countries included within All Other Countries in the table above, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49130">34</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49131">5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49132">8</ix:nonFraction>% of the total. Remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49133">36</ix:nonFraction> other countries included within All Other Countries. For the three months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49134">5.9</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49135">five</ix:nonFraction> countries included within All Other Countries, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49136">33</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49137">5</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49138">7</ix:nonFraction>% of the total. Remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49139">45</ix:nonFraction> other countries included within All Other Countries. </div><ix:continuation id="TextSelection_127679843"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024_ESsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49140">3,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_ESsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49141">3,715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United Kingdom</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024_GBsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49142">2,534</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_GBsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49143">3,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49144">2,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49145">4,423</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49146">1,573</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49147">5,495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49148">16,980</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49149">28,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49150">26,519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49151">45,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2024, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49152">7.2</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49153">five</ix:nonFraction> countries included within All Other Countries in the table above, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49154">27</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49155">4</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49156">8</ix:nonFraction>% of the total. Remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49157">49</ix:nonFraction> other countries included within All Other Countries. For the nine months ended September&#160;30, 2023, $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49158">11.1</ix:nonFraction>&#160;million of revenue was generated in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenue" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49159">five</ix:nonFraction> countries included within All Other Countries, representing approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49160">25</ix:nonFraction>% of Total Revenues, with each country responsible for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49161">4</ix:nonFraction>% to <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49162">7</ix:nonFraction>% of the total. Remaining revenue was generated by sales in <ix:nonFraction name="alur:NumberOfCountriesGenerateRevenueBySales" contextRef="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis" unitRef="Unit_Country" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49163">58</ix:nonFraction>&#160;other countries included within All Other Countries. <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P07_01_2024To09_30_2024_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49164"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49165">No</ix:nonFraction></ix:nonFraction> revenue was generated in the United States for the three and nine months ended September&#160;30, 2024. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30668">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventory </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30677"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49166">2,748</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49167">3,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49168">1,005</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49169">967</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49170">815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49171">1,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49172">4,568</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49173">6,171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is stated net of $<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49174">0.7</ix:nonFraction>&#160;million and less than $<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49175">0.1</ix:nonFraction>&#160;million for the provision for excess and obsolete inventory as of September&#160;30, 2024 and December&#160;31, 2023, respectively. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-67 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30790">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and Equipment, net </div></div></td></tr></table><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-30799"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Useful Life<br/> (in Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-49176">3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49177">618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49178">618</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="white-space:nowrap;vertical-align:bottom"><br/> &#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49179">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49180">1,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear" id="ixv-49181">5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49182">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49183">291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-49184">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear" id="ixv-49185">5</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49186">3,507</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49187">2,893</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49188">6,359</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49189">5,745</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49190">4,169</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49191">3,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ConstructionInProgress" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49192">890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:ConstructionInProgress" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49193">1,195</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49194">3,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49195">3,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfDepreciationExpenseTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-31050"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49196"><ix:nonFraction name="us-gaap:Depreciation" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49197">0.2</ix:nonFraction></ix:nonFraction>&#160;million for each of the three months ended September&#160;30, 2024 and 2023, and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49198">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49199">0.6</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, recorded as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49200">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49201">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49202">433</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49203">280</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49204">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49205">48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49206">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49207">131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49208">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49209">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49210">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49211">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49212">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49213">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49214">80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49215">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49216">215</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49217">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49218">778</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49219">558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-31256">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accrued Expenses and Other Current Liabilities </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-31265"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketing reimbursement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DistributorFeesAndMarketingReimbursements" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49220">930</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:DistributorFeesAndMarketingReimbursements" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49221">2,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49222">1,733</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49223">1,687</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedClinicalTrialsAndResearchAndDevelopment" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49224">81</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedClinicalTrialsAndResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49225">3,694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49226">592</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49227">1,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49228">493</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49229">1,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StandardProductWarrantyAccrualCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49230">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StandardProductWarrantyAccrualCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49231">44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:AccruedRestructuringCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49232">655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49233">4,128</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49234">3,966</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49235">7,973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49236">15,495</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with strategic initiatives implemented during the year ended December&#160;31, 2023, the Company&#8217;s management approved and initiated plans to reduce its cost structure. During the nine months ended September&#160;30, 2024, the Company recorded less than $<ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49237">0.1</ix:nonFraction>&#160;million in restructuring charges and paid $<ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49238">0.7</ix:nonFraction>&#160;million in restructuring charges. <ix:nonFraction name="us-gaap:RestructuringCharges" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt-sec:numwordsen" id="ixv-49239"><ix:nonFraction name="us-gaap:PaymentsForRestructuring" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt-sec:numwordsen" id="ixv-49240">No</ix:nonFraction></ix:nonFraction> restructuring charges were incurred or paid during the three months ended September&#160;30, 2024. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-68 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679757" id="ixv-31430">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Debt </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-31439"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49241">43,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49242">49,320</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amount of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49243">49,320</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49244">43,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:ChangeInFairValueOfDebt" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49245">13,230</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:LoanAccretion" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49246">148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49247">38,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49248">4,605</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49249">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the fair value for the Company&#8217;s Fortress Term Loan approximated the carrying amount. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Term Loans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company entered into a loan and security agreement (as amended, the &#8220;2021 Term Loan&#8221; and the &#8220;2021 Term Loan Agreement&#8221;) with Runway Growth Credit Fund, Inc. (&#8220;Runway&#8221;) that provided for borrowings up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49250">25.0</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the 2021 Term Loan Agreement was amended (the &#8220;Amendment&#8221;) to extend the maturity date of the 2021 Term Loan to <ix:nonNumeric name="us-gaap:LineOfCreditFacilityExpirationDate1" contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-49251">December 30, 2025</ix:nonNumeric> and provide for an additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49252">20.0</ix:nonFraction>&#160;million of borrowings. In December 2021, the Company issued warrants exercisable for <ix:nonFraction name="alur:ExercisableWarrantsIssuedAsConsideration" contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49253">132,979</ix:nonFraction> shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $<ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49254"><ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49255">0.3</ix:nonFraction></ix:nonFraction>&#160;million upon issuance and are classified as a warrant liability on the condensed consolidated balance sheet as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49256">130,053</ix:nonFraction> shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and certain financial covenants. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things, increase additional borrowing up to $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49257">15.0</ix:nonFraction>&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During June through December of 2022, the Company drew an additional $<ix:nonFraction name="alur:AdditionalBorrowings" contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49258">30.0</ix:nonFraction>&#160;million of the 2021 Term Loan and warrants exercisable for <ix:nonFraction name="alur:ExercisableWarrantsIssuedAsConsideration" contextRef="P06_01_2022To12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49259">88,440</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were issued. The fair value of these warrants was determined to be $<ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49260"><ix:nonFraction name="alur:FairValueOfTheWarrants" contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49261">0.8</ix:nonFraction></ix:nonFraction>&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, the warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49262">88,440</ix:nonFraction> shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were converted into warrants exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49263">90,476</ix:nonFraction> shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49264">58.0</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="alur:RepaymentOfPrincipal" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49265">55.0</ix:nonFraction>&#160;million repayment of principal, a </div><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-69 </div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679757" continuedAt="TextSelectionAppend_127679757_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_1" continuedAt="TextSelectionAppend_127679757_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_2" continuedAt="TextSelectionAppend_127679757_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679757_3" continuedAt="TextSelectionAppend_127679757_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$<ix:nonFraction name="alur:PrepaymentFee" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49266">1.1</ix:nonFraction>&#160;million prepayment fee, and a $<ix:nonFraction name="alur:FinalPaymentFee" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49267">1.6</ix:nonFraction>&#160;million final payment fee. The prepayment fee was calculated as <ix:nonFraction name="alur:PrepaymentFeePercentage" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49268">2</ix:nonFraction>% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as the <ix:nonFraction name="alur:FinalPaymentFeePercentage" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49269">3</ix:nonFraction>% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $<ix:nonFraction name="alur:OriginalFinalPayment" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49270">0.1</ix:nonFraction>&#160;million. The Company recorded a $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49271">3.9</ix:nonFraction>&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the three months ended September&#160;30, 2023 related to the 2021 Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49272">0.8</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49273">0.7</ix:nonFraction>&#160;million of contractual interest, and $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49274">0.1</ix:nonFraction>&#160;million of amortization of the debt discount, amortization of warrant, and term loan accretion. Interest expense for the nine months ended September&#160;30, 2023 related to the 2021 Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49275">5.0</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49276">4.7</ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49277">0.1</ix:nonFraction>&#160;million amortization of the debt discount, $<ix:nonFraction name="alur:AmortizationOfTheWarrant" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49278">0.1</ix:nonFraction>&#160;million of amortization of the warrant, and $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49279">0.1</ix:nonFraction>&#160;million of term loan accretion. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49280">60</ix:nonFraction>&#160;million. <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis" id="ixv-49281">The Fortress Term Loan had a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" format="ixt:date-monthname-day-year-en" id="ixv-49282">June 30, 2027</ix:nonNumeric> and accrued interest per annum at a rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49283">6.44</ix:nonFraction>% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49284">3.0</ix:nonFraction>%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to <ix:nonFraction name="alur:DebtInstrumentExitPaymentPercentage" contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49285">3.0</ix:nonFraction>% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.</ix:nonNumeric> The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49286">2.5</ix:nonFraction>&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#8220;Fortress Amendment&#8221;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49287">12.5</ix:nonFraction>&#160;million to $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49288">33.5</ix:nonFraction>&#160;million until March&#160;31, 2024, $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49289">23.5</ix:nonFraction>&#160;million from April&#160;1, 2024 to June&#160;30, 2024, $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49290">16.9</ix:nonFraction>&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $<ix:nonFraction name="alur:MinimumLiquidityAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49291">12.5</ix:nonFraction>&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provided that at any time after March&#160;31, 2024, each lender had the right to convert a portion of the outstanding principal amount, not to exceed the lender&#8217;s proportionate share of a maximum of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49292">20.0</ix:nonFraction>&#160;million in aggregate outstanding principal amount, into shares of Allurion Common Stock at a conversion price based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> volume weighted average price (&#8220;VWAP&#8221;) of Allurion Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#8217;s conversion right. As part of the Fortress Amendment, the Company prepaid $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49293">20.0</ix:nonFraction>&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49294">3.1</ix:nonFraction>&#160;million of fees were incurred and considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in-kind</div></div> and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees were amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>. In connection with the modification and related prepayment, the Company wrote off $<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49295">0.8</ix:nonFraction>&#160;million of the unamortized debt issuance costs, which was recorded within interest expense on the condensed consolidated statement of operations for the year ended December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of <ix:nonFraction name="alur:DebtInstrumentDefaultInterestRate" contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49296">3</ix:nonFraction>% that will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;), the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#8220;Term Loan Derivative Liability&#8221;) that is required to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded derivative was determined to be immaterial. The Term Loan Derivative Liability was </div></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_4" continuedAt="TextSelectionAppend_127679757_5"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-70 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679757_5" continuedAt="TextSelectionAppend_127679757_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_6" continuedAt="TextSelectionAppend_127679757_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_7" continuedAt="TextSelectionAppend_127679757_8"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679757_8" continuedAt="TextSelectionAppend_127679757_9"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fair valued to <ix:nonFraction name="us-gaap:DerivativeFairValueOfDerivativeLiability" contextRef="PAsOn09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-49297">zero</ix:nonFraction> in connection with the repayment of the Fortress Term Loan, with a corresponding $<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49298">2.0</ix:nonFraction>&#160;million gain recorded in <div style="display:inline;"><div style="-sec-ix-hidden:hidden127682733;display:inline;">other income, net</div></div> in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, the Company repaid all outstanding obligations under the Fortress Term Loan with proceeds from the Amended Note Purchase Agreement (as defined below) with RTW. The total payoff amount was $<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49299">48.0</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="alur:RepaymentOfPrincipal" contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49300">43.1</ix:nonFraction>&#160;million repayment of principal, a $<ix:nonFraction name="alur:PrepaymentFee" contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49301">2.7</ix:nonFraction>&#160;million prepayment fee, a $<ix:nonFraction name="alur:DebtInstrumentExitFee" contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49302">1.3</ix:nonFraction>&#160;million exit fee, $<ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49303">0.6</ix:nonFraction>&#160;million of other fees paid directly to Fortress, and $<ix:nonFraction name="us-gaap:InterestReceivable" contextRef="PAsOn04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49304">0.3</ix:nonFraction>&#160;million of accrued interest. The Company recorded an $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-49305">8.7</ix:nonFraction>&#160;million loss on extinguishment of debt in connection with the Fortress Term Loan repayment in the condensed consolidated statement of operations for nine months ended September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the three and nine months ended September&#160;30, 2023 related to the Fortress Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49306"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49307">1.7</ix:nonFraction></ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49308"><ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49309">1.5</ix:nonFraction></ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49310"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49311">0.1</ix:nonFraction></ix:nonFraction>&#160;million amortization of the debt discount, and term loan accretion of $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49312"><ix:nonFraction name="alur:TermLoanAccretion" contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49313">0.1</ix:nonFraction></ix:nonFraction>&#160;million. The average interest rate during the three months ended September&#160;30, 2023 was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49314">14.94</ix:nonFraction>%. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&#160;30, 2024 related to the Fortress Term Loan was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49315">2.3</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49316">1.9</ix:nonFraction>&#160;million of contractual interest, $<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49317">0.3</ix:nonFraction>&#160;million amortization of the debt discount, and term loan accretion of $<ix:nonFraction name="alur:TermLoanAccretion" contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49318">0.1</ix:nonFraction>&#160;million. There was <ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen" id="ixv-49319">no</ix:nonFraction> interest expense for the three months ended September&#160;30, 2024 due to the extinguishment of the Fortress Term Loan on April&#160;16, 2024. The average interest rate through April&#160;16, 2024 was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="P01_01_2024To04_16_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49320">14.94</ix:nonFraction>%. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company entered into a convertible note agreement with investors for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49321">2.0</ix:nonFraction>&#160;million with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-49322">5.0</ix:nonFraction>% per annum (the &#8220;2021 Convertible Notes&#8221;) and a maturity date <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-49323">36 months</ix:nonNumeric> from the date of issuance unless previously converted pursuant to their terms of the agreement. <ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-49324">No</ix:nonFraction> issuance costs were incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#8220;deSPAC&#8221;) transaction, closing of a qualified financing, or closing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> financing, all of the outstanding principal and interest would automatically convert into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $<ix:nonFraction name="alur:ConversionDividedByCappedConversionPrice" contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49325">600.0</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2021 Convertible Notes was less than $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49326">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49327">0.1</ix:nonFraction>&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49328">133,617</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49329">2.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2022 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, the Company entered into a convertible note purchase agreement with investors for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49330">1.1</ix:nonFraction>&#160;million with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-49331">5.0</ix:nonFraction>% per annum (the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes were to mature <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-49332">36 months</ix:nonNumeric> from the issuance date unless previously converted pursuant to the terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible Notes. </div></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_9" continuedAt="TextSelectionAppend_127679757_10"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-71 </div></ix:exclude></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_127679757_10" continuedAt="TextSelectionAppend_127679757_11"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_127679757_11" continuedAt="TextSelectionAppend_127679757_12"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679757_12" continuedAt="TextSelectionAppend_127679757_13"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2022 Convertible Notes was less than $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49333"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49334">0.1</ix:nonFraction></ix:nonFraction>&#160;million, consisting entirely of contractual interest. Interest expense related to the 2022 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49335">83,216</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49336">1.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of convertible notes (the &#8220;2023 Convertible Notes&#8221;) to certain investors for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49337">28.7</ix:nonFraction>&#160;million, with a stated interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-49338">7.0</ix:nonFraction>% per annum. The 2023 Convertible Notes provided that they would mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en" id="ixv-49339">December 31, 2026</ix:nonNumeric> unless previously converted pursuant to the terms of the note purchase agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of Legacy Allurion common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $<ix:nonFraction name="alur:ConversionDividedByDiscountedCappedConversionPrice" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49340">217.3</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the 2023 Convertible Notes provided that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $<ix:nonFraction name="alur:CappedPrice" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49341">260.0</ix:nonFraction>&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as <ix:nonFraction name="alur:PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49342">85</ix:nonFraction>% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the fair FVO election of ASC 825 as the notes contain embedded derivatives, including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2023 Convertible Notes was $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49343">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49344">0.5</ix:nonFraction>&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023 the Company entered into termination agreements (the &#8220;Termination Agreements&#8221;) with respect to side letters entered into with certain holders of the 2023 Convertible Notes. With respect to the Termination Agreement with HVL, the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under such holder&#8217;s 2023 Convertible Note (the &#8220;HVL Bridge Note&#8221;), including by way of (a)&#160;a $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49345">2</ix:nonFraction>&#160;million payment in cash by the Company to HVL on May&#160;2, 2023, $<ix:nonFraction name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49346">1.5</ix:nonFraction>&#160;million of which was deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $<ix:nonFraction name="alur:RepaymentOfPrincipal" contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49347">0.5</ix:nonFraction>&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49348">6</ix:nonFraction>&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the HVL Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the HVL Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified </div></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_13" continuedAt="TextSelectionAppend_127679757_14"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-72 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679757_14" continuedAt="TextSelectionAppend_127679757_15"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_15" continuedAt="TextSelectionAppend_127679757_16"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_16" continuedAt="TextSelectionAppend_127679757_17"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679757_17" continuedAt="TextSelectionAppend_127679757_18"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Termination Agreement executed with HVL, the Company agreed to issue to HVL a number of shares of Allurion Common Stock (&#8220;PubCo Additional Shares&#8221;) equal to (a)&#160;the outstanding principal and accrued interest under the HVL Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $<ix:nonFraction name="alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49349">5.00</ix:nonFraction>, plus (b) <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49350">300,000</ix:nonFraction> shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period, with changes in fair value reflected in earnings until the PubCo Additional Shares were issued. A $<ix:nonFraction name="alur:DeferredLiabilityForIssuanceOfAdditionalShares" contextRef="PAsOn05_02_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49351">3.4</ix:nonFraction>&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, HVL was issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49352">387,696</ix:nonFraction> PubCo Additional Shares with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49353">2.7</ix:nonFraction>&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further on May&#160;2, 2023, RTW and Fortress as the Backstop Purchasers entered into the Backstop Agreement with the Company, Legacy Allurion and HVL. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any HVL Bridge Notes remained outstanding prior to the consummation of the Business Combination, such Backstop Purchaser would, at the closing of the Business Combination, purchase up to $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49354">2.0</ix:nonFraction>&#160;million of the HVL Bridge Notes from HVL in exchange for shares of Allurion Common Stock (the &#8220;Base PubCo Shares&#8221;, &#8220;Backstop Shares&#8221; and &#8220;Conditional Additional PubCo Shares&#8221;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares were issued. A $<ix:nonFraction name="alur:DeferredLiabilityForIssuanceOfAdditionalShares" contextRef="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49355">3.3</ix:nonFraction>&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and Backstop Agreement, the Backstop Purchasers were each issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49356">950,000</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49357">13.4</ix:nonFraction>&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $<ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49358">6.3</ix:nonFraction>&#160;million of the HVL Bridge Note, leaving a principal balance of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49359">6.3</ix:nonFraction>&#160;million. Each Backstop Purchaser then purchased $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49360">2.0</ix:nonFraction>&#160;million principal amount of the outstanding portion of the HVL Bridge Note, Allurion canceled the existing HVL Bridge Note and issued a new convertible note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49361">2.7</ix:nonFraction>&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49362">2.0</ix:nonFraction>&#160;million each, and Allurion issued <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49363">700,000</ix:nonFraction> shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49364">3,084,389</ix:nonFraction> shares of Allurion Common Stock with a corresponding recognition of APIC of $<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49365">22.2</ix:nonFraction>&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2024, the Company entered into a note purchase agreement (the &#8220;Original Note Purchase Agreement&#8221;) with RTW as agent for the purchasers (the &#8220;Purchasers&#8221;) party thereto from time to time (RTW in such capacity, the &#8220;Principal Purchaser&#8221;), and Acquiom Agency Services LLC (&#8220;Acquiom&#8221;) as collateral agent for the Purchasers. Subsequently, on April&#160;16, 2024, the Company, the Principal Purchaser, the Purchasers, and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the Original Note Purchase Agreement as amended, the &#8220;Amended Note Purchase Agreement&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49366">48.0</ix:nonFraction>&#160;million of convertible senior secured notes (the &#8220;RTW Convertible Notes&#8221;). The RTW Convertible Notes bear interest at an </div></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_18" continuedAt="TextSelectionAppend_127679757_19"><ix:exclude><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-73 </div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679757_19" continuedAt="TextSelectionAppend_127679757_20"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_20" continuedAt="TextSelectionAppend_127679757_21"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679757_21" continuedAt="TextSelectionAppend_127679757_22"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679757_22"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annual rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-49367">6</ix:nonFraction>%, which interest is paid quarterly in cash or, at the Company&#8217;s option, in kind for the first three years. The RTW Convertible Notes will mature on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P04_14_2024To04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en" id="ixv-49368">April 16, 2031</ix:nonNumeric> unless previously converted pursuant to the terms of the Amended Note Purchase Agreement. The RTW Convertible Notes are convertible into shares of Allurion Common Stock, at a Purchaser&#8217;s election at any time after the earliest of (i)&#160;the date on which Stockholder Approval (as defined below) is obtained, (ii)&#160;December&#160;31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Amended Note Purchase Agreement), and (iv)&#160;the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on a conversion rate of <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-49369">617.2840</ix:nonFraction> shares of common stock per $<ix:nonFraction name="alur:DebtInstrumentPrincipalAmountForConversionIntoCommonStock" contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49370">1,000</ix:nonFraction> principal amount of Notes (equivalent to a conversion price of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49371">1.62</ix:nonFraction> per share, which represents a <ix:nonFraction name="alur:DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49372">35</ix:nonFraction>% premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49373">15,000,000</ix:nonFraction> (the &#8220;Next Equity Financing&#8221;). On July&#160;1, 2024, we consummated the Public Offering, as described elsewhere in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q,</div> which constituted a Next Equity Financing. The Amended Note Purchase Agreement provides that unless and until requisite approval of the Company&#8217;s stockholders is obtained (&#8220;Stockholder Approval&#8221;), the Company will not deliver Allurion Common Stock upon conversion of the RTW Convertible Notes in excess of <ix:nonFraction name="alur:DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal" id="ixv-49374">1</ix:nonFraction>% of the number of shares of Allurion Common Stock outstanding as of April&#160;14, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RTW Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives, including the conversion upon Stockholder Approval, the conversion upon a Fundamental Change Company Notice, the conversion upon a Make-Whole Fundamental Change, redemption upon the event of default, and redemption upon a Fundamental Change, which would require bifurcation and separate accounting. The RTW Convertible Notes were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes at issuance was $<ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49375">49.1</ix:nonFraction>&#160;million, with a corresponding $<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49376">1.1</ix:nonFraction>&#160;million loss recognized in Other income, net in the condensed consolidated statement of operations. In connection with the issuance of the RTW Convertible Notes and RIFA Amendment (as defined below), we incurred $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49377">1.4</ix:nonFraction>&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election of the RTW Convertible Notes and Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, the Company recorded gains of $<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancing" contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49378">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49379">3.1</ix:nonFraction>&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded gains of $<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancing" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49380">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49381">3.0</ix:nonFraction>&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Note Purchase Agreement contains financial maintenance covenants, which require (i)&#160;the Company maintain not less than $<ix:nonFraction name="alur:UnrestrictedCash" contextRef="PAsOn04_14_2024_MaximumMembersrtRangeAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49382">12,500,000</ix:nonFraction> in unrestricted cash in controlled accounts in the U.S. at all times, (ii)&#160;the Company to receive minimum trailing twelve-month consolidated revenue at amounts designated in the Amended Note Purchase Agreement, tested quarterly beginning with the twelve-month period ending March&#160;31, 2025, and (iii)&#160;the Company&#8217;s and its subsidiaries&#8217; consolidated business operations outside the United States to be profitable for the trailing three-month period, tested quarterly beginning with the three-month period ending December&#160;31, 2025. The Company is in compliance with the covenants in the Amended Note Purchase Agreement as of September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected paid in kind interest for the three and nine months ended September&#160;30, 2024 related to the RTW Convertible Notes. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679760" id="ixv-31789">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-74</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679760" continuedAt="TextSelectionAppend_127679760_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679760_1" continuedAt="TextSelectionAppend_127679760_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679760_2" continuedAt="TextSelectionAppend_127679760_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679760_3" continuedAt="TextSelectionAppend_127679760_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$<ix:nonFraction name="alur:RevenuesInterestFinancingLiability" contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49385">40.0</ix:nonFraction>&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to <ix:nonFraction name="alur:PercentageOfAnnualNetSales" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49386">6.0</ix:nonFraction>% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to <ix:nonFraction name="alur:RemittanceOfRevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49387">10.0</ix:nonFraction>% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If RTW has not received aggregate revenue interest payments equal to at least <ix:nonFraction name="alur:RevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49388">100</ix:nonFraction>% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW up to <ix:nonFraction name="alur:CashPaymentsPercentage" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49389">100</ix:nonFraction>% of the Investment Amount. If RTW has not received revenue interest payments equal to at least <ix:nonFraction name="alur:RevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49390">240</ix:nonFraction>% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to <ix:nonFraction name="alur:CashPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49391">240</ix:nonFraction>% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of <ix:nonFraction name="alur:RevenueInterestPaymentsPercentage" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49392">260</ix:nonFraction>% of the Investment Amount (the &#8220;Hard Cap&#8221;). In addition, prior to December&#160;31, 2025, the Company may prepay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-specified</div> payment amount (the &#8220;Prepayment Amount&#8221;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to <ix:nonFraction name="alur:PrePaymentsPercentage" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49393">165</ix:nonFraction>% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and separate accounting. The Revenue Interest Financing was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. In connection with the issuance of the Investment Amount, we paid $<ix:nonFraction name="us-gaap:DeferredFinanceCostsGross" contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49394">1.2</ix:nonFraction>&#160;million in issuance costs in August 2023, which were directly expensed through general and administrative expense due to the FVO election. As of September&#160;30, 2024, the Company has made $<ix:nonFraction name="alur:RoyaltyPayments" contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49395">3.6</ix:nonFraction>&#160;million in royalty payments to RTW. Refer to Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>, for additional information regarding the changes in fair value of the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, and in connection with the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement was amended pursuant to the Omnibus Amendment (the &#8220;RIFA Amendment&#8221;) by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned subsidiary of the Company, the Original RIFA Investors (as defined therein) and RTW, on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries for net sales less than or equal to $<ix:nonFraction name="alur:SalesRevenueNet" contextRef="P12_30_2026To12_30_2026_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49396">100</ix:nonFraction>&#160;million prior to December&#160;31, 2026 from <ix:nonFraction name="alur:PercentageOfNetSales" contextRef="P12_30_2026To12_30_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49397">6</ix:nonFraction>% to <ix:nonFraction name="alur:PercentageOfNetSales" contextRef="P12_31_2026To12_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49398">12</ix:nonFraction>% and increased the rate on net sales in less than or equal to $<ix:nonFraction name="alur:IncreaseInSalesRevenueNet" contextRef="P01_01_2027To01_01_2027_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-49399">100</ix:nonFraction>&#160;million on or after January&#160;1, 2027 from <ix:nonFraction name="alur:PercentageOfIncreaseInNetSales" contextRef="P01_01_2027To01_01_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49400">10</ix:nonFraction>% to <ix:nonFraction name="alur:PercentageOfIncreaseInNetSales" contextRef="P01_02_2027To01_02_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49401">12</ix:nonFraction>%. Additionally, the Prepayment Amount was modified such that, prior to March&#160;31, 2026, the Company is entitled to settle the Revenue Interest Financing for a prepayment amount that would allow the investors to yield a <ix:nonFraction name="alur:PercentageOfInternalRateOfReturn" contextRef="PAsOn03_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49402">20</ix:nonFraction>% internal rate of return. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $<ix:nonFraction name="alur:VolumeWeightedAveragePricePerShare" contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49403">7.04</ix:nonFraction> for the average of <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_Days" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49404">20</ix:nonFraction> trading days within any <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_Days" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49405">30</ix:nonFraction> trading day period (&#8220;Stock Price Drop&#8221;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49406">10.00</ix:nonFraction> per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $<ix:nonFraction name="alur:ConversionOfPipeInvestmentToRevenueInterestFinance" contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49407">7.5</ix:nonFraction>&#160;million of its initial PIPE Investment into </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-75</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679760_4" continuedAt="TextSelectionAppend_127679760_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679760_5" continuedAt="TextSelectionAppend_127679760_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679760_6" continuedAt="TextSelectionAppend_127679760_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679760_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE Investment. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49410">3.3</ix:nonFraction>&#160;million within Other liabilities on the condensed consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RIFA Amendment was accounted for as a modification with the change in fair value of the PIPE Conversion Option treated as an exchange between the Company and RTW as part of the RIFA Amendment. As such, the Revenue Interest Financing and PIPE Conversion Option were remeasured as of April&#160;16, 2024 just prior to the RIFA Amendment, to $<ix:nonFraction name="alur:RevenueInterestFinancingAgreementRemeasuredValue" contextRef="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49411">33.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="alur:PipeConversionOptionRemeasuredValue" contextRef="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49412">6.6</ix:nonFraction>&#160;million, respectively. The Revenue Interest Financing and PIPE Conversion Option were subsequently remeasured as of April&#160;16, 2024 under the terms of the RIFA Amendment, to $<ix:nonFraction name="alur:RevenueInterestFinancingAgreementRemeasuredValue" contextRef="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49413">39.0</ix:nonFraction>&#160;million and $<ix:nonFraction name="alur:PipeConversionOptionRemeasuredValue" contextRef="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49414">4.6</ix:nonFraction>&#160;million, respectively. As of September&#160;30, 2024, the fair value of the Revenue Interest Financing and PIPE Conversion Option were $<ix:nonFraction name="alur:FairValueOfRevenueInterestFinancingAgreements" contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49415">38.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="alur:FairValueOfPipeConversionOption" contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49416">9.9</ix:nonFraction>&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, the Company recorded a $<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancing" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49417">6.7</ix:nonFraction>&#160;million loss and a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49418">5.8</ix:nonFraction>&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded a $<ix:nonFraction name="alur:ChangesInFairValueOfRevenueInterestFinancing" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49419">5.4</ix:nonFraction>&#160;million loss and a $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49420">0.6</ix:nonFraction>&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. The changes in fair value were recorded in the Changes in fair value of Revenue Interest Financing and PIPE Conversion Option in the condensed consolidated statement of operations. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679764" id="ixv-31846">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div></td></tr></table><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127681654" id="ixv-31855"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for the Company&#8217;s assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49421">23,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49422">23,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49423">23,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49424">23,749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49425">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49426">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49427">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49428">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49429">5,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49430">5,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49431">810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49432">810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49433">38,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49434">38,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49435">9,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49436">9,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49437">1,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49438">1,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49439">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49440">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49441">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49442">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49443">93,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49444">531</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49445">93,155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-76</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127681654" continuedAt="TextSelectionAppend_127681654_1"><ix:continuation id="TextSelection_127679764" continuedAt="TextSelectionAppend_127679764_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_1" continuedAt="TextSelectionAppend_127679764_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_2" continuedAt="TextSelectionAppend_127679764_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679764_3" continuedAt="TextSelectionAppend_127679764_4"><ix:continuation id="TextSelectionAppend_127681654_1">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49447">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49448">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49449">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49450">30,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49451">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49452">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49453">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49454">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49455">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49456">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49457">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49458">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49459">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49460">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49461">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49462">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49463">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49464">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49465">74,463</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49466">5,943</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49467">68,520</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination on August&#160;1, 2023, the Company recorded a liability for Public Warrants to purchase the Company&#8217;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as September&#160;30, 2024 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49468">0.04</ix:nonFraction>, which is a Level&#160;1 input. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-77</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_127679764_4" continuedAt="TextSelectionAppend_127679764_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679764_5" continuedAt="TextSelectionAppend_127679764_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_6" continuedAt="TextSelectionAppend_127679764_7"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679764_7" continuedAt="TextSelectionAppend_127679764_8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Warrants, Public Offering Warrants, and Private Placement Warrants </div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-32743"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), and Private Placement Warrants (defined below) within Level&#160;3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, and Private Placement Warrants: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy&#160;Allurion&#160;Series&#160;C&#160;Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30,&#160;2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49470">3.65</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49471">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49472">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49473">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49474">6.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49475">3.59</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49476">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49477">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49478">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49479">2.94</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49480">3.65</ix:nonFraction>%&#160;-</div><br/> <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49481">3.71</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49482">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49483">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49484">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49485">6.5</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49486">7.96</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49487">3.58</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49488">1.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49489">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49490">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49491">4.75</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49492">3.58</ix:nonFraction>%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49493">1.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49494">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49495">90</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49496">4.75</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series&#160;C Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49497">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49498">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49499">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49500">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49501">7.25</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49502">3.95</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49503">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49504">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49505">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49506">3.69</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49507">3.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49508">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49509">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49510">100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49511">7.25</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear" id="ixv-49512">8.71</ix:nonNumeric></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expected dividend yield for all calculations is <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49513"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49514">0.00</ix:nonFraction></ix:nonFraction>%. </div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127681658" id="ixv-33103"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the three and nine months ended September&#160;30, 2024 and 2023 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:37%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49515">2,679</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49516">1,351</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49517">4,030</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681126;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49518">1,571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49519">555</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49520">2,126</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49521">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49522">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49523">53</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49524">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49525">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49526">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49527">715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49528">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49529">922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49530">110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49531">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49532">145</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49533">13,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49534">1,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49535">14,827</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681127;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49536">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49537">19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49538">7,187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49539">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49540">8,121</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49541">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49542">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49543">5,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49544">810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49545">6,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection_127681658" continuedAt="TextSelectionAppend_127681658_1"><ix:continuation id="TextSelectionAppend_127679764_8" continuedAt="TextSelectionAppend_127679764_9"><ix:exclude> <div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-78 </div> </ix:exclude></ix:continuation></ix:continuation></div> </div> </div> <ix:continuation id="TextSelectionAppend_127681658_1" continuedAt="TextSelectionAppend_127681658_2"><ix:continuation id="TextSelectionAppend_127679764_9" continuedAt="TextSelectionAppend_127679764_10"><div></div></ix:continuation></ix:continuation> </div> <ix:continuation id="TextSelectionAppend_127681658_2" continuedAt="TextSelectionAppend_127681658_3"><ix:continuation id="TextSelectionAppend_127679764_10" continuedAt="TextSelectionAppend_127679764_11"><div> <div style="line-height:normal;display: inline;"> <ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude> <ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></div> </div></ix:continuation></ix:continuation> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679764_11" continuedAt="TextSelectionAppend_127679764_12"><ix:continuation id="TextSelectionAppend_127681658_3">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49546">1,777</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49547">596</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49548">2,373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680849;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49549">647</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49550">200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49551">447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49552">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49553">75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49554">340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49555">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49556">929</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49557">715</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49558">207</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49559">922</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49560">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49561">179</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49562">821</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49563">13,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49564">1,670</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49565">14,827</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680850;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49566">587</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49567">163</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49568">7,187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49569">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49570">8,797</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49571">55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49572">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49573">5,970</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49574">810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49575">6,851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2019 Term Loan Success Fee Derivative Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The derivative liability for the success fee associated with Legacy Allurion&#8217;s November 2019 loan and security agreement with Western Alliance Bank (the &#8220;2019 Term Loan&#8221; and such fee, the &#8220;Success Fee&#8221;) was recorded at fair value as of September&#160;30, 2024 and December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within <ix:nonNumeric name="alur:FairValueAssumptionsOfLiquidityEventTerm" contextRef="P01_01_2024To09_30_2024_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis" format="ixt-sec:durwordsen" id="ixv-49576">four years</ix:nonNumeric> from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the 2023 Convertible Notes, using the share price at conversion ($<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49577">7.04</ix:nonFraction> per share). Upon the conversion of the 2023 Convertible Notes, the convertible note liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of September&#160;30, 2024 and December&#160;31, 2023 using a discounted cash flow (&#8220;DCF&#8221;) method under the income approach utilizing future revenue projections and a discount rate of <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn09_30_2024_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-49578">23.5</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal" id="ixv-49579">24.4</ix:nonFraction>%, respectively. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" escape="true" id="ixv-34051"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method (&#8220;MCSM&#8221;) using the number of shares convertible of <ix:nonFraction name="alur:FairValueOfEstimatedNumberOfShares" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49580">1,065,341</ix:nonFraction> and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49581">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49582">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49583">4.03</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49584">4.46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-49585">0.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-49586">1.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49587">130.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49588">82.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-79</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679764_12" continuedAt="TextSelectionAppend_127679764_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_13" continuedAt="TextSelectionAppend_127679764_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_14" continuedAt="TextSelectionAppend_127679764_15"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679764_15" continuedAt="TextSelectionAppend_127679764_16"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion Common Stock, with the change in fair value recognized in Change in the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities in the consolidated statement of operations. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" escape="true" continuedAt="TextSelection_127681661" id="ixv-34146">The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares was determined using a MCSM with the following assumptions at each valuation date: </ix:nonNumeric></div><ix:continuation id="TextSelection_127681661"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49590">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49591">3.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49592">3.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49593">3.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-49594">3.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-49595">4.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49596">105.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49597">87.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Term Loan Derivative Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan derivative liability associated with the Fortress Term Loan was derecognized during the second quarter of 2024 as the Fortress Term Loan was repaid on April&#160;16, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RTW Convertible Notes are accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently measured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes was remeasured as of September&#160;30, 2024 using a DCF method under the income approach with a MCSM applied to determine the simulated stock price at each payment date and event that may trigger conversion of the RTW Convertible Notes. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" escape="true" continuedAt="TextSelection_127681663" id="ixv-49598">The fair value was measured using the $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49599">48.0</ix:nonFraction>&#160;million principal amount of the RTW Convertible Notes and the following assumptions: </ix:nonNumeric></div><ix:continuation id="TextSelection_127681663"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%"/>
<td style="vertical-align:bottom;width:18%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49600">0.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49601">3.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear" id="ixv-49602">6.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49603">90.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-80</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679764_16" continuedAt="TextSelectionAppend_127679764_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_17" continuedAt="TextSelectionAppend_127679764_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_18" continuedAt="TextSelectionAppend_127679764_19"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679764_19" continuedAt="TextSelectionAppend_127679764_20"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" escape="true" continuedAt="TextSelection_127681660" id="ixv-34291"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, Term Loan Derivative liability, RTW Convertible Notes, PubCo Share liability, Base PubCo and Backstop Share liability, and Warrant Overallotment Liability categorized with Level&#160;3 inputs for the three and nine months ended September&#160;30, 2024 and 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:29%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49605">213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49606">16,793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49607">3,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49608">3,305</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49609">23,638</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49610">9,150</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49611">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49612">3,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49613">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49614">105,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49615">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49616">6,008</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49617">3,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49618">2,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49619">24,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49620">599</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49621">10,065</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49622">10,357</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49623">10,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49624">10,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49625">21,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49626">2,728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49627">13,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49628">37,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49629">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49630">36,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49631">5,440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49632">28,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49633">70,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49634">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49635">39,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49636">5,450</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49637">4,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49638">40,950</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49639">89,524</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49640">6,704</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49641">4,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49642">2,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49643">1,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49644">7,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49645">5,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49646">3,070</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49647">8,870</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49648">1,404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49649">1,404</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49650">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49651">38,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49652">9,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49653">1,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49654">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49655">86,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49656">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49657">178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49658">28,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49659">40,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49660">3,340</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49661">53,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49662">3,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49663">3,264</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49664">131,714</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49665">166</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49666">3,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49667">3,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49668">2,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49669">24,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49670">642</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49671">10,106</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49672">12,581</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49673">10,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49674">10,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49675">21,701</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49676">2,728</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49677">13,370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49678">37,799</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49679">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49680">36,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49681">5,440</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49682">28,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49683">70,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-81</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div></div><ix:continuation id="TextSelection_127681660" continuedAt="TextSelectionAppend_127681660_1"><ix:continuation id="TextSelectionAppend_127679764_20" continuedAt="TextSelectionAppend_127679764_21"><div></div></ix:continuation></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_127681660_1" continuedAt="TextSelectionAppend_127681660_2"><ix:continuation id="TextSelectionAppend_127679764_21" continuedAt="TextSelectionAppend_127679764_22"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_22" continuedAt="TextSelectionAppend_127679764_23"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679764_23" continuedAt="TextSelectionAppend_127679764_24"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679764_24"><ix:continuation id="TextSelectionAppend_127681660_2">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:26%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49685">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49686">36,200</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49687">5,600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49688">23,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49689">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49690">67,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49691">49,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49692">49,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49693">5,358</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49694">4,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49695">22,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49696">1,895</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49697">10,020</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49698">24,447</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49699">600</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49700">2,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49701">3,590</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49702">2,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49703">2,458</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49704">14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49705">38,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49706">9,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49707">1,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49708">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49709">36,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49710">86,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> liability, Term Loan Derivative liability, RTW Convertible <div style="display:inline;">Not</div>es, Pubco Share liability, and Base PubCo and Backstop Share liability at each period is recorded as a component of Other income (expense) in the condensed consolidated statements of operations, with the exception of the changes in fair value associated with the change in credit risk related to the Revenue Interest Financing and RTW Convertible Notes, which is recorded as a component of other comprehensive loss. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-36041">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49711">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49712">0.2</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2024, respectively, representing effective tax rates of (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-49713">0.8</ix:nonFraction>%) and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-49714">3.9</ix:nonFraction>%), respectively. The Company recorded income tax expense for the three and nine months ended September&#160;30, 2023 of less than $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49715">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49716">0.1</ix:nonFraction>&#160;million, respectively, representing effective tax rates of (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-49717">0.2</ix:nonFraction>%) and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-49718">0.1</ix:nonFraction>%), respectively. The tax expense recorded relates to the earnings of the Company&#8217;s profitable foreign subsidiaries. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024 and 2023, the Company maintained a full valuation allowance against its net deferred tax assets as the Company has incurred significant operating losses since inception and has concluded that its net deferred tax asset is not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> realizable. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024 and 2023, the Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49719"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-49720">no</ix:nonFraction></ix:nonFraction>t recorded tax reserves for any uncertain tax provisions. </div></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="alur:RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127682734" id="ixv-36055">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Preferred Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with RTW, pursuant to which the Company agreed to sell to RTW <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49721">2,260,159</ix:nonFraction> shares of a newly created series of preferred stock, the Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> convertible preferred stock, par value $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49722">0.0001</ix:nonFraction> per share (&#8220;Series A Preferred Stock&#8221;), and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49723">2,260,159</ix:nonFraction> private placement warrants (&#8220;Private Placement Warrants&#8221;) to purchase common stock, equal to the per share Public Offering (defined below) price for the shares of common stock and Public Offering Warrants (defined below) in the Public Offering (the &#8220;Private Placement&#8221;). The Private Placement closed on July&#160;1, 2024 with net proceeds received of $<ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49724">2.5</ix:nonFraction>&#160;million after deducting offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49725">0.2</ix:nonFraction>&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-82</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127682734" continuedAt="TextSelectionAppend_127682734_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_1" continuedAt="TextSelectionAppend_127682734_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_2" continuedAt="TextSelectionAppend_127682734_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127682734_3" continuedAt="TextSelectionAppend_127682734_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants met the definition of a derivative under ASC 815. The gross proceeds from the Private Placement were first allocated to the Private Placement Warrants based on its issue-date estimated fair value of $<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49727">1.7</ix:nonFraction>&#160;million. The Private Placement Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The remaining gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49728">1.0</ix:nonFraction>&#160;million were allocated to the Series A Preferred Stock. Of the $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49729">0.2</ix:nonFraction>&#160;million in offering costs, $<ix:nonFraction name="alur:ReductionInProceedsFromOffering" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49730">0.1</ix:nonFraction>&#160;million was recorded against the Series A Preferred Stock as a reduction of proceeds and $<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49731">0.1</ix:nonFraction>&#160;million was expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Certificate of Incorporation authorizes the issuance of up to <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49732">100,000,000</ix:nonFraction> shares of Allurion preferred stock. As of September&#160;30, 2024, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49733">2,260,159</ix:nonFraction> shares of Allurion Series A Preferred Stock were outstanding. The rights and preferences of the Series A Preferred Shares are as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stockholders have <ix:nonNumeric name="us-gaap:PreferredStockVotingRights" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-49734">no</ix:nonNumeric> voting rights. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock participates in dividends with Common Stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis when declared by the Board of Directors. <ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-49735">No</ix:nonFraction> dividends were declared through September&#160;30, 2024. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="alur:PreferredStockLiquidationPreferenceBasis" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-36103">In the event of any voluntary or involuntary liquidation, dissolution, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">winding-up</div> of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder&#8217;s Series A&#160;Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share.</ix:nonNumeric> </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:PreferredStockConversionBasis" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-36109">Each share of Series A Preferred Stock is convertible after the date that the Company&#8217;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#8220;Series A Stockholder Approval&#8221;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.</ix:nonNumeric></div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="alur:PreferredStockRedemptionBasis" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-49736">Each share of Series A&#160;Preferred Stock outstanding on December&#160;31, 2026 (the &#8220;Redemption Date&#8221;) shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the &#8220;Redemption Price&#8221;). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet.</ix:nonNumeric> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-83</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127682734_4" continuedAt="TextSelectionAppend_127682734_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_5" continuedAt="TextSelectionAppend_127682734_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_6" continuedAt="TextSelectionAppend_127682734_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127682734_7" continuedAt="TextSelectionAppend_127682734_8"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Certificate of Incorporation authorizes the issuance of up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49738">1,000,000,000</ix:nonFraction> shares of Allurion Common Stock. As of September&#160;30, 2024 and December&#160;31, 2023, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49739">64,369,381</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49740">47,688,096</ix:nonFraction> shares of Common Stock were outstanding, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC and TD Securities (USA) LLC, as representative of the several underwriters (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_28_2024To06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49741">14,406,508</ix:nonFraction> shares of the Company&#8217;s Common Stock and warrants (&#8220;Public Offering Warrants&#8221;) to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49742">14,406,508</ix:nonFraction> shares of the Company&#8217;s Common Stock at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49743">1.20</ix:nonFraction> per share and accompanying warrant (the &#8220;Public Offering&#8221;). The Public Offering closed on July&#160;1, 2024 with net proceeds received of $<ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49744">15.2</ix:nonFraction>&#160;million after deducting underwriting discounts of $<ix:nonFraction name="alur:UnderwritingDiscounts" contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49745">1.0</ix:nonFraction>&#160;million and offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49746">1.0</ix:nonFraction>&#160;million. The Underwriters fully exercised their option for additional Public Offering Warrants, with <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49747">2,160,976</ix:nonFraction> additional Public Offering Warrants issued at closing, for a total of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49748">16,567,484</ix:nonFraction> Public Offering Warrants. Further, the Underwriters exercised a portion of the option with respect to the Common Stock (the &#8220;Share Overallotment&#8221;) on July&#160;5, 2024 for net proceeds of $<ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49749">2.2</ix:nonFraction>&#160;million, which resulted in the issuance of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49750">1,927,265</ix:nonFraction> shares of the Company&#8217;s Common Stock at an offering price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49751">1.20</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Offering Warrants met the definition of a derivative under ASC 815 and the Share Overallotment met the requirements for equity classification under ASC 815. The $<ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49752">17.4</ix:nonFraction>&#160;million in net proceeds from the Public Offering and exercise of the Share Overallotment were first allocated to the Public Offering Warrants based on their issue-date estimated fair value of $<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" contextRef="PAsOn07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49753">13.2</ix:nonFraction>&#160;million. The Public Offering Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49754">0.8</ix:nonFraction>&#160;million offerings costs allocated to the Public Offering Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $<ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_01_2024To07_01_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49755"><ix:nonFraction name="alur:NetProceedsFromIssuanceOrSaleOfEquity" contextRef="P07_01_2024To07_01_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49756">5.1</ix:nonFraction></ix:nonFraction>&#160;million were allocated to Common Stock and APIC. </div><ix:nonNumeric name="alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-36137"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of September&#160;30, 2024, is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49757">7,108,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49758">530,778</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49759">19,231,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49760">18,759,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49761">2,260,159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_EarnOutSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49762">9,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_ConvertibleNotesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49763">479,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49764">57,369,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Warrants to Purchase Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127682736" id="ixv-49765">As of September&#160;30, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49766">403,658</ix:nonFraction> Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. </ix:nonNumeric></div><ix:continuation id="TextSelection_127682736" continuedAt="TextSelectionAppend_127682736_1"><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-84</ix:exclude> </div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127682736_1" continuedAt="TextSelectionAppend_127682736_2"><ix:continuation id="TextSelectionAppend_127682734_8" continuedAt="TextSelectionAppend_127682734_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_9" continuedAt="TextSelectionAppend_127682734_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_10" continuedAt="TextSelectionAppend_127682734_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127682734_11" continuedAt="TextSelectionAppend_127682734_12"><ix:continuation id="TextSelectionAppend_127682736_2"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49768">16,567,484</ix:nonFraction> Public Offering Warrants and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49769">2,260,159</ix:nonFraction> Private Placement Warrants outstanding to purchase Common Stock. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td style="width:36%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49770">0.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common&#160;Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49771">44,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49772">2.44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49773">6.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49774">130,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49775">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49776">8.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49777">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49778">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49779">7.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49780">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49781">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49782">2.3</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49783">73,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49784">0.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49785">2.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49786">9,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49787">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49788">2.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49789">28,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49790">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49791">3.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49792">17,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49793">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49794">4.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49795">8,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49796">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">7/1/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49797">4.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49798">18,827,643</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49799">1.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49800">19,231,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td style="width:34%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49801">0.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49802">44,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49803">2.44</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49804">7.2</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49805">130,053</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49806">6.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49807">8.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49808">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49809">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49810">8.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49811">45,238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49812">12.14</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49813">3.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49814">73,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49815">0.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49816">3.6</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49817">9,779</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49818">1.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49819">3.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49820">28,764</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49821">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49822">4.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49823">17,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49824">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:duryear" id="ixv-49825">5.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49826">8,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49827">1.05</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49828">403,658</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr> </table> </ix:continuation> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Compute Health&#8217;s initial public offering, it sold units at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49829">10.00</ix:nonFraction> per unit, which consisted of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49830">one</ix:nonFraction> share of Class&#160;A Common Stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49831">0.0001</ix:nonFraction> par value, of Compute Health (&#8220;Class A Common Stock&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden127682683;display:inline;">one-half</div></div> of a redeemable warrant (each a &#8220;Public Warrant&#8221;) that entitled the holder to purchase <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-49832">one</ix:nonFraction> share of Class&#160;A Common Stock of CPUH at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49833">11.50</ix:nonFraction> per share. On July&#160;26, 2023, Compute Health&#8217;s Public Warrant holders approved an amendment (the &#8220;Warrant Amendment&#8221;) to the warrant agreement that governed all Compute Health&#8217;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="6" scale="0" format="ixt:num-dot-decimal" id="ixv-49834">1.420455</ix:nonFraction> shares of the Company&#8217;s Common Stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49835">8.10</ix:nonFraction> per share and each whole Compute Health Public Warrant was exchanged for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightUnissued" contextRef="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="4" scale="0" format="ixt:num-dot-decimal" id="ixv-49836">0.6125</ix:nonFraction> Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for cash at a price of $<ix:nonFraction name="alur:WarrantsRedumptionPricePerShare" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49837">0.01</ix:nonFraction> per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price the Company&#8217;s Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49838">12.67</ix:nonFraction> per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $<ix:nonFraction name="alur:WarrantsRedumptionPricePerShare" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49839">0.10</ix:nonFraction> per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49840">7.04</ix:nonFraction> per share of any </div> </ix:continuation><ix:continuation id="TextSelectionAppend_127682734_12" continuedAt="TextSelectionAppend_127682734_13"><ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-85 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_127682734_13" continuedAt="TextSelectionAppend_127682734_14"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127682734_14" continuedAt="TextSelectionAppend_127682734_15"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127682734_15" continuedAt="TextSelectionAppend_127682734_16"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127682734_16"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#8220;Redemption Fair Market Value&#8221;) of the shares of the Company&#8217;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#8217;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of September&#160;30, 2024, the Company has not redeemed any of the outstanding Public Warrants. As of September&#160;30, 2024, there were <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49841">13,206,720</ix:nonFraction> outstanding Public Warrants exercisable for <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2024To09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49842">18,759,554</ix:nonFraction> shares of Allurion Common Stock. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Chardan Equity Facility </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a Registration Rights Agreement, each with Chardan Capital Markets (&#8220;Chardan&#8221;) related to a &#8220;ChEF,&#8221; Chardan&#8217;s committed equity facility (the &#8220;Chardan Equity Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49843">100,000,000</ix:nonFraction>&#160;in aggregate gross purchase price of newly issued shares of the Company&#8217;s Common Stock, and (ii) <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49844">9,482,468</ix:nonFraction> shares of Common Stock, which number of shares is equal to <ix:nonFraction name="alur:PercentageOfCommonStockSharesOutstanding" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49845">19.99</ix:nonFraction>% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;). In consideration for Chardan&#8217;s entry into the Purchase Agreement, Allurion issued to Chardan <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49846">35,511</ix:nonFraction> shares of Allurion Common Stock (the &#8220;Commitment Shares&#8221;). The Company recorded $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49847">0.1</ix:nonFraction>&#160;million to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and $<ix:nonFraction name="alur:ExpenseOfIssuanceOfCommitmentShares" contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49848">0.1</ix:nonFraction>&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $<ix:nonFraction name="alur:StructuringFeePayable" contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49849">0.1</ix:nonFraction>&#160;million related to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> structuring fee immediately following commencement. As of September&#160;30, 2024, the Company had sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49850">143,234</ix:nonFraction>&#160;shares of Common Stock to Chardan at a purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49851">0.4</ix:nonFraction>&#160;million in connection with the Purchase Agreement. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679772" id="ixv-36905">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Net Loss per Share </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share was calculated as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:54%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49852">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49853">21,630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49854">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49855">61,427</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared preferred dividends to participating securities (Legacy Series&#160;D convertible preferred stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49856">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49857">255</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-49858">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49859">1,697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common shareholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49860">9,004</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49861">21,885</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49862">5,580</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-49863">63,124</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted weighted-average common stock outstanding</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49864"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49865">64,086,265</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49866"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49867">40,335,457</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49868"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49869">53,310,214</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49870"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49871">31,558,538</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49872"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49873">0.14</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49874"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49875">0.54</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49876"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49877">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49878"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-49879">2.00</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share </div> <ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-86 </div> </ix:exclude></ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_127679772" continuedAt="TextSelectionAppend_127679772_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679772_1" continuedAt="TextSelectionAppend_127679772_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679772_2" continuedAt="TextSelectionAppend_127679772_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679772_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49880">7,108,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49881">4,270,229</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49882">530,778</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49883">429,321</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49884">2,260,159</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-49885">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49886">19,231,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49887">404,988</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49888">18,759,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49889">18,759,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49890">9,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49891">9,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49892">479,196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-49893">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49894">57,369,304</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49895">32,864,376</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679775" id="ixv-37381">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Incentive Plans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2010 Stock Incentive Plan (the &#8220;2010 Plan&#8221;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. On December&#160;11, 2020, the Company&#8217;s Board of Directors adopted the Amended and Restated 2020 Stock Option and Grant Plan (the &#8220;2020 Plan&#8221;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;), which provides for the award of stock options (both incentive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified),</div> stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. As of September&#160;30, 2024, a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49896">8,174,364</ix:nonFraction>&#160;shares of Allurion Common Stock are reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by <ix:nonFraction name="alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" contextRef="P01_01_2024To09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49897">5</ix:nonFraction>% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the compensation committee. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024,<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" contextRef="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49898">7,639,094</ix:nonFraction> options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2023, <ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" contextRef="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49899">4,529,673</ix:nonFraction> options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. The stock options generally vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-49900">four-year</ix:nonNumeric> period and expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-49901">10 years</ix:nonNumeric> from the date of grant. </div> <ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-87 </div> </ix:exclude></ix:nonNumeric></div> </div> </div> <ix:continuation id="TextSelection_127679775" continuedAt="TextSelectionAppend_127679775_1"><div></div></ix:continuation> </div> <div> <div style="line-height:normal;display: inline;"> <ix:continuation id="TextSelectionAppend_127679775_1" continuedAt="TextSelectionAppend_127679775_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679775_2" continuedAt="TextSelectionAppend_127679775_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679775_3" continuedAt="TextSelectionAppend_127679775_4"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679775_4" continuedAt="TextSelectionAppend_127679775_5"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-37421"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the condensed consolidated statement of operations was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49902">13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49903">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49904">24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49905">31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49906">791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49907">5,477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49908">2,109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49909">6,235</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49910">56</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49911">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49912">84</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49913">83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49914">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49915">5,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49916">2,217</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49917">6,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-37611"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the nine months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49918">3,886,038</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49919">2.67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-49920">6.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49921">5,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49922">3,686,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49923">1.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49924">447,644</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49925">2.28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49926">16,137</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49927">1.37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49928">7,108,316</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49929">2.28</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-49930">7.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49931">2,872,814</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49932">2.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-49933">5.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to stock option awards during the three and nine months ended September&#160;30, 2024 was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49934">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49935">1.4</ix:nonFraction>&#160;million, respectively. As of September&#160;30, 2024, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49936">5.6</ix:nonFraction>&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2010 Plan, 2020 Plan, and 2023 Plan, which is expected to be recognized over a weighted-average vesting term of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-49937">3.0</ix:nonNumeric> years. The weighted average grant-date fair value of the stock option awards granted during the nine months ended September&#160;30, 2024 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49938">1.30</ix:nonFraction> per option. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#8217;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-88</ix:exclude> </div></ix:continuation> </div> </div> <ix:continuation id="TextSelectionAppend_127679775_5" continuedAt="TextSelectionAppend_127679775_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679775_6" continuedAt="TextSelectionAppend_127679775_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679775_7" continuedAt="TextSelectionAppend_127679775_8"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div> <div> <div style="line-height:normal;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679775_8" continuedAt="TextSelectionAppend_127679775_9"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-37873"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49940">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49941">86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49942">4.36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-49943">4.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49944">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49945">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:duryear" id="ixv-49946">6.1</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To09_30_2023" format="ixt-sec:duryear" id="ixv-49947">5.8</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company issued RSUs to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div> for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2024To09_30_2024_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49948">62.5</ix:nonFraction>% of the RSUs awarded vested. Thereafter, the remaining <ix:nonFraction name="alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-49949">37.5</ix:nonFraction>% of the RSUs vest monthly over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-49950">two years</ix:nonNumeric>. All RSUs are subject to forfeiture if the grantee&#8217;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. In October 2023 and March 2024, the Company issued RSUs to its Board of Director members that vest in equal installments over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To09_30_2024_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen" id="ixv-49951">three years</ix:nonNumeric>, subject to continued service as a director through each vesting date. </div> <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-37959"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">of RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49952">643,635</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49953">4.45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49954">75,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49955">2.61</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49956">187,857</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49957">4.51</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49958">530,778</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-49959">4.16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to RSUs for the three and nine months ended September&#160;30, 2024 was $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P07_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49960">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49961">0.8</ix:nonFraction>&#160;million, respectively. As of September&#160;30, 2024, there were $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49962">1.0</ix:nonFraction>&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To09_30_2024" format="ixt-sec:duryear" id="ixv-49963">1.6</ix:nonNumeric> years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#8217;s Common Stock through payroll deductions at a price equal to <ix:nonFraction name="alur:PercentageOfPriceLowerOfFairValueMarketValue" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49964">85</ix:nonFraction>% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#8217;s payroll deductions under the 2023 ESPP are limited to <ix:nonFraction name="alur:PercentageOfEmployeesCompensationToPayrollDeductions" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49965">15</ix:nonFraction>% of the employee&#8217;s compensation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49966">2,226,122</ix:nonFraction> shares of the Company&#8217;s Common Stock are reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 </div> </ix:continuation><ix:continuation id="TextSelectionAppend_127679775_9" continuedAt="TextSelectionAppend_127679775_10"><ix:exclude> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-89 </div> </ix:exclude></ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_127679775_10" continuedAt="TextSelectionAppend_127679775_11"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679775_11" continuedAt="TextSelectionAppend_127679775_12"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679775_12" continuedAt="TextSelectionAppend_127679775_13"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <ix:continuation id="TextSelectionAppend_127679775_13"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ESPP will automatically increase each January&#160;1, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) <ix:nonFraction name="alur:PercentageOfDilutedSharesOutstanding" contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-49967">1</ix:nonFraction>% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-49968">1,600,000</ix:nonFraction> shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of September&#160;30, 2024, no shares have been issued under the 2023 ESPP. </div> </ix:continuation> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38112">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Employee Benefit Plan </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. During each of the three and nine months ended September&#160;30, 2024 and 2023, the Company&#8217;s matching contributions to the plan were less than $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-49969"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49970">0.1</ix:nonFraction></ix:nonFraction>&#160;million. </div> </ix:nonNumeric> <div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679782" id="ixv-38123">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseDescription" contextRef="P01_01_2024To09_30_2024" id="ixv-49971">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.</ix:nonNumeric> As a result of these amendments, the leases in Natick and Hudson will now expire between March 2025 and <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-49972"><ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis" format="ixt:date-monthname-year-en" id="ixv-49973">March 2028</ix:nonNumeric></ix:nonNumeric>, and additional operating lease assets obtained in exchange for lease obligations were $<ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49974">0.9</ix:nonFraction>&#160;million. In April 2024, the Company executed an amendment to one of its leases in Natick, Massachusetts. The amendment was accounted for as a modification of the existing lease agreement, with impacts to the lease term, lease payments, and related lease liability for the lease. As a r<div style="letter-spacing: 0px; top: 0px;display:inline;">es</div>ult of this amendment, the lease in Natick will now expire in March 2025 and additional operating lease assets obtained in exchange for lease obligations were less than $<ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2024To04_30_2024_NatickAndHudsonMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-49975">0.1</ix:nonFraction>&#160;million. In February 2024, the Company terminated one of its leases in Paris, France. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, the Company was a party to six different leases for office, manufacturing, and laboratory space under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> office leases in three cities. These leases total approximately <ix:nonFraction name="us-gaap:AreaOfLand" contextRef="PAsOn09_30_2024" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-49976">51,000</ix:nonFraction> square feet and will expire between <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P01_01_2024To09_30_2024_MinimumMembersrtRangeAxis" format="ixt:date-monthname-year-en" id="ixv-49977">March 2025</ix:nonNumeric> and <ix:nonNumeric name="alur:LesseeOperatingLeaseExpirationPeriod" contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis" format="ixt:date-monthname-year-en" id="ixv-49978">March 2028</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2024To09_30_2024" id="ixv-38141">The Company has a <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="P01_01_2024To09_30_2024" format="ixt:fixed-true" id="ixv-49979">right to extend</ix:nonNumeric> certain of these leases for periods between <div style="-sec-ix-hidden:hidden127680941;display:inline;">three</div> and <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-49980">five years</ix:nonNumeric>.</ix:nonNumeric> Under its real property leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. The Company also holds immaterial leases related to vehicles and office equipment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and lease liabilities are included in the condensed co<div style="letter-spacing: 0px; top: 0px;display:inline;">ns</div>olidated balance sheets. The short-term portion of the Company&#8217;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-90</ix:exclude> </div> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_127679782" continuedAt="TextSelectionAppend_127679782_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_127679782_1" continuedAt="TextSelectionAppend_127679782_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679782_2" continuedAt="TextSelectionAppend_127679782_3"><ix:exclude> <div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div> </ix:exclude></ix:continuation></div> </div> </div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679782_3" continuedAt="TextSelectionAppend_127679782_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Aggregate Lease Information </div></div></div><ix:nonNumeric name="alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38169"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information for the three and nine months ended September&#160;30, 2024 and 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49982">259</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49983">285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49984">794</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49985">834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49986">3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49987">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49988">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49989">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49990">59</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49991">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49992">194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49993">211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the <br/> measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49994">271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49995">284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49996">826</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49997">815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange <br/> for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P07_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49998">62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-49999">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To09_30_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50000">936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38326"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements as of September&#160;30, 2024 are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50001">273</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50002">1,044</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50003">739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50004">646</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="alur:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50005">108</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50006">2,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50007">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50008">2,456</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50009">878</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50010">1,578</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38439"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:15%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted -average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2024" format="ixt-sec:duryear" id="ixv-50011">2.9</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn06_30_2023" format="ixt-sec:duryear" id="ixv-50012">3.7</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-50013">9.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn06_30_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-50014">9.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Product Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not received any material product liability claims. Notwithstanding this, the Company has obtained insurance related to potential product liability claims. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Litigation and Claims </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, securities class actions, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of September&#160;30, 2024 and December&#160;31, 2023, the Company has <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-50015"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-50016">no</ix:nonFraction></ix:nonFraction>t recorded accruals for probable losses related to any existing or pending litigation or claims as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-91</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679782_4" continuedAt="TextSelectionAppend_127679782_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679782_5" continuedAt="TextSelectionAppend_127679782_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679782_6" continuedAt="TextSelectionAppend_127679782_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679782_7"><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">French Regulatory Decision </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2024, it was announced that the Agence Nationale de S&#233;curit&#233; du M&#233;dicament (&#8220;ANSM&#8221;), the French regulatory authority, has suspended sales of the Allurion Balloon in France, and the Company withdrew the device from the French market. The Company has implemented a remediation plan to reduce certain risks associated with the advertising, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">follow-up</div> program, and adverse events for the Allurion Balloon. For the three and nine months ended September&#160;30, 2024, the Company recognized a reduction to revenues of $<ix:nonFraction name="alur:IncreaseDecreaseInRevenuesForCustomerReturns" contextRef="P01_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50018"><ix:nonFraction name="alur:IncreaseDecreaseInRevenuesForCustomerReturns" contextRef="P07_01_2024To09_30_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50019">1.2</ix:nonFraction></ix:nonFraction>&#160;million for customer returns of the Allurion Balloon. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">NYSE Continued Listing Standards </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="alur:StockExchangeListingRequirementsDescription" contextRef="P01_01_2024To09_30_2024" id="ixv-38522">On August&#160;12, 2024, we received a letter from the NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#8217;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ending on the last trading day of that month. In the event that at the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2024, we received written notice from the NYSE that we are not in compliance with the con<div style="display:inline;">tinu</div>ed listing standard set forth in Section&#160;802.01B of the NYSE&#8217;s Listed Company Manual because the average market capitalization of the Company was less than $<ix:nonFraction name="alur:AverageMarketCapitalizationAmount" contextRef="P08_29_2024To08_29_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50020">50.0</ix:nonFraction>&#160;million over the consecutive <ix:nonFraction name="alur:NumberOfConsecutiveTradingDay" contextRef="P08_29_2024To08_29_2024" unitRef="Unit_TradingDay" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-50021">30</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ended August&#160;29, 2024 and the Company&#8217;s last reported stockholders&#8217; equity as of August&#160;29, 2024 was less than $<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn08_29_2024_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50022">50.0</ix:nonFraction>&#160;million. In accordance with applicable NYSE procedures, we submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice. If the NYSE accepts our plan, the NYSE will review the Company on a quarterly basis to confirm compliance with the plan. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38531">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Geographic Information </div></div></td></tr></table><ix:nonNumeric name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38540"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn09_30_2024_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50023">4,690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50024">5,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn09_30_2024_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50025">673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023_FRsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50026">1,010</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn09_30_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50027">5,363</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NoncurrentAssets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-50028">6,391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue</div></div> for information on revenue by geography. </div></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" continuedAt="TextSelection_127679788" id="ixv-38644">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Related-party Transactions </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Lease Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#8217;s then-Trade Marketing Director was the signor of this lease for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-92</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_127679788" continuedAt="TextSelectionAppend_127679788_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679788_1" continuedAt="TextSelectionAppend_127679788_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679788_2" continuedAt="TextSelectionAppend_127679788_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679788_3" continuedAt="TextSelectionAppend_127679788_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LNMP JPBS Invest. Additionally, the Company&#8217;s former Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50031">0.1</ix:nonFraction>&#160;million per year. The term of the lease was <ix:nonNumeric name="alur:OperatingLeaseStartDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-50032">August 1, 2022</ix:nonNumeric> through <ix:nonNumeric name="alur:OperatingLeaseEndDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-day-year-en" id="ixv-50033">July 31, 2025</ix:nonNumeric>. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">arm&#8217;s-length.</div> This lease was terminated in <ix:nonNumeric name="alur:LesseeOperatingLeaseTerminatedDate" contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt:date-monthname-year-en" id="ixv-50034">February 2024</ix:nonNumeric>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#8220;KKG Enterprises&#8221;) and Remus Group Management, LLC (&#8220;Remus Group Management&#8221;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $<ix:nonFraction name="alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50035">0.2</ix:nonFraction>&#160;million to KKG Enterprises and $<ix:nonFraction name="alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50036">0.3</ix:nonFraction>&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on <ix:nonNumeric name="alur:AgreementsTerminationDate" contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-50037">June 20, 2023</ix:nonNumeric>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Note with Hunter Ventures Limited </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, Allurion sold $<ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-50038">13</ix:nonFraction>&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than <ix:nonFraction name="alur:PercentageOfOutstandingCapitalStock" contextRef="P02_15_2023To02_15_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-50039">5</ix:nonFraction>% of our outstanding common stock). Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for additional information regarding the 2023 Convertible Notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Consulting Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion (&#8220;Allurion France&#8221;), entered into a corporate officer agreement with the Company&#8217;s then-Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The corporate officer agreement provided that BCC would receive base consulting fees of &#8364;<ix:nonFraction name="alur:RelatedPartyTransactionConsultingFees" contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" unitRef="Unit_EUR" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-50040">28,333.33</ix:nonFraction> per month and additional variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on <ix:nonNumeric name="alur:AgreementsTerminationDate" contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en" id="ixv-50041">December 12, 2023</ix:nonNumeric> by virtue of the termination agreement described below, effective December&#160;31, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Termination Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, Allurion France entered into a termination agreement with the Company&#8217;s Chief Commercial Officer, Benoit Chardon, and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC resigned from its duties as managing director of Allurion France effective December&#160;31, 2023. Allurion paid BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion paid BCC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lump-sum</div> termination fee of $<ix:nonFraction name="alur:RelatedPartyTransactionTerminationFees" contextRef="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50042">0.2</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Note Agreement with RTW </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, on April&#160;16, 2024, we issued and sold $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-50043">48</ix:nonFraction>&#160;million aggregate principal amount of convertible notes to RTW. RTW holds more than <ix:nonFraction name="alur:PercentageOfOutstandingCommonStock" contextRef="P04_16_2024To04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-50044">5</ix:nonFraction>% of our outstanding Common Stock, has the right to designate an independent director nominee to be elected by our stockholders, is entitled to designate one representative to serve as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> observer on our Board, and had the right to approve an </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><ix:exclude>&#160;</ix:exclude></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-93</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_127679788_4" continuedAt="TextSelectionAppend_127679788_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679788_5" continuedAt="TextSelectionAppend_127679788_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_127679788_6" continuedAt="TextSelectionAppend_127679788_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_127679788_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">additional director nominee for election In September 2024, we expanded our Board and appointed a new director in satisfaction of certain of these obligations to RTW as set forth in the Amended Note Purchase Agreement. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>, for additional information regarding the RTW Convertible Notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Participation in Public Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering, the Company issued and sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-50047">239,842</ix:nonFraction> shares of Common Stock and accompanying warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $<ix:nonFraction name="alur:AggregatePurchasePriceFromOffering" contextRef="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50048">0.3</ix:nonFraction>&#160;million. The Public Offering closed on July&#160;1, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Private Placement with RTW </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, pursuant to the Subscription Agreement, the Company agreed to sell to RTW <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-50049">2,260,159</ix:nonFraction> shares of Series A Preferred Stock, and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-50050">2,260,159</ix:nonFraction> Private Placement Warrants, for an aggregate purchase price of approximately $<ix:nonFraction name="alur:AggregatePurchasePriceFromOffering" contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50051">2.7</ix:nonFraction>&#160;million. The Private Placement closed on July&#160;1, 2024. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To09_30_2024" escape="true" id="ixv-38730">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Subsequent Events </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW PIPE Conversion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender <ix:nonFraction name="alur:NumberOfSurrenderSharesOfCommonStock" contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-50052">749,998</ix:nonFraction> shares of Common Stock of the Company representing $<ix:nonFraction name="alur:SurrenderCommonStockValue" contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50053">7.5</ix:nonFraction>&#160;million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October&#160;30, 2024, the Company and the funds affiliated with RTW entered into the additional Revenue Interest Financing Agreement (the &#8220;New RIFA&#8221;). The New RIFA has substantially identical terms and conditions as the RIFA Amendment, except that the amount of financing provided under the New RIFA is equal to the conversion amount of $<ix:nonFraction name="alur:ConversionOfPipeInvestmentToRevenueInterestFinance" contextRef="PAsOn10_30_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50054">7.5</ix:nonFraction>&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Restructuring Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2024, the Company&#8217;s board of directors approved a restructuring plan to reduce operating costs and better align its workforce with the needs of its business. The majority of the restructuring is expected to be completed in the fourth quarter of 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the restructuring plan, the Company is reducing its workforce by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_Employees" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-50055">113</ix:nonFraction> roles (approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-50056">50</ix:nonFraction>%). In connection with the restructuring, the Company estimates that it will incur <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> aggregate restructuring charges of approximately $<ix:nonFraction name="us-gaap:RestructuringCosts" contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-50057">3.5</ix:nonFraction>&#160;million, which will be recorded primarily in the fourth quarter of 2024, related to severance payments and other employee-related costs. The cash payments related to the personnel-related restructuring will be paid primarily during the first quarter of 2025. The charges that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-94 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to &#8195;&#8195;&#8195;&#8195;Shares of Common Stock </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Warrants to Purchase up to &#8195;&#8195;&#8195;&#8195;Shares of </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Common Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pre-Funded Warrants to Purchase up to &#8195;&#8195;&#8195;&#8195;Shares of Common Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195;Shares of Common Stock Underlying the Common Warrants </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;&#8195;Shares of Common Stock Underlying the Pre-Funded Warrants </p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g915839g01a03.jpg" alt="LOGO" style="width:2.30731in;height:0.471732in"/>
 </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">Allurion Technologies, Inc. </p> <p style="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PRELIMINARY PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">Placement Agent </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">Roth Capital Partners </p> <p style="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">&#8195;&#8195;&#8195;, 2024 </p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the estimated expenses to be borne by the registrant in connection with the securities being registered hereby. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Estimated<br/>Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,593.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial printing and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,593.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Directors and Officers </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in Section&#160;145(a) or (b)&#160;of the DGCL, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 of the DGCL shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 of the DGCL shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrators. Section&#160;145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section&#160;145 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director; provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL or (iv)&#160;for any transaction from which the director derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our Charter and Bylaws limit the liability of our (i)&#160;directors and (ii)&#160;officers, which includes each individual who has been duly appointed as an officer of Allurion and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service of process to our registered agent as contemplated by Section&#160;3114(b) of Title 10 of the DGCL, in each case, to the fullest extent permitted by the DGCL, and also provides that we indemnify our directors and officers to the fullest extent permitted by the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, we entered into indemnification agreements with each of our directors and executive officers, a form of which is filed as Exhibit 10.1 to this prospectus. These agreements provide that we indemnify each of our directors and officers to the fullest extent permitted by law and our Charter and Bylaws, and provides for advancement of expenses incurred as a result of any proceeding against them as to which they could be indemnified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a general liability insurance policy, which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June 28, 2024, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with RTW, pursuant to which the Company agreed to sell to RTW 2,260,159 shares of a newly created series of preferred stock, the Series A <span style="white-space:nowrap">non-voting</span> convertible preferred stock, par value $0.0001 per share (&#8220;Series A Preferred Stock&#8221;), and 2,260,159 private placement warrants (&#8220;Private Placement Warrants&#8221;) to purchase Common Stock, equal to the per share Public Offering price for the shares of Common Stock and Public Offering Warrants in the Public Offering (the &#8220;Private Placement&#8221;). The Private Placement closed on July&#160;1, 2024 with net proceeds received of $2.5&#160;million after deducting offering costs of $0.2&#160;million </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, on April&#160;16, 2024, we issued and sold $48&#160;million aggregate principal amount of convertible senior secured note to RTW in a private placement transaction, convertible into shares of our common stock based on the higher of (x)&#160;an initial conversion rate of 307.0797 shares of common stock per $1,000 principal amount of notes sold under the Amended Note Purchase Agreement and (y)&#160;a 35% conversion premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which we have raised aggregate gross offering proceeds of at least $15,000,000. The Notes bear interest at the annual rate of 6.0%, which interest is payable quarterly in cash or, at our option, in kind for the first three years. The maturity date for the Notes is April&#160;16, 2031. The Notes are guaranteed by Allurion Opco and certain other current and future subsidiaries of the Company, and are secured by substantially all the assets of Allurion and the guarantors. We used the proceeds from the issuance of the Notes to refinance our outstanding obligations under the Fortress Credit Agreement in full and to pay fees and expenses in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection therewith and in connection with the transactions contemplated by the Amended Note Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe each of these transactions was exempt from registration under the Securities Act in reliance on Section&#160;4(a)(2) of the Securities Act (and Regulation D promulgated thereunder) as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statements Schedules. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(a) Exhibits. </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;1.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Placement Agency Agreement.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118ds4.htm#toc445118_46">Business Combination Agreement, dated as of February&#160;9, 2023, by and among Compute Health Acquisition Corp., Compute Health Corp., Compute Health LLC, Allurion Technologies Holdings, Inc. and Allurion Technologies, Inc. (included as Annex A to the proxy statement/prospectus that forms a part of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.2+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118ds4.htm#toc445118_46a">Amendment No.&#160;1 to the Business Combination Agreement, dated as of May&#160;2, 2023, by and among Compute Health Acquisition Corp., Compute Health Corp., Compute Health LLC, Allurion Technologies Holdings, Inc. and Allurion Technologies, Inc. (included as Annex <span style="white-space:nowrap">A-1</span> to the proxy statement/prospectus that forms a part of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex31.htm">Form of Amended and Restated Certificate of Incorporation of Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex32.htm">Bylaws of Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390021007774/ea134809ex4-1_compute.htm">Warrant Agreement, dated February&#160;4, 2021, between Compute Health Acquisition Corp. and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on February&#160;9, 2021).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex42.htm">Amendment to Warrant Agreement, dated August&#160;1, 2023, by and between Compute Health and Continental Stock Transfer&#160;&amp; Trust Company (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex43.htm">Warrant Assignment, Assumption and Amendment Agreement, dated August&#160;1, 2023, by and among Compute Health Acquisition Corp., New Allurion Technologies Holdings, Inc., and Continental Stock Transfer&#160;&amp; Trust Company (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex44.htm">Description of Capital Stock (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.5**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Warrant Agreement.</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.6**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Warrant.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.7**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Pre-Funded Warrant.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Opinion of Goodwin Procter LLP as to the validity of the securities being registered.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523175696/d445118dex1032.htm">Form of Indemnification Agreement between Allurion Technologies, Inc. and its Directors and Officers (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4/A</span> filed with the SEC on June&#160;27, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118ds4.htm#ii445118_annexe">Sponsor Support Agreement, dated as of February&#160;9, 2023, by and among Compute Health Acquisition Corp., Compute Health Sponsor LLC, Allurion Technologies Holdings, Inc., Allurion Technologies, Inc. and the independent directors of the Compute Health Acquisition Corp. (included as Annex E to the proxy statement/prospectus that forms a part of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118ds4.htm#ii445118_annexf">Stockholder Support Agreement, dated as of February&#160;9, 2023, by and among Compute Health Acquisition Corp., Allurion Technologies Holdings, Inc., Allurion Technologies, Inc. and certain stockholders of Allurion Technologies, Inc. (included as Annex F to the proxy statement/ prospectus that forms a part of the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023009565/ea172635ex10-3_compute.htm"><span style="white-space:nowrap">Non-Redemption</span> Agreement, dated as of February&#160;9, 2023, by and among Compute Health Acquisition Corp., Allurion Technologies, Inc., Allurion Technologies Holdings, Inc. and Medtronic, Inc (incorporated by reference to Exhibit 10.3 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on February&#160;9, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex105.htm">Investor Rights Agreement dated August&#160;1, 2023, by and among New Allurion, Compute Health Sponsor LLC, certain equity holders of Allurion Technologies, Inc. and certain other parties (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023009565/ea172635ex10-5_compute.htm">Form of PIPE Subscription Agreement (incorporated by reference to Exhibit 10.5 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on February&#160;9, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-6_compute.htm">Amended and Restated RTW PIPE Side Letter Agreement, dated as of May&#160;2, 2023, by and among Compute Health Acquisition Corp., Allurion Technologies Holdings, Inc., Compute Health LLC, Allurion Technologies, Inc. and certain entities that have engaged RTW Investments, LP as investment manager (incorporated by reference to Exhibit 10.6 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023009565/ea172635ex10-8_compute.htm">Revenue Interest Financing Agreement, dated as of February&#160;9, 2023, by and among Allurion Technologies, Inc. and certain entities that have engaged RTW Investments, LP as investment manager (incorporated by reference to Exhibit 10.8 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on February&#160;9, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023009565/ea172635ex10-9_compute.htm">Bridging Agreement, dated as of February&#160;9, 2023, by and among Allurion Technologies, Inc. and Fortress Credit Corp. (incorporated by reference to Exhibit 10.9 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on February&#160;9, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10#&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1010.htm">Employment Agreement dated August&#160;1, 2023 with Shantanu Gaur (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11#&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1011.htm">Employment Agreement dated August&#160;1, 2023 with Christopher Geberth (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12#&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1013.htm">Employment Agreement dated August&#160;1, 2023 with Ram Chuttani (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1013.htm">Allurion Technologies, Inc. 2010 Stock Incentive Plan (incorporated by reference to Exhibit&#160;10.13 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1014.htm">Allurion Technologies, Inc. Amended and Restated 2020 Stock Option and Grant Plan (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;S-4</span> filed with the SEC on May&#160;12, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523260016/d559340dex993.htm">Allurion Technologies Holdings, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed with the SEC on October&#160;20, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1018.htm">Form of Restricted Stock Unit Award Agreement for <span style="white-space:nowrap">Non-Employee</span> Directors under the Allurion Technologies, Inc. 2023 Stock Option And Incentive Plan (incorporated by reference to Exhibit&#160;10.18 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523260016/d559340dex994.htm">Allurion Technologies Holdings, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.4 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed with the SEC on October&#160;20, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-1_compute.htm">Side Letter Termination Agreement, dated as of May&#160;2, 2023, by and among Allurion Technologies, Inc., Romulus Growth Allurion L.P. and Hunter Ventures Limited (incorporated by reference to Exhibit&#160;10.18 to the Registrant&#8217;s Registration Statement on <span style="white-space:nowrap">Form&#160;S-4</span> filed with the SEC on May&#160;12, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-5_compute.htm">Backstop Agreement, dated as of May&#160;2, 2023, by and among Hunter Ventures Limited, Allurion Technologies Holdings, Inc., Allurion Technologies, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Venture Fund Limited and CFIP2 ALLE LLC (incorporated by reference to Exhibit 10.5 to Compute Health Acquisition Corp.&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> filed with the SEC on May&#160;2, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-7_compute.htm">Side Letter Agreement, dated as of May&#160;2, 2023, by and among Allurion Technologies, Inc., CFIP2 ALLE LLC and Fortress Credit Corp. (incorporated by reference to Exhibit&#160;10.7 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-9_compute.htm">Contribution Agreement, dated as of May&#160;2, 2023, by and between Compute Health Sponsor LLC and Compute Health Acquisition Corp. (incorporated by reference to Exhibit 10.9 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-10_compute.htm">RSU Partial Forfeiture and Amendment Agreement, dated as of May&#160;2, 2023, by and between Allurion Technologies, Inc. and Krishna Gupta (incorporated by reference to Exhibit&#160;10.10 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1025.htm">Credit Agreement and Guaranty, dated as of August&#160;1, 2023, by and among Allurion Technologies, LLC, Allurion Technologies, Inc., the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time parties thereto and Fortress Credit Corp., as administrative agent (incorporated by reference to Exhibit 10.25 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.24#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1027.htm">Form of Restricted Stock Unit Award Agreement for Company Employees under the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (incorporated by reference to Exhibit&#160;10.27 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.25#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1028.htm">Form of Incentive Stock Option Agreement under the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (incorporated by reference to Exhibit&#160;10.28 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.26#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex1029.htm">Form of <span style="white-space:nowrap">Non-Qualified</span> Stock Option Agreement under the Allurion Technologies, Inc. 2023 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.29 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.27</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035224/ea177745ex10-8_compute.htm">Contribution Agreement, dated as of May&#160;2, 2023, by and between Shantanu K. Gaur and Neha Gaur, Trustees of The Shantanu K. Gaur Revocable Trust of 2021, and Allurion Technologies Holdings, Inc. (incorporated by reference to Exhibit 10.8 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.28</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523297799/d536638dex101.htm">ChEF Purchase Agreement, dated as of December&#160;18, 2023, by and between Allurion Technologies, Inc. and Chardan Capital Markets LLC (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on December&#160;18, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523297799/d536638dex102.htm">Registration Rights Agreement dated as of December&#160;18, 2023, by and between Allurion Technologies, Inc. and Chardan Capital Markets LLC (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on December&#160;18, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.30&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523182382/d445118dex1037.htm">Sales Agency Agreement, dated May&#160;15, 2023, by and between Allurion Technologies, Inc. and Covidien AG (incorporated by reference to Exhibit 10.37 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on July&#160;6, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.31</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1018.htm">Lease for 11 Huron Drive, Natick, MA 01760, dated June&#160;15, 2016, by and between Allurion Technologies, Inc. and Legacy Huron, LLC, as amended by the First Amendment to Lease, dated November&#160;28, 2016, the Second Amendment to Lease, dated March&#160;20, 2017, the Third Amendment to Lease, dated June&#160;21, 2017, the Fourth Amendment to Lease, dated August&#160;21, 2017, the Fifth Amendment to Lease, dated October&#160;30, 2017 and the Sixth Amendment to Lease, dated March&#160;15, 2021 (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.32+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1019.htm">Commercial Lease for 8 Erie Drive, Natick, MA 01760, dated January&#160;8, 2018, by and between Allurion Technologies, Inc. and 8 Erie Drive, LLC (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.33+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1020.htm">Lease for 3 Huron Drive, Natick, MA 01760, dated January&#160;10, 2020, by and between Allurion Technologies, Inc. and 3 Huron Investments LLC (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.34+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523142998/d445118dex1021.htm">Lease for 14 Huron Drive, Natick, MA, dated June&#160;18, 2014, by and between the Company and Fourteen Huron Drive, LLC, as amended by the First Amendment to Lease, dated June&#160;30, 2017, the Third Amendment to Lease dated April&#160;5, 2018, the Fourth Amendment to Lease, dated November&#160;16, 2018, the Fifth Amendment to Lease dated as of August&#160;12, 2019 and the Sixth Amendment to Lease, dated March&#160;15, 2021 (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-4</span> filed with the SEC on May&#160;12, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.35++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1828608/000121390023035169/ea177745ex10-1_compute.htm">Side Letter Termination Agreement, dated as of May&#160;2, 2023, by and among Allurion Technologies, Inc., Romulus Growth Allurion L.P. and Hunter Ventures Limited (incorporated by reference to Exhibit 10.1 to Compute Health Acquisition Corp.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on May&#160;2, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.36#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024036478/alur-ex10_36.htm">Settlement Agreement, dated as of December&#160;12, 2023, by and between Allurion Technologies, Inc. and Benoit Chardon. (incorporated by reference to Exhibit 10.36 to Allurion Technologies, Inc.&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March&#160;26, 2024). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.37#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024036478/alur-ex10_37.htm">Termination Agreement, dated as of December&#160;12, 2023 by and between Allurion France and Benoit Chardon Consulting. (incorporated by reference to Exhibit 10.37 to Allurion Technologies, Inc.&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March&#160;26, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.38</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523306003/d118660dex101.htm">Amendment No.&#160;1 to Credit Agreement and Guaranty, dated as of December&#160;29, 2023, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, the Subsidiary Guarantors from time to time party thereto, the Lenders from time to time party thereto and Fortress Credit Corp., as administrative agent for the Lenders. (incorporated by reference to Exhibit 10.38 to Allurion Technologies, Inc.&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March&#160;26, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.39#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024036478/alur-ex10_39.htm">Employment Agreement between Allurion Technologies, Inc. and Brendan Gibbons. (incorporated by reference to Exhibit 10.39 to Allurion Technologies, Inc.&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March&#160;26, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.40+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024045168/alur-ex10_1.htm">Note Purchase Agreement dated as of April&#160;14, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers party thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers. (incorporated by reference to Exhibit 10.1 to Allurion Technologies, Inc.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;17, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.41++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024045168/alur-ex10_2.htm">Omnibus Amendment, dated as of April&#160;14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC and certain entities that have engaged RTW Investments, LP as investment manager. (incorporated by reference to Exhibit 10.2 to Allurion Technologies, Inc.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;17, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.42++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024045168/alur-ex10_3.htm">First Amendment to Amended and Restated Letter Agreement, dated as of April&#160;14, 2024, by and among Allurion Technologies, Inc., Allurion Technologies, LLC, RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd, and RTW Biotech Opportunities Operating Ltd. (incorporated by reference to Exhibit 10.3 to Allurion Technologies, Inc.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;17, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.43++</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024045168/alur-ex10_4.htm">First Amendment to Note Purchase Agreement, dated as of April&#160;16, 2024, by and among Allurion Technologies, Inc., RTW Investments, LP, as agent for the purchasers party thereto from time to time, and Acquiom Agency Services LLC, as collateral agent for the purchasers. (incorporated by reference to Exhibit 10.4 to Allurion Technologies, Inc.&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on April&#160;17, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.44</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312524173365/d852262dex101.htm">Subscription Agreement, dated as of June&#160;28 2024, between Allurion Technologies, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on July&#160;1, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.45</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024097089/alur-ex10_6.htm">Eighth Amendment to 14 Huron Lease, dates as of April&#160;3, 2024, by and between Allurion Technologies, Inc. and Fourteen Huron Drive, LLC (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the SEC on August&#160;14, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.46#&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024097089/alur-ex10_7.htm">Offer Letter dated May&#160;17, 2024 with Ojas Buch (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> filed with the SEC on August&#160;14, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.47+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024120851/alur-ex10_1.htm">Revenue Interest Financing Agreement, dated as of October&#160;30, 2024, by and among Allurion Technologies, LLC, RTW Master Fund Ltd., RTW Innovation Master Fund, Ltd. and RTW Biotech Opportunities Operating Ltd. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.48**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Form of Securities Purchase Agreement.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;19.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000095017024036478/alur-ex19_1.htm">Allurion Technologies, Inc. Insider Trading Policy. (incorporated by reference to Exhibit 19.1 to Allurion Technologies, Inc.&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> filed on March&#160;26, 2024). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1964979/000119312523205104/d732912dex211.htm">List of subsidiaries of Allurion Technologies Holdings, Inc. (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed with the SEC on August&#160;7, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d915839dex231.htm">Consent of Deloitte&#160;&amp; Touche LLP (with respect to the Allurion Technologies, Inc. financial statements). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Consent of Goodwin Procter LLP (included as part of Exhibit 5.1).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d915839ds1.htm#sig">Power of Attorney (included on signature page to this Registration Statement). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d915839dexfilingfees.htm">Filing Fee Table. </a></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To be filed by amendment. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">++</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates a management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Portions of this exhibit have been redacted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(6). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(b) Financial Statement Schedules. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the index to the consolidated financial statements included on page <span style="white-space:nowrap">F-1</span> for a list of the financial statements included in this registration statement. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by section 10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td align="left" style="vertical-align:top">
prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the town of Natick, Commonwealth of Massachusetts, on December&#160;9, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ALLURION TECHNOLOGIES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Shantanu Gaur</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Shantanu Gaur</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer</p></td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shantanu Gaur as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign one or more registration statements on Form <span style="white-space:nowrap">S-1</span> and any and all amendments (including post-effective amendments) to such registration statements (and any additional registration statement related hereto permitted by Rule 462(b) promulgated by the Securities Act, (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following person in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Shantanu Gaur</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Shantanu Gaur</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Omar Ishrak</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Omar Ishrak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Michael Davin</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Davin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Larson Douglas Hudson </p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Larson Douglas Hudson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Nicholas Lewin</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nicholas Lewin</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Milena Alberti-Perez</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Milena Alberti-Perez</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">December&#160;9, 2024</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:35%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:18%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Signature</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Title</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Keith Johns</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Keith Johns</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap"> <p style="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">December&#160;9, 2024</p></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-11 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d915839dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated March&nbsp;26, 2024, relating to the financial statements of Allurion Technologies, Inc. We also consent to the reference to us
under the heading &#147;Experts&#148; in such Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;9, 2024 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>alur-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-December-2024 [02:30:49] {PM}-->
<schema targetNamespace="http://www.allurion.com/20240930" elementFormDefault="qualified" xmlns:alur="http://www.allurion.com/20240930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.allurion.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets" id="UnauditedCondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" id="UnauditedCondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" id="UnauditedCondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" id="UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
<link:definition>1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit" id="UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit">
<link:definition>1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" id="UnauditedCondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash" id="UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash">
<link:definition>1008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
<link:definition>1009 - Disclosure - Organization and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/BusinessCombination" id="BusinessCombination">
<link:definition>1011 - Disclosure - Business Combination</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/Revenue" id="Revenue">
<link:definition>1012 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/Inventory" id="Inventory">
<link:definition>1013 - Disclosure - Inventory</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1014 - Disclosure - Property and Equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
<link:definition>1015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/Debt" id="Debt">
<link:definition>1016 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption" id="RevenueInterestFinancingSideLetterAndPipeConversionOption">
<link:definition>1017 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1018 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit" id="RedeemableConvertiblePreferredStockAndStockholdersDeficit">
<link:definition>1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficit" id="CapitalStockAndStockholdersDeficit">
<link:definition>1021 - Disclosure - Capital Stock and Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1022 - Disclosure - Net Loss per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>1023 - Disclosure - Stock Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
<link:definition>1024 - Disclosure - Employee Benefit Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1025 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/GeographicInformation" id="GeographicInformation">
<link:definition>1026 - Disclosure - Geographic Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1027 - Disclosure - Related-party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1028 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1029 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1030 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/BusinessCombinationTables" id="BusinessCombinationTables">
<link:definition>1031 - Disclosure - Business Combination (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueTables" id="RevenueTables">
<link:definition>1032 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/InventoryTables" id="InventoryTables">
<link:definition>1033 - Disclosure - Inventory (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1034 - Disclosure - Property and Equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
<link:definition>1035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/DebtTables" id="DebtTables">
<link:definition>1036 - Disclosure - Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables" id="RevenueInterestFinancingSideLetterAndPipeConversionOptionTables">
<link:definition>1037 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1038 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1039 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables" id="RedeemableConvertiblePreferredStockAndStockholdersDeficitTables">
<link:definition>1040 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables" id="CapitalStockAndStockholdersDeficitTables">
<link:definition>1041 - Disclosure - Capital Stock and Stockholders' Deficit (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1042 - Disclosure - Net Loss per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>1043 - Disclosure - Stock Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1044 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/GeographicInformationTables" id="GeographicInformationTables">
<link:definition>1045 - Disclosure - Geographic Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" id="OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<link:definition>1046 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1047 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails">
<link:definition>1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" id="SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
<link:definition>1049 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails">
<link:definition>1050 - Disclosure - Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails" id="BusinessCombinationAdditionalInformationDetails">
<link:definition>1051 - Disclosure - Business Combination - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" id="BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails">
<link:definition>1052 - Disclosure - Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails" id="BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails">
<link:definition>1053 - Disclosure - Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueAdditionalInformationDetails" id="RevenueAdditionalInformationDetails">
<link:definition>1054 - Disclosure - Revenue - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails" id="RevenueScheduleOfRevenuesByGeographicRegionDetails">
<link:definition>1055 - Disclosure - Revenue - Schedule of Revenues by Geographic Region (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/InventoryScheduleOfInventoryDetails" id="InventoryScheduleOfInventoryDetails">
<link:definition>1056 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/InventoryAdditionalInformationDetails" id="InventoryAdditionalInformationDetails">
<link:definition>1057 - Disclosure - Inventory - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
<link:definition>1058 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" id="PropertyAndEquipmentNetAdditionalInformationDetails">
<link:definition>1059 - Disclosure - Property and Equipment, net - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" id="PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails">
<link:definition>1060 - Disclosure - Property and Equipment, net - Schedule of Depreciation Expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<link:definition>1061 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails">
<link:definition>1062 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails" id="DebtSummaryOfComponentsOfThirdPartyDebtDetails">
<link:definition>1063 - Disclosure - Debt - Summary of Components of Third-Party Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/DebtAdditionalInformationDetails" id="DebtAdditionalInformationDetails">
<link:definition>1064 - Disclosure - Debt - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" id="DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails">
<link:definition>1065 - Disclosure - Debt - Schedule of Future Maturities of the Term Loan Facility (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails" id="RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails">
<link:definition>1066 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" id="RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails">
<link:definition>1067 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails" id="IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails">
<link:definition>1068 - Disclosure - Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails" id="IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails">
<link:definition>1069 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<link:definition>1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1071 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" id="IncomeTaxesSummaryOfValuationAllowanceDetails">
<link:definition>1072 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails" id="FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails">
<link:definition>1073 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails" id="FairValueMeasurementsScheduleOfChangesInFairValuesDetails">
<link:definition>1074 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Values (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
<link:definition>1075 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails" id="FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails">
<link:definition>1076 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails" id="FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails">
<link:definition>1077 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" id="RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
<link:definition>1078 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" id="RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<link:definition>1079 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" id="RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<link:definition>1080 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails" id="CapitalStockAndStockholdersDeficitAdditionalInformationDetails">
<link:definition>1081 - Disclosure - Capital Stock and Stockholders' Deficit - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails" id="CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails">
<link:definition>1082 - Disclosure - Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" id="CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<link:definition>1083 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" id="CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<link:definition>1084 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" id="NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
<link:definition>1085 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails" id="NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails">
<link:definition>1086 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails" id="StockBasedCompensationAdditionalInformationDetails">
<link:definition>1087 - Disclosure - Stock Based Compensation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails" id="StockBasedCompensationScheduleOfStockBasedCompensationDetails">
<link:definition>1088 - Disclosure - Stock Based Compensation - Schedule of Stock Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails" id="StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails">
<link:definition>1089 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails" id="StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails">
<link:definition>1090 - Disclosure - Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails" id="StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails">
<link:definition>1091 - Disclosure - Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails" id="EmployeeBenefitPlanAdditionalInformationDetails">
<link:definition>1092 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1093 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails" id="CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails">
<link:definition>1094 - Disclosure - Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails" id="CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails">
<link:definition>1095 - Disclosure - Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails" id="CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails">
<link:definition>1096 - Disclosure - Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails" id="GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails">
<link:definition>1097 - Disclosure - Geographic Information - Schedule of Long-lived Assets by Geography (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1098 - Disclosure - Related-party Transactions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1099 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1" id="CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1">
<link:definition>1100 - Statement - Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1" id="UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1">
<link:definition>1101 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1">
<link:definition>1102 - Statement - Property and Equipment, net - Schedule of Property and Equipment (Details) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="alur-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="alur-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="alur-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="alur-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
<import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
<import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
<import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
<import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="RevenueInterestFinancingLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RevenueInterestFinancingLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangesInFairValueOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangesInFairValueOfDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueAdjustmentOfEarnOutLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueAdjustmentOfEarnOutLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueInterestFinancingDueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingDueMember" substitutionGroup="xbrli:item" />
<element name="RtwConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RtwConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="SeriesA1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesA1ConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesBConvertiblePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueDerecognitionOfLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesDerecognitionOfLiability" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockForExerciseOfWarrantsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockForExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyOneTermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandTwentyOneTermLoanMember" substitutionGroup="xbrli:item" />
<element name="FortressTermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FortressTermLoanMember" substitutionGroup="xbrli:item" />
<element name="NonCashLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NonCashLeaseExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangeInFairValueOfWarrantLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InterestPaidOnDebtRecordedAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_InterestPaidOnDebtRecordedAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NonCashInterestExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashTerminationOfConvertibleNoteSideLetters" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NonCashTerminationOfConvertibleNoteSideLetters" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashIssuanceOfCommonStockForCommitmentShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NonCashIssuanceOfCommonStockForCommitmentShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueAdjustmentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueAdjustmentOfDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AmortizationOfIssuanceCostsAssociatedWithWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromBusinessCombinationNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromRevenueInterestFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ProceedsFromRevenueInterestFinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromOptionAndWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ProceedsFromOptionAndWarrantExercises" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOfDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PaymentOfDeferredFinancingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromEquityLineFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ProceedsFromEquityLineFinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfWarrantsInConnectionWithFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IssuanceOfWarrantsInConnectionWithFinancing" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RecognitionOfAssumedWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RecognitionOfAssumedWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RecognitionOfEarnOutLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RecognitionOfEarnOutLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfRevenueInterestFinancingThroughOci" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfRtwConvertibleNotesThroughOci" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" substitutionGroup="xbrli:item" />
<element name="RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" substitutionGroup="xbrli:item" />
<element name="DebtIssuanceCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtIssuanceCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_WarrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EarnoutLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_EarnoutLiabilityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="IntellectualPropertyProsecutionCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="MezzanineEquityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_MezzanineEquityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfBusinessCombinationSharesCommonStockOutstanding" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDepreciationExpenseTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ScheduleOfDepreciationExpenseTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ComponentsOfRevenueInterestFinancingTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ComponentsOfRevenueInterestFinancingTableTextBlock" substitutionGroup="xbrli:item" />
<element name="EarnOutLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_EarnOutLiabilityMember" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingAndPipeConversionOptionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingAndPipeConversionOptionMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOtherPertinentLeaseInformationTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_BusinessCombinationAgreementMember" substitutionGroup="xbrli:item" />
<element name="NumberOfCountriesInWhichEntityMarketsTheProgram" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_NumberOfCountriesInWhichEntityMarketsTheProgram" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationCommonStockExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_BusinessCombinationCommonStockExchangeRatio" substitutionGroup="xbrli:item" />
<element name="CustomersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CustomersMember" substitutionGroup="xbrli:item" />
<element name="NewAllurionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_NewAllurionMember" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingAgreementMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PercentageOfAnnualNetSales" substitutionGroup="xbrli:item" />
<element name="RemittanceOfRevenueInterestPaymentsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RemittanceOfRevenueInterestPaymentsPercentage" substitutionGroup="xbrli:item" />
<element name="CustomerAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CustomerAMember" substitutionGroup="xbrli:item" />
<element name="CustomerBMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CustomerBMember" substitutionGroup="xbrli:item" />
<element name="CustomerCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CustomerCMember" substitutionGroup="xbrli:item" />
<element name="CustomersDMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CustomersDMember" substitutionGroup="xbrli:item" />
<element name="PipeSubscriptionAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PipeSubscriptionAgreementsMember" substitutionGroup="xbrli:item" />
<element name="AmendedAndRestatedRtwSideLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_AmendedAndRestatedRtwSideLetterMember" substitutionGroup="xbrli:item" />
<element name="FortressCreditAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FortressCreditAgreementMember" substitutionGroup="xbrli:item" />
<element name="BackstopAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_BackstopAgreementMember" substitutionGroup="xbrli:item" />
<element name="HVLTerminationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_HVLTerminationAgreementMember" substitutionGroup="xbrli:item" />
<element name="GaurContributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_GaurContributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="RSUForfeitureAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RSUForfeitureAgreementMember" substitutionGroup="xbrli:item" />
<element name="SponsorContributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SponsorContributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="SponsorSupportAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SponsorSupportAgreementMember" substitutionGroup="xbrli:item" />
<element name="ComputeHealthMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ComputeHealthMember" substitutionGroup="xbrli:item" />
<element name="WarrantAmendmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantAmendmentMember" substitutionGroup="xbrli:item" />
<element name="TermLoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TermLoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="SponsorLoanExcessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_SponsorLoanExcessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfPipeSubscriptionToRevenueInterestFinance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContributionOfCapitalByJointVenturePartner" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ContributionOfCapitalByJointVenturePartner" substitutionGroup="xbrli:item" />
<element name="RecapitalizationOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RecapitalizationOfCommonStock" substitutionGroup="xbrli:item" />
<element name="RecapitalizationOfAdditionalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RecapitalizationOfAdditionalShares" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationOneTimeInsurancePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_BusinessCombinationOneTimeInsurancePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DirectCostsAndFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DirectCostsAndFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConversionOfPipeInvestmentToRevenueInterestFinance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_ConversionOfPipeInvestmentToRevenueInterestFinance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSurrenderSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NumberOfSurrenderSharesOfCommonStock" substitutionGroup="xbrli:item" />
<element name="SurrenderCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_SurrenderCommonStockValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PipeInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PipeInvestorsMember" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_GrossProceedsFromBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="BusinessCombinationTransactionCostPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_BusinessCombinationTransactionCostPaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetProceedsFromBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NetProceedsFromBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WarrantLiabilitiesAssumed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_WarrantLiabilitiesAssumed" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepaymentOfNoteAssumedInBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RepaymentOfNoteAssumedInBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessAcquisitionAccruedTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_BusinessAcquisitionAccruedTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_BusinessCombinationNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LegacyAllurionEquityholdersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionEquityholdersMember" substitutionGroup="xbrli:item" />
<element name="RtwAndFortressMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RtwAndFortressMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleNoteHoldersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ConvertibleNoteHoldersMember" substitutionGroup="xbrli:item" />
<element name="ComputeHealthSponsorSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ComputeHealthSponsorSharesMember" substitutionGroup="xbrli:item" />
<element name="SideLetterTerminationSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SideLetterTerminationSharesMember" substitutionGroup="xbrli:item" />
<element name="EachCountryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_EachCountryMember" substitutionGroup="xbrli:item" />
<element name="AllOtherCountriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_AllOtherCountriesMember" substitutionGroup="xbrli:item" />
<element name="FourCountriesIncludedWithinAllOtherCountriesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FourCountriesIncludedWithinAllOtherCountriesMember" substitutionGroup="xbrli:item" />
<element name="NumberOfCountriesGenerateRevenue" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NumberOfCountriesGenerateRevenue" substitutionGroup="xbrli:item" />
<element name="NumberOfCountriesGenerateRevenueBySales" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NumberOfCountriesGenerateRevenueBySales" substitutionGroup="xbrli:item" />
<element name="ComputersAndPurchasedSoftwareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ComputersAndPurchasedSoftwareMember" substitutionGroup="xbrli:item" />
<element name="ConstructionInProgress" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_ConstructionInProgress" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DistributorFeesAndMarketingReimbursements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DistributorFeesAndMarketingReimbursements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedClinicalTrialsAndResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_AccruedClinicalTrialsAndResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedRestructuringCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_AccruedRestructuringCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LoanAccretion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_LoanAccretion" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_ChangeInFairValueOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TermCLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TermCLoanMember" substitutionGroup="xbrli:item" />
<element name="TermDLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TermDLoanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyOneTermLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandTwentyOneTermLoanAgreementMember" substitutionGroup="xbrli:item" />
<element name="AmendedTwoThousandTwentyOneTermLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" substitutionGroup="xbrli:item" />
<element name="FortressAmendmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FortressAmendmentMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyOneConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandTwentyOneConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandTwentyTwoConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyThreeConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandTwentyThreeConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="SideLetterHolderBridgeNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SideLetterHolderBridgeNoteMember" substitutionGroup="xbrli:item" />
<element name="NotePurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_NotePurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="HVLBridgeNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_HVLBridgeNoteMember" substitutionGroup="xbrli:item" />
<element name="RunwayGrowthCreditFundIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RunwayGrowthCreditFundIncMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesCPreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesCPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesD1PreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesD1PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="UntilMarch312024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_UntilMarch312024Member" substitutionGroup="xbrli:item" />
<element name="FromApril12024ToJune302024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FromApril12024ToJune302024Member" substitutionGroup="xbrli:item" />
<element name="FromJuly12024ToSeptember302024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FromJuly12024ToSeptember302024Member" substitutionGroup="xbrli:item" />
<element name="OnOctober12024AndThereafterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OnOctober12024AndThereafterMember" substitutionGroup="xbrli:item" />
<element name="AdditionalBorrowings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_AdditionalBorrowings" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TermLoanAccretion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_TermLoanAccretion" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentExitPaymentPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtInstrumentExitPaymentPercentage" substitutionGroup="xbrli:item" />
<element name="ExercisableWarrantsIssuedAsConsideration" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ExercisableWarrantsIssuedAsConsideration" substitutionGroup="xbrli:item" />
<element name="FairValueOfTheWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_FairValueOfTheWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_WarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepaymentOfPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RepaymentOfPrincipal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrepaymentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PrepaymentFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FinalPaymentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FinalPaymentFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaymentFeePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PrepaymentFeePercentage" substitutionGroup="xbrli:item" />
<element name="OriginalFinalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_OriginalFinalPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FinalPaymentFeePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FinalPaymentFeePercentage" substitutionGroup="xbrli:item" />
<element name="AmortizationOfTheWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AmortizationOfTheWarrant" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConversionDividedByDiscountedCappedConversionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ConversionDividedByDiscountedCappedConversionPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionDividedByCappedConversionPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ConversionDividedByCappedConversionPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CappedPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_CappedPrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" substitutionGroup="xbrli:item" />
<element name="MinimumLiquidityAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_MinimumLiquidityAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentInterestRateIncreaseEventOfDefault" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DebtInstrumentInterestRateIncreaseEventOfDefault" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentDefaultInterestRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DebtInstrumentDefaultInterestRate" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredLiabilityForIssuanceOfAdditionalShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DeferredLiabilityForIssuanceOfAdditionalShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentExitFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtInstrumentExitFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangesInFairValueOfRevenueInterestFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ChangesInFairValueOfRevenueInterestFinancing" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentPrincipalAmountForConversionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" substitutionGroup="xbrli:item" />
<element name="DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" substitutionGroup="xbrli:item" />
<element name="UnrestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_UnrestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueInterestFinancingAgreementAmendmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingAgreementAmendmentMember" substitutionGroup="xbrli:item" />
<element name="PIPEConversionOptionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PIPEConversionOptionMember" substitutionGroup="xbrli:item" />
<element name="ScenarioPlanOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ScenarioPlanOneMember" substitutionGroup="xbrli:item" />
<element name="ScenarioPlanTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ScenarioPlanTwoMember" substitutionGroup="xbrli:item" />
<element name="RevenuesInterestFinancingLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RevenuesInterestFinancingLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueInterestPaymentsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RevenueInterestPaymentsPercentage" substitutionGroup="xbrli:item" />
<element name="CashPaymentsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_CashPaymentsPercentage" substitutionGroup="xbrli:item" />
<element name="PrePaymentsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PrePaymentsPercentage" substitutionGroup="xbrli:item" />
<element name="RoyaltyPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RoyaltyPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="VolumeWeightedAveragePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_VolumeWeightedAveragePricePerShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfNetSales" substitutionGroup="xbrli:item" />
<element name="SalesRevenueNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_SalesRevenueNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseInSalesRevenueNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IncreaseInSalesRevenueNet" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfIncreaseInNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfIncreaseInNetSales" substitutionGroup="xbrli:item" />
<element name="FairValueOfRevenueInterestFinancingAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_FairValueOfRevenueInterestFinancingAgreements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfPipeConversionOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_FairValueOfPipeConversionOption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueInterestFinancingAgreementRemeasuredValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RevenueInterestFinancingAgreementRemeasuredValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PipeConversionOptionRemeasuredValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PipeConversionOptionRemeasuredValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfInternalRateOfReturn" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PercentageOfInternalRateOfReturn" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_DeferredTaxAssetsDepreciation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LatestTaxYearTwoThousandFortyTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LatestTaxYearTwoThousandFortyTwoMember" substitutionGroup="xbrli:item" />
<element name="ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" substitutionGroup="xbrli:item" />
<element name="DoNotExpireMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_DoNotExpireMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryForwardsResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_TaxCreditCarryForwardsResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" substitutionGroup="xbrli:item" />
<element name="RevenueInterestFinancingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RevenueInterestFinancingMember" substitutionGroup="xbrli:item" />
<element name="PipeConversionDerivativeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PipeConversionDerivativeMember" substitutionGroup="xbrli:item" />
<element name="SuccessFeeDerivativeLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SuccessFeeDerivativeLiabilityMember" substitutionGroup="xbrli:item" />
<element name="PubcoShareLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PubcoShareLiabilityMember" substitutionGroup="xbrli:item" />
<element name="BasePubcoAndBackstopShareLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_BasePubcoAndBackstopShareLiabilityMember" substitutionGroup="xbrli:item" />
<element name="TermLoanDerivativeLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TermLoanDerivativeLiabilityMember" substitutionGroup="xbrli:item" />
<element name="PublicOfferingWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicOfferingWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PreferredStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="CommonStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CommonStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandNineteenTermLoanAndSuccessFeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" substitutionGroup="xbrli:item" />
<element name="PubcoAdditionalSharesLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PubcoAdditionalSharesLiabilityMember" substitutionGroup="xbrli:item" />
<element name="BasePubcoSharesAndBackstopShareLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_BasePubcoSharesAndBackstopShareLiabilityMember" substitutionGroup="xbrli:item" />
<element name="FairValueAssumptionsOfLiquidityEventTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueAssumptionsOfLiquidityEventTerm" substitutionGroup="xbrli:item" />
<element name="FairValueOfEstimatedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueOfEstimatedNumberOfShares" substitutionGroup="xbrli:item" />
<element name="FairValueOfEstimatedPriceOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_FairValueOfEstimatedPriceOfShares" substitutionGroup="xbrli:item" />
<element name="FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="LegacyAllurionSeriesA1PreferredStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesBPreferredStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesCCommonStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesCCommonStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesCPreferredStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesD1PreferredStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="OtherCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OtherCommonStockMember" substitutionGroup="xbrli:item" />
<element name="OtherCommonStockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OtherCommonStockWarrantsMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionOtherCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionOtherCommonStockMember" substitutionGroup="xbrli:item" />
<element name="FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionCommonStockWarrantLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="DerivativeLiabilitySuccessFeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_DerivativeLiabilitySuccessFeeMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" substitutionGroup="xbrli:item" />
<element name="OtherCommonStockWarrantLiabilitiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OtherCommonStockWarrantLiabilitiesMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" substitutionGroup="xbrli:item" />
<element name="ComputeHealthAcquisitionCorprationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ComputeHealthAcquisitionCorprationMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicWarrantMember" substitutionGroup="xbrli:item" />
<element name="PublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="PublicOfferingWarrantsAndShareOverallotmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicOfferingWarrantsAndShareOverallotmentMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWithRTWMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PrivatePlacementWithRTWMember" substitutionGroup="xbrli:item" />
<element name="CommitmentSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_CommitmentSharesMember" substitutionGroup="xbrli:item" />
<element name="ScenarioPlanThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ScenarioPlanThreeMember" substitutionGroup="xbrli:item" />
<element name="ScenarioPlanFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ScenarioPlanFourMember" substitutionGroup="xbrli:item" />
<element name="ChefPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ChefPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="ChardanEquityFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ChardanEquityFacilityMember" substitutionGroup="xbrli:item" />
<element name="PreferredStockRedemptionBasis" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PreferredStockRedemptionBasis" substitutionGroup="xbrli:item" />
<element name="PreferredStockLiquidationPreferenceBasis" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PreferredStockLiquidationPreferenceBasis" substitutionGroup="xbrli:item" />
<element name="WarrantsRedumptionPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_WarrantsRedumptionPricePerShare" substitutionGroup="xbrli:item" />
<element name="NetProceedsFromIssuanceOrSaleOfEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NetProceedsFromIssuanceOrSaleOfEquity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnderwritingDiscounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_UnderwritingDiscounts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ReductionInProceedsFromOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ReductionInProceedsFromOffering" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfCommonStockSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfCommonStockSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="ExpenseOfIssuanceOfCommitmentShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ExpenseOfIssuanceOfCommitmentShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StructuringFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_StructuringFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OutstandingOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OutstandingOptionsToPurchaseCommonStockMember" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsToPurchaseCommonStockMember" substitutionGroup="xbrli:item" />
<element name="SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="EarnOutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_EarnOutSharesMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ConvertibleNotesMember" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtDecember012014Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtDecember012014Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtMarch302021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtMarch302021Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtSeptember152022Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtSeptember152022Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtJune042022Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtJune042022Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtJanuary172017Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtJanuary172017Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtAugust032017Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtAugust032017Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtSeptember082017Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtSeptember082017Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtJune192018Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtJune192018Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtJune252019Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtJune252019Member" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtJuly012024Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtJuly012024Member" substitutionGroup="xbrli:item" />
<element name="SeriesAOnePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesAOnePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesDOnePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesDOnePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesDTwoPreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesDTwoPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="SeriesDThreePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_SeriesDThreePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="LegacyAllurionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LegacyAllurionMember" substitutionGroup="xbrli:item" />
<element name="RevenueRecognitionMilestoneMethodOfRecognizedRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfSharesOfCommonStockHeld" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PercentageOfSharesOfCommonStockHeld" substitutionGroup="xbrli:item" />
<element name="PercentageOfPreferredStockRedeemableShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_PercentageOfPreferredStockRedeemableShares" substitutionGroup="xbrli:item" />
<element name="PreferredStockRedemptionValueToPrice" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PreferredStockRedemptionValueToPrice" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchasePreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsToPurchasePreferredStockMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_PublicWarrantsToPurchaseCommonStockMember" substitutionGroup="xbrli:item" />
<element name="WarrantsIssuedAtApril012013Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_WarrantsIssuedAtApril012013Member" substitutionGroup="xbrli:item" />
<element name="StockOptionPlan2020StockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_StockOptionPlan2020StockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="StockOptionPlan2020Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_StockOptionPlan2020Member" substitutionGroup="xbrli:item" />
<element name="StockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_StockOptionAndIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="TimeVestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TimeVestedRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="PercentageOfPriceLowerOfFairValueMarketValue" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfPriceLowerOfFairValueMarketValue" substitutionGroup="xbrli:item" />
<element name="PercentageOfEmployeesCompensationToPayrollDeductions" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfEmployeesCompensationToPayrollDeductions" substitutionGroup="xbrli:item" />
<element name="PercentageOfDilutedSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfDilutedSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="StockOptionPlan2020And2023StockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_StockOptionPlan2020And2023StockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="NatickAndHudsonMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_NatickAndHudsonMember" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseExpirationPeriod" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_LesseeOperatingLeaseExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInRevenuesForCustomerReturns" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_IncreaseDecreaseInRevenuesForCustomerReturns" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockExchangeListingRequirementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_StockExchangeListingRequirementsDescription" substitutionGroup="xbrli:item" />
<element name="AverageMarketCapitalizationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AverageMarketCapitalizationAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfConsecutiveTradingDay" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_NumberOfConsecutiveTradingDay" substitutionGroup="xbrli:item" />
<element name="OperatingLeasesAndFinanceLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_OperatingLeasesAndFinanceLeasesAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingAndFinanceLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingAndFinanceLeaseLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_OperatingAndFinanceLeaseLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LnmpJpbcInvestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_LnmpJpbcInvestMember" substitutionGroup="xbrli:item" />
<element name="KkgEnterprisesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_KkgEnterprisesMember" substitutionGroup="xbrli:item" />
<element name="RemusGroupManagementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RemusGroupManagementMember" substitutionGroup="xbrli:item" />
<element name="BenoitChardonConsultingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_BenoitChardonConsultingMember" substitutionGroup="xbrli:item" />
<element name="ConsultingAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ConsultingAgreementsMember" substitutionGroup="xbrli:item" />
<element name="TerminationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_TerminationAgreementMember" substitutionGroup="xbrli:item" />
<element name="ConvertibleNoteAgreementWithRtwMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_ConvertibleNoteAgreementWithRtwMember" substitutionGroup="xbrli:item" />
<element name="RTWParticipationInPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RTWParticipationInPublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="HunterVenturesLimitedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_HunterVenturesLimitedMember" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_OperatingLeaseCommencementDate" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseEndDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_OperatingLeaseEndDate" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseTerminatedDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_LesseeOperatingLeaseTerminatedDate" substitutionGroup="xbrli:item" />
<element name="AgreementsTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AgreementsTerminationDate" substitutionGroup="xbrli:item" />
<element name="PaymentsOfAdvisoryServicesRelatedToBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfOutstandingCapitalStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfOutstandingCapitalStock" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RelatedPartyTransactionConsultingFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RelatedPartyTransactionTerminationFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_RelatedPartyTransactionTerminationFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_OperatingLeaseStartDate" substitutionGroup="xbrli:item" />
<element name="PercentageOfOutstandingCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_PercentageOfOutstandingCommonStock" substitutionGroup="xbrli:item" />
<element name="AggregatePurchasePriceFromOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="alur_AggregatePurchasePriceFromOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestructuringPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="alur_RestructuringPlanMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>alur-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-December-2024 [02:30:49] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedBalanceSheets" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" roleURI="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#InventoryScheduleOfInventoryDetails" roleURI="http://www.allurion.com/role/InventoryScheduleOfInventoryDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" roleURI="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails" roleURI="http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails" roleURI="http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedRestructuringCurrent" xlink:label="loc_ALUR_AccruedRestructuringCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_ALUR_AccruedRestructuringCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyAccrualCurrent" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedClinicalTrialsAndResearchAndDevelopment" xlink:label="loc_ALUR_AccruedClinicalTrialsAndResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_ALUR_AccruedClinicalTrialsAndResearchAndDevelopment" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DistributorFeesAndMarketingReimbursements" xlink:label="loc_ALUR_DistributorFeesAndMarketingReimbursements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_ALUR_DistributorFeesAndMarketingReimbursements" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails">
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromBusinessCombination" xlink:label="loc_ALUR_NetProceedsFromBusinessCombination" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationTransactionCostPaid" xlink:label="loc_ALUR_BusinessCombinationTransactionCostPaid" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ALUR_NetProceedsFromBusinessCombination" xlink:to="loc_ALUR_BusinessCombinationTransactionCostPaid" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GrossProceedsFromBusinessCombination" xlink:label="loc_ALUR_GrossProceedsFromBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ALUR_NetProceedsFromBusinessCombination" xlink:to="loc_ALUR_GrossProceedsFromBusinessCombination" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_ALUR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_ALUR_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails">
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiability" xlink:label="loc_ALUR_OperatingAndFinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_ALUR_OperatingAndFinanceLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ALUR_OperatingAndFinanceLeaseLiability" xlink:to="loc_ALUR_OperatingAndFinanceLeaseLiabilityNoncurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_ALUR_OperatingAndFinanceLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ALUR_OperatingAndFinanceLeaseLiability" xlink:to="loc_ALUR_OperatingAndFinanceLeaseLiabilityCurrent" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_ALUR_RevenueInterestFinancingLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ALUR_RevenueInterestFinancingLiabilityNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="28" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromEquityLineFinancing" xlink:label="loc_ALUR_ProceedsFromEquityLineFinancing" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ALUR_ProceedsFromEquityLineFinancing" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentOfDeferredFinancingCosts" xlink:label="loc_ALUR_PaymentOfDeferredFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ALUR_PaymentOfDeferredFinancingCosts" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromOptionAndWarrantExercises" xlink:label="loc_ALUR_ProceedsFromOptionAndWarrantExercises" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ALUR_ProceedsFromOptionAndWarrantExercises" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfDebt" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_ALUR_ProceedsFromRevenueInterestFinancing" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ALUR_ProceedsFromRevenueInterestFinancing" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xlink:label="loc_ALUR_ProceedsFromBusinessCombinationNetOfTransactionCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ALUR_ProceedsFromBusinessCombinationNetOfTransactionCosts" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xlink:label="loc_ALUR_AmortizationOfIssuanceCostsAssociatedWithWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_AmortizationOfIssuanceCostsAssociatedWithWarrants" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfDebt" xlink:label="loc_ALUR_FairValueAdjustmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_FairValueAdjustmentOfDebt" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashIssuanceOfCommonStockForCommitmentShares" xlink:label="loc_ALUR_NonCashIssuanceOfCommonStockForCommitmentShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_NonCashIssuanceOfCommonStockForCommitmentShares" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashTerminationOfConvertibleNoteSideLetters" xlink:label="loc_ALUR_NonCashTerminationOfConvertibleNoteSideLetters" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_NonCashTerminationOfConvertibleNoteSideLetters" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashInterestExpense" xlink:label="loc_ALUR_NonCashInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_NonCashInterestExpense" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_InterestPaidOnDebtRecordedAtFairValue" xlink:label="loc_ALUR_InterestPaidOnDebtRecordedAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_InterestPaidOnDebtRecordedAtFairValue" use="optional" order="25" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_ALUR_FairValueAdjustmentOfEarnOutLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_FairValueAdjustmentOfEarnOutLiabilities" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_ALUR_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_ALUR_ChangeInFairValueOfWarrantLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_ChangeInFairValueOfWarrantLiabilities" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InventoryWriteDown" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="38" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashLeaseExpense" xlink:label="loc_ALUR_NonCashLeaseExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ALUR_NonCashLeaseExpense" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="41" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="43" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpenseNonoperating" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_ALUR_FairValueAdjustmentOfEarnOutLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ALUR_FairValueAdjustmentOfEarnOutLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_ALUR_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ALUR_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfDebt" xlink:label="loc_ALUR_ChangesInFairValueOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_ALUR_ChangesInFairValueOfDebt" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xlink:label="loc_ALUR_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ALUR_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsDepreciation" xlink:label="loc_ALUR_DeferredTaxAssetsDepreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ALUR_DeferredTaxAssetsDepreciation" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_ALUR_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ALUR_DeferredTaxAssetsLeaseLiabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="14" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/InventoryScheduleOfInventoryDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterials" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcess" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConstructionInProgress" xlink:label="loc_ALUR_ConstructionInProgress" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_ALUR_ConstructionInProgress" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails">
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:label="loc_ALUR_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_ALUR_RevenuesInterestFinancingLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ALUR_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:to="loc_ALUR_RevenuesInterestFinancingLiability" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>alur-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-December-2024 [02:30:49] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CoverPage" roleURI="http://www.allurion.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedBalanceSheets" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsTables" roleURI="http://www.allurion.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" roleURI="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RevenueAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueScheduleOfRevenuesByGeographicRegionDetails" roleURI="http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#InventoryAdditionalInformationDetails" roleURI="http://www.allurion.com/role/InventoryAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtSummaryOfComponentsOfThirdPartyDebtDetails" roleURI="http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtAdditionalInformationDetails" roleURI="http://www.allurion.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" roleURI="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfChangesInFairValuesDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitAdditionalInformationDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails" roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationScheduleOfStockBasedCompensationDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails" roleURI="http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_105" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentInformationTable_146" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_2963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_146" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_2963" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_2964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_2963" xlink:to="loc_dei_AddressTypeDomain_2964" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_2964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_2963" xlink:to="loc_dei_AddressTypeDomain_2964_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_2965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_2964" xlink:to="loc_dei_BusinessContactMember_2965" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_146" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentType_104" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentFlag_107" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityRegistrantName_112" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityCentralIndexKey_113" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityFilerCategory_119" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntitySmallBusiness_120" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityEmergingGrowthCompany_121" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityExTransitionPeriod_122" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityIncorporationStateCountryCode_126" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_2961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityPrimarySicNumber_2961" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityTaxIdentificationNumber_128" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_2962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_ContactPersonnelName_2962" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressAddressLine1_129" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4382" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4382" xlink:to="loc_us-gaap_AssetsAbstract_154" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_AssetsCurrentAbstract_151" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_156" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_InventoryNet_162" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_167" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AssetsCurrent_172" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_157" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_168" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_Assets_173" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4382" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_153" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableCurrent_149" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LongTermDebtCurrent_155" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_161" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_166" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LiabilitiesCurrent_171" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_165" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_170" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_175" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_159" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_178" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_Liabilities_179" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_180" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_4162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_TemporaryEquityAbstract_4162" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_4162" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3050" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_StockholdersEquityAbstract_182" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_PreferredStockValue_152" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_CommonStockValue_158" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_AdditionalPaidInCapital_164" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_174" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_StockholdersEquity_176" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_183" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4382" xlink:to="loc_us-gaap_StatementTable_4380" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_4381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4380" xlink:to="loc_srt_RestatementAxis_4381" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_4381" xlink:to="loc_srt_RestatementDomain_4383" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_4381" xlink:to="loc_srt_RestatementDomain_4383_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_4383" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4384" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3690" xlink:to="loc_us-gaap_NetIncomeLoss_228" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3690" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_229" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2480" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3690" xlink:to="loc_us-gaap_StatementTable_3054" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3054" xlink:to="loc_us-gaap_DebtInstrumentAxis_3070" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3728" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3728_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingDueMember" xlink:label="loc_alur_RevenueInterestFinancingDueMember_3055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3728" xlink:to="loc_alur_RevenueInterestFinancingDueMember_3055" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3728" xlink:to="loc_alur_RtwConvertibleNotesMember_3686" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_247" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StatementTable_234" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_238" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_238" xlink:to="loc_us-gaap_EquityComponentDomain_237" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_237_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_238" xlink:to="loc_us-gaap_EquityComponentDomain_237_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_CommonStockMember_241" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_246" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_250" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_RetainedEarningsMember_252" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementClassOfStockAxis_242" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_242" xlink:to="loc_us-gaap_ClassOfStockDomain_245" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_242" xlink:to="loc_us-gaap_ClassOfStockDomain_245_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesA1ConvertiblePreferredStockMember_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_alur_SeriesA1ConvertiblePreferredStockMember_244" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesBConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesBConvertiblePreferredStockMember_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_alur_SeriesBConvertiblePreferredStockMember_249" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_3009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_3009" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockholdersEquity_248" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_SharesOutstanding_251" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_253" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_254" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_256" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_257" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_258" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_259" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger_260" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2763" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2802" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_261" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes_262" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes_263" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities_264" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_265" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability_266" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability_267" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount_268" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares_269" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount_270" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares_271" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_272" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLoss_273" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_277" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4288" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4299" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4322" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_298" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_StatementTable_284" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_289" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_289" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_280" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_280_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_289" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_280_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_280" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_285" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_280" xlink:to="loc_alur_FortressTermLoanMember_294" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_NetIncomeLoss_287" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashLeaseExpense" xlink:label="loc_alur_NonCashLeaseExpense_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashLeaseExpense_283" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_DepreciationAndAmortization_302" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ShareBasedCompensation_308" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_313" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2654" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_InventoryWriteDown_322" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_alur_ChangeInFairValueOfWarrantLiabilities_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_ChangeInFairValueOfWarrantLiabilities_330" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_332" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_336" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_337" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_InterestPaidOnDebtRecordedAtFairValue" xlink:label="loc_alur_InterestPaidOnDebtRecordedAtFairValue_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_InterestPaidOnDebtRecordedAtFairValue_338" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfDebt" xlink:label="loc_alur_FairValueAdjustmentOfDebt_4199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_FairValueAdjustmentOfDebt_4199" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_343" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashInterestExpense" xlink:label="loc_alur_NonCashInterestExpense_339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashInterestExpense_339" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashTerminationOfConvertibleNoteSideLetters" xlink:label="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters_340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters_340" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_341" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xlink:label="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants_4249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants_4249" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashIssuanceOfCommonStockForCommitmentShares" xlink:label="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares_342" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_292" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_301" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_307" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_312" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_317" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_291" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_300" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_288" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_297" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_305" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts_310" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_315" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromOptionAndWarrantExercises" xlink:label="loc_alur_ProceedsFromOptionAndWarrantExercises_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromOptionAndWarrantExercises_328" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromEquityLineFinancing" xlink:label="loc_alur_ProceedsFromEquityLineFinancing_4039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromEquityLineFinancing_4039" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_331" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4115" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4120" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_4163" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfDebt_320" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_324" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentOfDeferredFinancingCosts" xlink:label="loc_alur_PaymentOfDeferredFinancingCosts_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_PaymentOfDeferredFinancingCosts_333" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_311" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_316" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" xlink:to="loc_us-gaap_InterestPaidNet_282" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_295" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfWarrantsInConnectionWithFinancing" xlink:label="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing_303" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_309" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfAssumedWarrantLiability" xlink:label="loc_alur_RecognitionOfAssumedWarrantLiability_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_RecognitionOfAssumedWarrantLiability_314" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfEarnOutLiabilities" xlink:label="loc_alur_RecognitionOfEarnOutLiabilities_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_RecognitionOfEarnOutLiabilities_319" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_323" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci_327" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci_4048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci_4048" use="optional" order="67" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xlink:to="loc_us-gaap_DebtInstrumentAxis_467" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_467" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_476" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_476_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_467" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_476_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_EarnOutLiabilityMember_468" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_473" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_RtwConvertibleNotesMember_3725" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xlink:to="loc_us-gaap_FinancialInstrumentAxis_472" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_472" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_472" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" xlink:to="loc_alur_PublicWarrantsMember_466" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_465" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_471" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_474" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_477" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_522" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_522" xlink:to="loc_us-gaap_EquityComponentDomain_518" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_522" xlink:to="loc_us-gaap_EquityComponentDomain_518_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_518" xlink:to="loc_us-gaap_CommonStockMember_513" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_528" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_528" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_528" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_TypeOfArrangementAxis_533" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationAgreementMember" xlink:label="loc_alur_BusinessCombinationAgreementMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" xlink:to="loc_alur_BusinessCombinationAgreementMember_511" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_CreditFacilityAxis_536" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_536" xlink:to="loc_us-gaap_CreditFacilityDomain_523" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_523_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_536" xlink:to="loc_us-gaap_CreditFacilityDomain_523_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_dei_LegalEntityAxis_538" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_538" xlink:to="loc_dei_EntityDomain_530" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_530_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_538" xlink:to="loc_dei_EntityDomain_530_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_DebtInstrumentAxis_540" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_srt_RestatementAxis_542" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_542" xlink:to="loc_srt_RestatementDomain_517" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_542" xlink:to="loc_srt_RestatementDomain_517_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_srt_RangeAxis_3598" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3598" xlink:to="loc_srt_RangeMember_3384" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3598" xlink:to="loc_srt_RangeMember_3384_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3384" xlink:to="loc_srt_MaximumMember_3381" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xlink:label="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram_521" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationCommonStockExchangeRatio" xlink:label="loc_alur_BusinessCombinationCommonStockExchangeRatio_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_alur_BusinessCombinationCommonStockExchangeRatio_527" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_531" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_535" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_NetIncomeLoss_537" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_539" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_OperatingIncomeLoss_2672" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_541" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_RangeAxis_560" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_560" xlink:to="loc_srt_RangeMember_554" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_554_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_560" xlink:to="loc_srt_RangeMember_554_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_554" xlink:to="loc_srt_MaximumMember_553" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" xlink:to="loc_us-gaap_SalesRevenueNetMember_556" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" xlink:to="loc_us-gaap_AccountsReceivableMember_567" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_571" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_571" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_547" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_547_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_571" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_547_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_547" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_564" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" xlink:to="loc_us-gaap_TypeOfAdoptionMember_563" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_563_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" xlink:to="loc_us-gaap_TypeOfAdoptionMember_563_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_563" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_561" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_563" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1805" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_MajorCustomersAxis_576" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_576" xlink:to="loc_srt_NameOfMajorCustomerDomain_559" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_559_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_576" xlink:to="loc_srt_NameOfMajorCustomerDomain_559_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersMember" xlink:label="loc_alur_CustomersMember_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_559" xlink:to="loc_alur_CustomersMember_558" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_572" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_572_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NewAllurionMember" xlink:label="loc_alur_NewAllurionMember_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_572" xlink:to="loc_alur_NewAllurionMember_551" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_580" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_580" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_548" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_548_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_580" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_548_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_548" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_565" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_ProductOrServiceAxis_582" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_582" xlink:to="loc_srt_ProductsAndServicesDomain_562" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_562_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_582" xlink:to="loc_srt_ProductsAndServicesDomain_562_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaap_ShippingAndHandlingMember_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_562" xlink:to="loc_us-gaap_ShippingAndHandlingMember_555" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_TypeOfArrangementAxis_584" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_584" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_584" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_546" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_550" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_DeferredOfferingCosts_566" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xlink:label="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable_570" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_SellingAndMarketingExpense_573" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_MarketingAndAdvertisingExpense_575" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_577" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_581" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_PercentageOfAnnualNetSales_583" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_585" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesNetOfInterestExpense" xlink:label="loc_us-gaap_RevenuesNetOfInterestExpense_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_RevenuesNetOfInterestExpense_587" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_591" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_592" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_593" use="optional" order="52" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_611" xlink:to="loc_us-gaap_ConcentrationRiskTable_598" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" xlink:to="loc_us-gaap_SalesRevenueNetMember_599" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" xlink:to="loc_us-gaap_AccountsReceivableMember_605" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_607" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_607" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_596" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_596_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_607" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_596_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_596" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_604" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_srt_MajorCustomersAxis_609" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_609" xlink:to="loc_srt_NameOfMajorCustomerDomain_602" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_609" xlink:to="loc_srt_NameOfMajorCustomerDomain_602_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerAMember" xlink:label="loc_alur_CustomerAMember_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerAMember_601" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerBMember" xlink:label="loc_alur_CustomerBMember_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerBMember_606" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerCMember" xlink:label="loc_alur_CustomerCMember_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerCMember_608" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersDMember" xlink:label="loc_alur_CustomersDMember_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomersDMember_610" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_611" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_597" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_680" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627" xlink:to="loc_us-gaap_ClassOfStockDomain_655" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627" xlink:to="loc_us-gaap_ClassOfStockDomain_655_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_655" xlink:to="loc_us-gaap_CommonClassAMember_628" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_655" xlink:to="loc_us-gaap_CommonClassBMember_648" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_647" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_647" xlink:to="loc_us-gaap_EquityComponentDomain_637" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_637_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_647" xlink:to="loc_us-gaap_EquityComponentDomain_637_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_637" xlink:to="loc_us-gaap_CommonStockMember_630" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_654" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeSubscriptionAgreementsMember" xlink:label="loc_alur_PipeSubscriptionAgreementsMember_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" xlink:to="loc_alur_PipeSubscriptionAgreementsMember_639" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_TypeOfArrangementAxis_660" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_660" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_660" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationAgreementMember" xlink:label="loc_alur_BusinessCombinationAgreementMember_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_BusinessCombinationAgreementMember_626" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_646" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedAndRestatedRtwSideLetterMember" xlink:label="loc_alur_AmendedAndRestatedRtwSideLetterMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_AmendedAndRestatedRtwSideLetterMember_653" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressCreditAgreementMember" xlink:label="loc_alur_FortressCreditAgreementMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_FortressCreditAgreementMember_659" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BackstopAgreementMember" xlink:label="loc_alur_BackstopAgreementMember_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_BackstopAgreementMember_662" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLTerminationAgreementMember" xlink:label="loc_alur_HVLTerminationAgreementMember_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_HVLTerminationAgreementMember_665" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GaurContributionAgreementMember" xlink:label="loc_alur_GaurContributionAgreementMember_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_GaurContributionAgreementMember_668" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RSUForfeitureAgreementMember" xlink:label="loc_alur_RSUForfeitureAgreementMember_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_RSUForfeitureAgreementMember_671" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorContributionAgreementMember" xlink:label="loc_alur_SponsorContributionAgreementMember_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_SponsorContributionAgreementMember_674" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorSupportAgreementMember" xlink:label="loc_alur_SponsorSupportAgreementMember_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_SponsorSupportAgreementMember_677" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_663" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_663" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_642" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_642_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_663" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_642_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_642" xlink:to="loc_us-gaap_ConvertibleDebtMember_631" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_dei_LegalEntityAxis_666" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_666" xlink:to="loc_dei_EntityDomain_657" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_666" xlink:to="loc_dei_EntityDomain_657_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_657" xlink:to="loc_alur_ComputeHealthMember_632" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NewAllurionMember" xlink:label="loc_alur_NewAllurionMember_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_657" xlink:to="loc_alur_NewAllurionMember_649" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_669" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_669" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_658" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_669" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_658_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_658" xlink:to="loc_alur_PublicWarrantsMember_640" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantAmendmentMember" xlink:label="loc_alur_WarrantAmendmentMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_658" xlink:to="loc_alur_WarrantAmendmentMember_652" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_CreditFacilityAxis_672" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_672" xlink:to="loc_us-gaap_CreditFacilityDomain_644" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_672" xlink:to="loc_us-gaap_CreditFacilityDomain_644_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_644" xlink:to="loc_alur_FortressTermLoanMember_636" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanFacilityMember" xlink:label="loc_alur_TermLoanFacilityMember_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_644" xlink:to="loc_alur_TermLoanFacilityMember_650" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_675" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_641" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_641_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_641" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_643" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_srt_RangeAxis_678" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_678" xlink:to="loc_srt_RangeMember_635" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_635_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_678" xlink:to="loc_srt_RangeMember_635_default" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_635" xlink:to="loc_srt_MaximumMember_634" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4173" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4173" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3174" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4173" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3174_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3174" xlink:to="loc_us-gaap_SubsequentEventMember_3158" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationCommonStockExchangeRatio" xlink:label="loc_alur_BusinessCombinationCommonStockExchangeRatio_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_BusinessCombinationCommonStockExchangeRatio_638" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorLoanExcessAmount" xlink:label="loc_alur_SponsorLoanExcessAmount_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_SponsorLoanExcessAmount_651" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_656" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_664" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_667" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_670" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_PercentageOfAnnualNetSales_676" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_679" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_681" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_682" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_683" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_684" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ContributionOfCapitalByJointVenturePartner" xlink:label="loc_alur_ContributionOfCapitalByJointVenturePartner_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ContributionOfCapitalByJointVenturePartner_685" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_686" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfCommonStock" xlink:label="loc_alur_RecapitalizationOfCommonStock_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RecapitalizationOfCommonStock_687" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_688" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_689" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfAdditionalShares" xlink:label="loc_alur_RecapitalizationOfAdditionalShares_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RecapitalizationOfAdditionalShares_690" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_691" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_692" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_693" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_694" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_695" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_AdditionalPaidInCapital_696" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_697" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationOneTimeInsurancePayment" xlink:label="loc_alur_BusinessCombinationOneTimeInsurancePayment_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_BusinessCombinationOneTimeInsurancePayment_698" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DirectCostsAndFees" xlink:label="loc_alur_DirectCostsAndFees_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_DirectCostsAndFees_700" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_701" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_702" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_703" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_704" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_705" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4158" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfSurrenderSharesOfCommonStock" xlink:label="loc_alur_NumberOfSurrenderSharesOfCommonStock_4196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_NumberOfSurrenderSharesOfCommonStock_4196" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SurrenderCommonStockValue" xlink:label="loc_alur_SurrenderCommonStockValue_4204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_SurrenderCommonStockValue_4204" use="optional" order="94" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_714" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" xlink:to="loc_us-gaap_TypeOfArrangementAxis_709" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_709" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_709" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" xlink:to="loc_alur_ComputeHealthMember_708" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeInvestorsMember" xlink:label="loc_alur_PipeInvestorsMember_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" xlink:to="loc_alur_PipeInvestorsMember_713" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GrossProceedsFromBusinessCombination" xlink:label="loc_alur_GrossProceedsFromBusinessCombination_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_GrossProceedsFromBusinessCombination_712" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationTransactionCostPaid" xlink:label="loc_alur_BusinessCombinationTransactionCostPaid_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessCombinationTransactionCostPaid_715" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromBusinessCombination" xlink:label="loc_alur_NetProceedsFromBusinessCombination_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_NetProceedsFromBusinessCombination_716" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiabilitiesAssumed" xlink:label="loc_alur_WarrantLiabilitiesAssumed_717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_WarrantLiabilitiesAssumed_717" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfNoteAssumedInBusinessCombination" xlink:label="loc_alur_RepaymentOfNoteAssumedInBusinessCombination_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_RepaymentOfNoteAssumedInBusinessCombination_718" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessAcquisitionAccruedTransactionCosts" xlink:label="loc_alur_BusinessAcquisitionAccruedTransactionCosts_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessAcquisitionAccruedTransactionCosts_719" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_BusinessCombinationNetOfTransactionCosts_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessCombinationNetOfTransactionCosts_720" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_729" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_729" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" xlink:to="loc_us-gaap_TypeOfArrangementAxis_724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_724" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_724" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionEquityholdersMember" xlink:label="loc_alur_LegacyAllurionEquityholdersMember_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_LegacyAllurionEquityholdersMember_723" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ComputeHealthMember_728" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeInvestorsMember" xlink:label="loc_alur_PipeInvestorsMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_PipeInvestorsMember_730" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwAndFortressMember" xlink:label="loc_alur_RtwAndFortressMember_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_RtwAndFortressMember_731" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteHoldersMember" xlink:label="loc_alur_ConvertibleNoteHoldersMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ConvertibleNoteHoldersMember_732" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthSponsorSharesMember" xlink:label="loc_alur_ComputeHealthSponsorSharesMember_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ComputeHealthSponsorSharesMember_733" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterTerminationSharesMember" xlink:label="loc_alur_SideLetterTerminationSharesMember_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_SideLetterTerminationSharesMember_734" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_729" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_727" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_771" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_756" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_srt_StatementGeographicalAxis_752" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_752" xlink:to="loc_srt_SegmentGeographicalDomain_749" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_749_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_752" xlink:to="loc_srt_SegmentGeographicalDomain_749_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_country_US_751" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EachCountryMember" xlink:label="loc_alur_EachCountryMember_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_EachCountryMember_760" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AllOtherCountriesMember" xlink:label="loc_alur_AllOtherCountriesMember_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_AllOtherCountriesMember_764" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FourCountriesIncludedWithinAllOtherCountriesMember" xlink:label="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember_767" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_755" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_765" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_765" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_750" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_750_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_765" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_750_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_750" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_758" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_srt_RangeAxis_768" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_768" xlink:to="loc_srt_RangeMember_754" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_754_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_768" xlink:to="loc_srt_RangeMember_754_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_754" xlink:to="loc_srt_MinimumMember_753" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_754" xlink:to="loc_srt_MaximumMember_762" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_759" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_763" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenue" xlink:label="loc_alur_NumberOfCountriesGenerateRevenue_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_alur_NumberOfCountriesGenerateRevenue_766" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenueBySales" xlink:label="loc_alur_NumberOfCountriesGenerateRevenueBySales_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_alur_NumberOfCountriesGenerateRevenueBySales_769" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_743" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_743" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_740" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_740" xlink:to="loc_srt_StatementGeographicalAxis_739" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_739" xlink:to="loc_srt_SegmentGeographicalDomain_737" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_737_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_739" xlink:to="loc_srt_SegmentGeographicalDomain_737_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="loc_country_ES_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_ES_744" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="loc_country_GB_2303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_GB_2303" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="loc_country_FR_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_FR_738" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_TRY" xlink:label="loc_currency_TRY_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_currency_TRY_742" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_country_AU_3953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_AU_3953" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IT" xlink:label="loc_country_IT_4025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_IT_4025" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CL" xlink:label="loc_country_CL_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_CL_745" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AllOtherCountriesMember" xlink:label="loc_alur_AllOtherCountriesMember_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_alur_AllOtherCountriesMember_746" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_743" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_741" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/InventoryAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_785" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_785" xlink:to="loc_us-gaap_InventoryCurrentTable_782" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_782" xlink:to="loc_srt_RangeAxis_784" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_784" xlink:to="loc_srt_RangeMember_781" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_781_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_784" xlink:to="loc_srt_RangeMember_781_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_781" xlink:to="loc_srt_MaximumMember_780" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_785" xlink:to="loc_us-gaap_InventoryValuationReserves_783" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputersAndPurchasedSoftwareMember" xlink:label="loc_alur_ComputersAndPurchasedSoftwareMember_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_alur_ComputersAndPurchasedSoftwareMember_793" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_797" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_800" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_803" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xlink:to="loc_srt_RangeAxis_798" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_798" xlink:to="loc_srt_RangeMember_790" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_790_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_798" xlink:to="loc_srt_RangeMember_790_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_790" xlink:to="loc_srt_MinimumMember_789" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_790" xlink:to="loc_srt_MaximumMember_795" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_791" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_796" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_799" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConstructionInProgress" xlink:label="loc_alur_ConstructionInProgress_3865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_alur_ConstructionInProgress_3865" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4385" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_814" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_812" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_812_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_812_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_CostOfSalesMember_813" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_815" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_817" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_818" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_2177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" xlink:to="loc_us-gaap_DepreciationAndAmortization_2177" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_2183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" xlink:to="loc_us-gaap_RestructuringCharges_2183" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" xlink:to="loc_srt_RangeAxis_2187" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2187" xlink:to="loc_srt_RangeMember_2186" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2186_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2187" xlink:to="loc_srt_RangeMember_2186_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2186" xlink:to="loc_srt_MaximumMember_2185" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" xlink:to="loc_us-gaap_PaymentsForRestructuring_2279" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_847" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_DebtInstrumentTable_838" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_838" xlink:to="loc_us-gaap_CreditFacilityAxis_837" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_837" xlink:to="loc_us-gaap_CreditFacilityDomain_843" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_843_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_837" xlink:to="loc_us-gaap_CreditFacilityDomain_843_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_843" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_840" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_843" xlink:to="loc_alur_FortressTermLoanMember_845" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_838" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_844" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_844" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_842" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_842_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_844" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_842_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_842" xlink:to="loc_us-gaap_ConvertibleDebtMember_839" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_842" xlink:to="loc_alur_RtwConvertibleNotesMember_3648" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_841" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfDebt" xlink:label="loc_alur_ChangeInFairValueOfDebt_3757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_alur_ChangeInFairValueOfDebt_3757" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LoanAccretion" xlink:label="loc_alur_LoanAccretion_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_alur_LoanAccretion_846" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_LongTermDebtCurrent_848" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_849" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_850" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_904" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentTable_859" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_CreditFacilityAxis_854" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_854" xlink:to="loc_us-gaap_CreditFacilityDomain_867" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_867_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_854" xlink:to="loc_us-gaap_CreditFacilityDomain_867_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_873" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermCLoanMember" xlink:label="loc_alur_TermCLoanMember_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TermCLoanMember_881" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermDLoanMember" xlink:label="loc_alur_TermDLoanMember_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TermDLoanMember_888" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_FortressTermLoanMember_898" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_DebtInstrumentAxis_868" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_868" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_883" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_883_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_868" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_883_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember_863" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember_880" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressCreditAgreementMember" xlink:label="loc_alur_FortressCreditAgreementMember_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_FortressCreditAgreementMember_887" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressAmendmentMember" xlink:label="loc_alur_FortressAmendmentMember_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_FortressAmendmentMember_892" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyOneConvertibleNotesMember_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyOneConvertibleNotesMember_920" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember_922" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_924" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterHolderBridgeNoteMember" xlink:label="loc_alur_SideLetterHolderBridgeNoteMember_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_SideLetterHolderBridgeNoteMember_926" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NotePurchaseAgreementMember" xlink:label="loc_alur_NotePurchaseAgreementMember_3780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_NotePurchaseAgreementMember_3780" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLBridgeNoteMember" xlink:label="loc_alur_HVLBridgeNoteMember_4097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_HVLBridgeNoteMember_4097" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_876" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_876" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_855_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_876" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_855_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RunwayGrowthCreditFundIncMember" xlink:label="loc_alur_RunwayGrowthCreditFundIncMember_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" xlink:to="loc_alur_RunwayGrowthCreditFundIncMember_866" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_TypeOfArrangementAxis_884" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_884" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_884" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BackstopAgreementMember" xlink:label="loc_alur_BackstopAgreementMember_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" xlink:to="loc_alur_BackstopAgreementMember_853" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_RangeAxis_890" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_862" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_862_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_862" xlink:to="loc_srt_MinimumMember_861" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_862" xlink:to="loc_srt_MaximumMember_871" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_StatementClassOfStockAxis_895" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_895" xlink:to="loc_us-gaap_ClassOfStockDomain_879" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_879_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_895" xlink:to="loc_us-gaap_ClassOfStockDomain_879_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockMember_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockMember_877" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_us-gaap_CommonStockMember_885" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesD1PreferredStockMember" xlink:label="loc_alur_SeriesD1PreferredStockMember_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_alur_SeriesD1PreferredStockMember_891" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_StatementScenarioAxis_900" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_900" xlink:to="loc_srt_ScenarioUnspecifiedDomain_860" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_860_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_900" xlink:to="loc_srt_ScenarioUnspecifiedDomain_860_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UntilMarch312024Member" xlink:label="loc_alur_UntilMarch312024Member_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_UntilMarch312024Member_857" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromApril12024ToJune302024Member" xlink:label="loc_alur_FromApril12024ToJune302024Member_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_FromApril12024ToJune302024Member_870" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromJuly12024ToSeptember302024Member" xlink:label="loc_alur_FromJuly12024ToSeptember302024Member_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_FromJuly12024ToSeptember302024Member_878" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OnOctober12024AndThereafterMember" xlink:label="loc_alur_OnOctober12024AndThereafterMember_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_OnOctober12024AndThereafterMember_886" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3778" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3778" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3311" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3311_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3778" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3311_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3311" xlink:to="loc_alur_RtwConvertibleNotesMember_3309" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_4392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_RestatementAxis_4392" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_4392" xlink:to="loc_srt_RestatementDomain_4393" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_4392" xlink:to="loc_srt_RestatementDomain_4393_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_4393" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4394" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_865" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdditionalBorrowings" xlink:label="loc_alur_AdditionalBorrowings_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_AdditionalBorrowings_874" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xlink:label="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds_882" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_889" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1_894" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestExpenseDebt_903" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_907" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_909" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanAccretion" xlink:label="loc_alur_TermLoanAccretion_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_TermLoanAccretion_911" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_913" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_915" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_917" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_919" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_921" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitPaymentPercentage" xlink:label="loc_alur_DebtInstrumentExitPaymentPercentage_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentExitPaymentPercentage_923" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_925" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExercisableWarrantsIssuedAsConsideration" xlink:label="loc_alur_ExercisableWarrantsIssuedAsConsideration_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ExercisableWarrantsIssuedAsConsideration_927" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfTheWarrants" xlink:label="loc_alur_FairValueOfTheWarrants_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FairValueOfTheWarrants_929" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_931" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_933" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_935" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiability" xlink:label="loc_alur_WarrantLiability_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_WarrantLiability_936" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_937" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfPrincipal" xlink:label="loc_alur_RepaymentOfPrincipal_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_RepaymentOfPrincipal_938" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFee" xlink:label="loc_alur_PrepaymentFee_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PrepaymentFee_939" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFee" xlink:label="loc_alur_FinalPaymentFee_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FinalPaymentFee_940" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFeePercentage" xlink:label="loc_alur_PrepaymentFeePercentage_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PrepaymentFeePercentage_941" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OriginalFinalPayment" xlink:label="loc_alur_OriginalFinalPayment_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_OriginalFinalPayment_942" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFeePercentage" xlink:label="loc_alur_FinalPaymentFeePercentage_943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FinalPaymentFeePercentage_943" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfTheWarrant" xlink:label="loc_alur_AmortizationOfTheWarrant_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_AmortizationOfTheWarrant_944" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_945" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentTerm_946" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_947" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByDiscountedCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByDiscountedCappedConversionPrice_948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ConversionDividedByDiscountedCappedConversionPrice_948" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_949" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByCappedConversionPrice_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ConversionDividedByCappedConversionPrice_950" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CappedPrice" xlink:label="loc_alur_CappedPrice_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_CappedPrice_951" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_952" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_953" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xlink:label="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice_954" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_MinimumLiquidityAmount" xlink:label="loc_alur_MinimumLiquidityAmount_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_MinimumLiquidityAmount_955" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xlink:label="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault_956" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentDefaultInterestRate" xlink:label="loc_alur_DebtInstrumentDefaultInterestRate_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentDefaultInterestRate_957" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_958" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_959" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xlink:label="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities_960" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredLiabilityForIssuanceOfAdditionalShares" xlink:label="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares_961" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_963" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_964" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_965" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2030" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitFee" xlink:label="loc_alur_DebtInstrumentExitFee_4230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentExitFee_4230" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_4245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_PaymentsForFees_4245" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_4252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestReceivable_4252" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4362" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_4365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_4365" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_4366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_4366" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4370" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4371" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4372" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xlink:label="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock_4373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock_4373" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4374" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xlink:label="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger_4375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger_4375" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xlink:label="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding_4377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding_4377" use="optional" order="119" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnrestrictedCash" xlink:label="loc_alur_UnrestrictedCash_4378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_UnrestrictedCash_4378" use="optional" order="120" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_973" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_DebtInstrumentTable_969" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_969" xlink:to="loc_us-gaap_CreditFacilityAxis_968" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_968" xlink:to="loc_us-gaap_CreditFacilityDomain_972" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_972_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_968" xlink:to="loc_us-gaap_CreditFacilityDomain_972_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_972" xlink:to="loc_alur_FortressTermLoanMember_970" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_977" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_978" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_980" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_us-gaap_TypeOfArrangementAxis_992" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_992" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_992" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_983" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementAmendmentMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementAmendmentMember_3639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" xlink:to="loc_alur_RevenueInterestFinancingAgreementAmendmentMember_3639" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_us-gaap_DebtInstrumentAxis_997" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_997" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_999" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_999_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_997" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_999_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PIPEConversionOptionMember" xlink:label="loc_alur_PIPEConversionOptionMember_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_999" xlink:to="loc_alur_PIPEConversionOptionMember_989" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_srt_RangeAxis_1000" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1000" xlink:to="loc_srt_RangeMember_988" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_988_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1000" xlink:to="loc_srt_RangeMember_988_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_988" xlink:to="loc_srt_MaximumMember_987" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_988" xlink:to="loc_srt_MinimumMember_994" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_srt_StatementScenarioAxis_1002" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1002" xlink:to="loc_srt_ScenarioUnspecifiedDomain_986" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_986_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1002" xlink:to="loc_srt_ScenarioUnspecifiedDomain_986_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanOneMember" xlink:label="loc_alur_ScenarioPlanOneMember_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_alur_ScenarioPlanOneMember_984" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanTwoMember" xlink:label="loc_alur_ScenarioPlanTwoMember_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_alur_ScenarioPlanTwoMember_993" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_3763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_srt_ScenarioForecastMember_3763" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_alur_RevenuesInterestFinancingLiability_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenuesInterestFinancingLiability_990" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfAnnualNetSales_995" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_998" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestPaymentsPercentage" xlink:label="loc_alur_RevenueInterestPaymentsPercentage_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenueInterestPaymentsPercentage_1001" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CashPaymentsPercentage" xlink:label="loc_alur_CashPaymentsPercentage_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_CashPaymentsPercentage_1003" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrePaymentsPercentage" xlink:label="loc_alur_PrePaymentsPercentage_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PrePaymentsPercentage_1004" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_1005" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_1006" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RoyaltyPayments" xlink:label="loc_alur_RoyaltyPayments_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RoyaltyPayments_1007" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1008" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_VolumeWeightedAveragePricePerShare" xlink:label="loc_alur_VolumeWeightedAveragePricePerShare_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_VolumeWeightedAveragePricePerShare_1009" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_SharePrice_1010" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_1011" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1012" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1013" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfNetSales" xlink:label="loc_alur_PercentageOfNetSales_4022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfNetSales_4022" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SalesRevenueNet" xlink:label="loc_alur_SalesRevenueNet_4060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_SalesRevenueNet_4060" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseInSalesRevenueNet" xlink:label="loc_alur_IncreaseInSalesRevenueNet_4103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_IncreaseInSalesRevenueNet_4103" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfIncreaseInNetSales" xlink:label="loc_alur_PercentageOfIncreaseInNetSales_4129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfIncreaseInNetSales_4129" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfRevenueInterestFinancingAgreements" xlink:label="loc_alur_FairValueOfRevenueInterestFinancingAgreements_4155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_FairValueOfRevenueInterestFinancingAgreements_4155" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfPipeConversionOption" xlink:label="loc_alur_FairValueOfPipeConversionOption_4175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_FairValueOfPipeConversionOption_4175" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementRemeasuredValue" xlink:label="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue_4193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue_4193" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionOptionRemeasuredValue" xlink:label="loc_alur_PipeConversionOptionRemeasuredValue_4206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PipeConversionOptionRemeasuredValue_4206" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfInternalRateOfReturn" xlink:label="loc_alur_PercentageOfInternalRateOfReturn_4244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfInternalRateOfReturn_4244" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4303" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1020" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1020" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1020" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_1016" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_alur_RevenuesInterestFinancingLiability_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenuesInterestFinancingLiability_1018" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:label="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt_1021" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RoyaltyPayments" xlink:label="loc_alur_RoyaltyPayments_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RoyaltyPayments_1023" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfDebt" xlink:label="loc_alur_ChangeInFairValueOfDebt_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_ChangeInFairValueOfDebt_1024" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_1025" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_srt_RangeAxis_1229" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1229" xlink:to="loc_srt_RangeMember_1232" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1232_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1229" xlink:to="loc_srt_RangeMember_1232_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1232" xlink:to="loc_srt_MaximumMember_1239" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_us-gaap_TaxPeriodAxis_1238" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_1238" xlink:to="loc_us-gaap_TaxPeriodDomain_1230" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_1238" xlink:to="loc_us-gaap_TaxPeriodDomain_1230_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_us-gaap_EarliestTaxYearMember_1235" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_us-gaap_LatestTaxYearMember_1242" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LatestTaxYearTwoThousandFortyTwoMember" xlink:label="loc_alur_LatestTaxYearTwoThousandFortyTwoMember_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_LatestTaxYearTwoThousandFortyTwoMember_1245" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xlink:label="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember_1248" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DoNotExpireMember" xlink:label="loc_alur_DoNotExpireMember_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_DoNotExpireMember_1250" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1243" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1236" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1236_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1236_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1236" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1234" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1236" xlink:to="loc_us-gaap_DomesticCountryMember_1241" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1233" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1240" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1244" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1247" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod_1249" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopment" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment_1251" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear_1252" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1253" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1254" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" xlink:to="loc_us-gaap_DebtInstrumentAxis_1186" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1192" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1192_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1185" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_EarnOutLiabilityMember_1189" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_RtwConvertibleNotesMember_3821" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_SharePrice_1184" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1188" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1191" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1193" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1157" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1157" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1157" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" xlink:to="loc_alur_PublicWarrantsMember_1151" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_DebtInstrumentAxis_1163" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1168" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1168_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingMember" xlink:label="loc_alur_RevenueInterestFinancingMember_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_RevenueInterestFinancingMember_1154" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionDerivativeMember" xlink:label="loc_alur_PipeConversionDerivativeMember_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_PipeConversionDerivativeMember_1162" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_EarnOutLiabilityMember_1166" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_RtwConvertibleNotesMember_3842" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1167" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1167" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1167" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SuccessFeeDerivativeLiabilityMember" xlink:label="loc_alur_SuccessFeeDerivativeLiabilityMember_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_SuccessFeeDerivativeLiabilityMember_1159" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1165" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoShareLiabilityMember" xlink:label="loc_alur_PubcoShareLiabilityMember_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_PubcoShareLiabilityMember_1170" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoAndBackstopShareLiabilityMember_1173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_BasePubcoAndBackstopShareLiabilityMember_1173" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1176" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_PublicOfferingWarrantsMember_3894" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3231" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1171" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1171" xlink:to="loc_us-gaap_EquityComponentDomain_1155" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1171" xlink:to="loc_us-gaap_EquityComponentDomain_1155_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockWarrantsMember" xlink:label="loc_alur_PreferredStockWarrantsMember_1152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1155" xlink:to="loc_alur_PreferredStockWarrantsMember_1152" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommonStockWarrantsMember" xlink:label="loc_alur_CommonStockWarrantsMember_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1155" xlink:to="loc_alur_CommonStockWarrantsMember_1161" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1158" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1164" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1169" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_1172" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_1175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_1175" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_1177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_1177" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt_1178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt_1178" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_1179" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability_1180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability_1180" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_DebtInstrumentAxis_1118" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1133" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1133_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1133_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xlink:label="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember_1115" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1131" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1136" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_RtwConvertibleNotesMember_3862" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1128" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoAdditionalSharesLiabilityMember" xlink:label="loc_alur_PubcoAdditionalSharesLiabilityMember_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_PubcoAdditionalSharesLiabilityMember_1134" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoSharesAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember_1138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember_1138" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1144" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1132" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1132" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1114" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1114_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1132" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1114_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1114" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1110" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1114" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1125" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1116" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1140" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1140" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1122" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1122_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1140" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1122_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1122" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1111" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1143" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1143" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1143" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" xlink:to="loc_alur_PublicWarrantsMember_1109" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_CreditFacilityAxis_1146" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1146" xlink:to="loc_us-gaap_CreditFacilityDomain_1121" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1121_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1146" xlink:to="loc_us-gaap_CreditFacilityDomain_1121_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1121" xlink:to="loc_alur_FortressTermLoanMember_1117" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1112" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssumptionsOfLiquidityEventTerm" xlink:label="loc_alur_FairValueAssumptionsOfLiquidityEventTerm_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueAssumptionsOfLiquidityEventTerm_1126" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_1130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_1130" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_LineOfCredit_1135" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1139" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedNumberOfShares" xlink:label="loc_alur_FairValueOfEstimatedNumberOfShares_1142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueOfEstimatedNumberOfShares_1142" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedPriceOfShares" xlink:label="loc_alur_FairValueOfEstimatedPriceOfShares_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueOfEstimatedPriceOfShares_1145" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_SharePrice_1147" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4077" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails">
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" xlink:to="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1074" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1074" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1080" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1080_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1074" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1080_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1080" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1073" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1078" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1093" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1093" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1075" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1075_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1093" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1075_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1072" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_1086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_1086" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_1092" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1095" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1098" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1096" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1096" xlink:to="loc_us-gaap_ClassOfStockDomain_1091" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1091_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1096" xlink:to="loc_us-gaap_ClassOfStockDomain_1091_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember_1070" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember_1090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember_1090" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember_1097" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember_1102" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember_1105" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4033" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4033" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4033" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" xlink:to="loc_alur_PublicOfferingWarrantsMember_3108" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3114" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1099" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1099" xlink:to="loc_us-gaap_EquityComponentDomain_1079" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1079_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1099" xlink:to="loc_us-gaap_EquityComponentDomain_1079_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockMember" xlink:label="loc_alur_OtherCommonStockMember_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_OtherCommonStockMember_1071" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantsMember" xlink:label="loc_alur_OtherCommonStockWarrantsMember_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_OtherCommonStockWarrantsMember_1085" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionOtherCommonStockMember" xlink:label="loc_alur_LegacyAllurionOtherCommonStockMember_3677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_LegacyAllurionOtherCommonStockMember_3677" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_srt_RangeAxis_1101" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1101" xlink:to="loc_srt_RangeMember_1077" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1101" xlink:to="loc_srt_RangeMember_1077_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1077" xlink:to="loc_srt_MinimumMember_1076" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1077" xlink:to="loc_srt_MaximumMember_1088" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1081" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1089" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1040" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1041" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3416" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1033" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1046" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1049" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1049" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1049" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1035" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1051" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1051" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1051" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember_1036" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PublicWarrantsMember_1045" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PublicOfferingWarrantsMember_3803" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingMember" xlink:label="loc_alur_RevenueInterestFinancingMember_1048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_RevenueInterestFinancingMember_1048" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PIPEConversionOptionMember" xlink:label="loc_alur_PIPEConversionOptionMember_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PIPEConversionOptionMember_1050" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_EarnOutLiabilityMember_1052" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_4074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_RtwConvertibleNotesMember_4074" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1054" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DerivativeLiabilitySuccessFeeMember" xlink:label="loc_alur_DerivativeLiabilitySuccessFeeMember_1055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_DerivativeLiabilitySuccessFeeMember_1055" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember_1056" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember_1058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember_1058" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember_1060" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_OtherCommonStockWarrantLiabilitiesMember_1062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_OtherCommonStockWarrantLiabilitiesMember_1062" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember_1063" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember_1066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember_1066" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1031" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1042" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3085" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3005" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3013" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3013" xlink:to="loc_us-gaap_ClassOfStockDomain_3048" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3048_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3013" xlink:to="loc_us-gaap_ClassOfStockDomain_3048_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_3014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3048" xlink:to="loc_us-gaap_CommonClassAMember_3014" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3048" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3029" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_dei_LegalEntityAxis_3032" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3032" xlink:to="loc_dei_EntityDomain_3052" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3052_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3032" xlink:to="loc_dei_EntityDomain_3052_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3051" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3051" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3051" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthAcquisitionCorprationMember" xlink:label="loc_alur_ComputeHealthAcquisitionCorprationMember_3025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" xlink:to="loc_alur_ComputeHealthAcquisitionCorprationMember_3025" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantMember" xlink:label="loc_alur_PublicWarrantMember_3023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicWarrantMember_3023" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_3035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_IPOMember_3035" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingMember" xlink:label="loc_alur_PublicOfferingMember_3050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicOfferingMember_3050" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsAndShareOverallotmentMember" xlink:label="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember_3056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember_3056" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_3063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_PrivatePlacementMember_3063" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWithRTWMember" xlink:label="loc_alur_PrivatePlacementWithRTWMember_3066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PrivatePlacementWithRTWMember_3066" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3073" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3062" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3062" xlink:to="loc_us-gaap_EquityComponentDomain_3017" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3062" xlink:to="loc_us-gaap_EquityComponentDomain_3017_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_us-gaap_CommonStockMember_3009" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3034" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommitmentSharesMember" xlink:label="loc_alur_CommitmentSharesMember_3049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_alur_CommitmentSharesMember_3049" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_3067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_srt_StatementScenarioAxis_3067" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3067" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3018" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3067" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3018_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanThreeMember" xlink:label="loc_alur_ScenarioPlanThreeMember_3024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3018" xlink:to="loc_alur_ScenarioPlanThreeMember_3024" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanFourMember" xlink:label="loc_alur_ScenarioPlanFourMember_3030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3018" xlink:to="loc_alur_ScenarioPlanFourMember_3030" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3072" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3072" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3072" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChefPurchaseAgreementMember" xlink:label="loc_alur_ChefPurchaseAgreementMember_3011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" xlink:to="loc_alur_ChefPurchaseAgreementMember_3011" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_srt_RangeAxis_3076" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3076" xlink:to="loc_srt_RangeMember_3020" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3020_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3076" xlink:to="loc_srt_RangeMember_3020_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_CreditFacilityAxis_3079" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3079" xlink:to="loc_us-gaap_CreditFacilityDomain_3021" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3021_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3079" xlink:to="loc_us-gaap_CreditFacilityDomain_3021_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChardanEquityFacilityMember" xlink:label="loc_alur_ChardanEquityFacilityMember_3026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3021" xlink:to="loc_alur_ChardanEquityFacilityMember_3026" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3082" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3082" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3022" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3022_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3082" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3022_default" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionBasis" xlink:label="loc_alur_PreferredStockRedemptionBasis_3028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PreferredStockRedemptionBasis_3028" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockLiquidationPreferenceBasis" xlink:label="loc_alur_PreferredStockLiquidationPreferenceBasis_3031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PreferredStockLiquidationPreferenceBasis_3031" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_3053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockConversionBasis_3053" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_3054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockVotingRights_3054" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_3064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_DividendsPreferredStockCash_3064" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3065" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3074" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3075" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3080" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3081" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3086" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3087" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3088" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_3089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_3089" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_3090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_3090" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3091" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3092" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3093" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3094" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3095" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SharePrice_3096" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsRedumptionPricePerShare" xlink:label="loc_alur_WarrantsRedumptionPricePerShare_3097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_WarrantsRedumptionPricePerShare_3097" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3098" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3099" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3100" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity_3101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity_3101" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3102" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnderwritingDiscounts" xlink:label="loc_alur_UnderwritingDiscounts_3103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_UnderwritingDiscounts_3103" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ReductionInProceedsFromOffering" xlink:label="loc_alur_ReductionInProceedsFromOffering_3104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_ReductionInProceedsFromOffering_3104" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3105" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3106" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfCommonStockSharesOutstanding" xlink:label="loc_alur_PercentageOfCommonStockSharesOutstanding_3107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PercentageOfCommonStockSharesOutstanding_3107" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3108" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpenseOfIssuanceOfCommitmentShares" xlink:label="loc_alur_ExpenseOfIssuanceOfCommitmentShares_3109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_ExpenseOfIssuanceOfCommitmentShares_3109" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StructuringFeePayable" xlink:label="loc_alur_StructuringFeePayable_3110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_StructuringFeePayable_3110" use="optional" order="83" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3057" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3057" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2999" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3008" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3008" xlink:to="loc_us-gaap_ClassOfStockDomain_3046" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3046_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3008" xlink:to="loc_us-gaap_ClassOfStockDomain_3046_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3046" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3002" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3036" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036" xlink:to="loc_us-gaap_EquityComponentDomain_3000" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3000_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036" xlink:to="loc_us-gaap_EquityComponentDomain_3000_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_3006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_3006" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_3045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_3045" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:label="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_3058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_3058" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_3068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_EarnOutSharesMember_3068" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNotesMember" xlink:label="loc_alur_ConvertibleNotesMember_3071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_ConvertibleNotesMember_3071" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3007" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3057" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3003" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2993_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2993_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtDecember012014Member" xlink:label="loc_alur_WarrantsIssuedAtDecember012014Member_3041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtDecember012014Member_3041" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtMarch302021Member" xlink:label="loc_alur_WarrantsIssuedAtMarch302021Member_3042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtMarch302021Member_3042" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember152022Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember152022Member_3059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtSeptember152022Member_3059" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune042022Member" xlink:label="loc_alur_WarrantsIssuedAtJune042022Member_3060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune042022Member_3060" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJanuary172017Member" xlink:label="loc_alur_WarrantsIssuedAtJanuary172017Member_3069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJanuary172017Member_3069" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtAugust032017Member" xlink:label="loc_alur_WarrantsIssuedAtAugust032017Member_3070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtAugust032017Member_3070" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember082017Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember082017Member_3077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtSeptember082017Member_3077" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune192018Member" xlink:label="loc_alur_WarrantsIssuedAtJune192018Member_3078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune192018Member_3078" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune252019Member" xlink:label="loc_alur_WarrantsIssuedAtJune252019Member_3083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune252019Member_3083" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJuly012024Member" xlink:label="loc_alur_WarrantsIssuedAtJuly012024Member_3084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJuly012024Member_3084" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3033" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3033" xlink:to="loc_us-gaap_EquityComponentDomain_2991" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2991_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3033" xlink:to="loc_us-gaap_EquityComponentDomain_2991_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2991" xlink:to="loc_us-gaap_CommonStockMember_2994" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2992" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3039" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3043" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1332" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1296" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1285" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1285" xlink:to="loc_us-gaap_ClassOfStockDomain_1312" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1312_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1285" xlink:to="loc_us-gaap_ClassOfStockDomain_1312_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1287" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1305" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1311" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1316" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1319" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1322" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDTwoPreferredStockMember" xlink:label="loc_alur_SeriesDTwoPreferredStockMember_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDTwoPreferredStockMember_1325" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDThreePreferredStockMember" xlink:label="loc_alur_SeriesDThreePreferredStockMember_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDThreePreferredStockMember_1328" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_CommonClassAMember_1331" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_dei_LegalEntityAxis_1303" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1303" xlink:to="loc_dei_EntityDomain_1313" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1313_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1303" xlink:to="loc_dei_EntityDomain_1313_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionMember" xlink:label="loc_alur_LegacyAllurionMember_1291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1313" xlink:to="loc_alur_LegacyAllurionMember_1291" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_srt_RangeAxis_1309" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1309" xlink:to="loc_srt_RangeMember_1294" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1309" xlink:to="loc_srt_RangeMember_1294_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1294" xlink:to="loc_srt_MaximumMember_1293" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1314" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthAcquisitionCorprationMember" xlink:label="loc_alur_ComputeHealthAcquisitionCorprationMember_1300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" xlink:to="loc_alur_ComputeHealthAcquisitionCorprationMember_1300" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" xlink:to="loc_us-gaap_IPOMember_1299" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantMember" xlink:label="loc_alur_PublicWarrantMember_1308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" xlink:to="loc_alur_PublicWarrantMember_1308" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_srt_StatementScenarioAxis_1320" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1320" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1292" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1320" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1292_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanThreeMember" xlink:label="loc_alur_ScenarioPlanThreeMember_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1292" xlink:to="loc_alur_ScenarioPlanThreeMember_1288" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanFourMember" xlink:label="loc_alur_ScenarioPlanFourMember_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1292" xlink:to="loc_alur_ScenarioPlanFourMember_1306" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1323" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1323" xlink:to="loc_us-gaap_EquityComponentDomain_1297" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1323" xlink:to="loc_us-gaap_EquityComponentDomain_1297_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1297" xlink:to="loc_us-gaap_CommonStockMember_1290" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommitmentSharesMember" xlink:label="loc_alur_CommitmentSharesMember_1307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1297" xlink:to="loc_alur_CommitmentSharesMember_1307" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1326" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1326" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1326" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChefPurchaseAgreementMember" xlink:label="loc_alur_ChefPurchaseAgreementMember_1284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" xlink:to="loc_alur_ChefPurchaseAgreementMember_1284" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_CreditFacilityAxis_1329" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1329" xlink:to="loc_us-gaap_CreditFacilityDomain_1301" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1301_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1329" xlink:to="loc_us-gaap_CreditFacilityDomain_1301_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChardanEquityFacilityMember" xlink:label="loc_alur_ChardanEquityFacilityMember_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1301" xlink:to="loc_alur_ChardanEquityFacilityMember_1295" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1286" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1304" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_1310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockVotingRights_1310" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockVotingRights_1315" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1318" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_DividendsPreferredStockCash_1321" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_1324" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xlink:label="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue_1327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue_1327" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1330" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfSharesOfCommonStockHeld" xlink:label="loc_alur_PercentageOfSharesOfCommonStockHeld_1333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfSharesOfCommonStockHeld_1333" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1334" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockConversionBasis_1335" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPreferredStockRedeemableShares" xlink:label="loc_alur_PercentageOfPreferredStockRedeemableShares_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfPreferredStockRedeemableShares_1336" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionValueToPrice" xlink:label="loc_alur_PreferredStockRedemptionValueToPrice_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PreferredStockRedemptionValueToPrice_1337" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1338" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1339" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1340" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1341" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1342" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1343" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1344" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1345" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_1346" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsRedumptionPricePerShare" xlink:label="loc_alur_WarrantsRedumptionPricePerShare_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_WarrantsRedumptionPricePerShare_1347" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SharePrice_1348" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1349" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1350" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1351" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfCommonStockSharesOutstanding" xlink:label="loc_alur_PercentageOfCommonStockSharesOutstanding_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfCommonStockSharesOutstanding_1352" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpenseOfIssuanceOfCommitmentShares" xlink:label="loc_alur_ExpenseOfIssuanceOfCommitmentShares_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_ExpenseOfIssuanceOfCommitmentShares_1353" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1354" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StructuringFeePayable" xlink:label="loc_alur_StructuringFeePayable_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_StructuringFeePayable_1355" use="optional" order="80" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1270" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1266" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1266" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1262" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1262" xlink:to="loc_us-gaap_ClassOfStockDomain_1273" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1273_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1262" xlink:to="loc_us-gaap_ClassOfStockDomain_1273_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1264" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1269" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1272" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1276" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1278" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDTwoPreferredStockMember" xlink:label="loc_alur_SeriesDTwoPreferredStockMember_1280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDTwoPreferredStockMember_1280" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDThreePreferredStockMember" xlink:label="loc_alur_SeriesDThreePreferredStockMember_1281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDThreePreferredStockMember_1281" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1266" xlink:to="loc_dei_LegalEntityAxis_1267" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1267" xlink:to="loc_dei_EntityDomain_1274" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1274_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1267" xlink:to="loc_dei_EntityDomain_1274_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionMember" xlink:label="loc_alur_LegacyAllurionMember_1265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1274" xlink:to="loc_alur_LegacyAllurionMember_1265" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1263" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1268" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_1275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_1275" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1368" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1368" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1361" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1361" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1358" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1358" xlink:to="loc_us-gaap_EquityComponentDomain_1362" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1358" xlink:to="loc_us-gaap_EquityComponentDomain_1362_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1360" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchasePreferredStockMember" xlink:label="loc_alur_WarrantsToPurchasePreferredStockMember_1366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_WarrantsToPurchasePreferredStockMember_1366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_1369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_1369" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_PublicWarrantsToPurchaseCommonStockMember_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_PublicWarrantsToPurchaseCommonStockMember_1370" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_1371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_EarnOutSharesMember_1371" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1361" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1363" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1368" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1359" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1390_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1390_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtApril012013Member" xlink:label="loc_alur_WarrantsIssuedAtApril012013Member_1380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtApril012013Member_1380" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtDecember012014Member" xlink:label="loc_alur_WarrantsIssuedAtDecember012014Member_1384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtDecember012014Member_1384" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtMarch302021Member" xlink:label="loc_alur_WarrantsIssuedAtMarch302021Member_1389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtMarch302021Member_1389" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember152022Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember152022Member_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtSeptember152022Member_1393" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune042022Member" xlink:label="loc_alur_WarrantsIssuedAtJune042022Member_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune042022Member_1394" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJanuary172017Member" xlink:label="loc_alur_WarrantsIssuedAtJanuary172017Member_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJanuary172017Member_1395" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtAugust032017Member" xlink:label="loc_alur_WarrantsIssuedAtAugust032017Member_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtAugust032017Member_1396" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember082017Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember082017Member_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtSeptember082017Member_1397" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune192018Member" xlink:label="loc_alur_WarrantsIssuedAtJune192018Member_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune192018Member_1398" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune252019Member" xlink:label="loc_alur_WarrantsIssuedAtJune252019Member_1399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune252019Member_1399" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1383" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1383" xlink:to="loc_us-gaap_EquityComponentDomain_1378" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1378_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1383" xlink:to="loc_us-gaap_EquityComponentDomain_1378_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1378" xlink:to="loc_us-gaap_CommonStockMember_1376" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1388" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1388" xlink:to="loc_us-gaap_ClassOfStockDomain_1387" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1387_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1388" xlink:to="loc_us-gaap_ClassOfStockDomain_1387_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1374" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1381" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1385" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1391" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1375" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1382" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1386" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1932" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1932" xlink:to="loc_us-gaap_EquityComponentDomain_1930" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1930_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1932" xlink:to="loc_us-gaap_EquityComponentDomain_1930_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xlink:to="loc_us-gaap_AwardTypeAxis_2350" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_NetIncomeLoss_1403" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1406" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1409" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1404" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1407" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_EarningsPerShareBasic_1408" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1410" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3160" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3160" xlink:to="loc_us-gaap_ClassOfStockDomain_3748" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3748_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3160" xlink:to="loc_us-gaap_ClassOfStockDomain_3748_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3748" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3133" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1415" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1419" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchasePreferredStockMember" xlink:label="loc_alur_WarrantsToPurchasePreferredStockMember_1420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_WarrantsToPurchasePreferredStockMember_1420" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_1421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_1421" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:label="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_1423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_1423" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_1425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_EarnOutSharesMember_1425" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNotesMember" xlink:label="loc_alur_ConvertibleNotesMember_1426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_ConvertibleNotesMember_1426" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1417" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_PlanNameAxis_1435" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1435" xlink:to="loc_us-gaap_PlanNameDomain_1431" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1431_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1435" xlink:to="loc_us-gaap_PlanNameDomain_1431_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanMember_1430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020StockOptionPlanMember_1430" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember_1439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember_1439" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020Member" xlink:label="loc_alur_StockOptionPlan2020Member_1442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020Member_1442" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionAndIncentivePlanMember" xlink:label="loc_alur_StockOptionAndIncentivePlanMember_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionAndIncentivePlanMember_1446" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_1449" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_AwardTypeAxis_1441" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1441" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1441" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1451" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1454" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_alur_TimeVestedRestrictedStockUnitsMember_1456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_alur_TimeVestedRestrictedStockUnitsMember_1456" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_VestingAxis_1445" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1445" xlink:to="loc_us-gaap_VestingDomain_1436" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1445" xlink:to="loc_us-gaap_VestingDomain_1436_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1436" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1429" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1436" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1438" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_srt_RangeAxis_1448" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1448" xlink:to="loc_srt_RangeMember_1434" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1434_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1448" xlink:to="loc_srt_RangeMember_1434_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1434" xlink:to="loc_srt_MaximumMember_1433" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_srt_TitleOfIndividualAxis_2609" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2609" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2609" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_1775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_1775" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan_1432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan_1432" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1444" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1447" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1450" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1453" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1455" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1457" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1458" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1459" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage_1460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage_1460" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xlink:label="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance_1464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance_1464" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensation_1465" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPriceLowerOfFairValueMarketValue" xlink:label="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue_1466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue_1466" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfEmployeesCompensationToPayrollDeductions" xlink:label="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions_1467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions_1467" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfDilutedSharesOutstanding" xlink:label="loc_alur_PercentageOfDilutedSharesOutstanding_1468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfDilutedSharesOutstanding_1468" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_CommonStockSharesIssued_1469" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1472" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1472" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1472" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1472" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_CostOfSalesMember_1476" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1478" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1479" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1474" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1474" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" xlink:to="loc_us-gaap_PlanNameAxis_1485" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1485" xlink:to="loc_us-gaap_PlanNameDomain_1483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1485" xlink:to="loc_us-gaap_PlanNameDomain_1483_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember_1482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1483" xlink:to="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember_1482" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1484" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1487" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1489" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1490" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1492" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1493" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1494" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1495" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1496" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1498" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1499" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1500" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1501" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1502" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xlink:to="loc_us-gaap_AwardTypeAxis_1514" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1514" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1514" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1523" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xlink:to="loc_us-gaap_PlanNameAxis_1517" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1517" xlink:to="loc_us-gaap_PlanNameDomain_1512" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1517" xlink:to="loc_us-gaap_PlanNameDomain_1512_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020And2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember_1511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1512" xlink:to="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember_1511" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1513" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1516" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1519" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1521" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1524" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1525" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1526" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1527" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" xlink:to="loc_srt_RangeAxis_1535" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1535" xlink:to="loc_srt_RangeMember_1534" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1534_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1535" xlink:to="loc_srt_RangeMember_1534_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1534" xlink:to="loc_srt_MaximumMember_1533" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1531" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1553" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LossContingenciesTable_1541" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_srt_RangeAxis_1542" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1542" xlink:to="loc_srt_RangeMember_1545" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1542" xlink:to="loc_srt_RangeMember_1545_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1545" xlink:to="loc_srt_MaximumMember_1543" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1545" xlink:to="loc_srt_MinimumMember_1549" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_srt_StatementGeographicalAxis_1548" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1548" xlink:to="loc_srt_SegmentGeographicalDomain_1539" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1539_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1548" xlink:to="loc_srt_SegmentGeographicalDomain_1539_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NatickAndHudsonMember" xlink:label="loc_alur_NatickAndHudsonMember_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1539" xlink:to="loc_alur_NatickAndHudsonMember_1540" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1547" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1547_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1547_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_1544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_1544" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseExpirationPeriod" xlink:label="loc_alur_LesseeOperatingLeaseExpirationPeriod_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_LesseeOperatingLeaseExpirationPeriod_1552" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1554" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_1555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_AreaOfLand_1555" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1556" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_1557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_1557" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1558" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1567" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInRevenuesForCustomerReturns" xlink:label="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns_4136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns_4136" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockExchangeListingRequirementsDescription" xlink:label="loc_alur_StockExchangeListingRequirementsDescription_4150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_StockExchangeListingRequirementsDescription_4150" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AverageMarketCapitalizationAmount" xlink:label="loc_alur_AverageMarketCapitalizationAmount_4180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_AverageMarketCapitalizationAmount_4180" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfConsecutiveTradingDay" xlink:label="loc_alur_NumberOfConsecutiveTradingDay_4188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_NumberOfConsecutiveTradingDay_4188" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_StockholdersEquity_4211" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" xlink:to="loc_srt_StatementGeographicalAxis_1662" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1662" xlink:to="loc_srt_SegmentGeographicalDomain_1660" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1660_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1662" xlink:to="loc_srt_SegmentGeographicalDomain_1660_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_1661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1660" xlink:to="loc_country_US_1661" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="loc_country_FR_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1660" xlink:to="loc_country_FR_1665" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_1664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" xlink:to="loc_us-gaap_NoncurrentAssets_1664" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1692" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" xlink:to="loc_us-gaap_RelatedPartyDomain_1676" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1676_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" xlink:to="loc_us-gaap_RelatedPartyDomain_1676_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LnmpJpbcInvestMember" xlink:label="loc_alur_LnmpJpbcInvestMember_1675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_LnmpJpbcInvestMember_1675" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_KkgEnterprisesMember" xlink:label="loc_alur_KkgEnterprisesMember_1682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_KkgEnterprisesMember_1682" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemusGroupManagementMember" xlink:label="loc_alur_RemusGroupManagementMember_1685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_RemusGroupManagementMember_1685" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BenoitChardonConsultingMember" xlink:label="loc_alur_BenoitChardonConsultingMember_1689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_BenoitChardonConsultingMember_1689" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1683" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1683" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1683" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConsultingAgreementsMember" xlink:label="loc_alur_ConsultingAgreementsMember_1670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_ConsultingAgreementsMember_1670" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TerminationAgreementMember" xlink:label="loc_alur_TerminationAgreementMember_1680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_TerminationAgreementMember_1680" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteAgreementWithRtwMember" xlink:label="loc_alur_ConvertibleNoteAgreementWithRtwMember_3788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_ConvertibleNoteAgreementWithRtwMember_3788" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RTWParticipationInPublicOfferingMember" xlink:label="loc_alur_RTWParticipationInPublicOfferingMember_3876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_RTWParticipationInPublicOfferingMember_3876" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWithRTWMember" xlink:label="loc_alur_PrivatePlacementWithRTWMember_3968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_PrivatePlacementWithRTWMember_3968" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_DebtInstrumentAxis_1686" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1686" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1687" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1686" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1687_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1687" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1677" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_srt_CounterpartyNameAxis_1690" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1690" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1690" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HunterVenturesLimitedMember" xlink:label="loc_alur_HunterVenturesLimitedMember_1679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" xlink:to="loc_alur_HunterVenturesLimitedMember_1679" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3969" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3969" xlink:to="loc_us-gaap_ClassOfStockDomain_3789" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3789_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3969" xlink:to="loc_us-gaap_ClassOfStockDomain_3789_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3789" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3357" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_OperatingLeasePayments_1672" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseCommencementDate" xlink:label="loc_alur_OperatingLeaseCommencementDate_1681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseCommencementDate_1681" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseEndDate" xlink:label="loc_alur_OperatingLeaseEndDate_1684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseEndDate_1684" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseTerminatedDate" xlink:label="loc_alur_LesseeOperatingLeaseTerminatedDate_1688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_LesseeOperatingLeaseTerminatedDate_1688" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AgreementsTerminationDate" xlink:label="loc_alur_AgreementsTerminationDate_1691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_AgreementsTerminationDate_1691" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xlink:label="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination_1693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination_1693" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_1694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_1694" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1695" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCapitalStock" xlink:label="loc_alur_PercentageOfOutstandingCapitalStock_1696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PercentageOfOutstandingCapitalStock_1696" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionConsultingFees" xlink:label="loc_alur_RelatedPartyTransactionConsultingFees_1697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_RelatedPartyTransactionConsultingFees_1697" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionTerminationFees" xlink:label="loc_alur_RelatedPartyTransactionTerminationFees_1698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_RelatedPartyTransactionTerminationFees_1698" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseStartDate" xlink:label="loc_alur_OperatingLeaseStartDate_2308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseStartDate_2308" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCommonStock" xlink:label="loc_alur_PercentageOfOutstandingCommonStock_4094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PercentageOfOutstandingCommonStock_4094" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4212" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4217" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AggregatePurchasePriceFromOffering" xlink:label="loc_alur_AggregatePurchasePriceFromOffering_4236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_AggregatePurchasePriceFromOffering_4236" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_SubsequentEventTable_1713" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_srt_StatementScenarioAxis_1721" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1721" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1714" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1714_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1721" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1714_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1730" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_1707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_1707" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1734" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1734" xlink:to="loc_us-gaap_EquityComponentDomain_1717" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1717_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1734" xlink:to="loc_us-gaap_EquityComponentDomain_1717_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_CreditFacilityAxis_1738" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1738" xlink:to="loc_us-gaap_CreditFacilityDomain_1722" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1722_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1738" xlink:to="loc_us-gaap_CreditFacilityDomain_1722_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1740" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1740" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1720" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1740" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1720_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_DebtInstrumentAxis_1742" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1742" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1733" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1733_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1742" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1733_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedAndRestatedRtwSideLetterMember" xlink:label="loc_alur_AmendedAndRestatedRtwSideLetterMember_3516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1733" xlink:to="loc_alur_AmendedAndRestatedRtwSideLetterMember_3516" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1744" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1744" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1708" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1708_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1744" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1708_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1708" xlink:to="loc_us-gaap_SubsequentEventMember_1719" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_3831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_RestructuringPlanAxis_3831" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_3831" xlink:to="loc_us-gaap_RestructuringPlanDomain_3517" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3517_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_3831" xlink:to="loc_us-gaap_RestructuringPlanDomain_3517_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RestructuringPlanMember" xlink:label="loc_alur_RestructuringPlanMember_3509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_3517" xlink:to="loc_alur_RestructuringPlanMember_3509" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfSurrenderSharesOfCommonStock" xlink:label="loc_alur_NumberOfSurrenderSharesOfCommonStock_3519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_NumberOfSurrenderSharesOfCommonStock_3519" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SurrenderCommonStockValue" xlink:label="loc_alur_SurrenderCommonStockValue_3554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_SurrenderCommonStockValue_3554" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_3834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_3834" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_3992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_3992" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3994" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_4084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringCosts_4084" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" order="1.0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" order="2.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>alur-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-December-2024 [02:30:49] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net of allowance of doubtful accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Total Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of term loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less: current portion of long-term debt, net of discounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: current lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Public warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_alur_RevenueInterestFinancingLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingLiabilityNoncurrent" xml:lang="en-US">Revenue Interest Financing Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_RevenueInterestFinancingLiabilityNoncurrent" xml:lang="en-US">Revenue Interest Financing liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingLiabilityNoncurrent" xml:lang="en-US">Long-term Revenue Interest Financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:to="lab_alur_RevenueInterestFinancingLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingLiabilityNoncurrent" xml:lang="en-US">Revenue interest financing liability noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xml:lang="en-US">Earn-out liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Lease liabilities, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies (Note 16)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value - 100,000,000 shares authorized as of June 30, 2024; and no shares issued and outstanding as of June 30, 2024 and December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable convertible preferred stock, and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xml:lang="en-US">Temporary Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xml:lang="en-US">Redeemable Convertible Preferred Stock (Note 12):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Series A redeemable convertible preferred stock, $0.0001 par value - 100,000,000 shares authorized as of September 30, 2024; and 2,260,159 and zero shares issued and outstanding as of September 30, 2024 and December 31, 2023</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ending Balance, temporary stocks</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xml:lang="en-US">Allowance of doubtful accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Par value common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Number of shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Total shares of Common Stock immediately after Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Number of shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xml:lang="en-US">Series A redeemable convertible preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xml:lang="en-US">Series A redeemable convertible preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Temporary Equity, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xml:lang="en-US">Series A redeemable convertible preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Series A redeemable convertible preferred stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Balance (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit" xml:lang="en-US">Gross profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Losses from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Changes in fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfDebt" xlink:label="loc_alur_ChangesInFairValueOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangesInFairValueOfDebt" xml:lang="en-US">Changes In Fair Value Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_ChangesInFairValueOfDebt" xml:lang="en-US">Changes in fair value of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangesInFairValueOfDebt" xlink:to="lab_alur_ChangesInFairValueOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangesInFairValueOfDebt" xml:lang="en-US">Changes in fair value of debt.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xml:lang="en-US">Changes In Fair Value Of Revenue Interest Financing And Conversion Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xml:lang="en-US">Changes in fair value of Revenue Interest Financing and PIPE Conversion Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xml:lang="en-US">Change in fair value of Revenue Interest Financing and PIPE Conversion Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:to="lab_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xml:lang="en-US">Changes in fair value of revenue interest financing and PIPE conversion option.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_alur_FairValueAdjustmentOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueAdjustmentOfEarnOutLiabilities" xml:lang="en-US">Fair Value Adjustment of Earn Out Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueAdjustmentOfEarnOutLiabilities" xml:lang="en-US">Change in fair value of earn-out liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_FairValueAdjustmentOfEarnOutLiabilities" xml:lang="en-US">Change in fair value of earn-out liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:to="lab_alur_FairValueAdjustmentOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueAdjustmentOfEarnOutLiabilities" xml:lang="en-US">Fair value adjustment of earn-out liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Termination of convertible note side letters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on extinguishment of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss on extinguishment of debt/ term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense), net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest Expense, Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xml:lang="en-US">Cumulative undeclared preferred dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xml:lang="en-US">Cumulative undeclared preferred dividends to participating securities (Legacy Series D convertible preferred stock)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss attributable to common shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares outstanding - Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic weighted-average common stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares outstanding - diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted weighted-average common stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingDueMember" xlink:label="loc_alur_RevenueInterestFinancingDueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingDueMember" xml:lang="en-US">Revenue Interest Financing Due [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingDueMember" xml:lang="en-US">Revenue Interest Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingDueMember" xlink:to="lab_alur_RevenueInterestFinancingDueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingDueMember" xml:lang="en-US">Revenue interest financing due.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RtwConvertibleNotesMember" xml:lang="en-US">RTW Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RtwConvertibleNotesMember" xml:lang="en-US">RTW Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RtwConvertibleNotesMember" xlink:to="lab_alur_RtwConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RtwConvertibleNotesMember" xml:lang="en-US">RTW convertible notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xml:lang="en-US">Change in fair value due to change in credit risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xml:lang="en-US">Change in fair value of revenue interest financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesA1ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesA1ConvertiblePreferredStockMember" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesA1ConvertiblePreferredStockMember" xml:lang="en-US">Series A-1 Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesA1ConvertiblePreferredStockMember" xlink:to="lab_alur_SeriesA1ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesA1ConvertiblePreferredStockMember" xml:lang="en-US">Series A-1 convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesBConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesBConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesBConvertiblePreferredStockMember" xlink:to="lab_alur_SeriesBConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B convertible preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xml:lang="en-US">Redeemable Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemablePreferredStockMember" xml:lang="en-US">Redeemable Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockMember" xlink:to="lab_us-gaap_RedeemablePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Common stock issued upon exercise of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Outstanding public warrants to purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Reverse recapitalization, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Reverse recapitalization, net of transaction costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xml:lang="en-US">Adjustments To Additional Paid In Capital, Warrant Liabilities In Connection Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xml:lang="en-US">Recognition of warrant liabilities in connection with the Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xlink:to="lab_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xml:lang="en-US">Adjustments to additional paid in capital, warrant liabilities in connection merger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Issuance of common stock in connection with vesting of RSU awards (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of Shares Value Common Stock for Conversion of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of common stock for the conversion of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xlink:to="lab_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares value common stock for conversion of convertible notes.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of Shares Common Stock for Conversion of Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of common stock for the conversion of convertible notes (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xlink:to="lab_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xml:lang="en-US">Issuance of shares common stock for conversion of convertible notes.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xml:lang="en-US">Adjustments To Additional Paid In Capital, Recognition of Earn-Out Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xml:lang="en-US">Recognition of earn-out liabilities (Note 3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xlink:to="lab_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xml:lang="en-US">Adjustments to additional paid in capital, recognition of earn-out liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xml:lang="en-US">Stock Issued During Period Value Derecognition of Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xml:lang="en-US">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xlink:to="lab_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xml:lang="en-US">Stock issued during period value derecognition of liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xml:lang="en-US">Stock Issued During Period Shares Derecognition of Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xml:lang="en-US">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xlink:to="lab_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xml:lang="en-US">Stock issued during period shares derecognition of liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xml:lang="en-US">Issuance Of Common Stock For Exercise Of Warrants, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xml:lang="en-US">Issuance of common stock for the exercise of Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:to="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xml:lang="en-US">Issuance of common stock for exercise of warrants amount.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xml:lang="en-US">Issuance Of Common Stock For Exercise Of Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xml:lang="en-US">Issuance of common stock for the exercise of Public Warrants (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:to="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xml:lang="en-US">Issuance of common stock for exercise of warrants shares.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xml:lang="en-US">Issuance Of Common Stock For Commitment Shares For Equity Line Financing Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xml:lang="en-US">Issuance of common stock for commitment shares for equity line financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xlink:to="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xml:lang="en-US">Issuance of common stock for commitment shares for equity line financing amount</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xml:lang="en-US">Issuance Of Common Stock For Commitment Shares For Equity Line Financing Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xml:lang="en-US">Issuance of common stock for commitment shares for equity line financing (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xlink:to="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xml:lang="en-US">Issuance of common stock for commitment shares for equity line financing shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued during period value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock isssued during the period (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of preferred stock in connection with Private Placement, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanMember" xml:lang="en-US">Two Thousand Twenty One Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanMember" xml:lang="en-US">2021 Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandTwentyOneTermLoanMember" xlink:to="lab_alur_TwoThousandTwentyOneTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanMember" xml:lang="en-US">Two Thousand Twenty One Term Loan.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FortressTermLoanMember" xml:lang="en-US">Fortress Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FortressTermLoanMember" xml:lang="en-US">Fortress Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FortressTermLoanMember" xlink:to="lab_alur_FortressTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FortressTermLoanMember" xml:lang="en-US">Fortress term loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashLeaseExpense" xlink:label="loc_alur_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NonCashLeaseExpense" xml:lang="en-US">Non-Cash Lease Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NonCashLeaseExpense" xml:lang="en-US">Non-cash lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NonCashLeaseExpense" xlink:to="lab_alur_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NonCashLeaseExpense" xml:lang="en-US">Non-cash lease expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory Write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Provision for inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_alur_ChangeInFairValueOfWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangeInFairValueOfWarrantLiabilities" xml:lang="en-US">Change in Fair Value of Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChangeInFairValueOfWarrantLiabilities" xml:lang="en-US">Change in fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangeInFairValueOfWarrantLiabilities" xlink:to="lab_alur_ChangeInFairValueOfWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangeInFairValueOfWarrantLiabilities" xml:lang="en-US">Change in fair value of warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_InterestPaidOnDebtRecordedAtFairValue" xlink:label="loc_alur_InterestPaidOnDebtRecordedAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_InterestPaidOnDebtRecordedAtFairValue" xml:lang="en-US">Interest Paid On Debt Recorded At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_InterestPaidOnDebtRecordedAtFairValue" xml:lang="en-US">Interest paid on debt recorded at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_InterestPaidOnDebtRecordedAtFairValue" xlink:to="lab_alur_InterestPaidOnDebtRecordedAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_InterestPaidOnDebtRecordedAtFairValue" xml:lang="en-US">Interest paid on debt recorded at fair value.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashInterestExpense" xlink:label="loc_alur_NonCashInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NonCashInterestExpense" xml:lang="en-US">Noncash Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NonCashInterestExpense" xml:lang="en-US">Non-cash interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NonCashInterestExpense" xlink:to="lab_alur_NonCashInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NonCashInterestExpense" xml:lang="en-US">Noncash interest expense.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashTerminationOfConvertibleNoteSideLetters" xlink:label="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NonCashTerminationOfConvertibleNoteSideLetters" xml:lang="en-US">Non-Cash Termination of Convertible Note Side Letters</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NonCashTerminationOfConvertibleNoteSideLetters" xml:lang="en-US">Non-cash termination of convertible note side letters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters" xlink:to="lab_alur_NonCashTerminationOfConvertibleNoteSideLetters" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NonCashTerminationOfConvertibleNoteSideLetters" xml:lang="en-US">Non-cash termination of convertible note side letters.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashIssuanceOfCommonStockForCommitmentShares" xlink:label="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NonCashIssuanceOfCommonStockForCommitmentShares" xml:lang="en-US">Non-cash Issuance Of Common Stock For Commitment Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NonCashIssuanceOfCommonStockForCommitmentShares" xml:lang="en-US">Non-cash issuance of common stock for commitment shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares" xlink:to="lab_alur_NonCashIssuanceOfCommonStockForCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NonCashIssuanceOfCommonStockForCommitmentShares" xml:lang="en-US">Non-cash issuance of common stock for commitment shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Debt issuance costs associated with debt recorded at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses, other current and long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Unrealized exchange (gain) or loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfDebt" xlink:label="loc_alur_FairValueAdjustmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueAdjustmentOfDebt" xml:lang="en-US">Fair Value Adjustment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueAdjustmentOfDebt" xml:lang="en-US">Change in fair value of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueAdjustmentOfDebt" xlink:to="lab_alur_FairValueAdjustmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueAdjustmentOfDebt" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of debt.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xlink:label="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xml:lang="en-US">Amortization Of Issuance Costs Associated With Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xml:lang="en-US">Issuance costs associated with warrants recorded at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xlink:to="lab_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xml:lang="en-US">Amortization of issuance costs associated with warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash outflows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xml:lang="en-US">Proceeds from Fortress Term Loan&#8212;net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payment of debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Proceeds from Business Combination, net of transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Proceeds from Business Combination, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xlink:to="lab_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Proceeds from business combination, net of transaction costs.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ProceedsFromRevenueInterestFinancing" xml:lang="en-US">Proceeds from Revenue Interest Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ProceedsFromRevenueInterestFinancing" xml:lang="en-US">Proceeds from revenue interest financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ProceedsFromRevenueInterestFinancing" xlink:to="lab_alur_ProceedsFromRevenueInterestFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ProceedsFromRevenueInterestFinancing" xml:lang="en-US">The cash inflow from revenue interest financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayment of Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of promissory note assumed in Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromOptionAndWarrantExercises" xlink:label="loc_alur_ProceedsFromOptionAndWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ProceedsFromOptionAndWarrantExercises" xml:lang="en-US">Proceeds from Option and Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ProceedsFromOptionAndWarrantExercises" xml:lang="en-US">Proceeds from option and warrant exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ProceedsFromOptionAndWarrantExercises" xlink:to="lab_alur_ProceedsFromOptionAndWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ProceedsFromOptionAndWarrantExercises" xml:lang="en-US">Proceeds from option and warrant exercises.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayments of Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayment of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xml:lang="en-US">Repayment of convertible debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentOfDeferredFinancingCosts" xlink:label="loc_alur_PaymentOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PaymentOfDeferredFinancingCosts" xml:lang="en-US">Payment of Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_PaymentOfDeferredFinancingCosts" xml:lang="en-US">Payment of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PaymentOfDeferredFinancingCosts" xlink:to="lab_alur_PaymentOfDeferredFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PaymentOfDeferredFinancingCosts" xml:lang="en-US">Payment of deferred financing costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromEquityLineFinancing" xlink:label="loc_alur_ProceedsFromEquityLineFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ProceedsFromEquityLineFinancing" xml:lang="en-US">Proceeds From Equity Line Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ProceedsFromEquityLineFinancing" xml:lang="en-US">Proceeds from equity line financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ProceedsFromEquityLineFinancing" xlink:to="lab_alur_ProceedsFromEquityLineFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ProceedsFromEquityLineFinancing" xml:lang="en-US">Proceeds from equity line financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Private Placement, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Public Offering, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payments of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US">Payment of debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental cash flow information on non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Purchase of property and equipment included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfWarrantsInConnectionWithFinancing" xlink:label="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IssuanceOfWarrantsInConnectionWithFinancing" xml:lang="en-US">Issuance of Warrants in Connection with Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IssuanceOfWarrantsInConnectionWithFinancing" xml:lang="en-US">Issuance of warrants in connection with financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing" xlink:to="lab_alur_IssuanceOfWarrantsInConnectionWithFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IssuanceOfWarrantsInConnectionWithFinancing" xml:lang="en-US">Issuance of warrants in connection with financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xml:lang="en-US">Deferred financing costs in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfAssumedWarrantLiability" xlink:label="loc_alur_RecognitionOfAssumedWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RecognitionOfAssumedWarrantLiability" xml:lang="en-US">Recognition Of Assumed Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RecognitionOfAssumedWarrantLiability" xml:lang="en-US">Recognition of assumed warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RecognitionOfAssumedWarrantLiability" xlink:to="lab_alur_RecognitionOfAssumedWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RecognitionOfAssumedWarrantLiability" xml:lang="en-US">Recognition of assumed warrant liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfEarnOutLiabilities" xlink:label="loc_alur_RecognitionOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RecognitionOfEarnOutLiabilities" xml:lang="en-US">Recognition of Earn-Out Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RecognitionOfEarnOutLiabilities" xml:lang="en-US">Recognition of earn-out liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RecognitionOfEarnOutLiabilities" xlink:to="lab_alur_RecognitionOfEarnOutLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RecognitionOfEarnOutLiabilities" xml:lang="en-US">Recognition of earn-out liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Issuance of common stock upon conversion of convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xml:lang="en-US">Change In Fair Value Of Revenue Interest Financing Through OCI</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xml:lang="en-US">Change in fair value of Revenue Interest Financing through other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xlink:to="lab_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xml:lang="en-US">Change in fair value of revenue interest financing through OCI</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xml:lang="en-US">Change In Fair Value Of RTW Convertible Notes Through Oci</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xml:lang="en-US">Change in fair value of RTW Convertible Notes through other comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xlink:to="lab_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xml:lang="en-US">Change in fair value of rtw convertible notes through oci.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash included in other long-term assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents and restricted cash shown in the statement of cash flows</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureTextBlockAbstract" xml:lang="en-US">Disclosure Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract" xlink:to="lab_us-gaap_DisclosureTextBlockAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US">Accrued Liabilities and Other Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xml:lang="en-US">Contract with Customer, Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xlink:label="loc_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xml:lang="en-US">Revenue Interest Financing, Side Letter, And P I P E Conversion Option [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xml:lang="en-US">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xlink:to="lab_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xml:lang="en-US">Revenue interest financing, side letter, and PIPE conversion option.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xlink:label="loc_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders Deficit [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xml:lang="en-US">Redeemable Convertible Preferred Stock and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xlink:to="lab_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xml:lang="en-US">Redeemable convertible preferred stock and stockholders deficit text block.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Capital Stock and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Employee Benefit Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Geographic Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related-party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification of Prior Year Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Risk of Concentration of Credit, Significant Customers and Significant Suppliers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xml:lang="en-US">Capitalized Internal-Use Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtIssuanceCostsPolicyTextBlock" xlink:label="loc_alur_DebtIssuanceCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtIssuanceCostsPolicyTextBlock" xlink:to="lab_alur_DebtIssuanceCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt issuance costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsPolicyTextBlock" xlink:label="loc_alur_WarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsPolicyTextBlock" xml:lang="en-US">Warrants [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsPolicyTextBlock" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsPolicyTextBlock" xlink:to="lab_alur_WarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsPolicyTextBlock" xml:lang="en-US">Warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">RTW Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnoutLiabilityPolicyTextBlock" xlink:label="loc_alur_EarnoutLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Earnout Liability [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Earn-out Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_EarnoutLiabilityPolicyTextBlock" xlink:to="lab_alur_EarnoutLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for earnout liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xml:lang="en-US">Revenue Interest Financing and PIPE Conversion Option [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xml:lang="en-US">Revenue Interest Financing and PIPE Conversion Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xlink:to="lab_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for revenue interest financing and pipe conversion option.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xml:lang="en-US">Product Warranty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US">Advertising and Marketing Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xlink:label="loc_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xml:lang="en-US">Intellectual Property Prosecution Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xml:lang="en-US">Intellectual Property Prosecution Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xlink:to="lab_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xml:lang="en-US">Intellectual property prosecution costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_MezzanineEquityPolicyTextBlock" xlink:label="loc_alur_MezzanineEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_MezzanineEquityPolicyTextBlock" xml:lang="en-US">Mezzanine Equity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_MezzanineEquityPolicyTextBlock" xml:lang="en-US">Mezzanine Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_MezzanineEquityPolicyTextBlock" xlink:to="lab_alur_MezzanineEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_MezzanineEquityPolicyTextBlock" xml:lang="en-US">Mezzanine Equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xml:lang="en-US">Summary of Risk of Concentration of Credit, Significant Customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="loc_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents and Restricted Cash [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Summary of Activity in Allowance for Doubtful Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xml:lang="en-US">Reconciles of Business Combination to Condensed Consolidated Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xlink:label="loc_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xml:lang="en-US">Schedule of Business Combination Shares Common Stock Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xml:lang="en-US">Number of Shares of Allurion Common Stock Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xlink:to="lab_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xml:lang="en-US">Schedule of Business Combination Shares Common Stock Outstanding</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Revenues by Geographic Region</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="loc_us-gaap_TableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TableTextBlock" xml:lang="en-US">Table Text Block [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TableTextBlock" xlink:to="lab_us-gaap_TableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="loc_alur_ScheduleOfDepreciationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScheduleOfDepreciationExpenseTableTextBlock" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScheduleOfDepreciationExpenseTableTextBlock" xml:lang="en-US">Schedule of Depreciation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScheduleOfDepreciationExpenseTableTextBlock" xlink:to="lab_alur_ScheduleOfDepreciationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScheduleOfDepreciationExpenseTableTextBlock" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Summary of Components of Third-Party Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Future Maturities of the Term Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xlink:label="loc_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xml:lang="en-US">Components Of Revenue Interest Financing [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xml:lang="en-US">Summary of Components of Revenue Interest Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xlink:to="lab_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xml:lang="en-US">Components of revenue interest financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_EarnOutLiabilityMember" xml:lang="en-US">Earn-out Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_EarnOutLiabilityMember" xml:lang="en-US">Earn-Out Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_EarnOutLiabilityMember" xml:lang="en-US">Earn-out Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_EarnOutLiabilityMember" xlink:to="lab_alur_EarnOutLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_EarnOutLiabilityMember" xml:lang="en-US">Earn-out liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionMember" xml:lang="en-US">Revenue Interest Financing And Pipe Conversion Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionMember" xml:lang="en-US">Revenue Interest Financing and PIPE Conversion Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:to="lab_alur_RevenueInterestFinancingAndPipeConversionOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingAndPipeConversionOptionMember" xml:lang="en-US">Revenue Interest Financing And Pipe Conversion Option [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicWarrantsMember" xml:lang="en-US">Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PublicWarrantsMember" xml:lang="en-US">Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicWarrantsMember" xlink:to="lab_alur_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicWarrantsMember" xml:lang="en-US">Public warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Assumptions used in Pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of Changes in Fair Values</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Assumptions Used in Black-Scholes Option Pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Domestic and Foreign Components of Net Loss Before Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xml:lang="en-US">Summary of Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Summary of Reserved for Issuance Upon the Potential Conversion or Exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule of common stock reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Schedule of Preferred Stock and Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of Basic and Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Stock-based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Option Activity Under the Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Unit Activity Under the Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xlink:label="loc_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xml:lang="en-US">Schedule Of Other Pertinent Lease Information [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xml:lang="en-US">Schedule of Other Pertinent Lease Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xlink:to="lab_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xml:lang="en-US">Schedule of other pertinent lease information.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xlink:label="loc_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xml:lang="en-US">Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xml:lang="en-US">Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xlink:to="lab_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xml:lang="en-US">Schedule of weighted-average remaining lease terms and discount rates related leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xml:lang="en-US">Schedule of Long-lived Assets by Geography</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationAgreementMember" xlink:label="loc_alur_BusinessCombinationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationAgreementMember" xml:lang="en-US">Business Combination Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessCombinationAgreementMember" xml:lang="en-US">Business Combination Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationAgreementMember" xlink:to="lab_alur_BusinessCombinationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationAgreementMember" xml:lang="en-US">Business combination agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xlink:label="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xml:lang="en-US">Number Of Countries In Which Entity Markets the Program</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xml:lang="en-US">Number of countries, currently markets the program</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xlink:to="lab_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xml:lang="en-US">Number of countries in which entity markets the program.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationCommonStockExchangeRatio" xlink:label="loc_alur_BusinessCombinationCommonStockExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationCommonStockExchangeRatio" xml:lang="en-US">Business Combination Common Stock Exchange Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessCombinationCommonStockExchangeRatio" xml:lang="en-US">Exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationCommonStockExchangeRatio" xlink:to="lab_alur_BusinessCombinationCommonStockExchangeRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationCommonStockExchangeRatio" xml:lang="en-US">Business combination common stock exchange ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xml:lang="en-US">Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xml:lang="en-US">Gains (losses) from foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:to="lab_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Total Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xml:lang="en-US">ASU 2016-13</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xml:lang="en-US">ASU 2020-06</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersMember" xlink:label="loc_alur_CustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CustomersMember" xml:lang="en-US">Customers Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CustomersMember" xml:lang="en-US">Customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CustomersMember" xlink:to="lab_alur_CustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CustomersMember" xml:lang="en-US">Customers.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NewAllurionMember" xlink:label="loc_alur_NewAllurionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NewAllurionMember" xml:lang="en-US">New Allurion [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NewAllurionMember" xml:lang="en-US">New Allurion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NewAllurionMember" xlink:to="lab_alur_NewAllurionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NewAllurionMember" xml:lang="en-US">New Allurion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Noncurrent Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xml:lang="en-US">Other Long-Term Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaap_ShippingAndHandlingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xml:lang="en-US">Shipping and Handling [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xml:lang="en-US">Shipping and Logistics</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue Interest Financing Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue Interest Financing Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue Interest Financing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingAgreementMember" xlink:to="lab_alur_RevenueInterestFinancingAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingAgreementMember" xml:lang="en-US">Revenue interest financing agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xlink:label="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xml:lang="en-US">Business Combination, Contingent Consideration, Number Of Additional Shares Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xml:lang="en-US">Earn-out shares receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xlink:to="lab_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xml:lang="en-US">Business combination, contingent consideration, number of additional shares receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketingAndAdvertisingExpense" xml:lang="en-US">Marketing and Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketingAndAdvertisingExpense" xml:lang="en-US">Advertising and marketing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingAndAdvertisingExpense" xlink:to="lab_us-gaap_MarketingAndAdvertisingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Uncertain tax positions for which reserves would be required</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfAnnualNetSales" xml:lang="en-US">Percentage of Annual Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfAnnualNetSales" xml:lang="en-US">Percentage of annual net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfAnnualNetSales" xlink:to="lab_alur_PercentageOfAnnualNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfAnnualNetSales" xml:lang="en-US">Percentage of annual net sales.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RemittanceOfRevenueInterestPaymentsPercentage" xml:lang="en-US">Remittance of Revenue Interest Payments Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RemittanceOfRevenueInterestPaymentsPercentage" xml:lang="en-US">Remittance of revenue interest payments percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:to="lab_alur_RemittanceOfRevenueInterestPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RemittanceOfRevenueInterestPaymentsPercentage" xml:lang="en-US">Remittance of revenue interest payments percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesNetOfInterestExpense" xlink:label="loc_us-gaap_RevenuesNetOfInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesNetOfInterestExpense" xml:lang="en-US">Revenues, Net of Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesNetOfInterestExpense" xml:lang="en-US">Additional revenue interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesNetOfInterestExpense" xlink:to="lab_us-gaap_RevenuesNetOfInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in accounting principle accounting standards update adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in accounting principle accounting standards update adoption date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in accounting principle accounting standards update immaterial effect</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTable" xml:lang="en-US">Concentration Risk [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerAMember" xlink:label="loc_alur_CustomerAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CustomerAMember" xml:lang="en-US">Customer A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CustomerAMember" xml:lang="en-US">Customer A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CustomerAMember" xlink:to="lab_alur_CustomerAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CustomerAMember" xml:lang="en-US">Customer A.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerBMember" xlink:label="loc_alur_CustomerBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CustomerBMember" xml:lang="en-US">Customer B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CustomerBMember" xml:lang="en-US">Customer B</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CustomerBMember" xlink:to="lab_alur_CustomerBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CustomerBMember" xml:lang="en-US">Customer B.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerCMember" xlink:label="loc_alur_CustomerCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CustomerCMember" xml:lang="en-US">Customer C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CustomerCMember" xml:lang="en-US">Customer C</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CustomerCMember" xlink:to="lab_alur_CustomerCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CustomerCMember" xml:lang="en-US">Customer C.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersDMember" xlink:label="loc_alur_CustomersDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CustomersDMember" xml:lang="en-US">Customers D [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CustomersDMember" xml:lang="en-US">Customer D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CustomersDMember" xlink:to="lab_alur_CustomersDMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CustomersDMember" xml:lang="en-US">Customers D.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xml:lang="en-US">Concentration Risk [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Balance at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xml:lang="en-US">Balance at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xml:lang="en-US">Uncollectible accounts written off</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeSubscriptionAgreementsMember" xlink:label="loc_alur_PipeSubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PipeSubscriptionAgreementsMember" xml:lang="en-US">PIPE Subscription Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PipeSubscriptionAgreementsMember" xml:lang="en-US">PIPE Subscription Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PipeSubscriptionAgreementsMember" xlink:to="lab_alur_PipeSubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PipeSubscriptionAgreementsMember" xml:lang="en-US">PIPE subscription agreements.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedAndRestatedRtwSideLetterMember" xlink:label="loc_alur_AmendedAndRestatedRtwSideLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AmendedAndRestatedRtwSideLetterMember" xml:lang="en-US">Amended and Restated RTW Side Letter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AmendedAndRestatedRtwSideLetterMember" xml:lang="en-US">RTW Side Letter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AmendedAndRestatedRtwSideLetterMember" xlink:to="lab_alur_AmendedAndRestatedRtwSideLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AmendedAndRestatedRtwSideLetterMember" xml:lang="en-US">Amended and restated RTW side letter.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressCreditAgreementMember" xlink:label="loc_alur_FortressCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FortressCreditAgreementMember" xml:lang="en-US">Fortress Credit Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FortressCreditAgreementMember" xml:lang="en-US">Fortress Credit Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FortressCreditAgreementMember" xlink:to="lab_alur_FortressCreditAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FortressCreditAgreementMember" xml:lang="en-US">Fortress credit agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BackstopAgreementMember" xlink:label="loc_alur_BackstopAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BackstopAgreementMember" xml:lang="en-US">Backstop Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BackstopAgreementMember" xml:lang="en-US">Backstop Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BackstopAgreementMember" xlink:to="lab_alur_BackstopAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BackstopAgreementMember" xml:lang="en-US">Backstop Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLTerminationAgreementMember" xlink:label="loc_alur_HVLTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_HVLTerminationAgreementMember" xml:lang="en-US">H V L Termination Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_HVLTerminationAgreementMember" xml:lang="en-US">HVL Termination Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_HVLTerminationAgreementMember" xlink:to="lab_alur_HVLTerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_HVLTerminationAgreementMember" xml:lang="en-US">H V L Termination Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GaurContributionAgreementMember" xlink:label="loc_alur_GaurContributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_GaurContributionAgreementMember" xml:lang="en-US">Gaur Contribution Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_GaurContributionAgreementMember" xml:lang="en-US">Gaur Contribution Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_GaurContributionAgreementMember" xlink:to="lab_alur_GaurContributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_GaurContributionAgreementMember" xml:lang="en-US">Gaur Contribution Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RSUForfeitureAgreementMember" xlink:label="loc_alur_RSUForfeitureAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RSUForfeitureAgreementMember" xml:lang="en-US">R S U Forfeiture Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RSUForfeitureAgreementMember" xml:lang="en-US">RSU Forfeiture Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RSUForfeitureAgreementMember" xlink:to="lab_alur_RSUForfeitureAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RSUForfeitureAgreementMember" xml:lang="en-US">R S U Forfeiture Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorContributionAgreementMember" xlink:label="loc_alur_SponsorContributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SponsorContributionAgreementMember" xml:lang="en-US">Sponsor Contribution Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SponsorContributionAgreementMember" xml:lang="en-US">Sponsor Contribution Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SponsorContributionAgreementMember" xlink:to="lab_alur_SponsorContributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SponsorContributionAgreementMember" xml:lang="en-US">Sponsor Contribution Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorSupportAgreementMember" xlink:label="loc_alur_SponsorSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SponsorSupportAgreementMember" xml:lang="en-US">Sponsor Support Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SponsorSupportAgreementMember" xml:lang="en-US">Sponsor Support Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SponsorSupportAgreementMember" xlink:to="lab_alur_SponsorSupportAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SponsorSupportAgreementMember" xml:lang="en-US">Sponsor Support Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ComputeHealthMember" xml:lang="en-US">Compute Health [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_ComputeHealthMember" xml:lang="en-US">CPUH Stockholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ComputeHealthMember" xml:lang="en-US">Cash - CPUH trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ComputeHealthMember" xlink:to="lab_alur_ComputeHealthMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ComputeHealthMember" xml:lang="en-US">Compute Health.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantAmendmentMember" xlink:label="loc_alur_WarrantAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantAmendmentMember" xml:lang="en-US">Warrant Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantAmendmentMember" xml:lang="en-US">Warrant Amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantAmendmentMember" xlink:to="lab_alur_WarrantAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantAmendmentMember" xml:lang="en-US">Warrant amendment.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanFacilityMember" xlink:label="loc_alur_TermLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TermLoanFacilityMember" xml:lang="en-US">Term Loan Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TermLoanFacilityMember" xml:lang="en-US">Term Loan Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TermLoanFacilityMember" xlink:to="lab_alur_TermLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TermLoanFacilityMember" xml:lang="en-US">Term loan facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorLoanExcessAmount" xlink:label="loc_alur_SponsorLoanExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SponsorLoanExcessAmount" xml:lang="en-US">Sponsor Loan Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SponsorLoanExcessAmount" xml:lang="en-US">Sponsor loan excess amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SponsorLoanExcessAmount" xlink:to="lab_alur_SponsorLoanExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SponsorLoanExcessAmount" xml:lang="en-US">Sponsor loan excess amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate purchase of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Purchase price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xml:lang="en-US">Conversion Of PIPE Subscription to Revenue Interest Finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xml:lang="en-US">Conversion of PIPE subscription to revenue interest finance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:to="lab_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xml:lang="en-US">Conversion of PIPE subscription to revenue interest finance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Term loan borrowed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ContributionOfCapitalByJointVenturePartner" xlink:label="loc_alur_ContributionOfCapitalByJointVenturePartner" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ContributionOfCapitalByJointVenturePartner" xml:lang="en-US">Contribution of Capital by Joint Venture Partner</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ContributionOfCapitalByJointVenturePartner" xml:lang="en-US">Contribution of capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ContributionOfCapitalByJointVenturePartner" xlink:to="lab_alur_ContributionOfCapitalByJointVenturePartner" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ContributionOfCapitalByJointVenturePartner" xml:lang="en-US">Contribution of capital by joint venture partner.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of shares forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of RSUs, Cancellations and forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfCommonStock" xlink:label="loc_alur_RecapitalizationOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RecapitalizationOfCommonStock" xml:lang="en-US">Recapitalization of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RecapitalizationOfCommonStock" xml:lang="en-US">Recapitalization of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RecapitalizationOfCommonStock" xlink:to="lab_alur_RecapitalizationOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RecapitalizationOfCommonStock" xml:lang="en-US">Recapitalization of common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Conversion of warrants into shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants converted into warrants exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Shares Issuable Upon Exercise of Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfAdditionalShares" xlink:label="loc_alur_RecapitalizationOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RecapitalizationOfAdditionalShares" xml:lang="en-US">Recapitalization of Additional Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RecapitalizationOfAdditionalShares" xml:lang="en-US">Recapitalization of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RecapitalizationOfAdditionalShares" xlink:to="lab_alur_RecapitalizationOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RecapitalizationOfAdditionalShares" xml:lang="en-US">Recapitalization of additional shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Shares issued upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Interest Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent" xml:lang="en-US">Accured interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Business Acquisition, Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Business Combination, Acquisition Related Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xml:lang="en-US">Business combination expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationOneTimeInsurancePayment" xlink:label="loc_alur_BusinessCombinationOneTimeInsurancePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationOneTimeInsurancePayment" xml:lang="en-US">Business Combination One-time Insurance Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessCombinationOneTimeInsurancePayment" xml:lang="en-US">Business combination one-time insurance payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationOneTimeInsurancePayment" xlink:to="lab_alur_BusinessCombinationOneTimeInsurancePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationOneTimeInsurancePayment" xml:lang="en-US">Business combination one-time insurance payment.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DirectCostsAndFees" xlink:label="loc_alur_DirectCostsAndFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DirectCostsAndFees" xml:lang="en-US">Direct Costs and Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DirectCostsAndFees" xml:lang="en-US">Direct costs and fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DirectCostsAndFees" xlink:to="lab_alur_DirectCostsAndFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DirectCostsAndFees" xml:lang="en-US">Direct costs and fees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xml:lang="en-US">Debt Issuance Costs, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xml:lang="en-US">Issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Shares issued upon conversion of convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Shares issued upon conversion of outstanding notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xml:lang="en-US">Aggregate recognition APIC amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xml:lang="en-US">Conversion Of Pipe Investment To Revenue Interest Finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xml:lang="en-US">Conversion of PIPE investment to revenue interest finance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xml:lang="en-US">Conversion of RTW PIPE investment to revenue interest finance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:to="lab_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xml:lang="en-US">Conversion of PIPE investment to revenue interest finance.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfSurrenderSharesOfCommonStock" xlink:label="loc_alur_NumberOfSurrenderSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NumberOfSurrenderSharesOfCommonStock" xml:lang="en-US">Number Of Surrender Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NumberOfSurrenderSharesOfCommonStock" xml:lang="en-US">Number of surrender shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NumberOfSurrenderSharesOfCommonStock" xlink:to="lab_alur_NumberOfSurrenderSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NumberOfSurrenderSharesOfCommonStock" xml:lang="en-US">Number Of Surrender Shares Of Common Stock</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SurrenderCommonStockValue" xlink:label="loc_alur_SurrenderCommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SurrenderCommonStockValue" xml:lang="en-US">Surrender Common Stock Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SurrenderCommonStockValue" xml:lang="en-US">Surrender common stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SurrenderCommonStockValue" xlink:to="lab_alur_SurrenderCommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SurrenderCommonStockValue" xml:lang="en-US">Surrender common stock value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeInvestorsMember" xlink:label="loc_alur_PipeInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PipeInvestorsMember" xml:lang="en-US">Pipe Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PipeInvestorsMember" xml:lang="en-US">Cash - PIPE Investors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_PipeInvestorsMember" xml:lang="en-US">Shares Issued to PIPE Investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PipeInvestorsMember" xlink:to="lab_alur_PipeInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PipeInvestorsMember" xml:lang="en-US">Pipe investors.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GrossProceedsFromBusinessCombination" xlink:label="loc_alur_GrossProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_GrossProceedsFromBusinessCombination" xml:lang="en-US">Gross Proceeds From Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_GrossProceedsFromBusinessCombination" xml:lang="en-US">Gross Proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_GrossProceedsFromBusinessCombination" xlink:to="lab_alur_GrossProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_GrossProceedsFromBusinessCombination" xml:lang="en-US">Gross proceeds from business combination.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationTransactionCostPaid" xlink:label="loc_alur_BusinessCombinationTransactionCostPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationTransactionCostPaid" xml:lang="en-US">Business Combination Transaction Cost Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_BusinessCombinationTransactionCostPaid" xml:lang="en-US">Less: transaction costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationTransactionCostPaid" xlink:to="lab_alur_BusinessCombinationTransactionCostPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationTransactionCostPaid" xml:lang="en-US">Business combination transaction cost paid.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromBusinessCombination" xlink:label="loc_alur_NetProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NetProceedsFromBusinessCombination" xml:lang="en-US">Net Proceeds from Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_alur_NetProceedsFromBusinessCombination" xml:lang="en-US">Net proceeds from the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NetProceedsFromBusinessCombination" xlink:to="lab_alur_NetProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NetProceedsFromBusinessCombination" xml:lang="en-US">Net proceeds from business combination.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiabilitiesAssumed" xlink:label="loc_alur_WarrantLiabilitiesAssumed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantLiabilitiesAssumed" xml:lang="en-US">Warrant Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantLiabilitiesAssumed" xml:lang="en-US">Less: warrant liabilities assumed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantLiabilitiesAssumed" xlink:to="lab_alur_WarrantLiabilitiesAssumed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantLiabilitiesAssumed" xml:lang="en-US">Warrant liabilities assumed.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfNoteAssumedInBusinessCombination" xlink:label="loc_alur_RepaymentOfNoteAssumedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RepaymentOfNoteAssumedInBusinessCombination" xml:lang="en-US">Repayment of Note Assumed in Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RepaymentOfNoteAssumedInBusinessCombination" xml:lang="en-US">Less: repayment of note assumed in the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RepaymentOfNoteAssumedInBusinessCombination" xlink:to="lab_alur_RepaymentOfNoteAssumedInBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RepaymentOfNoteAssumedInBusinessCombination" xml:lang="en-US">Repayment of note assumed in business combination.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessAcquisitionAccruedTransactionCosts" xlink:label="loc_alur_BusinessAcquisitionAccruedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessAcquisitionAccruedTransactionCosts" xml:lang="en-US">Business Acquisition Accrued Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessAcquisitionAccruedTransactionCosts" xml:lang="en-US">Less: accrued transaction costs at December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessAcquisitionAccruedTransactionCosts" xlink:to="lab_alur_BusinessAcquisitionAccruedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessAcquisitionAccruedTransactionCosts" xml:lang="en-US">Business acquisition accrued transaction costs.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_BusinessCombinationNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Reverse Merger, Net of Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Reverse merger, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BusinessCombinationNetOfTransactionCosts" xlink:to="lab_alur_BusinessCombinationNetOfTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BusinessCombinationNetOfTransactionCosts" xml:lang="en-US">Business combination, net of transaction costs.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionEquityholdersMember" xlink:label="loc_alur_LegacyAllurionEquityholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionEquityholdersMember" xml:lang="en-US">Legacy Allurion Equityholders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionEquityholdersMember" xml:lang="en-US">Legacy Allurion Equityholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionEquityholdersMember" xlink:to="lab_alur_LegacyAllurionEquityholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionEquityholdersMember" xml:lang="en-US">Legacy allurion equityholders.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwAndFortressMember" xlink:label="loc_alur_RtwAndFortressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RtwAndFortressMember" xml:lang="en-US">RTW and Fortress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_RtwAndFortressMember" xml:lang="en-US">Shares issued to RTW and Fortress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RtwAndFortressMember" xlink:to="lab_alur_RtwAndFortressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RtwAndFortressMember" xml:lang="en-US">RTW and Fortress.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteHoldersMember" xlink:label="loc_alur_ConvertibleNoteHoldersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConvertibleNoteHoldersMember" xml:lang="en-US">Convertible Note Holders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConvertibleNoteHoldersMember" xml:lang="en-US">Shares Issued to Convertible Note Holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConvertibleNoteHoldersMember" xlink:to="lab_alur_ConvertibleNoteHoldersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConvertibleNoteHoldersMember" xml:lang="en-US">Convertible note holders</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthSponsorSharesMember" xlink:label="loc_alur_ComputeHealthSponsorSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ComputeHealthSponsorSharesMember" xml:lang="en-US">Compute Health Sponsor Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ComputeHealthSponsorSharesMember" xml:lang="en-US">CPUH Sponsor Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ComputeHealthSponsorSharesMember" xlink:to="lab_alur_ComputeHealthSponsorSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ComputeHealthSponsorSharesMember" xml:lang="en-US">Compute health sponsor shares.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterTerminationSharesMember" xlink:label="loc_alur_SideLetterTerminationSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SideLetterTerminationSharesMember" xml:lang="en-US">Side Letter Termination Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SideLetterTerminationSharesMember" xml:lang="en-US">Side Letter Termination Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SideLetterTerminationSharesMember" xlink:to="lab_alur_SideLetterTerminationSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SideLetterTerminationSharesMember" xml:lang="en-US">Side letter termination shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EachCountryMember" xlink:label="loc_alur_EachCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_EachCountryMember" xml:lang="en-US">Each Country [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_EachCountryMember" xml:lang="en-US">Each Country</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_EachCountryMember" xlink:to="lab_alur_EachCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_EachCountryMember" xml:lang="en-US">Each Country</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AllOtherCountriesMember" xlink:label="loc_alur_AllOtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AllOtherCountriesMember" xml:lang="en-US">All Other Countries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AllOtherCountriesMember" xml:lang="en-US">All Other Countries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AllOtherCountriesMember" xlink:to="lab_alur_AllOtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AllOtherCountriesMember" xml:lang="en-US">All Other Countries</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FourCountriesIncludedWithinAllOtherCountriesMember" xlink:label="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FourCountriesIncludedWithinAllOtherCountriesMember" xml:lang="en-US">Four Countries Included Within All Other Countries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FourCountriesIncludedWithinAllOtherCountriesMember" xml:lang="en-US">Four Countries Included Within All Other Countries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember" xlink:to="lab_alur_FourCountriesIncludedWithinAllOtherCountriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FourCountriesIncludedWithinAllOtherCountriesMember" xml:lang="en-US">Four countries included within all other countries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xml:lang="en-US">Revenue from Contract with Customer Benchmark</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xml:lang="en-US">Geographic Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xml:lang="en-US">Geographic Concentration Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenue" xlink:label="loc_alur_NumberOfCountriesGenerateRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NumberOfCountriesGenerateRevenue" xml:lang="en-US">Number Of Countries Generate Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NumberOfCountriesGenerateRevenue" xml:lang="en-US">Number of countries generate revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NumberOfCountriesGenerateRevenue" xlink:to="lab_alur_NumberOfCountriesGenerateRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NumberOfCountriesGenerateRevenue" xml:lang="en-US">Number of countries generate revenue</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenueBySales" xlink:label="loc_alur_NumberOfCountriesGenerateRevenueBySales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NumberOfCountriesGenerateRevenueBySales" xml:lang="en-US">Number Of Countries Generate Revenue By Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NumberOfCountriesGenerateRevenueBySales" xml:lang="en-US">Number of countries generate revenue by sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NumberOfCountriesGenerateRevenueBySales" xlink:to="lab_alur_NumberOfCountriesGenerateRevenueBySales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NumberOfCountriesGenerateRevenueBySales" xml:lang="en-US">Number of countries generate revenue by sales</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="loc_country_FR" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_FR" xml:lang="en-US">FRANCE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_FR" xml:lang="en-US">France</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_TRY" xlink:label="loc_currency_TRY" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_currency_TRY" xml:lang="en-US">Turkey, New Lira</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_currency_TRY" xml:lang="en-US">Turkey</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_TRY" xlink:to="lab_currency_TRY" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="loc_country_ES" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_ES" xml:lang="en-US">SPAIN</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_ES" xml:lang="en-US">Spain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CL" xlink:label="loc_country_CL" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CL" xml:lang="en-US">CHILE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CL" xml:lang="en-US">Chile</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CL" xlink:to="lab_country_CL" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="loc_country_GB" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB" xml:lang="en-US">United Kingdom</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_country_AU" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_AU" xml:lang="en-US">AUSTRALIA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_AU" xml:lang="en-US">Australia</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IT" xlink:label="loc_country_IT" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IT" xml:lang="en-US">ITALY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_IT" xml:lang="en-US">Italy</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGrossAbstract" xlink:label="loc_us-gaap_InventoryGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryGrossAbstract" xml:lang="en-US">Inventory, Gross [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGrossAbstract" xlink:to="lab_us-gaap_InventoryGrossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Inventory, Work in Process, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Work in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryRawMaterials" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryCurrentTable" xml:lang="en-US">Inventory, Current [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryLineItems" xml:lang="en-US">Inventory [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Inventory Valuation Reserves</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InventoryValuationReserves" xml:lang="en-US">Provision for excess and obsolete inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputersAndPurchasedSoftwareMember" xlink:label="loc_alur_ComputersAndPurchasedSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ComputersAndPurchasedSoftwareMember" xml:lang="en-US">Computers and Purchased Software Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ComputersAndPurchasedSoftwareMember" xml:lang="en-US">Computers and purchased software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ComputersAndPurchasedSoftwareMember" xlink:to="lab_alur_ComputersAndPurchasedSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ComputersAndPurchasedSoftwareMember" xml:lang="en-US">Computers and Purchased Software Member</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xml:lang="en-US">Machinery and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment at cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConstructionInProgress" xlink:label="loc_alur_ConstructionInProgress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConstructionInProgress" xml:lang="en-US">Construction In Progress</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConstructionInProgress" xml:lang="en-US">Construction in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConstructionInProgress" xlink:to="lab_alur_ConstructionInProgress" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConstructionInProgress" xml:lang="en-US">Construction in progress.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostOfSalesMember" xml:lang="en-US">Cost of Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xml:lang="en-US">Sales and Marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DistributorFeesAndMarketingReimbursements" xlink:label="loc_alur_DistributorFeesAndMarketingReimbursements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DistributorFeesAndMarketingReimbursements" xml:lang="en-US">Distributor Fees And Marketing Reimbursements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DistributorFeesAndMarketingReimbursements" xml:lang="en-US">Distributor fees and marketing reimbursements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DistributorFeesAndMarketingReimbursements" xlink:to="lab_alur_DistributorFeesAndMarketingReimbursements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DistributorFeesAndMarketingReimbursements" xml:lang="en-US">Distributor fees and marketing reimbursements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US">Workers' Compensation Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WorkersCompensationLiabilityCurrent" xml:lang="en-US">Accrued compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="lab_us-gaap_WorkersCompensationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedClinicalTrialsAndResearchAndDevelopment" xlink:label="loc_alur_AccruedClinicalTrialsAndResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AccruedClinicalTrialsAndResearchAndDevelopment" xml:lang="en-US">Accrued Clinical Trials And Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AccruedClinicalTrialsAndResearchAndDevelopment" xml:lang="en-US">Accrued clinical trials and R&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AccruedClinicalTrialsAndResearchAndDevelopment" xlink:to="lab_alur_AccruedClinicalTrialsAndResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AccruedClinicalTrialsAndResearchAndDevelopment" xml:lang="en-US">Accrued clinical trials and research and development</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued Marketing Costs, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xml:lang="en-US">Accrued selling and marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyAccrualCurrent" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualCurrent" xml:lang="en-US">Standard Product Warranty Accrual, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StandardProductWarrantyAccrualCurrent" xml:lang="en-US">Accrued warranty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyAccrualCurrent" xlink:to="lab_us-gaap_StandardProductWarrantyAccrualCurrent" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedRestructuringCurrent" xlink:label="loc_alur_AccruedRestructuringCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AccruedRestructuringCurrent" xml:lang="en-US">Accrued Restructuring Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AccruedRestructuringCurrent" xml:lang="en-US">Accrued restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AccruedRestructuringCurrent" xlink:to="lab_alur_AccruedRestructuringCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AccruedRestructuringCurrent" xml:lang="en-US">Accrued restructuring current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US">Restructuring Cost [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for Restructuring</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRestructuring" xml:lang="en-US">Payments for restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-Term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Total principal amount of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LoanAccretion" xlink:label="loc_alur_LoanAccretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LoanAccretion" xml:lang="en-US">Loan Accretion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LoanAccretion" xml:lang="en-US">Plus: Accretion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LoanAccretion" xlink:to="lab_alur_LoanAccretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LoanAccretion" xml:lang="en-US">Loan Accretion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Less: unamortized deferred financing costs and debt discounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt, net of current portion and discounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfDebt" xlink:label="loc_alur_ChangeInFairValueOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangeInFairValueOfDebt" xml:lang="en-US">Change in fair value of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_ChangeInFairValueOfDebt" xml:lang="en-US">Change in fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_alur_ChangeInFairValueOfDebt" xml:lang="en-US">Less: Change in fair value of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangeInFairValueOfDebt" xlink:to="lab_alur_ChangeInFairValueOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangeInFairValueOfDebt" xml:lang="en-US">Change in fair value of debt.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermCLoanMember" xlink:label="loc_alur_TermCLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TermCLoanMember" xml:lang="en-US">Term C Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TermCLoanMember" xml:lang="en-US">Term C Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TermCLoanMember" xlink:to="lab_alur_TermCLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TermCLoanMember" xml:lang="en-US">Term C Loan.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermDLoanMember" xlink:label="loc_alur_TermDLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TermDLoanMember" xml:lang="en-US">Term D Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TermDLoanMember" xml:lang="en-US">Term D Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TermDLoanMember" xlink:to="lab_alur_TermDLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TermDLoanMember" xml:lang="en-US">Term D Loan.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">Two Thousand Twenty One Term Loan Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">2021 Term Loan Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember" xlink:to="lab_alur_TwoThousandTwentyOneTermLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">Two Thousand Twenty One Term Loan Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">Amended Two Thousand Twenty One Term Loan Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">Amended 2021 Term Loan Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xlink:to="lab_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xml:lang="en-US">Amended Two Thousand Twenty One Term Loan Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressAmendmentMember" xlink:label="loc_alur_FortressAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FortressAmendmentMember" xml:lang="en-US">Fortress Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FortressAmendmentMember" xml:lang="en-US">Fortress Amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FortressAmendmentMember" xlink:to="lab_alur_FortressAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FortressAmendmentMember" xml:lang="en-US">Fortress Amendment</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyOneConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandTwentyOneConvertibleNotesMember" xml:lang="en-US">Two Thousand Twenty One Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandTwentyOneConvertibleNotesMember" xml:lang="en-US">2021 Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandTwentyOneConvertibleNotesMember" xlink:to="lab_alur_TwoThousandTwentyOneConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandTwentyOneConvertibleNotesMember" xml:lang="en-US">2021 Convertible Notes.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandTwentyTwoConvertibleNotesMember" xml:lang="en-US">Two Thousand Twenty Two Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandTwentyTwoConvertibleNotesMember" xml:lang="en-US">2022 Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember" xlink:to="lab_alur_TwoThousandTwentyTwoConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandTwentyTwoConvertibleNotesMember" xml:lang="en-US">2022 Convertible Notes.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandTwentyThreeConvertibleNotesMember" xml:lang="en-US">Two Thousand Twenty Three Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandTwentyThreeConvertibleNotesMember" xml:lang="en-US">2023 Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:to="lab_alur_TwoThousandTwentyThreeConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandTwentyThreeConvertibleNotesMember" xml:lang="en-US">2023 Convertible Notes.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterHolderBridgeNoteMember" xlink:label="loc_alur_SideLetterHolderBridgeNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SideLetterHolderBridgeNoteMember" xml:lang="en-US">Side Letter Holder Bridge Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SideLetterHolderBridgeNoteMember" xml:lang="en-US">Side Letter Holder Bridge Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SideLetterHolderBridgeNoteMember" xlink:to="lab_alur_SideLetterHolderBridgeNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SideLetterHolderBridgeNoteMember" xml:lang="en-US">Side letter holder bridge note.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NotePurchaseAgreementMember" xlink:label="loc_alur_NotePurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NotePurchaseAgreementMember" xml:lang="en-US">Note Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NotePurchaseAgreementMember" xml:lang="en-US">Note Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NotePurchaseAgreementMember" xlink:to="lab_alur_NotePurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NotePurchaseAgreementMember" xml:lang="en-US">Note purchase agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLBridgeNoteMember" xlink:label="loc_alur_HVLBridgeNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_HVLBridgeNoteMember" xml:lang="en-US">H V L Bridge Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_HVLBridgeNoteMember" xml:lang="en-US">HVL Bridge Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_HVLBridgeNoteMember" xlink:to="lab_alur_HVLBridgeNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_HVLBridgeNoteMember" xml:lang="en-US">HVL Bridge Note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RunwayGrowthCreditFundIncMember" xlink:label="loc_alur_RunwayGrowthCreditFundIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RunwayGrowthCreditFundIncMember" xml:lang="en-US">Runway Growth Credit Fund, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RunwayGrowthCreditFundIncMember" xml:lang="en-US">Runway</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RunwayGrowthCreditFundIncMember" xlink:to="lab_alur_RunwayGrowthCreditFundIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RunwayGrowthCreditFundIncMember" xml:lang="en-US">Runway Growth Credit Fund, Inc.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesCPreferredStockMember" xlink:to="lab_alur_LegacyAllurionSeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesD1PreferredStockMember" xlink:label="loc_alur_SeriesD1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesD1PreferredStockMember" xml:lang="en-US">Series D-1 preferred stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesD1PreferredStockMember" xml:lang="en-US">Series D-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesD1PreferredStockMember" xlink:to="lab_alur_SeriesD1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesD1PreferredStockMember" xml:lang="en-US">Series D-1 preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UntilMarch312024Member" xlink:label="loc_alur_UntilMarch312024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_UntilMarch312024Member" xml:lang="en-US">Until March 31, 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_UntilMarch312024Member" xml:lang="en-US">Until March 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_UntilMarch312024Member" xlink:to="lab_alur_UntilMarch312024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_UntilMarch312024Member" xml:lang="en-US">Until March 31, 2024</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromApril12024ToJune302024Member" xlink:label="loc_alur_FromApril12024ToJune302024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FromApril12024ToJune302024Member" xml:lang="en-US">From April 1, 2024 to June 30, 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FromApril12024ToJune302024Member" xml:lang="en-US">From April 1, 2024 to June 30, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FromApril12024ToJune302024Member" xlink:to="lab_alur_FromApril12024ToJune302024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FromApril12024ToJune302024Member" xml:lang="en-US">From April 1, 2024 to June 30, 2024.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromJuly12024ToSeptember302024Member" xlink:label="loc_alur_FromJuly12024ToSeptember302024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FromJuly12024ToSeptember302024Member" xml:lang="en-US">From July 1, 2024 to September 30, 2024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FromJuly12024ToSeptember302024Member" xml:lang="en-US">From July 1, 2024 to September 30, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FromJuly12024ToSeptember302024Member" xlink:to="lab_alur_FromJuly12024ToSeptember302024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FromJuly12024ToSeptember302024Member" xml:lang="en-US">From July 1, 2024 to September 30, 2024</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OnOctober12024AndThereafterMember" xlink:label="loc_alur_OnOctober12024AndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OnOctober12024AndThereafterMember" xml:lang="en-US">On October 1, 2024 and Thereafter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OnOctober12024AndThereafterMember" xml:lang="en-US">On October 1, 2024 and thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OnOctober12024AndThereafterMember" xlink:to="lab_alur_OnOctober12024AndThereafterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OnOctober12024AndThereafterMember" xml:lang="en-US">On October 1, 2024 and Thereafter</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Initial cash proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdditionalBorrowings" xlink:label="loc_alur_AdditionalBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AdditionalBorrowings" xml:lang="en-US">Additional Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AdditionalBorrowings" xml:lang="en-US">Additional borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AdditionalBorrowings" xlink:to="lab_alur_AdditionalBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AdditionalBorrowings" xml:lang="en-US">Additional Borrowings.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xlink:label="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xml:lang="en-US">Borrowing Capacity Available Based upon Achievement of Certain Revenue Thresholds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xml:lang="en-US">Available capacity based upon the achievement of certain revenue thresholds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xlink:to="lab_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xml:lang="en-US">Borrowing Capacity Available Based upon Achievement of Certain Revenue Thresholds.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xml:lang="en-US">Line of Credit Facility, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationDate1" xml:lang="en-US">Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xml:lang="en-US">Line of Credit Facility, Date of First Required Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xml:lang="en-US">Equal monthly principal payments commencing date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xlink:to="lab_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xml:lang="en-US">Contractual interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of the debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanAccretion" xlink:label="loc_alur_TermLoanAccretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TermLoanAccretion" xml:lang="en-US">Term Loan Accretion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TermLoanAccretion" xml:lang="en-US">Accretion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TermLoanAccretion" xlink:to="lab_alur_TermLoanAccretion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TermLoanAccretion" xml:lang="en-US">Term Loan Accretion</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Interest, frequency of payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Basis spread on variable rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitPaymentPercentage" xlink:label="loc_alur_DebtInstrumentExitPaymentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentExitPaymentPercentage" xml:lang="en-US">Debt Instrument Exit Payment Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentExitPaymentPercentage" xml:lang="en-US">Debt instrument exit payment percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentExitPaymentPercentage" xlink:to="lab_alur_DebtInstrumentExitPaymentPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentExitPaymentPercentage" xml:lang="en-US">Debt instrument exit payment percentage.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExercisableWarrantsIssuedAsConsideration" xlink:label="loc_alur_ExercisableWarrantsIssuedAsConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ExercisableWarrantsIssuedAsConsideration" xml:lang="en-US">Exercisable warrants issued as consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ExercisableWarrantsIssuedAsConsideration" xml:lang="en-US">Warrants exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ExercisableWarrantsIssuedAsConsideration" xlink:to="lab_alur_ExercisableWarrantsIssuedAsConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ExercisableWarrantsIssuedAsConsideration" xml:lang="en-US">Exercisable warrants issued as consideration</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfTheWarrants" xlink:label="loc_alur_FairValueOfTheWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueOfTheWarrants" xml:lang="en-US">Fair value of the warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueOfTheWarrants" xlink:to="lab_alur_FairValueOfTheWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueOfTheWarrants" xml:lang="en-US">Fair value of the warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Description of interest rate variable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiability" xlink:label="loc_alur_WarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantLiability" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantLiability" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantLiability" xlink:to="lab_alur_WarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantLiability" xml:lang="en-US">Warrant Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Total payoff amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfPrincipal" xlink:label="loc_alur_RepaymentOfPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RepaymentOfPrincipal" xml:lang="en-US">Repayment of principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RepaymentOfPrincipal" xlink:to="lab_alur_RepaymentOfPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RepaymentOfPrincipal" xml:lang="en-US">Repayment of principal</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFee" xlink:label="loc_alur_PrepaymentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PrepaymentFee" xml:lang="en-US">Prepayment fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PrepaymentFee" xlink:to="lab_alur_PrepaymentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PrepaymentFee" xml:lang="en-US">Prepayment fee</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFee" xlink:label="loc_alur_FinalPaymentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FinalPaymentFee" xml:lang="en-US">Final payment fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FinalPaymentFee" xlink:to="lab_alur_FinalPaymentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FinalPaymentFee" xml:lang="en-US">Final payment fee</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFeePercentage" xlink:label="loc_alur_PrepaymentFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PrepaymentFeePercentage" xml:lang="en-US">Prepayment fee percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PrepaymentFeePercentage" xlink:to="lab_alur_PrepaymentFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PrepaymentFeePercentage" xml:lang="en-US">Prepayment fee percentage</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OriginalFinalPayment" xlink:label="loc_alur_OriginalFinalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OriginalFinalPayment" xml:lang="en-US">Original final payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OriginalFinalPayment" xlink:to="lab_alur_OriginalFinalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OriginalFinalPayment" xml:lang="en-US">Original final payment</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFeePercentage" xlink:label="loc_alur_FinalPaymentFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FinalPaymentFeePercentage" xml:lang="en-US">Final payment fee percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FinalPaymentFeePercentage" xlink:to="lab_alur_FinalPaymentFeePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FinalPaymentFeePercentage" xml:lang="en-US">Final payment fee percentage</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfTheWarrant" xlink:label="loc_alur_AmortizationOfTheWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AmortizationOfTheWarrant" xml:lang="en-US">Amortization of the warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AmortizationOfTheWarrant" xlink:to="lab_alur_AmortizationOfTheWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AmortizationOfTheWarrant" xml:lang="en-US">Amortization of the warrant</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt instrument maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByDiscountedCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByDiscountedCappedConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConversionDividedByDiscountedCappedConversionPrice" xml:lang="en-US">Conversion Divided By Discounted Capped Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConversionDividedByDiscountedCappedConversionPrice" xml:lang="en-US">Conversion divided by discounted capped conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConversionDividedByDiscountedCappedConversionPrice" xlink:to="lab_alur_ConversionDividedByDiscountedCappedConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConversionDividedByDiscountedCappedConversionPrice" xml:lang="en-US">Conversion divided by discounted capped conversion price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Unamortized debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByCappedConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConversionDividedByCappedConversionPrice" xml:lang="en-US">Conversion Divided By Capped Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConversionDividedByCappedConversionPrice" xml:lang="en-US">Conversion divided by capped conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConversionDividedByCappedConversionPrice" xlink:to="lab_alur_ConversionDividedByCappedConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConversionDividedByCappedConversionPrice" xml:lang="en-US">Conversion divided by capped conversion price.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CappedPrice" xlink:label="loc_alur_CappedPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CappedPrice" xml:lang="en-US">Capped Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CappedPrice" xml:lang="en-US">Capped price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CappedPrice" xlink:to="lab_alur_CappedPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CappedPrice" xml:lang="en-US">Capped price.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xlink:label="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xml:lang="en-US">Percentage Of Conversion Discounted Price Is Calculated Of Cash Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xml:lang="en-US">Percentage of conversion discounted price is calculated of cash price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xlink:to="lab_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xml:lang="en-US">Percentage of conversion discounted price is calculated of cash price.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_MinimumLiquidityAmount" xlink:label="loc_alur_MinimumLiquidityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_MinimumLiquidityAmount" xml:lang="en-US">Minimum Liquidity Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_MinimumLiquidityAmount" xlink:to="lab_alur_MinimumLiquidityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_MinimumLiquidityAmount" xml:lang="en-US">Minimum liquidity amount.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xlink:label="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xml:lang="en-US">Debt Instrument, Interest Rate, Increase, Event of Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xml:lang="en-US">Increase in interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xlink:to="lab_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xml:lang="en-US">Debt instrument, interest rate, increase, event of default.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentDefaultInterestRate" xlink:label="loc_alur_DebtInstrumentDefaultInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt instrument default interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Default interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentDefaultInterestRate" xlink:to="lab_alur_DebtInstrumentDefaultInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentDefaultInterestRate" xml:lang="en-US">Debt instrument default interest rate</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xml:lang="en-US">Debt prepayment penalty</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xlink:label="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xml:lang="en-US">Debt Instrument Convertible Price For Calculating Equity Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xml:lang="en-US">Debt instrument, convertible price for calculating equity securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xlink:to="lab_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xml:lang="en-US">Debt instrument, convertible price for calculating equity securities.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredLiabilityForIssuanceOfAdditionalShares" xlink:label="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DeferredLiabilityForIssuanceOfAdditionalShares" xml:lang="en-US">Deferred Liability For Issuance Of Additional Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DeferredLiabilityForIssuanceOfAdditionalShares" xml:lang="en-US">Deferred liability for issuance of additional shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares" xlink:to="lab_alur_DeferredLiabilityForIssuanceOfAdditionalShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DeferredLiabilityForIssuanceOfAdditionalShares" xml:lang="en-US">Deferred liability for issuance of additional shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt fee amount incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xml:lang="en-US">Fair value of term loan derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitFee" xlink:label="loc_alur_DebtInstrumentExitFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentExitFee" xml:lang="en-US">Debt Instrument, Exit Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentExitFee" xml:lang="en-US">Exit fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentExitFee" xlink:to="lab_alur_DebtInstrumentExitFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentExitFee" xml:lang="en-US">Debt instrument, exit fee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForFees" xml:lang="en-US">Payments for Other Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForFees" xml:lang="en-US">Other fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestReceivable" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancing" xml:lang="en-US">Changes In Fair Value Of Revenue Interest Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancing" xml:lang="en-US">Gain in fair value of revenue interest financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:to="lab_alur_ChangesInFairValueOfRevenueInterestFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChangesInFairValueOfRevenueInterestFinancing" xml:lang="en-US">Changes in fair value of revenue interest financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain recorded on derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xml:lang="en-US">Initial conversion rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xlink:label="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xml:lang="en-US">Debt Instrument, Principal Amount For Conversion Into Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xml:lang="en-US">Debt instrument, principal amount for conversion into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xlink:to="lab_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xml:lang="en-US">Debt instrument, principal amount for conversion into common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Initial conversion price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Estimated share price at conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xlink:label="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xml:lang="en-US">Debt Instrument, Convertible, Premium Percentage of Stock Price Trigger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xml:lang="en-US">Premium percentage of stock price trigger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xlink:to="lab_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xml:lang="en-US">Debt instrument, convertible, premium percentage of stock price trigger.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xlink:label="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xml:lang="en-US">Deb Instrument, Convertible, Maximum Limitation Percentage of Shares of Common Stock Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xml:lang="en-US">Maximum percentage of number of shares of common stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xlink:to="lab_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xml:lang="en-US">Deb instrument, convertible, maximum limitation percentage of shares of common stock outstanding.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnrestrictedCash" xlink:label="loc_alur_UnrestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_UnrestrictedCash" xml:lang="en-US">Unrestricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_UnrestrictedCash" xml:lang="en-US">Unrestricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_UnrestrictedCash" xlink:to="lab_alur_UnrestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_UnrestrictedCash" xml:lang="en-US">Unrestricted cash.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">December 31, 2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">December 31, 2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementAmendmentMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingAgreementAmendmentMember" xml:lang="en-US">Revenue Interest Financing Agreement Amendment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingAgreementAmendmentMember" xml:lang="en-US">RIFA Amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingAgreementAmendmentMember" xlink:to="lab_alur_RevenueInterestFinancingAgreementAmendmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingAgreementAmendmentMember" xml:lang="en-US">Revenue interest financing agreement amendment.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PIPEConversionOptionMember" xlink:label="loc_alur_PIPEConversionOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PIPEConversionOptionMember" xml:lang="en-US">P I P E Conversion Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PIPEConversionOptionMember" xml:lang="en-US">PIPE Conversion Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PIPEConversionOptionMember" xlink:to="lab_alur_PIPEConversionOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PIPEConversionOptionMember" xml:lang="en-US">PIPE Conversion option.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanOneMember" xlink:label="loc_alur_ScenarioPlanOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScenarioPlanOneMember" xml:lang="en-US">Scenario Plan One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScenarioPlanOneMember" xml:lang="en-US">December 31, 2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScenarioPlanOneMember" xlink:to="lab_alur_ScenarioPlanOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScenarioPlanOneMember" xml:lang="en-US">Scenario plan one.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanTwoMember" xlink:label="loc_alur_ScenarioPlanTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScenarioPlanTwoMember" xml:lang="en-US">Scenario Plan Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ScenarioPlanTwoMember" xml:lang="en-US">December 31, 2030</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScenarioPlanTwoMember" xlink:to="lab_alur_ScenarioPlanTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScenarioPlanTwoMember" xml:lang="en-US">Scenario plan two.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioForecastMember" xml:lang="en-US">Forecast</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_alur_RevenuesInterestFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenuesInterestFinancingLiability" xml:lang="en-US">Revenues Interest Financing Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenuesInterestFinancingLiability" xml:lang="en-US">Revenues interest financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenuesInterestFinancingLiability" xlink:to="lab_alur_RevenuesInterestFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenuesInterestFinancingLiability" xml:lang="en-US">Revenues interest financing liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestPaymentsPercentage" xlink:label="loc_alur_RevenueInterestPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestPaymentsPercentage" xml:lang="en-US">Revenue Interest Payments Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestPaymentsPercentage" xml:lang="en-US">Revenue interest payments percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestPaymentsPercentage" xlink:to="lab_alur_RevenueInterestPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestPaymentsPercentage" xml:lang="en-US">Revenue interest payments percentage.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CashPaymentsPercentage" xlink:label="loc_alur_CashPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CashPaymentsPercentage" xml:lang="en-US">Cash Payments Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CashPaymentsPercentage" xml:lang="en-US">Cash payments percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CashPaymentsPercentage" xlink:to="lab_alur_CashPaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CashPaymentsPercentage" xml:lang="en-US">Cash payments percentage.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrePaymentsPercentage" xlink:label="loc_alur_PrePaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PrePaymentsPercentage" xml:lang="en-US">Pre Payments Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PrePaymentsPercentage" xml:lang="en-US">Pre payments percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PrePaymentsPercentage" xlink:to="lab_alur_PrePaymentsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PrePaymentsPercentage" xml:lang="en-US">Pre payments percentage</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RoyaltyPayments" xlink:label="loc_alur_RoyaltyPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RoyaltyPayments" xml:lang="en-US">Royalty Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RoyaltyPayments" xml:lang="en-US">Royalty payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_RoyaltyPayments" xml:lang="en-US">Less: Royalty payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RoyaltyPayments" xlink:to="lab_alur_RoyaltyPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RoyaltyPayments" xml:lang="en-US">Royalty payments.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_VolumeWeightedAveragePricePerShare" xlink:label="loc_alur_VolumeWeightedAveragePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_VolumeWeightedAveragePricePerShare" xml:lang="en-US">Volume Weighted Average Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_VolumeWeightedAveragePricePerShare" xml:lang="en-US">Volume weighted average price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_VolumeWeightedAveragePricePerShare" xlink:to="lab_alur_VolumeWeightedAveragePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_VolumeWeightedAveragePricePerShare" xml:lang="en-US">Volume weighted average price per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xml:lang="en-US">Trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Issue-date estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfNetSales" xlink:label="loc_alur_PercentageOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfNetSales" xml:lang="en-US">Percentage of Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfNetSales" xml:lang="en-US">Percentage of net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfNetSales" xlink:to="lab_alur_PercentageOfNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfNetSales" xml:lang="en-US">Percentage of net sales.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SalesRevenueNet" xlink:label="loc_alur_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SalesRevenueNet" xml:lang="en-US">Sales Revenue Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SalesRevenueNet" xml:lang="en-US">Sales Revenue Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SalesRevenueNet" xlink:to="lab_alur_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SalesRevenueNet" xml:lang="en-US">Sales revenue net.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseInSalesRevenueNet" xlink:label="loc_alur_IncreaseInSalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IncreaseInSalesRevenueNet" xml:lang="en-US">Increase in Sales Revenue Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IncreaseInSalesRevenueNet" xml:lang="en-US">Increase in Sales Revenue Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IncreaseInSalesRevenueNet" xlink:to="lab_alur_IncreaseInSalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IncreaseInSalesRevenueNet" xml:lang="en-US">Increase in sales revenue net.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfIncreaseInNetSales" xlink:label="loc_alur_PercentageOfIncreaseInNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfIncreaseInNetSales" xml:lang="en-US">Percentage of Increase in Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfIncreaseInNetSales" xml:lang="en-US">Percentage of Increase in Net Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfIncreaseInNetSales" xlink:to="lab_alur_PercentageOfIncreaseInNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfIncreaseInNetSales" xml:lang="en-US">Percentage of increase in net sales.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfRevenueInterestFinancingAgreements" xlink:label="loc_alur_FairValueOfRevenueInterestFinancingAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueOfRevenueInterestFinancingAgreements" xml:lang="en-US">Fair Value of Revenue Interest Financing Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueOfRevenueInterestFinancingAgreements" xml:lang="en-US">Fair value of revenue interest financing agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueOfRevenueInterestFinancingAgreements" xlink:to="lab_alur_FairValueOfRevenueInterestFinancingAgreements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueOfRevenueInterestFinancingAgreements" xml:lang="en-US">Fair value of revenue interest financing agreements.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfPipeConversionOption" xlink:label="loc_alur_FairValueOfPipeConversionOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueOfPipeConversionOption" xml:lang="en-US">Fair Value of Pipe Conversion Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueOfPipeConversionOption" xml:lang="en-US">Fair value of pipe conversion option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueOfPipeConversionOption" xlink:to="lab_alur_FairValueOfPipeConversionOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueOfPipeConversionOption" xml:lang="en-US">Fair value of pipe conversion option.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementRemeasuredValue" xlink:label="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingAgreementRemeasuredValue" xml:lang="en-US">Revenue Interest Financing Agreement Remeasured Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingAgreementRemeasuredValue" xml:lang="en-US">Revenue Interest Financing Agreement Remeasured Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue" xlink:to="lab_alur_RevenueInterestFinancingAgreementRemeasuredValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingAgreementRemeasuredValue" xml:lang="en-US">Revenue Interest financing agreement remeasured value.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionOptionRemeasuredValue" xlink:label="loc_alur_PipeConversionOptionRemeasuredValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PipeConversionOptionRemeasuredValue" xml:lang="en-US">PIPE Conversion Option Remeasured Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PipeConversionOptionRemeasuredValue" xml:lang="en-US">PIPE Conversion Option Remeasured Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PipeConversionOptionRemeasuredValue" xlink:to="lab_alur_PipeConversionOptionRemeasuredValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PipeConversionOptionRemeasuredValue" xml:lang="en-US">PIPE conversion option remeasured value.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfInternalRateOfReturn" xlink:label="loc_alur_PercentageOfInternalRateOfReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfInternalRateOfReturn" xml:lang="en-US">Percentage of Internal Rate of Return</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfInternalRateOfReturn" xml:lang="en-US">Percentage of Internal Rate of Return</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfInternalRateOfReturn" xlink:to="lab_alur_PercentageOfInternalRateOfReturn" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfInternalRateOfReturn" xml:lang="en-US">Percentage of internal rate of return.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:label="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xml:lang="en-US">Revenue Interest Financing Liability Principal Amount Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xml:lang="en-US">Total principal amounts of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:to="lab_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xml:lang="en-US">Revenue interest financing liability principal amount of debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">U.S.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">U.S. statutory federal income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xlink:label="loc_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xml:lang="en-US">Effective Income Tax Rate Reconciliation Change In Fair Value Of Financial Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xml:lang="en-US">Change in fair value of financial instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xlink:to="lab_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xml:lang="en-US">Effective income tax rate reconciliation change in fair value of financial instruments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xml:lang="en-US">Tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">U.S. federal and state net operating loss carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Capitalized start-up and research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_alur_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_alur_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsDepreciation" xlink:label="loc_alur_DeferredTaxAssetsDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DeferredTaxAssetsDepreciation" xml:lang="en-US">Deferred Tax Assets Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DeferredTaxAssetsDepreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DeferredTaxAssetsDepreciation" xlink:to="lab_alur_DeferredTaxAssetsDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DeferredTaxAssetsDepreciation" xml:lang="en-US">Deferred tax assets depreciation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Bad debt reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other temporary differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Beginning balances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Ending balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Right of use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other deferred tax liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarliestTaxYearMember" xml:lang="en-US">Earliest Tax Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarliestTaxYearMember" xlink:to="lab_us-gaap_EarliestTaxYearMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LatestTaxYearMember" xml:lang="en-US">Latest Tax Year [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LatestTaxYearMember" xml:lang="en-US">Latest Tax Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LatestTaxYearMember" xlink:to="lab_us-gaap_LatestTaxYearMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LatestTaxYearTwoThousandFortyTwoMember" xlink:label="loc_alur_LatestTaxYearTwoThousandFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LatestTaxYearTwoThousandFortyTwoMember" xml:lang="en-US">Latest Tax Year Two Thousand Forty Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_LatestTaxYearTwoThousandFortyTwoMember" xml:lang="en-US">Latest Tax Year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LatestTaxYearTwoThousandFortyTwoMember" xlink:to="lab_alur_LatestTaxYearTwoThousandFortyTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LatestTaxYearTwoThousandFortyTwoMember" xml:lang="en-US">Latest tax year two thousand forty two.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xlink:label="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xml:lang="en-US">Expire Between Two Thousand Thirty And Two Thousand Thirty Seven [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xml:lang="en-US">Expire between 2030 and 2037</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xlink:to="lab_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xml:lang="en-US">Expire between two thousand thirty and two thousand thirty seven.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DoNotExpireMember" xlink:label="loc_alur_DoNotExpireMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DoNotExpireMember" xml:lang="en-US">Do Not Expire [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_DoNotExpireMember" xml:lang="en-US">Do not expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DoNotExpireMember" xlink:to="lab_alur_DoNotExpireMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DoNotExpireMember" xml:lang="en-US">Do not expire.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation allowance increased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Additions charged to net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Deferred Tax Assets Operating Loss Carry Forward Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Net operating loss carryforwards expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xlink:to="lab_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xml:lang="en-US">Deferred tax assets operating loss carry forward expiration period.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopment" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopment" xml:lang="en-US">Tax Credit Carry Forwards Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopment" xml:lang="en-US">Tax credit carry forwards research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment" xlink:to="lab_alur_TaxCreditCarryForwardsResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopment" xml:lang="en-US">Tax credit carry forwards research and development.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xml:lang="en-US">Tax Credit Carry Forwards Research And Development Expiration Year.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xml:lang="en-US">Tax credits research and development expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xlink:to="lab_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xml:lang="en-US">Tax credit carry forwards research and development expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Accrued interest and penalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="loc_us-gaap_ValuationAllowanceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xml:lang="en-US">Valuation Allowance [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAbstract" xlink:to="lab_us-gaap_ValuationAllowanceAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingMember" xlink:label="loc_alur_RevenueInterestFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueInterestFinancingMember" xml:lang="en-US">Revenue Interest Financing [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueInterestFinancingMember" xml:lang="en-US">Revenue Interest Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueInterestFinancingMember" xlink:to="lab_alur_RevenueInterestFinancingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueInterestFinancingMember" xml:lang="en-US">Revenue interest financing.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionDerivativeMember" xlink:label="loc_alur_PipeConversionDerivativeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PipeConversionDerivativeMember" xml:lang="en-US">PIPE Conversion Derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PipeConversionDerivativeMember" xml:lang="en-US">PIPE Conversion Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PipeConversionDerivativeMember" xlink:to="lab_alur_PipeConversionDerivativeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PipeConversionDerivativeMember" xml:lang="en-US">Pipe conversion derivative.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SuccessFeeDerivativeLiabilityMember" xlink:label="loc_alur_SuccessFeeDerivativeLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SuccessFeeDerivativeLiabilityMember" xml:lang="en-US">Success Fee Derivative Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SuccessFeeDerivativeLiabilityMember" xml:lang="en-US">Success Fee Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SuccessFeeDerivativeLiabilityMember" xlink:to="lab_alur_SuccessFeeDerivativeLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SuccessFeeDerivativeLiabilityMember" xml:lang="en-US">Success Fee Derivative Liability [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoShareLiabilityMember" xlink:label="loc_alur_PubcoShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PubcoShareLiabilityMember" xml:lang="en-US">PubCo Share Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PubcoShareLiabilityMember" xml:lang="en-US">PubCo Share Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PubcoShareLiabilityMember" xlink:to="lab_alur_PubcoShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PubcoShareLiabilityMember" xml:lang="en-US">PubCo Share Liability [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoAndBackstopShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BasePubcoAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo and Backstop Share Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BasePubcoAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo and Backstop Share Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BasePubcoAndBackstopShareLiabilityMember" xlink:to="lab_alur_BasePubcoAndBackstopShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BasePubcoAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo and Backstop Share Liability [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TermLoanDerivativeLiabilityMember" xml:lang="en-US">Term Loan Derivative Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TermLoanDerivativeLiabilityMember" xml:lang="en-US">Term Loan Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TermLoanDerivativeLiabilityMember" xlink:to="lab_alur_TermLoanDerivativeLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TermLoanDerivativeLiabilityMember" xml:lang="en-US">Term Loan Derivative Liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicOfferingWarrantsMember" xml:lang="en-US">Public Offering Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PublicOfferingWarrantsMember" xml:lang="en-US">Public Offering Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicOfferingWarrantsMember" xlink:to="lab_alur_PublicOfferingWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicOfferingWarrantsMember" xml:lang="en-US">Public Offering Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockWarrantsMember" xlink:label="loc_alur_PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PreferredStockWarrantsMember" xml:lang="en-US">Preferred Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PreferredStockWarrantsMember" xml:lang="en-US">Preferred Stock Warrants (as Converted to Common)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PreferredStockWarrantsMember" xlink:to="lab_alur_PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PreferredStockWarrantsMember" xml:lang="en-US">Preferred Stock Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommonStockWarrantsMember" xlink:label="loc_alur_CommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CommonStockWarrantsMember" xml:lang="en-US">Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CommonStockWarrantsMember" xml:lang="en-US">Common Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CommonStockWarrantsMember" xlink:to="lab_alur_CommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CommonStockWarrantsMember" xml:lang="en-US">Common Stock Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xml:lang="en-US">Fair value upon issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xml:lang="en-US">Change in fair value - OCI</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Exercise of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xml:lang="en-US">Exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xlink:to="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Exercise of Warrants</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Repayment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xml:lang="en-US">Repayments of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xlink:to="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Repayment of Debt</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xml:lang="en-US">Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:to="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Payments</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Derecognition of Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xml:lang="en-US">Derecognition of liability to equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xlink:to="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Derecognition of Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PrivatePlacementWarrantsMember" xlink:to="lab_alur_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xlink:label="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xml:lang="en-US">Two Thousand Nineteen Term Loan and Success Fee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xml:lang="en-US">2019 Term Loan and Success Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xlink:to="lab_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xml:lang="en-US">Two thousand nineteen term loan and success fee.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoAdditionalSharesLiabilityMember" xlink:label="loc_alur_PubcoAdditionalSharesLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PubcoAdditionalSharesLiabilityMember" xml:lang="en-US">PubCo Additional Shares Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PubcoAdditionalSharesLiabilityMember" xml:lang="en-US">PubCo Additional Shares Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PubcoAdditionalSharesLiabilityMember" xlink:to="lab_alur_PubcoAdditionalSharesLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PubcoAdditionalSharesLiabilityMember" xml:lang="en-US">PubCo additional shares liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoSharesAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BasePubcoSharesAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo Shares and Backstop Share Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BasePubcoSharesAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo Shares and Backstop Shares Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember" xlink:to="lab_alur_BasePubcoSharesAndBackstopShareLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BasePubcoSharesAndBackstopShareLiabilityMember" xml:lang="en-US">Base PubCo shares and backstop share liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xml:lang="en-US">Expected Dividend Yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Estimated Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xml:lang="en-US">Black-Scholes Option Pricing Model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssumptionsOfLiquidityEventTerm" xlink:label="loc_alur_FairValueAssumptionsOfLiquidityEventTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueAssumptionsOfLiquidityEventTerm" xml:lang="en-US">Fair Value Assumptions of Liquidity Event Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueAssumptionsOfLiquidityEventTerm" xml:lang="en-US">Fair value assumptions of liquidity event term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueAssumptionsOfLiquidityEventTerm" xlink:to="lab_alur_FairValueAssumptionsOfLiquidityEventTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueAssumptionsOfLiquidityEventTerm" xml:lang="en-US">Fair value assumptions of liquidity event term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Debt Instrument, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Debt instrument, measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedNumberOfShares" xlink:label="loc_alur_FairValueOfEstimatedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueOfEstimatedNumberOfShares" xml:lang="en-US">Fair Value of Estimated Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueOfEstimatedNumberOfShares" xml:lang="en-US">Fair value of estimated number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueOfEstimatedNumberOfShares" xlink:to="lab_alur_FairValueOfEstimatedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueOfEstimatedNumberOfShares" xml:lang="en-US">Fair Value of Estimated Number of Shares</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedPriceOfShares" xlink:label="loc_alur_FairValueOfEstimatedPriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueOfEstimatedPriceOfShares" xml:lang="en-US">Fair Value of Estimated Price of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueOfEstimatedPriceOfShares" xml:lang="en-US">Fair value of estimated price of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueOfEstimatedPriceOfShares" xlink:to="lab_alur_FairValueOfEstimatedPriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueOfEstimatedPriceOfShares" xml:lang="en-US">Fair Value of Estimated Price of Shares</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Assets Measured On Recurring Basis, Observable And Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xlink:to="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xml:lang="en-US">Fair value, assets measured on recurring basis, observable and unobservable input reconciliation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Interest Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xml:lang="en-US">Estimated Fair Value of Underlying Share Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xml:lang="en-US">Expected Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Expected Life (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series A 1 Preferred Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series A 1 Preferred Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xlink:to="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xml:lang="en-US">Legacy allurion series A-1 preferred stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series B Preferred Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series B Preferred Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xlink:to="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion series B preferred stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series C Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series C Common Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xlink:to="lab_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xml:lang="en-US">Legacy Allurion series C common stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xlink:to="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion series C preferred stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series D-1 Preferred Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion Series D-1 Preferred Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xlink:to="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xml:lang="en-US">Legacy Allurion series D-1 preferred stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockMember" xlink:label="loc_alur_OtherCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OtherCommonStockMember" xml:lang="en-US">Other Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OtherCommonStockMember" xml:lang="en-US">Other Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OtherCommonStockMember" xlink:to="lab_alur_OtherCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OtherCommonStockMember" xml:lang="en-US">Other common stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantsMember" xlink:label="loc_alur_OtherCommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OtherCommonStockWarrantsMember" xml:lang="en-US">Other Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OtherCommonStockWarrantsMember" xml:lang="en-US">Other Common Stock Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OtherCommonStockWarrantsMember" xlink:to="lab_alur_OtherCommonStockWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OtherCommonStockWarrantsMember" xml:lang="en-US">Other common stock warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionOtherCommonStockMember" xlink:label="loc_alur_LegacyAllurionOtherCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionOtherCommonStockMember" xml:lang="en-US">Legacy Allurion Other Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionOtherCommonStockMember" xml:lang="en-US">Legacy Allurion Other Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionOtherCommonStockMember" xlink:to="lab_alur_LegacyAllurionOtherCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionOtherCommonStockMember" xml:lang="en-US">Legacy Allurion Other Common Stock [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Assets Measured On Recurring Basis, Observable And Unobservable Input Reconciliation [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xlink:to="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair value, assets measured on recurring basis, observable and unobservable input reconciliation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Remaining Contractual Term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xml:lang="en-US">Measurement Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xml:lang="en-US">Portion at Fair Value Measurement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US">Reported Value Measurement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US">Total Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Legacy Allurion Common Stock Warrant Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Legacy Allurion Common Stock Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xlink:to="lab_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Legacy allurion common stock warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DerivativeLiabilitySuccessFeeMember" xlink:label="loc_alur_DerivativeLiabilitySuccessFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_DerivativeLiabilitySuccessFeeMember" xml:lang="en-US">Derivative Liability-Success Fee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_DerivativeLiabilitySuccessFeeMember" xml:lang="en-US">Success Fee Derivative Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_DerivativeLiabilitySuccessFeeMember" xlink:to="lab_alur_DerivativeLiabilitySuccessFeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_DerivativeLiabilitySuccessFeeMember" xml:lang="en-US">Derivative liability-success fee.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series C Common Stock Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series C Common Stock Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xlink:to="lab_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xml:lang="en-US">Legacy allurion series C common stock warrant liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series B Preferred Stock Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series B Preferred Stock Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xlink:to="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy allurion series B preferred stock warrant liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series A 1 Preferred Stock Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series A-1 Preferred Stock Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xlink:to="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy allurion series A-1 preferred stock warrant liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_OtherCommonStockWarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OtherCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Other Common Stock Warrant Liabilities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OtherCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Other Common Stock Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OtherCommonStockWarrantLiabilitiesMember" xlink:to="lab_alur_OtherCommonStockWarrantLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OtherCommonStockWarrantLiabilitiesMember" xml:lang="en-US">Other common stock warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series C Preferred Stock Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xlink:to="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy allurion series C preferred stock warrant liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series D 1 Preferred Stock Warrant Liability [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy Allurion Series D-1 Preferred Stock Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xlink:to="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xml:lang="en-US">Legacy allurion series D-1 preferred stock warrant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Stock, Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthAcquisitionCorprationMember" xlink:label="loc_alur_ComputeHealthAcquisitionCorprationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ComputeHealthAcquisitionCorprationMember" xml:lang="en-US">Compute Health Acquisition Corpration [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ComputeHealthAcquisitionCorprationMember" xml:lang="en-US">Compute Health</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ComputeHealthAcquisitionCorprationMember" xlink:to="lab_alur_ComputeHealthAcquisitionCorprationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ComputeHealthAcquisitionCorprationMember" xml:lang="en-US">Compute Health Acquisition Corpration.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantMember" xlink:label="loc_alur_PublicWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicWarrantMember" xml:lang="en-US">Public Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_PublicWarrantMember" xml:lang="en-US">Public Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicWarrantMember" xlink:to="lab_alur_PublicWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicWarrantMember" xml:lang="en-US">Public warrant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingMember" xlink:label="loc_alur_PublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicOfferingMember" xml:lang="en-US">Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PublicOfferingMember" xml:lang="en-US">Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicOfferingMember" xlink:to="lab_alur_PublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicOfferingMember" xml:lang="en-US">Public offering.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsAndShareOverallotmentMember" xlink:label="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicOfferingWarrantsAndShareOverallotmentMember" xml:lang="en-US">Public Offering Warrants and Share Overallotment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PublicOfferingWarrantsAndShareOverallotmentMember" xml:lang="en-US">Public Offering Warrants and Share Overallotment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember" xlink:to="lab_alur_PublicOfferingWarrantsAndShareOverallotmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicOfferingWarrantsAndShareOverallotmentMember" xml:lang="en-US">Public offering warrants and share overallotment member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWithRTWMember" xlink:label="loc_alur_PrivatePlacementWithRTWMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PrivatePlacementWithRTWMember" xml:lang="en-US">Private Placement with R T W [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PrivatePlacementWithRTWMember" xml:lang="en-US">Private Placement with RTW</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PrivatePlacementWithRTWMember" xlink:to="lab_alur_PrivatePlacementWithRTWMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PrivatePlacementWithRTWMember" xml:lang="en-US">Private Placement with RTW.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Underwriters</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommitmentSharesMember" xlink:label="loc_alur_CommitmentSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_CommitmentSharesMember" xml:lang="en-US">Commitment Shares Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_CommitmentSharesMember" xml:lang="en-US">Commitment Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_CommitmentSharesMember" xlink:to="lab_alur_CommitmentSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_CommitmentSharesMember" xml:lang="en-US">Commitment Shares.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanThreeMember" xlink:label="loc_alur_ScenarioPlanThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScenarioPlanThreeMember" xml:lang="en-US">Scenario Plan Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_ScenarioPlanThreeMember" xml:lang="en-US">Scenario Plan Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScenarioPlanThreeMember" xlink:to="lab_alur_ScenarioPlanThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScenarioPlanThreeMember" xml:lang="en-US">Scenario plan three.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanFourMember" xlink:label="loc_alur_ScenarioPlanFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ScenarioPlanFourMember" xml:lang="en-US">Scenario Plan Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_ScenarioPlanFourMember" xml:lang="en-US">Scenario Plan Four</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ScenarioPlanFourMember" xlink:to="lab_alur_ScenarioPlanFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ScenarioPlanFourMember" xml:lang="en-US">Scenario plan four.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChefPurchaseAgreementMember" xlink:label="loc_alur_ChefPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChefPurchaseAgreementMember" xml:lang="en-US">ChEF Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChefPurchaseAgreementMember" xml:lang="en-US">ChEF Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChefPurchaseAgreementMember" xlink:to="lab_alur_ChefPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChefPurchaseAgreementMember" xml:lang="en-US">ChEF Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChardanEquityFacilityMember" xlink:label="loc_alur_ChardanEquityFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ChardanEquityFacilityMember" xml:lang="en-US">Chardan Equity Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ChardanEquityFacilityMember" xml:lang="en-US">Chardan Equity Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ChardanEquityFacilityMember" xlink:to="lab_alur_ChardanEquityFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ChardanEquityFacilityMember" xml:lang="en-US">Chardan Equity Facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionBasis" xlink:label="loc_alur_PreferredStockRedemptionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PreferredStockRedemptionBasis" xml:lang="en-US">Preferred Stock Redemption Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PreferredStockRedemptionBasis" xml:lang="en-US">Preferred stock redemption basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PreferredStockRedemptionBasis" xlink:to="lab_alur_PreferredStockRedemptionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PreferredStockRedemptionBasis" xml:lang="en-US">Preferred stock redemption basis.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockLiquidationPreferenceBasis" xlink:label="loc_alur_PreferredStockLiquidationPreferenceBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PreferredStockLiquidationPreferenceBasis" xml:lang="en-US">Preferred Stock Liquidation Preference Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PreferredStockLiquidationPreferenceBasis" xml:lang="en-US">Preferred stock liquidation preference</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PreferredStockLiquidationPreferenceBasis" xlink:to="lab_alur_PreferredStockLiquidationPreferenceBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PreferredStockLiquidationPreferenceBasis" xml:lang="en-US">Preferred stock liquidation preference basis.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConversionBasis" xml:lang="en-US">Preferred stock conversion rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConversionBasis" xlink:to="lab_us-gaap_PreferredStockConversionBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockVotingRights" xml:lang="en-US">Preferred Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockVotingRights" xml:lang="en-US">Preferred stock voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockVotingRights" xlink:to="lab_us-gaap_PreferredStockVotingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xml:lang="en-US">Dividends, Preferred Stock, Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xml:lang="en-US">Dividends declared</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xml:lang="en-US">Equity Securities, FV-NI</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xml:lang="en-US">Issue-date estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xml:lang="en-US">Class of Warrant Exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercisable price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Shares issuable for each outstanding warrants exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsRedumptionPricePerShare" xlink:label="loc_alur_WarrantsRedumptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsRedumptionPricePerShare" xml:lang="en-US">Warrants Redumption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsRedumptionPricePerShare" xml:lang="en-US">Warrants redumption price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsRedumptionPricePerShare" xlink:to="lab_alur_WarrantsRedumptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsRedumptionPricePerShare" xml:lang="en-US">Warrants redumption price per share</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number of shares sold per unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xml:lang="en-US">Amount received on shares sold per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Gross proceeds from offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NetProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Net Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NetProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Net proceeds from offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_alur_NetProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NetProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Net proceeds from issuance or sale of equity.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnderwritingDiscounts" xlink:label="loc_alur_UnderwritingDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_UnderwritingDiscounts" xml:lang="en-US">Underwriting Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_UnderwritingDiscounts" xml:lang="en-US">Underwriting discounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_UnderwritingDiscounts" xlink:to="lab_alur_UnderwritingDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_UnderwritingDiscounts" xml:lang="en-US">Underwriting discounts.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ReductionInProceedsFromOffering" xlink:label="loc_alur_ReductionInProceedsFromOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ReductionInProceedsFromOffering" xml:lang="en-US">Reduction in Proceeds From Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ReductionInProceedsFromOffering" xml:lang="en-US">Reduction in proceeds from offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ReductionInProceedsFromOffering" xlink:to="lab_alur_ReductionInProceedsFromOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ReductionInProceedsFromOffering" xml:lang="en-US">Reduction in proceeds from offering.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfCommonStockSharesOutstanding" xlink:label="loc_alur_PercentageOfCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfCommonStockSharesOutstanding" xml:lang="en-US">Percentage of Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfCommonStockSharesOutstanding" xml:lang="en-US">Percentage of common stock, shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfCommonStockSharesOutstanding" xlink:to="lab_alur_PercentageOfCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfCommonStockSharesOutstanding" xml:lang="en-US">Percentage of common stock, shares, outstanding.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpenseOfIssuanceOfCommitmentShares" xlink:label="loc_alur_ExpenseOfIssuanceOfCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ExpenseOfIssuanceOfCommitmentShares" xml:lang="en-US">Expense of Issuance of Commitment Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ExpenseOfIssuanceOfCommitmentShares" xml:lang="en-US">Expense of issuance of commitment shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ExpenseOfIssuanceOfCommitmentShares" xlink:to="lab_alur_ExpenseOfIssuanceOfCommitmentShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ExpenseOfIssuanceOfCommitmentShares" xml:lang="en-US">Expense of Issuance of Commitment Shares</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StructuringFeePayable" xlink:label="loc_alur_StructuringFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StructuringFeePayable" xml:lang="en-US">Structuring Fee Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StructuringFeePayable" xml:lang="en-US">Structuring fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StructuringFeePayable" xlink:to="lab_alur_StructuringFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StructuringFeePayable" xml:lang="en-US">Structuring fee payable.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OutstandingOptionsToPurchaseCommonStockMember" xml:lang="en-US">Outstanding Options To Purchase Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OutstandingOptionsToPurchaseCommonStockMember" xml:lang="en-US">Outstanding Options to Purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:to="lab_alur_OutstandingOptionsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OutstandingOptionsToPurchaseCommonStockMember" xml:lang="en-US">Outstanding options to purchase common stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsToPurchaseCommonStockMember" xml:lang="en-US">Warrants To Purchase Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsToPurchaseCommonStockMember" xml:lang="en-US">Warrants to Purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsToPurchaseCommonStockMember" xlink:to="lab_alur_WarrantsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsToPurchaseCommonStockMember" xml:lang="en-US">Warrants to purchase common stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:label="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xml:lang="en-US">Shares of Common Stock Issued Upon the Exercise of Public Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xml:lang="en-US">Shares of Common Stock Issued Upon the Exercise of Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:to="lab_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xml:lang="en-US">Shares of common stock issued upon the exercise of public warrants.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_EarnOutSharesMember" xml:lang="en-US">Earn-Out Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_EarnOutSharesMember" xml:lang="en-US">Earn-Out Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_EarnOutSharesMember" xlink:to="lab_alur_EarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_EarnOutSharesMember" xml:lang="en-US">Earn-Out shares.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNotesMember" xlink:label="loc_alur_ConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConvertibleNotesMember" xml:lang="en-US">Convertible Notes [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConvertibleNotesMember" xml:lang="en-US">Convertible Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConvertibleNotesMember" xlink:to="lab_alur_ConvertibleNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConvertibleNotesMember" xml:lang="en-US">Convertible notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common stock shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtDecember012014Member" xlink:label="loc_alur_WarrantsIssuedAtDecember012014Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtDecember012014Member" xml:lang="en-US">Warrants Issued At December 012014 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtDecember012014Member" xml:lang="en-US">December 1, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtDecember012014Member" xlink:to="lab_alur_WarrantsIssuedAtDecember012014Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtDecember012014Member" xml:lang="en-US">Warrants Issued At December 012014.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtMarch302021Member" xlink:label="loc_alur_WarrantsIssuedAtMarch302021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtMarch302021Member" xml:lang="en-US">Warrants Issued At March 30, 2021 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtMarch302021Member" xml:lang="en-US">March 30, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtMarch302021Member" xlink:to="lab_alur_WarrantsIssuedAtMarch302021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtMarch302021Member" xml:lang="en-US">Warrants Issued At March 30, 2021.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember152022Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember152022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtSeptember152022Member" xml:lang="en-US">Warrants Issued At September 152022 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtSeptember152022Member" xml:lang="en-US">September 15, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtSeptember152022Member" xlink:to="lab_alur_WarrantsIssuedAtSeptember152022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtSeptember152022Member" xml:lang="en-US">Warrants Issued At September 152022.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune042022Member" xlink:label="loc_alur_WarrantsIssuedAtJune042022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtJune042022Member" xml:lang="en-US">Warrants Issued At June 042022 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtJune042022Member" xml:lang="en-US">June 4, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtJune042022Member" xlink:to="lab_alur_WarrantsIssuedAtJune042022Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtJune042022Member" xml:lang="en-US">Warrants Issued At June 042022.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJanuary172017Member" xlink:label="loc_alur_WarrantsIssuedAtJanuary172017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtJanuary172017Member" xml:lang="en-US">Warrants Issued At January 172017 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtJanuary172017Member" xml:lang="en-US">January 17, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtJanuary172017Member" xlink:to="lab_alur_WarrantsIssuedAtJanuary172017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtJanuary172017Member" xml:lang="en-US">Warrants Issued At January 172017.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtAugust032017Member" xlink:label="loc_alur_WarrantsIssuedAtAugust032017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtAugust032017Member" xml:lang="en-US">Warrants Issued At August 032017 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtAugust032017Member" xml:lang="en-US">August 3, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtAugust032017Member" xlink:to="lab_alur_WarrantsIssuedAtAugust032017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtAugust032017Member" xml:lang="en-US">Warrants Issued At August 032017.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember082017Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember082017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtSeptember082017Member" xml:lang="en-US">Warrants Issued At September082017 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtSeptember082017Member" xml:lang="en-US">September 8, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtSeptember082017Member" xlink:to="lab_alur_WarrantsIssuedAtSeptember082017Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtSeptember082017Member" xml:lang="en-US">Warrants Issued At September082017.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune192018Member" xlink:label="loc_alur_WarrantsIssuedAtJune192018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtJune192018Member" xml:lang="en-US">Warrants Issued At June 192018 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtJune192018Member" xml:lang="en-US">June 19, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtJune192018Member" xlink:to="lab_alur_WarrantsIssuedAtJune192018Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtJune192018Member" xml:lang="en-US">Warrants Issued At June 192018.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune252019Member" xlink:label="loc_alur_WarrantsIssuedAtJune252019Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtJune252019Member" xml:lang="en-US">Warrants Issued At June 252019 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtJune252019Member" xml:lang="en-US">June 25, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtJune252019Member" xlink:to="lab_alur_WarrantsIssuedAtJune252019Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtJune252019Member" xml:lang="en-US">Warrants Issued At June 252019.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJuly012024Member" xlink:label="loc_alur_WarrantsIssuedAtJuly012024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtJuly012024Member" xml:lang="en-US">Warrants Issued At July 012024 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtJuly012024Member" xml:lang="en-US">July 01,2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtJuly012024Member" xlink:to="lab_alur_WarrantsIssuedAtJuly012024Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtJuly012024Member" xml:lang="en-US">Warrants issued at july 012024 member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesAOnePreferredStockMember" xml:lang="en-US">Series A One Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesAOnePreferredStockMember" xml:lang="en-US">Series A-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesAOnePreferredStockMember" xlink:to="lab_alur_SeriesAOnePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesAOnePreferredStockMember" xml:lang="en-US">Series A One Preferred Stock [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember" xml:lang="en-US">Series D Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember" xlink:to="lab_us-gaap_SeriesDPreferredStockMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesDOnePreferredStockMember" xml:lang="en-US">Series D One Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesDOnePreferredStockMember" xml:lang="en-US">Series D-1 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesDOnePreferredStockMember" xlink:to="lab_alur_SeriesDOnePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesDOnePreferredStockMember" xml:lang="en-US">Series D One Preferred Stock Member.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDTwoPreferredStockMember" xlink:label="loc_alur_SeriesDTwoPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesDTwoPreferredStockMember" xml:lang="en-US">Series D Two Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesDTwoPreferredStockMember" xml:lang="en-US">Series D-2 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesDTwoPreferredStockMember" xlink:to="lab_alur_SeriesDTwoPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesDTwoPreferredStockMember" xml:lang="en-US">Series D Two Preferred Stock Member.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDThreePreferredStockMember" xlink:label="loc_alur_SeriesDThreePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_SeriesDThreePreferredStockMember" xml:lang="en-US">Series D Three Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_SeriesDThreePreferredStockMember" xml:lang="en-US">Series D-3 Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_SeriesDThreePreferredStockMember" xlink:to="lab_alur_SeriesDThreePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_SeriesDThreePreferredStockMember" xml:lang="en-US">Series D Three Preferred Stock Member.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionMember" xlink:label="loc_alur_LegacyAllurionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LegacyAllurionMember" xml:lang="en-US">Legacy Allurion Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LegacyAllurionMember" xml:lang="en-US">Legacy Allurion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LegacyAllurionMember" xlink:to="lab_alur_LegacyAllurionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LegacyAllurionMember" xml:lang="en-US">Legacy Allurion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common stock voting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Percentage of preferred stock dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Preferred stock liquidation preference per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_us-gaap_PreferredStockLiquidationPreference" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xlink:label="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xml:lang="en-US">Revenue Recognition Milestone Method Of Recognized Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xml:lang="en-US">Revenue milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xlink:to="lab_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xml:lang="en-US">Revenue recognition milestone method of recognized revenue.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfSharesOfCommonStockHeld" xlink:label="loc_alur_PercentageOfSharesOfCommonStockHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfSharesOfCommonStockHeld" xml:lang="en-US">Percentage Of Shares Of Common Stock Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfSharesOfCommonStockHeld" xml:lang="en-US">Percentage of shares of common stock held</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfSharesOfCommonStockHeld" xlink:to="lab_alur_PercentageOfSharesOfCommonStockHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfSharesOfCommonStockHeld" xml:lang="en-US">Percentage Of Shares Of Common Stock Held.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Original issue price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPreferredStockRedeemableShares" xlink:label="loc_alur_PercentageOfPreferredStockRedeemableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfPreferredStockRedeemableShares" xml:lang="en-US">Percentage of outstanding shares of redeemable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfPreferredStockRedeemableShares" xlink:to="lab_alur_PercentageOfPreferredStockRedeemableShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfPreferredStockRedeemableShares" xml:lang="en-US">Percentage of preferred stock redeemable shares.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionValueToPrice" xlink:label="loc_alur_PreferredStockRedemptionValueToPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PreferredStockRedemptionValueToPrice" xml:lang="en-US">Preferred Stock redemption value to price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PreferredStockRedemptionValueToPrice" xlink:to="lab_alur_PreferredStockRedemptionValueToPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PreferredStockRedemptionValueToPrice" xml:lang="en-US">Preferred stock redemption value to price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Preferred Stock, Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Carrying Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchasePreferredStockMember" xlink:label="loc_alur_WarrantsToPurchasePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsToPurchasePreferredStockMember" xml:lang="en-US">Warrants To Purchase Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_alur_WarrantsToPurchasePreferredStockMember" xml:lang="en-US">Warrants to Purchase Preferred Stock (as converted to warrants to purchase common stock)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsToPurchasePreferredStockMember" xml:lang="en-US">Warrants to Purchase Preferred Stock (as converted to warrants to purchase Common Stock)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsToPurchasePreferredStockMember" xlink:to="lab_alur_WarrantsToPurchasePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsToPurchasePreferredStockMember" xml:lang="en-US">Warrants to purchase preferred stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_PublicWarrantsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PublicWarrantsToPurchaseCommonStockMember" xml:lang="en-US">Public Warrants To Purchase Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PublicWarrantsToPurchaseCommonStockMember" xml:lang="en-US">Public Warrants to Purchase Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PublicWarrantsToPurchaseCommonStockMember" xlink:to="lab_alur_PublicWarrantsToPurchaseCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PublicWarrantsToPurchaseCommonStockMember" xml:lang="en-US">Public warrants to purchase common stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtApril012013Member" xlink:label="loc_alur_WarrantsIssuedAtApril012013Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_WarrantsIssuedAtApril012013Member" xml:lang="en-US">Warrants Issued At April 012013 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_WarrantsIssuedAtApril012013Member" xml:lang="en-US">April 1, 2013</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_WarrantsIssuedAtApril012013Member" xlink:to="lab_alur_WarrantsIssuedAtApril012013Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_WarrantsIssuedAtApril012013Member" xml:lang="en-US">Warrants Issued At April 012013.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">us-gaap_AwardTypeAxis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanMember" xml:lang="en-US">2010 Stock Option Plan, 2020 Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanMember" xml:lang="en-US">2010 Plan and 2020 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockOptionPlan2020StockOptionPlanMember" xlink:to="lab_alur_StockOptionPlan2020StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanMember" xml:lang="en-US">2010 stock option plan, 2020 atock option plan.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xml:lang="en-US">2010 Stock Option Plan, 2020 Stock Option Plan And 2023 Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xml:lang="en-US">2010 Plan, 2020 Plan, and 2023 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xlink:to="lab_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xml:lang="en-US">2010 Stock Option Plan, 2020 Stock Option Plan And 2023 Stock Option Plan [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020Member" xlink:label="loc_alur_StockOptionPlan2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockOptionPlan2020Member" xml:lang="en-US">Stock Option Plan 2020 Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockOptionPlan2020Member" xml:lang="en-US">2020 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockOptionPlan2020Member" xlink:to="lab_alur_StockOptionPlan2020Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockOptionPlan2020Member" xml:lang="en-US">Stock Option Plan 2020 Member</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionAndIncentivePlanMember" xlink:label="loc_alur_StockOptionAndIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockOptionAndIncentivePlanMember" xml:lang="en-US">Stock Option and Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockOptionAndIncentivePlanMember" xml:lang="en-US">2023 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockOptionAndIncentivePlanMember" xlink:to="lab_alur_StockOptionAndIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockOptionAndIncentivePlanMember" xml:lang="en-US">Stock option and incentive plan.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xml:lang="en-US">Two Thousand and Twenty Three Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xml:lang="en-US">2023 ESPP</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:to="lab_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xml:lang="en-US">Two thousand and twenty three employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_alur_TimeVestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TimeVestedRestrictedStockUnitsMember" xml:lang="en-US">Time-Vested Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TimeVestedRestrictedStockUnitsMember" xml:lang="en-US">Time-Vested Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_alur_TimeVestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TimeVestedRestrictedStockUnitsMember" xml:lang="en-US">Time-vested restricted stock units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Tranche One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Tranche Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options and RSU's Issued and Exercisable Under the Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xml:lang="en-US">Options and RSUs issued and exercisable under the plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xlink:to="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options and rsu's issued and exercisable under the plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of time-vested restricted stock units granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value of the stock option awards granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Remaining weighted-average period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Remaining Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xml:lang="en-US">Remaining vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xlink:to="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, award remaining vesting rights, percentage.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xlink:label="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xml:lang="en-US">Increase Decrease In Percentage Of Number of Shares Reserved For Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xml:lang="en-US">Increase (decrease) in percentage of number of shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xlink:to="lab_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xml:lang="en-US">Increase decrease in percentage of number of shares reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPriceLowerOfFairValueMarketValue" xlink:label="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfPriceLowerOfFairValueMarketValue" xml:lang="en-US">Percentage Of Price Lower Of Fair Value Market Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfPriceLowerOfFairValueMarketValue" xml:lang="en-US">Percentage of price lower of fair value market value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue" xlink:to="lab_alur_PercentageOfPriceLowerOfFairValueMarketValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfPriceLowerOfFairValueMarketValue" xml:lang="en-US">Percentage of price lower of fair value market value.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfEmployeesCompensationToPayrollDeductions" xlink:label="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfEmployeesCompensationToPayrollDeductions" xml:lang="en-US">Percentage of Employees Compensation To Payroll Deductions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfEmployeesCompensationToPayrollDeductions" xml:lang="en-US">Percentage of employees compensation to payroll deductions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions" xlink:to="lab_alur_PercentageOfEmployeesCompensationToPayrollDeductions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfEmployeesCompensationToPayrollDeductions" xml:lang="en-US">Percentage of employees compensation to payroll deductions.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfDilutedSharesOutstanding" xlink:label="loc_alur_PercentageOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfDilutedSharesOutstanding" xml:lang="en-US">Percentage Of Diluted Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfDilutedSharesOutstanding" xml:lang="en-US">Percentage of diluted shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfDilutedSharesOutstanding" xlink:to="lab_alur_PercentageOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfDilutedSharesOutstanding" xml:lang="en-US">Percentage of diluted shares outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title and Position [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title and Position [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Director Members</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xml:lang="en-US">Two thousand and Ten Stock Option Plan, Two Thousand and Twenty Stock Option Plan, Two Thousand and Twenty Three Stock Option and Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xml:lang="en-US">2010 Plan, 2020 Plan, 2023 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xlink:to="lab_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xml:lang="en-US">Two thousand and ten stock option plan, two thousand and twenty stock option plan, two thousand and twenty three stock option and incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options, Cancellations and forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Cancellations and forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-Average Remaining Contractual Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020And2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockOptionPlan2020And2023StockOptionPlanMember" xml:lang="en-US">Stock Option Plan 2020 and 2023 Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockOptionPlan2020And2023StockOptionPlanMember" xml:lang="en-US">2020 Plan and 2023 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember" xlink:to="lab_alur_StockOptionPlan2020And2023StockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockOptionPlan2020And2023StockOptionPlanMember" xml:lang="en-US">Stock option plan 2020 and 2023 stock option plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of RSUs, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of RSUs, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of RSUs, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Number of RSUs, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Cancellations and forfeitures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Defined Benefit Plan [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined benefit plan matching contributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NatickAndHudsonMember" xlink:label="loc_alur_NatickAndHudsonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NatickAndHudsonMember" xml:lang="en-US">Natick and Hudson [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NatickAndHudsonMember" xml:lang="en-US">Natick and Hudson</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NatickAndHudsonMember" xlink:to="lab_alur_NatickAndHudsonMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NatickAndHudsonMember" xml:lang="en-US">Natick and hudson member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription" xml:lang="en-US">Lessee, Operating Lease, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescription" xml:lang="en-US">Lease description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescription" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescription" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseExpirationPeriod" xlink:label="loc_alur_LesseeOperatingLeaseExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LesseeOperatingLeaseExpirationPeriod" xml:lang="en-US">Lessee Operating Lease Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LesseeOperatingLeaseExpirationPeriod" xml:lang="en-US">Lessee operating lease expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LesseeOperatingLeaseExpirationPeriod" xlink:to="lab_alur_LesseeOperatingLeaseExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LesseeOperatingLeaseExpirationPeriod" xml:lang="en-US">Lessee operating lease expiration period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease assets obtained in exchange for lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Area of Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfLand" xml:lang="en-US">Lease total area of land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, operating lease, right to extend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US">Lessee, operating lease, right to extend [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, operating lease, remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss Contingency Accrual</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US">Loss contingency for probable losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInRevenuesForCustomerReturns" xlink:label="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_IncreaseDecreaseInRevenuesForCustomerReturns" xml:lang="en-US">Increase (Decrease) in Revenues for Customer Returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_IncreaseDecreaseInRevenuesForCustomerReturns" xml:lang="en-US">Reduction to revenues of customer returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns" xlink:to="lab_alur_IncreaseDecreaseInRevenuesForCustomerReturns" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_IncreaseDecreaseInRevenuesForCustomerReturns" xml:lang="en-US">Increase (decrease) in revenues for customer returns.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockExchangeListingRequirementsDescription" xlink:label="loc_alur_StockExchangeListingRequirementsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_StockExchangeListingRequirementsDescription" xml:lang="en-US">Stock Exchange Listing Requirements Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_StockExchangeListingRequirementsDescription" xml:lang="en-US">Stock exchange listing requirements description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_StockExchangeListingRequirementsDescription" xlink:to="lab_alur_StockExchangeListingRequirementsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_StockExchangeListingRequirementsDescription" xml:lang="en-US">Stock exchange listing requirements description.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AverageMarketCapitalizationAmount" xlink:label="loc_alur_AverageMarketCapitalizationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AverageMarketCapitalizationAmount" xml:lang="en-US">Average Market Capitalization Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AverageMarketCapitalizationAmount" xml:lang="en-US">Average market capitalization amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AverageMarketCapitalizationAmount" xlink:to="lab_alur_AverageMarketCapitalizationAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AverageMarketCapitalizationAmount" xml:lang="en-US">Average market capitalization amount.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfConsecutiveTradingDay" xlink:label="loc_alur_NumberOfConsecutiveTradingDay" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_NumberOfConsecutiveTradingDay" xml:lang="en-US">Number of Consecutive Trading Day</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_NumberOfConsecutiveTradingDay" xml:lang="en-US">Number of consecutive trading day</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_NumberOfConsecutiveTradingDay" xlink:to="lab_alur_NumberOfConsecutiveTradingDay" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_NumberOfConsecutiveTradingDay" xml:lang="en-US">Number of consecutive trading day.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-Term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows paid for amounts in the measurement of lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating lease, payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Operating cash flows paid for amounts in the measurement of finance lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeasesAndFinanceLeasesAbstract" xlink:label="loc_alur_OperatingLeasesAndFinanceLeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeasesAndFinanceLeasesAbstract" xml:lang="en-US">Operating Leases and Finance Leases [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeasesAndFinanceLeasesAbstract" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract" xlink:to="lab_alur_OperatingLeasesAndFinanceLeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeasesAndFinanceLeasesAbstract" xml:lang="en-US">Operating leases and finance leases.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Operating lease and finance lease liability payments due next twelve months.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Operating lease and finance lease liability payments due year two.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Operating lease and finance lease liability payments due year three.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Operating lease and finance lease liability payments due year four.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2028</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Operating lease and finance lease liability payments due year five.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Operating Lease And Finance Lease Liability Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Operating lease and finance lease liability payments due.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Operating Lease And Finance Lease Liability Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Operating lease and finance lease liability undiscounted excess amount.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiability" xlink:label="loc_alur_OperatingAndFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Operating And Finance Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_alur_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Present value of total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingAndFinanceLeaseLiability" xlink:to="lab_alur_OperatingAndFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Operating and finance lease liability.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_alur_OperatingAndFinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityCurrent" xml:lang="en-US">Operating And Finance Lease Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityCurrent" xml:lang="en-US">Less: current lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lab_alur_OperatingAndFinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityCurrent" xml:lang="en-US">Operating and finance lease liability current.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Operating And Finance Lease Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lab_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Operating and finance lease liability noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">2028</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US">Lessee operating lease liability payments due after year four.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating leases, weighted -average remaining lease term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating leases, weighted-average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncurrentAssets" xml:lang="en-US">Long-Lived Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncurrentAssets" xml:lang="en-US">Long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Related Party Transaction [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LnmpJpbcInvestMember" xlink:label="loc_alur_LnmpJpbcInvestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LnmpJpbcInvestMember" xml:lang="en-US">LNMP JPBC Invest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LnmpJpbcInvestMember" xml:lang="en-US">LNMP JPBC Invest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LnmpJpbcInvestMember" xlink:to="lab_alur_LnmpJpbcInvestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LnmpJpbcInvestMember" xml:lang="en-US">LNMP JPBC Invest [Member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_KkgEnterprisesMember" xlink:label="loc_alur_KkgEnterprisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_KkgEnterprisesMember" xml:lang="en-US">KKG Enterprises [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_KkgEnterprisesMember" xml:lang="en-US">KKG Enterprises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_KkgEnterprisesMember" xlink:to="lab_alur_KkgEnterprisesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_KkgEnterprisesMember" xml:lang="en-US">KKG Enterprises.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemusGroupManagementMember" xlink:label="loc_alur_RemusGroupManagementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RemusGroupManagementMember" xml:lang="en-US">Remus Group Management [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RemusGroupManagementMember" xml:lang="en-US">Remus Group Management</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RemusGroupManagementMember" xlink:to="lab_alur_RemusGroupManagementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RemusGroupManagementMember" xml:lang="en-US">Remus Group Management.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BenoitChardonConsultingMember" xlink:label="loc_alur_BenoitChardonConsultingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_BenoitChardonConsultingMember" xml:lang="en-US">Benoit Chardon Consulting [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_BenoitChardonConsultingMember" xml:lang="en-US">Benoit Chardon Consulting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_BenoitChardonConsultingMember" xlink:to="lab_alur_BenoitChardonConsultingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_BenoitChardonConsultingMember" xml:lang="en-US">Benoit Chardon Consulting (BCC).</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConsultingAgreementsMember" xlink:label="loc_alur_ConsultingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConsultingAgreementsMember" xml:lang="en-US">Consulting Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConsultingAgreementsMember" xlink:to="lab_alur_ConsultingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConsultingAgreementsMember" xml:lang="en-US">Consulting agreements.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TerminationAgreementMember" xlink:label="loc_alur_TerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_TerminationAgreementMember" xml:lang="en-US">Termination Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_TerminationAgreementMember" xml:lang="en-US">Termination Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_TerminationAgreementMember" xlink:to="lab_alur_TerminationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_TerminationAgreementMember" xml:lang="en-US">Termination agreement [member]</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteAgreementWithRtwMember" xlink:label="loc_alur_ConvertibleNoteAgreementWithRtwMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_ConvertibleNoteAgreementWithRtwMember" xml:lang="en-US">Convertible Note Agreement with RTW [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_ConvertibleNoteAgreementWithRtwMember" xml:lang="en-US">Convertible Note Agreement with RTW</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_ConvertibleNoteAgreementWithRtwMember" xlink:to="lab_alur_ConvertibleNoteAgreementWithRtwMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_ConvertibleNoteAgreementWithRtwMember" xml:lang="en-US">Convertible note agreement with RTW.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RTWParticipationInPublicOfferingMember" xlink:label="loc_alur_RTWParticipationInPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RTWParticipationInPublicOfferingMember" xml:lang="en-US">R T W Participation in Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RTWParticipationInPublicOfferingMember" xml:lang="en-US">RTW Participation in Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RTWParticipationInPublicOfferingMember" xlink:to="lab_alur_RTWParticipationInPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RTWParticipationInPublicOfferingMember" xml:lang="en-US">RTW participation in public offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HunterVenturesLimitedMember" xlink:label="loc_alur_HunterVenturesLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_HunterVenturesLimitedMember" xml:lang="en-US">Hunter Ventures Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_HunterVenturesLimitedMember" xml:lang="en-US">Hunter Ventures Limited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_HunterVenturesLimitedMember" xlink:to="lab_alur_HunterVenturesLimitedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_HunterVenturesLimitedMember" xml:lang="en-US">Hunter Ventures Limited.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseCommencementDate" xlink:label="loc_alur_OperatingLeaseCommencementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseCommencementDate" xml:lang="en-US">Operating Lease Commencement Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseCommencementDate" xml:lang="en-US">Operating lease commencement date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseCommencementDate" xlink:to="lab_alur_OperatingLeaseCommencementDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseCommencementDate" xml:lang="en-US">Operating lease commencement date.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseEndDate" xlink:label="loc_alur_OperatingLeaseEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseEndDate" xml:lang="en-US">Operating Lease End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseEndDate" xml:lang="en-US">Operating lease end date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseEndDate" xlink:to="lab_alur_OperatingLeaseEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseEndDate" xml:lang="en-US">Operating lease end date.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseTerminatedDate" xlink:label="loc_alur_LesseeOperatingLeaseTerminatedDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_LesseeOperatingLeaseTerminatedDate" xml:lang="en-US">Lessee Operating Lease Terminated Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_LesseeOperatingLeaseTerminatedDate" xml:lang="en-US">Lease terminated date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_LesseeOperatingLeaseTerminatedDate" xlink:to="lab_alur_LesseeOperatingLeaseTerminatedDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_LesseeOperatingLeaseTerminatedDate" xml:lang="en-US">Lessee operating lease terminated date.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AgreementsTerminationDate" xlink:label="loc_alur_AgreementsTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AgreementsTerminationDate" xml:lang="en-US">Agreements Termination Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AgreementsTerminationDate" xml:lang="en-US">Agreements termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AgreementsTerminationDate" xlink:to="lab_alur_AgreementsTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AgreementsTerminationDate" xml:lang="en-US">Agreements termination date.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xlink:label="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xml:lang="en-US">Payments of Advisory Services Related to Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xml:lang="en-US">Payments of advisory services related to business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xlink:to="lab_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xml:lang="en-US">Payments of advisory services related to business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIssuedPrincipal" xml:lang="en-US">Debt instrument issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="lab_us-gaap_DebtInstrumentIssuedPrincipal" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCapitalStock" xlink:label="loc_alur_PercentageOfOutstandingCapitalStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfOutstandingCapitalStock" xml:lang="en-US">Percentage of Outstanding Capital Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfOutstandingCapitalStock" xml:lang="en-US">Percentage of outstanding capital stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfOutstandingCapitalStock" xlink:to="lab_alur_PercentageOfOutstandingCapitalStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfOutstandingCapitalStock" xml:lang="en-US">Percentage of outstanding capital stock</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionConsultingFees" xlink:label="loc_alur_RelatedPartyTransactionConsultingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RelatedPartyTransactionConsultingFees" xml:lang="en-US">Related Party Transaction Consulting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RelatedPartyTransactionConsultingFees" xml:lang="en-US">Consulting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RelatedPartyTransactionConsultingFees" xlink:to="lab_alur_RelatedPartyTransactionConsultingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RelatedPartyTransactionConsultingFees" xml:lang="en-US">Related party transaction consulting fees.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionTerminationFees" xlink:label="loc_alur_RelatedPartyTransactionTerminationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RelatedPartyTransactionTerminationFees" xml:lang="en-US">Related Party Transaction Termination Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RelatedPartyTransactionTerminationFees" xml:lang="en-US">Termination fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RelatedPartyTransactionTerminationFees" xlink:to="lab_alur_RelatedPartyTransactionTerminationFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RelatedPartyTransactionTerminationFees" xml:lang="en-US">Related party transaction termination fees.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseStartDate" xlink:label="loc_alur_OperatingLeaseStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_OperatingLeaseStartDate" xml:lang="en-US">Operating Lease Start Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_OperatingLeaseStartDate" xml:lang="en-US">Operating lease start date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_OperatingLeaseStartDate" xlink:to="lab_alur_OperatingLeaseStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_OperatingLeaseStartDate" xml:lang="en-US">Operating lease start date.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCommonStock" xlink:label="loc_alur_PercentageOfOutstandingCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_PercentageOfOutstandingCommonStock" xml:lang="en-US">Percentage of Outstanding Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_PercentageOfOutstandingCommonStock" xml:lang="en-US">Percentage of Outstanding Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_PercentageOfOutstandingCommonStock" xlink:to="lab_alur_PercentageOfOutstandingCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_PercentageOfOutstandingCommonStock" xml:lang="en-US">Percentage of outstanding common stock.</label>
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AggregatePurchasePriceFromOffering" xlink:label="loc_alur_AggregatePurchasePriceFromOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_AggregatePurchasePriceFromOffering" xml:lang="en-US">Aggregate Purchase Price From Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_AggregatePurchasePriceFromOffering" xml:lang="en-US">Aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_AggregatePurchasePriceFromOffering" xlink:to="lab_alur_AggregatePurchasePriceFromOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_AggregatePurchasePriceFromOffering" xml:lang="en-US">Aggregate purchase price from offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xml:lang="en-US">Number of employees reduced from workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US">Percentage of employees reduced from workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">Restructuring Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringCosts" xml:lang="en-US">One-time aggregate restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RestructuringPlanMember" xlink:label="loc_alur_RestructuringPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_alur_RestructuringPlanMember" xml:lang="en-US">Restructuring Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_alur_RestructuringPlanMember" xml:lang="en-US">Restructuring Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_alur_RestructuringPlanMember" xlink:to="lab_alur_RestructuringPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_alur_RestructuringPlanMember" xml:lang="en-US">Restructuring Plan [Member]</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>alur-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-December-2024 [02:30:49] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CoverPage" roleURI="http://www.allurion.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedBalanceSheets" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash" roleURI="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#OrganizationAndBasisOfPresentation" roleURI="http://www.allurion.com/role/OrganizationAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombination" roleURI="http://www.allurion.com/role/BusinessCombination" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#Revenue" roleURI="http://www.allurion.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#Inventory" roleURI="http://www.allurion.com/role/Inventory" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNet" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#Debt" roleURI="http://www.allurion.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOption" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurements" roleURI="http://www.allurion.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxes" roleURI="http://www.allurion.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficit" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficit" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShare" roleURI="http://www.allurion.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensation" roleURI="http://www.allurion.com/role/StockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#EmployeeBenefitPlan" roleURI="http://www.allurion.com/role/EmployeeBenefitPlan" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingencies" roleURI="http://www.allurion.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#GeographicInformation" roleURI="http://www.allurion.com/role/GeographicInformation" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RelatedPartyTransactions" roleURI="http://www.allurion.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SubsequentEvents" roleURI="http://www.allurion.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationTables" roleURI="http://www.allurion.com/role/BusinessCombinationTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueTables" roleURI="http://www.allurion.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#InventoryTables" roleURI="http://www.allurion.com/role/InventoryTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtTables" roleURI="http://www.allurion.com/role/DebtTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionTables" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsTables" roleURI="http://www.allurion.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesTables" roleURI="http://www.allurion.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitTables" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitTables" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareTables" roleURI="http://www.allurion.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationTables" roleURI="http://www.allurion.com/role/StockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#GeographicInformationTables" roleURI="http://www.allurion.com/role/GeographicInformationTables" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#OrganizationAndBasisOfPresentationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails" roleURI="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" roleURI="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RevenueAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueScheduleOfRevenuesByGeographicRegionDetails" roleURI="http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#InventoryScheduleOfInventoryDetails" roleURI="http://www.allurion.com/role/InventoryScheduleOfInventoryDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#InventoryAdditionalInformationDetails" roleURI="http://www.allurion.com/role/InventoryAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" roleURI="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtSummaryOfComponentsOfThirdPartyDebtDetails" roleURI="http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtAdditionalInformationDetails" roleURI="http://www.allurion.com/role/DebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" roleURI="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" roleURI="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails" roleURI="http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails" roleURI="http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#IncomeTaxesSummaryOfValuationAllowanceDetails" roleURI="http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfChangesInFairValuesDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails" roleURI="http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitAdditionalInformationDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" roleURI="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails" roleURI="http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationScheduleOfStockBasedCompensationDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails" roleURI="http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails" roleURI="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails" roleURI="http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="alur-20240930.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_146" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_2963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_146" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_2963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_2964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_2963" xlink:to="loc_dei_AddressTypeDomain_2964" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_2965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_2964" xlink:to="loc_dei_BusinessContactMember_2965" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_146" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_146" xlink:to="loc_dei_DocumentInformationLineItems_105" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentType_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentFlag_107" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityRegistrantName_112" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityCentralIndexKey_113" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityFilerCategory_119" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntitySmallBusiness_120" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityEmergingGrowthCompany_121" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityExTransitionPeriod_122" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityIncorporationStateCountryCode_126" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_2961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityPrimarySicNumber_2961" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityTaxIdentificationNumber_128" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_2962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_ContactPersonnelName_2962" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressAddressLine1_129" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressCityOrTown_130" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressStateOrProvince_131" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressPostalZipCode_132" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_CityAreaCode_133" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_LocalPhoneNumber_134" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_148" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_148" xlink:to="loc_us-gaap_StatementTable_4380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_4381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4380" xlink:to="loc_srt_RestatementAxis_4381" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_4381" xlink:to="loc_srt_RestatementDomain_4383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_4383" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4380" xlink:to="loc_us-gaap_StatementLineItems_4382" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4382" xlink:to="loc_us-gaap_AssetsAbstract_154" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_AssetsCurrentAbstract_151" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_150" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_156" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_InventoryNet_162" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_151" xlink:to="loc_us-gaap_AssetsCurrent_172" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_157" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_163" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_168" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_154" xlink:to="loc_us-gaap_Assets_173" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4382" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_153" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableCurrent_149" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LongTermDebtCurrent_155" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_161" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_166" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_153" xlink:to="loc_us-gaap_LiabilitiesCurrent_171" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_165" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_170" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_175" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_159" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_178" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_Liabilities_179" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_180" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaap_TemporaryEquityAbstract_4162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_TemporaryEquityAbstract_4162" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_4162" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3050" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_StockholdersEquityAbstract_182" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_PreferredStockValue_152" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_CommonStockValue_158" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_AdditionalPaidInCapital_164" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_169" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_174" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_182" xlink:to="loc_us-gaap_StockholdersEquity_176" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_183" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_185" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables_186" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_3634" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_3768" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_3893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_3893" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3958" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_187" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_PreferredStockSharesIssued_189" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_190" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_191" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_192" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_CommonStockSharesIssued_193" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_185" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_194" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_196" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_198" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_CostOfRevenue_201" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_GrossProfit_204" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_OperatingExpensesAbstract_207" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_SellingAndMarketingExpense_197" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_200" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_207" xlink:to="loc_us-gaap_OperatingExpenses_206" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_OperatingIncomeLoss_209" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="loc_us-gaap_InterestExpenseNonoperating_3258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_InterestExpenseNonoperating_3258" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_202" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfDebt" xlink:label="loc_alur_ChangesInFairValueOfDebt_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_alur_ChangesInFairValueOfDebt_205" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_208" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_210" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_214" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_212" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_218" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_211" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_220" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_215" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_NetIncomeLoss_217" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_219" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_221" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_EarningsPerShareBasic_222" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_EarningsPerShareDiluted_223" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_196" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_225" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_227" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_227" xlink:to="loc_us-gaap_StatementTable_3054" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3054" xlink:to="loc_us-gaap_DebtInstrumentAxis_3070" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3070" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3728" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingDueMember" xlink:label="loc_alur_RevenueInterestFinancingDueMember_3055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3728" xlink:to="loc_alur_RevenueInterestFinancingDueMember_3055" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3728" xlink:to="loc_alur_RtwConvertibleNotesMember_3686" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3054" xlink:to="loc_us-gaap_StatementLineItems_3690" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3690" xlink:to="loc_us-gaap_NetIncomeLoss_228" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3690" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_229" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_230" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2480" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_233" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_233" xlink:to="loc_us-gaap_StatementTable_234" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_238" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_238" xlink:to="loc_us-gaap_EquityComponentDomain_237" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_CommonStockMember_241" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_250" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_237" xlink:to="loc_us-gaap_RetainedEarningsMember_252" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementClassOfStockAxis_242" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_242" xlink:to="loc_us-gaap_ClassOfStockDomain_245" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesA1ConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesA1ConvertiblePreferredStockMember_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_alur_SeriesA1ConvertiblePreferredStockMember_244" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesBConvertiblePreferredStockMember" xlink:label="loc_alur_SeriesBConvertiblePreferredStockMember_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_alur_SeriesBConvertiblePreferredStockMember_249" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockMember" xlink:label="loc_us-gaap_RedeemablePreferredStockMember_3009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_RedeemablePreferredStockMember_3009" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_234" xlink:to="loc_us-gaap_StatementLineItems_247" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockholdersEquity_248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_SharesOutstanding_251" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_253" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_254" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_256" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_257" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_258" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_259" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger_260" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2763" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2802" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_261" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes_262" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes" xlink:label="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes_263" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities" xlink:label="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities_264" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_265" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodValueDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability_266" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability" xlink:label="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability_267" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount_268" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForExerciseOfWarrantsShares" xlink:label="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares_269" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount_270" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares" xlink:label="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares_271" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_272" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_NetIncomeLoss_273" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_StockholdersEquity_274" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_SharesOutstanding_275" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_277" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4288" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_4299" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_247" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4322" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_279" xlink:to="loc_us-gaap_StatementTable_284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_289" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_289" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_280" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_280" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_285" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_280" xlink:to="loc_alur_FortressTermLoanMember_294" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementLineItems_298" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_NetIncomeLoss_287" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashLeaseExpense" xlink:label="loc_alur_NonCashLeaseExpense_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashLeaseExpense_283" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_DepreciationAndAmortization_302" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ShareBasedCompensation_308" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_313" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2654" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_InventoryWriteDown_322" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_alur_ChangeInFairValueOfWarrantLiabilities_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_ChangeInFairValueOfWarrantLiabilities_330" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_332" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption_336" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfEarnOutLiabilities" xlink:label="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_FairValueAdjustmentOfEarnOutLiabilities_337" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_InterestPaidOnDebtRecordedAtFairValue" xlink:label="loc_alur_InterestPaidOnDebtRecordedAtFairValue_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_InterestPaidOnDebtRecordedAtFairValue_338" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAdjustmentOfDebt" xlink:label="loc_alur_FairValueAdjustmentOfDebt_4199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_FairValueAdjustmentOfDebt_4199" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_343" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashInterestExpense" xlink:label="loc_alur_NonCashInterestExpense_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashInterestExpense_339" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashTerminationOfConvertibleNoteSideLetters" xlink:label="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashTerminationOfConvertibleNoteSideLetters_340" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_341" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfIssuanceCostsAssociatedWithWarrants" xlink:label="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants_4249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants_4249" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NonCashIssuanceOfCommonStockForCommitmentShares" xlink:label="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_alur_NonCashIssuanceOfCommonStockForCommitmentShares_342" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_296" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_281" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_292" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_301" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_307" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_312" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_344" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_317" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_290" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_291" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_299" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_300" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_288" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_297" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_305" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromBusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts_310" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_315" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromOptionAndWarrantExercises" xlink:label="loc_alur_ProceedsFromOptionAndWarrantExercises_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromOptionAndWarrantExercises_328" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromEquityLineFinancing" xlink:label="loc_alur_ProceedsFromEquityLineFinancing_4039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_ProceedsFromEquityLineFinancing_4039" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_331" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_4115" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_4120" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_4163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_4163" use="optional" order="50" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfDebt_320" use="optional" order="51" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_324" use="optional" order="52" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentOfDeferredFinancingCosts" xlink:label="loc_alur_PaymentOfDeferredFinancingCosts_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_alur_PaymentOfDeferredFinancingCosts_333" use="optional" order="53" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_306" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_335" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_311" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_316" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_321" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_325" xlink:to="loc_us-gaap_InterestPaidNet_282" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_298" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_295" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IssuanceOfWarrantsInConnectionWithFinancing" xlink:label="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_IssuanceOfWarrantsInConnectionWithFinancing_303" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_309" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfAssumedWarrantLiability" xlink:label="loc_alur_RecognitionOfAssumedWarrantLiability_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_RecognitionOfAssumedWarrantLiability_314" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecognitionOfEarnOutLiabilities" xlink:label="loc_alur_RecognitionOfEarnOutLiabilities_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_RecognitionOfEarnOutLiabilities_319" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_323" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci_327" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci" xlink:label="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci_4048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_329" xlink:to="loc_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci_4048" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1724" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1724" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1725" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1724" xlink:to="loc_us-gaap_RestrictedCash_1726" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList_1735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1724" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList_1735" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1724" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1736" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/OrganizationAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_346" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_346" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_347" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_349" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_349" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_350" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombination">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_352" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_352" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/Revenue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_355" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_355" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/Inventory">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="loc_us-gaap_DisclosureTextBlockAbstract_358" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureTextBlockAbstract_358" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_361" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_361" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_362" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_364" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_364" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/Debt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_367" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_367" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_368" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_370" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock" xlink:label="loc_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_370" xlink:to="loc_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock_371" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_373" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_373" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_376" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_376" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2986" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock" xlink:label="loc_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock_2987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2986" xlink:to="loc_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock_2987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_379" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_379" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_382" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_382" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_385" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_385" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_386" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/EmployeeBenefitPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_388" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_388" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_389" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_391" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/GeographicInformation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_394" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_394" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_395" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_397" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_397" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_398" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_400" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_400" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_401" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_403" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_UseOfEstimates_404" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_DebtPolicyTextBlock_419" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_405" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_MezzanineEquityPolicyTextBlock" xlink:label="loc_alur_MezzanineEquityPolicyTextBlock_3904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_MezzanineEquityPolicyTextBlock_3904" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_406" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_407" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_408" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_409" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_410" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_411" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_412" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_413" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_414" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtIssuanceCostsPolicyTextBlock" xlink:label="loc_alur_DebtIssuanceCostsPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_DebtIssuanceCostsPolicyTextBlock_415" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_416" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsPolicyTextBlock" xlink:label="loc_alur_WarrantsPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_WarrantsPolicyTextBlock_417" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_418" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnoutLiabilityPolicyTextBlock" xlink:label="loc_alur_EarnoutLiabilityPolicyTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_EarnoutLiabilityPolicyTextBlock_420" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock_421" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_422" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_423" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyPolicy" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_424" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_425" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_426" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IntellectualPropertyProsecutionCostsPolicyTextBlock" xlink:label="loc_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock_427" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_428" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_430" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_431" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_432" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_433" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_435" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_435" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_436" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="loc_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_435" xlink:to="loc_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock_437" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_435" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_438" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_440" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_440" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding" xlink:label="loc_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_440" xlink:to="loc_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding_442" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_444" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_444" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_445" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/InventoryTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="loc_us-gaap_TableTextBlock_447" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TableTextBlock_447" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_450" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_450" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_451" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfDepreciationExpenseTableTextBlock" xlink:label="loc_alur_ScheduleOfDepreciationExpenseTableTextBlock_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_450" xlink:to="loc_alur_ScheduleOfDepreciationExpenseTableTextBlock_452" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_454" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_454" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_457" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_457" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_459" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_461" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComponentsOfRevenueInterestFinancingTableTextBlock" xlink:label="loc_alur_ComponentsOfRevenueInterestFinancingTableTextBlock_462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_461" xlink:to="loc_alur_ComponentsOfRevenueInterestFinancingTableTextBlock_462" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_464" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_464" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xlink:to="loc_us-gaap_DebtInstrumentAxis_467" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_467" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_476" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_EarnOutLiabilityMember_468" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_473" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_476" xlink:to="loc_alur_RtwConvertibleNotesMember_3725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xlink:to="loc_us-gaap_FinancialInstrumentAxis_472" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_472" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_469" xlink:to="loc_alur_PublicWarrantsMember_466" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_470" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_465" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_471" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_474" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_475" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_477" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_479" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_479" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_480" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_479" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_481" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_479" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_482" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_479" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_483" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2988" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="loc_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_2989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2988" xlink:to="loc_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_2989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2988" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3040" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_485" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_485" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_506" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_506" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_507" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_506" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_508" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_490" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_492" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_493" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_495" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock" xlink:label="loc_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_495" xlink:to="loc_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock_497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_495" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_499" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock" xlink:label="loc_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_495" xlink:to="loc_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock_500" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/GeographicInformationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_503" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_503" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_504" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_510" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_510" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_522" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_522" xlink:to="loc_us-gaap_EquityComponentDomain_518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_518" xlink:to="loc_us-gaap_CommonStockMember_513" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_528" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_528" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_525" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_TypeOfArrangementAxis_533" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_533" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationAgreementMember" xlink:label="loc_alur_BusinessCombinationAgreementMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_512" xlink:to="loc_alur_BusinessCombinationAgreementMember_511" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_CreditFacilityAxis_536" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_536" xlink:to="loc_us-gaap_CreditFacilityDomain_523" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_dei_LegalEntityAxis_538" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_538" xlink:to="loc_dei_EntityDomain_530" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_DebtInstrumentAxis_540" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_540" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_532" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_srt_RestatementAxis_542" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_542" xlink:to="loc_srt_RestatementDomain_517" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_srt_RangeAxis_3598" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3598" xlink:to="loc_srt_RangeMember_3384" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3384" xlink:to="loc_srt_MaximumMember_3381" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_519" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesInWhichEntityMarketsTheProgram" xlink:label="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_alur_NumberOfCountriesInWhichEntityMarketsTheProgram_521" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationCommonStockExchangeRatio" xlink:label="loc_alur_BusinessCombinationCommonStockExchangeRatio_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_alur_BusinessCombinationCommonStockExchangeRatio_527" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_531" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax" xlink:label="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax_535" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_NetIncomeLoss_537" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_539" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_OperatingIncomeLoss_2672" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_543" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_541" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_545" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_545" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_RangeAxis_560" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_560" xlink:to="loc_srt_RangeMember_554" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_554" xlink:to="loc_srt_MaximumMember_553" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_568" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" xlink:to="loc_us-gaap_SalesRevenueNetMember_556" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_557" xlink:to="loc_us-gaap_AccountsReceivableMember_567" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_571" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_571" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_547" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_564" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_574" xlink:to="loc_us-gaap_TypeOfAdoptionMember_563" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_563" xlink:to="loc_us-gaap_AccountingStandardsUpdate201613Member_561" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_563" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1805" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_MajorCustomersAxis_576" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_576" xlink:to="loc_srt_NameOfMajorCustomerDomain_559" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersMember" xlink:label="loc_alur_CustomersMember_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_559" xlink:to="loc_alur_CustomersMember_558" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_dei_LegalEntityAxis_578" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_578" xlink:to="loc_dei_EntityDomain_572" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NewAllurionMember" xlink:label="loc_alur_NewAllurionMember_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_572" xlink:to="loc_alur_NewAllurionMember_551" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_580" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_580" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_548" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_548" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_565" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_srt_ProductOrServiceAxis_582" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_582" xlink:to="loc_srt_ProductsAndServicesDomain_562" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaap_ShippingAndHandlingMember_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_562" xlink:to="loc_us-gaap_ShippingAndHandlingMember_555" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_TypeOfArrangementAxis_584" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_584" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_549" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_546" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_552" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_550" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_DeferredOfferingCosts_566" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable" xlink:label="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable_570" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_SellingAndMarketingExpense_573" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaap_MarketingAndAdvertisingExpense_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_MarketingAndAdvertisingExpense_575" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_577" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_581" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_PercentageOfAnnualNetSales_583" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_585" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesNetOfInterestExpense" xlink:label="loc_us-gaap_RevenuesNetOfInterestExpense_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_RevenuesNetOfInterestExpense_587" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_591" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_592" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_586" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_593" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_595" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_595" xlink:to="loc_us-gaap_ConcentrationRiskTable_598" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_603" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" xlink:to="loc_us-gaap_SalesRevenueNetMember_599" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_600" xlink:to="loc_us-gaap_AccountsReceivableMember_605" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_607" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_607" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_596" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_596" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_604" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_srt_MajorCustomersAxis_609" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_609" xlink:to="loc_srt_NameOfMajorCustomerDomain_602" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerAMember" xlink:label="loc_alur_CustomerAMember_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerAMember_601" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerBMember" xlink:label="loc_alur_CustomerBMember_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerBMember_606" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomerCMember" xlink:label="loc_alur_CustomerCMember_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomerCMember_608" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CustomersDMember" xlink:label="loc_alur_CustomersDMember_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_602" xlink:to="loc_alur_CustomersDMember_610" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_598" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_611" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_611" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_597" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_613" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_613" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_613" xlink:to="loc_us-gaap_RestrictedCash_615" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_613" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList_616" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_613" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_617" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_619" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_620" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_619" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_621" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_619" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_622" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_619" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_623" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_625" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_625" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_StatementClassOfStockAxis_627" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_627" xlink:to="loc_us-gaap_ClassOfStockDomain_655" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_655" xlink:to="loc_us-gaap_CommonClassAMember_628" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_655" xlink:to="loc_us-gaap_CommonClassBMember_648" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_647" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_647" xlink:to="loc_us-gaap_EquityComponentDomain_637" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_637" xlink:to="loc_us-gaap_CommonStockMember_630" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_654" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_654" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeSubscriptionAgreementsMember" xlink:label="loc_alur_PipeSubscriptionAgreementsMember_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_645" xlink:to="loc_alur_PipeSubscriptionAgreementsMember_639" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_TypeOfArrangementAxis_660" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_660" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationAgreementMember" xlink:label="loc_alur_BusinessCombinationAgreementMember_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_BusinessCombinationAgreementMember_626" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_646" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedAndRestatedRtwSideLetterMember" xlink:label="loc_alur_AmendedAndRestatedRtwSideLetterMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_AmendedAndRestatedRtwSideLetterMember_653" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressCreditAgreementMember" xlink:label="loc_alur_FortressCreditAgreementMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_FortressCreditAgreementMember_659" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BackstopAgreementMember" xlink:label="loc_alur_BackstopAgreementMember_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_BackstopAgreementMember_662" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLTerminationAgreementMember" xlink:label="loc_alur_HVLTerminationAgreementMember_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_HVLTerminationAgreementMember_665" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GaurContributionAgreementMember" xlink:label="loc_alur_GaurContributionAgreementMember_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_GaurContributionAgreementMember_668" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RSUForfeitureAgreementMember" xlink:label="loc_alur_RSUForfeitureAgreementMember_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_RSUForfeitureAgreementMember_671" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorContributionAgreementMember" xlink:label="loc_alur_SponsorContributionAgreementMember_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_SponsorContributionAgreementMember_674" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorSupportAgreementMember" xlink:label="loc_alur_SponsorSupportAgreementMember_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_629" xlink:to="loc_alur_SponsorSupportAgreementMember_677" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_663" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_663" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_642" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_642" xlink:to="loc_us-gaap_ConvertibleDebtMember_631" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_dei_LegalEntityAxis_666" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_666" xlink:to="loc_dei_EntityDomain_657" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_657" xlink:to="loc_alur_ComputeHealthMember_632" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NewAllurionMember" xlink:label="loc_alur_NewAllurionMember_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_657" xlink:to="loc_alur_NewAllurionMember_649" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_669" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_669" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_658" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_658" xlink:to="loc_alur_PublicWarrantsMember_640" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantAmendmentMember" xlink:label="loc_alur_WarrantAmendmentMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_658" xlink:to="loc_alur_WarrantAmendmentMember_652" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_CreditFacilityAxis_672" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_672" xlink:to="loc_us-gaap_CreditFacilityDomain_644" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_644" xlink:to="loc_alur_FortressTermLoanMember_636" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanFacilityMember" xlink:label="loc_alur_TermLoanFacilityMember_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_644" xlink:to="loc_alur_TermLoanFacilityMember_650" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_675" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_641" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_641" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_643" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_srt_RangeAxis_678" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_678" xlink:to="loc_srt_RangeMember_635" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_635" xlink:to="loc_srt_MaximumMember_634" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4173" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4173" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3174" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3174" xlink:to="loc_us-gaap_SubsequentEventMember_3158" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_633" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_680" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationCommonStockExchangeRatio" xlink:label="loc_alur_BusinessCombinationCommonStockExchangeRatio_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_BusinessCombinationCommonStockExchangeRatio_638" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SponsorLoanExcessAmount" xlink:label="loc_alur_SponsorLoanExcessAmount_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_SponsorLoanExcessAmount_651" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_656" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_661" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_664" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_667" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ProceedsFromRevenueInterestFinancing" xlink:label="loc_alur_ProceedsFromRevenueInterestFinancing_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ProceedsFromRevenueInterestFinancing_670" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_PercentageOfAnnualNetSales_676" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_679" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_681" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_682" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_683" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_684" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ContributionOfCapitalByJointVenturePartner" xlink:label="loc_alur_ContributionOfCapitalByJointVenturePartner_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ContributionOfCapitalByJointVenturePartner_685" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_686" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfCommonStock" xlink:label="loc_alur_RecapitalizationOfCommonStock_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RecapitalizationOfCommonStock_687" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_688" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_689" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RecapitalizationOfAdditionalShares" xlink:label="loc_alur_RecapitalizationOfAdditionalShares_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_RecapitalizationOfAdditionalShares_690" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_691" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_692" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_693" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_694" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_695" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_AdditionalPaidInCapital_696" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_697" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationOneTimeInsurancePayment" xlink:label="loc_alur_BusinessCombinationOneTimeInsurancePayment_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_BusinessCombinationOneTimeInsurancePayment_698" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DirectCostsAndFees" xlink:label="loc_alur_DirectCostsAndFees_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_DirectCostsAndFees_700" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_701" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_702" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_703" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_704" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_705" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4158" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfSurrenderSharesOfCommonStock" xlink:label="loc_alur_NumberOfSurrenderSharesOfCommonStock_4196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_NumberOfSurrenderSharesOfCommonStock_4196" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SurrenderCommonStockValue" xlink:label="loc_alur_SurrenderCommonStockValue_4204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_680" xlink:to="loc_alur_SurrenderCommonStockValue_4204" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_707" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_707" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" xlink:to="loc_us-gaap_TypeOfArrangementAxis_709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_709" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" xlink:to="loc_alur_ComputeHealthMember_708" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeInvestorsMember" xlink:label="loc_alur_PipeInvestorsMember_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_710" xlink:to="loc_alur_PipeInvestorsMember_713" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_711" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_714" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_GrossProceedsFromBusinessCombination" xlink:label="loc_alur_GrossProceedsFromBusinessCombination_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_GrossProceedsFromBusinessCombination_712" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationTransactionCostPaid" xlink:label="loc_alur_BusinessCombinationTransactionCostPaid_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessCombinationTransactionCostPaid_715" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromBusinessCombination" xlink:label="loc_alur_NetProceedsFromBusinessCombination_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_NetProceedsFromBusinessCombination_716" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiabilitiesAssumed" xlink:label="loc_alur_WarrantLiabilitiesAssumed_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_WarrantLiabilitiesAssumed_717" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfNoteAssumedInBusinessCombination" xlink:label="loc_alur_RepaymentOfNoteAssumedInBusinessCombination_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_RepaymentOfNoteAssumedInBusinessCombination_718" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessAcquisitionAccruedTransactionCosts" xlink:label="loc_alur_BusinessAcquisitionAccruedTransactionCosts_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessAcquisitionAccruedTransactionCosts_719" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BusinessCombinationNetOfTransactionCosts" xlink:label="loc_alur_BusinessCombinationNetOfTransactionCosts_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_714" xlink:to="loc_alur_BusinessCombinationNetOfTransactionCosts_720" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_722" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_722" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" xlink:to="loc_us-gaap_TypeOfArrangementAxis_724" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_724" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionEquityholdersMember" xlink:label="loc_alur_LegacyAllurionEquityholdersMember_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_LegacyAllurionEquityholdersMember_723" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthMember" xlink:label="loc_alur_ComputeHealthMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ComputeHealthMember_728" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeInvestorsMember" xlink:label="loc_alur_PipeInvestorsMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_PipeInvestorsMember_730" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwAndFortressMember" xlink:label="loc_alur_RtwAndFortressMember_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_RtwAndFortressMember_731" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteHoldersMember" xlink:label="loc_alur_ConvertibleNoteHoldersMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ConvertibleNoteHoldersMember_732" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthSponsorSharesMember" xlink:label="loc_alur_ComputeHealthSponsorSharesMember_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_ComputeHealthSponsorSharesMember_733" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterTerminationSharesMember" xlink:label="loc_alur_SideLetterTerminationSharesMember_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_725" xlink:to="loc_alur_SideLetterTerminationSharesMember_734" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_726" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_729" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_729" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_727" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_748" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_748" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_756" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_srt_StatementGeographicalAxis_752" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_752" xlink:to="loc_srt_SegmentGeographicalDomain_749" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_country_US_751" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EachCountryMember" xlink:label="loc_alur_EachCountryMember_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_EachCountryMember_760" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AllOtherCountriesMember" xlink:label="loc_alur_AllOtherCountriesMember_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_AllOtherCountriesMember_764" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FourCountriesIncludedWithinAllOtherCountriesMember" xlink:label="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_749" xlink:to="loc_alur_FourCountriesIncludedWithinAllOtherCountriesMember_767" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_761" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_757" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_755" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_765" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_765" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_750" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_758" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_srt_RangeAxis_768" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_768" xlink:to="loc_srt_RangeMember_754" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_754" xlink:to="loc_srt_MinimumMember_753" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_754" xlink:to="loc_srt_MaximumMember_762" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_756" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_771" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_759" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_763" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenue" xlink:label="loc_alur_NumberOfCountriesGenerateRevenue_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_alur_NumberOfCountriesGenerateRevenue_766" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfCountriesGenerateRevenueBySales" xlink:label="loc_alur_NumberOfCountriesGenerateRevenueBySales_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_771" xlink:to="loc_alur_NumberOfCountriesGenerateRevenueBySales_769" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_736" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_736" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_740" xlink:to="loc_srt_StatementGeographicalAxis_739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_739" xlink:to="loc_srt_SegmentGeographicalDomain_737" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_ES" xlink:label="loc_country_ES_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_ES_744" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="loc_country_GB_2303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_GB_2303" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="loc_country_FR_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_FR_738" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_TRY" xlink:label="loc_currency_TRY_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_currency_TRY_742" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU" xlink:label="loc_country_AU_3953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_AU_3953" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IT" xlink:label="loc_country_IT_4025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_IT_4025" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CL" xlink:label="loc_country_CL_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_country_CL_745" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AllOtherCountriesMember" xlink:label="loc_alur_AllOtherCountriesMember_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_737" xlink:to="loc_alur_AllOtherCountriesMember_746" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_740" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_743" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_743" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_741" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/InventoryScheduleOfInventoryDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGrossAbstract" xlink:label="loc_us-gaap_InventoryGrossAbstract_773" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_773" xlink:to="loc_us-gaap_InventoryFinishedGoods_774" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_773" xlink:to="loc_us-gaap_InventoryWorkInProcess_775" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_773" xlink:to="loc_us-gaap_InventoryRawMaterials_776" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_773" xlink:to="loc_us-gaap_InventoryNet_777" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/InventoryAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_779" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_779" xlink:to="loc_us-gaap_InventoryCurrentTable_782" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_782" xlink:to="loc_srt_RangeAxis_784" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_784" xlink:to="loc_srt_RangeMember_781" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_781" xlink:to="loc_srt_MaximumMember_780" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_782" xlink:to="loc_us-gaap_InventoryLineItems_785" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaap_InventoryValuationReserves_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_785" xlink:to="loc_us-gaap_InventoryValuationReserves_783" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_787" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_787" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_794" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputersAndPurchasedSoftwareMember" xlink:label="loc_alur_ComputersAndPurchasedSoftwareMember_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_alur_ComputersAndPurchasedSoftwareMember_793" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_797" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_800" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_792" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_803" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xlink:to="loc_srt_RangeAxis_798" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_798" xlink:to="loc_srt_RangeMember_790" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_790" xlink:to="loc_srt_MinimumMember_789" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_790" xlink:to="loc_srt_MaximumMember_795" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_788" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_791" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_796" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_799" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConstructionInProgress" xlink:label="loc_alur_ConstructionInProgress_3865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_alur_ConstructionInProgress_3865" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4385" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_806" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_806" xlink:to="loc_us-gaap_Depreciation_807" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_809" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_809" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_814" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_814" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_812" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_CostOfSalesMember_813" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_815" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_817" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_812" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_818" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_810" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_2177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_816" xlink:to="loc_us-gaap_DepreciationAndAmortization_2177" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_820" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DistributorFeesAndMarketingReimbursements" xlink:label="loc_alur_DistributorFeesAndMarketingReimbursements_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_alur_DistributorFeesAndMarketingReimbursements_821" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:label="loc_us-gaap_WorkersCompensationLiabilityCurrent_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_WorkersCompensationLiabilityCurrent_822" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedClinicalTrialsAndResearchAndDevelopment" xlink:label="loc_alur_AccruedClinicalTrialsAndResearchAndDevelopment_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_alur_AccruedClinicalTrialsAndResearchAndDevelopment_823" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_824" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_825" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_InterestPayableCurrent_826" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StandardProductWarrantyAccrualCurrent" xlink:label="loc_us-gaap_StandardProductWarrantyAccrualCurrent_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_StandardProductWarrantyAccrualCurrent_827" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AccruedRestructuringCurrent" xlink:label="loc_alur_AccruedRestructuringCurrent_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_alur_AccruedRestructuringCurrent_828" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_829" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_820" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_830" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_832" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_832" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" xlink:to="loc_srt_RangeAxis_2187" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2187" xlink:to="loc_srt_RangeMember_2186" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2186" xlink:to="loc_srt_MaximumMember_2185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2184" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_2183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" xlink:to="loc_us-gaap_RestructuringCharges_2183" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_2279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_2280" xlink:to="loc_us-gaap_PaymentsForRestructuring_2279" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_836" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_836" xlink:to="loc_us-gaap_DebtInstrumentTable_838" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_838" xlink:to="loc_us-gaap_CreditFacilityAxis_837" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_837" xlink:to="loc_us-gaap_CreditFacilityDomain_843" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_843" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_840" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_843" xlink:to="loc_alur_FortressTermLoanMember_845" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_838" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_844" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_844" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_842" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_842" xlink:to="loc_us-gaap_ConvertibleDebtMember_839" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_842" xlink:to="loc_alur_RtwConvertibleNotesMember_3648" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_838" xlink:to="loc_us-gaap_DebtInstrumentLineItems_847" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_841" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfDebt" xlink:label="loc_alur_ChangeInFairValueOfDebt_3757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_alur_ChangeInFairValueOfDebt_3757" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LoanAccretion" xlink:label="loc_alur_LoanAccretion_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_alur_LoanAccretion_846" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_LongTermDebtCurrent_848" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_849" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_847" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_850" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_852" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_852" xlink:to="loc_us-gaap_DebtInstrumentTable_859" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_CreditFacilityAxis_854" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_854" xlink:to="loc_us-gaap_CreditFacilityDomain_867" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanMember_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanMember_873" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermCLoanMember" xlink:label="loc_alur_TermCLoanMember_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TermCLoanMember_881" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermDLoanMember" xlink:label="loc_alur_TermDLoanMember_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_TermDLoanMember_888" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_867" xlink:to="loc_alur_FortressTermLoanMember_898" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_DebtInstrumentAxis_868" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_868" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_883" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyOneTermLoanAgreementMember_863" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember" xlink:label="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember_880" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressCreditAgreementMember" xlink:label="loc_alur_FortressCreditAgreementMember_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_FortressCreditAgreementMember_887" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressAmendmentMember" xlink:label="loc_alur_FortressAmendmentMember_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_FortressAmendmentMember_892" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyOneConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyOneConvertibleNotesMember_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyOneConvertibleNotesMember_920" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyTwoConvertibleNotesMember_922" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_924" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SideLetterHolderBridgeNoteMember" xlink:label="loc_alur_SideLetterHolderBridgeNoteMember_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_SideLetterHolderBridgeNoteMember_926" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NotePurchaseAgreementMember" xlink:label="loc_alur_NotePurchaseAgreementMember_3780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_NotePurchaseAgreementMember_3780" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HVLBridgeNoteMember" xlink:label="loc_alur_HVLBridgeNoteMember_4097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_883" xlink:to="loc_alur_HVLBridgeNoteMember_4097" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_876" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_876" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RunwayGrowthCreditFundIncMember" xlink:label="loc_alur_RunwayGrowthCreditFundIncMember_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_855" xlink:to="loc_alur_RunwayGrowthCreditFundIncMember_866" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_TypeOfArrangementAxis_884" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_884" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BackstopAgreementMember" xlink:label="loc_alur_BackstopAgreementMember_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_858" xlink:to="loc_alur_BackstopAgreementMember_853" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_RangeAxis_890" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_890" xlink:to="loc_srt_RangeMember_862" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_862" xlink:to="loc_srt_MinimumMember_861" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_862" xlink:to="loc_srt_MaximumMember_871" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_StatementClassOfStockAxis_895" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_895" xlink:to="loc_us-gaap_ClassOfStockDomain_879" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockMember_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockMember_877" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_us-gaap_CommonStockMember_885" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesD1PreferredStockMember" xlink:label="loc_alur_SeriesD1PreferredStockMember_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_879" xlink:to="loc_alur_SeriesD1PreferredStockMember_891" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_StatementScenarioAxis_900" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_900" xlink:to="loc_srt_ScenarioUnspecifiedDomain_860" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UntilMarch312024Member" xlink:label="loc_alur_UntilMarch312024Member_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_UntilMarch312024Member_857" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromApril12024ToJune302024Member" xlink:label="loc_alur_FromApril12024ToJune302024Member_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_FromApril12024ToJune302024Member_870" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FromJuly12024ToSeptember302024Member" xlink:label="loc_alur_FromJuly12024ToSeptember302024Member_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_FromJuly12024ToSeptember302024Member_878" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OnOctober12024AndThereafterMember" xlink:label="loc_alur_OnOctober12024AndThereafterMember_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_860" xlink:to="loc_alur_OnOctober12024AndThereafterMember_886" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3778" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3778" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3311" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3311" xlink:to="loc_alur_RtwConvertibleNotesMember_3309" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_4392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_srt_RestatementAxis_4392" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_4393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_4392" xlink:to="loc_srt_RestatementDomain_4393" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_4394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_4393" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_4394" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859" xlink:to="loc_us-gaap_DebtInstrumentLineItems_904" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_865" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AdditionalBorrowings" xlink:label="loc_alur_AdditionalBorrowings_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_AdditionalBorrowings_874" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds" xlink:label="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds_882" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationDate1_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationDate1_889" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1" xlink:label="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1_894" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestExpenseDebt_903" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_907" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_909" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanAccretion" xlink:label="loc_alur_TermLoanAccretion_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_TermLoanAccretion_911" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_913" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_915" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_917" use="optional" order="59" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_919" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_921" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitPaymentPercentage" xlink:label="loc_alur_DebtInstrumentExitPaymentPercentage_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentExitPaymentPercentage_923" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_925" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExercisableWarrantsIssuedAsConsideration" xlink:label="loc_alur_ExercisableWarrantsIssuedAsConsideration_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ExercisableWarrantsIssuedAsConsideration_927" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfTheWarrants" xlink:label="loc_alur_FairValueOfTheWarrants_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FairValueOfTheWarrants_929" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_931" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_933" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_935" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantLiability" xlink:label="loc_alur_WarrantLiability_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_WarrantLiability_936" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_937" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RepaymentOfPrincipal" xlink:label="loc_alur_RepaymentOfPrincipal_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_RepaymentOfPrincipal_938" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFee" xlink:label="loc_alur_PrepaymentFee_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PrepaymentFee_939" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFee" xlink:label="loc_alur_FinalPaymentFee_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FinalPaymentFee_940" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrepaymentFeePercentage" xlink:label="loc_alur_PrepaymentFeePercentage_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PrepaymentFeePercentage_941" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OriginalFinalPayment" xlink:label="loc_alur_OriginalFinalPayment_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_OriginalFinalPayment_942" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FinalPaymentFeePercentage" xlink:label="loc_alur_FinalPaymentFeePercentage_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_FinalPaymentFeePercentage_943" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmortizationOfTheWarrant" xlink:label="loc_alur_AmortizationOfTheWarrant_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_AmortizationOfTheWarrant_944" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_945" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentTerm_946" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_947" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByDiscountedCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByDiscountedCappedConversionPrice_948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ConversionDividedByDiscountedCappedConversionPrice_948" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_949" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionDividedByCappedConversionPrice" xlink:label="loc_alur_ConversionDividedByCappedConversionPrice_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ConversionDividedByCappedConversionPrice_950" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CappedPrice" xlink:label="loc_alur_CappedPrice_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_CappedPrice_951" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_952" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_953" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice" xlink:label="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice_954" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_MinimumLiquidityAmount" xlink:label="loc_alur_MinimumLiquidityAmount_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_MinimumLiquidityAmount_955" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentInterestRateIncreaseEventOfDefault" xlink:label="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentInterestRateIncreaseEventOfDefault_956" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentDefaultInterestRate" xlink:label="loc_alur_DebtInstrumentDefaultInterestRate_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentDefaultInterestRate_957" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_958" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_959" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities" xlink:label="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities_960" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredLiabilityForIssuanceOfAdditionalShares" xlink:label="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DeferredLiabilityForIssuanceOfAdditionalShares_961" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_963" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_964" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_965" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2030" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentExitFee" xlink:label="loc_alur_DebtInstrumentExitFee_4230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentExitFee_4230" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaap_PaymentsForFees_4245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_PaymentsForFees_4245" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_4252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_InterestReceivable_4252" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4362" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_4365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_4365" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_4366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_4366" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_4370" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_4371" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_4372" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock" xlink:label="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock_4373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock_4373" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4374" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger" xlink:label="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger_4375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger_4375" use="optional" order="110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding" xlink:label="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding_4377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding_4377" use="optional" order="111" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnrestrictedCash" xlink:label="loc_alur_UnrestrictedCash_4378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_904" xlink:to="loc_alur_UnrestrictedCash_4378" use="optional" order="112" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_967" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_967" xlink:to="loc_us-gaap_DebtInstrumentTable_969" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_969" xlink:to="loc_us-gaap_CreditFacilityAxis_968" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_968" xlink:to="loc_us-gaap_CreditFacilityDomain_972" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_972" xlink:to="loc_alur_FortressTermLoanMember_970" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_969" xlink:to="loc_us-gaap_DebtInstrumentLineItems_973" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_977" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_978" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_973" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_980" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_982" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_982" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_us-gaap_TypeOfArrangementAxis_992" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_992" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementAmendmentMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementAmendmentMember_3639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_985" xlink:to="loc_alur_RevenueInterestFinancingAgreementAmendmentMember_3639" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_us-gaap_DebtInstrumentAxis_997" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_997" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_999" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PIPEConversionOptionMember" xlink:label="loc_alur_PIPEConversionOptionMember_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_999" xlink:to="loc_alur_PIPEConversionOptionMember_989" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_srt_RangeAxis_1000" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1000" xlink:to="loc_srt_RangeMember_988" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_988" xlink:to="loc_srt_MaximumMember_987" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_988" xlink:to="loc_srt_MinimumMember_994" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_991" xlink:to="loc_srt_StatementScenarioAxis_1002" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1002" xlink:to="loc_srt_ScenarioUnspecifiedDomain_986" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanOneMember" xlink:label="loc_alur_ScenarioPlanOneMember_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_alur_ScenarioPlanOneMember_984" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanTwoMember" xlink:label="loc_alur_ScenarioPlanTwoMember_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_alur_ScenarioPlanTwoMember_993" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_3763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_986" xlink:to="loc_srt_ScenarioForecastMember_3763" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_982" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_alur_RevenuesInterestFinancingLiability_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenuesInterestFinancingLiability_990" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfAnnualNetSales" xlink:label="loc_alur_PercentageOfAnnualNetSales_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfAnnualNetSales_995" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemittanceOfRevenueInterestPaymentsPercentage" xlink:label="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RemittanceOfRevenueInterestPaymentsPercentage_998" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestPaymentsPercentage" xlink:label="loc_alur_RevenueInterestPaymentsPercentage_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenueInterestPaymentsPercentage_1001" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CashPaymentsPercentage" xlink:label="loc_alur_CashPaymentsPercentage_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_CashPaymentsPercentage_1003" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrePaymentsPercentage" xlink:label="loc_alur_PrePaymentsPercentage_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PrePaymentsPercentage_1004" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangesInFairValueOfRevenueInterestFinancing" xlink:label="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ChangesInFairValueOfRevenueInterestFinancing_1005" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_1006" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RoyaltyPayments" xlink:label="loc_alur_RoyaltyPayments_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RoyaltyPayments_1007" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_1008" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_VolumeWeightedAveragePricePerShare" xlink:label="loc_alur_VolumeWeightedAveragePricePerShare_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_VolumeWeightedAveragePricePerShare_1009" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_SharePrice_1010" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeSubscriptionToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance_1011" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1012" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1013" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfNetSales" xlink:label="loc_alur_PercentageOfNetSales_4022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfNetSales_4022" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SalesRevenueNet" xlink:label="loc_alur_SalesRevenueNet_4060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_SalesRevenueNet_4060" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseInSalesRevenueNet" xlink:label="loc_alur_IncreaseInSalesRevenueNet_4103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_IncreaseInSalesRevenueNet_4103" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfIncreaseInNetSales" xlink:label="loc_alur_PercentageOfIncreaseInNetSales_4129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfIncreaseInNetSales_4129" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfRevenueInterestFinancingAgreements" xlink:label="loc_alur_FairValueOfRevenueInterestFinancingAgreements_4155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_FairValueOfRevenueInterestFinancingAgreements_4155" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfPipeConversionOption" xlink:label="loc_alur_FairValueOfPipeConversionOption_4175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_FairValueOfPipeConversionOption_4175" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementRemeasuredValue" xlink:label="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue_4193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_RevenueInterestFinancingAgreementRemeasuredValue_4193" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionOptionRemeasuredValue" xlink:label="loc_alur_PipeConversionOptionRemeasuredValue_4206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PipeConversionOptionRemeasuredValue_4206" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfInternalRateOfReturn" xlink:label="loc_alur_PercentageOfInternalRateOfReturn_4244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_PercentageOfInternalRateOfReturn_4244" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_996" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_4303" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_1015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_1015" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1020" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1020" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1017" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_1016" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1019" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenuesInterestFinancingLiability" xlink:label="loc_alur_RevenuesInterestFinancingLiability_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenuesInterestFinancingLiability_1018" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt" xlink:label="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt_1021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RoyaltyPayments" xlink:label="loc_alur_RoyaltyPayments_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RoyaltyPayments_1023" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChangeInFairValueOfDebt" xlink:label="loc_alur_ChangeInFairValueOfDebt_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_ChangeInFairValueOfDebt_1024" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingLiabilityNoncurrent" xlink:label="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1022" xlink:to="loc_alur_RevenueInterestFinancingLiabilityNoncurrent_1025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1195" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1195" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1196" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1195" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1197" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1195" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1198" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1201" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1202" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments" xlink:label="loc_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments_1203" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1205" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1206" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1207" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1208" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1200" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1209" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1212" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1213" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1214" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_1215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_alur_DeferredTaxAssetsLeaseLiabilities_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_alur_DeferredTaxAssetsLeaseLiabilities_1216" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsDepreciation" xlink:label="loc_alur_DeferredTaxAssetsDepreciation_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_alur_DeferredTaxAssetsDepreciation_1217" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_1218" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1219" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1220" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1221" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1222" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1223" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_1224" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1225" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1211" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1226" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1228" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1228" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1237" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_srt_RangeAxis_1229" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1229" xlink:to="loc_srt_RangeMember_1232" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1232" xlink:to="loc_srt_MaximumMember_1239" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_us-gaap_TaxPeriodAxis_1238" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_1238" xlink:to="loc_us-gaap_TaxPeriodDomain_1230" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember" xlink:label="loc_us-gaap_EarliestTaxYearMember_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_us-gaap_EarliestTaxYearMember_1235" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember" xlink:label="loc_us-gaap_LatestTaxYearMember_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_us-gaap_LatestTaxYearMember_1242" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LatestTaxYearTwoThousandFortyTwoMember" xlink:label="loc_alur_LatestTaxYearTwoThousandFortyTwoMember_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_LatestTaxYearTwoThousandFortyTwoMember_1245" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember" xlink:label="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember_1248" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DoNotExpireMember" xlink:label="loc_alur_DoNotExpireMember_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_1230" xlink:to="loc_alur_DoNotExpireMember_1250" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1243" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1243" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1236" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1236" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1234" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1236" xlink:to="loc_us-gaap_DomesticCountryMember_1241" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1237" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1233" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1240" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1244" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1247" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod" xlink:label="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod_1249" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopment" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_TaxCreditCarryForwardsResearchAndDevelopment_1251" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear" xlink:label="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear_1252" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1253" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1246" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1254" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="loc_us-gaap_ValuationAllowanceAbstract_1256" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_1256" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1257" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_1256" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1258" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_1256" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1259" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1183" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1183" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" xlink:to="loc_us-gaap_DebtInstrumentAxis_1186" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1192" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_EarnOutLiabilityMember_1189" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1192" xlink:to="loc_alur_RtwConvertibleNotesMember_3821" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1187" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_SharePrice_1184" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1188" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1191" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1190" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1193" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1150" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1150" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1157" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1157" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1156" xlink:to="loc_alur_PublicWarrantsMember_1151" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_DebtInstrumentAxis_1163" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1163" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingMember" xlink:label="loc_alur_RevenueInterestFinancingMember_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_RevenueInterestFinancingMember_1154" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PipeConversionDerivativeMember" xlink:label="loc_alur_PipeConversionDerivativeMember_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_PipeConversionDerivativeMember_1162" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_EarnOutLiabilityMember_1166" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1168" xlink:to="loc_alur_RtwConvertibleNotesMember_3842" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1167" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1167" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SuccessFeeDerivativeLiabilityMember" xlink:label="loc_alur_SuccessFeeDerivativeLiabilityMember_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_SuccessFeeDerivativeLiabilityMember_1159" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1165" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoShareLiabilityMember" xlink:label="loc_alur_PubcoShareLiabilityMember_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_PubcoShareLiabilityMember_1170" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoAndBackstopShareLiabilityMember_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_BasePubcoAndBackstopShareLiabilityMember_1173" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1176" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1153" xlink:to="loc_alur_PublicOfferingWarrantsMember_3894" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3892" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3522" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3231" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1171" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1171" xlink:to="loc_us-gaap_EquityComponentDomain_1155" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockWarrantsMember" xlink:label="loc_alur_PreferredStockWarrantsMember_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1155" xlink:to="loc_alur_PreferredStockWarrantsMember_1152" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommonStockWarrantsMember" xlink:label="loc_alur_CommonStockWarrantsMember_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1155" xlink:to="loc_alur_CommonStockWarrantsMember_1161" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1160" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1158" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_1164" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1169" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_1172" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_1175" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants_1177" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt_1178" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_1179" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability" xlink:label="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability_1180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability_1180" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1174" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1181" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1108" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1108" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_DebtInstrumentAxis_1118" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1133" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandNineteenTermLoanAndSuccessFeeMember" xlink:label="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_TwoThousandNineteenTermLoanAndSuccessFeeMember_1115" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1131" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAndPipeConversionOptionMember" xlink:label="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_RevenueInterestFinancingAndPipeConversionOptionMember_1136" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_3862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1133" xlink:to="loc_alur_RtwConvertibleNotesMember_3862" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1128" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PubcoAdditionalSharesLiabilityMember" xlink:label="loc_alur_PubcoAdditionalSharesLiabilityMember_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_PubcoAdditionalSharesLiabilityMember_1134" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BasePubcoSharesAndBackstopShareLiabilityMember" xlink:label="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_BasePubcoSharesAndBackstopShareLiabilityMember_1138" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1113" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1144" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1132" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1132" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1114" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1114" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1110" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1114" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_1125" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1137" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1124" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1116" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1140" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1140" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1122" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1122" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1111" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1143" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1143" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1119" xlink:to="loc_alur_PublicWarrantsMember_1109" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_CreditFacilityAxis_1146" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1146" xlink:to="loc_us-gaap_CreditFacilityDomain_1121" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FortressTermLoanMember" xlink:label="loc_alur_FortressTermLoanMember_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1121" xlink:to="loc_alur_FortressTermLoanMember_1117" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1123" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1112" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssumptionsOfLiquidityEventTerm" xlink:label="loc_alur_FairValueAssumptionsOfLiquidityEventTerm_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueAssumptionsOfLiquidityEventTerm_1126" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_1130" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_LineOfCredit_1135" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1139" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedNumberOfShares" xlink:label="loc_alur_FairValueOfEstimatedNumberOfShares_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueOfEstimatedNumberOfShares_1142" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueOfEstimatedPriceOfShares" xlink:label="loc_alur_FairValueOfEstimatedPriceOfShares_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_alur_FairValueOfEstimatedPriceOfShares_1145" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_SharePrice_1147" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1148" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4077" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1069" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1069" xlink:to="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1074" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1074" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1080" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1080" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1073" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1087" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1083" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1078" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1093" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1093" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1075" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1072" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_1086" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_1092" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_1095" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1075" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1098" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1096" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1096" xlink:to="loc_us-gaap_ClassOfStockDomain_1091" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember_1070" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantsMember_1090" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesCCommonStockWarrantsMember_1097" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantsMember_1102" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1091" xlink:to="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember_1105" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4033" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4033" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3123" xlink:to="loc_alur_PublicOfferingWarrantsMember_3108" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4051" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3124" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3114" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1099" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1099" xlink:to="loc_us-gaap_EquityComponentDomain_1079" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockMember" xlink:label="loc_alur_OtherCommonStockMember_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_OtherCommonStockMember_1071" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantsMember" xlink:label="loc_alur_OtherCommonStockWarrantsMember_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_OtherCommonStockWarrantsMember_1085" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionOtherCommonStockMember" xlink:label="loc_alur_LegacyAllurionOtherCommonStockMember_3677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1079" xlink:to="loc_alur_LegacyAllurionOtherCommonStockMember_3677" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_srt_RangeAxis_1101" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1101" xlink:to="loc_srt_RangeMember_1077" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1077" xlink:to="loc_srt_MinimumMember_1076" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1077" xlink:to="loc_srt_MaximumMember_1088" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems" xlink:label="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable_1082" xlink:to="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1081" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems_1103" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1089" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1027" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1027" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1034" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1029" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1040" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_1044" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2976" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_1041" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3864" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWarrantsMember" xlink:label="loc_alur_PrivatePlacementWarrantsMember_3416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3421" xlink:to="loc_alur_PrivatePlacementWarrantsMember_3416" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1047" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1033" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1039" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1046" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1049" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1049" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1037" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1035" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_1051" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_1051" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionCommonStockWarrantLiabilitiesMember_1036" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsMember" xlink:label="loc_alur_PublicWarrantsMember_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PublicWarrantsMember_1045" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsMember" xlink:label="loc_alur_PublicOfferingWarrantsMember_3803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PublicOfferingWarrantsMember_3803" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingMember" xlink:label="loc_alur_RevenueInterestFinancingMember_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_RevenueInterestFinancingMember_1048" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PIPEConversionOptionMember" xlink:label="loc_alur_PIPEConversionOptionMember_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_PIPEConversionOptionMember_1050" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutLiabilityMember" xlink:label="loc_alur_EarnOutLiabilityMember_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_EarnOutLiabilityMember_1052" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RtwConvertibleNotesMember" xlink:label="loc_alur_RtwConvertibleNotesMember_4074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_RtwConvertibleNotesMember_4074" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TermLoanDerivativeLiabilityMember" xlink:label="loc_alur_TermLoanDerivativeLiabilityMember_1054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_TermLoanDerivativeLiabilityMember_1054" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_DerivativeLiabilitySuccessFeeMember" xlink:label="loc_alur_DerivativeLiabilitySuccessFeeMember_1055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_DerivativeLiabilitySuccessFeeMember_1055" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember_1056" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember_1058" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember_1060" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OtherCommonStockWarrantLiabilitiesMember" xlink:label="loc_alur_OtherCommonStockWarrantLiabilitiesMember_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_OtherCommonStockWarrantLiabilitiesMember_1062" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember_1063" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember" xlink:label="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember_1066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1032" xlink:to="loc_alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember_1066" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1038" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_1031" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1053" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1042" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3004" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3004" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3005" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3013" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3013" xlink:to="loc_us-gaap_ClassOfStockDomain_3048" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_3014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3048" xlink:to="loc_us-gaap_CommonClassAMember_3014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3048" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_3032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_dei_LegalEntityAxis_3032" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3032" xlink:to="loc_dei_EntityDomain_3052" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3051" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3051" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthAcquisitionCorprationMember" xlink:label="loc_alur_ComputeHealthAcquisitionCorprationMember_3025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3027" xlink:to="loc_alur_ComputeHealthAcquisitionCorprationMember_3025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3055" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantMember" xlink:label="loc_alur_PublicWarrantMember_3023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicWarrantMember_3023" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_3035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_IPOMember_3035" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingMember" xlink:label="loc_alur_PublicOfferingMember_3050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicOfferingMember_3050" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicOfferingWarrantsAndShareOverallotmentMember" xlink:label="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember_3056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PublicOfferingWarrantsAndShareOverallotmentMember_3056" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_3063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_PrivatePlacementMember_3063" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWithRTWMember" xlink:label="loc_alur_PrivatePlacementWithRTWMember_3066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_alur_PrivatePlacementWithRTWMember_3066" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3016" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3073" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3062" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3062" xlink:to="loc_us-gaap_EquityComponentDomain_3017" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_us-gaap_CommonStockMember_3009" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3034" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommitmentSharesMember" xlink:label="loc_alur_CommitmentSharesMember_3049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3017" xlink:to="loc_alur_CommitmentSharesMember_3049" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_3067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_srt_StatementScenarioAxis_3067" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3067" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3018" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanThreeMember" xlink:label="loc_alur_ScenarioPlanThreeMember_3024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3018" xlink:to="loc_alur_ScenarioPlanThreeMember_3024" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanFourMember" xlink:label="loc_alur_ScenarioPlanFourMember_3030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3018" xlink:to="loc_alur_ScenarioPlanFourMember_3030" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3072" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3072" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChefPurchaseAgreementMember" xlink:label="loc_alur_ChefPurchaseAgreementMember_3011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3019" xlink:to="loc_alur_ChefPurchaseAgreementMember_3011" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_srt_RangeAxis_3076" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_3020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3076" xlink:to="loc_srt_RangeMember_3020" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_3079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_CreditFacilityAxis_3079" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_3021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3079" xlink:to="loc_us-gaap_CreditFacilityDomain_3021" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChardanEquityFacilityMember" xlink:label="loc_alur_ChardanEquityFacilityMember_3026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3021" xlink:to="loc_alur_ChardanEquityFacilityMember_3026" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3082" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3082" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3022" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3005" xlink:to="loc_us-gaap_ClassOfStockLineItems_3085" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionBasis" xlink:label="loc_alur_PreferredStockRedemptionBasis_3028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PreferredStockRedemptionBasis_3028" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockLiquidationPreferenceBasis" xlink:label="loc_alur_PreferredStockLiquidationPreferenceBasis_3031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PreferredStockLiquidationPreferenceBasis_3031" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_3053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockConversionBasis_3053" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_3054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockVotingRights_3054" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_3064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_DividendsPreferredStockCash_3064" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_3065" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3074" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3075" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3080" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3081" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3086" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3087" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3088" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_3089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_3089" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_3090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_3090" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3091" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3092" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3093" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_3094" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3095" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_3096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SharePrice_3096" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsRedumptionPricePerShare" xlink:label="loc_alur_WarrantsRedumptionPricePerShare_3097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_WarrantsRedumptionPricePerShare_3097" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3098" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_3099" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3100" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NetProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity_3101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_NetProceedsFromIssuanceOrSaleOfEquity_3101" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3102" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_UnderwritingDiscounts" xlink:label="loc_alur_UnderwritingDiscounts_3103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_UnderwritingDiscounts_3103" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ReductionInProceedsFromOffering" xlink:label="loc_alur_ReductionInProceedsFromOffering_3104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_ReductionInProceedsFromOffering_3104" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3105" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3106" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfCommonStockSharesOutstanding" xlink:label="loc_alur_PercentageOfCommonStockSharesOutstanding_3107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_PercentageOfCommonStockSharesOutstanding_3107" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3108" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpenseOfIssuanceOfCommitmentShares" xlink:label="loc_alur_ExpenseOfIssuanceOfCommitmentShares_3109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_ExpenseOfIssuanceOfCommitmentShares_3109" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StructuringFeePayable" xlink:label="loc_alur_StructuringFeePayable_3110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3085" xlink:to="loc_alur_StructuringFeePayable_3110" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2998" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2998" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2999" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3008" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3008" xlink:to="loc_us-gaap_ClassOfStockDomain_3046" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3046" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3002" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3036" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3036" xlink:to="loc_us-gaap_EquityComponentDomain_3000" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_3006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_3006" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_3045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_3045" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:label="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_3058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_3058" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_3068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_EarnOutSharesMember_3068" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNotesMember" xlink:label="loc_alur_ConvertibleNotesMember_3071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3000" xlink:to="loc_alur_ConvertibleNotesMember_3071" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3047" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3001" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3007" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2999" xlink:to="loc_us-gaap_ClassOfStockLineItems_3057" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3057" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3003" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_2980" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_2981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2980" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_2981" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2990" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtDecember012014Member" xlink:label="loc_alur_WarrantsIssuedAtDecember012014Member_3041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtDecember012014Member_3041" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtMarch302021Member" xlink:label="loc_alur_WarrantsIssuedAtMarch302021Member_3042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtMarch302021Member_3042" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember152022Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember152022Member_3059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtSeptember152022Member_3059" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune042022Member" xlink:label="loc_alur_WarrantsIssuedAtJune042022Member_3060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune042022Member_3060" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJanuary172017Member" xlink:label="loc_alur_WarrantsIssuedAtJanuary172017Member_3069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJanuary172017Member_3069" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtAugust032017Member" xlink:label="loc_alur_WarrantsIssuedAtAugust032017Member_3070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtAugust032017Member_3070" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember082017Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember082017Member_3077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtSeptember082017Member_3077" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune192018Member" xlink:label="loc_alur_WarrantsIssuedAtJune192018Member_3078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune192018Member_3078" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune252019Member" xlink:label="loc_alur_WarrantsIssuedAtJune252019Member_3083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJune252019Member_3083" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJuly012024Member" xlink:label="loc_alur_WarrantsIssuedAtJuly012024Member_3084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2993" xlink:to="loc_alur_WarrantsIssuedAtJuly012024Member_3084" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3033" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3033" xlink:to="loc_us-gaap_EquityComponentDomain_2991" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2991" xlink:to="loc_us-gaap_CommonStockMember_2994" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_2981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2992" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3039" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3044" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3043" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1283" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1283" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1296" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1285" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1285" xlink:to="loc_us-gaap_ClassOfStockDomain_1312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1287" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1305" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1311" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1316" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_SeriesDPreferredStockMember_1319" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1322" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDTwoPreferredStockMember" xlink:label="loc_alur_SeriesDTwoPreferredStockMember_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDTwoPreferredStockMember_1325" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDThreePreferredStockMember" xlink:label="loc_alur_SeriesDThreePreferredStockMember_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_alur_SeriesDThreePreferredStockMember_1328" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1312" xlink:to="loc_us-gaap_CommonClassAMember_1331" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_dei_LegalEntityAxis_1303" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1303" xlink:to="loc_dei_EntityDomain_1313" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionMember" xlink:label="loc_alur_LegacyAllurionMember_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1313" xlink:to="loc_alur_LegacyAllurionMember_1291" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_srt_RangeAxis_1309" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1309" xlink:to="loc_srt_RangeMember_1294" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1294" xlink:to="loc_srt_MaximumMember_1293" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1314" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1314" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ComputeHealthAcquisitionCorprationMember" xlink:label="loc_alur_ComputeHealthAcquisitionCorprationMember_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1302" xlink:to="loc_alur_ComputeHealthAcquisitionCorprationMember_1300" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" xlink:to="loc_us-gaap_IPOMember_1299" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantMember" xlink:label="loc_alur_PublicWarrantMember_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1298" xlink:to="loc_alur_PublicWarrantMember_1308" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_srt_StatementScenarioAxis_1320" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1320" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1292" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanThreeMember" xlink:label="loc_alur_ScenarioPlanThreeMember_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1292" xlink:to="loc_alur_ScenarioPlanThreeMember_1288" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ScenarioPlanFourMember" xlink:label="loc_alur_ScenarioPlanFourMember_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1292" xlink:to="loc_alur_ScenarioPlanFourMember_1306" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1323" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1323" xlink:to="loc_us-gaap_EquityComponentDomain_1297" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1297" xlink:to="loc_us-gaap_CommonStockMember_1290" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_CommitmentSharesMember" xlink:label="loc_alur_CommitmentSharesMember_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1297" xlink:to="loc_alur_CommitmentSharesMember_1307" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1326" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1326" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChefPurchaseAgreementMember" xlink:label="loc_alur_ChefPurchaseAgreementMember_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1289" xlink:to="loc_alur_ChefPurchaseAgreementMember_1284" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_CreditFacilityAxis_1329" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1329" xlink:to="loc_us-gaap_CreditFacilityDomain_1301" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ChardanEquityFacilityMember" xlink:label="loc_alur_ChardanEquityFacilityMember_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1301" xlink:to="loc_alur_ChardanEquityFacilityMember_1295" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1296" xlink:to="loc_us-gaap_ClassOfStockLineItems_1332" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1286" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1304" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockVotingRights" xlink:label="loc_us-gaap_PreferredStockVotingRights_1310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockVotingRights_1310" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockVotingRights_1315" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_1318" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_DividendsPreferredStockCash_1321" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_1324" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue" xlink:label="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue_1327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue_1327" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1330" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfSharesOfCommonStockHeld" xlink:label="loc_alur_PercentageOfSharesOfCommonStockHeld_1333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfSharesOfCommonStockHeld_1333" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1334" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConversionBasis" xlink:label="loc_us-gaap_PreferredStockConversionBasis_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_PreferredStockConversionBasis_1335" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPreferredStockRedeemableShares" xlink:label="loc_alur_PercentageOfPreferredStockRedeemableShares_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfPreferredStockRedeemableShares_1336" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PreferredStockRedemptionValueToPrice" xlink:label="loc_alur_PreferredStockRedemptionValueToPrice_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PreferredStockRedemptionValueToPrice_1337" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1338" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1339" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1340" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1341" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1342" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1343" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1344" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1345" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_1346" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsRedumptionPricePerShare" xlink:label="loc_alur_WarrantsRedumptionPricePerShare_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_WarrantsRedumptionPricePerShare_1347" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_SharePrice_1348" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1349" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1350" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1351" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfCommonStockSharesOutstanding" xlink:label="loc_alur_PercentageOfCommonStockSharesOutstanding_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_PercentageOfCommonStockSharesOutstanding_1352" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ExpenseOfIssuanceOfCommitmentShares" xlink:label="loc_alur_ExpenseOfIssuanceOfCommitmentShares_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_ExpenseOfIssuanceOfCommitmentShares_1353" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1354" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StructuringFeePayable" xlink:label="loc_alur_StructuringFeePayable_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1332" xlink:to="loc_alur_StructuringFeePayable_1355" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1261" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1261" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1266" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1266" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1262" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1262" xlink:to="loc_us-gaap_ClassOfStockDomain_1273" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1264" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1269" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1276" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1278" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDTwoPreferredStockMember" xlink:label="loc_alur_SeriesDTwoPreferredStockMember_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDTwoPreferredStockMember_1280" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDThreePreferredStockMember" xlink:label="loc_alur_SeriesDThreePreferredStockMember_1281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1273" xlink:to="loc_alur_SeriesDThreePreferredStockMember_1281" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1266" xlink:to="loc_dei_LegalEntityAxis_1267" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1267" xlink:to="loc_dei_EntityDomain_1274" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LegacyAllurionMember" xlink:label="loc_alur_LegacyAllurionMember_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1274" xlink:to="loc_alur_LegacyAllurionMember_1265" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1266" xlink:to="loc_us-gaap_ClassOfStockLineItems_1270" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1263" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1268" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1270" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_1275" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1357" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1361" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1361" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1358" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1358" xlink:to="loc_us-gaap_EquityComponentDomain_1362" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchasePreferredStockMember" xlink:label="loc_alur_WarrantsToPurchasePreferredStockMember_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_WarrantsToPurchasePreferredStockMember_1366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_1369" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PublicWarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_PublicWarrantsToPurchaseCommonStockMember_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_PublicWarrantsToPurchaseCommonStockMember_1370" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1362" xlink:to="loc_alur_EarnOutSharesMember_1371" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1361" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1365" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1364" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1363" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1361" xlink:to="loc_us-gaap_ClassOfStockLineItems_1368" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1368" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1359" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1373" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1373" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1377" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1379" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtApril012013Member" xlink:label="loc_alur_WarrantsIssuedAtApril012013Member_1380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtApril012013Member_1380" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtDecember012014Member" xlink:label="loc_alur_WarrantsIssuedAtDecember012014Member_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtDecember012014Member_1384" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtMarch302021Member" xlink:label="loc_alur_WarrantsIssuedAtMarch302021Member_1389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtMarch302021Member_1389" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember152022Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember152022Member_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtSeptember152022Member_1393" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune042022Member" xlink:label="loc_alur_WarrantsIssuedAtJune042022Member_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune042022Member_1394" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJanuary172017Member" xlink:label="loc_alur_WarrantsIssuedAtJanuary172017Member_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJanuary172017Member_1395" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtAugust032017Member" xlink:label="loc_alur_WarrantsIssuedAtAugust032017Member_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtAugust032017Member_1396" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtSeptember082017Member" xlink:label="loc_alur_WarrantsIssuedAtSeptember082017Member_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtSeptember082017Member_1397" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune192018Member" xlink:label="loc_alur_WarrantsIssuedAtJune192018Member_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune192018Member_1398" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsIssuedAtJune252019Member" xlink:label="loc_alur_WarrantsIssuedAtJune252019Member_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1390" xlink:to="loc_alur_WarrantsIssuedAtJune252019Member_1399" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1383" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1383" xlink:to="loc_us-gaap_EquityComponentDomain_1378" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1378" xlink:to="loc_us-gaap_CommonStockMember_1376" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1388" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1388" xlink:to="loc_us-gaap_ClassOfStockDomain_1387" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesAOnePreferredStockMember" xlink:label="loc_alur_SeriesAOnePreferredStockMember_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_alur_SeriesAOnePreferredStockMember_1374" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1381" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1385" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SeriesDOnePreferredStockMember" xlink:label="loc_alur_SeriesDOnePreferredStockMember_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1387" xlink:to="loc_alur_SeriesDOnePreferredStockMember_1391" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1377" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_1375" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1382" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_1392" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1386" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1401" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1932" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1932" xlink:to="loc_us-gaap_EquityComponentDomain_1930" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xlink:to="loc_us-gaap_AwardTypeAxis_2350" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2469" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_1929" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_NetIncomeLoss_1403" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_1406" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1402" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1409" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1404" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1405" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1407" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_EarningsPerShareBasic_1408" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_2472" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1410" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1412" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1412" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3160" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3160" xlink:to="loc_us-gaap_ClassOfStockDomain_3748" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3748" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1413" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_OutstandingOptionsToPurchaseCommonStockMember_1415" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1419" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchasePreferredStockMember" xlink:label="loc_alur_WarrantsToPurchasePreferredStockMember_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_WarrantsToPurchasePreferredStockMember_1420" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_WarrantsToPurchaseCommonStockMember" xlink:label="loc_alur_WarrantsToPurchaseCommonStockMember_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_WarrantsToPurchaseCommonStockMember_1421" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember" xlink:label="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember_1423" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_EarnOutSharesMember" xlink:label="loc_alur_EarnOutSharesMember_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_EarnOutSharesMember_1425" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNotesMember" xlink:label="loc_alur_ConvertibleNotesMember_1426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1416" xlink:to="loc_alur_ConvertibleNotesMember_1426" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1414" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1418" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1417" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1428" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1428" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_PlanNameAxis_1435" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1435" xlink:to="loc_us-gaap_PlanNameDomain_1431" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanMember_1430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020StockOptionPlanMember_1430" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember_1439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember_1439" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020Member" xlink:label="loc_alur_StockOptionPlan2020Member_1442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionPlan2020Member_1442" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionAndIncentivePlanMember" xlink:label="loc_alur_StockOptionAndIncentivePlanMember_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_StockOptionAndIncentivePlanMember_1446" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember" xlink:label="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1431" xlink:to="loc_alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember_1449" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_AwardTypeAxis_1441" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1441" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1451" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1454" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_alur_TimeVestedRestrictedStockUnitsMember_1456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1443" xlink:to="loc_alur_TimeVestedRestrictedStockUnitsMember_1456" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_VestingAxis_1445" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1445" xlink:to="loc_us-gaap_VestingDomain_1436" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1436" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1429" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1436" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1438" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_srt_RangeAxis_1448" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1448" xlink:to="loc_srt_RangeMember_1434" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1434" xlink:to="loc_srt_MaximumMember_1433" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_srt_TitleOfIndividualAxis_2609" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2609" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_1775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1785" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_1775" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan_1432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan_1432" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1444" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1447" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1450" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1453" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1455" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1457" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1458" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1459" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage" xlink:label="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage_1460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage_1460" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance" xlink:label="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance_1464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance_1464" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_ShareBasedCompensation_1465" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfPriceLowerOfFairValueMarketValue" xlink:label="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfPriceLowerOfFairValueMarketValue_1466" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfEmployeesCompensationToPayrollDeductions" xlink:label="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions_1467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfEmployeesCompensationToPayrollDeductions_1467" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfDilutedSharesOutstanding" xlink:label="loc_alur_PercentageOfDilutedSharesOutstanding_1468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_alur_PercentageOfDilutedSharesOutstanding_1468" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1452" xlink:to="loc_us-gaap_CommonStockSharesIssued_1469" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1471" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1471" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1472" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1472" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1475" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_CostOfSalesMember_1476" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1478" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1475" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1479" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1473" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1477" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1474" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1481" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1481" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" xlink:to="loc_us-gaap_PlanNameAxis_1485" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1485" xlink:to="loc_us-gaap_PlanNameDomain_1483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember" xlink:label="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember_1482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1483" xlink:to="loc_alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember_1482" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1486" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1484" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1487" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1493" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1494" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1495" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1496" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1498" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1499" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1500" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1501" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1488" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1502" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1504" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1505" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1506" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1504" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1507" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1504" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1508" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1510" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1510" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xlink:to="loc_us-gaap_AwardTypeAxis_1514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1514" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1518" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1523" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xlink:to="loc_us-gaap_PlanNameAxis_1517" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1517" xlink:to="loc_us-gaap_PlanNameDomain_1512" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockOptionPlan2020And2023StockOptionPlanMember" xlink:label="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember_1511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1512" xlink:to="loc_alur_StockOptionPlan2020And2023StockOptionPlanMember_1511" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1513" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1516" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1519" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1521" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1522" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1524" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1525" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1526" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1527" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1528" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1530" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1530" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" xlink:to="loc_srt_RangeAxis_1535" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1535" xlink:to="loc_srt_RangeMember_1534" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1534" xlink:to="loc_srt_MaximumMember_1533" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1532" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_1536" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1531" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1538" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1538" xlink:to="loc_us-gaap_LossContingenciesTable_1541" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_srt_RangeAxis_1542" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1542" xlink:to="loc_srt_RangeMember_1545" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1545" xlink:to="loc_srt_MaximumMember_1543" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1545" xlink:to="loc_srt_MinimumMember_1549" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_srt_StatementGeographicalAxis_1548" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1548" xlink:to="loc_srt_SegmentGeographicalDomain_1539" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NatickAndHudsonMember" xlink:label="loc_alur_NatickAndHudsonMember_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1539" xlink:to="loc_alur_NatickAndHudsonMember_1540" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1551" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1547" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1541" xlink:to="loc_us-gaap_LossContingenciesLineItems_1553" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescription_1544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescription_1544" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseExpirationPeriod" xlink:label="loc_alur_LesseeOperatingLeaseExpirationPeriod_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_LesseeOperatingLeaseExpirationPeriod_1552" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1554" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaap_AreaOfLand_1555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_AreaOfLand_1555" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1556" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_1557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_1557" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_1558" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_1567" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_IncreaseDecreaseInRevenuesForCustomerReturns" xlink:label="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns_4136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_IncreaseDecreaseInRevenuesForCustomerReturns_4136" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_StockExchangeListingRequirementsDescription" xlink:label="loc_alur_StockExchangeListingRequirementsDescription_4150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_StockExchangeListingRequirementsDescription_4150" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AverageMarketCapitalizationAmount" xlink:label="loc_alur_AverageMarketCapitalizationAmount_4180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_AverageMarketCapitalizationAmount_4180" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfConsecutiveTradingDay" xlink:label="loc_alur_NumberOfConsecutiveTradingDay_4188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_alur_NumberOfConsecutiveTradingDay_4188" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1553" xlink:to="loc_us-gaap_StockholdersEquity_4211" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_OperatingLeaseCost_1578" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_1581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_ShortTermLeaseCost_1581" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_VariableLeaseCost_1582" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_OperatingLeasePayments_1583" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1584" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1576" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1585" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeasesAndFinanceLeasesAbstract" xlink:label="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1610" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo_1615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo_1615" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree_1619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree_1619" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour_1623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour_1623" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive_1626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive_1626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue_1629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue_1629" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount_1632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount_1632" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiability" xlink:label="loc_alur_OperatingAndFinanceLeaseLiability_1635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingAndFinanceLeaseLiability_1635" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="loc_alur_OperatingAndFinanceLeaseLiabilityCurrent_1638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingAndFinanceLeaseLiabilityCurrent_1638" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="loc_alur_OperatingAndFinanceLeaseLiabilityNoncurrent_1641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_alur_OperatingLeasesAndFinanceLeasesAbstract_1620" xlink:to="loc_alur_OperatingAndFinanceLeaseLiabilityNoncurrent_1641" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_3138" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3665" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3744" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3905" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="loc_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_3948" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4030" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4054" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_OperatingLeaseLiability_4108" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4125" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1608" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4159" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1644" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1644" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1646" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1644" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1648" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1659" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1659" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" xlink:to="loc_srt_StatementGeographicalAxis_1662" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1662" xlink:to="loc_srt_SegmentGeographicalDomain_1660" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_country_US_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1660" xlink:to="loc_country_US_1661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR" xlink:label="loc_country_FR_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1660" xlink:to="loc_country_FR_1665" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1663" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_1664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1666" xlink:to="loc_us-gaap_NoncurrentAssets_1664" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1669" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1669" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1678" xlink:to="loc_us-gaap_RelatedPartyDomain_1676" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LnmpJpbcInvestMember" xlink:label="loc_alur_LnmpJpbcInvestMember_1675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_LnmpJpbcInvestMember_1675" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_KkgEnterprisesMember" xlink:label="loc_alur_KkgEnterprisesMember_1682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_KkgEnterprisesMember_1682" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RemusGroupManagementMember" xlink:label="loc_alur_RemusGroupManagementMember_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_RemusGroupManagementMember_1685" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_BenoitChardonConsultingMember" xlink:label="loc_alur_BenoitChardonConsultingMember_1689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1676" xlink:to="loc_alur_BenoitChardonConsultingMember_1689" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1683" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1683" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConsultingAgreementsMember" xlink:label="loc_alur_ConsultingAgreementsMember_1670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_ConsultingAgreementsMember_1670" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TerminationAgreementMember" xlink:label="loc_alur_TerminationAgreementMember_1680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_TerminationAgreementMember_1680" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConvertibleNoteAgreementWithRtwMember" xlink:label="loc_alur_ConvertibleNoteAgreementWithRtwMember_3788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_ConvertibleNoteAgreementWithRtwMember_3788" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RTWParticipationInPublicOfferingMember" xlink:label="loc_alur_RTWParticipationInPublicOfferingMember_3876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_RTWParticipationInPublicOfferingMember_3876" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PrivatePlacementWithRTWMember" xlink:label="loc_alur_PrivatePlacementWithRTWMember_3968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1674" xlink:to="loc_alur_PrivatePlacementWithRTWMember_3968" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_DebtInstrumentAxis_1686" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1686" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1687" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1687" xlink:to="loc_alur_TwoThousandTwentyThreeConvertibleNotesMember_1677" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_srt_CounterpartyNameAxis_1690" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1690" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_HunterVenturesLimitedMember" xlink:label="loc_alur_HunterVenturesLimitedMember_1679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1673" xlink:to="loc_alur_HunterVenturesLimitedMember_1679" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3969" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3969" xlink:to="loc_us-gaap_ClassOfStockDomain_3789" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_3357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3789" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_3357" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1671" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1692" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_OperatingLeasePayments_1672" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseCommencementDate" xlink:label="loc_alur_OperatingLeaseCommencementDate_1681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseCommencementDate_1681" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseEndDate" xlink:label="loc_alur_OperatingLeaseEndDate_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseEndDate_1684" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_LesseeOperatingLeaseTerminatedDate" xlink:label="loc_alur_LesseeOperatingLeaseTerminatedDate_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_LesseeOperatingLeaseTerminatedDate_1688" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AgreementsTerminationDate" xlink:label="loc_alur_AgreementsTerminationDate_1691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_AgreementsTerminationDate_1691" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination" xlink:label="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination_1693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination_1693" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaap_DebtInstrumentIssuedPrincipal_1694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_DebtInstrumentIssuedPrincipal_1694" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1695" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCapitalStock" xlink:label="loc_alur_PercentageOfOutstandingCapitalStock_1696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PercentageOfOutstandingCapitalStock_1696" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionConsultingFees" xlink:label="loc_alur_RelatedPartyTransactionConsultingFees_1697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_RelatedPartyTransactionConsultingFees_1697" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RelatedPartyTransactionTerminationFees" xlink:label="loc_alur_RelatedPartyTransactionTerminationFees_1698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_RelatedPartyTransactionTerminationFees_1698" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_OperatingLeaseStartDate" xlink:label="loc_alur_OperatingLeaseStartDate_2308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_OperatingLeaseStartDate_2308" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_PercentageOfOutstandingCommonStock" xlink:label="loc_alur_PercentageOfOutstandingCommonStock_4094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_PercentageOfOutstandingCommonStock_4094" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4212" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4217" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AggregatePurchasePriceFromOffering" xlink:label="loc_alur_AggregatePurchasePriceFromOffering_4236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1692" xlink:to="loc_alur_AggregatePurchasePriceFromOffering_4236" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1706" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1706" xlink:to="loc_us-gaap_SubsequentEventTable_1713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_srt_StatementScenarioAxis_1721" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1721" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1714" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1730" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1730" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RevenueInterestFinancingAgreementMember" xlink:label="loc_alur_RevenueInterestFinancingAgreementMember_1707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1710" xlink:to="loc_alur_RevenueInterestFinancingAgreementMember_1707" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1734" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1734" xlink:to="loc_us-gaap_EquityComponentDomain_1717" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_CreditFacilityAxis_1738" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1738" xlink:to="loc_us-gaap_CreditFacilityDomain_1722" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1740" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1740" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1720" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_DebtInstrumentAxis_1742" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1742" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1733" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_AmendedAndRestatedRtwSideLetterMember" xlink:label="loc_alur_AmendedAndRestatedRtwSideLetterMember_3516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1733" xlink:to="loc_alur_AmendedAndRestatedRtwSideLetterMember_3516" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1744" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1744" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1708" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1708" xlink:to="loc_us-gaap_SubsequentEventMember_1719" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_3831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_RestructuringPlanAxis_3831" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_3517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_3831" xlink:to="loc_us-gaap_RestructuringPlanDomain_3517" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_RestructuringPlanMember" xlink:label="loc_alur_RestructuringPlanMember_3509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_3517" xlink:to="loc_alur_RestructuringPlanMember_3509" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1713" xlink:to="loc_us-gaap_SubsequentEventLineItems_1746" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_NumberOfSurrenderSharesOfCommonStock" xlink:label="loc_alur_NumberOfSurrenderSharesOfCommonStock_3519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_NumberOfSurrenderSharesOfCommonStock_3519" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_SurrenderCommonStockValue" xlink:label="loc_alur_SurrenderCommonStockValue_3554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_SurrenderCommonStockValue_3554" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="alur-20240930.xsd#alur_ConversionOfPipeInvestmentToRevenueInterestFinance" xlink:label="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_3834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_alur_ConversionOfPipeInvestmentToRevenueInterestFinance_3834" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_3992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_3992" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3994" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_4084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1746" xlink:to="loc_us-gaap_RestructuringCosts_4084" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>8
<FILENAME>d915839dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Allurion
Technologies, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Class<BR>Title(2)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>or Carry<BR>Forward<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price Per<BR>Unit</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Maximum<BR>Aggregate<BR>Offering<BR>Price(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee Rate</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Amount of<BR>Registration<BR>Fee</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common&nbsp;stock,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">par value $0.0001 per share(1)(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$15,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.0001531</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$2,296.50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><FONT STYLE="white-space:nowrap">Pre-funded&nbsp;warrants&nbsp;to&nbsp;purchase</FONT> common stock, $0.0001 par value per share(3)(5)(6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(g)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common stock, $0.0001 par value per share, underlying the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants(3)(5)(6)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common warrants to purchase</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">common stock(3)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(g)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt">Fees to Be Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Common&nbsp;stock,&nbsp;par&nbsp;value&nbsp;$0.0001&nbsp;per&nbsp;share,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">underlying common warrants(4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$15,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">0.0001531</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$2,296.50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$30,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$4,593.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$4,593.00</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of computing the registration fee in pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover an indeterminate
number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 457(g) of the Securities Act, no separate registration fees are payable with respect to the
common warrants to purchase shares of common stock, $0.0001 par value per share, offered hereby since such common warrants are being registered in the same registration statement as the common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to the common stock set forth in this table, pursuant to Rule&nbsp;416 under the Securities Act,
this registration statement also registers such indeterminate number of common stock as may become issuable upon exercise of the common warrants and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The proposed maximum aggregate offering price of the common stock and accompanying common warrants proposed to
be sold in the offering will be reduced on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">dollar-for-dollar</FONT></FONT> basis based on the offering price of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
offered and sold in the offering, and as such the proposed maximum offering price of the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (including the common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants) if any, is $15,000,000. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant may issue <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase common stock
in the offering. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share at which shares of common stock are being sold to the public in this offering, minus $0.0001, which constitutes the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> portion of the exercise price, and the remaining unpaid exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal $0.0001 per share (subject to adjustment as
provided for therein). </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g915839g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g01a03.jpg
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M*"@H*"@H*"C_P  1"  O .<# 2(  A$! Q$!_\0 '0   @(# 0$!
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MV1;JXJ75,DNHX#Q  GE]HHT:N+L+UOF=^I0Q@ZX8=.N\>VQWIQE/OICH!C$
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MK<)3MMPC8\MNR@= B?"&5L0B2!)FI8)'@I?"?UKZ#LM(9:0TTD(;0D)2E(V
M Y "FR-KU)^/C#WMU!AA>BE@P_*(E[M4ZYN/QTK2&Y*T*2>))3_*A)';0$Z3
M/K:N'T#'NQ3F4F?29];5P^@8]V*7$26YE/(4+CH?<9+3.X1K5HY8[A.<#<6+
M;$O.K/<E*=S^E++>KY?]9]08MO;<4U'>=*8L8G=N,T-R5J'>KA!)/?V#N%%C
M+I#L?HIP.I)'6PXK:R.Y)<3O^.VWVU3>B1':<SFZOK +K5O(1OW;N(W/Y;?;
M17@%HKDL5Q_J,'@> 6'"K>VQ:(;9D\.SLQQ(+SI[R5=P]@Y5:ZE2HDWW-@
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B3"N4R5:%,,\?$&WG"KFA21L"@=Y%2KNP)XF/#C95Y$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g915839g81a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g81a01.jpg
M_]C_X  02D9)1@ ! 0$!*P$K  #_[1<*4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2NL20 !  $!*ZQ)  $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             Y,   ;[          $                          0
M           &^P   Y,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   Y,     4F=H=&QO;F<   ;[    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   .3
M     %)G:'1L;VYG   &^P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      ,<0    $   "@    4@   >
M )G    ,50 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 4@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M9#G/V/<YSR1!+F; .[FL_>]VY#:8<TS$$&1K&J3K+'CWO<X#422=?FF:)<T
M;I($<3)X20VCD!Q(.18&D:GTQ/+M-/Y/^$3&\>V+WG:1 -;?:/H_VMK$OL[2
M\Q3=M&A$MT.GYW[J0QZ]T.IM!),0]D$#W?G?R4$J.0"2/M%D/G>?3;X;&^Q-
M;DN  JO<\$@D.8&\&=TZ_NIVXI(.ZF[<V =6@!P WA\_ROH)G4-;_@+IAQ(<
M1,!IU&W]WZ7]1)6J)U]SVEKGDM<9(TB4-6+,5PK#F5OT!-CB6EN@GV[5710V
M<6PL8Z++&'=,5LW B/SM%/U'M@"VT!Q)=^A\=7._E*LRVU@(8]S =2&DC\B<
MWWD@FQY(X.XZ?!)-MKUK=Q MOEL?X(3(DGP]/^JAFT,:&-R'C;!8WTP!SO:Y
MO[G[R#Z]W^D?_G'MJH$DDDF23)/FDJVQ9DN _17.>9,[F!NGYO[R"UQ=<QSC
M)+VDGS+@H*5?\ZS^NW_J@DA__])/^F[^L?RJ*D_Z;OZQ_*HJ5KKI=X3)VF'
M^!E)3S_4LZS,RK,6NQK,6DP\%[:]\':][GO_ )7\VQ57XV("/0(8^#M<<BF
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M2GZJ27RJDDI^JDE\JI)*?__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@   $L     0   2P    !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C R-#HQ,CHP-" P.3HT-#HU-0!R<C,Y,C8S-0
M     Z !  ,    !__\  * "  0    !   &^Z #  0    !   #DP
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @          /_A 4Y%>&EF  !-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C$R.C T(# Y.C0T.C4U ')R,SDR-C,U       #
MH $  P    '__P  H ( !     $   ;[H , !     $   .3          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
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M*"@H*"@H*"@H_\  $0@#E ;] P$B  (1 0,1 ?_$ !P  0 " P$! 0
M       !!0($!@,'"/_$ $D0  (! P," P(,!@$# P,!"0 ! @,$$042(08Q
M$R)!%E$'%#(V4E1587&1D]$5(T)T@;/",Z&Q)&+!<K+A)30U0R:24_#Q8__$
M !D! 0$! 0$!               ! @,$!?_$ ",1 0$!  (" P$! 0$! 0
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M/]RF F%U<^U&N_:U[^L_W'M1KGVO>_JO]RF F%U<^U&N_:U[^L_W'M1KF?\
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MJ-<^UKW]9_N%U1KOVM>_JO\ <I@)A=_U<^U&N_:U[^J_W'M1KGVM>_JO]RF
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MWKS^Y_XHQSSZ=/%N]G#?"M\^=0_"E_KB<B==\*WSYU#\*7^N)R)KCZ8Y_K0
M%9          $  %  $  %2B?0A$L5 (G)B\8Y-Y]J<$B"IOO,ETJ>,QJ99.
MBQ!&3!SE%X2RO>$U[R;QAOT]"&/+[R/*O4GVE9 Q>S/GGM,XQ6/(]R)-.R"!
MGG :X[C,W/9VJ!@F+)D^.QK,1B NP(H  @  H  )09 "  "@
M 2NY  R(]2 $  %          $  %          $  %           !*>,F.
M0B<$H+D;5/*;P6*DC_)C&3AQ'E$IQD_-+!9@DDPFT^(O@F6(TU@GUA&1'<0F
ML<F,(^:4L_@7Z(S_ !",6]W?@B+E#Y*R.K,9@*+J=UM(:PN!(9J01%^A.&N2
M5I#()?)!$  %          $       !0         ! !&0&()9   !0
M                          $H! S/M D@+@WG%4@C@A2?9"+F))1C*$L9
MPR5*3CC!+B;])!BLQ[F7#7?D=L3[ >:DU/E&4DERV.V'VR(,4U/A,]&HP7,N
M1VP8\@1W-YQP3)^D5EES:"!"SCD+LRK$D$D/U,B               !  !0
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M\2@_#7J\]BN\1QFXR24EP=^/FSR?6,[QC-)HR204LHC#.F:A(@G\2 @  H
M  "  "@    (  *
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MXHG%J3,V\Q(IR\1#LSOP^W/=C% E\$%,  10
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MNK:+J.G5''P/Y*]7[BOIRA#US/W'LX<ZQ&6<KD+U#>7D+L>@2028OU,H  (
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M#"1ODN(] AZ SBC(1+(
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M+QED1BY^>?>).<]CU;N:Y1 P2#*H )-8(#)(8$  @     @  H
M@  H                     'V?X%/F]>?W/_%'Q@^S_ I\WKS^Y_XHQS].
MGB_3AOA6^?6H?A2_UQ.1.N^%;Y\ZA^%+_7$Y)&N/IGG^M0">""L  "@
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MFVVGG 9.7".?5D8?=^I]+/O*X3[0 29:0     $H@!$^A    !0
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MC R2A@AD$L@H  B  "@                    (  *     @  H
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ML?4\?DS7#ED9 +GL8YYP=L^V4D@&\ ADD,@@ $
M                     #[/\"GS>O/[G_BCXP?9_@4^;UY_<_\ %&.?IT\7
MZ<-\*WSYU#\*7^N)R2.M^%;Y\ZA^%+_7$Y*)KCZ9Y^]28F1B5@  4
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ME/S\27HS/=N_P;>NV?Q'6*M"FL17I^9J8QV/K>+G<CS;@9&)DCJRAD$L@
MH    "  "@                                            (  * $
MOFG)+N7,H3\U-_<7_0.G/4+M59Q\L)8['.[L0A#UD\'U[X/],A8Z:VXK,\,\
M7]'DZY'3AQ=)0I1I4E3BL*)Z8)2Y8/E<M[Z[YD2NPEV ?/8<<C53C@P7#P9)
MX1#63.^S5?KE!W&G581CN;78H=*J>+;5+*M#+I1;2?HSKEQW./U!5M/U>=Q)
M_P JLU%8[G3CK&O;IM_&+:M:7,L2E)X3/>/3E1W+W7$O"3XCC@U=2MZEA?TK
MRF_Y2BF\'3VMSXUI3JIYWK)>65<>=O:TK%)4:*?WI&RTZG/,3+=MCR>,J\89
M<JL$OO:.><-Q:]9+,<2/.2IRCX,XIJ7')XPOK>I)KQJ?_P#4CWISH7&94VFX
M>YFXS7+U(2T75YUGGP9<13['3VL]]%3SNW<_@5^MV:U"W<9+.SS(\>E;MW%G
M7A-YG3EMC^!&LY+NF]TFGV1Q/PAZ7X]O.YI16Y)+A':1\J7O9XWEO&Y@Z$UE
M2-^'G_ZC/+/I\ @Y1E*#7*,C<U^W^(:Q<Q:Q%R:B:2[<GV?'MQYN222$2=$Q
M#()9                           !     %
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ML?4_CY=N-UY^83D@'M<4D !0
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M4 B3O?MS0R"604   )P02@A@@ED   %     0  4
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M)[?X^,XN/+:R ![&                        0  4
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M1@N&^3N/A.O]TOB\/1^GXG$1CMBO-G*/H?RY_P"''D  [L@
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M0R"605  $        0  4    !  !0
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M$VD1/R<(R2\N6?8X9].&H:P%V&<DKL-0()(+GI$  B@
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M9                                          $  %     0  4  0
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M1N;^4S*'"Y/M>#.N?3S;R2ER2 =DQ#()]"":  (
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M<]SZ6<<SBXW[0 "*          (  *
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MZDZEU.I4>=[R2W[B()M-$XP?4X\.N.&Z@ %0            !     %
M0  4    !  !0                ^S_  *?-Z\_N?\ BCXP?9_@4^;UY_<_
M\48Y^G3Q?IPWPK_/G4/PI?ZXG(G7?"M\^M0_"E_KB<B:X^F>?ZT !60
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MR2<9(:Y.N)$  J@
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MS?M0@D@UH  @  (  *  (  *
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M*>WU,J,HJ,DL9,(03J-R9[_%X=XN6\JF":3QZA_?W%2JE-1B&\G>_P#&=0
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M/5QS.+&_8WGG!"[DA&NS,,\$+D RU0 R01B"60%          $  %
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MP;XX">4\D F_;3(@@$S(B?0@ J@                 "  "@
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M   %                                     0  4
M         )1!*&(#D=B=Q=Q,0V\<9(CE=^26^..Y$=_]3,QIEN6/DF+SZ+!.
MY(C<V^&/HIS[R4O>QR,/T8R!A>\@E)A\&D$20B2XJ&02R"  "   @    "@
M              @  H
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M95(K/?!,XI1X>2)QR^6*CVH"(_)[$9?HC*+S!$1;0!;L<H<^X2J/L90>U;F
M;6W#>&81BT_>B=FZ6?3[S*4E!80JQ&%G[R1&+DG(%Q#     -@6'P")>5901
MC\F3,VO416^"D2I)TI+!G2,,*?J3\B6TA=ECN2W_ #>?<5DV[FR$\,F*:E)^
MA&=S F7F)B\+!@_+DF/FY8$L@EM8P0   4    !  !0    $  %
M                             !  2I)(@G9E;@,<LR7N9$7@GB3"#CCM
MR1N]&)/9]YG&,9+(&/A^N0JCB\;29)KLR%)+NN0(7O\ ^Q+FVL-8(<91\RY1
M*_F=^, 0D^_H"=S68D   %   7KR3&.SU((2;GR$3&6'(E0S'(G%8X]"-_\
M+X EI8Y9*2QP\F*6]8[$[/# */+R3+"YR8[G/@F,4_*VLH#*$5)=S"3VO!$L
MP[,*#:RP)SD(( 9$,DA]P(  4  $H,+L&$0  H               (  *
M             'V?X%/F]>?W/_%'Q@^S_ I\WKS^Y_XHQS].GB_3AOA6^?6H
M?A2_UQ.1.N^%;Y]:A^%+_7$Y$UQ],\_UH "L@             2HIIM^A PV
M^X$T:=2YGLIIO/N+NTZ?KJ"E*+P_Q+'IRTI6]I\>JQ\BX-"]URYE7J*A4VTX
MOA8] 0N.G*S@Y4HMR_R4]>%2A)TZD<,M;'7;N-9;JF8OCL6FOVE.\MXW-OA;
M5F7XBD<E%R@^8IY-N.GW$Z#N-C5./<MM/TN%6A3K5)QQG.,G474K=].5XT(8
MPL,E(^:L(SK))F*[%(Q?<GDE++)<,?U(#$!OW(*+?J$))U.8+L949.;\/'F(
MC/9\DVM,@IWE-M=Y%:S6]8]/UI+Q)1>TW8:+:1D]U3SOT+3J^[J:?"DK5[8>
M&LHXQZA7E/>Y/+9*TM[[IZIM=2@FX^\HJL94I.E46'V.EZ=URI3NE3NY9I/T
M-7J*WIN[4Z:3=5YC@E%'&&Q8SDE&=:C4HSV5%AGGM:FDLL5$F)LUK:I"BJCB
MU%FNHN;4$TF_7W"B >_@3IQQ*+?_ +O0BG0J5%MA!R?O0J=7CMR916.Y94=+
MK2IMOAI>IK5+&O3@YR3VH4ZM6'FJ**+.XTYT;%5Y)X*ZDOYJ<>Z9UFIISZ5@
MWWR*=7+V5L[JXC!9\S)O;.5O=SI//E63<Z?DUJ=!+WHV>J<K5*LE[D*=5%"2
M::]4#TM:<JRE*$&\/T-W^$7%6.^/EQSABG57 VZ]K4I1RZ<L+U/"E;U*B<H<
MI=T*1Y@RFI+RXP_O(I-U);(Q;?X"D0#VN:4Z:VN+3]YXQ3;2%( ]:M.5.FIR
MCPSS@]\>!2( Q@%0                                     #*.WU[F
M)#6>%W F%*I6JX@FR\M^GZU2GNE%X+#IBUIT*,JUS'*<>&5]WK5UX\HT:FVF
MGVP",[CI^LZ7\F+;7<HJ]&K:SVU(OCWEQ::[=JX2=3RYYX+?7;:G>:;*]I+R
MK"?X@CE;:WG<M*$>66]#I^X\/=4A)0_ LNEZ-*%C=59I;HQS'[BIN-;O)9A&
MMB"?' 6/6XZ>KPIN48O"_$IZM'P9;:G#^\O-$UNZK7]*E7FW2SAK'<]>L;*G
M"K*XHI*#]#*N7ENW>5>4R)@VXM=B'!I]S6,Z -87<B+[E(D&#DY/A-(]%C;C
MU"UCZ,M]%T>I?T:LDF]I4034N3M^E*SI:)>SAQ)+AA<5=/0*D,Q<68T^G:NV
M7E9HU==O56?\Q_D%K=ZXO%7_ +&8U$WFESLTY33P^QKTM.J7%K*M%/">!4OK
MFY35>IN27!OZ9>NCH]18;6[W%8BHH4W.O&A_4W@VM3T^5C/;)/+Y,-.;JZQ0
MFN,U$=!UMAUEZ^4)%#963N8M^XUKZD[:>TO.FN:=0K=:\U[+((T=N%GWD$MO
M!      $  %            )0$ G! 0  4
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MJ5VK_P#[;,(T""2 @                   0)01)B_4R,?>   4
M                        )2QYB"7\G'H#'I8RW7"C+M)G:ZDL=,PH>B>3
MBH8C6I2C_2^3M-3?QGI.$J/R\\X[AIQ$9[92BS*E+;53C[S"47#NN?4]+./B
MW$5M]435QVE.'C:!5J3[Q7!QKNJD=T$WC\3L;Y_%-)='.-\3G(Z9*=!U8\D5
MJZ9:JXGB;?+.HTKIZ@JJJN3S%Y.0A4G0J-1GM:-ZTU:ZI5HIU9.+819=7SG"
MYV168)=SG$]ZP=EJU.-;1_C,UF7O.+_JXX+C/(494Y92R>\85:D<J''X'FYX
M:;62ZTO5K:A#%6VWE95D+:4EG#/*M1G#/!U7\?TYQPK%1*?4;^WKY\.BH!5/
M&,F9/L2TVVU+!'])-,=OT3_^ZM1_^A_^#CKG_K5/Q9V/1/\ ^Z]0_P#H?_@X
MZZ_ZT_\ ZF17G"*EYGZ&SIE24;Z,DV:;RI+';U+G0=-J7-XJD4W!<]@UB^Z]
MBG2LGC'\M&O<P4.F+=Q@LOUP.M+R%R[>%/'\J.UX/2X:?2]!/"X KNE;>%6Z
M4IK//N-K6]6KV5Q.G3I1VIX[%'HU:XM+GQ8;IP3[(Z+VAT^;:NM.4I^^02-7
M3=<G2K>-6IQ2[<HTM==M*O&O2ES4>6D7MO<Z;>RQ&VA33]&4VN:/*C7@XU,P
MF_*EZ!K,65G=VEAI*K4]LJWN:*N6MW$IN4J<8KT2+C3].HV5BJUZXU(K^AGC
M_&M+IS;E81DH]D"-O2*JURC.WJ0BI)9X1R4J,;2^J4XO/F:Y/H/1VJ6=[?5W
M:V'@IP?F.$KQQK%;?SFH\!([>X5O:=.6]QB.]KU1RLNHIRW1C3@DN."UZCC5
M>@6^&U!>AQ.[>FMNS\0L=OHNKTKU2MZD8)R6%P4?4>GSTW4E3QY'SR:NA4YN
M_H*$FL27)>]?2:UBC#.];5R$BYG;VE/1J%>;6Z,,K*.8GU!4=1NE3@TN"\U^
M$Y:'8JDVH[/-@XBK%0RH+\B$=7I6OSO*\;:M2II3>WL5_4>G1I7[;\M-OC"*
M[0XREJ%)Q;W*1TO4.).BJC6[>LI@C.A..FV'B;(^(EE)KN4DM>KSK2DJ<5D[
M/4KZRM;:DJMHJJV++*2?4FC+RQTB.5Z@AHVH1U!.TKPBMWK@H=1M:='5I49/
M%/?C)TMIU%IC>+;2]M3Z:.?O+C^*:FZ<*,J4MV,LJQ<W6H4=-L/BUDH5)</+
M7)4T->K4G)3A'S%Q5M:&DI4[Q1K5,9R_<>$];TB*2_AL9->J!&Q=1A?:%&K*
M"4F_1%!H;C_%Z5+AIRP=95U&A<:&O LW3CR<IH<5'7*<FN=W8$=7K]Q0T]N5
M.,=_NP<C?ZI5OF_Y<4NW!8]8574O*D&FL,YE[J;XEDTYZFI4E'$<<DM-?*6&
M'!SBFWM?O)DFGS+<$8@(   %           /L_P*?-Z\_N?^*/C!]G^!3YO7
MG]S_ ,48Y^G3Q?IPWPK?/K4/PI?ZXG(G7?"M\^M0_"E_KB<B:X^F>?ZT !60
M           $ @1+F+]Y)*>/3(7%_P!,ZE\5CX5R_P"4;VH:12U%[[#&7R\L
MY/,JG#;BO>;%&\KVRQ2K2_,-.@L^G_BC\34,**Y6&>'4FIJM&-*F_)%86"FK
M7=U46Z=Q*2?]+9K3S)YDVR(9Q&.>QU=G>4H]/5J:?F:.8VQ=+"[F$*TX0=/+
MVOT"5E)[N68>A*82]#0C+#;)P8@,$IOL0"(SIN,824N[['OI-Q4M+OQ./#-5
M1W/EX/7<G':_0-X[6O6T_6*:Y;JXP5-QTO=3>;51P_>SGZ<ZEH]]&;D^^$;$
M-7O>ZJS6?3('3Z;HM'3EXU_A5%[F4W4VI0OJM.G2;:IO"*RM=75QS4KS:]V3
MR4XQ6$E*7O"U?=*WRMKW-9^7!:]6ZE05';:OY2Y.+G.<8J4<J1E.4ZD4ZC;_
M !"5GI]7P*T*C;YDCN[O4K:IH[;?\Q1X/GTVG!;3UE7J.GL66L KUG=/QHS?
M*SZG65)4=1TQXE_,PDCB8S<O+*.,'M&O4IK;"JU]R82KE:!5@U.KC9+W,Z#0
M[BSTR>Q/G!Q;U*ZV*#G*27WGCXM1U=\IM?<V"MW5*E.IJ=:K#UEDMKV_HU.F
MH44_/GE',J?,O7)"J2<-CS@"PT:I&AJ%&<GPGD]NH:\+C4Y5*;SCE%6F_1\^
M@CY6W)Y8*ZS2]2I:CITZ-\_.O*C4JZ!+.ZVPXOWOT.=3FI;J<MOX&RM1N80V
MJI+\P5U>ET[31H_&9O%>/!RNIW4K^]JU8O*;RSP5>I6DXUJCQ][/*K35-IPG
ME/O@%=7TK?THQ\"X?D2-;JJ_A<5(PI/,5PCGZ<I0>Z$FC'=)SW3>?Q"5:=.7
MGQ+4.>(XP=7JVJ6UMIE6A;/BM',OQ.!D^=\7A_<92G.JL2DP5BI+<\>I$<1S
MCL%';ZDN/&04;RR     $D$A$ ,!0                             #^
M0TOE>@)2]5W0%[TOJ?Q*3C</RM89OWVD4M0GXMCS+[V<C)NIW;B;-O?5[:.V
MG5E^9!T-IHL+:;GJ&/+RL,\M?U6E4I.WM6\<<,I*FH7$N9U)34O1OL>#2SOS
ME@=3TW8V4UOO<J2Y6&6VH.,VZ5LUX7H<+3NJN,;G'!FKVNFXJ<L>\"^_A-/>
MY-Y;?O*K4[&$&W'O^)J_&Z^[FK+\R*M2=1>:HV%>$4XIKT&TA+']622X#PPD
MD :"+QD/N0#+*<Y[G5:%>4Z.C7<)/F2.41G.M.G'PXMXD%36Q);HGGPX/WF=
M)>7:WR81BUE^@6HCC'X'3:=>T:?3]6FWYW(YM86?O)@I*BXIO&0E;=E-1U.C
M5E\G>F7'5MY2N*R\)Y6,'.RGY4EW1C/>Y>9M@7>AUHT83R\9-#5ZBE<N433\
M24/DL9<UF0*F6,+!B    0  4               !.2
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MCC&,XR(N,DWRYLQ\-9W(G#VXQP8Q[--\$'I&3CV]2'3E-^@<L)8283499<L
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M I&$TI=A"K&,6FB*:E%YFN"9J$NS",5AR;2,B?+MQ%D "&20^P$
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M<3<3&:?H1*<<XP,*'R^#)>')93*S&+22X(,I23^3Z&(  !0 !     %#[/\
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MXTDIQ]3F'M4FTN#<Z@;EJ=5I\9-2,/(\FF6*P^RP20NY(0(?8DA]@(
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MU,6\+!*4IQPD\HQDLS4><E$11).,97N$4Y=@((?8F/FW?<8[LA
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MN-SD]LNR[&3JSB]C^25G[0XI+*]>Y QZDXQ'/H%0#**RFS'/.  )P1@ "<$
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MH4?#NIO[W_Y H+Z,:%[6@EQDU6URD;FLPS?5I?>:*7&2X  *R
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M-N,GG)2W-Y7J73K*?.<FZ]=NI*/G?E^XFK71ZS**T.SMY/;.$D\?D:^MU/\
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M?3EZ"'E6.XEYEA $M[W>AE-JJL(Q4ML=N,_>2L0[ $]JVD$K$N0^P$  *
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M>?W/_%&.?IT\7Z<-\*WSZU#\*7^N)R)UWPK?/K4/PI?ZXG(FN/IGG^M  5D
M            #*+GAJ*6'W,2&VN4P8ZSH2LJ>H*D\=C+6)T:VJ^#%Y<YX-+H
M^&=151RV\=C8E3E3UZG.I#R^)G<9:;E?XIIL-G_\7U3->XL[;4+&K<PSN@1U
M395KN^E5H1;@_<;%E35MHE>C5\DI>\%<A&+<ON.BT>-C2LY59MNLNR.?<O#G
ML7F6<9.OTNUIT]'J5?#52?=(1:4J%*_HU7CM')Q]:DJ-TU'LF=]HDU.WK[J7
MA^5G!WJ4+V699Y8B5>]'W-/XXXU.^>#=ZRO-E^J4$L911]-U(QOXK'+DBPZO
MH5/XFIX;7 BYJ\U6=&G86M6;Y4$S4IPMM3LWE=DWP>'4S?\ #;6*;SX:X,.D
M)_RZD)K&(,1:PT2QH5+:XG)O,)-(SZ9LZ-UK%S&LO)&.4>VCX^*W<EPE(SZ<
MG&5]=;4HO8^1"L85K9:FK=?(;:94=0V<;.O*I#Y-1\'C1F_XNX/NY/G_ "6'
M4LO$M:,4LN/J(FZHK.LJ5>/XGT#7KR%/1;;.//3]Q\YB\R7EY3.VUF$KK1;;
M:N80]!&:J;2SHUK5U7G/<TM)LHW6LTZ=3Y&[T+70Z;J6CHXQ)#I^PJT];@ZB
M:CN[LL:QAJU&E9:XJ-ORMR[_ (ESU#6H6ZMXR_J@LE=U%*,.I6HQ4O,N?\CJ
M_3Z]Q*V=-R:V+MZ$*:AI]&ZL83MUF3[F%GIU*UL)U*R>],W;"/\ #=/IRKO.
M?1FU<W,+K39SI4D\>B$*KZ5K3U&UJM+_ *<<G)WE.,9RC'T9V%O=RA8UX>!X
M3<<9]YR\+&I4ISJ-ONRYB;K02VK)=]-7WQ>[S4?D?&"E=.2<DV3:9C5@N?E(
MJ9KZ.M/MZ%M4O5\M^9%'9T?CEY4N+CY#1MZU.<M(IJ%3;Y/_ (-?IW^=8NDG
MF23,MU-.YL;B[5I-O;)X-*OIE..H.%%9IJ7&3PT?3Z[UA2J4Y**E\IKL7-6[
MIT]0=%13DI8R"J/7[-4;R--=FD;FMV5*UTNUJ0[RCR3U#95Z^ITW%2VX1N]9
MT'0TG3XYW-QY^X%<=3<8S51^_!T>K:7"5"VJTERUEG,N&9;4^W)W?1THWU&4
M;B7%/A9$8KRGI5&6A1GC^;DTM-T^E#2;N=3AQ[%I4JIZ].U4OY.W/W&KU6XV
M-.-"C/BJN<"+FM6OIU.&D4KB+?F^\VM-48].W#7;)BE__+U&$I9PAI;C[,W<
M'+S.7 BO7IK9*VNVOH''7C_]54_^IG6].I4K.YS+EP_^#D+OFXJ?_4P5TO14
M*;E5<C?OKRA_$/B\L;65724<1JYEC)IZIE:I%)MO*_\ (2K'J'3K:WK6THM[
M*G+-B%2UHV\(4^8YP>^M6ZKK3XREW2&H5(6=*%&-IXF&O,%J=2TVUQ3N(YXC
MDJM1TNGX%.O+.V;X.AU=):2Y+A[4\&OHLX:M9T[:2PZ7(A5?;Z92G9/CSXX-
MFK0H6%I3ECS/N9:A>0L]1ITXI;%PS9U*JE;TZBH^*I^@B57WFG6USI,[U94T
M<A)P\3#SP=EJEP_X-.BJ3I-^AQ^8[DI1Y7J6+726'Q2WL%76?%S@LJ5A0OM,
MN*Z7FBN"+&E2H]/QN/!59[L;<%CI-55-'O).EX22[$AFJ/IO3K>K<5%<Y22R
M>E.M:.^^*T^4V>_3\XSN*ZX6(LHK''\>6>/,^1"G4EG"A4>SWE+3DTL'2=3)
M.<GG)S<98]#3-&EGGN02XY><D!              )6U>:7H01+MC&08ZOHZZ
M@J]3_P"DQUNO"YNEC'<U.DY+XS...6AJ]I4I7.])XR9:=3JE2C2Z=L/'[1[%
M5_Z;4M-E*'RLX,>I:S73=@FLM\8-?IF*C9^9I<]@/33=+IQI5JC7,%DV]+H4
M-3E*C46,(W=,N81I74=BGQV-2PKR=Q.,+?P>,[@.0U6A.A>3IK&Q/"+/I:F_
MC7/R31UBJZMS->J?<W>DVW>>'-X^\-5T.N5K>WJTO=CDT=3L;6XLZ=>&<R?)
MCU5IU7XQ2=.3FFNR-_8J.DV\:BP\XPP-"SC:T+=QYR;&J:;;U]/C4IYW*.6;
M5S3ITK=SA24S9I8K:76;CMQ!X0546,(0Z1J8^4I_N.D=KT[4=WRL<?\ 8FR@
MO96JW+GQ'Q^9ATG%.QU%N26%^?8(\-$T^%S6E*Y^0LLV%<V=>^C;-^5/;V,]
M FKF4Z&=CP^2LH:;76N)[)**GW W;O0X2U!^$GX:/>]JV5BX4XOS8Y+:E>TJ
M%Y4H32;2QDYG7=/K3OX5*<7.+YX"O?4]/I*UH75/.:LEDW86=K9Z>[A?]1>\
MRU*M&WT:RC./FW8:]QX:K/\ _19S7W<!EG"E:ZI95IR^53CE''5*<7-Q]S.D
MZ1_F65_)\)0.;K>:M)KCEA%[H-M3N;"Y4^\5P;_3>BTY1<JRPN2HZ?J.-RJ2
M?$WAG5Z_4C8V$84)8GE=@*"&ETHZHMV=F\V[+3Z%;6KNG3;Q&&2ZG1I1T=W&
M4ZBAG_)S_2]Q*6IW-5_U4V!L=+U53U/PGWW,U.J+I3U1T^.)\F.E2E'7H5(_
M)4F>.O4)PU25>46XSGP!TV^VI]/2DV]V4:%O&VO+"X;[QB>-_P"70)8?JN#R
MZ5\UC>J?'E YFI2A"I*,7Y<E[H%M3K:3>S?RH+@H[Z6*TJ:CZODM^EZV*ZMF
M_+5>&!:=)Z53KTG4N%PTS6HZ736IMU,^'N+KJ.I'2[6G3MI>;*7![W-"FM(E
M6WI3V)@4DJ%C1OJKIMMHV;2%/48.FUP>>A4X2G5J3BJCVF]H%;?>[/B_AK+Y
M TM)=&PU&=*'=/ ZGG3N+Q4E\IH\II4]?K)K.Z>$>MZOB^NT_&ANAM^4S/)<
M17I4;2WHN"YQR>&KZ?2J:2K_ /J;P6VMW"C3H^%;>(G[BNU:M*6CQ4HNG'<O
M(,'IIUE:4M/=:OG.W)S&IUZ;N92H?(9T->6W2MK?RH'.V=A.M%ONDLG3&-:D
MI4FO(WN,>?ZNYDW&&^*AYD\&.<]^"I@ "*
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M2-2-+R<]SRCV9-*<I2DA%83 D !$,@ED      0    !0^S_  )_-Z\_N?\
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M<0;EU>RN'YC4Q'N8O+64B5EKL:0Y]"#*,4UW[&(  $           "5)I<$
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M<8XV8P:&7R0BI6=PTJNZ/RGR8Y?.[N1W[@J  (H
M           0M[EB/8DRAP\@Q/DA\ON;VFZG5T^MXM''N*URS/E9,WQW[!K'
M11ZGK.HIM1_(K=3U:YO[C/&$\HK8OSI)9R9*>:CIXVX]2(O+;J*XH4U"IMV)
M8(K:[=5E+&/#:X*.=/,'!/<WZB-1TZ<:;CV[LJ-VVU"M3HSCQRS*RU&M;^-Z
M>(L&E6BE'=3>Y?<90;G3Q*.W[P5G;WE:C7=2+Y+F'4E>C#$-KDSGGFFGM\YE
M2BFFZCP7#&W=ZC4N:WBUN)_<6=KU#<4J<8U=NU+".=E).>(\F<LM8?<*L]0U
M:K=RPL>&N3P>HW%6A*E#'AOAFI%I4]K7)YTI^&VI<98&_IVISLI3C2QN:PS5
MK3E=7#=7Y+,8PBY2GG&3%3DI9V\ ;%C>5[&M_P"EQMSSDO/::YA#R*/B8.<A
M\IMO&3*;\-Y7F VI:C=SNOC$<;D\LMZ75-S\J:AN['.TYR>5MPF(J+DXYPP-
MVZU*YNKN-9XQ%F-U>RKXSW3R:M)J5.<4^2'!0IY;RP-NO?U*MNX_X-%2GM6[
ML944I4I2SV9,YIJ*11E&<V_Y/_41T%OU/<QH1HU5'=!<'/JFD\J6&85&Y222
M[>I(+#4M6N+JIBKMQ]PN]2K7%*%.6-L5@T$G.IMEQQW&UN3BLX)N?0W8WM6%
MOX4.Q%C?2ME)0[MY-12:>R/+$4HIIOS,RKJ^E;INZKU6TI*.>YC>=25XW,MJ
MCM3P<Q0KU*4FJ<W'WX)E_,SF7(&S>ZC5NKASJ=D\HWZ>O5_B3HRVM%&LPXQD
M-AFK&.J7'ASC3PDUAF6GZK6M(Y6.Y6)M9P06+71W745:K1=)*.R2\Q5:?J5Q
MIUW*M2PXRXY-%,EMM8?80KHJG44WYY8W^F"AN)^-<5*]1\S/+OW'?@0K;TV_
MJ:?<*=OW^\N)=1U4_$>W>SGL$-9[B%6=YJ]U=W'BU,9P:^J7T[Z-+./Y2-7)
M"XS]XAV;L-2KRL51XV(]M*UFZLXRAY?#D^2L7"PB4(6K]=05(.6QI)K!1UYN
MM<>)/U>3!(%1.^*D\=R,8(PNY/<   (9!+(            ?9_@4^;UY_<_\
M4?&#[/\  I\WKS^Y_P"*,<_3IXOTX;X5OGUJ'X4O]<3D3KOA6^?6H?A2_P!<
M3D37'TSS_6@ *R              W*,E%IX8,E)QB\13;!BYZ?M;2K=JE53V
MM$:II;M;^%&G'^76EA%79RJ4ZJ:;4LGT[3*?QK38UJ]%*I2AF#?J9:<CJFF6
MUCID8R7\W\3FHK:GCL774%6O<ZC.,HM<XP:T]+O_ "N%M*47ZX%(KZ>VKF*3
M;7N,H4Y*,G*+V(Z;I"P@[VO&ZBHN,6\-?B3J-U;;ZENHP46_E8+2.8A1J)RE
M3B]K,? JI-23Y.VM:].C;0A0HPK/WX,KZSW64KJO15)+[B4CAYJ--+Q(L>'E
M;XQ>TZ76K2$;2WG1@I*2Y9ZJA2H=.^+*,=V<<BD<EE.M&*3RV7L='J3LU6<.
M&5=.MLN%4\-.*>3Z)#5J;Z9HN-&GG\"5'S>K2;KJG466'"=*3BH2V_@=/96U
M*]K.Y:6(/L;4M:H0K_%E:T7GC=@4CB]D8OQ(IJ2]Y*G*HVI>O"+WJ6Q5M5C)
M+&Z.[!5Z;2C6NJ<:CVK*_P ES2/*A;58/B+:,9TG"IEQEG/N.WU"XHZ6XTXT
MX3X7+1M7T[>G94KE4:;;CNQ@O8CYY6A)KY,E_@G>ZD=E%/>CM;JK2U#2=\:%
M.$WWVHT.G:5O;QK3GMG43XBT2M9CF?"J0A_/B_R+70+2G=5%"HLQ;.NM:?\
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MZH2JWJJJI90I\>B.2U2UA0O&G+#SV-5F-",5OGD@ER<)/$<Y]2 @
M             ! ((DDC P$J41P3@!<U X)("U( "((,B ")(1*!6/J"60%
M $  %             0  47J2@B45   00 10
M              #^2!)^3 ,93BH[&9NG*M+;31BUOC'[CINC;:E6NY*ICB.>
M0KGG;U80;47N7;@UZ>5-NNGN?W'9QU&VHZA*A&G3GSCE&OJ=C1G?>+5Q2@W[
MN#.Z1S,[>KC=0BR'S!*I%[GW.ZI7"I5:5*WMH5:;7,L&AU)I\*,J5?:H^+))
MK'84CD_"G'_H1;CZBX\6"IJ2:BWSP=S"F]/M4Z5M&M3:3<FNQ7ZU*A<JVS"-
M/<^<+L2CF949QYH1;C@\ZL-K7BQ:S]QWENG86J^+6L+F'TFBOU-4KZ=-3IQI
M3?HD7-6.65%;-U*$C"49K#<6I?@=S1HU]-MDXV4:L?>T+^W^.:?4K2MXTG%9
MX0I'#2C4E#*3<_7!FZ,8TF[B,M_IP=GI=M&WTR%Q1HQKU&^8M'GJ56G>6=25
MW0A;3BL))=Q2.,A'',OD>AE+=MQ%-_X%5[IN*XA'L_>=5TO2I_%'7JPC))^J
M%(YA6TJE-RVR\O/8\J4H[MLD\G;TM8HU;F5M3MJ7F>WL5FH6-"CK#A6Q3]<8
M%(H(TJLMWE>/3@BWM]U9*47EG<4+OF%*G:0E#MNQW-34G*UNU5=M%1RO04BD
MU32790ISC%XE')5P@ZF7*+P?0^IM7BM/HKXO#/AK'!3TZ4*VEQK>'&,FN<(4
MCDJ:CAP@GG(6W.W:]R+[IVG3JZI&C.*Y;]#85M1_C]2DXK:IX[%I'-^!4D\[
M7@GP:DO^G%Y1V74=S0LIQM52IJFTO/@4)6]I0A4M(PN)R7*:)2..Q./_ %(M
M/\"_T*QHU]*NZTX^:"RBXU>V=SHKN:EO&C+..$:^@-QT6]48K&WG_N*N8T.D
MM/M[^YJN<6VHME!=T5\;KRC%[*<FCJNCIRA=5=D>-K%G0I5[6_@XQ\24W_Y"
MQR2<9+-)/+%&E-5XJ79G0Z#IJ=S6A66%!9Y16:S.,;MQHX;3] D=/9]/4JMC
MXTDLXSW.1U*E&C<N$?0L*6O5Z-MX33QC'<J*LY59N<NXQC<8  T   ! (#+T
M ]  0 *B B00P  4     0R"60            ^S_ I\WKS^Y_XH^,'V?X%/
MF]>?W+_^U&.?IT\7Z<-\*WSZU#\*7^N)R)UWPK?/K4/PI?ZXG(FN/IGG^M
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M4<OJLW*Y<JDE*1M5=9G<;U'!4M;ZK=1\A&,&Y-^X#<XR:BN $T  0
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M9KE&#>6W@B/'8%0O+*2A''X"E%N692_,R3PV8M<Y"UGN49M8R8B/ES@!
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MOJC3]2M-8R,>@8] R@ %4                     2O4E$1)+B0R,@8*0
M( 8& 0  (  $ ,# (( 8! # ! # (0  I  $I  %P  54$@ ""2&!  ,@  )
M0")]X1B  H                          !]G^!3YO7G]S_P 4?&#[/\"G
MS>O/[G_BC'/TZ>+].&^%;Y]:A^%+_7$Y$Z[X5OGUJ'X4O]<3D37'TSS_ %H
M"L@          E#)  G(R0 -RSO9VKS!M/[C*GJ%6G<*K3E*+SEX]31 *OY]
M02EENGYW_44]W<3N99DWCW'@ 5[4*O@R3@L->XV)7\Y75.M++<#1 +K8N[F5
MQ5<WD]?C]3XE*VR]K-( NDLR2Y?!8:5J4["INCEKW%>!"K*OJDJEU"M&.UQ>
M<(U[^[G=UG4FWDU02%;BOIJCX>7@V=.UBI:<2S.'I%E4!"KC4-:G<TW"$=D'
MW2*BFW&4FWE,@%A6[0OI48;897X'A3KRC6=3^K.<GB 75UIMTKB]S6EA\<LZ
M/4'<35/XM&4XI>AP=-RC/,'B1:6^NWMK#:JG 7MKJ+RI3_A:C<4U"K'G+7+.
M1N-0G4C.G%O;G!%YJ-U>Q?BU,IFA%)9]XAVUN6-Y.U4U'/F6";.^J6MPJM.3
M3[\&F E66IZC\>@FX)37=^\TK=]IR>7GLSR,EPN 5W.IZJJ.EV\4]WE['-WF
MM5*UOX,$X+WHKZMW.O3C3;?E/'&%SW!6Y8ZA6M6_/)I]T64^H9.DXTZ>Q^]%
M !%NMNA?5J=;Q-\G+.<Y+2'4&*;4J*<VOE>I0 0NMZ.I5U<^*YR;_$PK7<JE
M>-6/EFGG)J 0NKBXUF=:W5.I'=+Z3-=:A-4I06>>,FB@(EUOZ=J56UEYG*<?
MHLV[C793H3ITX;-WJBE,09NMNRO:EM.<LMRDL-F#N'N<EQ+WFN 5NRU&M-4]
MTI/9]XOKV5U)/F.%@T@"IB^&0N  )!  G(R0 )R" @)!("(9!+(   *
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MJ'X4O]<3D37'TSS_ %H "L@   (              $HDQ1.0B2/09 $  *
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M:Y80MK7*^4;T;RRIZ@J,:24D\9,^K7"5![<+CN,U'$ A-9?W&>WRYRC;+$
M
M                  +U 0&2(?<9("8  *             !]G^!3YO7G]S_
M ,4?&#[/\"?S>O/[G_BC'/TZ>+].&^%;Y]:A^%+_ %Q.1.N^%;Y\ZA^%+_7$
MY$UQ],\_UH "L@
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M*+P^QOZAJ$ZM.E%>B-2;;AE&F"<4L8,25EKD@*
M
M                 ?9_@4^;UY_<_P#%'Q@^S_ I\WKS^Y_XHQS].GB_3AOA
M6^?.H?A2_P!<3D3KOA6^?6H?A2_UQ.1-<?3//]:  K   H
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M_P"Q  E8:>>_H0F]N  B6^"  H
M                                 P2B?0(Q  4
M          ^S_ G\WKS^Y_XH^,'V?X%/F]>?W/\ Q1CGZ=/%^G#?"M\^M0_"
ME_KB<B==\*WSZU#\*7^N)R)KCZ9Y_K0 %9
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MX.UUJWHV%G\>MYIREY>#Y]<5'5JRFWEMY+AN?3Q!*6>Q"Y*Y@ "@
M
M      E$^\A#(1  "@       @  H                ?9_@4^;UY_<_P#%
M'Q@^S_ I\WKS^Y_XHQS].GB_3AOA6^?6H?A2_P!<3D3KOA6^?6H?A2_UQ.1-
M<?3//]:  K(
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M;/*#BJJ4?1EPY>D-N$F3&+46-DJM:2BLX);<7M97-@DT22WD@   H
M 2B"4$'VX()?8@*
M                                        @    "A]G^!/YO7G]S_Q
M1\8/L_P*?-Z\_N?^*,<_3IXOTX;X5OGUJ'X4O]<3D3KOA6^?6H?A2_UQ.1-<
M?3//]:  K(               (  *
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MJ<33[#-2  *@     $H@ 3D@
M                                                @  H    "!]G
M^!3YO7G]S_Q1\8/L_P "GS>O/[G_ (HQS].OB_3AOA6^?6H?A2_UQ.1.N^%;
MY\ZA^%+_ %Q.1-<?3//]:  K(       (  *
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MO<VW+A_>;U]JE>]EF6./<:<L3>]]Q$K  !
M                                                        !  !
M0 !  !0 !  !0     /L_P "GS>O/[G_ (H^,'V?X%/F]>?W/_%&.?IT\7Z<
M-\*WSZU#\*7^N)R)UWPK?/K4/PI?ZXG(FN/IGG^M  5D
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M&$81;<N_H89>6DN"6DV_$3304N,)/ K,0 "      !
M
M                  ^S_ I\WKS^Y_XH^,'V?X%/F]>?W/\ Q1CGZ=/%^G#?
M"M\^=0_"E_KB<B==\*WSZU#\*7^N)R)KCZ9Y_K0 %8  %     0  4    !
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MI6_AQBWPFC1M;"A2U2XI5I^6';/J>G3FCU;*^\:O);%+)9V]&WNM5NW)*7N
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M5J)HN8R\@ 5
M                                               0  4   ^S_ I\
MWKS^Y_XH^,'V?X%/F]>?W/\ Q1CGZ=/%^G#?"M\^=0_"E_KB<B==\*WSYU#\
M*7^N)R)KCZ9Y_K0 %9       !  !0
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M;?(CW8?<(@
M                               !  !0                  #[/\"G
MS>O/[E__ &H^,'V?X%/F]>?W/_%&.?IT\7Z<-\*WSZU#\*7^N)R)UWPK?/K4
M/PI?ZXG(FN/IGG^M  5D            !  !0               0  4
M            ,H=S$E< (<ME'U7;*XM&GZ%XN/\ )XW]%5;:2:SP3&=?(5'9
M*:EZ,\JRW;7%\)F]K=%T+N44L9;-2*3ACUP;QS9.567F4Y)KC"9$'6@VVW^9
MYP4EGS&_8:?5NW)QDVEW,M8U76G)8G)LB4Y3E&,7E%O>:'6HVWC*+<<XS@FV
MT"O.BY\Q;7&49^3!3.%15'&;:A^)E%U%)3IMN,>^66-+1;F=PZ,I2<ESC!L/
M0J]#^;ERIQ^5''<N>3%4]2K.?,YR4?Q/+>JK_E]CH[ZS\:RI>#;N+;YPCRJ]
M/U/ <H+PW[L%^3!1N>Q-1;;]?N,H2EX;<&_Q.SL^F%_#95)X<]N7P4-OHU5U
M9**;AGND9^3$5E*I5VR\S7^2;6YJ6U=592<E[F\F]6TBYH5=LXRQ/B/!L4NG
M[C<XSA+WX:+GDQ8PU7J&I>4:=*.%!+#P5BQLY[&]'2:KN?#5"6,XS@][S0Z]
MO'*BVO=@ORX11;Y2SMDWCT,XS<$G.<HY[89;6VB5JV?(X?X-._TZ="6VKG"[
M-F=\F)8UG4G*2<FVO>V;NGZC7M9N4)MI>]F-"PJU*+J1BW!?<>];0[JG2A5V
M34*G;@?)B5KZA?U+^\53+4\8X9J3E5A)^+*?/;DOM,TJ5*Y2JT\OW-%WIO3<
M=0IWE26$Z:;2:[$[XMUQ5%5)0>,X]QY0DUO\23W>AWFC:'&O!T]J<N><%!JO
M3]:$ZM6";C3?.$2W?I<4WCU*=/*G)9]S,%*+]7N(JR:BEMS@CNT]ITXXA'.3
MJ.CK;=>0J-<(YC&9Q2]7@^B](V?AV:FUYC6F.DGPL>A@9SYBL&!EO  !0
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MJ2RIQLK>XA2495)<HFZ.-C;2JU5X2;/:ZL*M&,923.RMJ5K:Z'4N71BYQ_\
MR-)JVVKVEQNI14H1RLF*KA=KD]K[&$/)O@LMOA'M=1E&O."X>67G2NGJ\5:I
M.GN\)9[=Q130L+B=FML7W,)1>-DEYEQ@[BA54JS@K5QAVQ@KM1L*5MJ5NW%-
M3Y:*N.?AIMU6HIQI^1<Y/.E1?CJA%-S?H=G\8\&LJ=.W;@VEPCRUNC0L-2HU
MU02\J854ZAH,[>RA547N:Y*'BG)Q?<[_ *@U2F])HR\/"DC@ZT54J.HF:QG6
M*6&W[S%]^.Q._+PR6UC 1@
M                         "4N""5V#"(  4
M    0  4     #[/\"GS>O/[G_BCXP?9_@4^;UY_<_\ %&.?IT\7Z<-\*WSY
MU#\*7^N)R)UWPK?/K4/PI?ZXG)(UQ],\_P!:@$X(*P  *
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M                          B5V#&1G@"  %
M !  !0    $  %#[/\"GS>O/[G_BCXP?9_@4^;UY_<_\48Y^G3Q?IPWPK?/G
M4/PI?ZXG)(ZWX5OGUJ'X4O\ 7$Y)&N/IGG[U)B9&)6  !0
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M*L0IY6PG"@G@RJQ=*&]QX['FJ4]N[#:%2(W<D2?),7A\F32] C%+"!.?0@
M H                @                    0  4
M                                               /L_P*?-Z\_N?^
M*/C!]G^!3YO7G]S_ ,48Y^G3Q?IPWPK?/G4/PI?ZXG)(ZWX5OGUJ'X4O]<3D
M37'TSS_6IR0 5@  4          0  4     2N!D@!  !0
M          E$$H"2&2 (CW(Y3Y[$L,N(J-=T^-U1EX<?,?.M0LIVE:2FLY?#
M/KJ2E'#*+6]'C7I5))<X]P2/F<GA^\S4/+G*-J]LJEK)J4'C[S2C3:;>66N>
MX+.6@FLN#7#,E5;XP)M4VF-^S/IUG05&UC=55))3<<)MG:2B[/1[B%6O"6YY
M23/D%*I5C)U*<FF_<STC=74TX5*L]K_]QRY8U6].:AJ\7"23<^Y]%TRC.HXU
MKFXIRI*.-N3Y,E&<Y9F\Q-A7EQ"EB-:>/_J)\:U]#T2=M"YU.E2DHNIPFV5F
M@RJ:9U Z-:7B4W]'DXZC>2I1E)59;Y=^2WZ=U7XM6<[AY>.\B?&N:Z_JJ\I6
ME[:_%^(U7YCTTK4[>UOI3RLR6#Y_J6J5;N[G*?:+\IHNK6<]^Z23^\G35KZE
MJ?QZA;5:ZNJ?AOS;4^30TVK'4[>K"I4CN4>[>#@U=W,UMK59[?<Y'@KBK3G)
M49RY]S-9Q9K9U6C*SNJE.4E*FY/L:;[)Q^3[C)N48-UGEOWF"6%GTD=,XIJ7
MPNY,5E'FZ,H>;DE9FO=@TP/F32_,]*$%5GLVMR? ITYU9>%!99V'3FA=IU(O
M/X#=7,3TSHFV4:E2/E.UV1C%*GPDC&C0A0IJ,?0/.?N)6\P:Y,D_+@Q K>)C
MQG)    $           "6UX<ECD@E2@DTWSZ(FF.GZ(DHRJK'.UF5M8JXU+?
M+F*D\H\^B%4^,U]T<0V,W]&JJAJZ2Q+,GPS,:A5=K2O'2E0GC.&:M_845JT%
M22A0VY<7[RQU*ZO9:G)QM(>$Y?**W5XRK:O".=KVKA,16]=.VM71C&C)P?RL
M&B[>TN=5Q3IN%+&<2+/Q;NV=""MHS@^,L\;^U52^WYV3]R$&=U\3MJU%>!)Q
M]<'/]1RMIU-UO3E#/O.BC7O85*<';1E#T;*CJ:G!IRX53UB@BJT.G2_B-)5E
MF+9=WFE497ZG3AY-R.9HS5.JIJ7,3Z'I<*=;2%5E);]K8&AU'IEO5M?%MH8V
MI)FKJ5A;T]/TU[?-)K)O]+UX7]*K2K/^MHI]=K[M3I6T7Y:<\+\P,M=MZ-G*
M-51\N%V+[5+RVIZ/0S%^:'!2=13_ )$8-)\(WKZU=WH]%Q[PB(IT7.C4OIRD
MGMP8U+RPEK+H^$VG/#^\UNDJ<J5S-3X6UE122?4J>>%4$%GJ6E0N-7G\7CBF
MN<,][VZL+:K2IJC))+$C8N*_@ZK-QPT^#4ZDL+FYJ4Y6]+.5Z"#/5["VN+&W
MKVT,;GE_@>6I:?0CH52K&&)IX-R<7INCVSK\5'PXOT)N:52^T2HZ4<Y?9""I
MZ;M+>YL;ISCF5.)9]!W%"&I^%*#RL_\ D=.:7*WT^]E5S%[#1Z1EC6)?Y_\
M(@UNH[FE4OKE4^,2*6SGBM&37&4;O4NGUJ.I5*B3<9RR:2<H[8[5G*$'?W=[
M;+2H;H-^0K;"TMX6T;SPWMJ+"1XW3<-/@\)^0L=-JRN-(I1H14IKG:(KSMX6
MEU&5-T9;GV;-32M&I._N]\-T(+*P;D;G4(R:=K%4UWE[C9Z:OH_&;Z+474V]
MF(-&U^*5;KPI49)?>:<[*%KJU&5/Y,I<(LH3U&5:4G:1C3S\I%3*K+^*T=W=
M3["#WUVG"KK7F7.$>-_;4U?6=.2RI?\ Y/?5=U37=V.-J,-0BWJMB_1,N)K>
MU#XAI\%OIMO)C=6]I?:55N;>#3@N[-'JQ2J5I*/8V-%DH].7JJ/!43I=M2I6
M,:US!S37&#>HW%.II-:=&#C)/"R>VCTY3T>CX,5/CU-:_I7\-.JPIVZ4&^Z#
M4<;>U).K)S><G0=$J#U&$GVP<S4A)59*OY6CH>DU%7"FY-8035E<7]A/5W1=
M.6[=C)JZ[8T8ZDG"/D?H53DGU!]V_N7>NN,+J,U+/8(K^K+*A1IVDJ<=N8\G
MK*QH2Z?HUMO+9O=3V%:^M[-THY6ST/6ZM7:],4:<^))@:W3EG;?PFYKUXYA!
MGK9W&GW4JE*E3?"X/'35&'3E[%RY;*GI9*-]5\V>/4+C>AIM%ZO&FX]^<&[3
MG0IWW@1HRS%X;P>E"A&>OT9J7..Q87M.^IUYNA:QDGZX(JKU",*VM0H?_P )
MKE&>M_P^PME"-/$Y+&33H?&*NMIW4-CP5W4DO$K;-W"> 1NRM*%UH$90C_,S
MW(T>RC_#[B=PL[.QETC<TI55:3EPEZF_K]".F49V]"6?C')<3?3CK^,'4DZ6
M.YX0YIR;XP;U?2:MK;*XEN:D_4T&YUTXQBBL(7O)(C&4%MEZ$A  !0
M
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ME).$R*OFX78F&$N6PRQ\S;<I9!,DO0@*
M                                      (  *
M                   !]G^!3YO7G]S_ ,4?&#[/\"GS>O/[G_BC'/TZ>+].
M&^%;Y\ZA^%+_ %Q.1.N^%;Y]:A^%+_7$Y$UQ],\_UH "L@    (  *
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M_,E%LN8K/9(R<&1K,>5*E3HK$4CT7)CMPS--=@UC&3Y(,Y0XW& -
M     0  4       $  %     0  4  0  4       $  %
M                  $
M
M          (  *     !]G^!3YO7G]S_ ,4?&#[/\"GS>O/[G_BC'/TZ>+].
M&^%;Y]:A^%+_ %Q.1.N^%;Y\ZA^%+_7$Y$UQ],\_UH "L  "@    (  *
M  @  H                                        $"4 1( 2(8QDD!
M4)->H:3]"0!&SCN0N#(%I#N$\>@ I#N1@D"D0GM)4ON (D._W$<QSSDD Q$4
MWW8E'#RB0%/$;CAHQ,O0Q             9!&()9   !0 E 0#+T(81 " 4
M              $  %             0!/H&!  "@
M
M                                                  "  "@ "  "
MA]G^!3YO7G]S_P 4?&#[/\"GS>O/[G_BC'/TZ>+].&^%;Y]:A^%+_7$Y$Z[X
M5OGUJ'X4O]<3D<&N/IGG^M ,#!6 # P% ,#  # P  P,  ,#  # P  P,  ,
M#  # P  P,  ,#  # P  P,  ,#  # P  P,! # P% ,#  # P  P,  !@
M, "402NX$@        $$JI!!(H $"@20."X0_P @ $2@ $1Z$$^C(P  P,
M,#  # P  P, #(Q1D!#()(P$ ,# 4'J,$H"2&20$0@,# 4 P,  ,# 0 P,!0
M# P  P,  ,#  # P  P,  ,#  # P$ ,# 4"& @)] R2&$0!@8"@&!@ !@8"
M &!@ !@8"@ P  P,  !@ !@8  8&  &!@ !@8  8&  &!@ !@8  8&  &!@
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MK7#Q]=K( &78
M
M
M
M
M              &TEE]C3N=1HT'B4D!N \:%Q&K!2B^&>R>0
M
M
M
M
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M,PC)2>Z+X,TU)!3G=]Q)"X7</&,9 DCG=]PRHKEF,6L/D#,
M
M
M
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M<L?@!('_ (   )Y;0  9  C.(MLE<K( #G/W#( $//H2NP
M
M
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MJ%:-6FI+N;,'E!<VI  4
M
M
M                      @ (<4^Z3/*YMJ=Q1=.I%2B_1GL -*EIM"G!Q4(
MX:,J-E"G0=/"PV;8"15W>C4:\,*,8LQLM$H6\<3C&3+8 BGN-#I5;B%1XQ%]
MC<_A]'P]FR.,&X 13T]#I*G*,L/)Y6_3MO1G.24?,B] .N*+V<MWG,8/_!ZT
M-"H485(I1\RP7 !,<_#ING"/EE%//<LI64?B<J#P\QQDW@%56G:73MX.,L29
MY76@4*\G+;')=)8 2-*UT^G0M_#26<8R>/\ ![=TYQE3B]S+, BKM](HT/\
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M:%'F*CN]Z+T ZXU;:T\&.'+)LQ6$2 9D  %
M
M
M
M
M
M
M
;                                '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g915839g82a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g82a01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2-.4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             A4   .;          $                          0
M           #FP   A4                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   A4     4F=H=&QO;F<   .;    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   (5
M     %)G:'1L;VYG   #FP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      8M@    $   "@    7    >
M *R    8F@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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MNUK1]*Q[OT=;/WUZ-T'I+\5AR<IK/MES0Q[&P134/YK"JV^WV?2O=_AKO?\
MZ-#JM;/3L"CI6%Z8<YQ8767W.B;;"/TESX_S6-_,_FU:QF.;7NL_G;#O?Y$\
M-_L,]BCD %]-1$L>_P!P\F!UC1_G-1T5+K%^LG6;,"BO$P8=U3-W-Q@1+:VC
M^>S;O^!QFN_Z]=Z5*O\ 4^I8O2\*S-RB156/HM$O>X^VNFIOY]MK_96N5QJ<
MM]UW4<\$]0RP#8!);34/=3ATG_14[OTCO\-=ZEJ2#?1O]$Z=CX>(*ZW&QY)=
M98\R]SW'===:[\ZZ^S])8K-AMI.X:L[A4&6/K<'-*T<?)9<(.CNX1!M%4RJR
MVN&I11:'<*ID89)WTF#W'9%QJ7-'NY10V4A](?$?E3Q"8?2'Q'Y4$O\ _]*S
M6X[W?UC^57ZG@M@]UDMLBQP/[Q_*KM-L?!,;B')+JK=PXE7&6;V JGG^/BIX
MCR:X\$%=&SN(3M=JA%RE7RBIEG":&D]ED^J*K18!NV'< >)'"ULXQBSX:K!=
M8'/CQ3A\I:T[&0?1Z#IG5.F.ZO3G=0:UAVN.X-]HM$-9D6M;_HV&QGJ?X+U/
M4?\ Z1=-E_63IN'G4XV2Y]#,E@=1FN$XSR[\SUP=N[;[O^_KSBT[:VNKEMM9
MD/!U5GI_7'4TFF]C+,6TD78]@W4./[WICW8UGN_G\?\ MU6(1D*U79<9XCP]
M=7T^UK+ZP"[8XPZM[==1JUS?WDL>_P!2C>^&O9(M!T#7-^FN<^JC^G4^L,?.
ML;B.8'5]-R"US:M2ZRS&R23Z]'_%_P W_AOTJL]7+^H 8F*",*[7.O\ HE[&
M^UF'7.VS9=_A[O\ 0?HO\*G&F( GHUCEGK&8.HEI.!BN/[.:[A[H+'YYK_.W
M>ZO#W_X']-_AD[K[0ZUK22VR#N/@?I5_@C/>&L:QL-8P=M! _-T50%IDMX<9
M^],O5D.D5)I(,@P0G3%%C;^)G!WLMT=V/8K19M<.TKGBK6+G/J]MFK?%.$D$
M.N4W<?$*-=S;0""#*(!J/DG(?__35K?>X_RC^5*JT@[7(A]Q=_6/Y4"QL%1M
MQMV?I:H[A/AM+="@8^0W@\J_2&D2$E=&+N42D:J#Q[B$6J )25T8Y^N,\>#9
M6#6R7Z_);N5K6\?R5DEH;!3XBP6OFTD/)E37;98^FEF][_<2> /Y3OS6JOE=
M(R,<;7.W.>Z0U@)U/MVZKH^C8%)H]?))BW5K)@;1]%S_ ,Y%R;NGU/\ 3QJV
MMM!T=WE1G<LXE8B:V#6Z-TVCI5,V>_)L.Y^X[FL/[M?[O\I:KL\V:-(CQ"Q+
MW9 .H,'S5G&<-H\4K62'5T7.FH">>5"!)CB3" ZR(:W75%!T1BQY- &:2:4\
MIS&J$Q">4Q*2F=5]E)EID=PM/%SZ[2!,&1H5DE18(M8?Y3?RA$&E$/\ _]1J
M;0XG^L?RI[1*%C?9)=_2/I.Y]/Q*M.^R0)]>?^MJ-MN9:75NGP6A@9TB#R@Y
M/V"-?7^7IJO1]D]3V?:?_ DDNT7!QD<*;70S3N4*C[-LU]?Y^FC#[+M;_/<_
MR$E*N!>+0.162/EJL,WC>T.XD _!=)7]E^T'^>C:9^AQ&JR<G]B[O\/\O33A
M=%ARUQ1MU,>U^2W<3Z;.P[PK-=+"X1Q\ AXOV/TF>GZVV-)V*S5]FG_"_P#1
M4:\VO;2Q[8C3Q55]3*03]RT!]GC3U/\ HK.ZKL^SO]/UMT:1LGY;DB@(*+6N
ML)[C0*XUP*Q,'TM-OK_/TUL5^A GUO\ H)\=F*=WJEE*4AZ'_"_]!/\ H/\
MA?\ H(K%I2E/^@_X7_H)?H/^%_Z"2E2G9'J,_K-_*$OT'_"_]!.ST?49_.?2
M;^YXA)3_ /_9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#(T.C$R.C T(# Y.C0U.C(P ')R,SDR-C,U       #H $  P
M  '__P  H ( !     $   .;H , !     $   (5          8! P #
M 0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M     0   48" @ $     0              2     $   !(     3A"24T#
M_0      "           _^$!3D5X:68  $U- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H
M   !+     $   $L     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,C0Z,3(Z,#0@,#DZ-#4Z,C  <G(S.3(V,S4       .@ 0 #     ?__
M  "@ @ $     0   YN@ P $     0   A4         !@$#  ,    !  8
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M8]I_E#ZC_P!OC_<4_P#"#\H?4:_U^/\ <4_\)XM3W+IICRZ_5_AQ_P"8]?\
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M 05#!( 5(P6P0!&"<  1 $^! $, ?(!0  $1X$%B, 0!(!4 3@, Q!8C!(,
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M@2&&! (D,!0020!&""Q $$H@E 25+>!4 W!< ""+%? DCP"A9)( (E 2N"
M@D    J@]#IGO&E\3_6SSIZ+3/>-+XG^MDK7+RU[[\N/Z27ZV*0R\]^7'])+
M];*(YO7$@01D*NF63%I[%LL"Z9)5/8CN8#$RNV6"!\L"^4BG/)"++8"DZ:QL
MC+5MU+.QMR1A/)G"=97"N[%23RDSAWVDJ:>R_J/;SIIHQU[923PC-Y=^>WS&
M_P!(>7A?D.-<V$J>?V'U.YL%+.4<:]TJ,D_1,^#MSV^:]DH2><EHRP>GOM'C
MRD<.[L)TV\(Y=<_;M.XSJHD#JY1GE3G%[HA*63.+Y05ZF,F*5TXLU58.2.?<
M6TFW@)I\+S+QDFI44DT\',C0K*HL(U0HU92RQ*E(KT%G*P-M8)IHU*WG..&M
MB].S<'LBZC.X[<&:K1D\[,[2MGZAD+1/E%T>=A9R;X?]0V.G-_\ Z/21MNU;
M(HJ:[GDFCC4=+;\%_4;(:1[%_4=BVC WJ$<<;C37GZ6F*.W;^0>K-17V)VZ=
M.+\"E>"QL4UQ9T5%<"HQ6,X-MSLG@Q0]*>"Q-T13D\),WVELY8;6"UK2BMV;
M?.=JQ$U(F-%K1A".[63I6M>E2YC%G"=5[[D>=?K-2,_<>HJ3MKF#CVQ.!K>B
M0E3[Z*CGV(K;5L36YW+6KW4I9?@7#RL^WS:YM9T*C3S_ %"]\'IM9I1G5DV<
MB5M%K8GBS_:2L"DTO$F%=ICYVS2>!#MGG.#%YKT\?/*VT;AKQ.M87DHS7I,X
M-*G-&V@IJ2SP3*O?RS'LZ&I.5/M>6L&&O'NJ]\6DS#:U'%8R:8R3>=\FN7@[
M[E=K3]0J48J+<FC1<W2KO9,Y%*65@UV_H\';EY.^FVAE;/)J@^W?)E@Q\=T7
M7-JHUL/EG2MKK'B<6*W'TYN+-2LO2T;C*\393J;'G;>X:.K;U\Q6349L=.$Q
MREL8Z<TT/A)%U&F$MBR8F+2&1DBRAB!K)":R3W) 5<2C0_T6MLE&OC(A45N*
MNZRHP<GC8;4]"+EPDCQ'6'4,;>C-0GN2U,<7K;J&4FZ%.3R\K9B/)KTQ4NM6
MC>W47.DUXKVG#Z;TRYZFU?SDHYI0FF_#8_0>@Z=2TS3H4*4<1BC.NO,-HVRH
MJ'FJBC"*W2-":E)N+V]9QM3G7HRE&CQ+DUZ1*JZ*\X8KI(;=:?0N9YJTXR?M
M&4J5.A3=.E!1PMFA\4\/UD=N^9%E'YQ_^HFM?0A5IJ525-Q>R1^:GX;=DO$_
M?'6W2%MU%;S56'=)K')^;^N/(]>6<ZU:SHKS<<M[^!=3'R*QU*O837FZDMO4
M>_Z6\H%Q;5(*I4J837+/GFHZ9<V55JK!I+V"(J7;E;-%U,?K3I/K^WNJ4%6F
ML^V1]%T[5[>ZBNUQW]I^%M*U:YM)I4Y8P?3^EO*-7M7%5:O'L-\UB\OU2^U[
MHNL-,^<=.=?VM]1IJ51N3QX'N[*^I5TI1EE-%8QKQN#6Q#J)RVX+3<7)*&34
M3%<$-;#*D6E''+*.,LDI%,;DM;!AKD$\F54:*C>WUD-(!8#,(AK8+%,$%@P!
M3&P8+M%0( D/!@1X%22 @! 2 $$@! $@!*(       ""J#T6F>\:7Q/];//'
MH=,]XTOB?ZR5KEY2]?\ GMQ_22_6Q:9:]?\ GUS_ $DOUBT\(YO7/2^2$1DE
M!5D2BJ) MDA;$$9 8F&=V43!OD"Z8)E,DI@7;\28LIX,%L##N44PL/)*>P<L
MAY85*FI9V,M>UC)/8Z$8KU$.*P,;Y[>=N-/BT_1_(<>]TI2SB)[65%26#+5M
M4_!&.N76=OG%WHVS]'\AQZ^F2AEI/^H^I7%BFGM^0Y%SIJP]C%Y:G;YO4MI1
MY3$JCGE'M;S3-GB/Y#BW&GRAG"_(8L=)7%]S0QG""-%>HTU*<H-Y%Y,68Z<_
M:%!+P#"SP0YX(\X%PQ_$2I&=UB54]1-7Q-E5V,SJ)M[E:M3DR=[[FRPQT*%3
MTCHQK>CNSB4*F_)N[LPV#-CJ4:B?!:M)8,5M)X2-$GE%2Q@O'LS%:O-9(VW4
M=CGP_<ZF66''MVGM!8"GNC/1K=\<#E-16#<KI]*R>[#)5O.0@TW@NLV1:FVI
M'2M[I4X2R_ RJ"4&S!=UFMHLWS]O-\E^KAE]7[ZCP982]8J$G)[C=L'3Q?/[
MZL-CVRV!TD%->*+Y)XKQ\UBBII>!>*2?@5R"Y)X-=?/:TQ>!L&\F6,S11DFR
M<\N?E71MY;+)MHO<YU)[HW47EF\QG-="DS33X,=)FNGP2IXTZ/);&V2L2_@(
M8F$FC70N6E@R10)XDS98[EM<^TZ5O53\3S5&KVLZ5K<\;L,X[JED9%G.IUNY
M<FFG4R:AC9$9#?;.XB$LC8?9(&+Y[&-:7FW+U":J[N#G:MJD+*SGW/#QZP8Y
MG5>LPM+:2C))[H^0*%UU+K2MZ"FZ<O\ 21JZKU:OJFH0M[:4FI5.UXWY/J/D
M\Z5AI%K"M4@O/YSG!BTD>@Z/T"AHVGTTHIU7%9>-\G?;?/@2TE'N]1-*:J0S
M@QKI(I4HQJI=R+TX*G3PD67C@&%1&6SVW)^R6X840[L\$%8[>U&>\MZ=>#C4
MI*2?.4:$I>LE]WBQJ:^<]6>333=;MJGFZ-.C-^J*/SYUMY*+W2:TY6].K4AN
M]D?L.J_-2<W**CCQ9AE[BU>-2G.,9J.SX9K4?S_OM)KV-27NF,J>/68(R=//
M;/+/VAUGY)]-UBG.5&A'N>7P?G?K/R8WNC5*DJ=/T5QVQ;+*8\=IFOW5A*+B
MY83]9]5Z0\I<HQA&K-;;;R/BU:-6E5G2K0FFO7%H50<J#<XO\IK4\7[0Z7ZT
MM;J&93@WCC)[.QU.E>1S!1^-'XBT3JBZL9Q[9R:?@CZUT?Y1JU%059U$LKE8
M-:S8_1=-^FVWL35J9F^U;'D^G^J;;4**DZBRUZSTUO<49T_1:?XQ*SF')*15
MQ[<D9?*)4N[9A$=W<!/:H_C "N"&7*O@+%,!@D (:V*#'P4 @,$@!7!&,C,$
M!%,!@M@@*C 8) (@          @D"J#T.F>\:7Q/]9YT]%IGO&E\3_62M<O'
MWTL7]SM__++];%1DR;]XO[K^EE^MBXLY/7/1J?L+*0K()A3E(MW"(OVLLGD!
MF2,$KC<E;E5"R3^,D@ )(( NGL"*HG/QA8NF3%X3*)DIA,ABD')3.Y9,$D61
M5KQ#(9(E5E%-&:K;J2V1L\"(X6[)C4M<6O9II^B<J[TY-/8];.,7X&:I0BT]
MC/C'2=5\]O=(3R<"]LI4<]JR?4+JT33V.'>Z;&47Z)CKF.W'=?.*G='.4*4U
MG<]/J6EM9[5^0\Y7M9TV\G/Q=^>B)OMXW"G+/@5[6L]PRGC!G'38I5\<&22Y
M-\X9$3I\DQ&>GE/)NIU6EC!GC#<=%%8KHVTO13-6<QW,%":4$GR.4\@D5N&C
MGU8MY-\]^3+5CB6W :G,*H3G!\9-/?*2RQ<'OP;;:UG5>R-34N1GC4DUP7I;
MO+V--U;NU24ERC!W[['21Y_D[_&VK<]L,(YDY=TF_67J2;*8V.O,>#OY.M]H
MCL,2RRJ1>)T<;=]FPV1)$>"0B SA$^!5\,&!2W-%"6YD1HHLSZ:=.C+@Z%![
MG+HO='1H/<&UT:3-=-X1BI&NGP1=K3%\%Q46,R&4Q# 1+K@:*ICZ59Q$$H:.
MM:7/HX9T:-9;8//0DU$U6M=YW9N,UZ6E/;(Z$^Z$O7X'(H72>%DV>Z(4J4IR
M>Z$J&W-Y&VHN51X>#Y/UYU&ZLY4+>6:DDTD=?K/J*%*C-9W>R63S_D_Z=JZY
M>/4;R+=.G+_214UU/)]HU&RB]0UA]GG8YCW;[GUC2-9LJUKBA4C)K;@^%>4[
MJ&:K1TVSS3C0GVY\#R>E=2:EHEQ&=2M*=-;X626,^5E?KFEB<.Y/\1>GOOC!
M\CZ+\J-I>]E"LG&H\+TFSZI9W$;F@JM.2<7[261TYZM:EMG 9WR1!Y1)AUB<
MYV*II-A'[(57N:5+/>T@S3MGPSF:OJ=.PI2?<G)<(U6]S2J3]&46*U+2Z%ZE
MWQW&(^=ZQK5?4:,I3FZ4<XRG@ZGDVMZM%74ZDY3[GE99KZBZ9C]2W"V7I]V=
MCL],V/N.S7<O24=R*[&[AE\^HPW6E6UU%JM0A//K1N3\YQL2U+PD@/CO7?DB
ML]456K;04)23>(['P[6?)!JUI6G&UMZE6.?6?M-1D^7D7*G&+S**?XBRC\D=
M$>2ZI"]A+4XRI[[IO@^OZOY,].N=-Q:3[9XYB?0;_1HUI^<@DFV9[FTN+:AB
MG+@LIC\_:ETSK734Y5+:-6I27BY>!W.C^OGW1M[^2IU/%,^I:OK%C1H0MM1B
MI.IZ.Y\2\IW3U"S4M4TOMC'*6QOE+(^\Z1J,+JW4TUAK8Z,8J2[DSXGY,.II
MW*IT*DV^UJ/)]GHR;I1:>QMY[3I%1D\;=N"@=.(J!)5[ OOZ&$1@,[$9(!HJ
M6]A& B$2& P $<DD 0020    5 M^(, 5 MCV$ 0!( 0N"0  ._IOO*E\3_6
MS@'?TSWC2^)_K8K7+Q.H/&H77]+/];%19;49?OC=_P!+/];%1D<GND^C<HE2
M%90)@PZ+\"V5ZQ*>"4T#&A2V+*1F4AD9>T:F'J1#91,G(T6 KD,C1;()X*Y)
MR46R&2F24\\!3$]R4Q8*0#<@F4R"(S35+8(RR+(X\0L.PB'%"U)^LG+]9%E1
M.DFF8;BU33V-^7ZP>&L,8OECS=U8*::Q^0\YJ.D[O$?R'T"I0[C#<6B:>QBQ
MUY[?*-0TV4$\1.7&C*$GE,^G:AIJE%['E[[3.V3PCECMSV\Z\X*N)KKT73;V
M%1@Y9SM\9,=?*$1@6[=B]3LI\R1EJ7U.&?$F+&F,/:7[XQ\3AW&M1BVDF8GJ
MDJCVRAC<CU#K1]:",XR6'C)YNE<U)/=LZECW2:;9#_';L[93DF>GTVVA%+9'
M%TV.R._:91TY^WF^3K')ZNA%3HJ..#S:CN>FZI7IT=_ \ZXO)UD>+Y.R9HHL
MCG%E6MCI'EMU1(M$$BR1H6B6(BBV B/ J^&6\"KX H.H\BLC*3PS+3?2?!OM
MWN<VE(WV[W!'4HO9&ND]C%0>QLI< :8/@:GL(@]QZX(BT2Z*1+ 2"0(M'@"J
M^RP,B^TC&'W!/P:W-,UJHS<=VV8M=UN%K0;<\87K"ZNXT;:4I;87B?.[R\JZ
MYK$+*A&3C-]KDN$5EJTG3Z_5VM]BRZ47W;'WS1=#M],TV-K1BEF*R\>)R.A>
MG:6A6<'YM.MC>2\3=U!U59Z/44*TH][6VY1XKKGR<TK]U;FCEUOLL)<L^/ZA
MH&I:=&?NJV:II\R1^F-)Z@M-6IKLG%-KU\E]5T:SU"BZ=6C&:8<^I]OROTOI
M%SJ.NT/<RDE&HN[M/T_HJ6E65.A6F^Z*W3$:5TA9:9.=6UI1C-O.P:Q:5ZU-
MM3Q//)+&^7HK:]IU5LS6FF>-TF%>G-1FV]STKN%0IKO>3G7:5M[E%-LX74-A
M4N;=SH.3?.QU+>ZA6^(:\OT8_8^H0KYIIU]>:?=8KIJ*?BSVECKMK7C%2J+N
M-.K:10NK>24$IM<GC*W35W1E4G3JX2X*CW]*I2K/$6I(M"2IR<7LF>1Z9I7L
M91\[4;/8."<-^<&51%^F^S@MVK/)%&*4,/=^LL18E1P3F/B0I8)6/4:@AI8W
MX%2I0J1?CDP:IJ2MUVJ+9;2KY74<]CBO:(CRG671OU6J4ZJG./8\^B?._*#H
MST[IV2J2E*FI<R/OMS.-*E*<Y+L2WR?F3R^]7JM4J:;9Y:RGB)TY]FO/>3"<
M_JG4[6\*IL?I+1KGNM80ES@^$^2[2)0A&O+9RQ+<^UZ=-12C%;HV\U]O0*GV
M+?Q# 1[NQ9>=@3*WRJ1)%LD9(EOVHT1@NV015, 6?!5(* )Q[2 @()("@J6P
M5"   "N +X]A %0+9( @"0 @"2, !W]-]XTOB?ZV<#!Z#35_F5+XG^MDK7/M
MX'4G^^5W_2S^<Q*>PS47^^5Y_33^<Q47L<WT)/I;)9,IDG(,6R2F5R'<%Q=2
MW+1D([B\9$9:(S+QEDSIH9&6P,/0"XR+]R!B4!5O8,C4Q8F/B4R2GR-%V"%]
MVQ"D-#DPR+4MMPR6!J>P9V%J64&=@+Y+9%9+9 NGR1DIDC/(3#XX9$Z::8N$
ML#._UF:;C!7M>Y/*.1>:>I)['I:F&MC+4I=R>Q/%UYZ>!O\ 2]WB)Y?7Y^XZ
M;4=G@^JW-JFGLCYSU=ITJO?VK@EY=>>GSRKJ%2K4>&9YU)R--2QE1F\Q?]1F
MJMI\&+'HX^R)9<GD?0@FA<8YW--%8,N\C31AN=O3(Y:1RK:.7N=W388DC-3J
M?3T>GT\)'=C'LH]QR;!+$>#I7-=1MVCIQ'@^:XX.L5O/5$O5L<N4=S75??4F
M_:+[-STR?3Y_?6LW:+[=S7*&PIH9]N<)425$N&"JA("W@5"*D-;%BKX8"_67
MI^TJ6I[&6FRFS;;O<P4GP;K<#IT'P;*3PC'1\#73>P&JGX&B+,U-\#XO8B&Q
M)*19= 619<%467 #$EVO(JDW0IU93X+3VAG.$>8ZIU^-O0E0I;SDML,U&7)Z
MHUF=S5]QVCS)RQA'T7R8=&QM;7W5=P:JSQ)91YOR7=(SO[J.HWT6XO?$D?<+
M:E&A04(1PHK"+$3"$HQ<6EV^!\H\IG15SJ]XJ]!3>$^&?1[N\K4ZN/-R[<G0
MI.->FG))_&:'YAJRU7I:234E&#QNV?2/)WU_4UB<*%=KN?L9[7J'I2SU:+C*
M%-/VHY?3W0]MH]3SE)04D_!$9S[>TH-.*?K(K6BJ3;9R:-:I3N%%]W:F=^$U
M*"D@W(P.UC1RTMSAZHJTF^S)ZN<%);B9VU-Q:<4]O49L:>+MK^I;R[9;'H+#
M5(2BE)[B-1TB,FY02_J,=K85(SWS@RCTE&MYWXALE#MP_'8YD[A6E+P96UU*
M%634F@KIT:-.DO01;.612J1DN47V\#-6(QA $EE$8V(U$DD$FH.?<:?&M-RE
M\8RSH0I0:1HJ-QQ[3R_7?4-'0-(JU'-*:3VR(P\KY6^MZ>C6%2A2J)3::Y/S
MITW:7/5.O>Z[E.5.6=_QAK^IWG5W4$XIU'2\Y\:/K'1>@T]*LX14(]ZWS@Z<
ML==9'H.G+"-K1A3@L821[+1Z>+B2:VP<*WI.#BXGK=)M_P#-HU'RS;ANULB2
M7E'!4O\ COS%4'@3XD8%8L^T$$@955\$(L^"$ $,L0!4"WX@ J06*_B @"<!
M@"""Q& ((+!^("H%L>P *@6Q["/Q 0=_3?>5+XG^MG!P=[3?>5+XG^MDK7+Y
MYJ;_ 'SO/Z:?SF)BV,U-_OI>?TT_G,3%F'T)?HS+(R1DJ^"+%N[!93*<D9"I
M[MR5,6V5[@8T*I\9>,]C*FBRF#&V$RZEL983W'1EZR,GTW[2YGC+!93R1DYL
MCN%MAD81;.03*@7%Q=2SP3D6N2R>/$&+KC8DHF&08OG *13/Q!GX@AG=L1SX
ME>[XBO<"'19;(A2)[RX>)Z>>2^(X,T9#(S!/HJO2[L]IYW4+"-7O[ED]5E-&
M.YMTU)DK<ZL?)>H-'[7)PB>$U*W=)O)]SU33U54MCYUU-I/:Y-(R]OQ=;'A:
M7!MHI8*2MW3DU@=11SL>J65KM8Y>QW]-I2>/6<BRAZ1Z73:>%GP.<]N?5KJV
M47M'Q*:E*5.3@^3I:93C*<3-U!"*N9?$=N7S/^BN%![RR7QZA<?LF-B>CGT\
M/M2>R,\UZC14X$/@II9 ,%P1$-[$9!D,",[$9(9#?(5#)@]RC819E6RE(W6[
MW.=2?!T+=[@=2B]D:Z2V,5%[(VTGL@-5.1HB]C)2Y-,>"(;$9$7'<O)]R27@
M$J_B77!2GA+#Y,NIWT+.@Y3:6Q<36;6M2C;4Y0<CRO2.D5>I^H(U)QS0I3]+
M.V48[BG>=3ZKYJSC.4&T\Q/T!T?TY0TO3:/9%*JH^EMXFC':TNQHV%&-M;Q[
M:<4;)1]%M<H76KQHP[GR%&YC5V6 )=)5J:519"%*-.+\VL#^ >$@N//U[RM;
MW3[GZ#>.#KT90KT\P_*%>TA7PVMR]&FJ%-X*8H[>E)[IY0^G!1AV^!RJVL1I
M5>QJ/)MM;R%=>BUGU$&H&DP3SP 5$HJ2P9YT<)X6YI E@\]J-G5J)GGJE&O;
MU,QX3W/H$H*2W1@NK&$U+9$P>?M-446LMG=L[Z%1<[G"O]+E!-P3,]C2N(5<
M-2QDF#V??E;,E'.H5O-4UYQX^,93OZ=2:PUA$Q96S.^"9-1SD%*+CW+&XBI4
M49.I4>(+D+I6H7<*-I5JRDHJG'.[/REY8NKZ^N:K*RLZG=%[<>T]UY</*!"%
M)Z?I]6/G&^Q]KP_$^7^3GIVK<72N=14LN6?2W-2,]6/4>3OIE6]K"O6BO.2B
MGR?3+2BDDY+<XU&M1L7"DI)+A'J-)I>Z<2CNCI)CAOE]5T]%LW4D_.+;.QZ5
M05.BH0\#/8T%1I_B]1HSE[%2<2"2;2*89;N(R5TEL5P&"27P1/=4P1@L0^1@
MJUL0D6?!"(B-B&6*XW"H D ((+%0    P&"R(? %, 6*X @"0 @,DD &3O:=
M[RI_$_UG!.]IWO*E\3_6R5KE\UU1_OK>_P!//YS%0D3JLE]5K[/P\_G,5"1S
M?0D^C\DHHI(LF35B? HVR^PJ05#91R(;*,JF=Y*F9^X.X#9&>_)HA4.7&>!T
M*NW(2QTE,O%F*E46!\)Y\2,8TH$+C(LGZP8MD,D(G !D%+)#X!!K%E(G)1!D
M&+Y#)3(9!B^2,E<K!&08:GL">XK+)3!AN0SZA2EDLF4PZ,QLEW1,RD,C-KD)
M8S7-'.=CRNMZ:JJ>5G\1[7"DF<V_H93PC.-<]V/CFL:6Z52>(_D.&J;C-Y/J
M>N6'?3EB.YX&^M)4:DNY8.?3V?%WI5A',CU5E#%OD\_IT4YH]%3EB"A'DY\S
M[=N_6NWI*:W.=KE7NOY1]AU=._<Z'=/;8\[JM3SFHRE#>.#T<Q\G_HK.X]KR
M6B1+.Q*9UCR*5#/+@?.2:,\]T5"FP0-$<(B!D$>T,H*C?!5\$LI)[,*HV$7N
M5;"+,JU4GP=&W>Z.72?!T*#W ZU!\&VD^#GT/ VTO #92Y-4.#'&2ACN?)L@
MLQ37!$,B.BTH[<B(M#()0S.7')8E0WYF#J57LCPFN:A4U:]]RVV7Z7;L;NL-
M=;D[:W>[/4^2_I#SLHWUU'[+$EDTCT7DLZ4CI&G4[BX@G7]>#Z'&.'Z/#)C3
MA""2227@@A*+SVO. I=>C&KF,DL"*-MYB?=X&R2S',3)J=94[*K/.\4 V5S!
MRPFL_&:%B43R^C2JW%;O_P!#UGIXI1CN!9;(&DUA@GE91"SG=;!7'OM+IU'*
M44NXQZ7;5Z%^U)OS>.,'HO-K.=R>W?A8 *?!8      &DP !<Z,9+#1G]S4X
MMM11LSO@,(#S^J0GA]F3S\*U6WG)/.[/=5*$9IY2.37TJ-6,I)>DB6+&.QU=
M*"C4>R]9Y/RI]<4=(T:M"A/%5K;M?L)ZOK+2+2M5G)Q]%X/S9J^IW?5&O.WC
M)RI=S3W)C%ZQ&DZ?==4ZW*\JMRCW=WI'VG3[2C:6:2BE))'.Z,Z?6EV\.R.9
M-8?L/4U],55)1;_$;D<;UKCZ=I535;UN/V,'G='TS1K!6E",=MCG:%IT;&DG
M!9<EOD[L98AB)M.?;1*IMA%J;VW$4FM^XLWZ6W!'0W."<E,[ FL 6!@I(C(
M0R=B (?!")\ 2"(P1XEF1@@@"0X"H(P6\&5\0#\08]@$  /@ Y @@M@@" )
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MJ<GD=&>QSJ=8?"JB)K=">Y;O,D*F2W?[4#6GO#O,W>2I^T&G*6Y9,0F,3]I
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M4QL9<@;:4LCXLQ49&J#(T?%EXL5$O$(?%DY%QX+H"ZY)*Q+!0  !!#  (
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MQ@O2<?$QW,ZM"+[7L;VWRMRLHJK#$D($655UHMSY1J,]2<;:#P%K<>="M
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M)^LD, 02MPP0N20(P1@E\@#$8.Q8^]:?Q?\ 4Y!V+'WK#_SQ)6N?;\U=4O\
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MM4PF8)3[I&:W+]-T'W(J_$71EB)?G.#4<.Z/$  Z5P@  R9B@",ADHD
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M"(1)TKE$D8!$^!F*C 89(&@);!@%L&0# 8#(    $-!AD@!7##!8@"/ , !
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MDFDP8537IHUSC^YB*:Q/V&J>]/"(S6&"])^HN$5Z1,MC?+S=5!)&"3HQ B?
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M(D  !5!*(!$$@!#Y*) @ ) @ )(;R (@ )V " )X1  '@P#P914
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M<#O!B:/ ][)AIEK\,33>!E=B(<A8Z5D\21T*_I46CFVIT8O,1'G^1Y;5;?\
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'=V^  0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g915839g83a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g83a01.jpg
M_]C_X  02D9)1@ ! 0$!-0$U  #_[28.4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 361?  !  $!-9%\  $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ]    >@          $                          0
M           'H    ]                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ]      4F=H=&QO;F<   >@    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /0
M     %)G:'1L;VYG   'H     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      ;=0    $   "@    4    >
M )8    ;60 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M187AP#8+*VQ!]O\ ,L8[VSMVN5@?2'Q30? J;&&9/ 24_P#_V0 X0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0
M &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M%    )P!.P "    "0   +"':0 $     0   +P   #H   !-@    $   $V
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,C0Z,3(Z,#0@
M,#DZ-#4Z,S@ <G(S.3(V,S4       .@ 0 #     ?__  "@ @ $     0
M!Z"@ P $     0   ]          !@$#  ,    !  8   $:  4    !   !
M-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0%.17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   $V     0   38    !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HQ,CHP-" P.3HT
M-3HS. !R<C,Y,C8S-0       Z !  ,    !__\  * "  0    !   'H* #
M  0    !   #T          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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M-F)SH<'P""0E0T31)N%T@B<W9/%%56/_Q  9 0$! 0$! 0
M 0(#! 7_Q  C$0$! 0 " P$  P$! 0$      1$"$@,3,2$B05$R!!1A_]H
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M%L KE[8=L<0 Y568[5G&L#*".3M6.U./*&4,')VI>U.+*&4,'(ZS\!VQQO!
M.7MAVS.(!7)VWL+VS.+8; <JK>)>U. ) <_:D=8X<% Y>V';'%L$$<JK,=J<
M::&4,')VK':G'E#*&#D[4=J<>4,H8.3MF.V./*&P')VP[8XAL%<O;#MGX'%L
M-@.7MAVK.-8&4$<G:CMCCR@\#".3MGX#MCBV&P5RJLQVIQIH901R=J7M3BRB
M/V#!S=J.U.!(8"MA55@R4TS4PS)9&(V\KQ!K*3.2G4[F17*")IE
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MB8L &@*0C2;ER_ ;%V*C'O+N"D%A-HYH5$UN<  VTT^@.&E+ERCF3RLHB@
M        &,Y\J,F\(UI/+>0+GFR<<GAX+T'4J'<0 L2@! *"%0 (    !"@
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M[0^V@96R#6\]H?;05Y0^V@96R#7\[H_;05W1^V@96P#@\ZH_;1%=T7^^@8V
M:_G='[:)YY0^V@96R#7\[H?;15=47TF@8Y^XB.&5S22RY(Q5[0^V@8V080JQ
MJ+T7DS;0, ,/&>XF0B@N&X\W<0           H #7XN! ,!9%"9,%BEWDOP.
M7&YMV-XZ<\-O!JOH2,4MS!*]=;UHU8+'4Y3SNFW2IU&IRV._I5(SAE/(;E9@
M *        &,I8+*6$<$I!"3YC'E)%OO&2C+N,65,C$$! 5  H  @%(4@%
M$!2 4@    "@@%   @   H$*0H!  " I *0H $!0(4  0H @*0  4   !"@"
M%!  *0 4A0 ( *"% $* (9&)D@0 !%1[,YJ4CCQL89PP-U//0'#1D<Q%
M   DGA <=61P]XE++!4,HF00N)JD*    !=Y"H /Y$12& _D!@& [Q@@,5@
MH$*  [@%T F!@8Z@:F"6YD1%(L  %,HF4 5%RAE&)1@N4.X@  $  (H$ *!
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MYQU.T?NC\K-KC]4_]_S,J7E:M5_VG_O^9^$^97(\RN47J;Q?O4_*U:-;TO\
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MLHF=B 8!2% $* ("@" H $*    A00 "@"(%  @* 0! !00 "@"   @@ *0
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MG:MX3/-ZI+-5^\L9Y-"/>WU)U>YDD1K#*Y@" 4        9"F+Z@9("([P@
M H.X)9(WO@"K<T]1N5;T)/.Z-Q>@FSP_'NJJRL*E3*7<2_%GU^8>4SC&4G.C
M"HHM9CL?BE6M5N;B4I2<\^)V7%-^[[4JC6ZYF<>G6RQEHO"+SY8QM[-/TI+"
M-VC0A%-Q64C>L;9UYJE"+DWX';W?#E6C4H1RXJHM\H[3B\O+G^O/\J:VCL%'
MEW/4?-6;Y5VW+EG5Z[I#TRYY74YEA,UUCG>==9S?W4.;V( G5F<Z)YZI'7ZA
M'";2V-]FM>0<J;)8[^/R.DCO,V)T\4LX.!P<)LY95G*'*<.4>KCSUP-,F"ML
MAC6]B-$_D9$+J;$W]I4L@J)JS$P7<#(P_!=2R>Q,F2CS&N/%CEC<TU9?0[C"
MBO T--I\J.P;6<,[\>+S<[_BI-+.-@VGLC;M+&XN]J<)M>Q'>T>&*M.PK5JL
M91<8YW1OJ\W\GENG5&.$\XBFCT.@Z.K^AS2FE+=&-_HRLH3;J)X'59>3STZ4
M9K#21IW&GKK'.? _;^$/)Y#6-.IW',L8RS4USA.VM+VI:QBN>*SDG5OC>4K\
M-N5."S%<C6V4?HWDPXPK6-Q&A6J<T6N5<QYOB'2U;UY1SZ.7L><I5)VUW&=+
M*Y'DYV8]?'EK[9T*_A=T(S4\Y1W">Q^0>2?7E>:70C*2=3!^N6TNTI9.>MY^
M.1$0SC8+Q-8PH (             *A>XA0EJ//<([;H9V$5A!)7?Z-7YH\K9
MVIYO2*F*IZ1/*R2NL  10  #AKO*PCF[C6GZS8B./<RCT)D&D5D&0  (!00
M 4@ H  $*@! 4 0 "@$ H( * 0"D*0"@@ I     !%(!0 !"D  % $   H
M$ %! !2  4 @  H $*@   A00"D*0 4$ I  *$" 4!#(Q=#*/4Q6Y2#:BTT4
MX:?5',10  8S>$:\GN<]7H<'>40A7U(6,H 4"% P 1.;EEAEZ"45*&7U DI1
MIT9R?0_!/*KQW6C=?)UE+TY3Y-MS]DXKN?--%K33Q@^:N$;+YP\?W<ZV91HU
ME+Q(L=MPOY,;S7H*MJLFHRWZM'L:'D6T&GB-7G<N_$S]8O\ 3J=2RA&C^B22
M]38ZRUT*=M/M>VJ3QW-F-5X=>0[AYJ+Y*N_]XZ'C;R,:;8Z35K:?&>81<MY9
MZ'[U1CFC!3ZI'#?6D;NA5H5/4G%K/O&C^>%[3J6M]7IS<L4YN)H\W+.4LRW]
MI]5<4>0ZVOKVK4HU:F*DFWA'GX^0))M=I5:739D[+CYV[67VI?$=K+[3^)]$
M?0(N;':5<^YB/D$4D\3JO'L9H?.ZJ2?[TOB;>CVOGNHTJ,NTE&4DGC)^^OR!
M)K#J5EGV,]?P-Y%K/2+A5:\YR<=_2B-&.B^1/0*^D4+BXC5YI4XR?I^PWWY$
M^'9TUV:J<JZ^F?K$K*-2QC;\SC&*45CV'76>DRIJXA*K4Q+9/)-'Y%JWD@T&
MWHYAVBAW9F>"XBX3NN%<WVC3;IT]^KD?16M\*J_TR-LKBK%IYRGN:6F\#T;3
M3JM&M5G73R_TFYG5>1\CO&D]5M_-[R6*T,)YV/V&.)+8^3;.=71?*56H1S"E
M*YPDMDT?4^F5>UHJ2Z&N+-;2ZF-1;Y,O:A+N-Q$(4A44A<# TP(7 P (48 A
M0 !"X  A<$ %[B/HRQ65E "%2WP7E:8,8@RY=@HL#$&6!RL"$,N5CE!C$HP7
M T8@N"I 0%PQRC1B4O*.4" KB3  AER^T8 Q!>_!7%I 0AERO&>X@$+'J/YA
M 9$2,3),@SI/TS8-6GZYM$6  "@  XZ[Q3;/+WD^:J_>>EO7BWDSRMQ^L+&.
M0A)Y,68[Y*PR  4        ,7U,B8 L0NHCL$$  @HWA&,.N2]=@\*.P''=3
M:I2:\#\4\L>HNGHU6*>^3]IN&O-YY>^#YQ\L]=I5*4GU?^H'Y%;Q=:K*<O$[
MVWCRT]O Z:Q[\'=VVU/?J=.$</)R;VAWCLKQ5MMO$]3?\56URZ4ZBDYTUW'A
M^YIA-IJ.,I]YVD_'EW7O%Q'85*=.4XSSDZ'B?4J%[<MT$TL+J=(JO*W%);&$
M8N;YWU,_VW/@4F>HRL9-,56624HX,.9214\##C;&C7M.9O"-3S.7-L=T]\^P
MD5%K.#E>.O3QYY'22M)9"M)'<N*\"J*\$/5#VNE=G(Q\SF=[A>"&%X(>J'MK
MH_,YA64SO,+P06%W(>J'MKI/,I$\RGX'>[>"&W@AT./E=&K*;-BA9M/<[1)>
M")T8G$Y>1C1I\D3)8Y]^B*F1[;KJ=9/QPO.Z]3H?$5'3HI267[CL-4XT\[M*
ME"FL*2QT/#IYJ1;2P9*7I3V6.XB]V_I.IU-/J--^B-5U.5T\-^BSK8PYUS2>
M&7G;V:V06<WZKP;Y1UHVFJV6<)8-?4^,+:\NJEUOVDDS\R@W!O'>8R@Y3SS,
M+>?XVM2O9WU:I4EZN6>?OHJ"?)WG<SEZ/)%;/JSKM1BJ=-..[.?)OQ<GOO(K
M?2AJ"HR?2)],:74YZ"P?)/DLN>SUSF;P^4^JN&Y\UE!OO1QKV<?CN,9!,[F6
M-C3 "%(      @       .\ !*C++9$$]P1SV4N6HCU-O+FHQ9Y*D\-'J-/>
M;:)*Z<6R "-   QF\1->3W9SUO5.!]"HP !4"@@%! !00H$* !  !00H A0!
M"@@%( !2%( *" "@ 0%(!40% $* (4 " % A2%   "  "D* (  *"  $ !2%
M $ *!"D*! 4 0%(  * ("@0  4A2  4 (E(BD6,X=QL&M'N-E$(  *PJ]#@7
M5G/5Z&NN\L1&0K(5%(4( EN9/H8Y"(!>X11FH-A8\OY0%CAVX_D?A7D5CGC3
M5OXE_H?OGE#CCANX_D?@WD3?_P UU;^)?Z$5]+5ZT:%#,EG"/+TN+8U]=I6,
M:#Y9/&3T]U156GB73!T]GP[:T;U7G*^TB\G,=]!\V=L)&1C2W<FNAD2QJ !)
M/$6T3%>=XIUAZ?3CV<6Y\V^/ W^']2C?VV8QP^C/+ZOI][J&L5>7'9\NV3;X
M.MKG3ZDZ5S^]+;!IAZ^53$L<C9D-V\KH UQ  %7.QC/]3/W,J)/]3/W,1*^3
M^+%__$V/_P"2?3.@+_I\#YGXK_\ YG1__)/I_0(?]/B:XLMN/J,K6R,G'$68
MOH;1CW@$*C(N"(N1BF!C9C(;V)@Q(7<;A>L,#<;DW!UAAE0W .L& ^@*R)9V
M96^58B1+J8M.+R18*,D\F:R^\QYW)81G3ALTVL@7KWC+2ZF+Y8/=HQG4ACUD
M!R8SOD9]IA"K!Q?I(L7!_O(#+KWDPVNIR04?%&<>1=Z X8P>3E5/Q9FI1[FA
MS1\408]FB=DC/GCXH<T?%!6'9>T=G[3/F7BAS+Q0'&Z7@R.F_$Y>:/BAS1\4
M!KN+7>8*6.YFT^5KJCBE%>**CC51>!5.*W:V,7A=YB\2BTV@.1I2WB,]S9A!
MQC'E31E&.^6U@(.365W&)74CZN-R    !40(RI^L;<>AJ0]8VX]$&H  B@
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M+&Y37G81:G)-D2Y7R]QW.L:'<64(U)8PV=0XM=>H  !        $*    4
M0(4!4*NH""$>\Z[4NG\SL8G7:CT_F<N;MXG9^3M\NN+W'UMPRU+3J>?LH^2O
M)U'GUQ+V'UOPS3Y=.I_PHXUZY\=RUL@^A>Y$?0L2H  @B]Q$4*         #
MQ ( !D\3']Q^\R\2?N,+%I=3U6F_5('E:1ZG3/JD/<*W&T #+8  ,*O0X'WG
M/5Z' ^\L1BB I40H  $ %(  !0 !  *0 4@* !"@ " 5 @ H   A0("@
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MWK 5IIAO'4VYV52/JQ;$;*K-/FIM!&KW9(<E6DZ3:9QY  9&2@!D9"@&4,H
M4F4,Y H)@!%!%DI " 0%CWG7:CT9V/B==J7J,Y\W;Q.S\G,N77$_8?6_#,V]
M.I_PH^1?)]^VE[CZXX6_9M+^%'"O7/CNGT!5T)WLL0!0!$4       $*R("@
M+H   #(3I!E[B3]0+%IGJ=,^J0/+0/4Z7]3@2M\6T "-@  PJ^J:[[S8J^J:
M[[RHQ *5$*0  4(" % $* ("@" H A2%  @  (H  @ H $ *!"D*!   *0 4
M @ H $!2 4   0H   " H   "%( *0H$ *! 4@ % $ * (4 0  "HA0! 4"
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M0X>1[/!'S;Q@V_*7!^%P?47##YM(I,^6N,Y<GE*BE^(/J+A)YT6E[SEQ>IW
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MRU7UBQCDP1DC%&2*P  *           &"!5"Z@=X074Q761DNICWR!Q:]_\
M5W[CYG\MGUZ6/][GTQ?_ *A^X^:?+3]?E[O]16X_--(WJ-'>.EODZ32?UO\
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M;Q-[@']N+W'UOPO^S*7N1\D< ?MM/V'UOPM^S*7\*.#U3X[Q=!WA=!WEB'<
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MU2!Y:D>ITSZI 5N-H &6P  <=;H:Z[S8K=#7CWE0( 5 % $   H( *0 4 @
M  4A2 48RB&2>P$P,,N1T()AD>Q<LJCD#$Y:<&T90IG+%806,8T\=3-)( B@
M                          P=-,XITVNAL #4<68FU*&3BE#&<%9<:3?0
M894L#($P$7) ! "@4A0(4@ H(4 0H A2 "@ "%( *BOH2(?0BQ8]4;:Z(U(]
M4;:Z(@+O 7> K"KT-==6;%7H:ZZEB498=2,SIK<$;$>B !%     'DO*7_9N
MX_D?@WD-_MIJ_O\ _1^]>4I-\-W&/8?@OD.VXTU?/VE_H!]+7;_0(ZC"W.XO
M5_RZY3I-TV=/'#ER([MHO*DN1[HP@\<WB<D$I1RWN=['/C6A?V%.[B^9/!UK
MT&@G'8W-?NJ]KIE:=O%-H\O<<0WT*%!3@E*0D.5>FI:%0YGEK&#AJ:+3G2GC
M9H\I\YKVE>*G-)=.\[W6-<JV]K&=-;<J;^ QCNWZ.BTZ<4UNSMK.W5&&YY[A
M#6JFHJMVBVCT/1IN3&-\>:J2Y]C.4>;#0Y(I==S!2><=Q,7LY*7ZQ'>4G_R\
MOX3HJ:]-'=TE_P O+^$X>5KA\?*?&V_E)BO_ .H/J#A%8T6E[SY?XR6?*937
M_P#4GU)PPL:127M.7%JNU !I   #&HO1,B264P-5[,G<93ZLB3QN5&(0!44A
M0!"H!=X%1.\JZ$[PTYZ:[SE..FMCD.<'X_Y?/V%6]Q\N55Z<CZD\O:_Z%7]Q
M\NU&NTD>[P?'+DP2*D6)G%(]#FQY2I&94A BC**P6.QEW 0@9#<OXRR[C1U/
M]6;J-+4W^CP<.=:C5TM;G:]QU6EO<[7.Q.&K6**,H91V88RZ$,FTR!8Q[C!G
M(S!]1%8F)G@QPR6MR1%U/H?R#K]'/W(^>4GD^B/(/M3GGP1YO)\;C]\AZJ]Q
MC5]4RCZJ,:B;6QX_[::H*TUU)@TRRI^L;:Z(U::>39CZH:B@ B@  UM1^JS/
M+5.IZC4OJLCRU39EC').XJ($5A0 %   "       !"D H0(!5N8YQDN<%:2]
M;O!'5ZTD[>)\W^6=KSU^X^CN()QIT(\S/G#RRN,KS,7W!K^GYYHWZP]&D><T
M;]8>EBCKXWB\U&MPEL5]2KH=K\>;BQP,&6!%99(M;5O'$&;5*4J4?0_>V9K6
MBS&63M-/A3E)JJ\)= L<$*]:VERPSX[',[ZXFN5M[G>4+:A.//'#E[4<EU96
M4J3E&6*B73 P>>\XJ223R^4QN+JXK/$F^5=QV=DZ4*M2+Q_-&=G1A/4W"HDH
M8"XZFC?5NRDM]MD82N*];EZ^CN>M6G6<5)9];V'%4M+2'*D]E[ /-SO*TX<L
MLXZ"PJ7-*G.,)8YF>AE;6=2OA/;'@:5S2C1OZ48+T'U&+&C&XNUGGDW@V+;6
M:U&FXRYL'=4J%E)^G+TG[#@U.UMJ5'T,-^X8.@E<5ZU;G2E@QIW=6%6IE,]!
M1E1[-)*/3P.6%M93I5'-XDUX$Q=>8G=U;CKG A<5H;;X.WL+2CV[C+I[C<J6
M%%RVZ##70QN*TEZ.23N*DMI=3U-"TM(0?,]\>!UNI6]"+4Z;[P:ZN>H5Z<4E
MG&#"K>UJM+#;.]N+6WE9<T-YX\#STN92<<+ 1C!)PR^I2)8,D5!&MJ/Z@VD:
MNI?J /.RZLZW5?41V3ZR.NU7U(G/F[^)O\ ?MI>X^M^%OV92_A1\D< ;:TO<
M?6W"C4M-I8^RC@]<^.]71%[S'*74RQMGN+$ ,C*!H@              !D\3
M']QF7B8_N,+&5(]3IGU2'N/+4CU.F_5(>X5N-H &6P  <=;H:\>\V*WJFNML
MEB(4@*@ 4" %  A0!"D (H" $,B!<H0H!B%*,!,0J62)9.:G AC&$-SEC#!F
MDD"+@  H                                &@ ..</ X91-HPG#*V*F
M-8&;@TS$)B$+T&44 "A<8@RV(#$!2!    "@"% $!0 0?0(I%A'JC;71&K%;
MHVET1""[P %85>AKKJS8J]#775EB4[SEI'%WG+2Z@<P (H     \MY1_[-W'
M\C\"\B.W&FK_ ,2_T/WWRC_V;N/Y'X'Y$?[::O\ Q+_0#Z5O:G_+I8.EBLM[
MG=7\HJW7,=%"XI<S6=SKXF>;-/E;6,EA+TFN4D6I-M="KULH[5.+7U"U\YM)
MT\XR=)<\/<_F\G/:#ST/1KF;?@7=IIO8G$Y/&:GP_3KW?/"IRO'<)\.2N:79
MNZ>,8P>K\VA.H^XM&S=*65C!IQG%TG#^B?)G:?I.;/L.]IIF<7%N2:+'W!N?
MB>\+&Y9$BB-RLZ?K([R'ZA_PG1T_61WD/U#_ (3AY%CY2XP__F=#_P#)/J7A
MO]E4SY;XP_\ YG0__)/J3AO]E4SC&G9@ T   !]& ^C U9>L7N)+UAW%1#$R
M9B6%4$ 12%(!DNA%U+'H1>L1*VJ?JF1C3]4R(U'Y%Y?/V%6]Q\L5OUK/J?R^
M?L*M[CY9J[U7[SV^#XY>0B<D48)'+$]#FB1D@5!%1DB(J!!D+XD\2SXG+Z(T
M=2]0WX]32U)>@<N3IP:6F+TCMFMCJ],6YVS0X5>3BP,&>PV.C#'& 98V)@(Q
MZC!DD4:.)A=Y6$9K?%BO61]">0KU)^Y?U/GQ>L?07D*]2?N7]3AY/CI/K]]A
MZB,NXQAZB,CQNC5K=21Z&57J8]Q6&<#8CT-:!LKHB-0  4  &MJ/U69Y:KU/
M4ZA]5F>6J]2QFL>XB+W!%84        !    !"A 0%(4''*+/TW"*ZEAZQV>
MFZ>Y3YY+8E6.LOM*\XM6ZB]59/E[RW0C#49*'1;?YGV/J,(JQJI87HL^./+?
MF.HS3ZY?]3+I)^/SC1O7/2KU3S6C?K#TT5Z)Z/%/QX?/QBI;#H9)8#.F/-)&
M.0AC<O<7^ER-NVRH,W;6G.:?+DU+?#I,[;2:L(-\QCM6&O3G<TY-1YOB6$KF
M4FFI;GHK2I:RJ-S6QG"O9\\O1[QM(\Y*WK0]+#R<495G5YDVI>\]+YQ;U9RC
MC9'6RE1I:CB2S' [5N.N=2Z^W(<UPUNY'?QKV;?J&?:V6/4&UK(\XE7YMI/)
MC.-Q.:J2E+$3T#JVC>(PPS:JT*$M-JN..;N&U'E)UJB::F]B5:U:JMYOXDE3
M?:26>AANMLDVCD56<8^NRPN*CSZ;./E;6[(H-=XVLL^UJ1GS1FTSD5U7?[\O
MB:Z34NIFL^(VK'-YQ5?6<OB85*E2:]=LPW\2P;3W&T<T;JHJ?)EG'Z3>68)O
MFSW&?-L5=%O(R1%T*BQ!&IJ7Z@W$C4U+]0S4'G'^\=?J_J4SL'^\=?J_ZNF<
M^3OXG8>3_P#;:SX'U[PG:3^1X3CGU4?(/ "SKD?<?;?D^Y9Z)3BU^ZCSUZ^,
M:\$\M3ZEW6W<=MJ=@XN4X+8ZK=+#ZB'*("%*P(!!!J   (         !D\3'
M]QF7B8_N,+&5(]3IGU2!Y:D>ITSZI 5N-H &6P  85>AKOO-BKT-=]Y40B*0
MJ*  ( 4"%  @!0(5 @-Q=AL0$.]4N#')5(+NJBQ61%9.:E'&<@(0[SD2P@"*
M                                          "2CDX*D.4V#&<<I@:F
M>X&4X/)CC UE4\H$Z#+*=K%+W&.65;@[:$ * !0! 4  0"@A0" 0)1E'JC:7
M0U8=4;2Z&5@ "JPJ]#774V*O0UEZQ8E7O.6D]SB?4SIO<#8 70$4     >5\
MH_\ 9JX_D?@?D1?_ ,TU?'VO_1^^>4G^S-Q_(_ O(A_;35_XE_H!]*7\55M4
MIGE*^GRYI2I-MY\3U]ZTK='1><P4I+8Z^)GFZ-5-0H9C&.QG#4;B$?TJ2.WC
M*$Y9V8G2HSSFG$[UGBT:>KTE2?:/$O<91U:U;7IOX&V[&V:WIQ,/,;9?]N)G
MBO)IUM7HJHW&6WN,J&LT)/$I&XK.V[Z</@<=33K67JQBG[$:9PIZC0><2,O/
MJ"_>-*>D9;Y9M"&B[>E78_!O1NZ4WB,D<T:D6NJ.I>A3SF%S)'#/2ZD-G>33
M]X([^E).HDFCO*;_ $#_ (3QNF6-2E<+GN92]Y[.BHJU:;SZ+W//Y6X^4^+U
MGRFP:_$GU)PW^RZ9\L\7Q3\I\&I_^3T/J;AO]E4SC&G9@ T   !]&#&IZH&O
M+UF,K ?4A4.XA 5%!"@0J 0%708W"+G<B5L4^AD8TO5,B-1^0^7S]A5O<?+=
M2+[5GU+Y>U_T*O[CY?J+](SV^#XY^1C&)FD$BI'H<=%DN BA!%(.XBP;",2Q
M-3XG)E%;FGJ*S!I&_#J:>I+%.37@<.;KP:6F+,]CM7N=1HL7VNYW,MG@O"KS
M8!;AHJ1U<D7M#P0QR/HR,6.8G,,$:ZD1<F#9FM\56.8^@O(2\PG[CY[[SZ"\
M@_J5/<CAY/CI'[_3]1&1*?J(IX_[=&O5ZF'<9U##N*PM/J;,?5->F;,>B(U
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M816*Q2]!FAJ:]"!V4<*+1U^J>I'V&.;OX6]P%+EUQ/V'V?Y.KK.ETE[$?%_
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MO(+C]+CP1CE&Y=?05+U$8UGC8RI[4T:]669X/-K00 J+#UC:71&K#J;4>B(
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M2.RP&5       !"@!D\3']QF7B8_N,+&5(]3IGU2!Y:D>ITSZI 5N-H &6P
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M(RAU-E=$:L.IM+HB$  %  !K:A]5F>6J>L>IU#ZK,\M5ZEC-0!= 5@
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M#ZQY?CY5G'TG[PC.I^LE[S$],>"W]"%)W%15T.OU+U#L%T.OU+U#GS=_"WN
M?VRO<?9GDW?_ $^E[CXRX"_;*]Q]F>3;ZA2]QYZ]G'X]Z "-   CZ,Z75[?;
MFP=V^AJWE+M:;18S7E8^CU"W>3EKPY:C1Q+9X*PH         #)XF/[C,NYF
M/[C]X6,J1ZG3/JD/<>6I'J=,^J0%;C: !EL  &%7U37?>;%7H:[[RHQ!05$
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M +K_ $"OL'2%_P C#W&PUZ1Q:.O^1A[C8DO2".);-@K6Y !5T(7N8@@ **0
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M,D"(H $10!)+*V*'T 1QRF&')[&4?5D6W6^ 1WVBP]#FP=J:.DQY:!O&72?
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M?8F%Q^3_ $Q5.GR?7_*__1/I>G^ K?E?_H_6?HTT/[$Q]&6A?8F!^3?2]/\
M 5ORO_T%Y7YQ>?D^MM_=?_H_6/HRT+[$RKR9:']F85^3W/EEOJ]+LK6QKPEX
M\K_]'GKZZXCXVK=A-UH4ZFV' _?Z'D[T6W:E3IRS[3O=/X?L;&<948+*]A,'
MB?)3P12X>M%*YAS5YK.?:?I-1^EA%<5E8PDO 87,VS42UDL*)(/":$NOL(RQ
MD (% 4@%! !2%(  * ("@ "  4  N\A4"* "*#( !&6-MS%%3 806"; "M;/
M!COXC<984W\1'F\1EE381=PG@9)D"M[&*>2Y6'@<K4<OH 16]B?NY)#TLX F
M65,KCCJ50RLIA&.2&?*3E]H&(,N4G*!"C P#%I^L;<>B-6&TC:CT06  (H
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M2 5%R8@"Y&0 :9 (!4   3  N29( :RR3( P,C( #(R0 7((4!D9(4 " "@
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MOU+U3'-Z/$W>!?VS'^1]M^3?]B4OX4?$G O[9C_(^V_)O^Q*7\*/,]G'X]<
M T     !QW#Q2;\#D..NN:E)")?C\3\H_&-?3-0=.A24NO>=3PKQ_.M6E&[A
M&"?>V7RJ\/W5?5'4I9:WZ(\[PKPK<UKG]-&7*GWHZ.%C]67$VFXR[B/Q,EQ-
MIN/K$3K(\(6_(DX0YO<5<'V_V8? )([+YS:;CZQ$GSGTW'UB)UWS/M_LP(N#
M[?OC +CLEQ1IOXB)'Q1IOXB)H?,^V^Q#X#YGVWV( ;WSGT[?_F(_$1XHTY0?
MZ>/Q1HK@^VW]"'P,X<'VO(\P@%C;I\6Z;%_KX?%'I-/XQTI6T7.X@OYH\A#@
MRT;]2F>CT[@BQ\VASTH/^1*U':?//1_Q4/BO_8^>>C_BH?%?^S5^9&G?<4_@
M/F1IWW%/X&6FR^,M'_%P^*_]F*XST7/UR'Q7_LX5P/IKZT*?P'S%TO\ #T_@
M495>--&_%P^*_P#9P_/;1UTNH/\ FB5>!-+W_P"7I? XX\#:7'_QJ;"8Y?GQ
MI'XF'Q0^?&D_B8?%&'S)TK\+3^ ^9&E?A*?P LN.=(C_ .3#XHBX[TA_^3#X
MK_V1\#Z2^MK3^!5P-I'X2E\ *N.M(_$0^*,9<;:1+_RH+^:,UP-I'X6G\"?,
M329XQ;4ECV!8XI\=:2I[7,,>.487''NE1I2[.O"4L>*.:IP-H_-A6U)B? NC
M.A*,+2FJCZ/ B6/R/BGCBYKW[=M4DH)YVD>S\EG%D]4OE:U7EX[V>5XE\GMQ
M2U"<K?'))X243UODNX.J:1?JYJXSCP-?TS(_5*ZQ0F?%_EH?_P FN_\ $?\
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M/H18L>J-M=$:D>XVUT1 7> N\!6%7H:Z[S8J]#77>6)48#!40I  * !"D*
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M88?B5 )8 #  5'[PNF[+@8"-&Y2[3UC<H_JT:ES"+JFW225-8\ 1D  H
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M57Y-QITC\XU+@N5I:3KT;F-:4=FHEL>"+B_MX5:M1T$EG,D>DX%5=UKB5_\
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MMSU0 0 $      ,GB1>HRKO,?W&%C*D>ITSZI#W'EJ1ZG3/JD/<*W&T #+8
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M'Q.B^3+S#_YIBGI=VGO<LBQWG:+.$9KH=12L+B,M[AG94(2A'$I\Q%CE  4
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MY94ZOR>ZHSMI2C4331@MXY/7^4NC:T-8C"U:]*.6EXGD.;&U/?Q]A94P !6
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M-X0&-6HH0;9YF_JN=79['::K<\M/">YT,I.<\LU'.TEL@B2?<6*V#(  H
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MG5I\];38.>,<S9U-KQG6MM2C<*FZENI9=+.S7@>3DFUR]P2Y%BGMXEZQ>[]
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MB7P)YO6^Q+X'VK\R-!_ TQ\R- _ TQW7TOBKS>M]B7P+YO6^Q+X'VI\R- _
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M'KXN\WJ_8E\">;U?L2^!]J+@?0/P-,?,?0?P-,O=CT/BSS>K]B7P'85?NY?
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M9UNHWBC2:CU+$M<&I7>,QBSJ.9RRV6<W4FVR/"6Q7-CW@D>K*
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MQ2/TCR;>4*WX=I3C4J07,DMSWL/+79K_ +M(^=UPKJ_-+-G5Q_"S+YJZJO\
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MT/61LQ]4RL4 !0  :VH_59GEJW4]3J/U69Y:KU+&:Q2V*N@70(K
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M32^RCS5[Y?Q[._NXPC*/>=!5JNH]WL+BNZLGN<45Z)8S:8\"^\ J
M 0       [F1>HRD_< M);GJ=-^JP]QY:D>ITWZK#W"M<?K: !EL  ''6]4U
M\8R;-7HC@EWEB,"D!4 4 "  4@*!DGLQ2:BGDQ( 6TLL?O98 &%>+JKEEAQ-
M"KH=C5RY4ES>Y'9 S#74KA^PQ^J7P1/F]8_=+X([=8*6$MCJ8</V"ZTE\$<U
M/A[3I_\ 97P1V!G3ERY&M:Z[YM:=]RO@@N&]/72BO@CN(2R9&?T=*^&M.?\
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M6'N/+TCU&F_5(>X5KC];0 ,M@  PJ]#79SUO5-?/4J("D*@4@ I"D  H $0
M%"(5 @ A_,B@" $*.X(K+)3P]CFA/*-8SB\#%;2>4#BIU%T9RII]#+0
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M\3']QA8RIGJ=,^J0]QY:D>ITSZI#W"MQM  RV  #CK=#6CT9LUNAK1[RQ%!
M5%  $*  !"@ " "D    4  0I"@0H $;QT.2%3!QM$P!N1DF9&I!M'-">%N3
M%E<H(I)E(H                           !A.:70#)O!QRF82FS#J7&5E
M++,1@A0*" 4  " H$*" "@@%! !2 H A0! 4  $"490ZHVET-6'5&TNAEJ
M*..KT.!/=G/6Z&NNI8#(9&)8E4+J0!%3])Q.OU+5:5A0G5K;1AU-YXA%R?4\
M=Y2L/1+C#PW$,]L;5KQE:7%:,'3E&,GA2?1FW?\ $]K9UNSRFO8>#N;:BN%[
M"I2E^E4<]?:=7HM'S_4%&[<LK=")>=?J-7B>UIVKK2C)272'>S@L^++6YA4E
M.+IJ"SB6QXW5XR?&.ETI95!4VFNYG#Y1+?DK65*P>U6?+/E\-RL]M?H]EKEO
M<V?G,)?HGT/-5M<KW&N4H6M;DH9]*/B>.N[^>D4X:73;PFNO4Y:EK7L[VWJX
M?--<R+U->]ON*;>QBZ<(N=7I)QW.AX9XEK7O%M:%2<O-U#*B_P"9U7!M/SG4
MM4=\]M^7/\C1A.-CQ5=.V>5V;7]1U-?H]3BNA1K.E*,I+..9=$;-UKUK;V\:
MKFI.:S%)GYS85)5M*O$\-N;W[S@N+&Y<K2<&\Q>4F]AAK])TWB"C?3Y%"4:O
MM1WL7*,/2><GYQP[>+YP3IWV(S45LC]#3<L9]7!,771WG%%I1N.PW<LX:+<\
M26M&BN6G*?\ =BMSQ%G9PON(KUR;Q3J91C;752WXKN*44G3Y&O2+U-?H&G:]
M;7-&4T^S2[I&E4XMMXWG8JG-[XYL;'@[^4Z52=6LW&AG=HXKZYNHVD9VL8RI
M26>9]<#JG9ZW7=6K.Z@[>KZ,I);'LM/FW:4\^NXY/R"TK5G86\X[U')=3V-*
MYX@I.CV5&+I.*WP,76IQEQ5/3]7M;:,9J,I8FL=3*RUBYN-8K+G<+.$>90EM
MXG7\>TW4U?0I7,4JLI>E@X=6=;Y?O:,$E15)X:]S+U->DAQO:*E*,H2FHO&5
MT.:/&%FG!0I2:EU>-D>(X5L:/S;O92;=3M'C/O.PTJR?R)J4HK,E#9L8:]W<
M:[:T;.-PIJ2EMA,X]/XAM[RJJ>'"3Z*6Q^.Z/?U8QITJ\GM(];.WN:VOVM:G
MCE4%T?N.;4K]/3V36^0C"U4HVM-/KC<Y$588+C8=Q>XC3'&Q#+N(5 @*!#*'
MK&)E%X8&*?Z5F<4G5)##J,QEE5<H%>1\I,7\D5XQ>[B>0TZCJMGPY9W-"X4:
M:>6L]Q[KC>RKWNEUJ=O'FJ2CZ*/%1M=;GH]IIW8K$&E+;N-1BQD^*+W5*L;*
MWJN%7"6674=0U/A^]M)5Z_-3GO)+OZF5UPI?6*C=6E/-=),QU#3=5UV\LE<4
MEV=/:;2Z=0RMKJ.I\07]P[2NXTTLI,\Y7HZE0UU)5>:X7>O#)Z*PTO5]"U2[
ME:4DZ,XXBVCEX>TG4:NMSO=3IJ*Y7[B)^MFOQ14J6L+2A4:N,8?O/7Z15JQT
M+GO&W.$&WGW'Y3H&EW%SQ;5K0BW&G5E_4_9JEMVUE.E)8;BUA!9K\YL[_4]<
MU.<;6OR4=]F+S4=2TRPNZ$[C-:7JR\#EI:;J6D:K/S*EF&_4XKS1M2U&PNJE
M6G^E73 -KC4]7I:9:WM6YYDWS/'>:$M<U+5M9[*WKN,>7'*S?C0U26FVUC.E
MZNSV,]$X9O+#B2-S.FU3Y2IM:*K:U3U:A:>=851],FW8:OJ=O7U6VK7&72AZ
M/L>#M[G1;B?$MG=<CY(2R:&H:)<4[S6+OE>)0;C\!IM=1P[4UR\T>5Y*ZSB;
M.2EQ7=7<)V2J25?/*F_$T^#:VL5>'I4:5)8YWW'9QX2N:497<*;\Y7I)>T:;
M6>HW&L:30LZE:XS"<L81QOB"]K:[R1<XT.3JUMDY+VRU[68VM&M1CRT9)O'@
M;-QIU]'4';*DO-^3UL;Y!^M:ZO-0IT*DJEU&HGNN5YP:/$-.YJ4M)J5)<W/,
MYK3AG4;:C<1G&3C.65GWG9ZYI5^[#251IY[*66$_6K>W]Q8:SRJIA*GT_D9:
M+5U;7J=Q4M[GE5.36[.2XT*\U+7I5:L&HNGC;W''HMGJ6@^<TJ=/T)S;RP?K
MJY<3:A&\N--E6DZU'T<]QSW%75[/1Z5Z[G#=1)O/M)2X7OJFI5;Z5-YK2R>A
MUW1+NZX8IVT8>FJB>"-1Z[0*\[C3:<IRS)K=G82RHX74\%9ZI?:9?66GN*Y)
MK#V/<VLG..Y*Z<7)0B\>DQ+9X+)\KV)C.X;U$4$##*GZQMQZ(U*?K&W'HB-0
M !%  !KW_P!6F>5J^NSU5_\ 59GE*OKLL9J(N2(/J5A<@@0%&1W$ I $ &"@
M @!X@  @ 0[@NC!#O)+8=XGW!8UM1^JOW'S!Y9G_ -1?^^\^GM1^JR]Q\O\
MEE_:#_G_ %#4?GNF9=3*[CNXYJ3A#Q>#I-+>)L]!8X=U3S]HZ\'F\O#]?K7D
M]\F,M:MH7-90=%]4V>X7D7L_NJ?Q/5^1R"^;5-^X_0.5167T,\N=U?'XIC\5
M^ABS2_54_B8_0U9M?J:?Q/VIM268O8P6&\[8).=;OAC\:7D9LVOU5/XF-7R-
MVL:4NSI0YL;;G[73Y9)X8E%)$[T],D?&7'_"U3AS4W1DEC&=CR:;/V[_ (A8
M+Y1REORGXBCMQOX\ODX962;*I&)5U.F.4C,JR0R1E JR(HJ[R@C(F.I0"*B8
M,D@R8862HH!9&7@% F9!-E 5'*3[R>EXF1,$-3,O$F_>9$$36*V@T=%KVT8(
M[Y^J=%Q!TI^\SS>CPKP9^V8H^MN#/V92_A1\D\&_MJ)];<%_LNE_"CS_ -O;
M/CT?>@_69.]%?5FD  0 $    F-A@H (       9/$Q_<9EXD_<86+2/4Z9]
M4@>6I'J=,^J0]PK<;0 ,M@  XZR]$U\8R;-7H:[[RHQ !44@* (      H$!
M2    0!0(4  0  5$*!=@]TL$*A2+%M=6<D:B2.((BMF,U(R-3+70SC-H@V
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M,Q[FS@G;QEWX.4PHP=&E&"W6.IF9KK*#((9-%W@(%&=/J;2Z(U8=3:CT06
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M/P+R3^R.QUK'!49*$_ JA-]Q>QUK$&?9R\!R2^R.QUKC:>###.9PECH8\D_
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M@(;5! #:H( ;5! 4VKX@@!M4$ TV@ &FU4" :;5! 33:H("Z;5! --JE1B5
MT[P"  "@0 H$*" "D*! @ *0  4A0  )1E'JC:70U8=4;2Z&6H  HPJ]#77>
M;%7H:Z[RQ*C 8*@%U 0&4()MO))9SGN1@G3C)R;?,94WE-]Z(UU:-[I]K?RB
MZU++B]LEMM(M;>JZU&FHU,8;-NC5=6<XRPL=#J^(=9H:10C4N)--RQL6,Y'.
M]+M.=SE23D:M'AO397$JRH14V\L["VN'6ITZL6L3BFCGY7%N46LRZE9R.CU#
M1**G.=""C-K&3QMIH-O:5ZOGMLZLY2;32/U#G<ERT^5R->ZG"G2<ZL897L*O
M5XGAKAJ4M0K5:Z3H9S3@^X]C<Z1:5[:-.O3C*,7E+VFOI6H0NJ]2%/'H=3M$
MHN>6UR^\'5UUSHUE?04+JDIJ*PL]R,*W#NGRIPI3H1<(]$=K57+2ER8S[36K
M7]*CV<*LO3ELL$.KJ+KARTE!T;6G&FT;7#FD?)5I5C.49-RRL'9R:454??L*
MBA&2J9]!=0N1C*$*L)1G'*:Z'5/A;2:E9SJ6T>?KD[>4HTX.IG9]#IZ&LT:]
M]4H3D\0CD);&RM$LJ4XU*5&*G'9,SOM'M+WL95Z492ANGX&OI^N6UW1J^;SR
MX/&YQZ-JWRA=75&C)<U)X>0F1;CAO3*M:4JEM&4WU9R4>'=.HV\J,+>*A)Y9
MVD9R5+EEAS,5-P79SVD^A-.KJ*?"^E=IS>;Q4HO*9M3T>QJ-1G13P\Y-Z*A)
M/GDLKVEA*G*.&]EN.QU=9></:?<UHSJT(O"P94M!L*=*=.%&,8RV:.PIU%53
MEE<B>#)N-3H^@TZNHM-!TVUK?HK9*?VCMXQ<,0SZ."=IAX;62RCB.:GJ^P'%
MF_1VC+.? /H<4(PB\TFVGUR<KZ$;0A2 0%(5%   (A8IM[=0(MW@2?++E9E)
M2P\=4>2U?7ZRU;S&W:[;&4F$>KD^1)IY]QDN6<5*74_.*O$^HZ9*K&[<>>3]
M#O-:VXEUNZE4JTE'DBLO?N+(FOTZ>'+F77V#=+T=CPUEQ/=5]#J5:+3N5+&Y
MIT>*=5M[ZC2U#E5.H]\>!<->T>L4?.)6\=ZD>N#9JV]&[M6KB*E'KAGY-<WU
MU#B2XJZ<^9S:2YF>@TGB*_IZE*TU3$6X-K 9=_IFMVD%<QI0PJ4N4[NRKQN*
M*K16%)=Y^/65W.E#5JDF_P!8\?$[2MQ3J5II%@K7E_2R4>H'ZI!J4]\%GG'5
M;'YO:\3:A:ZS&WOFE!PYMC&^XHU6ZHUYZ:XN%/KE@?I"G3JIKFC*:]IE0E*2
M:DSQ/ M>M<5)5KN3[6:W6=LG:\;:G4T?2'<6VU;*2,XT[^/-&4L=,G(DN1O;
M)^84N)N(86CO*RAYK%9D\[X^!V=UQ-<UM-MKBU:YY^(->YIS?9\U1[&O4NZ5
M*:IQFG*?1)G@[7BJ^JZC*RO&D^7.QT5&ZU'YRT.23:YMLR!K]"G2L=6NJE"X
MH\TJ77/>;=GH5C;UN>C14-CQ.EZQ6HZUJ7G#2E!-K!L_.+5ZMJKJER]ES<O7
M_P"BL\7Z!02A!Q\.@E&.5*2V/SG5N,+I7-O1M'FI);KVDAQ+K5M7I0U)15*L
M\4VGU#;]#E<4>WY.>/-X9,XI16:>R_J?E,Z^I1X\E%O]'R<V,G;W_%.H0OZ5
MM;XYWMOT#+WZ?,I\JQ+Q$.547*LTWXG0<-W^IW=2I&_4.1>!S<5NNM*J>8^O
M[2*[2TN(5U+LY*23[CFB\M]V#\DX6UB^T_3[ZI)[*>^6=E'B+672C<R4?-5O
ME/N#.OTG.W0LO1:74ZCAG6):Q8JO0WB_$[>GSP34\;DQN"74%\2(*SI]3:CT
M1JT^IM+HB+  !0  :VH_59GEJGK'J=0^K3/+3]9EC')C[ D.\O>5@ 7> H
M             ,C>$2.VS[P_5+4VY6%C5U%N%"27@?,7EIJ2GJ;6>[_4^G+O
MTJ,\^!\R^6F.-0DU_O<-\7YOI^'+='?VD93K4XI^BW@\_IF\V>BL7BYI?Q'3
MA\>/S?\ 3Z*\G' &E:IH<*]S;0E-XW9ZWZ+-#7_B4F<_D=?_ ,7@_8>OM+I3
MJU%+HF9O)Z.'CG+B\4O)9H;_ /#IF7T6Z&NMG3/=^=T^:2ST+;W,:LN5,DY6
M-SP1X%>3#1>ZTIX]QDO)CHC_ /#I_ ]Y4N:=/*;W%.[IM=1[$]4>#7DOT3?_
M )2F5>2_1?PE/X'O87$)-[[$G=TX=63NL\4>%^C#1?PE/X$EY,-%Q]4I_ ]R
MKZB^\>?4GT>X[T]7%X5>3'1DOJE/X!>3+1OPE/X'NG?4DMV(7U*3QD=JGIXO
M#?1EHWX2G\"_1EHWX2G\#W4KF"6<[&$;VEG&1VIZN+Q*\F>B_A*?P#\FFBO_
M ,2G\#W'GE)O9G/!J4<KH.U/5Q?GZ\F6C?A*?P*O)GHWX2G\#]! ['IXOS]>
M331?PE/X%7DST;\)3^![_ P.U/3Q> ^C/1OPE,/R::-CZI3/?X)A#M4]/%^?
M_1KH_P"%ICZ-='_"TS] Y4.5#L>GB_/_ *-=&2WM:9QKR<Z(^EK3/T"XIJ5&
M:77#P?C'%7$?$>AZO%4N16O5Y>Y9RJ7PQZA^3C1<?5(? \EY1^"=-TS1>WM*
M$(3R^AZ3ACRD6>H3C;W$GYQT>%WG/Y5>2KPYVJ?7/]#7&W7/GXY.-?+5>*YY
MQCW,\]Q!ZD$>CN?UU7^)GG=>7HQ-<G#Q?4X)DXZO'EVZ'UOP9-RTJDW]E'R3
MP1'.L)'UQP7'&DT_<C@]\^._6&\H;N3\"Q>,C!I@  4)@H $>Y0@)@8*
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MC4I^L;<>B(L  %  !K:A]6D>6GZS/4ZC]6D>6J>L6,<F/>5]2#)6%  4
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M $HZ8\K8XEY3]+6<I%G"LWRS_7)POY.K;1W"K.K&I4ZO*.3RLI4^&\1Z+/\
M0X?I/TO!Y'RA<?V.J:0Z%!9>Y9QL_7/R<Y>-Q^(5OUM7/VF>9U^JO12\3T-S
M4YH5:G19/&ZG6[:JUGU67E7'Q<;KT'DXMI5M;Z=Q]9<,4W2TV"QW(^</)%IL
MZFH1KM>BT?3NETU"QCA=QRKW3XVX+*+W"B\IH/9LK          @  0 (
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M?-R5PND9+^0<;I_NS?\ (^C_ *,[+OA(SAY-K./JP8TWB^;Z5G>5GA4:C_\
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M4 ,D %600 4A2 4(@ N1D$ N6,D %!"@0I $94_6-M=$:E/UC;CT1&H  B@
M UM1^JS/+5/6/4ZC]5F>6GZQ8S4[B]P[@NA7-  %           0
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ML?77D1_L38?PGZ!'HS\^\B?]B;#^$_0H]&<*]OBOX&)D^XC,NEB(J(6)5D_
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M:54JU;6"K]1C;>B\QRMRX]%M[$QV4&^XO-VB37<16(!"HH! *0% $!0!"@
M0"@@  H @  H(5 0  "D %! !0" "@  "    *@$ (4B",J?K&VNB-2GZQMQ
MZ(C4  10  :VH_59GEJGK'J=1^JS/+5.I8QR3N"9"(K#( (*
M@      ![P,)^MT RQ''K&">6UDQJ2I4H2G-X2.J>NV$927;1S[6B2,WECM\
M[EP=1#7;!1SV\/S(OSAL/OX?%&I&?8[8FYU7SAL/OH?%#YPV/W\/S(UU:[NU
M&_@=5\X;'[Z'Q0^<-C]]#\R)U-XNUW\"G4_.&Q^^A\4/G#8_?0^*+U-CMOY
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M4_6-N/1$:@ "*  #6U'ZK(\M4ZGJ=1^JS/+5.I8QR8]Q$7N"165  !
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M.#]<\ARY:JSOZ3,6-\+7[K!+=)Y)R-;LJ6')H8?>]C%>SC\1%"0P941>X(!
M=P $*B%"  "@    ,GB8_N,R\3']QA8RI'J=,^J0]QY:D>ITSZI 5N-H &6P
M  <=;H:\>\V*RV-?&,EB("D*@"D !%( *0H$!2 4 )9 +O*1%1%BK=F-7?9]
M"I[EGB0!822/,:OP?9:G<RJ7%.+SXH]-W%SE8+K-XO$_1WI/W-/\H^CO2ON:
M?Y3VI"ZSTCQ7T=Z5]S3^ ^CO2ON:?P/; =CI'B?H[TK[FG\!]'>E?<T_@>V
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MQ1)2:[LIA= W&3Z&)D^ABRLU"@@4*" 4A2 4  "%  $  H $ * ! !0" 4@
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MM@  PJ]#7?5FQ5Z&NRHA "HH1"@0% $  % (!2Q[S$RCW@BI# 3&3*F,$ *
M ?0"98! BY8W( +DJ,2QZ B@ :H !H              0  C*1@,DW "*@^@
M70/H&HA8D+$+5  9   #Z ,#$8+@8&(8& ,EBX8"0R$P8  (A2  "D H  @*
M "*^A$'T(L6/5&VNB-2/5&VNB(07> N\!7'66QKJ.YLU>AKKO+$"!@J(5=4
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M?++JBDC&.\?0W0B3&/5V1411D105    0  "@0H  @ %   @ %(4 "%  @*
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M H(4 0H $!0 ! *0H @!0!  !2 "D*  ( *  ("D H(4 0H    $" "D* !
M *    $*" 4A0 "(5 0%($94_6-N/1&I3]8VUT1&H  B@  UM0VM9GEJFTVS
MU.H_59GEJO4L9K'OR.KR.XB*PR"                     .@"QW@KI^+5S
M:!=J&[<3Y;U2PN97U7]#/&3ZUG2I7-&K2J1S%['13X-TF;<IT%EFY<<KQU\L
M^876=J$_@7Y/NON)_ ^I:?!FC=E]762?,S2/PZ.DY.?1\MJPNON)_ >877W$
M_@?4GS-TC\.A\S-(?_CH=CH^6_,+K[B8\PN_N)_ ^I/F7I'X=#YEZ1^'0[+Z
MWRWYA=?<3'F%U]Q,^I/F7I'X=#YEZ1^'0['K?+?F%U]Q,>877W$SZD^9>D?A
MT/F7I'X=#L>M\M^877W$QYA=?<3^!]2?,O2/PZ'S+TC\.AV/6^6_,+K[B?P'
MF%U]Q/X'U(N"](_#HOS,T?\ #H=CUOEKS"Z^XG\!YA=?<3/J7YEZ/^'0^9FD
M?AT.QZWRUYA=?<3^ \PNON)GU)\R](_#H?,O2/PZ'8];Y;\PNON)_ >87?W$
M_@?4GS,TC\.A\S-(_#H=E];Y;\PN_N)CS"[^YF?4GS,TC\.A\S-(_#H=CUOE
MOS"[^YF/,+O[B?P/J3YF:1^'0^9FD?AT.QZWRW\GW7W$_@/,+K[B9]2?,S2/
MPZ'S+TC\.AV/6^6_,+K[B8\PNON)_ ^I/F7I'X=#YEZ1^'0[)?&^6_D^[^XG
M\!\GW7W$_@?4GS,TC\.A\S-(_#HG9B<'RU\GW?W$S]<\C%K5H5H]I!Q]+O/T
MGYF:0W]71OZ9H5EICS0IJ."=G3CQ=I+9I+?)ETV)B,MT9-Y1BN\^( #(
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M(U(]4;:Z(@+O 7> K"IT-==YL5>AKKO+$J,!@J(4A0 ( *0I !4 ! 4 0
M4@ H $'<4 0H $+W$    4A0 (4 "  "@@ H(!0"  4 1%(4" %0 A0 (4@
MH0Z  D4@7  ! A0! "X 8&!DH7$P!D@12   4 0  4@*@("D01E3]8VUT1J4
M_6-N/1$:@ "*  #6U'ZK,\M5ZGJ=1^JS/+5>I8S6/<1&7<1(K"@      ]P
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MJD!6XV@ 9;  !A5Z' ^\YZO0UWWE1"%!40 H$*" "D* !"@ 0 "D*!"@ "
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M: $ !%  )@@![E3V(4&@!  *0 4  0%0 (=P @" 1G3]8VET1J4_6-M=$1J
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MN\V:BRC7>V2Q*Q8(V"ZB@@&B@8V(   %   @* (4B H  G<  *0 "A @%(
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ML;JU="2]#H6UM86E&,*:Z+!"1L/T7RKH"1>V'U*&HA0@&@( @,Q*  0""*
MT  (#N "7X  )#.!GEBR-9#WDD&H[+1J7-4;:/1+9'6Z70[.GGQ1V2Z&6X
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MH$*!HA0!H$*!H  :(4 :!"H#0  T0% T0% T"% T"% T0%&PT"% T0% T0H
MT0% T0% T0% T0H T -@-$* -$* -$!2#0!1D:("_P @-$!0-$* - A0D-$1
M2X TQB4J2P,#3&)5U+@RIPRP8SIP.9;$BL+!3+0          )-<T6F>>U*T
M<9.2Z'HCBN**K4W'IDLJ6/'RC@RBS<O[65%OEW1I0_O%87O WYO9XAA! ( T
M )D"@@R!03(R!0"%P5  8 !!@H (@@ 10    7*H !E  #*(!DJ*( ,@ ,@
M 4N" #(  9( (")B@A08  &*" N+BA$*,  @P4$R,D103)?B !,@   BH$+L
M@L$,&/-X&2\0,8;,R<LO",=W+9&]96DJDD\#2.33;1RGF2V/048<D<&%O25.
M"1S$M;D  1H       !)+*.&2P<YC..46(UO$Q.24<&.-]RZC$&;BL&*&@0H
M&B H&B H&B% &B HR-  #0(4#1 4#0(4#1 4#1 4#1"@#1 4)#01#)K"(-$*
M ! 4#0(4#01"@:!"@:'< !H@* (4!;C1 9-8(-$* -$* -$!0-$!2I#1B$98
M0P-,0%P,(:8Q!E@@TQ"H :'>9162)9.6G3]I%6E#!R@$4          &$X[,
MUW%IFV8R@FF$:VPRNXR=-HPQAE1<;&)DF8@
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MO!LAI/J!IK*ZE>,'/.GE/!KN+BWDJ(  @
M  &43$RB!9=# SET,                    %B0RB ET,3*70Q
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MO+A>)R.CL140.+"[AA]QSJD9Q@DPL:T82?<<L*>VYS8!!C&"1D %
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M$C,+(UZ%K"FMDCG2P4$7  !0                  #&<%)8,@!PNB8.FS9
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M80P@ &!@ !A#  #  "@ "           #  #"\!A                 !3
MP@ @  H    "        H,
M      !B "H!  !W  0 !%CU,@"+  !0               &+Z@ J   =QD@
M 0 !%                "8 $ N  !C( 1%CT* "  "@
M
A             "  "@                       /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g915839g83a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g83a02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1K@4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             M,   <M          $                          0
M           '+0   M,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   M,     4F=H=&QO;F<   <M    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   +3
M     %)G:'1L;VYG   '+0    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      01P    $   "@    /P   >
M '8@   0*P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ /P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M'](=0H2-$='_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #
M     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0
M +P   #H   !+     $   $L     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,C0Z,3(Z,#0@,#DZ-#4Z-3@ <G(S.3(V,S4       .@ 0 #
M     ?__  "@ @ $     0  !RV@ P $     0   M,         !@$#  ,
M   !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!
M  0    !   !1@("  0    !              !(     0   $@    !.$))
M30/]       (          #_X0%.17AI9@  34T *@    @ " $2  ,    !
M  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@   $L     0   2P    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C R-#HQ,CHP-" P.3HT-3HU. !R<C,Y,C8S-0       Z !  ,    !
M__\  * "  0    !   '+: #  0    !   "TP         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
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M29^*,_%-"H29^*,_%-"H29^*,IH5"3/Q1E-"H291D)H5'5)JV*:^5K&!SBK
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M\X?=[MQ16.^B)'T\;3I.H'?XH/3F2!Q(8<I^X;\%YQ-9^*8XLPU^#&,N^/\
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MUBC?"'8+AA4'#M@?;Z]TSGY&$U5E8*$T<3FR%V3XJU2'VM@E4:D"$(10A"$
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MT1,).-/5;!ATM./%4G"=L^C[3"Q_MZ=U=Q@!G>6%A<;;(0 =T*-P(0A (0A
M(0A (0A (0A (0A (0A (0A (0A (0A !#.90$,YE3_4KA7?=G+%V+\4D_4M
MI7?=G+%6+\4D_4M\C?LY!)'[3_-*SV4D?M/\UID]"$%2AA3#NTCHGE-7.MP,
M  QA*,>"0(4^I@!P@[G*,(PM+\-+02">83LI<),)@$(PC!3 )$J% B$J$"(2
MH0"$)<*A$)<),(!"7"3" 0C"% (0A0"$(0"$(5@$(0J!"$(!1[A]T>I"CW'[
MH_R0K&6K\7E\UO&^S\E@[5^+R^:W;?9"K(<C4E<FJ-2%U'"&G;DD0H9!T(Z(
MZ8PC*,I]3U 0W;DC*5%P90-LX0A#!E&4(5!E",(0"$(0"$N$84"(2X1A#2(2
MX1A#2(0A4"$(0"$(0*$("% )4B5$(A"$ >16<XS_  ^/]2T9Y+.\9_A\?ZE8
MAW"WV/R6@/-9[A;[%:$\U8%SLF!H!..J<CQ1<(&@#9(  #MS3DBE)":1IPE:
M,#9"%%P#;*#N"$(3Z8!L$(0@$(0H!"$*@0$("8%PC"$)B#"1*D18$(0J!"$(
M!"$(!"$(!"$(!"$(!"$(%Z+*WO[]%^I:GHLM>_OL7ZD1I*#[LU=AS*XT/W9J
M[*H0[\T'<8(V2HPHN0T  8 "4C*$JS5R&M;@[)>:5"@;C=+E"%H+E(A" 0A"
M!<(PA" PD2HP@1"7",*A$)<),(!"7"1 (0A )0D0I0J1*DZ+, A"%L"$(0"$
M("!DWV3_ "618?[V'_.JU\_V3O(K(,_%F_\ .JD1L(MX1E*QH P$D(S$ E#-
M/5:0$'"32"W!3P,]4F .JE#',:=\#*<P804@R$]HN0H;@8 2%H(P4N4J>T,-
M#0#D )<#P2X1A/:*,I$(0+E(A" 2Y2(0"$(4 A"$P"$(3 (0$N$"(2X1A#2(
M2X1A#2(2X2(!"$* 0A" 2M2)6H5'N)Q1RK&VG\5>5L;G]SD6.M/XH]=9^,MS
M%]F/)(X9YHA^S'DE/58Z6!H !57<K)27$$3M._@K4<BD"O/XF,K!P+:87:FM
M?GS6CI:6.FB$<3=AR7=*H9" #!V"C5=!#51/CE;D.4H)0KIC*/X$M+I-9:_/
MP*N;=9Z6WM @;R\59)"IJD0=TJ10^#HDRE2(L&490A%*A&$N%4(A&$N$P(A&
M$83 (0A0"$(2 0A"H$(0@$(0@$(0@ AG-R AO,J?ZCA7?=G+%6+\4D_4MK7?
M=W+%6+\4D_4M\C?L]D)(_:?YI6>RDC]I_FM,GH*$%2AA34KB ,GDJ:KXDME-
M*(Y:D!WDL-1<I% M]WHZ]Q;3S!Q&ZFYS)@;A)$M/RC*Y33L@<!([&>2YRU4;
M'Z=2N&I.4930<@'Q3N1WY)AHRC*0N')NY7)]1%'L]V'*X:[(PD!!&Q1\.JF&
MEPC":",[H!\>711=.PC"0?R0<]$32HRAN#YI >9Z*X:7*,J,*R S&-CP7CFN
MQ=D=S=#3\HRF:^0_,GXWQT3#1E":PEQ?GHE!'4IAI4)"1^R,Y)Q[*F&EPC"$
M)BC"1+E(BA"$(!"$(!1[C]U?Y*0H]Q^ZO\D*QEJ_%Y?-;QOLCR6"M7XM+YK>
M-/=59*C"C7*J]4HI9]@&-RL;!Q7<ZGZV"G:^F]_"*W>$8518[S%<X7N:X$QG
M#\="K+UF'!(>$Q-=,(V5<VZP>L")SP''DBGN7;5DD0QAJ8>RRPD7/M"3W-TY
MTC6C<^:83HY"YB5CO8.5#;=Z4S]CV@UYQCXIB^T6*$TO8&Y)21O$@)9OA,-A
MZ$TN#1NFF=FDNU=U,38Z(36N:YH+3G*0O ."F+L/1E,[1H'>36RM+2<\AE7$
MV.N49533W9CA.9B&B,[84BDN$-0T%K@0478G91E,[5@YG9.#XR,AR&PJ1(QP
M>,@IV%E81"7"$"(0A H0@(4 A"$0(0A 'DL[QG^'Q_J6BZ+.\9C^P1_J5@=P
MM]BM >:S_"P^H_8+0.V!QS50(Z+-WJ[7*C)["F#F^)53;^)[K4SN8^E:&@[H
MNMTA4E+>==2(9L-.%<!X+,YY\D33\?%&$QCP=G<TV.3+BU^QZ)A[1UQ\4829
M;G&5#J+G2T\XBEDP\\DP]DW"%SCE;*W6PY;XI>U;@G/<\4P]CD)!(QP.DY7,
MU$;3I>[#_!3#75"K[G<6T8:,C4X9&5WH:D3TS9'8!*+*DH3)YHH(B^1VEH5=
M%>()A,(G@EC20J:M4*ELMX%;%(^;#=+L;>:N&N#FZA[*8FPY"X]NP'GW?%0H
M;@Z2=S !H!YIAL6:.J8Z08[IR4YI&-TQ=@0EPC"BD0EPD0"$(0"$(0"$(0"$
M(0'19:]_?HOU+4]%EKW]]B_4JC24'W9JZDKE0?=@GR.#&ESO9"(>.24!4=?Q
M3:*# JJH,.<;A+#Q-;*AFJ"H#AY*8:NNB,J+25D=4W,3@5(:002IAIR$UN^?
M! ._P20TY(F!^7$#DE#LN("IIR$IY?%-!(]O8*8NE0D!)?@>SXI<@G YIAI4
M+B:F,5/8:OK,9PNI<&COG"N)I4J:'!PRS<(R0-U9#3D)H>WGT2Y&,]$-A4)&
MG.?!1:^NAHX7/>X#"&Q+2+E#.R6".1IR'C*ZNQC+=TS30A-SRQ^Z49R?!3#2
MH(2-SOD)0BD0A"F*$(0J!"$(! 0@(&S?9.\ED&?BP_YU6OF^R?Y+(,_%FJ1&
MQA^Q;XX00X]40_9#'@FN:XDC?"TA=09[1'S2:FO&SA\UDN)9*VEI9YH6$A@)
M"K>%J^OKJ 5$K,<UFK'H+7 [)<!92R7]DKI!5N#-!P,*_P#7X.R$O:#LSR*>
MJ;$M"A07.DFDT,F!>>04B2HCA!,ITA/4]HZH4&*[4<DO9LF!?X)'W:EC<1)(
M GJ>T3T*%])TH@[8R#LO'"2.ZTCV.?V@TCJKB^T3D*OAN]+-)AD@(Z(N]R;;
MZ"2H?@!HRA[18(51:[U#74;)F.!)&3\%(CN]')*(VRC4A[)Z%"ENE)$2))0$
M"Y4YCUM>"U#8FH5:Z]4+"!), 3R76"YT]1+V<+PYW@J;$U"9-*V"(R2G2P;D
MJ%%>J"9^B.<%R'LL$N5!GNM'3O#99@''D$X7&F='J9("U(;$S*,JN9>*-[](
ME&4^:Z4D !FE#0>2J;$[*,J%37*EJGZ89-1Y\ES^EZ,.<QTHUCHAL6.4*%+<
MJ:"G$LT@:T]<*'4W^D;2OE@D#@WFI8;_ .+E(J&U<24U;J D&H#)PIL%YHYY
M.RBE!E/(*8:LL(PD!):"4N$Q1@>*&^TA*$L$6Y?<Y%C[3^*/6PN7W.18ZT?B
MCUN?@W,/V8\D'JDA($8\D/R-VKGT:<.J1JKJZ]T%!)V=3,&N\"N$'$=MFD#(
MZ@%QV&RUS^)JZ0F%Q+,LW*9)41QC#G .3#75*%%FK8(8FOE> "<+M'(V0 L.
M04Q-=,I"D&HN(QL$FH X<<.3#3OV1^RY"HB+BW6-0Z+H#@$GDIAI0C":U[7Y
MT'.%"BNM*^XNHNT';M&2U7%B?A&$C79.$%X#B#LF+I<E&4FIH!).R4$$9Z)B
M:,HRD&2TGJF2RMCB>]QV:-T-=,HRJ:+B6V.=H-2-7AA6'K<;8#,]V(R-37?!
M#4G*10J.Y4U4[3#('.7&OO$%'5,AE>&ER8:M$*DGXEMT)P^<#?P5A;;A37&$
MR4L@>SQ"BRI2$(10A 0@$(0@$(0@ AG,I0AH]I3_ %*C5WW=RQ=B_%)/U+:5
M_P!V>L58C_>DOZUOD>@,]E)'[3_-*SV0DC]I_FM,GH*$%2CC4?8R?I*\IF-(
MV[_VN#MN\>2]6G&8G@<\$+"T-G8;D7S9U:CA8BU3VF=\%UJWTL$D<(&0 .FZ
MLV<221TCYW/+0TXTDK3UM(VDHI74\;2XM.=EYI<:;UNW3,&1.7[-'[K<C-JY
MXFNE5(VW2Q2.#9'#DKET\L=,UTI.O2#NJJMH9!:[5W<NBP795A5R35F"UHTZ
M=.RAKD[B!U2W1!+H='L=UW_B9T=)V;]3Y,^T%EH[.VWU$SYG.';'/-6L=LF=
M3MFIF:H_$H:EMO\ 41QOF<V30W?JJV[W6JFIX*J)[FLD>!S5[44DT_#=8SLV
M]IHP,!4E9130<(VMI8-;9,E!:U=UJJ811%[@YS0=7@I=CO4E34=B2XN:0"?%
M5=V<^JD@<]H$+6 .<.:7A1CQ<9NR&6?E)45J>*J_Z.M3J@'<$#8JBI^(7MI
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MJW,DY<S');B+(V<,E47#EI?1Q!Q'>6@;K\!A%DIZ$(6'0)$J16+ A"$ A"$
MA"$ A"$ ?966O?WV+S6I/LE96]_?8O-4::@^ZA.E;KC<T\B$V@^[!='9P2$8
M>?\ I LM"VC@EDA#BZ0#DI/T30TW#DDU/ &O#1@@*;QQ335M%3QL&=,@*DFE
MD'#[XG-WP$2UC[56UD)+HW/T#<X\%>-XD8ZC(#L/!\46VEDCHZEH8"XQD!9.
M"R58I):FI:6D/Z%,-:VW\1&&ICCF)D$IP-UI+I<645#VSF$@K"6>@CJ*JG?"
M2YS"-65K^*J66IM0BA;DCHDAJABO=2^IU,CE$9.>JDW.^/,.(,Q/'-1*>[2P
M".G,3-8VY!0;G'+)4.DJ6AC#RPKAJXM7$A]7D[;+WCENBEODM;42M[S&L;JR
M>2SENHIY'N,;<LRM/14(?3S,<-+BPC92Q8K_ .))#$^>*0EC':2 5J;36>L4
M+9ADN>,KS>WVQU%25%++GM'R%P!\UZ+PU3/IZ"/4-M(4&(N=57'CEM/#,YG<
MRKRMO_L4^KZP=TG/51;Y2NI^+Q< /J@S3E5%9;G13OJI<@/.H%:&AI>(G4Y,
M#PYY ]I0G<1RMJ"9)#ISRRH+J6K=;VU%OC$F>9/@JNMI1.YN"1-C<?%!L:WB
M,,H62,8YQ.VRK6<0U3GB#O@OY<TVAMD_J</<#B#N"IL]&_Z<HRQ@T8 <@G\/
MWUU14OI7-<7QC=1_2#*8[!-4Q@@MVQU3.':.2FXIN$KF@,>.ZIO&,$U7996:
M!J)V"#.VJ^ST]-;A,'ELF!OE7UVO3A5=A XLVSJ57<:5[[?:8XF#6P .PH-?
M%+]*&*I&F+3[0YY5@N;1Q$:BCK7')=#MSYJ&SB.=C8YG.=H<<:.JJ[!0STM/
M<=;=W',7Q7"HCD?#"T-_M0>-3.F%*DKU>EE[:FCDY:AE=0HMM&*&$=0W=2@L
MUJ$0A"-!"$(!"$(! 0@(&S_8N\ECV?BP6OG^R=Y%9%GXL/\ G52(V$/V0W2N
MR8R-6Z(=XAY+F6 3;DX6D5_$^!8*O(R[LRL]P.2>&@WD[!6LN%''5TLD3B<.
M&%"M%HBH*7L@3C"BQC+;;]=#<7'!DUG2?!1+O65%)::./6<ZL$_!;VDL\%-!
M.PDZ)#DJ%7<-4U=3M8"2UFX6]CGE9NV2:[K3OB=@:=QE6W&-7*T4C&$L#G8<
M>2[V7AF&BK&SO<[4W8#)5Q>K3%=(</VTCNX34]6>CH88RV=D\8=I\505%>PM
MJ]9U%O+=7])PN\U&)W/$?CDKC-PC$V5[82YP>=\Y38>M9.JN,\O#3>S<6?6*
MRNDDM%#;6AQT3,!>5I'<&P.MK:8:M(.5-NO#]-54,5/(2'L;I:>JAE9+M=1C
M92OPX.&X*U7%,!FX<>'N_P"F,J-9.$HZ,@R%VW+)*OZ^@CK*%],XD C"AE>=
M7*?Z*L-O-&[O/.'Z#T7>G?KE8Z%^'$9V*O:;A.,=I'.7&-H[N<I;5PLR"H[3
M+MO'*&5G9:T3"=CSWXQS)466NG%@+F/[VK&5JZW@Z)TSWQ%WUGM<UTAX1I&T
MWJLCG:<YZHN5F;S3O[2SX.#(!J^/-2('R4'$CFM=W,#9:NML$=0^D/Y:<8;_
M #_\I3P_3&M-6]QU(946]25#:3ORDQO;D_!5@HJ=MLCGIY(Q+S)!&ZU-PM[:
MV@=3GV2, ]504_"KH8F0-<\QM/4E#*@6PQUTW]K<-3=AJ*IZFLGBND]/$\F+
M.D86MK>%X]0=&7AP'0I]+PQ##B1Y<7.YY5B65G:^DEI;$ZI#_K=7-<]4E<Z@
M;([(. <K:5MEIZJVNIFDEI.5QI^'(8C"23]7R0RL3=)I[5?W1TTA#=/LM205
MS98YL_;'D[/);"HX7AJ+VZMDR01CJH#.%(!6'LR[2X[\T,K/62IGJ*YU/<9"
M^$<M7)7%XML3:8^J2,$1'>:"K6NX6@<SLX"=0\-BBAX:+:=\<KG;\LE"?&<M
MU)&VG/J[VQR8[Q7.V3LIZG!.9L[.RM%'PL(7OT%V"/%<Z3@V-E:V:0NV^*C<
M:RWO,E'&YQR2%*7&FB$,+8V\FA=NB+"%*D* BHUR^Y2>2QUI_%'K8W+[G)Y+
M'6C\4>M?X-O'O$W'@ETNP<E)&2(ACP2Y)SJ7.H\SXU[,<21QS,+VEO)5]UDA
MB=1NH*1['-/>+0M#Q-0.J.)(Y&MRW3_579M0AMW:,8USPW(R%OG\1G/IZJ,8
M >Z,_%-NETGGA:Z![M31N0577$NJV&&1H;/GDW;92+53.AH:@2#IL2B:G.K7
MQV2GEK,R9*[S\1-FA;ZD2S2,;%0[A&^KL$,$ !<#NJJEM8M0_M!<"[=#6I/$
MQ@HVZR72';FH8O\ .0:F0/#!XY466T"HAAJ(07-R"K6Z4O:V)\4;!JQ_1#68
M-VK9K@)(I'MC<>65?UEXJ&N;&Z4MVZE4;Z6JIF4NF,<]RI=RCBDK&R53BQVG
MD$P;/ARXMJHG-#"'-&Y\5A;A42,](%0(<]H&9R M7P=VK1*&M&C\I\0JIMMG
M_CN>JT @QXW5Q76DXD?%!/VS7:VG91)N)WQM9/)JP\XPN-_I97F1U*P&0=,;
M$JBJX:FKHX(&-!JF.R]O@@W--Q$R:MAB<"&N'4J#/Q8*:Y5%-("&'NL).P*J
M*RW5D-O]=8SZZ, !<[G8:BZVNCJM)[88=)A1-7EOO51#5CMIB^,[XRM'6LEN
M-'_9W&-KAO\ %8:VT@GJF0,))  *V=RJ)Z*U!M(T%S&][*&LE>[1!2VT]EI-
M5JSD<UUOES<RU4E,V8"1\>GGR*KZ"N965O:UCCVO+3T5M6<)QUU.:@.?D#4W
M<H:B\$2N@JS')*'O:TDD%6\[(KI>H7EH+6'!6<L=LEM-QDG?JTENGFM-PA"9
M#.]W/7D*TU6\94-(V2%L$(+G/ .%K.&Z".@H6LB;I#M\*D92R/OT_:MS&#ME
M:^,88T8Q@+*PJ$(4K80@(2 0A" 0A"!6\T-ZH:AO51*CU_W5ZQ-C_%)?UK;5
M_P!U>L38_P 4E_6M\CT!GLI(_:?YI6>RDC]I_FM,GH0A2ACAG.5%[&)C^T+0
M,=5**R7&5UJ*=AIJ(_7O&6K(T#2-;R_O1OV"Y"WT.[FQ,R52\/W*2>V.BK3]
M?&S)\U$;=Y!;Y7L/?#L#=:E3&K%)"YFDM!'^R2*CBAV# 0JRTW5O8Q]N>\_X
MJUFK(H.\\[*90R:V4\Q!DC:[')=((8HQV;6AL?@H<M\IV$-U;GDH;+DZ2O+&
MGN@93*J[=$QK3&&9:[FN<M'!)"V)[ 6-.0% J+]3PD#.<<TY]WI7T[9=7/XJ
M91*DHJ=T19V(PG4M#3TS28HPTX5;#Q)2NF;&3SZJTEF8ZE?*PY:&DE3*%D,+
MX3VQ:69ZIC>PD9H8P.;X!8>>ON%RJ'0V_>'///5=J"LN=OJV,J1W2<%3*-=%
M;X(9-<<8#ETEHZ>I^TC#B%!J;W3QX =EVRZP5T4=-).7=W&3NKE$J.EACBT,
MC '@N3+;2!_:")NKFJ^/B6A(#BXY=LI,]RAHPUSW;2#4-U9*GQ-;3Q!VH, *
M#30OD$N@%XVRH%'?:6KE=&TXP,I\UZI:1VF1RN4V)D]/',-,H!'Q3::BIZ<?
M51@>2C_25,8C*Y_<(R-U&I.(Z.6;LV$X3*?%G-$R1CFR#4T_R4=MNI61_5Q-
M6?@XECDN+J<.)#G85S/>*2C/9N<25/Q/B<R&(8<UH!">QK!(9-(8X]5!CN-/
M(PS1N[@Y[J@XEXHB:V)M([<NP=_BJL;-NXV0-SA0K/,9Z6-QYEH*FG9Q1J%*
M1*4BRU A"$"X1A 2H$PHUQVI'^2DJ-<ONC_)7E&,M?XM*?BMVS=H6$M?XK+Y
MK=1>R/V52FR#+3\$D0!CP>>5QKZIM)$Y[SW1N503<76V&,.+CDG"2HTSR#@8
MR$9P-A^RI)+W!$(WM/=>,\U FXD#:DZ7#1YK3+4&5D4@9(\:BD R\EIY\UE*
MBY1UE?')J[HYX*Z5'$#(R]L+LEFZFK[1I9Y8H&ZGX:/$IT<C)(M43AOX+S^X
M7V>OM<DI/U8."05TMM^[*GCP3@#=--C>B71%JD'7D4K<O <-@L+>>)99*7M*
M<]W.-EK+#525-#&Z7JT%-66)SG:!G&<]4YCCD YW7.=[6,<7^R!E963BCZYS
MV.Q#$<.RLKL:V3O'26YPG#&PPLY5<1Q14452UVTIVW47^)P#H.>T.X6D]FJ[
M1A+AG&E<F31OR]A#G\EA;1Q!45-QJXZ@GLPK1UVIK? :AKC@'JLZLL:T:"W+
MA@KFVIB?(8@X:L*CK[[%%#2N>[ FY8*J'7!CKJ_U=QUZ>649V-E2S!PD&G8%
M=6N#MVC98'AWB29S;@:SV8G;?-:$WZ**V056H=G(< Y19U%Z1J!SND ;@D'!
M\%$IJH2M;,S[/&^50UW$4;*V1D;CW#WO)%V-2QYQWLI^I9ZIXEI18WUT3NZT
MZ2561<6L:(3*3IF]E1-;/6,X"YFHBUZ2\ K/U5_@A861N/;XRLY1W:2LNK6@
MG9V#NM9$EKT@;G9+C!";%W(AGFE<"2"HU"\D92)5&@C* DZHR5&4B%&AE9[C
M,_V"/]2T/19[C/[A'^I6!W"WV'R6@)6?X6^P^2OW*QFDSB,XW*1@#1OU5/=[
MS%;I-SMCDJR#B9G;M-02&//<51JB0)]);@8YIM1NYK@,XY+.7'BB!M9ZHP_7
M8RN4W$S2PLB))&Q3\36J;I<TD\U7&W,GF,DK<Z>6574'$-+)%V;WGMAN=U7S
M\3O,I;3GD<)J[&P@;I!:!AHY!.9NQP.YRLK)Q-V%-&Z4_6..-ET??Q UK-6)
M7]YN5=38TA!< -6G"?I =G.RSELO\529A.[O1-R<*&.*H9"Z:-_]F:<'?JI=
MJ[&NE=L!ISGJ@ -9N1GQ69K>)XS#&:9VQ&^5,LMYAK&!CR>T4RFQ>C!& 5R#
MM,A'-5E;=X**ICCD=C7RW4*FXCI);I40-=ES&Y.2F4V+]TL<8/:/:2@2-(#F
MOV*RC;G!5,FDUG2P[[JEK>(9HJB%E,>X7@?S22I;'H4E7$R00EP[0_E4B,#0
MO.+M=9(^*J1SCW"P9 _97MGXB9-721/<<9P,JDZE:AO=;DG2%S=+'S#FZ1[1
M4/B*=U/;WR,Y?!8BU7N:JM]WUDYC!TGP1O8]!CJ&O<>Q.IOP7=AT@AQYKS7A
M?B-]/;F&4GF05IW\0P30$L<.UQMNC-L:75MMNE;N,E9:V\0YF[.=V^RTS).U
M8',Y$+*Z>.:1&,#="+ A"$4(0A (0A (0A ?E*RM[^_0_J6K_*5E+W]^B_4B
M-+0?=@NI.Q7*B^[-71V-SU1EPJ8P]@RW.ZZ.C:8L<QCDN,]?#3-S,[GLEIYX
MIHS)&X:!SW0.C@C#" T#4,+FVCB[ PO:"TG*XMNE,^H,6K!!\5WK*Z*)F-0U
M>:LU,%-0TU.'&*,-<5)C ,9#]U%@JH)8M0<,@;[IC;G3.D[-KOWRD]E-;;Z9
MLQ<Z$..=BNM30T\[=+F!<JNX,IP"\C0?BE@KX9X\P.W^*?V,=8**GB;AD8 7
M5L,<;B6M&XPH+;G$91&'#'7=2Y)8X(72YVPI=_TCE-;J<R=H8P2%+8T,8T-V
M"I+9Q!!62&+5OG'-377:E$ACU;@XYJ+L2*BGAF=IDB!'BN=11P.#&/B#F\E)
MAE9+'JC(.5RJZV*FP)B 3R6D(VGA@@[.&,!ONA<3;*,@O$#=7BG"NIV,[4NV
M*=2UL$S78<,>:#K%#&V(:6!*88@\.<T:^BC.N,,#M+G#3TW55=;MV=;&&.V/
M+=59B\;#&V4O:WO'FFU3.V&EPP$ZB?VE.),C+E57:]Q6^314$ \U#8M6T\79
MM&@;<BN4M#3S',C 3XJK?<YW]@Z$CLI"/DK">OIJ5VF9^'8\4FLVQVCHH&MQ
MH"Y_1M*Z8O,;=:Y_2U+@$/\ +=2(ZN%T?:!R$2(6AK<<@.27._)08KI32RZ
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MD;G8+.<(7:2[T<SICWP[ 3'7Q\59/#*<,9LI::O:NI93QF3;2-ETBG#HVO\
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M"0=5+^B-7_=7+%V+\4E_6MI7_=G+%6+\3D_4M<CT!GLA)'[3_-*SV4D?M/\
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M6(NU=5T=S=1L8][ ,Y3;=453'ETKGL:3U6RO=FEG=VM* )_$J)2V&>HA>VL
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M@.IZ1^<=%Z@V-N_Q3&Q,#MANB8S7!L$T%-(Z=KLN'(K/\3VFJ^EC6Q:CJ.-
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M'5HD)B#M.GJKB/13ENG RE"A6JH=54<4I=LX9W4U2S&I]*A(E!5BX&I$H2*
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M1Y%;*>=U-%)+D1!PWRO6;-50ST3&4[]6EH!66_A:IB:&-FS%GV5JK-;FT$&
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M >3NO:*F%E1$YCP"".JHCPW &.C#&X<<\D]D])NEX2K7UE"WM0&]WD%=T[=
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M73U><PV^LAI:E[X>1VRMAPW*Z6TQ,>T!^#D!6K8(G1.8YH+3SV20Q1T[<1,
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MR$D?M/\ -:9/2.2I'*4CF2A&$+FV ES\$!"L2A"$(!"$80"-D8*$"'F@(PE
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M C 1@(# 1LC 2;(%0@81L@-D;),-1L@79(C;Q2@-0(A+LC91=(A+@(P$-(E
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MTL]6,MW']FWR">T[<DR+[-N.6$[O8.%*0CD9^"4%W5&ZRW"(RC!28/BFA>B
MDP0EW0",(&4;X5 A)EW@C+O!0*ER/!-R4JL"Y'@C(\$B-T#LHS\$U&Z)AV?@
MFY1NA%)GX(S\$J% )<)$*A<)"4(W0)GX(R?!&Z-T4H.4(&48*($(W0@$(PC"
M!#[.R'9TC&R492.42N%=M1NZG"Q5C<?I23N_F6TN'W1V%CK)VC;E)RQJ6X1O
M6>RDC]I_FE9[*2/VG^:VR>FO.$Y<IB0L]$)J" X>*CDG.ZY[YYE<VY8F:F^(
M2ZV^*AX/B4[X+42I>IJ34U1 G-"S["3J:EUA1@U+A/82-2-8^"CX2@'Q5]AW
MUA&L>*CI>B:.Q>$G:-!WPHSBN+G$]538L.T;XA':-\0JPDCJD:XE,J;%IVC3
MR(1J:J^,G/1= 2AL3=34FIOBH>Z.B&IFIJ74U0<N3AE,-3-34FIJC;X3<.\2
MF&I>IOBC4WQ47!1@IAJ5J;XHU-\5%*:"?$(:F:FHUM\5#.4B'MB;K;XA&MOB
MH7S2_/YH2IFMOBC6WQ4,)P ^*&I6MOBHUQD:*1^$:0H=W(902'J$@S-H>#=I
M?-;V,C2%Y=8*DNO,H)ZKT^'=@/P6L-#SWAAN4TQDR:@_;P748'[HTC"8AA(!
M&V5QTN,[B3W>B[Y8G%NV04P<W8(TYYICW")H!=YKG454, )<=PL[<[MJ+A&Y
M0:)U93,."]H*8+C2NR.U;LL%+/(]Q).5S9J!)R=TP>A1UU+OB5I*:RMIVN?]
M:W<K#1-//)7=K2K@V;ZR -UMD#@>B5M3 P9,H)/)9./4!CHN[&9.2KZU-C5,
MGA]LO;ND?/$'9$@\EGADC"< 2<GFGK5U?^L1N(PX9*4SQMG#-LX5)&2TY"<2
MXR:R3J3UHNG2Q9P7C*421CNAPSX*DYNSU2Y.O7G=3$U<]M&WFX([>+&S@J8G
M*9NF&KMDT<AW< 4IF9DC4-E1AQ!R$I>XY3!=>L1N.EKAYI!/$#I+@J,$CDD)
M).2F&KI]0PNTZP!XIWK,31LX8',JB+B1S3"3I(\4Q/:- *F%QU"0)@KHW9PX
M8&RSS>[L,I6DM! /-,7VC2MJ8,;2-R@U4.?M LOR<3DY32XYZIZFM4*N#_$"
M0UM/G[0+*9)7-ROJ:U_KE/\ XC4>NT_^(U8LN=XHU'Q3U-;&2XTD3"^69H8.
M9*R?$%YM]=]735+'X/3*H^*7N%CJM).=*\@X9K967+#WD_NGJ:^D.&G,CIR[
MIXJ\,\6D.U@96-X1JNVMCM6YP,*R=K<,9V"8:T(GB]\([>+WPLZ"4H3TI.FA
M[>+WP@5$7OA9\!"LYJ^S0>L0^^/DCUB'WQ\EGMT9*OJFM!V\7OA';Q>^%0 [
M(&4]1?\ ;Q?X@1V\7OA4/[HR5/4U?>L1>\$=O%[P5 "4N3XJ>E-7W;Q>\$=O
M%[P5#E )3TIJ^[>+W@@31G\P5$@95]*:ONUB_P 0([6+WPJ+)2Y/_"GJ:O!-
M&/S@H]99XA4>3XIP)3U-77K,?O!'K$?B%2Y*,IZFKOMH_P#$".VB_P 0*B)^
M*9J/BLX>T:#MH_\ $";V\7OA4&LINHIA[1H>WB]\([>+WPL^'(+BF+K0^L0^
M^$WUB+WPL\7)A<KBZT7K4/OA)ZW!UD"S#WX4260C)RF+[-EZ]3 ?:M33<:4?
M]5JPLDKM]U#FF<.J&QZ$;G1EV]0UI\%F[C50U=PC,4H=H/18RJG<UQ=G=<++
M5N;<&@$[N4Q-CUT5,-+2B:HF#6_%<1Q%:<'^VQ[<^:P7I?K9:+@ALU.[2\NQ
ME?/4/$%7VA#I'8<=]UEKGG7UZ.)[27Z16QY4Z"YT<XS%.T^2^1:>XRR2-+)#
MDGQ7LO LY?2@R$EWFIKIZ5ZVVIB/-XPG&>$;EX6=B<3&3GHF0R%[#J\DCG6B
M]<@'_4"?ZS 1M(%@7U,GK9;JV!PK1CCI"J-3ZS#[X1ZS#[X68U%&3\4-:<5,
M/^($IJ8/\1JRVHX3"XH-5ZU!_B!'K<'^(U90$^)37$^)31K?7(/\0(]<@_Q
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M2@(PA*K(:3"4!*!E/:U:PTS"3!7<,70,"8(P:2ET*3@#HC+4P17-30%T=U3
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MA#30E"7&$80TB$X)"-T-- 2@)<)<(:0;I<! "4(: $N$82@(:;A*$H:EPAI
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MI!/&1CFLSJH\QJFADAW/-=:$ZI0!R5Y=+,X.<0.JKJ.E,$PU!=I1=TM,XAN
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M '7V'Z)[HVOX>ICJ!)!7LFX\'DC=C!*5-:,)R1S"$(5 A"$ A"$ A"$ A"$
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M(Y@/K$O+WBN=6/5!?J4_]5G^M.%[IO\ %C_UA>5MX8EZ5$O^HIXX7GZ5$O\
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M0K$-&4H0 E)&%I"81RZ)O>Z!.:7C\J@0%*!E)EYZ!&A_4(%Y)O-. QS1L>2
M"5(E0*D+L!!*850CG;+GN2NH;E*UF"H.;6%/#0 GG 37%".;SLHTCAE2"0H\
MY#=TUI&G(TE45?4-8UPZJ;<*L,!&5E;A6$EVGFIJXCUM1JRJFHFP#NGU$Y<#
MJV4 PRROQ&,IUTO/!"_)V!*LK322UCQI! ^(4BU62:1[72,[N=ULH*>GH6 C
M ("Y7MWX\1MJL<<+ Z<-.RLWU--2M(C '[JDKKTUH+6.69KKNY[C@KE>Z]/'
MA7UYNS2"&G^:S$M?K)W_ )JHJK@Z1S@25%%01N2N.UZ9XEUZZYIY_P UQEJ2
M\DZMBJDU&>J>V7N\U-KI/'(DO<24P%PZKAVJ3M?BHWZ)#CD8)W5IPEM<6?J5
M#VPU*\X/.JXL\UU\3R>;G&T]-@)X"9O^;_PLUZ%6 TL^?AS\UI_34/\ T$S]
M7_A9GT+QEU+4$$XV7K?,Z^UZV T1[)HW.^ /BND9#68*XU32]AT<_@L;=+'1
MT<;F_E_DH[Z6(\PW^2K.SJHG$L!.?BG-DK.L:U[8S)/]3#;J9W-@^2Y.LU&\
M]^,$+B:BK:/LUS;753']Z,83W,ATG#UL=_T!\@N#N$[6_P#_ !Q\@I8N$GYV
MI/I.-NSW85_D,BLDX*M3P1V#=_)0IN [;@X@;\@M'])4I;GM=TUETI>LF4GD
M/7ED)/1_1.SIA'R"C2>CF YTL;\ENQ=:<[!X*[QUD;QL5?Y#TY>9R>CIWY=/
MR49_HXJ#G2Y@_9>K>L,/5-]8C\4_D3TY>/3>CJM:3AS/DH<G -P;GO#Y+W.-
ML<B4Q0XW 5GD8OCE_'@3^#*^,G.__P 5P=PS6LYL=_I7T!ZM"[\C3^R#1P=8
MV?)7^1/XGSRZRUC"?JG_ .A-%LJF\XI/])7T1ZE3D?81G]DTT%/U@C_TJ?R)
M_%'SR:.H;SAD_P!)3FT\NG[&0'])7T$ZV4SA]A'_ *5&EL=*XDF%@_97W2^)
MXE2QSM_([Y%=98YCN0?DO8'</T[CLT?)<I.%:>0;_P D]T_C>/M:X9!!^2[P
M@Y7ITG!5.[<DA<OX+@')Q^:>Y_'6!:\AJ02')P5O'\&18V<5'=P8 ?J\E/8G
M%C'ME)/53()-M\K0_P )2,.S2E_ARH8-HU=7%(7GF$YDGBK26QU>,"-<?H.K
M;_TRFF(\;@X[A2XPS'+=*RUU3?\ IKL*&J W9LFKB,]H<'\N2?PP2+Q&T'K_
M %0^BF:'Y'1)PLQS;[&'#K_59:>MU1/J48'@JG"N:K[G'R5.B -3@U($H0#A
MH(RG9 :/BD?WB$CN6%5B+7RB"-SW<E\N>E*[>MW>9C7'#'>/Q7T?QK5>JV*:
M;.X7R#Q35FINE0_.=136N42>H[6E+AG V5>XC+0!S4EHQ;W#XI*5@>]F5-;D
M6+ (;> !W\JZL-ODU->=P[=5(9VM0(F^RO0K)1@4\>W(!</+W8]/B\<J5! 8
M(@YY&@G8*1-4-8SZLCET**^E?)2 1@[;K+R^N1$X:2T+S\_VKT9BRGN%4''L
MWG"[TE[J(W?6N<51LNPBVF !7>"N@J'X802O3_!,UC^6QN+5>XY\@@@_%6XJ
MFD;$+"M[2)K3&W<\EW;6UD+=4K,,\5POCDKKSY+8V\=Y@I,E[@?AE1+AQ;35
M$3XF12$D'<+S2HKNUJ'%\A&_+*N;?=*>GISC2YV.H7?Q>.//Y.V%XQC+KF)8
MVEH+B>2][_\ \>;N9&MI7N]AA.Z\*XANGKE: UC=CX+TWT%.F^F) T;:.B]7
MID>3JZ^FY+A'&X!VZ07.$_\ \JK;0231Y=G.$@M4G^;YKCF,RKEM=$[JGBJC
M/4?-4[;9*/%/;;Y1U**MA41GD4\2L/Y@JMM!(.I3Q1/\2@L#,P=0F>M1^*@F
MA>>I2&A?\4%@*F,]4\2L/55C:)X/,KJRD>.I03^T;XH[1JC-@>!U1V+OBB)/
M:-1VC?%1NQ=\4&!WQ0.K9&^K/7E=(0>+9_,?[E>FUD3A3/SE>8461Q;-GQ'^
MY0UZ-5 BF9X:0JL9R2K:I(]49GW0H#<%JQ6HKJ^-QB<5G'PD2.)ZE;&H =$Y
M4M73@;@+EU^+&:KVB-A)PL])5ADFQY*_ON1&X!8R:FEDD.G/->/N_574=Y[(
M9)_FNL7$S0_22?FJ$VZ9S>JC&U3-.0#\U>.AZ7;+FV=H[P^:FR%K^6%@+2Z:
MGP#E:FDJ\M&2N\ZTOXL- :24X/ &P7$2ZEVC;D+I')UC>X+J)B.:YZ<-4:9Q
M&5OVHFNJ1A0:B<X=@J*^9RXOD)!4T0IIR7D*13;M5=4G0\J702AVV5SN"8X>
M"Y!FZ*B0-'-1_6  3E<NCZXW28,C*\VXJO79M>T.W\UL.(J_3 X [X7C7$#I
MZJJ< ,C*YNDXM5=56OFF<YSLK@2T\]TKZ*9IQI.4L-NGE<!I*]'-F.T\9\#&
M/.VR[2P/:SN$84FGL=1I!#3\U9TEGG$1#VG*LZC7\;.4LTL4X SG*TM--4MC
M!<_9,J+2Z!\;BSKE=^T[X8,8PGRIZKBP2MJ*EK).>>J]DL%OBAIFO !\EX12
M2.I:EKP,#*]DX)NXJZ=C'NW7.R:Y]1KVX V')-+R=L[+JTM(P.J8]H"LKC8C
M2%RX.. <J6YN5R>P*;%5T@#G8(7.I;B!V/!3I(N>.:CU;-,#L^"F?5C)UH[C
MLJX]'8/TB,<M2IK@>Z['BKKT<G^\!^I>GC\5[K'[ 3(/;E_4ND?L#R7.#VY?
M-=F77X*EXAWI)!GHKCO=I_EPJ;B-@]7<?@LT>,TT+SQ548=MA;&FBE<,9*R5
M.2SBJH/3"W5O?J9L%BK'-L,@/-==+VCFI;B<[ +A(7\@-UA<<W-(P2>JYROD
M;+J&=*Z:7D#(W71X<(R"T94B,-Q#,)KG3#220Y>K\,8%M9YKRR\L:RXQ.=SR
MO4N%"76MA//*U!>LY)X36[!*%TB'$91C9"%1'G&Q5;-[2LZCD563>U^ZL#J;
MVE:1#NJKI=WA6T8PU5,+I":^,$)Z$5RC;I&% NK"Z!V%:*+< /5G*QFQE]!!
M4B*D?)R7 3M=,6M.[2K^VC,0)QA:CFK&V]X._)28K=U*M2.>%S>_2-TM^-(8
MHF-"RO%&&0R >"U4TYTG2L)Q;4$!P)7G[O\ 5OAY5<F.;5N<WWB5K^&9)ZBF
M$8<>2SU5 9'.+!DY6HX&>YE1H<!D+P<\WV>C_'5_"+ZF;5(W*YUMG=9Z9[V'
M&V5ZD(AI&&C./!9CBZE=44CV-&Y!"[=<Y=<,^O'Y[I+5S&*1Q(7H7!M,P0%^
MV0L(+%-!4E\C" MKPJXLA?'ODG9<;_\ 9TSXN;E5%I<T<EG)'ZY_W5]70]PZ
MANJ)C,5&#XK7DZEF1Z_!,GUJN'!AS5K+G^&._3_19NPM TK2W,'Z,=Y?T7;_
M )IG+AY[M>;\/_\ N"?]2]*FYCR"\TX?.>(:@>#EZ9+N6^07KCS5S:$X!/#'
M 92872,D 3FHQA (1#@G-7,.">"%5/!P5&NF# =.QPNY.RAWMPAH'O;N0%FD
M82Y31PO<Z=PPL5?>)!'EE.=CMLJ?C"_SSUKXFNV^!6=:YSQEQ))^*Y=-I-55
M35;RYSCA#<AN =USC'=W72)N#E<Y6\=H&Z<EY2O:=>KH@@. W(2ZB!O['4K6
MK(A-A[:20,&2=@H-39YH09YP=O%;KA"U,J)Y)2.XW<%=>,G0O@=&P- &VP4R
M/5PPMLNPA)8_D$VNO0FJ#''S^"S=P!BJ'Z2<94[ABA=57$.<"6K'J[\]++U2
M28:G#.5!K;.YV7-:5Z=#90V!AT;8\$UUIU#9FWDF.OKS8\EI;#)+. ]IP2MS
M9>'HX(FNT;X6HI[(UO>+ /V7<QLA.D=.BL8O$5(A$;" W!2T]SEHY!EQQE6,
MK 1G&ZJ:^'M&.('LA2LWCXWO#UT%;&,G<J]',;KR7ARZ>IS@.=@9\5Z)37-D
MD;'!W,>*R\W?.14^D ?W<Y>1%O?DWZKU3CJI[2W$-7E67ES]NJ[\/'VB.83(
M0"K?A>)WTO#OU5-()NT)8U7'"8G=>(>[U71QQO?2 TMMMO\ -6G!A_NMOFJK
MT@N(MUO#]CE6W!F/HD'XHU&MM_M*\@Y!4=O]I7D&X18@7?[!ZQ7$@Q;(OU#_
M '6UN_V+EBN)?PR+]0_W16JX&_#G?LM$5GN!A_=Q\@M&1T5#$J5XT>TE#"1D
M+4C)B4@ (QC9,>6QM+G' "J' _!#G8YD+/7KBFCM\1+I&Y\UA*WCNKK9C';0
M'G.RBO61,!R<$]LA*\FI[OQ.PZYZ8"/QR?\ PM%9N+,S-AJR&R'H@V^"Y&G"
M9!.V>(/:<Y3Q[!<4!A(GM87#(7/F<=4 <I0W*<&%=&M5#0W"<0,;)3L$QSL(
M.3PF.V&Z)7%0ZBH#6G)4TATTK6#*I+E7AH=@I:VL!80#_-9FKG,TA:PG.<+-
MK<CE75KI'$-)5>8I9"< [JWIK<_&J1NRM:2*FC>TY&H=,+.QUYXM_P 9:&RU
M$[\D$#XK46JU4U*S,X:2/%2JNZ14[",,'[+*76^!Q.'X\BN'7;U<>*_^-'7W
M&* $0C ^"S-SO!((#EG:F^2@D-((/B535MP.Y<Y<KU7J\?CQ<SUY>22Y5M15
MG)P57-JBYI(*X%TDS]+ 25->CF<S]2_6=SXKC-5$'8KN+=.QFIS< [J!4L#7
M'4BVQUBJCG<J2VI!'-4Y<![)0U[L)&?9=>L#Q3#4CQ5497#FN9GR>:N'NM14
M9?S6LX'=JN#/-8. N)!*W' )S7L\UT\<^O/Y[,;_ --?_L./]7_A9OT*DBEJ
M,=<+2^FO_P!AL_5_X6=]"H_LD^W@O2^3_P#L]9 '9@KE(_2-EUQW=US>P:3I
MW7/_ %TL^.+9#E(7G*1S7CF$T/ />*U9KE(ZM[PW"1T+7#<! EC YIOK4>K&
MI3U7#O5H\;M"C24%.3O&NKJR,?F3F5,3OS)ZF.+;=2:3F)1Y;73N]F/"L.V9
MC8IS"7\@$PQ3ML[<Y&RZ_1[F-(:X*R=J:E:P.WSNF&*;Z,J/\0+FZVU(/VBO
M6Y'-+AI3%]5534M0P;R+L.T!W.<*:6CHETMPF&8AB5[1R*XR5<C?RGY*R '@
M/D@L:>@^2F&J^DJI'O.058N)+4QD,8)(P"G$G/3"!6$A*9-\$)VKN_LFM ZI
M%AS=^6R4Y V<FY\$FZJY#FDX.3E)GS2@EHV2@G.X1FP C')*-\Z3I2ZAC=(=
M)SND,)APYO"<",;N4:4$9TY4<NE'(+6IZK#N^*-#3X*M#YNH76-[\]4/5,[!
MKO! I6=0,)(G$KMG9#U1:BBA,4ATCDLA;V-CX@8 .O\ 5;.?["3?\JQ=$!_$
M+,^/]54QZ748-''Y*G\5;SC^QQX\%4K7+--"<D1E:9 .Z0'O%!("3!YA1(PO
MI>J^PX7J6 X)(7RI7@N^L/,KZ1]-TV+=+$#N0%\\7* LIHR>JE=.5?SI2%*H
MX,,U;*$<Z-+5,I:G$3FYW 672)UK/]X GDO3[2 ZG;I\ O+;:UQ >!WLKT3A
MVH<6,:?@-UY_-^/9X8U%.SZLZAD84$T FUN'+*NJ=@?'IQWEPFS '8'=ZKS<
M=>M>WTEC.U%AIYLYCRY08>'XZ:74W#0M*ZMIXP27;JLJ*SUIQ;&=O@O9/-\>
M>^#Z2>$N= (G@AIW5IQ!3%_#WU3"7^(\E"MU&UC\N<23XK;6ZF;-;>R> 3\0
MN7OJ_P =GQY-3\.RO<U[^O-:"+AMOJKB&;@+2O,%-*YLVEN.6RELKH&TDFDC
M&DKT>+IY_)P\*N5&VGK7DM]EQ7MW_P#C_3-?6NE+-BQ>+WBL;572HC:1DO(&
M%]&^@BV.IK9#.]N-32,KT7N8\MY>PL:  G)!S2KBP$(0@$(0@$(0@$(0@$(0
M@$(0@X5N],]>54H_]6S^8_W*]6K/NS_)>4T__NV?S_J41O[A(&4K,^ZJ=M8T
M;94Z\._L;?TK*!Y+ESK4:!U2TQ%0*ZH;V>RBN>>RPHM0UY:.>%)-N4BDNLA>
MX@;J-2PM)R1U4NL9N25 $QC.R\WE\?\ XUJQ$3<; )P@:>B@QU94R*H)'1<9
MQ8::^D;S 1%&6/\ @NKIBC7ENW-=.8F_$B%V"K.G<"%0=H6E2J>M YG^:]$9
M7AQI_91I&ARCMJPX>TG-G!ZIL".IP5S=3['92FRM\4.<TM.$V#,75FD$JFBK
MC$\@E:*ZZ7-< L?5Q/$A(&RX7I<J?5W,ENQ7*.X:V$* V/6,;Y76.E+0>:Y7
MI>8@UY,\A:>14/Z&B/?<T9YJZ[ :LE=6Q9&#R6+7M\7$K.?0L4CB=(4^BLD
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M<34UN)TOW"JKKZ1'3-,37C!V7T?%^/#Y9BZX;PV_U!.^7+TVH<UP&D8V7DO
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M]EP3FM('><"F(<$?NFA[<;% PXI@<G-\D!NR3.,I@"[X)6Y/1-&ZZM<0%,-
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M.?7D\]^)_IDS_ K!_F_\*F]#&105/[*Z],3L\$,_4%5>AH?V"H_9>G'S9_\
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M29'BC4$"H37/P4SM!XK6)KJF'FF:TFHDIB&5Q_LSUY;2_P#NR;S']5Z97O\
M[.]>74;O_5<WG_4J+'IDWW-OZ5 _*%-D.:)OZ5"SW0C4_ ?8*-M(1_TSA-=[
M*B N 2:PHTKB%P+W9ZJ"?K\$YFY5:9"!S0RK(.%!9/ +2%!DHPYQ)"ZQ5 <-
MRG]J.6R"&:!AZ!(:)@:=@IW:M#=R%PEJ6@'O!9[@S-UH6@/.%A[O"V/*W-[K
MV-C?APZ]5YM>JTR$Z<KS=1J(K'L:_FI\+F.'/HJ"(222;96CM5NED:,C&RYX
MU$&M:'L*H)6/BFR!LM\;02[!";4\/,,1=AN<*WEFL[;)C(P-*G>J<W$<UTI*
M$0RXQU5SV ,8P%RZF.=OU0,C#3NA\K =R%=BVEX)&%FK[!+3.)&0/)9CZ'_/
M5U;JB*,AP=N%;5?$5.R,1E[<D+SR@KW9PXE3A0NJG=IJP!XJVO;S'6Y2]O4O
ME8<M.ZYTES$<P:"%TJ6""GTAI<>6RHV1O$^2TA8UNSX]-M=V$3(SD;K:T%:*
MBE#]6Z\@BD<(HL'P6VL%6X40;DYV77FO/W&NFQ/329.X&R\2XOCJ1>7XU:,^
M/Q7LU+E].YP/3=93B2V,E8Z4M&<\UVDUX_)_XPUNI'%@=@YZJ\MU.UTF#S4B
MDIFQQD;) .RDU#KMLM>OQYYS5D:=NC90JJ40,*LJ F88*K.)(NSCV*X=\NT\
M>QF+A4F9Q:W=1:ND<:7+AT4RVT_;5 R,A7-VIVQT6P'LKAZ_7/KGU^/+YZ/$
MY..J]A]%8TRQCXKS.=N9CMU7IWHP']H9YKZ/@GQE[Q'[ \DR#VY?-.C]@>29
M3^U+^I>IET=@G"AW&-TE-(U@R2%-QNF%ASXA9L'BMWL]Q9>YI8HMME/IY;RQ
M@;V(Q_SX+U6:FA<=3H\D]4P4<,<;B6C*DY&$H)*GLI/6AI.DK'W^H.'AOBMM
M=W%M5,U@PW=8F^SQ0M?EFHKKS4]=8.O,DCB%7FE>'YR5;U%5'++AHPN[*?4
M<+S^1ZO'XU?!3DEH*M(:-N, #*8_3&YJE02Z797A[>[CA-HZ< :7# 4BHMS6
MLUQ#=-A=V@R-E:41![KB"KR=^/XOO1K6SQYBE)W<O4V.) *\]X6I6MJHW-;@
M97H3-AC"]OC_ !\SR3.J>HE4<@J6HM6,-/Q79S<:#VRK!0*#VRIZ 0A" 7*J
M&8'+JN=2,PN5GZE9"E']OF\UIZ'[(+.4S?[=/YK246T073ISGZEA(3E*FXW*
MXUU4O$->8*21HYX61L=9)ZVYSN15]Q.,G2>15%31B$ @;KR^5V\<6=VK0Z([
MK(U,NIYW5K7N):=U12\ROG^2/=Q'*7&"HDAP%TF<=U%D?E<Y'>1PJ' I8-(;
ME1JEX;U212@CFNGC<NF&XV:#5R$>*Q4CM)6PXQ?_ &F09ZK'2MR5]3Q?CR=P
MCCJ:%WI3IJF^"X8PT>:E4S@)F]W/)=/]<+7OGHK,88TN.!A>FW"^T5&X1R2X
M.%YEZ+RUU.S+>BZ<?S:+T&-V[BW'+IOAQ1;R-IDG\46__%7C;I7#DY)VSO$K
M;B]E_B>@_P 9 XHH!RE7C/;/\4YLSNKEFCV8<4T/^*G#B>@_Q0O&1.?%/;.[
MQ1=>RCB2@=MVJ?\ Q#;R,=JO&V3NSS2>MO:_F@]B^G:!N_;)PO\ ;W<Y5X\^
ML>6G!2PU3G C5N4'K\=^HQ*0']Q=7<04C9&B-X(/->/2U<HC[-K7:AU72"6H
M:W?4?CA.CF?7L#;O1SR.$<F7]0JJ\R9)P=EB^%XIG5TCWRY&VRTEUE[O/HN-
M?1\$<+8[,TBLGCZLJGL[LSO5W(,0%9>BH,CME&E=AO-=7')*CU&S%EKF(/$+
MLT1_2LU9CC.3T6CO?>HC^E9:V.TR$?!1UYBR8,O.=UF+NW16EW+O+4QC#U0\
M21:>^!U4=8JK\>UMI.=LC=/@C$EI;&'.#G-P %R:156U\7YB5 LCY9;E' ,Z
M6.P5GO\ $2[;P[)3QFH>"79ZE<;O2B$:P,%>DUL3&T :&@'']%A+S"Z;4T''
M1<^7#R5K/1;=P V)Q&%ZW'+"8]6>87@?"M'+1 /$F,+2R7:J#2&RG 7M\<^/
ME^:_7J@D8-19OXY3::2%S3K=NO)ZB]UC(#V<KLK/&]W(DGUIP71YO]>]"1@<
M[204YLC#OE>!Q<17%A(-2XI[>)+AC/K+OFJW'O?:M'@G,F&.B\"/$UP_[AWS
M7:#B:OZU+E=*]>NW>:<K'<3.:**)H.2'?U63GX@K2TDSN*A?2D]68P]Q(U!2
MI'L/"=7ZM;343'2U@&X6FIIZ>I8*JG=K=)S6-MS?6>%9HV[.+!NJG@^\NM=P
M=35;\L'=;E9=)7J3P\]Q@R#NG-?ANAW/DN39=A(PZ@0#LG-Y]H?-3&YTXS5
M@[CS@*$]SIW$#DI\L;*HZG8;YKDX,A&W161GNZ;34@9N\E=)JID0P, JOJ*M
M^X;E1AJE)UE:G+"14UCRW+>J*89.9-BN1DB9AKB-E NM:62M$/+'1=(+W5HY
M<BA[6@9R=2A4U1VE-&7#O*2T.=)D\EI*=N\8/1#VM?#V;]Q\4CWX=W4CAMDG
M=3",%Q-:GVZH;4P Z/:*Z6JN;40!V>\0MA60QU4+H)0#K& 2O/+C22V2YO.,
MP$X'@N?4:7I(:"YN[NBYZG.)+N?@DAD:Z-KVN#LISCGI@KC8.;BHTIV*[O*B
MS'8J"#4GNE4=8[<JXJG=TJCK'=XJQ4&3FFLW22.W21E:BNPPG+FTIX*TR4@8
M3HF[)H*[1\MD:@,>VRL[/+V3@"=O!1(QD%+%W)!A2QN5:7/#HB?$+!W6/ZP^
M"]$JX/[(QWBW*Q=U@W<O+8^QX<QDYP,$87"+)=I"G5$?>.%.L-K=45(VVR%)
M';NY$CARU2S3M=OA>Q\/4(CA:US1GR5=PY96PM;EN^%LH(!$P$#DNW,?/[Z^
ME9"(FXP%F;H/[VIOU+4OD!!*RUR.;K3?J71P\OXZ>F0?^AV?J']% ]#3?[NJ
M#Y*R],G_ +'C_6/Z*'Z'!BV3^05CR/0B,!-)P"NCN2XO.Q5:_P <,O#SIW7>
M,/<-PN0=I)09GCV49CN6/'(!-)?C!:,+AV\G4%*V<NV**ZX1@I ]+JV40FDE
M-+$[4@E*IFC;FFG'5="5Q=G5^ZS@>$B4<DB8T1"$BF$"7*1"BE0D0AI0D0A6
M%'FE2)56<+IRD P4YIYIO573#\[)!@GX(Z(;S30H:T=$[.R: G!$ *5)E"BP
MJ4).B LK"2D"%_DL31#_ -1L/Q_JMI.W,4F#T6+H3CB-@/C_ %6_]9Z;N\3O
M9;V!O/"\_J+:*IYEGD>/W7I5?$U]#'MT61KH,,<.07HX_')A:]I:714S&OZ;
MA9:MLTLDSW31@!>K4]OB#7OP"Y9CB#ZETI+< !8\C<>.\0,$ <T;86+JI"XG
M<D96AXJKNTJI& ]2LRX%V/B5PCNYX.-EVIW'#@<Y5I04/:1:G*KE'9U4C.@*
MTA8AC.4^(;N3<X72 8=YJ58Z0,^M'BM9:6X:/(+-Q-':K3VO9@_9<J[<1<P.
MP=U8-+3&2=E5,.%TDE+8C@KE9KT\_$:XO[1VD'V2NW#D3I[S&03HQR5=63-C
M9K)]I:ST?4G:T9JG#<$C*[>/AP\O3S;T@DBX/8TG <=LK(YR,+8>D&)S;G,X
M\BX_[K&L]I>F3(\?5U(B&D'/53K4W-6"H/DK*U8$H)6*O#>4;SV#2[9H 5_P
MFQYKGRP.<=O%9!U5FW/:W8X6]]$S&Z=4I#B6]5KFNG7XW]FO,C2V.?8>*UE/
M5M>&&-RS)H8W@O8-)4,5%123@#+F@^"W9KS/5Z"K);AYV5H'9 TK"6:Y>L1A
MO(K8VTDQ[G*Q8L3!R0A"BD<<+GD)[DPX5B4 CQ378\4[9,>K(S7%[L9W7(/.
M5U>1CDN8<T'DMR.>NK7'"Z,(YE<FD)VL<DL67'*X:74[EYG1!G\4S;[Y'^Y7
MIM3I]7?GP7EU*X?Q;-YC_<KG9C?->AUSA'1-P>BJ35M$;>\CBFJ["W@CW?Z+
M &^'(;JZKE>LKI/KT>"I:3S2B=H+MUBJ>['8ZEVCNQ)=ERG\F+Z6M-)(TDI0
MYN%F3<\?F7,WEH_,%/Y93TL:.5S2#@JLJ)M!V*JY+RT#(.5P%=VSME?Y$Q<Q
M59QL5T-:0>:K8'=U$KMECV^HE2W%P_,H%9<7%A[Q7&0YRH-3( T@IUWJR*6Y
MU,DCR,G&56=@)';[JQJRTDX7"'#=UR_52+?0M:X'2M9;:=IC'=')5-DC[>0#
MXX6M]6]7ARNG,173QM83\%!JI"(R/@ILP<2<KA-"#%OX+72_JC:T.DW\58,T
M!F&G=0I(RV0X2F?1MIW7FZYUGU6$+]+L.Y*)Q#2Q55*<<\+CZTWF\AH4.Y7^
MEIHB'/:=O%2<.G-QDO4>RET-')3'U<D!:QO@JN;B""HKG",M"E-8:@!^I2</
MH>/RS(O;9B0%T@&XZJ-54Y?4:V-&D?!1J.5T;].O974DT;(=( )*Y]S'IEV*
MZ-FJ1H_DMC9(2V,;;;+/V^%KI=;N7-:..MCA8&L()"QSMKEWC1LG,$8C'YU'
MXF:*:P=H_8Y4>QE]=4 N! :5#]+%P;!9NP8=P5]'Q^/>7SO+U_:LU/7L$)P=
M\*GK>(/5H&C(V*I75CC$,GF%3W!YD8=UT_C^)*W5IXR@:X"5X'DNUWO5-7-'
M9OR2O&*MSXI<M=@*32W"9K1B0E<NO$W*]AX=&J49QI5Q=F,-/(,]%Y%:N(JB
M!XU$X5V_B9TD3@7%<IX_K/7U)[$"4[=5O/1IW:T#IJ7E45Y#Y<9YE>I^C)W:
M53'#Q7?CES>[L]@>22#VI?-.C]@>2;![4OZEUD8=4@)(/P2H6@C=PF2MU+HA
M!Y]Q"XQU$X8!G=>;W5TKIW=J.ZO0N/)O4YA(>3W87FW$=0)7_5G&1T4W'3F,
M55/[*O<2=LK1V^M9+$&@[X5#%2NJ*EP<<G*T--0BBBUNPN'=UZ.+B-7@AS2F
M4\F7;E0[I< 78 Y*I;=BR33I.%YKR]G/;=02D,PWGA2J.=T,FJ4X"RENNGK,
MC&MVQLBY7.0U78-! 8>?BKS,3KO7N7!%QBJ9&Z=\'"] !&,KRCT;541:S# #
ME>K1D.:".2]?C_'S?+/[6GJ-6'NGX*1G?"C5?(KM'&URH/:*GJ!1Y!V4]0ET
M(0A%"9/]DY/3)MXW)/U*R]./[;-YK0T@^J"H(CIK7[==U?P.Y#3@877K\<Y^
MI71)G;*0N/@F@DGX+A:ZLWQ+I+E0T[FN."M#Q-%J&6K.TPTG?FO'Y>M>GQQP
MN#<-*SM2[!(6BN[B1L,#"RE;+@D=5X^_KU\6.,LG-09I<#FNW92R#+6$A<WV
MRHW)#L%8DUW]L5=4]SR0$M-#(05+BM$SY<D'"L:RF%+2GEG"Z>/ESZNO*^+V
MGUJ35XK+/V6FXG>75;R3U6;E]DKZ7B_'E[<7'("F4;L3-'DH#.>_13:$CM1X
MY72_KR7]>]^BTN=&T <@NO'M,Y]_:1[BY^BS:)A'@KCC7!NXVWT+<8Z89U+)
MJ. FFCEQR5T&;E.T#&ZVXJ+U27P2^J2^"NBS9<W;+-%4*60=$YM/)X*Q*:.:
M&(792-WPN4K'XSA6ND.&%QD:&,=D(L^*U@>0H8J)A7Q1Q^TYV I[7]P@-W51
M<'F&KAD;LX'(1=7=945E/.62M:'!6-MN;7T<O;X#QR"RTMQ?/(7/)U8YE,I:
MP'4W/,J=?#C[7I/"+3+422'V2,A6ET=SW5;P8,4NO5L6J3=I,1/P[)"\]KZ?
MAY^"QG^T/6@G/]G*SG#3]4DFH+05&],2"K';KXJ]7?*XU;L,2 G6X+C6.(8L
MNO*-=SFC/Z5DZ)V*DA:NXG-(>[T64B&*@GDHZ+TC#FJLXDCS2@X4^FRYG>.Z
M9<8>TIGZMQC91J,7;&D/)RIW"<,;KO*[ .'9.RKJ>%XJ#WB!DK5<)4K6U,CL
M#)/-8ZK.-!=,:=?Y,+$5KFOJ#CQ6UO/=86],<EA:T_7G'BIXY]>7R]+FD:&T
MPW3XWQX(<J>.H<UN-6R'SGH5[N)D?+\MVKN&*)S7EW+"R=>TMD=V?+*L65+B
MPC61LH0F #G/9J"W'%71O )UIX>#G')0ZR8.F):,;\DC)\/]G92UTYB=@'J4
MK ,\RF-.0"3S71K0.\7+'LM2 T%A3*!SV5C<CNY"1]6R.,C;*CVNH[6X =,A
M3V21[E8__;[RSGI"RETHC([M6Y$C3JV6VX08'6<@C(+0N=RHF.U!K  5N34M
MQ&X$XC?.T4]4>]G&Y6UGG:<8]DKR"X1R6JJ[>#.&] M[P[<FUU"W+LOT[A7"
M=+FHG:^/LH#W^>%Q[VG#N:8QO9'M.9\$I=JW6N)K6Z1[6@$E5-=6=CG25;@@
MC!W46JI62YV"Z2"@[62H((RIU-")".T4^&EBC: &#*D,8P?E#5 0PAK1CD%V
M?)J80Q1YJAL0V.5$-69!W6X5A4U\[:=I+RH[*LU)^K7..)TQS(<A3(X&1L[H
M *J1#;*XN.H]YO),NUN9=:#1(.^ 2#C?*D]GB4$#;JNV0Q^<X"YV-/-:(SVJ
MI=!79!)[N?!7N0Z,/'(J=Q9:16L,T0&MHV(68M52X/=33DM,8YGJN5@LWJ'.
M=BI8(>TL)PX\E7S$L<6$Y'BL8(54>Z5159W*NJWN$M!R,<U05CN\59%1'E+&
M5R<Y+&[=:D$AI71JXM*>'+6)71=8=U%U+K&_!V5B2K&,8"!CM N,4FW-.<_D
MIC<Z:>H=JHXQ_E6/O,)WPM'13=K12Y.X&WP5'5G7EAW*X7E]+P^1FZ6A=/+C
M'5>B<+6,0L8\MWP.BK^&K9J=K<W.Z]!H86QPM &%G';OOXETD 8T8 4A\H#=
M*Y!^ENRXN?E=.?CQ]7:Z/=AAW69KW9NM-^I:$NSG*SE3O=8?U+3'D_$_TQ;\
M$1_K']%&]#X_NR;R"D>F 9X%C_6/Z+EZ(1BUR_$!(\K?XV4.=V"5,*Y2-!!R
M%IK_ ! [7P3/7 T[D*5V(?G QA1Y*/)1B4K:MKQ@$)0_?.R8VC(Y%<Y:=Y&-
M914ELS?%=!,,<U5FFD;^8X76,/:,'=#4_M6^*0R!5=1(]IR,J,:Z4'V'?)!?
MAV4A *J(:YQYL7;UAQ')!8'DD4 5H;[245T;N3@IC6IJ7"C,J6CXI6S@]4PU
M(PC"Y]NT#HE9*'GF IAI^$81D >T$ @\BF&C"1*YN!S30-N:F$I0E31D%.&Z
MC00 G!OQ33L40XG 7+M=)*>X@M*JJM[VN[H)2"T$H/).!SU5&VID W:4]M9(
M#[!6F5V!OD\DH50*]Q&"PA2:>IU$*+$]'DD8<C*-PLK#)B6Q2>2QM$,\1L\_
MZK92G,,F?=6,MY_]0-\_ZK7^L]/2JD?V&/R6?K8XY6$$[J]K78HH_)4FH.VV
MYKT\?CD@,IGQ'N<BLCZ0&%E"]^P)VV6\SB&3//&RP?'[O[H).^ZQY&X^;K[$
M36/)SN2HE/$'.8/B%;78=I6./0%=[+;^WJ2X^R-UPCNZ3D4="7; K'3RZZAS
M_$K9<0Q%]4V"/=I'(*BO-J--!&_EE;GXBNU9>%*!QH(42G9WADY4ZB(>)6O&
M_19JQ,I]W K06]V&_LJ.W18CTNW*MJ!CFNW.RY]_';QW?BU$FZ)9"YA 38]R
M1CHF/:<'.RQS-KT=?(JI0^JJHH!D]\!>T<+6EUOLW9%N"=^2\HLT':W>( 9.
MMO\ NOH,TA^C6D#!TA>WQ^/)KP>3O:^?/2=3=G4 XW)7GLD6G=>S>DVB$KX!
MI[V5YW=K=V$)=I3IR_QGX6ZE-I.[( %#C=WB!MNI,()=D.W7*UOAI87-?2EC
M?:(7H'HT>^G>ULFS<87G=NPXL"WUB?V0@+=CG?"O+KU^/9)6_P!E+HO!,M\<
M4VILV-6/!<O6!+1L##^4!3K1&,Y(7:/)?U+MUN,4P=&-EK;8\AAU'DJJF 5@
M]I92R%A(.%,-3G5D8_,%P?<6#\P^:\?XHO\ 5T5Q>SM'M:"LZ_BVJP[ZUZF+
MKWTW2,?F;\TTW6GP>^/FOG.IXKK2-II!^ZANXIKM_KWIA:^E?IFF ]L?-<I+
M[3#\X^:^:7<3UY_Z\BCR<25Y_P"O(K(P^DY.(J49^L'S48\24N?M!\U\W.OU
M:[/USUQ-[K<_;/6XQ8^FV<2TG^(/FE'$E)GVQ\U\X4M[JCSE>K:&[S%N3*<K
M7,CGUL>XUG$],Z)S6R#?XK'V.>*IXGE<#U']5@);K(6[2%:O@%_:5H>=W$C)
M6.YCIQ6]XX:#;NX?R_T7DI8[M!YKUWC1I-NV'Y1_LO+# _6#@KP]O5RDPO<'
M ;J9'&]P)"9#$0X9:<J?2QG)R%Y?);CT<2(,\4@8>:I*ITK"=RM?+'W#LJ*X
M4^2>ZN?-J]8K:-[Y),.6BH&8&2J.CB<R<DM.%;.E>V,AH(7?G:XU9NJ1&.:Y
M.JP1S5"^65SM]25LCP>3EK[CBN'SC254UDV<X3NT>1[)4>0.<3W2N?UTB"_+
MB4L;'%X:%);"[W2N]/'IFW9NNG$5I.'*(Q-#R.N5>U<A>W3X*KMTI; =N2[R
M-<8R_40"N_,9-GTYYJ-.<1GPPHE55Q4H+I9F_NL?Q!QM#3-<R(!YQC93#F+Z
M:=K).\0J>[WZBI6'+P'#XKS6Y\53U<A+7NBRL_55\TI/:2ERF.DC67SC#M Y
MM,_/[K'5MSJ:DN,SB 3XE0I'9)PAC"1NM<\.?3K22N@D$K7$@^*]!L,E95T3
MG1MSC98*#3NTC9>E^B9S9621R8(+^J>CIX^L1I)JBF?]:"#E28[H'.&HK4\8
M6+$?;1-V)SLL/V8+2'#0X>*\WD\;V\>2-/%<CV/<.^%;<-,DK*D:\D+)VBEF
MJIV,CR0"-PO8N$[0V*F:QS U^ <J^+PN7D\B^M=''2T^I@WQOLO&_2W<R:U\
M1=L/C\5[-<)A34;P#R"^<?2'7">[RYW_ /Y7MD]9CQ=7:BQ2B6$8/(*#5/+2
M5&HJDL!SR4ET[)>8"OOBQ57" /:3\% AS&=NBLZZ=H!"K&G4XXY+G[:U*[LJ
M"3I(P%*:\%F 2H;6@)K7D.V.R<Q=U.IVD3@Y*]V]%9#9(L\UX/2/^N;DKWCT
M68,D7CE=)&:][C]@>29![<OZD^,]P)E/[4OZOZ(PZH0A30)#R*5('<TT>>>E
M:B=/;XW1C=I)*\/?6/=7]F_*^G[[1-K**1K@#W3C9?/_ !/P^Z@K7S8( /@N
M=KU>/+$>WVXB7M .977B&5\5*0-ME/MDNF!A<$ZYQQU<9;LLV.O,>=R=\/)5
M;,PNR& Y6OJ*&.,D$CY*#40Q1-R,']EQL=YRA6&DE8[4 ?%;3Z'@GI8IR#VK
MCNJOAJHAC<X3Z0">JU5,Z*220L>.SQW?!21F\U>\&4C::>-L?+/BO7*/[!OD
MO%^#JW36!KCGO%>R6]VNE8?@O3Q^/%Y9]2L;Y4:J&Q*DKC5>PNL>>_B/1\RI
MPY*'2^T5,1.0A"$:"9-]F4],E&8RD2_C/1- JY''Q177ME$X@DC'P3X?O4C3
MXIE;9&UDF2[G\%NWXYS]5$O&C&DX)V^"CNXVZ G/D5:C@^ GO/'R2_P=3ZLZ
MVX\EY[-=XK8[R:]AU'^2Y-'UAQR3;\*>RMTM<T?R4:S50KR"PYRN'7CUUYN%
MNF\;L#?"QLS)'U>"#C*]4^BFN9WAS'4*OJ;13Q/U'3GR7/\ BUTG>(M@ML+H
M 9&[J;46^ 'V=EUIG1QLTL./)=)"'C8[K4\.-?RJ6JHXXVDL:L=Q%J,;AC;"
M]*CI0\8<LQQ;;V-@<6@<O!9G&5N=:^?^)(\5#_-9F88:5M^)H,2/VWR5BJL:
M<KU>-S[1(N94JD^\-\PHD/,J=0MS,T_%;OZ\U_7OWHNV@C\E<<7@NN[?TJG]
M& ^IC'P6@XMC_O9I_P JW'/IFW-P4S==Y<!RY$A;<7(Y3' D87? 2X"S1'#-
MBD+%+& $QQ;E&D8AP'=4>8R.:0K%N!OL4V*,S3 !G5&;\4K87C.0J.OAFFKX
M8VCF<+T:MMSH6EW9]/!4-JC:[B"F#XP0).H51DJVVUD%6YO9NP!X+G#12@DF
M)^?)?2QH:$-#WT<+R?%H7!])1EX'T= !XZ0L]NOCGUB."8]%M E!!T]4MP:&
M,>3G&5IKF886.9#&R/ _*,+'W*KA@I9'32 ;]5Y:^KX?D3>&B'/EQMLKZ1KV
MTQW"Q%HO< )$#@XGP6@95SR,QV;B#\5N.G=CF-7:.W7&N+@SFGELX<3H*BU1
ME(W85*G/1*LN-(<^"S R)RM36!XHSEGY5FFC,A)67674^F=W"I)&N!X_RJ)$
M0(BI-.\&-_DHW*R-4WL*@X"TO";B2]RI+M&"YS@KWA0!L+S\%SZ7_'>_S8SN
ML9.=4IV)WZ+27^3)=A2^!:.&I=-V\;7[_F&5KQ_KP^9CB#[CODE+26^P[Y+V
MT6.C+,^KQ?Z4ALU&!]WB_P!*]W,^/F>2_7B#6'<:'_)<I(I<%H8=)^"]O-DH
MW#[&(8_RA0JNVT@IWL;#'JZ'2EN,<O&*.VME]8,@W:W(53'%)VQ8[&G*]-GL
M#99Y&QR:"3@@!0*[@\P1N>UY/[+EUTZR,=6.9'&P*.ZJ9V0&ZYU;"RJ>QSB=
M)QNNT$K!W2P%<O9<1WADH&D'*D6*$QW$:O$*5%5QECAV+1\4EL>UUQ&/$+7-
MTD^/?>#3FU8_RA6LL&MI57P2W-K_ &"ORW 7IX<^HQ5VH<R:9ALLW1U<UENH
MP<0R/Q^R]*N%*V:C?JP)>@6.N]N$D#QCO@'&V^5JQF-C#.RIIQ41',:5KL^2
MP'"5WEM\XH:LGL\YU.*WKI&]D)&$%I&0D^-P\^:0'?=0)*PYP$WM'NY95U4]
M[FL!<>2BRU9>=,97-K9'G#L@*1' Q@SS*HYPTSG[R<E*$$;#L$WM3RPD.3U2
M)70NTC9-#G$[I&N YI7.&-E5AE14-AC/CC95[*LS'"ER0]JTEYP H;:0E^8\
MD?!2Q4^EFRPL?R*R7%EG?"_UJE'7)\EM*.DV&K8J344C9H71N:'#&#D+EU!Y
MC05'K<1E![[-MTLSM;3GVD[B.WR6FZAT )ICNXC897![Q-%VD>_DN8KJEY&6
MO]I4=9G45<5+P_+CLY4E6[<JQ8B.3HQNF%VZ<PK4'8)R9J07+IB4[*>P[K@7
M)S7[IC*PB.R>X[*-"\87?5LF)J=0U BC>TG&5RAB,]62.2AN<=0PM!9*?5I)
M&Y7.QZ?#U6EX=IPVG.VZO6C2Q1:&'L8QMLNSY=MERL>KV#W;+B7ICY%S<Y6,
M\S:[AV051R[W2']2MF/[I5.XYN</ZEIGR_BR]+W_ +%C_6/Z)GHD&+5)Y!/]
M+PSP/&/\X_HCT3#%J?Y!6/(W)3'\BNB8_D56O\<HMG%*3NDC!+CA!:<HP5Q[
MNRCR$YV79S3I7(-.O= YC,MW"'1M *"2$@R0@C2M:.:Y%D;SL"N\A ?@E.C<
MS.V%9!P%(WH$QU,X>2L.TP-FKF^0EI[B8135M(9,Z% BM\[7Y/)7H!WQNF$O
MS["8J+#"YH&5RJ7OC&RLX6YQJ"ZS4\9;WL*"FI9G./>RN-QK'P-[BN(Z-N>Z
MN-71,([^/D@HZ2[OD."=U;>OF-F25!CM@;.7-Y'X*94T)?"0WP0<FWQI?IU*
M;%<0X9SLLP;5*)B<NQE7$5*8Z7#CNF&K(7*/."5)CJ6/&Q6+F;+VW=+N:M:,
MRQQ9)<F&M$'@]4X;]5FG5L@=@94J&L?IWRIAJ]VQA-$3#[0"HWW(M=S76"Y:
MM@F&K0P,)Y(-.S')<(ZS;<(-P8.>%%#Z5K]@%TAI=!&R1E:Q_+&5V9+J*A'9
M@TA*3E-!)2 K+4),/[/)^E8JV;\0#S_JMG4NQ32?I*Q-H?GB%OG_ %6O]9Z>
MDW$$4$?DLRR7$N"5J;D/[OC\ECZ@Z'DKT\?CDESR8;@'F%@?2),#;"P'?*W)
M!?#GP"\YXV)E<^//+=8\C<>-5D67R>)*FVISJ2%SCMD):J'->&="5.N<0@M[
M<#?"X1W0;=)'/<6R3XP$O';(9*./L2%F#ZS*]PI]><_E*95TMS,0[9LND;Y*
MU_B(%-F-W>4NG+1)D=5'8,QG5L<I87$.VZ+*Q>TYQ-MR5Q1O&ZHZ%VK<\U9T
M4@#\9ZJ^3G^NIX^LZ7=. 7$E,JBT D=%UIG,P=U6W2<-B< 5R\4^O3Y._P"K
M1>CJB]=O;SC(:05]!NA:VD;'CH%XYZ%Z<&I?*1G+0O:*CV-0Y +Z,F<OG7K>
MGC?I0IC%54N![3OZK&\24(-L+B.G]%Z1Q]%Z[5TK6C.EW]5F^+[<^.T'#3R_
MHN%=<^/#NRQ.\#Q76#+9M^2YU#'QUD@.>:ZP]^1<:WQ%_;-L.)Y+></YF#,=
M-UY]32:6!H\%Z;P;#BBCD(YA:Y;[_&VM$[BYL1/-;2VL+8\_!8FULQ<X6]%O
MHR(X?V7HY_'CZ_76*ITR:<J_I7=K!@]0L8R754<UK+9(&QC*N,O(O2K2F&LD
MD:-LKS(SG)'5>]^E2C;+:GS!HZ[X7SVY^*ES<<BIBZ?*\D+@7+NZ4!Q& H\D
M@WP%*H#DUSPN;IAX*/)4)$=0_O$(>XX4#UAP>=ET;,YVVE;D93*>8AWP4DU1
MZ%5K7.')J5SSC?9:D<^EFRJ)(&5Z?Z,R73L\PO'X).^%Z]Z+OM6?LL>3\;XC
MUOB&)LEO /NC_98T4$>EIPMK>MZ 8]U9D#N-7CLUZ>?D1!2-#P,+J*9HY!2=
M'U@2AIR5SZ\>QOWQ&-."-U'DM[7G<*RTGHC05.?"G\FJIEK8'9PG/MK",85G
MI(2AA*Z3QXFJ=MJCSR2?14>KDK?3I2:2>2>B8K/HR,= F&VQ^"LRPHT%8G!*
MJQ;V#HE]09[0"L3&2,(#=#!E;G.-:2EIQV;@ L[QG?F6FWZ0X!XRM1#((VG*
M\']+EU=+<I:=CCAK^659\9UG[KQ35U[W@O[N50R/+G$R'*Y$ZARP4#;F<IC>
M8;*ULHP%QE&EN/!=W$'X+B07''-,3VQQB&7;J:QHPN+(B-UV:#A7\631(P-9
MJ"W'HNF,52&CF7K$2Y$6ZT_H^F[*[P9]DN73B:Q98^@71LJ:4-GY87FG&=GC
MCK-5+C3CQ5WQ-Q.RFI^SB<-7+8K!"MJ*^0F1[\D^*Z_PRI_+8]0X,M,<-+%(
M=.L@$[K>T[9(V@M(RO"([U56<P%[GZ"=LE>D<*<4PUSV"25H! ZK4\<Y7^3V
M:'BJ416R1Q.^G=?,O$\_;71YSG<_[KWOC2H:VW3%DNMI"^>+H[55.<3U_JN?
M<^GZ8<-:,=0G128&<KF_!:U-)TM7&\M2.53&9"=ERC9HYJ<P@M46H/>V5G*X
M4;G9<2,.7>$9;E,<WO*7XIU(XBH:O?O11N^+S7@%./[0WS7O_HG]N);C->^1
M_9CR3*?VI?U?T3X_LQY)E/[4OZD8=D(0@34C ^"8^5K-G'"8Z5HWRK(SKJ6A
MP(=R6,XSX?97PN[)HR5<U-\BAD<QSF^"XLK341DMPX*SAJ6_X\CFMSZ4F-V,
M-595%T(.DK8<3,=%,Y[FX!*S%:&R4SBWFL>7G([\=UE:V<N>=1SA4]PJVM:1
MNN]PD+9W#XJJK(3*-EY)/KT\]NE.:FIF:(78!*U%M]=IQID?EN,8538',IIF
M:\<QS6T@DCJWD-Q^P6\2]5,X.=VMSB;@[E>[VP:*2,=<+RS@>UL;71S'D"O5
MVZ"T!KN2[<3X\GDOUV /5<)G @\]E(4>HQI("Z1RIM*-U*46CYE2DI A"%%"
M9-D1G">FR^P42_C,RR&.J<X@\U:4E4U[@.1^*JJJI:*IS78&Z20/<=4&7*ZY
M[C3ZV]?Y)'$ .)( PJ:GN!A $_=55Q-?6LIW"!P)P5SZZDCISUK%^DZMC-1I
M&_DHO!ESCIXF;X*SUT?)7U+G2YV*KI8YXMH <#XKS?R?6Y7M,G%5-%#WRXNQ
MM@JC-XDN,Y$1<&9SR7GE).]\C6SN(&PYKT3ACU9K 6NR<=5VXQ-JVIXNS9E^
MY4N%S"=@4M4YK6$GDJT7&*)QRX;%:MD2;5[ [?=9_BAP=&1CHNQOD#![84"N
MK8ZMIP[HN'74>KQRO'^+*?,LA QS7G-RB+7.7KW%E/\ 6/TC;=>97>G(U;)Q
MV[]3XS,9(>0K.A![0%5A86R%6MLWD:"O1_CQW]>]^BOO1,'7"TW%8[.X@R$>
MRLOZ+CH8T_!2O23<9([CI;[BU'GZ_5=-.QTC@T@;KGV@]X?-9>2I>XY!.Z9V
M\F>9^:VSRU@D;[P^:.U;CVA\UD^WDSS/S2B:3Q/S62_K5]JWQ'S2=HWQ'S66
M$[_>*.W?[Q52M2V:-IR3E6MF@>ZH9)GN$Y6,M>JIJV1Y.Z]>MUKA;00Y<0X#
M=6(9Q"UIHR6<\+"6F/5Q#3X:?M/!>EFTPR0$.D=GS4:W6&F@J>V+MVG(5D1H
MAIQH/@J?BBIEMMFJ:H$YC&1@95\# YF0_O*%<PRLM\U(_!8\8Y+GY7;Q/GV7
MB^ZUM3,YCI SGNU5T5XEN]6*"</<]_4MPO8)K7;Z"%[&M:78P>Z%06FRT<U]
M94Q8U#H N/+V_9%IPQP92T]/'(^(:^><K7Q44#&:0S<*7#$&1@<@DF8&MRTE
M=?F.-[O_ *BNI8>6E<W6VG>-V)YD(*[P/U!8QC^2S_4&:V0/86EFW)9ROX:'
M:N="T +;'"9I)<>Z,+4D=>/-?_7F-1:JF(D=/@N/8RQ-(+7?)>G2PQG.IK?D
MHSZ: C=K?DLV1WY\SR6NIWO:2&G'Q"N;2P0TATC!(6KNENA?$2T#]@J*HA$,
M1 Y87#K'IY\GQEKPYQ<<E:+T=$9ESXK+W4%SG8\5JO1O3O!E)&RUXY]>?R]S
M'HN'=ELN8!(.5/C#1%A<RP="O9S/CYO=VJ]P("K:V-P8XK0N8W2H-P:#"X-"
M8D^1@)IW0U3B#@Y4RKKG2T1R[=0KI1S.J7%K2=TL%#.YA:6;+G8U[/(KZ'-K
MY7-(&2HD,^EV_-:V^<*5D]3(YL3L9Z%4+[(^DD(F#FD+/K%UQA<2#@\U(L>H
MW0;]0N'JP9DM)P%)X?(-R'FKS)$?1' V]LP? +0 X<05GN!?N'[!7T[PUQPN
MD^!'@'O.QJ5#<86%SCU*EU=669 5543.D!.5K6;&6OM 7R&1@[WBKSA&\QU<
M3Z:IR7,.D9V2:-9PX+-W2D?05;*JER0TY=X*:S/CT%U-&)CMLD=+%$\-#2H5
MDN3;Q;FZ"#/U:%*BB:"1)LY:CK*EM?J&W))IWYII 8S*YLF#G8717;.%RJ)"
MR(AO/Q3SC"9* 8CGFLVLJUM3+VAU$X5A#.'   Y4:&G,DG+JKBGH&MW.5-1R
MCC=(#JY*934P8-@NL; W/)/U@+G;];A6MT\DCG8_=(X]5PDDY#*@AWFW1UU%
M(QS<CXKS&J:^WU3X<$1DX PO6@_+M Y%4?%5DBKJ0NA&96[[*)'F5P9V.3S'
MP5%5=XY"TD$#]9HJH:9"<J%=[/+3,+FM.E2M2,TZ5@[N#J3HLCF5Q<W$A+N:
M<"XN&.04UK$II2]%R:4_.RWKF"4C7;IKBF:MU93$Z%RD!VR@1/PI#7[*ZF)D
M U/'FMA88Q@9')9"W]Z4>:W5FC 8/)9M=O'%]J^KP5%D>=\)TKL-45[URM>O
MF'%YSS1JR%PU[I0Y6-8[L).P*J]8;=(@[WE.AD(DST5=L^[0_J2.7D_%MZ7W
M?^B8L<M8_HG^BP8M1^+0F>F)[6\%Q-SOK']%*]&+ +0#XL"Z/&V.<)CB.H*Z
MZ?!)@^ 1?\1P\-)(!0),]%V(/5JYG<\@HS 3EJC2:R>XX97=T>0N AP_))13
MXXW_ )R"NH  3 W;8E("X*P1YFLU]YI72..-P[K2N<LIS@@)\4VD<@K$/[)_
M0A<9FN:TC4%(;-K7&=FH$@[H( ;/G9X2GM@-W#Y)S&2@^RNQ,F/8"#C$]V>]
MGY)YG!:<@IT?:Y]@)[L:'9&Z!::4:<@)LQ$C#J2PL#F+G+ .S.Y0)%"0,ZAI
M\%W+-3"&$ J%%3GJ3CS4A["UG<))0<!3R"3+G C*E=E&YO>&5!:Z8/W;ME3&
M/.-T$#L(.U/U9)RI3(6.:6AI PF,J=,A[HYJ6RISG8<D%5)0L#CLNC:'5&-.
M NSY&N)R5*A+>R&Z"DJK/(YA(+5#AMU3"X'4,%:A^\9PBF:WO:D%'5-D9"=/
MM*H;-*U[NUU$=-EM&0L<[?DN-320DC 'R2D9BGJ7F7# X?LM+;SEF79RG,HH
MC'L!GR76*(1C"Q5CKGPY(3FA,=E9:1[B[30SN'N%8+A&8SW<N<<D./\ NMQ>
MW:+7.?\ (5YUZ/G]I=CX:S__ -+5_2?7L]=^'QY\%BZHZICX+:W,8M\?DL=/
M'[17HX_''HUDCM&&G9>?\2]ZZ3-/(!;J!^&R9Z+S[B)Q-TF=T(6/(WXV'?3A
M]T9@=5SXN&BECC8<'5@JZMU*9*LR8SARS_%;BZX:.FL!<I'7NI_!MFAF:'F/
M?*O.)K7'%0OPW'=*G\$P-@I1KV4WB\M=0O#?=58YKP&HBTS/!&V2HU. 7/"M
MKC'IF?MU*JJ<8F?GQ7.O1/Q96PXDTNY*>3I)+%5L=V<N59Q'5$2?!=_%_:97
MG[_K5E!4XIP2>\J^K>Z1V,YRHAJ"': IE,S6]I*[>'P_=QGR^7^N/;_0]2B.
MC8\C<L"]'JW.TD#DL=Z,8@+7"0/RK9SCN%7SS+\<_%=C#5D';W')&=+DO$=
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ME:>:7A^Y=K'J,+B&Z6K>T\[*N..6,C)&7;K/7&B;/"XXSX*MX;N$]!5NIZC
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ML?T7B,(#7'9>W>DYN+4?T?T7B3.:\G7Z]_,F.CF@O&R>UHPD_.%T;S*YMR0
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M8'P7L_#U@HFT+RR(!Q.>:M'6^*"(M+<ZA@869X?I_/7AUMM'J\P:]FX\0K^
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M:XS55QI3&PN ^(6>>W7KAA:>M$!(>[=O+)4JYEERM[ S&L;G"=#PI525>97
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M,<-?@3OTA17^T5*X9_ G?I"BO]HH.>4N4B%D+E!V"$CN2A"X#@N],T-*CM.
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M1VQA@.W-=(^=?T4+ QN"IK@"%7]H6G9=HYB1NM#N!T2:4YA'-&049 ;@)CM
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M[U._'( I[7. (3*AKO5'Y'BIKI'SMQ#M>*G4/S*K:X-D*O>,8Q%<Y2.KE1-
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M4X1VV*BW)A83Y)?H6E'LQL;^RZFHD V*XR5,F^2N=\K4Y<WVB,>S(UJX/M@
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M%EX@C:3]8/\ 4L_728]@?>*0#!D:HS[U2#/UC%XY)Q)3[Y=_^RCOXEIO>_\
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M@'J%ZL+7#44@Q'AV%BQTZ[R*=]_>]NDMV5?+4B9Q+G*_EL,8;LW?R4,V'O;
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MYIRYR<MD3'3 \5QDQXI-_%<I"=]U2$)P>:XO<,IKB5S)W1J.P=@+E,X%IRE
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M5W1>CJBCP^1P./@MWDCDDU9!!25OGK%%:^'J>@>>RC:0>N%;/@+6:6#=20X
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M&/\ T!)_"5+_ (,?^@+5H098<*TN,=A'_H"0\)4G^!'_ * M4A!D_P"$J3_
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M="GNU(\9/HTICS#O]*YGT6TCNCO]*]I[./W0E[)GNA9U7B)]%=(.A_TIG_\
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+0@,;H0A (0A!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g915839g86a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g86a01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1@\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 2P    !  $!+     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             M@   6#          $                          0
M           %@P   M@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   M@     4F=H=&QO;F<   6#    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   +8
M     %)G:'1L;VYG   %@P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      -I     $   "@    4P   >
M )N@   -B  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 4P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MU%M%_P!9,O&] V6NZCE>HXV^F+&FQ_IT^\>GC[-O\^C/Z/6UCC^S;26MC?\
M;*BPN]T.W-'YVU^Q2M>C9<D9CI/Z#'(=$M-38T_=;^:I#/<! Q\:.2/1;J?-
M7?L6*ZMXKPK9(+Z7_::YVN@T_:6G]WW?0478>(]I]/"M:^UKC0[[2PMGLUS-
MNYSF.=_-[DM%:N6X[G%T ;B3#1 $_NM_-2;^=_51,C&NQK#5> VP"2T$&/\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300B      %&34T *@    @ " $2  ,
M   !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q
M  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
MO    .@   $L     0   2P    !061O8F4@4&AO=&]S:&]P($-3-B H5VEN
M9&]W<RD ,C R-#HQ,CHP-" P.3HT-CHQ-P!R<C,Y,C8S-0       Z !  ,
M   !__\  * "  0    !   %@Z #  0    !   "V          & 0,  P
M  $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$
M!     $   %& @( !     $              $@    !    2     $X0DE-
M _T       @          /_A 4Y%>&EF  !-30 J    "  ( 1(  P    $
M 0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    2P    !   !+     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#(T.C$R.C T(# Y.C0V.C$W ')R,SDR-C,U       #H $  P    '_
M_P  H ( !     $   6#H , !     $   +8          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M<9&A!Q874E0((S,T0G.!-39R)$-B)2:QP422HH+1\/_$ !@! 0$! 0$
M           ! @,$_\0 '1$! 0$! 0 # 0$          !$!$@(#$S$A0?_:
M  P# 0 "$0,1 #\ ^J0
M
M
M
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MK/YEG&24\F$[JE"DYR:R8]#5Z,ZCBF0;1R2>,DE$7":YDBL*
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MBNXXNTMZ]*O4Q&2S+P M<4:G5A=35-[9\3#TJI<S?.^;YFPU'2:M;]XTVV_
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MO=V\<WB5:S92I*4<9(X6I.G=IN+ZF6GJUC3Q0CEF3'H6+.>:"PC(2P
M##O[I6]+G>QF/H:3B&,IV;2SD#&K:]&/]2,W3-4C</#:.#NZ59-84OD;OAB%
M137,F!W"W!$=HKX$@          !1--O;H'"+:RD4W%54H.3.<O=;Q<*,?\
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MT2 "6%@   O>                                     +H
M
M          0TF2E@ !_D          "CE>=BL
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M%+3:$88Y3.]Q3R>]@C!6FT5/*B9M.G&$<(K2P@"  "X
M
M
M                                         !A   &D^H
M     :3Z@    &                &L]0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    MN7I!%S*W]Q"::R45:L*2S)I9+'E="KZ,:B3 RG)+J2GE;%N,XX2RF3M
M#+;V8%>0W@H4XR3PQ*:Z JL%.6MWT#:2<GW 2Y)/!)8A=T9RY5)9*YRC"+FW
MA(%7&\ Q+?4*%:;C&:R9.4VL,*J RD1)M+99 D%,)<W58*@
M                                            >R,>[NJ=".9R2+=+
M4+=QVJ)L#,3RLH%JG.-1<T7U*G42EAL)5:W!:G6IQ6)22R8\KRE2GRRGL(5F
M<RS@DQJ-Q3K9Y)IX\"^FEWEA4N232?>2VD6746?%DTW)R?,L(0JZWA9">5L4
M.:SAD=HG+$615P
M
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M;7H^)5P1:UK^[<Y2EZ^.H,>YVMS"O'F@NID&!IEK&UM8)MYP9R>5DBI  4
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M6FUE6;RE@ZS[+[2E1>(-MI=X:QZW2GSQR5ENA%1@7"-
M
M                       $.275@2"VZT%WEN=W3BNJ^8&0#7O4(YV93Y=(
M#9 U4[RH^A1&ZK.2 W ,'M*I/:5 ,T&%VE0B52JN@&=D97BC53N*J+#NJR W
M@-33OYI8?<75J&.N -B#!AJ$'U,B%S3E'/,@+P*%5@^C*TT^C
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ML7L6E=54P-V#5QOIKJ5K4,=4@-B# A?Q;W9E0N(274"Z"F-2+Z,JR@
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M-0;6%AD.UI\[ERI/X$;S$VC;I;EX12BL(!0
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M[/,\=Q+QTP:&-[64MV95/44H^F!M$EC&-AC,D_ QZ%Y3JQSDR4TULPIW]
M           %,IQBLMF)6O$D^5@9CE%=6BU.O",6U)9-5*M4JR,BC:RJ;R M
M7%[-^HBU3J5IO=,V=.RA'J9$81CT0&I5"K+KDO>;V^K-D ,*G80CUW+GDE/'
M0R0!85M37]**U1@OZ47 !"A%=$AA>!( C"\!RKP1( I=.#ZQ10Z%-_THN@"R
M[:F_Z46:UE&:VV,P :QZ>T]I;$NWG%;9-D --4[6ENDRJC=33]-&VE%26&8]
M6UC+. **=VGU9>I5XS>,F'*RQXE$Z<J,>:/4(VN5X@U%*ZDWZ1L:-:,UC*R"
MKPRC'JUHT5F327Q**-U3JOT))_Y!66"WS[[%S?8   H,^X  ^FP2P$1+H ;:
M6P:\$6ZM:-.&9-& ]4@I83"-GT(EA_$TU?4JF/0,#SI7Y^KS\ .H6RSU*(3Y
MGAQ.9>JW3:Z_(S[/4Y\O[T#<I!))]37K5*3EC/4S:4Z<UE-%1>!"DF]AA+=$
M:2 GD
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M6I+*         $2SC8D :RZ4Y)I9*;:U<O6-HXI]PC%+H!:IV\(+H7DL=
M                          %+A%YRLE0 U]6UYG+EV,"I"I;U')R>$;N3
MY6\&@XH[?R2<J+WP&7(<:\41LK:>*N&EXFLX"XO5].*G4Z^+/,N.Z.J5[BJG
MS.&7_2:+A&[N=+O8Q:FDGX!'V-:R56$9Q?5(R4<9P3J[NK2"DWG".RB\Q#6)
M  4#0(SU ;)&#=ZA"CE918U34%13C%[FHITYWLVO?WA%5S<UKB;Y,\K\"NQT
MZI4DG-LW%G94Z-%1E'TD9<88]4#&IZ?!02>[*5IM)O+2^1G)M=0VP,16%%?T
MKY%%;3H2AZ.QG17N#R^@',7>F5*4\QE)ENG6K4)8;EA'4..5Z>YAW.GQK1;7
M4"C3[Z-18DUEFRBLK/B<I6MJEI5RNGN-QI%]VWH3?1=X,;5+ ">>@"@
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M47EIV<W-%_3KK,7%O?H9US!5*31H(QE0N.7IEA72IY28+=":=&+]Q7'U0)
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M,N.TII=YG'.Z?<=C546SH:<N:":[PJ0$
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M)WS'EW:1?HX! R5G$A $B@(R,A$@$/8M1((1+6!0! (J1@@)@3@8(R,@21D
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MV[SK;NXMI6,XJ"4GWG(S475GCQ-XR94Y_P""C&,I"E)=I_@JEODTRI !ED
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M( 92GLQ3RD%[RK*0%*>Y7S/!3E8',L 4=X) :04N#;R5D]P$06.\2;P2@UE
M4I[ E+!242@P@Q@$$@",DY(8115@AK!*# @ $  %$KH"%T) @@ @ D 02  E
MT%,2Z(4RC967\"H8%?\ B2,^R_@5# K?Q9 4($X( A$D$A$$@+<J CT (J6L
MX*U+_J(O/0I@4OU\D*JII]M6EXDTWRTVBJ&R;[V6Y$6J'N&L"*W*Y= M0GB.
MQ$9$1Z/)."X9J7)E',\E>,D<H6C8B3+H1$%2RI^BLE(EZ2*FZJYW)=2JE^[E
MDM0]$F3;",RK>-TN7+,2,G++93$N)I+8".;<2E\2CJR634(O<KE+T2VMF2VV
MB(MX<I9\#(SZ."U#HPF^8">7J2R4]BEA<$20B0J4]QG;O*6,@'DA+<J $#!(
M+!&"0!   @I!(  @D   ()P025 A=Y)"!@2 10$$A$(=P0[BHKGW%%7U8_$K
MEW%%7I'XF=;\OHG]GG^3G_S1[TCP7]GG^3G_ ,T>]+H</7Z]?Q_@@$##HU7$
MG^G5?@?&'&O^X[_^ZS[0XC_TRM\#XPXW_P!QWO\ <9T\//\ *Y]$B2PR&>GR
M\R451*(HJ9-:W\0^K&",^)*)$",DY)$1"*DMB (1) ! P,$#<1#*7<$T@!$.
M;.Q*([P:QK#O*OZ2$.X*I'<5 "@N1BL$$?#(0Y=RII8*.X$@DE="!$03(ALD
M@"4]BE]22"$20 !( +B@  $$@N @P@P  (  *")CZR^)!,>J V$/X)@S]9F=
M3_@F#/UF!:_J944_U,K @ J I &#* [A@) HB>X8(:!0)9(1*9%3RA1P@@BY
M@AK!!4#68([@B00 ".X05]Q3$@")%?>4SZD+8JYO<(1*CE$<HYAS"$0 !% ^
M@($$)E3D0!!*W(  (,@D   "02)B"ADAD$@  0  4%T)(   $  A@2"(AE$R
MZ(4R)=$54P-C9?P*A@UOXDC.LOX%0P*_\20$+H00MBH"D$R]Q 0)CT9 11+*
M2H$$1*DO212,]2:RK3WDB.J*28O!!"6Y,NA.4,@4I;%.65K&0\!5*94MT4Q1
M<7044LB*)R,E*-;!+ R4C%Q+W)Y5RD JIY/1R4+))($XP%NBDE$1. 1_D$1+
M\"8Q*<@"7U)DO1*>\AE,2B2E=24(TD8( @DC)($$ D8*E0-R2 4W !2@ ,J
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M 8"!G5, D@A$9#)P1@$0NI5C)251 *))5C8I?4@I!7RCE*10"OE*,=2X8@D
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M&TN5.BVUE=#:\5:FE3T[LJD5OON;2.I49V,&YQSE=XI&KJ<)VE"TH]H\2<?
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MFVT(3;\"J&CVUU;OE6^? G3+B%6G4YFN@AJ=*S@_23P%9-EPO0MJ<I5(^LO
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M9"/$E$!<2 "*@D@D 4RZ$HB71%QE4^B(FO17Q#[B9^JOB9UOR^B/V>?Y2?\
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M\_0IC'FFI9Q@I5VI!RFVV6J:?:X1=>_>32Q!YZA%J44IOQ!$H?O)2SU[@7$
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M"JG/$FY;LH($5-24Y0:YGN1'FC%8ENB0((J2G/&6RYSX@DEN4 0I#:KF6\?
M5&G)."P@B!%NJU)9W0BTLE*)+B;_ $>&]@V 5$(D $.YE#6Y4":$=B6\D BA
M!("&1GW %4&2"0&22GO)0$D/J2B'U )DY(((D2P@ 1.0G@@@$59! 05) [@$
M    !I  $!  H  RT $ 2""0 ()+$  (4&0!"B9 ))"()3V()! )X! (D/<
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M0   ( D &F0         $7  !0 $   ""0 1!(%$ D"B 2!0 &    @D$ 2
M  ! #O)1'>2!*(?4DAE  $      " 11/<0.X ""00  :9      @D&6@#
M@D ""2"2IH "H  ""0"-() (    (%Q-  5       P,     &0 "]PP
M@D@BXD@D$4   ( HADH@E!!@, T  0 !0   (   #+0 0!)!(   (A#N"'<5
M%<^XHJ^K'XE4GG!35]6/Q,ZWY?1/[/7\G/\ YH]Z70\%_9Y_DI_\T>\I['#U
M^O7\?XJ70$+H##HU/$/\A5^!\8<9?[EU'^XS[/XA_D*WP/C#C+_<NH_W&=?#
MA[:+^G_)'<B?Z".Y'H\O/@51*2I$UG5+)!!$P9*Z$,E=$7&L"0"J@$$D0(!)
M !!(           ""0 $>A!,2B2"2D"00""0          ()( D@D
M &F0            !")()(T $$ D  ""0@ "" 2 !&22,%Q3(R,#!1( (
M  ""0      "!DG&2,%#(3R,# $@ @@D      -,@    @"/0@F(:2020 !!
M)!!)!)<0 !4%T)*5T*@( ((TD@$D    @"XF@ "   $D$E   1W =P $,DA@
M(]2IE,>I6R*H)() $$D(&)!!)%""04%T)(70GN @(!%9& P          "
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M 20"0!&Y(+@C<;DHD"DD @ @D 02  )70%$8!)#   @$;D@HC<$@  "
M   J      %L %   ()!!!(!0  00! HD@D!4$@$     4  $@  0)R00"*L
MC) *AW,  "&B0!"ZE39 (J"0"H$$@A@ ,!: 8(!4]P[B2.X% @"H,      !
M%    ( D $5!( $ D  02$0B&20RHJQNB*WJ1^)4^XIJ>JOB9UT\OHC]GA?]
M'/\ YH]ZWP>#?L\_R<O^:/>D</7Z]7Q_A'H @8=&JXB_D:GP/B[C3_<VH_W&
M?:/$7\A5^!\7<:?[FU'^XSKX>?Y6A[O\E2Z$-;$KH>CR\W^G<%U'<%U)K6@
M(@   ( $@     !  D@DJ 00142!D9 AB(81%21WDD ""014$D$@ " )! *)
M!!(  @@D$$@02     @D         0"0 ()(-,@7> 0Q( (T!= %T*'<$.X(
M"0,D%!@,$  $   ""04$20B<@0 "  0 )  +H21W#)1)#&0P  (    $ "2
M!(!  D@D"  420  )( $@ @@D  ""0()   $ 202    @D  ""0   @D
M  +B  *@                0B2$!*)[@AW 0        ""3+0  ()  @D
M  ()  @D@D(A$,E$,J*WW%-3U5\2I[8*:OJKXF==/+Z)_9Y_DY_\T>](\%_9
MY_DY_P#-'O*:./K]>KX_Q4N@(70'-T:KB3_3:I\8<;?[DOO[K/M#B/\ TVM\
M#XOXV_W)??W6;\?KS_,T<BDJEU*3T8\V)! &M;^  "     ""0  0!1((R,@
M " B5T!*([@  "H)!)! P2 (!( C )(   ",#!4NA.Q11@+8KV*7U  $$$@
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M\05!!5Z/B-L;=053D9 R"F1D?X&?<"F1D9&05)!(W!0 @ "?\#_ *  % $5
MJD$X(P((!/Q&WB3=*@DG;Q(V[F2E 3D9]PI49 SGN&"Y_0 P,%@9&1@8$ #!
M&0)!!.2H ?X!%02-R4UW@4DC,?$>CX@023L^\C$?%A #$?%AKP% $89&&%B<
MC(29/**L1D9*N4C (C(R,$X^(90"4L#/N0$ G/N)R"H  4()W *@D#<" 2L+
MJ/1!4$CT2?1(5 )]'Q)S'Q!5()V[AD)4%+*\C*8JXB7<1/HOB%+]XA6]=?$S
MNMX^B?V?'_T-3_FCW7F/"?V?%_T4_P#FCW?NZ'+T]/Q_BN#]$"/J@YNK5\1I
M^;JK3/C#CC/WCO=U_%9]E<0RJU+"M&,<]Q\?\::7=5>(;UJ$OXC-^=<OEQR]
M12?>0E+'4S*FE7<7_#E]2%I=U[.1WS7#/+%Q+Q&)>)E>;+OV<AYKNO9R^I*O
MKS_&+RR\1RR_,C*\V77LV/-MW[.1.DSPQ>67YD.67YD9/FV[]G(GS;=>SD.E
MX8O++Q0Y9>*,KS9=>SD/-EW[.0Z.&+B2_J0P_P QE>;+KV<AYLNO9R%.&+A_
MF&,>MN97FRZ]G(+3;M=*4F*<,7,1F)E^;[SV+'FZ\]B_J*G#$S$C,? S'IUY
MC^"_J4^;KSV+^1*O#%S'P"<>[J97FZ\]B_D3YNO'_P!I_(4X8O++Q0Y9>*,K
MS9=^S?U(\V7?LW]2U.&-ROQ(V\&9:TR[7_;>Q/D%Y[ EAPP]O!C;P9F>07GL
M'\AY!>>Q8Z.&(H/Q"@_S(R?-=W[-_4E:7=_DD.CAC<C_ #(J4'XF1YLO/9L>
M;;M?]M_4=+PQ^S?B.1^)D>;+OV<OJ/-EW[.7U%3ABN+3ZHC$O$RO-EW[.7U'
MFRZ]G+ZEZ7ABXEXCEEW,RO-EU[.7U'FRZ]G+ZCHX8O++\R'++Q1E>;+OV<AY
MMN_9R'1PQ4L>MN2N7P,J.G7:_P"W(J6GWGLG\B='#$7+X,-)KT=F9:T^\]B_
MD'IUV_\ M/Y#I.&%RR\2'&7BC,\V7?Y)$>;+O\DB]+PQ.67BB<2\3)\V7?Y)
M$^;+OV<AT9X8N)>(Q+Q,KS9=^SD%IEW[.7U'1PQN1^(Y'XF5YLN_9R'FR[]G
M(G1PQ>1^)&(^!E^;+OV<AYMO/9/ZEST<,7EAX,C$/ R_-U[[)CS=>^R8Z3AB
M<L? 8CX&9YNO/9,>;KSV3+T<L/$? <F?5V1F>;KSV3^I'FR[;WIR^HZ.6*J;
M\2>27BC)\UW?LG]0],N_9OZCI>&(TEUW(]'P,M:;>)?PFR?-UY[)_(G1PP_1
M\ L/U=C,\W7GLG\B'IMV^M)CHX8O++\Q'++\QE>;+OV<AYLN_9R+T<,:,9/O
M)Y'XHR5IEW[.7U)\V7?LV.DX8O(_%#D?BC*\V7?LV/-EW[-DIPQ>1^*)Y'XH
MR?-EW[-_4>;+OV;%.&-R/Q0[-^*,GS9=^S?U*?-MW[.7U%.%CLWXCLWXHO\
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MM)_21'W"TG])$ 73G$2X!TO'HVD$4QX TO.]K  4YQ5]P=*_2P)^X.E8VM(
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M^DA]0^ =*_2P %.<%P#I6/Y6!3]P-+S_ "L/J *<XJ^X.E_I(?4C[@Z5^E@
M*<X+@#2OTL"?N!I7Z6  NG.'W TK]+ ?<'2_TL !=.</N#I?Z2!/W!TK]+
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M#I7Z6!'W!TO])  73G!< Z5WVL"7P%I/Z2'U %.<1]P=*_21)^X6DX_E(?4
M4YQ'W TK]+ ?<#2OTL !3G#[@:5^E@/N#I7Z2'U %.<1]PM+_20)^X6E_I(
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g915839g87a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g915839g87a01.jpg
M_]C_X  02D9)1@ ! 0$!,0$Q  #_[2B:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &$< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(S.3(V,S4< @4
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <QPQ(         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $QPQ(  0 ! 3'#$@ !  $X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             $+   !X@          0
M               !              >(   $+                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   $+     !29VAT;&]N9P  !X@
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    $.$))300,     !WS
M 0   *    !9   !X   IN   !W7 !@  ?_8_^(,6$E#0U]04D]&24Q%  $!
M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !9 * # 2(  A$! Q$!_]T
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M5=B^^ZN^GTZ[L6LLK9755^A;_@MC_P"19_(['*IZ-EWNO&?9C.>0;!59L!>
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MA*0G224M(2D)TDE/_]D .$))300A      !5     0$    / $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T
M &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      49-30 J    "  (
M 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !
M  $   "\    Z    3(    !   !,@    %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#(T.C$R.C T(# Y.C0W.C Q ')R,SDR-C,U       #
MH $  P    '__P  H ( !     $   >(H , !     $   0L          8!
M P #     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "
M   " 0 $     0   48" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!3D5X:68  $U- "H    (  @!$@ #
M     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !
M,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $     0
M +P   #H   !,@    $   $R     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,C0Z,3(Z,#0@,#DZ-#<Z,#$ <G(S.3(V,S4       .@ 0 #
M     ?__  "@ @ $     0  !XB@ P $     0  !"P         !@$#  ,
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M*"@H*"C_P  1" 08!V0# 2(  A$! Q$!_\0 '  !  $% 0$
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M3KXJFX@D$(+D6,.Y5[?%$U5$6"LE=#"Y[1D@(NLZ+P^]]K4]'<Y::*(.<QV
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M"(B"A /!7"N.FK;63NEGIVO>>IPNZ3A8RWUB[S5C/J:^=^V^RT=O>!21!@+
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M]V6GU88JRA$M1N'K\=<KT^KNU/;;*VK>0V)K 0TGP7SQVAQL^DA[23@2-_\
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M *8Z]5]0:BHXZJUU F8#AI/(ROGG1=#2O[2618R,G@C_ +@M0M>Q:(UHZ_\
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MRA\U"QSASE.DX>2LN]3<;SMI+,PPY!#FA>ZVF/;10Y&T[!D>2U+=I^AM[O\
MA8&L '0!=9H#6]. I;K7CSC5KW.-),(>7[3C'FO$KE>;A;;\XW"VB:+'5Z]W
M$8ZMXRN9=+%0W//I<#7E9C7J/%+]?K=66N:.*WP"9XXP.<J_L=LM8;G4SR1N
MBA>P[?)>I#0EB:_>*%NY=R@MU/11AE+$(VCCA;Z<^'SUVH6RNM>JQ74T+G,
M^L/Y*46[M%J)+7%314[7U ;M \<KUFY6:BN3-M; )1[ERZ;1-CI9A-3T36R
MY!3I>'SM-1W.NUD*NKIWL<Z1N0?>O;-7.KX=+,?0PNE>V-OJCW*5.T_;Y9N]
M?3M,@.<K?DI6F#NFMPW&,)TD\5X;;-40AACNEJA9(W@EP\5&-9%EXFB^2Z)C
M'=X#^C\LKWZIT99JMSG5%&USSR2KJ'2%FHR##1M:1RG1PT=*4$\>FVQ5(<'E
MC>#[EX9<16Z:UI45;8'%CY,@GQ7T_$&EFUK2&MXPN3==,6NY$NK*9LA3I;X0
MJR:NJ[[3.BCI@UQ9U"\EHV5-IU/+/<:7O6&0G](OI&TZ?H+5ZU)3B/C'"PW#
M2ELN$F^IIFN)\2G2<5YE<M205MMDCH+;$Z1S2#M'10[LOM]9!KR*:IIW1M]O
M\U[]0Z1M%%DP4C6D]5GAT_11U@J(H&M>/%.CBO)NW6BGEGI)(8R\!BE>@()6
M]G#0]A#S$X;?Y*:U]HH[B *N$/V\#*V*2@@I:,4L+-L(& U.EGA\Z]FENJ:;
M6O>OA( D=R?XE]"5["Z@>1UVK#0Z?H:2?OHXFA^<Y74=&'#:>BE]-\/FT4%2
M>T621T)#"X<J1=KVEJFM;%74T3I#'&!@+UUU@M_I)J# .]\UNR0130&*1FYA
MXPKTSQ'@&E]3P6VACI:ZVP]Y&W&7#DGXI<;]4W>N;#;[+&6!P.YH\/BO8:K1
M%AJ9#)-1,<\\Y6Y:].6ZVNW4E.&'ID)TG"!:YTU)<]+AT5,63-A'J-\U ]#Z
MEN&E7/I:NF(:.!N7T:]@+2US>"N'7:/M%=*9*JD8]WN3HX>4:QU;<-0VA])3
M4FUCN=S53L&MU325-8Z>(M+G=3[UZ[2Z6M-/'LBI6M:MNVV:EMY>:>,,W'P4
MU9Y=!HX7.OE&VMMTD+QD$'\ETP,!4('BL:WGT^1KA:KC07BMI(F/$50\C'FO
M<-#Z;;#H..&5F)=AX4OFTS;IJKOY8&N>#G*ZT-.R&(1QC$8' 6^F>'R3=+;<
MZ2JJ+=%"\Q22%V/YKZ%T+9!2:4@C<W;))%AR[TVG+;+4=^^G:91^TNHR!L<3
M6,X#1@)T</FS5UBK;%JF2MBHC- 3U/3JI'!K*@90[7VVG$X'U<'G_->SUULI
MJZ$LK&->/:H^-!6#O#))0M+_  *O2</,](UM7<KWO9:&MB#LAP'3_-;/;C13
M5-NC$+"7!X]4+U^V6BCM["*.$1@JVX6>CN!Q5PB3QY3I.'GUM%13]G\A#"R1
ML0P/Y+QVV7&1MRF=5T;97>;OYKZ#UW0SQ::J([;^CPW  ]R\?TO<+=02.;?+
M7-/+T) _]*STQ?*VGO\ '%("^V1.:.>0O2M :TH[O_PK61PO8=H8U1BMONF>
MX<(['.21@8'_ *7,[-M/SSZD-?1Q&GIA+NV.'.$V$\_;!VFV^IFU6U\<3BWO
M@5[Q8HR;33@C:1&T'X*E98:*LD;)-$TO&#DKIQQB-C6, #0,+&NT\QX)VTT5
M1->[9W$1< 3G'O*](T932G2'<R,+7%C@ I'7V6BKI&R5$(>YG0K;AIV4\ CA
M;M:%>CB/EZ\TU?IG69K(Z=SVAQ<"?:O8M":TJKV\QS4K6;1U"E]RT[;KD=U7
M3M>[S*ML^G*"UR.=2P-83Y)TD\8[ &6C/"\Y[9J::HT[4,A87$M\/<5Z0M.N
MHH:V)T50S>T^!66K'D78S;I?DFHIYV%@?&6J)ZCLUQTEK!UQH:9\L0SZWARO
MH*W6NFM^131AF?)7UULIJ^(LJXP]OD597.^'D\/:=/'08]&89@WZOM^*AMCL
M%QU5JN2Y5E.^*,O#QY=<KV[YBV'O=PH6AWFN[0VNFHHPRFC:P#R6NL.+7FO:
M ZY6^F;Z)2NFA:T CP7 I-2T,U(UM?;H(WM&#D=5[=4TL53&8IV!S#X$+@5&
MA[',XNFHFN)3HX?/UTIGWJ_L%GI U@D:[,?EE>HZS==:*RT_HU*Z5K86AS?;
MM4ZM6EK5:G]Y0TK8W'Q"ZD],R:,Q2M#FGP3I.'B%NU122TXCN-L@BD:,'(Z_
MYJ)7R%UWOL?R11AK-S3F/WKW^HT19*B0OFHVN*V;=I6U6YX?1TK8W^83I9X9
MM,4\L%LIVRY#@P9RNRJ-&UH 55S=H(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B#',2!G&5%-1V^1]='5LC,@8/J^"ESAGJK2T$8(R$9L0FS6^:HKG2NI_
M1QG/'BIO&,- 5K6^#1C"R#@(L@B(BB(B B(@(B( SDJASX*J(*9YPJ]!PB(*
M \<JJ(@(B("(B B(@(B('@J>'*JB"FT9RJHB $X*(@M\\]%1H#CN&5>@&.B"
MW+L].%7)\E5$%.O5,#"JB@HWQ\D(R0JHJ*;>54^Q$04!5?>B(*.&1A"#QA51
M (RK0P Y"N1!1P\D \U5$%,>:K@8PB( & J$ JJ(*<\85I#2_P!JO3'.4%,C
MH@ PJX"(*$<)X<*J(#>G*(B"G&"%5HP,!$04YW>Q51$% T!'9VG'551!09V\
MJA;ZOJJY$%-O'*YE=9Z6K=F2%A/B2T%=1%=3$?.E;>\?U3/_ *KH4%HI:)N(
M8H\^>T+H(IIBQH /M52 Y7(HJT@8PJC#1A51,%",JH1$P$1%05.O'@JH@>Q
MB(*'/\D!R55%,!4.?#JJH@H?J^U48-K.5<BHI@8./%4.0  KD04(\D PJHB8
M8Y3/*(IBF!E6AN'DJY%10$.!1HQE5 PB@M.'<>*J.BKA%10M!"M:,$A7H@H.
M 4'CE51 ' 1$0%1N<<]55$%K&[2?:KD1!:!GER9/\E<B@M'/(5P0#'1$@H<*
MJ(J*;1DE/Y*J("H3A51!:  <ID^/178"*"@QC(0'KE51!8P;0<J[ (545%,<
M81F<'*JB@M #3G/57(BHM+ 3E4+ 3R5>B&"(B"P;MQ!^JJQ@@'*N1!:_I@#J
MC&!C2&JY$%FS)R5?CC"(ABUC0WHF,N5R(3Z4 QE4?DM('57(@L RWVA7#@<J
MJ(*9.?8JHB@I[3U0<YR%5%0\%0 #A51 PB(@*@&,JJ(+6L#3GQ53G''551!;
MSCH@&T>KU5R(+(]V#O&%<.,JJ(*>'*'E5106Y\!X*X(B"F 2J\HBHHX951T1
M$%'9ZA4:0X9 5R 8Z(+!SU5PZ<*J(*<.!1I'0>"J!A%('L0>Q$5!",A$4P6D
M!PP?!,%K<-5R*BUV".2C1CIT5V$4%CVAQQSE7 ^715146DNR-O17?FB(+7QM
M>TAP!!\"%QJS3=!4N+G0Q@GR:%VT1,B/1:6H(_\ I,/O:NO24<-*T-AC8T>Q
MN%M(KJ<PR,X1$4:%0D^"JB"WWJK55$00D#JB(J@ /*H0"<*Y$% "/<J>/'@K
MD0/#A6@G.'*Y$%#G'"J!A$06MSDYZ>"KGP"JB B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B @.2B(*#.3GHJMQCA$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$7(U#=H[3035$I&&-S@E634MR:Z<DT<8)>X!:SKI
M2-.#*U?,NO.TZMKZA\=NF,0!\%!IM97QQQZ:\E=)^*UPO^B/M+Y5H_OFI\JT
M?WS?BOBMNL;V!CTURK\\;W^-=\$^*I^S'VG\JT?WS4^5:/[YOQ7Q9\\;W^-=
M\$^>%[_&N^"?%3]F/M/Y5H_OF_%/E6C^^;\5\6?/&]_C7?!/GC>_QKO@GQ4_
M9C[3^5:/[YOQ3Y5H_OF_%?%GSQO?XUWP3YXWO\:[X)\5/V8^T_E6C^^;\4^5
M:/[YOQ7Q9\\+W^-=\$^>-[_&N^"?%3]F/M/Y5H_OF_%/E6C^^:OBSYX7O\:Y
M!K&]_C7?!/BI^S'VG\JT?WS?BGRK1_?-^*^+?GA>S_\ FN3YWWO\:Y/BJ?LQ
M]I?*M']\WXI\JT?WS?BOBWYWWO\ &N3YX7O\:Y/BI^S'VE\JT?WS4^5:/[YO
MQ7Q;\\+W^-<GSPO?XUR?%3]F/M+Y5H_OV_%/E:C^_:OBSYX7O\:[X)\\+WC^
MV.3XJO[$?:?RK1_?-3Y5H_OFKXL^>-[_ !CT^>-[_&O^"OQ4_8C[3^5:/[YO
MQ3Y5H_OF_%?%GSQO?XUWP3YXWO\ &N^"GQ4_8C[3^5:/[YOQ3Y5H_OFKXL^>
M-[_&N^"K\\+W^-<GQ5/V8^TOE6C^^:GRK1_?-^*^+?GA>_QKE3YXWO\ &N^"
M?%3]F/M/Y5H_OF_%/E:C^_:OBSYX7O\ &N5/GA>_QKO@GQ5?V(^U/E6C^^:G
MRK1_?-7Q8-87O\8]/GA>_P :]/BI^S'VG\JT?WS4^5:/[YJ^+/GA>_QKD^>%
M[_&/3XJ?LQ]I_*M']\U/E6C^^:OBSYX7O\:]/GA>_P 8Y/BI^S'VG\JT?WS4
M^5:/[YJ^+/GA>_QKT^>%[_&O3XJ?LQ]I_*M']\WXI\JT?WS5\6?/"]_C'I\\
M+W^,>GQ4_9C[3^5:/[YOQ3Y5H_OF_%?%OSQO?XUWP3YXWO\ &N^"?%3]F/M+
MY5H_OF_%/E6C^^:OBSYX7O\ &N3YX7O\:Y/BI^S'VG\JT?WS?BGRK1_?-7Q9
M\\+Y^->GSPO?XQZ?%3]B/M/Y5H_OFI\JT?WS?BOBSYX7O\:Y!K"]_C7I\5/V
M8^T_E6C^^;\4^5:/[YOQ7Q8=87O\:[X*GSQO?XU_P3XJ3_1'VI\JT?WS?BGR
MK1_?L^*^*_GC>_QKO@GSQO7XQR?%3]B/M3Y5H_OV?%/E6C^^;\5\5_/&]_C7
M?!/GC>_QKO@GQ4_8C[4^5:/[YOQ3Y5H_OF_%?%?SQO?XUZ?/&]_C7)\5/V(^
MU/E6C^^;\4^5:/[YOQ7Q7\\;W^-=\$^>-[_&N^"?%3]B/M3Y5H_OF_%/E6C^
M_9\5\5_/&]_C7)\\;W^-<GQ4_8C[4^5:/[YOQ3Y5H_OF_%?%@UC>_P :Y/GA
M>_QKD^*G[$?:?RK1_?-^*?*M']\WXKXL^>%[_&N3YX7O\:Y/BI^Q'VG\JT?W
MS4^5:/[YOQ7Q9\\+W^-<GSPO?XUR?%3]B/M/Y5H_OF_%/E6C^^:OBSYX7O\
M&N3YXWO\:[X)\5/V8^T_E6C^^:GRK1_?-7Q9\\+W^-<GSPO?XUR?%3]F/M/Y
M5H_OFI\JT?WS5\6?/"]_C7)\\;W^-<GQ4_9C[3^5:/[YOQ3Y5H_OF_%?%@UC
M>_QKE7YXWO\ &N^"?%3]F/M+Y5H_OF_%/E6C^^;\5\6_/"]_C7)\\+W^-?\
M!/BJ?LQ]I?*M']\U/E6C^^:OBSYX7O\ &O3YX7O\8]/BJ_LQ]I_*M']\WXI\
MJT?WS?BOBP:PO?XQR?/"]_C'I\5/V(^T_E6C^^;\4^5:/[YJ^+/GA>_QCT&L
M+W^,>GQ4_8C[3^5:/[YOQ3Y5H_OFKXL^=][_ !CE7YWWO\8]/BI^Q'VE\JT?
MWS?BGRK1_?-7Q:-7WO\ &.3YWWO\8Y/CI^S'VE\JT?WS4^5:/[YJ^+?G?>_Q
MCE0ZPO?XQZ?%4_9C[3^5:/[YJ?*M']\U?%GSPO?XUZ?/"]_C7I\57]F/M/Y5
MH_OFI\JT?WS5\5_/"]_C7I\\;W^->K\5/V(^U/E6C^^;\4^5:/[YOQ7Q7\\;
MW^-<J_/&]_C7?!3XJ?L1]I_*M']\WXI\JT?WS?BOBSYX7O\ &N3YX7O\:Y/B
MI^Q'VG\JT?WS?BGRM1_?M7Q9\\+W^-<@UA>_QKO@GQ4_9C[3^5J/[YOQ3Y5H
M_OFKXL^>%[_&N3YX7O\ &O3XJG[,?:?RK1_?-3Y5H_OF_%?%GSPO?XUZ?/"]
M_C7I\57]F/M/Y5H_OF_%/E6C^^:OBSYX7O\ &N^"?/"]_C7I\5/V8^T_E6C^
M^:GRK1_?-7Q9\\+W^-<GSPO?XUR?%3]F/M/Y5H_OF_%/E6C^^:OBSYXWO\:[
MX)\\;W^-=\$^*G[,?:?RK1_?-3Y5H_OF_%?%GSPO?XUWP0:PO?XUWP3XJ?L1
M]I_*M']\WXI\JT?WS?BOBSYX7O\ &N^"?/"]_C7?!/BI^Q'VG\JT?W[?BGRK
M1_?-^*^+#K"]_C7?!4^>-[_&N3XJ?L1]J?*M']\WXI\JT?WS?BOBOYXWO\:[
MX*HUA>_QKO@GQ4_8C[3^5:/[YOQ3Y5H_OVKXM^>%[_&N3YX7O\8Y/BI/]$K[
M2^5:/[]OQ3Y5H_OF_%?%GSOO?XQRK\\+W^-=\$^*K^Q'VE\JT?WS?BGRK1_?
M-^*^+1K"]_C7?!/GA>_QKD^*L_LQ]I?*M']\WXI\JT?WS5\6?/&]_C')\\+W
M^,>GQ5?V8^T_E6C^^;\4^5:/[YJ^+/GA>_QKD^>%[_&N3XJ?L1]I_*M']\U/
ME6C^^:OBSYX7O\8]4^>%[_&O3XJO[$?:GRK1_?-^*?*M']\WXKXK^>-[_&.3
MYXWO\:[X)\53]B/M3Y5H_OF_%/E6C^_;\5\6#6%[_&N^"?/&]_C'?!/BI^Q'
MVG\JT?WS?BGRK1_?-7Q9\\;W^,<GSQO?XUWP3XJ?L1]I_*M']\U/E6C^^:OB
MSYXWO\:[X)\\;W^-=\$^*G[,?:?RK1_?-3Y5H_OFKXL^>-[_ !KO@GSQO?XU
MWP3XJG[,?:?RK1_?-3Y5H_OF_%?%GSQO?XUWP0:PO?XUWP3XJ?LQ]I_*M']\
MU/E6C^^:OBSYWWO\:]!K"]_C'I\56?Z97VG\JT?W[4^5:/[]J^+/GA>_QKO@
MGSPO?XQWP3XJO[$?:?RK1_?-^*?*M']\WXKXM^>%[_&.5/GA>_QKO@GQ5G]F
M/M/Y5H_OFI\JT?WS?BOBSYX7O\:Y/GC>_P :[X)\57]F/M/Y5H_OF_%/E6C^
M^:OBSYXWO\:[X)\\;W^-<GQ4_9C[3^5:/[YJ?*M']\U?%GSPO?XUZI\\+W^-
M<GQ4_9C[4^5:/[YOQ3Y5H_OF_%?%?SQO?XUWP5?GC>_QKO@GQ4_8C[3^5:/[
MYOQ3Y5H_OF_%?%?SQO?XUWP3YXWO\8[X)\5/V(^U/E6C^^;\4^5:/[YOQ7Q7
M\\;W^-<@UA>_QKD^*G[$?:GRK1_?-3Y5H_OFKXL^>%[_ !KD^>%[_&O3XJ?L
M1]I_*M']\U/E6C^^:OBSYX7O\8]4^>%Z_&/3XJ?L1]J?*M']\U/E6C^^;\5\
M6?/"]_C'I\\+W^-<GQ4_8C[3^5:/[YOQ3Y5H_OFKXL&K[W^->GSPO?XURGQT
M_8C[3^5:/[YJ?*M']\WXKXL^>%\_&N0:PO?XUROQ4_9C[3^5:/[YOQ3Y5H_O
MF_%?%GSQO?XUWP5/GC>_QKO@K\5/V8^U/E:C^^:GRK1_?-^*^+?GC>_QKD^>
M%[_&N4^*E_TR/M+Y5H_OF_%/E6C^^;\5\6_/"]_C7*GSPO?XUR?%5G^B5]I_
M*M']\WXI\JT?WS?BOBSYX7O\:Y/GA>_QKD^*I?\ 1(^T_E6C^^;\4^5:/[YJ
M^+/GA>_QKD^>%[_&N3XJ?LQ]I_*M']\WXI\JT?W[5\5_/&]_C7JOSPO?XUR?
M%3]B/M/Y6H_OV_%/E6C^_:OBSYX7O\:Y/GA>_P :[X)\57]B/M/Y5H_OFI\J
MT?WS5\6?/&]_C7?!/GC>_P :[X)\53]F/M/Y5H_OFI\JT?WS5\6?/&]_C7?!
M/GA>_P :Y/BI^S'VG\JT?WS4^5:/[YJ^+/GA>_QKD^>%[_&O3XC]F/M/Y5H_
MOFI\JT?WS?BOBSYXWO\ &N3YXWO\:[X)\5/V8^T_E6C^^;\4^5:/[YOQ7Q9\
M\+W^-=\$^>-[_&N3XJ?LQ]I_*M']\WXI\JT?WS?BOBSYXWO\:[X)\\;W^-=\
M$^*G[,?:?RK1_?-^*?*M']\WXKXL^>-[_&N3YX7O\:[X)\5/V8^T_E6C^^;\
M4^5:/[YOQ7Q9\\;W^-=\$^>-[_&N^"?%3]F/M/Y5H_OF_%/E6C^^;\5\6?/&
M]_C7?!/GC>_QKD^*G[,?:?RK1_?M^*?*M']\WXKXL^>%[/\ ^:Y/G?>_QKD^
M*I^S'VG\K4?WS?BGRK1_?-^*^+1J^]_C7*GSOO?XQR?%3]F/M/Y5H_OF_%/E
M6C^^;\5\6?.^]_C')\[[W^-<GQ4_9C[2^5Z/..^:J_*U']\U?%;M77LCBN=E
M7MU=>]A_XYV5?AJW_3'VO!60S?4>"M@$'HOC*Q=H5ZHJ@&:J<YH/BOH7LQUS
M'?X602.'?!N3RLW\=C7C\\]/2$5 <MR.55<W<1$0$1$!$1 1$0$1$!$1 1$0
M$1$!$1 1$0$1$!>-=OMUDHJ-M.UV!*PY7LJ\'_I'#,E*3X,*UY_KG^7^/GK:
M XR9)<[S6,CDN/59 02>>%C(.[<?JA>KR^?Z JJG!.1T556!$PB B(@(BH@J
MBHB"J)A4Z(+@<)D*W*9"F&+LA,JW*)@NRJ9"IPBJ+@0G"M&54(NJJB(FJ*O"
MHJ<HBX83*I@JG*N)BY4P$5$Q<$&$3"J:KG"90=$X4PE$1%,4RF41,!,JG"IA
M,%V45,($P51454 J@*)P@K_-$&$]R8FF53**G@A%4P$16&X8"8")RJ:8"8"(
MAI@)@(B&F F B(:8"8"(AIPF4]Z<(:(J\)PF'2B)PG"'0%7 143"*\*G"!.B
M*KPJ8"(@<*JHG*@JB*B@JBMZJH055>%;A5PF,]*\)D*F$PF+TKE,A.$X3#3*
M A.%;E,-U=D)GE4"946*90%.$&%J G"<(F)I@)@(@5- 43A.%,.C*!5&$ 4I
M+H@*J J)%$RA5%J1-5RG"H@"M@KPG"HBBJ@!5X5/!$17A4150U1%54!"F&J$
M)@(45-,!7#"M13#=7 IU5N$&0IC4783A6Y*ISE,75X16JO@F,57"*@3!3$E5
M*HJ*B+J[A#A4PF%<73 3 1%4U4 *N K0J\H:KA.%3E$PU7A.%1$57A.%1$%>
M$Z*B<>*B&4R$X5.%"&0F4P$PC6JH %1%6%V G"H.BIRJJN G"HB*<)QA,(HA
M@)@(BII@)@(B&F G"(%,-51455,-43*J$X3#5,IE5X3A,-,IE.$X4PU3*)@(
M M*KPJ<93"80B[ 085N"JCHIA[5X5$PJ(OBJHJ)A,/1PB85%IC553*JJ\819
M5 2F57A.$75>$X5$1%<!4X3P5$4X5>%1%!4(J *N% 1,(@(BH@JB(@(F%1!5
M/!4PJX0 <!5RK405RF50*J@93**B T N.5<6D<A4PP@X/*HTEJT7^+L@C!ZJ
M>]CEQDH-1Y#R&EN % L^.%*^S4.?J%GA@A8].OX;]OLRWO=)21N=U+05L+5M
MV#00!I_8;^2VAT7EKZ,_@B(HHB(@(B("(B B(@(B("(B B(@(B("(B B!$ ]
M%X/_ $CSZU)_AE>\'HO!OZ1_UJ3^ K7C^N7Y?_+YX:,$HX\;?!5'BK7=5ZO+
MYU ,=%54"JJ@B(@(B("(B*HJHB(*A550H 1!T14$1$!$1!4!5;]5RM<3M50#
MA2I)]KFCA=&VVBKN3#Z-$\\]0%ITD3I:B.,#ZYPOH_1M+2:2T>9:UC1(YP/K
M >*Q:[>?+YVN5#-0R-CF86GVK3<PYX*]V[8;%#76VGN5"P%HCW.VCWKP=Y(=
M@+7G[2^<5!VNYY"RTD3JFH;$P'+C@+$_(9G'*D&B8G2:@M^0-ID&?BKJ2->[
MV"KM<(EJ&$-)QT7'=AK=QY]B^@^W*G#K'3Q4\8W;^<-7CD>DKC40&5D)+!UX
M*FM\H\&;@UV[ *JXAK\=0MFKM\E.XQU#2TMX6&G8Z23N8&ES_<KKGZ\+ 0XX
MZ)M(<?$*01:0N<S \0GD9'!6E<+166\8GB(S["IIY\_33HZ9];4B&%I+CY+H
MW2QU%M8QU0TC<,C(73[.R8M00N<T'D=0O1NW!K?D^W[6-!=$.@]ZG37+R&W6
M2JK0^2%CG- SP%HR1&&0LD:0[R*]-[/;X;=;98^[:XF(CD9\"H#>9'5ES>X-
M <2> /:FIRY1Y/3 52/5X.5W*/3-SK8RYD/J>>"J5.F*ZC82^)V!["G1RXC?
M7& .5>V"3!(82!U6Y1T-5-.(Z=F3[E[?2:!IH='BH#7&KEBRX%O0Y33EX&&[
MSZN ?)=2"Q5<U&^:.)Q \0$N5CK+;*)I8R&;NI'M7HEDU++!IN:.*&,C')+4
MTY>3/S$\QR,(>WKE6ANX[Q]7R6]=9)*NXRR.: 7GP"W*'3=PKF@TD1(]H5U>
M7%!&"?)5'#2[KGP7;K=,UU&,U<3FM'D%Q7-='(0P<#S5URL6L.6D.&"K@  <
M\E''<=Q6]2VJ6KB=)$TNV^Q36O/ESQZN<C*I$TN!*Z]%9*ZK?W4,1+A["LM;
MIVXVYG>30D-]Q36KY<4.$AVM&TA4<=AP>5FCIQ)+MCSWCO!;<MHJX\#NSN/L
M34X<TG>,@85P.YI '*Z=PM%510=Y/'M9C)X6&CMU35[31L+MW7A7HX:&"UF3
MR?)5>\!S0&]5(WZ0NC&F8PG&/(KB3TLU,YS9V%I]R:<,!;X@\)D..X##?)98
M8O2'M9 "YY.",+N,TA<9&!W='!YZ*:<H[C!ZJF"7%3FP]G];6%[IXW-8SJ<+
MBWFRFCN4E-3#<YIPFG#@CIU5K#WKBUOJX\5TY[)4153(7L=WCAD#"7.TU-#&
MPS,+6N&>B:<.=(SC:TC(\0JR-VD '*Z%LM$]7S QSL^Q=+YG7-C3(^([/<FI
MPCCVX P48X.R,8]ZS34TD$[VO!!:?$+=HK565\.Z&/(ZY 5Z7AS(V\G)X1Q$
M9/[65V;;IZOKR^*.(Y!QT6*NLU9;9#'41N!S@9!36IX^G*!X^JJAX .1E=RW
MZ<N55#WL<)+?<5HW*V5%"[_B&%KO#A36;&BP;N<X5S1M.2<A&QE[<E;MJM[[
MA*V&($DD*Z3RU8Z:4AS]IV^"Q.);X97OM'H*FCT542R-=Z3W66C'BO&;A9*Z
MCW.FCQ'G@D*:M\N4&Y&<JF-V0.,+9I*)]7)MIVESNG3*ZPT?=C&7MA.W'D4U
M9Y< -PU PMZG*VJV@DHVXJFN:0?):K8P7!T>2 KK'J*9))X(5?#!."KHWE[W
M #HMJAMD]=49C:3[@I:SY\ZT\[#AP)RNW3Z<K*B@],C:3$1GHLM5IFXQP&5T
M)V-]A7M^D((V]FI8^-O>"!V<M]BG3?#YP<TL<0[P.$(QSE;=>UOI\T7AO/YK
M>I--U]8 8XB8_/"='#BCS\%D9'WAPW@KL5NG*RF9Z\9VM\<+1M[-U8P.!!!P
MFK/+>JM-U=-21U$@/=O;D%:=OMD]=*Z.G87N SP%[QKF.-NA*##6Y[GKCVE>
M:=F-W=:KI*\,8\&,M]894Z7E#:^BDH9A',TAQ]BT\\EN.JFFL)9;Q>F]TP;C
MX *-UEOJ;>\^D,VYZ+4J<M #8=KN2A&TYZA9(HWS5&T#)/"W*JSUM"T.?'B,
MC.2$TY<YYX!'CX*[(+=G1W5;UOM536O/HK"YWN73FTC<V1]_)%R/(*ZG".M'
M>-./5(\_%"/5QXK/6TSX9 RH:6O'08PMJ"U3STX=$PD#K@*:<.<.6;0.?--V
MW (R5V:2PUE3&?1XR6CJ<+EU,+X*@QO&'-."FG.*,&YP;CDG"[<NF*N*@-6X
M'NP,KD4SB:^$#[8_-?16I*:%G9A/(UK=^QO./^TIN+)KYO<PEQ:'8(5 S=Z@
M=ZP\5F[ILM0[N\EY/1=>@TK<:S])!$23YA6>CAP<C.W'/FJQ,)W9/1=>OT]7
MV\GTB(C^2Y9'K%H^L$[.,8@/:KW-Y&#A=6WZ<KJ]F^&,D>Y9:O3%PA89'Q'#
M/84TY<-SL8&#E9FTTDTF8VDM]BV*.BDJZGN&M.\=>%[5HC0D'S:=45+3WWAD
M>].CEX.3N>1C;L."NM066IJHW2Q1N>S&> MO4&GZFCK:MQC(BWGG'@IGH&_.
MM]GE@;&QS2P@$C)3HY>85,#Z=QWCIX+%CO,%IQCJNQ=G/J[F[#1EQZ!89K-/
M&6 L=F3IPITG#F9SZHZCQ51]0L_:/0J14^D+H^'?'"2W&>BX]3124\A94M+7
M@^2O1PUG## WJ?-,%G)Y"RTL,E1-W<#2YQ..B[K=)7=\8<8?T?N32>4;SOR1
MEN%67UFC;QCK[5/;%V?UU?$Y]1&6QM."<*+Z@MS;97201DDL=A-7'*8>^(:T
M;3[5W(]/5;Z)]0&.V-&2<+DC(E:7@ Y'1?1-L@8.S2N+HVY,(P<<J:DCYT>S
MNB0XY*L(+.I7=BTW5W&9SZ:,GQZ+3NEFJ:%I%4QS?Y)I?+G.!X.>$(,QPSU=
MO)/FJM#I<,:,XX"[-!INXUK,T\1/\E.DX<4/#@<-Z*^"(S2M8SESC@!=>OT]
M<J$9J(2& <X"PZ=B$=]I<_>#(*:L\LU;IZJH:)M5.P]V[@<+B;#SROH?M2AC
M^CRE=$QN]SP.&KQ>'2USJ(]T41+#ST*3TO"/A^#C&?:KG$-];P6[74,MM)CE
M80\\<A:]/!)*[NG-R?8M:G+"00W=U"H 7 '.%(:;2MSJ82^&$E@\2%JUVGJV
ME8#-&X8]BG1PY+7 .R1PF"<@'KT6Y26ZIK'=S W*QU=*^D=L>"'#S5Z.6L7;
M0&=3YK/# ][@P<N/0*M+2S5;PVG;N?[EV*2CJ;=<(I*AF",'!"FKRU:FQU<$
M#9I(W-8>>1U7+:\&0MQT7JVK-0R5E@I8.ZC:&MQD-PO+61232XA;EQ/@$GHY
M8FG!.5=C()7>BTI<YV!W<G!'D5HUUHJJ'<)HR!X\*Z<N:&[V[0X ^:H_U?4
MR3XK+#3MG?W<>=RWWVJJBDCC$9[QX]4834OES!P,'JWJJQD2G(& NE7V2NHH
MA)51[=WL7-:<99A-9PV9SAP5"TCQ66"E$SPR'<YY\EVH-)7&=F8XG? IK7+@
M./'"W:"AEJI6MB!>3X!9:^S55O!%7&YH]RE?9,W-_@ :'-WCJ/:%.E\^45N]
MKGM[\S1N:/(A<TX ]J]H[:J.:>[.C@B;MP/JM7FXTI<6PFH,1VCV%)ZUN^$>
M;D\="A]7@]5GGCDCF+)&X+2KZ:@J*R7;"TNSY!7ISQK%P#3PK6NX^KC*D8TA
M=-H>V$[<9/"YMPME51G_ (B/:/<FG#0:WU>>%3.W@C/M6W0T,U=+W<+<GKP%
ML_)%<^H;"R(YZ?54TX<HG:.?%7-9ZFXD>Y=^?2ESBBWR0D-]RX<M*Z.0A^0[
MR5TX6AIE!+3MVJGU&Y/K>Y;EOH):O=' UQ)..BZT.C[FUN3$2WPX6>CA' <#
M.$P0,D+T&@[/ZM]N?45+"UC?8H95P.97/IHVDEKL#A.CAH;P!RU58/5)<I)!
MI2Z5,(?W.&=1PN=<K+54+\53"W \E94Y<QSMF'8R/)5V]XW>#M'DJ,/K.!'J
MA5QEN1T5U,4!XZ=$!V@D\Y\%O4=NJZOBFCW?R769HZZ"(RNA.0,]$UJ>4:SM
M;EW!5[&DD8!.5GJJ1\4^VK:6N]RFG9WI9UYNU.)V'T?=R0/!3IJ>4&DAD:-S
M@0%8W)/'*]>[4-&>@ ,MC'.:'==J\LFI'T$VR88>DJ?D\M0G(..,*@((QXHS
M<7O<X<+<H;;+72?\.TN>?8KK'B--K2,[BD?5V[^2D3M'W3N>\,1]G"Y%PH):
M/:VL86YZ<)KI?+4 P51YPX8'"STT!J'[(02Y=RDTC=IH7/;"2/<5.F.$>D(P
M,#JK2=C\'D+IU]FK*$GTJ,M_DM%L9?ZH&2KJ\L8:9'>J,!5< <M'4+NTNF;K
M/"'10^H1G.%AK-,U]"SO:B-P:?8G2\.5"TRC: =W1=J73E734/I,C#L(W X7
M-H!MK8PT?M!?0NJF0_1]%AC=W<>2G1R^<!QD^"-&[@<%9&L?),8VMR<KMTNE
M+G6Q][3Q9 ]BO1RCX.,M/54!QX+KUMDK://?1D$=>%S2U[7$XX33E8B(C B(
MBB!$"((B("(B B)X(*(@14$1$!$1!0- )..5<J>:(GI<"I;V;.(O[,>Q1$*6
M]F_Z_9[PL>G3\/\ 7V3:V@4,&!^PW\EM+5MG]A@_PV_DMI>6OI^?X(B**(B(
M"(B B(@(B("(B B(@(B("(B B(@!$1!0]%X/_2.^M2?P%>\.Z+P?^D=]>D_@
M*UX_KE^7^/GD=2J'JKO$JT]5ZO+YWKZ43*J$510%,JJ(*93*JB8*93*JB"F4
M543!3*'E50>*"@5<(BH83"(@81$04')PF23M"NCX=E5@C<Z0^>>%FU?*;=EN
MGWWB] !I(B(<5/NVBNJHY([;20N,88#ZJ[79%:8[!9'W>H '>Q9*Y-X[1=,5
M]<XU=#(^1N6[L+F]'G^.MHDR7S1==153")!'M;GWA>#:IM3[5>)Z=X(+2O=M
M(Z]L'RE%1T5*^,SNVY(49[<=/-AJ'W.-H+97<86O-PKQEF7##N NYHZ(C4MO
MV2''>CI[UQ'<L+<>LNWHAP&I*%I'K=ZWG^:E^W+_ *^E.TBNI+7I^&:IACE=
MNZ.7G>F>TBEJ+I%226Z)D3CM)_V5VNW:5S=.4[7'/K?Z+PJPO[JZPEP)Y4=9
MZCVCMAL--46JCKZ&)K>\]9VU8>R?3%$*'Y3K&,< .CEW-9R8T';7CZKF=%3L
MVGAN&DG4<#@V49.#_-"_:*7OM*@I*Y\%/;XBR-Q;D#_VI98I[;K>RU#6T\3*
MAD9.!USA>):BL5;2W2I:87N#I"<@>U>N]BMGFLU'65U7ZD;X\@.]RE)$!T_;
M'VS6C*><%H#@>5,NW,XH+?M&?T(Q_FN)45<=U[16R0D=UP%V^W%S116YC1@B
M(#\TU<9.QVBIZFSU+IX6N>(''GW*%66C@K-;B&9H8S<>#_$I_P!BH/R36;N2
M*=WY%><0TU77:Q(MTPBGW'!)Q^TFICUC6'I-IIZ5MHM9J&;?6+!_[4?H]1U3
MFRQ7*Q]W&6GUW#_VK*C4U]LL?=5SY)VM'[(RNWH^]TFIW24]=12XVDY>W"&/
M+VZA@M>H.]AI62,W$EO^RO?&ZB;\S17"F&#%NV^ Y]Z\ [2[92VJ^.;1M#&'
MG *]DL\9K>S/NXO6?Z/T'O1(\;U/K!MYA;"*5C,/ZC_]5Z?I"AI9.S^X2F!C
MG@=5X956RII)!WL+V^OU(]J]YT9F+LYN.>N$(@&A---O&JYS(W]%&[<1X84U
MUQJJWZ5G] HJ*%[F@<C_ /5<KLGN45+J2M9.X#OLM&5Q^V*P58U ^KB89(G#
MC:,^2:N?21:4UW:+M'+#=(((\G&7?_JO,]>MH([O.ZW2,?&7' ;T'59](:*K
MKJ][F1F, \EW"Y>K+*^SUKXI7-<X''JE:CE8X0^I@CQ7T!V(T%)-9*Q]13L>
M6^?\EX ,XRXY7T-V&M+[#7AIQ_L*6XWXC@ZKUG16.[S04EOA<]CL' _]J1Z-
MU%;]94SJ2>CBCD=QT_\ :\J[1K/5QZGK)VQ/>U[L# 4Q[$[#4T]:*R9O=QMZ
M[N%-UJHW<[$VUZ[IH>[_ $3YP,>&,KV?5-):+-0-K9X8>@ZKS36%PBJ]>T4<
M1&YL^,CWJ3=M\KV::BC+N1_Z34U!M0ZC@U)(;?34D;=_J@M'_M>@6VBM^C]*
MP5-5!&^62/@.\UX3I*H%/?8)W'#&.Y7O.N*-VH='T+J(@EC,D?%--B%47:C$
MVM#7VV)T9.W!]_O4F[0]-4-TTTZ\4#6,+8@]S6>!*\8I;!7&X-B[EY]8<X]J
M]]O#!9^SFII9WM[V:$8&4694([&+/2SFJFEA9+)&S<&GSP59JS5<M#>C V@#
M T@;?Y^]=#L;I*J#TNI9("S9DM'CPNA>:RR5-Q=)76F>2H'&X-57'?IJTW;1
M%1+W'H;FQCUPO&M)PB35+V22=_EX&3[U*]3ZIJ1:WT=IIYX:8C#FEIZ*&]G?
M>#48=)PXN'7WH8]NU:RTZ<$59/#"^1L8.UWN7D.K=54VH;E21^BQT\+"!N'3
M'/M4Q[>YW=[#&3EA@!Q_)>3:5I&7.^4E/-@Q.D#2#Y*2LVS7LE'<[=:=,P"V
MT<59/T);U_-8M,7FY5UU8RILKF0'S''YKIZMME!IG3\+[=2N[S(&6<J-Z3U%
M>*V]11L?)'%XY&$U9B[MMT_!0T])54\(C=+DN 74[%:&GJK0Y\T+78:3S[EL
M]N9>++;W2G<<')"IV).SIZ9[>&['<?R32_3BWG6U%8KJ^"DH89!NY<!T_P U
M/Q2VS4FEH+CZ/$V5K=[@OF_53\WNI S_ %A7ONA7=WV=2'Q,!5)ZB(T_:#0V
MZX^ALH871@[<_P _>I)VF6FCN>F&W*GA9&1%N.W^:^?YB7W9Q(.[O#^:^A[S
MD]F;\NSBG'Y(Q7S8UIR?6X4ATE>X[161O,+9,'Q7 >1T"K"W#V$=,A"?3ZQB
MU&':'EK_ $489#NV>!_S7@NK-8B^T\%,RC;"[O ,M'F?>O7+/BN[,YH8""X4
M^" O JNVU-ON$<M3$\1=X,<>U)<:MU[=I33U#I?2DESJHF3R !X#O=E1A_:A
M#\H;3;HFQ-=\1\5/9MNH- RQTCAN# W&?8OGRIL%<RY20O@>3NP,!)5>XW&W
M4&L--/K::ECB=@GU1Y+Y\N$+J*OFAVY#7D+Z,T3&;+H5[:HACMKN#[E\]WZH
M$]UJ]G4R'!_FM1S]M>@IO2:V./.TR.POH:P6JWZ/TF*VLBCFD/V_<OGZR2B"
MZTKI><.7T5JF#YQ=GS!0D%X/3^2S3\40%_:9!-4R0FVQ=T78Z>'Q7JE)5TUQ
MT!++ QD.8'<-]R^:A8ZUE883"\/+L9POH;3]NDH.S5PG(#^X=D?R4=<>1=GV
MG67O5+H9A^CW..[^:] U545>GS'2T%G,X^KO _\ :CW8[7PT^IW-D..7_FI'
MVCW>YTE8R2 O=$22-HRFF+M&UM5>)9::YV/NF%N ]P_]J!=I&G&634<;8> X
M;L#WKO:=U'J"X3O;3R2Q;1G)!"C6MJZX5-_C^4I^^<  ACTC7./H_H,CUC!_
M_P!%0WL-ABFNTS)X!(!$>JF6NP'Z$MY!X$'^I45[!/[P5 \.Y/\ JI"QKZNJ
M*>UZSIWLB;W8ZCPZJ2=I5EANVF:.OH86Y$>]VU07M@)AO[2WIS^:GW9==Q?+
M!56R=VXB/8P'W*ZF(%V4:>%UO@,[?T;>3GV94F[3_1*^\TEKM[6\M#26^:F5
MKLL.C++-53!K92'8(7B5OO;G:S94SO):),Y5U/X]@AM#=+Z7II*:@%74O;AW
MF/R4;M>H+MZ8/2+$XL)QM(XZ^]3G4USJ'Z6HZBV.=N+<G:O,(=4WJ:I[L"8/
MSC.T^:+$E[3M+PS69ET; VGD9%N+!X\K>['[=1U=B?)50L^H<EWAPHYKJX7Q
MMG:RNJ]T4D?U?8I)V43?\IU( .[NG<X]B?9].9J/5%KTZ^>CHX(9CD^L/_U7
MBUSJO2[A/4!FT2.+L>2W-5N<+M4%YW'>?S7&<YQP6]%KRY^JV;<[_CHLC]L?
MFOHO4!/T8U!(XV-__M*^<Z!S36P@#G>/S7T;J,__ .+:@9_8;_\ VI3R\BT&
MR@=>6OKBQC6OSAWBO0]2:CD@G[FR6ILL0QA[!U_S4>[(=.4-XJJJ2X1"01#(
M'P6_JV\&S7>6DM5/+&QG3#5BNL33244FHK=)#<K0(''H]P_]KQN]VF"AUQZ*
M<=WWX:?=E>S=DMUN=P9(:V1VWP#AA>2Z^@DFUU.(7!LG?>J?YE2+Z_CU/4-.
M^S6EKK-;?2A@<L"C%%J2O$[67"P;(2?6+A_[22]:CL-*V*IG?+$ /JC*Z>FM
M417JY0T%PI)G]\=NXMX"NL/.[G?Z>AU%//!11[7.' \/\U[AHN_MK-)&K]'
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M()&2P?\ A0+2^MI;-"(7M=+$.-I/"D#^T.T2\FQQ;O%W'*G+<]O0-*:AAO\
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MYZX56N!)X3D[;5RJ355;Z@<N<<X6IN>3T"M+27D X3;_ -RL\LZS0O=!*V7
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MZ%7E)Z>K6KM)$3&FIIX7/\RT'_1:^K>TNLN- ZB@8V.%W/JX"\R:[<,$<A4
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MJ-24XCD<6M!S@%1*UU?H=8R1G)!SRM#H, \J[ :,YY3E?D3W46NZFZVJ"CD
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M-2_Z.]2_NZ1!V=ZD_=TB=)/Q5$ WG/BA;GJI?]'>I/W=(GT=ZD_=TB=-?$B
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MW86=$TR,'HD'W83T.'[ 6=%-.8U_0X?L!5]#@^["SHKIS&#T2#']6%3T.'[
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MJ5=5!!$>\D#!YE9*:9D\(,3PX'Q"&LYZ<(> J-X&"<JT9;G)SE%7@Y'"HYP
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M][)7%V&C*])&=W&,*CFM=U:#CS":G*!:?LE755[ZRL<<..0UW@M^2Q/.L67
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M31QN):T;CU6K<[92U;,5#!R>H"W#/&TX<X E7[P6Y'K#S468U+=;*>ACVP-
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M*SR6:\]GIJJ*\321$;=WFMBZ25E0W82/BI^S0-4YH=F0D^.%7Z/JL/S^D/\
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MN<T9PN;I:]ON;)WSC8&.('MY3#I)CRC?$^*P/G#6[B?5\USJ:\03W$T\<@)
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M@'+@/>5;Z1&XX;(S/B,HOTQ0T5-3P=U%$P1]-H'"TAIVUB7>:.').3QU73
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MHBZ;<<86\7 @G(PL/?0YVB1FX^&54<VFT_;8\?\ !0Y;T.%V(6-C;M8T- \
MM*YU!IZ*9[' .:TD+GZ.KY[C;W33G)#R.5*L2!$11H1$0%:_ZI5R$9"#YW[6
M-(7&ZW$OIX'N:7'HO/CV;7C9S32+[%<T>*HZ,'J%TGO''U^/7QO5=G]VIX'/
M?3R!H')40JX'4T[HI/KMX*^X-3M8VSU)<,@-7QIJP!^I:X@8;NX7?\?K8\GY
M?/-<<$D<]%V+'8ZF[DBD8YY:<$!<AI#CA>R_T? STBI#QD[QC_)/58\^=0_Z
M.;PXG_AI%DC[.;PTC_AI, A?7;(FD9(65K&],+C?;U^?Q8A79;;*BVVB.*HC
M+7!H'*G2MVD$8/"N7.W7?S,@B(HT(B("\N[:?U6W^->HKR[MI_5;?XD6//\
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M1;([!P2&YPNE?<-MCADM '@H-:*FW^@742.:Z0="1R$.DWGU#104C*HD[7G
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M-4&0=P#S*-H77J'!L1+C@*(T[9+I<SU+87<(E=O3M(::WLBDZ@YRNN%8!ZH
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M9X'.$H*V.KC+XR"$-;B*@=QR@.?!%51$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M#&WV:@EV@-. ?-29CMS!CH>5XM+5MJHZ2XAI$\CP7N\>J]7L]8VKM\;HW@X
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M1$!$1 1$0$1$!$1 1$0$1 @(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(BF B(K@)A$3 PF$13 3"(F B(J"(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(M6X50I8@\^)P@VD6.GE$T8<%D0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1
M$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1%1QP,E ]BJ%H>FM-:(1U
M*WPB"(B*(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("(B B(@(B("(B B(@(B("*U[VL87/. .JBM\UO9[7(X3U;&N;
MX%!+$)PO)JSMBM43R&5$9 ]BTSVTVT.SW\>/<IH]ER@*\9?VU6X. $T?/L0]
MM= ,?I(^?8FCV94R,X7C0[:Z 2;7218]R-[:;>"?TL9/N31[,B\:^FFA'_4B
M^"#MIH?O(_@J/947C1[:J$?MQ_!6'MLH3@-ECS[D'M!.!E <A>,.[:Z$.QWD
M7P1_;51!PQ)'CQX0>SIGE>,/[:Z)N#WD>/<MF'MFM3F^O41M/N4T>O(""<+S
MRS=J%FKI WTN/)]BG%!<*:N8'TLH>"/!4;:*UG&<JY 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M>*X&L2101D?;7?7 UE^KH_XT&_8^:)JZ"YMCSZ",+I#IR@$X&43H.50'^005
M16.EC9]9X"IW\7VV_%!D18Q,PCAP*KWK0.7!$U>BQ]_'C.\?%89Y]T3^Z.[
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MY'FBYEN?N?@N)7311$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1 14R/$H'-/0@H*HF40$1,C.$!$5 04%40$'H<H@(B @]"@(B9'F@(B("(B
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MH^&DGJ579CQ*[XIH?LH:: =0$$?YQT3!7?%/3],!5%+!]D((_L]I5=OM7?\
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M5R@YX6T*-RJ*-X/13@^:-<# ZK>H(PX\A6MI'YY"Z-' &#E7QYQCW^7640M
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M-&9B[:QV1A:S])4T5<VK@<\RCC"MGU,^.=S?1SM!ZJUVJR1@4Y_W_-5SZ2J
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M.WTLM7**=]$^/'&\A>HX'/DK&L8#P!E&>7G<-+4Z=J7.A@?/WA\!T78I#5W
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M+S3TE3W,K@'>]7#72)P/-!RT'HN/570LJH&1N&V1=,3Q[1O>T'VG"8:RY!.
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MJWTB;[U_Q5A)(ZX5H'M5Q-9O2)OO7_%4](F^]?\ %8\<=53^:8:S>D3?>O\
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M.1YKK66V5-"W#Y003E=DM'BJD@CA*0P,#/*\V[=L'23<?:/Y+TGP7FW;J/\
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MNO4]3=J".F,;^'CP\EZ7Z/&6ENT8/L6"*WPQ/W!K?@FIR@QM\C;U:CW;L,C
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MB:O'(X1&XQ@(BBH_ZCO<JJC_ *CO<@B\'Z];_OQ"DH4:@_7K?]^(4F:K&?\
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M]HK7SD'*SU1_3R?Q%:Y7K\_QX/?I>!EJQ5W$!69OU5@KOZ@KG[:_$FO8H?\
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MZF5D>W>["M9/#U:_/\US[Y;IJT,$4Q9CR7&;I^MC/%9(1[UUG\8U*S.PCUG
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M?US_ "'YKZLHO[-'[@OE+L:/_P R/<%]64/]E9[@O!^2NOEG1$7)M0JH&$1
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M@PN.!@86XQL;@';0<C@D+SC5-X,E-3U4#-X>_@!="@U94,J8:26F.7-!R?\
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M!^X;2KHY&'ZK@5YWJ9M=3VZ$4TTF=PS@K:TH^8U$3)ZMSI#SM)1=J>;L EW
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MQGKY+Z?%NIP>(FK(*2G;T8T%!!M%:89;&-$;,8QX+T",$, =U5(XF,^J,*]
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M2UO!\PHW%RX&LOU?'_&N^N!K+]7Q_P :*W;#_8Q[ETES;#_8V^Y=)$C4NO\
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M0)Z%!]@(.6V\MQP/\EFM]?)*\@]"5O>A0_8"OAI8X>6@*+%^">5>3QA6DDG
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MM(2"PG"Z7'*T:VA;4D\H.2W4L3GX,9ZKI45T94.QMVA:!T['OSWF%MT]J$>
M'GA!U<^(.0N7<;TRCSF,N72B;W;-I.5H5UL;4Y)*#FP:GBF)'=$%=*TW)M7&
MXXQ@^*Y\>GF EV[!6[0VL4[#ZZK,=,@'UEYOVYG.E!_$?R7HP :W&Y>;]N>/
MFF,']H_DL-QX]V C.H"?*9?5R^4OZ/OZ^/\ C+ZM6H@B(J"(B B(@*A *JB
MB(@(B(.?<;525TK7U,6]S>A6Q!3QPQAD;0&CHMA %=3%&@CQ08!X54\5%%R-
M24CZVWNC8>I76)Y/"M<.%8E<*RVU])1R1O.=P6I26:2"MJ)@>'L+0I.?JG 5
M&#+<D8*K'+S673M4UTS)LO<]Q(..BV[;I>I93S%[_6 ]3CHI\6-QDM!*JU@
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MP3?PG\E\,ZI_O15_XSOS7W-=?[!-_"?R7PUJDXU15_XSOS17UOV._P!S:/\
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M432U@W<K-:CTC341CL3&$'("C-PN57;Z:I:^7](7'8I/I&NEN-CBFD:T./&
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M@WD'IE5F5SK'?IG5D]*[>&YP,A9+-2RG5U46.P=F>5OVZR7!]>V6II@P Y)
M6S+:*ZGU%/5TT68WMQE%UJU=YJ;=:JR61Y<]CCC"XL.H*J6%D[>\R>>BE,VF
MW5='*)P0]QSCJN93VR[4KVP14;'0 X#B/#X(SK6EO5PJJ-IAD<R8G&XK.Z:X
M45ZM],9LQU R\#QX7:=9ZA\0S" [.< 86>JM$L]RHJA[<"$846(Y0T,S=45K
MFO&T'@9]JLOERJH[L(O7<W'4+MU5LK:>YOJ:2(N$I];.>BUKM0W456ZFI6O8
M1R2/_2-QV='R5,M--W\X>2?5 /123UA"=QR<*+Z*LLUN;-)4[@^1V[!/"E+_
M *CO<I6D8I_U\W_?B%*&J,4_Z^;_ +\0I.U$BJ\W[9?U!4_PKTA>;]LOZAJ?
MX5EI\<57ZXG_ (EZ%V3;?G.W</V5Y[5?KB?^)>A=DV#J=N?LKT3_ ,O)?_3Z
MUDJO1[6PL:<[!T"Y;+XX-P^*0X]B[)F;!;HRX C8.JTH*R&8.)8S \@%RQWU
MK178U/Z(1O'CR%<VOF <"';1[%D%VHH,M]7>/8%:R^4SW%HV?!,-:]7?'0QM
M C?GW+;IKG+-2%^'?!65]91B)A<6Y)\@MB"N@BI"\ ;/<$Q-:!ODC7;1&_/\
M*N=>9FMR6//_ /"MR*Z4+SQLS[@KY;C2@>L&X]P3%USF7>=WK[7X_A5QOKVR
M,8Z-_K''1;+;K2@\!FWW!5]*IJGUV!OJ<] F&M:X5\L;MT3'\^Q617:9E.YT
MC'G^2W?E>FV^N&_S 6O)=XILBG8QQ\L)AJL-UDDC#FL>![0JF_\ =@AT4A/L
M"ZM$WOH&F6-K21X!9XZ2$9]1I_D%FQKS7"H[S+4SM;M>UI/B%K=H!/S?JO\
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M JH0<(B"(A11$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%YMVV?W;J?\
M#7I*\V[:_P"[M3_AJ4>-?T=G9U9*W_M*^J&<,&5\L_T=F@:NF/\ VE?4K>2#
MX86,%^<CH@)'@ASSCHJ9<K)5Q4''@A>!U5,N6M5%V/5ZIE61M"0'HJ[ES&LJ
MBW+'+"&7+?Q(,)E,CL;CY)N/DN*67/<?T@5[67+[83*8ZY.?!![ER"VY#]L*
MK([F>>\"94QU]R#/5<AHKA( ]X*ZT>[N\NY*93%-YR1CA <'R5'N(;PF,A9R
MHN!&3RO-^W3^Z@_B/Y+T;:./8O.>W3^Z@_B/Y+4AKQ[^C]^OC_C+ZM7RE_1]
M_7Q_QE]6K<!$1 1$0$1$!$1 1$0$1$!$1 1$0%%[K8Q6:ACJ)&[HPW!!''52
MA$&A26NCIQ^C@:UWFMEE+"R0R-C >?%9D1,:E1;:2H=NFA:X^962"C@IVEL,
M8:#Y+.B&,#*.G9*9&Q-#SU*>B0;P_NQN\UG1#&C+::*60ODIVN<>I6:&BIX8
M^[CC#6>06PB&1H,L]"R7O&T[0_.<K)/;J6?'?0M=CS6VB:9&O345/3?U$09[
ME?+3Q2D&1@<1TRLJ(8P"C@#]PC:'>:/I(7RB1S 7C@%9T0R-!]GH'O+W4["X
M]2LKZ* TYB# &8X"VD/1#(\]N6GGQ7-L[@9&M]BV]-:=V5M1.\$1R<X4Q.R8
M%CVY_DLC&!C0UHP AD8XZ6&.+NV, 9Y+&:"F,3XS$-C_ *P\UM(AD:8M=&(A
M&(6[/)4I[514[]\-.UKO-;J(8  =$1$41$0$1$!<#6/ZOC_C7?7 UC^KV?QH
MC=L/]C:NDN;8?[&%TD(T[L":"7'V3^2^'=5$#5%4?*9WYK[DN;@VAFS]D_DO
MAG4P'SGK=WC,['Q17UKV.@_-&D=G@M''\@IVH)V.G_DZC ^R/R4Z/U3A!KU<
M;2PY&5RQ%'OXC'5=*LD+8URA*=^<'KY*QFNKL:8#ZJQ4D30YWJX]JR"7] >"
MK*67EP(*J+:F-I<#C<MF.,",?LK4JIBQWJ@K:BDWQC<"@QU,0.SC/*SQL '1
M8*F7:&AH/7R62%[SU45>(QRL#81W[CA9P]_*U1(\3.0;8C&U8YXQL(50]Q8K
M)GG9_)!?2L#6< +86M2NRP+946"(B*+!+T*SK7=P3NZ+-FHA>H'5(G<(MP'L
M673AJG,(F#NO&5WY_1'3$28W+)$(HWM#< +$E9J&UTUS@KY>[;(]F>  M>HJ
M;O/PV&5G\E/91$#G+,E7.<U@SN8NWA$'9+=&[062''L5UR?='01]TR0'/.%.
M&M:X9P%4-#N".BZ?0@,1NPBY;+GW*L%7=1N!@EX\<*?<9P ,*C&GG.%D1>R5
M%<Z?]-&_&/%2G<21D8X5K&['DX"O<X$Y(18K@*B>'"*-0550*JE%!U6Q'T6N
M.JSQ=%!>B(BB(B B(@85,#R540,)@(B"FT'J$VCR540Q3:%0L:3DA7(B8U:V
MBCJH2QX7#.F8R[;G]&3G"DR(8UJ&DCI(@R,8X6S@(B*UZVDCJZ=T4@RURX@T
MS$'$-?ZA_94C0Y\$&M;Z..AIVPP@!H\ELIA$# \DPB(*;1Y*H&.B(@+#4T[)
MV;7C(/4+,B##34T=/&&1MVM'0!9L#R1$,4#0/!-H\E5$%-H38/)51#%-H3 5
M404VCR5<!$0%1WU'>Y55'_4=[D$8I_U\W^?YA2=O11>G_7S?Y_F%*&E6I%2<
M+S?ME9FP5)W8]5>D+S7MDYL50/#:I%?'-3CY8G&?VEZ%V4C;J5A_[5Y[5L O
M$^T\[EW+1<JJVU FHW[)!QE=Y_'E]?5U]QP=U-;XFN(/J *L=-3L8 -H7RG%
MVI:@BC:T5AX&%1_:OJ/</^,*G"_+'U3);Z1[LEC<JT6ZD:<AC<KY:/:QJ//]
ML*J.U?4?XLIR?+'U.ZBI7-P]K2%5U+3NB,8P&KY7':MJ3\65<.U74>>:LJ<I
M\T?4<=OI&'HU974E(1R&KY7^E347A5E!VI:C_%E.$_9CZC] I,\!N%DBI*:,
M$-P,KY9^E+46/[64^E+40_\ RS\$Y/V8^IC149SD-5L=%21.W,:U?+GTIZB_
M%GX*OTI:B_%E3D_9E?5;96-X!&%D;,WS"^3_ *4M1_BC\%4=J6H_Q13A9^:/
MJ\RMQU"A_:/51LL-0W<"3&X+P =J>H_Q9^"YEYUW>[G"8YJ@N!&%N>$]?EV(
MC5Y$L@Q^T58> "KBV9SR9.251V/LG*ZR/'[]:M )YZ!:EP;NI78*W^K,86E7
MMVTC^5/==?PQ,NQ'B]L\?TH_)?9-"?T#5\;=AO-[&?O0OLFA&(&^Y>6_U]+S
M_&PGBB* B(@(B( \<J.7C3WI-09J=_=2./+@I&.4Y1$1HM*F"X-J9:@R/ QD
MK'+I)TD\KV5!8UY]8>:F/ 5..<>*)D1ZUZ?;0"0=YEKFEH6A3Z3=W4T;IB(W
MN+MJEY (P54'P"ID0L:/>V0?\2XQ@\-4DI*%M'1/B:<\%=)6[0<Y0QYC\@5=
M5=C-$Y\6'=0%*;;IUL,<IE=ODD&'./BI$R%L8.QH&5> <)J<H;+I"1\?=LJG
M,BW9V^"Z@L$+#"\<.C&,^:[Q!\%0M\"$TY<6CM#(ZQ]0."Y5DL[7W@5F>0W;
MA=K;M&!T56MP$TGE%X]-O94S/CE+6R')"UI]*S.G);4NV9Z*8D'P*J,^*C61
MS[7;64#-K"N@F.<HBB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("\W[:_[LU9\HEZ0HYK33IU#;9:42"/>W;DJ4?.O]'7+
MM52?PE?1>KKP++99*DG!:%$- ]F+M+W%U2)V.R,>J%,=7V'Y>L<M%N#7._:*
MF#R>7MF?&]S 6X''16?32_S9\%=+V'O?(YWI<7/L5OT&O_%Q_!=)(X7U[T';
M2_\ [/@JN[:'N'(9_P#54^@U_P"+C^"#L/>#_:XO@KD3KVJSMH(&#L_^JH>V
M7QRWX*]O8?YU,7P0]A__ /4Q?!,AU[6#MG=SC:?_ .%/IG=_V_\ U60=B/&/
M28O@GT(__P!3%\$R)OMC^F9W_9_]54=L^.I;GW+)]"/E4Q?!#V( C^TQ9]R9
M#?;">V3G(V'_ /A5WTU/Z>I\%0]ASO"KB'\D'8:X'FKB^"9#?:CNV>0\89\%
M=]-+@0#L^"JWL.>'$^EQ8]RM'88]^3Z9%GW*9&YJ7=GNO3J*IG82#M\A[D[<
M3NTF"?M'\E?H3LY.FIW2"=CL]=H4FUMITZCM(I&O:S!SDJ5N/G;^C]Q?C_C+
MZM7F&@NS(Z:K?2#-&_UMV %Z<03T*RVJB(J"(B B(@(B("(B B(@(B("(B!C
MA$1 1$0$1$!$1 1$0$1$!$1 1$0$.<<(B"@ SG"J/%$0 B(@(B("(B B(@(B
M("X&L?U>S^-=]1_6(S;V8^VB-ZP_V-JZ2YMB&*-ON720C6KXO2*21C><@KYO
MOW9+755ZEJ(X7%KI"[JOIGHB*B_9_9Y+/8X::48+0!@J3C.55$&*5H>TX )"
MT2R4._JQU73 PB# 0_N_J#*QTXDW$.8 %MHKJ8U:D/!]1@(6:($L]8 %9$4T
MQK5&YI:&L!R5G8W Y"N1#%N.JPMC/>NXX6PB&*;1C&%9+'EAPLB(N,4# U@6
M5$0$1$!:]4TNC<&]5L'HL3FGE6)4(N-%5NJG&/=Q[5J/ENV\-?'@#C.5/#$-
MV?%4-,UW5H*61,02<74M:YK2?YK- *^:4-EW#^:FWHS<8P,!4]%9NSM&588Q
MTH='%&TCG"S-)W.X5W=E-AR4M,6-.&DD)@9SGJKMAQC/"=VI*8H6\9"JT$#.
M%=L/FFTIJXL15V.38Y!0*J;'*NPX06^*SQ]%B$9RL[!@8051$441$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 0'/1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5'_4=[
ME54?]1WN01BG_7S?]^(4F"C%/S?F_P"_$*3]%47>"@_:;::JZ6:>*FCW.<%.
M!T0@$8(R%%?%DG9=?C<YI!2N(+L]5N?1K?0>*0_%?8)IXADA@5!3Q_9"Z3UC
MEZ\:^/CV:7_J:0X]ZO/9I?=N?1#\5]?^CL^R$]'9CZH5^1R^!\?P=FE]/)I#
M\5L#LUO8_P#Q#\5]<"G8!@-">CL^R%?D/@?)0[-[W^$/Q51V;7H]:4_%?6GH
M[/LA5$$?V0I\A\#Y,'9K>!_^,?BKOHWO'X8_%?67<1_8"=Q']@)\D7]>/DWZ
M-KQ^&/Q51V;7C\,?BOK'N(_L!.XC^R$^0_7CY/'9M>!_^,?BJCLWO'X8_%?5
M_<Q_9"&"/[(3Y#]>/E'Z.+Q^%_S51V<7G\+_ )KZJ]';]E5$#/(*_(S/\[Y5
M'9Q>/&E/Q63Z-KOLW"F_S7U/W#/$!5[EF,8"?(U\#Y8C[-[N]N[T;_-5'9M=
M >:;_-?4H@8!@ 85#3L^R$^5G]9\HS]FUX+W!E+G^:Y5=V97Z1CF^B''O7V
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M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(!4?UAZMN9_&I
MN)JJ%T]"QH!SN1&U8CFC;[ET5H6>%T-,T.'@M]""(B*(B("(B B(@(B("(B
MB(@(B("(B B(@*BJJ)$,!51$41$0$1$#"(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("MD_JW>Y
M7*CQEA \D$5I3_S P?[ZA2@J/0TKF7MKR#_O"D("L2KF]%54&?%546"!$0$1
M% 1$0$1%01$0$1$!$1 1$4!$1 1$3 PB(J"(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(
M@(B("(B B(@*V2-LC</&0KD0 ,# Z(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(+3&POW8];S5R(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B$X" BIN"J@(F0F4!%3</-50$1$!$1 1$0$3(\T0$14W#S051$)P,
ME 16[PJ@@H*HB("(B B(@(B$X" B!$!$1 1 B B("#XH"("B B$@=53</-!5
M$!!Z*F1YH*H@.40$14W#S051 <]$0$1$!$3(\T!$R/-,CS0$1$!$3(0$3(\T
MR/- 1$0$1$!$1 1$0$1,\90$5&G(520$!$R/-,CS0$3(1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!4<,A51!@_:PLZH6C*J@L>?)4&5>&C.55$8.<H_<!PL^!Y)A
M!;&21RL<N_/ X69$5B#B&\JXN5Q (52 40SQE8Y,F/CJLB8X16N-V5>,K+@>
M28"(QC*QX<"MA" @MCSCE5>,M*J!A$5A PJ@K+@>2IM"(H7<>U69*R!H"KA!
MBR4&5EPB*Q<JN2LF F$&,$H25D1!B!.%3<<K-@*FT>2(Q;CE5).%EP/),!!;
M'T.5<B(JCLXX6(!W*S(@UV[EE#CA7X'DF!Y(-=VXNX5Y:["RX"(F,+00J$.R
MLZ806L52/)5 QT1%8G JA!PLR81&%N5E:#CE5PB*M.<<+'ERS)@>2(P@N5V"
MLF B*Q$'"LY6QA,#R1&#<[R3+EGP/),!!@#G+,T<<JN!Y(BK"!RK5EPF!Y(C
M$<@*L1)SE9$ QT11/!$06G*H,J]$&,Y5A<Y9TP/)$803XJ\YV!7X'DB*Q-RK
M79RLX "H6A$8P#C*<K*F BK&@JV3<'<=%E3"(Q-)5[795V!Y)A%$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
:0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035694544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALLURION TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001964979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">3841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">92-2182207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Huron Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Natick<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">647-4000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Shantanu Gaur<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Huron Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Natick<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">647-4000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029325232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,654<span></span>
</td>
<td class="nump">$ 38,037<span></span>
</td>
<td class="nump">$ 7,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance of doubtful accounts</a></td>
<td class="nump">9,935<span></span>
</td>
<td class="nump">18,194<span></span>
</td>
<td class="nump">29,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">4,568<span></span>
</td>
<td class="nump">6,171<span></span>
</td>
<td class="nump">3,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">2,414<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">44,829<span></span>
</td>
<td class="nump">64,816<span></span>
</td>
<td class="nump">43,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,080<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">50,699<span></span>
</td>
<td class="nump">71,712<span></span>
</td>
<td class="nump">51,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,393<span></span>
</td>
<td class="nump">10,379<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,643<span></span>
</td>
<td class="nump">53,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="nump">905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,973<span></span>
</td>
<td class="nump">15,495<span></span>
</td>
<td class="nump">15,793<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,244<span></span>
</td>
<td class="nump">65,425<span></span>
</td>
<td class="nump">75,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">7,381<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingLiabilityNoncurrent', window );">Revenue Interest Financing liability</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out liabilities</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">23,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">36,090<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">1,578<span></span>
</td>
<td class="nump">2,306<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">9,867<span></span>
</td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">114,510<span></span>
</td>
<td class="nump">142,199<span></span>
</td>
<td class="nump">83,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Redeemable Convertible Preferred Stock (Note 12):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A redeemable convertible preferred stock, $0.0001 par value - 100,000,000 shares authorized as of September 30, 2024; and 2,260,159 and zero shares issued and outstanding as of September 30, 2024 and December 31, 2023</a></td>
<td class="nump">979<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value - 100,000,000 shares authorized as of June 30, 2024; and no shares issued and outstanding as of June 30, 2024 and December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">150,692<span></span>
</td>
<td class="nump">143,007<span></span>
</td>
<td class="nump">99,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">2,890<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(218,379)<span></span>
</td>
<td class="num">(212,799)<span></span>
</td>
<td class="num">(132,192)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(64,790)<span></span>
</td>
<td class="num">(70,487)<span></span>
</td>
<td class="num">(32,314)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock, and stockholders' deficit</a></td>
<td class="nump">$ 50,699<span></span>
</td>
<td class="nump">71,712<span></span>
</td>
<td class="nump">$ 51,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033830032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance of doubtful accounts</a></td>
<td class="nump">$ 8,243<span></span>
</td>
<td class="nump">$ 12,671<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Series A redeemable convertible preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Series A redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Series A redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Series A redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">64,369,381<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">64,369,381<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034827056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,367<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">$ 26,519<span></span>
</td>
<td class="nump">$ 45,232<span></span>
</td>
<td class="nump">$ 53,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 64,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="nump">4,232<span></span>
</td>
<td class="nump">7,549<span></span>
</td>
<td class="nump">10,165<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,485<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,111<span></span>
</td>
<td class="nump">13,968<span></span>
</td>
<td class="nump">18,970<span></span>
</td>
<td class="nump">35,067<span></span>
</td>
<td class="nump">41,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">5,197<span></span>
</td>
<td class="nump">13,989<span></span>
</td>
<td class="nump">18,060<span></span>
</td>
<td class="nump">36,127<span></span>
</td>
<td class="nump">46,857<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,405<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,212<span></span>
</td>
<td class="nump">7,191<span></span>
</td>
<td class="nump">13,247<span></span>
</td>
<td class="nump">21,623<span></span>
</td>
<td class="nump">27,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,043<span></span>
</td>
<td class="nump">18,942<span></span>
</td>
<td class="nump">20,746<span></span>
</td>
<td class="nump">30,657<span></span>
</td>
<td class="nump">46,024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses:</a></td>
<td class="nump">15,452<span></span>
</td>
<td class="nump">40,122<span></span>
</td>
<td class="nump">52,053<span></span>
</td>
<td class="nump">88,407<span></span>
</td>
<td class="nump">120,575<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">82,736<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,341)<span></span>
</td>
<td class="num">(26,154)<span></span>
</td>
<td class="num">(33,083)<span></span>
</td>
<td class="num">(53,340)<span></span>
</td>
<td class="num">(79,078)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(32,010)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,586)<span></span>
</td>
<td class="num">(2,264)<span></span>
</td>
<td class="num">(7,331)<span></span>
</td>
<td class="num">(10,566)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,426)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrants</a></td>
<td class="nump">9,703<span></span>
</td>
<td class="nump">3,868<span></span>
</td>
<td class="nump">14,210<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(821)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfDebt', window );">Changes in fair value of debt</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="num">(6,008)<span></span>
</td>
<td class="nump">10,020<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption', window );">Changes in fair value of Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="num">(11,104)<span></span>
</td>
<td class="num">(2,040)<span></span>
</td>
<td class="num">(9,608)<span></span>
</td>
<td class="num">(2,040)<span></span>
</td>
<td class="num">(2,192)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAdjustmentOfEarnOutLiabilities', window );">Change in fair value of earn-out liabilities</a></td>
<td class="nump">2,260<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="nump">22,140<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="nump">29,050<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,929)<span></span>
</td>
<td class="num">(8,713)<span></span>
</td>
<td class="num">(3,929)<span></span>
</td>
<td class="num">(3,929)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Termination of convertible note side letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,598)<span></span>
</td>
<td class="num">(17,598)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="num">(643)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(344)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense):</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">4,558<span></span>
</td>
<td class="nump">27,713<span></span>
</td>
<td class="num">(7,997)<span></span>
</td>
<td class="num">(1,265)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(5,591)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(8,935)<span></span>
</td>
<td class="num">(21,596)<span></span>
</td>
<td class="num">(5,370)<span></span>
</td>
<td class="num">(61,337)<span></span>
</td>
<td class="num">(80,343)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(143)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,004)<span></span>
</td>
<td class="num">(21,630)<span></span>
</td>
<td class="num">(5,580)<span></span>
</td>
<td class="num">(61,427)<span></span>
</td>
<td class="num">(80,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(37,744)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Cumulative undeclared preferred dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,907)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (9,004)<span></span>
</td>
<td class="num">$ (21,885)<span></span>
</td>
<td class="num">$ (5,580)<span></span>
</td>
<td class="num">$ (63,124)<span></span>
</td>
<td class="num">$ (82,304)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (40,651)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.51)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.51)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - Basic</a></td>
<td class="nump">64,086,265<span></span>
</td>
<td class="nump">40,335,457<span></span>
</td>
<td class="nump">53,310,214<span></span>
</td>
<td class="nump">31,558,538<span></span>
</td>
<td class="nump">35,581,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,918,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted</a></td>
<td class="nump">64,086,265<span></span>
</td>
<td class="nump">40,335,457<span></span>
</td>
<td class="nump">53,310,214<span></span>
</td>
<td class="nump">31,558,538<span></span>
</td>
<td class="nump">35,581,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,918,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangesInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangesInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of revenue interest financing and PIPE conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueAdjustmentOfEarnOutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of earn-out liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueAdjustmentOfEarnOutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033093984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,004)<span></span>
</td>
<td class="num">$ (21,630)<span></span>
</td>
<td class="num">$ (5,580)<span></span>
</td>
<td class="num">$ (61,427)<span></span>
</td>
<td class="num">$ (80,607)<span></span>
</td>
<td class="num">$ (37,744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value due to change in credit risk</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">$ (21,630)<span></span>
</td>
<td class="num">(1,990)<span></span>
</td>
<td class="num">$ (61,427)<span></span>
</td>
<td class="num">$ (81,307)<span></span>
</td>
<td class="num">$ (37,744)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingDueMember', window );">Revenue Interest Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value due to change in credit risk</a></td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value due to change in credit risk</a></td>
<td class="nump">$ 3,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954031289072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Redeemable Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Series A-1 Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series A-1 Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Series B Convertible Preferred Stock</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 4,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (94,448)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,807,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,611<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for the exercise of Public Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,744)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,744)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="num">(32,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,801)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="num">(49,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,993)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,098,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="num">(32,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,427)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2023</a></td>
<td class="num">(52,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,619)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,460,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="num">(32,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">8,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">8,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Reverse recapitalization, net of transaction costs</a></td>
<td class="nump">58,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Reverse recapitalization, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,735,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger', window );">Recognition of warrant liabilities in connection with the Merger</a></td>
<td class="num">(13,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with vesting of RSU awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes', window );">Issuance of common stock for the conversion of convertible notes</a></td>
<td class="nump">25,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes', window );">Issuance of common stock for the conversion of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities', window );">Recognition of earn-out liabilities (Note 3)</a></td>
<td class="num">(53,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification</a></td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability', window );">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares</a></td>
<td class="nump">16,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability', window );">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount', window );">Issuance of common stock for the exercise of Public Warrants</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for the exercise of Public Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount', window );">Issuance of common stock for commitment shares for equity line financing</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares', window );">Issuance of common stock for commitment shares for equity line financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,607)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="num">$ (70,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="num">(212,799)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2023</a></td>
<td class="num">$ (49,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,993)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,098,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,996)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2023</a></td>
<td class="num">(71,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,989)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,126,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Reverse recapitalization, net of transaction costs</a></td>
<td class="nump">58,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Reverse recapitalization, net of transaction costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,735,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger', window );">Recognition of warrant liabilities in connection with the Merger</a></td>
<td class="num">(13,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with vesting of RSU awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes', window );">Issuance of common stock for the conversion of convertible notes</a></td>
<td class="nump">25,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes', window );">Issuance of common stock for the conversion of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities', window );">Recognition of earn-out liabilities (Note 3)</a></td>
<td class="num">(53,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification</a></td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability', window );">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares</a></td>
<td class="nump">16,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability', window );">Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount', window );">Issuance of common stock for the exercise of Public Warrants</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for the exercise of Public Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,630)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2023</a></td>
<td class="num">(52,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,619)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,460,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance, temporary stocks</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="num">(70,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="num">(212,799)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock isssued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with vesting of RSU awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for the exercise of Public Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">5,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,586<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2024</a></td>
<td class="num">(66,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
<td class="num">(207,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="num">(70,487)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="num">(212,799)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2024</a></td>
<td class="num">$ (64,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,890<span></span>
</td>
<td class="num">(218,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Mar. 31, 2024</a></td>
<td class="num">$ (66,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
<td class="num">(207,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,898,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with vesting of RSU awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount', window );">Issuance of common stock for the exercise of Public Warrants</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares', window );">Issuance of common stock for the exercise of Public Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(3,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,162)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2024</a></td>
<td class="num">(70,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,980)<span></span>
</td>
<td class="num">(209,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,972,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="nump">5,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock isssued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,333,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock in connection with vesting of RSU awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">8,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,004)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2024</a></td>
<td class="num">$ (64,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,890<span></span>
</td>
<td class="num">$ (218,379)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock in connection with Private Placement, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance, temporary stocks</a></td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, recognition of earn-out liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital, warrant liabilities in connection merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for commitment shares for equity line financing amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for commitment shares for equity line financing shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for exercise of warrants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfCommonStockForExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for exercise of warrants shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfCommonStockForExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares common stock for conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares value common stock for conversion of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares derecognition of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_StockIssuedDuringPeriodValueDerecognitionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value derecognition of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_StockIssuedDuringPeriodValueDerecognitionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954031254976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,580)<span></span>
</td>
<td class="num">$ (61,427)<span></span>
</td>
<td class="num">$ (80,607)<span></span>
</td>
<td class="num">$ (37,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">824<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">6,349<span></span>
</td>
<td class="nump">8,357<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
<td class="nump">12,675<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized exchange (gain) or loss</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory</a></td>
<td class="nump">1,052<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(14,210)<span></span>
</td>
<td class="num">(2,189)<span></span>
</td>
<td class="num">(8,364)<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(1,895)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption', window );">Change in fair value of Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="nump">9,608<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">2,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAdjustmentOfEarnOutLiabilities', window );">Change in fair value of earn-out liabilities</a></td>
<td class="num">(22,140)<span></span>
</td>
<td class="num">(24,330)<span></span>
</td>
<td class="num">(29,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_InterestPaidOnDebtRecordedAtFairValue', window );">Interest paid on debt recorded at fair value</a></td>
<td class="num">(2,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAdjustmentOfDebt', window );">Change in fair value of debt</a></td>
<td class="num">(10,020)<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs associated with debt recorded at fair value</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="nump">1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NonCashTerminationOfConvertibleNoteSideLetters', window );">Non-cash termination of convertible note side letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,098<span></span>
</td>
<td class="nump">16,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt/ term loan</a></td>
<td class="nump">8,713<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants', window );">Issuance costs associated with warrants recorded at fair value</a></td>
<td class="nump">942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NonCashIssuanceOfCommonStockForCommitmentShares', window );">Non-cash issuance of common stock for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">7,199<span></span>
</td>
<td class="num">(3,883)<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(22,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">551<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
<td class="num">(1,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current and long-term assets</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(789)<span></span>
</td>
<td class="num">(733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(578)<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
<td class="nump">4,664<span></span>
</td>
<td class="nump">3,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(7,777)<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">8,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,026)<span></span>
</td>
<td class="num">(43,111)<span></span>
</td>
<td class="num">(63,982)<span></span>
</td>
<td class="num">(46,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(1,606)<span></span>
</td>
<td class="num">(1,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(611)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(1,606)<span></span>
</td>
<td class="num">(1,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from Fortress Term Loan&#8212;net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,780<span></span>
</td>
<td class="nump">59,780<span></span>
</td>
<td class="nump">29,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts', window );">Proceeds from Business Combination, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,078<span></span>
</td>
<td class="nump">61,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromOptionAndWarrantExercises', window );">Proceeds from option and warrant exercises</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromEquityLineFinancing', window );">Proceeds from equity line financing</a></td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,750)<span></span>
</td>
<td class="num">(10,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Private Placement, net of issuance costs</a></td>
<td class="nump">2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Public Offering, net of issuance costs</a></td>
<td class="nump">18,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(1,357)<span></span>
</td>
<td class="num">(3,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of promissory note assumed in Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PaymentOfDeferredFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,261<span></span>
</td>
<td class="nump">116,394<span></span>
</td>
<td class="nump">95,986<span></span>
</td>
<td class="nump">30,537<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(9,376)<span></span>
</td>
<td class="nump">72,075<span></span>
</td>
<td class="nump">30,398<span></span>
</td>
<td class="num">(17,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">38,421<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
<td class="nump">26,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">29,045<span></span>
</td>
<td class="nump">80,098<span></span>
</td>
<td class="nump">38,421<span></span>
</td>
<td class="nump">8,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">5,022<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow information on non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IssuanceOfWarrantsInConnectionWithFinancing', window );">Issuance of warrants in connection with financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred financing costs in accounts payable and accrued expenses</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">$ 1,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RecognitionOfAssumedWarrantLiability', window );">Recognition of assumed warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,762<span></span>
</td>
<td class="nump">13,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RecognitionOfEarnOutLiabilities', window );">Recognition of earn-out liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,040<span></span>
</td>
<td class="nump">53,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of common stock upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,569<span></span>
</td>
<td class="nump">25,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci', window );">Change in fair value of Revenue Interest Financing through other comprehensive income</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci', window );">Change in fair value of RTW Convertible Notes through other comprehensive income</a></td>
<td class="nump">2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,659)<span></span>
</td>
<td class="num">(57,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of Term Loan</a></td>
<td class="num">$ (47,720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AmortizationOfIssuanceCostsAssociatedWithWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of issuance costs associated with warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AmortizationOfIssuanceCostsAssociatedWithWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of revenue interest financing through OCI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of rtw convertible notes through oci.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of revenue interest financing and PIPE conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueAdjustmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueAdjustmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueAdjustmentOfEarnOutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment of earn-out liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueAdjustmentOfEarnOutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_InterestPaidOnDebtRecordedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid on debt recorded at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_InterestPaidOnDebtRecordedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IssuanceOfWarrantsInConnectionWithFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants in connection with financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IssuanceOfWarrantsInConnectionWithFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NonCashIssuanceOfCommonStockForCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash issuance of common stock for commitment shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NonCashIssuanceOfCommonStockForCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NonCashTerminationOfConvertibleNoteSideLetters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash termination of convertible note side letters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NonCashTerminationOfConvertibleNoteSideLetters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PaymentOfDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PaymentOfDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromBusinessCombinationNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromBusinessCombinationNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromEquityLineFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from equity line financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromEquityLineFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromOptionAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from option and warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromOptionAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromRevenueInterestFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromRevenueInterestFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RecognitionOfAssumedWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of assumed warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RecognitionOfAssumedWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RecognitionOfEarnOutLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of earn-out liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RecognitionOfEarnOutLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=alur_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=alur_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033877776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,654<span></span>
</td>
<td class="nump">$ 38,037<span></span>
</td>
<td class="nump">$ 7,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in other long-term assets</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 29,045<span></span>
</td>
<td class="nump">$ 38,421<span></span>
</td>
<td class="nump">$ 8,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033771264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td id="fin915839_13" style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Organization and Basis of Presentation </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Organization </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Technologies, Inc. (&#8220;Allurion&#8221; or the &#8220;Company&#8221;) is a vertically integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#8482;</div> Balloon. The Allurion Balloon is the world&#8217;s first and only swallowable, procedureless<div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px">&#8482;</div> intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement. Allurion sells the Allurion Balloon and connected scale through distributors or directly to health care providers. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also offers tiered access to artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#8220;VCS&#8221;) and, collectively with the Allurion Balloon, referred to as the &#8220;Allurion Program&#8221;. The base tier of the VCS is free of charge to those purchasing the Allurion Balloon, as well as customers looking for a weight-loss management platform for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. More full-scale versions of the VCS are available to health care providers on an upgrade basis. Allurion currently markets the Allurion Program in over 50 countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia and Mexico. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Business Combination Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#8220;Legacy Allurion&#8221;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#8220;Business Combination Agreement&#8221;) with Compute Health Acquisition Corp. (&#8220;CPUH&#8221; or &#8220;Compute Health&#8221;), Compute Health Corp. (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#8220;Closing Date&#8221;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#8220;CPUH Merger&#8221;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#8220;CPUH Merger Effective Time&#8221;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#8220;Intermediate Merger&#8221; and the time at which the Intermediate Merger became effective, the &#8220;Intermediate Merger Effective Time&#8221;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#8220;Final Merger&#8221; and, collectively with the CPUH Merger and the Intermediate Merger, the &#8220;Mergers&#8221;, and together with all other transactions contemplated by the Business Combination Agreement, the &#8220;Business Combination&#8221;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#8220;Final Merger Effective Time&#8221;). Shares of Allurion&#8217;s Common Stock (defined below) began trading on the New York Stock Exchange (&#8220;NYSE&#8221;) under the ticker symbol &#8220;ALUR&#8221; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#8217;s business operations continued as our business operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Under this method of accounting, Compute Health was treated as the &#8220;acquired&#8221; company for financial reporting purposes and Legacy Allurion was the accounting &#8220;acquirer&#8221;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#8217;s common stock, $0.0001 par value per share (&#8220;Common Stock,&#8221; &#8220;Allurion Common Stock&#8221; or the &#8220;Company&#8217;s Common Stock&#8221;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#8217;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the &#8220;Exchange Ratio&#8221;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the condensed consolidated financial statements have changed. Refer to Note&#160;3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div> for further discussion regarding the closing of the Business Combination with <div style="display:inline;">Compute </div>Health. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references in this prospectus to the &#8220;Company&#8221;, &#8220;our&#8221;, and &#8220;Allurion&#8221; refer to the condensed consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#8220;Legacy Allurion&#8221; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Basis of Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). They should be read in conjunction with our audited financial statements as of and for the year ended December&#160;31, 2023 included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K,</div> as amended (&#8220;Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K&#8221;).</div> The financial statements as of September&#160;30, 2024 and for the three and nine months ended September&#160;30, 2024 and 2023 presented in this report are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. A gain from remeasurement of less than $0.1&#160;million and a loss from remeasurement of s$0.3&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, and a gain from remeasurement of $0.4&#160;million and loss from remeasurement of $0.3&#160;million for the three months ended September&#160;30, 2024 and 2023, respectively, are recorded in the statements of operations within Other income, net. The Company translates the foreign functional currency financial statements to U.S. dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments were immaterial for the three and nine months ended September&#160;30, 2024 and 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Going Concern </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the interim condensed consolidated financial statements are issued. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred recurring losses since inception, anticipates net losses and negative operating cash flows for the near future, and may be unable to remain in compliance with certain financial covenants required under its credit facilities. Through September&#160;30, 2024, the Company has funded its operations primarily with proceeds from the sale of its Common Stock, convertible preferred stock, issuance of convertible notes, issuance of term loans, and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including losses from operations of $33.1&#160;million and $53.3&#160;million and cash outflows from operating activities of $29.0&#160;million and $43.1&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively. As of September&#160;30, 2024, the Company had an accumulated deficit of $218.4&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and the potential of being unable to remain in compliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="font-weight:bold;display:inline;">1.</div></td>
<td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Organization and Basis of Presentation </div></td></tr></table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Allurion Technologies, Inc. (&#8220;Allurion&#8221; or the &#8220;Company&#8221;) is a <div style="letter-spacing: 0px; top: 0px;display:inline;">vertically </div>integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion Balloon. The Allurion Balloon is the world&#8217;s first and only swallowable, procedure-less intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement or removal. Allurion sells the Allurion Balloon and related hardware accessories through distributors or directly to health care providers. The Company currently also provides, free of charge, artificial intelligence (&#8220;AI&#8221;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#8220;VCS&#8221;) and, collectively with the Allurion Balloon referred to as the &#8220;Allurion Program&#8221;. Allurion currently markets the Allurion Program in over 50 countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, Hong Kong, the United Kingdom, Italy, Spain, Australia and Mexico. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#8220;Legacy Allurion&#8221;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.), entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#8220;Business Combination Agreement&#8221;) with Compute Health Acquisition Corp. (&#8220;CPUH&#8221; or &#8220;Compute Health&#8221;), Compute Health Corp. (&#8220;Merger Sub I&#8221;) and Compute Health LLC (&#8220;Merger Sub II&#8221; and, together with Merger Sub I, the &#8220;Merger Subs&#8221;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#8220;Closing Date&#8221;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#8220;CPUH Merger&#8221;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#8220;CPUH Merger Effective Time&#8221;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#8220;Intermediate Merger&#8221; and the time at which the Intermediate Merger became effective, the &#8220;Intermediate Merger Effective Time&#8221;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#8220;Final Merger&#8221; and, collectively with the CPUH Merger and the Intermediate Merger, the &#8220;Mergers&#8221;, and together with all other transactions contemplated by the Business Combination Agreement, the &#8220;Business Combination&#8221;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#8220;Final Merger Effective Time&#8221;). Allurion shares began trading on the New York Stock Exchange (&#8220;NYSE&#8221;) under the ticker symbol &#8220;ALUR&#8221; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#8217;s business operations continued as our business operations. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America. Under this method of accounting, Compute Health was treated as the &#8220;acquired&#8221; company for financial reporting purposes and Legacy Allurion was the accounting &#8220;acquirer&#8221;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of </div>  <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#8217;s common stock, $0.0001 par value per share (&#8220;Allurion Common Stock&#8221; or the &#8220;Company&#8217;s Common Stock&#8221;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#8217;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the &#8220;Exchange Ratio&#8221;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the consolidated financial statements have changed. Refer to Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for further discussion regarding the closing of the Business Combination with Compute Health. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, references to the &#8220;Company&#8221;, &#8220;our&#8221;, and &#8220;Allurion&#8221; refer to the consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#8220;Legacy Allurion&#8221; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;) and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;), and Accounting Standards Update (&#8220;ASU&#8221;), of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company&#8217;s equity structure has been restated in prior periods to reflect the number of shares of the Allurion Common Stock, $0.0001 par value per share, issued to Legacy Allurion stockholders. As such, the shares and corresponding capital amounts presented in the consolidated balance sheet and consolidated statement of redeemable convertible preferred stock and stockholders&#8217; deficit have been retroactively restated as shares reflecting the Exchange Ratio established in the Business Combination. All then-existing Legacy Allurion redeemable convertible preferred stock and Legacy Allurion convertible preferred stock were converted into shares of Allurion Common Stock at the closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include Allurion; and its consolidated subsidiaries, Allurion France SAS, and Allurion Middle East, LLC, which were both incorporated in 2017; Allurion Hong Kong Ltd., which was incorporated in 2019; Allurion UK Ltd., which was incorporated in 2021; Allurion Italy, Srl, Allurion Spain, Srl, Allurion Australia Pty Ltd. and Allurion Mexico S. de R.L de C.V, which were incorporated in 2022; and Allurion Technologies, LLC, which was incorporated in 2023. The Company&#8217;s operations are located in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region, and it operates in one business segment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. Gains (losses) from remeasurement of $0.1&#160;million and $(0.7) million for the years ended December&#160;31, 2023 and 2022, respectively, are recorded in the statements of operations and comprehensive loss within other expense, net. The Company translates the foreign functional currency financial <div style="letter-spacing: 0px; top: 0px;display:inline;">statements </div>to U.S.&#160;dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">equity transactions. The effects of foreign currency translation adjustments were immaterial for the years ended December&#160;31, 2023 and 2022. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Going Concern </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred recurring losses since inception and anticipates net losses and negative operating cash flows for the near future and may be unable to remain in compliance with certain financial covenants required under the Fortress Term Loan. Through December&#160;31, 2023, the Company has funded its operations primarily with proceeds from the sale of its convertible preferred stock, issuance of convertible notes, issuance of term loans and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including net losses of $80.6&#160;million and $37.7&#160;million and cash outflows from operating activities of $64.0&#160;million and $47.0&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. As of <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023, the Company had an accumulated deficit of $212.8&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the Company&#8217;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations and debt service payments, and the potential of being unable to remain in compliance with certain financial covenants under the Fortress Term Loan, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Due to the substantial doubt about the Company&#8217;s ability to continue operating as a going concern for twelve months from the issuance date of these financial statements and the liquidity and revenue covenant clauses within the Fortress Term Loan, the amounts due as of December&#160;31, 2023, have been classified as current liabilities in the consolidated financial statements. The lender under the Fortress Term Loan has not invoked the material adverse change clause and the Company has met the liquidity covenant as of the date of issuance of these financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035462384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of Significant Accounting Policies </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no significant changes, except as described below, to the significant accounting policies disclosed in Note 2 of the &#8220;Notes to Consolidated Financial Statements&#8221; to the consolidated audited financial statements as of and for the year ended December&#160;31, 2023 included in our Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-K.</div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the RTW Convertible Notes (defined below) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The RTW Convertible Notes accounted for under the FVO election was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the RTW Convertible Notes were recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the RTW Convertible Notes were expensed as incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Reclassification of Prior Year Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustment has been made to the condensed consolidated balance sheet as of December&#160;31, 2023, to present the Legacy Allurion common stock warrant liabilities as part of the Warrant liabilities line item. These amounts were part of the Other liabilities line item in prior years. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Mezzanine Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mezzanine equity represents the Series A Preferred Stock (defined below) issued by the Company. The shares of Series A Preferred Stock are redeemable at a determinable price on a fixed date, which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. Refer to Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock and Stockholder&#8217;s Deficit,</div></div> for additional information regarding the Series A Preferred Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue for the three and nine months ended September&#160;30, 2024 and 2023 or accounts receivable, net balance as of September&#160;30, 2024 and December&#160;31, 2023. The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity, </div></div>which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> effective January 1, 2024 under the modified retrospective method of transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> did not have an impact on the Company&#8217;s condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Summary of Significant Accounting Policies </div></div></td></tr></table>  <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reclassification of Prior Year Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consolidated statement of <div style="letter-spacing: 0px; top: 0px;display:inline;">operations </div>and comprehensive loss for the year ended December&#160;31, 2022 to present the change in fair value of derivative liabilities as part of Other income (expense), net, and to present the change in fair value of warrants as its own line item. The change in fair value of derivative liabilities was a separate line item in prior years and the change in fair value of warrants was part of Other income (expense), net in prior years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue for the years ended December&#160;31, 2023 and 2022 or accounts receivable, net balance as of December&#160;31, 2023 and 2022. The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts&#160;Receivable</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer C</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2022, the Company adopted ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset and a current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> lease liability as applicable, in the consolidated balance sheets if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having an original term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will either renew or not cancel the lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#8217;s incremental borrowing rate. The </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#8217;s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of the lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Non</div>-lease</div> components include costs that do not provide a right to use a leased asset but instead provide a service, such as maintenance costs. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash consists of amounts held in bank savings and checking accounts. Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds. The Company&#8217;s restricted cash consists of cash that the Company is contractually obligated to maintain and deposits of cash collateral held in accordance with the terms of various corporate credit cards. Restricted cash is included within other long-term assets on the consolidated balance sheets. A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in <div style="-sec-ix-hidden:hidden127681918;display:inline;"><div style="-sec-ix-hidden:hidden127681919;display:inline;">other long-term assets</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in a single operating and reportable segment. Operating segments are defined as components of an enterprise for which discrete financial information is available and is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) in order to make decisions regarding resource allocation and performance assessment. The Company has determined that its CODM is its Chief Executive Officer. The Company&#8217;s CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since the Company operates as one operating segment, all required financial segment information can be found in the consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s products include the Allurion Balloon and related accessories. See Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue </div></div>below<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for financial information about sales in geographic areas. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying value of the Company&#8217;s financial instruments such as cash and cash equivalents, accounts payable, and accrued expenses approximate their fair values due to their short-term maturity. The carrying value of the Company&#8217;s term loan approximates its fair value as the interest rate and other terms are that which are currently available to the Company. The Company&#8217;s </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">assets and liabilities recorded at fair value have been categorized based upon a fair value hierarchy, which is distinguished between observable and unobservable inputs in accordance with authoritative accounting guidance: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that the observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, which include the costs of material, labor, and overhead, are stated at the lower of cost or net realizable value, with cost generally computed using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> first out method. Estimated losses from obsolete and slow-moving inventories are recorded to reduce inventory values to their estimated net realizable value and are charged to cost of sales. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in a recovery in carrying value. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include computers, laboratory equipment, machinery, and leasehold improvements. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated on a straight-line basis over the shorter of the estimated life or the lease term. Expenditures for repairs and maintenance are expensed as incurred. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Internal-Use</div> Software </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Software development costs consist of certain consulting costs and compensation expenses for employees who devote time to the development projects of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software, as well as certain upgrades and enhancements that are expected to result in enhanced functionality. The Company amortizes these development costs over the estimated useful life, which is determined based on our best estimate of the useful life of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software after considering factors such as continuous developments in the technology, obsolescence, and anticipated life of the service offering before significant upgrades. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined the amount of internal software costs to be capitalized based on the amount of time spent by our developers on projects in the application stage of development. There is judgment in estimating the time allocated to a particular project in the application stage. A significant change in the time spent on each project could have a material impact on the amount capitalized and related amortization expense in subsequent periods. As of December&#160;31, 2023 and 2022, capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software was immaterial. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt Issuance Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company defers costs directly associated with acquiring third-party financing. Fees incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. Fees incurred in connection with a modification are deferred and amortized as a component of interest expense over the remaining life of the loan if due to the creditor. Third-party fees incurred in connection with a <div style="letter-spacing: 0px; top: 0px;display:inline;">modification </div>are expensed as incurred. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the Business Combination. The Company deferred offering costs classified as a long-term asset until the closing or termination of the transaction. At the closing of the Business Combination, these costs were recorded in stockholders&#8217; deficit as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. Deferred offering costs are included in other long-term assets. As of December&#160;31, 2023 and 2022, there were zero and $2.3&#160;million of deferred offering costs recorded within other long-term assets on the consolidated balance sheet, respectively. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity </div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;ASC&#160;480-10&#8221;),</div> then in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock </div></div>(&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40&#8221;).</div> Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or are warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;480-10,</div> the Company assesses the requirements under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40</div> or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its convertible instruments and other contracts, including warrants, to determine if those contracts or embedded components of those contracts are required to be accounted for as derivatives, either in whole or in part. If an embedded derivative is bifurcated from a debt host contract, changes in the fair value of the bifurcated derivative are recorded in the accompanying consolidated statements of operations. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the convertible notes issued between February 2023 and August 2023 (the &#8220;2023 Convertible Notes&#8221;) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The convertible notes accounted for under the FVO election were each debt host financial instruments containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the convertible notes were </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded as a component of Other (expense) income in the consolidated statements of operations. As a result of electing the FVO, direct costs and fees related to the 2023 Convertible Notes were expensed as incurred. The convertible notes issued in 2020, 2021 and 2022 are accounted for as disclosed in Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>. In connection with the closing of the Business Combination on August&#160;1, 2023, a portion of the 2023 convertible notes was repaid, with the remaining balance converted to shares of our Common Stock. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain holders of Legacy Allurion common <div style="letter-spacing: 0px; top: 0px;display:inline;">stock </div>and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive up to 9,000,000 additional shares of Allurion Common Stock (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Earn-Out</div> Shares&#8221;) upon the achievement of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> targets. The contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration contains a settlement provision that in the event of a change in control, the number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares issued may vary. This settlement provision precludes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liability from being indexed to the Company&#8217;s Common Stock as a change in control event is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">fixed-for-fixed</div></div> forward or option on equity shares. As such, it is classified as a liability under ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity </div></div>(&#8220;ASC 480&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration is remeasured on a quarterly basis over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> period with changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration recorded in Other (expense) income in the consolidated statements of operations, and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration may materially impact or cause volatility in our operating results. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a revenue interest financing agreement, dated as of February&#160;9, 2023 (the &#8220;Revenue Interest Financing Agreement&#8221;) with certain entities that have engaged RTW Investments, LP as investment manager (collectively, &#8220;RTW&#8221;), under which the Company received $40.0&#160;million upfront (the &#8220;Revenue Interest Financing&#8221;). In exchange, the Company is obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for the Revenue Interest Financing Agreement under the fair value option election of ASC 825. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument that contains embedded features. The embedded features include requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events, a change in royalty rates upon the occurrence of certain contingent events, and the Company&#8217;s ability to prepay the Revenue Interest Financing. As the Company has elected the FVO, these embedded features would not meet the criteria for bifurcation and separate accounting as the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis on each reporting period date. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering in the Revenue Interest Financing, the Company and RTW entered into the RTW side letter under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE (as </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">defined in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div>below) subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by the PIPE subscription (the &#8220;PIPE Conversion Option&#8221;). The Company accounts for the PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;). The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other (expense) income in the consolidated statements of operations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable are unsecured and are carried at net realizable value, including an allowance for doubtful accounts. Trade credit is generally extended on a short-term basis; trade receivables do not bear interest, although a finance charge may be applied to such receivables that are past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors that may affect a customer&#8217;s ability to pay, such as historical expense, credit quality, <div style="letter-spacing: 0px; top: 0px;display:inline;">the </div>age of the account receivable balances, and current economic conditions. Amounts determined to be uncollectible are charged or written off against the allowance. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity in the allowance for doubtful accounts: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2023&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2022&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,675</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Uncollectible accounts written off</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers </div></div>(&#8220;Topic 606&#8221; or &#8220;ASC 606&#8221;). In general, the Company&#8217;s sales contracts fall under its standard sales agreement whereby control transfers to the customer upon shipment, satisfying the performance obligations of the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when control of its products is transferred to customers at an amount that reflects the consideration it expects to receive in exchange for those products. The Company&#8217;s revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a good or service to the customer, meaning that such customer has the ability to use and obtain the benefit of the good or service. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has provided customers purchasing the Allurion Balloon with an implied license for access to its VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#8217;s contracts. Further, the customer contracts and related purchase orders do not include nor specify rights or obligations associated with the VCS software. Based on this assessment, the Company determined the implied license to be immaterial in the context of the contract with customers purchasing the Allurion Balloon, and as such did not allocate any value to the implied VCS license. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from sales of its Allurion Balloon to distributors and health care providers. Customers <div style="letter-spacing: 0px; top: 0px;display:inline;">typically </div>purchase the Allurion Balloon, including the gastric balloon and related accessories together, although customers can purchase the gastric balloon and its accessories separately. Therefore, each component of the Allurion Balloon and accessories represents a distinct performance obligation and is separately identifiable. In arrangements with multiple performance obligations, the transaction price is allocated to each performance obligation using the relative standalone selling price. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account internally approved pricing guidelines and market conditions. Revenue is generally recognized upon shipment of the product because at that point, the customer obtains control of the product and has the ability to direct the use and obtain the benefit of the product. Components of the Allurion Balloon are typically shipped to the customer together, resulting in the performance obligations in the contract being satisfied at the same time. Components shipped separately are recognized upon shipment at their relative standalone selling price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue at the transaction price, which reflects the consideration it believes it is entitled to receive. Transaction price includes estimates of variable consideration for promotions and prompt pay discounts, which are recorded as a reduction of transaction price in the period the related product revenue is recognized. The Company may also make payments to customers for marketing programs. Payments to customers for a distinct good or service that reasonably estimate the fair value of the distinct benefit received, such as marketing programs, are recorded as a marketing expense on the consolidated statement of operations and comprehensive loss. Shipping and logistics costs inclusive of these payments to customers and other costs included in sales and marketing expense for the years ended December&#160;31, 2023 and 2022 were $3.3&#160;million and $3.6&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses incremental costs of obtaining a contract, such as sales commissions, when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company&#8217;s consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the sales tax practical expedient; therefore, sales and other taxes assessed by a governmental authority that are collected concurrently with revenue-producing activities are excluded from the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the significant financing component practical expedient, which allows management to not assess whether the contract has a significant financing component in circumstances where, at contract inception, the expected contract duration is less than one year. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Warranty </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not provide general rights of return of products sold to its customers. However, the Company does provide for rights of exchange to its distributors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">end-use</div> customers for products that fail to conform to the Company&#8217;s specifications for a limited time following delivery. These performance specifications include that the Allurion Balloon (i)&#160;is successfully filled upon initial placement when used according to the instructions for use provided by the Company and/or (ii)&#160;remains in the patient&#8217;s <div style="letter-spacing: 0px; top: 0px;display:inline;">body </div>for 90 days or more once placed. Customers may exchange product within 30 calendar days if they discover product nonconformities through a reasonable inspection and within 30 calendar days after discovery of any hidden or latent product nonconformities that could not have been discovered by a reasonable inspection. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These instances of nonconformity have been immaterial, and the Company&#8217;s management expects instances of nonconformity to be extremely rare. </div>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses research and development costs as incurred. Research and development expenses consist of costs associated with performing research and development activities, including salaries and benefits, stock-based compensation, product development costs, materials and supplies, clinical trial activities, depreciation of equipment, and contract and other outside services. Payments for activities that are provided by outside vendors are based upon the terms of the individual arrangements with each vendor. Costs of certain of these activities are expensed based upon an evaluation of the progress to completion of specific tasks and actual costs incurred, using information provided to the Company by its vendors. As payments for these activities may differ from the pattern of costs actually incurred, additional costs are reflected in the consolidated financial statements as prepaid or accrued research and development expenses. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advertising and Marketing Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses advertising and marketing costs as incurred. Advertising and marketing expenses are included in sales and marketing operating expenses. Advertising and marketing costs for the years ended December&#160;31, 2023 and 2022 were $10.8&#160;million and $16.0&#160;million, respectively. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Intellectual Property Prosecution Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurs registration and prosecution costs related to its intellectual property. The related costs are expensed as incurred and are classified as a component of general and administrative expenses. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for net operating loss and tax credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines whether a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company has not identified any uncertain tax positions for which reserves would be required. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method to compute basic and diluted net loss per share attributable to common stockholders, when shares meet the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders less the cumulative undeclared dividend by the weighted average number of common shares outstanding for the period. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Legacy Allurion Series D convertible preferred stock were contractually entitled to receive a cumulative dividend, whether or not declared, and therefore, Legacy Allurion Series D convertible preferred stocks were participating securities. The holders of all other redeemable and convertible preferred stock were not entitled to cumulative dividends. The preferred equity holders were also not contractually required to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination with Compute Health, the Company&#8217;s equity in previous periods has been retroactively adjusted to the earliest period presented to reflect the equivalent number of shares of Allurion Common Stock issued to the Company&#8217;s stockholders in connection with the Business Combination. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Business Combination. See Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>, for details of the Business Combination. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense for awards based on the grant-date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The Company accounts for awards issued to nonemployees under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2018-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (&#8220;Topic 718&#8221;): Improvements to Nonemployee Share-Based Payment Accounting</div></div>, with the measurement date for nonemployee awards being the date of grant. The fair value of stock options is calculated using the Black-Scholes option-pricing model. The fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is based on the fair market value of common stock at the date of grant. The Company records forfeitures as they occur. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, comprehensive loss consists of net loss and other comprehensive loss, which includes changes in the fair value attributable to instrument-specific credit risk related to the Revenue Interest Financing with RTW. There were no differences between net loss and comprehensive loss presented in the statements of operations and comprehensive loss for the year ended December&#160;31, 2022. </div>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses: <div style="letter-spacing: 0px; top: 0px;display:inline;">Measurement </div>of Credit Losses on Financial Instruments (Topic 326)</div></div>. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets such as available for sale debt securities, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> effective January 1, 2023 under the prospective transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</div></div>, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The Company does not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> to have a material impact on its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</div></div> which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which require public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034970960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Business Combination </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately 0.9780, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Legacy Allurion common stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio, (d)&#160;each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#8220;Rollover Warrant&#8221;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#8220;Sponsor&#8221;) to CPUH, which balance was $3.7&#160;million at the time of the Business Combination, were converted into 525,568 shares of Allurion Common Stock. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive 1.420455 shares of Allurion Common Stock. Additionally, the Company assumed 13,206,922 outstanding public warrants to purchase an aggregate 18,759,838&#160;shares of Allurion Common Stock at $8.10 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company incurred approximately $22.7&#160;million of transaction costs, consisting of legal and other professional fees, of which $15.2&#160;million was recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital as a reduction of proceeds, $2.5&#160;million was recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $5.0&#160;million was recorded as an expense in general and administrative expenses on the condensed consolidated statement of operations and comprehensive </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">loss. Of the $5.0&#160;million recorded as general and administrative expenses, $3.6&#160;million relates to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $1.2&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW (as defined below). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,897,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,386,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">387,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,301,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Trust Contributed Shares. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">PIPE Investment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023, with certain accredited investors and </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">qualified institutional buyers (the &#8220;PIPE Investors&#8221;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of 5,386,695 shares of Allurion Common Stock at a purchase price of $7.04 per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $37.9&#160;million, following the CPUH Merger Effective Time (the &#8220;PIPE Investment&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement (the &#8220;Revenue Interest Financing Agreement&#8221;) with certain entities that engaged RTW Investments, LP (together with its affiliates, &#8220;RTW&#8221;) as investment manager. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million (the &#8220;Investment Amount&#8221;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. The Revenue Interest Financing Agreement was amended pursuant to the RIFA Amendment (as defined below) on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the Company entering into the Revenue Interest Financing Agreement, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#8220;RTW Side Letter&#8221;) on February&#160;9, 2023 under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE Investment into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by its PIPE Investment. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#8220;Amended and Restated RTW Side Letter&#8221;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued 250,000 shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of Common Stock of the Company representing $7.5&#160;million in consideration for the New RIFA (as defined below). Refer to Note 19, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Subsequent Events</div></div>, below for further discussion on the RTW conversion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Fortress Credit Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#8220;Fortress Term Loan&#8221;) pursuant to a Credit Agreement and Guaranty, dated as of August&#160;1, 2023 (the &#8220;Fortress Credit Agreement&#8221;), with Fortress Credit Corp. (&#8220;Fortress&#8221;), as administrative agent for the lenders party thereto from time to time (the &#8220;Lenders&#8221;). Under the terms of the Fortress Term Loan, we borrowed $60.0&#160;million, which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement (as defined below), Allurion issued an aggregate of 950,000 shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for further discussion on the Fortress Term Loan. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Backstop Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#8220;Backstop Purchasers&#8221;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#8220;HVL&#8221;) entered into the backstop agreement (the &#8220;Backstop Agreement&#8221;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing, (a)&#160;each Backstop Purchaser purchased $2&#160;million of the aggregate principal amount outstanding of HVL&#8217;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $2&#160;million each and (d)&#160;Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion around the Backstop Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">HVL Termination Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#8220;HVL Termination Agreement&#8221;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#8217;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL 387,696 shares of Allurion Common Stock. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion regarding the HVL Termination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Gaur Contribution Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#8220;Gaur Trust&#8221;) and Allurion entered into a contribution agreement (the &#8220;Gaur Contribution Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, 79,232 shares of Allurion Common Stock (the &#8220;Gaur Trust Contributed Shares&#8221;). The Gaur Trust&#8217;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RSU Forfeiture Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Krishna Gupta, a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221; or &#8220;Board of Directors&#8221;), entered into a letter agreement with Legacy Allurion (the &#8220;RSU Forfeiture Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit 79,232 restricted stock units of Allurion (the &#8220;Forfeited RSUs&#8221;). The Forfeited RSUs were terminated and cancelled without consideration therefor immediately following the closing of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Sponsor Contribution Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#8220;Sponsor Contribution Agreement&#8221;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, 161,379 shares of Compute Health Class&#160;A Common Stock (&#8220;Sponsor Contributed Shares&#8221;). The Sponsor&#8217;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Sponsor Support Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion entered into a support agreement (the &#8220;Sponsor Support Agreement&#8221;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Sponsor&#8217;s 21,442,500 shares of Compute Health Class&#160;B Common Stock, and all 12,833,333 of the Sponsor&#8217;s warrants to purchase shares of Class&#160;A Common Stock, into 2,088,327 shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement recapitalized his or her 30,000 shares of Compute Health Class&#160;B Common Stock into 21,120 shares of Compute Health Class&#160;A Common Stock (the &#8220;CPUH Recapitalization&#8221;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of 1.420455 (the &#8220;CPUH Exchange Ratio&#8221;). </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Conversion of Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $21.8&#160;million were converted into 3,301,222 shares of Allurion Common Stock with a corresponding recognition of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital (&#8220;APIC&#8221;) of $25.6&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further information on the Company&#8217;s convertible notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Public Warrants and Warrant Amendment </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company assumed 13,206,922 outstanding public warrants (the &#8220;Public Warrants&#8221;) to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $13.8&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-share</div> settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock and Stockholders Deficit</div></div> and Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the Public Warrants and Warrant Amendment. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the share price achieves certain targets (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Earn-Out</div> Shares&#8221;). The Company accounts for the potential issuance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares as a contingent consideration arrangement, which was initially valued and recorded at $53.0&#160;million. See Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Business Combination </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately 0.9780, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Allurion Common Stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio (&#8220;Rollover Option&#8221;), (d) each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#8220;Rollover Warrant&#8221;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#8220;Sponsor&#8221;) to CPUH, which balance was $3.7&#160;million at the time of the Business Combination (the &#8220;Sponsor Loan Excess&#8221;), was converted into 525,568 shares of Allurion Common Stock (the &#8220;Sponsor Loan Equity Issuance&#8221;). For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive 1.420455 </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shares of Allurion Common Stock. Additionally, the Company assumed 13,206,922 outstanding public warrants to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company incurred approximately $22.7&#160;million of transaction costs, consisting of legal and other professional fees, $15.2&#160;million of which were recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital as a reduction of proceeds, $2.5&#160;million of which were recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $5.0&#160;million of which were recorded as an expense in general and administrative expenses on the consolidated statement of operations and comprehensive loss. Of the $5.0&#160;million recorded as expense, $3.6&#160;million relates to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $1.2&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Net proceeds from the Business Combination, less the repayment of note assumed in the Business Combination, less the accrued transaction costs at December&#160;31, 2023 are presented net in the consolidated statements of stockholders deficit within line &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221;. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The warrant liabilities assumed are presented separately from the &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221; line within the consolidated statements of stockholders deficit. </div></td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,897,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,386,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">387,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,301,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stockholders, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur <div style="letter-spacing: 0px; top: 0px;display:inline;">Contributed </div>Shares (as defined below). </div></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023 (the &#8220;PIPE Subscription Agreements&#8221;), with certain accredited investors and qualified institutional buyers (the &#8220;PIPE Investors&#8221;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of 5,386,695 shares of Allurion Common Stock at a purchase price of $7.04 per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $37.9&#160;million, following the CPUH Merger Effective Time (the &#8220;PIPE Investment&#8221;). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement with RTW. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million (the &#8220;Investment Amount&#8221;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, in connection with the Company entering in the Revenue Interest Financing, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#8220;RTW Side Letter&#8221;) on February&#160;9, 2023 under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion common stock acquired by its PIPE Investment. Refer to Note 9, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</div></div> below for further discussion on the Revenue Interest Financing. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#8220;Amended and Restated RTW Side Letter&#8221;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued 250,000 shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Credit Agreement </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#8220;Fortress Term Loan&#8221;) pursuant to a credit agreement and guaranty, dated as of August&#160;1, 2023 (the &#8220;Fortress Credit Agreement&#8221;), with Fortress Credit Corp. (&#8220;Fortress&#8221;), as administrative agent for the lenders party thereto from time to time (the &#8220;Lenders&#8221;). Under the terms of the Fortress Term Loan, we borrowed $60.0&#160;million which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement, Allurion issued an aggregate of 950,000 shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for further discussion on the Fortress Term Loan. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Backstop Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#8220;Backstop Purchasers&#8221;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#8220;HVL&#8221;) entered into the backstop agreement (the &#8220;Backstop Agreement&#8221;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing (a)&#160;each Backstop Purchaser purchased $2&#160;million of the aggregate principal amount outstanding of HVL&#8217;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $2&#160;million each and (d)&#160;Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion around the Backstop Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">HVL Termination Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#8220;HVL Termination Agreement&#8221;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#8217;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL 387,696 shares of Allurion Common Stock. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further discussion regarding the HVL Termination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Gaur Contribution Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#8220;Gaur Trust&#8221;) and Allurion entered into a contribution agreement (the &#8220;Gaur Contribution Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, 79,232 shares of Allurion Common Stock (the &#8220;Gaur Trust Contributed Shares&#8221;). The Gaur Trust&#8217;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">RSU Forfeiture Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, Krishna Gupta, a member of our Board of Directors, entered into a letter agreement with Legacy Allurion (the &#8220;RSU Forfeiture Agreement&#8221;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit 79,232 restricted stock units of Allurion (the &#8220;Forfeited RSUs&#8221;). The Forfeited RSUs were terminated and cancelled without consideration therefore immediately following the closing of the Business Combination Agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Contribution Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#8220;Sponsor Contribution Agreement&#8221;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, 161,379 shares of Compute Health Class&#160;A Common Stock (&#8220;Sponsor Contributed Shares&#8221;). The Sponsor&#8217;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Allurion entered into a support agreement (the &#8220;Sponsor Support Agreement&#8221;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the Sponsor&#8217;s 21,442,500 shares of Compute Health Class&#160;B Common Stock, and all 12,833,333 of the Sponsor&#8217;s warrants to purchase shares of Class&#160;A Common Stock, into 2,088,327 shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement (the &#8220;Additional Class&#160;B Holders&#8221;) recapitalized his or her 30,000 shares of Compute Health Class&#160;B Common Stock into 21,120 shares of Compute Health Class&#160;A Common Stock (the &#8220;CPUH Recapitalization&#8221;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of 1.420455 (the &#8220;CPUH Exchange Ratio&#8221;). </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion of Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $21.8&#160;million were converted into 3,301,222 shares of Allurion Common Stock with a corresponding recognition of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital (&#8220;APIC&#8221;) of $25.6&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for further information on the Company&#8217;s convertible notes. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants and Warrant Amendment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company assumed 13,206,922 outstanding Public Warrants (defined below) to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $13.8&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">net-share</div> settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capital Stock and Stockholders&#8217; Deficit</div></div> and Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the Public Warrants and Warrant Amendment. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the shares price achieves certain targets. The Company accounts for the potential issuance of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares as a contingent consideration arrangement, which was initially valued and recorded at $53.0&#160;million. See Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div> for further information on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039260016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Italy</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, $1.8&#160;million of revenue was generated in five countries included within All Other Countries in the table above, representing approximately 34% of Total Revenues, with each country responsible for approximately 5% to 8% of the total. Remaining revenue was generated by sales in 36 other countries included within All Other Countries. For the three months ended September&#160;30, 2023, $5.9&#160;million of revenue was generated in five countries included within All Other Countries, representing approximately 33% of Total Revenues, with each country responsible for approximately 5% to 7% of the total. Remaining revenue was generated by sales in 45 other countries included within All Other Countries. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United Kingdom</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2024, $7.2&#160;million of revenue was generated in five countries included within All Other Countries in the table above, representing approximately 27% of Total Revenues, with each country responsible for approximately 4% to 8% of the total. Remaining revenue was generated by sales in 49 other countries included within All Other Countries. For the nine months ended September&#160;30, 2023, $11.1&#160;million of revenue was generated in five countries included within All Other Countries, representing approximately 25% of Total Revenues, with each country responsible for approximately 4% to 7% of the total. Remaining revenue was generated by sales in 58&#160;other countries included within All Other Countries. No revenue was generated in the United States for the three and nine months ended September&#160;30, 2024. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is domiciled and is summarized by geographic area as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently no revenue generated in the United States. For the year ended December&#160;31, 2023, $13.3&#160;million of revenue was generated in four countries included within All other countries in the table above, representing approximately 25% of Total Revenues, with each country responsible for approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">5%-9%</div> of the total. The remaining revenue was generated by sales in 55 other countries included within All other countries. For the year ended December&#160;31, 2022, $16.0&#160;million of revenue was generated in four countries included within All other countries, representing approximately 25% of Total Revenues, with each country responsible for approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">6%-7%</div> of the total. Remaining revenue was generated by sales in 50 other countries included within All other countries. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034968592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventory </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is stated net of $0.7&#160;million and less than $0.1&#160;million for the provision for excess and obsolete inventory as of September&#160;30, 2024 and December&#160;31, 2023, respectively. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Inventory </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory is stated net of less than $0.1&#160;million and zero for the provision of excess and obsolete inventory as of December&#160;31, 2023 and 2022, respectively. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033185648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and Equipment, net </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Useful Life<br/> (in Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="white-space:nowrap;vertical-align:bottom"><br/> &#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3-5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(4,169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.2&#160;million for each of the three months ended September&#160;30, 2024 and 2023, and $0.8&#160;million and $0.6&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, recorded as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Property and Equipment, net </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:22%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimates Useful Life<br/> (in Years)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3-5</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Less accumulated depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,851</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Construction in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.7&#160;million and $0.9&#160;million for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023 and 2022, respectively, recorded as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-hidden:hidden127682954;display:inline;">875</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039307728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accrued Expenses and Other Current Liabilities </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketing reimbursement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,973</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with strategic initiatives implemented during the year ended December&#160;31, 2023, the Company&#8217;s management approved and initiated plans to reduce its cost structure. During the nine months ended September&#160;30, 2024, the Company recorded less than $0.1&#160;million in restructuring charges and paid $0.7&#160;million in restructuring charges. No restructuring charges were incurred or paid during the three months ended September&#160;30, 2024. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Accrued Expenses and Other Current Liabilities </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributor fees and marketing reimbursements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with strategic initiatives implemented during the period ended December&#160;31, 2023, the Company&#8217;s management approved and initiated plans to reduce its cost structure. The Company recorded $1.0&#160;million of restructuring charges during the year ended December&#160;31, 2023, of which $0.4&#160;million has been paid as of December&#160;31, 2023. The restructuring charges are included in operating expenses in the statement of operations. Substantially all of this charge represents the severance cost of terminated employees. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035461888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Debt </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amount of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,230</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,643</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the fair value for the Company&#8217;s Fortress Term Loan approximated the carrying amount. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Term Loans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company entered into a loan and security agreement (as amended, the &#8220;2021 Term Loan&#8221; and the &#8220;2021 Term Loan Agreement&#8221;) with Runway Growth Credit Fund, Inc. (&#8220;Runway&#8221;) that provided for borrowings up to $25.0&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the 2021 Term Loan Agreement was amended (the &#8220;Amendment&#8221;) to extend the maturity date of the 2021 Term Loan to December 30, 2025 and provide for an additional $20.0&#160;million of borrowings. In December 2021, the Company issued warrants exercisable for 132,979 shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $0.3&#160;million upon issuance and are classified as a warrant liability on the condensed consolidated balance sheet as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for 130,053 shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and certain financial covenants. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things, increase additional borrowing up to $15.0&#160;million. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During June through December of 2022, the Company drew an additional $30.0&#160;million of the 2021 Term Loan and warrants exercisable for 88,440 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were issued. The fair value of these warrants was determined to be $0.8&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, the warrants exercisable for 88,440 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were converted into warrants exercisable for 90,476 shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $58.0&#160;million, consisting of $55.0&#160;million repayment of principal, a </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$1.1&#160;million prepayment fee, and a $1.6&#160;million final payment fee. The prepayment fee was calculated as 2% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as the 3% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $0.1&#160;million. The Company recorded a $3.9&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the three months ended September&#160;30, 2023 related to the 2021 Term Loan was $0.8&#160;million, consisting of $0.7&#160;million of contractual interest, and $0.1&#160;million of amortization of the debt discount, amortization of warrant, and term loan accretion. Interest expense for the nine months ended September&#160;30, 2023 related to the 2021 Term Loan was $5.0&#160;million, consisting of $4.7&#160;million of contractual interest, $0.1&#160;million amortization of the debt discount, $0.1&#160;million of amortization of the warrant, and $0.1&#160;million of term loan accretion. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $60&#160;million. The Fortress Term Loan had a maturity date of June 30, 2027 and accrued interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to 3.0% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee. The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $2.5&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#8220;Fortress Amendment&#8221;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $12.5&#160;million to $33.5&#160;million until March&#160;31, 2024, $23.5&#160;million from April&#160;1, 2024 to June&#160;30, 2024, $16.9&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $12.5&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provided that at any time after March&#160;31, 2024, each lender had the right to convert a portion of the outstanding principal amount, not to exceed the lender&#8217;s proportionate share of a maximum of $20.0&#160;million in aggregate outstanding principal amount, into shares of Allurion Common Stock at a conversion price based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> volume weighted average price (&#8220;VWAP&#8221;) of Allurion Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#8217;s conversion right. As part of the Fortress Amendment, the Company prepaid $20.0&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $3.1&#160;million of fees were incurred and considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in-kind</div></div> and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees were amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>. In connection with the modification and related prepayment, the Company wrote off $0.8&#160;million of the unamortized debt issuance costs, which was recorded within interest expense on the condensed consolidated statement of operations for the year ended December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of 3% that will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;), the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#8220;Term Loan Derivative Liability&#8221;) that is required to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded derivative was determined to be immaterial. The Term Loan Derivative Liability was </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">fair valued to zero in connection with the repayment of the Fortress Term Loan, with a corresponding $2.0&#160;million gain recorded in <div style="display:inline;"><div style="-sec-ix-hidden:hidden127682733;display:inline;">other income, net</div></div> in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;16, 2024, the Company repaid all outstanding obligations under the Fortress Term Loan with proceeds from the Amended Note Purchase Agreement (as defined below) with RTW. The total payoff amount was $48.0&#160;million, consisting of $43.1&#160;million repayment of principal, a $2.7&#160;million prepayment fee, a $1.3&#160;million exit fee, $0.6&#160;million of other fees paid directly to Fortress, and $0.3&#160;million of accrued interest. The Company recorded an $8.7&#160;million loss on extinguishment of debt in connection with the Fortress Term Loan repayment in the condensed consolidated statement of operations for nine months ended September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the three and nine months ended September&#160;30, 2023 related to the Fortress Term Loan was $1.7&#160;million, consisting of $1.5&#160;million of contractual interest, $0.1&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. The average interest rate during the three months ended September&#160;30, 2023 was 14.94%. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&#160;30, 2024 related to the Fortress Term Loan was $2.3&#160;million, consisting of $1.9&#160;million of contractual interest, $0.3&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. There was no interest expense for the three months ended September&#160;30, 2024 due to the extinguishment of the Fortress Term Loan on April&#160;16, 2024. The average interest rate through April&#160;16, 2024 was 14.94%. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company entered into a convertible note agreement with investors for gross proceeds of $2.0&#160;million with a stated interest rate of 5.0% per annum (the &#8220;2021 Convertible Notes&#8221;) and a maturity date 36 months from the date of issuance unless previously converted pursuant to their terms of the agreement. No issuance costs were incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#8220;deSPAC&#8221;) transaction, closing of a qualified financing, or closing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> financing, all of the outstanding principal and interest would automatically convert into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $600.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2021 Convertible Notes was less than $0.1&#160;million and $0.1&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate 133,617 shares of Allurion Common Stock with a corresponding recognition of APIC of $2.2&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2022 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, the Company entered into a convertible note purchase agreement with investors for gross proceeds of $1.1&#160;million with a stated interest rate of 5.0% per annum (the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes were to mature 36 months from the issuance date unless previously converted pursuant to the terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible Notes. </div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2022 Convertible Notes was less than $0.1&#160;million, consisting entirely of contractual interest. Interest expense related to the 2022 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate 83,216 shares of Allurion Common Stock with a corresponding recognition of APIC of $1.2&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of convertible notes (the &#8220;2023 Convertible Notes&#8221;) to certain investors for gross proceeds of $28.7&#160;million, with a stated interest rate of 7.0% per annum. The 2023 Convertible Notes provided that they would mature on December 31, 2026 unless previously converted pursuant to the terms of the note purchase agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of Legacy Allurion common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $217.3&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the 2023 Convertible Notes provided that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $260.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the fair FVO election of ASC 825 as the notes contain embedded derivatives, including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2023 Convertible Notes was $0.1&#160;million and $0.5&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023 the Company entered into termination agreements (the &#8220;Termination Agreements&#8221;) with respect to side letters entered into with certain holders of the 2023 Convertible Notes. With respect to the Termination Agreement with HVL, the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under such holder&#8217;s 2023 Convertible Note (the &#8220;HVL Bridge Note&#8221;), including by way of (a)&#160;a $2&#160;million payment in cash by the Company to HVL on May&#160;2, 2023, $1.5&#160;million of which was deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $0.5&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $6&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the HVL Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the HVL Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Termination Agreement executed with HVL, the Company agreed to issue to HVL a number of shares of Allurion Common Stock (&#8220;PubCo Additional Shares&#8221;) equal to (a)&#160;the outstanding principal and accrued interest under the HVL Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $5.00, plus (b) 300,000 shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period, with changes in fair value reflected in earnings until the PubCo Additional Shares were issued. A $3.4&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, HVL was issued 387,696 PubCo Additional Shares with a corresponding recognition of APIC of $2.7&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further on May&#160;2, 2023, RTW and Fortress as the Backstop Purchasers entered into the Backstop Agreement with the Company, Legacy Allurion and HVL. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any HVL Bridge Notes remained outstanding prior to the consummation of the Business Combination, such Backstop Purchaser would, at the closing of the Business Combination, purchase up to $2.0&#160;million of the HVL Bridge Notes from HVL in exchange for shares of Allurion Common Stock (the &#8220;Base PubCo Shares&#8221;, &#8220;Backstop Shares&#8221; and &#8220;Conditional Additional PubCo Shares&#8221;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares were issued. A $3.3&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and Backstop Agreement, the Backstop Purchasers were each issued 950,000 shares of Allurion Common Stock with a corresponding recognition of APIC of $13.4&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $6.3&#160;million of the HVL Bridge Note, leaving a principal balance of $6.3&#160;million. Each Backstop Purchaser then purchased $2.0&#160;million principal amount of the outstanding portion of the HVL Bridge Note, Allurion canceled the existing HVL Bridge Note and issued a new convertible note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance of $2.7&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $2.0&#160;million each, and Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate 3,084,389 shares of Allurion Common Stock with a corresponding recognition of APIC of $22.2&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&#160;14, 2024, the Company entered into a note purchase agreement (the &#8220;Original Note Purchase Agreement&#8221;) with RTW as agent for the purchasers (the &#8220;Purchasers&#8221;) party thereto from time to time (RTW in such capacity, the &#8220;Principal Purchaser&#8221;), and Acquiom Agency Services LLC (&#8220;Acquiom&#8221;) as collateral agent for the Purchasers. Subsequently, on April&#160;16, 2024, the Company, the Principal Purchaser, the Purchasers, and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the Original Note Purchase Agreement as amended, the &#8220;Amended Note Purchase Agreement&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $48.0&#160;million of convertible senior secured notes (the &#8220;RTW Convertible Notes&#8221;). The RTW Convertible Notes bear interest at an </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">annual rate of 6%, which interest is paid quarterly in cash or, at the Company&#8217;s option, in kind for the first three years. The RTW Convertible Notes will mature on April 16, 2031 unless previously converted pursuant to the terms of the Amended Note Purchase Agreement. The RTW Convertible Notes are convertible into shares of Allurion Common Stock, at a Purchaser&#8217;s election at any time after the earliest of (i)&#160;the date on which Stockholder Approval (as defined below) is obtained, (ii)&#160;December&#160;31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Amended Note Purchase Agreement), and (iv)&#160;the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on a conversion rate of 617.2840 shares of common stock per $1,000 principal amount of Notes (equivalent to a conversion price of approximately $1.62 per share, which represents a 35% premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $15,000,000 (the &#8220;Next Equity Financing&#8221;). On July&#160;1, 2024, we consummated the Public Offering, as described elsewhere in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">10-Q,</div> which constituted a Next Equity Financing. The Amended Note Purchase Agreement provides that unless and until requisite approval of the Company&#8217;s stockholders is obtained (&#8220;Stockholder Approval&#8221;), the Company will not deliver Allurion Common Stock upon conversion of the RTW Convertible Notes in excess of 1% of the number of shares of Allurion Common Stock outstanding as of April&#160;14, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RTW Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives, including the conversion upon Stockholder Approval, the conversion upon a Fundamental Change Company Notice, the conversion upon a Make-Whole Fundamental Change, redemption upon the event of default, and redemption upon a Fundamental Change, which would require bifurcation and separate accounting. The RTW Convertible Notes were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes at issuance was $49.1&#160;million, with a corresponding $1.1&#160;million loss recognized in Other income, net in the condensed consolidated statement of operations. In connection with the issuance of the RTW Convertible Notes and RIFA Amendment (as defined below), we incurred $1.4&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election of the RTW Convertible Notes and Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, the Company recorded gains of $1.8&#160;million and $3.1&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded gains of $10.0&#160;million and $3.0&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Note Purchase Agreement contains financial maintenance covenants, which require (i)&#160;the Company maintain not less than $12,500,000 in unrestricted cash in controlled accounts in the U.S. at all times, (ii)&#160;the Company to receive minimum trailing twelve-month consolidated revenue at amounts designated in the Amended Note Purchase Agreement, tested quarterly beginning with the twelve-month period ending March&#160;31, 2025, and (iii)&#160;the Company&#8217;s and its subsidiaries&#8217; consolidated business operations outside the United States to be profitable for the trailing three-month period, tested quarterly beginning with the three-month period ending December&#160;31, 2025. The Company is in compliance with the covenants in the Amended Note Purchase Agreement as of September&#160;30, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company elected paid in kind interest for the three and nine months ended September&#160;30, 2024 related to the RTW Convertible Notes. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Debt </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consisted of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021 Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,643</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53,360</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,853</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the fair value for the Company&#8217;s Fortress Term Loan and 2021 Term Loan approximated the respective carrying amounts. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Term Loans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Term Loan </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Company entered into a loan and security agreement (as amended, the &#8220;2021 Term Loan&#8221; and the &#8220;2021 Term Loan Agreement&#8221;) with Runway Growth Credit Fund, Inc. (&#8220;Runway&#8221;) that provided initial cash proceeds of $15.0&#160;million, all of which was drawn down in March 2021 and provided for additional borrowings of up to $10.0&#160;million, in $5.0&#160;million increments, based upon the achievement of certain revenue thresholds within specified time periods, as defined in the 2021 Term Loan Agreement. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the 2021 Term Loan Agreement was amended (the &#8220;Amendment&#8221;) to extend the maturity date of the 2021 Term Loan to December 30, 2025 and provide for an additional $20.0&#160;million of borrowings, of which $15.0&#160;million (the &#8220;Term C Loan&#8221;) was available based upon the achievement of certain revenue thresholds within specified time periods as defined in 2021 Term Loan Agreement as amended. The agreement provided for equal monthly principal payments to commence on December 30, 2024 such that the borrowed principal amounts would be repaid in full on December&#160;30, 2025. However, if certain revenue thresholds were achieved prior to April&#160;15, 2023, the borrowed principal amounts would be repaid in full on December&#160;30, 2025. The revenue thresholds were achieved in June 2022. In connection with the 2021 Term Loan, the Company paid issuance costs of $0.7&#160;million which were amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company issued warrants exercisable for 132,979 shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $0.3&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheet as of December&#160;31, 2023 and 2022 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for 130,053 shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and financial covenant. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things: (1)&#160;change the interest rate to the higher of the prime rate or 3.25% <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">plus </div></div>the applicable margin of 6.44186%, (2) extend the maturity date of its outstanding term loans from December&#160;30, 2025 to December 30, 2026, and (3)&#160;increase additional borrowing up to $15.0&#160;million (the &#8220;Term D Loan&#8221;). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During June through September of 2022, the Company drew an additional $15.0&#160;million of the Term C Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. In connection with the Term C Loan under the 2021 Term Loan, the Company paid issuance costs of $0.3&#160;million, which were amortized over the remaining life of the loan. Upon the additional $15.0&#160;million draw on the Term C Loan, warrants exercisable for 44,220 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were issued. In 2022, the Company recorded a warrant liability of $0.4&#160;million in connection with the Term C Loan on the consolidated balance sheets. In September 2022, in connection with the amendment of the 2021 Term Loan, the Company committed to issue warrants exercisable for an additional 44,220 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock if the Company drew on the entire Term D Loan. The fair value of these warrants was determined to be $0.4&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of December&#160;31, 2023 and 2022 (see Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>). Upon the closing of the Business Combination, the warrants exercisable for 88,440 shares of Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> preferred stock were converted into warrants exercisable for 90,476 shares of Allurion Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During October through December of 2022, the Company drew an additional $15.0&#160;million of the Term D Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $58.0&#160;million, consisting of $55.0&#160;million repayment of principal, a $1.1&#160;million prepayment fee, and a $1.6&#160;million final payment fee. The prepayment fee was calculated as 2% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as 3% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $0.1&#160;million. The Company recorded a $3.9&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2023 related to the 2021 Term Loan was $5.0&#160;million, consisting of $4.7&#160;million of contractual interest, $0.1&#160;million amortization of debt discount, $0.1&#160;million <div style="letter-spacing: 0px; top: 0px;display:inline;">amortization </div>of warrant, and $0.1&#160;million term loan accretion. Interest expense for the year ended December&#160;31, </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2022 was $4.3&#160;million, consisting of $3.8&#160;million of contractual interest, $0.2&#160;million amortization of debt discount, $0.1&#160;million amortization of warrant, and $0.2&#160;million term loan accretion.&#8195; </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fortress Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $60&#160;million. The Fortress Term Loan has a maturity date of June 30, 2027 and accrues interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest is payable in arrears on a monthly basis. An exit payment equal to 3.0% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) is due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee. The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $2.5&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#8220;Fortress Amendment&#8221;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $12.5&#160;million to $33.5&#160;million until March&#160;31, 2024, $23.5&#160;million from April&#160;1, 2024 to June 30, 2024, $16.9&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $12.5&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provides that at any time after March&#160;31, 2024, each lender will have the right to convert a portion of the outstanding principal amount, not to exceed the lender&#8217;s proportionate share of a maximum of $20.0&#160;million in aggregate outstanding principal amount, into shares of Common Stock of the Company at a conversion price based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> volume weighted average price (&#8220;VWAP&#8221;) of the Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#8217;s conversion right (the &#8220;Fortress Conversion Option&#8221;). As part of the Fortress Amendment, the Company prepaid $20.0&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $3.1&#160;million of fees were incurred and considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in-kind</div></div> and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees will be amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470. In connection with the modification and related prepayment, the Company wrote off $0.8&#160;million of the unamortized debt issuance costs which was recorded within Interest expense on the consolidated statement of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fortress Credit Agreement contains certain financial reporting and other covenants, including the maintenance of a minimum liquidity amount and maintenance of minimum product revenues over trailing twelve-month periods. Upon the occurrence of an event of default, the Lenders may declare all outstanding obligations immediately due and payable as well as increase the interest rate 3.0% above the rate that is otherwise applicable. The Company has determined that there is substantial doubt about the Company&#8217;s ability to continue as a going concern (see Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation</div></div>) and there is a risk that it may not meet its covenants under the Fortress Term Loan in the future. Therefore, the amounts due as of December&#160;31, 2023 have been classified as a current liability in the consolidated financial statements. The Company is in compliance with all covenants as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of 3% which will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#8220;Term Loan Derivative Liability&#8221;) that is required to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-remeasured</div> at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">derivative was determined to be immaterial. The fair value of the Term Loan Derivative Liability was $1.9&#160;million as of December&#160;31, 2023, with a corresponding recognition of Other income (expense), net in the consolidated statement of operations. The Company classified the Term Loan Derivative Liability as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> liability within Other liabilities on the balance sheet as of December&#160;31, 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense from August&#160;1, 2023 through December&#160;31, 2023 related to the Fortress Term Loan was $4.1&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">million</div>, consisting of $3.8&#160;million of contractual interest, $0.2&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. The average interest rate of the Fortress Term Loan during the year ended December&#160;31, 2023 was 14.94%. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scheduled future maturities of the Fortress Term Loan for years subsequent to December&#160;31, 2023 are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Convertible Notes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2021, the Company entered into a convertible note agreement with an investor for gross proceeds of $2.0&#160;million with a stated interest rate of 5.0% per annum (the &#8220;2021 Convertible Notes&#8221;) and a maturity date 36 months from the date of issuance unless previously converted pursuant to their terms of the agreement. No issuance costs were incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#8220;deSPAC&#8221;) transaction, closing of a qualified financing, or closing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified</div> financing, all of the outstanding principal and interest would automatically convert into common shares or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $600.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2021 Convertible Notes was $0.1&#160;million, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate 133,617 shares of Allurion Common Stock with a corresponding recognition of APIC of $2.2&#160;million, and are no longer outstanding. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2022 Convertible Notes </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2022, the Company entered into a convertible note agreement with investors for gross proceeds of $1.1&#160;million with a stated interest rate of 5.0% per annum (the &#8220;2022 Convertible Notes&#8221;). The 2022 Convertible Notes mature 36 months from the issuance date unless previously converted pursuant to their terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible notes. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2022 Convertible Notes was less than $0.1&#160;million and $0.2&#160;million, respectively, consisting entirely of contractual interest. Interest expense </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">related to the 2022 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate 83,216 shares of Allurion Common Stock with a corresponding recognition of APIC of $1.2&#160;million, and are no longer outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of the 2023 Convertible Notes to certain investors for gross proceeds of $28.7&#160;million, with a stated interest rate of 7.0% per annum. The 2023 Convertible Notes provided that they would mature on December 31, 2026 unless previously converted pursuant to the terms of their agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $217.3&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. Additionally, the 2023 Convertible Notes provide that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into common shares or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $260.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2023 related to the 2023 Convertible Notes was $0.5&#160;million, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;2, 2023 the Company entered into termination agreements (the &#8220;Termination Agreements&#8221;) with respect to side letters entered into with certain holders of Legacy Allurion Convertible Notes. With respect to the Termination Agreement with one of the side letter holders (the &#8220;Side Letter Holder&#8221;), the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under the 2023 Convertible Note (the &#8220;Side Letter Holder Bridge Note&#8221;), including by way of (a)&#160;a $2&#160;million payment in cash by the Company to the Side Letter Holder on May&#160;2, 2023, $1.5&#160;million of which is deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $0.5&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $6&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the Side Letter Holder Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the Side Letter Holder Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Termination Agreement executed with the Side Letter Holder, the Company agreed to issue to the Side Letter Holder a number of shares of Allurion Common Stock (&#8220;PubCo Additional Shares&#8221;) </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">equal to (a)&#160;the outstanding principal and accrued interest under the Side Letter Holder Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $5.00, plus (b) 300,000 shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the PubCo Additional Shares are issued. A $3.4&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the consolidated balance sheet and the related expense recorded through Other income (expense) on the consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2023. On August&#160;1, 2023, upon closing of the Business Combination, the Side Letter Holder was issued 387,696 PubCo Additional Shares with a corresponding recognition of APIC of $2.7&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further on May&#160;2, 2023, RTW and Fortress (the &#8220;Backstop Purchasers&#8221;) entered into the Backstop Agreement with the Company, Legacy Allurion and the Side Letter Holder. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any Side Letter Holder Bridge Notes remain outstanding prior to the consummation of the Business Combination, such Backstop Purchaser will, at the closing of the Business Combination, purchase up to $2.0&#160;million of the Side Letter Holder Bridge Notes from the Side Letter Holder in exchange for shares of Allurion Common Stock (the &#8220;Base PubCo Shares&#8221;, &#8220;Backstop Shares&#8221; and &#8220;Conditional Additional PubCo Shares&#8221;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares are issued. A $3.3&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the consolidated balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and the Backstop Agreement, the Backstop Purchasers were each issued 950,000 shares of Allurion Common Stock with a corresponding recognition of APIC of $13.4&#160;million, and the liability is no longer outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $6.3&#160;million of the Side Letter Holder Bridge Note, leaving a principal balance of $6.3&#160;million. Each Backstop Purchaser then purchased $2.0&#160;million principal amount of the outstanding portion of the Side Letter Holder Bridge Note, Allurion canceled the existing Side Letter Holder Bridge Note and issued a new convertible note to the Side Letter Holder for the remaining balance together with all unpaid interest accrued since the date of issuance of $2.7&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $2.0&#160;million each and Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate 3,084,389 shares of Allurion Common Stock with a corresponding recognition of APIC of $22.2&#160;million, and are no longer outstanding. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035482688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing, Side Letter, and PIPE Conversion Option<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock', window );">Revenue Interest Financing, Side Letter, and PIPE Conversion Option</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$40.0&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of 260% of the Investment Amount (the &#8220;Hard Cap&#8221;). In addition, prior to December&#160;31, 2025, the Company may prepay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-specified</div> payment amount (the &#8220;Prepayment Amount&#8221;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to 165% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and separate accounting. The Revenue Interest Financing was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. In connection with the issuance of the Investment Amount, we paid $1.2&#160;million in issuance costs in August 2023, which were directly expensed through general and administrative expense due to the FVO election. As of September&#160;30, 2024, the Company has made $3.6&#160;million in royalty payments to RTW. Refer to Note 10, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements</div></div>, for additional information regarding the changes in fair value of the Revenue Interest Financing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently, and in connection with the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement was amended pursuant to the Omnibus Amendment (the &#8220;RIFA Amendment&#8221;) by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned subsidiary of the Company, the Original RIFA Investors (as defined therein) and RTW, on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries for net sales less than or equal to $100&#160;million prior to December&#160;31, 2026 from 6% to 12% and increased the rate on net sales in less than or equal to $100&#160;million on or after January&#160;1, 2027 from 10% to 12%. Additionally, the Prepayment Amount was modified such that, prior to March&#160;31, 2026, the Company is entitled to settle the Revenue Interest Financing for a prepayment amount that would allow the investors to yield a 20% internal rate of return. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $7.04 for the average of 20 trading days within any 30 trading day period (&#8220;Stock Price Drop&#8221;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $10.00 per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $7.5&#160;million of its initial PIPE Investment into </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE Investment. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $3.3&#160;million within Other liabilities on the condensed consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RIFA Amendment was accounted for as a modification with the change in fair value of the PIPE Conversion Option treated as an exchange between the Company and RTW as part of the RIFA Amendment. As such, the Revenue Interest Financing and PIPE Conversion Option were remeasured as of April&#160;16, 2024 just prior to the RIFA Amendment, to $33.0&#160;million and $6.6&#160;million, respectively. The Revenue Interest Financing and PIPE Conversion Option were subsequently remeasured as of April&#160;16, 2024 under the terms of the RIFA Amendment, to $39.0&#160;million and $4.6&#160;million, respectively. As of September&#160;30, 2024, the fair value of the Revenue Interest Financing and PIPE Conversion Option were $38.5&#160;million and $9.9&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&#160;30, 2024, the Company recorded a $6.7&#160;million loss and a $5.8&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded a $5.4&#160;million loss and a $0.6&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. The changes in fair value were recorded in the Changes in fair value of Revenue Interest Financing and PIPE Conversion Option in the condensed consolidated statement of operations. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Interest Financing, Side Letter, and PIPE Conversion Option </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">1</div>, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of 260% of the Investment Amount (the &#8220;Hard Cap&#8221;). In addition, prior to December&#160;31, 2025, the Company may prepay a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">pre-specified</div> payment amount (the &#8220;Prepayment Amount&#8221;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to 165% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and <div style="letter-spacing: 0px; top: 0px;display:inline;">separate </div>accounting. The Revenue Interest Financing is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. For the year ended December&#160;31, 2023, the Company recorded a $3.4&#160;million gain and a $0.7&#160;million loss through the consolidated statements of operations and other comprehensive loss, respectively. In connection with the issuance of the Investment Amount, we paid $1.2&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election. As of December&#160;31, 2023, the Company has made $1.1&#160;million in royalty payments to RTW. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the Revenue Interest Financing and PIPE Subscription Agreement (as discussed in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>), on February&#160;9, 2023, Legacy Allurion entered into the RTW Side Letter with RTW, subsequently amended on May&#160;2, 2023. The Amended and Restated RTW Side Letter amended and restated the existing RTW Side Letter in its entirety, in order to reflect that any conditional additional shares issuable to RTW would be calculated net of any Backstop Shares issuable to RTW under the Backstop Agreement. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div>for discussion around the additional shares issued to RTW in connection with the Amended and Restated RTW Side Letter and Backstop Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $7.04 for the average of 20 trading days within any 30 trading day period (&#8220;Stock Price Drop&#8221;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $10.00 per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $7.5&#160;million of its initial PIPE subscription into additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE subscription. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $3.3&#160;million within Other liabilities on the consolidated balance sheet with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other <div style="letter-spacing: 0px; top: 0px;display:inline;">income </div>(expense). </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s Revenue Interest Financing consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Royalty payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,092</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Change in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,708</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing, side letter, and PIPE conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028980416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for the Company&#8217;s assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination on August&#160;1, 2023, the Company recorded a liability for Public Warrants to purchase the Company&#8217;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as September&#160;30, 2024 of $0.04, which is a Level&#160;1 input. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Warrants, Public Offering Warrants, and Private Placement Warrants </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), and Private Placement Warrants (defined below) within Level&#160;3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, and Private Placement Warrants: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy&#160;Allurion&#160;Series&#160;C&#160;Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30,&#160;2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.65%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.59%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3.65%&#160;-</div><br/> 3.71%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">6.5&#160;-&#160;7.96</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.58%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.58%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series&#160;C Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">7.25&#160;-&#160;8.71</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expected dividend yield for all calculations is 0.00%. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the three and nine months ended September&#160;30, 2024 and 2023 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:37%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681126;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681127;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,187</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,121</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div></div><div> <div style="line-height:normal;display: inline;">  </div> </div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680849;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(647</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(447</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680850;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(587</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,187</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,797</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2019 Term Loan Success Fee Derivative Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The derivative liability for the success fee associated with Legacy Allurion&#8217;s November 2019 loan and security agreement with Western Alliance Bank (the &#8220;2019 Term Loan&#8221; and such fee, the &#8220;Success Fee&#8221;) was recorded at fair value as of September&#160;30, 2024 and December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within four years from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2023 Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the 2023 Convertible Notes, using the share price at conversion ($7.04 per share). Upon the conversion of the 2023 Convertible Notes, the convertible note liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing is accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of September&#160;30, 2024 and December&#160;31, 2023 using a discounted cash flow (&#8220;DCF&#8221;) method under the income approach utilizing future revenue projections and a discount rate of 23.5% and 24.4%, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method (&#8220;MCSM&#8221;) using the number of shares convertible of 1,065,341 and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion Common Stock, with the change in fair value recognized in Change in the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities in the consolidated statement of operations. The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares was determined using a MCSM with the following assumptions at each valuation date: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Term Loan Derivative Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan derivative liability associated with the Fortress Term Loan was derecognized during the second quarter of 2024 as the Fortress Term Loan was repaid on April&#160;16, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The RTW Convertible Notes are accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently measured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes was remeasured as of September&#160;30, 2024 using a DCF method under the income approach with a MCSM applied to determine the simulated stock price at each payment date and event that may trigger conversion of the RTW Convertible Notes. The fair value was measured using the $48.0&#160;million principal amount of the RTW Convertible Notes and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, Term Loan Derivative liability, RTW Convertible Notes, PubCo Share liability, Base PubCo and Backstop Share liability, and Warrant Overallotment Liability categorized with Level&#160;3 inputs for the three and nine months ended September&#160;30, 2024 and 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(599</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,357</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,870</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,581</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,020</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,447</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,590</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> liability, Term Loan Derivative liability, RTW Convertible <div style="display:inline;">Not</div>es, Pubco Share liability, and Base PubCo and Backstop Share liability at each period is recorded as a component of Other income (expense) in the condensed consolidated statements of operations, with the exception of the changes in fair value associated with the change in credit risk related to the Revenue Interest Financing and RTW Convertible Notes, which is recorded as a component of other comprehensive loss. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Fair Value Measurements </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative Liability-Success Fee</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination on August&#160;1, 2023, the <div style="letter-spacing: 0px; top: 0px;display:inline;">Company </div>recorded a liability for Public Warrants to purchase the Company&#8217;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as of December&#160;31, 2023 of $0.45, which is a Level&#160;1 input. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Warrants </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the warrants within Level&#160;3 of the hierarchy as the fair value is derived <div style="letter-spacing: 0px; top: 0px;display:inline;">using </div>the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (level 3) inputs. See table below for the assumptions used in the pricing model: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7.25</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">8.71</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.42</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.41</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">1.02<div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>-&#160;1.10</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">4.6</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">4.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">3.88</div>-<div style="letter-spacing: 0px; top: 0px;display:inline;">3.92</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">8.2</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">9.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expected dividend yield for all calculations is 0.00%. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the years ended December&#160;31, 2023 and 2022 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680782;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680783;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(720</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(548</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2019 Term Loan Success Fee Derivative Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The derivative liability for the success fee associated with Legacy Allurion&#8217;s November 2019 loan and security agreement with Western Alliance Bank (the &#8220;2019 Term Loan&#8221; and such fee, the &#8220;Success Fee&#8221;) was recorded at fair value as of December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within four years from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">re-measured</div> at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the notes, using the share price at conversion ($7.04 per share). Upon the conversion of the notes, the convertible note liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">PubCo Additional Shares Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PubCo Additional Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, <div style="letter-spacing: 0px; top: 0px;display:inline;">just </div>prior to the close of the Business Combination, using the number of shares issued at the close of the Business Combination of 387,696 and an estimated price of shares at settlement of $7.04. Upon the issuance of shares, the PubCo Additional Shares liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Base PubCo Shares and Backstop Shares Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Base PubCo Shares and Backstop Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, just prior to the close of the Business Combination, using the number of shares for each Backstop Purchaser at the close of the Business Combination of 950,000 and an estimated price of shares at settlement of $7.04. Upon the issuance of shares, the Base PubCo Shares and Backstop Shares liability was derecognized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Revenue Interest Financing was accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of December&#160;31, 2023 using a discounted cash flow (&#8220;DCF&#8221;) method under the income approach utilizing future revenue projections and a discount rate of 24.4%. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method using the number of shares convertible of 1,065,341 and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liability </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion <div style="letter-spacing: 0px; top: 0px;display:inline;">Common </div>Stock, with the change in fair value recognized in Change in the fair value of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liabilities in the consolidated statement of operations. The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> shares was determined using a Monte Carlo Simulation Method using the following assumptions at the valuation date: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Term Loan Derivative Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Term Loan Derivative Liability associated with the Fortress Term Loan was recorded at fair value as of December&#160;31, 2023 using a DCF model that includes default interest payments expected to be made based on future revenue projections and cash flow assumptions and a discount rate of 24.4%. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, PubCo Additional Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, and Term Loan Derivative Liability categorized with Level&#160;3 inputs for the years ended December&#160;31, 2023 and 2022 were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,408</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29,050</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,092</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, PubCo <div style="letter-spacing: 0px; top: 0px;display:inline;">Additional </div>Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> liability, and Term Loan Derivative Liability at each period is recorded as a component of Other (expense) income in the consolidated statements of operations, with the exception of the change in fair value associated with the change in credit risk related to the Revenue Interest Financing which is recorded as a component of other comprehensive loss. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Assets and Liabilities Not Carried at Fair Value </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Fortress term loan is carried at amortized cost. The fair value of the Fortress term loan was estimated to be $43.2&#160;million on December&#160;31, 2023. The fair value was determined using a discounted cash flow approach. We classified the fair value disclosures for the Fortress Term Loan within level 3 of the fair value hierarchy because the fair value is derived using a significant unobservable input, which includes a discount rate. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded income tax expense of $0.1&#160;million and $0.2&#160;million for the three and nine months ended September&#160;30, 2024, respectively, representing effective tax rates of (0.8%) and (3.9%), respectively. The Company recorded income tax expense for the three and nine months ended September&#160;30, 2023 of less than $0.1&#160;million and $0.1&#160;million, respectively, representing effective tax rates of (0.2%) and (0.1%), respectively. The tax expense recorded relates to the earnings of the Company&#8217;s profitable foreign subsidiaries. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024 and 2023, the Company maintained a full valuation allowance against its net deferred tax assets as the Company has incurred significant operating losses since inception and has concluded that its net deferred tax asset is not <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">more-likely-than-not</div> realizable. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024 and 2023, the Company has not recorded tax reserves for any uncertain tax provisions. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of net loss before income taxes are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,259</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation between the effective tax rate and the statutory federal income tax rate for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">D</div></div></div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div>c</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;">m</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">b</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div>e</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">r</div></div></div>&#160;31, 2023 and 2022 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of financial instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30.5</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.4</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. federal and state net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,051</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">start-up</div> and research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bad debt reserve</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57,985</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(623</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other deferred tax liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,636</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded income tax expense of $0.3&#160;million during the year ended December&#160;31, 2023 due to foreign operating income. The Company recorded $0.1&#160;million of income tax expense during the year ended December&#160;31, 2022. The Company maintains a valuation allowance for the full amount of the net United States deferred tax assets, as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased for the years ended December&#160;31, 2023 and 2022 by approximately $24.5&#160;million and $10.9&#160;million, respectively, due to an increase in deferred tax assets having a full valuation allowance primarily due to the operating losses incurred, capitalized research and development expenses and tax credits generated. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had $132.2&#160;million and $131.7&#160;million of federal and state NOL carryforwards, respectively. Of the federal NOL carryforwards, $12.8&#160;million expire between 2030 and 2037 and $119.5&#160;million do not expire. The state NOL carryforwards expire between 2030 and 2042. As of December&#160;31, 2023, the Company had $1.5&#160;million and $0.9&#160;million of federal and state research and development tax credits, which expire beginning in 2031 and 2028, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to the Company&#8217;s valuation allowance are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions charged to net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Realization of the future tax benefits from these assets is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#8217;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize net operating loss and research and development credit carryforwards in the future. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to US federal income tax, state income tax in Massachusetts, and income tax in certain foreign jurisdictions. The Company&#8217;s historical income taxes in foreign jurisdictions have been immaterial to the consolidated financial statements. The Company is not currently under examination by the Internal Revenue Service (&#8220;IRS&#8221;) or any other jurisdictions for any tax years; however, all tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the U.S. IRS or other authorities if they have, or will be, used in a future period. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the unremitted earnings of the Company&#8217;s foreign subsidiaries are immaterial. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interpretive guidance on the accounting for global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">low-taxed</div> income (&#8220;GILTI&#8221;) states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. The Company made the accounting policy election to recognize GILTI as a period expense. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023 and 2022, the Company has not recorded a tax liability for any uncertain tax positions. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. There are no accrued interest and penalties as of December&#160;31, 2023 and 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954032875008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock', window );">Redeemable Convertible Preferred Stock and Stockholders' Deficit</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Preferred Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with RTW, pursuant to which the Company agreed to sell to RTW 2,260,159 shares of a newly created series of preferred stock, the Series A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> convertible preferred stock, par value $0.0001 per share (&#8220;Series A Preferred Stock&#8221;), and 2,260,159 private placement warrants (&#8220;Private Placement Warrants&#8221;) to purchase common stock, equal to the per share Public Offering (defined below) price for the shares of common stock and Public Offering Warrants (defined below) in the Public Offering (the &#8220;Private Placement&#8221;). The Private Placement closed on July&#160;1, 2024 with net proceeds received of $2.5&#160;million after deducting offering costs of $0.2&#160;million. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants met the definition of a derivative under ASC 815. The gross proceeds from the Private Placement were first allocated to the Private Placement Warrants based on its issue-date estimated fair value of $1.7&#160;million. The Private Placement Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The remaining gross proceeds of $1.0&#160;million were allocated to the Series A Preferred Stock. Of the $0.2&#160;million in offering costs, $0.1&#160;million was recorded against the Series A Preferred Stock as a reduction of proceeds and $0.1&#160;million was expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Certificate of Incorporation authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of September&#160;30, 2024, 2,260,159 shares of Allurion Series A Preferred Stock were outstanding. The rights and preferences of the Series A Preferred Shares are as follows: </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stockholders have no voting rights. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock participates in dividends with Common Stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis when declared by the Board of Directors. No dividends were declared through September&#160;30, 2024. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">winding-up</div> of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder&#8217;s Series A&#160;Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A Preferred Stock is convertible after the date that the Company&#8217;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#8220;Series A Stockholder Approval&#8221;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(ii)&#160;pre-funded</div> conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.</div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A&#160;Preferred Stock outstanding on December&#160;31, 2026 (the &#8220;Redemption Date&#8221;) shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the &#8220;Redemption Price&#8221;). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion Certificate of Incorporation authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of September&#160;30, 2024 and December&#160;31, 2023, 64,369,381 and 47,688,096 shares of Common Stock were outstanding, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC and TD Securities (USA) LLC, as representative of the several underwriters (the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell 14,406,508 shares of the Company&#8217;s Common Stock and warrants (&#8220;Public Offering Warrants&#8221;) to purchase up to 14,406,508 shares of the Company&#8217;s Common Stock at an offering price of $1.20 per share and accompanying warrant (the &#8220;Public Offering&#8221;). The Public Offering closed on July&#160;1, 2024 with net proceeds received of $15.2&#160;million after deducting underwriting discounts of $1.0&#160;million and offering costs of $1.0&#160;million. The Underwriters fully exercised their option for additional Public Offering Warrants, with 2,160,976 additional Public Offering Warrants issued at closing, for a total of 16,567,484 Public Offering Warrants. Further, the Underwriters exercised a portion of the option with respect to the Common Stock (the &#8220;Share Overallotment&#8221;) on July&#160;5, 2024 for net proceeds of $2.2&#160;million, which resulted in the issuance of 1,927,265 shares of the Company&#8217;s Common Stock at an offering price of $1.20 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Public Offering Warrants met the definition of a derivative under ASC 815 and the Share Overallotment met the requirements for equity classification under ASC 815. The $17.4&#160;million in net proceeds from the Public Offering and exercise of the Share Overallotment were first allocated to the Public Offering Warrants based on their issue-date estimated fair value of $13.2&#160;million. The Public Offering Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $0.8&#160;million offerings costs allocated to the Public Offering Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $5.1&#160;million were allocated to Common Stock and APIC. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of September&#160;30, 2024, is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,108,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">530,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260,159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,369,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Warrants to Purchase Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of September&#160;30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common&#160;Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">7/1/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">18,827,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Compute Health&#8217;s initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class&#160;A Common Stock, $0.0001 par value, of Compute Health (&#8220;Class A Common Stock&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden127682683;display:inline;">one-half</div></div> of a redeemable warrant (each a &#8220;Public Warrant&#8221;) that entitled the holder to purchase one share of Class&#160;A Common Stock of CPUH at a price of $11.50 per share. On July&#160;26, 2023, Compute Health&#8217;s Public Warrant holders approved an amendment (the &#8220;Warrant Amendment&#8221;) to the warrant agreement that governed all Compute Health&#8217;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 1.420455 shares of the Company&#8217;s Common Stock at an exercise price of $8.10 per share and each whole Compute Health Public Warrant was exchanged for 0.6125 Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for cash at a price of $0.01 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price the Company&#8217;s Common Stock equals or exceeds $12.67 per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $0.10 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $7.04 per share of any </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#8220;Redemption Fair Market Value&#8221;) of the shares of the Company&#8217;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#8217;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of September&#160;30, 2024, the Company has not redeemed any of the outstanding Public Warrants. As of September&#160;30, 2024, there were 13,206,720 outstanding Public Warrants exercisable for 18,759,554 shares of Allurion Common Stock. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Chardan Equity Facility </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a Registration Rights Agreement, each with Chardan Capital Markets (&#8220;Chardan&#8221;) related to a &#8220;ChEF,&#8221; Chardan&#8217;s committed equity facility (the &#8220;Chardan Equity Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000&#160;in aggregate gross purchase price of newly issued shares of the Company&#8217;s Common Stock, and (ii) 9,482,468 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;). In consideration for Chardan&#8217;s entry into the Purchase Agreement, Allurion issued to Chardan 35,511 shares of Allurion Common Stock (the &#8220;Commitment Shares&#8221;). The Company recorded $0.1&#160;million to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and $0.1&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1&#160;million related to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> structuring fee immediately following commencement. As of September&#160;30, 2024, the Company had sold 143,234&#160;shares of Common Stock to Chardan at a purchase price of $0.4&#160;million in connection with the Purchase Agreement. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock and stockholders deficit text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954142021280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock and Stockholders' Deficit</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Capital Stock and Stockholders&#8217; Deficit </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion certificate of incorporation authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of December&#160;31, 2023, no shares of Allurion preferred stock were outstanding. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Legacy Allurion Preferred Equity </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Legacy Allurion preferred stock was retroactively adjusted, converted into common stock at the Exchange Ratio, and reclassified to permanent equity as a result of the reverse recapitalization. As of December&#160;31, 2023, there is no Legacy Allurion preferred stock authorized, issued, or outstanding. The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Authorized (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Issued&#160;and<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,276,786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,276,786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,513,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,486,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series B Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,298,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,245,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,113,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,927,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,684,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,644,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,644,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,498,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,498,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,029,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,921,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors, and the Legacy Allurion common stockholders were entitled to elect four members of the Board of Directors. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Legacy Allurion preferred stock participated in dividends with Legacy Allurion common stock on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">as-converted</div> basis when declared by the Board of Directors. The Legacy Allurion preferred stockholders were entitled to receive dividends, when and if declared, on a pro rata pari passu basis according to the number of shares of Legacy Allurion common stock held by such holder. The Legacy Allurion Series D preferred stockholders were also entitled to a cumulative dividend that accrues at the rate of 6% per annum. The dividend accrued on a daily basis from and including the issuance date of such shares, whether or not declared. Through the date of the Business Combination, no dividends had been declared. </div> <div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">winding-up</div> of Legacy Allurion, before any payment were to be made to the holders of common stock, the holders of shares of Legacy Allurion </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">preferred stock then outstanding were entitled to be paid out of the funds and assets available for distribution to Legacy Allurion&#8217;s stockholders, on a pari passu basis, an amount per share equal to (i)&#160;the Legacy Allurion Series A, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> Series B and Series C preferred stock, a per share liquidation preference equal to $1.092, $2.850, $3.563 and $4.935, respectively, plus any accruing dividends accrued but unpaid, whether or not declared and (ii)&#160;the Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> preferred stock, a per share liquidation preference equal to $17.809, $9.338, and $15.137, respectively, plus any accruing dividends accrued but unpaid, whether or not declared provided, that, if Legacy Allurion achieved a revenue milestone of $65.0&#160;million in a trailing twelve month period (the &#8220;Milestone&#8221;), then in lieu of the foregoing, the holders of the Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> Preferred Stock were entitled to receive an amount per share equal to $11.8725, $6.2256 and $10.0916, respectively, plus any accruing dividends accrued but unpaid, whether or not declared (collectively, the &#8220;Preferred Stock Preference&#8221;). After payment of the Preferred Stock Preference, the funds and assets available for distribution to Legacy Allurion&#8217;s stockholders, if any, would be initially distributed on a pro rata basis to the holders of common stock in Legacy Allurion in proportion to the number of shares of common stock held at an amount per share equal to 150% of the Original Issue Price of the Legacy Allurion Series A Preferred Stock ($1.092), plus any dividends declared but unpaid thereon (the &#8220;First Catchup Amount&#8221;). Any remaining funds and assets available for distribution to Legacy Allurion stockholders, if any, after the First Catchup Amount would then be distributed on a pro rata basis to the holders of common stock and preferred stock in proportion to the number of shares of common stock or preferred stock held. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series&#8217; applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock. </div><div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redemption </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Legacy Allurion Series A, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> Series B, Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1,</div> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2,</div> and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> preferred stock were not entitled to any redemption rights, other than those under their liquidation rights discussed above. Upon the election of the holders of a majority of shares of the Legacy Allurion Series C preferred stock, up to 50% of the outstanding shares of Legacy Allurion Series C preferred stock were redeemable at a price equal to 1.5 times the original issuance price, plus all declared, but unpaid dividends thereon, on a pro rata basis in an equal semiannual portion, after January&#160;17, 2022. The Legacy Allurion Series C contingent redemption upon a deemed liquidation event resulted in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Common Equity </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Allurion certificate of incorporation authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of December&#160;31, 2023 and 2022, 47,688,096 and 27,079,856 shares of common stock were outstanding, respectively, after retrospectively adjusting for the effect of the reverse recapitalization. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of December&#160;31, 2023, is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,693,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants to Purchase Common Stock </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of December&#160;31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12/1/2014</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3/30/2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/15/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/4/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1/17/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8/3/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/8/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/19/2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/25/2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">4/1/2013</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">16,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series B Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">60,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">8.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series C Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table>  <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Compute Health&#8217;s initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class&#160;A Common Stock, $0.0001 par value, of Compute Health (&#8220;Class A Common Stock&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden127680787;display:inline;">one-half</div></div> of a redeemable warrant (each a &#8220;Public Warrant&#8221;) that entitled the holders the right to purchase one share of Class&#160;A Common Stock of CPUH at a price of $11.50 per share. On July&#160;26, 2023, Compute Health&#8217;s Public Warrant holders approved an amendment (the &#8220;Warrant Amendment&#8221;) to the warrant agreement that governed all Compute Health&#8217;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 1.420455 shares of the Company&#8217;s Common Stock, par value $0.0001 per share, at an exercise price of $8.10 per share and each Compute Health Public Warrant was exchanged for 0.6125 Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for cash at a price of $0.01 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $12.67 per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $0.10 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#8217;s Common Stock equals or exceeds $7.04 per share of any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">30-day</div> trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#8220;Redemption Fair Market Value&#8221;) of the shares of the Company&#8217;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#8217;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of December&#160;31, 2023, the Company has not redeemed any of the outstanding Public Warrants. As of December&#160;31, 2023, there were 13,206,922 outstanding Public Warrants exercisable for 18,759,838 shares of Allurion Common Stock. </div><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Chardan Equity Facility </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#8220;Purchase Agreement&#8221;) and a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), each with Chardan Capital Markets (&#8220;Chardan&#8221;) related to a &#8220;ChEF,&#8221; Chardan&#8217;s committed equity facility (the &#8220;Chardan Equity Facility&#8221;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of the Company&#8217;s Common Stock, and (ii) 9,482,468 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#8220;Exchange Cap&#8221;). In consideration for Chardan&#8217;s entry into the Purchase Agreement, Allurion agreed to issue to Chardan 35,511 shares of Allurion Common Stock (the &#8220;Commitment Shares&#8221;). The Company recorded $0.1&#160;million to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital and $0.1&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1&#160;million related to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-refundable</div> structuring fee (the &#8220;Structuring Fee&#8221;) immediately following commencement. As of December&#160;31, 2023, the Company had not sold any shares of Common Stock to Chardan in connection with the Purchase Agreement. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033185648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Net Loss per Share </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share was calculated as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,630</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61,427</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared preferred dividends to participating securities (Legacy Series&#160;D convertible preferred stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,697</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common shareholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9,004</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,885</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,124</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted weighted-average common stock outstanding</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,086,265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,335,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,310,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,558,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share, basic and diluted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.14</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.54</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.10</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,108,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,270,229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">530,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">429,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260,159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">404,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,369,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,864,376</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Net Loss per Share </div></div> </td> </tr> </table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share was calculated as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,607</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared dividends to participating securities (Legacy Series D convertible preferred stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,697</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,907</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82,304</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,651</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted weighted-average common stock outstanding</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,581,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,918,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders, basic and diluted (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information. </div> </td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,301,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297,854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible notes (as converted to common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,693,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,325,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035484768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Incentive Plans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2010 Stock Incentive Plan (the &#8220;2010 Plan&#8221;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. On December&#160;11, 2020, the Company&#8217;s Board of Directors adopted the Amended and Restated 2020 Stock Option and Grant Plan (the &#8220;2020 Plan&#8221;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;), which provides for the award of stock options (both incentive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified),</div> stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. As of September&#160;30, 2024, a total of 8,174,364&#160;shares of Allurion Common Stock are reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by 5% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the compensation committee. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024,<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>7,639,094 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2023, 4,529,673 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. The stock options generally vest over a four-year period and expire 10 years from the date of grant. </div> <div></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the condensed consolidated statement of operations was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the nine months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,686,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(447,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,137</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,108,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,872,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to stock option awards during the three and nine months ended September&#160;30, 2024 was $0.6&#160;million and $1.4&#160;million, respectively. As of September&#160;30, 2024, there was approximately $5.6&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2010 Plan, 2020 Plan, and 2023 Plan, which is expected to be recognized over a weighted-average vesting term of 3.0 years. The weighted average grant-date fair value of the stock option awards granted during the nine months ended September&#160;30, 2024 was $1.30 per option. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#8217;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company issued RSUs to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div> for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, 62.5% of the RSUs awarded vested. Thereafter, the remaining 37.5% of the RSUs vest monthly over a period of two years. All RSUs are subject to forfeiture if the grantee&#8217;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. In October 2023 and March 2024, the Company issued RSUs to its Board of Director members that vest in equal installments over three years, subject to continued service as a director through each vesting date. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">of RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(187,857</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">530,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to RSUs for the three and nine months ended September&#160;30, 2024 was $0.2&#160;million and $0.8&#160;million, respectively. As of September&#160;30, 2024, there were $1.0&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of 1.6 years. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#8217;s Common Stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#8217;s payroll deductions under the 2023 ESPP are limited to 15% of the employee&#8217;s compensation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 2,226,122 shares of the Company&#8217;s Common Stock are reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ESPP will automatically increase each January&#160;1, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) 1,600,000 shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of September&#160;30, 2024, no shares have been issued under the 2023 ESPP. </div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Stock Based Compensation </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Incentive Plans </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2010 Stock Option Plan (the &#8220;2010 Plan&#8221;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. On December&#160;11, 2020, the Company&#8217;s Board of Directors adopted the 2020 Stock Option Plan (the &#8220;2020 Plan&#8221;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#8217;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#8217;s Common Stock. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#8220;2023 Plan&#8221;), which provides for the award of stock options (both incentive and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-qualified),</div> stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. A total of 7,822,700 shares of Allurion Common Stock were initially reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by 5% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the Compensation Committee. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, 4,529,673 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2022, 5,717,072 options and RSUs were issued and outstanding under the 2010 Plan and 2020 Plan. The stock options generally vest over a four-year period and expire 10 years from the date of grant. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the consolidated statement of operations and comprehensive loss was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general, and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the year ended December&#160;31, 2023: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,301,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(375,051</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(298,562</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercisable at December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,735,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to stock option awards during the year ended December&#160;31, 2023 was $2.7&#160;million. As of December&#160;31, 2023, there was approximately $2.5&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2020 Plan, which is expected to be recognized over a weighted-average vesting term of 2.1 years. The weighted average grant-date fair value of the stock option awards granted during the years ended December&#160;31, 2023 and 2022 was $3.98 and $2.36 per option, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#8217;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies which are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted- average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-employees</div> is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#8217;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option-pricing model are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8194;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.56</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2022, the Company issued RSUs under the 2020 Plan to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 1, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Organization and Basis of Presentation </div></div>and Note 3<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">, Business Combination </div></div>above for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, 62.5% of the RSUs awarded vested. Thereafter, the remaining 37.5% of the RSUs vest monthly over a period of two years. In October 2023, the Company issued additional RSUs to Board of Director members with annual vesting over three years. All RSUs are subject to forfeiture if the grantee&#8217;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the year ended December&#160;31, 2023: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant<br/> Date&#160;Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">226,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(918,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December 31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total stock compensation expense related to RSUs for the year ended December&#160;31, 2023 was $5.7&#160;million. As of December&#160;31, 2023, there were $1.7&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of 2.0 years. The weighted average grant-date fair value of time-vested restricted stock units granted during the years ended December&#160;31, 2023 and 2022 was $4.32 and $4.51 per share, respectively. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div><div></div><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#8220;2023 ESPP&#8221;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#8217;s Common Stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#8217;s payroll deductions under the 2023 ESPP are limited to 15% of the employee&#8217;s compensation. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 1,422,309 shares of the Company&#8217;s Common Stock were initially reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 ESPP will automatically increase each January&#160;1, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) 1,600,000 shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of December&#160;31, 2023, no shares have been issued under the 2023 ESPP. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033877008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Employee Benefit Plan </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. During each of the three and nine months ended September&#160;30, 2024 and 2023, the Company&#8217;s matching contributions to the plan were less than $0.1&#160;million. </div> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Employee Benefit Plan </div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contribution. During the years ended December&#160;31, 2023 and 2022, the Company&#8217;s matching contributions to the plan were $0.1&#160;million. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035484768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases. As a result of these amendments, the leases in Natick and Hudson will now expire between March 2025 and March 2028, and additional operating lease assets obtained in exchange for lease obligations were $0.9&#160;million. In April 2024, the Company executed an amendment to one of its leases in Natick, Massachusetts. The amendment was accounted for as a modification of the existing lease agreement, with impacts to the lease term, lease payments, and related lease liability for the lease. As a r<div style="letter-spacing: 0px; top: 0px;display:inline;">es</div>ult of this amendment, the lease in Natick will now expire in March 2025 and additional operating lease assets obtained in exchange for lease obligations were less than $0.1&#160;million. In February 2024, the Company terminated one of its leases in Paris, France. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2024, the Company was a party to six different leases for office, manufacturing, and laboratory space under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> office leases in three cities. These leases total approximately 51,000 square feet and will expire between March 2025 and March 2028. The Company has a right to extend certain of these leases for periods between <div style="-sec-ix-hidden:hidden127680941;display:inline;">three</div> and five years. Under its real property leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. The Company also holds immaterial leases related to vehicles and office equipment. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and lease liabilities are included in the condensed co<div style="letter-spacing: 0px; top: 0px;display:inline;">ns</div>olidated balance sheets. The short-term portion of the Company&#8217;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Aggregate Lease Information </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information for the three and nine months ended September&#160;30, 2024 and 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the <br/> measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange <br/> for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements as of September&#160;30, 2024 are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">646</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(878</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,578</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted -average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Product Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not received any material product liability claims. Notwithstanding this, the Company has obtained insurance related to potential product liability claims. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Litigation and Claims </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, securities class actions, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of September&#160;30, 2024 and December&#160;31, 2023, the Company has not recorded accruals for probable losses related to any existing or pending litigation or claims as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">French Regulatory Decision </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2024, it was announced that the Agence Nationale de S&#233;curit&#233; du M&#233;dicament (&#8220;ANSM&#8221;), the French regulatory authority, has suspended sales of the Allurion Balloon in France, and the Company withdrew the device from the French market. The Company has implemented a remediation plan to reduce certain risks associated with the advertising, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">follow-up</div> program, and adverse events for the Allurion Balloon. For the three and nine months ended September&#160;30, 2024, the Company recognized a reduction to revenues of $1.2&#160;million for customer returns of the Allurion Balloon. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">NYSE Continued Listing Standards </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;12, 2024, we received a letter from the NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#8217;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ending on the last trading day of that month. In the event that at the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">six-month</div> cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;29, 2024, we received written notice from the NYSE that we are not in compliance with the con<div style="display:inline;">tinu</div>ed listing standard set forth in Section&#160;802.01B of the NYSE&#8217;s Listed Company Manual because the average market capitalization of the Company was less than $50.0&#160;million over the consecutive 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">trading-day</div> period ended August&#160;29, 2024 and the Company&#8217;s last reported stockholders&#8217; equity as of August&#160;29, 2024 was less than $50.0&#160;million. In accordance with applicable NYSE procedures, we submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice. If the NYSE accepts our plan, the NYSE will review the Company on a quarterly basis to confirm compliance with the plan. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Commitments and Contingencies </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases. As a result of these amendments, the leases in Natick and Hudson will now expire between June 2024 and March 2028, and additional operating lease assets obtained in exchange for lease obligations were $0.9&#160;million. As of December&#160;31, 2023, the Company was a party to seven different leases for office, manufacturing, and laboratory space under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> office leases in three cities. These leases total approximately 51,000 square feet and will expire between June 2024 and March 2028. The Company has a right to extend certain of these leases for periods between <div style="-sec-ix-hidden:hidden127682050;display:inline;">three</div> and five years. The Company also holds immaterial leases related to vehicles and office equipment. Under its leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of ROU assets and lease liabilities are included in the consolidated balance sheets. The short-term portion of the Company&#8217;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the consolidated balance sh<div style="letter-spacing: 0px; top: 0px;display:inline;">e</div>ets. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Aggregate Lease Information </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(563</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(908</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table>  <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Liability </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not received any material product liability claims. While product defects and adverse patient reactions associated with the Allurion Balloon have occurred, and are expected to continue to occur, the Company does not have a history of product defects or adverse patient reactions that the Company&#8217;s management believes would give rise to a material product liability claim. Furthermore, the Company has obtained insurance related to potential product liability claims. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Litigation and Claims </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of December&#160;31, 2023 and 2022, the Company has not recorded accruals for potential losses related to any existing or pending litigation or claims as the Company&#8217;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#8217;s consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954032710048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic Information</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Geographic Information </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue</div></div> for information on revenue by geography. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Geographic Information </div></div></td></tr></table>  <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue</div></div> for information on revenue by geography. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027575840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-party Transactions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Related-party Transactions </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Lease Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#8217;s then-Trade Marketing Director was the signor of this lease for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LNMP JPBS Invest. Additionally, the Company&#8217;s former Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $0.1&#160;million per year. The term of the lease was August 1, 2022 through July 31, 2025. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">arm&#8217;s-length.</div> This lease was terminated in February 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#8220;KKG Enterprises&#8221;) and Remus Group Management, LLC (&#8220;Remus Group Management&#8221;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $0.2&#160;million to KKG Enterprises and $0.3&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on June 20, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Note with Hunter Ventures Limited </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, Allurion sold $13&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than 5% of our outstanding common stock). Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for additional information regarding the 2023 Convertible Notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Consulting Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion (&#8220;Allurion France&#8221;), entered into a corporate officer agreement with the Company&#8217;s then-Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The corporate officer agreement provided that BCC would receive base consulting fees of &#8364;28,333.33 per month and additional variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on December 12, 2023 by virtue of the termination agreement described below, effective December&#160;31, 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Termination Agreement with Related Party </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, Allurion France entered into a termination agreement with the Company&#8217;s Chief Commercial Officer, Benoit Chardon, and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC resigned from its duties as managing director of Allurion France effective December&#160;31, 2023. Allurion paid BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion paid BCC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lump-sum</div> termination fee of $0.2&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Note Agreement with RTW </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Note Purchase Agreement, on April&#160;16, 2024, we issued and sold $48&#160;million aggregate principal amount of convertible notes to RTW. RTW holds more than 5% of our outstanding Common Stock, has the right to designate an independent director nominee to be elected by our stockholders, is entitled to designate one representative to serve as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-voting</div> observer on our Board, and had the right to approve an </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">additional director nominee for election In September 2024, we expanded our Board and appointed a new director in satisfaction of certain of these obligations to RTW as set forth in the Amended Note Purchase Agreement. Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>, for additional information regarding the RTW Convertible Notes. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Participation in Public Offering </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering, the Company issued and sold 239,842 shares of Common Stock and accompanying warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $0.3&#160;million. The Public Offering closed on July&#160;1, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Private Placement with RTW </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;28, 2024, pursuant to the Subscription Agreement, the Company agreed to sell to RTW 2,260,159 shares of Series A Preferred Stock, and 2,260,159 Private Placement Warrants, for an aggregate purchase price of approximately $2.7&#160;million. The Private Placement closed on July&#160;1, 2024. </div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Related-party Transactions </div></div></td></tr></table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Lease Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#8217;s then-Trade Marketing Director was the signor of this lease for LNMP JPBS Invest. Additionally, the Company&#8217;s Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $0.1&#160;million per year. The lease commenced August 1, 2022 and was to end on July 31, 2025. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">arm&#8217;s-length.</div> This lease was terminated in February 2024. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#8220;KKG Enterprises&#8221;) and Remus Group Management, LLC (&#8220;Remus Group Management&#8221;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $0.2&#160;million to KKG Enterprises and $0.3&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on June 20, 2023. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Convertible Note with Hunter Ventures Limited </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;15, 2023, Allurion sold $13&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than 5% of our outstanding Common Stock). Refer to Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div> for additional information regarding the 2023 Convertible Notes. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Consulting Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion, entered into a new corporate officer agreement with the Company&#8217;s Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e which is solely owned by Mr.&#160;Chardon (&#8220;BCC&#8221;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The new corporate officer agreement provided that BCC would receive base consulting fees of &#8364;28,333.33 per month and additional </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on December 12, 2023 by virtue of the termination agreement described below. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Termination Agreement with Related Party </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;12, 2023, Allurion France, a French soci&#233;t&#233; par actions simplifi&#233;e and wholly-owned subsidiary of Allurion, entered into a termination agreement with the Company&#8217;s Chief Commercial Officer, Benoit Chardon and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC will resign from its duties as managing director of Allurion France effective December&#160;31, 2023 and Allurion France will pay BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion France will pay BCC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">lump-sum</div> termination fee of $0.2&#160;million. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039309152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Subsequent Events </div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW PIPE Conversion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of Common Stock of the Company representing $7.5&#160;million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October&#160;30, 2024, the Company and the funds affiliated with RTW entered into the additional Revenue Interest Financing Agreement (the &#8220;New RIFA&#8221;). The New RIFA has substantially identical terms and conditions as the RIFA Amendment, except that the amount of financing provided under the New RIFA is equal to the conversion amount of $7.5&#160;million. </div><div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Restructuring Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;6, 2024, the Company&#8217;s board of directors approved a restructuring plan to reduce operating costs and better align its workforce with the needs of its business. The majority of the restructuring is expected to be completed in the fourth quarter of 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the restructuring plan, the Company is reducing its workforce by approximately 113 roles (approximately 50%). In connection with the restructuring, the Company estimates that it will incur <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">one-time</div> aggregate restructuring charges of approximately $3.5&#160;million, which will be recorded primarily in the fourth quarter of 2024, related to severance payments and other employee-related costs. The cash payments related to the personnel-related restructuring will be paid primarily during the first quarter of 2025. The charges that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027838560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Use of Estimates </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">RTW Convertible Notes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">RTW Convertible Notes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the RTW Convertible Notes (defined below) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The RTW Convertible Notes accounted for under the FVO election was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the RTW Convertible Notes were recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the RTW Convertible Notes were expensed as incurred. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 Convertible Notes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounted for the convertible notes issued between February 2023 and August 2023 (the &#8220;2023 Convertible Notes&#8221;) under the fair value option (&#8220;FVO&#8221;) election of ASC Topic 825, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments</div></div> (&#8220;ASC 825&#8221;). The convertible notes accounted for under the FVO election were each debt host financial instruments containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the convertible notes were </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">recorded as a component of Other (expense) income in the consolidated statements of operations. As a result of electing the FVO, direct costs and fees related to the 2023 Convertible Notes were expensed as incurred. The convertible notes issued in 2020, 2021 and 2022 are accounted for as disclosed in Note 8, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt</div></div>. In connection with the closing of the Business Combination on August&#160;1, 2023, a portion of the 2023 convertible notes was repaid, with the remaining balance converted to shares of our Common Stock. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification of Prior Year Presentation</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Reclassification of Prior Year Presentation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustment has been made to the condensed consolidated balance sheet as of December&#160;31, 2023, to present the Legacy Allurion common stock warrant liabilities as part of the Warrant liabilities line item. These amounts were part of the Other liabilities line item in prior years. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reclassification of Prior Year Presentation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>  <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">consolidated statement of <div style="letter-spacing: 0px; top: 0px;display:inline;">operations </div>and comprehensive loss for the year ended December&#160;31, 2022 to present the change in fair value of derivative liabilities as part of Other income (expense), net, and to present the change in fair value of warrants as its own line item. The change in fair value of derivative liabilities was a separate line item in prior years and the change in fair value of warrants was part of Other income (expense), net in prior years. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MezzanineEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Mezzanine Equity </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mezzanine equity represents the Series A Preferred Stock (defined below) issued by the Company. The shares of Series A Preferred Stock are redeemable at a determinable price on a fixed date, which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet. Refer to Note 12, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Redeemable Convertible Preferred Stock and Stockholder&#8217;s Deficit,</div></div> for additional information regarding the Series A Preferred Stock. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risk of Concentration of Credit, Significant Customers and Significant Suppliers</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue for the three and nine months ended September&#160;30, 2024 and 2023 or accounts receivable, net balance as of September&#160;30, 2024 and December&#160;31, 2023. The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risk of Concentration of Credit, Significant Customers and Significant Suppliers </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue for the years ended December&#160;31, 2023 and 2022 or accounts receivable, net balance as of December&#160;31, 2023 and 2022. The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts&#160;Receivable</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer C</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#8217;s operating results, financial condition and cash flows and damage its customer relationships. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2022, the Company adopted ASC 842, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC 842&#8221;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) asset and a current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-current</div> lease liability as applicable, in the consolidated balance sheets if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having an original term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will either renew or not cancel the lease. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#8217;s incremental borrowing rate. The </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company&#8217;s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of the lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into contracts that contain both lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-lease</div> components. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">Non</div>-lease</div> components include costs that do not provide a right to use a leased asset but instead provide a service, such as maintenance costs. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">right-of-use</div></div> assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents and Restricted Cash </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash consists of amounts held in bank savings and checking accounts. Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds. The Company&#8217;s restricted cash consists of cash that the Company is contractually obligated to maintain and deposits of cash collateral held in accordance with the terms of various corporate credit cards. Restricted cash is included within other long-term assets on the consolidated balance sheets. A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in <div style="-sec-ix-hidden:hidden127681918;display:inline;"><div style="-sec-ix-hidden:hidden127681919;display:inline;">other long-term assets</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in a single operating and reportable segment. Operating segments are defined as components of an enterprise for which discrete financial information is available and is regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) in order to make decisions regarding resource allocation and performance assessment. The Company has determined that its CODM is its Chief Executive Officer. The Company&#8217;s CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since the Company operates as one operating segment, all required financial segment information can be found in the consolidated financial statements. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s products include the Allurion Balloon and related accessories. See Note 4, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue </div></div>below<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>for financial information about sales in geographic areas. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying value of the Company&#8217;s financial instruments such as cash and cash equivalents, accounts payable, and accrued expenses approximate their fair values due to their short-term maturity. The carrying value of the Company&#8217;s term loan approximates its fair value as the interest rate and other terms are that which are currently available to the Company. The Company&#8217;s </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">assets and liabilities recorded at fair value have been categorized based upon a fair value hierarchy, which is distinguished between observable and unobservable inputs in accordance with authoritative accounting guidance: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;2 inputs: Other than quoted prices included in Level&#160;1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that the observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Inventories </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories, which include the costs of material, labor, and overhead, are stated at the lower of cost or net realizable value, with cost generally computed using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">first-in,</div> first out method. Estimated losses from obsolete and slow-moving inventories are recorded to reduce inventory values to their estimated net realizable value and are charged to cost of sales. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in a recovery in carrying value. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment include computers, laboratory equipment, machinery, and leasehold improvements. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated on a straight-line basis over the shorter of the estimated life or the lease term. Expenditures for repairs and maintenance are expensed as incurred. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Capitalized Internal-Use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Internal-Use</div> Software </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Software development costs consist of certain consulting costs and compensation expenses for employees who devote time to the development projects of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software, as well as certain upgrades and enhancements that are expected to result in enhanced functionality. The Company amortizes these development costs over the estimated useful life, which is determined based on our best estimate of the useful life of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software after considering factors such as continuous developments in the technology, obsolescence, and anticipated life of the service offering before significant upgrades. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined the amount of internal software costs to be capitalized based on the amount of time spent by our developers on projects in the application stage of development. There is judgment in estimating the time allocated to a particular project in the application stage. A significant change in the time spent on each project could have a material impact on the amount capitalized and related amortization expense in subsequent periods. As of December&#160;31, 2023 and 2022, capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">internal-use</div> software was immaterial. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtIssuanceCostsPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt Issuance Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company defers costs directly associated with acquiring third-party financing. Fees incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. Fees incurred in connection with a modification are deferred and amortized as a component of interest expense over the remaining life of the loan if due to the creditor. Third-party fees incurred in connection with a <div style="letter-spacing: 0px; top: 0px;display:inline;">modification </div>are expensed as incurred. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Deferred Offering Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the Business Combination. The Company deferred offering costs classified as a long-term asset until the closing or termination of the transaction. At the closing of the Business Combination, these costs were recorded in stockholders&#8217; deficit as a reduction of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital. Deferred offering costs are included in other long-term assets. As of December&#160;31, 2023 and 2022, there were zero and $2.3&#160;million of deferred offering costs recorded within other long-term assets on the consolidated balance sheet, respectively. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity </div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(&#8220;ASC&#160;480-10&#8221;),</div> then in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock </div></div>(&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40&#8221;).</div> Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">480-10,</div> warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or are warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASC&#160;480-10,</div> the Company assesses the requirements under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40,</div> and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">815-40</div> or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates its convertible instruments and other contracts, including warrants, to determine if those contracts or embedded components of those contracts are required to be accounted for as derivatives, either in whole or in part. If an embedded derivative is bifurcated from a debt host contract, changes in the fair value of the bifurcated derivative are recorded in the accompanying consolidated statements of operations. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_EarnoutLiabilityPolicyTextBlock', window );">Earn-out Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Liabilities </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, certain holders of Legacy Allurion common <div style="letter-spacing: 0px; top: 0px;display:inline;">stock </div>and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive up to 9,000,000 additional shares of Allurion Common Stock (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#8220;Earn-Out</div> Shares&#8221;) upon the achievement of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> targets. The contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration contains a settlement provision that in the event of a change in control, the number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares issued may vary. This settlement provision precludes the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> liability from being indexed to the Company&#8217;s Common Stock as a change in control event is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">fixed-for-fixed</div></div> forward or option on equity shares. As such, it is classified as a liability under ASC 480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity </div></div>(&#8220;ASC 480&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration is remeasured on a quarterly basis over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> period with changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration recorded in Other (expense) income in the consolidated statements of operations, and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> consideration may materially impact or cause volatility in our operating results. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock', window );">Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Interest Financing and PIPE Conversion Option </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a revenue interest financing agreement, dated as of February&#160;9, 2023 (the &#8220;Revenue Interest Financing Agreement&#8221;) with certain entities that have engaged RTW Investments, LP as investment manager (collectively, &#8220;RTW&#8221;), under which the Company received $40.0&#160;million upfront (the &#8220;Revenue Interest Financing&#8221;). In exchange, the Company is obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for the Revenue Interest Financing Agreement under the fair value option election of ASC 825. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument that contains embedded features. The embedded features include requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events, a change in royalty rates upon the occurrence of certain contingent events, and the Company&#8217;s ability to prepay the Revenue Interest Financing. As the Company has elected the FVO, these embedded features would not meet the criteria for bifurcation and separate accounting as the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis on each reporting period date. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company entering in the Revenue Interest Financing, the Company and RTW entered into the RTW side letter under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE (as </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">defined in Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div>below) subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by the PIPE subscription (the &#8220;PIPE Conversion Option&#8221;). The Company accounts for the PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC 815&#8221;). The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other (expense) income in the consolidated statements of operations. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable are unsecured and are carried at net realizable value, including an allowance for doubtful accounts. Trade credit is generally extended on a short-term basis; trade receivables do not bear interest, although a finance charge may be applied to such receivables that are past due. The allowance for doubtful accounts is based on the Company&#8217;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors that may affect a customer&#8217;s ability to pay, such as historical expense, credit quality, <div style="letter-spacing: 0px; top: 0px;display:inline;">the </div>age of the account receivable balances, and current economic conditions. Amounts determined to be uncollectible are charged or written off against the allowance. </div>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity in the allowance for doubtful accounts: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2023&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2022&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,675</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Uncollectible accounts written off</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition </div></div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers </div></div>(&#8220;Topic 606&#8221; or &#8220;ASC 606&#8221;). In general, the Company&#8217;s sales contracts fall under its standard sales agreement whereby control transfers to the customer upon shipment, satisfying the performance obligations of the contract. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue when control of its products is transferred to customers at an amount that reflects the consideration it expects to receive in exchange for those products. The Company&#8217;s revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a good or service to the customer, meaning that such customer has the ability to use and obtain the benefit of the good or service. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has provided customers purchasing the Allurion Balloon with an implied license for access to its VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#8217;s contracts. Further, the customer contracts and related purchase orders do not include nor specify rights or obligations associated with the VCS software. Based on this assessment, the Company determined the implied license to be immaterial in the context of the contract with customers purchasing the Allurion Balloon, and as such did not allocate any value to the implied VCS license. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generates revenue from sales of its Allurion Balloon to distributors and health care providers. Customers <div style="letter-spacing: 0px; top: 0px;display:inline;">typically </div>purchase the Allurion Balloon, including the gastric balloon and related accessories together, although customers can purchase the gastric balloon and its accessories separately. Therefore, each component of the Allurion Balloon and accessories represents a distinct performance obligation and is separately identifiable. In arrangements with multiple performance obligations, the transaction price is allocated to each performance obligation using the relative standalone selling price. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account internally approved pricing guidelines and market conditions. Revenue is generally recognized upon shipment of the product because at that point, the customer obtains control of the product and has the ability to direct the use and obtain the benefit of the product. Components of the Allurion Balloon are typically shipped to the customer together, resulting in the performance obligations in the contract being satisfied at the same time. Components shipped separately are recognized upon shipment at their relative standalone selling price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue at the transaction price, which reflects the consideration it believes it is entitled to receive. Transaction price includes estimates of variable consideration for promotions and prompt pay discounts, which are recorded as a reduction of transaction price in the period the related product revenue is recognized. The Company may also make payments to customers for marketing programs. Payments to customers for a distinct good or service that reasonably estimate the fair value of the distinct benefit received, such as marketing programs, are recorded as a marketing expense on the consolidated statement of operations and comprehensive loss. Shipping and logistics costs inclusive of these payments to customers and other costs included in sales and marketing expense for the years ended December&#160;31, 2023 and 2022 were $3.3&#160;million and $3.6&#160;million, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses incremental costs of obtaining a contract, such as sales commissions, when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company&#8217;s consolidated statement of operations and comprehensive loss. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the sales tax practical expedient; therefore, sales and other taxes assessed by a governmental authority that are collected concurrently with revenue-producing activities are excluded from the transaction price. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has also elected the significant financing component practical expedient, which allows management to not assess whether the contract has a significant financing component in circumstances where, at contract inception, the expected contract duration is less than one year. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Product Warranty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Product Warranty </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not provide general rights of return of products sold to its customers. However, the Company does provide for rights of exchange to its distributors and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">end-use</div> customers for products that fail to conform to the Company&#8217;s specifications for a limited time following delivery. These performance specifications include that the Allurion Balloon (i)&#160;is successfully filled upon initial placement when used according to the instructions for use provided by the Company and/or (ii)&#160;remains in the patient&#8217;s <div style="letter-spacing: 0px; top: 0px;display:inline;">body </div>for 90 days or more once placed. Customers may exchange product within 30 calendar days if they discover product nonconformities through a reasonable inspection and within 30 calendar days after discovery of any hidden or latent product nonconformities that could not have been discovered by a reasonable inspection. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These instances of nonconformity have been immaterial, and the Company&#8217;s management expects instances of nonconformity to be extremely rare. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses research and development costs as incurred. Research and development expenses consist of costs associated with performing research and development activities, including salaries and benefits, stock-based compensation, product development costs, materials and supplies, clinical trial activities, depreciation of equipment, and contract and other outside services. Payments for activities that are provided by outside vendors are based upon the terms of the individual arrangements with each vendor. Costs of certain of these activities are expensed based upon an evaluation of the progress to completion of specific tasks and actual costs incurred, using information provided to the Company by its vendors. As payments for these activities may differ from the pattern of costs actually incurred, additional costs are reflected in the consolidated financial statements as prepaid or accrued research and development expenses. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Advertising and Marketing Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses advertising and marketing costs as incurred. Advertising and marketing expenses are included in sales and marketing operating expenses. Advertising and marketing costs for the years ended December&#160;31, 2023 and 2022 were $10.8&#160;million and $16.0&#160;million, respectively. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock', window );">Intellectual Property Prosecution Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Intellectual Property Prosecution Costs </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurs registration and prosecution costs related to its intellectual property. The related costs are expensed as incurred and are classified as a component of general and administrative expenses. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for net operating loss and tax credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines whether a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company has not identified any uncertain tax positions for which reserves would be required. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Share </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method to compute basic and diluted net loss per share attributable to common stockholders, when shares meet the definition of participating securities. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">two-class</div> method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2023 and 2022. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders less the cumulative undeclared dividend by the weighted average number of common shares outstanding for the period. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Legacy Allurion Series D convertible preferred stock were contractually entitled to receive a cumulative dividend, whether or not declared, and therefore, Legacy Allurion Series D convertible preferred stocks were participating securities. The holders of all other redeemable and convertible preferred stock were not entitled to cumulative dividends. The preferred equity holders were also not contractually required to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination with Compute Health, the Company&#8217;s equity in previous periods has been retroactively adjusted to the earliest period presented to reflect the equivalent number of shares of Allurion Common Stock issued to the Company&#8217;s stockholders in connection with the Business Combination. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Business Combination. See Note 3, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>, for details of the Business Combination. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation expense for awards based on the grant-date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The Company accounts for awards issued to nonemployees under ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2018-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Compensation-Stock Compensation (&#8220;Topic 718&#8221;): Improvements to Nonemployee Share-Based Payment Accounting</div></div>, with the measurement date for nonemployee awards being the date of grant. The fair value of stock options is calculated using the Black-Scholes option-pricing model. The fair value of Restricted Stock Units (&#8220;RSUs&#8221;) is based on the fair market value of common stock at the date of grant. The Company records forfeitures as they occur. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2023, comprehensive loss consists of net loss and other comprehensive loss, which includes changes in the fair value attributable to instrument-specific credit risk related to the Revenue Interest Financing with RTW. There were no differences between net loss and comprehensive loss presented in the statements of operations and comprehensive loss for the year ended December&#160;31, 2022. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity, </div></div>which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> effective January 1, 2024 under the modified retrospective method of transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> did not have an impact on the Company&#8217;s condensed consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><span></span>
</td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses: <div style="letter-spacing: 0px; top: 0px;display:inline;">Measurement </div>of Credit Losses on Financial Instruments (Topic 326)</div></div>. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets such as available for sale debt securities, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> effective January 1, 2023 under the prospective transition approach. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2016-13</div> did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"> Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity</div></div>, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The Company does not expect the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2020-06</div> to have a material impact on its consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-07,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</div></div> which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2023-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</div></div>, which require public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s consolidated financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_EarnoutLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for earnout liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_EarnoutLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IntellectualPropertyProsecutionCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual property prosecution costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IntellectualPropertyProsecutionCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_MezzanineEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mezzanine Equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_MezzanineEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue interest financing and pipe conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954032711824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Risk of Concentration of Credit, Significant Customers</a></td>
<td class="text">The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended&#160;September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text">The following table presents customers that represent 10% or more of the Company&#8217;s total revenue and accounts receivable, net: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accounts&#160;Receivable</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer A</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer B</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer C</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Customer D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,037</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted cash included in <div style="-sec-ix-hidden:hidden127681918;display:inline;"><div style="-sec-ix-hidden:hidden127681919;display:inline;">other long-term assets</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents and restricted cash shown in the statement of cash flows</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,421</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of Activity in Allowance for Doubtful Accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes activity in the allowance for doubtful accounts: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2023&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8201;&#8195;2022&#8195;&#8201;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for uncollectible accounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,675</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(436</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Uncollectible accounts written off</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,671</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(741</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of cash and cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029072688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Reconciles of Business Combination to Condensed Consolidated Statement</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; CPUH trust (net of redemptions)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash &#8211; PIPE Investors</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gross Proceeds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">76,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: transaction costs paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14,665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net proceeds from the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">61,652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: warrant liabilities assumed (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: repayment of note assumed in the Business Combination (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,500</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: accrued transaction costs at December&#160;31, 2023 (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(580</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination, net of transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The Net proceeds from the Business Combination, less the repayment of note assumed in the Business Combination, less the accrued transaction costs at December&#160;31, 2023 are presented net in the consolidated statements of stockholders deficit within line &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221;. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The warrant liabilities assumed are presented separately from the &#8220;Reverse recapitalization, net of transaction costs (Note 3)&#8221; line within the consolidated statements of stockholders deficit. </div></td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding', window );">Number of Shares of Allurion Common Stock Outstanding</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,897,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,386,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">387,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,301,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Trust Contributed Shares. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Equityholders (1)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,897,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Stockholders (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares Issued to PIPE Investors (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,386,695</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to RTW and Fortress (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,900,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares issued to convertible note holders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,301,222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">CPUH Sponsor Shares (2)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,262,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Side Letter Termination Shares (3)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">387,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of Common Stock immediately after Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">47,301,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Consists of Legacy Allurion common stock and Legacy Allurion preferred stockholders, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur <div style="letter-spacing: 0px; top: 0px;display:inline;">Contributed </div>Shares (as defined below). </div></td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Reverse recapitalization, net of transaction costs&#8221; line, which is less the Gaur Contributed Shares (as defined below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#8220;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#8221; line. </div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Business Combination Shares Common Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035927040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenues by Geographic Region</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Australia</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">543</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Italy</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">626</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,956</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,001</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United Kingdom</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,534</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,431</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,573</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All Other Countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,980</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">45,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue by geographic region is based on the country in which our customer is domiciled and is summarized by geographic area as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,569</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Turkey</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Spain</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Chile</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,078</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42,240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Revenues</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,467</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">64,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035696464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Table Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventory consists of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Finished goods</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,427</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,096</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Work in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">967</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Raw materials</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Inventory</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,865</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034768800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Useful Life<br/> (in Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="white-space:nowrap;vertical-align:bottom"><br/> &#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3-5</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(4,169</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in progress</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,080</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:22%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Estimates Useful Life<br/> (in Years)</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computers and purchased software</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">Shorter&#160;of&#160;useful&#160;life<br/> or lease term</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Machinery and equipment</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3-5</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,002</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;at cost</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Less accumulated depreciation and amortization</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,559</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,851</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Construction in progress</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment&#8212;net</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,382</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ScheduleOfDepreciationExpenseTableTextBlock', window );">Schedule of Depreciation Expense</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.2&#160;million for each of the three months ended September&#160;30, 2024 and 2023, and $0.8&#160;million and $0.6&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, recorded as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">558</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0.7&#160;million and $0.9&#160;million for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;">December&#160;</div>31, 2023 and 2022, respectively, recorded as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">367</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">568</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sales and marketing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total depreciation and amortization expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">746</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="-sec-ix-hidden:hidden127682954;display:inline;">875</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ScheduleOfDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Depreciation Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ScheduleOfDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034770400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketing reimbursement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">81</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">592</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">493</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,973</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:74%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributor fees and marketing reimbursements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,687</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trials and R&amp;D</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued selling and marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,505</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,105</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">489</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued warranty</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued restructuring</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,966</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses and other current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954041001536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Components of Third-Party Debt</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consist of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amount of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,230</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,643</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s third-party debt consisted of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fortress Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021 Term Loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">58,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Plus: Accretion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of long-term debt, net of discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,643</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53,360</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: unamortized deferred financing costs and debt discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,605</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,853</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term debt, net of current portion and discounts</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Maturities of the Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scheduled future maturities of the Fortress Term Loan for years subsequent to December&#160;31, 2023 are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">December&#160;31, 2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028600768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract with Customer, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ComponentsOfRevenueInterestFinancingTableTextBlock', window );">Summary of Components of Revenue Interest Financing</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the Company&#8217;s Revenue Interest Financing consist of the following (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total principal amounts of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Royalty payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,092</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Change in fair value of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,708</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term Revenue Interest Financing liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ComponentsOfRevenueInterestFinancingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components of revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ComponentsOfRevenueInterestFinancingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027946576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for the Company&#8217;s assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RTW Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present the fair value hierarchy for assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:51%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">30,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue Interest Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PIPE Conversion Option</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term Loan Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Success Fee Derivative Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,943</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">68,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:58%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement as of December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Total&#160;Carrying&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Money market funds</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrant Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derivative Liability-Success Fee</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock Warrant Liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total Liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,551</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions used in Pricing Model</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), and Private Placement Warrants (defined below) within Level&#160;3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, and Private Placement Warrants: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy&#160;Allurion&#160;Series&#160;C&#160;Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30,&#160;2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.65%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.59%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">3.65%&#160;-</div><br/> 3.71%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br/> &#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">6.5&#160;-&#160;7.96</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Offering Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.58%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">September&#160;30, 2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.58%</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value&#160;of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series&#160;C Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Other Common Stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;D-1</div> Preferred Stock warrants (as converted to Common)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">7.25&#160;-&#160;8.71</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the warrants within Level&#160;3 of the hierarchy as the fair value is derived <div style="letter-spacing: 0px; top: 0px;display:inline;">using </div>the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (level 3) inputs. See table below for the assumptions used in the pricing model: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Measurement&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Interest<br/> Rate</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Fair<br/> Value of<br/> Underlying&#160;Share<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected<br/> Volatility</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Expected&#160;Life<br/> (Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31,&#160;2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.95</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Common)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.88</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">7.25</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">8.71</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.42</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series B Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.41</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.38</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Common Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.11</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series C Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.92</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other Common Stock Warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">1.02<div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>-&#160;1.10</div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">4.6</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">4.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legacy Allurion Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock warrants (as converted to Rollover warrants)</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">December&#160;31, 2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">3.88</div>-<div style="letter-spacing: 0px; top: 0px;display:inline;">3.92</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">8.2</div>&#160;-&#160;<div style="letter-spacing: 0px; top: 0px;display:inline;">9.7</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Values</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the three and nine months ended September&#160;30, 2024 and 2023 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:37%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,679</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,351</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681126;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,571</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(555</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,126</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127681127;display:inline;">Change in fair value</div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(55</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(19</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,187</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,121</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div></div><div> <div style="line-height:normal;display: inline;">  </div> </div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Public&#160;Offering<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Private&#160;Placement<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680849;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(647</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(447</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">715</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">922</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value at issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,827</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680850;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(587</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(7,187</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(860</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,797</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table reconciles the changes in fair value for the years ended December&#160;31, 2023 and 2022 of the warrant liabilities valued using Level&#160;3 inputs: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock&#160;Warrants<br/> (as&#160;converted&#160;to&#160;Common)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock<br/> Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">510</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680782;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(23</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="-sec-ix-hidden:hidden127680783;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(720</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(548</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(75</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(340</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(589</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(929</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">642</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">821</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option-pricing model are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8194;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.56</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Values</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, Term Loan Derivative liability, RTW Convertible Notes, PubCo Share liability, Base PubCo and Backstop Share liability, and Warrant Overallotment Liability categorized with Level&#160;3 inputs for the three and nine months ended September&#160;30, 2024 and 2023 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:29%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,327</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,638</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(201</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(599</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,357</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; June&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,950</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89,524</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,070</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8,870</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,404</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(166</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,400</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,330</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(12,581</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,440</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:26%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">RTW<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January&#160;1, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">49,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,358</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(22,140</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,020</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(24,447</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(600</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,990</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,590</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Repayments of debt</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,458</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; September&#160;30, 2024</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">38,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, PubCo Additional Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-out</div> liability, and Term Loan Derivative Liability categorized with Level&#160;3 inputs for the years ended December&#160;31, 2023 and 2022 were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:41%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Success<br/> Fee<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023<br/> Convertible<br/> Notes</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PubCo<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Base<br/> PubCo&#160;&amp;<br/> Backstop<br/> Share<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Revenue<br/> Interest<br/> Financing</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">PIPE<br/> Conversion<br/> Derivative</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div><br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Term<br/> Loan<br/> Derivative<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; January 1, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of warrants</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">178</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value upon issuance</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">28,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">40,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,340</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">53,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">133,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(164</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,751</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(642</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,408</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29,050</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(17,147</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value &#8211; OCI</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payments</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(10,750</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,092</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(11,842</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Derecognition of liability to equity</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(21,701</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,728</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(13,370</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,799</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Balance &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,600</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,895</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember', window );">Earn-Out Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method</a></td>
<td class="text">The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares was determined using a MCSM with the following assumptions at each valuation date: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">105.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text">The estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">earn-out</div> shares was determined using a Monte Carlo Simulation Method using the following assumptions at the valuation date: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">87.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember', window );">Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method (&#8220;MCSM&#8221;) using the number of shares convertible of 1,065,341 and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.03</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">130.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method using the number of shares convertible of 1,065,341 and the following assumptions: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.46</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">82.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method</a></td>
<td class="text">The fair value was measured using the $48.0&#160;million principal amount of the RTW Convertible Notes and the following assumptions: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:18%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">90.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954136677936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Domestic and Foreign Components of Net Loss Before Income Taxes</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of net loss before income taxes are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;&#8195;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S.</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(81,259</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(38,267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">916</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss before income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,601</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reconciliation between the effective tax rate and the statutory federal income tax rate for the years ended <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">D</div></div></div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div>c</div></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">e</div></div></div><div style="letter-spacing: 0px; top: 0px;display:inline;">m</div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">b</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"></div>e</div></div><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="letter-spacing: 0px; top: 0px;display:inline;">r</div></div></div>&#160;31, 2023 and 2022 is as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State income taxes, net of federal income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in fair value of financial instruments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30.5</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-deductible</div> expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.4</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effective tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">U.S. federal and state net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">36,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">25,051</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">start-up</div> and research and development expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,868</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development tax credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,780</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">659</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bad debt reserve</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other temporary differences</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">34,276</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(57,985</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Right of use asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(623</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other deferred tax liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,636</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(792</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to the Company&#8217;s valuation allowance are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Beginning balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22,579</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additions charged to net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,501</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Ending balances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,985</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034986432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Summary of Reserved for Issuance Upon the Potential Conversion or Exercise</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of September&#160;30, 2024, is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,108,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">530,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase Common Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,260,159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">479,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">57,369,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding</a></td>
<td class="text">As of September&#160;30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common&#160;Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">7/1/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">18,827,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <span></span>
</td>
<td class="text">As of December&#160;31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12/1/2014</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3/30/2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/15/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/4/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1/17/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8/3/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/8/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/19/2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/25/2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">4/1/2013</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">16,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series B Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">60,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">8.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series C Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954036486880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock and Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts):
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr>
<td style="width:54%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Authorized (1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Preferred&#160;Stock<br/> Issued&#160;and<br/> Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series A Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,276,786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,276,786</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,513,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,486,048</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,842</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series B Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,298,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,245,515</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,113,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,927,446</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,684,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">842,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-2</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,644,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,644,616</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-3</div> Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,498,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,498,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21,029,888</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,921,042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company&#8217;s securities as of December&#160;31, 2023, is as follows:
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public warrants to purchase common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,693,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding</a></td>
<td class="text">As of September&#160;30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock. </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:36%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30, 2024</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common&#160;Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">7/1/2024</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">18,827,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">19,231,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td style="width:34%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying&#160;Equity&#160;Instrument</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Equity</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Common Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr> </table> <span></span>
</td>
<td class="text">As of December&#160;31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td style="width:38%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2023</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual&#160;Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares&#160;Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average&#160;Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">12/1/2014</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">44,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">3/30/2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">7.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/15/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/4/2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">1/17/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">8/3/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Equity</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">9/8/2017</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/19/2018</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">6/25/2019</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom;text-align:center;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Liability</div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">403,658</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Issuance&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Remaining<br/> Contractual Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Underlying Equity Instrument</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet<br/> Classification</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares Issuable<br/> Upon Exercise<br/> of Warrant</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">4/1/2013</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">16,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">1.95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">12/1/2014</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">1.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series B Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">60,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">3/30/2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">8.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series C Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">130,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/15/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/4/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">9.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">D-1</div> Preferred Stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">45,238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">12.14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">1/17/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">73,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">8/3/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,779</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">9/8/2017</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">4.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">28,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom;text-align:center;">6/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">17,977</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center;">6/25/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center;">6.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center;">Common stock</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:center;">Liability</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">8,988</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">436,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033773488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Basic and Diluted Net Loss per Share</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share was calculated as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(80,607</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,744</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cumulative undeclared dividends to participating securities (Legacy Series D convertible preferred stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,697</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,907</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to common stockholders</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(82,304</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(40,651</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted weighted-average common stock outstanding</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35,581,656</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26,918,484</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders, basic and diluted (1)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2.31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1.51</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share</a></td>
<td class="text">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding options to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,301,960</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Restricted Stock Units</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase preferred stock (as converted to warrants to purchase common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">297,854</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrants to purchase common stock</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">264,801</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">138,857</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Shares of Common Stock issued upon the exercise of Public Warrants</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18,759,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible notes (as converted to common stock)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">171,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,693,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,325,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027801136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the condensed consolidated statement of operations was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2024&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8194;2023&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,477</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,109</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">84</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,539</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in the consolidated statement of operations and comprehensive loss was as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:70%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general, and administrative</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,198</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,357</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under the Plan</a></td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the nine months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,686,059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(447,644</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(16,137</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,108,316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable at September&#160;30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,872,814</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the year ended December&#160;31, 2023: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;option)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in&#160;thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,301,968</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,437</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257,683</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(375,051</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercised</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(298,562</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,886,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Exercisable at December&#160;31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,735,884</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used in Black-Scholes Option Pricing Model</a></td>
<td class="text"> <div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">86</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.36</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option-pricing model are as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:69%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2023&#8195;&#8194;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8195;&#8194;2022&#8194;&#8195;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.56</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity Under the Plan</a></td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended September&#160;30, 2024: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">of RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant<br/> Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">75,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.61</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(187,857</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;September 30, 2024</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">530,778</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4.16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the year ended December&#160;31, 2023: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> RSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Grant<br/> Date&#160;Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(per&#160;share)</div></div></td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;January 1, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,415,104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Granted</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">226,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancellations and forfeitures</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(79,232</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Vested</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(918,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Outstanding&#8212;December 31, 2023</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">643,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.45</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039376368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock', window );">Schedule of Other Pertinent Lease Information</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information for the three and nine months ended September&#160;30, 2024 and 2023 is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:72%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Three Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months<br/> Ended<br/> September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">23</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the <br/> measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">826</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange <br/> for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">15</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other pertinent lease information is as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">918</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable operating lease costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows paid for amounts in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,084</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">807</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease assets obtained in exchange for lease obligations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements as of September&#160;30, 2024 are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">273</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,044</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">646</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,810</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(354</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(878</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,578</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future commitments under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-cancelable</div> operating lease agreements are as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2028</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: present value adjustment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(563</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(908</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock', window );">Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:15%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted -average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average remaining lease terms and discount rates related to our leases were as follows: </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:85%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other pertinent lease information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted-average remaining lease terms and discount rates related leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035477824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets by Geography</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,363</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): </div> <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:78%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">United States</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">France</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">All other countries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-lived assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035800304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Country </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Country </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Country </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfCountriesInWhichEntityMarketsTheProgram', window );">Number of countries, currently markets the program | Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax', window );">Gains (losses) from foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (300,000)<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">$ (700,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,004,000<span></span>
</td>
<td class="nump">$ 2,162,000<span></span>
</td>
<td class="num">$ (5,586,000)<span></span>
</td>
<td class="nump">21,630,000<span></span>
</td>
<td class="nump">$ 21,996,000<span></span>
</td>
<td class="nump">$ 17,801,000<span></span>
</td>
<td class="nump">$ 5,580,000<span></span>
</td>
<td class="nump">61,427,000<span></span>
</td>
<td class="nump">80,607,000<span></span>
</td>
<td class="nump">37,744,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,026,000<span></span>
</td>
<td class="nump">43,111,000<span></span>
</td>
<td class="nump">63,982,000<span></span>
</td>
<td class="nump">46,981,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Losses from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,083,000<span></span>
</td>
<td class="nump">$ 53,340,000<span></span>
</td>
<td class="nump">79,078,000<span></span>
</td>
<td class="nump">32,010,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,799,000<span></span>
</td>
<td class="nump">$ 132,192,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax', window );">Gains (losses) from foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationCommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">0.978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationCommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination common stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationCommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfCountriesInWhichEntityMarketsTheProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of countries in which entity markets the program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfCountriesInWhichEntityMarketsTheProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034444256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,197,000<span></span>
</td>
<td class="nump">$ 13,989,000<span></span>
</td>
<td class="nump">$ 18,060,000<span></span>
</td>
<td class="nump">$ 36,127,000<span></span>
</td>
<td class="nump">$ 46,857,000<span></span>
</td>
<td class="nump">$ 50,405,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions for which reserves would be required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Logistics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Long-Term Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=alur_NewAllurionMember', window );">New Allurion | Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Total Revenue | Customer Concentration Risk | Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer Concentration Risk | Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable', window );">Earn-out shares receivable</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RemittanceOfRevenueInterestPaymentsPercentage', window );">Remittance of revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesNetOfInterestExpense', window );">Additional revenue interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | New Allurion | Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RemittanceOfRevenueInterestPaymentsPercentage', window );">Remittance of revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, contingent consideration, number of additional shares receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromRevenueInterestFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromRevenueInterestFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RemittanceOfRevenueInterestPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remittance of revenue interest payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RemittanceOfRevenueInterestPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesNetOfInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesNetOfInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alur_NewAllurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alur_NewAllurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alur_CustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alur_CustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954022472368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Total Revenue | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Total Revenue | Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alur_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alur_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alur_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alur_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alur_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alur_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=alur_CustomersDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=alur_CustomersDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954146861888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 28,654<span></span>
</td>
<td class="nump">$ 38,037<span></span>
</td>
<td class="nump">$ 7,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash included in other long-term assets</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="nump">$ 384<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 29,045<span></span>
</td>
<td class="nump">$ 38,421<span></span>
</td>
<td class="nump">$ 8,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028257280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at beginning of period</a></td>
<td class="num">$ (12,671)<span></span>
</td>
<td class="num">$ (741)<span></span>
</td>
<td class="num">$ (741)<span></span>
</td>
<td class="num">$ (354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts</a></td>
<td class="num">$ (1,065)<span></span>
</td>
<td class="num">$ (4,953)<span></span>
</td>
<td class="num">(12,675)<span></span>
</td>
<td class="num">(436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Uncollectible accounts written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,671)<span></span>
</td>
<td class="num">$ (741)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954037851024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 22, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 09, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Outstanding public warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="nump">$ 150,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business combination expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationOneTimeInsurancePayment', window );">Business combination one-time insurance payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Earn-out liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000,000<span></span>
</td>
<td class="nump">1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business combination expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,206,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_BusinessCombinationAgreementMember', window );">Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_SponsorLoanExcessAmount', window );">Sponsor loan excess amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DirectCostsAndFees', window );">Direct costs and fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RemittanceOfRevenueInterestPaymentsPercentage', window );">Remittance of revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance', window );">Conversion of PIPE subscription to revenue interest finance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance', window );">Conversion of PIPE investment to revenue interest finance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | New Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ProceedsFromRevenueInterestFinancing', window );">Proceeds from revenue interest financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | New Allurion | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RemittanceOfRevenueInterestPaymentsPercentage', window );">Remittance of revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_AmendedAndRestatedRtwSideLetterMember', window );">RTW Side Letter | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfSurrenderSharesOfCommonStock', window );">Number of surrender shares of common stock</a></td>
<td class="nump">749,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_SurrenderCommonStockValue', window );">Surrender common stock value | $</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_FortressCreditAgreementMember', window );">Fortress Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_FortressCreditAgreementMember', window );">Fortress Credit Agreement | Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan borrowed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember', window );">Backstop Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Aggregate principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RSUForfeitureAgreementMember', window );">RSU Forfeiture Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_PipeSubscriptionAgreementsMember', window );">PIPE Subscription Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate purchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,386,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,333,773<span></span>
</td>
<td class="nump">143,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Outstanding public warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,976<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accured interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationCommonStockExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Business Combination Agreement | Warrant Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | RTW Side Letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Backstop Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | HVL Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Gaur Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ContributionOfCapitalByJointVenturePartner', window );">Contribution of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Business Combination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Sponsor Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ContributionOfCapitalByJointVenturePartner', window );">Contribution of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Sponsor Support Agreement | CPUH Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,088,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock | Sponsor Support Agreement | CPUH Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RecapitalizationOfCommonStock', window );">Recapitalization of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,442,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RecapitalizationOfAdditionalShares', window );">Recapitalization of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationCommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination common stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationCommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationOneTimeInsurancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination one-time insurance payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationOneTimeInsurancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ContributionOfCapitalByJointVenturePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution of capital by joint venture partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ContributionOfCapitalByJointVenturePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of PIPE investment to revenue interest finance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionOfPipeInvestmentToRevenueInterestFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of PIPE subscription to revenue interest finance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionOfPipeSubscriptionToRevenueInterestFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DirectCostsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct costs and fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DirectCostsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfSurrenderSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surrender Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfSurrenderSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ProceedsFromRevenueInterestFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ProceedsFromRevenueInterestFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RecapitalizationOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RecapitalizationOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RecapitalizationOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recapitalization of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RecapitalizationOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RemittanceOfRevenueInterestPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remittance of revenue interest payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RemittanceOfRevenueInterestPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_SponsorLoanExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsor loan excess amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_SponsorLoanExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_SurrenderCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_SurrenderCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_BusinessCombinationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_BusinessCombinationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alur_NewAllurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alur_NewAllurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_AmendedAndRestatedRtwSideLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_AmendedAndRestatedRtwSideLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_FortressCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_FortressCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RSUForfeitureAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RSUForfeitureAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alur_PipeSubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alur_PipeSubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_HVLTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_HVLTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_GaurContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_GaurContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_SponsorContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_SponsorContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_SponsorSupportAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_SponsorSupportAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alur_ComputeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alur_ComputeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954036548576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_GrossProceedsFromBusinessCombination', window );">Gross Proceeds</a></td>
<td class="nump">$ 76,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationTransactionCostPaid', window );">Less: transaction costs paid</a></td>
<td class="num">(14,665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromBusinessCombination', window );">Net proceeds from the Business Combination</a></td>
<td class="nump">61,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantLiabilitiesAssumed', window );">Less: warrant liabilities assumed</a></td>
<td class="num">(13,762)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RepaymentOfNoteAssumedInBusinessCombination', window );">Less: repayment of note assumed in the Business Combination</a></td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessAcquisitionAccruedTransactionCosts', window );">Less: accrued transaction costs at December 31, 2023</a></td>
<td class="num">(580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BusinessCombinationNetOfTransactionCosts', window );">Reverse merger, net of transaction costs</a></td>
<td class="nump">44,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember', window );">Cash - CPUH trust</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_GrossProceedsFromBusinessCombination', window );">Gross Proceeds</a></td>
<td class="nump">38,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember', window );">Cash - PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_GrossProceedsFromBusinessCombination', window );">Gross Proceeds</a></td>
<td class="nump">$ 37,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessAcquisitionAccruedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition accrued transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessAcquisitionAccruedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BusinessCombinationTransactionCostPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination transaction cost paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BusinessCombinationTransactionCostPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_GrossProceedsFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_GrossProceedsFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NetProceedsFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NetProceedsFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RepaymentOfNoteAssumedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of note assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RepaymentOfNoteAssumedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_WarrantLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_WarrantLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034735888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="nump">64,369,381<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">47,301,409<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_LegacyAllurionEquityholdersMember', window );">Legacy Allurion Equityholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,897,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember', window );">CPUH Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,165,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember', window );">Shares Issued to PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,386,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RtwAndFortressMember', window );">Shares issued to RTW and Fortress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteHoldersMember', window );">Shares Issued to Convertible Note Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthSponsorSharesMember', window );">CPUH Sponsor Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,262,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_SideLetterTerminationSharesMember', window );">Side Letter Termination Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of Common Stock immediately after Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_LegacyAllurionEquityholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_LegacyAllurionEquityholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ComputeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RtwAndFortressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RtwAndFortressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ComputeHealthSponsorSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ComputeHealthSponsorSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_SideLetterTerminationSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_SideLetterTerminationSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028597152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue | $</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 7,200<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfCountriesGenerateRevenue', window );">Number of countries generate revenue | Country</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_EachCountryMember', window );">Each Country | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_EachCountryMember', window );">Each Country | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_AllOtherCountriesMember', window );">All Other Countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfCountriesGenerateRevenueBySales', window );">Number of countries generate revenue by sales | Country</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_FourCountriesIncludedWithinAllOtherCountriesMember', window );">Four Countries Included Within All Other Countries | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfCountriesGenerateRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of countries generate revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfCountriesGenerateRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfCountriesGenerateRevenueBySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of countries generate revenue by sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfCountriesGenerateRevenueBySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alur_EachCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alur_EachCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alur_AllOtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alur_AllOtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alur_FourCountriesIncludedWithinAllOtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alur_FourCountriesIncludedWithinAllOtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035669856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenues by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,367<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">$ 26,519<span></span>
</td>
<td class="nump">$ 45,232<span></span>
</td>
<td class="nump">$ 53,467<span></span>
</td>
<td class="nump">$ 64,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
<td class="nump">4,618<span></span>
</td>
<td class="nump">6,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
<td class="nump">4,423<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=currency_TRY', window );">Turkey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">3,517<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
<td class="nump">5,495<span></span>
</td>
<td class="nump">5,494<span></span>
</td>
<td class="nump">4,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CL', window );">Chile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_AllOtherCountriesMember', window );">All Other Countries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,347<span></span>
</td>
<td class="nump">$ 11,122<span></span>
</td>
<td class="nump">$ 16,980<span></span>
</td>
<td class="nump">$ 28,143<span></span>
</td>
<td class="nump">$ 35,078<span></span>
</td>
<td class="nump">$ 42,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=currency_TRY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=currency_TRY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alur_AllOtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alur_AllOtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954026682816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGrossAbstract', window );"><strong>Inventory, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 2,748<span></span>
</td>
<td class="nump">$ 3,427<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 4,568<span></span>
</td>
<td class="nump">$ 6,171<span></span>
</td>
<td class="nump">$ 3,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028903104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Provision for excess and obsolete inventory</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Provision for excess and obsolete inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035011840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 6,359<span></span>
</td>
<td class="nump">$ 5,745<span></span>
</td>
<td class="nump">$ 4,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(4,169)<span></span>
</td>
<td class="num">(3,559)<span></span>
</td>
<td class="num">(2,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConstructionInProgress', window );">Construction in progress</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment net</a></td>
<td class="nump">$ 3,080<span></span>
</td>
<td class="nump">$ 3,381<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alur_ComputersAndPurchasedSoftwareMember', window );">Computers and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 1,943<span></span>
</td>
<td class="nump">$ 1,943<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 3,507<span></span>
</td>
<td class="nump">$ 2,893<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alur_ComputersAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alur_ComputersAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033072448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035186464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Schedule of Depreciation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 778<span></span>
</td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">$ 895<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028940784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DistributorFeesAndMarketingReimbursements', window );">Distributor fees and marketing reimbursements</a></td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 2,834<span></span>
</td>
<td class="nump">$ 6,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AccruedClinicalTrialsAndResearchAndDevelopment', window );">Accrued clinical trials and R&amp;D</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">3,694<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued selling and marketing</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyAccrualCurrent', window );">Accrued warranty</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AccruedRestructuringCurrent', window );">Accrued restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">4,128<span></span>
</td>
<td class="nump">3,966<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,973<span></span>
</td>
<td class="nump">$ 15,495<span></span>
</td>
<td class="nump">$ 15,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AccruedClinicalTrialsAndResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials and research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AccruedClinicalTrialsAndResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AccruedRestructuringCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued restructuring current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AccruedRestructuringCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DistributorFeesAndMarketingReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributor fees and marketing reimbursements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DistributorFeesAndMarketingReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029464352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954037836816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Components of Third-Party Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="nump">$ 49,320<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="nump">$ 58,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfDebt', window );">Change in fair value</a></td>
<td class="num">(13,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LoanAccretion', window );">Plus: Accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of long-term debt, net of discounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38,643)<span></span>
</td>
<td class="num">(53,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized deferred financing costs and debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,605)<span></span>
</td>
<td class="num">(1,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and discounts</a></td>
<td class="nump">36,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="nump">$ 49,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangeInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangeInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_LoanAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Accretion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_LoanAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45953944784656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">7 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 14, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,103,000<span></span>
</td>
<td class="nump">$ 49,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100,000<span></span>
</td>
<td class="nump">$ 58,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt/ term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,713,000<span></span>
</td>
<td class="nump">$ 3,929,000<span></span>
</td>
<td class="nump">$ 3,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="nump">28,700,000<span></span>
</td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="nump">$ 1,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,750,000<span></span>
</td>
<td class="nump">10,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 757,000<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="num">(643,000)<span></span>
</td>
<td class="num">(344,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancing', window );">Gain in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancing', window );">Gain in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember', window );">Backstop Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_FortressCreditAgreementMember', window );">Fortress Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Interest, frequency of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Fortress Term Loan had a maturity date of June 30, 2027 and accrued interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to 3.0% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Fortress Term Loan has a maturity date of June 30, 2027 and accrues interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest is payable in arrears on a monthly basis. An exit payment equal to 3.0% of the Fortress Term Loan (the &#8220;Exit Fee&#8221;) is due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneConvertibleNotesMember', window );">2021 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionDividedByCappedConversionPrice', window );">Conversion divided by capped conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneConvertibleNotesMember', window );">2021 Convertible Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneConvertibleNotesMember', window );">2021 Convertible Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RepaymentOfPrincipal', window );">Repayment of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionDividedByDiscountedCappedConversionPrice', window );">Conversion divided by discounted capped conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_CappedPrice', window );">Capped price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice', window );">Percentage of conversion discounted price is calculated of cash price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Debt prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,084,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember', window );">Side Letter Holder Bridge Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities', window );">Debt instrument, convertible price for calculating equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredLiabilityForIssuanceOfAdditionalShares', window );">Deferred liability for issuance of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember', window );">Side Letter Holder Bridge Note | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember', window );">Side Letter Holder Bridge Note | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember', window );">Side Letter Holder Bridge Note | Backstop Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredLiabilityForIssuanceOfAdditionalShares', window );">Deferred liability for issuance of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember', window );">Side Letter Holder Bridge Note | Backstop Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_NotePurchaseAgreementMember', window );">Note Purchase Agreement | RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 16,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Common Stock | RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617.284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock', window );">Debt instrument, principal amount for conversion into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger', window );">Premium percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding', window );">Maximum percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_NotePurchaseAgreementMember', window );">Note Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_UnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember', window );">HVL Bridge Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities', window );">Debt instrument, convertible price for calculating equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredLiabilityForIssuanceOfAdditionalShares', window );">Deferred liability for issuance of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember', window );">HVL Bridge Note | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember', window );">HVL Bridge Note | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember', window );">HVL Bridge Note | Backstop Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredLiabilityForIssuanceOfAdditionalShares', window );">Deferred liability for issuance of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember', window );">HVL Bridge Note | Backstop Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of the debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TermLoanAccretion', window );">Accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AmortizationOfTheWarrant', window );">Amortization of the warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of the debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | 2021 Term Loan Agreement | Runway</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds', window );">Available capacity based upon the achievement of certain revenue thresholds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt/ term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Total payoff amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RepaymentOfPrincipal', window );">Repayment of principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PrepaymentFee', window );">Prepayment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FinalPaymentFee', window );">Final payment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OriginalFinalPayment', window );">Original final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FinalPaymentFeePercentage', window );">Final payment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | 2021 Term Loan Agreement | Runway | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Amended 2021 Term Loan Agreement | Runway</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermCLoanMember', window );">Term C Loan | Amended 2021 Term Loan Agreement | Runway</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds', window );">Available capacity based upon the achievement of certain revenue thresholds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1', window );">Equal monthly principal payments commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfTheWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermCLoanMember', window );">Term C Loan | Amended 2021 Term Loan Agreement | Runway | Legacy Allurion Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ExercisableWarrantsIssuedAsConsideration', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermCLoanMember', window );">Term C Loan | Amended 2021 Term Loan Agreement | Runway | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermCLoanMember', window );">Term C Loan | Amended 2021 Term Loan Agreement | Runway | Series D-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ExercisableWarrantsIssuedAsConsideration', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember', window );">Term D Loan | Amended 2021 Term Loan Agreement | Runway</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.44186%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfTheWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of interest rate variable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">change the interest rate to the higher of the prime rate or 3.25% plus the applicable margin of 6.44186%,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember', window );">Term D Loan | Amended 2021 Term Loan Agreement | Runway | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfTheWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember', window );">Term D Loan | Amended 2021 Term Loan Agreement | Runway | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember', window );">Term D Loan | Amended 2021 Term Loan Agreement | Runway | Series D-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ExercisableWarrantsIssuedAsConsideration', window );">Warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember', window );">Term D Loan | Amended 2021 Term Loan Agreement | Runway | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AdditionalBorrowings', window );">Additional borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt/ term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Initial cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of the debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TermLoanAccretion', window );">Accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.94%<span></span>
</td>
<td class="nump">14.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.94%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentExitPaymentPercentage', window );">Debt instrument exit payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MinimumLiquidityAmount', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentInterestRateIncreaseEventOfDefault', window );">Increase in interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentDefaultInterestRate', window );">Default interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of term loan derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain recorded on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other income, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt fee amount incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment | Until March 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MinimumLiquidityAmount', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment | From April 1, 2024 to June 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MinimumLiquidityAmount', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment | From July 1, 2024 to September 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MinimumLiquidityAmount', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment | On October 1, 2024 and thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_MinimumLiquidityAmount', window );">Minimum Liquidity Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Fortress Amendment | Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Side Letter Holder Bridge Note | Backstop Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Total payoff amount</a></td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RepaymentOfPrincipal', window );">Repayment of principal</a></td>
<td class="nump">43,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PrepaymentFee', window );">Prepayment fee</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Other fees</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan | HVL Bridge Note | Backstop Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion of outstanding notes | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Aggregate recognition APIC amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AdditionalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AdditionalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AmortizationOfTheWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of the warrant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AmortizationOfTheWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowing Capacity Available Based upon Achievement of Certain Revenue Thresholds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_CappedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capped price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_CappedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangesInFairValueOfRevenueInterestFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangesInFairValueOfRevenueInterestFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionDividedByCappedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion divided by capped conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionDividedByCappedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionDividedByDiscountedCappedConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion divided by discounted capped conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionDividedByDiscountedCappedConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deb instrument, convertible, maximum limitation percentage of shares of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible, premium percentage of stock price trigger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, convertible price for calculating equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument default interest rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, exit fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentExitPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentExitPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentInterestRateIncreaseEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, interest rate, increase, event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentInterestRateIncreaseEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, principal amount for conversion into common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DeferredLiabilityForIssuanceOfAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred liability for issuance of additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DeferredLiabilityForIssuanceOfAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ExercisableWarrantsIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercisable warrants issued as consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ExercisableWarrantsIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueOfTheWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueOfTheWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final payment fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final payment fee percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_MinimumLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_MinimumLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OriginalFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Original final payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OriginalFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion discounted price is calculated of cash price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RepaymentOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RepaymentOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_TermLoanAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Loan Accretion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_TermLoanAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_UnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrestricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_UnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the first payment under the line of credit must be paid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_BackstopAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_FortressCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_FortressCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_SideLetterHolderBridgeNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_NotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_NotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_HVLBridgeNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyOneTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=alur_RunwayGrowthCreditFundIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=alur_RunwayGrowthCreditFundIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesD1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesD1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_TermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_TermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_FortressAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_FortressAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_UntilMarch312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_UntilMarch312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_FromApril12024ToJune302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_FromApril12024ToJune302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_FromJuly12024ToSeptember302024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_FromJuly12024ToSeptember302024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_OnOctober12024AndThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_OnOctober12024AndThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954040968320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Maturities of the Term Loan Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="nump">$ 49,320<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="nump">$ 58,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">December 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">December 31, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954037719360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2027</div></th>
<th class="th">
<div>Jan. 01, 2027 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th">
<div>Dec. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2023 </div>
<div>USD ($) </div>
<div>Days </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th">
<div>Apr. 17, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancing', window );">Gain in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="num">$ (700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenuesInterestFinancingLiability', window );">Revenues interest financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PrePaymentsPercentage', window );">Pre payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangesInFairValueOfRevenueInterestFinancing', window );">Gain in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value of revenue interest financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RoyaltyPayments', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | December 31, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_CashPaymentsPercentage', window );">Cash payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RemittanceOfRevenueInterestPaymentsPercentage', window );">Remittance of revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestPaymentsPercentage', window );">Revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_VolumeWeightedAveragePricePerShare', window );">Volume weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance', window );">Conversion of PIPE subscription to revenue interest finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance', window );">Conversion of PIPE investment to revenue interest finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Maximum | December 31, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_CashPaymentsPercentage', window );">Cash payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestPaymentsPercentage', window );">Revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Trading days | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | Minimum | December 31, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestPaymentsPercentage', window );">Revenue interest payments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Issue-date estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementAmendmentMember', window );">RIFA Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfRevenueInterestFinancingAgreements', window );">Fair value of revenue interest financing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfPipeConversionOption', window );">Fair value of pipe conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingAgreementRemeasuredValue', window );">Revenue Interest Financing Agreement Remeasured Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PipeConversionOptionRemeasuredValue', window );">PIPE Conversion Option Remeasured Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementAmendmentMember', window );">RIFA Amendment | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfIncreaseInNetSales', window );">Percentage of Increase in Net Sales</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfInternalRateOfReturn', window );">Percentage of Internal Rate of Return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementAmendmentMember', window );">RIFA Amendment | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_SalesRevenueNet', window );">Sales Revenue Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IncreaseInSalesRevenueNet', window );">Increase in Sales Revenue Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_CashPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_CashPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangesInFairValueOfRevenueInterestFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of revenue interest financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangesInFairValueOfRevenueInterestFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of PIPE investment to revenue interest finance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionOfPipeInvestmentToRevenueInterestFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionOfPipeSubscriptionToRevenueInterestFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of PIPE subscription to revenue interest finance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionOfPipeSubscriptionToRevenueInterestFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueOfPipeConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of pipe conversion option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueOfPipeConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueOfRevenueInterestFinancingAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of revenue interest financing agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueOfRevenueInterestFinancingAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IncreaseInSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in sales revenue net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IncreaseInSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfIncreaseInNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfIncreaseInNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of internal rate of return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PipeConversionOptionRemeasuredValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PIPE conversion option remeasured value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PipeConversionOptionRemeasuredValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PrePaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre payments percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PrePaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RemittanceOfRevenueInterestPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remittance of revenue interest payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RemittanceOfRevenueInterestPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingAgreementRemeasuredValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest financing agreement remeasured value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingAgreementRemeasuredValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest payments percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenuesInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenuesInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_VolumeWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_VolumeWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_PIPEConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_PIPEConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45953942028688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfDebt', window );">Less: Change in fair value of debt</a></td>
<td class="num">$ (13,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingLiabilityNoncurrent', window );">Long-term Revenue Interest Financing liability</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenuesInterestFinancingLiability', window );">Revenues Interest Financing Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt', window );">Total principal amounts of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RoyaltyPayments', window );">Less: Royalty payments</a></td>
<td class="num">$ (3,600)<span></span>
</td>
<td class="num">(1,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ChangeInFairValueOfDebt', window );">Less: Change in fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueInterestFinancingLiabilityNoncurrent', window );">Long-term Revenue Interest Financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ChangeInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ChangeInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue interest financing liability principal amount of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenuesInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenuesInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035357232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (81,259)<span></span>
</td>
<td class="num">$ (38,267)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (8,935)<span></span>
</td>
<td class="num">$ (21,596)<span></span>
</td>
<td class="num">$ (5,370)<span></span>
</td>
<td class="num">$ (61,337)<span></span>
</td>
<td class="num">$ (80,343)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035018096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory federal income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments', window );">Change in fair value of financial instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.50%)<span></span>
</td>
<td class="num">(29.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033343552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of Deferred Tax Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">U.S. federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 36,092<span></span>
</td>
<td class="nump">$ 25,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized start-up and research and development expenses</a></td>
<td class="nump">10,868<span></span>
</td>
<td class="nump">5,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">2,275<span></span>
</td>
<td class="nump">1,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Interest expense</a></td>
<td class="nump">3,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Bad debt reserve</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">59,621<span></span>
</td>
<td class="nump">34,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(57,985)<span></span>
</td>
<td class="num">(33,484)<span></span>
</td>
<td class="num">$ (22,579)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(623)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred tax liability</a></td>
<td class="num">(1,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,636)<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033301072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,501<span></span>
</td>
<td class="nump">10,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,092<span></span>
</td>
<td class="nump">$ 25,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rates</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TaxCreditCarryForwardsResearchAndDevelopment', window );">Tax credit carry forwards research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear', window );">Tax credits research and development expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TaxCreditCarryForwardsResearchAndDevelopment', window );">Tax credit carry forwards research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear', window );">Tax credits research and development expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod', window );">Net operating loss carryforwards expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod', window );">Net operating loss carryforwards expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod', window );">Net operating loss carryforwards expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=alur_LatestTaxYearTwoThousandFortyTwoMember', window );">Latest Tax Year | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod', window );">Net operating loss carryforwards expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember', window );">Expire between 2030 and 2037 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=alur_DoNotExpireMember', window );">Do not expire | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carry forward expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_TaxCreditCarryForwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_TaxCreditCarryForwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forwards research and development expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=alur_LatestTaxYearTwoThousandFortyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=alur_LatestTaxYearTwoThousandFortyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=alur_DoNotExpireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=alur_DoNotExpireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028955648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balances</a></td>
<td class="nump">$ 33,484<span></span>
</td>
<td class="nump">$ 22,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Additions charged to net loss</a></td>
<td class="nump">24,501<span></span>
</td>
<td class="nump">10,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balances</a></td>
<td class="nump">$ 57,985<span></span>
</td>
<td class="nump">$ 33,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028534368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.36%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember', window );">Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember', window );">Earn-Out Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029222448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in Fair Values (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 4,030<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 2,373<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="nump">14,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">$ (8,121)<span></span>
</td>
<td class="num">$ (2,126)<span></span>
</td>
<td class="num">$ (8,797)<span></span>
</td>
<td class="num">$ (447)<span></span>
</td>
<td class="num">$ (548)<span></span>
</td>
<td class="nump">$ 821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
<td class="text">Fair Value Adjustment of Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(929)<span></span>
</td>
<td class="num">(929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 6,851<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">$ 6,851<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_PreferredStockWarrantsMember', window );">Preferred Stock Warrants (as Converted to Common)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(340)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(589)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember', window );">Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="nump">13,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(7,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">5,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">89,524<span></span>
</td>
<td class="nump">23,638<span></span>
</td>
<td class="nump">67,699<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,530<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
<td class="nump">131,714<span></span>
</td>
<td class="nump">133,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">7,054<span></span>
</td>
<td class="num">(10,357)<span></span>
</td>
<td class="num">(24,447)<span></span>
</td>
<td class="num">(12,581)<span></span>
</td>
<td class="num">(17,147)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in fair value - OCI</a></td>
<td class="num">(8,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt', window );">Repayments of debt</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="num">(10,250)<span></span>
</td>
<td class="num">(2,458)<span></span>
</td>
<td class="num">(10,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,799)<span></span>
</td>
<td class="num">(37,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">86,304<span></span>
</td>
<td class="nump">70,762<span></span>
</td>
<td class="nump">86,304<span></span>
</td>
<td class="nump">70,762<span></span>
</td>
<td class="nump">67,699<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | Success Fee Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | 2023 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,701)<span></span>
</td>
<td class="num">(21,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | PubCo Share Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">3,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="num">(642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,728)<span></span>
</td>
<td class="num">(2,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | Base PubCo and Backstop Share Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,106<span></span>
</td>
<td class="nump">10,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability', window );">Derecognition of liability to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,370)<span></span>
</td>
<td class="num">(13,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | Term Loan Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,895)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | Revenue Interest Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">6,704<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="nump">5,358<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="num">(3,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in fair value - OCI</a></td>
<td class="num">(5,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt', window );">Repayments of debt</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">36,600<span></span>
</td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">36,600<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | PIPE Conversion Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">5,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
<td class="nump">3,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">4,250<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">5,440<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | Earn-Out Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">4,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,040<span></span>
</td>
<td class="nump">53,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="num">(24,330)<span></span>
</td>
<td class="num">(22,140)<span></span>
</td>
<td class="num">(24,330)<span></span>
</td>
<td class="num">(29,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">$ 28,710<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">$ 28,710<span></span>
</td>
<td class="nump">$ 23,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants | RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">40,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Fair value upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in fair value - OCI</a></td>
<td class="num">(3,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">$ 36,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Derecognition of Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Repayment of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_SuccessFeeDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_SuccessFeeDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PubcoShareLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PubcoShareLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_BasePubcoAndBackstopShareLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_BasePubcoAndBackstopShareLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_PipeConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_PipeConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_EarnOutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039572784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember', window );">Fortress Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Loan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected Dividend Yield | Level 3 | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=alur_PubcoAdditionalSharesLiabilityMember', window );">PubCo Additional Shares Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfEstimatedNumberOfShares', window );">Fair value of estimated number of shares | shares</a></td>
<td class="nump">387,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfEstimatedPriceOfShares', window );">Fair value of estimated price of shares</a></td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=alur_BasePubcoSharesAndBackstopShareLiabilityMember', window );">Base PubCo Shares and Backstop Shares Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfEstimatedNumberOfShares', window );">Fair value of estimated number of shares | shares</a></td>
<td class="nump">950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfEstimatedPriceOfShares', window );">Fair value of estimated price of shares</a></td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember', window );">Term Loan Derivative Liability | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandNineteenTermLoanAndSuccessFeeMember', window );">2019 Term Loan and Success Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssumptionsOfLiquidityEventTerm', window );">Fair value assumptions of liquidity event term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Estimated share price at conversion</a></td>
<td class="nump">$ 7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember', window );">Revenue Interest Financing and PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueOfEstimatedNumberOfShares', window );">Fair value of estimated number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,341<span></span>
</td>
<td class="nump">1,065,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember', window );">Revenue Interest Financing and PIPE Conversion Option | Estimated Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt instrument, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember', window );">RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueAssumptionsOfLiquidityEventTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions of liquidity event term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueAssumptionsOfLiquidityEventTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueOfEstimatedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Estimated Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueOfEstimatedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueOfEstimatedPriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Estimated Price of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueOfEstimatedPriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_FortressTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=alur_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PubcoAdditionalSharesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PubcoAdditionalSharesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_BasePubcoSharesAndBackstopShareLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_BasePubcoSharesAndBackstopShareLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandNineteenTermLoanAndSuccessFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandNineteenTermLoanAndSuccessFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RevenueInterestFinancingAndPipeConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954032768128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details) - Black-Scholes Option Pricing Model - Level 3<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Other Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0359<span></span>
</td>
<td class="nump">0.0395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series A 1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series B Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series C Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series C Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0365<span></span>
</td>
<td class="nump">0.0388<span></span>
</td>
<td class="nump">0.0392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series D-1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series D-1 Preferred Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Interest Rate | Legacy Allurion Series D-1 Preferred Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.0371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Other Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Other Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">1.05<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Series A 1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Series B Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Series C Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Series C Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">6.73<span></span>
</td>
<td class="nump">6.73<span></span>
</td>
<td class="nump">6.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Exercise Price | Legacy Allurion Series D-1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">12.14<span></span>
</td>
<td class="nump">12.14<span></span>
</td>
<td class="nump">11.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Other Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.61<span></span>
</td>
<td class="nump">3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Series A 1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Series B Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Series C Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Series C Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.61<span></span>
</td>
<td class="nump">3.74<span></span>
</td>
<td class="nump">7.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Estimated Fair Value of Underlying Share Price | Legacy Allurion Series D-1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.61<span></span>
</td>
<td class="nump">3.74<span></span>
</td>
<td class="nump">11.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Other Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Series A 1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Series B Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Series C Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Series C Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Volatility | Legacy Allurion Series D-1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Other Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Other Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Other Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">3 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">4 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series A 1 Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series B Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series C Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series C Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series D-1 Preferred Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Expected Life (Years) | Legacy Allurion Series D-1 Preferred Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, assets measured on recurring basis, observable and unobservable input reconciliation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_OtherCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_OtherCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_OtherCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_OtherCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_LegacyAllurionOtherCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_LegacyAllurionOtherCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesBPreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesBPreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCPreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesCPreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45953944639232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 23,749<span></span>
</td>
<td class="nump">$ 30,582<span></span>
</td>
<td class="nump">$ 4,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">23,749<span></span>
</td>
<td class="nump">30,582<span></span>
</td>
<td class="nump">4,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">93,155<span></span>
</td>
<td class="nump">68,520<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Common Stock Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Revenue Interest Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Earn-out Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">23,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">36,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Term Loan Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Success Fee Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Series C Common Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Series B Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Series A-1 Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Other Common Stock Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Series C Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Legacy Allurion Series D-1 Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Private Placement Warrants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">23,749<span></span>
</td>
<td class="nump">30,582<span></span>
</td>
<td class="nump">4,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">93,686<span></span>
</td>
<td class="nump">74,463<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Common Stock Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Public Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">5,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Revenue Interest Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">38,500<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | PIPE Conversion Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Earn-out Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">23,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | RTW Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">36,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Term Loan Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Success Fee Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Series C Common Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Series B Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Series A-1 Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Other Common Stock Warrant Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Series C Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Legacy Allurion Series D-1 Preferred Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">23,749<span></span>
</td>
<td class="nump">$ 30,582<span></span>
</td>
<td class="nump">$ 4,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Total Carrying Value | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionCommonStockWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionCommonStockWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PublicOfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_RevenueInterestFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_RevenueInterestFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_PIPEConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_PIPEConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_EarnOutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_EarnOutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_RtwConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_RtwConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_TermLoanDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_DerivativeLiabilitySuccessFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_DerivativeLiabilitySuccessFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_OtherCommonStockWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_OtherCommonStockWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029935328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 05, 2024</div></th>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,301,409<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Public warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,043,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,942,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,746,000<span></span>
</td>
<td class="nump">$ 30,657,000<span></span>
</td>
<td class="nump">$ 46,024,000<span></span>
</td>
<td class="nump">$ 15,365,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,066,000<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="nump">150,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,007,000<span></span>
</td>
<td class="nump">$ 99,875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember', window );">ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Amount received on shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ExpenseOfIssuanceOfCommitmentShares', window );">Expense of issuance of commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StructuringFeePayable', window );">Structuring fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,976<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,482,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfCommonStockSharesOutstanding', window );">Percentage of common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,064,000<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember', window );">Commitment Shares | ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Public warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,567,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,567,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant | Scenario Plan Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantsRedumptionPricePerShare', window );">Warrants redumption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant | Scenario Plan Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantsRedumptionPricePerShare', window );">Warrants redumption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,160,976<span></span>
</td>
<td class="nump">14,406,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,567,484<span></span>
</td>
<td class="nump">14,406,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_UnderwritingDiscounts', window );">Underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingWarrantsAndShareOverallotmentMember', window );">Public Offering Warrants and Share Overallotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Issue-date estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingWarrantsAndShareOverallotmentMember', window );">Public Offering Warrants and Share Overallotment | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingWarrantsAndShareOverallotmentMember', window );">Public Offering Warrants and Share Overallotment | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWithRTWMember', window );">Private Placement with RTW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants converted into warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="nump">1,927,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NetProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from offering</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health | Public Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Class of Warrant Exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Compute Health | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares issuable for each outstanding warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PreferredStockRedemptionBasis', window );">Preferred stock redemption basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A&#160;Preferred Stock outstanding on December&#160;31, 2026 (the &#8220;Redemption Date&#8221;) shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the &#8220;Redemption Price&#8221;). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company&#8217;s consolidated balance sheet.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PreferredStockLiquidationPreferenceBasis', window );">Preferred stock liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder&#8217;s Series A&#160;Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A Preferred Stock is convertible after the date that the Company&#8217;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#8220;Series A Stockholder Approval&#8221;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and (ii)&#160;pre-funded conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Private Placement with RTW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Issue-date estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ReductionInProceedsFromOffering', window );">Reduction in proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ExpenseOfIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of Issuance of Commitment Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ExpenseOfIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NetProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance or sale of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NetProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock, shares, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PreferredStockLiquidationPreferenceBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock liquidation preference basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PreferredStockLiquidationPreferenceBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PreferredStockRedemptionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock redemption basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PreferredStockRedemptionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ReductionInProceedsFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in proceeds from offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ReductionInProceedsFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_StructuringFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Structuring fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_StructuringFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_UnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_UnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_WarrantsRedumptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants redumption price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_WarrantsRedumptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_ChardanEquityFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_ChardanEquityFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingWarrantsAndShareOverallotmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PublicOfferingWarrantsAndShareOverallotmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWithRTWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PrivatePlacementWithRTWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027589200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">57,369,304<span></span>
</td>
<td class="nump">32,693,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">530,778<span></span>
</td>
<td class="nump">643,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">7,108,316<span></span>
</td>
<td class="nump">3,886,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">19,231,301<span></span>
</td>
<td class="nump">264,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember', window );">Shares of Common Stock Issued Upon the Exercise of Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">18,759,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember', window );">Earn-Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_ConvertibleNotesMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">479,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027651984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">19,231,301<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member', window );">December 1, 2014 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">44,272<span></span>
</td>
<td class="nump">44,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member', window );">March 30, 2021 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">130,053<span></span>
</td>
<td class="nump">130,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member', window );">September 15, 2022 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">45,238<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member', window );">June 4, 2022 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">45,238<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member', window );">January 17, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">73,349<span></span>
</td>
<td class="nump">73,349<span></span>
</td>
<td class="nump">73,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member', window );">August 3, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member', window );">September 8, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">28,764<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member', window );">June 19, 2018 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">17,977<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member', window );">June 25, 2019 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">8,988<span></span>
</td>
<td class="nump">8,988<span></span>
</td>
<td class="nump">8,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJuly012024Member', window );">July 01,2024 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">18,827,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJuly012024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJuly012024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954031061136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,301,409<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Public warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,381,000<span></span>
</td>
<td class="nump">$ 6,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,066,000<span></span>
</td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200,000<span></span>
</td>
<td class="nump">150,692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,692,000<span></span>
</td>
<td class="nump">$ 143,007,000<span></span>
</td>
<td class="nump">$ 99,875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember', window );">ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,234<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ExpenseOfIssuanceOfCommitmentShares', window );">Expense of issuance of commitment shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StructuringFeePayable', window );">Structuring fee payable</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,976<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="nump">9,482,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfCommonStockSharesOutstanding', window );">Percentage of common stock, shares, outstanding</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember', window );">Commitment Shares | ChEF Purchase Agreement | Chardan Equity Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period value</a></td>
<td class="nump">$ 35,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,567,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,567,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Public warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,206,720<span></span>
</td>
<td class="nump">$ 13,206,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,554<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant | Scenario Plan Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantsRedumptionPricePerShare', window );">Warrants redumption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.67<span></span>
</td>
<td class="nump">12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember', window );">Public Warrant | Scenario Plan Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_WarrantsRedumptionPricePerShare', window );">Warrants redumption price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="nump">7.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Class of Warrant Exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="nump">0.6125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember', window );">Compute Health | Public Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=alur_LegacyAllurionMember', window );">Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,029,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">common stockholders were entitled to elect four members of the Board of Directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue', window );">Revenue milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfSharesOfCommonStockHeld', window );">Percentage of shares of common stock held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series&#8217; applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConversionBasis', window );">Preferred stock conversion rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of Series A Preferred Stock is convertible after the date that the Company&#8217;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#8220;Series A Stockholder Approval&#8221;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and (ii)&#160;pre-funded conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,113,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PreferredStockRedemptionValueToPrice', window );">Preferred Stock redemption value to price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock | Legacy Allurion | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfPreferredStockRedeemableShares', window );">Percentage of outstanding shares of redeemable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember', window );">Series D-1 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.8725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember', window );">Series D-2 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.2256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember', window );">Series D-3 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Compute Health | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares issuable for each outstanding warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="nump">1.420455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ExpenseOfIssuanceOfCommitmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense of Issuance of Commitment Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ExpenseOfIssuanceOfCommitmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock, shares, outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfPreferredStockRedeemableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of preferred stock redeemable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfPreferredStockRedeemableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfSharesOfCommonStockHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Shares Of Common Stock Held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfSharesOfCommonStockHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PreferredStockRedemptionValueToPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock redemption value to price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PreferredStockRedemptionValueToPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue recognition milestone method of recognized revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_StructuringFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Structuring fee payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_StructuringFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_WarrantsRedumptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants redumption price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_WarrantsRedumptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ChefPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=alur_ChardanEquityFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=alur_ChardanEquityFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_CommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alur_PublicWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=alur_ScenarioPlanFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=alur_ScenarioPlanFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=alur_ComputeHealthAcquisitionCorprationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alur_LegacyAllurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alur_LegacyAllurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954039579296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=alur_LegacyAllurionMember', window );">Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,029,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,921,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,276,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,113,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,927,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember', window );">Series D-1 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember', window );">Series D-2 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,644,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember', window );">Series D-3 Preferred Stock | Legacy Allurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alur_LegacyAllurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alur_LegacyAllurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDTwoPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDThreePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954029550352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">57,369,304<span></span>
</td>
<td class="nump">32,693,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">530,778<span></span>
</td>
<td class="nump">643,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">7,108,316<span></span>
</td>
<td class="nump">3,886,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchasePreferredStockMember', window );">Warrants to Purchase Preferred Stock (as converted to warrants to purchase common stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">19,231,301<span></span>
</td>
<td class="nump">264,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_PublicWarrantsToPurchaseCommonStockMember', window );">Public Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember', window );">Earn-Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_OutstandingOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchasePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchasePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_PublicWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_PublicWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=alur_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034798400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">19,231,301<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtApril012013Member', window );">April 1, 2013 | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member', window );">December 1, 2014 | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member', window );">December 1, 2014 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">44,272<span></span>
</td>
<td class="nump">44,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member', window );">March 30, 2021 | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member', window );">March 30, 2021 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">130,053<span></span>
</td>
<td class="nump">130,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member', window );">September 15, 2022 | Series D-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member', window );">September 15, 2022 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">45,238<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member', window );">June 4, 2022 | Series D-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member', window );">June 4, 2022 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">45,238<span></span>
</td>
<td class="nump">45,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="nump">$ 12.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member', window );">January 17, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">73,349<span></span>
</td>
<td class="nump">73,349<span></span>
</td>
<td class="nump">73,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member', window );">August 3, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member', window );">September 8, 2017 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">28,764<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
<td class="nump">28,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member', window );">June 19, 2018 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">17,977<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
<td class="nump">17,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member', window );">June 25, 2019 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining Contractual Term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares Issuable Upon Exercise of Warrant</a></td>
<td class="nump">8,988<span></span>
</td>
<td class="nump">8,988<span></span>
</td>
<td class="nump">8,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtApril012013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtApril012013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtDecember012014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtMarch302021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember152022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alur_SeriesDOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune042022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJanuary172017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtAugust032017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtSeptember082017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune192018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=alur_WarrantsIssuedAtJune252019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954030981072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (9,004)<span></span>
</td>
<td class="num">$ (2,162)<span></span>
</td>
<td class="nump">$ 5,586<span></span>
</td>
<td class="num">$ (21,630)<span></span>
</td>
<td class="num">$ (21,996)<span></span>
</td>
<td class="num">$ (17,801)<span></span>
</td>
<td class="num">$ (5,580)<span></span>
</td>
<td class="num">$ (61,427)<span></span>
</td>
<td class="num">$ (80,607)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (37,744)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Cumulative undeclared preferred dividends to participating securities (Legacy Series D convertible preferred stock)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="num">(1,697)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,907)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (9,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,580)<span></span>
</td>
<td class="num">$ (63,124)<span></span>
</td>
<td class="num">$ (82,304)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (40,651)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common stock outstanding</a></td>
<td class="nump">64,086,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,335,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,310,214<span></span>
</td>
<td class="nump">31,558,538<span></span>
</td>
<td class="nump">35,581,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,918,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common stock outstanding</a></td>
<td class="nump">64,086,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,335,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,310,214<span></span>
</td>
<td class="nump">31,558,538<span></span>
</td>
<td class="nump">35,581,656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,918,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.51)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1.51)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45953944590608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">57,369,304<span></span>
</td>
<td class="nump">32,864,376<span></span>
</td>
<td class="nump">32,693,169<span></span>
</td>
<td class="nump">6,325,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_OutstandingOptionsToPurchaseCommonStockMember', window );">Outstanding Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">7,108,316<span></span>
</td>
<td class="nump">4,270,229<span></span>
</td>
<td class="nump">3,886,038<span></span>
</td>
<td class="nump">4,301,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">530,778<span></span>
</td>
<td class="nump">429,321<span></span>
</td>
<td class="nump">643,635<span></span>
</td>
<td class="nump">1,415,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchasePreferredStockMember', window );">Warrants to Purchase Preferred Stock (as converted to warrants to purchase Common Stock)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,857<span></span>
</td>
<td class="nump">297,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">19,231,301<span></span>
</td>
<td class="nump">404,988<span></span>
</td>
<td class="nump">264,801<span></span>
</td>
<td class="nump">138,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember', window );">Shares of Common Stock Issued Upon the Exercise of Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">18,759,554<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="nump">18,759,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_EarnOutSharesMember', window );">Earn-Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_ConvertibleNotesMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">479,196<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_OutstandingOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_OutstandingOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchasePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchasePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_EarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_EarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alur_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954034495808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,369,304<span></span>
</td>
<td class="nump">57,369,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,693,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
<td class="nump">$ 6,349<span></span>
</td>
<td class="nump">$ 8,357<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="nump">64,369,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,688,096<span></span>
</td>
<td class="nump">27,079,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Board of Director Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage', window );">Remaining vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of the stock option awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="nump">$ 2.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alur_TimeVestedRestrictedStockUnitsMember', window );">Time-Vested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of time-vested restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.32<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanMember', window );">2010 Plan and 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan', window );">Options and RSUs issued and exercisable under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,529,673<span></span>
</td>
<td class="nump">5,717,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember', window );">2010 Plan, 2020 Plan, and 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan', window );">Options and RSUs issued and exercisable under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,639,094<span></span>
</td>
<td class="nump">7,639,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,529,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020Member', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_StockOptionAndIncentivePlanMember', window );">2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,174,364<span></span>
</td>
<td class="nump">8,174,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,822,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance', window );">Increase (decrease) in percentage of number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,122<span></span>
</td>
<td class="nump">2,226,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfPriceLowerOfFairValueMarketValue', window );">Percentage of price lower of fair value market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfEmployeesCompensationToPayrollDeductions', window );">Percentage of employees compensation to payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfDilutedSharesOutstanding', window );">Percentage of diluted shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember', window );">2023 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in percentage of number of shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of diluted shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfEmployeesCompensationToPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees compensation to payroll deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfEmployeesCompensationToPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfPriceLowerOfFairValueMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of price lower of fair value market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfPriceLowerOfFairValueMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, award remaining vesting rights, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options and rsu's issued and exercisable under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alur_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alur_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_StockOptionPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_StockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_StockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027257552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Schedule of Stock Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 5,539<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
<td class="nump">$ 6,349<span></span>
</td>
<td class="nump">$ 8,357<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">6,235<span></span>
</td>
<td class="nump">8,198<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035659664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details) - 2010 Plan, 2020 Plan, 2023 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning balance</a></td>
<td class="nump">3,886,038<span></span>
</td>
<td class="nump">4,301,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,686,059<span></span>
</td>
<td class="nump">257,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancellations and forfeitures</a></td>
<td class="num">(447,644)<span></span>
</td>
<td class="num">(375,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(16,137)<span></span>
</td>
<td class="num">(298,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending balance</a></td>
<td class="nump">7,108,316<span></span>
</td>
<td class="nump">3,886,038<span></span>
</td>
<td class="nump">4,301,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">2,872,814<span></span>
</td>
<td class="nump">2,735,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">1.86<span></span>
</td>
<td class="nump">5.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Cancellations and forfeitures</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">1.37<span></span>
</td>
<td class="nump">1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Ending balance</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="nump">2.67<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,565<span></span>
</td>
<td class="nump">$ 9,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033656496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.36%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027928912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details) - Restricted Stock Units - 2020 Plan and 2023 Plan - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Beginning balance</a></td>
<td class="nump">643,635<span></span>
</td>
<td class="nump">1,415,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">226,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Cancellations and forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="num">(187,857)<span></span>
</td>
<td class="num">(918,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Ending balance</a></td>
<td class="nump">530,778<span></span>
</td>
<td class="nump">643,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">2.61<span></span>
</td>
<td class="nump">4.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancellations and forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="nump">4.51<span></span>
</td>
<td class="nump">4.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alur_StockOptionPlan2020And2023StockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alur_StockOptionPlan2020And2023StockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027248896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined benefit plan matching contributions</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027998464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 29, 2024 </div>
<div>USD ($) </div>
<div>TradingDay</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 936,000<span></span>
</td>
<td class="nump">$ 936,000<span></span>
</td>
<td class="nump">$ 1,677,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease total area of land | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, right to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has a right to extend certain of these leases for periods between three and five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has a right to extend certain of these leases for periods between three and five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, right to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency for probable losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_IncreaseDecreaseInRevenuesForCustomerReturns', window );">Reduction to revenues of customer returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_StockExchangeListingRequirementsDescription', window );">Stock exchange listing requirements description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August&#160;12, 2024, we received a letter from the NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#8217;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfConsecutiveTradingDay', window );">Number of consecutive trading day | TradingDay</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (64,790,000)<span></span>
</td>
<td class="num">$ (52,756,000)<span></span>
</td>
<td class="num">$ (64,790,000)<span></span>
</td>
<td class="num">$ (52,756,000)<span></span>
</td>
<td class="num">(70,487,000)<span></span>
</td>
<td class="num">$ (32,314,000)<span></span>
</td>
<td class="num">$ (70,582,000)<span></span>
</td>
<td class="num">$ (66,162,000)<span></span>
</td>
<td class="num">$ (71,218,000)<span></span>
</td>
<td class="num">$ (49,657,000)<span></span>
</td>
<td class="nump">$ 4,837,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=alur_NatickAndHudsonMember', window );">Natick and Hudson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseExpirationPeriod', window );">Lessee operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AverageMarketCapitalizationAmount', window );">Average market capitalization amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Natick and Hudson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseExpirationPeriod', window );">Lessee operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028-03<span></span>
</td>
<td class="text">2028-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseExpirationPeriod', window );">Lessee operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Natick and Hudson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseExpirationPeriod', window );">Lessee operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-06<span></span>
</td>
<td class="text">2024-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AverageMarketCapitalizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average market capitalization amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AverageMarketCapitalizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_IncreaseDecreaseInRevenuesForCustomerReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in revenues for customer returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_IncreaseDecreaseInRevenuesForCustomerReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_LesseeOperatingLeaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_LesseeOperatingLeaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfConsecutiveTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading day.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfConsecutiveTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_StockExchangeListingRequirementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock exchange listing requirements description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_StockExchangeListingRequirementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alur_NatickAndHudsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alur_NatickAndHudsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954028233248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 1,123<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts in the measurement of lease liabilities</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Operating cash flows paid for amounts in the measurement of finance lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="nump">$ 1,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954027830080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeasesAndFinanceLeasesAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingAndFinanceLeaseLiability', window );">Present value of total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingAndFinanceLeaseLiabilityCurrent', window );">Less: current lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2028</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liability</a></td>
<td class="num">(878)<span></span>
</td>
<td class="num">(908)<span></span>
</td>
<td class="num">$ (905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 1,578<span></span>
</td>
<td class="nump">$ 2,306<span></span>
</td>
<td class="nump">$ 2,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due next twelve months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability payments due year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease and finance lease liability undiscounted excess amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeasesAndFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeasesAndFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035017072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, weighted -average remaining lease term (in years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, weighted-average discount rate</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954033606592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Geographic Information - Schedule of Long-lived Assets by Geography (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 5,363<span></span>
</td>
<td class="nump">$ 6,391<span></span>
</td>
<td class="nump">$ 5,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">4,690<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="nump">$ 1,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954035752528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-party Transactions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 28, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfOutstandingCapitalStock', window );">Percentage of outstanding capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants into shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,231,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,658<span></span>
</td>
<td class="nump">436,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes | Hunter Ventures Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Debt instrument issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ConsultingAgreementsMember', window );">Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AgreementsTerminationDate', window );">Agreements termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteAgreementWithRtwMember', window );">Convertible Note Agreement with RTW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PercentageOfOutstandingCommonStock', window );">Percentage of Outstanding Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RTWParticipationInPublicOfferingMember', window );">RTW Participation in Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AggregatePurchasePriceFromOffering', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_PrivatePlacementWithRTWMember', window );">Private Placement with RTW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Conversion of warrants into shares of common stock | shares</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AggregatePurchasePriceFromOffering', window );">Aggregate purchase price</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_PrivatePlacementWithRTWMember', window );">Private Placement with RTW | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock | shares</a></td>
<td class="nump">2,260,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_LnmpJpbcInvestMember', window );">LNMP JPBC Invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseEndDate', window );">Operating lease end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_LesseeOperatingLeaseTerminatedDate', window );">Lease terminated date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_OperatingLeaseStartDate', window );">Operating lease start date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_KkgEnterprisesMember', window );">KKG Enterprises | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination', window );">Payments of advisory services related to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_RemusGroupManagementMember', window );">Remus Group Management | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination', window );">Payments of advisory services related to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_BenoitChardonConsultingMember', window );">Benoit Chardon Consulting | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_AgreementsTerminationDate', window );">Agreements termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 12,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RelatedPartyTransactionConsultingFees', window );">Consulting fees | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,333.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_BenoitChardonConsultingMember', window );">Benoit Chardon Consulting | Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_RelatedPartyTransactionTerminationFees', window );">Termination fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AggregatePurchasePriceFromOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price from offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AggregatePurchasePriceFromOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_AgreementsTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_AgreementsTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_LesseeOperatingLeaseTerminatedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease terminated date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_LesseeOperatingLeaseTerminatedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease end date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_OperatingLeaseStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_OperatingLeaseStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of advisory services related to business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfOutstandingCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding capital stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfOutstandingCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_PercentageOfOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_PercentageOfOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RelatedPartyTransactionConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RelatedPartyTransactionConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_RelatedPartyTransactionTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transaction termination fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_RelatedPartyTransactionTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alur_HunterVenturesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alur_HunterVenturesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteAgreementWithRtwMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_ConvertibleNoteAgreementWithRtwMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RTWParticipationInPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RTWParticipationInPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_PrivatePlacementWithRTWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_PrivatePlacementWithRTWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_LnmpJpbcInvestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_LnmpJpbcInvestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_KkgEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_KkgEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_RemusGroupManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_RemusGroupManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_BenoitChardonConsultingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alur_BenoitChardonConsultingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_TerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_TerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45954026049712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Events<br> $ in Millions</strong></div></th>
<th class="th">
<div>Nov. 06, 2024 </div>
<div>USD ($) </div>
<div>Employees</div>
</th>
<th class="th">
<div>Oct. 22, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Restructuring Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees reduced from workforce | Employees</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of employees reduced from workforce</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">One-time aggregate restructuring charges</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | RTW Side Letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_NumberOfSurrenderSharesOfCommonStock', window );">Number of surrender shares of common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">749,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_SurrenderCommonStockValue', window );">Surrender common stock value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance', window );">Conversion of RTW PIPE investment to revenue interest finance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_ConversionOfPipeInvestmentToRevenueInterestFinance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of PIPE investment to revenue interest finance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_ConversionOfPipeInvestmentToRevenueInterestFinance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_NumberOfSurrenderSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Surrender Shares Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_NumberOfSurrenderSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alur_SurrenderCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Surrender common stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alur_SurrenderCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=alur_RestructuringPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=alur_RestructuringPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alur_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alur_AmendedAndRestatedRtwSideLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alur_AmendedAndRestatedRtwSideLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MTMOO[J R$QG"0&</P"AR0ET99#3 'KB'#VRG#]GERII9Z>.80I,<@B@P^B-
M*IX;&1D6,@NB@>D;]R""7T,BQQ29#($CXNJ #YC)50 Q))EF@1?Z VB%>R3!
M=B;Y,RG+Y 0Q)D($!F<L "L_\ TIUAJ]-3WVW(*/@ N3I%\S=%W(9,(J@7[/
M"KF4R8J'+@C/8 @ 3 D]Q\@P@)E/=+/87LDW!H'TW$/LW'.5E,64UT?;G9BL
M@J5H33-@16@4Z9KM=7JKYAZ0B!V0%ERN\63>E5,B*KA@U@F2F'PC\[\N:0&8
M&:H!3W(2A0<NV=NCL5+$_(L^;W2+\_1PD@'5$2A!ZA,*8$6HHR^5("OL#^GK
M*8;8*:8E\R/=TP2/:#\IMCI,JT#"JJ[#M"*>AP=T]!!#[!"SFS..Z0!V/K#K
MZ8N@!63G$JQ#? S8A=0/W0$Q/;^0(_S"-YM,J%7K;HJ70TK(Q,ED^I3#Z?V-
M'%4(^Q] B5;/\.!'X&[A2([B$1P=AK'')>);%SG?V(JQC4H]:#\IW9;LGLFQ
MNT)+P=.?+_$D'^ M6"N2O7H/=DQO\5C>#N/;<QJQ<]J2E:H_7J*R#W2Z%^AM
M%^A*!?H,O7,^.HZ#Y810HL<DEW0P1=AQSIS=/U2MDU)1;2W6O,S^E@632J7:
M)=L*MKF3B>IE\_^W9ER0,^([9]B+FKN_6<E?7&15I4"YX>-:5$)>*/(8<M<8
MQBQMGPX?$7PF)B!&^D)M 1@9TY4UM&]MNIY'26@=&DW/7_-\Q<KJ/^K0*TLS
M ??_D3"RC<R8WN*QO!T&L4=<8D?<V['Z]W_K@FE=NSBM*Q^4?$4O'@F+VT8U
M6=SH[C:3PT.@'JZI':[5+"D7]TWLP9,?$Y=U9 %,]&448#( 7;1'9&I'Y,O5
M*E/,*(E%G29,LP*ER3:3! /J,,D6JRU%_>0 LG.IH^^>QH!=%(7!P.X$[5&9
MVE'Y,DWK39TG@G6;$GPC^\]:'?D_,I05\IZA]SFO*I!=*("XH;$6 *RF@;'P
ML]?UK0>4>R>41S<'NUBTV154;,+PE.#0V/I;P(8D,) 4,L14LNO .03M"9N>
M0M@5-'& TDPVGOIN8#8G8!<X^Z=9K3# CA**!V";]K!-[;!MK!S.3N89E6]/
M#XAGG!Y#!P/4W#F$#@8@;\,' [1G9GKT@/,QXW65/Z-O3"UMV0H4,RH5C^HM
M'LO;801[*J;!*$<K="0";$,XIK=X+&^'(>SIE(ZR6VKW\NH(FKNJ7F0<68SU
MSL/(],A)[<AYTG:-W<>KXQ(9F2:D^C<E\5COW,5EMO=UFOJ6\'])^9 5%<K9
MO73O? QD;<K=YWF[&\&WS0=K=UP(OFDNURR1.5D9R-_ON5SCMS?J&[CN(\GY
M/U!+ P04    " "+,8I9?"Z9B_@#  #8$0  &    'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;+5878^B2!3]*Q5VLIE)9IL/$;1726SIR70RVV/&[MV'S3Z4
M<-5* ^56%3JSOWZK@$811#0]/F@5G'NXYU!UO3#:4?;"UP "?8^CA(^UM1";
M6UWGP1IBS&_H!A)Y9DE9C(6<LI7.-PQPF 7%D6X9AJ/'F"2:-\J.S9@WHJF(
M2 (SAG@:QYC]N(.([L::J;T>^$96:Z$.Z-YH@U<P!_&\F3$YTTN6D,20<$(3
MQ& YUB;FK6_V54"&^)/ CA^,D9*RH/1%31["L6:HC"""0"@*+'^V,(4H4DPR
MCW\+4JV\I@H\'+^R?\K$2S$+S&%*H[](*-9C;:"A$)8XC<0WNOL,A: LP8!&
M//M&NP)K:"A(N:!Q$2PSB$F2_^+OA1$' :9](L J JRN ;TBH-<UP"X"[,R9
M7$KF@X\%]D:,[A!3:,FF!IF96;243Q)UW^>"R;-$Q@GO^7'R[#\\W?MH^O71
MOW^<YZ/YUR\/_D0=OIM\F3Q.[]'\\_W]TQR]GV$&B5B#( &./J#?T//<1^_?
M?4#O$$G0TYJF'"<A'^E"9J>NH0=%)G=Y)M:)3.:PN4$]XR.R#,MN")^VA_L0
MR' S"^\UA/O=PZUJN"XM+7VU2E^MC*]W2HW  N3^$(@NT2>2X"0@.$(SRDFV
MWO^>++A@<M7_T^14SFTW<ZM2<,LW.("Q)O<Z![8%S?OU%],Q?F_R[2W)_#<B
MJWC:*SWMM;%[DTA6*6DD*$]#FB[$,HUDY0AHFHC&%9?S]3,^50&WWL"RY>K8
M'OI3!YF6XYI5E%]'N?8>4]%CEWKL5CUS8 0XFLCZ&8(LYXL(4$"3+3!!U%A:
MN 0F3R)9!H*7CVB#&=KB*(4FK?FUW(,$C1O#,(YT3+O!_-;,K[S/_=*7_MOZ
MPM>R*'&$4[&FC/P'89,_^36=P]ML%)\CBSHC_58=5[KDE"XY/\4EPGG:[)!3
MTVU9CF'VAT?^U'''OK1F?J4O;NF+^U-\D4T1%_*OBR2K)G/<CN;4<<?FM*9_
MI3F#TIQ!JSFSBTI**]>E?T.#;H7G+*RB>UCJ'EZFNU/)&'8N&9V1?A=D1:)I
M[%LYXRJ1IW=\.^&E=[A@:UO[K9"J[(,.UKQ*]ID-W<YZL7;SO/8V2%7[OLLT
M6QLN;TKC6':3739SP72V0>B(\\_CJIKV79[9WN95-77:J 5CXZXZWJH78/UN
MV*K.??=GMK=_C3I;]JI=R\6Q>\ZP-ZC=P3K2=IW!P!@ZQ_KJ2,LUW.&@[YQ0
MM^_AS/8FKE'=N2U9[[Q.2:PC3TFL(T](U ^>HM4[CS\P6Y&$HPB6,M2X<243
MRU\CY!-!-]F#]8(*^9B>#=> 0V *(,\O*16O$_6L7K[,\?X'4$L#!!0    (
M (LQBEFV9@\$20H  '<S   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
MM5MM;]LX$OXKA&]QV 7J6"0E2LHE 1*_U :V25"GMQ\6]T&VZ5A76?)*5-+N
MK[^AK/B%'"GNKN]+:RO/#*EGAL-Y:.GJ-<N_%BLI%?FV3M+BNK-2:G/9ZQ7S
ME5Q'Q46VD2G\99GEZTC!U_RY5VQR&2TJHW728XXC>NLH3CLW5]6UQ_SF*BM5
M$J?R,2=%N5Y'^?<[F62OUQW:>;OP.7Y>*7VA=W.UB9[E5*HOF\<<OO5V7A;Q
M6J9%G*4DE\OKSBV]G'"N#2K$OV/Y6AQ\)OI69EGV57^9+*X[CIZ13.1<:1<1
M_/<B^S))M">8QQ^UT\YN3&UX^/G-^ZBZ>;B9653(?I;\%B_4ZKH3=,A"+J,R
M49^SU[&L;\C3_N994E3_DM<:ZW3(O"Q4MJZ-80;K.-W^'WVKB3@P #^X :L-
MF&G@-ACPVH"?.H);&[BGCN#5!IYI(!H,1&T@3 />8.#7!OZI4PIJ@^#4$<+:
M(*S281N_*OB#2$4W5WGV2G*-!F_Z0Y5!E37$/$YULD]5#G^-P4[=?+F__3*8
M/ T'I/]P/QC>3[>?I@^_3@:W^O+T"?[[-+Q_FI*'$7EX''Z^?9H @'3)E^F
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M/UX6PQ7H$D"6DKNR@'G",/UL/7L[O5G!W$!L2?VV@LJS8B.K-PY@E&CQW[*
MV;^9RS_*^"5*]!%<6JYG,-5LB256O%[+11RIRL=2 :YQ</ LETL8L8+HAP?S
M0M_[)@8M'?]9@2[(5$IRKT^5>'5_RS*O1?;V]0Z-P2I4[^!!^+7,GZNW* J(
M 3"U?:!H=W7WIL9M]7Z"<?V.7O8I<GU +X?8]1&]G*#7V>5'S/^874ZPZ[<<
M_L#QO_"WETIZ^UO;OI+R*<J?8TB:1"[A-IT+'S:@?/N6Q_:+RC;5*P"S3*EL
M77U<R0CZ1@V OR\SX+K^H@?8O6MS\S]02P,$%     @ BS&*6>@],ZU=!
MQ1D  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RUF6MOHS@4AO^*Q8Y&
MK;0MUY#+))':<)E(TZ0JZ<QG"DY !9PU3C+[[]<&2@-QV%3C?FB#S7F?8\XY
MMA,S/B#\FD<0$O [3;)\(D6$;$>RG <13/W\%FUA1N^L$4Y]0IMX(^=;#/VP
M$*6)K"F**:=^G$G3<='WB*=CM"-)G,%'#/)=FOKXWWN8H,-$4J6WCJ=X$Q'6
M(4_'6W\#/4B>MX^8MN2:$L8IS/(890##]42Z4T>NJC%!8?$SAH?\Z!JP1WE!
MZ)4UYN%$4MB(8 (#PA ^_=C#&4P21J+C^*>"2K5/)CR^?J,[Q</3AWGQ<SA#
MR:\X)-%$&D@@A&M_EY G=/@.JP?J,5Z DKSX#PZ5K2*!8)<3E%9B.H(TSLI/
M_W<5B",!Y? %6B70V@+CC$"O!/JE'HQ*8%SJH5<)>FV!>49@5@+S4@_]2M O
MDE5&MTB-Y1-_.L;H #"SIC1V4>2W4-.,Q!DK18]@>C>F.C)]7MP]6_.5;8'9
M<F'9"Z^\\I8_YM8=Z_96]./!7JP\L'3HK8?')_L[M9O_M,%\0=LVN/JQ]+QK
M< .>/0M<?;D&7T"<@56$=KF?A?E8)G2@S)T<5(.Z+P>EG1F4#AY01J(<V%D(
M0X[>ZM8/_T_O=.M5K0,@TPC78=;>PGRO=1(]N+T%NO(WT!3-X QH=KE<Y\7C
MS[S;?^;=Z99;,*!R]:S<O5RN=:1"KRM>+WC&&=Z"KN\)RKEE62I[A9(MXOOI
MS5!1:,CVQ[GB6&FJJ2M-,XMCUNL-6E8VQ\I4#:W?-',X9@/%5%IF+L=,[_>-
M]R=HA,RH0V84.OU,R)8D@A@$**6[7<2VH3VD,YRV(;ABH;P>\8)I=*6!;;&C
M?.L'<")1:@[Q'DK3KW^IIO*--S]$PBR1,%LDS!$)<P7!&B73JTNFUSG+9I&?
M;5B5@+4?8[#WDQT$(?TC" 3UO0##,"8 Q_DKKX)*%^91-=/YTYI L\YQ?+0R
M3CV:;8>V2(?.J<.;?MNC*\AC(Y%FG4BS.Y&-63\O9CTO5^;I@ZAZ>^4T+ULY
M>:SAL)T'#HRW<G+,!JI^LG)RS#I6SGX=O7YG])[@'F8[%C<":6X(<.+,SX(X
MV_!BV,GZZ(HI$F:)A-DB88Y(F"L(UBB505TJ@T_89 <B2T8DS!()LT7"')$P
M5Q"L43+#NF2&G[_)#B_99#O'\='*./5XNLF*=.B(A+F"8(V$J\K[SW6E>T-9
M_0(SE.TA)O%+ L$"$<C_A=W)^>C*()1F":790FF.4)HKBM:LEJ/#'?43]I0*
M*JIT1-(LH31;*,T12G-%T9JEH[V7CO;Y>TOEX_A;-?WFW=Y<ND?RX0HY]:F=
M_G@0ZM,12G-%T<K,RT>'PRG$F^+</Z>+PBXCY1%0W5N_6[@K3M1;_??J:*9R
M^BUU9//Z'?:.HCBD?G=;ON!X\/$FSG*0P#4=@G+;I\G"Y3N#LD'0MCBR?D&$
MH+2XC* ?0LP,Z/TUHMM>U6 .ZC<WT_\ 4$L#!!0    ( (LQBEEK-7(CI!\
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MMJU);$IB"8FEL=ID;EA_3NY\2B9K9B0F2"PGL8+$)(F5$-8: .Q)DTN9&(>
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MM4 UJ7]3*H=/S:-,WX*(F\Q5;,Y<??NW(,P%1A]!T:@6JB6HEL::2:7TWX)
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MWGPKG_Y@?8,\86]1YG7[K_/48]T39[&MFW+=%^8U6&=%]W_ZW#MBIP"W Q?
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MMFDLMFDLL61LU!=TZ MJLGY^Q9>.O*S!0=:5]-J28GUX/#_UO- ]FSWN^A5
M^8CB8 R+ 5CH^JX"2P 8"0)*!]BHE=[02L\8<1?+__.9CR]'3>TT)5^/%F6Q
MR'+F%+SY6;$HU\SY5;CAG?A9?+E(ZY6SK=E23$7E$+"I.6 ]FP%KTUALTUAB
MR=BH*_VA*WUSP);%:=LY.>/+N<.>.<.I&=09G1U_)Y0\'RG!JV-\%"J1JV-"
M3)6PU3$(N1-!&PPM#8PMC1EWWR)+._Y3+)UT759-]D_[!=3@0*M$$"B-F>L8
M/J25!@-VJ*\T6,>$D0>W-QS:&QK;>]N4B[].!4E;.GQ$BGZ=;&JH/1YCI,PE
M<QWD$QHIC=5!(?'464D'41+ K8V&UD;&UMY4Y6/6LF-.SITMGX/RENO>\5DI
M72S*+9^KH)9'>J2YOJ>T7 ?1R"-*RP%+V \44PE@BOAPTY$K.:)K;/R/@FN0
M//N']S1[7JS2XH'/OP]<A;QSN#.FUJ/>Z&Y=3K'2GW, A+6F0Y:0NK(E( J1
MB<;O$&1T1,]GQ2-?ELKJ!6PQ GK;PVJ3=51 M28#ID@4J4TV5OV-4SO"TC78
MZ)IY%PI\R;U/L\IY3/,M<\I[YRFMJK3@3"5+[[*\77]!=V&@PRA&*F6!<!B%
MZM0 P4+BJW,_  NQ.Q$EDB,C(^V;=,625=EC*L3P7F\0*,@C=:X 8>J,$@,H
M%!!MQ "H:,(3DJ$B,T6=\L0WQD<._WA9-(P'8^-\SHJ4TSI!T_AJ>7-YDSCS
MD@^OJAULUYNIQ:1__FZM(]]55TX A5WJJGX"4"C"JI^,+7[K,)-L&!D9VJ1'
M65H5I^5V_SCS@/&#D>J,.8BC1 V;&,1%KJ>%UW]!/)%DGLA,/8= VZ39TN$A
MM61W32LFJB5?R=)FQYV@VW26R-VATJ^YN1;'$G_HH<C5(]+20\>NE507F;GN
M]&QWUX"NU/DG;Y6+M0C4<23PD!I_AZ 2<Q/>ZB+)CI&9'L<BV+*ZWO(YCG&"
M7',MF]9U*10"C[ZGK%D='9 ZKT4:^9U#*&U-C0]")>8VOM6'DG,C,^D>Q&/V
M.I0-^A$!!)FJJ_\<0B%5BL0 "KLA4;VCHW9I^WCG49)M;";;0Z-YD]=\B6SU
M)!];BW9M[!1'43;,J;,E)Q6LX3APVC<_Y]CM#:RS:PZ-5#%Z&"RQ5;>QCR6G
MQV9._X5+%K$BL&>Q3;3-ZI78;'J=P6:MZ[FN24'^@75J'@9("8XY@"*1*G_B
M@U")N35O]9:D^=A,\R_-LUC/]NLC9C*L<_"(JCK)7*MC%U:KUA);UL8](M4&
M-JL-.3&^=DT[0:S7/*9KL2_3:E7Q1=9NHSKU*JU@<FA^TM&SA-5M>PSH$ZS.
MPK8>.>X**7<P->Y5=U2H5O:=ZYJ)D<)US0XW!_>@L25MT?O?IK78JK7$EK5Q
M1TD5A<TJZJ+?I1/3%..:G*^C8'_HXB9 ZL;+'$"=DE!E"#$$0T3=LDX@&,8A
MFMBSQ%("X7T2R+!;A8$==Y5%SP'0::BZ(X90)'#5S4D(AI WL?F"I1S!9CER
M4[%6X_7LL'[OE,V*\0EP6U5B]FO'85D\G+;K>C<X08] 6^DJOP9 U-4<HH-P
MJ+D#4$5>,-7I4GE@L_+XTIZT[-D3P#K_/_4BC<0 *%]CRQ J4+?G$A!%INBR
MU C8K!&&8;U)7R;'M$[4N:-5(0^@"%65=PR@J*]M,D*V")XX82)2&Q"S-N"-
MK;9,!GH;V>-8W]/O!-@D#X) #7( 1L- C7( A5SM- 9 A;L[EF-?2 Y/S!S^
MZI!C7] %.N<6VU?85WT X"CA:E'U H#S212J>S:@/3\*T80G)#\GV$A!Q"Q?
M'Y2@89,#SZU:BZU:2VQ9&_?(3L:,F9_?;*O%*A4#E//R324BLWEI!RO[>YMM
M!"4'^P?8V_?5>)M#*(35#? 8A/FN>C(,PKRI-9E(7DSV9ZJ,AF<V1.F>X:EO
MR4-. %"0$R 8X 0(-NT$R3F).9%%'G'L&YE64U&L6HNM6DML61OWB&3$Q,R(
M;ZIRP=BR=NZK<JW(Y_'^&AR<.H.EH>NJ^]@ #(>!"HL/@R4 #"%W@CD1R9K)
M/M:\ZXK/9=5PA]?.=\&1OY1I\<M/(4;X]X+!<Y6E[?7>84"B2Q2H1_SQ8; $
M@.$HG!S.DED3,[.^25]V]PF5[7W02Y8VT'LOV;06$X"0$ZJ=XD$P[.,)7TK>
M3O8FU.Q$WZ=MS7_GT3<OUW?]IO?[-K./^[JITJ).N\3R:4\;'W>TIW7^[F-7
ME0PQ!./45F-^ENHV3AF5JH&:5</8U55_#C^<J=R_+E)@4JG50P0*R I7FS[C
MPV")K;J-W2H%"-V;&+3CUG(S)/Z]IK^P9U8MLAI>2:BN!C0% F"0FA 20X;4
MTX@$LD0FQC"5PH.:#P;&'A#4EK-< =H34_KN/]'4N/G1Q\YU5JTEMJR-W2[5
M!36KBV]L(Q>B@VB+V>#1HQB2#&Z@KASQ@;C$5NW&[MQ)J3<KE7$4W[3Y6LRY
MR?D3A9.'96C_:D^!;")?W?:;FZMS=&1;W:.W96W<%5(O4?,>O=(5V[L\6SC7
M]_>LXE/),1VA;ZBC$*O)Q'-S;8[N":LZR9:U<4](G43WZ*2CJ2Z%-O?U]!0(
MIK/.V%R]HYWY7Z1+4:FTJ%EIC2;L#0]M[LVR>NG2.%+NV76W10*Q8-#55K47
M!8XAL*>3LH-@B:VZC5TM)1H]0J+Q>:/BGAW(B"%XK>HTJ]9BJ]82"LFY<.**
M )5RCNY)U7K=[MN(='F1!'+WLN-X\Y8?A=*ML';[!X AY).(JI$*Y65%H;KI
M!\"(ZTU=%/&DW/+V)'!Q5_RZ9(M*G,.]$_?5VD]B@+<>$A*A_2 (\V.:M]?<
MQ)="C5790B36B-_!&VO \4U$ E4X +" RU=5.@ PXA(M60MZ* JB:.J6GU10
MGEE!S8]QA\@JNF,/65&(@!(3*6<%)71=^),'9%6%%*OQ!,!"5\TOB0]")0 *
M^^[4";XG)9:WYXK%L2YBXD30Z!Q=?>'(I2I+!6"AJ^?[ 3# U0EH#4]L87I2
M"7GFJ\FWV\TF;UEZFCO+K%[D9;VMNNU<X8_[G%O,BNY]"A.+J6=5&UFU%ENU
MEMBR-NXLJ;.\/1=#VN5!Y&ET%ZFZ[2>P2R =%:CY@0#*:V^\CP-41X4N45,Q
M !2AP<2JZ.W<8S:?_XSB$XQ(D85:R#3GX8BL6!Z\>GIVKS';O<=L]R+S?Z&)
M/*F)O#V:J#_5G3[4%8M]OEUV;#X](#/%_,2C^PXX3PI4'@^ $%'S5T#0Q&B0
M,L@SRZ#+G=.V(6E8L**R*/KWQK0)Q<;-0_,SCO:836NQ56N)!US:)E.<2PHD
M;]^]%%@501';76-7<H[ 3@%ND[BN>O<"1OEJ?.HH[2T620_:??$$BJ;N+GI2
MQ7AF%?.-+<J'(GN]<O$JS=7[K& ZI=GTT8$):!W.\[75[2!88JMNXU= 2$7D
MFQ61XM9#[RV:K1[K45]7,1[1;X0>!DMLU6WL4:F<?+-RNIS*^]]NVD/2X1KM
MH2<$YN<=[6M #7F>K^8/'@9+;-5M[&LIP?RWW7(W7&AN5E6Y?5B]IF:6:UZQ
ME7B[VB/KWU\#]H$NDGPMM<1<V6-7+."1IWH"BJUGCCM JCS_;7?KOWW_L[\Q
MW@7WE0CNM_I>/ZO"4:0YWZJZLVHML65MW$E2W?EF=8==C&3N$.ABJS==K%J+
MK5I+;%D;=X54G;ZEK$/?JG*T:BVV:BVQ96W<(SLOP3(KQ]$!D'F06!6$O;7Q
M.^$"W],68N!0#L EMFHW=J,4D+Y90.HYBJ +K2I$J]9BJ]826];&W2&EI!]:
MFF>LGJY9M19;M9;8LC;N$:E?_7WZ]>!Y)M)G!AH$VALYS \\VMG 4S&0V6?K
MJ9T;9SNOQUVSZJ%]+W'MM'L=W6M0AV^'=Q]?M&_\5;[_A#[,$?!]C#XDW9N-
MI?GN1<M?T^HA*VHG9_?\4>YO 6]ZU;V[N/NC*3?MRWGORJ8IU^W'%4N7K!(
M_OM]R4EM_X=XP/ &Z?-_ 5!+ P04    " "+,8I9BH(!:#P#  "P"0  &
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M+*RH>H[*ULM=' [Z/3Q0NT-OSJ.B01!='T<EYU'7_4&O"3H2TVW$=%\5<Y!
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MLTK11]E"VKFB1>N%P="JL?C(,:,&Z<#>*TB _ONP0Q+#HW<TA7@D@W+<8N6
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MT-I[&Y)U7\J@UJN :XHZ*FI4B,W!_C1A-V(20#DR54 _U>8L;=K,Z0G7&NB
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MEOQRH22820/P?&;@'\,;VJ#]5>='_P902P,$%     @ BS&*69I; Z:F)
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MF#T\/M\%(M1.[X'C596;#TS XFV\B<JJK@U\.1  ?;<3\$")M;11R=H.EFE
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MDN:%N*"N8H<[P7LUC0XZ;%0A[!.B*Y,((IUEC 205!'MD"$R1"YB56LEV,K
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MUYY64W=&7LV[BQMI".B><Z2JH;2A(E37B.Z+*.>CAN4X]U0"HBA^.PTUV0<
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MB+#4Y_;S7W&43P=^_.(.5VVKEU=*]+R2\2K*0LF'2\KMUO88&7' OE6( BG
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M!5L22PB/D4$\9S9;\<!_!%8&1"OIL'=*L@X&G6X^.9\(0.8B OE62' ? HT
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M9(/H;_S]1/'67)KON*(KN!D6])&$0F^@]1GG:C71!M:?7=-_ %!+ P04
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MXI3!H66DT)1?UG!/K1DM7I-[0OCO;5SE.&I@#4(_@44SH'TK?:*TS(U4(Z6
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M#GQHBWY_;=&[FZ&WFP'?9OOS9MOS^^QZ_@1LM#U5%DT1)+?ICF"0!9\OS,O
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M' "_SW+ I?R &USFQ4<ZWHO_!U!+ P04    " "+,8I95_?R;?$+   A,@
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M./$;35P$//$2?W$/,Q*Z>1$O5UYT_^LOCJ;:SU/FI2D'H%XT8V'@70=AD 4
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MI*.)M,M$:.:8<,.([9MCVYNUG#&IAQ&3+GTY;BJ4ZHP^D>7T,@4;7VW%'@$
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MJ15[$HXBI%">._HH,WH0MP] B,Q"F-UH(=SK$@JQPL-3$#P9P&5%L12Z15B
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M112$$0T^L+;'CF82:C)-H_7;-?K5!!#VQ1X]&'Q;VY>T'4Y6:4)APVX-N74
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M8INDG[.54KGXLH[B[.79*L\WSP:#S%^IM<SZR4;%>+)(TK7,\35=#K)-JF3
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ML-B0\AW;MFS]KQ'3%?&=$.Z+2WZ.F@.&Y_"&LO!8!W-#1:=3\>P.Z):@@CB
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M0FZM+K8\_E ]@)XPS1E0I/):1G-$*_8K/PP*KF:L]"T4R";/4,59IZ@GK(%
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M =[/RU(W-R2@_8W)Y;\!4$L#!!0    ( (LQBEG/Y]WBI@8  ,@4   9
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MN8\"\/M2 NS^!1<8+B]/_P102P,$%     @ BS&*6<5.]+;;#   C#@  !D
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MJ-.L/#F*B1L?2\&; @6S4>JX)@[$ 3G>."1$Z\T47#G'72K+0Q$BA;;9P;"
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MFIPOETHB6],"O)\;H!UNZ(#F<Z;S_P!02P,$%     @ BS&*669R8L8+ P
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M%.HKD3T*O+L.O+N-_1\R;#M/=+ 'F[G@BQ3Y^Y+*009,:S3:AU12H=%.9[F
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M:.'3E*T-N76]ZF]Z.=:FT+X3Z*J!\G4+NWJP;_L[.S"I>BF4E@ N1;9 B16
M>P' O^CP!"7.%B#@,[BT?N7#K08#\4UM. "!BO46S;<650-P.9VNC"Y*8TL.
MDV!SB$.\#I;ZBNC'-4IOG^QK0TP;W(!E*#O[@*NJ=]6[2=12EPA&L!1HR/ZF
MUVYH<R%\J8+"DT>')]%Q?S*9#"83/UOD= D)E7(UP=UB8N.4Q6N5"#'Q'VA=
M]P:40TH0"$3O4=70(*TMJ=,K5=*01? U]M7#0#,G*I:+,-1M8!":E##6G\,'
M?X/W+YS#;=W#@/NK) \)#L!I1&H+(Q2I&*RBC:;%M1*)"T](I7$42AS1WTKC
M2E'//C6!U[YAE0@;&SFCX*#% ()^/A?^AK[B65^DH$>+Q][T?M>ATE:&;R98
MMX8[4VM75O4W4BKT3H36@%VW@GLG)F&8IF+MRV43^0WBU8BY.ZBY#]$M_&H]
M*&LQYX/KW.C<SS9)&8193)Q56G75] :X?4YJ#A=<!GF(7L9S72HO29 Q@ >=
MA0KX5VRI!_ .0:_:_:5#*LO*O#BP9;[=LC>#Y\.G+=]<X#45!G\>+^-T[0;8
MI["_P&"2L?&CL"= XQ2KI$VJWGYXW/1VO@#U@NQLS5H>%P(Y;BFIZHX/S09>
M/6J1]JL]<AIZY WUR#Y+JUN=H944<4N\X\-E E&?B()LI#2LG:TT8DQX%\W@
M9UJ:A<)-DEK#'29"E 3?U+,0GBO>&N.2$?YJK1SW8=(NW!Q"U,&M#A>$5:'<
MTH'NG<W:;K-A![3%%Z0D>8G4\S-R*+]%H9'4Y >FQ'+%&B,)%6 [#\W;PP[,
M40:K,@47ZUDF%SST]N !TMH*?S='L$CU+?&Q:T#QH4:Y3>YWU27DNH3,F J(
M,(0*C$4TJ,KTI@)M'%M?,6P&7C1YTC\^C)A%%0H]JQT< :8X#L0D<\D-DMMY
MFVGJVY[4H'H_["?60KDV'3$=B\X;>#/=AGZ\:6V<:5M/VB (^7V(:FGD+4FX
MSGB\D:SOZJG\N$Z]8B-];S!TH;,4Z[UB';+V5($253D[ZD>/1OWQT9,6=#?0
M%)\NH!-YE9I&E6.$XXIB6^5/%:Q_!+EH\'@#N2WVN[#KVM_MW[#=+\"^^P+L
M1]U\!5*_I *(R>;.RU]@N"\$*'%-;-UOO^ZW7_?;K_OMU_WVZ^_8?K6'M_^#
M[=?6=HO&]#^TX?H;EUM-I/P(6ZZO 7B_Z?JA-EW?>YGUER?LG[0M^^&694NT
MIFIC]F?LR[R<S?->)F:#OWY[UJE LTCK^B''L/4;(OAVX7]:9:$5% X_)VJ^
M;7Z]=>%_M#1<'0\__<*]#%#2K6L.TM'@\5$O[*[J!Z<+_XNDF79.Y_YC*G"C
M,W0 [^<:W;!Z( '-;]K._PM02P,$%     @ BS&*62 G,9<<!   20D  !D
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MLC" [0Q^SZ*Y+I(BU4D>F1J^ %Y5FT@7^!"R2UUOX&[6R^C7_>O]Z+_/SJZ
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M7,BG99F#-'>+70!>4UW'?;=S]'!W]%&>.N(['9=*VGQ!K,&>4L"9-Y'.84\
M;\MY?DYN>[3P:)O!+]<-&$8:?NDCWE$(!D37(X,5*$0Z4(A(Y5_#$8/Q":;
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MP'JS1FTOW]PE"R7GKX>5VUY:8P+.-2"3CF#H L^M6Y@$'ID)'1D@9&3:[W#
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M=,."N-@I>%N;BEV=E60><&=-^#X%/,MKS_A%=1Z0L"*4KHDOSW'OKDO2.A!
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MP Q"SDC\$+@COU-QZXZ%)3.VLB9L.C1#8P8,(QO7<E/>9R+QNV&(D'H=H>*
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M>0G*N?R!"]R6U1<"[^W_ 5!+ P04    " "+,8I9R5O2]9\$  #P#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6S55UMOVS84?O>O(-2E2  ONMFR
MXS@&'*?%]M B<-(-P[ '6CJVB$BD2U)QLU^_0^H2.5&$=MC+'FS>SNT[-Y'S
M@Y /*@70Y%N><77EI%KO9ZZKXA1RJL[%'CB>;(7,J<:EW+EJ+X$FEBG/W,#S
M(C>GC#N+N=V[E8NY*'3&.-Q*HHH\I_+I&C)QN')\I]Y8LUVJS8:[F._I#NY
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MJW<^P88ER_=%N=!B;Z_H&Z&QC]MIBD\RD(8 S[="Z'IA%#2/O,4_4$L#!!0
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M ?<;EQ+(7ZO>1M'JA:(+M+:U&-V!C:WKCNS P],FUSGS[Y8BS,W;AK"XW!4
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MTAB9VLN840 5!>#Y0L*L*Q;HH/KOR?@?4$L#!!0    ( (LQBEF;9'NCS0,
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M1T([!=Q?*V4/"W? \7=K\0]02P,$%     @ BS&*68I!1#S; @  4@<  !D
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MW5=H]82:+^&E-%^R:WP]=$ZV4O&J!6,$5<&:D3ZU>3@ 3)UW %X+\/X6X+<
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MG9-):!'1=/#&4+PV37#-%;94,\WQT0.A'7!_P[G:&_H'W3,:_P902P,$%
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M4L*( :*YM#0=Q2MS[I]S1;<(TTSIGH="3Z#_"\[5IJ,5;&^.T_\ 4$L#!!0
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M[W(6.T2V5Y-VH45M_^YKH?&N8*<[O,V!- ;X?B.$/BR,@_Y^N/P;4$L#!!0
M   ( (LQBEG^/"##+P0  &\,   9    >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;*U736_;.!"]^U<0:E$D@!I]68[MV 82I\$NT!1!XFX/BSW0TM@F*I$J
M2<7-_OH=4K*2V(JZF^S%(JF9QWG#Q]%XLA7RN]H :/(SS[B:.ANMB['GJ60#
M.54GH@".;U9"YE3C5*X]54B@J77*,R_T_8&74\:=V<2NW<C91)0Z8QQN)%%E
MGE/Y< &9V$Z=P-DMW++U1IL%;S8IZ!KN0'\M;B3.O 8E93EPQ00G$E93YSP8
MSV-C;PW^8+!53\;$,%D*\=U,?D^GCF\"@@P2;1 H/NYA#EEF@#",'S6FTVQI
M')^.=^A7ECMR65(%<Y%]8ZG>3)VA0U)8T3+3MV+[&]1\;(")R)3])=O*-AXX
M)"F5%GGMC!'DC%=/^K/.PQ.'H?^"0U@[A/_6(:H=(DNTBLS2NJ2:SB92;(DT
MUHAF!C8WUAO9,&Y.\4Y+?,O03\\N8:G)T8(N,U#'$T\CI'GA);7[1>4>ON ^
M(M>"ZXTBGW@*:8O_O-L_"#L /.32$ IWA"["3L0[*$Y(Y+LD],-^6T#=[I>0
MH'M@W:..<*(FOY'%B[KR>\E4D@E52B!_GB^5EBC>O]J276'UV[',A1ZK@B8P
M=?#&*I#WX,P^O L&_ED;T?\)[!GM?D.[WX4^NZN* A$K,A=Y(3APK<QLL6$R
M_7A#I7X@)C=M6>B$;@]\L0&2/-M(XXK9FO*'#^^&87!ZIG#-;%[8S5-S,(G
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M_S?69GK>5T/COWLU>E^HRIC0A$.*H<'UX,8CJAIGU<;(THV02!I\_VZ9XQ<
ME'7 \U1*L]_8!,TW9?H/4$L#!!0    ( (LQBED"L;'^$ \  &96   9
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M8VL[KG=3#NCXX P12")LA@B>@$03O(E(/ DDIC4"\.9%.)N[P<L_?K(9M4Z
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MW$W(FZBXK@_P[6A[_;FH3_U/YO7=Z1,1I \,%+BBI=[8W#9D?1^I7[38VCO
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MK=_9S2LIJT)?9I2 LI4!/%]6\-.UNU$!^K>^TS\!4$L#!!0    ( (LQBED
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ME<RD06\^\D4N]-L+WX!5B_6SUL)-8X&<L)"B7ZO2K#5Z7R[%<@ _'\=C,J+
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MR16>!O3(U3:KH2WU.:WPB%R#G5#7V?KO=KAOAW^%G-2OS$G]ZIP\1+R8DZ.
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MJX# #5LP7^F:+G72.NA]*DT'HO#5E"8HUC1.9C/)9\C5WNZ"9(QU>["+G'Y
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M$&>U3*\6E)"]*@5="P!*FX#2+%":#4IS0&DN*,T#I?F@M "4%D+1VEK>+DK
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M2Q+-""T-^._S/&>O)V6 S0[A\;]02P,$%     @ BS&*66K23J.4"@  EH,
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MOE'92FNU0QXRI;)E]7(AHZG,RP3Z\UF6J><W909/6?ZM^IKC_P-02P,$%
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M5M[[AR+/MX7WQF"B%254BU M1C6!:A+5%*II5$M0+44U0VEV>.N*4O *%:4
MK2BA6H1J,:H)5).HIE!-HUJ":BFJ&4JS\UM7E )W1>ENM5RLEX4W6V;;:M)X
M&^5LOMR<_Z29&VP=WM."4MBXD@$Z;(QJ M4DJBE4TZB6H%J*:H;2[%S6!:7
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MU9]_62[+YV^V WQ;%K_O'O:[_P=02P,$%     @ BS&*60H=0.^: P  $0P
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M11-0?_^0Y]7S1=/ [ACE]#]02P,$%     @ BS&*67NL9P&W @  )0@  !D
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M2;$E[C]B%AV"?0%*(<Q+)!9*4-!@%EM#N MJ;7[CS.U?;IL%UY]2?WO(ZN0
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MC58UZ<248O:?\**@O54N$2I0 BL%=2X&2@DOBL2B(UEFRJ8EDZH(,\U8U=7
M=8":7S$F]QV]0%6I^[\!4$L#!!0    ( (LQBEF;MGZ\<@0  -T9   9
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M'%Y_2Z@;DA75Z?H+DY+EU>4&2 )<&ZCG*Z:JY*:A#^S;+SJ+?P%02P,$%
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MAHCY,,3HSSU!?V#I!=KX5O026[$Q>?D-8_+D3D2_81CK;57NZIVW2OH_=OT
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M1C4'U5Q4\U#-1[4 U<+1ZQ*!47\LD</&J):@6DII[5@ZU1N,Q/T&R((EM/,
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M93F/Y7R6"U@N9+F(Y6*62U@NQ;A.5#5Z06;B7A#E>R$(J<FKD!I-^D.*;?I
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M^W11S3OJ$_AHGP&JA:@649I<UTU.T%#G!'_-XDEU86]2W9_XC]5MBEOK%8T
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M-1/5+%2S4<U!-1?5/%3S42VH->DT63G'[4QR8=MB_;W%(FIL<DTW6<"!^M:
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M42U M1#5(DI;U_A9_BA$8<9%?'TU$]F#N!73::Z-T^6\Y*NS YMWM4S<EW.
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ME_D4O7_W ;U#A*+/"=L*-9P8NE)%J.?I+LMH/A;1!&>BF4-^AT+O!@5>$#7
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M-9E?KV5JD_4R\WJ!/W%?]OUPJM:!T(-6Z(%1:+7>P9ZNP*\1D3M%N4)J1%\
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MBS$5N;N2VC6T6)67-#.AM<C+QR4P/-\: _R^$$(_-\R]3WTQ./D/4$L#!!0
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MBZG=D-SN4[M]/Z@E#*4Q*(U#:0)*\U$T_::\QBGVG.-U*0_J'$-I#$KC4)J
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MI7=YA9I4W7?KB9&+JG5-I<%&6 T+_%6!L@7X?":EV4SL"]J?7_H;4$L#!!0
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MD!>G>XH+R5;Y\94G)B5+\H]+(!'P;(#Z?L%4FU9>9 ZJ,U;3_P%02P,$%
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MC,JA6T9!:364QJ T#J4)%$W-/2E(YH MH^P,[TPA-J!*]+?3U%"?#$KC4)I
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M#N91R7,)RF,H-37))* M\MT^SR,HX$'5&$I-K8T O,B\9$<[S\UB9".#A<T
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M&"],@&J-A!@7-X]"GY_8]3B4G.:R1).QZRG0&$N?4#D&D],*)-%GO# %.M]
MS *'O_?%>-)/NX9%0I2<YIJ$A/'"5*C>/"@!<O,8])F)I4:4G.:Q1(ZQZ^'/
M&$N:4#D&D],*))%FO##\.=\ZS ++6@<6_U!RFFL2_L4+TY\6@#DU4FX>GCYI
ML?"(DE/M3R1^3%Q/@"98Y(3*,9B<5B ).9.%"=#9KF(6H!N(14++RXLF>YWF
MEL1_R<(@Z+)N0DR3FP>G.XU=9T3):>9+")FXG@9-L/0)E6,P.:U $GTF"].@
M\[T$2X=0.69[>>-[-T:S)!),%F9"E[422JK</#+=92Q-HN0TYR6:3%R/A"98
M%(7*,9B<5B )19.%D=#Y/H)%1:@<L[V\>$$?D; P69@U7=I':)<DV,5%J!R#
MR6GF2W29N)XU3;#\"95C,#FU0*G$G^G"K.EL*[$(I..;)JGI31.+1C9J3,/(
M:)5%(Q\U0L(Z;RIA8'I:A/6$S+HEGF8^$/*$A<HQF)Q6"(DP4]?3KBF60J%R
M#":G%4BBT/1'TZX6@64=Q:RQK*.8-4[J*!(,IJ<%6T_L*(:$FOE Z!,6"Y4H
M.:T0$FBFK@=>4RR/0N483$XKD,2CZ8\&7BT"V5&H)$CF4R46L?PH4#:KQ6Q:
M!2&<=M[><]ZQLBLO+Q[*._ZV;.ZJ7>MM^&VO[:^RODQ-=7?_]$U7/_0^GWD?
MZZZKM_LO[WEYPYMA@_[WMW7=';XY[_6_U,VG_1B7_P=02P,$%     @ BS&*
M6?3]?I2R#   U98  !D   !X;"]W;W)K<VAE971S+W-H965T-S<N>&ULS5U=
M;]LX%OTK@G>PF ':6M\?W21 &TXQ!=IMT'2F#XM]4!PF%F)+64E.)L#\^*5<
MVQ1%BA8UQX!>FC@E#\ES>2D>\_+J[+DH'ZHEI;7UYWJ55^>S95T_OIW/J\62
MKM/J3?%(<_8_=T6Y3FOVL;R?5X\E36^WE=:KN6O;X7R=9OGLXFS[MZORXJS8
MU*LLIU>E56W6Z[1\>4]7Q?/YS)GM__ UNU_6S1_F%V>/Z3V]IO7OCU<E^S0_
MH-QF:YI769%;);T[G[USWA+'\9L:VR)_9/2Y:OUN-6.Y*8J'YL/'V_.9W72)
MKNBB;C!2]N.)7M+5JH%B'?G?#G5V:+2IV/Y]C_YA.WHVFINTHI?%ZGMV6R_/
M9_',NJ5WZ695?RV>?Z.[$04-WJ)85=M_K>==67MF+3957:QWE5D/UEG^XV?Z
MYXZ)5@4V4'4%=U?!'5K!VU7PAE;P=Q6V5,]_#&7+ TGK].*L+)ZMLBG-T)I?
MMF1N:[/A9WEC^.NZ9/^;L7KUQ8<T*ZT_TM6&6I]I6FU*RJQ:5]9KZYK-L=O-
MBEK%G=4J]5M&R[1<+%\L-NNL=U5%6>DTO[4^9>E-MLKJC%9[J%LKK=MUV:>/
M5;5)\P6U6&_IMAXS_E>ZV)1EEM];[],JJZR?":W3;%7]PKK!J[]JE7MM_7Y-
MK)]_^L7ZR<IRZ]NRV%0,K#J;UXR49FCSQ8Z ]S\(<'L(N*:/;RS/?F6YMNLK
MJE_JJQ.Z8-6=;75/49T,K^Z*U>?,D@=SN@=SNEL\OP?O$WVB*\M1T:"MV*PO
M;ZO'=$'/9VP!J6CY1&<7__R'$]K_4I&"!",@,($P[T"8MT7WCL[_5T<GLS!3
MFU+_+O*R,W7_\XDU8'VLZ;KZK\H*'M(*2# " A.LX!^LX&NG[;>B3E<[_E6L
M_:@=;&LWC[*G"]>+_.1L_M2F0R[EV4'LBJ6(7,I/W.!02.A_<.A_,*#_K4FC
M&L0/B+#5<. YG2$HRB2^UQF!MB\C+14>1AH.66"LOZRKS<TJ6UC?T[),<[79
MM%"FDQT)1D!@ H71@<)H4DM.A+0"$HR P 0KQ <KQ'_?9>,!+JLH([NLMB\C
M1YH<1IH,=-G/14Y?K,]I^< 4Q8=-SWY)BV8Z7Y!@! 0FL.C8?*=L3\IO=]T!
M&0**1E!HHBE:HL7Y6_N%7?7PR(9!44RU8U 4Z]\R.'RK[@S9JZM$PWM]36/3
M0W?K*#21-;Y?=Z:U87>@.W8H&D&AB:;@FW9GR*[]R"-TA]%VGL1S@J#KBG*Q
M, Y<N^N*<C$W")P>5^3;=T>_?]^Y(GM$?J+WZ>+%>K=:;<KF>ZG+8KUF/Z[K
M8O&PW^L>'3)H@[YC!HE&4&@BT5P]..&TO!<J0:!H!(4FFH*K$$>[O1[HO9'D
M;U%W ZPH$[M.UW%/L==W^&;?T>_VN8/O9.N7NSNZG4<Z_:H'-9X]2#2"0A,)
MY9K"2:;ER%!5 D4C*#3Q&U^N2USM9GN8(^\P1)D:=1ZOE_J6C+_7/85(<+E(
M</4B@?O\5_9;OF'3*Z\I:XEIWRQ/\P6;?4JJM+#&WY0CT0@*3:2T=;K@3LKK
M7>RA!?;4XA0ZR.4ZR-5N[@=ZO2<+W#BP);=7% O=;C&B[]'8$7.YX>KE1NL9
M_O'J5[8SSY]HN3V _O+8G"$K"=!"&D\@)!I!H8ET<LWC!M/R9:@J@J(1%)IH
M"JZ*7/VARC!?#F4AS7RYZ\IRJ2"4/?D4TL/ETL/52P_NR;^F9?ZZV'!)_:(<
M.O0( XI&4&@BE5S8N/&TO!@JB:!H!(4FFH)+(E=_SC+,BQ/)/QV%%\NE7"])
M)#<^A?#PN/#P],*CM<'^]GWW/*ZSFQ5E$ZM6#U^/:!S_ )4K*#2132Y7/&=2
MGNQ!90X4C:#01%-PF>/I3V8&>?(.0]PTVUT?O=0W94S,26*E6L%2>M'!/?X;
M+=?6IR+-+4++["EMHC?U#W$]M/%\P\8^G4+9>%S9>/ZT7!^JBJ!H!(4FFH*K
M(@\0R:7',.9/#OIRXJ1S0$90;8J\<(GB#8G[:CS_>K-8T*JR/E ZW/>AQS!0
M-()"$XGE6LB;5C28!]524#2"0A--P;64!P@)\^1X+\?O/O./ER&J,K&M/LCV
MN ;QAL1ZJ0ZRKYFKLKETJ3_15GLO].P%BD90:&+8,I= _K1BPGRH?H*B$12:
M: JNG_PA,6%'O%>/8<P?5/3XBF@TOV=%\+F6\0=%F?6O".^MJY+>T;*9H@:+
M@KY98R:A*@F%)E+.59(_K1 U'ZJLH&@$A2::HG6O!!"BIL<PY@\JAWPYX,VS
MO9Y%@:L<?VR\VVY1>/?:&;DL0*41%(V@T$32N83RIQ7[YD-%%Q2-H-!$4W#1
MY0-BW_08QOQ!E9*OBKGK616X_O&'!LE]J9>T'!7[JF_"F#3H^1 *3:27:S-_
M6B%S/E2V0=$("DV\K<EE6P (F=-CF/('12.!',[G!GV76+F$"H9&S/5^>S!J
M4Z!OUIA)J.I"H8F4<WD63"NB+H#*-B@:0:&)IN"R+0!$U.DQC/F#:JU #N,+
M8[]G4> 2*A@:=M>S*)"Q6D'?L#&74-V%0A-);^43F%9P7@"5;5 T@D(33<%E
M6P (SM-C&/,'U5J!'!(8V5'/LL E5*"74%?;DS]J7:U81YJ<08>;--N5HO=J
MJQ[6F"FHJD*AB91R_15,*Y8O@&HU*!I!H8FFX%HM ,3R!7*47NQTXW_T#1G3
M<@K=%'+=% [139?,T5^::;:=JRIF]#"F,PN*1E!H(H5<8X73"O,+H=H+BD90
M:*(IN/8*AX3Y]6>1".4(/U46"44Q518)1;'^+!(A5RTA0+6$LC)(O# .NR.1
MBT6^'W:3V2B*]5_"#[G0"(><U8B+"^A&OKYE8R> *@T4FL@Z5QKAM)1&"%4:
M4#2"0A--T4JM!E :H6(WW[V1KR@CW\C7=V;L8+E^"(<<P4C>/B2K'%1!0-$(
M"DTDE2N(<%H*(H0J""@:0:&)IN *(@0HB%!6$'*".54A.<.<OCLCAQMQ91"9
M*P/#;!OZ%DPG$Q2-H-!$=KEHB*8E&B*H:("B$12:: HN&B+ W:!(WNLKLFWH
M6S+FY12G)Q'7(=$0'2(M &:I-_1M&,\[Z.D*"DWDEZNCR)_6$@"53% T@D(3
M3<$E4P2X(Q3)MWI4J3=4Q12I-_0]&CMBKDRB(<I$?KH/SL.AQS>>3=#S$12:
MR&TK&_2T+@!%V'S0V(30IY!/$9=/$> "4"1?W%'DX5"44N3AT/=G['BY1HF&
M:!3)K8<EY=!C&\\CZ#$)"DW,+,[%4#RM6T$Q5#E!T0@*330%5TXQX%90+-^\
M423E4)12)>70=VCL@+D^B8?H$WD?/C1#AQ[>>"Y!)0X*3:262YQX6O=Z8J@:
M@J(1%)IH"JZ&XB%G1<?<VE?LK>4,'?JFC(DYA3:)N3:)AV@3R?W-TW7HVS&>
M?-!S&A2:R#%70_&T+O+$4/$$12,H--$47#S%@(L\>@QC_N2K-XIT':@V15Y:
M+[<9HF2D96!,[@Y]2\;L0<]X4&@BRUP_Q=.ZT1-#)1<4C:#0Q%<<<<F5 &[T
M)/*M&2EWQX R1%6F+W='PJ5*,D2J'(U_N1Z?R$/? =/Y T4C*#21?"Z;DFG=
MPTF@,@N*1E!HHBFXS$H $6UZ#&/^H-HH4:33[DODD7#)DT#"XZ[_5E8/?1^,
M:84J*Q2:R#]75LFT N42J "#HA$4FF@*+L 20*"<'L.8/ZAJ2N0 O=ZL'@D7
M0\FHD#ITB@]]+XR)A1X@H=!$"W#9E4PK_BZ!:C,H&D&AB:9HO?04$'^GQS#F
M#_NR4\7MHIX4'X[=?HGIJ$"]\1D_CC1H2B(6CL#@.H2W7E5J3RMV;]\?F#V@
M,@\&U[&'V[('((#O"(@YB=A7L-J*FTE]Z3\<N_5N57M4$!\V&\B13IASBWVG
M*@JN8X366U7M:47Z[?L#LP=4]<'@.O9HO1O6!H3['0$Q)Q'[UE=;#C/L30WB
MV*W7N=JC @/1F4*.=,.<7>R+7%%P'3.T7N5J3RN&<-\?F#V@(A &U[%'ZVVS
M-B"0\ B(.8G8]\O:<@1C;]H0QVZ].-8>%73XN<CIB_4Y+1]H;7W8Y+<]G&'?
M PN%(S XD5RGI>Z<:44>[ON#L@<4CL#@.O9HB3]GR)E>?XJ!??UC.0;VY0+A
M&T,YR8"J7'^6 <=IR29G5%QA?QH@]7"QL@H*1V!P'9);^LN95H3AOC\P>V"E
M& JN8X^6%', 889[D+;/Q5(>H"--F7,#E47S:DEI3=(ZO3A[3.\I>P[?9WEE
MK>@=@[??-/>/RNQ^>?A0%X^,RIEU4]1UL=[^NJ3I+2V; NS_[XJBWG^8,_SG
MHGS8MG'Q?U!+ P04    " "+,8I91WSWPAHB  !M) ( &0   'AL+W=O<FMS
M:&5E=',O<VAE970W."YX;6S-W6MSH]B!QO&O0G6VLC-5/6Z![I.>KNHQ]ZMK
M.MFIK:U]04NXS49"#D+NZ=1\^ 4)&1V$CD3RW\KFQ<1VB]_!R'K@H ?T_NLF
M_^OV*4D*Y;?U*MO^].:I*)Y_?/=NNWA*UO'V;O.<9.6_/&[R=5R4W^9?WFV?
M\R1>[A=:K]YI@\'DW3I.LS<?WN]_]I!_>+_9%:LT2QYR9;M;K^/\V\_):O/U
MIS?JF^,/?DF_/!75#]Y]>/\<?TD^)<5?GA_R\KMWK\HR72?9-MUD2IX\_O3F
MH_ICI&J#:HG]0_XC3;YN3[Y6JM_E\V;SU^H;9_G3FT&U2LDJ6125$9?_]Y+<
M)ZM5194K\K=:??,Z:+7@Z=='W=S_]N5O\SG>)O>;U:_ILGCZZ<WLC;),'N/=
MJOAE\]5.ZM]H7'F+S6J[_Z_RM7[LX(VRV&V+S;I>N%R#=9H=_C_^K=X2)PNH
MHPL+:/4"VJT+#.L%AK<N,*H7&-VZP+A>8'SK I-Z@4E[@?&%!:;U M-;1YC5
M"\QN76!>+S"_=0%U<'SF!C<O\OIDMY_MRW\>QZ=;O?GY5H]/N'KVC$\N+7)\
MRM6;GW/U^*0?_N#?'?[B]R\7/2[B#^_SS5<EKQY?>M47^]?<?OGR59)F53Y\
M*O+R7]-RN>+#+\DR*1/G\RI1[C?92Y(7:?7U0_DB3?(\62J?BLWBKTJ<U5\]
M;5;+)-_^NZ(GC^DB+90?E(_+95J]U..5XF2'Q*I>^-_I21&GJ^WWY4/^\DE7
MOONW[]^_*\I5K@9^MZA7SSJLGG9A]89*L,F*IZUB9,MDV;&\+U]^?FWY4+Z\
MJDF =^6V?MW@VG&#_ZQ)17>WNE,&X[>*-M!&'2MT?\OBZL7%]6N+9W>*-KNX
MN"%?7$\6=XIZ6'S8L;@I7_SC[LOKRG<M;LD7_Y0\WRG#P<65M^6+!W%>+GYY
MTSFWC]ZU\NX-6UZRN'?[RG<M[O]SFR[XYW[W\(8_&\G*1[<OKDE>@L/7S!ON
MO>$%[WX5;[?*YK'.MO_RRW]7G")9;_^[8^5^/F"C;JPZ?OMQ^QPODI_>E =H
MVR1_2=Y\^.,?U,G@3UVO;A+32<P@,9/$+!*S2<PA,9?$/!+S22P@L9#$(@@3
M,FGTFDDCF?Y!3U_299(MM^7<9K&*\\Z#E9^E1M\H(C&=Q P2,TG,(C&;Q!P2
M<TG,(S&?Q (2"P_8>(]59V5>/@S>OWLYS1=H."%?QJ_Y,I;F2S.AVU8'/6^5
M[5,9,ELEWA5/FSS]>W?>2,V^>4-B.HD9)&:2F'7 )B=_5.J@_I_XQV63PSHD
MYI*81V+^S5LW((<-;QXVNN610AQ,7N-@\@_%P697;(LX6Z;9EZX\D*)]\X#$
M=!(S2,PD,8O$;!)S2,PE,8_$?!(+2"R<G&5%.TUDCQ!29/J:(E-IBOP:YWF<
M%5ME<3AU7,9)FA4;Y>OQY\EO2;Y(M]7IY:XXD>I]XX3$=!(S2,PD,6MZOG^9
M:T-U.%!;1Q?DJ Z)N23FD9A_Z\8-R%'#\U%'@^%D/&ME0<?#AI.IJG8'PNPU
M$&;]#BN>XUQYB5>[SI>_U.K[\B<QG<0,$C-)S"(QF\0<$G-)S",QG\0"$@L/
MV/3T6.&NG'6THBNZ^C A1N:O,3*7QDBX6W].\NH=FIO.4DBQOCE"8CJ)&21F
MDI@UOSQ-;9^F(,=U2,PE,8_$_-LW;T".&]X^;G330X4L4 >O85!5>F0'%<=C
MB'*:L5YOLL.Q15<0R*&^28!J.JH9J&:BFE5KU_8=-CJJ@VHNJGFHYM^X?0-T
MU/#&4:/KCQ-CX*2HIO8[*+ARKE+.]0X#4M-1S4 UL]:$J>&TG+2.!G/QJ;8Z
M'CDI9Y'SX>SLI4ZNH8-J+JIYJ.;?O(4#=-RP\V]@,IL-YI/VR_W\D=IT,)W/
MQI,++WBM><%K\OW^[O,J71Q/)BJK-/Z<KM(B3;:=+W<IUOOE3FHZJAFH9J*:
M56NG[X)/RS_6\WD .JR#:BZJ>:CFW[J! W38L&/8R70R/I\(4,.*F=$T.U5I
M2:MY1^+:P0%:ZD0U'=4,5#-1S:JU:R>K;714!]5<5/-0S;]Q^P;HJ.&-HT;4
MJ&)4-(5+5=JW^N!LM[LX6R35C,)/OL2+;\K'U6J75]>N+$XNA7D6W]-0'C>Y
M4CPEQ_<V]\N_ON'Y79K5TY.NBUU^EJ]2[]@A-1W5#%0S:TTXOS2;CN>SX:P]
M)R''M5'-0347U3Q4\U$M0+40U2)*$T.L:76J\EKGKQU-BS*QTD7G&ZYRK'?\
MH(5.5#-0S40UJ];F)V$VNSL[8X+V.5'-134/U?Q;-FZ #AG>,F1$#2GF1%/W
M5.5]3RO)DCQ>[:_CC9?K-$NW11Y75^9WY@3:\T0U'=4,5#-1S:HU8:H_& T[
MSJ6@1<Z.8=79?*2=C>NBXWJHYG?\%MI@.IITG"@Y?^1P,!E/SQX9=CRR!+51
MQUF0CFTX'HKG2\17<E.Y5.6=R\,UJVDY>2EG),MRNI)]49Z3<M:RO%RTDI.]
M7\]HTQ+5#%0S4<U2SSMWX\'D_"_2KA\H_$5.9V>/<]#5<U'-0S4?U0)4"U$M
MHC0Q79K^IBHO<)[<R^,Y3I<_I)FRB)_3(EYUY@K:X$0U'=4,5#-K3=P]:!V]
M&JM^I'#BHPR-^?G>V$97T4$U%]4\5/,[GXS.31R@ X== U>'=^=''E''0^?S
MV51R/-%4+55YU_+^R3"5AUV^>(JWB?+Q2YXDZR0KE-^5^Z<X7\:98OQMEQ;?
M%#->5&^_?NL, K2"B6HZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):1&GB?;2:
M7JAVJ))!M_'1T'(HJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1I8D9U916
MM9ZEU>UFM:S.URB[+"TZ8PJMK:*:CFH&JIFH9J&:C6H.JKFHYJ&:KYV72\L9
MDC8<M>9EZ*AAQZCM^1@UH)@J33-6DS=C/ZXWNW**EB>+)'U)ELHFNSU>T)HL
MJNFH9J":B6H6JMFHYJ":BVH>JOG:>:EUU'51'3IJB&H1I8E)U/1M-7G?]A]Y
M-TI.]HX@M'N+:D:M"6?XNB^@--&!+52S4<U!-1?5/%3S42U M1#5(DH34ZBI
M\FK2EEW/=ZWD6._\(34=U8Q:.[\LNQT^Y*@6JMFHYJ":BVH>JOFH%J!:B&H1
MI8GATU1P-7D%U_CM.<D.EP&D)Y<45/<J2(O]6VF'N5EG%*&%7%334<W0+MW*
MLAU%:-46U6Q4<U#-134/U7Q4"U M1+6(TL0H:EJ^FKSE6WZ]6Q2'6=ACDI0'
M0]\NW7I1+O5.'K3BBVJ&UM'%[$P>M+R+:C:J.:CFHIJ':CZJ!:@6HEI$:6+R
M-*UD3=Y*OC_<F>G3I3LSR1?O'3=H QG5#%0S4<U"-1O5'%1S4<U#-1_5 E0+
M42VB-#&4FC*S-D,+0FB;&=5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42UB-+$
MC&KJUYJ\?OVON N%?)5Z!QW:UD8U ]5,5+-0S48U1SN_G^MH/FW=^\WM?)0F
M/LCK>-!P/&XU>'QT]0-4"U$MHC3QDT^;TO10?C/=?^0->SG9-R]034<U ]5,
M5+-J3;C3XOE58.B8#JJYJ.:AFH]J :J%J!91FAA 32-Z*&]$GYXIVE]D!EQ^
M)A^R=T"AG6E4,U#-1#4+U6Q4<U#-134/U7Q4"U M1+6(TL0@TYH@T\BS2T.T
M>(UJ.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6D1I8D8U]>RAO)[=]S,3Y%SO
MD$*KV:AF#,]O4CL?S;31I'5#41,=UD(U&]4<5'-1S4,U']4"5 M1+:(T,7^:
M8O90VKW\\)#DBW(V%W]YK40>/[[I^(G3;Z]&DG2$WI%$:CJJ&;6F#D\R:7"G
MSN?S=B21PUJH9J.:@VHNJGFHYJ-:@&HAJD64)D924]<>RNO:)]>*/-37BMQ?
MOE9$CO5.'[2@C6H&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:&%%-C7LX0<\L
MH55N5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B2A,SJBE\#_G;4,O)WD&%
MEL!1S4 U$]6L8>=MJ,]O8FX/;[P--;IZ+JIYJ.:C6H!J(:I%E":F2]/<'LIO
M0WW?7#S[Z7#BFFH*H!UO5--1S4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B2A/3
MK.EX#^?H? ZM9Z.:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:D%&CIA<^
MXGOA<K)O4*&:CFI&K0E3H?%8;7W(FXD.:J&:C6H.JKFHYJ&:CVH!JH6H%E&:
MF$!-,7PD+X8_[#ZOTH52?Z)I9]Z@-6]4TU'-0#43U2Q4LU'-0347U3Q4\U$M
M0+40U2)*$V-):V()K7F/T)HWJNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1
MI8D9U=2\1_*:=WWH5%__KZS2^'-U!CSMONFD'.L=46C)&]4,5#-1S1IUW!M\
MJ TF4ZW]/APZKH-J+JIYJ.;?O(4#=-SPTKASK75OA(@:5XR-IIT]DE8M/_QZ
MO%_(E0JVG.D=&*2FHYJ!:B:J6;4FW$%W,IY,1[-1.S#(<1U4<U'-0S7_YBT<
MH..&J!91FA@J3;]Z).]7_RMN:"1?I=X!A;:T4<U -1/5+%2S4<U!-1?5/%3S
M1QTW6I]-Q_.S>RX%Z+CAI7%GPUG[J.?_HET]:MK5(_E-LL7SS,KORJ=%DL5E
M/BD/JSA3_OR4)]WO=J$U:U334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(DH3
MPZJI68^FZ-EGM&&-:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEI$:6)&-67M
MD;RL?8BFYSQ==!\WH95K5--1S4 U$]6L6IN='IYK=Y-I^]01VJ5&-1?5/%3S
M;]N\ 3IH>-N@$36H& ]-^WDDO\/UZUGF/%GNUL_5M?>'L-A_3O7^K$YG;* M
M:%334<U -1/5K%I3IR=_8X.[@=J.#;3>C&HNJGFHYM^V>0-TT/"V02-J4"$V
MQDTA>2PO)%\Y36-N=GE7;,C5OK&!:CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6
MHEI$:6)6-=7EL4J>I1FC/694TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)*
M$S-*:S)*VD&\=I9&OG3O3$)[RZAFH)J):E:M"8?FT[M!N^"##NJ@FHMJ'JKY
MMVW> !TTO&W0B!I4C(>F0CR65XC_P;,T<K5W;*!=8E0S4,U$-:O6YL*$OGV.
M!AW20347U3Q4\V_9N $Z9%AKZE@V9D2-*29&TQX>2XN$QQ,TT>-CDE\H#LN%
MWNE :CJJ&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEI$:6(N-07D\1@]&8-VAU%-
M1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BRA-S*BF@SR6=Y!?9UOU%1')4DFS
M8M-<\%!?!1%_7G5/N] N<JT)GRQ:/O;L W_UC@>JH]%@,AZT.MX&NH(FJEFH
M9J.:@VHNJGFHYJ-:@&HAJD64)F9-4R$>7[E3<[S:7TRUO\RJ,TS0TC"JZ;5V
M.OE6[[1VV*!=8%2S4,U&-0?57%3S4,U'M0#50E2+*$T,FZ8+/)9W@<\^<'"[
M62WWIY!W6=IY4R\YV#M]9N='*)V7\.I=C[QP+(/6>E'-0C4;U1Q4<U'-0S4?
MU0)4"U$MHC0Q7IHN\5C>)0Z30GG.-XLD66Z5QWRS+I-&<OH9K1#7FG!;C[$V
M&)Q]((*.CFN@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:4)\3-I.LD3>2?Y^%Z7
MLMAL.P]FY,OW39Q:$PY1!EV!@PYKH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&E
MB8'3%(LG\GLB_R5;)OG7/"VJT%FFV\5FEQ6=-_630[V31[TU>="Z,*J9J&:A
MFHUJ#JJYJ.:AFH]J :J%J!91FI@\6I,\\KIPJ]VCO+YC%6?+PV=R*=%+DL>K
MU6;_.5V=F81VBE%-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BRA-#*ZFR#P9
MDO6?"5I@1C4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$MHC0QHYKJ]$1:@=S?
M(S7Y81D7B9)LBW0=5P6@QSC-+W_6EESLG5.C\_G=L/-<-CJN@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAJD64)F904Y.>R._3W.^M-#G6.WXZ[A4['77&#]J 1C43
MU2Q4LU'-0347U3Q4\U$M0+40U2)*$^.G:4!/Y WHZV^EH17GR7ES>=:9-^B-
ME%'-1#4+U6Q4<U#-134/U7Q4"U M1+6(TL2\:5K0$WD+NN_Y;.5WY7ZS7F^R
MPWFDSH1">].HIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD64)N984[">S-#3
MVVB[&M5T5#-0S40U"]5L5'-0S44U#]5\5 M0+42UB-+$C&I:VA.RI2W'>D?4
M_&RB-U8[9WIH21O53%2S4,U&-0?57%3S4,U'M0#50E2+*$U(GVE3TI[>=./H
M/C.]C\ME6MWQ+%XI#W&Z_"'-E/OX.2WB55=@R<?O&UBHIJ.:@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAJD64)J9:TP2?HK>8GJ)U<%334<U -1/5+%2S4<U!-1?5
M/%3S42U M1#5(DH3,TIK,DK>&>\W[Y-CO2-*NW'>APYKH)J):A:JV:CFH)J+
M:AZJ^:@6H%J(:A&EB>G3%+^G\CM8/^3I2]6H?%B58^PG=L>97V?ZH+UO5--1
MS4 U$]4L5+-1S4$U%]4\5/-1+4"U$-4B2A,CJNE]EU^2D[@1FE&DIJ.:@6HF
MJEFH9J.:@VHNJGFHYJ-:@&HAJD64)F94TPN?RGOAKZ?+-[MB6\39\M+T#6V$
MHYJ.:@:JF:AF3<^;])HV&:CC>>O3/]!A'51S4<U#-?_6#1R@PX:H%E&:&"E-
MUWLJ[WJ?S\R^IL63\LN??^T,%K3XC6HZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H
M%J):1&EB1#7U\.D4G9FAU6]4TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)*
M$S.JJ7Y/Y??6_F<_-$3.]PXMM L^/;\;=^=AMH$.:Z*:A6HVJCFHYJ*:AVH^
MJ@6H%J):1&EB'C4U[RE9\Y9CO=/GO.:MC3O?[D=KWJAFHIJ%:C:J.:CFHIJ'
M:CZJ!:@6HEI$:4+ZS)J:]^R?O!>W?/F^@5-KIW?_[[Q?$CJJ@6HFJEFH9J.:
M@VHNJGFHYJ-:@&HAJD64)N9-4\">W7@K[B3O+!3)%^\=-VCC&M4,5#-1S4(U
M&]4<5'-1S4,U']4"5 M1+:(T,92T)I0T\K3U#*U<HYJ.:@:JF:AFH9J-:@ZJ
MN:CFH9J/:@&JA:@649J844TO>R;O9?_:<7I:><[31>=)ZAJ3?N#KO7S$WLF#
MUJU1S40U"]5L5'-0S44U#]5\5 M0+42UB-+$Y&GJUN67TA/4O3^,M@:%&]/.
MM:DV&;<32#IR[P0B-0/53%2S4,U&-0?57%3S4,U'M0#50E2+*$U,H*9,/2-O
MLEUCPCGFKI/,]_)1>Z</VI9&-1/5+%2S4<U!-1?5/%3S42U M1#5(DH3TZ?I
M7<_DO>O[S?IY5R2*G<2KXJDS<="N-:KIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@
M6HAJ$:6)L=1TK6=HUWJ&=JU134<U ]5,5+-0S48U!]5<5/-0S4>U -5"5(LH
M3<RHIFL]DW>M/\6K9'_BZ-+-_^7+]TXEM$R-:@:JF:AFU=KIC%EM399M=$0'
MU5Q4\U#-OV';!NB(X0TC1M2(8BXTG>>9O/,L3JF4WY7Z;K/UFUR=28$6GU%-
M1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BRA-R*EYTXZ>#\@YUASM2J.:CFH&
MJIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:F%%-HWHN;U3W?WM>#O:.*;1CC6H&
MJIFH9J&:C6H.JKFHYJ&:7VOJZ6QI<-?JJ03HF.%-8T;4F&*L:$VLR.]"?39%
M<QZBSC!!R]"HIJ.:@6HFJEFH9J.:@VHNJGFHYJ-:@&HAJD64)H934X:>#]%Y
M&7J7:E334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(DH3,ZJI3<^EI<@FH^J3
MVHKQV^(ISKXDR\Z(DF*](XK4=%0S4,U$-:O6U-/F^N!NHFJM@W,;'=9!-1?5
M/%3S;]W  3IL>.NP$36LF!E-T7E^I>C<_UP.>O]H5--1S4 U$]4L5+-1S4$U
M%]4\5//GYS>95MNQ@M:<KP\840.*@=)TE^=7NLO[@Y"/ROUFO=YDA^E29XR@
M#694TU'-0#43U2Q4LU'-0347U3Q4\U$M0+40U2)*$\.I:3#/T0;S'&TPHYJ.
M:@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@649J844V#>2YO,#_$N?(2KW:)LC@<
M0EVL,LNAWO&$5IE1S4 U$]6L6IL*$_W!8*"V3^"@=694<U'-0S7_QNT;H*.&
M-XX:4:.*8='4FN=7;N7<__0-VFI&-1W5#%0S4<U"-1O5'%1S4<U#-7]^?C/R
MLU1!J\K7!XRH 85 40=- ;GZNN\)'.5WY=9VSA6^;\"PG,YR!LN9+&>QG,UR
M#LNY+.>QG,]R <N%+!=A7"O#U),,4\GS/$<.RRRTH,QR!LN9+&>QG,UR#LNY
M+.>QG,]R <N%+!=A7"NSM)/,DM>?/QTF<.EVN]O?:?5QDRM)O'@Z_3SGLX\,
MZZ[V7!FJ?YZA'6F6,UC.9#GKR*G:Z3'_W4@;C,;MB@\[M,-R+LMY+.?WV,X!
M.W388^@(&[H5,\.3F)'?U?GJ#3*N /W# RTOLYS!<B;+64=.N*FVVKYNQV9'
M=5C.93F/Y?S;-G' CAK>-FJ$C=I*B]%)6DCKAQ\^)7F:5&>#'O+D,<GS9'FY
MT7/%ZA\<)*>SG,%R)LM9+&>SG,-R+LMY+.>S7,!R(<M%&-<*K/%)8(W9,S]H
MFYGE=)8S6,YD.8OE;)9S6,YE.8_E?)8+6"YDN0CC6IDU.<DL>66Z.;;:3\J4
M\JMD_5RDFTSY'&_3SD\MO&+V#RZT0,UR!LN9+&>QG,UR#LNY+.>QG'_ME694
MYU/W39G](4(]N3EXK1F.<-JU?"7JR2*INC:'!P_5MXHVT";*=\53HOSQ#S--
M&_SIE^9UJ\=%LO^I^J?OJP%7*^5SHL2[8K..BW11?O]M_S)/UN5XG[\IE5*]
MPQYGW_8G?A?Q]DF)"R4^#8/]9V\IR=]V\4HI-OME7C:KW3KYX6N2?GDJ2BI^
M2?+X2_TQ7?L>T.MO6P_1O*=??E']+/S/3X:RW.T_DKGZOOB:9,4W9;')MLEB
M5Z0OY8_R>+\9EO&WRDPW2R4Y;)AR^RAIMECMEJ^+GSPV79>_7EINBO*W+9^^
M1?+ZJ-:FNK09'ZI?X[@=[Y0_EP^Z-"-5TFV]1?=GS_?;;ID42;Y.L^:3RPX#
MM4?XOMH6L?*8_E9JR]?U::WD]V^5KT]I^0=4_B'N5L6V_,65=?+WO\=9=8Q9
M/BUIM=FJX\_TL7R*]\M]5_T5I<O]$U!NN76<E1NW?NSWQV>@?N*KWU.=_FF[
MW_2;55JM2/G'$:_BK%SQ[5.2%'?=NU>T\,]R$<:U=J_3D]VKM+![MGM=I>7F
M7\;U2ZKZMR3K_DR[*W+_G2QZ!0#+&2QGLIS%<C;+.2SGLIS'<OZUUYMS2+7D
MI8JZ,O>J?5JUG\J*./^FE#NW-&N^/7DQOE66Z;8,OMWAF_*!7]/]7N:'W?/)
M#JR*RK?*<_QM7?FO^]9U7*9LO5=\VJR62;X]J<6>[.W/=AS[['^.\[3\SW:[
M.QQSEV,7Y1ZXM$^PT]WGG;(_F+BH'A9KUJ]<V;18E?]<KF.U*ZSVJ^7.X?B+
ME2,GQ;;:PR3EM]4!P'-:E/OY<BML=_GS:E?^F[@-]E]OXW6Y['I3;LWR^_U.
MKQZXM;K*U\UNM7P=.2VWS*Y<_<.#7_<\XA'1_28K#R>*M-I[MG^]KV5J*H^[
MZCAF<7C8X5<3QJQ6NWSZE7BY3*LGM?Q]ZG5]/8BI?I%E^E+N(K/EMMQAE_O/
M:I#/Y9;99<]QND?WJ[I_)B_L -&K25@NPKC6#G!VL@.\<D5):P=X>,*VU?XO
MKXX;+TPPT:M+6$YG.8/E3):S6,YF.8?E7);S6,Z_]E+KGF!VS546)^$:/Y;S
ME'V>[R<?^R#OFACL7[['_5'\_)QOJLG94W+ZBJYW$O*Y;9I5J?JZ:Q1"NYS5
MQ(O%)E_NIQW[W6 %KM)M4<W>\MWJL-#KW/%T[O;Z&W]J5E7YN%_3>-5,Y/[R
M7$]]I(]_>^@_W3A?+[E,F+0?=KWBG+O>ZH<-\%WZ_8&*E:Q]'4U[JPBS[N;1
MEP\J3E:D?C:+=+W_-9HGZVVY9_R?7?FX8]]K4:Y;7#X!RW1UF'GO#Z+*77\U
MS_XN/:YO^9?ZP^,N6Y:CG3SSK]VP]+!M2W"MQ%_RI#G%4&_@2A..IDX_X;M:
MC__O&^3"80!Z!1C+11C7.@R8GQP&R*\5:Q\&O&P.+VC)(0!ZK1C+Z2QGL)S)
M<A;+V2SGL)S+<A[+^==>9MFF.YS0"\E8+L(X,9S4DZO.5/E59_K9'+ SD>1*
M[T1".9WE#)8S6<YB.9OE')9S6<YC.?_("7=W;Q<8T2%#EHLPKI4_)U>,J?+/
MM&@='+U]/>QM#EN[ XF]<@SE=)8S6,YD.>O(G5Y<K6F3@3J>M_O2Z, .R[DL
MY[&<?_-6#MB!0Y:+,*Z5.-I)XERYWNO23/GWZDWIE^I$T,.J7(']VQS[TS"_
M_/G7[@QBK_9".9WE#)8S6<YB.9OE')9S6<YC.9_E I8+62["N%::G5Q6IJ*?
MCW'DL,QB+S)#.8/E3):S6,YF.8?E7);S6,YGN8#E0I:+,*Z562<7MY5?2XLJ
MV^TN^6'_EENR+=+UOF_W&*?U_1>[<TM*]L\MDM./G/!!W--!]3_QX-Q@!S99
MSF(YF^4<EG-9SF,YG^4"E@M9+L*X5B2=7+ZFRC^.X^PTU',L32/VZC64TX_<
MM7MH&NRX)LM9+&>SG,-R+LMY+.>S7,!R(<M%&-<*HY/KTE3YU3+];RY[1>P?
M2.Q5:35W]=REP0YLLIS%<C;+.2SGLIS'<C[+!2P7LER$<:U$.KF41Y5?6F#E
MF^U6><XWBR19;I7'?+,NXZD\8KKX]AQ[ 0_*Z4=.F*X-NJ=K[+4Y*&>QG,UR
M#LNY+.>QG,]R <N%+!=A7"N/3JZL4.5U[ZC.'F6QV5XX(&*OHD Y_<@)!T3=
M^<->'X%R%LO9+.>PG,MR'LOY+!>P7,AR$<:U\N>DTJW*NZ:_),O=8G\A<YKU
M.BQBB]THIQ^YR=EAT5DJL95ME+-8SF8YA^5<EO-8SF>Y@.5"EHLP3DPE[:3+
MK<F[W%:2)7EUK6^V5.+E.LW2;9''U>4[G6$DUWJ'$<KI1^Y\CM8.(W1<D^4L
MEK-9SF$YE^4\EO-9+F"YD.4BC#N$T;O]77#TN(@_O%\G^9?D/EFMJFMI=UE1
M#7+R4R5/'JNL^O&C]N;=V<\M]4=/[?BYK_X8=/T\5'^,]C]_UPS[X?US_"4)
MXOQ+FFV55?)8KL+@;EHFQ?Z2NN,WQ>:YC,\WRN=-46S6^R^?DGB9Y-4#RG]_
MW&R*XS?5 %\W^5_WO^:'_P502P,$%     @ BS&*6;":$%IK!   .1D  !D
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MEM1W*^/VB5YJA,9[ H[WY!C<VU+?K8S;YW=I_QKPB1WP/T:K3?G-(0ZJ)?K
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M3:":1#6%:AK5 E0+*<VLM2K_,;#G/]JN)VQG.A<9FODH->/3,>/1>#*<UH)
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M?VQP-1H/ZJ7U&LF-:97<F-J3&S?/+,79\GH,S6R@FH=J/JH)5).HIE!-HUJ
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MN+'LT.@'JGFHYJ.:0#6):@K5-*H%I58;(_;J=\:H1LUZJC(=LU8/(O)>NMR
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M4Y8?*LEO!-UEN_0K*@2-L\LM1B%FRD ^7U/9UL6-JN!PM&?P/U!+ P04
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M4"'[LE-WY):IIX+Q*%;ZI0R7Q7T21^A)WD8#-=GHR9,>DD9!:0$434]?MR^
MO?-0,=!]!5 :!:4%4#0]H=W> IZL=U]$Q?RAEGBN[=MV?__^F*77W_>BS[8,
MIL?_@_$E7;U/INO]<NZ__53(>MZ/BM<TX=2Y#DJCH+0 BJ;GHMM&(/@LQ(N
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MP3L*\YB.=,;[*5K3EU6?9F6?K M]LL$7G+,-!4$>HUBB][OU@__2A]UZT^H
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MPUEQN$$P1D0$\/LKC-G+B6B@WMV;_ M02P,$%     @ BS&*657(C3(>!0
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MOP0DN.<X9?_*YK<<WY:/GR?#6[9&(1YJ(MLQ3)^Q-OKU%^@:O\FT?4NPX(W
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M)PC2\B:X?.!D7=R-S@GG)"V:*XPB3',#\7Y!"-\_Y /4]_&C_P%02P,$%
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M<U((R@K$R6YFW;J3]5CA*\!72H[BY!JIF6P9^Z9N/B0SRU$)D8S$4BE@^/=
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MQT?,][004+\=I.#<!# %7G\_J&\D*ZO7URV3\#)<7:8$)X0K /R^8TP^W:@
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M3@^_DZH@7_K%-"W*O^!0M74L$.\+3K-*+*X@2_+C+_Y9@6@)H/>* %4"=*K
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M*TW: @  [ @  !D   !X;"]W;W)K<VAE971S+W-H965T.38N>&ULK5;;;IM
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M(4V+EV^J"9[3[-OJ85[_'U!+ P04    " "+,8I9O^GQ'\,#  !S$   &0
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MZ=NG2+4&E[:E^2991$?VP]G;[\M,7K^Q]/WDW<E)[^'\>K?]K R<VXZ1].H
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "+,8I9>K+>BK(&   800
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MWP MFSR_H'VWY6>39-L?]F__*<&'?P%02P,$%     @ BS&*6;?ZQO#1 @
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M>CL!O1WU=@)ZN]G+$@&]'?5V GH[ZNT$]';4VPGH[:BW$]#;46\GH+>CWDY
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M/@_=>.OY6N/^IOE.JZ?+M=WM_M?EU\'9USC-E>?Z/F-\^@M02P,$%     @
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M_&/P]B=02P$"% ,4    " "+,8I9!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (LQBEEH?/R[[0
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( (LQBEF97)PC$ 8  )PG   3              "  <L!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ BS&*6;/#>T>'!   H!,  !@
M             ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( (LQBEF"KY S&@@  # I   8              " @<D,  !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "+,8I9?"Z9B_@#  #8
M$0  &               @($9%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL
M4$L! A0#%     @ BS&*6;9F#P1)"@  =S,  !@              ("!1QD
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (LQBEGH/3.M
M700  ,49   8              " @<8C  !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6Q02P$"% ,4    " "+,8I9:S5R(Z0?  !*XP$ &
M@(%9*   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ BS&*
M68$8K30C#@  35H  !@              ("!,T@  'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;%!+ 0(4 Q0    ( (LQBEF*@@%H/ ,  + )   8
M      " @8Q6  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M" "+,8I9\]0(&K(2  #A60  &               @('^60  >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&UL4$L! A0#%     @ BS&*69I; Z:F)   YX(  !D
M             ("!YFP  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M% ,4    " "+,8I9ET=B^A$4  #@>@  &0              @('#D0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (LQBEG*0'FO]@0
M -<0   9              " @0NF  !X;"]W;W)K<VAE971S+W-H965T,3(N
M>&UL4$L! A0#%     @ BS&*60@\F^<_ P  Q0@  !D              ("!
M.*L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " "+,8I9
M#=6&N;D$  ""#0  &0              @(&NK@  >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;%!+ 0(4 Q0    ( (LQBED44$A@TP0  %\.   9
M      " @9ZS  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%
M  @ BS&*60H]4?]<'@  ;*L  !D              ("!J+@  'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "+,8I95_?R;?$+   A,@
M&0              @($[UP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+
M 0(4 Q0    ( (LQBEEQ'0MNFA$  *]<   9              " @6/C  !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ BS&*60)@$AV3
M"@  V!X  !D              ("!-/4  'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"% ,4    " "+,8I9E#8RRIL-   8+   &0
M@('^_P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (LQ
MBEF+R&"K=0L  &\B   9              " @= - 0!X;"]W;W)K<VAE971S
M+W-H965T,C$N>&UL4$L! A0#%     @ BS&*6<_GW>*F!@  R!0  !D
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M=#(V+GAM;%!+ 0(4 Q0    ( (LQBEDXF<J,@PD  -\F   9
M  " @3H_ 0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @
MBS&*62 G,9<<!   20D  !D              ("!]$@! 'AL+W=O<FMS:&5E
M=',O<VAE970R."YX;6Q02P$"% ,4    " "+,8I981:? CHG   'G0  &0
M            @(%'30$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4
M Q0    ( (LQBEG)6]+UGP0  / -   9              " @;AT 0!X;"]W
M;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ BS&*6=JYL!X.!@
M21D  !D              ("!CGD! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX
M;6Q02P$"% ,4    " "+,8I9FV1[H\T#  !Z"0  &0              @('3
M?P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( (LQBEF*
M040\VP(  %('   9              " @=># 0!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L! A0#%     @ BS&*6<3T'[[C!   10X  !D
M     ("!Z88! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (LQBEF-]HJ6=P4  " .   9              "
M@9^F 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ BS&*
M68L\^/ B!@   18  !D              ("!3:P! 'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6Q02P$"% ,4    " "+,8I9 /E&VIP&   L%P  &0
M        @(&FL@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0
M   ( (LQBEG-_AB(/P4  %H,   9              " @7FY 0!X;"]W;W)K
M<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ BS&*60Z&>3V2!@  J!4
M !D              ("![[X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q0
M2P$"% ,4    " "+,8I9?08]COH$  !!#P  &0              @(&XQ0$
M>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( (LQBEF=%5+4
M#P,  "4(   9              " @>G* 0!X;"]W;W)K<VAE971S+W-H965T
M-#4N>&UL4$L! A0#%     @ BS&*6<!9$L8$!P  +3P  !D
M ("!+\X! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "+
M,8I9:M).HY0*  "6@P  &0              @(%JU0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (LQBEE4FT OBP0  %8F   9
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M970U,BYX;6Q02P$"% ,4    " "+,8I94!08Z@L%  #-*   &0
M    @(']!P( >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (
M (LQBED<XDQX@@4  ) I   9              " @3\- @!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L! A0#%     @ BS&*644=NBH_!@  4CD  !D
M             ("!^!(" 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M% ,4    " "+,8I9>ZQG ;<"   E"   &0              @(%N&0( >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( (LQBEDVC6@ E (
M +\)   9              " @5P< @!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L! A0#%     @ BS&*66UQP_#O!   (2   !D              ("!
M)Q\" 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " "+,8I9
MV+A&7]H"    "@  &0              @(%-) ( >&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (LQBEFW$4<@R 0  ,\@   9
M      " @5XG @!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%
M  @ BS&*6: S#+G5 P  'PX  !D              ("!72P" 'AL+W=O<FMS
M:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "+,8I98 !\%_T"  "U"P
M&0              @(%I, ( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+
M 0(4 Q0    ( (LQBEF;MGZ\<@0  -T9   9              " @9TS @!X
M;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ BS&*6:@-1@=0
M40  )-(& !D              ("!1C@" 'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6Q02P$"% ,4    " "+,8I9CRB3>O$"  #A"P  &0
M@('-B0( >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( (LQ
MBED%2A%4,PX  &K7   9              " @?6, @!X;"]W;W)K<VAE971S
M+W-H965T-C8N>&UL4$L! A0#%     @ BS&*6=UIS$O4 P  ;!,  !D
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M=#<Q+GAM;%!+ 0(4 Q0    ( (LQBEF+!UD JP(   @'   9
M  " @7RT @!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @
MBS&*68=(S'N5!0  ;R4  !D              ("!7K<" 'AL+W=O<FMS:&5E
M=',O<VAE970W,RYX;6Q02P$"% ,4    " "+,8I9%GJ=',41  "?Q@  &0
M            @($JO0( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4
M Q0    ( (LQBEE*@KS(>0<  (-    9              " @2;/ @!X;"]W
M;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ BS&*6?X(N32A$
MI.@  !D              ("!UM8" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX
M;6Q02P$"% ,4    " "+,8I9]/U^E+(,  #5E@  &0              @(&N
MYP( >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( (LQBEE'
M?/?"&B(  &TD @ 9              " @9?T @!X;"]W;W)K<VAE971S+W-H
M965T-S@N>&UL4$L! A0#%     @ BS&*6;":$%IK!   .1D  !D
M     ("!Z!8# 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (LQBEGUX9#-' D  )9:   9              "
M@4A) P!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ BS&*
M6311KXF<!@  YB,  !D              ("!FU(# 'AL+W=O<FMS:&5E=',O
M<VAE970X-2YX;6Q02P$"% ,4    " "+,8I9$Z_$U1H&  #2+@  &0
M        @(%N60, >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0
M   ( (LQBEF+6K4\5PL  !5X   9              " @;]? P!X;"]W;W)K
M<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ BS&*6?,$A:>)!   Z1L
M !D              ("!36L# 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q0
M2P$"% ,4    " "+,8I95<B-,AX%  ";%P  &0              @($-< ,
M>&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    ( (LQBEF]1<%W
M4@,  +0+   9              " @6)U P!X;"]W;W)K<VAE971S+W-H965T
M.3 N>&UL4$L! A0#%     @ BS&*6<TLELG' P  : T  !D
M ("!ZW@# 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    " "+
M,8I9U&HXWL("  !W"0  &0              @('I? , >&PO=V]R:W-H965T
M<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( (LQBEDR7UZ>2@X  ,"B   9
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M970Y-RYX;6Q02P$"% ,4    " "+,8I9"=7>S'(-  "2R@  &0
M    @(''G0, >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    (
M (LQBEF_Z?$?PP,  ',0   9              " @7"K P!X;"]W;W)K<VAE
M971S+W-H965T.3DN>&UL4$L! A0#%     @ BS&*649W#^62 P  :1H   T
M             ( !:J\# 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "+,8I9
MEXJ[',     3 @  "P              @ $GLP, 7W)E;',O+G)E;'-02P$"
M% ,4    " "+,8I9>K+>BK(&   800  #P              @ $0M , >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ BS&*6;?ZQO#1 @  ,CH  !H
M         ( ![[H# 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ BS&*616+*+]4 @  .3@  !,              ( !^+T# %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     &L :P!D'0  ?< #

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>878</ContextCount>
  <ElementCount>573</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>235</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption</Role>
      <ShortName>Revenue Interest Financing, Side Letter, and PIPE Conversion Option</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Capital Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficit</Role>
      <ShortName>Capital Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/GeographicInformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Related-party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/BusinessCombination</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/Revenue</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables</Role>
      <ShortName>Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Capital Stock and Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables</Role>
      <ShortName>Capital Stock and Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/CapitalStockAndStockholdersDeficit</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/NetLossPerShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/StockBasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/GeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.allurion.com/role/GeographicInformation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails</Role>
      <ShortName>Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails</Role>
      <ShortName>Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Revenue - Schedule of Revenues by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails</Role>
      <ShortName>Revenue - Schedule of Revenues by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/InventoryScheduleOfInventoryDetails</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Inventory - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/InventoryAdditionalInformationDetails</Role>
      <ShortName>Inventory - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Property and Equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Property and Equipment, net - Schedule of Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment, net - Schedule of Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Debt - Summary of Components of Third-Party Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails</Role>
      <ShortName>Debt - Summary of Components of Third-Party Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/DebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Debt - Schedule of Future Maturities of the Term Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails</Role>
      <ShortName>Debt - Schedule of Future Maturities of the Term Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails</Role>
      <ShortName>Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails</Role>
      <ShortName>Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Summary of Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in Fair Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Capital Stock and Stockholders' Deficit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails</Role>
      <ShortName>Capital Stock and Stockholders' Deficit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails</Role>
      <ShortName>Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails</Role>
      <ShortName>Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails</Role>
      <ShortName>Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>1085 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>1086 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>1087 - Disclosure - Stock Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>1088 - Disclosure - Stock Based Compensation - Schedule of Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation - Schedule of Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>1089 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails</Role>
      <ShortName>Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>1090 - Disclosure - Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>1091 - Disclosure - Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails</Role>
      <ShortName>Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>1092 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>1093 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>1094 - Disclosure - Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>1095 - Disclosure - Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>1096 - Disclosure - Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>1097 - Disclosure - Geographic Information - Schedule of Long-lived Assets by Geography (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails</Role>
      <ShortName>Geographic Information - Schedule of Long-lived Assets by Geography (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>1098 - Disclosure - Related-party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="d915839ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>1099 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alur-20240930.xsd</File>
    <File>alur-20240930_cal.xml</File>
    <File>alur-20240930_def.xml</File>
    <File>alur-20240930_lab.xml</File>
    <File>alur-20240930_pre.xml</File>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="d915839ds1.htm">d915839ds1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g915839g01a03.jpg</File>
    <File>g915839g81a01.jpg</File>
    <File>g915839g82a01.jpg</File>
    <File>g915839g83a01.jpg</File>
    <File>g915839g83a02.jpg</File>
    <File>g915839g86a01.jpg</File>
    <File>g915839g87a01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2251">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d915839ds1.htm": {
   "nsprefix": "alur",
   "nsuri": "http://www.allurion.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "alur-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "alur-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alur-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "alur-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alur-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d915839ds1.htm"
     ]
    }
   },
   "keyStandard": 391,
   "keyCustom": 182,
   "axisStandard": 44,
   "axisCustom": 0,
   "memberStandard": 68,
   "memberCustom": 145,
   "hidden": {
    "total": 20,
    "http://fasb.org/us-gaap/2024": 16,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 878,
   "entityCount": 1,
   "segmentCount": 235,
   "elementCount": 978,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 2251,
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.allurion.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
     "longName": "1002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
     "longName": "1004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
     "longName": "1005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit",
     "longName": "1006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
     "longName": "1007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:NonCashLeaseExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash",
     "longName": "1008 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash",
     "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Reconciliation of Cash and Cash Equivalents and Restricted Cash",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.allurion.com/role/OrganizationAndBasisOfPresentation",
     "longName": "1009 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.allurion.com/role/BusinessCombination",
     "longName": "1011 - Disclosure - Business Combination",
     "shortName": "Business Combination",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.allurion.com/role/Revenue",
     "longName": "1012 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.allurion.com/role/Inventory",
     "longName": "1013 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.allurion.com/role/PropertyAndEquipmentNet",
     "longName": "1014 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "1015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.allurion.com/role/Debt",
     "longName": "1016 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption",
     "longName": "1017 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option",
     "shortName": "Revenue Interest Financing, Side Letter, and PIPE Conversion Option",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.allurion.com/role/FairValueMeasurements",
     "longName": "1018 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.allurion.com/role/IncomeTaxes",
     "longName": "1019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit",
     "longName": "1020 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficit",
     "longName": "1021 - Disclosure - Capital Stock and Stockholders' Deficit",
     "shortName": "Capital Stock and Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.allurion.com/role/NetLossPerShare",
     "longName": "1022 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.allurion.com/role/StockBasedCompensation",
     "longName": "1023 - Disclosure - Stock Based Compensation",
     "shortName": "Stock Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.allurion.com/role/EmployeeBenefitPlan",
     "longName": "1024 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingencies",
     "longName": "1025 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.allurion.com/role/GeographicInformation",
     "longName": "1026 - Disclosure - Geographic Information",
     "shortName": "Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.allurion.com/role/RelatedPartyTransactions",
     "longName": "1027 - Disclosure - Related-party Transactions",
     "shortName": "Related-party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.allurion.com/role/SubsequentEvents",
     "longName": "1028 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1029 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "1030 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.allurion.com/role/BusinessCombinationTables",
     "longName": "1031 - Disclosure - Business Combination (Tables)",
     "shortName": "Business Combination (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.allurion.com/role/RevenueTables",
     "longName": "1032 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.allurion.com/role/InventoryTables",
     "longName": "1033 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.allurion.com/role/PropertyAndEquipmentNetTables",
     "longName": "1034 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "1035 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.allurion.com/role/DebtTables",
     "longName": "1036 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables",
     "longName": "1037 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)",
     "shortName": "Revenue Interest Financing, Side Letter, and PIPE Conversion Option (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "alur:ComponentsOfRevenueInterestFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "alur:ComponentsOfRevenueInterestFinancingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsTables",
     "longName": "1038 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.allurion.com/role/IncomeTaxesTables",
     "longName": "1039 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables",
     "longName": "1040 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Deficit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables",
     "longName": "1041 - Disclosure - Capital Stock and Stockholders' Deficit (Tables)",
     "shortName": "Capital Stock and Stockholders' Deficit (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.allurion.com/role/NetLossPerShareTables",
     "longName": "1042 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.allurion.com/role/StockBasedCompensationTables",
     "longName": "1043 - Disclosure - Stock Based Compensation (Tables)",
     "shortName": "Stock Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingenciesTables",
     "longName": "1044 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.allurion.com/role/GeographicInformationTables",
     "longName": "1045 - Disclosure - Geographic Information (Tables)",
     "shortName": "Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "1046 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "alur:NumberOfCountriesInWhichEntityMarketsTheProgram",
      "unitRef": "Unit_Country",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "alur:NumberOfCountriesInWhichEntityMarketsTheProgram",
      "unitRef": "Unit_Country",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "1047 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:SellingAndMarketingExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails",
     "longName": "1048 - Disclosure - Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Risk of Concentration of Credit, Significant Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "longName": "1049 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails",
     "longName": "1050 - Disclosure - Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Activity in Allowance for Doubtful Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2021",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
     "longName": "1051 - Disclosure - Business Combination - Additional Information (Details)",
     "shortName": "Business Combination - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "P01_01_2023To09_30_2023",
      "name": "alur:ProceedsFromRevenueInterestFinancing",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn08_01_2023",
      "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails",
     "longName": "1052 - Disclosure - Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)",
     "shortName": "Business Combination - Reconciles of Business Combination to Condensed Consolidated Statement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "alur:GrossProceedsFromBusinessCombination",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "alur:GrossProceedsFromBusinessCombination",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
     "longName": "1053 - Disclosure - Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details)",
     "shortName": "Business Combination - Number of Shares of Allurion Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
     "longName": "1054 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails",
     "longName": "1055 - Disclosure - Revenue - Schedule of Revenues by Geographic Region (Details)",
     "shortName": "Revenue - Schedule of Revenues by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_ESsrtStatementGeographicalAxis",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails",
     "longName": "1056 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:InventoryFinishedGoods",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.allurion.com/role/InventoryAdditionalInformationDetails",
     "longName": "1057 - Disclosure - Inventory - Additional Information (Details)",
     "shortName": "Inventory - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
     "longName": "1058 - Disclosure - Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment, net - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "1059 - Disclosure - Property and Equipment, net - Additional Information (Details)",
     "shortName": "Property and Equipment, net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "alur:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "alur:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
     "longName": "1060 - Disclosure - Property and Equipment, net - Schedule of Depreciation Expense (Details)",
     "shortName": "Property and Equipment, net - Schedule of Depreciation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfDepreciationExpenseTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "1061 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "alur:DistributorFeesAndMarketingReimbursements",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "alur:DistributorFeesAndMarketingReimbursements",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails",
     "longName": "1062 - Disclosure - Accrued Expenses and Other Current Liabilities - Additional Information (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
     "longName": "1063 - Disclosure - Debt - Summary of Components of Third-Party Debt (Details)",
     "shortName": "Debt - Summary of Components of Third-Party Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "alur:LoanAccretion",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.allurion.com/role/DebtAdditionalInformationDetails",
     "longName": "1064 - Disclosure - Debt - Additional Information (Details)",
     "shortName": "Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
     "longName": "1065 - Disclosure - Debt - Schedule of Future Maturities of the Term Loan Facility (Details)",
     "shortName": "Debt - Schedule of Future Maturities of the Term Loan Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
     "longName": "1066 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)",
     "shortName": "Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "alur:ChangesInFairValueOfRevenueInterestFinancing",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "alur:PrePaymentsPercentage",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails",
     "longName": "1067 - Disclosure - Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details)",
     "shortName": "Revenue Interest Financing, Side Letter, and PIPE Conversion Option - Summary of Components of Revenue Interest Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "alur:ChangeInFairValueOfDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "alur:RevenueInterestFinancingLiabilityPrincipalAmountOfDebt",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ComponentsOfRevenueInterestFinancingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails",
     "longName": "1068 - Disclosure - Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Domestic and Foreign Components of Net Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails",
     "longName": "1069 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "longName": "1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "1071 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails",
     "longName": "1072 - Disclosure - Income Taxes - Summary of Valuation Allowance (Details)",
     "shortName": "Income Taxes - Summary of Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
     "longName": "1073 - Disclosure - Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details)",
     "shortName": "Fair Value Measurements - Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
     "longName": "1074 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Values (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in Fair Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "PAsOn06_30_2024",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2024",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "1075 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis",
      "name": "us-gaap:LineOfCredit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
     "longName": "1076 - Disclosure - Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assumptions used in Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
     "longName": "1077 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
     "longName": "1078 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Deficit - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023",
      "name": "us-gaap:DividendsPreferredStockCash",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
     "longName": "1079 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
     "longName": "1080 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
     "longName": "1081 - Disclosure - Capital Stock and Stockholders' Deficit - Additional Information (Details)",
     "shortName": "Capital Stock and Stockholders' Deficit - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis",
      "name": "us-gaap:PreferredStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
     "longName": "1082 - Disclosure - Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details)",
     "shortName": "Capital Stock and Stockholders' Deficit - Schedule of Preferred Stock Details Prior to Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
     "longName": "1083 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)",
     "shortName": "Capital Stock and Stockholders' Deficit - Summary of Reserved for Issuance Upon the Potential Conversion or Exercise (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
     "longName": "1084 - Disclosure - Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)",
     "shortName": "Capital Stock and Stockholders' Deficit - Summary of Warrants to Purchase Classes of Preferred Stock and Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "1085 - Disclosure - Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details)",
     "shortName": "Net Loss per Share - Summary of Basic and Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R86": {
     "role": "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
     "longName": "1086 - Disclosure - Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details)",
     "shortName": "Net Loss per Share - Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
     "longName": "1087 - Disclosure - Stock Based Compensation - Additional Information (Details)",
     "shortName": "Stock Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails",
     "longName": "1088 - Disclosure - Stock Based Compensation - Schedule of Stock Based Compensation (Details)",
     "shortName": "Stock Based Compensation - Schedule of Stock Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails",
     "longName": "1089 - Disclosure - Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details)",
     "shortName": "Stock Based Compensation - Summary of Stock Option Activity Under the Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails",
     "longName": "1090 - Disclosure - Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)",
     "shortName": "Stock Based Compensation - Schedule of Assumptions used in Black-Scholes Option-Pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails",
     "longName": "1091 - Disclosure - Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details)",
     "shortName": "Stock Based Compensation - Summary of Restricted Stock Unit Activity Under the Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
     "longName": "1092 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1093 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To09_30_2024",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails",
     "longName": "1094 - Disclosure - Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Other Pertinent Lease Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails",
     "longName": "1095 - Disclosure - Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails",
     "longName": "1096 - Disclosure - Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails",
     "longName": "1097 - Disclosure - Geographic Information - Schedule of Long-lived Assets by Geography (Details)",
     "shortName": "Geographic Information - Schedule of Long-lived Assets by Geography (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn09_30_2024",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "1098 - Disclosure - Related-party Transactions - Additional Information (Details)",
     "shortName": "Related-party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "P07_01_2024To09_30_2024",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P02_15_2023To02_15_2023",
      "name": "alur:PercentageOfOutstandingCapitalStock",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1099 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "unitRef": "Unit_Employees",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d915839ds1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "AU",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r1049"
     ]
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Summary of Activity in Allowance for Doubtful Accounts",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance of doubtful accounts",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "alur_AccruedClinicalTrialsAndResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AccruedClinicalTrialsAndResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Clinical Trials And Research And Development",
        "terseLabel": "Accrued clinical trials and R&amp;D",
        "documentation": "Accrued clinical trials and research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Accrued selling and marketing",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "alur_AccruedRestructuringCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AccruedRestructuringCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Restructuring Current",
        "terseLabel": "Accrued restructuring",
        "documentation": "Accrued restructuring current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r215",
      "r830"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r120",
      "r225",
      "r825",
      "r858",
      "r862"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r19",
      "r29",
      "r645",
      "r648",
      "r733",
      "r853",
      "r854",
      "r1111",
      "r1112",
      "r1113",
      "r1125",
      "r1126",
      "r1127",
      "r1130"
     ]
    },
    "alur_AdditionalBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AdditionalBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Borrowings",
        "terseLabel": "Additional borrowings",
        "documentation": "Additional Borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r1049",
      "r1283"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r1125",
      "r1126",
      "r1127",
      "r1130",
      "r1214",
      "r1284"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r265",
      "r266",
      "r267",
      "r268",
      "r281",
      "r337",
      "r338",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r408",
      "r409",
      "r417",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r687",
      "r688",
      "r707",
      "r708",
      "r709",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r779",
      "r780",
      "r781",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Aggregate recognition APIC amount",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r153",
      "r601"
     ]
    },
    "alur_AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital, Recognition of Earn-Out Liabilities",
        "verboseLabel": "Recognition of earn-out liabilities (Note 3)",
        "documentation": "Adjustments to additional paid in capital, recognition of earn-out liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r524"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "verboseLabel": "Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56",
      "r153"
     ]
    },
    "alur_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Additional Paid In Capital, Warrant Liabilities In Connection Merger",
        "verboseLabel": "Recognition of warrant liabilities in connection with the Merger",
        "documentation": "Adjustments to additional paid in capital, warrant liabilities in connection merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising and Marketing Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "alur_AggregatePurchasePriceFromOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AggregatePurchasePriceFromOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Purchase Price From Offering",
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price from offering."
       }
      }
     },
     "auth_ref": []
    },
    "alur_AgreementsTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AgreementsTerminationDate",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreements Termination Date",
        "terseLabel": "Agreements termination date",
        "documentation": "Agreements termination date."
       }
      }
     },
     "auth_ref": []
    },
    "alur_AllOtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AllOtherCountriesMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Other Countries [Member]",
        "terseLabel": "All Other Countries",
        "documentation": "All Other Countries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r566"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "terseLabel": "Allowance of doubtful accounts",
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "negatedPeriodStartLabel": "Balance at beginning of period",
        "negatedPeriodEndLabel": "Balance at end of period",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r340",
      "r385",
      "r388",
      "r391",
      "r1249"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Uncollectible accounts written off",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "alur_AmendedAndRestatedRtwSideLetterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AmendedAndRestatedRtwSideLetterMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended and Restated RTW Side Letter [Member]",
        "terseLabel": "RTW Side Letter",
        "documentation": "Amended and restated RTW side letter."
       }
      }
     },
     "auth_ref": []
    },
    "alur_AmendedTwoThousandTwentyOneTermLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AmendedTwoThousandTwentyOneTermLoanAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Two Thousand Twenty One Term Loan Agreement [Member]",
        "terseLabel": "Amended 2021 Term Loan Agreement",
        "documentation": "Amended Two Thousand Twenty One Term Loan Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of the debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r127",
      "r467",
      "r1228"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Debt issuance costs associated with debt recorded at fair value",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r467",
      "r1118",
      "r1228"
     ]
    },
    "alur_AmortizationOfIssuanceCostsAssociatedWithWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AmortizationOfIssuanceCostsAssociatedWithWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Of Issuance Costs Associated With Warrants",
        "terseLabel": "Issuance costs associated with warrants recorded at fair value",
        "documentation": "Amortization of issuance costs associated with warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_AmortizationOfTheWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AmortizationOfTheWarrant",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of the warrant",
        "documentation": "Amortization of the warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Land",
        "terseLabel": "Lease total area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r183",
      "r217",
      "r253",
      "r301",
      "r309",
      "r325",
      "r328",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r634",
      "r637",
      "r692",
      "r819",
      "r914",
      "r1005",
      "r1006",
      "r1049",
      "r1079",
      "r1170",
      "r1171",
      "r1236"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r229",
      "r253",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r634",
      "r637",
      "r692",
      "r1049",
      "r1170",
      "r1171",
      "r1236"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total Assets",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r1037"
     ]
    },
    "alur_AverageMarketCapitalizationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "AverageMarketCapitalizationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average Market Capitalization Amount",
        "terseLabel": "Average market capitalization amount",
        "documentation": "Average market capitalization amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AwardTypeAxis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "alur_BackstopAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BackstopAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Backstop Agreement [Member]",
        "terseLabel": "Backstop Agreement",
        "documentation": "Backstop Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r416",
      "r1251",
      "r1252"
     ]
    },
    "alur_BasePubcoAndBackstopShareLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BasePubcoAndBackstopShareLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base PubCo and Backstop Share Liability [Member]",
        "terseLabel": "Base PubCo and Backstop Share Liability",
        "documentation": "Base PubCo and Backstop Share Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_BasePubcoSharesAndBackstopShareLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BasePubcoSharesAndBackstopShareLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base PubCo Shares and Backstop Share Liability [Member]",
        "terseLabel": "Base PubCo Shares and Backstop Shares Liability",
        "documentation": "Base PubCo shares and backstop share liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_BenoitChardonConsultingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BenoitChardonConsultingMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benoit Chardon Consulting [Member]",
        "terseLabel": "Benoit Chardon Consulting",
        "documentation": "Benoit Chardon Consulting (BCC)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Director Members"
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "alur_BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing Capacity Available Based upon Achievement of Certain Revenue Thresholds",
        "terseLabel": "Available capacity based upon the achievement of certain revenue thresholds",
        "documentation": "Borrowing Capacity Available Based upon Achievement of Certain Revenue Thresholds."
       }
      }
     },
     "auth_ref": []
    },
    "alur_BusinessAcquisitionAccruedTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessAcquisitionAccruedTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition Accrued Transaction Costs",
        "terseLabel": "Less: accrued transaction costs at December 31, 2023",
        "documentation": "Business acquisition accrued transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r622",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r622",
      "r1030",
      "r1031"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Aggregate purchase of shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Purchase price per share",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Business combination expense",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "alur_BusinessCombinationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Agreement [Member]",
        "terseLabel": "Business Combination Agreement",
        "documentation": "Business combination agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_BusinessCombinationCommonStockExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationCommonStockExchangeRatio",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Common Stock Exchange Ratio",
        "terseLabel": "Exchange ratio",
        "documentation": "Business combination common stock exchange ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Aggregate purchase price",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r17"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Earn-out liabilities",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r162"
     ]
    },
    "alur_BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Contingent Consideration, Number Of Additional Shares Receivable",
        "terseLabel": "Earn-out shares receivable",
        "documentation": "Business combination, contingent consideration, number of additional shares receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombination"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r623"
     ]
    },
    "alur_BusinessCombinationNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationNetOfTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Merger, Net of Transaction Costs",
        "terseLabel": "Reverse merger, net of transaction costs",
        "documentation": "Business combination, net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "alur_BusinessCombinationOneTimeInsurancePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationOneTimeInsurancePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination One-time Insurance Payment",
        "terseLabel": "Business combination one-time insurance payment",
        "documentation": "Business combination one-time insurance payment."
       }
      }
     },
     "auth_ref": []
    },
    "alur_BusinessCombinationTransactionCostPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "BusinessCombinationTransactionCostPaid",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails": {
       "parentTag": "alur_NetProceedsFromBusinessCombination",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination Transaction Cost Paid",
        "negatedLabel": "Less: transaction costs paid",
        "documentation": "Business combination transaction cost paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "verboseLabel": "Business Contact",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1082"
     ]
    },
    "country_CL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CL",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHILE",
        "terseLabel": "Chile"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "alur_CappedPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CappedPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capped Price",
        "terseLabel": "Capped price",
        "documentation": "Capped price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Total Carrying Value",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r213",
      "r991"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r170"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash and cash equivalents and restricted cash shown in the statement of cash flows",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r131",
      "r249"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r131",
      "r249"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r131"
     ]
    },
    "alur_CashPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CashPaymentsPercentage",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Payments Percentage",
        "terseLabel": "Cash payments percentage",
        "documentation": "Cash payments percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle accounting standards update adopted",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r208",
      "r264",
      "r337",
      "r373",
      "r374",
      "r375",
      "r381",
      "r382",
      "r408",
      "r417",
      "r604",
      "r613",
      "r614",
      "r624",
      "r625",
      "r627",
      "r640",
      "r641",
      "r653",
      "r654",
      "r687",
      "r688",
      "r708",
      "r728",
      "r729",
      "r779",
      "r780",
      "r851",
      "r852"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle accounting standards update adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r208",
      "r337",
      "r373",
      "r374",
      "r375",
      "r381",
      "r382",
      "r383",
      "r408",
      "r417",
      "r604",
      "r613",
      "r614",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r639",
      "r640",
      "r641",
      "r642",
      "r653",
      "r654",
      "r655",
      "r658",
      "r687",
      "r688",
      "r708",
      "r728",
      "r729",
      "r779",
      "r780",
      "r851",
      "r852",
      "r1089"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle accounting standards update immaterial effect",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r280",
      "r378"
     ]
    },
    "alur_ChangeInFairValueOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangeInFairValueOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of debt",
        "negatedLabel": "Change in fair value",
        "negatedTerseLabel": "Less: Change in fair value of debt",
        "documentation": "Change in fair value of debt."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChangeInFairValueOfRevenueInterestFinancingThroughOci": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangeInFairValueOfRevenueInterestFinancingThroughOci",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of Revenue Interest Financing Through OCI",
        "terseLabel": "Change in fair value of Revenue Interest Financing through other comprehensive income",
        "documentation": "Change in fair value of revenue interest financing through OCI"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChangeInFairValueOfRtwConvertibleNotesThroughOci": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangeInFairValueOfRtwConvertibleNotesThroughOci",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change In Fair Value Of RTW Convertible Notes Through Oci",
        "terseLabel": "Change in fair value of RTW Convertible Notes through other comprehensive income",
        "documentation": "Change in fair value of rtw convertible notes through oci."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChangeInFairValueOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value of Warrant Liabilities",
        "terseLabel": "Change in fair value of warrant liabilities",
        "documentation": "Change in fair value of warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "alur_ChangesInFairValueOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangesInFairValueOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Fair Value Of Debt",
        "negatedLabel": "Changes in fair value of debt",
        "documentation": "Changes in fair value of debt."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChangesInFairValueOfRevenueInterestFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangesInFairValueOfRevenueInterestFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Fair Value Of Revenue Interest Financing",
        "terseLabel": "Gain in fair value of revenue interest financing",
        "documentation": "Changes in fair value of revenue interest financing."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Fair Value Of Revenue Interest Financing And Conversion Option",
        "terseLabel": "Changes in fair value of Revenue Interest Financing and PIPE Conversion Option",
        "negatedLabel": "Change in fair value of Revenue Interest Financing and PIPE Conversion Option",
        "documentation": "Changes in fair value of revenue interest financing and PIPE conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChardanEquityFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChardanEquityFacilityMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chardan Equity Facility [Member]",
        "terseLabel": "Chardan Equity Facility",
        "documentation": "Chardan Equity Facility."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ChefPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ChefPurchaseAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChEF Purchase Agreement [Member]",
        "terseLabel": "ChEF Purchase Agreement",
        "documentation": "ChEF Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/CoverPage",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r222",
      "r223",
      "r224",
      "r253",
      "r286",
      "r287",
      "r291",
      "r295",
      "r303",
      "r304",
      "r371",
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r476",
      "r477",
      "r480",
      "r483",
      "r490",
      "r692",
      "r868",
      "r869",
      "r870",
      "r871",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r902",
      "r923",
      "r946",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1084",
      "r1120",
      "r1131"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r303",
      "r476",
      "r477",
      "r478",
      "r480",
      "r483",
      "r488",
      "r490",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1019",
      "r1084",
      "r1120"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants exercisable price",
        "terseLabel": "Weighted Average Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Shares issuable for each outstanding warrants exercised",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of warrants into shares of common stock",
        "verboseLabel": "Warrants converted into warrants exercisable",
        "terseLabel": "Shares Issuable Upon Exercise of Warrant",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Class of Warrant Exchanged",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "alur_CommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CommitmentSharesMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment Shares Member",
        "terseLabel": "Commitment Shares",
        "documentation": "Commitment Shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 16)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r176",
      "r821",
      "r901"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r426",
      "r427",
      "r975",
      "r1154",
      "r1160"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1284"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1070",
      "r1071",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1125",
      "r1126",
      "r1130",
      "r1214",
      "r1282",
      "r1284"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Par value common stock",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Number of shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r902"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares of Common Stock immediately after Business Combination",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Number of shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r902",
      "r920",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r823",
      "r1049"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "alur_CommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CommonStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants",
        "documentation": "Common Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.allurion.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ComponentsOfRevenueInterestFinancingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ComponentsOfRevenueInterestFinancingTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Revenue Interest Financing [Table Text Block]",
        "terseLabel": "Summary of Components of Revenue Interest Financing",
        "documentation": "Components of revenue interest financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r233",
      "r235",
      "r240",
      "r813",
      "r836",
      "r837"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ComputeHealthAcquisitionCorprationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ComputeHealthAcquisitionCorprationMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compute Health Acquisition Corpration [Member]",
        "terseLabel": "Compute Health",
        "documentation": "Compute Health Acquisition Corpration."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ComputeHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ComputeHealthMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compute Health [Member]",
        "verboseLabel": "CPUH Stockholders",
        "terseLabel": "Cash - CPUH trust",
        "documentation": "Compute Health."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ComputeHealthSponsorSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ComputeHealthSponsorSharesMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compute Health Sponsor Shares [Member]",
        "terseLabel": "CPUH Sponsor Shares",
        "documentation": "Compute health sponsor shares."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ComputersAndPurchasedSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ComputersAndPurchasedSoftwareMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and Purchased Software Member",
        "terseLabel": "Computers and purchased software",
        "documentation": "Computers and Purchased Software Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r87",
      "r88",
      "r336",
      "r974"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r87",
      "r88",
      "r336",
      "r864",
      "r974"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r87",
      "r88",
      "r336",
      "r974",
      "r1088"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risk of Concentration of Credit, Significant Customers and Significant Suppliers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r192"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r87",
      "r88",
      "r336"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r47",
      "r48",
      "r87",
      "r169",
      "r974"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r87",
      "r88",
      "r336",
      "r974"
     ]
    },
    "alur_ConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConstructionInProgress",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction In Progress",
        "terseLabel": "Construction in progress",
        "documentation": "Construction in progress."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements",
        "documentation": "Consulting agreements."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ContributionOfCapitalByJointVenturePartner": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ContributionOfCapitalByJointVenturePartner",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution of Capital by Joint Venture Partner",
        "terseLabel": "Contribution of capital",
        "documentation": "Contribution of capital by joint venture partner."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConversionDividedByCappedConversionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConversionDividedByCappedConversionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Divided By Capped Conversion Price",
        "terseLabel": "Conversion divided by capped conversion price",
        "documentation": "Conversion divided by capped conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConversionDividedByDiscountedCappedConversionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConversionDividedByDiscountedCappedConversionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Divided By Discounted Capped Conversion Price",
        "terseLabel": "Conversion divided by discounted capped conversion price",
        "documentation": "Conversion divided by discounted capped conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConversionOfPipeInvestmentToRevenueInterestFinance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConversionOfPipeInvestmentToRevenueInterestFinance",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Pipe Investment To Revenue Interest Finance",
        "terseLabel": "Conversion of PIPE investment to revenue interest finance",
        "verboseLabel": "Conversion of RTW PIPE investment to revenue interest finance",
        "documentation": "Conversion of PIPE investment to revenue interest finance."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConversionOfPipeSubscriptionToRevenueInterestFinance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConversionOfPipeSubscriptionToRevenueInterestFinance",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of PIPE Subscription to Revenue Interest Finance",
        "terseLabel": "Conversion of PIPE subscription to revenue interest finance",
        "documentation": "Conversion of PIPE subscription to revenue interest finance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of shares",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Shares issued upon conversion",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r446",
      "r447",
      "r457",
      "r458",
      "r459",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes payable",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "alur_ConvertibleNoteAgreementWithRtwMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConvertibleNoteAgreementWithRtwMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Agreement with RTW [Member]",
        "terseLabel": "Convertible Note Agreement with RTW",
        "documentation": "Convertible note agreement with RTW."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConvertibleNoteHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConvertibleNoteHoldersMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Holders [Member]",
        "terseLabel": "Shares Issued to Convertible Note Holders",
        "documentation": "Convertible note holders"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes [Member]",
        "terseLabel": "Convertible Notes",
        "documentation": "Convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r253",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r692",
      "r1005",
      "r1170"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Revenue",
        "verboseLabel": "Cost of Revenue",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r449",
      "r478",
      "r739",
      "r760",
      "r817",
      "r993",
      "r995"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1168"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1168",
      "r1169"
     ]
    },
    "alur_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]",
        "terseLabel": "Customer A",
        "documentation": "Customer A."
       }
      }
     },
     "auth_ref": []
    },
    "alur_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]",
        "terseLabel": "Customer B",
        "documentation": "Customer B."
       }
      }
     },
     "auth_ref": []
    },
    "alur_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]",
        "terseLabel": "Customer C",
        "documentation": "Customer C."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r336"
     ]
    },
    "alur_CustomersDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CustomersDMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers D [Member]",
        "terseLabel": "Customer D",
        "documentation": "Customers D."
       }
      }
     },
     "auth_ref": []
    },
    "alur_CustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "CustomersMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customers Member",
        "terseLabel": "Customers",
        "documentation": "Customers."
       }
      }
     },
     "auth_ref": []
    },
    "alur_DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deb Instrument, Convertible, Maximum Limitation Percentage of Shares of Common Stock Outstanding",
        "terseLabel": "Maximum percentage of number of shares of common stock outstanding",
        "documentation": "Deb instrument, convertible, maximum limitation percentage of shares of common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Issuance of common stock upon conversion of convertible notes",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Shares issued upon conversion of convertible notes",
        "terseLabel": "Shares issued upon conversion of outstanding notes",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r251",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r434",
      "r435",
      "r445",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r461",
      "r468",
      "r469",
      "r471",
      "r705"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r96",
      "r97",
      "r172",
      "r175",
      "r259",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1047",
      "r1121",
      "r1155",
      "r1156",
      "r1157",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total principal amount of debt",
        "verboseLabel": "Principal balance",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r175",
      "r472"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Initial conversion price per share",
        "terseLabel": "Estimated share price at conversion",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r448"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r100",
      "r151",
      "r152",
      "r448"
     ]
    },
    "alur_DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Premium Percentage of Stock Price Trigger",
        "terseLabel": "Premium percentage of stock price trigger",
        "documentation": "Debt instrument, convertible, premium percentage of stock price trigger."
       }
      }
     },
     "auth_ref": []
    },
    "alur_DebtInstrumentConvertiblePriceForCalculatingEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentConvertiblePriceForCalculatingEquitySecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Convertible Price For Calculating Equity Securities",
        "terseLabel": "Debt instrument, convertible price for calculating equity securities",
        "documentation": "Debt instrument, convertible price for calculating equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Trading days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "alur_DebtInstrumentDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentDefaultInterestRate",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument default interest rate",
        "terseLabel": "Default interest rate",
        "documentation": "Debt instrument default interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of interest rate variable",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "alur_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentExitFee",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee",
        "documentation": "Debt instrument, exit fee."
       }
      }
     },
     "auth_ref": []
    },
    "alur_DebtInstrumentExitPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentExitPaymentPercentage",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Exit Payment Percentage",
        "terseLabel": "Debt instrument exit payment percentage",
        "documentation": "Debt instrument exit payment percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r705",
      "r706",
      "r1015",
      "r1016",
      "r1047"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Issue-date estimated fair value",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r691",
      "r1015",
      "r1016",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Debt fee amount incurred",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Interest, frequency of payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r92"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate During Period",
        "verboseLabel": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r464",
      "r1227"
     ]
    },
    "alur_DebtInstrumentInterestRateIncreaseEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentInterestRateIncreaseEventOfDefault",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Increase, Event of Default",
        "terseLabel": "Increase in interest rate",
        "documentation": "Debt instrument, interest rate, increase, event of default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r447"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Issued, Principal",
        "terseLabel": "Debt instrument issued",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1047",
      "r1121",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r1014",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Debt instrument, measurement input",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r259",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1047",
      "r1121",
      "r1155",
      "r1156",
      "r1157",
      "r1227",
      "r1229"
     ]
    },
    "alur_DebtInstrumentPrincipalAmountForConversionIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtInstrumentPrincipalAmountForConversionIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Principal Amount For Conversion Into Common Stock",
        "terseLabel": "Debt instrument, principal amount for conversion into common stock",
        "documentation": "Debt instrument, principal amount for conversion into common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Aggregate principal amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r62",
      "r65",
      "r91",
      "r150",
      "r152",
      "r259",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r470",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1047",
      "r1121",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "terseLabel": "Less: unamortized deferred financing costs and debt discounts",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r473",
      "r704",
      "r705",
      "r706",
      "r1015",
      "r1016",
      "r1047"
     ]
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred financing costs in accounts payable and accrued expenses",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "alur_DebtIssuanceCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DebtIssuanceCostsPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs",
        "documentation": "Debt issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "RTW Convertible Notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Issuance costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1226",
      "r1227",
      "r1229"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r173",
      "r593"
     ]
    },
    "alur_DeferredLiabilityForIssuanceOfAdditionalShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DeferredLiabilityForIssuanceOfAdditionalShares",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Liability For Issuance Of Additional Shares",
        "terseLabel": "Deferred liability for issuance of additional shares",
        "documentation": "Deferred liability for issuance of additional shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "alur_DeferredTaxAssetsDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DeferredTaxAssetsDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "Deferred tax assets depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized start-up and research and development expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "alur_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liability",
        "documentation": "Deferred tax assets lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "alur_DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Loss Carry Forward Expiration Period",
        "verboseLabel": "Net operating loss carryforwards expiration period",
        "documentation": "Deferred tax assets operating loss carry forward expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "U.S. federal and state net operating loss carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Bad debt reserve",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails",
      "http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "periodStartLabel": "Beginning balances",
        "periodEndLabel": "Ending balances",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other deferred tax liability",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined benefit plan matching contributions",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair value of term loan derivative liability",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r119",
      "r166",
      "r167",
      "r230",
      "r995"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain recorded on derivative",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "alur_DerivativeLiabilitySuccessFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DerivativeLiabilitySuccessFeeMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability-Success Fee [Member]",
        "terseLabel": "Success Fee Derivative Liability",
        "documentation": "Derivative liability-success fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Liabilities",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r79",
      "r80",
      "r81",
      "r84",
      "r258",
      "r279"
     ]
    },
    "alur_DirectCostsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DirectCostsAndFees",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Costs and Fees",
        "terseLabel": "Direct costs and fees",
        "documentation": "Direct costs and fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenues by Geographic Region",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r526",
      "r557",
      "r558",
      "r560",
      "r1033"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_DistributorFeesAndMarketingReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DistributorFeesAndMarketingReimbursements",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributor Fees And Marketing Reimbursements",
        "terseLabel": "Distributor fees and marketing reimbursements",
        "documentation": "Distributor fees and marketing reimbursements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPreferredStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends, Preferred Stock, Cash",
        "terseLabel": "Dividends declared",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r153"
     ]
    },
    "alur_DoNotExpireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "DoNotExpireMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Do Not Expire [Member]",
        "verboseLabel": "Do not expire",
        "documentation": "Do not expire."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "country_ES": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "ES",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "auth_ref": []
    },
    "alur_EachCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "EachCountryMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Each Country [Member]",
        "terseLabel": "Each Country",
        "documentation": "Each Country"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earliest Tax Year [Member]",
        "verboseLabel": "Earliest Tax Year",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "alur_EarnOutLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "EarnOutLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-out Liability [Member]",
        "verboseLabel": "Earn-Out Liability",
        "terseLabel": "Earn-out Liability",
        "documentation": "Earn-out liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_EarnOutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "EarnOutSharesMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earn-Out Shares [Member]",
        "terseLabel": "Earn-Out Shares",
        "documentation": "Earn-Out shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r283",
      "r286",
      "r291",
      "r294",
      "r295",
      "r300",
      "r620",
      "r631",
      "r662",
      "r663",
      "r814",
      "r838",
      "r997"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r276",
      "r286",
      "r291",
      "r294",
      "r295",
      "r300",
      "r620",
      "r631",
      "r662",
      "r663",
      "r814",
      "r838",
      "r997"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r291"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r297"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r296",
      "r298",
      "r299"
     ]
    },
    "alur_EarnoutLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "EarnoutLiabilityPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnout Liability [Policy Text Block]",
        "terseLabel": "Earn-out Liabilities",
        "documentation": "Disclosure of accounting policy for earnout liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "terseLabel": "Effective tax rates",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1036"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory federal income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r577",
      "r607",
      "r1036"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r1036",
      "r1124",
      "r1205"
     ]
    },
    "alur_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Change In Fair Value Of Financial Instruments",
        "terseLabel": "Change in fair value of financial instruments",
        "documentation": "Effective income tax rate reconciliation change in fair value of financial instruments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584",
      "r1124",
      "r1205"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1124",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal income tax benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r1036",
      "r1124",
      "r1205"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesReconciliationOfEffectiveTaxRateAndStatutoryFederalIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r584",
      "r1124",
      "r1205"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining weighted-average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options",
        "verboseLabel": "Stock Options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r205",
      "r237",
      "r238",
      "r239",
      "r260",
      "r261",
      "r262",
      "r266",
      "r274",
      "r277",
      "r279",
      "r302",
      "r377",
      "r384",
      "r409",
      "r492",
      "r602",
      "r603",
      "r616",
      "r617",
      "r618",
      "r621",
      "r630",
      "r631",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r661",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r708",
      "r710",
      "r733",
      "r834",
      "r853",
      "r854",
      "r855",
      "r877",
      "r946"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Issue-date estimated fair value",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r665",
      "r689",
      "r817",
      "r818",
      "r1037",
      "r1066",
      "r1068",
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "alur_ExercisableWarrantsIssuedAsConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ExercisableWarrantsIssuedAsConsideration",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable warrants issued as consideration",
        "terseLabel": "Warrants exercisable",
        "documentation": "Exercisable warrants issued as consideration"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ExpenseOfIssuanceOfCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ExpenseOfIssuanceOfCommitmentShares",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense of Issuance of Commitment Shares",
        "terseLabel": "Expense of issuance of commitment shares",
        "documentation": "Expense of Issuance of Commitment Shares"
       }
      }
     },
     "auth_ref": []
    },
    "alur_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expire Between Two Thousand Thirty And Two Thousand Thirty Seven [Member]",
        "verboseLabel": "Expire between 2030 and 2037",
        "documentation": "Expire between two thousand thirty and two thousand thirty seven."
       }
      }
     },
     "auth_ref": []
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "FR",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueAdjustmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueAdjustmentOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Debt",
        "terseLabel": "Change in fair value of debt",
        "documentation": "Amount of expense (income) related to adjustment to fair value of debt."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueAdjustmentOfEarnOutLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueAdjustmentOfEarnOutLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Earn Out Liabilities",
        "terseLabel": "Change in fair value of earn-out liabilities",
        "negatedLabel": "Change in fair value of earn-out liabilities",
        "documentation": "Fair value adjustment of earn-out liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Changes in fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r13"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r679",
      "r1037"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r679",
      "r1037"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r669",
      "r1040"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r669",
      "r1040"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions used in Pricing Model",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r1040"
     ]
    },
    "alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured On Recurring Basis, Observable And Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Observable and Unobservable Input Reconciliation [Line Items]",
        "documentation": "Fair value, assets measured on recurring basis, observable and unobservable input reconciliation."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisObservableAndUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured On Recurring Basis, Observable And Unobservable Input Reconciliation [Table]",
        "documentation": "Fair value, assets measured on recurring basis, observable and unobservable input reconciliation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value at Issuance Date and on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r680",
      "r1038"
     ]
    },
    "alur_FairValueAssumptionsOfLiquidityEventTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueAssumptionsOfLiquidityEventTerm",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assumptions of Liquidity Event Term",
        "terseLabel": "Fair value assumptions of liquidity event term",
        "documentation": "Fair value assumptions of liquidity event term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r680",
      "r1038"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r678",
      "r679",
      "r681",
      "r747",
      "r748",
      "r749",
      "r1015",
      "r1016",
      "r1027",
      "r1028",
      "r1029",
      "r1037",
      "r1040"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r680"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r669",
      "r1037",
      "r1220",
      "r1223"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r676",
      "r677",
      "r678",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r812",
      "r1037",
      "r1041"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r513",
      "r518",
      "r666",
      "r679",
      "r747",
      "r1027",
      "r1028",
      "r1029",
      "r1037"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r666",
      "r667",
      "r668",
      "r669",
      "r679",
      "r749",
      "r1015",
      "r1016",
      "r1027",
      "r1028",
      "r1029",
      "r1037",
      "r1040"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r680"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r680"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Values",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r675",
      "r680"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r669",
      "r1037",
      "r1220",
      "r1223"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Derecognition of Liability",
        "terseLabel": "Derecognition of liability to equity",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Derecognition of Liability"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Exercise of Warrants",
        "terseLabel": "Exercise of warrants",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Exercise of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r680"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "terseLabel": "Change in fair value - OCI",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r680"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Fair value upon issuance",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r680"
     ]
    },
    "alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Payments",
        "negatedLabel": "Payments",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Payments"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Repayment of Debt",
        "terseLabel": "Repayments of debt",
        "documentation": "Fair Value Measurement With Unobservable Inputs Reconciliation, Recurring Basis Liability, Repayment of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r680"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r678",
      "r679",
      "r681",
      "r747",
      "r748",
      "r749",
      "r1015",
      "r1016",
      "r1027",
      "r1028",
      "r1029",
      "r1037",
      "r1040"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1223"
     ]
    },
    "alur_FairValueOfEstimatedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueOfEstimatedNumberOfShares",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Estimated Number of Shares",
        "terseLabel": "Fair value of estimated number of shares",
        "documentation": "Fair Value of Estimated Number of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueOfEstimatedPriceOfShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueOfEstimatedPriceOfShares",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Estimated Price of Shares",
        "terseLabel": "Fair value of estimated price of shares",
        "documentation": "Fair Value of Estimated Price of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueOfPipeConversionOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueOfPipeConversionOption",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Pipe Conversion Option",
        "terseLabel": "Fair value of pipe conversion option",
        "documentation": "Fair value of pipe conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueOfRevenueInterestFinancingAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueOfRevenueInterestFinancingAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Revenue Interest Financing Agreements",
        "terseLabel": "Fair value of revenue interest financing agreement",
        "documentation": "Fair value of revenue interest financing agreements."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FairValueOfTheWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FairValueOfTheWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the warrants",
        "documentation": "Fair value of the warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r680"
     ]
    },
    "alur_FinalPaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FinalPaymentFee",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final payment fee",
        "documentation": "Final payment fee"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FinalPaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FinalPaymentFeePercentage",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final payment fee percentage",
        "documentation": "Final payment fee percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Operating cash flows paid for amounts in the measurement of finance lease liabilities",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r721"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r386",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r470",
      "r488",
      "r651",
      "r686",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r835",
      "r1012",
      "r1037",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1050",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1216",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Unrealized exchange (gain) or loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r694",
      "r695",
      "r696",
      "r943"
     ]
    },
    "alur_FortressAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FortressAmendmentMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fortress Amendment [Member]",
        "terseLabel": "Fortress Amendment",
        "documentation": "Fortress Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "alur_FortressCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FortressCreditAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fortress Credit Agreement [Member]",
        "terseLabel": "Fortress Credit Agreement",
        "documentation": "Fortress credit agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FortressTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FortressTermLoanMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fortress Term Loan [Member]",
        "terseLabel": "Fortress Term Loan",
        "documentation": "Fortress term loan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FourCountriesIncludedWithinAllOtherCountriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FourCountriesIncludedWithinAllOtherCountriesMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Countries Included Within All Other Countries [Member]",
        "terseLabel": "Four Countries Included Within All Other Countries",
        "documentation": "Four countries included within all other countries."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FromApril12024ToJune302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FromApril12024ToJune302024Member",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From April 1, 2024 to June 30, 2024 [Member]",
        "terseLabel": "From April 1, 2024 to June 30, 2024",
        "documentation": "From April 1, 2024 to June 30, 2024."
       }
      }
     },
     "auth_ref": []
    },
    "alur_FromJuly12024ToSeptember302024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "FromJuly12024ToSeptember302024Member",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From July 1, 2024 to September 30, 2024 [Member]",
        "terseLabel": "From July 1, 2024 to September 30, 2024",
        "documentation": "From July 1, 2024 to September 30, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt/ term loan",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r57",
      "r58"
     ]
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnRestructuringOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (Losses) on Restructuring of Debt",
        "terseLabel": "Termination of convertible note side letters",
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "alur_GaurContributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "GaurContributionAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gaur Contribution Agreement [Member]",
        "terseLabel": "Gaur Contribution Agreement",
        "documentation": "Gaur Contribution Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r925"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r974"
     ]
    },
    "alur_GrossProceedsFromBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "GrossProceedsFromBusinessCombination",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails": {
       "parentTag": "alur_NetProceedsFromBusinessCombination",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds From Business Combination",
        "terseLabel": "Gross Proceeds",
        "documentation": "Gross proceeds from business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r123",
      "r182",
      "r253",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r692",
      "r999",
      "r1005",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1170"
     ]
    },
    "alur_HVLBridgeNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "HVLBridgeNoteMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H V L Bridge Note [Member]",
        "terseLabel": "HVL Bridge Note",
        "documentation": "HVL Bridge Note."
       }
      }
     },
     "auth_ref": []
    },
    "alur_HVLTerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "HVLTerminationAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H V L Termination Agreement [Member]",
        "terseLabel": "HVL Termination Agreement",
        "documentation": "H V L Termination Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_HunterVenturesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "HunterVenturesLimitedMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hunter Ventures Limited [Member]",
        "terseLabel": "Hunter Ventures Limited",
        "documentation": "Hunter Ventures Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "country_IT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IT",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r143"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S.",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r576"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r178",
      "r182",
      "r815",
      "r832",
      "r999",
      "r1005",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesDomesticAndForeignComponentsOfNetLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r576"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r416",
      "r420",
      "r671",
      "r675",
      "r680",
      "r848",
      "r850",
      "r930",
      "r987",
      "r1039",
      "r1253"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r420",
      "r671",
      "r675",
      "r680",
      "r848",
      "r850",
      "r930",
      "r987",
      "r1039",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r577",
      "r578",
      "r588",
      "r598",
      "r1036",
      "r1211"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r577",
      "r578",
      "r588",
      "r598",
      "r1036",
      "r1211"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r571",
      "r577",
      "r585",
      "r586",
      "r587",
      "r590",
      "r597",
      "r608",
      "r610",
      "r611",
      "r612",
      "r873",
      "r1036"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "verboseLabel": "Accrued interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r200",
      "r278",
      "r279",
      "r301",
      "r313",
      "r328",
      "r575",
      "r577",
      "r609",
      "r839",
      "r1036"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r573",
      "r574",
      "r590",
      "r591",
      "r596",
      "r600",
      "r867"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 33.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 41.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 38.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1117"
     ]
    },
    "alur_IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Percentage Of Number of Shares Reserved For Future Issuance",
        "terseLabel": "Increase (decrease) in percentage of number of shares reserved for future issuance",
        "documentation": "Increase decrease in percentage of number of shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current and long-term assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "alur_IncreaseDecreaseInRevenuesForCustomerReturns": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IncreaseDecreaseInRevenuesForCustomerReturns",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Revenues for Customer Returns",
        "terseLabel": "Reduction to revenues of customer returns",
        "documentation": "Increase (decrease) in revenues for customer returns."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IncreaseInSalesRevenueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IncreaseInSalesRevenueNet",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in Sales Revenue Net",
        "terseLabel": "Increase in Sales Revenue Net",
        "documentation": "Increase in sales revenue net."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IntellectualPropertyProsecutionCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IntellectualPropertyProsecutionCostsPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property Prosecution Costs [Policy Text Block]",
        "terseLabel": "Intellectual Property Prosecution Costs",
        "documentation": "Intellectual property prosecution costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r465",
      "r474",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r466",
      "r1017",
      "r1018"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r1114"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r246",
      "r247"
     ]
    },
    "alur_InterestPaidOnDebtRecordedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "InterestPaidOnDebtRecordedAtFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid On Debt Recorded At Fair Value",
        "negatedLabel": "Interest paid on debt recorded at fair value",
        "documentation": "Interest paid on debt recorded at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "terseLabel": "Accured interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r1246"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1286"
     ]
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalUseSoftwarePolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Internal-Use Software",
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_InventoryGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGrossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 26.0
      },
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Total Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r992",
      "r1049"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r212",
      "r227",
      "r398",
      "r399",
      "r401",
      "r777",
      "r996"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1108"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Valuation Reserves",
        "verboseLabel": "Provision for excess and obsolete inventory",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r1109"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/InventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in progress",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Provision for inventory",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock For Commitment Shares For Equity Line Financing Amount",
        "terseLabel": "Issuance of common stock for commitment shares for equity line financing",
        "documentation": "Issuance of common stock for commitment shares for equity line financing amount"
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock For Commitment Shares For Equity Line Financing Shares",
        "terseLabel": "Issuance of common stock for commitment shares for equity line financing (in shares)",
        "documentation": "Issuance of common stock for commitment shares for equity line financing shares"
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfCommonStockForExerciseOfWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfCommonStockForExerciseOfWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock For Exercise Of Warrants, Amount",
        "terseLabel": "Issuance of common stock for the exercise of Public Warrants",
        "documentation": "Issuance of common stock for exercise of warrants amount."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfCommonStockForExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfCommonStockForExerciseOfWarrantsShares",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock For Exercise Of Warrants Shares",
        "terseLabel": "Issuance of common stock for the exercise of Public Warrants (in shares)",
        "documentation": "Issuance of common stock for exercise of warrants shares."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfSharesCommonStockForConversionOfConvertibleNotes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfSharesCommonStockForConversionOfConvertibleNotes",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Shares Common Stock for Conversion of Convertible Notes",
        "verboseLabel": "Issuance of common stock for the conversion of convertible notes (in shares)",
        "documentation": "Issuance of shares common stock for conversion of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Shares Value Common Stock for Conversion of Convertible Notes",
        "verboseLabel": "Issuance of common stock for the conversion of convertible notes",
        "documentation": "Issuance of shares value common stock for conversion of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "alur_IssuanceOfWarrantsInConnectionWithFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "IssuanceOfWarrantsInConnectionWithFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Warrants in Connection with Financing",
        "terseLabel": "Issuance of warrants in connection with financing",
        "documentation": "Issuance of warrants in connection with financing."
       }
      }
     },
     "auth_ref": []
    },
    "alur_KkgEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "KkgEnterprisesMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "KKG Enterprises [Member]",
        "terseLabel": "KKG Enterprises",
        "documentation": "KKG Enterprises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year [Member]",
        "verboseLabel": "Latest Tax Year",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "alur_LatestTaxYearTwoThousandFortyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LatestTaxYearTwoThousandFortyTwoMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Tax Year Two Thousand Forty Two [Member]",
        "verboseLabel": "Latest Tax Year",
        "documentation": "Latest tax year two thousand forty two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r726"
     ]
    },
    "alur_LegacyAllurionCommonStockWarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionCommonStockWarrantLiabilitiesMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Common Stock Warrant Liabilities [Member]",
        "terseLabel": "Legacy Allurion Common Stock Warrant Liabilities",
        "documentation": "Legacy allurion common stock warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionEquityholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionEquityholdersMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Equityholders [Member]",
        "terseLabel": "Legacy Allurion Equityholders",
        "documentation": "Legacy allurion equityholders."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Member",
        "terseLabel": "Legacy Allurion",
        "documentation": "Legacy Allurion."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionOtherCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionOtherCommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Other Common Stock [Member]",
        "terseLabel": "Legacy Allurion Other Common Stock",
        "documentation": "Legacy Allurion Other Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series A 1 Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Legacy Allurion Series A-1 Preferred Stock Warrant Liability",
        "documentation": "Legacy allurion series A-1 preferred stock warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesA1PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesA1PreferredStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series A 1 Preferred Stock Warrants [Member]",
        "terseLabel": "Legacy Allurion Series A 1 Preferred Stock Warrants",
        "documentation": "Legacy allurion series A-1 preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series B Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Legacy Allurion Series B Preferred Stock Warrant Liability",
        "documentation": "Legacy allurion series B preferred stock warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesBPreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesBPreferredStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series B Preferred Stock Warrants [Member]",
        "terseLabel": "Legacy Allurion Series B Preferred Stock Warrants",
        "documentation": "Legacy Allurion series B preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesCCommonStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesCCommonStockWarrantLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series C Common Stock Warrant Liability [Member]",
        "terseLabel": "Legacy Allurion Series C Common Stock Warrant Liability",
        "documentation": "Legacy allurion series C common stock warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesCCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesCCommonStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series C Common Stock Warrants [Member]",
        "terseLabel": "Legacy Allurion Series C Common Stock Warrants",
        "documentation": "Legacy Allurion series C common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesCPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series C Preferred Stock [Member]",
        "terseLabel": "Legacy Allurion Series C Preferred Stock",
        "documentation": "Legacy Allurion Series C Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series C Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Legacy Allurion Series C Preferred Stock Warrant Liability",
        "documentation": "Legacy allurion series C preferred stock warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesCPreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesCPreferredStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series C Preferred Stock Warrants [Member]",
        "terseLabel": "Legacy Allurion Series C Preferred Stock Warrants",
        "documentation": "Legacy Allurion series C preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series D 1 Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Legacy Allurion Series D-1 Preferred Stock Warrant Liability",
        "documentation": "Legacy allurion series D-1 preferred stock warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_LegacyAllurionSeriesD1PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LegacyAllurionSeriesD1PreferredStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Allurion Series D-1 Preferred Stock Warrants [Member]",
        "terseLabel": "Legacy Allurion Series D-1 Preferred Stock Warrants",
        "documentation": "Legacy Allurion series D-1 preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, operating lease, right to extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "alur_LesseeOperatingLeaseExpirationPeriod": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LesseeOperatingLeaseExpirationPeriod",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Expiration Period",
        "terseLabel": "Lessee operating lease expiration period",
        "documentation": "Lessee operating lease expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments Under Non-cancelable Operating Lease Agreements",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "alur_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "2028",
        "documentation": "Lessee operating lease liability payments due after year four."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, right to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r1230"
     ]
    },
    "alur_LesseeOperatingLeaseTerminatedDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LesseeOperatingLeaseTerminatedDate",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Operating Lease Terminated Date",
        "terseLabel": "Lease terminated date",
        "documentation": "Lessee operating lease terminated date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r104",
      "r107",
      "r253",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r635",
      "r637",
      "r638",
      "r692",
      "r900",
      "r998",
      "r1079",
      "r1170",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders' deficit",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r177",
      "r827",
      "r1049",
      "r1122",
      "r1149",
      "r1224"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r211",
      "r253",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r635",
      "r637",
      "r638",
      "r692",
      "r1049",
      "r1170",
      "r1236",
      "r1237"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1217"
     ]
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Line of Credit",
        "terseLabel": "Loan",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r175",
      "r1247"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r1121",
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_LineOfCreditFacilityDateOfFirstRequiredPayment1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityDateOfFirstRequiredPayment1",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Date of First Required Payment",
        "terseLabel": "Equal monthly principal payments commencing date",
        "documentation": "Date the first payment under the line of credit must be paid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Maturity Date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101",
      "r1121",
      "r1168"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan borrowed",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r101"
     ]
    },
    "alur_LnmpJpbcInvestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LnmpJpbcInvestMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LNMP JPBC Invest [Member]",
        "terseLabel": "LNMP JPBC Invest",
        "documentation": "LNMP JPBC Invest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_LoanAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "LoanAccretion",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Accretion",
        "terseLabel": "Plus: Accretion",
        "documentation": "Loan Accretion."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.allurion.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Long-lived Assets by Geography",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of term loan",
        "negatedLabel": "Less: current portion of long-term debt, net of discounts",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "December 31, 2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r259",
      "r463"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtScheduleOfFutureMaturitiesOfTheTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "December 31, 2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r259",
      "r463"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and discounts",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r55",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r433",
      "r567",
      "r1013",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r433",
      "r567",
      "r1013",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency for probable losses",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r1085"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r336",
      "r1022",
      "r1060",
      "r1064",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and Advertising Expense",
        "terseLabel": "Advertising and marketing costs",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r520",
      "r567",
      "r669",
      "r776",
      "r847",
      "r849",
      "r863",
      "r892",
      "r893",
      "r954",
      "r957",
      "r961",
      "r962",
      "r964",
      "r985",
      "r986",
      "r1011",
      "r1019",
      "r1032",
      "r1040",
      "r1041",
      "r1045",
      "r1046",
      "r1061",
      "r1172",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Estimated Discount Rate",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise Price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Expected Dividend Yield",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Life (Years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Interest Rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Estimated Fair Value of Underlying Share Price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r669",
      "r1040"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r669",
      "r1040"
     ]
    },
    "alur_MezzanineEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "MezzanineEquityPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity",
        "documentation": "Mezzanine Equity."
       }
      }
     },
     "auth_ref": []
    },
    "alur_MinimumLiquidityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "MinimumLiquidityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum Liquidity Amount",
        "documentation": "Minimum liquidity amount."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r520",
      "r567",
      "r669",
      "r776",
      "r847",
      "r849",
      "r863",
      "r892",
      "r893",
      "r954",
      "r957",
      "r961",
      "r962",
      "r964",
      "r985",
      "r986",
      "r1011",
      "r1019",
      "r1032",
      "r1040",
      "r1041",
      "r1045",
      "r1061",
      "r1172",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r336",
      "r1022",
      "r1060",
      "r1064",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "alur_NatickAndHudsonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NatickAndHudsonMember",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Natick and Hudson [Member]",
        "terseLabel": "Natick and Hudson",
        "documentation": "Natick and hudson member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 42.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Cash outflows from operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 39.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedLabel": "Net losses",
        "definitionGuidance": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r179",
      "r209",
      "r231",
      "r234",
      "r239",
      "r253",
      "r265",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r278",
      "r279",
      "r288",
      "r371",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r620",
      "r631",
      "r663",
      "r692",
      "r833",
      "r922",
      "r944",
      "r945",
      "r1077",
      "r1170"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shareholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r269",
      "r270",
      "r272",
      "r273",
      "r283",
      "r284",
      "r290",
      "r295",
      "r631"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "alur_NetProceedsFromBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NetProceedsFromBusinessCombination",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds from Business Combination",
        "totalLabel": "Net proceeds from the Business Combination",
        "documentation": "Net proceeds from business combination."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NetProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NetProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds from offering",
        "documentation": "Net proceeds from issuance or sale of equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r272",
      "r281",
      "r300",
      "r337",
      "r338",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r408",
      "r409",
      "r417",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r687",
      "r688",
      "r707",
      "r708",
      "r709",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r779",
      "r780",
      "r781",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r272",
      "r281",
      "r300",
      "r337",
      "r338",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r408",
      "r409",
      "r417",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r687",
      "r688",
      "r707",
      "r708",
      "r709",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r779",
      "r780",
      "r781",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NewAllurionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NewAllurionMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Allurion [Member]",
        "terseLabel": "New Allurion",
        "documentation": "New Allurion."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Interest Expense",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Noncash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NonCashIssuanceOfCommonStockForCommitmentShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NonCashIssuanceOfCommonStockForCommitmentShares",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Issuance Of Common Stock For Commitment Shares",
        "terseLabel": "Non-cash issuance of common stock for commitment shares",
        "documentation": "Non-cash issuance of common stock for commitment shares."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 40.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense",
        "documentation": "Non-cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NonCashTerminationOfConvertibleNoteSideLetters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NonCashTerminationOfConvertibleNoteSideLetters",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Termination of Convertible Note Side Letters",
        "terseLabel": "Non-cash termination of convertible note side letters",
        "documentation": "Non-cash termination of convertible note side letters."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow information on non-cash investing and financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense):",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "alur_NotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NotePurchaseAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Purchase Agreement [Member]",
        "terseLabel": "Note Purchase Agreement",
        "documentation": "Note purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NumberOfConsecutiveTradingDay": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NumberOfConsecutiveTradingDay",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Consecutive Trading Day",
        "terseLabel": "Number of consecutive trading day",
        "documentation": "Number of consecutive trading day."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NumberOfCountriesGenerateRevenue": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NumberOfCountriesGenerateRevenue",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Countries Generate Revenue",
        "terseLabel": "Number of countries generate revenue",
        "documentation": "Number of countries generate revenue"
       }
      }
     },
     "auth_ref": []
    },
    "alur_NumberOfCountriesGenerateRevenueBySales": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NumberOfCountriesGenerateRevenueBySales",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Countries Generate Revenue By Sales",
        "terseLabel": "Number of countries generate revenue by sales",
        "documentation": "Number of countries generate revenue by sales"
       }
      }
     },
     "auth_ref": []
    },
    "alur_NumberOfCountriesInWhichEntityMarketsTheProgram": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NumberOfCountriesInWhichEntityMarketsTheProgram",
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Countries In Which Entity Markets the Program",
        "terseLabel": "Number of countries, currently markets the program",
        "documentation": "Number of countries in which entity markets the program."
       }
      }
     },
     "auth_ref": []
    },
    "alur_NumberOfSurrenderSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "NumberOfSurrenderSharesOfCommonStock",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Surrender Shares Of Common Stock",
        "terseLabel": "Number of surrender shares of common stock",
        "documentation": "Number Of Surrender Shares Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "alur_OnOctober12024AndThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OnOctober12024AndThereafterMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "On October 1, 2024 and Thereafter [Member]",
        "terseLabel": "On October 1, 2024 and thereafter",
        "documentation": "On October 1, 2024 and Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingAndFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingAndFinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Liability",
        "totalLabel": "Present value of total lease liabilities",
        "documentation": "Operating and finance lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails": {
       "parentTag": "alur_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Liability Current",
        "negatedLabel": "Less: current lease liability",
        "documentation": "Operating and finance lease liability current."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails": {
       "parentTag": "alur_OperatingAndFinanceLeaseLiability",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating And Finance Lease Liability Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "documentation": "Operating and finance lease liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses:",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "negatedLabel": "Losses from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r999",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137"
     ]
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due",
        "terseLabel": "Total lease payments",
        "documentation": "Operating lease and finance lease liability payments due."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2024",
        "documentation": "Operating lease and finance lease liability payments due next twelve months."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due Year Five",
        "terseLabel": "2028",
        "documentation": "Operating lease and finance lease liability payments due year five."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due Year Four",
        "terseLabel": "2027",
        "documentation": "Operating lease and finance lease liability payments due year four."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2026",
        "documentation": "Operating lease and finance lease liability payments due year three."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2025",
        "documentation": "Operating lease and finance lease liability payments due year two."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease And Finance Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: present value adjustment",
        "documentation": "Operating lease and finance lease liability undiscounted excess amount."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OperatingLeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseCommencementDate",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Commencement Date",
        "terseLabel": "Operating lease commencement date",
        "documentation": "Operating lease commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r1048"
     ]
    },
    "alur_OperatingLeaseEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseEndDate",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease End Date",
        "terseLabel": "Operating lease end date",
        "documentation": "Operating lease end date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities",
        "negatedLabel": "Less: current lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetailsAlternate1": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows paid for amounts in the measurement of lease liabilities",
        "terseLabel": "Operating lease, payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r721"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "alur_OperatingLeaseStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeaseStartDate",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Start Date",
        "terseLabel": "Operating lease start date",
        "documentation": "Operating lease start date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases, weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r1048"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases, weighted -average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1048"
     ]
    },
    "alur_OperatingLeasesAndFinanceLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OperatingLeasesAndFinanceLeasesAbstract",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfFutureCommitmentsUnderNonCancelableOperatingLeaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases and Finance Leases [Abstract]",
        "terseLabel": "Total",
        "documentation": "Operating leases and finance leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r164"
     ]
    },
    "alur_OriginalFinalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OriginalFinalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original final payment",
        "documentation": "Original final payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "alur_OtherCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OtherCommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Common Stock [Member]",
        "terseLabel": "Other Common Stock",
        "documentation": "Other common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OtherCommonStockWarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OtherCommonStockWarrantLiabilitiesMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Common Stock Warrant Liabilities [Member]",
        "terseLabel": "Other Common Stock Warrant Liabilities",
        "documentation": "Other common stock warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alur_OtherCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OtherCommonStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Common Stock Warrants [Member]",
        "terseLabel": "Other Common Stock Warrants",
        "documentation": "Other common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossAlternate1": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent",
        "terseLabel": "Change in fair value due to change in credit risk",
        "verboseLabel": "Change in fair value of revenue interest financing",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r636"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19",
      "r165",
      "r232",
      "r235",
      "r274"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Long-Term Assets",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income (expense), net",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "alur_OutstandingOptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "OutstandingOptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Options To Purchase Common Stock [Member]",
        "terseLabel": "Outstanding Options to Purchase Common Stock",
        "documentation": "Outstanding options to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PIPEConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PIPEConversionOptionMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P I P E Conversion Option [Member]",
        "terseLabel": "PIPE Conversion Option",
        "documentation": "PIPE Conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PaymentOfDeferredFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PaymentOfDeferredFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Deferred Financing Costs",
        "negatedLabel": "Payment of deferred financing costs",
        "documentation": "Payment of deferred financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Other Fees",
        "terseLabel": "Other fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Restructuring",
        "terseLabel": "Payments for restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1116"
     ]
    },
    "alur_PaymentsOfAdvisoryServicesRelatedToBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PaymentsOfAdvisoryServicesRelatedToBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Advisory Services Related to Business Combination",
        "terseLabel": "Payments of advisory services related to business combination",
        "documentation": "Payments of advisory services related to business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "terseLabel": "Debt prepayment penalty",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of debt issuance costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering cost",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 43.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "alur_PercentageOfAnnualNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfAnnualNetSales",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Annual Net Sales",
        "terseLabel": "Percentage of annual net sales",
        "documentation": "Percentage of annual net sales."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfCommonStockSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfCommonStockSharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Common Stock, Shares, Outstanding",
        "terseLabel": "Percentage of common stock, shares, outstanding",
        "documentation": "Percentage of common stock, shares, outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Conversion Discounted Price Is Calculated Of Cash Price",
        "terseLabel": "Percentage of conversion discounted price is calculated of cash price",
        "documentation": "Percentage of conversion discounted price is calculated of cash price."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfDilutedSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Diluted Shares Outstanding",
        "terseLabel": "Percentage of diluted shares outstanding",
        "documentation": "Percentage of diluted shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfEmployeesCompensationToPayrollDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfEmployeesCompensationToPayrollDeductions",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Employees Compensation To Payroll Deductions",
        "terseLabel": "Percentage of employees compensation to payroll deductions",
        "documentation": "Percentage of employees compensation to payroll deductions."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfIncreaseInNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfIncreaseInNetSales",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Increase in Net Sales",
        "terseLabel": "Percentage of Increase in Net Sales",
        "documentation": "Percentage of increase in net sales."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfInternalRateOfReturn": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfInternalRateOfReturn",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Internal Rate of Return",
        "terseLabel": "Percentage of Internal Rate of Return",
        "documentation": "Percentage of internal rate of return."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfNetSales",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Net Sales",
        "terseLabel": "Percentage of net sales",
        "documentation": "Percentage of net sales."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfOutstandingCapitalStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfOutstandingCapitalStock",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Outstanding Capital Stock",
        "terseLabel": "Percentage of outstanding capital stock",
        "documentation": "Percentage of outstanding capital stock"
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfOutstandingCommonStock",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of Outstanding Common Stock",
        "terseLabel": "Percentage of Outstanding Common Stock",
        "documentation": "Percentage of outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfPreferredStockRedeemableShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfPreferredStockRedeemableShares",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of outstanding shares of redeemable",
        "documentation": "Percentage of preferred stock redeemable shares."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfPriceLowerOfFairValueMarketValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfPriceLowerOfFairValueMarketValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Price Lower Of Fair Value Market Value",
        "terseLabel": "Percentage of price lower of fair value market value",
        "documentation": "Percentage of price lower of fair value market value."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PercentageOfSharesOfCommonStockHeld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PercentageOfSharesOfCommonStockHeld",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Shares Of Common Stock Held",
        "terseLabel": "Percentage of shares of common stock held",
        "documentation": "Percentage Of Shares Of Common Stock Held."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PipeConversionDerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PipeConversionDerivativeMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Conversion Derivative [Member]",
        "terseLabel": "PIPE Conversion Derivative",
        "documentation": "Pipe conversion derivative."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PipeConversionOptionRemeasuredValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PipeConversionOptionRemeasuredValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Conversion Option Remeasured Value",
        "terseLabel": "PIPE Conversion Option Remeasured Value",
        "documentation": "PIPE conversion option remeasured value."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PipeInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PipeInvestorsMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pipe Investors [Member]",
        "terseLabel": "Cash - PIPE Investors",
        "verboseLabel": "Shares Issued to PIPE Investors",
        "documentation": "Pipe investors."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PipeSubscriptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PipeSubscriptionAgreementsMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Subscription Agreements [Member]",
        "terseLabel": "PIPE Subscription Agreements",
        "documentation": "PIPE subscription agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "alur_PrePaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PrePaymentsPercentage",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Payments Percentage",
        "terseLabel": "Pre payments percentage",
        "documentation": "Pre payments percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConversionBasis",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Conversion Basis",
        "terseLabel": "Preferred stock conversion rights",
        "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r109"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Percentage of preferred stock dividend",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r955",
      "r958",
      "r960",
      "r965"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreference",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Preferred stock liquidation preference per share",
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r109",
      "r1120",
      "r1174"
     ]
    },
    "alur_PreferredStockLiquidationPreferenceBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PreferredStockLiquidationPreferenceBasis",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Liquidation Preference Basis",
        "terseLabel": "Preferred stock liquidation preference",
        "documentation": "Preferred stock liquidation preference basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r476"
     ]
    },
    "alur_PreferredStockRedemptionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PreferredStockRedemptionBasis",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Redemption Basis",
        "terseLabel": "Preferred stock redemption basis",
        "documentation": "Preferred stock redemption basis."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PreferredStockRedemptionValueToPrice": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PreferredStockRedemptionValueToPrice",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock redemption value to price",
        "documentation": "Preferred stock redemption value to price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r902"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r476"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r902",
      "r920",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value - 100,000,000 shares authorized as of June 30, 2024; and no shares issued and outstanding as of June 30, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r822",
      "r1049"
     ]
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Carrying Value",
        "documentation": "Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r902"
     ]
    },
    "us-gaap_PreferredStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockVotingRights",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Voting Rights",
        "terseLabel": "Preferred stock voting rights",
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r109"
     ]
    },
    "alur_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Warrants [Member]",
        "terseLabel": "Preferred Stock Warrants (as Converted to Common)",
        "documentation": "Preferred Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "alur_PrepaymentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PrepaymentFee",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment fee",
        "documentation": "Prepayment fee"
       }
      }
     },
     "auth_ref": []
    },
    "alur_PrepaymentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PrepaymentFeePercentage",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment fee percentage",
        "documentation": "Prepayment fee percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification of Prior Year Presentation",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Warrants",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrants [Member]",
        "terseLabel": "Private Placement Warrants",
        "documentation": "Private Placement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_PrivatePlacementWithRTWMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PrivatePlacementWithRTWMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement with R T W [Member]",
        "terseLabel": "Private Placement with RTW",
        "documentation": "Private Placement with RTW."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ProceedsFromBusinessCombinationNetOfTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ProceedsFromBusinessCombinationNetOfTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Business Combination, net of transaction costs",
        "terseLabel": "Proceeds from Business Combination, net of transaction costs",
        "documentation": "Proceeds from business combination, net of transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "alur_ProceedsFromEquityLineFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ProceedsFromEquityLineFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Equity Line Financing",
        "terseLabel": "Proceeds from equity line financing",
        "documentation": "Proceeds from equity line financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from Public Offering, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from Private Placement, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "verboseLabel": "Gross proceeds from offering",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r868"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Initial cash proceeds",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r1121"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Proceeds from Fortress Term Loan\u2014net",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "alur_ProceedsFromOptionAndWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ProceedsFromOptionAndWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Option and Warrant Exercises",
        "terseLabel": "Proceeds from option and warrant exercises",
        "documentation": "Proceeds from option and warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ProceedsFromRevenueInterestFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ProceedsFromRevenueInterestFinancing",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Revenue Interest Financing",
        "terseLabel": "Proceeds from revenue interest financing",
        "documentation": "The cash inflow from revenue interest financing."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r778",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r989",
      "r1020",
      "r1059",
      "r1061",
      "r1062",
      "r1065",
      "r1067",
      "r1163",
      "r1164",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r778",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r989",
      "r1020",
      "r1059",
      "r1061",
      "r1062",
      "r1065",
      "r1067",
      "r1163",
      "r1164",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r193",
      "r196",
      "r197"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r214",
      "r831"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 23.0
      },
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetailsAlternate1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r726",
      "r816",
      "r831",
      "r1049"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r193",
      "r196",
      "r829"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r726"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfActivityInAllowanceForDoubtfulAccountsDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for uncollectible accounts",
        "negatedLabel": "Provision for uncollectible accounts",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r389"
     ]
    },
    "alur_PubcoAdditionalSharesLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PubcoAdditionalSharesLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PubCo Additional Shares Liability [Member]",
        "terseLabel": "PubCo Additional Shares Liability",
        "documentation": "PubCo additional shares liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PubcoShareLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PubcoShareLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PubCo Share Liability [Member]",
        "terseLabel": "PubCo Share Liability",
        "documentation": "PubCo Share Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering",
        "documentation": "Public offering."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicOfferingWarrantsAndShareOverallotmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicOfferingWarrantsAndShareOverallotmentMember",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Warrants and Share Overallotment [Member]",
        "terseLabel": "Public Offering Warrants and Share Overallotment",
        "documentation": "Public offering warrants and share overallotment member."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicOfferingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicOfferingWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering Warrants [Member]",
        "terseLabel": "Public Offering Warrants",
        "documentation": "Public Offering Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicWarrantMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrant [Member]",
        "verboseLabel": "Public Warrant",
        "documentation": "Public warrant."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants",
        "documentation": "Public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_PublicWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "PublicWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Public Warrants to Purchase Common Stock",
        "documentation": "Public warrants to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RSUForfeitureAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RSUForfeitureAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R S U Forfeiture Agreement [Member]",
        "terseLabel": "RSU Forfeiture Agreement",
        "documentation": "R S U Forfeiture Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RTWParticipationInPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RTWParticipationInPublicOfferingMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R T W Participation in Public Offering [Member]",
        "terseLabel": "RTW Participation in Public Offering",
        "documentation": "RTW participation in public offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r512",
      "r520",
      "r552",
      "r553",
      "r554",
      "r567",
      "r669",
      "r750",
      "r759",
      "r776",
      "r847",
      "r849",
      "r863",
      "r892",
      "r893",
      "r954",
      "r957",
      "r961",
      "r962",
      "r964",
      "r985",
      "r986",
      "r1011",
      "r1019",
      "r1032",
      "r1040",
      "r1041",
      "r1045",
      "r1046",
      "r1061",
      "r1071",
      "r1158",
      "r1172",
      "r1220",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/InventoryAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430",
      "r431",
      "r432",
      "r512",
      "r520",
      "r552",
      "r553",
      "r554",
      "r567",
      "r669",
      "r750",
      "r759",
      "r776",
      "r847",
      "r849",
      "r863",
      "r892",
      "r893",
      "r954",
      "r957",
      "r961",
      "r962",
      "r964",
      "r985",
      "r986",
      "r1011",
      "r1019",
      "r1032",
      "r1040",
      "r1041",
      "r1045",
      "r1046",
      "r1061",
      "r1071",
      "r1158",
      "r1172",
      "r1220",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243"
     ]
    },
    "alur_RecapitalizationOfAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RecapitalizationOfAdditionalShares",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recapitalization of Additional Shares",
        "terseLabel": "Recapitalization of additional shares",
        "documentation": "Recapitalization of additional shares."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RecapitalizationOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RecapitalizationOfCommonStock",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recapitalization of Common Stock",
        "terseLabel": "Recapitalization of common stock",
        "documentation": "Recapitalization of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RecognitionOfAssumedWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RecognitionOfAssumedWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition Of Assumed Warrant Liability",
        "terseLabel": "Recognition of assumed warrant liability",
        "documentation": "Recognition of assumed warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RecognitionOfEarnOutLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RecognitionOfEarnOutLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of Earn-Out Liabilities",
        "terseLabel": "Recognition of earn-out liabilities",
        "documentation": "Recognition of earn-out liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Cash and Cash Equivalents and Restricted Cash [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents and Restricted Cash",
        "documentation": "Reconciliation of cash and cash equivalents and restricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock and Stockholders Deficit [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Deficit",
        "documentation": "Redeemable convertible preferred stock and stockholders deficit text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemablePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemablePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Preferred Stock [Member]",
        "terseLabel": "Redeemable Preferred Stock",
        "documentation": "Description of type or class of redeemable preferred stock. For instance, cumulative preferred stock, noncumulative preferred stock, convertible or series."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r59",
      "r253",
      "r371",
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r692"
     ]
    },
    "alur_ReductionInProceedsFromOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ReductionInProceedsFromOffering",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in Proceeds From Offering",
        "terseLabel": "Reduction in proceeds from offering",
        "documentation": "Reduction in proceeds from offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r519",
      "r737",
      "r738",
      "r820",
      "r828",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r919",
      "r921",
      "r953"
     ]
    },
    "alur_RelatedPartyTransactionConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RelatedPartyTransactionConsultingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Consulting Fees",
        "terseLabel": "Consulting fees",
        "documentation": "Related party transaction consulting fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r926",
      "r927",
      "r930"
     ]
    },
    "alur_RelatedPartyTransactionTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RelatedPartyTransactionTerminationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Termination Fees",
        "terseLabel": "Termination fees",
        "documentation": "Related party transaction termination fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r519",
      "r737",
      "r738",
      "r820",
      "r828",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r919",
      "r921",
      "r953",
      "r1235"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r738",
      "r740",
      "r874",
      "r875",
      "r876",
      "r928",
      "r929",
      "r930",
      "r950",
      "r952"
     ]
    },
    "alur_RemittanceOfRevenueInterestPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RemittanceOfRevenueInterestPaymentsPercentage",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remittance of Revenue Interest Payments Percentage",
        "terseLabel": "Remittance of revenue interest payments percentage",
        "documentation": "Remittance of revenue interest payments percentage."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RemusGroupManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RemusGroupManagementMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remus Group Management [Member]",
        "terseLabel": "Remus Group Management",
        "documentation": "Remus Group Management."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RepaymentOfNoteAssumedInBusinessCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RepaymentOfNoteAssumedInBusinessCombination",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Note Assumed in Business Combination",
        "terseLabel": "Less: repayment of note assumed in the Business Combination",
        "documentation": "Repayment of note assumed in business combination."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RepaymentOfPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RepaymentOfPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of principal",
        "documentation": "Repayment of principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of convertible notes",
        "terseLabel": "Repayment of convertible debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of Term Loan",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Total payoff amount",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r1121"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of promissory note assumed in Business Combination",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r449",
      "r478",
      "r739",
      "r760",
      "r817",
      "r994",
      "r995"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r987",
      "r1005",
      "r1244"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r300",
      "r379",
      "r380",
      "r617",
      "r618",
      "r620",
      "r621",
      "r630",
      "r631",
      "r657",
      "r661",
      "r662",
      "r663",
      "r707",
      "r709",
      "r732",
      "r733",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r1138"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r300",
      "r379",
      "r380",
      "r617",
      "r618",
      "r620",
      "r621",
      "r630",
      "r631",
      "r657",
      "r661",
      "r662",
      "r663",
      "r707",
      "r709",
      "r732",
      "r733",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r1138"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash included in other long-term assets",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1119",
      "r1245",
      "r1248"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsReconciliationOfCashAndCashEquivalentsAndRestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash and cash equivalents restricted to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of employees reduced from workforce",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of employees reduced from workforce",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r422",
      "r423",
      "r1159"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_RestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Costs",
        "terseLabel": "One-time aggregate restructuring charges",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RestructuringPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RestructuringPlanMember",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Plan [Member]",
        "terseLabel": "Restructuring Plan",
        "documentation": "Restructuring Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r153",
      "r826",
      "r857",
      "r862",
      "r872",
      "r903",
      "r1049"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r260",
      "r261",
      "r262",
      "r266",
      "r274",
      "r277",
      "r279",
      "r377",
      "r384",
      "r409",
      "r602",
      "r603",
      "r616",
      "r617",
      "r618",
      "r621",
      "r630",
      "r631",
      "r643",
      "r646",
      "r647",
      "r650",
      "r661",
      "r708",
      "r710",
      "r853",
      "r855",
      "r877",
      "r1284"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r301",
      "r310",
      "r311",
      "r324",
      "r328",
      "r332",
      "r334",
      "r336",
      "r509",
      "r510",
      "r778"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r301",
      "r310",
      "r311",
      "r324",
      "r328",
      "r332",
      "r334",
      "r336",
      "r509",
      "r510",
      "r778"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r1087"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r988"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.allurion.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r511"
     ]
    },
    "alur_RevenueInterestFinancingAgreementAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingAgreementAmendmentMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Agreement Amendment [Member]",
        "terseLabel": "RIFA Amendment",
        "documentation": "Revenue interest financing agreement amendment."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Revenue Interest Financing Agreement",
        "verboseLabel": "Revenue Interest Financing Agreement",
        "documentation": "Revenue interest financing agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingAgreementRemeasuredValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingAgreementRemeasuredValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Agreement Remeasured Value",
        "terseLabel": "Revenue Interest Financing Agreement Remeasured Value",
        "documentation": "Revenue Interest financing agreement remeasured value."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingAndPipeConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingAndPipeConversionOptionMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing And Pipe Conversion Option [Member]",
        "terseLabel": "Revenue Interest Financing and PIPE Conversion Option",
        "documentation": "Revenue Interest Financing And Pipe Conversion Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing and PIPE Conversion Option [Policy Text Block]",
        "terseLabel": "Revenue Interest Financing and PIPE Conversion Option",
        "documentation": "Disclosure of accounting policy for revenue interest financing and pipe conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingDueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingDueMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Due [Member]",
        "terseLabel": "Revenue Interest Financing",
        "documentation": "Revenue interest financing due."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Liability Noncurrent",
        "verboseLabel": "Revenue Interest Financing liability",
        "terseLabel": "Long-term Revenue Interest Financing liability",
        "documentation": "Revenue interest financing liability noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingLiabilityPrincipalAmountOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing Liability Principal Amount Of Debt",
        "totalLabel": "Total principal amounts of debt",
        "documentation": "Revenue interest financing liability principal amount of debt."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing [Member]",
        "terseLabel": "Revenue Interest Financing",
        "documentation": "Revenue interest financing."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOption"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Financing, Side Letter, And P I P E Conversion Option [Text Block]",
        "terseLabel": "Revenue Interest Financing, Side Letter, and PIPE Conversion Option",
        "documentation": "Revenue interest financing, side letter, and PIPE conversion option."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueInterestPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueInterestPaymentsPercentage",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Interest Payments Percentage",
        "terseLabel": "Revenue interest payments percentage",
        "documentation": "Revenue interest payments percentage."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenueRecognitionMilestoneMethodOfRecognizedRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenueRecognitionMilestoneMethodOfRecognizedRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition Milestone Method Of Recognized Revenue",
        "terseLabel": "Revenue milestone",
        "documentation": "Revenue recognition milestone method of recognized revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RevenuesInterestFinancingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RevenuesInterestFinancingLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails": {
       "parentTag": "alur_RevenueInterestFinancingLiabilityPrincipalAmountOfDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues Interest Financing Liability",
        "terseLabel": "Revenues interest financing liability",
        "documentation": "Revenues interest financing liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesNetOfInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesNetOfInterestExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues, Net of Interest Expense",
        "terseLabel": "Additional revenue interest",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r301",
      "r310",
      "r311",
      "r324",
      "r328",
      "r332",
      "r334",
      "r336"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for lease obligations",
        "verboseLabel": "Operating lease assets obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r1048"
     ]
    },
    "alur_RoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Payments",
        "terseLabel": "Royalty payments",
        "negatedLabel": "Less: Royalty payments",
        "documentation": "Royalty payments."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RtwAndFortressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RtwAndFortressMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RTW and Fortress [Member]",
        "verboseLabel": "Shares issued to RTW and Fortress",
        "documentation": "RTW and Fortress."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RtwConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RtwConvertibleNotesMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RTW Convertible Notes [Member]",
        "terseLabel": "RTW Convertible Notes",
        "documentation": "RTW convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "alur_RunwayGrowthCreditFundIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "RunwayGrowthCreditFundIncMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Runway Growth Credit Fund, Inc [Member]",
        "terseLabel": "Runway",
        "documentation": "Runway Growth Credit Fund, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Amount received on shares sold per unit",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold per unit",
        "verboseLabel": "Sale of stock",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SalesRevenueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SalesRevenueNet",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Revenue Net",
        "terseLabel": "Sales Revenue Net",
        "documentation": "Sales revenue net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRiskOfConcentrationOfCreditSignificantCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Total Revenue",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r1087"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1129"
     ]
    },
    "alur_ScenarioPlanFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScenarioPlanFourMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Plan Four [Member]",
        "verboseLabel": "Scenario Plan Four",
        "documentation": "Scenario plan four."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ScenarioPlanOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScenarioPlanOneMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Plan One [Member]",
        "terseLabel": "December 31, 2027",
        "documentation": "Scenario plan one."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ScenarioPlanThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScenarioPlanThreeMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Plan Three [Member]",
        "verboseLabel": "Scenario Plan Three",
        "documentation": "Scenario plan three."
       }
      }
     },
     "auth_ref": []
    },
    "alur_ScenarioPlanTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScenarioPlanTwoMember",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Plan Two [Member]",
        "terseLabel": "December 31, 2030",
        "documentation": "Scenario plan two."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r260",
      "r262",
      "r265",
      "r266",
      "r269",
      "r270",
      "r279",
      "r300",
      "r617",
      "r620",
      "r621",
      "r630",
      "r631",
      "r657",
      "r661",
      "r662",
      "r707",
      "r709",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r865",
      "r1089",
      "r1091",
      "r1092",
      "r1093",
      "r1128",
      "r1138",
      "r1150",
      "r1151",
      "r1215",
      "r1232",
      "r1233"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r521",
      "r1085",
      "r1129"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Dilutive Securities Excluded from Computation of Basic and Diluted Net Loss Per Common Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r622"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Reconciles of Business Combination to Condensed Consolidated Statement",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77"
     ]
    },
    "alur_ScheduleOfBusinessCombinationSharesCommonStockOutstanding": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScheduleOfBusinessCombinationSharesCommonStockOutstanding",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Combination Shares Common Stock Outstanding",
        "terseLabel": "Number of Shares of Allurion Common Stock Outstanding",
        "documentation": "Schedule of Business Combination Shares Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "alur_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Summary of Reserved for Issuance Upon the Potential Conversion or Exercise",
        "documentation": "Schedule of common stock reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Summary of Components of Third-Party Debt",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1209"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.allurion.com/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r66",
      "r67",
      "r68",
      "r69"
     ]
    },
    "alur_ScheduleOfDepreciationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScheduleOfDepreciationExpenseTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "terseLabel": "Schedule of Depreciation Expense",
        "documentation": "Schedule of Depreciation Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Basic and Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r286",
      "r287",
      "r291"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Effective Tax Rate and Statutory Federal Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r1036",
      "r1205"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Domestic and Foreign Components of Net Loss Before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r116",
      "r117",
      "r118"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Maturities of the Term Loan Facility",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "alur_ScheduleOfOtherPertinentLeaseInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScheduleOfOtherPertinentLeaseInformationTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Pertinent Lease Information [Table Text Block]",
        "terseLabel": "Schedule of Other Pertinent Lease Information",
        "documentation": "Schedule of other pertinent lease information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r726"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r926",
      "r927",
      "r930"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r419",
      "r420",
      "r421",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r121"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r525",
      "r527",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity Under the Plan",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r158"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsTables",
      "http://www.allurion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Estimated Fair Value was Measured Using a Monte Carlo Simulation Method",
        "terseLabel": "Schedule of Assumptions Used in Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity Under the Plan",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r148",
      "r150",
      "r152",
      "r153",
      "r222",
      "r223",
      "r224",
      "r303",
      "r476",
      "r477",
      "r478",
      "r480",
      "r483",
      "r488",
      "r490",
      "r868",
      "r869",
      "r870",
      "r871",
      "r1019",
      "r1084",
      "r1120"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock and Common Stock",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r59",
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r109",
      "r110",
      "r150",
      "r152",
      "r153"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitTables",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants to Purchase the Classes of Preferred Stock and Common Stock Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "alur_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Remaining Lease Terms and Discount Rates Related Leases",
        "documentation": "Schedule of weighted-average remaining lease terms and discount rates related leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of Risk of Concentration of Credit, Significant Customers",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r47",
      "r48",
      "r87",
      "r169"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r889",
      "r890",
      "r891",
      "r956",
      "r959",
      "r963",
      "r966",
      "r973",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r990",
      "r1021",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1063",
      "r1071",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Geographic Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r301",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r314",
      "r315",
      "r316",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r336",
      "r1000",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1009",
      "r1010"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r331",
      "r334",
      "r1001",
      "r1002",
      "r1008"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseMember",
     "presentation": [
      "http://www.allurion.com/role/PropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and Marketing",
        "documentation": "Primary financial statement caption encompassing selling and marketing expense."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1 Convertible Preferred Stock",
        "documentation": "Series A-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SeriesAOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesAOnePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock",
        "documentation": "Series A One Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1175"
     ]
    },
    "alur_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1175"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1175"
     ]
    },
    "alur_SeriesD1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesD1PreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D-1 preferred stock [Member]",
        "terseLabel": "Series D-1 Preferred Stock",
        "documentation": "Series D-1 preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SeriesDOnePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesDOnePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D One Preferred Stock [Member]",
        "terseLabel": "Series D-1 Preferred Stock",
        "documentation": "Series D One Preferred Stock Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1103",
      "r1104",
      "r1175"
     ]
    },
    "alur_SeriesDThreePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesDThreePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Three Preferred Stock [Member]",
        "terseLabel": "Series D-3 Preferred Stock",
        "documentation": "Series D Three Preferred Stock Member."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SeriesDTwoPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SeriesDTwoPreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Two Preferred Stock [Member]",
        "terseLabel": "Series D-2 Preferred Stock",
        "documentation": "Series D Two Preferred Stock Member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Remaining Vesting Rights, Percentage",
        "terseLabel": "Remaining vesting percentage",
        "documentation": "Share-based compensation arrangement by share-based payment award, award remaining vesting rights, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares forfeited",
        "negatedLabel": "Number of RSUs, Cancellations and forfeitures",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancellations and forfeitures",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of RSUs, Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant-date fair value of time-vested restricted stock units granted",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of RSUs, Beginning balance",
        "periodEndLabel": "Number of RSUs, Ending balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of RSUs, Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r525",
      "r527",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "alur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options and RSU's Issued and Exercisable Under the Plan",
        "terseLabel": "Options and RSUs issued and exercisable under the plan",
        "documentation": "Share-based compensation arrangement by share-based payment award, options and rsu's issued and exercisable under the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Cancellations and forfeitures",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of the stock option awards granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Number of Options, Beginning balance",
        "periodEndLabel": "Number of Options, Ending balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price, Beginning balance",
        "periodEndLabel": "Weighted-Average Exercise Price, Ending balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Cancellations and forfeitures",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r530",
      "r549",
      "r550",
      "r551",
      "r552",
      "r555",
      "r561",
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfEstimatedFairValueWasMeasuredUsingAMonteCarloSimulationMethodDetails",
      "http://www.allurion.com/role/StockBasedCompensationScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Original issue price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of Common Stock Issued Upon the Exercise of Public Warrants [Member]",
        "terseLabel": "Shares of Common Stock Issued Upon the Exercise of Public Warrants",
        "documentation": "Shares of common stock issued upon the exercise of public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Logistics",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r1048"
     ]
    },
    "alur_SideLetterHolderBridgeNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SideLetterHolderBridgeNoteMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Side Letter Holder Bridge Note [Member]",
        "terseLabel": "Side Letter Holder Bridge Note",
        "documentation": "Side letter holder bridge note."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SideLetterTerminationSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SideLetterTerminationSharesMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Side Letter Termination Shares [Member]",
        "terseLabel": "Side Letter Termination Shares",
        "documentation": "Side letter termination shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r250"
     ]
    },
    "alur_SponsorContributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SponsorContributionAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Contribution Agreement [Member]",
        "terseLabel": "Sponsor Contribution Agreement",
        "documentation": "Sponsor Contribution Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SponsorLoanExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SponsorLoanExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Loan Excess Amount",
        "terseLabel": "Sponsor loan excess amount",
        "documentation": "Sponsor loan excess amount."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SponsorSupportAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SponsorSupportAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Support Agreement [Member]",
        "terseLabel": "Sponsor Support Agreement",
        "documentation": "Sponsor Support Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StandardProductWarrantyAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StandardProductWarrantyAccrualCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard Product Warranty Accrual, Current",
        "terseLabel": "Accrued warranty",
        "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StandardProductWarrantyPolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Product Warranty",
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability."
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitScheduleOfPreferredStockDetailsPriorToBusinessCombinationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/CoverPage",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r222",
      "r223",
      "r224",
      "r253",
      "r286",
      "r287",
      "r291",
      "r295",
      "r303",
      "r304",
      "r371",
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r476",
      "r477",
      "r480",
      "r483",
      "r490",
      "r692",
      "r868",
      "r869",
      "r870",
      "r871",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r902",
      "r923",
      "r946",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1084",
      "r1120",
      "r1131"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r113",
      "r114",
      "r205",
      "r237",
      "r238",
      "r239",
      "r260",
      "r261",
      "r262",
      "r266",
      "r274",
      "r277",
      "r279",
      "r302",
      "r377",
      "r384",
      "r409",
      "r492",
      "r602",
      "r603",
      "r616",
      "r617",
      "r618",
      "r621",
      "r630",
      "r631",
      "r643",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r661",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r708",
      "r710",
      "r733",
      "r834",
      "r853",
      "r854",
      "r855",
      "r877",
      "r946"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r889",
      "r890",
      "r891",
      "r956",
      "r959",
      "r963",
      "r966",
      "r973",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r990",
      "r1021",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1063",
      "r1071",
      "r1176",
      "r1250",
      "r1254",
      "r1255",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r302",
      "r710",
      "r778",
      "r866",
      "r888",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r902",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r921",
      "r924",
      "r925",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r946",
      "r1072"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r521",
      "r1085",
      "r1086",
      "r1129"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r302",
      "r339",
      "r710",
      "r778",
      "r866",
      "r888",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r902",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r921",
      "r924",
      "r925",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r946",
      "r1072"
     ]
    },
    "alur_StockExchangeListingRequirementsDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockExchangeListingRequirementsDescription",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Exchange Listing Requirements Description",
        "terseLabel": "Stock exchange listing requirements description",
        "documentation": "Stock exchange listing requirements description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)",
        "verboseLabel": "Outstanding public warrants to purchase",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r62",
      "r110",
      "r113",
      "r153",
      "r462"
     ]
    },
    "alur_StockIssuedDuringPeriodSharesDerecognitionOfLiability": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesDerecognitionOfLiability",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Derecognition of Liability",
        "verboseLabel": "Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)",
        "documentation": "Stock issued during period shares derecognition of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock isssued during the period (in shares)",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r109",
      "r110",
      "r153",
      "r868",
      "r946",
      "r968"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "verboseLabel": "Reverse recapitalization, net of transaction costs (in shares)",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock in connection with vesting of RSU awards (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r153"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon exercise of stock options",
        "terseLabel": "Exercise of stock options, (in shares)",
        "negatedLabel": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r109",
      "r110",
      "r153",
      "r536"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r113",
      "r114",
      "r153"
     ]
    },
    "alur_StockIssuedDuringPeriodValueDerecognitionOfLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockIssuedDuringPeriodValueDerecognitionOfLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Derecognition of Liability",
        "verboseLabel": "Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares",
        "documentation": "Stock issued during period value derecognition of liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock issued during period value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r109",
      "r110",
      "r153",
      "r877",
      "r946",
      "r968",
      "r1078"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Other",
        "verboseLabel": "Reverse recapitalization, net of transaction costs",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r113",
      "r114",
      "r153"
     ]
    },
    "alur_StockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option and Incentive Plan [Member]",
        "terseLabel": "2023 Plan",
        "documentation": "Stock option and incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_StockOptionPlan2020And2023StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockOptionPlan2020And2023StockOptionPlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfRestrictedStockUnitActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2020 and 2023 Stock Option Plan [Member]",
        "terseLabel": "2020 Plan and 2023 Plan",
        "documentation": "Stock option plan 2020 and 2023 stock option plan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_StockOptionPlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockOptionPlan2020Member",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Plan 2020 Member",
        "terseLabel": "2020 Plan",
        "documentation": "Stock Option Plan 2020 Member"
       }
      }
     },
     "auth_ref": []
    },
    "alur_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2010 Stock Option Plan, 2020 Stock Option Plan And 2023 Stock Option Plan [Member]",
        "terseLabel": "2010 Plan, 2020 Plan, and 2023 Plan",
        "documentation": "2010 Stock Option Plan, 2020 Stock Option Plan And 2023 Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_StockOptionPlan2020StockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StockOptionPlan2020StockOptionPlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2010 Stock Option Plan, 2020 Stock Option Plan [Member]",
        "terseLabel": "2010 Plan and 2020 Plan",
        "documentation": "2010 stock option plan, 2020 atock option plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' deficit",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Stockholders equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r113",
      "r114",
      "r139",
      "r904",
      "r920",
      "r947",
      "r948",
      "r1049",
      "r1079",
      "r1122",
      "r1149",
      "r1224",
      "r1284"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Capital Stock and Stockholders' Deficit",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r252",
      "r475",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r492",
      "r652",
      "r949",
      "r951",
      "r972"
     ]
    },
    "alur_StructuringFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "StructuringFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Structuring Fee Payable",
        "terseLabel": "Structuring fee payable",
        "documentation": "Structuring fee payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r743"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_SuccessFeeDerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SuccessFeeDerivativeLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Success Fee Derivative Liability [Member]",
        "terseLabel": "Success Fee Derivative Liability",
        "documentation": "Success Fee Derivative Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "alur_SurrenderCommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "SurrenderCommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Surrender Common Stock Value",
        "terseLabel": "Surrender common stock value",
        "documentation": "Surrender common stock value."
       }
      }
     },
     "auth_ref": []
    },
    "currency_TRY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "TRY",
     "presentation": [
      "http://www.allurion.com/role/RevenueScheduleOfRevenuesByGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Turkey, New Lira",
        "terseLabel": "Turkey"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "lang": {
      "en-us": {
       "role": {
        "label": "Table Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_TaxCreditCarryForwardsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TaxCreditCarryForwardsResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carry Forwards Research And Development",
        "verboseLabel": "Tax credit carry forwards research and development",
        "documentation": "Tax credit carry forwards research and development."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carry Forwards Research And Development Expiration Year.",
        "verboseLabel": "Tax credits research and development expiration year",
        "documentation": "Tax credit carry forwards research and development expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1208"
     ]
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Redeemable Convertible Preferred Stock (Note 12):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "verboseLabel": "Series A redeemable convertible preferred stock, $0.0001 par value - 100,000,000 shares authorized as of September 30, 2024; and 2,260,159 and zero shares issued and outstanding as of September 30, 2024 and December 31, 2023",
        "terseLabel": "Ending Balance, temporary stocks",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r438",
      "r439",
      "r440",
      "r443",
      "r444",
      "r565",
      "r824"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Series A redeemable convertible preferred stock, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r59"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Series A redeemable convertible preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Series A redeemable convertible preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "verboseLabel": "Series A redeemable convertible preferred stock, shares outstanding",
        "periodEndLabel": "Temporary Equity, Balance (in Shares)",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "alur_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)",
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of preferred stock in connection with Private Placement, net of issuance costs",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TermCLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TermCLoanMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan",
        "documentation": "Term C Loan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TermDLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TermDLoanMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term D Loan [Member]",
        "terseLabel": "Term D Loan",
        "documentation": "Term D Loan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TermLoanAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TermLoanAccretion",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Accretion",
        "terseLabel": "Accretion",
        "documentation": "Term Loan Accretion"
       }
      }
     },
     "auth_ref": []
    },
    "alur_TermLoanDerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TermLoanDerivativeLiabilityMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForAssetsAndLiabilitiesMeasuredAtFairValueAtIssuanceDateAndOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Derivative Liability [Member]",
        "terseLabel": "Term Loan Derivative Liability",
        "documentation": "Term Loan Derivative Liability."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TermLoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TermLoanFacilityMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Facility [Member]",
        "terseLabel": "Term Loan Facility",
        "documentation": "Term loan facility."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TerminationAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Agreement [Member]",
        "terseLabel": "Termination Agreement",
        "documentation": "Termination agreement [member]"
       }
      }
     },
     "auth_ref": []
    },
    "alur_TimeVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Time-Vested Restricted Stock Units [Member]",
        "terseLabel": "Time-Vested Restricted Stock Units",
        "documentation": "Time-vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1139",
      "r1234"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r1141",
      "r1142",
      "r1144"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r470",
      "r488",
      "r651",
      "r686",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r835",
      "r1037",
      "r1038",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1050",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1216",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223"
     ]
    },
    "us-gaap_TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation Adjustment Functional to Reporting Currency, Gain (Loss), Reclassified to Earnings, Net of Tax",
        "terseLabel": "Gains (losses) from foreign currency translation adjustment",
        "documentation": "Amount of reclassification from other comprehensive income (loss) to earnings, after tax, related to translation from the functional currency to reporting currency, as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r120",
      "r1225"
     ]
    },
    "alur_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationSummaryOfStockOptionActivityUnderThePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two thousand and Ten Stock Option Plan, Two Thousand and Twenty Stock Option Plan, Two Thousand and Twenty Three Stock Option and Incentive Plan [Member]",
        "terseLabel": "2010 Plan, 2020 Plan, 2023 Plan",
        "documentation": "Two thousand and ten stock option plan, two thousand and twenty stock option plan, two thousand and twenty three stock option and incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Twenty Three Employee Stock Purchase Plan [Member]",
        "terseLabel": "2023 ESPP",
        "documentation": "Two thousand and twenty three employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandNineteenTermLoanAndSuccessFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandNineteenTermLoanAndSuccessFeeMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Nineteen Term Loan and Success Fee [Member]",
        "terseLabel": "2019 Term Loan and Success Fee",
        "documentation": "Two thousand nineteen term loan and success fee."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandTwentyOneConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandTwentyOneConvertibleNotesMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Convertible Notes [Member]",
        "terseLabel": "2021 Convertible Notes",
        "documentation": "2021 Convertible Notes."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandTwentyOneTermLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandTwentyOneTermLoanAgreementMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Term Loan Agreement [Member]",
        "terseLabel": "2021 Term Loan Agreement",
        "documentation": "Two Thousand Twenty One Term Loan Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandTwentyOneTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandTwentyOneTermLoanMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtSummaryOfComponentsOfThirdPartyDebtDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty One Term Loan [Member]",
        "terseLabel": "2021 Term Loan",
        "documentation": "Two Thousand Twenty One Term Loan."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandTwentyThreeConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandTwentyThreeConvertibleNotesMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfChangesInFairValuesDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Three Convertible Notes [Member]",
        "terseLabel": "2023 Convertible Notes",
        "documentation": "2023 Convertible Notes."
       }
      }
     },
     "auth_ref": []
    },
    "alur_TwoThousandTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "TwoThousandTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Convertible Notes [Member]",
        "terseLabel": "2022 Convertible Notes",
        "documentation": "2022 Convertible Notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r265",
      "r266",
      "r267",
      "r268",
      "r281",
      "r337",
      "r338",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r408",
      "r409",
      "r417",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r687",
      "r688",
      "r707",
      "r708",
      "r709",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r779",
      "r780",
      "r781",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/BusinessCombinationNumberOfSharesOfAllurionCommonStockOutstandingDetails",
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/DebtAdditionalInformationDetails",
      "http://www.allurion.com/role/OrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails",
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionSummaryOfComponentsOfRevenueInterestFinancingDetails",
      "http://www.allurion.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.allurion.com/role/GeographicInformationScheduleOfLongLivedAssetsByGeographyDetails",
      "http://www.allurion.com/role/RevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "auth_ref": []
    },
    "alur_UnderwritingDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "UnderwritingDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriting Discounts",
        "terseLabel": "Underwriting discounts",
        "documentation": "Underwriting discounts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Cumulative undeclared preferred dividends",
        "negatedLabel": "Cumulative undeclared preferred dividends to participating securities (Legacy Series D convertible preferred stock)",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r292",
      "r293"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions for which reserves would be required",
        "verboseLabel": "Uncertain tax positions",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r589",
      "r1035"
     ]
    },
    "alur_UnrestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "UnrestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrestricted Cash",
        "terseLabel": "Unrestricted cash",
        "documentation": "Unrestricted cash."
       }
      }
     },
     "auth_ref": []
    },
    "alur_UntilMarch312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "UntilMarch312024Member",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Until March 31, 2024 [Member]",
        "terseLabel": "Until March 31, 2024",
        "documentation": "Until March 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r190",
      "r191",
      "r194",
      "r195"
     ]
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.allurion.com/role/IncomeTaxesSummaryOfValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Valuation allowance increased",
        "terseLabel": "Additions charged to net loss",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r1040",
      "r1221"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r1040",
      "r1221"
     ]
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Black-Scholes Option Pricing Model",
        "documentation": "Valuation technique calculating price of option."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.allurion.com/role/CommitmentsAndContingenciesScheduleOfOtherPertinentLeaseInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r1048"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.allurion.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204"
     ]
    },
    "alur_VolumeWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "VolumeWeightedAveragePricePerShare",
     "presentation": [
      "http://www.allurion.com/role/RevenueInterestFinancingSideLetterAndPipeConversionOptionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volume Weighted Average Price Per Share",
        "terseLabel": "Volume weighted average price per share",
        "documentation": "Volume weighted average price per share."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantAmendmentMember",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Amendment [Member]",
        "terseLabel": "Warrant Amendment",
        "documentation": "Warrant amendment."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantLiabilitiesAssumed",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationReconcilesOfBusinessCombinationToCondensedConsolidatedStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities Assumed",
        "terseLabel": "Less: warrant liabilities assumed",
        "documentation": "Warrant liabilities assumed."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.allurion.com/role/DebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability",
        "terseLabel": "Warrant liability",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liabilities",
        "verboseLabel": "Public warrant liabilities",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.allurion.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/FairValueMeasurementsScheduleOfAssumptionsUsedInPricingModelDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Warrants term",
        "terseLabel": "Remaining Contractual Term (in years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220",
      "r1221"
     ]
    },
    "alur_WarrantsIssuedAtApril012013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtApril012013Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At April 012013 [Member]",
        "terseLabel": "April 1, 2013",
        "documentation": "Warrants Issued At April 012013."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtAugust032017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtAugust032017Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At August 032017 [Member]",
        "terseLabel": "August 3, 2017",
        "documentation": "Warrants Issued At August 032017."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtDecember012014Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtDecember012014Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At December 012014 [Member]",
        "terseLabel": "December 1, 2014",
        "documentation": "Warrants Issued At December 012014."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtJanuary172017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtJanuary172017Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At January 172017 [Member]",
        "terseLabel": "January 17, 2017",
        "documentation": "Warrants Issued At January 172017."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtJuly012024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtJuly012024Member",
     "presentation": [
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At July 012024 [Member]",
        "terseLabel": "July 01,2024",
        "documentation": "Warrants issued at july 012024 member."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtJune042022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtJune042022Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At June 042022 [Member]",
        "terseLabel": "June 4, 2022",
        "documentation": "Warrants Issued At June 042022."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtJune192018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtJune192018Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At June 192018 [Member]",
        "terseLabel": "June 19, 2018",
        "documentation": "Warrants Issued At June 192018."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtJune252019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtJune252019Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At June 252019 [Member]",
        "terseLabel": "June 25, 2019",
        "documentation": "Warrants Issued At June 252019."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtMarch302021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtMarch302021Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At March 30, 2021 [Member]",
        "terseLabel": "March 30, 2021",
        "documentation": "Warrants Issued At March 30, 2021."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtSeptember082017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtSeptember082017Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At September082017 [Member]",
        "terseLabel": "September 8, 2017",
        "documentation": "Warrants Issued At September082017."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsIssuedAtSeptember152022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsIssuedAtSeptember152022Member",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfWarrantsToPurchaseClassesOfPreferredStockAndCommonStockOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued At September 152022 [Member]",
        "terseLabel": "September 15, 2022",
        "documentation": "Warrants Issued At September 152022."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsPolicyTextBlock",
     "presentation": [
      "http://www.allurion.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Policy Text Block]",
        "terseLabel": "Warrants",
        "documentation": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsRedumptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsRedumptionPricePerShare",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitAdditionalInformationDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Redumption Price Per Share",
        "terseLabel": "Warrants redumption price per share",
        "documentation": "Warrants redumption price per share"
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails",
      "http://www.allurion.com/role/RedeemableConvertiblePreferredStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock",
        "documentation": "Warrants to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "alur_WarrantsToPurchasePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.allurion.com/20240930",
     "localname": "WarrantsToPurchasePreferredStockMember",
     "presentation": [
      "http://www.allurion.com/role/CapitalStockAndStockholdersDeficitSummaryOfReservedForIssuanceUponThePotentialConversionOrExerciseDetails",
      "http://www.allurion.com/role/NetLossPerShareSummaryOfDilutiveSecuritiesExcludedFromComputationOfBasicAndDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants To Purchase Preferred Stock [Member]",
        "verboseLabel": "Warrants to Purchase Preferred Stock (as converted to warrants to purchase common stock)",
        "terseLabel": "Warrants to Purchase Preferred Stock (as converted to warrants to purchase Common Stock)",
        "documentation": "Warrants to purchase preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted",
        "verboseLabel": "Diluted weighted-average common stock outstanding",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r295"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.allurion.com/role/NetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.allurion.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - Basic",
        "verboseLabel": "Basic weighted-average common stock outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r295"
     ]
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WorkersCompensationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.allurion.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workers' Compensation Liability, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-51"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001193125-24-273671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-273671-xbrl.zip
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MSZ5_LBH#BS5SY 0V5G%+M["QT^++G+%I7F7U0EE@@M7,@BHF>%HU:<^-6I@
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M8;2AT0C&GB6Y#6S63$,5_'26USO#K\XN/YU]OOSX'CD9MA8 -ERU Y#7:PF
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M9CV _Y#&*_&R/ B;!)/,YXKP^ND!6O JA%D6][-KW$J5("SNK0:#PNF L8M
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MXFU\9^;F/JV85;R=Z1D,T!U$$8TC]H@DE[;/Z$E0 PI](<%;I/@WI/MAMHQ
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M\.I N=^!2U,NQ[X=!VU![26%Y>%P;D+GV]DE#X;[7< 4\K^D#^P4UF0VW:"
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M1OH*_CG(GM)7[ (.*3W:/^SA,0.!@9!@_G"]D*?:/@RR89:^Q'4L4R$36U4
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M+ 51N[^OQD.)G"595!>ZJ],+&1U42H+4[BC<^BJ@ 5K^/H!9"9 YO1300I\
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M&[J)DE_F$17+$-($X44J7DV4>+.4:^%&&-1 QW%\Z7Y$O2SNTT!P@&27AIG
MJ7,CWKD9BPD/@L&,M\O/+:7DZYE=&E8\MQLE%3WS(.A(3=MYSKE+PG1&5D^+
M[^E'8N%S3TXM&.-F?*Z<+>-"L#I2V)HB4KB*<.M!OS9T/22]P@NUKT1:$Y87
M^6F-T>;++L 4?\)]@=V;\S])0K)@>I%$%]$,-)U7D2!?R")UKO!V5JH^X';J
MC2\QJ-AL*J SERI6$,/[@;I)<8+8K_X.W=:,==/Z"L> 92[-JHSZT6&R50+
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M$6 DSW1K 1(O7H_(&%9DJH\.#L[LYF[:E&H29,_<=T"LXM";W#X!4M LNN7
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M0Y0B)H0>NV[[5^EL!K)R"4/+PKG?;;A *6X$XB,TZ+A[K[O ];[*P.#5@<G
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M)T!K?;%3F(&.=!@=EHWUX6\P;D[YRRU3-3/=47^"L)S2TR(4"_()=SKNTB8
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MV.'S'4.\,,^[N";T(;>^O8:]2Y34@'"H=%:62+AQD21E,/U*BL=@BH?BQ6N
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MK?.(6*Z%, <_Q,^3(A^415X$241/S%M7PYR1HM(,A>]'0$KCP1):J,5&_#+
M7<ZJ3^0T8LO?91S1D&HO( KMJ>B0E*Q/QX,?5RK&"&ZC#QUAP32_I5<8X?R*
M]-+1CQA*QL>TE")T!.7JS#7%,QC7*Q:'V68Q*KX?L5.-\\B +0A6Y6*$-I[0
MKA\Q4XLVV9<>K)PV*' _(O%9'K=BG2!Q-'18:U:@!^.;O(AG04&BKR55U&!<
M/RL1+L%H3:J##[Z[4M,$PJ..UW4L&:H^U(;&C8I4]@\^#RLI B'1KDVGDJB2
MCC/UK@M1T?T(\&Q\;MT!C?#E,FX4G-G)Q8RZ-DLOG.LJHZ,]3X)U6UXG=U2
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MJ*@:O7 DVMV)Q(JO94 M)[M-8$"Y"K+#];:O7X;,VOU]S"C7M3&JEY;U)M1
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M(254&NZ.I:F1_H DNH+X3F_Q>Y."0=)P38R%7)3/LSCLP8OT RB4LR%-:JK
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MQWL?*-2INY:O1SH)I2&C4$L <"]SQX2 ZJG@\H/,PENIU@P5:AFR_5Q%=<B
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MSSGY5TE7E.OWRI/?CPQ:.V+=263.PKH\'9X=6\XFW)9$F!"+T9P*?>@@\Z]
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MAD75 3KJFF&M)ULSICYF6NF0*]KYGVVE0ZZ>;T#G7#N\BCF?Z)S;SOI]B-.
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M.S,IM+X8-G@JI5G!1=T(<<:JSY);/>M7FK-,7Q76C;Z)TVHJ01-#V*J6E6F
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M'K).A9'G+(F(%IILJ7-/4"ZME9063F_=#=6&;NV?JJ?9#>-H+WBTP-230L'
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MSTR. "]8W481>R$?)+=!'%VG%\$Q)OZS$;<&.H\8-DDP!$C;'E&",[*'KTB
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M8E./;K>$S^%8MTWFCT9V<Z]=F*6\-OM,2%]:A82A ZV"@7>XTCR:%@\]U21
M\!WPK8<Q:SS_4\[Q>+;EOKJ]/I#-(BW.Q-*5!F2W=>"W:S*?=RWHEP%+IP4R
M5,WDK>V.52W/*J3UZ@O.P[A0IUVU)(;PUW2RZ-T;3LEB(.J*2 TQL,LV7JBL
M%:JNL8-50H%X;4;L*=TV/\!S]MN6F2M8G\W^,DY+!;04FJ^R^JOA<I=QXQ=$
M!QFL;N#\W)+,) '4PSD'5="MW!.N$%6+-^^;NL8\ Y$Q9;$=F;<%V\B_YG:@
MINF$H(!<<TR7)*HE:;;FT(>O=KCJ+\D>066W&"\Q):MYFB6)U=$LQRZ=K#)
M33);(P+35A4I:B\E.],[=J1L0;GJ:%$-1L='I,V\YZ7AW^7;39QBI\L)*1G$
M/E?.OW*#04D0IV$!-*NYC7"4@VV4,)<CH7*LZPY"@RKE/G9I2#GO8&>;$O^+
M9E>,MG#)+:N[BF^3(,2F)TV6'0#%SFEETL_0=2= LR)&#35\$-T$R01IFKON
M%<40.0%3%UIG1B68IEVG9*4.DMO38Q*'NSWQI.6KZH@^@/5-)9FERE7DB-.C
MNH/U:-TX^0;B?"5JIT6IC>9I(>HYN-6Z5I6:!"2LU79/S@YD@0]ZQG._ZF!6
MNZ)3)MQXP3O=(M+_4<_T)4@P*Q]2E'D<DFFC?]BF4?\7G9:W1#^S2,R9&2:G
MB$AS564CO",0N"+*K'WXYYL1C[KI?8QE*5LV_&2GT_,&M1]%O F](!O\LD_!
MN4&2W+D;U/"$:J80Y0IQMF .BL"'GAXV?1-U$@Q7 Q>G_ R*CCC[ ;??9;_,
MVVF@?X<T;# V8F@N80S$^HUP(\1E7!RS(DA^SK/3D5"0?Y,)+N/TA*,J<5&6
MZAP9OVQ\+0;8?7R7,[^MB:V908P;1MGE![4,S6YXCTR7[LL@+Q<UO_,,O+6%
MI=D@'_%3G*9T?&GT&Y-SH>&[2HU.\=<V>)@FBU<-VU>S7HTTI[.N5B-MJ9>U
MZOYT/";L4"Q(*-L?DNSU.MUG^8$Q8Y'BP[H'CRN$O51#->E2<HM-:5&'&#QW
MQTS"101\25:<<IZ)@(K*WD3$;5>06N\(S*'".J+24_47_L#D-H@CLI'0Z)30
MTFMMEB&78C+"ZJ$,;;*AV\/*BZE*_;+:!76CC:<4L'8U5DRB,8UG%?P(5)H7
M0;"E4:2@$2N=2!'C)P"'2$+&K4U<E;:11-<E/E@EBK+OPV?XC8-DPE$!I^TD
M9*..5GM"R^C!%Y,I$O:6$^D"@LC_I5EZ5KVYZP[$ZB)T7$$L!.BX(MC3600S
MR:SP9A279+6G[B@MO1*=G\I/6?GOF-D,[3F";1=>SP"LY1)M/"-%75I4$Z/'
M4TE?>:$WS-<W&+6<(%Z=L%2=KY0>6Y(5F[_\"E94Y<\5K.(NS0VI$R+DVN""
MNKK!=7J1I2EF^0)HU0-CM)Q3%[XBY]SD4I;L(-BKZ2G(VAYX'0?(F+KY)'SM
M2!@.)(2/MAN!T%[D'10\K:+P/$^B__@\(1M2;<@N3S2(HG(V=OEMD-,0B^K?
MG00HF@5]AKX]KO1SC,00 )+<7ZT'P/M%M?].]H%5U\VO.IW#N ?+C(G\08?,
M26#^1# H+PKI.<RF+D.78C9=F>!KW.$P>Z*A5+3.TI8_VJ_,GJY<O0.M+^_"
M4A+QO6-#1LN>583-XW.@LO1S2406H3H30_V:.5%)Y,U[<,%<SVWP#C@K?V'A
M:9HK,UB/S:L@3W>G4E_^VXX,1+^E_!M&F-*<$2*X>MSSR(&I'-D)O,"V"ZK4
M:KPPI-PU>*XI@?'K^3/W@F4I9 _>Z4.^HLS9(/#*K.\-[KM=%YZ]=$NYI,YX
M2[M!#35JR3>(=P#G;X^4KKO7#+/#@8"Q*+/P=W0ZLKR2=:>K2P?OBE29Y^P"
MTPG+)J\C?9TV%9!W>U52P(?G/#L]/>_"6+68CNS,UQ([5E9%[>WK%'4JB!/G
M6IV-$U7]H=W%-<":/+/@0M%QC>!E)7A6/N.<:O$QQ\]DSQN_T'YHV6RPM7T2
M]'LK/CSNK?R I6&@S@;:P&" _YD-5_G:28/#<MF-LUGZ?B#-E4%":TOU\&LO
M Q7/S=@8J3!>B9$:)ZYHGZ3B?F6FR0;<1JOD#=FC#=),4YZ7KZ)/V$YY&$,D
MN^L&N6IV*<.&7E/:#7@4=X:]H'RHE&_V7%;Q,^VM/5?WA);Z*6FVXJ H,.QS
M23DPQ&QO,E0 ('>;#J.TMW0([XFN8YX4JW(C@N0V*]@APM67DAI6HH@W<:%/
M[3CSE\!T9XY1,B@?NTH2G\8TG^@\:Z9Y :JOH-_:[Z"KE%AI'CPO1-'!J<!L
M"-/KT&SP6O_3.&V,VJ1^OY;':])HMGE>HWV%#WH5HV'_RJEXSEYI96'B4F%4
M="U.$\T*NJ;.HBVS/F7R:BQV^5.0QG\$O)Y/6F1)' 55SNA;,I>U9]XQ<8W9
MLXDYGZE_C\9CKA$9JDVW7W;^WO;,%*?;=W]!;KO7A++[U)E903/4G5D1 ZM#
MYT$1%S0U5LMU703B$A=A'M?9V;<\]B=.GVX)<1B3O2S^4IX3=G\?HUOS?'<-
M.C?3"#KHX@:Q;_+$=.U7-VWYCLZ'F>*VGT;UM]%O].N(?1[HT0GDD+)AD0[C
M*JW6G&IJ;<WFU%$O5D[DPV+YUQ%YM"]:WH=(ENKS*M9=\Q0,X6<>?S\OX..G
M--['89"6XY8ZVPY\OG^WE4EXTM<2KG3M&"_:Z7 (\C=J]0U2@CY[=T*C\.K=
M"8I>U$M2J]7&..O)/*J2@?\ARF2%U-9BHFVF8H@HFWF PM%ED\'"QDS;=@"+
M+;E,-BA#+>D*S/2LHJU,:32XLU ?#>@\W8.Q !>:IY<X_4R1Z7NYBU-19@><
M6]AFZQZ\WEO92B7>1_& 'Y:HN:;E[_]JZI78;\>9$^^-G*9M#6"TL>OV7:P'
MCCH#:(5'</L^7< 5:Y+1K+MBSL_3 G%AL3#F6BJ?#PBTW MO!EI?IU6%E9AI
MBWD08N7-D^ I0QG!->GVS<VUUI-YS5VFY5],9%8U7Y?O/%8*V#1E9N2(.<O,
ML/%5HH6ER;E-Z,%)&EW5F7(L[*<%K=^2+$9))*5*&,T&,2IV0=+0K<2F6L^0
MI"R)W?3  LW-WKIULP;XV5DR/1)79:-GDK0O(JL+M$HU<[#J8\#IZY*0YBOI
M/!HFW.UH('7W5U;WAB[]^+U*=))0<KO(,KIT6C. LBYZOUW'JC!J1B77D.[3
MZ?-6N[CE27>L&&V5[(*FJ4E+F_5D[@_YOSV?;XP4-^X%JKZP01(MV2C4I/W2
M!E7?6L':Y6/,V A=59FA.J-3CX(FOP= U,+,*J:(=)A9O[SEJVA9L3E/4A!X
MSD4AY5F:>:+K5JYB5=,/N2S-@GJ\ 3!BL^ H*<!0HC-G DS +;@;[^L!L]%2
M&H#AYXV2Y$2_21)F80$MZ7V^.;*42'A-([U]VK0)]U9B,9UF3'@/XS)=DW*[
MR;-4W,<1OL$E^2U]1'!]>]4FS=FQ.%N=09VM9W\9XF88!=65J9BZ98-HQXCW
M3%QW^I8%79/_774R3B'^!4"[OH*A8<]\2.?BN #FK9M+8P:I[5:E+I;9[Q;$
MAICJ9H,*BHUDB(UNNC+6O?\$%$V:C=9-L#FTTY-Y7(L-_ _GJ)/RID.PDG77
M9BZ&RZW-1( !R6;O8J #AI).WU58 M_.3!#D(PYH\X/L"3NT*AAW.U90\A3X
M05-%/01?G,YZM%1>PSYTW(OQ$K0U(LW7=_9C,0]B%(5Q$J @9!<[I".#!9$^
MZD:*(G!;.EH,V(-X&_18(!_&>M(K;JNCH6%#C_ 6>!PB@3=8B1V4C^@0 /+A
MG'1&$V%\H'<TG?Q]MWE5&>6>YFTF^RSVW^<LB8@^7N)]',;:6];9>O9W1C/#
M*(B;S;K37A;+IEO$^F-;S6[/J.H:_G!F/6/R3_6@ )[,S*4G@Y.952F)Y<G,
MLL#HYO\\-L H&F 4766)*F4IJ:X\TL[]']!T1>4&FB9 =7,*'?KP^:K>03+5
MZ@KN'TX1HJZ<ND*S-!I]PA-Z5^CY\3"#/(W3I^(6Y_?/@=7F7$WBT^M4\RUH
M2-44D;:(-5Z++VH8>\$K-0P\"&!LK*Z&!A R6JLJP0RXA741X!,NT4U6%.A8
M"[ FI!N-I1$QGA\^[O87V8'&'#*7[0XG 4UA2<LV,O8>@P)'M\&;;8+(J1V#
M/)\<.09"NAS:^.R<MD95<[2E9>^>\(K>!<TS]>KGF%/F?5W8/^^R:A6C-[7G
M-:)?.0K.\ =?9A:0F;GU7.9NCU^%@NOQ/5K#]>#V%(_8\L=R,Y<QO_!TNJMS
MZL5K;**+=.)!2=T<G>.4;#]7DX=XQ*R)D8G.4P8!R*O#,<G>,*XF@+[[LUI@
MW+J!@Z1)/C%JMB7G[SNK#FJ(LM>M:XB[F"BH5*X5Z9P5, U*9X5*7UIWB$ON
M::81C5HF.R^<AKVW0G8+@4L_?O7.24*)XM7TO*I,MX?UQ7J,FE )7-UG<SUX
MM5PGG#I:&V(-:X4E9->P6"PHZ^H5T6;A& %3/U=R^(GR=8>/64ZYLE@EU"0^
M+]S4? M[5]X4-6U78N1-0R]</QG&'00OCI>W-M2 *+*S5B*@5F6-QPGU,\Z>
M\N#X'(?H.MUG^0'\?,<!:B95@;:RU=G1;9"7;P\YV2<0M;7,=FXF]9J[U"B'
M> S#2!"C05VBE9AAV[D1$WW:30PHP-S,LU,O*X"=G673('!5=GL6*<^.@I1K
M5"X'6SX"E'X\H=-C@?]Q(LO,U8OEI;&:Q*?/H^9;K(M2-T6\[4I,MFGH!7?
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M-( :3"HZ/1H!-J8M5Q:E9B@YD@^OH0SU0QY$F S$KGS&^99+4MSA$)-- BT
M9;ICMZ3WZ*O;2C2<U+HI:MO"6[ %A()TZIW0-G3SG:#F*9$1T_$/1$Z:)Y%F
MZ?@U+I_K=W_V^UO7CKRF,W*44;5<4C2@N@OT2OIH'DBN1\]FDY;@,GM*8^CW
MU>,0*F8U&@-/3U7ZR&H:Y-%MGD4GPA8_SGTSKEL&.J_5^/02B-4M>'M4$:":
M8GU'3ZZB#26"+<!G 2RQZ)X%JCPM30797(?TJ=HET=XD8Q&<5U]H3GBS5V=%
M[741LI%&M,6<BCG<'3I4$:Y/86:6$_R>VP&%XIIC#4$O"K6-V-EX039PEI%=
MUI0>%<DLA;"#:"D8GM:C+--DH;KR,<A_Q^4J(D(LX374$DML33A)I:<F28+#
M\A0DS<N /"MP>*+.K4N4XZBN?)V9CI-3%L!?]X*:IR&=?E85'^E59K 3T D(
M[AU[0L/7ZJQS@2D]UE-Z[$PI4$SF=1J2'>=#\,7A=8.2Q.LC("7?XMC3IHBT
M79]_.DH,Z!>E>L2(+WST< &I>FV/=B,E8 5LNWO[?AWL]>F NU1-<>S;-1;'
MMM0+2V#Y.?1K*IIVJ]SQVSNR7[QF2>KB%\RJW)F/ L?TYO. <)2TSH6 UZ)?
M,XE+:P"?K:L&\ 38"@>-XS'KK;1JCI\)8X0)OJ1R+NQ7,OLN/)=4M91+5DZU
M(46<=GVKVVP"T@4/NH:J"P)E]5-=X.=%K3[AUVT3;4*V=2GY,>3)BUS5R[TK
MCVHV0D[1Z7I%;1^HW\GZ]&X&B6DH1%HF-*5Y=J3I&97B5WD<J^;T;::V]:>L
M1/].?-BJ7TBM'JL 0^T>B_X)!ZD?\1]_!,2%QC2?BG4XN8G*U_&HD?LA&AL"
MQ"G@56T>.<".,>WPTSNQ] @>J\/)R8/O_\#Q/GS&T2G!Q6[?2WZ^V].DY^=O
M]/]_"$+R89M%=U1O/K>:HZ05]EYU+]),^;P,P.,;^P'QWM!O#RS>$GP9GFD
M3H=#D+_5TKH7# #=I8Y'O+!+'0_W26\_J*1Q$E??DF=L)K_I)W5F"+1X C)+
MY_Y>@LPS%A)?L],OP[-+TG!P?5_SX  ^%9E1<08O1M:F-98/1WP!)*P!PG[
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MR?G;_\S(VOA7\MT3V1P'>9GJ7F_9]^#14[:72N) M+D;Z.+#R6DE%=8!JGI
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M2Z-/9 #X/S3*847M-16 C31#=#7!:A49C%*,XWT;DK]QUYE1PZ8KL,:2F+3
M&DA^+JB"!%>ZR4*\;W'.=%1WFZ0D\7GUH^9;L*FD:6=98,T1:<\7"!@=&,$^
MV-&M+52$.PX#3J!>U%QD14D\//H+8E"NTC(NWUC$=1#6?W;,-F#7(^PK'$NI
M[=[G= @1HUS-*YV18G8%"F4" 3_<<<&LQ9,>%\!"/?;IL'N'$WK];:N9-IW
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MS^U4$HD6FX;E8O01YT\XWR"ZY2*V>TWV88)4ATJJE$LE0 K<(MABT'2*MSP
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M?/TI(SI!,;9)LBN?:5X4VFMLVGXKF_M2$C6_0B+/)$&L*6K:0FK,),;!U,<
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M XH2V5*4^$7V7?#Z,2 3$P>)%;#[[2%P/>!8 VO2$C5-UP%J _.4XT/]]U4
M6H8/)9YEX/ +Y\NX").L..78Q5.544% 6\J]$N"H;;XVOU4]#4KLJ.? +X(N
MV%U$:<IQHV@/@9H!QQJ#6+5<0SH;[7@K02(;;+_PN+&(-)8UA@#&C2::N+4B
M:XD>5@^Q$@["^/K%PE^#Y,2?7> "YR_2("<;(@ALR'A78Z1IC>KFOO,UCQ*
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MLK37JV%3V@HKBO6PC%X780E9'W&Q1U06=<)E"&-0A??%&UI2UP, Q608*94
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MYA:(L%9;&Q/!V)7.B/ U?WS)CR495#]^)1J^;3),/\/6?IX+C)4ON]A7X8U
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M/_3)I\D RPZ7+APJ-'6$-51H+9L]5%@GS8%QVJSY%DX,%OB)WP,N^#&\8 =
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M)6/YZJ"RY;7#-EGIJH$8:N[)?R.Z[I[(-AMFUA-,<A31PEG)4;IJ>&" OZ@
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MTM<<-36@I@K4Y52BO^XG+85,V+74UI]_>O\WN6EPV;MF(728R@L.GF9YO5S
MM&I@FC4P94] [IJV+.NVW&+[1Q!D?3S+,9@D;#83[5B.P&[&99!)5ROK-:FN
MWI+I?*F='$^36(:1P6\MFV!3\!K"3<S&ZQ-KYHEYY[9/U+5/R=NG71!SQ>XV
MBRC7;&FV7L-:O.?L-;5.D2FU9DCP"7S7-#6$ #$/L=-)??W#U2ZUKX.V++NV
M?&K:DOUN02Q9O-+46W%ERZN/Y%N:54FYB,=5)87>XR;H+RKSVU6T< "+DSK?
MCQ>2=(X' XQV25(E! P:Z1*D##8!K$7JV\ $.O9KC\[!T[Q[?)F^I@G.$OKJ
ML71\,Z<20' I;=."K??<>%,!>VP<:&#CQ$C1HG^F>)>$Q"0]('7,TJ,1A&F7
M:1GGQZR:Q; I84!F3=IBP*A&+D0B&=ET55;I/N(,ZID2$H'D.-,11PXRW^^&
MMO_\>XH+XH^7MUO\2MQJ_("HL@*8ET35-BF.9+3EV<3E\_FO 0R<[=I*\="H
M04.!7> O1>7,7P\UJP?XHKS*0CM$!C FG]6$)G>@M>WG%Z'\$!:CR0?M0$(I
M!8&^2>U5B12XP!EB(N@#\*C!SHY:YR!8(8>-E -RS'A!/-6!K0T^XO@E2_\\
MZM;%9 (><2[5>0R-MB Z/QR*/(I?6#!MQ0+HY-7^'Z-&[7P@P&C[:[D(*&BD
MO; >-@'TQ+IVT$,'H'\5E=@<Z(]W11JGV?.G/,$[;7=K4PDHP!2VR2'72I\A
M+H_J"A"K ;AK7F3DQUT4__'N(7XAGRLGK0N+4#ILZBFF Z87TC6G_,ZSY#Y]
M?JG*#1EP5!'+A#Y>GE#0SJX:C\2SM&^,RO80)(WQO +4JV&898Q5 D,]5V;N
M>^:D4^;X)-T<;(YI-P>8+BY8GI?E<<\(7M*K/W\>TX1F?'DEWZ('[61G5\SE
MO5]QU%ND6+#H"?,[2+4X8O+L#"CDY<*9MO$\=M'0MEUK&V:V51.V^;\G:(C'
MZ8M^/L%H=U-O[8;S?QJ%YN2XR<JJ8%ZPZ()U@AX[7:T-XEW;)]I]-A+!=*OS
M#$E[A@35H9IA:]R%F@'+"SENTPQOMA<%)C154&%8S"/P1_H)JY%Y]OR.WW>@
M#[Z1F,.+PH!;JVR408)UJJW'T)QJ:!>CM\VVW6?^?*1SLLV6GW[4CML4DMY'
M;"HK%&,U LMNEYT+LGNH3!1RE&9MSVMC#V[MR5I[RDE[_(_,M%B;'I/Y 9K=
M:&QMP#FF-EUZP7.8/1*$)/;8!E,W,[G@:&UDS02K#XTU 9)Z$F5:3J\'L=F4
M7@%JCE9:<"5].G;3YDXYSQ+- Q>/]/<F*S-NOP>QDN/88ZKC _QKW1/)FXDG
MDKMO(O)1DQ>3V9=!]MB\H$^Z#A,L]*S7;7Q \)5#,.(0W/=>Z2Y:"#YQ"/80
M1]?ZCWT(LHD[%>E]%_Z>TGU:_G%=8.(4TMF2OG#6N695)8#GFY6V&9QSIO*(
M5H":&D(\\6QEY<"0D,X[ZW&H._>L!R'0U1R>'Y\-8&;<R9F0!KV,,V6-T2V<
M^ID /I +BT)F5@U-"(D\"HSIK]E( 09"%S:\G\<54120*!-V&+"$W[X/D2(&
M]G23M>$D[DN6X&+W1H=)/?M"XH\,=#KRR! 'PARFQZ_YC@PLE>DM+.4!.22S
MR(!(G$*=;&!L,K6LO>G9E0V)-TK(Z<BCQ!OH+6JZN3;[]G1?.(!;TP-;;&Y+
MLQW&L%AC9%-KP&VZQ>B'?^*H$!_/#.%JM(@RTRO1(L06+('>XN<H?CO?D7^G
M>?: BQ27Y^_OB @N"IRP=*MF25#GU.1KV7*6E>(](%H):FI!O!ITCMZCMJ8Z
MTVX(652A; 9;3YT/Y<%**3".C=9 7;9MU+1M6;?MN_?HT+9MR=JV>7[259*V
M*?T_N@HZFHH@8X[.1D/Z?3R9@+.ZP4%%&R,(:X.-/_S.CC5+F[5LFA4BT%Q<
MY/L]^6%9E%'5 AEBE-89TNT"\4H"#RXKFAI46-$#5AM3/*%U=D!9U)1ETY0Q
M;TJ/H<35F$53$6A <=.%7YS,F&5U@\,*+D[&+/[P.S_$N!FS7(",62Z=+<GH
M:H(,-5HK#:EW^>YTEF1\V!Q4P#&#LC;B>,3Q[)"SN&W+KFW7CCJ;Z@47O5&8
M.K+(2ON*'E)MQQYE!8=C?,  L$!M, ZK@3'@J0=4&''1TLW]:<-:=#+KL'52
M4/32!JX)FH70X;JT(Q@"&G28'G$TBY"&[>!Q/F_7_9G)P@REC8/?>+ 15E>Y
MFE&!#(8MNE7O:)LQX%T;=6'=\KI-,WQ3X;W^QN<JWSSAVUY]S_F_\46_CMCG
M(4):0.[,U>Z,%KOSE&_1">Q>^R;=.M2&NDVGQ>1W=:-.E1Q.DJ7-7#20)(>2
M-%C:Q(:KI&1[Q<53OBR;H<Z>J71KZ_8/"[2^QS3++N7,19Y51117QVC'S^_^
MD&;H#?P$K"E#;-(N]NGA^UV3WKG<ZP+_><09&08;/VHBEX9YT41AC>J\>%LV
M@!3G%FVC>,1$US!@+YBTVLQZMT20!GZM1+3&$&8!I$2W:!V3)TDD30/W5$X[
MYC-_D40I#OTPCFB/:H[438@">9W$@2FAL44&,:,7?"3X NS_V=QH5M_?DP3O
M]_M6J((Q*Q=L?R^TA5E?+S2$%SC=Y06=KIY7K5+M/^@#?KN<JJ>-PE:U>(29
MG75CR-72**KZ-\G[0)3%9Y\@G-&"8T#.:#XOX+P@$R]Z7_\>'XB&.#G?TP<E
MYP#4NB:/(+6W4IQY<TD+A/H902PW[3&OHAUJZN$&0K)M)B3'C)N)1["G =^;
M#\2GI("?!GQO-%8=/@WX/I3!MY$=M<Y!#(;DL#%Y&O ][)B:[3Y<[*+28C0]
MEH$91PN:CS'""B!6(JRQ\[3/%:/F:8?[A8IZFTJS,]4WP7PQS?DG(8#JWF]*
MG(>T6+<29*1$60DO?G+BY!E^^Q05?^#J^I@E\N.J.@&?N6]D.@MK&;0@XB41
M*PJ=X6:^YJ I;90@$=+8*!'B[ "G>+KT-HV>:&ZI%%M=DS*J".9HIYF-NA-W
M4Z>;4:^B<$Y]^K$WD .A%@!6G [UC=X91T47M6J;K6;J;#C:=16Y.B9^B8OT
ME5CWBALMWQZ.<8S+\AK+%\#,17U%$C,[Q+?(&JF6,6_O:CE$!"%CQ3R+^LI/
M60<6#2R -N"_;Y09,7XQVG8MVLJZP;88>\X*TZKN)#N,4%M@66)$:Q>E4.D8
M%<YXPK_M@8PM;"$^)Y_,FOAVF5?&N*W'B?&F\\MTD<I_<KP% <JPPO"2Y<VF
MJC2'7+B1RK\'@HI75J"?F58OR*BUL-W'@4N:9L]/[)(D)ET0O$QK##"]\&SR
M*E+NAAO G#M!GN0FT!AF!_ZYB8B#C&)+&]\B,;'[0";)6&"\IFPN#YS3PV3M
M39X5(Y1UX]6-"RW[A]G:, @*EV0$,6\P7^N_YJD$ERP7A3^>,;5Y:7;,< <S
M_CT0U$C&"O0S$X8&.8Y9V.[B,A+H;$R2DW!!\#*M,<#,HK/)>WF*LS'G3CBY
MV9@=^.?F( TRBBUM_'$84^0D71#(%A]@XX?O)D[T*\ZP*60\'F-3:3YYUK(\
MZ]^/ZLK#G&6S49_?+N$2D ?9M& 9GV73(L4+QGN3)#N@ZP0]HEUK@Q"&.H&@
M<&]M" <_\-*"'93&-###D1<N/,0O.#GN\&;+>K6/;^SD]",]7:T@@E+*(PO4
MV@M'EVB9L_J(?;YMLB6RXJ!'[0T:80PA@Q;P@Q^^5#T<&VE/O2NE?.)'J;V
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M<"@U"@@N6S'O6O'0M&)_".XJ>C1''6?$#"-1W^>'[3S>'O0,,2@L-"DX_EM
M;?) <5!<7]XXJ]*ZGM_WI_S\\.&70YX]ON#F"M-F.W@65_-:QM):O0W:EUHO
MN>TR6IUK#A736E'UTKL$1PH.GV@N(0-)@.Z FV4X(<9P.A(.*\SF+>O!H1_*
M$+^GC8X-'' /#H?!,]O.M@.OHB(CHRB3EW\FBWI;&YS44UB6(:7>D6+-'0;
M$#)+8;@E/3D,ADMX*V/ ;,G.SK6ETS=^>):V*GW:X<]YI7\M:[JTO]>R)-J*
M;R*U!1$K"9JA?;;6@.]EJ6 Q>B]K=4P8OI<UP\L9+>G_0.-Y5J5)NCM6Z2ON
M[@=??8MWQP0G=)>>],V'(S=XLZ7<3[/GLKFQ^/%MNH+S;\J4GZM^U>-QRG6]
M)UR1Z17NW_3_G98'32OO 47C@Y$>( 1(P,_1'E_F^RA577W3BX)386"'(9[/
M$)5"OW.Y '$M-HX9.,66\8*P>UQ611I7=3;$+UE:E?</7[2OZ&KD/&)+9X%X
M>JPI7R\', GT Y$I?P1^5=>-+5 7T-;1WB>EC=@PYK,1%?SD6.I62BZB0UI%
M.SY;(QKBXI5T?'EQ?:R.!6Y.3R@(/J,NGSF49E@Z]2!M=X"QKJ99PV@J8@F#
M>%7MF1.@[$CN3.;K7O4-ZJ)OZ99;FDHL]9H&:2Z8A;1'<Y$,EQ?M47+2R$0(
M.I/9H^1XB31%&?J=B83P])6B%8R2:0V:P,%N-U_O/J\N<<QZDY_>__S3^W\W
MV^Y6R_K>[]98(MV K/=JSBO42"(N&L*.MZ51K07OSQ M"+[#;0*OR2UN;]BR
MVN-VCC'7AU<:!3^1QGKY\!,I^-Z.RQ."4$2>LL' PTP,??B),N#G]R&1V,2@
MH?;!\%>*)R5YUP73+.8Z =5:K'T@S<*4>O\?I/#/=LR5"$.Q5V:+@;-;4<1E
M0^*PJ5E]&QAH?@Z&RTJ4*?F\/L1F<=HAU-9B]C^.&?[IW^U)+<I!\7G" @/_
M4BG$Q4)BL8$Q3/-_#XRZ,A@I6;LJAF81=C&65J-IE!VCXNW]7\C8_"^63)T2
M!2/KI!TF/N:"B$L&15DCDSK]V03X+^$P5XXL-7E7AM4\_KJ!UUHL/C\^'\OJ
MIP_V))Z2A.+PI!4&/N9RB N&Q& C@VKM/P1&7SFDE.Q=&4^SR.L$5ZO/@'_Z
MJSU[)<+@,^"1+3;3$BX:$HM-K>IF5G\-C,M*C)G-?U<#V++Y[V*@K3G]??\W
M\H6_VD]_AW*0T]^1!:93%BX6$H<-C*DU9]3]:S#4E>%(._]=#42SY[^+P+0F
M3W_^#_*%O]GS="@'R=.1!::NY6*A\51C3*TYX^G?@N+I%(ZT/%T-1+-YN@A,
MZ_%T]T8WD'^V/*DARL'Q5+# R+6[-\3%PN*IUIA:\S-:*"":3L-(0],5,323
MIN98JJ_B1A7Z[QZ6]DS.__6GR2->MVF&;\BH7'6#22<(?42O;X/%,3TJAIA<
M>&?UA&8Q.J\GM,F25!:XH%>$-AF^(\5P4=3GP36I*C12WE)1Z+075Q"H #I'
M1 2U,O#9:&8;\N[]V RXY ]&4!HF=_"'([/D#:OCR<]+=$RKCX:,-I+R^<:<
M4GM)"WP,A,UNC0!]&DX/(N$=.#V"/.+_8A;^)5+>\2_37@*=BR#QO]0(>/PK
M032-?R6"/.+_<A;^)5+>\2_37@*=RR#QO]0(>/PK032-?R6"%D]5+F=-5>12
M?J<J"NVEF ARJC+#D."F*CHH34Q5O.#(8JKB"D^?YBU6J9GZ^#6?P52IE&>F
MRK67>I:(!,A4>T/>_1P:4S50FF*J#QS9,-41GM9A*BDTIU=5R/EFJ\("N7^I
M4(B,G6',NP_!<58'JDG6>D&4%6_=(<LM=V_Q<Q2_G>_(OXD5:KY.E_7%48FF
M8^_Q8J@I5[L+@(;S] 7CFPH( XZMC@(C7LWS+L!&:I>!Y=></K#*-M^4.Z@R
M"9@<0R.MU9F$>&&^:0KT"+:UZCPCT"O7O)C4'"CWSQ1@%!E^IM#BY_'W0;]V
MF;ZF"<Z2^ZC"W?N$"L";B?M\#-[,'N$QQF%'?88:241%SU G#/0\_$RS!F],
M'EHC.6^2NAK0]^,M\">\(V\!/@ RW:9_'M.$]83\#UB=NLY(&HQ*,FNT3.H)
MHDZ2,HHGK0N!4/;&<0;M>K8=.ML.Q+9RRC8X9BG!J":6$HF+'I=_Q=D1W^,X
M?\Y26OVG=(>)8S/\"5<O>;+9UG_['YS4A673FWEU^7N&?I:E8N)1]A?4JP>U
M%2%>$]IL45<7JD5 GJQW:O.^$09\M7X^7$=/V0-CU?!]>Z?M5_0PV[8EVG/,
MDK%)T6&VX"*N5DGZ3W1/O,WS=[Q+9%'%2-17$#&S0S$"))&ASA*[&;TL166!
MG[V?91'!33G].-++A$7>(H4%XJ3/W/N F_4+]RO SO^J#E>&'_._*](8-\\G
MJ$[&R&5\GHM1:"YY-(P7)O-76AQZS&VC_Z9(G],LVO&[%61PG<*F==:B1C@*
MHX.,HRYM.%:_QPG&>YK.MWV-7MNSZ6J Z."T5JE[A;SWU&_70Q1M-4%T#68M
M)^TA/#:;=4>QL/G&"U5=PSE^GTW4<\\>AOZ5_!4_YHRW4@H9R7HCCYDEFM4:
MYFDNB%ZI)'M)%RKV6C?1D"N^V\>,)4O;J52WD__QU- B9D?OI77C]4Y1$&RI
M<\(&[2HGDSE#/:D0UC4-++F(BN*-]I.L;#@+EC(@J=<J92AR<$V^>XK<YIR4
MJ;3O*_-::Z27G1][#]][.SFE><K)D6F5PK0?HA+%_&U+\CM2\FM/:O*Q^1\!
MDPA ^J _QQ=\X#TM@1EM)Y,3>.2L58J"18W;-M-HD.UL2#UXU+Q3M;=FI(Z8
M%A5X&UQ;V"2,%/A3[)/A<[ :!GCJU*5]E<0^N F$+2"'LP@0-)I-)9:WFK8/
M6RV;+IFL[-AK-1\LD^F*@F"Y="=L,$EY2L7X2ST?0LHW9&(.UYV_ _4!O&O7
M@DF=1G=5),W+HKL<40#[*?$+3HX[++Y'?4E?"\;)QS<>D5@J&]T3@;-J\[D'
M,\O:<2,VLMV.##UQR.3/T--;TW&R.L[0348? *=S],>O^3N>Z:@^[1' &X0+
MVE_8,YG?^'[>-2?]9?)(/M!_Q'T"Q*-R/E\L'VDX!MYD.=#7R*=<*CP]/N5/
M?YO%'\FH*"' .^"L9/'\G(;@9TSC>_GQK2MS%[W1WS%U.YVSY(ZT@?C ^E3T
M6^5SOK>HW?M+!N,U/@>^R[P2W"8WJ%?"FA=N2OJ(6X-,AWI1CYPQL,/A^ $-
MQP^W821'-&W+,8A-&](+(#_CBK@ZW^/;O"S/7Z-T1T<HCWEO0OZ2[Q(R,R.4
M2N/SI[(JHKA2X'1VC1[A.]_J,:I)38A7A7Z@E?V(VNKH D5_-:FN\0RQ.M'O
M3:U R7X<^H#,&@N*S?^$I.-")(]9NA#&7LC[&Z:7[\@L_)7X_QF3=B#S[_;(
M8[>C:,!:^ZH\TG6&G<(21%T%JNM O!)Z<J<YZ=G5TW9,X"1U8/DESO)]FH'S
M<RY8Q\2<BU3/"TOG694F%$7I*W[ \;%(JQ275]_HL 8GU\0]= A[Y(MMXN*!
M^9J3FP^!+$<Y\I&PXMNK%M7UOIVAIEYT=?> +J)=?-SQ6W!!+4BYQ(U\K<HE
M:/PL8RU3V&2"Y>X3/A?/W/G%A$8T44S+(PICU*N>=J;B+"^8^9IK" DK?H[Q
M<PJ\.M_GQTPUKG14_^DPJO7(2G0Z0_P+,.-1+\XI.^?@@7/BH7-PXYSV[OH9
MBB:=<T)A9L@HQS%F2"?/(^+YB[?F@^'%WP 9!R_WC'"5KJZ[G=^^8Z*H7S_J
M?X"NP/8+UA]!["MAC9 =X4@^.'8$(C\W&>J]#,WN[K"8SUL*0_V$,UWD)T3_
MCGZG)4 1-N5*X>3^A!^]MK-V.Q9P(U6[!=IK;5XFB/96;SG.WRR49:^E2\<;
M=@^*UDT*_#3ZE2:+K;&\MVRVYA:-$?'S3^]_JL\2\]*(%J=G]7Z>^#UHEMN%
M1C+]HRSAIM&?X%+=6B)PF/(6 GYFJ6\7MA"_I9ASN!TZ&$;CWSO+8ZU5^#Q+
MR&\_.(X/ZEK#B1H:ZQ?&DG/.Q0^G%F;F>*7G"/[/J#$^\$!D0@#+\.0-_8Z"
M5E L<!OMK -9 #%*GD9=<"!S.5@^<!O=@QR3V+$\( (OAX@;FA%NWV0T14GZ
MBJW&#3)! -I);5#ZEG9OK5A(?;JQ.4%USFH@R9CI 46V#+5$4]ZA*6W1Y'(&
M\/@U?WS)CR7Y E'M\2OYQ!M[A>-J?]CE;Q@S/=J;TUH.SZ_/%[476#QN(WHP
MN*F+M1&OK7[&I*FO'MAT^0& @X%#![ 8<?5P=P<6(Y;B=Q Z@@"O441Q#.*J
M#^**@[AB(,8-B/G:1)<'84X,6GYYH6\=#ZC:]UD5,CZO*R@T5PTDW+\IHDD*
MXUQAKQ<B=/@0;D+HP+&D:TWW^%=<5C31<UD5:5S5&4>^9&E5:KI1(UEO7::9
M)4)D(6+ON!SJ!.OND(F"=H-K&077%UH ;MCO^4:;61^WH(%>>0,570/Q_NM(
M1?WW6]0,>B!<O44^*.6Q;QIJ-_9G_=< ML<GO#B.YQ,N]-G VKWQ43G_C2S=
M&6^;.8!]\4EO2IH:X JMY'0..WY31%G\@C?TN0?-N-2J%OC+Z!+K)C.HCT]P
M=>>6SE!=!WM.&Z;W=V-HSXX [[ZKL&AXI5T%Q$!H1J:N#FC6JR4HFO6MFTTS
M.KL/G68J0WMVA$TS 8OV-!. &$:R%ME1TUN#&TTN*H<GI9TO5%R5G7[6''Z^
M#>/^DCNH6*=5,<;)DHW+N4K4*U_G67)?'IN\=%ER]0T7<5K2$]E?L@07CR]L
M)5:Z_>GK\]XV4;WYTSGESIK53+8B?O_PY7^UJ0/I+WJ:(*8*JE[PY&:IC\U=
M,#>/?%3R9X>XBW#/1<?610?0_62__![N2I\@N<WVMH%)_L3(&_=)'@U)7O;*
M'6J21YSD>0_ 17G\7X8(!GI^;8Z7V7_JI9([7*1Y\GZ-X=KD9TYAX#;MGQ7Z
M$SZ2:U;9^*>"FI"Y\E5CXF'2Q),8KBI(XVS@JF",OXCRI%?\::SXU;=#6O!W
MK9G:NG#BYAN^8XDCSZP02+JOP$>1E;S4,S&0*.*2*),AQ"5+PAZ17/UY3*NW
MFZRL"C:Z+#=D6$6&>5%6CPA_X=G=:Z-&R;;8'R^C"E]':<'>K5IC..->QU,8
M"ZW0,FO$/Z8EZJF)F)YD=!YES;3]#'%=4=I$R3,D).!C11!5&5&=I]]R\W7>
M*N16:ST7U9Y[IE+O$NJY+?4<?TTQWZ)*>_B"R^)3&_OZ]+(2GS6R10>>Q,AZ
MK>#O;%B^5N0/NT\.I^?]GOO7D'K1\/K)=>,W1%_X@H<W^MFBH[0#/(GX'4B4
M/H%8W)XLQ\5K&N-I4S_39T'I8(E953[F5;3K__TB+ZO/>?5/7-WC.'_.TO_!
MJO66%;\)<55B!<]9GZ-IO],$3EHQ^6V%WG"%NKIADR+Z=-F7K&C_/-QWB4D%
M85S_6(MSTNLC:Q'NM$,5C\O7>5'_BI93;3_Y5N1["&HR'Z\8Z?@GT38O4.^C
MWUGD,_7K/:;GS^F&U]=Z_/&N&1G"KUW#,-M;E%32.NQ=M/[VWSW%#<V02R_X
M$^"LL:.F_MXI[*YI/+;ZECW_)HM^]5=/;./-TH&]?7R)O2>Q"V="-&<[<B8L
M@SB@RO[3]E3F8<?+5X,_CFKJO=5"4#?&""48P3BT\\-K$,')(RG='";US\AU
MSY N8^:BHZ/L?Z@0$%G4S.R0Z2I5TTT6%YBH<HGY_]FZ9_V-S7;X"MD]+LE@
M&].Q\?6Q.A:8GJ^-LE@:Y!U5[BN6N_+%&!A-O:BI&-UDO2"+-EOQV;ZF?D0^
M@/@74/,)@*B\NFM^2.J:?Z2[1AW.J4NRUCDE=T[1.(>N%FRY<U*)<[R%;*=,
M&D3F\&AD%(!7QTP#F86(<15*^];=%6F,;_.OU,)VJ^A35/R!*]DN]XPZ? 5&
M2\N$]Q$&H8Y5@%@-],=N\Q?Q6B!V@AU;27!W8%;NF)7DQ]XF[IY;^3IEI;=@
M-0>K@Y@$!E2CT /0E&M$D6:-L^R/8!]S,E@EKMA=XN08LRUKDVAB7A=$5+&P
M5-U8;47#R?%CCNJZ4%<9<(QQ9C-N;1Y,.ZJ<3B^8S8G49I"(8XMK:>0! ;5U
M! )IZ#7B4?U\.!^R]=ZD-HD_<EF(>*.P1#UZ:5Y0KZ=I/5'@:#+/(@*JI+:H
M'BGG<HM 8H4.<]+8X 5PUK%@A69R='&X+*K>YB3YJ=N8)#_\O\>THH\(WI!/
MOJ;),=I)\@XJRGH@NDI3,:<C*<<N9=_E)=OF!4Q'J'5Q@W.M?_TAX+>T>KG'
M_+7Y\B4]/.976956;]*$A;-J@4*-UCH3/ 'F/5S09$JLF;77:BC\F-.CNB2.
M%C@F-987+V0^ME>\(& BY EC6MW'D&("-/JW(JB1 4K YL:,^FT8D-F(.8CZ
M-#!#D.>GIXW.0)WOF!HI?3A[?,J)GG\JS9^A=OH]D">IW7K,^CCDU3?ZD3H5
MS$5T2*MHUS_H'=:+U"O 2_XZ]0K8\L-&O"/5/?^",UR0@5B6G"?[-$O+BEZB
M?\5UB\LS\\^LQR=[+"T46,'ESU!= P/_L(Z&&%"Y^SV:"DKM.5@5*#L'J.%<
M.="&D%N##*3.OQ3:I0$K+ZW0#=Z&D9MT)43-.LMN#R<OI*O5JI>T!*WKIE9P
MR;0"CQ0QMFDN\F%ZM]EFL7L3_-KQU/DV/&V43Z+:H7#,/SL(NGL8$6>C9U:G
M7F S*,(>:9O]0BJP4D!/-'KWO?:)/*+2U O7LO<@+8KRIR,#?DHVM+:9?ET>
M_O%::#^).V[?3_"8\T0F.%#%=S9)$!GD!SDPZ%:2]S@MBO*G.X>Y1Y:_( R>
MGJBW!\N/I*K6:-Q_ZX12#$UY:LTD0KWOG=4'Y)UW3?PV]4,5%95V;<B#^[IK
M *T7/N+G-&.709ZBW2JG_[D/KK(D4 ]<,0F9^:>4X4@::USG,)(&FI,(R<,,
M3+\4>;G*:T"JKYU06)[VEM_L;NRKWT/R-IG[)L+2*6?,U!-MW:QJ Y:=1$RZ
MSHLM3NF]H=:(%6/2Y-=.*"9->VO-F-3[8A>8W$6DOW&_9?B9+A.N'9/,W#<1
MDR[H"&E7G\UBT[-M5]4I1RH%_5Q'*@7W3B)2]=XZ6GU"._&M$XI24YY:,T;U
MOK?:A-;+F,G$<5,3N4[LE&.1E&"N(Y&472<1AWIST%$2W=HNS&YF^EEN4VMP
M0C'+W*O>EN:$U-Z-)ORJ]W>R9F?I[:;XNVFG?*_K>JZ]]%VN_9F$PQ57!$UB
M81@]3+DD5;NS7L:E%B'U-$Z].Z>W*1T^)[%RG^-F6+VJQ[6Q]!06+-TSWCJ0
MNJ?[:033B74/J(AJK<HIA55[/Z\:6R<73K_7 +O<]]HH>[I+L"L%".<!>&9T
M.(THW*@.'H,M%3FE"&SKXU7C;ZO,]Q]]E_I=OUI0_WS:8]Q9(<!YE)W%_S!B
MK/FR.M#"M+$&(4559U[UML5VFE%T-3^;AL_O:'\.8J75DMQAORBD73UN\^1?
MY%E51'%UC':/N-C_K N?OK4YA=>(%GD;;K^O>T&CIQ:B>IW88T9._2^$6W,W
MG<0;2,M#@[,7DI;'A9.(PO*>16:?ZEU,$&U.* K/\S;<X/9[B\)N_&\1A<,:
M ,/$"=<A>4&0.(FUA%Z7<T/,2+,RC64/?'CXY@FM%Z@\YVTHVWX9XM$1"$^>
M/S\7[ [#V/0S52KS4YK]:QFYXLFJ:3J>VMAR:(6G(:3PT=,<*8J^\S8@#">6
M^7*E(IA]?R,Y"2M7'+!)*!GVN*Q]X>F\+(_[QJ8#CLG(\Y)F,,=9<D\@L\;X
MS/S;IS!.L_#D"C&N]RQ<[_L\@1[5 #4J(*K#B0W<%KBVM3]I[']+\2[L#6]7
M7'4V<K,EZI+7U8?)GV@VL?,LH9G$1G]1Y^BSKL;;^^?6]@G!8IS'CJ=<HR?G
M6,(U\>^ B>J6F]OFD^LL!$TI-Q.@PZ?# =%I]A:X(Y3V$J6-4"HD4CNA3&A7
M?Q[3ZNTF*ZN"N;+<5"^X>'R)LGI0^#G/Z$OD.%GO0KF]#J<PAIKAV17&4EP+
MU%,#,3U0113I9I.M+B>=;<V!R[NKZ_</7[Z3%&PKN.4[N)LY-_(Y&XG.#7LG
MWJ$,[U"!]"=C%;Z+[D3P*UQO,KZS>6)3].6N'H?+4[A^Z9C0_L+D-)M//$K^
MR@(_:)0<J_!=1$G!KW!1DJMRPAGKECM['">YP/<9)J<9[2],3M/YQ,-D.T0>
MG3!B?<(E07^[W N[<&&@WG<17JW:(XCE#N$L)5,545U[&U'?^7+(G-8R<]R_
MV@K*FI[\EUIT,0[H .LQQM'\Q'O77K:%,/M7.P6_BQ[6LDW@^MB>HF"]+/ Z
MT<*V,NT73C?MC-?(Y*^CF!.63KRK&,XNP^PMK'7\+CH,^Y8)9TGL7[7C6-YF
MIGW'O\Z*6X#]Q,R Y*>KB%]P<MSAS?82;],,)Q]Q1OY1T9-2Y65:QKN\I!W<
M(STNK@KG=O7X#+F6%HXI5DNA6JP^G\A*@SY</ZOE!-#/:38OP!3UZ=2Y)7^Y
MJ?!>]6:<H;Q'()I:9 3 3A3]3H41DP8%I%6+C8%HU5P^ <CN+J=/Q^;XZ-7^
ML,O?<$'5*S#];52\]0N=[_-C5NF1.;MB_Y"=[P,9EON%ZZ>WFTK1H-9A25XO
MS#!P-5\\U;QF1X[W416_T.7?N%<%Z.S>#0\D?%]( B^!X#8O2ZH":16<Q:E^
M+"03\$A<J<YC$-*":% RA+&-VN5C+*G]O>!FSV<R!8C_.,^2OQ^3,M?<WY$4
M]G5+1Z:K<!:#E6/+A[PDY%V;V4J#W:510F)P8V9]/!C=BYGAXA>.BSTKZO^2
MBT!GD^&^2@@R[JH&]E.Q-Y"QO+X-M$$89M1^B\L2X\T!%Q%5Y19');[$9#"1
M'J98TC=9)^D31EHK!"PQ"9HXHI9!3.@,]<1@QLUS;"%%4")7W"L3S  ET,$,
M30L&)U-?N/IV2 O6'4@/%%O(^AJZ&%HR#?DQXE$G"7(MP8%%>6O1CEF$.XL.
MDQ9Y&_W88&XP&/(..*.QT<K-Y'_H=$^W%C;;+R5->X"KS5,5T5GV37;U+7ZA
M^QC7>3$T]S:-GM)=6KTI>L9%M7KL-9=9/VYE5MN[?/N.U(=8A:BID>Y<-G72
M0QA"#&KKA>ERW3IB,\)Y1.LL4=YS!NX[@Y?*GW;I<S2Y>K78":^X>,I/W@T^
M1S$. L-XA.,@*GB)B><%CC;;6S*Q582X?B&/$6N@FY#[C/R1WIFA?X:)(TKU
M>*2K\BK:H:A6=3>AJD^8BVT]1JW8T&#34GXZX#&_^E9A)3A-A($GIX(MQO/3
M.NM/E2,N&\XDU=BFT4#P#!4T-%*3\*1)T-/7:>"9S&"G40?&H*MO:4D4B?%F
MNXA,BGJ >:6RT)AB;24T1(_YAGZOBB,9L42[4MSS@2/?',-U/%2:"DU*+99-
M^*D%,AA5VUSP[">:!=Z2HU,5 )-STB9C5G:O%/"1%-PS#HMM$XG7VL9G017P
M"SAVB#1AFAR. 'MD;^=Q7!RCW7EU$17%&_FE[O2]H3S8SIG<(LTFVANJ)8&H
MM,2*N&<%74$X%/D3/<F =N2OL%=\K/"FWAK4@&W!CLA-%A=\GX7__R:[QZ\X
M.V)Z4^?B6%;Y'A?WN#H6V=16\HPZ?.V06%HV1E<CCGYH*OB1+E<U=3"P-;6@
MNAJ 79.%5M[CY!@W@]NBL8T,>>/&M&+:-&_;)W, .MA& 4.GT7:*,Y0F?906
M?92.F])ZBT65P[E9N+PE@V@2EN[QG\>TX"\IJX\0V%?A-7>SL5W3&7';G8Y:
M'O4K@#M?X,R^=M5^5]M7].T#/H8P%YUB\F8 :)HG;O;5A*[B17UYZU-4_(')
M..:05M$N_9](>?[?5-!7;#"Q0=B3J*\9<B$TE (YGK_8E#TW)1Z:$DV:XHWQ
MQO@:\-PON(S8O5;+N"(R3TVWV9+Y28GC8Y6^XL<BH@EX+J.I,Q$F0MZ.?&MT
MEZ?AZTF@6@01&8@3X+-MB'LV5+4-B6B#OY/A)D@:GA#W!B.SD^*NF\+_^:?A
M&MU%7JKNX4T5]KC@-:FK_-!)O6I,R\$L;5GJRQ=^8U(,=.%*CHCQ*I4<#IYR
MMN1%1=>13: [5=AK%I,)7<5T(J30.UH*'KL6"M.MBE# *\>$F+Q"!@@OX/TU
M*E*Z4FV"W8FR'J$[I>D8"$T9>-Q::1L(:*58&&-6"@2 H4*=ST5UPTPF #9D
MZ.FL'38T9:&.XL[0/([*%[3=Y5]+=(A2ENRNGONQ)R>J%S)!))4=^2H/.WW(
M"+"K3YFFXHX9Q$#)R-9ZV_P@:26X =.8%^I!TY@47HA\G68T,2)7H$BS.#U$
M.P,^:^0\TEIGP1@W=?F6VXW(>BPWPKVM&4NHOJU=H*6\3^H8(7',(",8+EC@
M&C*T/,^2_A?+\Z>2S-ACZ7JUL;BO12]S>S2=(D^A.N!2B7YOY"&R(<PW[9&>
MP@=;^;*$V& -# )?1JMA+G"VZW V"%C.MJV'2HYT;*_;--'D\H@_XV_5XU>\
M>\6?\JQZD1Z#<5 Q3$"8YP--J$#GXTC1W?!K.UU$JD:T;L0K1[QV\#CBQB,4
M>X$$F 4P5X0>:(S/"$JNL5[?:QQ'JW9X]=9.4%!"L)Y1K%<<ZWM6.UA8^R>.
MBL>ON;-HUM87;!#K+'86NVB5)';EIQ"QY.83-/W'Z02J$7"7Q:<U4+M.6#)!
MKV4T>J/HK;[FL#&(5#EU['YQC6''H=IJQY&(UGHRL4CB H*K_WUBT:@/80?Q
MR#E^5XQ(6AS/BDFT5M"H=$U\[#0H\0J#CDFUS6Y#$JWT5"*2Q $$4G\YK8#4
M1^_R>.0<NNN%(RV$YT2C+:D4-ABEKVY'2+S"L(,1M]EQ,"*5GDPPFG8 @=1?
M3RP8]=#K(!BYANZ*P4@'X5G!B%0*%HR<!:& @X_#H',*H4:V,U9#$?)XQ3*,
M+@LU)Q!B'(86OP'E2Y:D94R/*N#DZEN,RU)]_VMIK6&%&H7U2^).OUK$ZW5^
MM^QOW D9?H[(5QS$(0M?T(0B_XD.1%]ZG.65IC] 4?+?Q[*B* X\/.D0/R-6
M>8&[P\ U"_;Z*';LPQYSV+N][=9J([-,&[;D@MXCD\(&>2LHPH[[$0X=>YA%
M%@M;[@9A(]_6*3B'8 (Z"6<'LNE(X05A=L%@%M(43/=&YXMC46"#P8A6/AAR
M=Q;-XCBJY6''$?;&\1%#S/\^AE.X3!_ASX[P:X#/#>]-0*CJZ.MV]!8&/I.V
M7!@)^E4$$PP&=LV+!UT5D L<LPR\S;/G_G7%D^C[12C:!865<.@F+ACB414:
MLK8*@(?7)O)<"HLU//%E0A,%7)/92K2CJ\,38<5%I<#Y78UM-\[YVM9X1G/4
M/6%T%Z5)DPHVX<D4>,ULCR><=+"S70%U;M@=IDVRP=H!.APRF]T(6%YE:$0V
M.QEM2V.V+;O)/&^5K& XU!E:5]B=15D%<(,BK/RL^^R: J2G_(3P+%9Z/];N
MSEZH(Z0+<3F7@R-0AD<]R1'O!76%2C_)<=AY!/1_FMNES5#')A<C=!$-^_!T
M_%+MU#?/MZ0]=0>69U8&^9:MB:V&C]M*#@2RVD#/*+NR&_1(X"*@:M^[]8O2
MV0_@+D!K/MKLEIS]BQA:YQ]']M;?.^CF@^S=%W?J?K?*'9@7RC' N0B<VXV'
M,XRV."BWL+Y0"&=Y($S'OG .Q:UA?5C'X9P@VHJS.C@#Y$14'0K32H!E130[
MG#.F%TR'9J[Y8SAGO S!HLX4*" % -^_8?H\*$[JYP;$%_W>&P/?I"HP1AC9
MJ:5*4PMJ7F?P\G[EK/2B"PUF+"O/T-?&XG=1;?+4LY;HAS1C<YGRQW#8: YM
M-4W-<0W/W\NZ_[PG0Y<[3'"F'%O:5Q4*?Z?MM.=O4P^B%9VANJH@&6QK\IC!
M+8&;,18B!875Z&#HJD"R%5T5,/;SI$'\@I/C#F^V[3N Q!'T0>HBBW;-@X T
MM2(]RG:;OA+-R1"Y*A]I6G %>9=6[/.IA*4^$%XIJ"ND1X6Z!SQ)G:BIM'W*
MDV>>9,<$6<6(UXQ^9W6#OH#N!AK"*PA.<.&%&Y8*WJ89OJGP7G4\9WZ5'OFP
MP&[QO==YZ*=U(E8I* 66(F ,_J7-[P7VW0E9KH4"SF)1CS"=T'/R^'4?63"[
MVZ::[IBFT:2F/F$O0\ 8SK+F]SYRV=&ET+NHJ-X>BR@K(_;$=/GQ;? 7BP&+
M17U XQ0;B\6@S,H@5@CUY$,;=5@WJVJP8=VFGL88)GJ=?TO5HPKS2KR.(RQL
MDX&4#A!(G"EZF$W9(P!$#'AL8-MRXFC MMF\0_(RIZM)AM!K"@-!K-75%DI<
M,!@P#7VN LW0X4M.?V7[PS\.3_%-]HK+ZA.FCX9*#W=-EO5V=FM:4V$X]?G3
M'?K'W<<+Q NBWWE1B"=#9JH,=\)* 8;A :JUD6!V/LHA(A90Z+_^>+[*"!@.
M15KB4DVAZ;*^*"31=.RP__JO7U"O'"2#YFD,1B 5% 8$6AT'1@2:YUU7%^/O
M\?Y8_E+DQ\.G*(N>V>MA:O:H)'QQ2*FU./X@A1$KC;KBD(1RH#X8N_2 &7#,
M$UJ,F.; [:YH]Q%G>5I=O$1%DF?T-?GCCFY1J9FG$?)%/IWN8T_R\J@60)T$
M) 6=&0%&1",(#;CH#S]&='2'HQ\^7ES\Z(J:7;WGSP5FK->,)U42ODBIU'KL
MR9[KNM*0;%RN/1@-]7 9<- 35HP(.-?K45O:%>?H.:DT8\JVJJ@YIY+PQ3FE
MUL+QU*YP!UM(SBW7'HQS>K@,..<)*T:<F^WUJ,/,WNG*"2'V*RZJ]&F'/^<5
M;K7Z+:U>[JNOVJ[/1-AC+VADRT1P:^00%>PQ]"L11?>/OP%WCVN9!=EOFL-N
MW(5ZQIQI;[JXD3+:2)'02,X6>QY_8[LN] %U:LI-=G=\VJ7Q9KO%A7;Z:2KM
M;1'(U!IA:H\>T6]H((O2#'%IU(B#+A#--NU1;QC<TI$5_(;+2/ZQ9[:DM*2A
M#N.&.O"&RFMA1[>^RZ+J[3N3G[H]9_(#B5M'MJQ,=S0_1WLL.>P@+^J![PH]
MQ7#:%4.T'.!9!9U[&XCK?+M:V]_C VFB%YK'O^ETQGI(CR!8RGM"B8U%!M !
M/)LPJWWZB+)NG 4CB[^S>G\EGSB2%KU-]VF%$_5P0BGB:PRAUGL,$%X:-<51
M71YRI.#$ + 1@0%L!L, 7Y@QZON=N-Y_9A?)L;=;H^L3.E'XXXVWRNL0TI.W
MMZ'<>#!K',.SC$++.'OLZR+?$X+$K%>Y))^617F=%,QC71/:ZQ[CZHN@RXF[
MD1Z"_0(C^&WLN&]$ G3!TP)-BH>R5H72C(>P7+3&.N_R766).4/;PC#$['35
M\9&4#(.&)BKS]L9$Y8!(-\*%@FMK@&(&Q>P][8I04WF)FLT9K&27B21DXDW!
M"L,LFYT<% MG6M,D):F5!^6C.:RTF3-7Q-3L-)FFV!KGQ!PUCRL2=X<<>ONJ
M*NXJ!'Q15J7SV)N]HSS]C6,@>L[4O.II#LI-+5H&E/0#%2,F.G*\*]8UF38W
MV_/D-2WSXNT!%Z]IC,MZSOJ8?SR69)Y:EF0(_52K(*/DW-I\\76VM<(3IDTV
MX'R+FJI04Q=J%C*J'#75H5Y] '1?Q?"H,;QL#"\ZPY\:PV.YX=ZBQ3*4#T))
M ! WBC-AM+C_]=-+_%3=9&55,!?=E.41)W=%FM&-7($>O:4]C9S'E5.=!>,&
MHN51)W"&N,@9:H5@\GK,LB-M!5#*)""7>XVP-%[K-0+2DAZ;YT&+GO%FNSE6
M915E"1F<7T2'M(IV#U4>_R'MGDU$O?7%1G8(T:B5HO&H)X=J0<0D(;I8!_;D
M/7OBVIYRRAY_/:<YVH;=I&>HF?6)OIIHT8W/R:VB[GS_-<93FX VPO[N@9K9
M8KX1V+OF0&5!+H?.LZFG^79"<X\71"WP-;HKZAM<AM=&EX&,GR>J>B"+ATWE
M[B[WI**]98 9U!:D@;DM6F-.[OZR6%CLUEO5USU$?DM09D+P-2&VA.'F4!,I
M7HV::YVMW8>*?-A\<[=7'&9[MZ^O;H.7E0UCB]=,;;YY43*U ]KF%3"BV.A=
M!R SMGKG>=S9FK5D&)_O]WDV:P+<EX2>_PZLL)C^,KG@9K\K6 ,^]Q5Q9C3U
M70EDBV:^%LTSF/CRYF'S7G?[O\\%>[7KKCX6?U>D,::YH)O;.O*-8+VDOQUA
M RO$?;Y:"#52B(DA*B>]&.9EEWB1-<T%!W2@8H![Q:;(&FT:>X65X>ZQPP;A
M:><=7V>SR5%]?"KQGT=B\]4K^8\V!?5D<9\9IJ?U%=ZW:(LA5BZ(O-$*5PMI
MH15^AL#%K<'5![D('#YN%5<=1(S<AG'#0>=[#5@$QWNZ,T.WV^+J2./8>9;4
M\_Z+O*P^'^F%G\WV+B]3EC[Z:I?6I]<4<)I;H=?[-3-M%A=)>A6Q+-#-L@FM
MZPSQVN@(L*T/=17";"T[,[XS#N\/N_P-LR,-R3$FYK/>\6M>_+'-"YC1BQM\
MBY>1EH [8$*3^4J:)_J7\YS4'CS5Q]YPRWOVW!ZI?[57]U:, SK/#.>]WU]@
MF.2)FR@Q21+_(8-JJ;XI*Q:&(G2CJYJ?K%0 ))-IN\GPNRK=T_1(S62S&!A
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ME75@K3EP8^K4A")F][C;H=B$UCH<="[%"P/Z,QHB-8D1LXD!$=-XTK<95:#
ML(MG=R (;"\CJP+8":=7TXV,&HF8Q=.^LL@7%@5KO A@(]RZJ*6.,[7JO9B9
M,Y)%4&.;"9T?<0"WH3?!MICU,@#RU"V*!-T7<W1NRE'&DMTS5&ZH^9U@?H:-
ML@=OA@TE4='A_GZ_MB%*OG 4R$%\K\>\715)2<*[:,3>_R_V(25NHRQ@[M?9
M6Y,Y(0R$.F,C2H?4W08A2ZY@YS4IDK5+B%LK"7C/7:1-  (AS=A6TB%ISS,O
M#!=G5"EI:R6'^P=[+I(F (&09FPRZ9"TFQE+)D$T^9+$/[(I=\=[D7S$"6L
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MJAY%I5N8G)>&MO(IZ&VQZ4_;RJ9 ?L0.!"L3NB;.'D6[V]FX&6W8X!3CY R
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MR\^S5@ZPNQ=!(T!@[2$TFG'Y+1IQ3S+/^+O*.,;1\4PH/M>G(@EP%OC!O%A
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M".^NW/K?BK5=J/AUSMVIE4 'R2,<MP(OK'ZNA6!*YHO6;8.$J8.A;$PDEN2
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M#JB0.1)I9H#.Z8$ER.O3X2@2?%UG',FJ 2<'G8XD06=X?&H8IWG"=$:27@.
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M*6KPG 59QGWM@_&&;CYZ'X585KAPLZ=!(R",S[C*-Q4$DB_&%:-HA;+,!KS
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M.(6:(+1UI<;6C"[R\N@]7J:N"8BIHP*;4"28XW6QTM[.H7VD[L2U1^HPLHT
MV[JM8Y7QBUGA[*TB#+D;^2G[\1R,V#W+X$-ROK4JP]Z6VI%OB6T#N#N[LM.&
MZ]LXR1(^-169&#7'M+02@"5>BFUQJP$3X93V]8Q+S_^>9O%<=R46%X>]"W7X
ME:WE5P8089#V$8Q__//^A24SLQV5M!* I;ZE8XE-#9@(I[1O7WSQ<IY+)TN"
MU]R 544U $R=KM42KUI D<B,CMZOP';(S]]@J1BS(,L3IKLMEM09GIQ2QT+;
MV@LK42*$TN90>9X#M+C):%77!-C4UV MD:N+%:&8-BU+U?GG?#Z'79X9N^)*
M );ZIIE=8F4P$4Y=B5>_CZ,)?'IVS5XSC4R=HN*P'A$?86U:HW&$"-/&-JGN
MC=&;F)2^0G&%X<D1\3D()T>/S#H.A$XWTL,4KYB")G-@&K$;@O(P!HBW5C)R
ML  .% C")L4#KBGS?Y_$;W^,6%"R"?]8D0@_#._9Q MOHBS(/I#Y5E *])S8
M+FQCFD6!(01V'$:EYJ[L-SJ#;A89GAP3[85026\3LMUAA UC6Y M[QJ/\LHS
M]@_FA=E4D:YNNR@H(M'")9:N8*>)]AIAPMB" Q/G:VSOU, ?EJINNLGIV"H(
M$SR155R;#*3/R"T*5YX,K:+8_RR.0MD@>0HF4U7X"5H'IA)BWX;-3;\")D*\
M S??A,!T[T.):L&8Z<=E#(PK X+KB!"*=Q]IA 4(YJ]AX%?]504%"LK"C$7]
MS)%*Y(*)%T>"\$.;0;?J:.'Y5MO,Q*5!%L2'ZB9$R; @5#ES6ZWP<=]Z/-TF
M>C[#"P]/3HGYM+HP(O@0CETPGJPA4B^%@N(P(U$_9(+0HD-B'0-"X^[OHREB
M<+A;^S[V%$<+<6E09^HGA5!Y"V92&0B$'MJ8FD5'%_CD'(E+PT)!O3LQX4@&
M N'(E>MC=Y$?S]CR6N0]_XCZ"IFD%DQ$U)D3+*Y_2J (_0[<)4.@*5=$:3T8
M0L1>!25C1D3742%)&'9_AZPUU5]8Q!(OO(A&%Z-9$ 5ID4__C=V\SUF4JM_A
MU*H/0B)V VMP*";? !^B!*37SQ3OACWQP ?)\V[+O\/X(+;MV)BZ!9 0TJBN
MD>GPA8[)C1(@ :+E5B!GA(AZ3Q$JJ%(1*9](? ]F^4Q*QEH9 $ET-!1*>YL0
M06\12ERQU_ KP^S?.8CFYHU'=ZF#F) :PZ/]TT\4R"1'B9#N@ %'@$NY9T7K
M# _WJ8-0Y3QI<[N&!V'7@3Q#&\B46U-A>9 "M9=*Q9 6KVMH$$X[,@;M(G7)
MO<:3=;)JPY.S3Y0&08T4T0"RH!S!9>Y:BJ6;=W_*]R-/_ ^8>="@"9 =\9A6
M,R2P'1HC1%BFO;)5!<)S(RATF<M@QG-V8[0BQ8<GQ\36H4842M$@61V="0HJ
M0FKYLPU5?LOG*0@RK2)MV4CQWJ2\+DB(V!5CRK<A-(1\5Y(1":13)M5;I&Q(
M[](T9Z-!PO_+%["'G.](0":%.,J_FJW>#3XP/#EQ;-K8!7Y$UUQYDD\@B@+C
M8Q+XLJ3\TGH@&>+3FT7-V(2%$.[*S3+AQB=* T!1_%!<PRMAR!89DV9 ;L07
M#]NJ@SY*1#MH,R0])K'/V"B]!<%@V7_0*$:-NL.34^(37Z,-I#XTA%7:+$BK
M)[<'XXLHRKWP@67/7LA$!W=%#8#IV)90"Q#"&VU&HR<V"[*,O[8T&&^HW:/W
M45R.7N'"J#1J!(31O_2C:G8;8$0(IPW-JI]:-K.IOL3"F0?EO4E;(&#'-NHM
MH2):X$KP5W&R+<\8UWG"GW(KW](LSAX/[$?Q)_GC#CH-@*R(0Z*;;LM,\"&Z
MT-E%O?99 D B@_%Z8&3E+KZ,DR3^ ?BOO#G\)?N0Z(1),R"YGKR@9JH9YBB1
MIS]<,13R"_=W49HE.5\/G]@\3_RIE[(1H&>H-=B@-DC)T;.\-CA$!6A3/-6S
M%H%&>_,@\\++C_^(@RC[)^#)$_;H)5DDNW&MVP*(H7]/#&AM$(P (CR[8JHK
MEK=+KL#\5CJ+THJD90:ERX]5D6J#?/'#2T8+V^9B**2#;,J2EZD7#0IAI%4*
M-#:ZB\J55+:WZ*X7P)ICAU(R(2&J399V_8GYY7 ,_O*JX;GRKN)G6DDEP.F8
M$5$7$\*=*X%^PGNJ@SQ+X>0^$AL6=:N"?!R++3!#AC#ORMN#0I!+3QGSX6B6
M!2R]\L*0C2X_%O?'JX+&^2WT6P;I.F;OL@H<42MCJZ?EW#3;4^'JO?7RZ*Z_
M,&S6')Z<N^B!T 6&,.I*D"$2ME%:<!J$LE0503:.V35-<"&<NV+$K%GJ>0#%
M59YP@9997_WR!PGQ&K5!2HZ:+[7!(2K04<SA;NW8]2%02R"Y6N.:VK>5#8-L
M';5NVL"-/(MK;.\DLX=S]VXU:Q91.2"#0@ R?4&J@$0<M6W*$2$<.QS_>!6G
M&6R.RA<K1S=%ML!:PG#^9\/K"CHM@C0=LXM: 8RHCRMVTM46^M$+1G=191B6
MJ =2 Z3AJ/U1"@BAU^$ QIIXGEC(WSC3G1#4C8#,'+,[-L6(Z 5MZ*( Q"!B
M+\&,W45IGO"8C\I^CAD/]%L ,3AF;FP$$.&9-ICQ&A8E/RNT$0Y"MPPW!FV7
M')[NN6C\P8 @_%#DS&\6D5#VL8K(*O!]2>)4-AVC=4 BCIIX%) 0DEVQZ/'8
MBM6!<WG_:N6XU+7PF34$LG/4YM,$)Z(CQA9 LJ/ZQ>A?>9H5?NR7&-F3;CP>
M\F>035=RNF4>C^*0;MWM? (D[JA1R*X$$)USQ>2X<(CQYXX+CYB>(UI6#>3B
MJ)%(C4K,]IDKP8_BZUD9P .IKEW4N@^\UR(85,O[T*I=D*SC1J,6L!&%(@^E
M7+M(< <_EC-FV]L7ZI:&1^0Y;ZQ<OM!&BF@ [6.:RPB*0E='E;$\U8I*TZD+
MV%TS%9IB0WBE?>EAV>]:?_\)?T$',%IA>'3@VC*O!0BAK;U1[X^ZE*"?WS<E
MQW^W)CKVGO&>+B6P)3RO>MSI=S^>E5\5K$A/S(<U)PBYE@K^_!+#S#7BZ6%'
M?,6*PV#$S9S+[+/7+/.",/V5=).27KSR7+:^X1YD60W6VM-N?:Z&";5DOEC3
MW%RG^SVQ .%,(#[:1DC% ]:!-ZUX+KW!N!;CKDCW*2P/\G3M_;*"-;$&2" B
M[P?VGV;#-[QEIAO#U\!/]XFM_!(Z$=-,$X3(TP6./O%YND=\^FG$@?! A(!#
M$@/2I@99GMCB1/5*W791D &Q+=06:2@XY%:X8W8OFTE;3_>I$RY;7'C52)'0
M6JI9MO ,UO,1"3:=V C6J0N@^^PX*R@1C%]]:(C?HF^Q*QL!=]Q)8Q"W(J@-
MZ/ML;<:(-0&'F#"TJ3TOJ8W8A%L"K)D46=9PO*IK NX^6Q,Q4G6!B0DU=S'&
MF1?:HK/RE2T<&P%++](TGPG3J,HK ,8^!PQBY"GP(&:)CCR%Z(W">1G8-A@_
MQ!FK.GP7&0Q&@R9 $'WVY&#$&B-$J*;UX0F@7_A^DK.1QC4 PQ9 #'V^/JQ:
M4W4!(CS3>NH$6@G+RF!LRK*J_O#TH,\QHP;[)@D\A.'V/CLJY\]Z&N[!^**J
M5'-^U6)</HFOY^#@Y_'U'/1DWXLS8<O7<X!NA'\>7\^!<R8GSIJ1K^< M37]
MEZ]'9M ](+9J2.BTY.LYP)^IIK)"WK.)YW\L%M4R%]DT#J%3"B>"LB+ =<VE
M<+#U4*<)U#YZA=JZ\@Y<<^4A%*+@+'F%+.=-:NO,.R0^Z-BB#05GR9=C.]U5
M]H-?ZXN3#,2NX$U4%K 1!S[9(@Y'9\EK8YFYVFT9;C'[A\X***L#6(F=;_9F
M3A7*MLZ:G:][U:N!I07!8!$4U /$GV13HX?4EM_&:@1X,&+W+(,V7U@RJX[L
M.N0J*P)FXN.I+78UH=*Z>/H9%'/@7#0J;J%0([7E^>G>4E$S %>V8;T$Q))J
M())>^W$/T+!3-2I;KI\ZT9WX!*JK9ZMKSG?1.$YF1?O=F_NKWO!@A^(M IB.
MBZO5.1Q19BS1L/QKMC \/3KK=#Q=!ZDWF20\9";@5P"K?JH,_K)JPU/J5X>-
MA"T>6FJ _;+IITE6HQM^6E$-/PR7UZ*^L'B2>/-IX'LA8LN7E@?LQ$<<-3/K
MC&K Z9?=7D4EFVPBN8YG7B"*?)&6!_4GVO1H4"+@4(Z#RL*^QF'*_-\G\=L?
M/G]S*/DH::Q^6+%8_6+X[5E V>J/( @BNY"&N-?YV>QT'XWB-YX_O2K[*3\P
M;A4<GIX065:-B9 !(+T*@9!R$8;%PS=E=P/561XI#OB(3O#-")+"L&3DMDK3
M;9RO.GL7^6$.NWF^I0HB0P;-6P*I$!W/FI';%"'IQ08+Y_*(O\];9HUY"M+O
MEQ^7+/*G,R_YKH@9454%\1#[1TRWG&;(+%G2*6PQF_ 6X- -J6Y5D"JQ34:/
M.UW>1>@L6=F[YUUQO%;&"&G5!QD11P;IL2C6  .(CEOC!>.$AU29S_F+6C"P
MB(FW.-VO@W+9[+X!C0,SG^57M4".Q-$J2K8T2=[$M N3>S<DKS:Y6R"5<[JR
M+@B'.*I,R9R8<$UD.[N"L3M+XA-W,4N,P,N_PW@@YJZ)T7>C^PA!QD:I;JR\
M1>?14;=1 B1 :/_8D#-"1+VG"!7&IJANJ/@:1,$LGTG)6"L#((G"A832WB9$
MT%N$$M*W"%2\>.]J7NIE0#^)?%>ZO&SW%N'%%;,0,F_?:\3KJ*H.3T\=-0OI
M(4.8=\ NI#C\EC;1()I<I"F#_QN]>._-K06BUD#XQ.%<>A0WLAW@@!&-<26E
M_];V^I$E_!?>A"F>#D:KP1Q*'+C;1A'4R)# !6/;D:U[98MKVTL'QQ<6\4SR
MK(*->854]0 M<4A1$QX-H"%$TJ;B4'7]\H._3HIF:-"L#@)P<+(V1XA0W#X+
M1Y?QF*LPY>H7Z>7'RD#RQ":?/3SS\*0/^^=VX9E'Q)97(V$;;:%K '_6\,S#
M?DZF-6:VS[T*.#]K>.8A9=R+G!(!AW(<#H9GWLC",V^>09G[&71VN.65WNPT
M:7AF"T:^7$H8^7(Y/#BD>MNO,27+7O<G4;49)[=/$DYNGP [D>NH,26+3I,&
M8HH9*=X \A>45#_5.*E^,WQY^D\1*[4_PT1 : LWXV6KV_T)E30;*Q??)&/E
MXMOP\)S2<=1HL"Q[39H/H 4G=R\23NY>AD=[5!FJ&G.R[#7I/?X6G%S=2SBY
MNH=)P#5*%IWN979E6Y<PCHALM,:LJ&'0ID;NM]OUJ)\N%=3"8(;,W? ]A5GM
MYMVFVU74&@BPGQ[Y#8H;N5UQP&XG7^:)UB)0QH^5:7_YJ^XM^<M/%P_":!CN
MQ16&IZ>'G8Z]93=N@RA(09!?XG@DFV;%%:#?Q*F(9/(4CQL9$DM&>*)5=(GL
MSSCY?A<53YZD6J2N50!1$%]H:$&J (DE<SPUJ4_>CZ\>="+P0BU.Z^5!$,3Q
M""THW09BR3A/S>@#TUHIH!C )KY>V(*_9?]MF?$WGU?J=M_1DQ1/JTU/D/IA
MG.8),]E^;-<"CLYIQL%583#-5$$"PO+#TS/B_#Y*D2J&QS8:IT(!#"[EG/5E
MK[@M\FW_\$:_G?+I&U[&.2-,V[,A9H2'>D][X9G?X9V/,\+</5O"WN9#T-O^
MN.=;+4,ZUL;MPB""OIR65-.:"H0EEW[WEL0EH']Z85Y&GP,3R9LPUE==":1!
M;#+&&%+PB2#9W3,$G>R\X3 _9TGV<1&-^*LF<^XW@3/%ROXG*M#]AGS1B\?0
MB[)Z5S2VY<JZ0.1IIT-J6[I;?=-_9$W>!& COJVM*7[QZ#.#V:^]O0WUULJ?
MHE%[>'K>FU?7=)@4:X,VT'X=*&PH@E:*%8W:(!_B([TVB88ZL(FQ9Z^L58]M
M)/Q-A\<\\:=>RD;/\3C[ 5+3>I%$5A4@$^^JM'E9I]4,H-N'H7L&N/BK<7>S
M>1*_E4]\*)/I2&J!4(@MUPU9U\;6GT#H)H3?YDD49-QF&8UN@W?^+S7?>*7A
MV1[Q9:V6=*N@]2?(N@G;7SV07L22M:.2DFY)+1"*FY.Z-K;^Q&[OP")_3GSP
M:K/C%D#I5V9:NT;Z<VJS\$K,"B/].3I-4N6*M9\PZXSP)8HM80N,]-N][6/:
M5OO.DW/"0'L=7K9[ZWCD-CIOZWA3U)5A#28.T=VI46@#I[NQW"C";RD;Y^%]
M,)99BC5JPV A5@1=$@U58!-B'_.RVE"$(FZLB0X4%4$VQ &,.Z*_ALY6PE<B
MYB]\/Y_EH9>QT36#'OM!%1DW#UG!532ZF,5)%OQ5_!Z5B$1';'T"Y$V<=:2=
M-MF50^OLMN>EWD7\&DM5UHHU.DJS)"\>$BXBNB>).)I=4GIX>$:=G+\9TVI,
M?4R :V.=D =%RZH-CPZI0W%VM$BLP%E+KTL20XU$<O0DHGJW 1QG>QUG8JLM
M#)*.UXM!'_OJJUD7HWCX;$/9U76N?H0]U?'>O,]9E++/-VBZO9+09=33V7Y?
M/67KXA</-C.8SD8]W44P'MDRN=P]_PAG21[M)*D%\G ERJE@3LR^$J"ST4T(
M,F5<D[0>R(3\DI*",".>ZZCZ=1W#@.FK.,T&XR+AL=(#OE46L).'B"NI$7.*
M8'$[;HD'O(/\IC"+7;,W%L;%/%;MBC0>>%36!B&17_-H2+@V.K<CF<I<YB&W
M?8UF/+5#\1#!&]-5 JWZ("CRB]@-U<  G]M!3L\L#'G>FVCTU4N^LPS^K:L#
MJJH@'N*(F<;TZT'K8;13GYS1^\1.*!M[=UV<_0JF:FCYVO"$:!K"-FH-#_:I
MTV_HDJ:VC(FQ68K7HKHB>.'[2<Y&U83&8_3+5(GEA=C[P'L-PB +6+H:0-I5
MNK>I7;/7S"BKA[C"\.Q@SX(?[IKO%(+7',K?LD)0RP7DB06SUQRF^B(H'G/-
M:3< ':;.QR<1I,!!9XC,[>QB/+,6?)E?A($14PW=<I0L;IY+5%2C-@B)V$JB
M3[\Q+-(D9%@>W7(*O(*2//_L2Y%A"Y18?&#$AK=9*R -ZG2L9F.\"3RW\Y-5
MB)=3&3<8I>H1+JL&8B&V>IL/;34>MTUF%3[868Y9FA88^"*F3312$41#;"AK
M3+44D=O&L;L(/LS2[-'[X.=#-<GB"B *ZG<MC<F5(7'<T)5YT<A+N-Z.<C_[
MTTL2.!U^%-KLA6J.M>J#H(C/ON:4&P C-7C)]V6PPRBB_^"L"ZL/RJ:J"N D
MMEDVVW'A6/KS=$N345N8&2J,-3.#>KC**X)HJ%]2-!ZG.HCZ\R9,PTT6?ZXC
MK1:?A96I"?VF30W/#HD#C!IMQ!I@M':UD20H5ML0V9,P66O6R<.#;G=+M:>@
M:RM+<90OKE(4!SS]\#YE*\.#?>J,MS+1(ULG8WS]BNVSEAL!P!'O>\VI6*=4
MA*=?<7E6,R0 0,+WO#8%C5"QUM=^A<Y9OXP/('MR&[\4]S8EHOZZ;=1;/S3!
M_%!9JI,WK<?4=*H/#PZH4E3;FAD;P'4V-_(ZQJF73*19D47%N0R)G38&3.E0
MO8;+;2,@')4*%_-MG*QAE$4Z(55 @*?$-H36/"NP[<K<U\E)D>_FG_/9S$L^
M!F/N<HXC#G4P?ID&R>C12[*/8L/O\)&PZSN2K]E=<<=:YV:7H#3TN*>VU4-)
M,!@"HU\'.9.;'-"U(+OU_"+L0G$W:[LPH.^!AT-(B9A!#$*_#G>-"53>M1(5
M'YY1/_.+L:+#81U#SY)"O_R(7Z9QGGK1Z.4'B.%C$+$7ELSN8R^2YX16UP3
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M1.SH<+F)@^I%W08;PXM)PICT97'3)D!LO:)RDQS#[:(0'>T#O5@JDEEAF++
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MH;["&B -=XPT6E@09HTM-DW]B?K#NNU@1M3[V#%3CQDRA%[:^)^ROW+^5D4
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MV/1(ML?X%B7,CR=1\%<Q1U;',]F& JG!!>+X656.#*':':-C[2CNS8*H6NH
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M=ZBRABV)0((+ES5 ZNN6.P\#?N++EBINQ(RB4&R)_=FZ<7G#GH/P_6R9._+
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M=9MRV#!XR]/A9ZKHNAFE8G<P1^JMS. YWXJ_\XYRSUXY:+['+.7XV[B'X9N
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M";5ZKH(::;Q_%PHB;>,^DU45Y;/FK*84_Y.T OLYM )ML(3T4B48Y#*5 U7
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M LG6/5ZR0[CVFK3C4VH5(04WTB.W72@(E<9Q)5M';?THEHZI=(64]A<L?+7
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M[$>\UNU]B-*V@K4[4TD>S(=WHK\91.+9].R-I<$S6Q_\E()0M7-$C16.Z:O
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M@/K46. 22&BE/P/82C,8W@G[2@O[1#T>]4>VV+MT#.*YP$)C_JW68TH_0=N
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M&>;G@5MJ/[7E0:)\HT&MZ'N!XLV=Z_/@-<J#>75C]YZ[1?K&IE=)>E7D1<K
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M.GW'\G<J?\%0*5T":PBP]V,3HD!HZ2I\GN3!?#!:SXL4+-B:W65[, %1DL%
M)#>!=KX23]2+;Y,X[,CXYA7<%E1*A .1OH/5UE5YAR[.["QLJHLB4\A@O.(3
M63"'5:_A91J]ESZ-1U2CAKU0MS4ST-[)'\:W]$+D75_Y-#X^]NL4M*M?X4;P
M7!) %ST>06_YIJ?Q";4"R/ ^U,3NN0* $6@DP-[Z74_CSP<?;@C:1D^K1&"@
M,B,"<S;C/ZL*K;=Z&;<.M1"GI1/^+O#W4*5 ,[QJ^HJGHX.Q]QDA+4%;4RIH
M%57IUTL,HJ^=WL=-2:UB-)#_*"S06>F@8]3&<I*Y3BXIEA]Y-#KP?@K2PVA-
MU(!F!$' X7%;O8;<.(=[LS[5@MI9[<#1SB\-Z6JW!9D HL/;P?QA!ZTM402G
M\\.WROONR@!!VXOEM'G/73N[9_/2P\LH^L?)$5^'>RBZLY*ED7;O5K\*P!)+
MW+0A1Z>S:X.WE&Y.=OU,"KO>G>]8&II,#NI7@04]6SRV=!\<O*6T<ZJ98U,;
MHJ;@L)DS;A)NC^B-VP$N7F5?WE?/OP\_'2RK6=RSUR0MSVK5(S_6A'.W7N0,
M]/%KDZ[5N+@O@Q9CROUF)<L%/KQE<OTJZ&U>S UQ3'S+6,&1N+-:0>U564&+
MU9^.CXDE!*RPUW0,'<A>E2NT6"7J^)BR!I&"% &-"B1.%#K,6/BOY^3MCW)5
MD+Y73"[_L"%R^1=/WQX$K&W^$8 1Y4_I&+Q)T<YGNU/CT(R4JWL)*5?W@(ZP
M!&@[4M:?[;F<@MFT<*-1S*?M*\&>Q%OD'J9+2U9QJ^ZB@8-M(H 5,(GC;#\*
MT(D/T3JR)G8%!&=?=UH&V=TN YAW09J_/Z9!G/%]!7_ E7KWZ.>I=[:JIL >
MW0Y7_&U?WAO_8K"QU7X?AWU"+("GR8QZ7VL*VJWMK(5NT(2J*,NI_Q(P%W'4
ML@O-V$1N"-^MS7!+;T%WQ/C# )]X/6?,E9KR!C:J#3*69QDO7O_S^CV\CM]8
MELNK*(N>!53$&0JHJ9O,J""X*#+Q?W\\7\;\C:]IE+%,SH[H60Z-6I'4A!T)
M!!<U'N[9HLC^3)/B]6L0!\]E($W.$=X"8'K4CY1 7!1=^,+B),K/7X)TFL0@
M^U_,X4Q#3IFT$8 ESL<Q84T'"ZE,0N?UQ[(^=IJ"\"0XI6)A*GP>+$%][F9]
M#2I#VE7L@&RY68,#H95;_OV;OZE;2UDYWO!-8&KB.).,4+$+M,-H23#!UH)U
M,VQM%%+E(SC> A 27]EHQXE@;%>B["R&T,>4#+E>45P9??79<C;Q%N#[^\*F
M$B6MQ '>-]^@\ R?BVZ3?"-A_'>4O]SG/Y7=5-WX:7Q"76O*9H_5!DRK.H#M
M?Q[_AL5'!(KQ\&77\5WQ?1Z%DQG_(N7"6J_UT_B4.B)DC7 CQ+2*  CC=VGT
M!DF6\R#<N.KCWW*BI8V>QI^/]Z5#ZP#U_+;^!?N>7\=9GA8:FZO=AV'R<NB\
MWL[."H5IZV+]\/NJ)J3;8,&4P7RL"=B"N"8S2I .GSM(;-V(M[4A>OR9/+XD
M11;$T\>?_(/?2VV'K<6%8HMD\@[H"TX1NL.0:#UM#M#:G7:+([4B+?6\O%.=
MOL*X!5:19""+'N7 /Q-OH.R-S@J0G2^9#YIO?,]>BS1\J9>%V<8FS3_6;@^F
M) I]*@C;9=<4E*TKYK8&[G^7W_H7_^PBA<*VBXA[M7R<EC0!D$1'$6W($(S1
M:G"=+X=3EV->9MN?SX,LF\S**L6*-33:!O83Q$=/]I?2*K2VKH(/OZ*N U*N
MI7<?AC 0-=L*;L2,HE 0*CW(<7I@:<2RL[O59Y;8E =,DE9/X_$GXA4U2A/2
M3Y5@$'I]$;1$!K0;K;L,\J:PGG'HBE^O&8[;H!&O,(Y^#=_IK14./CYQ*"%+
M0I689RDJA%V7"O& (@&+J_#L!3<#MM"6MX(X@YN)['(6]:$A5+I4-.<RGNHS
MN'P8T)%?#[)#7!,1PA=M=1N1".#J8)M)R5.W!-S$YT;MF=2&A]!J'*6R2NLF
MOZ26I2!C$VT %O)V'%6A0K@S5S2T>H"[G+$GL[/I6Y0EZ3M?RK]%X5I.[#'Y
M4F0<?);QF>'[$A5ZLMOJ;6 ?XO3*]JQW@HS<_? E?M4\=KG.LH*;,(UBR&>8
M:Q\-;K4#T_@X)9N 0WCWI1Y-$^)5$#*E C+6! SBT#6'CFSOX$*(IDW36DJB
M!<]\OS\I\BP/XBE?=9P'KU$>S,O0#3K JYL"<C>O[.F,YMKX$&9IT[$0X)M4
MX"O&T.+V6HT!/7%HLCV[)@@1?FFO_R$ :NO-%@1OM0;\WFZDC" B%+L4GGK(
M.1+]J,;Z\:?#,;50O*VXQC8FA#7:2!0V;R2+11*WFE$W+9_X;_FX(#:#A]#J
MRSW#AP!.3TI MP4<>_$_O'#;9M4&X#JNF4UV*&CPFJ>CPY'/1P<ML").8AS^
M(I-_7AZK_ETFE.>3]!YTB]?H65BD41ZQ[#R8S]GTR_ORN6SYH.QXJ>.;P< ^
MKNOLPD?\BRPC[.SY.2WK5MPM<ZGNTBAD("2VNB*"AUA5+3GDL;?[-&UXB(A'
M]PC;((IH#\7WC/U3\%=>OI6W4=Q00MOY+ UM;Z3)T^CDX'C8F;KY)4IA,\'C
M_*-'U'H <GLB,RZ.Q2TY,EUU[0>^M@QXE]%1UJX_RT$?$I\S2;AHDJ<"X98T
MF(JYY?=_B[-7%D:SB$WE.MG8\V JHDV1BA !?0H43FAD$ZJKG%#7R=3NC#I
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MR?VQMVP]]JQYX6]O 8E1O"6*SDG[MQ2(T5!&:B>TH2PT@)\VV"<+.+X+;*<
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M>?((PGV ,'26&F="XC!Q_@C%O9AE<)&:Y\"%,^%0N#AU!."^ -B"-6/S7$@
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M_EIQ_M2<<;#E+EYF8"Z"["KA8B7KMTRY**E\89YMXB490 50I@( OPD5 "J
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MT'H[0?5#0'<RU<U9K"1R'2)/X39'VO1$XO&V^2Q^I/HR8GC%"5I[:7*Y"%#
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M"EX4'T6H'\_[Q)$U@ZA=V3( _O783\G)^.2YUY/[K>?F<<#]\//S=Y<Z#7_
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M(#:Y2L@0!)/KIG @%O=DPX/<"I$[%:^D >*V[*, :3$A'J&U>;"B?HQ;]R@
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M:/KL8@CVVI8>R+O4-R>R\0N[]D[8 %Y,7?TE,DAO2@=?.[8TTG2B2N^:,Y;
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M??=D'26?&S:QVD^AER#1)87D^0HH]BCV&XC][>?^Y\%GR3_^8J&H<\.:^()
M>C _9XLX\]_A?VCD,C9B12>R!3-SQK],Y(^ C&F!V1UN"M5RKW"C(Q[9J\..
MJEK$MOU_[N WS?57AL>-@Z_-IO3=M>CQ'DM[6PH6X19AE=!P!1][UM!\-S;
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MT6+7YINF+FQ^#0CK\^;)V>E/\L\_M7[^Z?+G(- >W] *-IM6"<G',)S!(YM
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M'L1T;>JHT1@3D(YMAV5,S?86(?YZ:6$";-..+IFTD-RPA)I[\DDH U%S= H
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M=3;8J:MN][H^L#D]0=B4!9O3@Z_@R?RK.P38W%YUI<[#M71]^\?M=1<^W#Z
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M@J>68D\0/H(L%PZ!JA.:63/\./AFX'ZI4X-?W)0:UOC&#ON=(F/5J78M2KK
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M*'%XAKZ6%94-S1D7J6,9J;4ETXEV91K5'H*W?&HYO/=-GP]K8O_$E%U>3.\
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M!%B"Q_P#[(J'(N@T4T$G,(=[\X$+8R"4(IVQJGHEL%;5DK6J<^K1I_045?>
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MX$=Y(;_+"SGN",I-F^[;W'3O*G.T8*F:ZVT\131B'FB!JA1T8_#OY@&( H#
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M;G KKU\_IPCKPPL?"WKOMXNS^_BW..+PV(WW/GAZC9/J]/C!V$GUUQ8.4+Q
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MZ[J>/BU%DI:0'<TG3SL9_"V>]'BZ@STOO9D7;BQT>JJ=NF:4S"OL_R.9CC<
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M,8Y:VF+L@88)2O2XNB[Y")H![CGOPK)BX6I]%DG)-Q<>G3OGP:YUK;J8EM.
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MN<Q8= @2>/*S]CF"]0 B) _\&0&4+6N1>\@O#7<@1BIQN)G$PJQ+Q_\1PDW
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MJA;_I@P0Q5K[=/N!CHRLHK3!$%RR-7+1'&]=2AX7\WR@>:YK2!LC)V*;5=+
ML&FU7=RE@>LF"QPE8+Y8Y,4B'UKF(#6NPZZBI&FSV=4K2R]:ZPVB<Q=@P6^:
MT$^(>S<;:4LJ?\&'];RBU//THP\;P]^#EVZ/"/SX"_%T%F-""NMB\UWPP7O-
M>X?'A!;:Q?XO]O]0W+0=M?6HL3S2H4Z9.WR>P8E],T6"D0S.%N]4VA@9!2:3
MGLDEX.1(+( 6,5^L^F+5;R#.(/Z>04Z)P""2+[_>M4NP9NE9\&)L%V-[<$\
M9;#KU31(R'/TEF298]&OFTU']#DCRVM;U5=BBZYL>O!-(FNSKG;E\6*\%^-]
ML/'6B"JG3?R'JJE0U9@_>I&^X"1 $-'#ZI=J-0Y5(GYX,=6+J3X4F.M/1BPX
MC*QY2\<CSBPPD*S>+\>NYY8#3GEY D-!J#@_?;'-BVT^T#8=L(I3^)H?D(;!
M0\FG_=5QM:O$7!&@$A8H')16HJ.#&I 0?+1@%4<Z8B5H'"*CK&_(G"XV>['9
M!]JL RX2F3V%E9OV/)\]B%-VY>J5U.+V@ 5+!?3G,=C^VG)<:M5"=BQ5"0DT
M4-<G*:B.<0^;17E3UKN+95\L^PU8MA5M;\. ,M[*2KHI7L35<OU9[+8DDJ 0
M]G9ML.F]\//J%<:&LKF+#]3'E\,0E@2C 2(S-QWV@+W^>SL.VYHZ.ZI=_R$Q
M> ^8:5I#(7PFB#-)\AQ7X?6AY$[+::=P!EXI,7RQ4K//*%_6S&7-/#2"F4>:
M@+4W>/#P06+F)=3(XH7)HERMPC*@CV!DGGWVU?,75_CQH\\^3'(;) G3MJ\T
M1;(*D]\S'5%O*0ZN;@QUF--Z675']_>"UE&B&;(*RX0/IU'.C:,FG @8/9CC
M6";-\TH;&#]R64F7E?3 E30VU#8%QD?''"B%PD(<^K+LNEHYNDX4PR^V>+'%
M-XT'*G_QU6="U.[KZR[Z3Q:^HJ+TQ?HNUO?0#N?REQ2K2S:X%?9X:D@JCV&O
MWBWPN?]F@N-_NO3SS/3S7);]_X!ESPW"J^-BLZ-BILHF>?KP"$=7I;FU(U6#
M[(N276F:2CHY/5;*P]S#=>JU*,!,>J'"=SPL^U*-NACY@VEZV^X5I3A)-5$R
MH,.161)284F.J"1G5/?6@[^'ZB.4<ZPWX&*7%[M\,T2H%,_W6\*+T/F3W2TY
M1?0=46^[BNV:4')7WD;>=V)192&+M"%@51XX78IL"FBX+GPS%[M]$Y1NGK;#
M@%+ GDBKVL2,FS)8I5<47]=]2;W$7O8LA+O#]K_&\A6=1&[:W:IL2)*1$W['
M8K$-P0HU(-*?-[NV7:O^1O=N,,Y<,0^%-(Y*?]AF$>(KUJ\F'<!52B(BQ!BG
MFHX1/R5J(P"_]]5_C5#C%0F$LCFA_C##3').R615]EL:V3O:;W\;V=V[FOI_
MJIR,26F]J;$O+QCE-;D>="JS6T3:#DK<QOIA-"'<ZUS<W:+;C\LG9=]7^Q#"
M5KUVZ#(_"/M@1VCRBAN!;\9=$X96"##$14<G+S*C)';NXN['ZOS_"45?8AXZ
M.88;]%1&<?0W/8"+7/0='>[];W CZFU>=;' B.JW%<;#-?>]UU%DK5=0W&S"
MB'EE*66*@6([3; ^\ZE!)&J4)06AQ#:!O$KG=+S%2&ATFXK >&5W],_-.DW:
MHH\J_5(ZT$M6\-H1'U4/E:@FO%]-FE0LGR)"@Z84)1J/C*^*8L]P)L-MZYX9
MJ4CKW!74H#430(]QS^X%>)@1?$4"U@H[ ZX]' \BB,K>:B#5BQ!AEV&D?GD2
M@FO"VTH4HWJS^MJB@X%'KLK5-CK8^(S4LLZB6O1PUR.1D V5R-=#M)-\;O"%
M:WA*-X6BJ\4BOA1E(:\/DJ5!)=0Z_@P&6$BBE!H@OJ?V;C.;49GHI+H.;A$,
MCD1&87285BJ.?XC8!K:(ID7]C0!RP'!Z/==TEI;5BAB>3EB6EYR5<;8!#H\
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M/=,]5]'C\)Z1D063T\8$QHDR_*P !4_9#3@BWK;=;GU+X'U;"-[ZOVF0B&W
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M!.'\B$N5<!B?'$@HOJ?TBC';X81"(135Z3Y]YF]'13HGT7Z@5-@@:TLBK>3
MXY^?9-AV]&V52>?$&6N=56EMEX[JV"V-E"D,UV>9E\-5UIPTQ6CJ%:@%(:SX
MC&'CA'].YZ&D_/,*65$;="7W/E4Z8?W$I>BB,I= PJY @K)APU[9(1=< B8)
MG^_HQF%T:8:]X(5?KRNL[%04E5;;L ,C!3%E7GH<+M;U4.M:U3<UN^>.4&6@
M> K_-45.HO*]V-G%SMY$?[5LC1=KNEC3@[L >QR5^+22]DW/'+(N%G>QN#=H
M<1LF01--^ R?=;&UBZT]7)DJ1/J4)@1"KEFS-].N')*-V0F=)RL' PN1H(0N
M-GBQP0?98%=MQI[3+B10<4#U3\0=-*$2@>8NH689GPVH1#6)!E[&@[ J<S[%
ME"*2JX'O;7E<C!<KOECQPZV84KO2$4%;MZ,:=4+M;4_=KV2N258Y\ZG$M7@Q
MR(M!/BB,K.I_ WM(O5&9/()'CW+%8K$L%8?PWZ;A_Y,+D/!1&_Y?J,8!UUJ2
M/7N6C"*W3E_^H9A !,>BIIMXS36S1NV#LP7@35J<'']/1<2H5A B.40]2C%]
M^V[W1-K+*":8=#X:T6X48]&:)M5_(MIDO@RG#XY2>]I3CHI?N>&^ 6/&UE)J
MW0EE?P4N7O"D,GYH\A[]$':8*NOBDSZ>5=G0:-7, ZZB4USIHZ(N&?/3Q9<$
M;JY!';N4_CE !=Q-DHX]PD=/Y1<8A;VO>V82II>59D2C3^A'([@7K4]R0&8:
MKU'@)-DP+I6QTLZ<$85; +PB_?_2O$"$NWW-G?EH->>QGVLS);!YH?VE0@.\
M2 _I$\J\S>G^I(B,N*_Y!,L]Y@%O2ETL3? MDUX,U+S.D[S6:/?M(UJ^GT$@
M^'(LP1#((*Y'JM4.E>I&H@/]'&3!, E0.>VK&[17 B7*3-:P'.[)ZQ,O0$3L
M7>59QO,;/5U\4?6'>LCTA?C>H)NGSL18#*:5)>(J Z8@W.LZBD*P%07'0R7P
MJHO]"? $;$E2\@W[[YISC%UUJ.BON1-JN\A,G4J[WL,'/%U\!0Q12>W5!;-%
M!Z?8CCU+R$@/:YE]3Z%IL^3=86BE?%\N7GQ[Y4]7).!#K-F-N F>=VK4Y-;6
MG[95M'_RXB%ZINO$]Z+O2?<@I5R#7=''\]MP<\@8-KA)"=\W-E[]^,75\V]^
M^/_Y]KK&]?[7L#_XQ(^???P1RZ5T5:JQ(]VN,G/)(+'5Q6ZL^[IE1EX1(M9O
M9;28DW>AAFMX 2>NRXX9RU^IP'6IQX98S>+4CL><F3\ZA5T-VQ3]X? +]$DB
MB#(-&KU>7&2K4A3/"J\CW!P33U7F;E".\<U1Z''\ 8DA(N06E)V"&C,OJ(;+
M0>C7'X2F!D@;;H.3$7I 2&V#=M&J9-UK%ZJLJ9]OS1%:V\4 [9(PNICE&R#G
M(R>JUK:IQ1_''?.^&TD,J"]V>;'+-V67E#: 96HN7FB67=923G\>Z:\M^ ;D
ME\B:$_-10NN2Y+P8ZYMUHB(B1EMY/-:U5+-DVRO7[6% ZMU%O"=3GF]3X/(T
M.MXE-#A%D,@5Y6DO"E.$]@8:@B5:$N^]C5#TS@0SUTR+I-CJ&9Q+,6WAF-=D
M]1U_RPH-($2L\PXVO!D9YV9LC+%0#(S/("^_?.Y24M>Q&22L:2@M)EQG$)2+
MG^FWX[!N;QOI1,8EHN2YBJ-3OYM<3.GJ?"5)VF1JU82O$[JS;=VIGA]:LEY5
MK#TH)!?QT4TKL+#&#H@QSHJHXD66%;U3I,/(&=36,^0>]I[@Q=0;,8.<OJ0$
M.IS7@!PT47GLHF5%FK&V<>=V&Y2)\!_W@%*OD\_DJ99*VB7^V-0U=)#6^7/Y
M9*3,;^J*15IU^TUF2%*Z*F-,2=.2,P5\*=%M]@;I;'$YKHD:C[76V-A9>9#M
M_ Z32I59I6;/G<Q')B[94+8Z[/:5MO(3+]3(G!;>F4@;]DJ=-R5TA3]7!F#
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M=Y50:YO^ ?!(P'$G7DWS.4E"$(NN3<DSA2XU1.)HTF)_X_>A$"0F&A8]A[@
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M30K(0RSC@KM$F]U9*U815RAC;H.5AXWDFO1_K>=D9<=&]HEV4$2L8?<4Z5E
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M)2+SO!Q;)9GB+ZR:F2<\UD1L#YNYD?2HO+LO;/)YB7QTL>"694*)4(:+L/Z
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M%V**2A*O;O*,3IO362?*/Z(Q&C/ "Z>&M%#)1-0&N>22W2><QATWANK1^.<
MY)"N)L%!M:O]YQ'[LPUQE]3D JEJ$DL'W\A),AQV6HI+&*6(6Z$5"IH=OHNL
MG72HQ'PP75+.$2ST8">)\R8_SV8K)><5IS7X.(5W2CHBYRLY[P27RP];177&
MEH9JUU=, XXU MU+[OX:<Y;[TZY%QBTE)R=SN]NSF$*[).11C&N.U@'+=#'2
MZJ%]_[ITS.T71C]8&!NP(PY30"MN^VL0K>_LKD .$.7PO(2RMA$Y,0DNGE+-
M]OG:D.:W1>#(XC(/O)&B?%Q@P030#QW5DJ<0G1*")O/NRQ^%[$6X+@M?1M0/
M655"D<:/1AF"Z/)?P:'NH_S07[5'(;PF19QKUGI<.U?ST5^UVLV.XJ;*@$4G
M^CBZ"&+6?:F4MDW)7ZEB[^)S4JFA<%RI9Q;]+?WJEH:;B(!VFR=AV4@>3VCP
M1C0U$O\&XM[K$KQ8BR5?JP"S.[TL[Y*M]$GN=MJCCP11F.@;IMDD_UT8AH(3
M0)0,UCOR-_"O_%[81V4,ENU:MOHF3)8<G=B*Y^\]K2G1\'\R,^@RV!8UJVK0
M9CKXC*.= <_NJ&F!(;338^W<XCS$P/K<X=JM5H?04.B@]B28^L,\BF\*A4SD
M8Q^AH>>'B';1Y0O8^%ET5>SCL=9;<D#4<AI^LG.3# Y:CWM#.7#^FODM>8S_
M:ZQZC]F#$ 9F%,5"P<)9,2->X$3R/+QO&!)B"QPBR_R!3KQKG>D4TF3KE5(&
M=/J/O)'2\D*G62X5RJOI10EI<]C!&9!%A9=7=3>8?7K,EH$6SQ-5(N'5I=Q$
M(4U"@!N+]ZZ)A@]WM(!*$(%A3R@,R%,L#*(4P>,.=&Y'5P=V4OPID%%'=-QV
MU61.W[Z%OCB#\8R 07G?M5,#]D4F$<G67(1;?JB5,'"(G;.__MCL-'ZD#J2=
MQ]BA32QB0?SWPFE=RSS-.CW>IM?7?3?&X.H#EQ5@7^(A16+MGA\7 512;5,@
MHLM:S<(((K+W'M>7LX\+$+2P+Z55C,I[G)O_])*;?]M,1RD01.M *,1YK$ZZ
M65X%>]SKFM9JE".3C1!4\X.$(J<N!L.0*ZL*,1V!Z&57Q57N%BMM<'&WJU0,
M2\(N_KS#5X6=@8]'GN@,_;(??9)A/)/[<SLF2,-.W>,%"J9QXZ*2-R41'$&(
M TN&UZ;XC+F,!A(R+:_#<@[1G&A(\.[I+F+:8Q-WE0<^/.0)3S%&>#@>A),>
MI$_TO/VV4A_ZT5\(.C1L>Z%*VT L@D\X#4-V.$V-8Y4 RGZ@^)66D*>36E:V
M'YO2I>AIQ1'=4U,!UUEN&&':>Z?OCT9D+J=WF\(@PK/W@>4XT+,+&#5-$9]
M=&']%B5L*CL4<.IXG60&$'W>XS62+\DS=WIY$?[%<";V^:G:9\EGUDYTOEQ%
M*;$!+HUI <LEL=(W0S*,TVEAX+8MK'O.ZIT&EX9#+.GILV2S@&[$^<D.?&Y\
M69 )@YP,%-OC_(@LB/GZAEW!&QV."HN(4SLRLQ@@W,\I =>=Y+]F.'-G'58T
M(>X](6Z2'M2\#*TXZRBA)2>30%XXO:FUD<"#^'M"9@'. 6[AT(U H/.34^43
M_=[9U:0@0M4+;K(Z0L&",9(*4PJNJ5--V=2!@O?$B](H,WS4:I**$\HEPH(S
M=ERRL2DH)^.4C)$5>G2(7+=*3VBV==:C,T][1^' FBH'FP1<I6@'R@EPCL(B
M6EG=G+SXX&>BM-P=A39F=_SP7C XQ;B&*%R1<-[I33W-(_!<N^$"C(V'52BD
M8>7(9^H:T01Z=GB*CC!SWCK-OV:L6AU^-_I\G@74!2G2J*+M90;59+BSPW"8
M-[+DPU75$76R4YJKM_>(6[A1[HA;*=,5+UP1ULR=M;HQ,)G'&+NB&^ R J0U
MO4CWR4T4UV.7Q.3A]SKF<"0TI.UB4@PQI (M>OJ5X5$SKQD[WU=;HFY-FWMD
M4<8CL%M"CCHR283>(\IIHVY1$N8X83][&D@:1KR?LA2!B&8F*-"<[XE4D+(U
M."[[&8#R8Z$;W2:<-EW&[ &;2K K5W=WE/'\9QQ5P>D7&6%T^8^FOG,D8DTJ
M@A",,@YA8>=.CQM39/F!6RYPB3&B!0%%GKN%/W.@RY"DUZU=_Q0LC4$/?/AU
MMK4\^B80Q;72XMT)]UM^LG%G<1Z5>S5#Q/8 =55\[N?]5O-#6&ZN.U"$GJ6/
M0M9^/40R&*+MFR25IBLJM@CJ>[OYUV9=71[68BWHANC?=%O.CQ<E"AA.W;9I
MH\L2[R?1C'D--*98YZ Z5H^0O8\+(!@(,G-PY0@F?<S827=L7VBOZ%(PWQS+
M2FW%QMR2*VJO-ADP5IHF0X259XX@6:<@/Y)<"(<H,\]$ LNW*84_"/4/=Y+J
M^XA_1@PF_EH Z.D<E1UO;EMJXNQVZT>AC,4*JG@;CJJS$G/%UGW-/7-78-L/
M3ZX[-.Y4-S6!5$PQHP!%$F>_B0!T+M*'^@QVHWOT*775$YHE"7![ZU3"H8HO
MTLMC%$RY4(F8</(U(XN<GL,XB-6UA;7#A""K@1=8D>]C1/PG52I374KF-NE1
M(FUQ"Y\%/X1_%';7#,5S8BM-V4*UV2[>R:[@/@H7DH'MXI[WPO?MB[U+G'.?
M4)A271+A19^9N:HBK9#NVS4:T(GZYJ9]13]$OT__\A%?VAZ<;#NZ]UF >WK;
MN6J<%H$_+$E[7AIZ9$ .Y?!QNS0;P-VG1$WU,A0P&PF43JO=.GU'P<.TN\KN
MT@V:S@EK'&CQ4R$#2#+:OL^P+'FEN^&6>$@G)5W<\?6FURXTH>"[O#@<R^J"
M?7!7<^1%]'OLX#ZQS:WGK6?QX:REV^:Y%X8J:"?"NX+90>A9Z#768Y1#<J^5
MYI#.1(N/X(9I]^0MPC:D,LK4_]@P98/ %AF9:CC%%Z8LB*T6"6MNDFJEBR^\
M\7\$*TL$(3BH"5_F[(0T4:CUX@[A^]0H,D<\(%[LIEU-7+L3+T)C(_ #RN\H
M,^+?C&C]Y%6^_-$3]]4*;JFD,39/_/15]<H_1!2>I\FU>SBW^FN.JY/K(* D
ML]TEN3QA.Z 1#>;'S6!$PR+"P'O*UQQVZ;83+@5MB_>[^^)/EPK/VZWPD)VE
MA0*+#6P[R\R65KEM/>[ [98/")QELYNZS/,XLQ.]A<H2G#9#F)^OV&]+2_PY
MAQS5YZ5!DK1I((L]B\E6D$M8BS@%*WP4J2)BR=#6XN.\!)1[7H^WSEU!S(,9
M&.IU/$SA,F("\Q,H/!\1 3-J-Y1ILEQ5AAGD,C;!X=<,F(.&XC#O $\=T*QY
M)HP7CF=:!T+GZ:[.!5GW!GU#\HLJ@%LMU3$V\=ZWCNR+\62[N<\PTGD],I#J
M0-)MEO"W@Z!T\Z7B3,-G\/+BUV^1(Y[;D/)5FN9_  &[:6M"]["UW_E2!;?+
MGK:7&5MQ(Y(E: I4F S2/2%!L54D[.'KA"E6.D%-"R3FD5(T)ET >[F'CY<[
MRNT?K0,D8QBCH4'$5\1#G7011.AV-6&4+U]5:(O/F/?.E,6_KF\$5,12)A@N
MXMDQ3H\-=[#[#M"P#JK>T(<).3A.R^$:Z.R8$/X9:D\<+V#>C#GA;-8>B/KJ
MEP-1:4C5,=R_W[;= !\V*#0]YCZ[E T#_M^CGUR6GWHB-NVN;B?'*\WN>88;
M WV"1F1=)9%]'M#;\\Q']L@EW959/'7 >]OQNFN2DVXO=\[ CJ3)ALCTE1Y&
M5,AX!@(0@8_,ISS7;G<B3=AJV]DI;+/;T?D P ^[F;VU3+]E#>)\#\K](OI8
M4H+6B]E+)1FV[,TU?Y(I,\=D1AKA,* "!\/H8!P*S]1A%!6<G#/DY,0M7L7B
M^3:X!PSY?Y3!-T>9W&D1A &<1I4VD OTFO#;<4^5ZG8M8L11<YEJM^M6T;7A
MAO.-CW78@&Z2[?"U&TP%-DQV$)S56&F65_.7;L2(K QL(:VSO2BD%?&<EJ^*
M?PS_".\IAZ]XW#[3VHC,5]WTG)]9&PC9[KQA7@\ G&UHQ<<#CYW4@(#U%A #
MW8_)#D3N/%*"(I<*^<1P?-T-6Y.0H19!-7#EZRC=.-CFXTTU;\=IY:]5U>O7
MJ9EJ/""9LSP*?$%*XJA!^S)Z0J849H=?QDCECZ+]4I+VENPH&JRB52!NHG&/
MNO.M"@D<9KM+BX3KA[.ZD1F+O^CS_$B#Q]>@F&_LXXMR@*Y_]?W/6CW2("L-
M89ARB#D?86 AI!2_ZMD>C*IIYB)O?R/X*LQR&/$]L%0<!%!'&* 5QL@]TYB2
ML^W6O4-Z:X,\PZ*I6M<+-V58M;NCJ;;Z'F*)PX#RBK01,]X;L*R.UJ[,-UI1
MNL6KJCHDM!'9%NM<^=_R88Y#]J>8J3B9N$@2%?_/_\==L7*ES[_[_HLOOW_R
M_+M__O/JQ<LO_Z8_G$]*Y'.V!!G8WYZY;,#O@NWO=@<J<#37_^MWS_C?%+/+
MO_$HEE]PJ0AV7W]#',Z?6J=I@D]_']]H6,]]XI/??T:,BA3H2"8A#,[O%OCQ
M?_V.,@ETA;]\_/&?3E[BH]E+3._KKZE7F/NBF[U%.F&+TPF*>PY_EC'YW?^N
MD7XXM'U?<R*/3E@N"ZU+^QP!,07\?%)#-2J'8RS($86C#_^R6&3LHQ_T'VJN
M&U?*J5AX#W,[<\G:$?.TW'E<FE"JW3"IVTS2N;M_J;S_#&L,$QO^T]%_Z+*7
M57=9=?=>=>FJ2FN)I_$D:3(&<$*?=R_[Q4GZ7HX5<JP/15$7<[Z8\P/-V776
MQC,!J+%\0OFLWPXK F1[-[1#:/($G%X)>W4O^96+T5Z,]LT9[?(^K101F:]U
MP0G"ZG20]!DRTQ>3O9CL&S)98UTQ6-AI"1H/N322G;X*88,<10V[_?1N&WV[
M4L.2T)1<IC8ET?./S3DFBGO D-.141P/[G9C-_/00W<QWH0B++*AG$@(RCI5
M*WL2D1;(P0^5E%MC%I_$TY3!W\VB)ZL4U,2,@-A["TCX\P60\!8!";^.[07+
M1+G7A*.%_MF4^RH6EZ>Y+#[<5\T)II7E6),82HD"W:J];FH%^D6ZE8A+,*""
M M$S,$"U?D0V,"WJQ%$JC)Q:_NE'#*5O)CO95RIM2HGBD:I'"2&.%?RC:,Z$
M,I:3SHPS)4%=!I5IDQ^CL_4/4O6/#^I+Z]S/M3BV8RRMVR=GDCS+RH+TIXLO
MQL[XO/%YOF4W RB^5> F4PYWU<^5M9<X_G6RK&O4=(.%9GEWZ7KC#:'M_44\
MF;G;%50'1K T\9:9EGW:G,,GCP@15SG5DDL,*AI$WP/[_6S73*Y;=>[%@,B.
M1#PGAE_4YE"*I[0]50=V?O;]!']WB!0GG7QV-P4#RI!QJZC22:1KO[#EZ/Q!
M/.H%@[^IK*0=J8Z_F>RCN4M)&,/II.@@R;<350DV %Y"?K6DN@937#!_PSN;
M4YH78==M4:2+',^W9;?NV>T,=3_5."&4 &Y 5LQ2NM"G3%MHH'PMU/"\^MMD
M)+3B+D7VA)FU,BT#5U!D+\IOQC5ZH3V1'.XQ,E:UL3#5;$2]YKD4,C+5ALA.
MF4VT"KBV85J"!R"9 6MDE2*?YG/K#JH&_ TA$0#A^9HS6*QS8/;MR]W?W4@]
MB:(HT.H5CEL^+NJJIWB4G.9D&[%6W5.[%P__V1U*JV&>\B/?CXI9]6NVLQG!
M[//;USO&]/;3W:(0RK(654).:B6<U*A,Y%K.:D/<6_;"X_68^ T-R(+?O2]B
M#;G^UG?#WNNK/56Y:\:2&-PM\GH:@6HB//(XL<N\T$NN:W)&^(6;XZY+24!S
M43MET2I2#9<WK]FB3/H<VCBAED1N1BC&B1!)G3%,M?JE6HU2H\UJO<7]YGMM
M*NX>W/AKK<Q9"H!X32.'3,%T$0417G&/UN:[!6M^:YF:$Q(O)Q5<7E^[9D9+
MY:%B-E'+QI&>P2#(!GF7KQ1,:H-4O(YC\S(X "6&SUQK:'9OQ9O(]2H*-KTV
MX3O7\99;8.9;#V<&6TXOB>R-ZZ)3Z"[Z;AG+5/4L53L[I(#/@?.\[/7+1=SI
M_0RG*P C%A< ,]!A/P /H^-(!F2F)QB63_:"5%::?F0:"@;79/)"A?20ZJ=9
M+H:=)$5F3Q?_="J'/&QA?8<X EFZUCAD)?R&>QZB(I%H-@_3[Q)37R40\YX"
MV51$+Z*$HFQ>[*>C:W^6(,,[%8"8:3XV(=,9!;W7D,VC$H^P'$F2 2_/C\B'
M.C6CLMXQ_;2GQC^4H/#,Y=@*XU!1\;5V6R_KV-PF$JI9WF]3@6G"943#P"HC
M0YL=,VI9DR<ODNG2K=HN'/* <D9*,.>X^14^ 06*U/C SI"B%_VM[W[C2+1.
M!GOJ]7\5C_%KALFQZ6/2FE@QO#X5HLB95L'LS,3INU$$&\X00K==%':Z0_)U
M*F7%V\B,=%5^#)U7@[6S;6D25&+@47:*NX!21128#=0NM?OD7DTRV[JK)IZ1
MA:\08-"FH!2D?<D,GX1$I8H '8$@=Z@'ZE?5T2EB\4/I9JSH/[66L&%UOM?T
M?+/1R5,]FUWS9LWM'3Q[?<<!#K3,K-W9\U1@ZD#<1!O8["YZFC?=CVCU"S).
M N6,-F9)Q50[?'[@E;O]T4XR7_AN\9Z%.-U@R686F;V>+G[:$G/=K6!A!M1X
M6U)-':4.QNF4S9%9ME9#-OP;'R&@H4:-L H3ML%Q*!6./',> ?><?K1XGRLZ
M?[E4=-XVB:A:E??FTJ 5MA0<*&/6(:55R-<)^&?"SM\-Q@N7?83W(KTNUR5O
MJBY;;MG6Q\M"P/62P950]^YGXKB2V:^% &D^SSN_P<YMK733L*75[;WTUA^!
M%$Y]4Z04U03U/?,;V@VHP( 3A]3$8Z$TC6R(ST+P<<CZV^8O-+39R7MLTKB)
M#PAT%;Z%L@#@XCSZ68H,Z3IF[Z&7H297BE+DA4[I.>L)97)05*4<SB"?>KCY
MYV&&(N^@3RXZ>M0['C$9=.Y%N,>%$=*BIU.6I6WY<AJPW>C4"DV^<8I#?KIN
M0["'@%N_C3.NJ9$GO]]8SW>(0$ZK_YXXN8'ZC4](L).&^GGUE+0*4;\0BZ!4
M2KVHS0@J_6Y:C)$GT=QZ#$;#Q]!8_T'_X6L'^DYCMF"7<J"E\DYXH4<N$$QH
MIZ9JO;Z7KDMZ]<\=S5)73X3WD.Z%&"UZ>[%>]DJD[!?V8T6BS[.2G\G2)PVS
M-W6[PZE\MCW4U&O.ZEZ*=/T/+7>#XH..^ 7C$0*0[?]E[\N:W#:RK-_G5S <
M[@@I JJN*BV6[.F)*,MR6]UV2R'9XYA'D 2K8(, &TN5.+_^R[OFS42"9%FR
M2OJ&+]V6!&+)Y>9=SCVG::&5F)JIO876KF@A<4[H2NOPD_NL@T]E-/?E#W3\
MR>I$659Q)7@'B<KP4I_52CH!)9P 2]#\+K))AC^&[\.?R0^1NU)+6W%)+6WT
M8!UTBDAW+[&F]4G#W3I37D.(<@YU.&A^O?LLE&5]"#B+V>K0IY',P"1>7YGT
MVF(U<!(/N)MZ)8"G@](FN$*]AURH)[F;]!()[;JX^Z8;OQ;E_@GP&M_5[711
M,7$!523^D@?SQ6Z=*G5,TYGWAO=06;BHC5)H^Y3<ZJ:(N!B920XD( JJ%=^@
MK@J=$A"FLO<1<(U9\M@@T6)8@SB=.(0-40KX[5'A#&$&)!H1\H=IBWFQY,9O
M2)[OXM[:,[>>$7CGU)J&<I&*C^?3. XO UXF*YU%V<R=ZQ-,0=\.X0<F",>2
M'U;E0[VX(A4FVV<E)[=FG TQ+*G50NF<FSNEI9QGE5EWQ<0D*=#8LE"^63^8
M+0MC(()JRX^3O#LW?X!WY^ZH;&\* Y\(SXWD(F!R\M',)"T=E1BE0QFLY&]N
M>FFUZMBV?+8)E:N(L6]W]2G;-8%I0U2-+IB$D#Q 3YCO9\ZM;6QM7);020B;
MW4*%[0N*G'*4"@NK"M:B1VW4W15> 1]9Y%#X0B'!?,;,::80TC;;O.JWS*0V
M0_)[)L@W7X"DELR*S/7UR'&&E.SXMK/)ZW&F&J][,^>,*@$X0=*I6&[]2A=?
MGY%%?S7U1T12$WVK4>$V&_93WPVF'$<R(:K;%>0\D4^F,TP&ON8/  0P.N9O
MTA62:COQ]<'2-D@]# _Z9O$[M=5WBK$,SZ@L*,A9KXZFPOF:304N&E!X $0*
M<&Q&PR]N6Z$VJZX .0A20#,0=-ZB#'G,Z7SL0)&J MB@R*EL6;)!_JC7A82=
M/5]#XX:E;L9RT+C4*\K!YI4M?PEGAG$<YXH^ Y<"^O-5O*"_*FS2'V@2"86Z
M;I2EW7O9K7-4(K99\_EWNT#1/X0O1UR""83$ Q*6^;+CQ6SDRZ("4E7^#I$&
M+1L3L<*I2I+C%)MQC038VYPU4'(Q7%:\4(1?2K715^&@F35C#FJ#N(L[O'WI
M1J?& C$MTAQJ.V!L\-@/ZV,! O6M65:?<6[]V3&W_M$%NJ88\+NAXY"EX#2/
M('4FUR%%#!9-BO0O-X*U("X1LEEE&VU+873SNT,W1402QEN+F.[%22G8[;-\
M,&11O/LU<OHH.0EQS8-\^=N .3WX5@)3Z\]$[UASQ%HZ:#EC+X/7-PU**R+]
M5:-GP)P*EERY=#=GX0(Y *^::HGXAI>L5HA"69E'O(3.& 5F*,%#!+DTJOPJ
M)3'2EBB4[EPCXKX!=J32!?TR;:)FA)1M +.GDZD_2$H%H'VX"@ PJ< ^Y9;H
MW'E\-R0XS]V:$ 4XX;4(G7_K5X3(+407\&&K".E DL0K)D2A W51Y$OD1\.6
MD.M""*HBNG81/T"?:EVX![B?K#L&AMZ:@UZ!P,"#/PMX\''=.F?)O768N\%W
MFFCD*$XN3RQM?G3,1*T/H]RPI4!VW^I&?"DAEQTP%>6<.:ML8)B^KW"A4CJ&
MZ\2(0=3%9<XVAIQ-V> +70&!QNK'7H@O+;T_^@LI[0%)"";(+:!,P/2A5D=+
MR#0#$0?.@?;*FA%![D24C!FLZ-*PON]C*>0T&P,,8N7C/72J 60IV$F=Y*JF
M=R*<%H?M/+NY*'4TUH-0'KE0H"%JV<)L&]K A+P<:H9P:@JZD0:&!@>]1G \
M%A758V"6JLIPV@<,0?@W0=(%**V\> AV*"4$)I&C& [)#.5$)#Y%Y'C\U9S1
MIGMA;L,T(5!L4[LU\0 E&]WLULOFQLN6B+J,SSM"#!X\,C6DP4/+->#DR8]=
M-3;7D=:O"4@I@3X>"I*>P!V%4&:HO[)+A//V[TE$I?!L,R N+"@;(E3E)^<I
MJ1%Y$++=8Y,T_<8GP?D,2G^(^_Y=TWPR>YU6-Q'K2Y\A=J*A["ZE1T?I: BL
M\F[?3L![(K5;FT,9!X]/W7U^4RHHV:N ^NRUMPDD;=A)/U!..1*1%.V-79-7
M"5*Y,'K "TR&RYTRZXUL-7TGHJ.C4!_M@+$-P/<SD  2DSP62U!Z%:TB%("&
MMV.*O_G@[L0*.@TN_[PF 2"XF8E4D[<+U$R):,PKRT+RV#EQL$#<-(#F(:T3
MXZVBF^;W*( 9*<-B/BM(N^,NIN$;K\V)I6\2_OAUH_N%GYDG/G17&CWD:QH9
M'3[U^9U--<G61"Z''#ZD\'#L-(,THSN=_9T# AA1(=RV.U7J]A9&3'Z8L,D#
MC17S,59,G< @V%@\)4IDCQ;3\F/5B*P T*0X46H*O>!\/505IO#&+<B']')-
MJ1G%+0SVVSN!YD9_*1TKXV0-9]OCKMD)%?J#]'%&12M.V%@*6":XD,6=&?!W
M\.K,BSH;27J, ;MIA75MF89.RF4)0$J)/4@\DDS8)L>&)@$2-6V$0@E@[1[Z
M4<2"-*937FYM0EPK"19\)C'_>C4$B',4<P#=:K!P\31VBRRG(XIN [S!&,LV
M[@AK*=5_NR8(S,S1#S!SMT(K*+T1/P;9!.T+"-JVH4$"QCG3,-]R\89;. U/
M$60*<R\$8)2@\:7P&YN#P='N9F",=#H2D-ES_N+BWP]%DGEYF>C[A<Q'=2TX
M 7F>:14_'/M_=P4X_@@5ND7BXBS*'M'8C]$T5MEO LI%+@)F@M A)X!W">%?
M4-R@1++HGW-YRRX'W->(O0J!2A[Y[[6:W4X (0KF9^A*W+.8^0UY?$P"_V/E
M[BG0@2#$C8 H9>35MNN9 QX4$."0%)0*+R]Y :HP2F"-'DQ0Y[$;:PR2Q[P4
MM=\'),FLYH1I+DX@3.</%^^3KN?!O$6Z/O(KL!TDLRB[EL7WYH3GM(G^7^3,
MPAO1&)8B]DBH TRP>18&+.0:!'!J4:<VQWB =O>(A$TG>"R5=GXV5;XH/F=2
MI<>GQS+!)T^J-#K3!!S)"%JM?)JL3M EF$GB9U!;8ARP10(N,^:<R-"U$3\V
MT()*%:7O"E$9I<J\SPU1[93.H( IAPUZ8::4/-F9/L$\ 93\^KS;4U!$;[BS
MLS-C\AGB\K,,=E-  05[2Q$=!J@-^]21#V640$T4V:?Z30-Q/UL3<P_[]U N
M?G?CO!PHNTD5DZ'=Y%T7,>PM,+EQ5;KO6TMYR7DEA9NSF/$AP$($YCFD/$!3
M#[U;,"?%)H09'_AYQ/J$XIWS[6COI9@[0FX%>HX)LX/.C&SF_+TE:D@ BFAY
M778DUZ3X1Z$:-[+T*O),"0'_"C[=NAP0!$#D%2C"&-5JNAZ"?88X]5=4Z_,M
MQ"T7"=<%;1&\ J:.&8CLQ:8IM&+UZVGXYLA2!8(Y:4B')8TWM D"S+5+3J_T
M6&H41L@QX!'[$&U@N9'9B\HDS+]0ZV=?)?APV9B2N^'F?KPQJXOG/C=%,U?[
MR5/P TE0<#XWW<Z3Q0M*UA!X9+R$?-^VB<K)934+1FAOV@!QCM&GYTSQUX^!
M&2$L#!ZS8K<0OS"^?TGZL\LH%ALO"E';-'<ACU/O8^$BX]_K":?+9<S.$2#N
M.5(ERBKJPX^FE]%*3&43,_1$/'%)]Y0%D[R"S)1(TWB#3&Z-6X@XI?T*PA>'
M.*MIWI((&1:P!N"K&#L3K!93%O; 4C0S?(1-:())_$OF7?*. A]LU['3GE!*
M\:W*^QK#/]TFFF@(_T"OC&PIJ0BH4/U=^&S?8XXL\XA[1HKX7+-10-]!!9_\
M**GC"K<'%;I]=PHGH'^^4CPD]_$UXCG*>J(>6<S< =N2B"[)OLUHI2\&=R)B
MK"UG .=6Z:IOT(^1Y)O=]EA5@DVR;(C=-Z$VLI=O!6RM=F? X41H?](S,?TV
M8TS QT]N>?77B5WKT4('+.A)LCPPT /<Q9U>!1;#1>1/3.^T@78.9$!@)%84
MB]M^ZD0 S=I7>'D2JI,N"A9[2C_-] ;<PHC[AYS,?A+9&:1'8\*RFMMJW#"$
M>G&-LQT(E=$GCS;=SN$V.R )?PFDOI$4O^P-H)[HMX(VC[BOP);#N% RBE3X
MLD,ZWP+1PH!_U<\CCAD,X5!UH.M)J?92](A)"(45F56A"-+3L_6@D"'.SX]/
M0%!T<__P[X%=X_1Y*&=P&(%A*FR#_: +B7\,Y"1EC\:R?&9)0BT^H,AIN:A3
M6DU/9*K Z\;/8RA($R"R:"*BA1!^=0R3'&*1: 9ZA3J1:AQQBM"E#Q5DHPTD
M<3$EFL&+LS6F3#I*J. !K":M#1),%<B?+0UXPBV\>&"MK;*@>8>Y.X/H&K9@
MN*S%]>_<LF\;["$/<#=4X#?C+T)2AI1!_W5ZD-C@L)NSC1$SRH4;  2:0_:1
M7;$>AX%1O&*R@T5<K'FA2085VS\_^E'SL6UC*+8YLHRB MAMN[Z@Z&J?/R'_
MGG(J,IGQ%;$R7H6K3CO0;'B][Q@*NZD_A 4/6N['@I<P;!K/&5W(6%11<2 G
ML]=AS[CU%<*:^M0IM;<AGPN>0/%(V1PXPWD< =U7^[8F&M:<J(WD_7TL$;8=
MC@L1FZ$/!NR>YDB29O7^SB[2;(:RI:&.UT1GZ3?^T3N4^LS3$(S=H?K$-Y)(
MY5;LJ.XOK=AD8#[C*LG9L4KR<9LI?+^^0@@H)8*("FV^%DR:;^4G)+Z'SD@;
MHVD/XM04-'LO8:L0KB*S1UN Q "I5K?6D28B2,OYO*8EP84..U$\8)_.-@AH
MBD-]_ HL.OS3OP<MX8P=BI)"W]!\N;_4WG9X_1N4%%?R]C"^NUA /Y_[$FFV
M%F,VDJ[>?;915T60KL+\F&3_/L&\B5%VEVQ6J.'NI:'5'ZM1C?>MNZ:PYV;J
M_$BKN1OP))]9 45_7K8)CGX[$38TOZ-:FGBFF?=1G3M_"7+CX,PJ=(.Q 5#(
MT7!),WO^3)$/A3-V"2()&;GCN5%.A=\BQ*Q"1T+[&<$<(?\(XR=53T.V>@1(
M55AMK[0>?LXUC*8H/_C2R=6A;XWYEVOP28SCR$@U63X RR0SE"]: $+2VFBA
MS2=ZU:":*,/\=MB J0(5<(")OBD6'$"EKT#8=#M4],D=D//"[F4/GUJ@/((6
MZ0V4^6.[*4R3 K$88Y*(LDQ2SS0^#&6A('GLK(/G];#0K:E1'"T!WXLU\57;
MHJ>0;E%V+*RP7+;H5%W,.XI@W#DXNQR<\P.9,,6-C&^8&9@TW%LA:0B,0=N(
MM96BO:;.(_#E^VZGQ: 5J-_CGBC"') \@%&9%_T-Y)XN(=W%C&&FP4E46GYS
M2V!!*?U=3X,<>,(4>>@>#;]FNB2?M.# ?T<#")KV*%KY^.T^007?3XW'MO9;
MZ:%!XC8N/Q@KRI7,J+6%L$FT!"C^JD"#99%O%-:C>9)1\@16RP+[*I>I%]%F
MGM01<#+[KA#GFCL+!+@/U4'RL\&& C-1QV@]ZGDC$\*H*MH"_#.*\GINL!=S
MJ7V59$8U:TC@KLN!RV6\%&UNG8XR6C0P'$/M5B L WPS\%(-Z.^FP#IZ>MAK
M;3[HF./<1F;%.Q*P2K0]>4=NC>!POE\P?9^@=_'*4P(:&(:)I(P;1T7$CN&^
M;N+18N$BDL,!8\/E@/["LED,:"]<8+IV01<&YJNB4 RT=TR"Z@4D\SK*?7NC
MXP\$.3NS.!=DWG3A:2( $X@5T@(.CAKWP.H06+SH5M!G"LH%OU8 D_ZE[\K-
M>8W]2>6"9JZHZ0S!,GOK3LP;-VST)^?K#[#25X+FD!FC"0@&&J]I:KL/DJ)H
M2^6C<0XAU2K48GL9,7G0KKE,5B%*[PMT/05"JI=4K@JDQ0MZTT9O2NFJ\:L<
M-/?P#C+K.]]=&$OC/9'/ZF$]AU+5*KDOG \VM1\$G(*0&;*:W"UI>B[,EPKO
M"'RP0(8@.3V%RC?1$[ZU-$F[>346W:XIN]@U_8]X?'!O&LB1PFF_<.X:,6RQ
M4!R[;X(2,9HCSK9O.BT'+@;&(\A@8$\@ CE@B #'X&5W<D[C8U#H!QS&QKP^
M>)1N1'X(Y1Z0 5,ZX$T4>DM[H+"WFZM"<Y(UYTRIZS_#;S--17,WP4TMG(7T
M^<$"GFG=UDYN%KI&F*.BA^#K0(*]"LFZ?+Q+8&A& %GGR',,0%?B-79"15 0
M/LA,+B!9[Z 0!NIE9>L6-OB2BV(/+=)G!UHH""F2+VBKP_1)*TLRXS!6A*'C
MBHDSN,IF2VB*4X\(J_S?[VFRN:LCZ")H[D.]J:::Y,3UT6+4?J7>$Q)=2*OZ
M2*XC:&G')%DH'!SA@RU6-H8V)=1E?&% 6KL5$-N$"7W;!+8*F!(/Z" 39@+C
M'ON7Q J+%F\I"'>K3OBR5D%SU^Y\5Q=CD=R:X;C>G$W$UB()CV)IBDVH3$)X
M#@SW"H%':>=7JWOBX->R,RWML%"0P HQ*!90)7'ZC=BJI%%6Z",,G3@GE$"!
MM0SFN+NRK2%N'(1M1FF7@PX1PH?KY#%(.-_DOMWG,RX,G!\+ ^];&'B_9 &B
M& TMQQ_<5HQ"#>&0\O,=7/;.Y\9O)Q)F"E<M &3'3ZDLCM)0@;6[ 9%1."P9
ME+JW+_1@=9R9J-*CVW_#1*=([H9"4U6^I6>R82' ?"-.5WQ,H T2"D<R[9=M
MOM:0,N@126GL2(L:0.KN(,^$2V>ORPKKG294R9D4$C;2R;*U;)MQTHP&YQN]
M;A+%'7&-.R&&-\XSH:CBQ M0JT>DE!$Z3G'I&V-"]H$M'L+@9FG)4(OHR!]%
M_.TX%6<[5,*EB5A%7CY&#S!XRX^_++Z3CF1M6W8!+T+"*8<[</$_Q:$09K_'
M6]Y\I6_\-J!_MR2U(9J%4G;I5N#^Y-LL%7-#4*Z\;..9"/N#E-A)O:2VS1F\
M04#;Q:+8]-;0I+32 RGNZ;GN$PH+J*OPL:?W9R:I _[<;M&6<R 1J;J"L%,;
M2NMRL_1^CG=<'AN(_=F3/MAI"XZL6QBAS.K&XB)TL0VL0LH<3;%[:'(VTV60
MJ8"D@=F2XCV][FU$U"@41E0L)"M&G2$H3M)4/OMDV-6S($GB0>S^G"E&^>'4
MB>^% %-,H6&-%9NHRGJ#E \\=SX%FGXS18 11&]!#4"A529PCS BDK:Z"!&/
M)L6F?TA3#,HTU)K&WSDO*FB!0\<D$/!$Y4YF+)@!:4][\!SW5]9J2(7BDTL;
MP$Z]J-S:AM/KOY^_#3LBZ9A%PL46E*,[7&+<OJ;.'E8G*59Q_[?JD=\?8AX7
M;.)7BZ8]DVGB]-D?^6L# *:>U^:F2#"\1U%QX0[)2THN0YR<A5U'MJU72DCD
MWB'1!_$&WDV"(CT90QM/".9GXAG10=)5A\D![3/ER2+J/8%9,P6ZF0SA/O>^
MP2]FUO0AB.B%!U<:F9+!%P:J@W7=X=EB;GD][/V=^2#E -*34%\2$0]VG7FC
MX(OTC.D4:]4-&\CAN&,83^J>-="7Q;KVQ$4*<Q(U*#Z'N*@3NB@C"1?!V1L@
M$K68+XNPE1993L&E8$I46 D\LLDM!P[/=5,N!3O$@'#)($0I=-]UV)-::18V
M(F)2?#QZ NREK%]1!VA'M]8$I&YP_ZU8Z5XXLW*".0HFH2MBAWE..D(D7H&=
M:LJ[21=0Z0U<I!K ^IN<F' YZ.F8KLB%C3PC8ZH)F7'+F5%(QU,/W7ZV?0^1
MGD)PIDK5P8 !#UUJ6O3@U ;,58[#*2^3Y/5*2C30.PN@2>Q5QLV3EFD>UPY@
M:ZNM']M$P&,5&])WQ[&3A<+]K8C&<[]KUJR%MP+P ,J.'.)H 8\7 /^+HE5)
M>3/NU',/O9_\8G@25_E6?!JJ-&E?BKYH>8#),<]VO_'6 ^9%,MD+JIY@0@]&
M'T-YB-_=1TJQ';':WHQH]AM[U_5<6Y(F=#8ZTN"?,N&DLQCPY.'V_Y&*+GO[
M;8V?L(8PK!6$/K>%D_AMBF-689BJRJ7>'7='P,V(3FBK/<QWIX#;;4KN[XZ0
M=LW*O^;:[1T0J<@T%/I0@P-;]7JH8(UR($E 71;PDP=<E^T@U$2!/AEU\,,@
M5W2>UB!0#KGGLLN['MGS5B6"?8JV=3_JUGAPPI\KR,&LAUK.3(Z@H"D3(K<6
M<]C^+Q?;>=$^R/L^7_S>'40&2+]PP^5>'A:[6A()?I#1N(8&9KSM%<7<@)-9
MDWP]T05 &HDJ^F!+VLN\YOPYB4'Q-51U5D8#:2F9^*DYQVE.??.X3KLD\DIJ
M+(M*\O !EU4S=X/T\NVKV?E7IZ=G7R/7JD%U0JN(D-T!?H_R W&=7*07EW(V
M8N(@Q.H.&R+4M,\Z/Y^!*=):3F$?;<2^Y/SE!\/Y@<]6TMO^RIY-SJOB"I$P
MRKY:](V;2ZHN/#P#3MGSQT$N15_+#Q]@P]0C^ZRK&P^/U8V[KFZ@KD%LC]%\
MBJN7*7R"RW62$4IXU0=NHB L)?;/%68<G->\4@PJO)EXDDUD2M@(P3^19CRG
M(-YMJJ;$!B7!?7LMBI#AEE(97<KL8SCA.7,Y_E@,G1MUV*Q/S\^^^J:#39QG
MK#S#L,>K<F,">?F%H;4$5]L(>-"AM(Q82L:\B-YC)H_'G5[2^P=I<:87X/ZI
M//8#V-%OAPT9]Z#O3[A/1L<0_L5,3QD+"YAO_1%ZY:ZGXY##'H_#$AI'O)&<
MD_"W@'7U#J2P!BZE#9W*W@24!XM)7]TUFRM =B[4CX &N?6F1X)2>FUN&N9S
MD>7 B&/;$S9@(*,//9FIP+5&=\#>X-S5>E$L/;N,%B1H\>DV:$9^E^1V@=ZE
M*I:7['_TQ+03 'I(&1*N7\"<XW!A^0.=(9XQW0[>OS64CY816=_13[>L8EM<
MXP/8=^IJ*<UZT$%'NZW>P,+WCA2 F]P*;NK+ACN].1'9PYN,ZT 8S^@G,688
MNN&Q]?[:O;QM@@P;( *"26*,10I6IIN VVU8:(R:L_H<-6D1RTQ4!TIC88=H
M/(4R+PF^:318[$[V#5D ')((V<BTQH8%*"*^"6AVFAU$;)%E"*T!U0%)P' _
M,D*HUJ;1+8;-B"JVGV L]:NZ^APU%$2MG$/>9$$U42@JXW$L^8ZVRX)\H#%A
M[1)/&3(S?.3X='!$E="T)E^@R4C>\Z'-=\YAZ0VA+:=(LZPL06G8D]OQ.XOV
M8A=CEI@&[QWE@ACO$XA$CF17IHZJR5>.XG%-CRBQ*X?>=Q5EOHHKP54IK#.R
M*AY0EY8.JX''Q\ TQ=9+H4B8J>RRLGQ5N.KB6)1Y25@BJ(OOB-J4)<:D[M?N
M//K=K=/%[W, IZD7Y0LQW:8 VXK6!3!-"]2'\"M;_H[SXF3"B#]</QDEA]&W
M8B8MG+["4)+[96B0N%QA\T>AV(GP9**BE5AT_U!8[I08HOFA!!S@0B L<O^O
M37%<548Y,/>=0%SA#OJ%G(]1 <RB^-B6:99@_,IPS(+9AXW$,B&0?Z #W'E^
MY@U#/H+]FT<XCTKM,5D7X+:0"/JN0783V/0J%]WXN?*&BOE>!N@^X@SHU[$5
M]EOEB8_R)H.^(,C[C_^DNCO?Z=M7;[Y[\>;!\U<__GCQ^NV+K^4_=EOM>*_.
ML4KX]:F)I+Z8@>3.!N+O^O)O7YS2GR&9P7_&5]'8S(1QE%WX&I/Z=-4R#+$>
M_\5_4;],7?'P+]\ BAVR+1R%N<'Y8H;_^;<O( J#.SP]/W\R>8NSY"W&S[7W
ME#ND?FAF;Q9.V&SZ$#UP^*-H\XO_L@DO2E5M4#@%O)A$/LN<=]Q+M:*+>(>:
M_H^AE7K[-[@H<23<_[3P/["PCLOTN$P/7:9!KK33O.AQ91U7UGNNK,"35Q\?
MTQ"0KM $/ 9*SL>[.JZZXZI[_U47U^"R4;DIPZ09EJ_WUGKV7N!")Q?>/VA6
M#]B+U%B,<7R4&N/6)NY9E-S'=:%T9$2U=%S^Q^7_7LN?\5H*2@RBQ9/]Z^M/
M!^C^6A"L5O)'8_!8 BL28""QU&["-A5.5+0)W,[*"9KVBJ!7$"A>$ M,O8$:
M>Y,@X<8YZLA\PV A]U<!" TRU0H4H1[OPSL1,3DINEZ Y;=B>D8ZKY!*2/C\
MZ:1N %1A,CX[6"[L[LO*JAV;-CWWB**TF4RFU\77)28M@S9QS\/LZ:K$!+00
M=HJ(["5$X,N(4\L@R4R?!8Q%Q8R*UV$_CW[R#7\R]>P,S C84XVD&</M.TGH
MC!I,Y>5,/M8_!7X#!!?)=R"D%'<-F?H0)I*H-"0M19YGD-2D@N9+R,,P=J81
MV7:W*0B6 _C(GI#TY"P1"FE5:.-)XLV89-#S<D*JK6JVTDG-+0.4K"9L5Z G
MXY&+A'>"(:#2?$>0[:M<U;A$=T5!4S9)KPG65701C?QO^&^8RY$BVB>8WWZ%
M&FQ:9A7FLTH)-!F=$='S)] 4!6CA(646$M($)!Z+D-?>MGC?(1T8<L@14&QH
M.YU(#P3#:@@V03 Q$N0".ZP4PN:ELJPO5N*'^Y$K-,4-&FY5?Q6,(&; >6@A
M]\?VA8'P>AV2!LI+H&5T[ASK^!I=DSHJ"7S&4(U'1ZC&QV6HQ#+3T$)]AUKF
M\/PDV71QKABIK0*+6,UK6&+<T^%V^:IP%UV7E^[HK$%0[CLH*!@N'FK!=P?R
M8OM 1#>2M$X808M)D788;W[!?7E@&+5L=1<>0=J*W:(%$0;ZNZ)S[BKK!,*9
MCQ]K.W1PC^?U7=&%_:R,)+8?O^NQG*]<@7RJ>TIF'#U#[TQN$8YP4*QA+<E=
M=HC+V!<=>A'BHUTXBP*'/S#W0?6;;ONF,*?]A3-.YZ>GSV;WN-GAXLV;"^YR
MN)]B7,S75"J9?%G#=>->XX>7KR\N3NC_&);>$?6?<" RQ*XK! %CJM^(\W;[
ML5P.>:6@&F^E$Z,R]S35_*^+O"UL?=?^-=H&-_97S:"2HGI34;4 C0^6."*R
M<?25G8?/:')@96,A'B%#8QX,EIFE#@9H!,'2SM 5HWZS\+MW?2$!>6A <3)8
M+10"%L;]FP/>!>Y<\!7JM)8(,XF[P[U I17K/TBEU=A)ZKC-BSGAI#^;ND=,
M'3PY-Z:^,![07</OV[R[KED C,)9@9^ .[M5SDKWFM^Y/ZP52WEVBEA*][\_
M_/!6^.GSV;^:GO5.7[<-P<;>#%6QSB$;,[N'ZYYL% 9/)"P+54/W*HS[=&\D
M: LM+;KU^%/>NG]UCSR[3U=BM *8=>A/!1"=YSDWQ(D=RV[CE.LF,&8SXG0R
M>D1<EX38J \0+C=BKL8CYZR(,P&TGM+(&M[\P=IQ3\).4PJ<XO7\!_8Q=6#Q
M,D?8'@]D8/<)EL<*9F!O(9?5M'6Q5?08[9=XIQ"-(L3'OG%II+UCE_4-8LMW
MOC*1>6+3CP'T0$"/D$'B-3#R7],/-Q2S.L^"7#,MKM$M(,)L%GS4Z"D#5-/N
M:/B7O9(U(!1V; >;A=X2WR?*<3+7U9:P]O:KX-^7$-SRB< -2A'#5^%6TE9Q
M5<R5ILC/(*YW>Y.W<D<TR-1Q#D<GO3[LRF 88+U)FW=LF&B-F#$M1P #P4.N
MDO&3["]LTYJW3;Y$UIF\ZV+/'EO].-,QO6;\/\*WTF&)2A'TI@1T):MN@WE$
M>^B1&QH  @]VT2"O87317-BV/.Y<:H0]7!!ZQN^;&(@[)65E[2JD*:%5JTA_
M;(7/>,5Q$SW,PO<_/Z>"COP=6%F+NU,]SM^+8D/BAA"0L;5*!].TQ*D9K^R1
M,V&H5Y#$R+DUF/5R)#]H8%*<>L/FZ4!SXBT-/!U2C^_E]\6=<Y]PD<W.'J-'
M]GP&%[@7>P27D)%S%R"R!;M@F6QI&V"1$SANR@J:W!_B<LS ()T,4J$R1)O#
M:,$4.1=G6 M8$0<M3#CT2"3&1+ =L6XL&1;ZCMU;X#?VT;M %E']HC$)/?>R
M346Z\&"#K@O_/12%(*Q3FGJ4W.DGX)!E)WF&BE#$5H5&RN8$R,2!U]R+/ Y8
M)A<;(<ZFTV'60?6$SX3L-%:?7@UG^I"U!*E3(6T&3X)LK9IH9MNEU?Y6OAH\
MDSN2LAE+5R$1EV78%/K@D%K\Q2_9['E>Y\L\FUT,P$?F_,F 1#;!<X@%L>L)
M(F$WP MF$J9E0YXBQTB<RM5!1R1O,.N:%A;6[A+[8S&STS%GI:S.HC/@1D^V
M7K81+>,(&4VJ5^Y,>.XV/M'H.GO6(#8=_OWOY*Y0W/W:V]\W^J$:H_W]N]=O
M?(QF-)# Q]R2X3A_#-[MV5..1+H!OK]8(FRTN$;ZU!>_T.<;8Z_DSPCFYW -
M@730F.!V@YN6Q,\"YX6Y^L"E)S=*6N#?*]I0#E?8@3  A*,NM!.#S5W -\>G
MNWMC8/<O@!:U\\1%EE_;74*.SS9(',+:"6)LRI_6-7^XXC&ES=9M@&89DD(@
M@;AW0_P[B:(<-;!S'836TKQPJ[UL[H*2RIZR*S<4S8UJ I <Q3_=GY?-6DT@
M&''/=P_?5<_^D=?.8&Z#IK53V@<X=PN.(X2Z)A2\X"?,F)._H+0IMI/[_CC!
M:L9AG3S-U,IR=,Z"=Z*+SK)='Z8[UOT[[+Y?W60OV_PFK^YSWN3L*=BVIMTT
M;:[[&+[O'HBJ]<0S7@0O.9/W0WDVP\8D68M?_@F0W@5X>B9JN4\5I&B 0"OD
M7A0+XP?]$U^#W0+^DQZK[L^QD='/Z5"RA;40_AGZ#L&&OW0+QSC#1IJ8U@)\
M'69+Z<5H:>RY'^-]2PP-$<X+D>O8Z%'X3ZY+PQL0]KC_/K@X<[Y8!:$M#V>Q
M] UE)]Z,<-EH_$XV=<* ?@CC)!)C>&,%+V*/EZBV@$U/_B1P[EF.8:P/D-WM
MYC#D5\W-I&= 3MJ 86.4/0-NB5I\QR!2\2X_?MIG7%EX?*PL?-S* @?!TQD*
M=-><PP)^!-1A[69IZE&/"D#>]Q[X_]K)U,\'!P35;AS0+^\A4EN!6P9K?]C
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MTEUO.&$2.ZL4TC@B ,B#?69G4,WYU':"D=92GVA987>X>[7_34>Z\$C?S2M
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M\0!RHHB QNM1IE8@HL+%%-U3/$ <(VFW,B/+]D+;/,/?DI*W>R/R-?-./V%
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M^K[0%AO6NG+M$T>8:K-O1EI4_L6.2_^X]-]SZ8NF!,E=S[=6@MD-=(T]]3'
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MUVD ?$@E[KYY(;YC\&RJD.*/=Y_R'__,_G42WVY6FR+S$.6-'5(!RE"&>WO
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M.*V"'E"'@D,N*@&TEY"==E=XTA'C$;)VU1[S[B_/YTCB&0A_C2;(5GH0DQ'
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M ;+#C[%<L2Z=Q[Q242SRVT0CUJOTV%9:HKU Y\#$@K[]ER-GFV_:Y$J"R>U
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MZHJ?.%F4CSC8'B<S"@*[9JT_%)Y"^Q%6-G'R.^8Y:V7V5Q[6&<2]F43#J6=
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M0+ZU_T@1>2;K0,,:\QR4=*L$W3L@C?T>S^:8R&-MTI><Y^.[)3M ED9QB\&
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MP=!X_6CPM1?08['NK4D>U[7;=QDD+GL3Y26=SSR/&Q %'QP6T*M1;,[+Z$0
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M3(5YV;#3BLC%";;$Q=,0+D+U[@R#<\KB= O03NNI0]R>K7;NB(.#K*+99QQ
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M/]KM1]B-LH=G987.-BZQEKP4T8(*GG!&R7!@:<2%&D;Z@3AE^ZBR;5 'K9'
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M 9^'3 XW#CB.6O8[>!R*EGSU,L&,*"P ?!YV+W:-#/EBBQV$8A6._;>B\EV
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M%&?TX%Y^202!UE$"'\SZFW303QP=E],&=B*"NO2OM.( !:/9]-6$3 KJ/6%
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M(O-Q<J:SSCEQ,G/UC@CV<DS E\@8K(U^ -F79O..9.H>&;-Y6D]<J,!*_[K
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M0'MN:&Q#8]?6K"%48V<FP*I.CK!*EB-'<]+'KBTYK26PU&U4AJEY8J/ @BB
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MHGZZ':W%/. ^T.?[/*:Q1A-QY^/B&9 ;QL^B?X69N^B)3++L_JCSP#@(NWM
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M1M6LEP_KR=5!Y0'F7,!41#]%JBT<6C!&GK/Y6B3$%XK4DP:OZ:FJ\B0'*Z4
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M2^,(-G!8(@9\XJ%"344J*>)L]S0:"6[-Q V04!9_A1H1%YW,R4)L#%"$^S&
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M+.3@&/DW%HP:]7;O4+>X$Q302+<MGB]>N'D?7B"Y-*3#O?</R7W /-$<N<#
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M4V&W22_<A-.R3/QVSE$AB \-]P543USO6<C2ULMRP_7GB\8U&1MT,FY'GZS
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M3BY&8]6S+ S8_A+)G)($O!0!#"9A)?N<7Y&YI7M'ZF ;G,0$<[^DDY/7$L;
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M6ZW6GF98?81Y7<4]LG!UNC#<J"RGQ<N__ 4D-I!FENX!(?[%-%\)S(X)%IG
M>M2V8\>5;[/[^;AQ/S^L^YE[M@VQK34F]82!826"YD?4AKWD$,[, EN@3XP"
MH7K?3JE G*(@("CBD'AZG!;,=<SOZ?T_,N[N(O!HM9]TWL@K20/X.49ARQP!
M:FZ692NC.*);(>XG9_3767_&[AWQ1VW$RT/ZRSFW8DMD;]]\EW9,3D!I!Q<C
MBSA_X[C0$'P,S35*BZ:V>REZMA)%WQ (S,)@[0H$B-=SE+(IOE]+.VHK*<AO
M*HY%"T+J/L&]*5F8%K/8[_$S*P2O@QJ=QJ@6 <,5N\2H#+ <="Q>75WM%7%_
M#SC<7F!;=GI?8R0-//PA<7RVQ-4AF_5PI:C;\#.&S_+@2B_%GLMEA59D:]^2
MR@P&4B%^:9S<6_[6QNCD3Y1PWV*O!5C,]>=P R_,A=#UTEWD5ER?;4_9MP@"
MVV[],PS^'RLSX^N:/_\_N+5"*-4_KA1VQ[O_5#%'SAL@G(%I_5N.,B=H@ 1!
M;;.&LSSEH)*;>W3.%=+B^.CN1"_PV?;!SN"%<>[K)>$>I4509$@@J#U&!1!.
M#W.<.!A%6Q8-47^[FB-#(DT*!:AM+$A/=G(8(<8&ID*LK'/@O=)$(X_8!$DJ
M<CJ,)84!69\)2NZ(P#7PP9XU!XP::EZF:7@:$R9'A7-C"JJ)S(6O:6&YBMX6
MR38I'! ??W0$8TE2 26C?_8P%648Y_&J'([[47O? W\9HQNN#X8%K>&!U=9Z
MTY;1WOO8()-[TK+%,*;93IW9PD[ZW2 %&"C*DX(Q_CDUBP*NC,F>6Y!@:T#]
M:2E+&#DZ_P-N18!V9WIM"7AN&GN8&>;T$ 8NBG.7%,G*?&6&R%FK<,0*_9X"
M:Z<R>P$T'@"%I(54+X*5*$ "9#J&['?5X+5Q-S@"Q;2'L[!O4@V?$K3-C$QM
MQ:B.+H%820_@58C?TQ$ VXT=?](HP ^H ,_QG)I#"9(!K/'[2?O@N'OR_[7;
M/__VX?2/T[^_^?#FCR_B;#D/7K\[/_MZ?O[NXQ_!Z1^OX?]/W__[_-UY\/%M
M\/;='Z=_G+T[?1^<??SC];LO^LSG-^=?WW^A1SY^>O/Y%/]P_N#JQ2K/PA=R
M@V -,V$")$5_QCHI1VBB\75AW8:%GZ@X$E4,/A1=2/M(L"(8 ZZPT7OB8&YF
M-XY-FAEA/(K;E/WLVMV"PMGH1V269AR$G."EBIS%D&.YO6C^(I$I.8(:8EQP
MOQ:CIGH?ML-;%9F22X<FO8P\!Z-<[)V;N_'QZ?J_=4-O<(X:\&"U8+C=Q3BY
M'3X:AAT3?Z]F+5NU0CS"SI91KUBV*' >5R!3=L=9]@T/R-D)AD=EP<B0?'*@
MDJW/W9#1%X(1-0)@XH.D)B?<O%:EF7:N9042B"5!GXYUT17QLIE4PH"*0UK;
MD!3'GTNQ+F+)G2F3$G56,13.(NI>CR+[7+\F0A8'>RLS>B\S.K>&E%H1,M!G
M+%EXR]/1/]6=Q%M*CL^Y E:U2ID<X_ :-:TP RPB=KAN\OE3,87,M!P[TW$G
MPU]"_?557%W#S*XJ,Z847%;])<W,X&\YT8B!>VVQG;S,QD)UNI<.M"A0DQ,&
M_;0<22_G;*(%2FPA_*[?.7,@]Z4@$-7*_O5MOF<*'F[SN3W=C,KWYC?&S.2+
M!G 2C.R\?W^FF1L8<Y]BSV2@7[@3 G]9U+\9?)SVP4QXE_;W@AU*4T)S;\%'
M\*D7/[C E;[D>[(+/EYB?0@\\-!Q0=U"@I0?BW>IDN?7EUA&*;WHAQG<0@ZS
M8PDL>[U6V],K'^C%!:YDEY!XS$FP!<Z[%8P1D&LZCDKJ 4,5M!CCSWJQJ.OH
M$)-GM5*0.;.^Q':O63>88A=Y-/$<4M4_6N_4$#XV4U3,JRP?#TQP:ICD!<OY
M+,7^9E>$6(>*?6A+K7;)8L%4D^@B0M")?M##YP2MWEUD[81^YX=-721];CCD
M''/*AT_(Q53&8U#X8C=3[=04+^].LRLRSO-XDI6FHA+%>8)Q=LI&Y#X^ ??B
MC$L4#+T8[">\5.*IF/+NA&R9@SJ *>P7Z@+%.H",8@V"!F<D-/I=O9;F9GG_
M2G(2GV?XV/D,_0\Z_7^=G>O\]QY:H_S(_6W,1M2=7X6L?M??HE1C4D!''F$N
M1E,0WZY3U^8?8RVZ;)??X5TQ[\!VO(CSZQ#UI Q1J*Y#=I; U0'=(8F(CB@-
MAJ.SFW "V_,\.\<-H-K;A#C&D$G+#8?K-57D%?<2<"/%.+4XD%>Q:MRF$Q_:
M<&84%W+>;VG7X,EYYNO^RI+=@QN4[+;W'JKP]O8N")XA*IISW%ZIY67P!B9X
M;8()BQY$-(582N;L0V=9FG*T_1Q6Z+#:!0]X;!N!N@NZ"&109CUTW$;3J<_X
MI]-J(QED[A<Y);92K9 8$_'B:7%+M<LX3=C-)GQ>+EK(D+!#S$Y']_(E9^*,
MXW@:B@/LDD#CI8H+7;"H&R"<=-*7;&68IPU=Q"G?C1M)!6./RDX;>4J7MXPC
M3NO$P45NJ*N:5^ZJH/3>,HEU@TZ==.R[D:H=XZ1'B3S N. ^>KPIZFNK)>X>
MA!57"1;1I;,REY86DB/':S6[>I&AH1V7G.)$Q. 4S4K-7C:%W=TUF*BBR,HN
MV5U/*J %[8-@#&N= 2<H;E"HW?# ]7E@9TMYH!6,J.!P#A_PE&+$>59SW.P=
M;"=0?V'8F(Q0W('JC\@]9;8+_U/1^Q?KJ*K%5I7(=Z!J!*?O'(6?&><XYO:T
MZ)7IC]!_A1Y@[0>ES.5;?$T]C7&A[M4V.$)YU"<7"#+?O6!N<U0=!P+D7$F'
MT>L8Q+<)5635MIR^4V7=1B(EY3'$X(E;>22-:[$,E&?I-.8!GMS']I2Q1B7X
MM'<1S50Y>2"=*[F"-PJ*%!3546;2S?D5PV>IV2\VT+1HCX\!&*+2)!&=(!C4
MZ5W/Z>8.DHRC5)95_14EC]M#F<.9:H%25\TI(K&- RQXWH4MGH@SAS!O*$RK
MS4[9JB:A"GH\_>!*%+?-@JEQT)[(>(>Q4<%T3/V@*,6>7)\T?2_J&05?T"HF
M']X7I=<;T=L9D\5[2V\?4^(&E-W-QB_C653W26\9"W]TY443#L_9 :1]D7K.
MG;Y1BEM"CO&4.DA/$.!NBN5;S@Z5NB[/U5DQQ?Q2N'F3S-A0ILQ#$G&];E0)
ME42D@FUN\E@Q'183:IU>.Q_B 0?@@2SZM@>@_M91X#C0ZIP5S7"+@WOM5A/<
M>]CL-M^V3FNO%_[@D1\KQL8=)FF81./4 V ^YQJ42! LHW@PSQ#K4N;9ZV N
M<YF,D_\D!MA]]0W&,,@N.O%0B#EWDO.THSR)Z(++S7UXK\9'KQ$\QO--TD*1
MC2ETPW6*@EZ?# ; N=X 7PJ#TR&6KH3!>W24!J>3F'\\@Y,:1";Y\+1(HMU/
M$>, 8NF;!O@HH^YMEG'UV.M\=A&<.C7J3K_8MZ]/C6I&Q62:&U\2WHK3X]6Z
M=N/O\63JC?+N]1O'W^DHCH:03K^^/CU[]^7?%F*JQ,!6>!,?\/[Q[E4<?S/M
MEC0D1"G+.:PPHU965"X"%PU;SO+HE#(B5KB4Q5U&8]5-8-+6$(9]P /1P@)&
M<2+ 1F#MRG07+&)!00C%C,G!JPJ5/,<O82R#")NC>%CD1J)Y+W@],Q@?Y2C)
M!Y7,^RX)!9NE3[7;:0XR1B7DP4'+7BSOH]*=HGU$V9'5FDBYETI>X^B&<S>A
M6BD,^#**W;"T\_D\]JH-U)V'/N-8B@'-,5$1/0?N1'> 0WIP/^XYE:)RKBUV
MSR(Y3[5/! E(=QI4,V#WE$V&!V#*1L94UBU!7@&9@:5PY7*)>P2*VRP6UPXW
MKJ2>[0*"*HA7,X//B2D"\ARB%V)+-!Z5LG^X=986,H(^@S;$<#;&'#[BJ4YM
ME?;A!LZ"[G\M;J\T9I>:6KA  A5*F;9QJHYGMR9+CHWSM'2) [-&>/J7SN'>
M 6L=$VP4+S''7_8/]CK^KS6\?[N, ;X;TL40KCQUYZ-L7CDE+.$5D8+3.=@[
MK)G-87MOOVXV%!FG?BB4.%SX7Z)5,VF+[\P@OM'GS9<=$#^W9Q]K[ %A='&L
MC#):*9D+2:ENI]F0<(\+[B(6*?--HAEB_SXFQKH1\(DA?P#'H5(Z.6>II@NX
MBR$'2141"U;&(];7[6%9*&6X(NJLD%Z<CB*]2/%WJ0*TO=^-=E$):<..2=[+
MPFAV!<4-]T#3"F+4U1#116=F8_35&QQ*4[>%!Q@Z'5BU'JPHLGX2F8Y']N)3
MS$:01"40*MTTF2T2!^&^N=B+R!D93/.!]D3'V:1(,(Y+P:D#Q.^P[Y4.QRI&
M!0;RT$OHU$1J%T_NP^[!U9C/"&3]@C.5IQZ< ?]N4RR))<R 96'ZRH*4FOE3
M,7?(,+#%=TKW3%MB"I]S+UEHFJI5V:G0.)>NUO)7+@G-,8ZG77_A0[.<2_9
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M;:V=1?\UE5!XU:I,33_O[(/_&>5=>Z"B]ZGT^@+]Y0LY1LV\T2=S&8TEZ*0
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MB0]M,54=S"OF6<65)5V"<LDQ _&7_>-* LS%!?+5,G9P0VW\V17CHLAQO=9
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M642I-PY2O+#G6'2)\%#M_5,0ZK' +=:(GC0+R"L54'OO>O%"R<ON_@ZRF/M
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MWUFE=J-ZW):=(+;VDV E.]WPZ."97R6"^._ X1RW3_;O969;LQ5W2PZ--K*
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M@(GK/([!2()G7LBSK@*'JB/:\)%(ZVEPK:R%9 E8PFWZO!IC,O$D7C2;@[1
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M5N;7IZ/)!C\,-('$<DUC:V;AA&JLGHR#5'?:V67F<@^NXU[8&CPB9W,?FI;
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MC_Z;W_%Q:EL88+P\!GH(1E@@A*0-TV?XPBBODI)%TV"5C^Q*BHQ1TA<"Y3F
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M:9"/$BO\V2N+^-#B;8UF8N[P,S7O!6?H8:#?F#3TG!M&07HB]H=.G(A\XV*
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MJP%\RKZ' L5W9C@5&5;[(*8$,92:%;FU[SFX[NP<TYK8;![3 ^R5<5X@A9(
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M@$*S]E,)NIA;X@QB6^+QL\LR9*T7 [=NCYZFJ4HAV31%,&6""=%<H,Y/[*X
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M^%H '0.?"W7QSZD?)Y@@$,*+XP1'D,DOU/5QZPPY@DU_2A6_@%DK+_8&>$\
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MW/LAR&L:G@<ROX)N)]2'&_OQ.)NC7V#,]"C]NV *X5\O]]U!F^]0LN"%VB\
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MIZJ_T>Q-A* U>$(2""@,<>8#"QM^R..4%#ARSQ3-NL.3R,D),J_1BT/.%%-
M43:3I/0\AY([D0;&I):\XSTYH,+(H2)-?CF1-EU-OD><PD0?): .I_3W..\(
M11?+WYM7@O4GWH0(I7+KLB0>R799MUONWT;7:4[%]&B6IB _,37 #[AL27?W
M#ZX>G^@^^7 /$]G0[CVH5ZIK >[T;Y]/\M?B<1NC\;WKB$N0@7F+[41B3IZ2
M?P;F42;&4=:)6EWR4?>RA:MC4?"R4*"$HH0YC?-&SP*01YC]YBFU8(DT<2N>
M/[9)I:EA_+(BIYAV'A]73C'I><&QLMCY2H),6M:/@Q[?27?F#ADXEN8'Q:<R
MU3M.-A3.C6/9V[U&%=M2GVC'^D0?MT:B;%YMAO6".;Y-QFFI#4Y5(RE-@V;]
MN>7DX3T_R:URTC.F_D_V>QI^L-PTR@<[F^HS?(&E#?@:&:&A1$&@X])39<N*
MO68!39)P\^Q:CL5P1W2.%K.B30Y7U#<*W#:'#L7P&FT$UMI!U2C'6P+#BZ@F
MH\6^K" @K2R:EF'&',@E>Q+UNH+&+].I73GGM[P/LD$E9"C60X>3AZ(+'Y/[
MU)O@:!UL'>!1-2^=MF"V5'Y=%4"U_?QY?4XP!O5E+_5^" QBRK)A62BC^OD5
M<C'U].*Z4S5!PGPAZ0!\'K+R N^*KGLB5&LFS X@S9,AI,H-R,O#Y09F?:I.
M9Y]S"ON4,P;PIW/=!&<#2VL:O3J;T-GZP!@;,?4#*DRX&Q_]2N6-X<+[..+_
M?(G"/79RR+X N6M?Z7>W]O"K\/N90'.---(I]H1)=;1=_Z$<\6YME3V;#CBH
M*Y!X+5\GW=/:VV3"RW Q53A0.;!142FIU,=X2YT/<:%_I -<30L^?%G'*E+Y
MG<U)U<'>.2$^OW)"P8S*XV6G2-UJKF8<"29+"C69TI5B9.7RQ?Y[*_$:WL/8
MB^7X'OFAJ%L<?_BWGS=J*KDG#3O><$QHRT6++=TL6(^J;S2BJ(!9VH/9PF2G
M[E)<DY.;O?"'0Q78U"A+DTY%S/PG"V4;=B,/L(B(FX=LS&CR9NEX.X8W*2>I
MI8""QU3N6:X&*2'-_DXMP=BGMWF0T#X\37@&'):>'DFGSKMFN'?"=0(</&KP
M]EFJMW]@!_W B J>^F^RYT_W]#PUN*8]QO\]PFL9I_(2/]GE?Z=1,3VVE"PK
MR\-(H?7FY-6;4P*<!AG.+/<TORD L$Q]FX=+AFM*8U/9(81$83SG[!CY?Q(T
M2T3Y+J?[20</TU_)P\-5KR4%N6A"+!UW4V!PVETTHCX:DN7FW3;EFC,14 2$
MA0IZEZ5NO.U8W5J*SIN&?_F<4HU^'W104.?YD.34'5*B$27>I'G?Z3/#MCE2
MMHV*'9GA;/R;4E:#*UG";?@.]0O8 -.MJ.3[O$H^CL 1[WD>@M$K:DU5A:FA
MV+!237.6?1A%ODP!S7?6<;B"4-]#5YV8J/M7V1:[!5>I-_E/QJU/5E;.,ZJI
M&*%<UEWO5S,PCN%LZD>R$9\1=6!XY"),6AL5N(W,B9FRA5J%PLL0X])?O/;#
MUN'A*VT71!@J6?GK=6/ZCT)%GS'E.L7Q'=_$A-S'45C4E/[.XTDZ_DL* "8
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M'/*)WTL1;(H(H-9S2LW"9;9)(A_52&1C-@X=EP(G.W@0=A?PCG>74X'A?#4
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M7NH!68 ]Y2QB?TS#8J,L+M[&)(O]\)Q^W&D[ %,<5@T'N8*[G<_%Q(<C!5<
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MVKD^[_[1MNY:_\\Z[U[W.O!3:&'O;4.7NH@VB,-'YC-4\_*/X]ZQ@HX#L"-
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ME1L!T. 8@H@F9O.%,*W(TZ<BY"QE2*U>EN(X]P?L,):!I _!V:=(^R3[/,
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M?0=@_*%YF1]_(ER#@<3A))H  Q<@(XQ4VX[:,'9Z:Y(T0HH[(KVZVI)*<LX
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MV9K$33&9E\5%\/PP$!M^N-3[<9_+VMZ\^?AI,S!S-OF1,JR'AY,#WS3C\-B
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M,[:^V>#V?G$/:= B42S)<;*I"' A0#4B/Q$709R3<#(&@ /"YGD6!EO/$VM
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MV.W[BSIVV.DV2)KSD#1Q#Q)/$V(.P=ZP^89G@P=FJSXD0-B*MXLO^Y+0Q0<
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M@,2*R<50E+RZ!D\[T6>O.J:H@'@4PE .*)0S0(2\MQ@XBX(ZA)<NV(.)'7C
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ME%'DO2,VH!A8T!Y^+_A&&;A(%)[*N8508A>AR&.>8Z5 *@HN(YW$_R9_/1A
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M8M^J^N<O5$&^08U[=66[>EK4Y71?G8,J/P&@EAY07[?QA%K%^+;7/?ALTM]
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MR-Z8BU7C7[2=P#OR)Z)L^_.Y.-\G(1=$&)[[3_?<YL G@%R:BXZO(O\;*%R
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M06A;[+7/QI$U9@&U,EC.$U(&'BZV=!\05)PR Z>7_WI+)&=E!D;Q,'Y3]HE
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M$#0 %G%H<?O)W43+Y>)Y")R1-78"Q!.-'EG(P"1CE0R4QUE#(BS@'^*&.V*
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MT)(5O^RK($RMEYH'9U6STL6M='S_AYMZQQ.7\\VN>KET<-9LVI5&Q2S]G&Z
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M&PDEGT9AZ/-A>@C2>R/27PL?W)64+@-=H8[']4CP*H!S7.BC\2><C(6@KL_
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M#2ESAJ69RI-Y/OU;NY\::[35PV'&;C L/YZC]%)\W:)G!3F)5K8(S1-SX>$
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MLQNFL/ T<NY]=YS>.T-\5[#YXX1I*4?*H?RJ$)]WQTFDGH+C.8I]#D/!U^^
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MZ5J?ZP[I S)^]K_Z;-:1)(A]S.L#)LH5V<J-(S5QL4>YD7Q+M/,6#,(@' 9
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M;<+A(Q!82_S&I""NA]'LG9'D(<]Y H(_R?/;*JT#Q&< $@9>AEM,SB*4YW&
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MR*5L-Z[$KV8TN<@&$6>4$5]"]Z!E29CD;)I7.3T\<5EHB5NQS@O+#G8#(ET
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M(&&H_\)0B?J-4(GZ6X=*U&^$2M1_L:A$94IM=7I6OQ%.49]PBAI^0Z[Q&E/
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M,/STN]D+RW\DF&]3-Q />C3D-FJ/Q8ETD_OST,/_>6\@ZCYI=+KJO[.C^XE
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M_E?UC_D^G2(5V< [.?[K;P."*OJU+3/_M2T&'$PTQO_R\C;A21>->_OW5#
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MKAK[DT_H@3@4$PX#KXFFV*?;+XDB%GXY=W=H)(%WTP/F#"FIM:Y8H7UOD1Q
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M]O6MTHGD"#O3; #?Y(QE\M?S!;4O)?GP%?Q__K:;B#"<E3ONUBA'FY0@S+:
MTS4.!(W3Q>3F,<81RFQ#0QDXA)$(?W?O[F+_SI52@']E<9!X@6"AKY)/'+84
M/F9.OFOA_@)NY!+6>(TO@<*^BQQ[14?>/!^LRMBT$C;-65QSP/ODL&L'O+OM
M-M@>_^]_6+ -X>1-$<TSO/O?/436AI_EQM+/90\#;$ ,_.GM]:=W[S_M7UQ?
M79W?W+[_5?UCODNRR.8&U&_]U[;M<CJ#N6D?E>5@"ZA1WZ_N]RCPZ"$O[^
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M;J*\A\3BA851A,,NP5QT4.!*NF/% )>OG:(<&8U.)?8909Y8'E <!Q.('K7
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M[U_@NZ\W)CNB9AUW6]/!H-VM3+-*$V4W-7-EF;1Z#&C\8:U/IQ!3:IH#:9J
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MO%7">HN\G19YNR<OVB!2GQ/Z[[UPN< O"Z)"_:V"]6N%UM\+KS\%84?IC'O
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M *9W(E#2-W??0<+9BF076??#:]^:*=,QZ% 0VO&H/9PD] 6DZLFF]@/42%\
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MKAK2W*O#_U*/;HY>;B7W6]%!F;$L1:Q+$43W.Z,[@Q5V4[M<RN[$SGF;Z,U
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MZ#GMP;C42KEB.>'S$4WO"Y_-U6;MD)^DIC#?^_&_W<P"77[:TJA*:4R41FH
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M_1$W@.!*\%?7D:LN5RMFSOUKOZM\L3GN/9J,AH.<]Z9KW7M[[YW, HIS1%C
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MH#V;8L9^7S'[.STP:-!JGCW;+6#/:JUIM]./=R:U%;!?9T^*@<)%%KJ0&L5
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MX3M 8F<P0) N*UVV(^O2<W7,\"A&EI;FMCK]N1P]]Q G(2SX_R"I8*;?[X.
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M'"R4,_8?F<^\.'1S5#]??[L*%'1K\W/A80<CR5IRB_\_J9GYFW"* 8T6_CR
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M)^^U$(MJQBR*5G!NFF2S*6//9#E>^19;^L T6(^:)"9ZRQ6=V( '4W3GH.*
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M!K(-T 5T#&F6?VE@/>PW@>UEZ9&!4D"G>>(;>&B'JT.N<I/?M]LR*J1T\=&
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M]@W]DW_*TN_  FTR!Y:X0EW@=?_TI@ZZ1^/?TMW+$2T(@"-O))PHF"G<L;P
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M@.%_UVQ0(#"4E"9T\;^Y+HIT1['\Z?MJCBRO,)R@KG0,_)_,<4*DJOA5UB/
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M>\($80)-TG6D/77*D4;F3B)L $JIH+=XS(8FDYX:>6@!K3TC0'O0R3ZL*^6
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M)$I//L<LW)[<+JVK8<VW<EH"#13T%*FE>8J.U>2?6M& F@?[Y\%VJ1/EU$
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MX7!HM8/HGW#EA@LWJHD?WA8,WFN#$N;$0J7[XW_^?(I0J$H(L(<(,!E[$D>
M(%U+3"8>'Q8/2)9)E$-)KA(G^LB)9 .7!"?2UR3F2I&FX3@*1N_ZG(LN_$PE
M$D*9E3@V)+@/8. M:0BF0,YM!UX'"%Y-!M:'EQ:H84LAL(7\=.@L)5\XJ?9_
M8OLC6_H#V.79,,>O^C,%R%<"E-R8DH]>^4I2NO(R(G& U.OV_Q?LT;TV'=?V
M4"RO'<<#A>!;P67A5W\H75_X@]]_<#KY9!)4XM+OV.XY=9&RR3'X#5Y-.NOA
MU7H028\/KW#C&[4MCK !N1!;0?%Q;J*M>EMI*XQ:7*>L!/:3EL6&MLS__.,K
MSPF->;JD>\1'7TF*A73]\36"5@PA6Q$_D(\L0".^PO4!5[\V;YMXISZ9\WMG
M7@HNB6E'Z4,Z'OJ,Z,]WLLDX9*K_GWC87'^6$-!(6(4(M\%F1MD2;B)YV3-0
MX#>S&\]U7(T*1@B$=.^F'(*D"M:ZTFCJ5J71AJW&*%D8[1<JD^/9"('] 9/'
M#J9&(_[8E.+'98-]'Y?ABDB<E44\IM%C,YL]@0GUJ^*D"V]M.(K9[U;9+W_/
M%BXIU653P?WHN'NYLID)F@7KL/W?OZGM]F>7_X.J2?+/=!S]>6'H,W$%]UV!
M+C.,MS/K%:O5.-ZCHT]UC1=5"_=?2UK1A-%-+'MAD0?,$FYQ+4[*7"YU',D7
M9EJZ"]> S,/<0B:MG!_\HW8^PU)Q%G #KY,FOB+M[,\UT+Q@7M'!SB<,.]'?
M[2:W$_Z+_4WYE_-S?P<.6TS/=CP-Y@8$X(^"K_F4:;N+6V>J$$ 8.'8X$:&D
M8!C?4ZZCHMB>"P<FOHX7[1$5_:1'[OD.1'G&&.U%8=#M7N?S"E6?L;<(*7X%
MCUI6]L,(A![^:+<XBN!,$Z0+'[#=3F9;0!XW.)??[]+M32N'N5$:(W4@M]OM
M9CN)*^@,@D"_*(P8:._U%8HV*':$G&,_R<L0!#-$/MI+%:3HF*[..L/4$24J
M-D<4YU)!*")V9DA$=N#$>(&%K,)K?RCQL15=EBD^S>6J5NMGE3+>/+-3EV:7
MNTI4X>-7<XV_'1]_1F#/CJI6/=I($"TFKBMHLVSPHS^#()5($(; +C[:D *X
M$;LC96W%CXS>729+VH*K[<QHE@+T26.$I2EY3%/4&P1HXS\P'M_+#+M7W,J
M90/ZF>*(3J>M+:A9F O@%#38@3'UC]Z"8 -3>F8\,F#)X')W-VQLZ3KXA>P
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M6J]I@*1-M6R 1MY73;4DM9Y@3[ GV!^^.5L9JW7@3YBK6%R;4#[)F.IGZFQ
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MW\$B6Y_!SLR)L2$P)]/ESNHJO&E@-7OEMH$!H89J&)EAE?3;+;(UU%_G)D
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MS!]VV0S'(L^!!] #,7/ DG)<7C;B.%/@8A.N/5K8RV0^%^ 7MPK'AJD,@28
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M9X*'Q-'I.T],G!FXG_A]2T")/O""[SQ5;A<NUK7[RDX841'R_<432!,!?%T
M7_D45_;AS,+SZ1R$4P0/O$&LP.-X'3&PZ3&S&]3Y9T %$ 9W12YF,VX'<%F(
MA[/GL[GW!9Z1 ^I60#3#=X[$UA&"G+9"<EQ:%^!/+B%:%G\N4C,7[B_K5W#H
MQQ[ 8]X$I> 1A S0X13T2FSYQH\A\24^<"_.MWC&\VGM\4<V!-I5&)\/!SK.
M$F+B-UX$=R@H#I9H ][AS(*U>0YZYI[M2*&)H?>K\NE10DO <.( FF72>_"&
M$-BQG/W82M0E0DH&\XK<6((V+[M%K02PN0SU\#!<!UG"0]M!E_1 ,@@EJE>7
MO(SQI-<M@=Z4)@2\;0+0?#U!%(RB4_P5(1F\7.STTS!$!="X.?81MJO+2 3O
M$L<O 1=KF:?K4-VD12\1L@1^PE83I$4@*:0&LR1H0!.6NJH?M7GSA HV0R57
M#&W>1:J\(;I7<+@,EV4,QB$C0[,ST(#VQMTFIEYZ_U;27+HSF29/E7LP.Y@7
M_^+0V#\334;N>9.13ROB\A'HQT:X<TO $7HCJ@[_Z[C_D<\$@RG#$^3F?^\O
M0HFR@(/4E6PX_ _\Z+W.0.4*C:GK'W?A8;<L\^6!>ZK\$)U/ -<L+D22,+A&
M\>$V'X.[G7!R2>3L1K$+HBOIIL(L]41:?L;S0;C\F3"1^8'A,C2R0-:*5K2!
M.T^V$G5'O*9),%,8+P S"VP\"X#J*6#>PW[10X9.@'EX+J[8")Q^>!S##)']
MX_3^5/FCW[^-B.V'1#F8O3/@8X</8HJ^>$UGP4UQTU,@(D;;YI [=$8!A01>
M.MQX%$)TV=QQQ986[ARL:F&:KLJ^9_GN& B6OR80<6!B<JC!'6C:;!0L">N.
M$C9PSZLKL#QO@5\K&OJ,I>_29K[, A4AL#ALU##.:@DIA[A>QC*L5I" MY@&
MX=:0(%9O%KN1WX9 BK4?"P_GP$7$37'N0\<-^OBAY2J 5O3L#'F'>)%>+2KZ
M8^;GYB]803U^ARL:8?U7Z-L"0Y%NC/%B_J(9,W% 3'C38^#G#V#(/9-LA+X6
M9R94#['W^+DA1;OM*$^.,WJV\&QQY?$"AR'(,=Z)0&X E^:"(8"^'>X4QK,L
M0#]< !8"U@<6YGZ?<&GH+.:N256Q9O+LF[ZNZ$4[B2]!*G",<'?(Q$1/V<S\
M-\#??PWV_LL1M(^>N+B$7W\9RCL73VZ!I=47";^;!P3M+;\GB9N +"R 7,S?
MQ#LU6 @&?F*+=Z[?ABWU4HCSHS>'O?!\[C#F'[M41 ) ?$F7)\W.TH)"&W\I
M'KQL\\-'\DB2%#;:$H/='*GMS[$3>73O3WUY;6EG)"S#?643.^PJ8;W[[*Z^
MLKN/)$BDOI7Z7ELQ-B/JP/(UML,Q[P2,/9%F[(6TQL8P>@IR)HJ*BO@"*A@@
ML;&]&P8DP>0&S>.1,9OGA@8>#13 7&UP14Q23,'TE,4\\+_$G2=X#;"+^Q.'
M*?>&(WZ]T&R(*0:A2AUO3Z@J?W\C?X_?S"V&6],=N%RC'/'"K%OF<OMDWUS,
MG["MG_+)CSO7F[6>=JIIVGK"'B:RR:9%<S1@\!LC;UW,?%(#/74U4A2_Z<W(
M]9I5%IFEJ$"*D-16/<&R@T@E5U,#\SQ)X^#:H[<83H1F*!$N8ITN_ BF%S?]
M E4JZ+; IZ"8+AJ\7@PJ+A/V^/H*8U03-7R:AU$VH1(G*1I+33!!P4"X;?$A
M3DR@=\D0H.R8@9,B9 _T]8I=2IH/%#(6V+'<\N,VRQQTRA=K)M2W+?&C8"6Q
MA<3H/3"0[_"#U:RL3JP38_CSSX07AFZ,[[RZ>N$A6SV\SME@W,>.UD*]ZK]8
MWL_8=\=OO@]2+2^X$$&2<VQ>* D/K?(7F%)+;-5X%U.UD*FZ[4Y"U"KN9PI=
M"!Q$H>\ 4?8XM;Q)9(]NI.%E"\CR!/J]N72' "JG,G"I*D.@/Q->**A)",>@
M]8?'^25J]3'"81NCM[-7!>&);8"]<(>$C82*?;ID);RJ;(HJR=RG?:-*&UXG
M8U0[!:&6<BJY6;UPN3&$(SD7'N\TZP)'<FM8P$2>'%N\,$+DQ%>WMI; #A3?
M+*S!0EPM/^PI=_C@II_!>@%"XQ%N-I(Y ")[AQ,$M_@$32W"YC")J4=AR,M9
MN$NNS0UI3&Y +ENH+N:XBCL0$^)EIDPOB@=])4F*W< 7<5]M0B@H7,F;\:JD
M;UD6T$FN_T1Z$0[4^/*V1@RC16Z#PKN60L%JD!,[9%#F':->*SE8V.9B9 E]
M%S9GS?87UEQ+ !4$U+MH@%O<61KZ-D/'EKN8LJ 4ZVDQC=@1/[QG0R!&[NG"
M.\)##8]C2XC20&N\OSB+_*5]^S6B?GG0>;*C=]B"2IQ?W#<5^2^?%I98+G>U
MRO#JDBP!&VB"3AYA!\0VA&$ZGH8H3KHHCQQ]O?8(!#[RQ0CSP 3^P^2O^[-(
M(>61^Z1'?\RYXRYZZ$?TD 3798B8Q#=\X]ZHX 67_?MO$<2 &EZQ^&TQQ4@%
M[-@<2:7WWPL[IO6B3S\@DT0Z,#GR^)Q)J8^_@E:KB.C_6B,;$8..=Q%(,HOZ
MMHW):'?<*XTNP4M,PDI[C(2NG?P?59[;& .0&0LAP'-;1(@5N1CDU"VP7F_6
MQ/LT+>% !)/Q"M@7#),)_8DGD;+M>8Z>R&4=G-DB/L!]S:'4^*I,G&=TDJL!
M&C'95QX.D;=2Y;91\GX"DQF-;7/T[X47I,ZA^+'$!%,,GT^Y@U6H>.A17K@\
M+W+I$;#5X"#"V*!(Z>-]<N=Q\1LZ]E')]4)0!<(OL/##W0MW07 [/!U3'X*'
MUQ[B,,),VF ]%D^:%BE_O]CJ(GCV[8SG#SXRGNP\#,)2XP7W3JPN#S^17XX9
M@IS;"E'[!@N^$CA5[3AD3)X]_/AO[@IQEDQ"6/$4?2ZQY,?@!2(1$?246*!!
M3/,36!A+H80AD^!6CF?A)W=B:UG.T_,28G C9SI%$?6"@;I( 8HR[V[]5^7:
M'YVJ,IR\\)C,C QNL>5+3I6_)MQ0%K$5GE&*L1-3F3K#^&+E89*P#W53K$=X
M \*@#4\TX,>/^&H/ TI+X.4ZM@AQRV#3<C=&'@D*RZ 3J#H ON#\E1V\N9P%
M-VI +7"!]5=7MLPP<2;K*T]H27*PA>\/XAS<L@ FL=]RCO'Y=4*;Z(=BX3*$
M]H-S%X0XS^2&_H!OO78\[XX-IX !.*;9Z,&YD!Z9&^8/Q@_FRTXE8#^_FR_6
M;#$3K@+/]>]PYTD^@97*V+BGK;6'4Z"-3H%U-YL0Z,"NT\ D,$5:<C)PO9+!
M=*]1&LTXX#Q@?+BV!P0["$'C#0B&\>6]SU"T? //"4; !2ZV$'I)4-%^3]/S
MYKMHN(L86&]"LT[#6RBX9%#+D8#KVCX$+-3!CU&PS#-P8WK[<NO>V$$B'8 #
MF12 $P=00_/%81ZD1_@2/?)P#0[PQ+,^27U</8!PMUM.<WE K3JJF;?YL)3Y
M04G'LQH_SK8<>JZ8;2+]_7+R<)3G$<L%27A8QJKB67LRB,5/>0[V9!5J*MU"
MD8HL$G<MGK3K(B33L!7(V5/K_>$@69TY0#IN&9P\ 7MA7)-AT(T[<9XG(B&4
MY[9R;@Y\^$B@H=$UDFG_PO7Q](2>:Y^G2P*3N":Z=U'!]K&D"6L_G<4C*)N/
MSL)/M.3EA%!DU2 >+/+MGAPQKUL 3<H+QY;> YY[RU_(N9!_>=Q6V\=1A5L5
M4;]#;X^QDAW3W9@=LYPJL%=^3$)L?I](?O/ \F2:>^VN5>8\F?T2FMI'DB=S
MV&U/]B2!]MYY-*D>-I8<-!]ST:'NCK63EO#+H\-%YD/ZUM":<T4',T_E?5P)
MP1.'N\J$/LE3)\*A$%'*KQFXR(0R-3-?T86VL(-Z6%%.()S:LSGZ;(*@1'#P
M1<?%T($ST!0N29$O+;/N,3HWA%\M'U-2I>J'*IBH6M^@'JE+6< (FO&"JU/X
MNIB:'"6_\G6MI]]ZIJ!^?&XI369;#HA(<HDFH*Y,.%W^F'?0G3J@,0HPXD)Y
MUBX#%(S"D:D[1OYVIXBP01]H#A*SN.D(YSSM1#C")/7X7IR"HNIJ^<;X\S*D
M](9Y. B^[(I;*&CWI3($[(.67;W6,XR=O#OI[2]/R]7 X<AOFJ[[$,C;J ;+
M'1O:W8JZ^-&WUQ\>SG@-(=0/7U8&"FA@?\/3]8R?O2G@X]O.DS! >6R\3?AI
M.>5XSM/F<-JJ#!]A'P5S.%S,%B)!#^N\AM8N;J@[AL<-&P5NI'[TEG/QD@_U
MT/P@U'%>@MYYRQ.W+-M%H,I;,NO@9U$$!08;KH+'O=%-%W)L(*B#\)6#00#&
MSVMQDA<2Q_H6KSM9M5_7SJW54R8\X=94'#RO!)S"@U/"BN=^[0X5Z6ER4/]%
M9<5F(CU46./8+"[PE@7%.HY4;<2A*0.)T:(C[U/T4EC=(Y-9(1]2H+;H3>MJ
M$=K_(A,@,/&YL;[1Q8"OW=&E(*+ TC^'WLG MQ J5TNN!6^_5,6X4V%+8LT'
M$VI,^ 991VXN^5<47G:U9?M!Y#)6XNO)P'-4W(AY&Y%O4]0:^?XT"K[%@Y&R
M99<EG8G20R1C\D.L6N?Z9%#_>;K9'Y%H:G)'X7XCV[;VA;R/)% !#1Z[\0:/
M[896E0:/Y6[G6*=VCCC+#4TU42(?8X)XAEC !N]KZ9B5WYI7X@0BT':6= @1
M&($#1.9L\*XDV,3U,2BT5X,,B_AC\5+M8,^8E0U'KG!R8VJY4@]LVJ#X/L@:
M/(O+["C7+BP""%HNQ#-DP_LS39K#?)?\\M."O+0=Q"[8%X/QA>?SBH]=;:EE
M\1H3G$U],T,>0V3IASA30WB6(+@D=).X1ON&6B.22M$:0:5M)2E8>MN6FNX!
M,\W,_S L79&[YLD3J K-99H2:D.FR',2.@VR /)<-,AV4TX5_"XE ->) YW\
M";]YTS-^I"Y*2;&'7A<IVTG+3(P.*R.1218]Q"485V5/E>_Q>G$1L>/P>^5%
M\XXH7O-84)?%*[#F+F\>$ZTO23+*]IQ8W\[?$35P%3'S-_"!N:%>%#M<(11_
MUP[VL>W-%MA#=3['!JHQJ?[OQ>B)?QZK*!ERE?/*#LTA578D"&""[F%),N%&
MXD[$,/4R;&#"F[<&-A/JN,$9Y &2+.XW>>4W_7(PV,YM$H"*,[1$O#6H&8Q#
M*@!0#+2QU>#+@C!M+"_ =QGZ9!' X2J!27C6=I3@*G)+I:TG'I&I N(+$ \2
M4' CF'T<)*\6FV)F$J]^$P1I>HXP 2.$2ZI?3,6%T*)<^.A7] ('_#+B! ER
MKXD8_LS)9&QB>]BP0(P'E;=\-382X8U)@X3%(<]8'UG8=S4PY; +:.R)#6T"
MMAU;Y^S1YUK1Z\=,@_C9U3KNL^ONX2]4H,+8@]"JBC_ PMXL2SV D+R35[S:
MSRGJQL0SS$51LS-?*O"X_-<@JL"4MB&O.+L_4QZ [8=*I]XLNI8Q4FBO;"R&
MG\6GUG)]+U:O@@M>*A[9 *UEJ$:P HA$D. MF$ &/OH*\*X?.PBL<"6<^V0[
M,-2&1ZCYCIF)@L=#*>DR>="@ \MER2]YYC$H"_U(V.,VR%TVA2>).W!.^+D>
MB(]1'*ORX+:7.UO&<J!-/_E!=,['7(>BSP[>; XG:R<Z5RQ.E3-QO 3'9_)[
MQUL(E:=WA1EZ',3#H#X9GXPGXRF?I*[Q.?B^#1K-I@P_3-OFVX@B@M&*91H;
M.@BCM?,SX3&F!:$9PY?$N]ZP"9ZJ<(B)-LJ.3-/S67!P6+RIO.F++N&!CS+"
M]0EZ]E%%"/R.KN7]9ZVNF<7+U8$H5=EI3M0:"(N,\<+VL K_#8A+0'*(!\[@
MC6=0)1*/6EJ&;7FZ>V2Q= ^L+4]WK[8\W3*WY>GNU9:G2VUYRI @U-VK+4^7
MM^79IC7?8GGX+3_$HGSYX4JZ?6S8TD=5ZG;WHT,H#UNC7H&QJ"_'"OW_1>=A
MB4K-SY:Z@XB,7NGSB#>7B4HLN+8HBSYY#GMH/<L)!>(E\7).KH6*_HQ+4!$]
M_FPG*(23@=U0[4BL? ,](238J!_4#$<F;.\HL5PR(-RZR?Y;[J"6&^!OW-JE
MY]G$AC3^LA_*B\\#5/Y*N 4I!<B+S0+H!&#GJDK\::$-)CZK+&%N/X.:]_+Y
MSO[[7Q/3,T27G)0-Z\[F;F%'85B'T%4$> OF]6@YLE@E=$IYLJ4#+\3MHWR2
M68K)C9)E9R[9AUJ:Z<+6C)JH;7R;*$\:,383'1Y\;F'*9J,B21*'5''+;&R]
M,&%V!6'R0"A8V-][93\K0O>3L_#1Z8JK ?D!,$"&%O=^WI1&LEEFK/0Y4O1Z
MT7Z!NPB*<9-G#>"V_$FT3 NW*C.:U+6V2+%$%<L6V4G66FND3?A]EU>/E^3@
M#"S\HCLP!\^X98@_?50(=8\\,H4PE'IR!&)^@8-870H]GX53ESC1Q#ZY7V!3
M%ORD6"%VF> \DG&-,$5JRM/>T-<<3\0164@1#+B4BGD@ JTFENL=S!9?'4TN
M?6=!]K48%K=6-(DY6:A<800<5B.RHO%9_IU+817<B^4O@D0U'CSW1,T@\+@K
MY_D)5];4FEE!LX7UK^+I7+!F=;>AZEQ[V[ .T?$BBA6 ]+?8+Q%P?^12=0)D
M'(#P_RY,#*RL9Y9CBXUH-B F9[X&F71\5L1P$L&3!_V""7?R^Z0_26!4C"B#
M-RSLA8?1AC@"']FK(R-X0;93[-/5B$\TUA#DO,U'C'%?$NY]8LV+:88?9[EH
M!!H>F2)X$AR"@7HZ<_A'IKVA8^-& 0O&(%X W.H[U4C_#$3#VIOB71?7/OSV
MBET;1:/&8#MA[X7OV),[O,QON@=:]>Y$J/6&^6^\^QM0U 3GH>W2U+$>)M^>
MU/=(NNV\.:Q]#] F]Z0X5M!VLP M42V UM R JU>_VG(MJTR30T;,,@S<)]]
MYX.9C*"K9R\3CABZ]32AF]@FY6C%@H%I@FOE(YE<^&U3)W7?\7F6" =+.FWP
MT&;=H)*'-OS;'?F2O8&GRO;L]>&$C;!1)@Y4C>%T,!98Q;\O>693QJGL'>";
M)5PW1!9%;!"+]*Y(ET^D7HKDGE"GU+7?$*)<M=P)A]M,HB_*AG#CKH'&#I<'
MR94(];TK$8I/[D>70RSV%Z;YBX5_T63("#/]DS+Y]=]J_]B6*R\V+K^A'=R\
M_O<NC[<*?;R4B^=I]SM482C[T$-MVZH4N2Q%DFODISIMSK$.(B#O[344.[YF
M]65#!]G"%@6+XL6"8H/G]5,-4R"XSU3YF\;_K!:;!("-);G+'/>UR&N>12CR
M9-ZG$B5?9! :" VYH2$P.)3(XL@*)21$JT,V#UQO_\[5]=\?W7_TE O4V04(
MUK5MXO)BT76#QE4UL56O'K8((V7#R)J/@,[(E,_(%(BF4 I!Y\VQ<6G1 #<(
MX$3A1R!8B,Z)SJL-\,PH/'U]2G3I,8?_>7)QN-B)K/09#AD;C[=J6@"OCY9'
M\$*I>*:1<L(O?:#'37)'FR"BJ?1WPXE8\B9AG-#N1&KU6U_S[A?$Z9E7Y'S-
M+[;<WQ8:_G  NGRQY6:MIW<2XL+OQOUON\G+E$CE0&@M.;WIV&BM!;36)5I;
MHK6;?_337] 12_?M"87'QG%MX+@Z<5S&M)9)#F"FI)H1N76 W)I$;MF+MO03
M>@^1W+I ;JVLR"T;T[-Z%N:WJEB8^6MBY=I_7E;/M^/2P; YM;X^<^&X#T6R
M>DCBT/Y3V_]R6_&M79,RKX6-%Q*[6 OLB:8-ECOB#5*LV"P.;\&;SV*G!_@D
M'((@>NJ)V[ R>NXZH\50M/5^9M,I_LM?>(*/85WRD^4!B/B=OWC#7MZK%NNB
ML8I$]C.4/7+#19@6'^4Q9R[*<OS4<A7G$8 <C/'PEXJU5^:?C2TLH)CZS+5%
M>U@O++;?M"%XRH-[/=$T%VO51P"A7VQEF]AW;ZG4 P%HX8A?:\P[;TRGT?P)
M;-?*F_Z82CAYUAS!.SVVTJ)GM1PD&I$BVW.H2P-';-%.(AH4):9$\6)O<X;3
M>..+W%"%O4\["2"BV"@)U['AQZ%HCBA:W*31Z&:'BAPMWHFBVSSR=CAH5_*^
MG/V1,\<R_/B@@R4D%=QCX@IG4C]A%TS NR:8][)__RUH?-.__Y%Z]W[\IA.M
MI<9&7R:!/I_&,MAD631)$'UEO(![12^J@>R1+8KF7.L7EUKB]S_9Z E#L=B6
M#S54WL[B I#L1^)B\&S+CDCJ$J:%(/(L'&$TMN08G%C_<]EZ+&QT$^L (MI.
M/"VL$2_V<]G,P14%XX]B+YDY("D]*?0\T?E<- H)F]<.HTV'?6S#642\#^Y0
M[N[M)05"?WO[&]Z&]<J."RT+I.=\RJ)+]W "C4QWY/V88W<BR41;YY']W/@T
MDIO6BMLT45LU[])QMTA08>#$C1;>I>EDN?,.VBMZK6>*5:Y*[RQ92'*0.+'P
M-,T&]$ =Y_!S&>"/+SSA%;.XMY.1^7J"_>!.F+V,CWJM]S\FJ'+NJR**6QMK
M>(GZ0 .?B(9_+O-=)QC&I\R8/Q%CNOCP>GFPX^0"<SB1$[8D>$0?[:SQG#IV
MKV:!]G/!2:@,&-[$84:M-[*PAZ*_ADFAR8'J"O)GL^:VQWB,:LUD;^F[M4;^
MV(SVN":X8SM7N#=HEKQGR]A]YK]W#VS^>W>O^>_=,L]_[^XU_[U[///?CWDB
M?(CF/9X*),6^89ZEH$XU+,HK:9AM-"AO'%_Y7^:'IF?A!N8-V">H&@0=A_,Q
M,8T3K5T.$_.>B<E0=^&,C4]BWDJ]HWW^HES-T $GD><[\C8N8H(GS\/A8$NS
M4*)&L7)@V?(0,=#^7/Y:U&U8,)TJ:G+*#5VX@AK@3'0V$=/[^&@05' MCV,'
M6Q*&)@::@6,+8SJB$[/RR(!@^$@4<PRO6NDMHS>#3M/X!<&7B2$CX<@E^;[@
MZDYO;*BRRZ/<^[+NC@.Z@N:XV$9Q.I7=HX/OD!U@HM%@R7K@JI+/1WMY4OU%
MP 0M'X,!6*M>Q>TZ:82P8GHP G<&P,V=.[OEX,XK,7OFP7S!N4J",=N-),:,
M[MR9(>>+1_A2/@U(S)H6/!?G,]F"G;O@5Q@X&AX#U/3D\";$DEJY)P?GZM@X
MQYK3N1KW]*]) ERYS_<X-RT^;M!\>L(VQ[YH;_WOA6MY(VL8=+%/C_6!4;E_
M#9Z XRMD)FQ3;0%B1YDSV9OFGA0D8KA.$DONHL$EMVU*>8#T-SD'$+;X:-G\
MFR-2S'J =$-?\O%WVS1 .H]2(8,&2,/= >4K,=(OT:CHOA"Y"R\^PUDONFO^
MP'TR;>N_9AB2_,:'OO$1+='0DN43S DB0E*(RT'/\:@N"M3%3(Q5P^N)N)$Q
ME=E\ 9#XDYE3^'6^<+V%*<;I;GRP#\<2E\OB8$A^N;DZU<\4(]5$"!?D&@>)
MW+F,BK@B8+(\[?=4^2']P "8R.,;15'4E4T$9_RS*8(V4SA#<70M/_%=55P'
M2>.+Z6NQ$=[RGE$PH'LHP2F.U>!8BDWB6[C8!YR/&\75P[7IJ[H%XNO?'/5$
MYQ[J8*H+ZG;X#6*L2Y!88+-PVC#W;2SO&B&"Z[6$OL!'"2Z!N1 %]L=<'OIX
M!N*69!?') "IRB?SLZ!J,1Z"[W/KQ!O1X1%'#H;#/L(;S\2-8O"$9<=FR@8C
M/B2D8J:(7-W%BYQ&>(>7.;UA6.&%CRJ<OFYH<,['V"1H &(A?!W!B_E[5]6
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M;4Q7+H(IK2&H\T)539PB!%(:5.S!OVDOP%TO-!4U*3Q]NQ#%O]9Z%2I@))%
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MR\[RZN-<&UK"Z9$FZ?'"D)SHNJ]GWP[(9+8[6[(GG**18MK8Y(B?H?&[T;&
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M8J,](!UY?C;.HLE@1#IF ,&,N4EV4);8J&BE':@$:?@)OBXT:M&CE1KSJY_
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MR7%J.[:[C3SR ,<MU@X6\DBE)@5 )E\2X:AWPZ.H#KOV@D?1;4-,VNZ=CV,
M*:H5C>0.H@X6@YS6\5.WW<>\8T9VXL#N]:F0EF8B9'7M'1QJ\%2H.\R35JN
MQW,J],X#:4@6W68Y['"!;$_U"+A%Q46W#3&D&5MOL2NV=H\P;83=BZ8^$ZRA
M%7O&G>:2N?TC,5\KS?&2-U'T)*!^CE>GM:WCI<6!66H1-$LMZ'MI4>=+^Z^_
MUM;J?<@'XQ\6+W=+J-L6E=9%*X4O>4NR@45S>'[C[(YM66.H3T)1*H$D.[KJ
M7E<,P3RE >NX+>:T>!,K6O0@B*<!?W96ELU/3';"[I3H%&-,VAVA2-KWEC<+
MO1T+A2O=B.A]A"/#3CM/39BHMJ,SJ%G>/IAL=4RM\K-$A+G -/DR*!A6M/*
MWT*JMA,/C?Z+!&0I]TS$[S:O5X+/*@M"Q!6 #T6C<SB9#/LDL[4=YY-TNHU)
M=R!\C A8G5>3YK:T>QUY:Y-&""UM]L. E2XVTJSL$(RO88MN+^&)Z'XC]1Z;
M) ^VGV5A[.;V_3J]QN1;G.\7A+(+M$4?K<DPP>H$\$>:$KP@@2DR@ZI"=.UN
MR:CW[V9M+RVL7)S^!<XHATITC<0;XYR=N]MNQNYN+B[]EB1;-QU.GR;U1XF4
M S4(+3BNV9Q$ O[0Q*;#P$7[;ET"=IUY#Q8UL-+CJ?HS%33%E#0S[YW$6GL0
M&F.*  (>"$L(9^.*/>K3C0]1,>40%7PZ/;RT?R4^VX&= W30L?H!_@;;E_]-
M=*.+KZ&T\>)A_$X,.0D7Q'2+1CV 4KS:'2HF'I@@(Z+OUM474O\G$(Z$YV'#
MRRGTY9+74@0@0SP,UL#@.?@.?3VEF)PB\DOO;A_YTSYL+NDY_A]N\"GU=@WZ
M"-N=C7,A"#U?HY#-C,4:*>FA$P3R(>ZV#&*:&);M,E]B4RK_JY,Z)MPCL=8]
M%+0DB#L&O6*67G91UM;E+<6F"E5!1 >YQH7D+Q L7/U2/Y+EF;#2U+"KAEM=
MA)Z1<O+8LV_CODW()L<,7<HGXD84;2%RIZW0%LZUI+D1"55ZDIG'7S\@TC%A
M&UC/#V# N,,0-L1)&Q<=+=]E]5!@/4RL[-C)MRF7[GU\.;DCZ_R%[&U.1/7"
MN&7[EV3N4R1YNZT"TCQJ3-K=;G/0CM9Q96*)Q?:0H0P^FH9KM2YNOESF2 ]<
MS/X/Q(LJN.\M'[;I1C> 5Y?<%H;2!G_ TWW6?N:M^[7AX'YT$6* GD?'#(=T
M$<7#-J9UM(4%ZM66-]XKG,L#,M"I8K+NG[JYUNT-JL).L5S=TNT^.U;2SK/N
M'=AH;>&9=Z+[!CZHP+[I8FH_T^TY7M*N5 KN*VG7;1=.VL7LNB *>\+.)"<
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MT2PEF\";7H ;OBI=G<%^YUH6&9H!8O,5RVKC2FC*J7_IC1J3C)D 8&*6WJG
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M'L5/$87. P6:"4&6=/SY 7G'M6X@Q&KZ%P@Q"?R9MH"XXA+5L5#7DN:.N:D
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MH^DKK[]!8-*('E1>^>354<T#3GZ1V5>]\$BAV,#F/+GH.+;JD3ICLBJ"0Q7
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M#T;+D:N>DBL55JJP<F\>4Q<\IIFUQE+-2GIT^UA?U9UJQ0/% \6#U\>#$SM
MK6CATY7?PZ&JG]3ZJK4^E6%*W>E7[%&?;A+0!__0$95BI4D;_.2S4-*[GF J
MZCOGM\MNSFUBMN"U]/H)M_8ZXDL^WNXW)L.VRD&H'(2BQ1%56ESBLWOLQ&>-
MM-B@1"UV8M'-P7R>&QIMX'HWQW%I=KR!\FM"&H'SU&7ID3?]L#'I=^OON]1*
M1BMY0E<ML1PIL3Q)7[(F!%&9F#Q>R37.^48D&^6>G)Q[XO*V(O8 \12;XV$4
M!UHI0&41%$$JY<H>/^=21176;96KPE2&94M?A@8Z,>UF >0FN"[ES9R2-\/9
MZW$W3AG<K1]@?QBZO<$9]]=S2L^6IPC:C<FHK3P99;@502JDRRKJR51/?77*
M5%\J\9+JK"0CPBMGY02<E:1!%D>.7' &UZC9CYG[KBR2,M&*(,IGJ8,6ZY6L
MQ50"9LL$3.P8&^7/G( _DS5C_ A:H-^8C)NCOG)EE.56!*F0-JNF*U-!!38H
M5X&I!$SN;D.9OIH@L%80@/^3;IMGUGK%W1VO>VFCW)^CN#_(CNNU5Y._R;W7
M:X"6TATV)FWE^BA+KPA2+4VV!Z53):>I'.4U*E=YJ>3-E@=2]W^(W,W*0"B,
M;];J2(W7M=KR-<C=W*Y>),827X\<^8P;D^Z@V1HK!T;9:T60"FFS2KHAU5-@
MO5;)"DSE;E)]E;LU.%^.HWUF3/O(J+#*^,%4SN7(;HO/"H\3@E/ J%-*P/3:
M$,/TE/.B;+4B2'5TVK[53Y5\H'+46*=$-19Q84X$6?EUC<I0'% <4!Q0'#C%
M@3VGCZC,)_DH(-532>67XP5V&Y-QMSD8#6H?T-9%TBH)&U:.</5. _Y+H<B>
MQBX[T4"^3RJ\W>^K8%Z-)JE9**-XH'B@>/#Z>$ V!?ZCPQVCLW^X;>E("\-%
MQ"R4SK4##XM_2?QJY)N:''2/"MPINHA(=B$U%2$Y0E.&[;7<$6(_IXOUC$T^
MGPUY-.9^H+F$Y.;]V_J9V<8TYG=I$!+\"=TCPUSKY%FAPW /S[UC"T;.P?=V
M9S@8M0?]'G>DX$J(>E>AJRZ62V;._&N_MQMY[ST<#P=Y[TW7NO=V7SN! Y0M
M"7$ /Y+20@\,G"?V3E^\Z!NG,9'(Y]W[[Z&7R/%6,>LM\G:=T-L]>?Z4R#^-
MZ9_W8C/!CGO_8LQ63R!0K5_>3Q=,MW$O/]&$H7V_2J?0JW23&15)8\FJIGT^
M&$:YYWXLC_W2:.Y7T;%@O^K:DXW>]=]6UK0QN4?MHEES+&U=,8*"TX.[)(..
M,9_(7Z9>GU]#_W57*RM&H1?=]6K>@@/?B%$+@;]S:1B=]XV "L&TXOM BE%?
MKRSW$YN3$S_"VQ67C&XAR>CE40]Q2@4,!'%KRA:+I3Z;07#UWXU6@WX775CT
M>Y16SDJW0<X^7-]^_'1[=GE]=75Q<_?IG?M#L:PPI_&X\\M[;OW>M00AW[5<
M&F(D1/^=!1G3;_\"6U/+M,3B&4/OZMC_G<0MR,IK>\W=DYWF:P.U"9)A_G>C
M/?#D0DC!A^O[^^NO[]KG+;3S_##B;RWZ)SLYP3=?2/D4; @LIK<P=:!1[D"3
M4@>:[J#R^LBFE&7@SDFWW=0ZK4XW,O4PP"]M6SH$ O^2^1<O6YI@B":T@.^3
MGO>7J_?!!>Y^G\C=/*GJ>$(E'&%Q@[H(%9W_\-=S#S?X;R1HZ?*C>%(.3RBO
MR%^OK3AP9 YT% >.S($,*[8+!THP71EE VE+I[H!K2:% \78>>$X;!6<PJQE
MLC(QSY;C2WE<TSU>I-9X*FLL226<T,Z_U)TGC?VU-G[H"^9!YZOMK-98P36>
MGH4_6 O=5\MD&WSVGVRES>%-][S3BY:3;/7EXO4DW%7)5TK2[GSOMK&4I%N#
MTL#OQ-"OQ,_/R,Z$[Q,!2NZ.'38FW5:S/^K$5Z-L*2?%],RK$L]*UA-622)'
M2B*+%",J>NR='E%7)51"=U2O; NW93_M'OG=C0JL<+\"7MWWK/X*%2>JLD+%
MB:JL\!"Y[Q,*@'EOG$X.MPI]ZQSZEA,RC%7(H(+8<F2KWU*RI<)1%8Z6Y4[M
MT*EP*(]O/TNL@?.M>*%XH7BA>*%*L@Y:DB7US:NZ++7&JJ]1I:NRMO\5>]2G
M&^UBL5C;&')?6L_/\#^:$*^)6?):!.GIQ%-:A=%!:I77^LYY[K*<<YP8+O@M
MO?YQ\=#[[<8$HE25S5#9#$6/BNBW2J(?U4BE=<I5::<7"1UNS#B$I,;4=7J.
MYNGL>@?E[H1']!)?7;8>>?MW&Y-^<]SKGH)/4R])K>0Y8+6$LZ>$\[2]S/H0
M165N,@=K@D8RUTS[@EW6S%EIGPU3-[&K6GDN)^*Y"!:['/88?&0ST:<I=9U6
MPI0ZI1*5G5!$.;9ZJV:>IJ(:;5"Z1E-YF>WS,E]N/HD1X@[ND>LE<D8Y.2?B
MY"![?>YRYAY9'0PQ#AXH_T:9<D64JFJV:OHW%51FH[*5F4K5%*FQDVFL"2)K
M!5'Q/NFV>6:M5\('"LTG5S[1$7PB9,GUVCMGWIS26/+^N#'I=)OCL7*(E.U7
M1*FH6MN#!JJ2*U6*)ANT2M=D*M&S?>L\LY^U*TLWM8_,-G[H*^,'4\Y-!9R;
M_<9(R&;DLL_DXCJK'.W0;DS:S=$X8=JA,E[*HBNB'%O!5=)9J;!.ZY2MTU3Z
M)\NON5N#J^8XVF?&E&=3+<\F9K\*;@&S3BF',^B"'N@IQT;9<$64:NJW?:NB
M*OE'Y:BT7JDJ+>K7G!"4T6O$KE2<4)Q0G%"<J,P*3_S<X& 01AQR5X&4G-(I
M03D>8[\Q&?::$ R?0B!<&VFK9.=M.0(V.*$.6@71<D+[[413 ,/&9#!J]CN'
MK.<XH33 ZT0+5;Q0O%"\4+RHV!)CS [\5X>[X@]@WM#F&^9:)_N6N.+V*%=T
MWOMEETB\*&YPY&KZV:-)T0:(A-L9*^#J-'IY"-E+DY&+@RC&\30=1"E*Y)*3
M&T%Z1LD9HB-.M]=TS6;.>K'2K+FV>F+:A[4#"W8<1&%],$QBM ;_7JP?U\Z*
MBT>[J:&3UZ0OP'5+W=S ;:8HCC.XX\(]$D(G2@N_^<K2EFOP\G2'R3<@WWSX
MW@G OYYK]W!%^ ZZ#=^T=7P87(CW^/:_=Y\TW9S1G_R5K+0Y>(7:#W0+-7RQ
M1[H:/5C\>6D;4Z;ICG;'EBMR)?G[=5OT@CVDR7^F^\AW3_#$&[Q/C#_<&G_O
MMM ?[J5A+/'^<WWQQ716]AJ=U@1?]?N2V=_I@;+7VO&<UE8!IW74F+3.6]&3
MJZ8&+NKT23-0,L@-%RS7#'3DS[5T*461BPBI)DOE",MJ@MHG^59Q E] P.60
M9\JPWY^'/.SG=+&>L<GGL^&0*.!^X.W*J*9S-27_7^CO1-I[>-@=6S BY,5R
MR<S9]W9G.!B.AX/>]QZ7#_@&FUVLLJ[N!Q>:0")*989(A!])6=L'!B+!WNF+
M%WWC-";2^WGWCGG9XJ_7+_1Z@]#K/7F!C<@/C^F?]\)L@6U[_V+,5D_ \M8O
M[Z<+IMMH-I\@JLEXERU>95#H58;!5]&B9D&R;0$;>3X81OGG?BR;,XWL66%S
MIVM/-JJ/OX$B;4SNT8BC0KM$+478DGK(\&1)A?3XF(T5^#OGUNB\;P0V(9K]
M]P$70%^O+/<3F[\M?M382@B'A3@W:B3MJYR'"Z_)?0ECM+N6K.D:Y^OYG&%*
M1OH+VN,;*B@!$[[0IY20R>,!<9OT#6PA&-:0P?72/'P4VX4Y"^#J4N)G=FUZ
M*2*XX)MEVNZO=%2 WR>9NF?3)]/X:\T<VAXH+Q\6X':$;'FK_;U%>:W>O>7;
M](;&P/ N<3?8:^:;UVYGV.LFN_.E.'+WDB,&CA5X.+KC&',#G"!T>/(@[*>P
M4GLS8W.0@YGVP!;6R]M,UH:NUUZ,U9-AROY$U_4WG]R<'_IA^('DL8$3,L.*
M)+B1[[Q]@,?]>78W?;(60 .+VMO)D\,+GJT96[@^S-IAZ,5,94=VKED/#K-_
MD#9\0PO2.F_I?=9F]$_=M]SO<<[!1P2GD_Y&+T6N+:X'"+U^IE4X^,09?($^
M#RS)?=L=&9%%^'=Q[IDD2!W?/4OTUD+>&42%]-)3ME@L]=D,ED.>)OXN= W]
M'C4,SDJW06X_7-]^_'1[=GE]=75Q<_?IG?M#[B/D,:Q2LOX\Z'W7$BM_UW(-
M!N9'0]E6^E9W_$NN[*=X2->[.O9_ZA9[NT4)Y0:CK*)]32Q.$[+LF_?S_G+U
M/O?!3L[[1.X&_BWL&I.';?S.(HLC;M ^;V'(Q L[_M:B?[(/=+@3%C+KNWH$
MJ>Z(=,;"7_(CJ*2@,=\/"14KLECA(MG]^F##KKI5?#@2'S[]9/;4<!CG R6%
M%"..P@AG93S#-ICQ5\20@?.$ @?^H37G'_T.'K>]P$(D_CGEUQ0'C\W!GTN(
MVME,L,U:@/ONMZE5DQNGS ?^AE?&7&R--__+=-MY6QX[2O -QU6O1!WO;Y@>
M)Z4;9@K-!K$D<_C/E_Q_-S:#"-.&H)5'H"]> (\Y!,*06V$*P1*!ZMM3:A.-
M'OKP'S"W4\/2L,-WFKE9APMS=HM?<*[7*PCZS1E59GGA 56 I9^.[:M:+#B"
MBPO\I2?D\C"NP!'<W0J<!5PJM;!=S^E"NF'X-6X-Y\_/-O/ H]'9EN\4OOY^
MLV1THVC*D0,SWO LT5=,$LDWBEX?=RBX7 ?/ GO>6>!9)_]AX+#5F'3/!]'V
M_%]JN T.6B'Y"G> &^20<UPAT=_J&'S8;DP&YT-5*JT$/U/P_4J/VDM]!XL_
M!B<QTU9Y/0<0?9)Z/PBOI/P7<GBZC<F>X1=_V4K^*RKY\2?O:8*/V%,G(NQN
MR@-?Z:"2+DGOF<.F[V9K>\-T.RBY/718^I[L"DY5&4AK? @<K<-F5_SS^^O5
M$[,#I_BGG2'15'+D1-P$DEQI2'FLLOSTUQJ!?:SGI65BS> KRHG@@,'S_O@D
M<B)*^LN3_M/*APP:D_9Y2X$/*Z%/%?H3RH4,52Y$27RVQ)]<"F2D4B"GD0+9
MIRM3Y<P'#H Z'_?JE?EX-04G?DIDWX/FY+*5CV=MD5]1E2LJ+Y.DP?<L@/5V
M@?CV^=BN1!7,5\,TGM?"N#@V?-%\K'XN:)18'\/%]TP40%)EI)*6K_K/!":_
MBLSAJ(W2,HQ&E/O(')*(G9*N5KOEE/.)(YS\TSE70S^4_+^^,JM15Z46E>R_
MYCJK44\E&0\9HM8G:5F.YU0P?5E^-)HGL3GJ4TE7.*\I0DLA?:^2O[GCR$HG
MKD>#QF1X/AY$$]?Q79-52E^?3I8Z"5%'I865NUE-=W-OR3(N^J[DQT*0ID[S
MJW2R;4AE>B-5IG>B4E\\'58/<=\NHS#"\KP2!TTH83^JL!?,?9VRI(]5[NR4
M)7V;3%?=Q+V('S-NJ4Q97<OQ=LY&5$6P\V0SQNW&I'<^C*2KJIW'> 5E>,F@
MP"K%H;R">G@%VZ<XN/![LA^;:%X_@/8P='MS!^993C17.<$Q[J@$QTG+_!8)
MCAH(^U9!W[BKTANG+.I%TQLG*^<]E=PX93G?*KE1*V$OY,'T56KC]:8V*B'6
MN1(;@T,D-G[UAJFJ 3U,#>BI^"U*2,:I 3UJ0,^K8T6]!O2<(@?4:)ZJ,$*-
MYJD[!]5HGDKQ@;^A&LU3_2/:,%)*8"#/ZT8T^<BF\K%NVQ_%TU5)T?*3HNW.
M]RX-N.[6!Z?[),$CQE3//HH>]ZITJ=H IXP4,1ZI23Q*\%\;1,1X3%A!"AY%
MB?ZK1(CHMUJ-2;NE3H?+/QVNH[17N:^_WVIC7W^G9I7PIYM-.>U1/)$$B:9R
M(R?B)JA)/.DN E7 C_<[D^2D?(17+_>GE GIM[IJ!H\2^E<T@Z??ZJDLB)+X
M5S>#I]_JJ^3'B20_7L<0GGYK0),0QO7*>;S"TA(UA$=E9"J@P&OJLE1J9DZE
M<S.J7$7M@-=8K])OC=1D$R7_K[-LI=]292M*]E]UW4I;U:TDR7[%1YO4<OO4
M<[1)OYU0(L/EKJ39)O5@\$G,-NFW.XW)2)IU6>9L$Q\Z(_2PI!0=@6EH$?B,
M8#ZN]XN<C&NWPLFX4!;.;[O3X*$&W&*F;0RVF"&Y-'VQT.!5INL%$=31#*?<
M>; ER'J2_'T4KUNQO,56_FN[6W^0J9/D"P&CQ;I58?3+<\W-):>9#X^@+FHR
M*&Y!F-FU><NF:QLAES_HCN'\;EH/#K-_H)+A&3L&?)W"M\3;_UQ]6(#^#K&[
MU?[>HBW8N[=\MC<T!J^_A*6L[#7C7S',-9M= !GP5G=LP>A5OK<[P\&H/>B/
M?%)TNVVL CFL8KM_8G#!8F&]X'PDCBED"Q+ E2OX\_0)S12H-5.; V6U'TA:
MTGSXU]63S9@&>T0SP773GN%A3XX&HHGG _&XO70UJB_-FM,]Q F"MO#YQ9\R
MT]8.KHLVA+@)K .WU#M/%$X(4XD8MA.HTK 0J-)H=R"AUW"+5X"(=(I8"9ZK
M+H!$T _G/WH@Z1P[01=GG-[A)?]U98DN??D84T%='(I]G.P2[SBW@@#WBAT'
MVTTTKX*_GSNU0G'DN/J-8#;Y"WI@FXHGQ^3)O;72%[5"X2&?L]*U4M$P9IMB
MJ0_Z0C>G3/NOOXTZ[?9[[9]KDP7BDNYV=4JUP0SPPF(I2?"'L7J*A,!., 9V
M@A&S-XJ([A67!AF(>+C[O4"R-*Y,,IQN^/WNHYQM..MZZ89N@71#OS'I- ?#
M\?'/,97H)(N.5%9;$;D9-";M9K=? 0#_JIW^D4KMO(?_M<>]4E:GR*&TRAZT
M2CF*8=B8])JM;GD3;$KR^D[(N9.7B>>69\;/LR=C!L]\Q__'\^WMSB FST#Y
M[6!Z6_;@#^D0EJ&.WI2S"Q,VX6^Z85Y9CO/%G"[6,S;[8G[2;1,N<\)'*$-Q
MA-*5CE .ZS(Z0";XK,!6Q_K/9G^X7Q_@[4E8O7J)V<'<R^(R-FY,^OW]-H*?
MAH35V*]2Y%#Z1]8_Y:J03@M3'.#LE*=$5")R:U_5[8C!ZH>70)K^1#U-V'7V
MOO>?2\3KN6N^3\"][+3!].\7#/<T+'_UY>HHZ<JY\9/-SO[-;"LH1AW/.8C(
MDO(6E/.DR%%_0U:R(>J6:XA40C/+2?S(L KW$5B+X@>>HEL;NT%@#4961#F-
M!?=:@*C7<^_S4W =$4VMM]\CB-/P'6LC7]5-27;Z8 Y&^RV8. WA4GZ3(D?]
M54_)VF/0F(P[)6J/J#<IN87+G^E>H;ACGD:1PE)9W-D41:]T$2Q=U+O:CP]O
M6DT-_WV;Y# &.IGJM,)];?7_S]Z[-K>-(_O#[Y]/@=)L3B55M,.+1%%Q5E6.
MD^S)5B9VQ9Z=^K]*T1)L\0Q-:GB)X_WT3S< 4J1(72B3$BEC:M>Q)5Z ON&'
M[D9W>V?8_A%*'AQ^A)('AQ^AY,'A1RC/.S1SWJ'\,+8\]%!3CNEA_$1;8_!A
M;SS46M!=0@K.:L%IW9$'W>J-=74HI>8X7!R2$B_$DC1C#$;HQM'W>,CA*+PX
M!F#BJ1^SNCHMA>WU#+'5>R?)!<D%R07)!<F%PW)!)OX\NTQ%7WILZCT5W&^E
MQ\; 6N-:<V>*I>#4(#BM\]@86F]L=-S-)Q-3)#E>K$EIQBKHL);TFS,+,DJW
M,]S[O*BH;$?$"<,8T=]Q9'9WV,I(<C1.CKT>U_X"BD57GJS)%7'_P0N=)B5.
MRW!=IGA_^@;6[*,Y7&> !3<4;=#Q8-S+$B1>GS6MS%JZ18AO87ET[.#I&F0B
MTRRF&3'J8_T:<]CQ;>5+DJ)FY ![T/<52V_.G$A/7VTURX:R9EG;BKDL&_H6
MGPPT3*PG)<]N=5S&VGLZT!C"8B(/!W9=P/:Y[:DN8U9O/%0TJUZ\(L7L$&OE
MOC9%U85LU!M;ICQ#WW$1:U9(^BH(B:+I#9: /=),R)=X?DGR0/) \D#R0/)
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M0I)"DD*2XFC7]>/)&# QNVZHUUI$Z C6\,X(8W?R!:K+)I:WJOW$J!3.%N^
M&A8HJS<VALIP--J;IZ;S3:=@V"3T76?:SBKH-0RO'NC4TLFU?'B2]I+VDO:2
M]I+VDO:2]I+VDO:2]I+VQTE[F5!?1^>I:SJ/F!^%4]909?.INEND=Z3>S=9>
MKQ$>E>GPV2O944.J7+OKAEM8R=E4S$X7J3AV >MR$10+JS@K_4X7<3YR^6I5
MB9.MY4KGG34T*5@2'T@J2"I(*G1FP6G)"F+TQD-5&9I-[3"/+Z7BI766E]27
MU)?4E]27U)?4E]27U)?4E]27U)?4E]1O@OILOPP_T..P:F0XB/RXX!.235ZP
ML$!$[EVKGT0*C\H^25O\O2*C(^-LF5",YG%G"_W%*E6./Y^((H_)!R29/?<W
M?(L?:.!,^-_H,'&\V!8."'Y=YN?2)<R3<0/OOZ8N95Z+'YH^-"T-F[,2<26=
MGD=+5YW/Y]2;+J[]H?6V>';FKN%H:/9_Z-N^1%RN<5D;9PBP-.$5)%CF8%:V
MA&A-G7#NVD_OB./AMV<5)Y20H0K1]-V(MNU+Q.5Z7IQ6"#)+WED29/PHDZ1T
M2^_\@+ZSW4?[*>QEF9 ^NTC_'>:G5YN?L32_6>HI$PE1(_;?F6 WV)NS1V<:
MS4 SU5=G$Y?: 5JR6>]M$Y,QJDVFOYI9F<PJ+6MV>*[:J3DL<C#YF-WZ*$SI
MK>].SWK%1XOOV=>),BQTP2:S #VGOT7^I#>^0>N*Q68NT$'K1>'[M_:2N5E/
MR>(GF>&4&<3,UYQ[UNG R=E.S$M+K#K/4;/CR$\^"?CD\:/=M*Z_DT'0F8.6
M46M"77=N3Z>.=__/'AH^^!M]P<G?Q<F'D1T GS]<?O_XZ?O)Q>77K^=7UY_>
M);]4RA/,B#Q??=^I@C3O5$$5=#+G_=7L'MU\M8T+6;Q!3RXN_I2WR]LKWEY_
MSJRUH?(7$<,B0E47P/5T,(_.MH7NE1\#:Q48 ^^?/3VU! (EBSNU4Q5!*D](
M_DUE_VV.WG'[N63N71K!AR?"^" F_W5&!&+_56+[*ZT4(A/T_6WP=DP^4\I_
M6>0;\;_30%]^T:B9J)(W^:M9IC2C?Z:F%O^ 5=:2S-@C,T3^)B=_DL4IU";)
MY90,V2-#KKY<?<IJ!^9)%JR79,C^&)(#_9G<"2*2)TC%MV.*XLEEG+1DD O1
MP3A[0X,'07_?+BJ9Y,SA5J6;/R5": DOKN+;"Y\3GY6TDGIQ.%Y@G3%.?\85
M/L__L1_F9_S3I/:89%<KV'7C1[;;%,7E2=XZ3O+^V_9B.WCB=-78,=Z^/,;[
M[ QI3?]A:$=XC-<:],9:7Q[3D8<2CDOEVG2,UV3'>'5YC+?% M;I8[Q#/,8K
MCXFW6+ZZ>8S7ZHUU0QF-I&"U5K!VZ 9#@P=T#[8/BF)%&<4:#:2T230JJ2"I
M<)3VMQ'3.5)[8W.HF/66H&_:-W<L+C@4._(3987$<\Q?#,,8?7*R/^"AC(XD
MA22%)(4DA23%H4G1#&!;@=>^P,)+PU5-A/J9)D+]75S*T>.ZGJE[\B:/M-ZX
M/U*T3GO[I,Y)4DCSTX)]H]ZP,9$Y';ML*"]FMG=/B>.1NW1K*3>31V26)"D.
M8Z'_93O>5S\,OWCL".WTBX>!.;BL.=#8GCR$D8%A8F-0:U->*8#[%< NYRF,
M^H V%'T@=RXY 5S1=[>E$MBJ3(;*O7I'@]Y8UQ6MWI+WQ]O\N:5"V(&LA^JB
M:3:0_B EL_62V:Q;L;H8#D$,5475I864>S9)BA=NG1JV-9A@VE?Z_6%3MD;F
MK51T,Z;GR"XOODB7XQ$9*DF*UMCLRVA&@PO_81[0&04C]!,>-_$?EC,-N^2#
MK&[Z1[UQS2=6),8\)B65I)"DD*:[7<Z!H:H"8*_[0)BTV\>DH9(4+]58-6QZ
MM-[84 ;-F1Z9JK2+#^$[G=M/* $AUBV?PGHDO09'9,(D*399<S#@0=VF/%6J
MRSM$>"_(+S!4L76XTJ\W24DBS&-21$D*20I)"DD*28J7C5\:!B)&PT"DL-_L
M? =Z&+8H8=O*EH@U#*\>,]#2R;5\>)+VDO:2]I+VDO:2]I+VDO:2]I+VDO;'
M27N9MEVAX\<UG4?,6\():*BRZ4=-=3Z?%5UK;]./H=J733^.P$DL5:ZUQ3:&
MZJ W-BQET.DR;<<N8!TNIC%4S=YXI%B=+J9QY/+5JE(96\O5D)4AD'+57KGJ
M0/6+K+3=.;_H].2_-/#S@F:ER*L@:A**=5WB6E$L=ZB.6.LU578PDIL=284C
MM#.-6 U-[8TM4S'4IEPDQY?Z8\Q_D:D/W*/M]$_7,;[V!@<D]27U)?4E]27U
M)?4E]27U)?4E]=L_N[:/3U*_+=1G^V7X@1Z',=N3HQ/!\6*;;\K+QZKIQ;&R
MH69S=/JOL@DZFKJ<H+.4F=,;W\PHF9053O3O2 3?B;0/\IE2,DW=[3!SX05A
MR3D&R3A'"?..*D1$KTD2OB9I_%HA5U^N/I%%K))<SG'F"LE./>N*(,(705P:
MP=/8I_ @Y-4O( #GY*^SJ1/.7?OIG>,A9X 5&+(ZN8Q%$8?LJ#&$0#"&0#Z6
MSNK[S9^Y265'5G@-S)B_ >=]%=].?'(]LX/< VUO2C[8(<7O+WSQY^2O$ :_
M?#&Q(T+MR8S,86C^E#@A">@$!7)*[)#89.(_S'T/^(U<8F51@'E8"H6\IK_F
MU OI&^0F\@\D:XH?3/$WEM)F1Q2U!?Y)ZUSX\"+NZU+(HQ/-V)WTUX0RMB2B
MP,4D7)(3.PS]B<,>FMZZ$*A)0*=.1 (G_ OFX+++(I]=M%H^&'&6&2"D"J0"
M"+.>(CZCR"1;*8:X?AB>DD0IUZE<1GTL4)^,!JJ+/Q?ZMZ3OW,'V+7X UDV6
M/)"\7,V-_>NC$TY@0'% ;T!W/[C^Y*^M#A7V" TG]AP>&07H>TR<?(:I]C7F
M9T.30B;4=>?V= JD_&=/[;&_A<:PO\5$,QY4$(< +,6'R^\?/WT_N;C\^O7\
MZOK3N^27K=,2F<'AIO.=>O;H3*,9?*:^ZFV3_9AW%/*;P9X5,QNSOE_,53S+
MV_>*-J+ ^T=NT&]]=UJ\6M-.$R':9OW9/-JM5J-,SF71IJ]/NLR\G;#7KUBU
MJI&!BS(!689W%@B27^#*)VLVM9IAA2C;>UH8"&$:(_L7$=81C<0_UD<+4EW]
MQ&_Y0#UZYQ3._@[+U72]%W^0>O'-"EY\4'#U5"N)+:/U 7*X. FTG/7,;(4!
M:F)F.LY,WS S>!I;-J)9 % $Y^F!*)('&/0L)-1#3J]('59 %L(YG> :[S[A
M7[ PA!3M_SVA=W?\&R8@L Q2MB1N*';V*;DKI>9WN/."KRGPV,MT1=U)8N:P
M-&0)NXC[G.@['/[6#*1P\>CWJS>,D(W-=2L9JGNN_=[8.!V5S#4O!J=D6V.Q
MN^09*$DNPN<($%'-)L?($-7X\;O]RWF('WB,,0RB[XC M@DI[J:R@\,8HX/.
MV=QBSJTT-3FJ-:U^PW)COB]3L]>Y6N4246YJLB8E-3=\3Q0F>R(JVE\D6RYA
MGEAZQ_ L)// !^U@(!\&"0#-(V%\"Q#:L0.'+C8X^_0@G+/1KEAZ&=.1%4IV
M/C &QXO@_[A](W>QZ[+-).,LL5W7?V0G@NQ[N 0VA@[L4CT: >/N:!#@#A)(
M"?M."I_;8>[!,QOWIYBO@9M<H(]S!V@<MX5<<D +<2<(,P@=? 7^X)M<'"C>
MC:D?K. HVNQU[\9-J.='M?LL'H"Q)Z[S%PC."2X;)U[B70!I 2#_7V1_9SB-
M)%VO\W]XJ W J?_2*2B\6 &6%3R?6;-KGLQ)2">HTH^@?6"5\]H\VI1!M,-(
M"R:HCI'J:F_L^27)/$L?1 L[PQ8<BFE.P%($-,B;&(0_0#5D7X-M^>F@-R[O
M)UEX,QKVDK#*3=_IE-('E/",[^<J$,IW'?F3O\X]_N\,-J:P['\$'DR<Z'F.
M%.$,HM-SH#X^ZIJZE!'QAZ8/34L?&OV<NV4PD.Z6O;A;=.EN866)$[7(^413
MQ2!,(Y@)SNJ&P U$Z,ANCAI2XJDI.2Z<7TVJTJTJ08JF"']_!\LUT'Y2><U=
M$/+3WS%ZX/.46K/2-N+&NO3(OV./<I.I6XD7([NN4N8UQ_TJ0$>;H<!)X @H
M<P\;573ND]=X"TJ!KIY=9R\Y3RYA7VIG;[CS_OO-GPH!E!S&B)G@R=S=GGTQ
M>SASXH=@Y_!?]-2O7SBO88&[O&.2"38?H /\@2&/\$L8QEC:_2:PO9#?NFR_
MS1^ZE=CO]/<?5RQF0Z]<0%I)(B^,(YMB>YT XZ?,Z_E19HI@^3R_K.1N3:(C
M[+1(YM;EU3QDL\@NZ%^^?4Y7='7[K82N87D^W505;5#T71#^'D1?-J#11_<)
M RL\D,/F@M_,4QD.<;A<7/A4R7GM*!6&=_+31T ML.DD8Y<*0YG;2;AH@S\@
MSY,K.[@,&#.F+-OZB@9,;LH05^MD Y#>#]AT_! C?KZ(,#>IJJK%#2<&"KF,
MD->)MB>,7UHC$GWG <GUS! S%/GKE\%W-,BI F-6O!/!2RY@QT:G'YZ2/'=Q
M82DNKH=+F]50W8G"QEHEG/,1DWDR9/(H9IQ274R*I+,B"5%2.PL&$PSL9(:A
MX(G_\ !4%TI"_XYM-_$$+#C*#Q&0RSM@(^Y?7\-6E.V<;RELE-_@L"8+)^7"
M4F0?SIB]_* _T]$O/5&$C@LOSBPFA8DF\^.^CB(=,-X);_!Q97.?^,JFB9TC
M6WIPDPU;D DL+BRX2YV?>/W*0 W;+GRCT96XYW/@/^!R@IX#,!I,8/ABOLX#
MG_Y>JSS6XF^$7<I8/RVVSU[RL=Z!U89W3>,)\V[X";<F?LB#^YLLKNAW(::3
MD/ ";^\JY09;!)0V>%!*=[$DB^.LPJYV]9/*$&(%1)C=TTP8\N.N"OJ+N:K&
MGT\L/MOD@U4;^"R>7<J!8 1<N?5=O4$^G\^I-UU<^T/+CVV5API+"2U1!3_*
M;%9O*?HXW]GNH_T4]L:9*:7/+B9R;)Q5R7BKS$Y?FMTLW6:+?C@C]M^9V/ 9
M@)T6^_*SB4OM )/29KVW#4Q%KS058S6C"ANY['Y0.S6'1>XE'V?W;H1MWBKO
M[6PR"] B_ 96HC>^8=M>,&08!D!+]?ZMG9?D#70L;.48&!Z_7];9[$9=[-.3
ML9'2C6>95F9A-N.[=3IPO()3(K=UMN/(3SX)..'PH]XN(F!4$H'^2N?(*JOU
M[/2,U1")/  $0(S!X(B3I)[9V;S#&-X<D//K"V)I XXU[@,_#!?0X0YP (<O
MA1<]PHZ9W#E!&+$@PR2;C;9F6+>V0"X8"W!PQWJ"272$AA$L/?B,?-KDA@67
M@Y(%?/[\\YMS@0$++SKWIM]\'KWPEF.@K=WDU+!>8XV.TV+3]*7U>H/T(%9&
M-PC :/C<Q9C^ S_I.\6$2F R,*F<9P"C$'+R4[[(;R=,<S #.O<#!JU$-B;R
M7J1)V@0C5 2@-P:5R"(ZP+Z&;\IS,_E48'AP,SYX28*WP&R5,6^KO2CU")&%
M0E0LC)"'R\P$%)1_U6;Y%#8_[((:,?0+X,1HFWPNU)O<7D59N]/[SG<XOO?%
MRTI_LCE]>50VU&U2<![M;*:TB*>O$WF>3ATDU.:.16&8MLCG^1?U:&"[L)"=
M3Q_ NH51P!9ND=[S MFT5=HFLDFL#BRA_9Z3D5'<SA$RN2S<-L$_G]_/GK@F
M,W[?1T_.75!NI, %^HXQ5R-B& KS?P)8>$5*2!S-_  >RY,]'&%?\<)XCD:\
MBE.91Q[.DT=.*R4:U.;P-V C"5M"1>7_7^?R3VFTY%8_)6L3,I0=J'(91R X
MWK1H49<JF[0PA&*L]]Z6T'.E#60HP5_00@ VYM5F&L0Y04$&TU2MLH?Q5R(P
MM3'K A.;PG<;5,U:H6K9'6-E55L5+A7;W*K!GQ6/$\'7PN7_87$BPJ,"!PZM
MWJQ9^T34G,QL,(MK3_+DY9[/KS3HL:(YV'/4)ROR_6PB4.+E(SPN)^1UDVD_
M0GG[Z/QT0#JF[9<X#(Q&SL29LR106-&G8N@AWV!>\!@.OY8E*=8>R+7#$Q&Z
MI5/A'N,;X$< "&B571N'>_O$K-P'WPY85.:C [ R\@.4K[7+3,*,,"_L%W8X
M:UY7U@*Z53'"=:EWQ@!/>Q97EPS?<.U(R1;- C^^GZU:HU^@<GYU_HX1HZ*D
M7*7+Z(%U='5"8E[L,H-?C)V5A=N?W3=,#9LY?N'P'P_1,HR/N3D_?3?V(M@4
MH4O*\19_NHMQ*R"K(>P38OX'7%BW17ET&&@ZB>?"GN23V3$;A+E+$)*Y+KFE
MP,XI37PQR2(,-RT@VTK[R5QW8$0=^ &[@L1T,><</#OSL*PI/26?T+6W\JG\
MML7X\/Q&Y')_D0A-(SQ,)L93T?%L,N4GC^TY2C_2-HR#N1O#=WD:\% ]2!FQ
M'_P84ZTPU]Q.7KPT7/+HQ^XT?;,#E(EA^/SB]&Q ,AMN8=:E"7(_>.QB&E%B
M^G%JN7?BL'&]P<16%!7<C?*QIGD*.)&%X5LL%4"9V)O;#L\2PZ$R3IX6@,J+
M,WZ9D@>MP"850.YBZ >P=R,LY9#(T5J#X(2Y3#2>'L&"2NA98&I6=K FS.)_
M>XZY\#1QKR0<6]KH<3TKO!_S,1>&*Z=2@._L"?KBF/,BK9;@.B''Z[&[V$Y^
M^W_7G_+IF\F,,UL5<LY&:KN+[)L_YKZ7WX^67:_PV$:!G.5SBA )9K;#PC!B
MC!(P$Z9?+RP))\!K1[0&MHG'\L7RYCQ'E5S:T^+JU28_,Q#!S0CDFJ<\)<Q2
MP&[]7QRF1Z5(<M)AZN#*]U,LG*%(@ZMY!7SM)/.?!_3D#H.6TUR:9,B=?B)R
M)3QY"$&3]%H!MP7;<(RY%93^HL'$"=/9M9W,!=/_XBP_9O _\-SK%IK\$JB[
M&/">[3WNLLQ5]K[<0&5EU<>*/I/L7HNG&9HY:YIAQT<849J=F4*^O'$+V/F+
MA5XF,(Z)/.QD"4-OP>*A/"DSIW.(QA^H2'U!-S_HD'U/Q:6+?,\%4LQM_=-%
M81JSF!E3R$>@)#.]L&7E^A8%-B/#U'Y* M94*+''3K>[\32]/7.M\P#3PS(^
M,-LY(LWTJB52K2+C%4XCGP6Z;I$.%B=:&.VF%)3OP?%LGC^.)'F]]';VAC<<
M\K,F#'Q-7[X,!_DF*10$EC!VN8E]H/_]K\U.[E-^QF."(LAC#GC?:Y0BP+(L
MY 5CL5DY(7[MFX0#R[@A%W.Y%9WLPAFE446TV[5\0V-EON'JY*OJV4S5,@\'
M'<L\'%2:G=GFS$.STE2&+R3SL.6Y@L-*3+.>VU"TTR<$Q7+<BN.!>PN<\TFW
M*6J.25Y)S'SKN'G>];>YBD$I?C0VQ=,+Q-HVF-X<M4:]L=E7#'.D&%;)J;$M
M3H!5FY.F_S"TTK('M<VIK_;&_:%B6I:BCLQU[,][4)<B^LL%6@Z0_E+YD*_'
MLY\?,6T8\7SI*=\_LI>L..7[;\JRYF X7[]>,"FX^4@6"<GD]1_7YV_P.X6P
M]#%1PHCG'XGM24A_L@RE=$CH."L=B#B'S@\=;GNVF*59LZ&Q4\9[/U[,CKXE
MR84UG4G<5>(U[&ZL]%53&:C%&FX9B2_;H.2T .E9/+.XXEA@Z8G%K5:-1H^-
MMHDS>GV<B5"_TX18O@'>G B>F2G;'6]Y0/KY-%QYN%G?B9 &YF[K):OYPBW"
M4B$G$TY$I)$0Y/RQU+PL+QU*71+T]A])K85/S\]A[6-_]<'&C.[EHZBYU0H
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M]).MF,ZA"4*7Y?SXYV7\K*Y.DM8E,?/:/>B--S1%P$Q/RLFXPW& @]=T,$T
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M$9TBQ;8F6+KNLX6:NPB^>#>PXH?\UB4BJMH/E2WU_1N_;F+^^')UF7-KQ+>
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M?7\; %.+>+R2T=\S?XZ1,]_@GSQCL@Q@3-K;6/8I#2_:G.@=%UH$\UTS%$=
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M;]Q7%<,8*/U!6>*!%.(]"O%6WL^Z.&\U*L1[G<JH-QX8BJ&IBJZ5>?>D$!]
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M<.Y-;ZBW5*][Z?M'>-O3%I>P6H.MZ3,STJS>V% LRU14PY*QUL.)9+(;$/N
M9)?&]F>=%M0_KC_^ ,#R@Q&BO(]-%7D=]<;ZJ7D4:0$-FM":.R%L%-=TPYK9
MJN(F55^39]!F$2YIN8#X,2>*NMH;FZ>C8F^!S@EB5VUFNOMF^^ZN6\GGI]9@
M+?:!,C [=]"X>< ^V!=@9XU8Z53"\FWUF1$L_")Z[/PK\,-PNY."+=?HNOI6
MC70=(;J)$'UP%(FN+931L)*05L#JW93=>C&[CH413ZT6'ZY^1@YH?1<=?HS'
MYZ?;V[)_P7MXBQXRF#4#VG%''>P8&QX3&'C=+!KXO*#:ETIM]UIN4>M# _W>
MN-\?*F:_WEH$;R08V!8,E,BH1 35A'B 7CR]Q0YGB0B:1 1'M/ GJGY4._Y-
MBSS:$]X?^B/+!N9&D-F&,)M7G1+G*&Q@?6NXB97B%<VH-XPAE_"ME_!$,.4"
MON,"/L0M?<WR*Q?P?2S@1W06]B7699&<D)R0G)"<:,T(CSS3TSA<IF=ZF)(D
MYRB/:8]Y^&3/[H#WFI(]=:LW'BJ::BG&<30JZ[1<5LSX[(ZTUKS5'+7=5]P*
M>6U]QF?+O27;9'P:*MC/H\CX;$(0!6I)>PXWE7%X1 Z,EUDH1_)"\D+R0O*B
M94,\CD3WO?DKQ'Z%%6&RHU65GZ3'8MN=88:>TF.1(FX-RP!;0_B_=A2]=SIU
MU"HCDM)9L9V\ZNBLZ$MGQ2&<%:O%=96S0CMF9X71&P^.PEE1L\ULTD_QOFKU
M5U;ZLOY"H(O6)*5-24A 72P13R)?7)74!45U"K,U/B,44G:@8>MJG^31#LD_
M=EF:MFLR^NEA[OI/.=7)J@HS"3=/\ZW.V0Y2*V]6L/+]WE@]+490.!F )2ZC
M)="L%BJ4&Z7#4V& .6!%5):C@@*B%LXIEINE[M,I.0^)?[=*<!24N( R^;'G
M\\#_!2^-X+Y-=$QI08.? $C*R?K-]W[2$!<%)N1,1[+?7_AA],V/_A\%0DW\
M>P]T;3EO=0G:+-EX+)N[]!&8=#Q]OO3IKH?"=V.3B>O )F$%IL1>D,X[;S4F
M0)DP:S-B0<F<\0C)/3_[O%51X;2@L$+ X$YFQ F9=9J(5]RBD4J'XX,%)C9Y
M%,OZB<W7=8+#8)8*%G.<PUI\T9B4\!32SWX@/L+KMH06]8O05MA@V!L;IVIA
MD6(UTDX)UI%.2$T24C/FGDQ!!,B=[03D)]9<0)HCG\L6D40:=BD8O?L2LNO!
M\R7$R+[\")/]#',M*R_1C%6N<RMBL13=8M,K,L<JO6QHIV5UN9M')[-E$:(V
M&("L]#!K *K]P"P.?(K2PV0/KF:"1>(PD:H/KCWYZ^1Z,O-=>!%_S,D<!!HO
M>/"GU$W+F-MA&#\(:^7Y^&R'/YL7$[^EKO]X2CXE=NBGCR<Z72R4#F1G%Z*L
MV=X3 Y'#LQ#_!H$FO&(]2NV4HC$"09\2WA6.08%4C83"S!Q0F0 Q9?8E\*4-
M[ '^8++3'/^>Q[<N6+()>ZW#JKC;$0$!(:$#Y+4#-):9@7'M75A281B7333<
M1(6HAFS8,)))S W\@K+PBKGKW#GPX0.-9OXT,=8!G<.ZCHGVG*SYR4T6NZQT
M -GB\X(9*ZWYG&ED_BX^+S%)&**H9U\8(?!P8L/7Q(G(U*>,S60&;R!A?'<'
M,@&#SE)?C(D*AP8*F8W4 ?3QTYG"U&"N=NA[7#[L$ 0SGL,-G Y(1B&F>9IO
MSX:LZF6W'D3L/:JV6@!5/TE9*]3;X<0*DFWP2@XQY>-C9ZJ"YMM!.@#+GASJ
M,L7D8LVH4*81?-(<.<!CD?YS^PG?FCPJ3+0.E JDB#+:WL5XHI*_.W#"OT[N
M<.,1L/4&=(_+!,BJ$\W$W2EU00#HDHP5A_G'Z34\')D)"Z*8S"0.0##@<?3N
M#AZ%?FQF#,!BI89FDXTL;59 "C5V\T&'U8\JL[85K&NQ>"AWNM!?$S>>TO'G
M$XL[IY(/TNX:\!E*A>/%-E\F4M=]VFLC^SU;:K!5QC5U*5M8SN>P"$]_:/K0
M'(Z&P\&/ 5\RX0Y85J--5YOY@:Y:D3"6L40BRLHGI]&96XIB]<YV'^VGL#?.
MS"]]=LEDJT_/K#2]X=+T9FE@222TCMA_9R+.8H!J\W8)FJJ^.INX@,S0[S#K
MO=TTEQVF,JPT%2L_E15-/428*=?IYM0<%OF7?)RM34M8<=K*36ML,@L03OT&
MJS'@#&970(_1ZX=KU?NW]E(#F0V4S&O 0G>S/Y/A9:-D(DB6#)"D(\S=4:*J
M^=6 \=\Z'3@YM<8XWUDNYH>-1I)/ DX_WGMD!U&P*HG":)-+MZ0)3Q:*Y^#R
M51Q,9G %[F<0<G,\OT!LM7;GL8;&ZECK*D/\;-B;Q9]QN("?#,*2M1 V :#;
M[Z'2;3:B18!XO#50>.S->$QKAV8\EE:I&8_Y_#8X ]D&I[0ZNMGQ#A'?4#]_
M9_HI&JZ@DO)?BYIZ7,TB6B-$76\SLDB=:6>#ER.EN=$I=7PI/1!*W'$RK6RC
MESMU7&<0=$+)_Z2$_&Y'NW5YG\>K?-0G^O9.ZCZ>J-!JS99YM5.6@A2*+85B
M;8/XFH1"ZXUKKA;Z:@^F^(@L[O?4_^K@*DS#B#EBI=7=2<&0FI^!F%\$+6NS
MN?W=U$OOC?NG1H,*)JUNO4)1R>;N*!0&"L6@&"UNN]5]40 X'XN3YOA9>.>C
M(.:A(3 F$TI;W!6)V ?^'30J$1+^;FUO66K$<O/0HS*X-9_$6*==VQ^XV"Z)
ML6]B_RWMX <<)&?7<G;)8&[%V2&F+%M-<7;'HQI$LU:9J9Q1R@>&JYJDRCD/
MA2 N_IX:LZK98RL>YT1 SDGQ\N^P<P&:H:WD&9"X#(8D[T;/)ER4D]9L(M[^
MQ2,?Z8074 /9TY5LMAIQ6/EJ\OWZCQ"S\&SRP*\4:60??,Q"A3\^.@'(N!_P
MS+,T13&,;_\/,\8P4]V'SS%M,V"R[4U@+66I9Q/7#T6RW93EA ,RP/P)S$ 4
M26EA#)N5,+R+7?(!TR[A=QSAK>/Q? WV3AQR'%'RO]1V\568/@F3%6])1I2^
M)3PEUY22;S[<8B@E4?Y]"DC9K'(2@6D-CL>M DL.O?5CGH67D"_AR);T.25_
M)"E_:-S".X$?D]S49:8H9 NDN8O%9#_^P[GS'34XO*(!AK4 ;6UY.* <Y+(<
M<GC]9$8O/9I-+Q=O*TLN7X:FQF[0U((U5S\M-AA\E="7*11+(Q6R27D^*:#+
M.Y S92D1M9SVL,X$NT-\]B,]\ODL#BSL&S-OS+K!#%>F]&_!LIM'?[\L&_7&
MQG CRY!5/*W(?4J.VRSRL#=CBIT9)0C 3V%L>6JF*EM*8<>C'TQ#ZN6(-5![
MX^C1YWA_&1B<DG/7%0*.^?>+)6#1ZXDXG*8\P9NF2=$BI\Z/0Q+RXT?\/!7:
MZYDSQ_2L+98@?K( =J<AF0.Y6.Z_L/^G!-:[2[A,+'<&6R=^MX/);'&V;M7J
MAVMVX75B..+$ 9,/S)3^&W/&89L(!M]EI?:YM+1,0MAL+N]2TEW, +\^).>F
MPB"Z<2),2_SB,9\:S(FI;W."I8%@L:.TI:*E9*4IS;],185)QS3A"SS'C^]G
M_-1,LOSCX9C3;++VMCF9A:5MB0;GWK2,*N=XI-.)GFI-RAP-1JN]! T>1F*)
MD>S0"TMCA T.O 8>D!R;2$$N/^>&9IK8@@"YTX[BB&/^A&/Q./4VZ9O'GJ8Y
M-'=(TQSJ^T[37/,(F6'7X6PO7F,IMT5E*9I[&P"LM+C\MCG+[WBYGYSVY3P7
M9W[Y'^SD+_\5S_\2='SQ/YG[JU,9@AO-2;V574K$HUE':S/#.ZQHOIXG2(#5
M4'M32>!6NSO;$GA/5:+LK&M70D0K!E]LX?!OVXOMX(EH351#K$-9]AAY_?1W
M#'#Y"^P<@YAM'"^QVLO-S/9$08:T],;*^H>:_L/@084=/#/%2AO/J\Y24XG#
M@=X;FWU#,8VBBZ8UQ;JVK\S5'2FK6O&C=0)8;[V0 <L ZS<GA ?).VAVN=E3
ML=T5@_\7+R(A%Y5UZIZO\M.4U[^M:TN_-QX.%-B$=6YI.1*!JZFLU.$ELN;%
MAC6 -^L]^?-2-SV'784N,./!%:$LYOA>1,/"8\J8:Z9N;$/VL^$FPA*Y/4MG
M_L,V(-T ;J\/M9!R(KU4Y&;VQIHU5*Q!O3W6WTCLMK7(2>Q6+II#=E1LG]CM
MB%J^O<2NT)(3;>'$2]H6M2T6U'0[[V-;C#>'@UJUR-8%_*S>>  ",ARVN(F0
M# >U4 !K1GDC1'D-MHD_:I3W,IMF2EZTAQ<['G(\?#\J=B8A*7;;PNY3U8\(
M--#4QU2Q Y5^V Y4[:"$AI0H8J4:NE#ACU8VGFJ&D#KVBRD&BI_3)\I+9LZU
MNJP_5.F)B2H]H19G"8^N.]1VI^5- QEG%BR\:.:T_N2U/-1>O#R1!'&D/2E+
MS^6T+4?;07P\7I2?'X+>\L1T_AB@/?7G3+>X*AID[=1?XV7HS-#5,W[U]=45
M^UL[>W-*_LAJ-?^2S)DRA_$M^D(BQW9=>*GK9GH//=A/6-<U]B([@+G"VA[X
M< %VX$E>OK'M4G(@;FX_L9L!'<03$8^.\!PK=BD6)Q>QX\[J,\>+\\&7=ZRW
M\5<?EH'+NW03^+L=_$6C"M[_E8U?5[8^V':_5T^Q(;/?&UMK#@>[2(#D#]:U
MZX&1@#?O"O,-X.ST[UL* L^L,B YK%B6M.>YNZ/!HL<3+,5>*@PI<TOX&)<(
M%Q["=9T')VFDM!U;$[J'6;M]XU_Q=WY,7WDD[,4FG6O86Z!]=D$_3'NX<V F
M;A<6"_8*\,5M "/PA3U':\X6[1!P*:SA%)?<SZRIU)<PC#%+I5*C\AI969-K
MT#1[8UW1=5/1]"+T)_PM"6/7&DS4G$!0B2$O.XYF?L!@%2O((0A6IG;LH#D>
M9UHL)UZ<G%M?C"'_OI^VX_(N7VN>GFW*\]R.1J-*;6PT=4U+HT[U^OI\8HUR
MA-RZNU%U&FMJ-2)K7>OPI6G5)JBWN<<7C*[29(R7TN5KSSVY=A)$H[=*76JP
M([#C03CU"%M\-D:LQ#1A4-WQ)M@PD?)2$^(P&[=NFI+%>%[AR[0#5?96[ED1
MA8!NGSC A!T*7SQ>.V^V!7$?'3=&OQ-;;C*AUB,!;4, ;:LQVUV,O)ER$A!_
M,?O,\NO'P=(2G"(#Y^&!3AW>5WT>T EEMR:ETH0O##CXVEG)CQ($QEGQA=65
M68^S?K=_.0_Q0UJ)Y3O&\%A(K/T(#'LJ*Z:JEAZI6$-^!;=!0%!'Y-^%,2B%
MD/P">LIV$.8Z8D_A3R>, AOKOP@^9A#9!G^FYR>/9HUP;RGUD@I I0!O)1!;
M58O$JEZ+9*TO+A?D]=(N@1^H1^^<"!D=UE1RQM)PU6Y+992T'LH"%O2V2M=9
MBI;RVV'G5:S"6UBU]GBT71N<5CK-7C[<ZJ&V9V3\9%Y/V/M7A.2J$2)ULPF)
M+KH627D4;X\^QFR[[1DK0-57M==_O8&-8^0$+.F"N?=X>; )>N-#0H%2#BH2
MZ[:<>OE.R:?DB[SGCR&>I.95X-QB&<=XGK0T?^ K!7?RA JN82&-$J/(.B=X
MMDN^TY\40"T1GGM%&$@G6 PG[]7(3BTWB@?[+\HJ;843G*7O(69)A\;B'^C_
MBB:SPE7S%)VPAO8)@[,W QD^\DI0O-_]W<XASB18HI1N]=D TR[?R<L3HC*>
ML=@6KC_(/6]3E.LCR*B'@9#%XU!@A10''[.$R%YT_N#'7K158>#5J&!#L.O+
MM\\[1;M&FU*.FIET'HCN.NG=(GQ#%C0NR]M>%_++PX%5*03-@@%0?Y:\!5C@
M@N&1>^I-'!HB$UP_!-#]/#BP>E^<;,(L/0<:=$."AGV!!E."!D:(C!ZP!2"G
M";N#!U*"'DJRJ5]2 /@K^CQ:4L7\3PSNBNR5%"B!G0Z)X_WTW9])8<DX9,##
MABTE0B4G%P5@ (Z5LD2:XV-X,='LG1%O3P[X"H7+OXULQRN+W,( _ <PTK<<
MNH;D+O ?<D/P^'-@$%@E<X++X2*C*REIFLR#US9UD>*'"3>M77N^XA:=7@*X
MLU'7F&!\A+4C<.9;YTGEUV"-1>\_T]N .<322KWG\7T<1D541^@O.F&.'AB8
M-^7JSZ <PD8@-[+ Y0(+#/N&OKN_%/([L ! )K D$N8"K_O?>!IBT";_+;M[
M.46*=:M?O)$!1L%,$23B)8O]J7,'UO?_;^]+NQI'LD2_UZ_0H;OF9,X8I_>E
MLA_GD"1DT4T" U37ZT]Y9"N,525++BV WZ]_]]Y8%-J\81L#FM-3F6E;H8@;
M=U]#.VZQSD"!H;P;6M@P[V&GM$J%IRK8<+!AJ!12_BMT>53$WZ<\@1LU?MBX
MS"?BWSFV.: AE;0'79$>H=.%0Z*:T56. TH5"B(G%+\/]/-5XIUH8*37<YAQ
M[ZCK/6)"$M .H'_XB'X4U6&Y3;_.Q29R7^:ATBFN1;#++W+M::IR3W4>*G:@
M\6V#EL0WK7YQ&P($\:#?F'?OF],QRLM,_^)?L(?P(1D@N.]#3" Z3/4Q[C8*
M*&;M,S:T,S9^-'I[<$90[M2UYDPA2;=NI@"J"(ABW%H>7^(_L63!40&/L8GV
MTW",!R(<YK_R!J OB"8*RV0>4C_[J]%O 0YD8>&56/W</15KGWE^\B(N).7,
M,<BT_E9KP'D;-@M.1ZOV%YDHP%*/I[[MY+0ZC_FG&Q,\\A[/799_IK@A91@_
MDQ=NGA6JYZN"V3U#0Y>-.Q2WM(/X^!JOU%AEFC_:&=:X>1)9VH&Q06)I:2*^
MI0SY/2&6=KZ!GR467?](T8N:,6#E4\BUZ=N CF<XS>*%5+;%Z=OJ-$2J0$4^
M4 D066 _@>J+.6A(Q^)0(XJIC,AU".M'.#&&_'2<Z!P3+&P,O,P,JG$2,9-$
M5#BG!'15&P4N['!(O7307!-@Y=O2H,_5OB$0$N-L*5#?\JPI<SKU/9"=/+XW
MGRR.?69>C2[@D"NEFP=_C<(B%]P*P;1NY^"H72^(I/T588[2B ESA+A+2O/:
MK!I2X*"SW2('W:I*15=3*MH9_73SNN/*'L=5#]2;IR55Y_OT\@[$*Q[OO-.G
MD&4P<I%IU>S5<6Q\-FBQ\C9.46(SH,.KT5H[TL$XLI^8=9@,.2+H^@='RA)G
MM'@&(8;,)PM<&2L:L^*YLT%,"1HKPC*!0_OI<&Q;P%Q_X7^@$[-7Z[?J6;9#
M#$5PFT(DG <O-6B)_H6C -<,_R\]2Z57.S@:@9E:,*4G TJ>F&Y3:0IP2."/
M< "0!QRB27D!^A; U:22-)?S'I.>\'RANU DG6+\2HD156PX> WC^MDOTO."
M3-?%7'33^@-L_HEZ49Z)_0#BEKS,4A/D4H#)X4SP+UXK Y_-: G;'4:^+\9N
MQ:G^3N 98\\!M+$G*!U@64<BE5:R\\!@-8=QGX$0/^ROR)[BRU]&W.,Q,( '
MZ@B-&QIM7/9N>CTB[D-O= CV0\)S^$&43]Q<_28+)Z3R2ZI&0J^W!>+ A6+J
MFB5O'D?7(5IA]=4SE'Q7*/G88(1N?V ZE)8;C$'L"J,G& /B'U(!E2"!H@3C
MM$X?6R=V0&5;-!'.#$@9PT6.AT,?4U!B(D&,PPPQ@Q 8%30-$E[V\&Y0N/?%
MR;?[G<>KIUZ>'?9KB1S&HHC<JAF]>G!KV=307N/'Z\KCI0VO<KS]S>*ES:UR
ME'>3PYO"_)ABC]1_%)?40G$BG"2W9^0*A#SJW&A&\!IHT%P)#5K;S1Y^V6#=
M\?V]S^YQ4@\IH,:Y-DPV)X)7:&/%8_&H1<PU1I51X:!5M44W.?"N5Z<\E!V&
M$^ELJ#ORPRDW7@RSY[1>4$7<Z"\,Q%R]P/A B@M/[ T^RL%V&YMKMR=Y&)P1
M]!O%8^UHJEW14+ME!]*UY(^S_WVUCU.FPN8G7VUH,M=&!ZDE)U%U7OD<-<K.
M-[X3;^!#TDZ10?"_9KE$)I&GO*%MW] E,N\7OZ!W2^"O?5!BW*;R55'M&P![
MLP1[B>WO!NQ;P_;-2YX%#8_GIR876GO[U=08#,64.Y=Z>RUW/86]'M=K&OKW
MM9]=O<]L,K2%W;R6:@JX*)NCJ>+CS>7CX[T&4$8[F_KT#% NQX[>Q?TEJH^V
M<W]-N+^<UDKE_3WG_@H<;-NX/QR>UV^5][>5^]L!_;4/CGK-;=W?=O2*-Z,^
MW,9QXY?6'YZYP#K-ZN'LF BS#TI$Y^"H^>I9V!Y?X0[X6/?@Z/5K$7MXA3M4
M)7J@"I9DN,4[W $9]@^.Z@7#^/94FWC[7HI_R^S(=Z=DR)/O@8[1KX& >OU^
MBOV]PNTSMWX=KC#;4[:\PN=>X>YTC#[.;W@#[HK]O<,=D"&Z#.L%DU7W5,EX
M,[I$'/$8FL'8&%'JVM2T12G&A/>Q$#GX/(%B B@3B5YHWBB;OO\^5)&DTT],
MW\OTS]^A/M("*NINBXK*B]P=.VQC!*44:5NZR!WJ)IV#HUZC8)9D>9&;NL@=
M4&07+C)GGL@^*RAOWPN2SM68UTZ#*RZY337>BK8BYFW#'V /;6%OKPX@.VN.
MLD/5H'=PU"D=%B]YV3M4'_JY0ZS*R][]96^9LMN8HGIPU&]N2U<D%4.V1,W4
M3Z_:^T*!Z[N)'8/"V4:+ YN-3J$*LIU."WQ<&C9;4)UF=]GL**W&J,:18GI)
M8=DA-LYXG^6&G=[*Y8:][BKEAIU=5>R]#U5=KS!XLUF <UFE-&)YWR"+IJO:
M*";^0X.-GS'V>CUQ4T=GX;9R,TJ7^R)J:+\5JW,#)/$U8I>P\-TC<QX8K]E\
M 8+ .&*EUGI=B;/O0G)T2EK1:04%QMVC]P(DTCPXZC:WE?%2RHQ%=- MZ2!#
M!]B(X04HH75PU&EMU5@O1<4Z)-)[VR12V!4WCSZ.<=XL$LF9%[V$A=$&A:K6
MVQ6-:,@^?9J+TF*U)7P!"Q"DX)F5J454K_,.=-,G4;CNWP\^U"H&_N]C$<;K
M_IG7LKU2YB_-T.ZHM7ER(D+I11'L[04X6@=D3*57SS9N+^5^#IDT=T4FB#&_
MX$SO !,2'T!(,JW']%O1"#X\@VQ^<W%J*^^P??HTA)_FCNO<!0UU#XZ:[8TZ
M63Z6:D&I%KQ7M>"=9UT7!>YWP<FPN+72:I=>@'W4!E0K_613_K="(PN4@0(B
M.>% >0%:Z1\<];H;]0644K^4^N]*ZE]X[CWO+%,T<N2E=("7Z[2D.-NEYPY?
MBKG5:Q@Y;F^6O97<[2URMY4R,%/C&7ZG5S+K& X+C#$[?RPX=JVOPLR_,4,6
MW/#Q5GRL^T93-%O-XOD-VQN&]2@@<&AR$!B^A($V09;/4Y+N#L-'0.B#ON)I
MV6*XMTJ@?-L9D]W.RAF3G?8J&9/U@I3)I9]OET,2<+$WT]XXI\T^%6'M=[?I
M]W419?_I/=/RI90WY@HYRO6G,: ?WXI'8VX12E+K7Z@)U1<8 3D#5V>4A:UK
M]9@@7>UG-+7=%E^]LSOJQ"562]U1X^"H6>UNYXY*=\12C$KQJ83*_<:XTE+.
MB!3*ZZ;8-?.'J_HFII'/=.=$[)LX;*S@G&@>'/6K&\W9_?G-,+(M7FNGJ%AT
M0]?:VNJUSG=6%#"H>J^(0R7X4=+T7Y4;K3QQM6!(IQBKN6H!Y[7O6=$P-)3C
M,6_6Y@[G6NJCSL=F .PYQ*'3S'[ H=/PH1IY/A4[C^=3#QW3G@15X](+'^UP
M'(2FBUJ]$8[MU'1X7%GKJA%$/@V=UKPJ4P_GU\Y_SUSHO OLN;!#T72$G%0G
M!)@7QJ!SWMB-RW5@9)$?T$AB$63PW!0N3,R9,6!#;X+C4Q\\YX$W6GDP?=N+
M G'98JK[/<<'L- 0L70W7(5:L; G<S)U&'_! X#40GR!+X#%3FD7-K6>"YF#
M,WXCOAQ.<9T9Q,IA;PQ6\&:,'<K% >/A3N ;T!JQ.!V'J,.N MC44)P'^]I9
MP 8IK1)^@$H+$]]6C6,P;O&OIN/,*@;HG9PH<F TB *XV" 70H9)$]]G2!T<
M$@(TX=@,Z3=(JP.L.H>=X"CW64Q:L(GYE=\ WJ] YMI7=?JJF27<!6EC7A#@
M]&DX(W.',QI.;SK'X8GI^S/X\-^83?><F,KYY5E!4(74>A!RCYYO!<Q-RK?V
MPC31-3=>;_QHUI=IX[#FQCM8Y9\CEU,?$)M&;Q*P:;[U@$@"\'O .SO#^9*>
M:[Q0]F0'%/G#GS+.KYV8J\"GD@ #'1&H-5#W<P!XYX(.0XT;$3<LAMX$8NN$
MEC@EF5%? =>3A&0\\@\U'H][PUG':K.(CT!! 1#-P(%=PAXG^$75T 64Y;%
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M4O_(T3\H $$M"##"1ZSZUPCIW/@WG(\:"US8$ZKV>?$NG5*?%,W1VI6T:A$
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MWA-60""6TH9H<\:8XQ=' !JN3;@6N8[Y.(J<3 AFZW5U&1XUV V/VCR#(I1
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ML(A& GY0X@%<=Y]4=(JA'W)]&<=7@P;M\2H,YE-Q$SU(*X \(A^&2*U54;\
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M":":Q\D-:^]W=K6+>YS?/W&OLQ7P ;/XW<XJ4 ^,E0+TEG2;;>AT VV!7?B
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M-08.LGY880P 72D\+^%&K ;)=@WN5*(PWH6]ECO'$>"C/\RKP;81I9("<"2
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MH:NTV+*)>)(C\CXG9\_Z,"D-&]%@K%1C^' :3E1),5KO^&H]MR%!B^_H5KL
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M&F:E'?-7209JVU$!MO="C\K!:5,W:PZ$*B!-EBTX8E@J'+652$:Q"@"J+:V
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M/R#Z:3Y=J4/(#R<-O_EOXLM/V&0Z:'8' 6@4F[R@;\8#AO;VRU)!YW2K'P6
M"=;S(ZJQ/Q1';_'W%[VW"=H[-!;(_O;O"K>E]O_\\Q\A_Q'R'R'_$?(?(?\1
M\A\A_ZN$C/W^?R80U.*,2:U),X>^6=?G[AN]PXZC=]QA].@=1X\9,WJGL7N.
M';OSSF/WV7V/7??<;Y_]]]]OGWWW/6#"E(D''#CYH'WW[3^J?_)AAT\]<NKX
MB0/(P!'(E".F'M%E,F+,F#%C=QJ[]]BQ>Q]QP+X''/&SGV_^U#=NISZX[_51
M(R;UC1PW8M2X$=^L[IO0US=RY*@1(T;T??N,V:EO]*@==ARY<W?8O6??B%&C
M1HX<O<,N8T:.Z0Z/&#EJASZ@R+B]#MEI;]09K^_CX.[XQ21";S1/.?7BZY;8
M[+@K8=P^>=Z^AZ8*IUUZ'V R?D3?CR1\RP0,'38.B.\]H[X=ZALW:J]#T!WV
MQN*3G#:[*_'/;Y[MVW74"+#F4>/Z9O95*JE%5R\2=EZ-'+-@S1$[3ZTM.G^/
MXQ]>?\V,E;'%!_3_:L^]^N[8]Y[VFJ.O^C-SPU]N/U9\X)3:-WUS_.=_<>4N
M^<"K\9>G;T(G/S3I[!/WO</*BM,NWV7UTPM"Q2]FM29JMU3D=RY;J+?6'KSW
MQ@OVN!LO[/301U.S1\\_[N*1+SR1^/-IVJNWCIQSVJM_.^>X7V=WON/PP-*+
MKAE?>1'F7WE'^*;OX^M^==%EY?YQUU[=N6.D[>IS+GP^^,&$#>N1=>\,3+.]
MXGK\SJONO\3[TKD;<POGCSO3=LR;CUU9?N'6$[/W<],/GO/Z[L^KZY1[!>38
MJ>H5NV3VECM/#Z8.OTP+[K/\L:E+]_E$G7!.X* 58W-K/SG[Q7_,?S$Y_LE7
MUT]8^/:A7RZ$W'L\&)LY?NBNN2?N SN.7CF>NONY&QX=.-*1?1.^Z87=_GSE
MNZNCZ]Z9.7;HR=<??W_C";>][OEZPCPB=//RRZD3KI!6W(-BDVZ<\J>S7W/K
M(]:?<$'DOJ,JY?M?KI_ZEW&+,O?<?4QVIW$W^ Y=<LCU?WQF,G__M3N]MKY:
M6&@/)!:-WS"/U5K<72?KKE\,')D\-NDY_O1W5VV:,._N_:.YZB,WO[7BF7W?
M>F7!WVVA&U^:_LN1UHGS+CA@^<I=_O'Y55_,04^[=7_C[3\>+[<6CH^M^NT;
MH]&^6X(O'[3Q USXKSO>:>TBC?YZQL#TEUY1CY:@)K_Z4',/:6VV\NOQ^YRW
M0EI0S2UM#"RM[';_T^*5_S3(74*2*^<Z[ZS3#Y[RBU&KOOQPPI7*ZY[?._+H
MS7=-OJ"X=$F#7G'0B?FKA:G.EP/Q#?OZUU_Z_*QC4ZO>/'Y\[H*Y^4?.^Z/1
M?\5>]U_XYF3CU(1OOVFOWC,X=OHY1]UR][-+0Y_^MKB7_OO='[.N?CAWV=1Y
MLX+>/\VY<>'9N[_4;GU9>6+6(\<9NUQ^M/H[478HUNF+!D>2(X]9-_OE]UY[
M_AA': X4WD^<]=J2O2;SS;L_O'^OH:?\QU]^W'Z7$HL8<^.3>^]]5O]?ERZI
MKSQZU7UA^YYG3.3B8[Y>>OTMUB5/#CZS_Y0/EC]_C_2BLFK-B,^?>&+5O.,O
M?>_ MY@_[/_T^;://]S_TDF>!9],^,W<M<&=/W_ST#UPQ4,<JVR8_384NN"H
M':>4CSYCU%KG^_OL-'GY6V^]N/JQ])%+KQ+_<<*D7:76:W\\LTC]O?_.9W*O
MK+WF\<Q!\,S%KWWZ^4>WV X*L_28YRZY\*8CUD>_O/K=LY3F 2O6#;Q]PM^.
M#>[]J^:78Y<^>,Q11P^NO_ZJ<U^^?:SCTU_<=/3G%SS07O+Q*?>_ET@\<MFL
M@06^7Z]?-F;TIG)BV4=VHW;CJC5W+Y]U$SOO07&6>+W'NNNWS4/*]:4[3@G,
M.'W<@^?.N?W2 >A8Z,/;(O?>]Y=7J97(WD\_V/?I'Y=\X/S0-W.5=-F#TYZX
M.4-M#"QZ^8+=+IM^[UY[.=8>'_OUIW.C=][_U.&)9GTO57H[?\Q;R__K_5A?
MYJLA>L["VJAW%KTR<?W)2<?LU;\Y[8[QQ^[RP,DO1Z;?M?BC$_:^88_PI<LW
M[+.8"'SH]W\T^LROC_K@N&43[CKBW!?_6OSBH'EC/KPD5!GRG7WBR[XW6T<@
M<_:VR>6W9ISR=.+4D_>>]=7<I_8XZH%;B;L.4AY\*I?D5N]Y[:5?+3KX<7.F
M<$3A0,G[E['E_HWSA]+__'3DE<99Y W/K)E\U6.V)S8\\]6(V'/S7CLL/^6$
MBT^MW/[K8QW"PN?3RPJ!]9?5Y4L_/6KWDW9XZDK?I"?.>W750[XE>QXVH^#X
MY,:-:_YB+/]\C/3%0T-O/CQKZS@_\I:O3O_;1:]:J]]H?;DJ^]&\31<^/O^X
M&4KQFN@UYESHXZ._?A'Z_(F3?>7X;0<ONSVV,+8RHG]U9N.K7;[I._&OT-C/
M#^0VW7>1.?>=IP_<^?4SUYK?]%U[T7M/'3OWT=*U]WBNN6&/#P[BW[C^I!O_
M<)MG9B9V8N']S^Y*7?W;F:N77#3OY*\NSJKGGG3SU5\\\.('ZJ*3J,M.7EQX
MZFR_>/"\=8<%OWYARGVV69_?<MOYFP)V;O7'%[YV$SSCB@U/[_?*I VWKOCM
M.WVS!JYY9L,M]R>7/3>9_YOZ\)A?GO//,S.K)_GW$A><ZCOUBOM/SG^Q^]_\
MPO7V)UT'NER).1?\9M3LD5=.KJZYYJ+S9[R[9G^N,_77?_[P["M6IMZ^\J*_
M!I\\\)([IQY^SI29#Y]^\;I?1B\=6G;KQ%_^=>4^&Q*E)TO_^/N?W]A_8^&*
M<5-6S/EPGVF#$^N7/'7TZ=7,A>Q[>_]^MP?.DT./WKQQRM3G-LVY_87;KOBZ
MM&;_99\^EXR_8-QP5*&E8FX]<]T+M^X9F/'U:<OC_+39[YQTKC9XB>^8W:'J
MY!535K__V;MWK4N]<,ZX9QO4W:L6[W++,0]ZOUZW_(+'7KMKG:>]X[P51V4G
MOH6T#Q[!W7_+NTO*9SYSZ9_ON.,@/SQX_$-9[=/=T]6;$O,B&XF^ONM&/_N'
MZS\]X<GG#_ELR3-GG!0,SIWS;+OSP,FA*T]Z?&C&_ _[;]EKS3$7CKMTX<'W
MDB_=L?SS"]^.7JT]_\JZL]N[P\].N&KA74M777_RKR8OW2]K(];V]=^][JS:
M6TE_XEY;9?FC_[A!^'#,S>>?]QSV\<K/#^<W??;E4F9^Z-V-1RU[^(7QTFP>
M&])?>^[J@SZ;O.S,^UL37KK)=X6U\Z=__Z;O^O!9PIL'[W988,K&TZ:1L=JX
MBU9\]?;A[C<BG^3L3XYHG7-FXH0Q?SW\@]<^BX^^9/)N'V6?._29CW\U>MG]
MH;&WSRO\Z9E8L![*/W91>=0[(\_(OSV?^-N4,]XY:V_EP7>]_0^?F<G,/M5\
MU7GTQ4LFUU<<V'CM+D)<GGM[ITM/6W_4W0[7NQ_N=?(GBVZXU3EWXMA?3)KW
M3=\3,=OLO[_@G8K^?=KD=V_Z[!3?2;>L_BCA6WS!HR],_73N'.2)FW;WK#G/
M_<B-"U9_LF[<Q] OIGX(VXX;BMU_/FDL?OB>W1\8<\#Y&QZ+9J\/]'UJ/^T#
MYT?LB^\QI_D&?J=\:JR+'C)@;BCN,/ZCBS\(*1=\>A#_ZFX;CYYR:.W%!]6=
MY_YN?NYJ8>ZLVPY3?G?4X*J=WKUEH\,=6#_[Y*?6FQM.O/Z)TX+:7[03A@9N
M;E;GWO:)\,<+_SIAQLJ#GS^K?\:I*W_]!]<>QQ0?#+P4O&#A+]%]Q[_PWDT;
MI7,WO/J^/T%>]LI(\ZN'/KI5^(C^U>UG/&<\^KFV=%;\@]-+$Z?<96XZ;MK[
M]ZR>?N/+B84K0U\D[KYFYAU77O#DJW/"%\_VAJL/^U4F=&(N><Y!TSTS?G/5
MF5_J,^[Y^/7RII3MJ]'KZO43DGM>X[OLU7_,O_CP1^3;[DG]5^/)\>/O^<LO
MGIHXZXBG^R]9,_^0H.O87WY]Z=V)DY -TY?]\^9G]UCXS-"(PS8\\$IDZ=O%
M.Q=(X=;E"PY9<]5=:Z_=[=S B]=HB[#1N5W]GWTX<?Z^VX"EA4NOS>7U.Y\[
M?^7,^>?,\SY__.]GS2CM5\JNNVO9N5]\=/KSV.\+NZUZ\,:'3OS=*9]T7 ^/
MV<GUU(._L=Z[CEZ\UA.6QYVRY_'?E2#7;0P<$UKV;GJY/^\7CX\$RALGGKWG
M;1O[-]GK;WR]\(K?[_R'5VKGGCT?#U]^SX3[[UW[ZHLG_FG3=9D+XD^M4Z_-
M/;&O_O>#^1T6V>\\O$G$RI/O.9Q;_MI:ZO'GQBS?-&^M:].&"T];_\3M,\BE
M4Q8FA'7/T-3 ^Q_,9LA$;$F@[_W77RJ?$3Q?V6>-?-P;Q5>S^[]\XBF?W?XW
M3^"?##/Q+#3SV=S6HMP!.\@KD8^/+JP87-,B?Y\__KZ==MYAHC3DO6S.L:=-
ML)'[I)Z;;URZ<N&AJVYHKEB]4EIVVTMK_GBUU/SZW.=>'NK3QA[Y<?*3XL9_
M3/NF[[SFES?E72J[XY4'_?ET]J%3#K_UR,M?.8L=F]IGWO77OS?/_]Y7Q,B;
M.Y//FJ6=0/TM_?R#MP922U?MVKSL\-,7]#?Z)VR:^MX\5G(=.7G7E?M?^\JF
M)0,S\W>\?\;,.Q?G[AQUY!F7W;=BY>##_!)\Q9'!XUIG+YBVXYYCLLN^W..
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MEUV%/4';#77;#P#$_(6"ZP,H 5C;7[>G $0RUA!+D+F<.@![>QIP"E,#6-]
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M3JHX77\AZ"0WU<ES(8VMIZ.1Y&QFGPO:V,*?$DS<\''%#Y9[Q;K@^U Q:P7
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MZ#ZYK4NK(OT\O$M0_;.4O;/^HXO?]K>=W<@%S'I;?V=_@MIM 60 U@ (P!(
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MG@QMN4>A+!MAIZ,W^.*IY[6(TFMKIL659:/RN6_-;G@OGX,*Z08349P^H3Q
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M",.GW 5R?22[ZMBAEW&MJ_GQ%^EC=Q9]_TG!5^/'LF=Z[)TG4L?'[,IBVV/
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MT,_-S781W0Y!CKL%L*K?;53.OU!F_R8@=S!,YU[=3684M4U,,G%4&FR+<^>
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M=,1Y0KU+G8SX-D;Z.BWX(_ !X7-!6A>?Z@("[/]]6UG8^<J6QSS;S  .#Z"
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MN"O56KSE['-MPG.T<Y<M^W2]SQV["3<-V8_+FVSE''V85=147:E5S@V') =
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M^CB)5E7'78M'!ZI'5#7++IN(U/G5[G]GP*5R P @;UN?Z2TDHAQ!UH1_$ES
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MS)61&Y]=9A3GFO'%G/+^&?=OGYSCX;3"PF06W<V$#68V0P.M$,8Z,U0RU2D
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M2DKGBP9L2\V&EGF4SSUX,-"/,V041J6-:JCPI\;E=A0'%E:W-HW<NEW'[):
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M_>&G>3V:=(= :VX1!&H=$'Z',(^IU)C^U4,W-;+TNG*\XV7-\/**6M$  Y'
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M$$IH@B"$IH*T8 ())'0L2(T!0J_J2U,I08$$A02$$$*H4D('!04$!)0D(!!
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M&)R*4_YB.(QHJC1%6"T!91]DIVJU6%1-<_U3W!B4X?*SIZPB/L2FIW-S2Q)
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MK75G"-X] O8PMV3:DK%@N1JU-Z5/Y[XM3N@_8U#Y,<E;DO@7)52^K<J(\5\
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MXD87S8F7DZ#S\$=W:EN^KBU)^*?]$4^1]\%QD,UJ6TN,)XX4!')Z1P-[:N:
MOOI1/8+ \L.HHQ/'!CDZL!E,F95\TI<0B]?6^:"5+M\R*0S4B.*DK98Y'#CJ
MQ=R:5!5_C]@Y0L61X0XPP@D(J_P7 **\VSI[11NZ%/VTHV#\6=A1R]:I(4'
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ME S3I$3XO<R"Z6(>LX,,KT 2#H?;QD(*EFQ$];C>K+9BQH8RU%U6YJ^TR[V
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M[O/% H0T+^\+/ 2 F5G\X[W_Y)-TP,DGN8?X_O6?EO\8X[*ZC0*?Q+G3H8(
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M2N-]0OS&O4%&T7 4+'@X>Y3'T. T>IF37,_<39%F4/1E]:66(Q!U'()3U,S
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MC7Y[6^#J];N\8,W2VVHX;S)BZVVAEI;_D=NL 8WSCAU#T;_ML&/PA_U&AEL
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MK9B7W-=Q;ECNLB_05O?#W.,VCBY42-G,5<"OZ'ZZ/TIFB<A9WAJ?(K*^2KR
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M?BB41N\_@V@/N5_AZB%F3AX/2[Q37@7NUW9!!<TXU.<C.J08'O LY?ZAGS6
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MCK_?M> ^<?VA/.<8*124B@.'@!KLD4PDVB_]Q]2'V[G%KHV%='?]"T^5U#W
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MJ[B,1&+2OJU&T4G]KB*_Q2T-. *^3G=BZRQ1:-PN+3RQH"K@-#MQR*A^OML
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MWTHKDN(@!BNZSO$E9DFC/,!/5 <%6\W[VFG><MQJ8."+&RWT!.;,LH.)W#%
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M55/#@J V*RCS/[US>E597595ZG<,%Q[S\PS+=U,E%\&6O^L[/ISED4D?,C]
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M?H+TR.Z5O;O_R<#_Q%C'8@V)6__>)H-/\A3BQE9>TM  K]/0[ $\?@PX>Q9
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M\&.5YPV '/L:;9(^I[HR):0F*Y>;#Q<M6QTH0-I"W$@U3YZ2[4J.N)$^H\W
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M.ZB[#37G IX1,ZNWOG/9)-.ZSS@AX/<AAII VG3>9[\XWVA1I7,GE77<W?@
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M#X<>O?X#1M=M[6!(A!P+"P'XEW(,Y/D+T)\"B&I !5!$X*=EM'$44UH/#G-
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MLU(>%<Z'0&/7(8#O$F1RN0M)95) 5%\-#0Y94A_;R+PL?[^+W=>T+B=D7T5
MY_ER<=;:I 72?=*M",G.55\]+=!+V?LBMS>#5&-:*EB5>< _1?ZS>$(K^ZUK
M8@ML0Y*^GPZ!L[TM30I,8>-/D"Y>;VO,#\(42AHLBRJ>[4=\#:ZY-2=;,=$6
MX#!IE+^T*=6^T^'1/3:Y/#O9/[CS94=A^-4&?I!>S:W]&H5AP_U;4?%:8>T3
MJ[/K>4O+6QNPM[1ZAT!5RVY8<$GQMM*,PL;6(>"EN\<9">?^[-I6W#?YJN7
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M-FD![N/1^!910B6QG*?9'$KA]H\11BA93G25_GQ#V(1;SJ'_D?LW4C^TC$M
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M%^E(K%S9UVM@I=WS#S$C187>.0D+1@75R=*3O[JV[1RN+-8;'LW_@OMZ8WC
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MD2Y8(A7Q^#BCE??&,7;BS8 ^TX#14IX-2)GC()N3=Z:X9F=^W#YX(J/"YYO
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MV]B;N@UR[@ID\LZ0Z7MVRU9-SC?PNPK[=B&,+[,W[R^5F6RVUX6;<YXG:60
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MC10Q"!]+^;2$BWH^G91Z[F-TQ_9:[*&IA8RT2]OSOC4$OZK'0UGV0D-U/YG
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M8.#6!W_^BB^RG4?ZAZ_KAHJ478KCSGQCXWY=TXQ6:^3@@;G8X.QF+1-[H]?
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MN7N=W>W;_0A0Z6GI:@$0,$E") %@=_X8A<DI% ;E?PKE"Q<7$@%DU'0-\?
M;')GA1P'8"Q'M?]RAP( ^,<*-0&(T&AQ63$I<4E6*#X@8^B.0*/\4:X8N#4*
M[0(7A*MZ>06@W5$^<&-75R3:W<<-;BXH"G?0-H&+B@F)B N)23C '40=]K@>
MQ7&ENI;G0DOP^9:\B ]=Q;2#X4U<G1RN;A);#WX@N!*I+T@18QR \0W @$5\
M+,S$'V/NC$)YX3!T?3!(I$^ ]WX>>U?W0F/+E+BVYN[!6 PU=PRVS1\TD6@C
M)V^DA::-Q4]F>PU,T"B4JSD2$^!K[.R! ,%D@ F !E#@/U< #I@#2  #! "^
MN"8DOC^Q]\FH>6%\?DA$YAS@[H5Q]\&1!,O$.&QU0UO]O=Z0Q^)#!7_3^- O
M&AO[8L".]0>A##B]?#$^^TJ 2CJC?Q;,W/P-_ZA!^ZC_4?#!_%$P</;R_UDP
M<L,$_BQH>GMI_"R _?@':36$I]N/CM@3$##35E,';S!<W@4.=T$%.*N@/@+[
M21OM\Q>8FM=?\=30+A:6/A@M+C,O#/!+4O-R@?\=W,S?"X.#FP1[J?C;,F3M
M@4D"D0@,"JWAA''Z:14F;B;^^U:!S?^XJ^,Z >F*^3OR%N#L^#NX.<)K#VZ"
M1JC8_@13@=/ U_H4$AQ<<+Q L]_O,0ILA1DHDQH*@T%Y>Z%\W'XT(=NOP8KP
M"YQ\'V[F[G;JUPK2_0I0MI]@K.7 YO=D@$C&GP:'!;)_QUG5,5P=Q1\:*$?M
MM<(CQQ6Q,S\85V;Z66;'45W!E8GWVT%PK;BI]KIY?_CWN,#6<'D=0-C5%:SQ
M J\$/QKM0;)OI?Z$B.&NQ\'K/D02=Q7\ X*C^167!V?2[M\FV#2V^C]?A^L+
MHKT>Q<D%0%7V/C_JV'_VTUZ9&9N#2?Z4'I=@;0! F/6SZ_Z:?H%A\;#X_XCP
M,_WA& "? "^L@4&Q;)U1 3XN_G^:EPB,Z+Z86&/^Q9" /UD<H/;3,O?$,/MI
M>#@5"/R]W!%(?RLO ^S4@?S&!Q]7!V8.817!%70U?J%-Z(9&!?C^!B) H=W=
MW']Z14US;"-C' PLDSL%8%#:2!\DV@F#=,%)'^*[[]1)]I"Q$&R-KK<;_/^"
M_K  M-=O2P.N\W^'&/J[_;Y\$#AY82R<W'Z#42"08#MD,$;77\?"T&#?01'M
M@W]#)CZ%0H>J>KF[[?<4Y9[R.OM@;.^Z(%V= G >BC@0B<;\#;K5/OAW=%)G
M-W64%PK]2^=2[S50T_Y9@17#".6#O1-C4+[@,N2/_+7C2+S COP+E,P9Y^K^
M B=%8QW:G\"X&<2SUP[\0)67@#_@U+@L9,_SX-'B2M@!A>'*6'R )>!'AV$'
MR@3,?@2 9"S<%F $(+M]NV-D-KKJZ@XF9L9:N@::6&( F8Z!NP\*"DXF;W!M
M Q<PN(WM<3CA>W R$8-S&#0;)X2_KZ&YE@7.R#35X?X@$O!' FFL]^P-4Z>@
MC@D<#OS/$C7"%PT. @24%Q!W0?J#9@LY#^:]@C"^6#BV#VB=/;%Y*%9?6C0H
M()AGQ.;=]O(".)R]O HV[^+M TX7*%9F7Q=O%VR^'LQ?"@S 3B.8 9B_$.B.
M# +S76#^B%> MSN8QWI96F^D$SBU<3UZ!(-$G +S(M@105N8@:LDG@)HHV1N
MO^2=?\EC0,/%*J6.\@W!C3"<!\$+%Y65E8'K((.\D!B,H(D3PM,)# _54=Z^
M3CXA +"G,RX=PO8M'.QD*5%9*2E!,2'17SKJ7U;^-Q-V;/=R*Z:X,8/0O_T#
M]G=XJ#N@_8$K&NSZ'S#G6P!0&0T C -_P(YD@;,,'+>*UE_TH<?:RRD,QE=.
M6#@H*$C('8D0PG;HS_1?(OPWTB_\A+#D?G8/7&-OAL.Q_88 YW$ &N[OZX1
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M#I@<,#E@<L#D@,D!DP,F!TP.F!PP.6!RP.0_S(3DCZ,-D#XNBIQ!G,I*NX.
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M/V)]WVMB&02!9/5.)8\N9UPB@.B8@',7&@4'G3N(>%@5=#"<^  1.(U4\/'
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M8AWXA /W2$5*U>9X=)UKQW=:W](37Q<R52S;,N8> B9X>\^_(22OH[*$H@!
MC":7*>RRLHG <;?"3J5"6(O*FIQ#UT>]$?HVX!K6D<^F+C[MPUT+ZJ%)5+D
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M@%H G9E^_6O ;TX^Y;X > =@];I.#*I10=^D)D.@3G,O=6O)J,$)XO?J7!P
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M[%=;2A7TMP0CI1<6(J4]+H5$)RK$0CO[$B0OWA%1HM)2>,VMP$5S#4!+:PH
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M*.U]Q8&T9R?*:=@3<*K.&ZRC/\7"'65G1/=L$P*9>NP.^X8@?@9%R T_!U-
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MJ,7XH4DRQ[!NV6M&MGNE14Z,_$WH\KA"_!RL68]?5/\*(LH&+D>9L(B)M&K
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MYQ0;./Z7 :0$R(P!(J\*&80K/"67S9_ V[A(_I8F\A+@PCKZPOT\4"54\?8
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MV(Q,93$*'A-*;*L.Y+@?^TQ)A*B29\1"&>2;JD0+'ES/J_J7@(_GWF;.!U2
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M8,.BDXC-]T$B_FYMU\'I]SZE>:K[+[9T\:(,D4)X!@B-\7[;-9(NX[1(+>7
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M4.'"P)I/[G9:;=R UNZMU?[O[390XL\E0 ^E:UG2#7272@K #&])&\.'()<
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M81##,QZ^V@@.+0&0BG\B('QZ_S: 0.J5;F97]2NH@T_P/QN?MG_+?4<DX[:
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M&/@EH/(2\#2_P,GG$L!"[E PG.;P=NU"CFG.3*F/>-90E&1H'J#]QV?3C!C
M@3,Q)DCE<);K6[9NPNT*XGT*4/<Q\:W<$N7:%SD=-6-YH,?U0 WP/!E/Z%5"
MGG(JS0$9K[9]>1"3>0?=TLRI?UM>V_3%RT7D3FTNK>T*_[Y,T&PG6*)W3?/;
MAZG/NYOQ;C*4<Y5]>14/#$KIP^B\/ @J- [IJ+5M-])C6^S7V6*08ZLZ[[,A
M&B)W%=:554(DX^[X*'#(-VI%3=3Q6/%\J/WQL+(D?(S(YZ:-@=.$^+@5/4_X
MO:&U2\#]J7O<;H._5/F1A7*'H5J01+/BTIB+9XF2'M8:&MJ[O>FAAR*BXQ*^
MX37IAV&1=LMS0T^'9C,#T$*&/9ESPR#FA-[39@'GZBS7T/[IMR?=S-6RNI26
MRX=!#E^]NCF6V!F2WG8CQMO)3+HY.F-=$YFI;7303&$FN=:]W\*W'O<OJO#$
M(1> T>2\1IM>P"8'*-LS9O[MA>+CH Y"FPZ%'GB"HZ633&X_DMO#DLF'H;CL
MW2_O[XA?[Y".EM%RSH K=]7/KQP;JA%P8.&;"^V+F[R7@(<$A/9)_ FMM,VI
MC^+X%"L%*8:F(%I\12CBNGFGDF.52=O9\&.F D+7EH:A=LM^+'DYWD>5>0%W
MI6$:'Z;)><GNE+2M7@)^S_M=1]>=VDR[OUU_@_#[+E7L*CH6NZ<Y5F7*1%:B
MO)@T.3?$U7Y,FQ5P8*$;<I)H/=8-W.6>'K,+A)\P=2;)L"3)W'==:/@8JN]4
M]QLNF"NS=@:S[&:F%$^=O0XSHK6NU)"%73<T)XL[9JIIIQ$_OC;O_6;LT=0;
MLV.502@:C#_488N(""F /3K6F:J$G]#(W$N=4/8D-_XR]UHJ\HG9%W"6_A'#
M?KE[)#/R I2^P!6@WM?;F]FJ,+WQ5CV$>)9XH;49G]6/L;%13^X^X']=R_W7
M<\>5ID-A0Q2E_6_C46%<6QU+'4NY?X[@4__D:Q1/[RAQF_G](7#H,/5C+XST
MTK\W8?\)Y/6SZ<]B SI.XI7;6_I68_9ZW,YV@,PG)R-#5GHJ.&07&)T>?X+C
M[Z'</U='<JS,Y\&\WR.=V>JFU$!+$L!47>C=072U;MH46JHT@@RR<,04G6C7
MW9(>'3L5?.9Y"0 NL0]=@):8XYV.C-LJD1RU^Y[Q34F:6\*&(O:*D08@^_W^
MS LF(GMJ;Z97LQ@S(:4:VKUGN6@9"PQD $J*!^25@,TD*S3IN)FO3+IF1!HY
M; EVB4VR=ZYURJ75[22#,Q*5MO^PRQ[M>$FE57BQ,X0+J@AV8H&(WPI"XTSJ
M>K]*^O%;LDAL-I":LK(9%C%D:X'-R]8X$[[>;X)K04)SBED9B4B8[DSBXB>U
M. E:R5>_RDS%5LPY35WYK06N'GI5I7<,?PSD=8^6R<8GS^A6VBY@O.<&5S\L
MV&')9EKTK-@?0WK?PU^IPC7\8ASC5VS"NJ$;L+O5;Y=Z[$J>,0':_L.HZKC*
M-^CU\[!P1\;(V]"9N:D^J/,C-IL,47% EU7;JS67,'_BN%*%[9_XK,Q:#SU$
M&IJV6YNZ8<H'2SD^BJFJ!+,V,G3&3VT!I3#O!B(-/OX)5:5O&8>X--M^S+XI
MW37%Q(E*ZG)3C->RN!.(,FXVWY!H"S]7NV/"@G!3^SR\:DS6R Y&.EDQLY0%
M5-1[V*C+C.V^*_S9?T'IJ50/+TT]@Y6>)7BWX/PS'>X<'W1*3^,5X]1DC"85
MJL):X5N2+S0U_42J*/C;HF3K;:(UCJ+Y>\,0PH8IGYFU,O%P6W_;<?N8.IOA
MY8TM?UF_5,F5V:]?N<[<6X!E > ZHYT?OEL[RC EKZJ3XAK.?]ZUIW@ PF>N
M1X23 LN7@,="2&IZR%+U<5NGQB5@?A@Z"UQ%%=N<ZY_"@JI+%G9$<&J+7[+>
MSF3OUNWZ<^9NF3NJDNY+>K#+:IRSB=<@<'"@P<9+QT?A"6M=0.F!0:Z9.JR^
M\1OODH%7VH#YN*U;363,6F^?.$C?9%';Y'T(Q%W9D7'\W3KX0E$N*=7>7E9V
M;&C)/E/NFUE%Y:^TB!&7J(.7[,/]S-OG[(O];:.@S0Z&@0)4(W#F@-U>DY_I
M"] E+>;A?JAG4CYSFZ;!L(C)%K(C)_)GM$GK6&KTI(JB3=0/FU/GU::H1?'V
M(D61Y()*>E<6B+.ID=2@0R%EMLP<W*K7?U9Z@8%AL/I6BD2HH,:J(_LZ#>LQ
M2,%I2VO*ZL],*N\S5-^R.P.HAB!E/%2O_TN?MA$U9&"X4F&X29(X1RB_ M-;
ML4._/Q=HPW2=<,\K0B%M9_)=_P%U^=E4)U$%6+XX8UE*M.[0!C;D9A1W4)J7
M3L59T9)6-+"=H+W -*Q4JV6M*#4YU[!M13=I,CF0JJ.OMR.%B*SX&-<E9:0\
M%^/2YTG:/.#Z!9VV(I7)^N= (767_+Z#=>N6S,US\N&';]I,Q,S# )4X!12!
MVR;')G[F ,?'F,(DR9# ;3]S)KN >TL'F1V5BRF=LT$T>7$U$W0:C1YA)H8=
M,I%U74/5,R?&RB4:#D=TVS,!_1Y#\=R\QT;HO'?=9Z^,!W]Z%QW'.3_YJ"T0
M6*3'WAT+NEAO")U$.W&YP\ZZD88M>1D^OF%<P"/6LYXA2B.6X I\!HI4XNH\
MA&#D;*D2X7I:5>#/G6!"L[2%-1:8SGF QP5E74KWZ._AP=FAH*L;.MC7XV[H
M+@D.04#FM?,CIW;R]Z7 =,"+?PBB.O"B']I:]X=[W8MVL16+&1 YULMP#;]R
M=%;-@^LW/;Z;DW[ZK/N<RLF,F(3D/B'@FH+LE4/='/?_:!ZTKC0/^2^,7:)9
M:0/T23[+ S)]KA$.=%NE/@[MFO]66>'\L%4@V(@N\Q?<X7@K"LX>-LBRI./0
MHG72+W_^N2V.5ZGYB6Q3M!(WFFK7.ZQ92J$1F(*D.WA 6I#<<PE8"5W(S"H5
M&8\!RUX"EL]GC_QX^-^<ND,0TZ'1WLK[$N$?(MG#S8;G*79K?,?W.S:.9[#%
M8!U[J'4L9[Q^"4@]P!ZV-TF?R#>X"?ZI;>X,!G(@%KS23R7*&K E(W;K3XM7
MIZ)P;9N>"/VI2A'THGT+-;/0.XMR>XV\!& PEP!<;G8G*78 QYA_C4;-][\\
MO<NU"_GI%>#3-G\)>*4MX0D'[]:=WUUQAW[*/0%?P(:\0X2!A0+[EBE> 9]/
MQ/KV+P'7#+$E"!>\'=Q.9$JG)J 8H!X&-ZJ.ZMBWT#>FX(CQ$\O:?*5?)87Y
M-URQ19G<,6O^Q^@R4S$#RE5;/_PC#)/*ON''=)6$H@W)":#?^CLK6O4O'8=W
MKP?L:C90EKOW*BXR#"X6P2$89="**56+I?D-_FL^76,B=X:42!Y];7RKE%\0
M7/@=C_":/"$!;MD;@/.Z#/AT[2F@ZK<6<3(>AR" P#*D3$#V%=%M/;9ZDB$4
MD>1Q2*N>)I2"R9XB6FM$=IS]<[@%R60KYWR%GBM#+H@_F4#GD'US_OM^T2<V
M?4WN4(FH%]R<W\S#:7<C8M!$]SLC$Y*?!]_"OX>+L/!3Q+0X)'/_V6N<G"U2
M<N6(RST)\=<5S1"/8EMY4(I\X%)@X$LU?^Q1\*B2TOR^.>4'-7"Z$MI\,E11
M:;_7:_0I3!/"9*#@069.HC<?>$@;Z_370P@^2"_T'6+]U?%6Y[>ICO"Q-@S<
M?!6ND7W&<SS6Z:N3+N6,PGP!BO;&.QMXV+GSM))GJ"\)(V)/59\7PB#+.YY8
MEGX.W/\5:<F3*;+!Q9)0:?N%K:<4)'UF(3M@&286UBKWIN).._R-Y7,^N=8[
M['K.UA_-BP[I/=/D30>1HW5X$JJ,I,LM"M'J"Z[U$I47+<<"(W5$'VGJ Q>7
M!6G63JFGNSRHIWO:>;?EMC&W@DX9[5^?W?*<5*U(S'=YJ?<B=N:U!=!8H\2;
M4"<?_3' ^9#V4>$?9]_*?&'O:P9 _!);]J\R8) D60%ZE2I^FZ4XSB3T@PN%
M/L_'B=<6HI7:MIQ*?8;AHLZ4&;-)9+L4WXJB5A@BQ[Z$0VY)ZL)#<M*98*PZ
MVM((-\J*#Y6Q;=[3H5^[LDZ]KS-L()3?Z#>LW%6>(TK*C$C]3-7;PNB=_LO*
M(N[5FHA,\,)\Z 7;%EX=9D#UBG\BSCB.89^!MB]/'=OKU@V@C3#)T;:Y80#)
M'QPS=3#BZ;/B]+$?+(B9^SUNJV&R%^(>O%AM5#*?=&^)TB#2(EI4= %)KO6[
ME2DE?/Q; 0#?C)(BBAJWD49S57;U?S;2V*'4,^I.]![JS+V[%1S[CN!W!S[)
M!*GKOI6T5>3[A\U_?.H;KL*S$N))5M-4L/+IW-7G"T:^8;N38)X$D?48C1)O
M5=LW\)Y^YZB+J3IBIG:S=ITUK-MA/K!"BTR=5=>TM=0:Z+C&;9V!SO7IO%UN
M?*CI&9KL'4)T)9']O!EGF)A('Q=IVDGFAV6YX;]T?B4L$-:2K&=$[.O[T*\.
M6'$^XZFC=)16J8Y0!DT[A;6"6T,,-+YZO6))V'0<S)6 \;($>6_'D^W69H:8
MQM2ELMVYJ(VY!/@-4SWW[)3Y G2,DJ735[>:@6\?%SWW_IUZ)'&V^75]!PY!
M10S/'?])/(N R"9X>VE*RJ8^KW9F%1O-=-X6WS_P7#Q; 3&.R-T[M].L1K+7
M*OOHBZP($3?9]@8O<[I&.O8B:95NY 0A%>DSWO>6!7.Q_5)6H;(D[[WV;7.)
M9KW+W$/=O7W3V2LI.3T8Q#175(;043.NU#<AT%M$.(@G=*2%M="4[\M!V@]>
MM@RUE(#4B[MMX+GT]VKT\QT/$CZ/7#%=6.<$I]:OM#EJ'KZ%+: 18I7?8="F
MDC&O4#5\0S3FL^LX@K.(F<=-*E7=YNZ']$<UF;7JN6N>12KO$6P5'F'[MGYX
M$!UG8\7',4)T,'Q(S*#X6JN^$M'A$\S:[Q-"31U=:P>'46?0F@-(/?FM:!P/
M.[W(H_1A]O=Q C;YM&%/"=X! .3)JM+XRT0AJ#7U1,7 VT'A/:UBW/N9,4:]
M/PM#>LVI@NTAB%!?E=6(+= +!Y+<TE )IU6E%/5E5F<%$=\RP;TL!6?P792$
M\YO#S<>)DM]J[L#D\E:BJ2./>MKBOU28$&F$-%=^=Y>?Z(MH?(LJ#M(?V2L=
ML$:RLY2E%:J2(XF&;1G>6:\)]5RQV^0O2FQT1>"'6&;JP[^,8[?#I_]EK=Y]
M.-:Z4PV!)5!);V&24+^S+P&9=3NW=4?<F0=2-L6L651?Z!5FG/ON_Q8!Z[S@
MY.U2_.SAK]WK_^ 9"0<!WJ= 11Z)>*64;*9,M#%Q 8 09Z>*L\T@=9[4BZ(E
M:5 GP0J6\H2R[?YX\Q8 R'=BPJ> :X\!%6SRUW)^O?KT6% 0<"OX^[4/Q&JT
MM+C?RE\C*6(UP*=D8K6G  "AX>UKT0KAE*\MV)Z2&N%*XBI\P=<6S MNSDX&
MW'[XO=%C_Q&D3+MXS(1(O=5%X&N,U&GX\@.(N,P[$?_C&&[QH+'JL_P./ZIQ
MR*:3K;7B'=4LJ\ 9;\F!MZM.41LM!L7QD[Q1/<.]0A/.MP_<DP2'0S>LE,6>
M&TNI@),.LR^::^^O'W32>/C [K;6BI>>!GB"4/'VY3'-C$DH^[M4/I.N6W#1
M*0?^ &:&,2]LX0T3% M[T,F!_;$;MF0VM*G+SZ4DN$STYRX,4+XYX506+S[3
M5BSNG?UXF$G5\;NK/;P8>E,-!LM$'.@'FZ"<!%W!\'UL"AR8>7$ON:EH9)59
M)VQAE;7G2.*T1PJW'#N4LK3J4"+C<@G@5"M$Q4@='QSKD_+?;?,\1,"SM!Z5
MH^$S;-8"DS71U/X*3 (.)<!&+7Z4-?1;IES)>IS)H['F'53(2GI)HISYWB+S
METQ2#^EJQ<(D1-#)'GF#%LM<)@@JD-60;[+:&!F/?!13O-27!S$V412(<P72
MSC$)YQJ&&?8A09R)NC=VV%)4U=/.9FT5%43@$#*1 ^5;F8]Z7J@JY*SI:\2[
MV7$6O>\L/@=<1;JDBX,/8.'.31FQW9E3#2@* [=8A6KBV-Y4I]^& E907:4X
MB0[#M&U)XTE=1&!0BR[MB6=@)GZAL&^O1\T^UC&Y=K*)C^>G!'I$!)9!I%YP
M3!:4NMQYXU/4,;Z>DW=*DBA*/)*;-HC@R2PML#E)U^MTE4:!2,TB,V?5.H_B
M7.(2V5?KR6IS0[25%1];,=ZD&W3\(515-IA922+HYQ LHJC>$0Q873905$-&
M5=[M7VV%2YEM?S!<9<@J17VT ^GZQ>\^$=VF&N@MR=5X\HT^#*6D5!$Q&7',
M.!GD+*L4IRX_4C&(?&[R!2M 2=Q8<:$Y-SQFN-N?W2J3"G*3-A7&G,DFI9(,
M#EC;,]O@IT5%KB@*V SIBW-!!K<37F^[N+>T4)M$)D??V>1QCE/_$H3X+@$4
MR#ETVI:'#-_)C&%I&-<:1'9 L]^,.P>Y[E[ WDMM>!A$SB>G5+D*^L8;:^E_
M;:C3N*#BUSH176RO<,O1L)6[/7%M2%4AF]@]G]_1-]%'O[TM:L%9,JZRBY6F
M5B6(*+<40:.-E &M7$-(2V2MW'/039>XV?=Y?&QU8!"L0D]7V3TA<9'F\45B
MI XDE=D[L+LL]M59Z4\C5D3C/S$2OK\W5>V,B<GJ:3H*K=,X>.7H+J4\27A>
MQ#SO538_=<C*/P-J3KAY^@;X^]0>RX,5P8TPH2L>C'/5!;C6]GY'H0[_^UQ>
M!5*!.&9N!\AQ9@Y^-< H01E9>92H2K)SMJ83:3=#PSXYZIFU?3[HI3Z0'EVV
M#)-LK.9V-%C:[XWA\EI>GC$_L&Q&VPENLNP(&BEGS*U12/S>]JE[J')[\8CJ
MO5?=J%_]H]#.)=%X6,Y+N/C^N)<9N_&>S-1Z?=#7C=,Y0/EZ#"6DSC^ ^>J<
MLB<SMOYB6L9JS,O_6LT>7&7JP@Q(P<31'\F\,K<C%SA]:GM.['EKIN&P&O;X
MD]X8HJ7R'7AM9@>4UG_<IJC3ZUC^Y>+M[NWI3KES1:O4_O*';=TI*$7RDSLE
MC B4-/..VG'^.2S)'3B;L@,^%?&V@$PYJ$[+_/UGF=$YQ\N\\QY;Y$>>4*_C
MP6]/W8L>JGJ,S=IS>+UG2]\E@%QU6CW*1+BWCIH\\!(PVK0W!C+F2[X$Q+&:
M$/0=70)BTK>?S-6CC: [R((?"R<[:=YLS)0RGA!@@%\+C6=[7]W-J][ WQ#;
M>)VA3OY8T;YIUK]\2QYZ\AC;;=BV3#@&W7],]5XT[%@1#.":RV79N7V<2NM0
M&L9_ELF_&#R,#V'V06RS=RFSN;:4L,)>Z\W"&2%<'D9-3.)RU P>Z7*151+;
MD86SH=8)I*E[IH8:9IXW4R7N!/-R9L%2ZP/,=V4XYX+BCC;&M,*_N*%!1;OZ
M+1&#_%&YNC&AAVXFK+L>#DIJ";D[[>S?(E4-YZN^9D&H5Q?SA&#XX'Y!H%9>
MX7.KE@L#YDL 6]4E@.(2H..%<*#F>'<HP[<[#$ND#@.[7@*RQ2M1L)Z-F+2/
MW[\X+#N73E:,:=I\WVB8WRU/H/XL*6QOH)NJ4*8#EQ =/(#/A**DCE<EA1GN
MQRTVC'.? IMH>@Y[E-^,L5F#-+G$HS5NI!7Z1)0BH6_W:,9FIM>XG_0H-S[A
MWQ]FSO]Y]IGSX]VQFU',E1JNB(ICE^]L$]7]FX% NYP3VS&IL\DIZF9GR&9I
M^Y=L(DSJSVS7P3<%F(3]Q4WJE"(A^CKC.@@YI0F:J2G7AS,O9^F;PT#F1(A\
M^\97KB@6JEK2M[*6'RX!0C"U'.0+IWNB'@9ZFR3% J6T?QIG!J)9(NP224+%
M-1JN6XZ!&FCE?D(KG;-\M$^7'CU0]SY1'WVV)/FZO_(<NB>^(5ZV&*WLD3\,
M?3SP4?A<=I.3$Q,TKLD+H-B_YA,2;,X,:6*7WI:72#SAYDVP'0#9[1FH>/=3
M+DV.4AO^(+5\W9CD4/'C#G=D,B%DPKNX3/UK*K6X.7$,.%>P'(%6#SR\Q_(S
M'VFH%A^,8%Z4MQ8M<@V>_:642"2R6B$<[/U4+=Q!OC*TU8?+,T\]1E1%I8/-
MB==80CUP6UR2DU2@,;,Y_&=A80%29H?+EN]+QI,'RBP1Y5G\;$8PHE<.><'3
M@W5F?_&*+9<]N;FA;I ![]:QQL5G,+%#WO@_].(9",1$7(A<^(7,J6X0JGI<
M('[M<IXJ7P+H<(L-OX3!F9I']!'+D.6ZHI73D/9]?),W1(Z/N0B-:4DJ!0@
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M(A3W-EX]_6UKB7LC_AOLA_#FYELJ@S&X<;";-@UR\;X91 *-UE2:_*#OT)<
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M\]"4<U1>7;R7HACM]MO;^9M&\S)/TJ['K&IRNS(?D>MQ:VJ@=H7'?:QID_5
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M5"282KV4\;8$0DR#>2M>:,:EISS8<]^RJ"K!QWD@KC0:K%1"^%:!P$W5EWX
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M3QA'R!ZL2BG\79)G.&3<)8-U!6E:J,Y_XI:6B[M=J<'K=PUDYY) KZF)6W&
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M 5'#+8BO0(.YEA%4:=]LG,\S0RVZ&B4)C1:KX(9^.0\C3_L$\;08WA05UQ-
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MK/I(/MI\5\&2Y\P*W5Z;CZY)T<"53OK[ 6->9"4PYGCM,BPLDNDS>_7MBUQ
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M5X8;<G,>J.UNPB^UM'+;[X^:^%WW<DZ0VHGM'W&GR.MT>G@STG88]O,G.M<
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MJK[SVY 1_BIW\U&R3Z+5YBK-5U=;;&1A,5"GO7WNSYQDSH*R1O>2",1X/R\
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M=V%==4__W3F6\J0&CUEGA>(M9QL.9YNO58A"YKRZ'YO5SHW:#(H[TK:RJNI
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M.WMFEAFTOQK5JZO9-.+99/.=T!6L]XD-<901383A=6-A4FN2 C]?F!6HU >
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M0^D%*I<CF\8!Q,/L)?4Z-&@.&JZJH_F#W>-%82K!J>I([_XP!Q:R.I:_;6^
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MX^J(_?F'=Y*S]P)2=#75MS,BN9BXQB=ZGI82(S5:Y=J^3%(GL.SXJ-XW>,/
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MNOVX.+)0R8A22^(Q6AV:AQ)D.WS9=("&CZ;L)^KSA.17:R]*RDNQFNQZ5!G
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M$44"I?A:G;4,TMUJH^W-Y?,MKW0ZL&5C@65S1VS)K^J]FR&&CPVWMW@+DZ]
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MS3U#3,[!FL%VU)=VP7+B+J\A?G,JQJT#BC=HQ]64$QP?']&].E0'8;HT=,L
M7 U[5W@U&5"&1Q=9J1PCZZ!=I4.)!ZOTZ<6E\?DCO/T)% M5HP---AL3JD43
M!VTVI:^7$GOB:?C[[W&)UX7B>!8<V*+DQQW@Y))U([1ICH9RC;0-XL,2X;3)
MH/D)7)/J_FI-I5^=! _<&@:M 0-*H4 H"NPZES)>ES,AQV73@AT C$T)'JSA
M/H$-#$ AX;SF1^'K-B+,7)CXP.>.+%3-Q)\+H9?V%G"=6Z5I;<:DR1HE_YI7
MXL/P H5\S9-TT4\<WB0 I% IK)@&?!8"3!QP)@(!?#@@#M<%'?&E@R/KWG'
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M%%(>"CB3#Q,[XX5>NO"]/;RP\O(/):WHRA0D%9+<W!4.P75I@!1;J50G/B7
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M?LO LU, @"?<*(BX )< *"?#)VL ?%EKB!780DX=@'JR#B!$E@#6]Q#]3L8
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M 5\G'_PX>&6QPI74_'M?TU!=^N/45<^+$LV V81[+[8DVO0K*W>DWA?5H,X
MT#7JO:*\]K288@A6UX["2&_Y94WTU;O-W]'+:VMO1]=Z?6/QD63S9PG(4&C9
M@:_478/5YY559<O#=D0S&E,G -LM\\/0%M_&'5N_T3'3(P?N$T#CX$[EIG[D
M]"H1IJA4ID>E8#OJ%-XH#AJTZ1:TXJ['8O#=&[E42XV%IM_L3,7N&N),"-M(
M3!VHT7M7H&&66MCFM_@)Y&OK5S6V!E7;CBR/=4]$/#R,>8Y'4AW&F1[NS?)
M)(U(>7A=)N9E7\Z1Y\'0XP'>96[[ILPA2Y^R],P=':^J)-&J,0MUWMVF%;7^
MA.55D%/1 X$I\1*J ,+T5]G3#L4/R7T8R@O6*W='/^Y1B)IX]WRX[LJ?1:]0
M/IF9B_O,^.Y U1A'V6Y=P?VCH.(4BS6OO*$2G[UV"[Y$@EIR42F#%L>RI";Q
MQDQ1D\EM4C #-E7^JF-!G6E53K"H#1:)KGF+S&?*;X;TD!O+(D:C3N_PRZHP
MARTJZU>\/OK*[/HUY\,:RP;<;\>Q7IFP!Q4_9DR/$YJL5G^6M/I]IR>.Q;_
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ML1&.[""I?:V-(Y4&L68)^EY:8& $<<_)R.D9 R-R%ZU_>NH  %P R *L 1"
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MCW)X+(:(>FIH=:/)4G?.=W)KP\1.PRO5/I_H7*N^&\MJZV;OK&(I&[O=K!W
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M4=9N"GF0Y6&HZ0C#+PX'!_N=Y#J_Y5-EJH&FIBYFC-R(AJ=WGFA#_R3(A]7
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M'7?327!1DVA-%R[AW*<^]0PWWA&!O-E!EUUA3LQG,V)BMRB=[\S9O!O#+9"
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M>C9)A/'.*!';9<ECWJ?_@R61?CL6QQF8S3RK=-7E,-9;G-_Z:ME'?G),;&/
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M.92)K?84;VU)M;5X?='V?ELADSU4L*1RL>Y50VO](RF"G-**YG$VJHCM]:I
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M&08&=X?BU@)E&*"XN[1 H7@_Z"OGG/^YZUOWKI6]\V2RLR?)2A[)3IX?&6:
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M)I 67:1=1E!7;X'QY$62K]!G<)AED BD#\/FF/<SG?L8G6#Z+7O2D+@.-7&
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MHMS^"\<X]>]E7P&(FL(FE*J8(9-5#J^U"1%TBX=7 ?RS3&@.B$T,"4/SR6=
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MHZ4E!=:6THZYJ=V7SU!^&@\6Q%J)R]Y35KL7E5II(RJ,&^IRJ [+_.^%Q,=
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M)]U/*%[H5@P"3/PV*Q7*2Z,:\$A\-RH(FK3D>%QUL$<!TG0H[V=2,P1P8MQ
MV28[DN14L\!O.-1M$(LO'A0^Q_5:1N4<7V*0*SD=*+P,*!F#8U Y9-@C8J-
M._L'E0Z<7*)N^@=]V<B19*.3T]-!4VU#)E;/M6VI.O0,=-AGM7<DLV#2O)SD
M'.)6)0[6C"$-SK8 1Y*W5"P^7,+:Q/V;E=3ZYN9T%>?FY'1K]MDGV=<E*9;'
MN<CDHP;#. ONNV^Z+W3KP!!%!,IP''5#G4]V:(LH!(5XMPE:)ZT@-JL>RLH
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MM[JA/M<K7I#94G[:\PXEEB.>R,5_V</VX5-_EYY#+E5!-L*R4A2G;?GU9YX
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M @66/5W'@RO"MC=:RB6(-/*E[>;60'^_OQ>5V,>F4=EO+NJX1+3?0D]@=<0
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M]_36LM=71=DQOL7([G,9,*O%L1);%]0IDM(:/?D"?R^-K#*",J9FY6\S3+5
MC)KARH!,&%W%1F)=:O/7*@OKL_'C1AV6>X**<VE4'J)T#4_L^VI8\W)L-NT#
MG87,U8G.15GTO;MYI7@19@6LW W+PVB_'4*EQBE_=T8D(*<0ZS3Z># M\SE+
M0*E9JNOCEJ"[]M <M&ODM\6;N+"R^DT]ZZO?B_EO= +_/^=5:)(0I9PS3%J%
M#E@&W9(G!SXL)L_D/NN)I[T"7#OY&W)U?6XPQ/_I4]I+.9O#!39C<LN]U.2
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M=CG=L&IV2P<S!-=,P*WK"C9F1BFA&J!BO]B+35:Q$E-"BS)V1]*"(=#W]O[
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MT?JX,)-T4&W ]*=1] -MNS<C8SGS^]T,R5I#5>I"WMO+73,.O87O'_1_*@5
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M.=T,FJ4X"RENNGK,C&MVQLBY7.0U78-! 8>?BKS,3KO7N7!%QBJ9&Z=\'"]
M!&,KRCT;541:S# #E>K1D.:".2]?C_'S?+/[6GJ-6'NGX*1G?"C5?(KM'&UR
MH/:*GJ!1Y!V4]0ET(0A%"9/]DY/3)MXW)/U*R]./[;-YK0T@^J"H(CIK7[==
MU?P.Y#3@877K\<Y^I71)G;*0N/@F@DGX+A:ZLWQ+I+E0T[FN."M#Q-%J&6K.
MTPTG?FO'Y>M>GQQPN#<-*SM2[!(6BN[B1L,#"RE;+@D=5X^_KU\6.,LG-09I
M<#FNW92R#+6$A<WVRHW)#L%8DUW]L5=4]SR0$M-#(05+BM$SY<D'"L:RF%+2
MGEG"Z>/ESZNO*^+VGUJ35XK+/V6FXG>75;R3U6;E]DKZ7B_'E[<7'("F4;L3
M-'DH#.>_13:$CM1XY72_KR7]>]^BTN=&T <@NO'M,Y]_:1[BY^BS:)A'@KCC
M7!NXVWT+<8Z89U+)J. FFCEQR5T&;E.T#&ZVXJ+U27P2^J2^"NBS9<W;+-%4
M*60=$YM/)X*Q*:.:&(792-WPN4K'XSA6ND.&%QD:&,=D(L^*U@>0H8J)A7Q1
MQ^TYV I[7]P@-W51<'F&KAD;LX'(1=7=945E/.62M:'!6-MN;7T<O;X#QR"R
MTMQ?/(7/)U8YE,I:P'4W/,J=?#C[7I/"+3+422'V2,A6ET=SW5;P8,4NO5L6
MJ3=I,1/P[)"\]KZ?AY^"QG^T/6@G/]G*SG#3]4DFH+05&],2"K';KXJ]7?*X
MU;L,2 G6X+C6.(8LNO*-=SFC/Z5DZ)V*DA:NXG-(>[T64B&*@GDHZ+TC#FJL
MXDCS2@X4^FRYG>.Z9<8>TIGZMQC91J,7;&D/)RIW"<,;KO*[ .'9.RKJ>%XJ
M#WB!DK5<)4K6U,CL#)/-8ZK.-!=,:=?Y,+$5KFOJ#CQ6UO/=86],<EA:T_7G
M'BIXY]>7R]+FD:&TPW3XWQX(<J>.H<UN-6R'SGH5[N)D?+\MVKN&*)S7EW+"
MR=>TMD=V?+*L65+BPC61LH0F #G/9J"W'%71O )UIX>#G')0ZR8.F):,;\DC
M)\/]G92UTYB=@'J4K ,\RF-.0"3S71K0.\7+'LM2 T%A3*!SV5C<CNY"1]6R
M.,C;*CVNH[6X =,A3V21[E8__;[RSGI"RETHC([M6Y$C3JV6VX08'6<@C(+0
MN=RHF.U!K  5N34MQ&X$XC?.T4]4>]G&Y6UGG:<8]DKR"X1R6JJ[>#.&] M[
MP[<FUU"W+LOT[A7"=+FHG:^/LH#W^>%Q[VG#N:8QO9'M.9\$I=JW6N)K6Z1[
M6@$E5-=6=CG25;@@C!W46JI62YV"Z2"@[62H((RIU-")".T4^&EBC: &#*D,
M8P?E#5 0PAK1CD%V?)J80Q1YJAL0V.5$-69!W6X5A4U\[:=I+RH[*LU)^K7.
M.)TQS(<A3(X&1L[H *J1#;*XN.H]YO),NUN9=:#1(.^ 2#C?*D]GB4$#;JNV
M0Q^<X"YV-/-:(SVJI=!79!)[N?!7N0Z,/'(J=Q9:16L,T0&MHV(68M52X/=3
M3DM,8YGJN5@LWJ'.=BI8(>TL)PX\E7S$L<6$Y'BL8(54>Z5159W*NJWN$M!R
M,<U05CN\59%1'E+&5R<Y+&[=:D$AI71JXM*>'+6)71=8=U%U+K&_!V5B2K&,
M8"!CM N,4FW-.<_DIC<Z:>H=JHXQ_E6/O,)WPM'13=K12Y.X&WP5'5G7EAW*
MX7E]+P^1FZ6A=/+C'5>B<+6,0L8\MWP.BK^&K9J=K<W.Z]!H86QPM &%G';O
MOXETD 8T8 4A\H#=*Y!^ENRXN?E=.?CQ]7:Z/=AAW69KW9NM-^I:$NSG*SE3
MO=8?U+3'D_$_TQ;\$1_K']%&]#X_NR;R"D>F 9X%C_6/Z+EZ(1BUR_$!(\K?
MXV4.=V"5,*Y2-!!R%IK_ ! [7P3/7 T[D*5V(?G QA1Y*/)1B4K:MKQ@$)0_
M?.R8VC(Y%<Y:=Y&-914ELS?%=!,,<U5FFD;^8X76,/:,'=#4_M6^*0R!5=1(
M]IR,J,:Z4'V'?)!?AV4A *J(:YQYL7;UAQ')!8'DD4 5H;[245T;N3@IC6IJ
M7"C,J6CXI6S@]4PU(PC"Y]NT#HE9*'GF IAI^$81D >T$ @\BF&C"1*YN!S3
M0-N:F$I0E31D%.&ZC00 G!OQ33L40XG 7+M=)*>X@M*JJM[VN[H)2"T$H/).
M!SU5&VID W:4]M9(#[!6F5V!OD\DH50*]Q&"PA2:>IU$*+$]'DD8<C*-PLK#
M)B6Q2>2QM$,\1L\_ZK92G,,F?=6,MY_]0-\_ZK7^L]/2JD?V&/R6?K8XY6$$
M[J]K78HH_)4FH.VVYKT\?CD@,IGQ'N<BLCZ0&%E"]^P)VV6\SB&3//&RP?'[
MO[H).^ZQY&X^;K[$36/)SN2HE/$'.8/B%;78=I6./0%=[+;^WJ2X^R-UPCNZ
M3D4="7; K'3RZZAS_$K9<0Q%]4V"/=I'(*BO-J--!&_EE;GXBNU9>%*!QH(4
M2G9WADY4ZB(>)6O&_19JQ,I]W K06]V&_LJ.W18CTNW*MJ!CFNW.RY]_';QW
M?BU$FZ)9"YA 38]R1CHF/:<'.RQS-KT=?(JI0^JJHH!D]\!>T<+6EUOLW9%N
M"=^2\HLT':W>( 9.MO\ NOH,TA^C6D#!TA>WQ^/)KP>3O:^?/2=3=G4 XW)7
MGLD6G=>S>DVB$KX!I[V5YW=K=V$)=I3IR_QGX6ZE-I.[( %#C=WB!MNI,()=
MD.W7*UOAI87-?2EC?:(7H'HT>^G>ULFS<87G=NPXL"WUB?V0@+=CG?"O+KU^
M/9)6_P!E+HO!,M\<4VILV-6/!<O6!+1L##^4!3K1&,Y(7:/)?U+MUN,4P=&-
MEK;8\AAU'DJJF 5@]I92R%A(.%,-3G5D8_,%P?<6#\P^:\?XHO\ 5T5Q>SM'
MM:"LZ_BVJP[ZUZF+KWTW2,?F;\TTW6GP>^/FOG.IXKK2-II!^ZANXIKM_KWI
MA:^E?IFF ]L?-<I+[3#\X^:^:7<3UY_Z\BCR<25Y_P"O(K(P^DY.(J49^L'S
M48\24N?M!\U\W.OU:[/USUQ-[K<_;/6XQ8^FV<2TG^(/FE'$E)GVQ\U\X4M[
MJCSE>K:&[S%N3*<K7,CGUL>XUG$],Z)S6R#?XK'V.>*IXGE<#U']5@);K(6[
M2%:O@%_:5H>=W$C)6.YCIQ6]XX:#;NX?R_T7DI8[M!YKUWC1I-NV'Y1_LO+#
M _6#@KP]O5RDPO<' ;J9'&]P)"9#$0X9:<J?2QG)R%Y?);CT<2(,\4@8>:I*
MITK"=RM?+'W#LJ*X4^2>ZN?-J]8K:-[Y),.6BH&8&2J.CB<R<DM.%;.E>V,A
MH(7?G:XU9NJ1&.:Y.JP1S5"^65SM]25LCP>3EK[CBN'SC254UDV<X3NT>1[)
M4>0.<3W2N?UTB"_+B4L;'%X:%);"[W2N]/'IFW9NNG$5I.'*(Q-#R.N5>U<A
M>W3X*KMTI; =N2[R-<8R_40"N_,9-GTYYJ-.<1GPPHE55Q4H+I9F_NL?Q!QM
M#3-<R(!YQC93#F+Z:=K).\0J>[WZBI6'+P'#XKS6Y\53U<A+7NBRL_55\TI/
M:2ERF.DC67SC#M YM,_/[K'5MSJ:DN,SB 3XE0I'9)PAC"1NM<\.?3K22N@D
M$K7$@^*]!L,E95T3G1MSC98*#3NTC9>E^B9S9621R8(+^J>CIX^L1I)JBF?]
M:"#E28[H'.&HK4\86+$?;1-V)SLL/V8+2'#0X>*\WD\;V\>2-/%<CV/<.^%;
M<-,DK*D:\D+)VBEFJIV,CR0"-PO8N$[0V*F:QS U^ <J^+PN7D\B^M=''2T^
MI@WQOLO&_2W<R:U\1=L/C\5[-<)A34;P#R"^<?2'7">[RYW_ /Y7MD]9CQ=7
M:BQ2B6$8/(*#5/+25&HJDL!SR4ET[)>8"OOBQ57" /:3\% AS&=NBLZZ=H!"
MK&G4XXY+G[:U*[LJ"3I(P%*:\%F 2H;6@)K7D.V.R<Q=U.IVD3@Y*]V]%9#9
M(L\UX/2/^N;DKWCT68,D7CE=)&:][C]@>29![<OZD^,]P)E/[4OZOZ(PZH0A
M30)#R*5('<TT>>>E:B=/;XW1C=I)*\/?6/=7]F_*^G[[1-K**1K@#W3C9?/_
M !/P^Z@K7S8( /@N=KU>/+$>WVXB7M .977B&5\5*0-ME/MDNF!A<$ZYQQU<
M9;LLV.O,>=R=\/)5;,PNR& Y6OJ*&.,D$CY*#40Q1-R,']EQL=YRA6&DE8[4
M ?%;3Z'@GI8IR#VKCNJOAJHAC<X3Z0">JU5,Z*220L>.SQW?!21F\U>\&4C:
M:>-L?+/BO7*/[!ODO%^#JW36!KCGO%>R6]VNE8?@O3Q^/%Y9]2L;Y4:J&Q*D
MKC5>PNL>>_B/1\RIPY*'2^T5,1.0A"$:"9-]F4],E&8RD2_C/1- JY''Q177
MME$X@DC'P3X?O4C3XIE;9&UDF2[G\%NWXYS]5$O&C&DX)V^"CNXVZ G/D5:C
M@^ GO/'R2_P=3ZLZVX\EY[-=XK8[R:]AU'^2Y-'UAQR3;\*>RMTM<T?R4:S5
M0KR"PYRN'7CUUYN%NF\;L#?"QLS)'U>"#C*]4^BFN9WAS'4*OJ;13Q/U'3GR
M7/\ BUTG>(M@ML+H 9&[J;46^ 'V=EUIG1QLTL./)=)"'C8[K4\.-?RJ6JHX
MXVDL:L=Q%J,;AC;"]*CI0\8<LQQ;;V-@<6@<O!9G&5N=:^?^)(\5#_-9F88:
M5M^)H,2/VWR5BJL:<KU>-S[1(N94JD^\-\PHD/,J=0MS,T_%;OZ\U_7OWHNV
M@C\E<<7@NN[?TJG]& ^IC'P6@XMC_O9I_P JW'/IFW-P4S==Y<!RY$A;<7(Y
M3' D87? 2X"S1'#-BD+%+& $QQ;E&D8AP'=4>8R.:0K%N!OL4V*,S3 !G5&;
M\4K87C.0J.OAFFKX8VCF<+T:MMSH6EW9]/!4-JC:[B"F#XP0).H51DJVVUD%
M6YO9NP!X+G#12@DF)^?)?2QH:$-#WT<+R?%H7!])1EX'T= !XZ0L]NOCGUB.
M"8]%M E!!T]4MP:&,>3G&5IKF886.9#&R/ _*,+'W*KA@I9'32 ;]5Y:^KX?
MD3>&B'/EQMLKZ1KVTQW"Q%HO< )$#@XGP6@95SR,QV;B#\5N.G=CF-7:.W7&
MN+@SFGELX<3H*BU1E(W85*G/1*LN-(<^"S R)RM36!XHSEGY5FFC,A)67674
M^F=W"I)&N!X_RJ)$0(BI-.\&-_DHW*R-4WL*@X"TO";B2]RI+M&"YS@KWA0!
ML+S\%SZ7_'>_S8SNL9.=4IV)WZ+27^3)=A2^!:.&I=-V\;7[_F&5KQ_KP^9C
MB#[CODE+26^P[Y+VT6.C+,^KQ?Z4ALU&!]WB_P!*]W,^/F>2_7B#6'<:'_)<
MI(I<%H8=)^"]O-DHW#[&(8_RA0JNVT@IWL;#'JZ'2EN,<O&*.VME]8,@W:W(
M53'%)VQ8[&G*]-GL#99Y&QR:"3@@!0*[@\P1N>UY/[+EUTZR,=6.9'&P*.ZJ
M9V0&ZYU;"RJ>QSB=)QNNT$K!W2P%<O9<1WADH&D'*D6*$QW$:O$*5%5QECAV
M+1\4EL>UUQ&/$+7-TD^/?>#3FU8_RA6LL&MI57P2W-K_ &"ORW 7IX<^HQ5V
MH<R:9ALLW1U<UENHP<0R/Q^R]*N%*V:C?JP)>@6.N]N$D#QCO@'&V^5JQF-C
M#.RIIQ41',:5KL^2P'"5WEM\XH:LGL\YU.*WKI&]D)&$%I&0D^-P\^:0'?=0
M)*PYP$WM'NY95U4][FL!<>2BRU9>=,97-K9'G#L@*1' Q@SS*HYPTSG[R<E*
M$$;#L$WM3RPD.3U2)70NTC9-#G$[I&N YI7.&-E5AE14-AC/CC95[*LS'"ER
M0]JTEYP H;:0E^8\D?!2Q4^EFRPL?R*R7%EG?"_UJE'7)\EM*.DV&K8J344C
M9H71N:'#&#D+EU!YC05'K<1E![[-MTLSM;3GVD[B.WR6FZAT )ICNXC897![
MQ-%VD>_DN8KJEY&6O]I4=9G45<5+P_+CLY4E6[<JQ8B.3HQNF%VZ<PK4'8)R
M9J07+IB4[*>P[K@7)S7[IC*PB.R>X[*-"\87?5LF)J=0U BC>TG&5RAB,]62
M.2AN<=0PM!9*?5I)&Y7.QZ?#U6EX=IPVG.VZO6C2Q1:&'L8QMLNSY=MERL>K
MV#W;+B7ICY%S<Y6,\S:[AV051R[W2']2MF/[I5.XYN</ZEIGR_BR]+W_ +%C
M_6/Z)GHD&+5)Y!/]+PSP/&/\X_HCT3#%J?Y!6/(W)3'\BNB8_D56O\<HMG%*
M3NDC!+CA!:<HP5Q[NRCR$YV79S3I7(-.O= YC,MW"'1M *"2$@R0@C2M:.:Y
M%D;SL"N\A ?@E.C<S.V%9!P%(WH$QU,X>2L.TP-FKF^0EI[B8135M(9,Z% B
MM\[7Y/)7H!WQNF$OS["8J+#"YH&5RJ7OC&RLX6YQJ"ZS4\9;WL*"FI9G./>R
MN-QK'P-[BN(Z-N>ZN-71,([^/D@HZ2[OD."=U;>OF-F25!CM@;.7-Y'X*94T
M)?"0WP0<FWQI?IU*;%<0X9SLLP;5*)B<NQE7$5*8Z7#CNF&K(7*/."5)CJ6/
M&Q6+F;+VW=+N:M:,RQQ9)<F&M$'@]4X;]5FG5L@=@94J&L?IWRIAJ]VQA-$3
M#[0"HWW(M=S76"Y:M@F&K0P,)Y(-.S')<(ZS;<(-P8.>%%#Z5K]@%TAI=!&R
M1E:Q_+&5V9+J*A'9@TA*3E-!)2 K+4),/[/)^E8JV;\0#S_JMG4NQ32?I*Q-
MH?GB%OG_ %6O]9Z>DW$$4$?DLRR7$N"5J;D/[OC\ECZ@Z'DKT\?CDESR8;@'
MF%@?2),#;"P'?*W)!?#GP"\YXV)E<^//+=8\C<>-5D67R>)*FVISJ2%SCMD)
M:J'->&="5.N<0@M[<#?"X1W0;=)'/<6R3XP$O';(9*./L2%F#ZS*]PI]><_E
M*95TMS,0[9LND;Y*U_B(%-F-W>4NG+1)D=5'8,QG5L<I87$.VZ+*Q>TYQ-MR
M5Q1O&ZHZ%VK<\U9T4@#\9ZJ^3G^NIX^LZ7=. 7$E,JBT D=%UIG,P=U6W2<-
MB< 5R\4^O3Y._P"K1>CJB]=O;SC(:05]!NA:VD;'CH%XYZ%Z<&I?*1G+0O:*
MCV-0Y +Z,F<OG7K>GC?I0IC%54N![3OZK&\24(-L+B.G]%Z1Q]%Z[5TK6C.E
MW]5F^+[<^.T'#3R_HN%=<^/#NRQ.\#Q76#+9M^2YU#'QUD@.>:ZP]^1<:WQ%
M_;-L.)Y+></YF#,=-UY]32:6!H\%Z;P;#BBCD(YA:Y;[_&VM$[BYL1/-;2VL
M+8\_!8FULQ<X6]%OHR(X?V7HY_'CZ_76*ITR:<J_I7=K!@]0L8R754<UK+9(
M&QC*N,O(O2K2F&LDD:-LKS(SG)'5>]^E2C;+:GS!HZ[X7SVY^*ES<<BIBZ?*
M\D+@7+NZ4!Q& H\D@WP%*H#DUSPN;IAX*/)4)$=0_O$(>XX4#UAP>=ET;,YV
MVE;D93*>8AWP4DU1Z%5K7.')J5SSC?9:D<^EFRJ)(&5Z?Z,R73L\PO'X).^%
MZ]Z+OM6?LL>3\;XCUOB&)LEO /NC_98T4$>EIPMK>MZ 8]U9D#N-7CLUZ>?D
M1!2-#P,+J*9HY!2='U@2AIR5SZ\>QOWQ&-."-U'DM[7G<*RTGHC05.?"G\FJ
MIEK8'9PG/MK",85GI(2AA*Z3QXFJ=MJCSR2?14>KDK?3I2:2>2>B8K/HR,=
MF&VQ^"LRPHT%8G!*JQ;V#HE]09[0"L3&2,(#=#!E;G.-:2EIQV;@ L[QG?F6
MFWZ0X!XRM1#((VG*\']+EU=+<I:=CCAK^659\9UG[KQ35U[W@O[N50R/+G$R
M'*Y$ZARP4#;F<IC>8;*ULHP%QE&EN/!=W$'X+B07''-,3VQQB&7;J:QHPN+(
MB-UV:#A7\631(P-9J"W'HNF,52&CF7K$2Y$6ZT_H^F[*[P9]DN73B:Q98^@7
M1LJ:4-GY87FG&=GCCK-5+C3CQ5WQ-Q.RFI^SB<-7+8K!"MJ*^0F1[\D^*Z_P
MRI_+8]0X,M,<-+%(=.L@$[K>T[9(V@M(RO"([U56<P%[GZ"=LE>D<*<4PUSV
M"25H! ZK4\<Y7^3V:'BJ416R1Q.^G=?,O$\_;71YSG<_[KWOC2H:VW3%DNMI
M"^>+H[55.<3U_JN?<^GZ8<-:,=0G128&<KF_!:U-)TM7&\M2.53&9"=ERC9H
MYJ<P@M46H/>V5G*X4;G9<2,.7>$9;E,<WO*7XIU(XBH:O?O11N^+S7@%./[0
MWS7O_HG]N);C->^1_9CR3*?VI?U?T3X_LQY)E/[4OZD8=D(0@34C ^"8^5K-
MG'"8Z5HWRK(SKJ6AP(=R6,XSX?97PN[)HR5<U-\BAD<QSF^"XLK341DMPX*S
MAJ6_X\CFMSZ4F-V,-595%T(.DK8<3,=%,Y[FX!*S%:&R4SBWFL>7G([\=UE:
MV<N>=1SA4]PJVM:1NN]PD+9W#XJJK(3*-EY)/KT\]NE.:FIF:(78!*U%M]=I
MQID?EN,8538',IIF:\<QS6T@DCJWD-Q^P6\2]5,X.=VMSB;@[E>[VP:*2,=<
M+RS@>UL;71S'D"O5VZ"T!KN2[<3X\GDOUV /5<)G @\]E(4>HQI("Z1RIM*-
MU*46CYE2DI A"%%"9-D1G">FR^P42_C,RR&.J<X@\U:4E4U[@.1^*JJJI:*I
MS78&Z20/<=4&7*ZY[C3ZV]?Y)'$ .)( PJ:GN!A $_=55Q-?6LIW"!P)P5SZ
MZDCISUK%^DZMC-1I&_DHO!ESCIXF;X*SUT?)7U+G2YV*KI8YXMH <#XKS?R?
M6Y7M,G%5-%#WRXNQM@JC-XDN,Y$1<&9SR7GE).]\C6SN(&PYKT3ACU9K 6NR
M<=5VXQ-JVIXNS9E^Y4N%S"=@4M4YK6$GDJT7&*)QRX;%:MD2;5[ [?=9_BAP
M=&1CHNQOD#![84"NK8ZMIP[HN'74>KQRO'^+*?,LA QS7G-RB+7.7KW%E/\
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MGN!?N'[!7T[PUQPND^!'@'O.QJ5#<86%SCU*EU=669 5543.D!.5K6;&6OM
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MBF:WO:D%'5-D9"=/M*H;-*U[NUU$=-EM&0L<[?DN-320DC 'R2D9BGJ7F7#
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MAY+8\/L;VF"1G"S%54QTS&ND.-LJ';;_ "^OAM&=62 <^"D:LKW3A^KCI7B
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M&A0Y:D=[?R4=SNU)YY7>FHM9)FR&]$"4,DCB7').=E:/9B+5S)YA<Z:/L3N
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MHW/)2FECQD^TK#A^E;65K&.&6YPN?DY=?%UB@LEIDJ*ENMA[I!7J=%3M@A:
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M\OX])X@M#;UPZ*=PZKS.X>BYSB3%)I7LL#NSH 1R7$2.?G*Z\O$^>[AZ.ZR
MG0Y[E05W"UPIP?J9"OJ,B,^VT']E&EH::<',;?DMXO\ CY*EMM; XZZ60CXA
M17P2 G7$6>:^L*GAB@F![2)N#_E"I*[T=6FJ!^K_ )!3&8^:XP^/=KU(BN-9
M$?JY'#'4+VJO]%5,,FF8<^2S]?Z,;@&D4T8/[)(K 0<17.([53Q^ZNJ#CJOI
M_M9WO'Q3Z[T?W:#)?$=O *BJ>'JJFSVD;O\ 25H;>E]*!9@/I]1\?^%7E#Z4
M(G'OP ?->-34TL>?JWY\EP/:CHX*5'T;1<?T-1@.<QBLV7Z@J6Y%7&%\N.?.
MS=KG;?%=8;O5P?\ 4=CS*@^HXKA3G[.J8[]U)95D^SW@OF"'B^M@.8I#G]2M
MZ'TF7>$X,FWQ*#Z/94>+$Z5S0,Y7A]%Z4IR!V\@^:N:7TFT;R!*\YZ]Y!ZM3
MS_!%4P2-/UFE8RV\?6F8 &3?S"MFWN@K!F*4;_YD%S3-#1@NR/%=9W:6]UN5
M7TDT3F@"1O\ J4F:30W+7-/[H"!^MW>9U4B41M&-(4&"=[W8&%*D>UHQ)S0<
MF!A=LT<UV=&-"XQ/C+ME)<X%FR" Z$AV6NW4F%CR.^[ 7( ]ID$8"FQYE  P
M@BU!D80&'(71CB& N.Y1+F-V.:Z-B)8">J!&2)KIAE/$(PH[XAJ2D2FO#F8"
M0)(X]+ <)0HIP2I E/)9:_QC_2/)HM8&>8*RGHMWK1^K^JOO2K)HML0!YJ@]
M%1S6-_5_5*G+W>3:CC5-/&'ZBKB?:BC\E5-//"Z\,=,I?PZ*)^!T7FM3.9:X
ML<< $+V"^P-?;ZAQ&[6E>(7WM:>=LL8."X#*UTG+=5,;8K%*_KI69X>LS*ZM
M[8C.2"M'6.,G#^GJZ,+MP12&-@)'1,.ZU-'2-B@:T#HH5ZB IB,<PKB$9'DJ
MV\#4PCP4L.*\,XWI=-4_ \5Y^^'2Z3 7J_&\&J5YPO/V4O:&;;DN'4>N7XS>
M#@MZ+M ?RI]0P1RD+G$#KRNGA_\ O'+RW^M6E*T,&RF4PQ.U0Z<9"FPGZ]B^
M]U<\;XO$WM]#<# _05)CW5L X,9DK)<!D&Q4GZ5H:V8AI:U?-M]M>ZSUQ1<3
MU;I8RQI^"PM9;^TB>YW-;6JA=(22,CXJJN,79TSM@O/F1VEVO%>(X\5\8'0J
M/, V12+ZXONOP#E"K7_7Z<KS=1Z>;\!&JLASR7KW#1T6J,,.,@A>1<IXCX+U
M/A>;^[H0?%=?'&.ZU]@H]R]W//5::F8=8 Y*HMC@UK0.JTE!&, E>BN"PIF:
M&97</V*XZML)6?%99KO$6D[A1;E;8J^CE8X Y"E,# 5)I]."$88FGX$I! "8
MVY4F/@NC&/JVK8N(#<!*-*)C*Q\(43?^FWY+LWA6B'_2:M*-*,M0Q0LX:I0-
MF!=X[!3-_P"F%<@^",X0Q6,M%.T>P%U9;J=O_3"FZAXA)K!=S"&1#JJ*$0.+
M8P"O.Z %O%4S6[#(_P!RO2JR1K:=^X7FM%D\53%OB/ZKEVZ\-AQ&T1T +W<V
M_P!%C#)&&@Y"N?2%6R4]LS_D_HO(V7Z5VVKE\5Y^GHYCT82QN9N0AKV>(7GK
M+]*W;4NS+[)[RY?ZW(WP?'XA*',\0L&+[)[R<+[+[RJXWC3&>9",1YYA847R
M3WOYI[;W+GVOYJ4QN0UGB$QS(\[D86.;>Y/'^:4WQX&2Y1,;.$LC.<!2/7&N
M&D!>?3<6QQ-TN=OYJ/%QC&TY+OYK4K+T2HK&P0OD=C &5X+Z1KL*ZZRZ#W3A
M:2]<9]O3OC8[VAC8KS6KUU=2YVY)73E%?(  7@;A<VSA[<%NZFO@,32V4$9Y
M*N=H;([')=)!UC.2GYP>:CPNSE="=UG!*8>ZH<KL2*3$=E%J-GY3!*BW8G]"
MN,![BZH$;N<+3<.'36PGP(6::-QYK8\*T9E<'@<BM<?K-K9<0PZK5#(!N2LF
M(\@^:W]93=K:(V$>R,K!ND[.8LQU7KG7SZY>OU=6TDL:T\EK[ UO;!I Y+/6
MNGU0L> KN@>8*D$KR>;N3_7H\?CU5<6@MK(](VRL7Q1(7QN8Y;_B)AFEC<T+
M"\8TKV1.D(7B_DVNEYSXP<C 'G3XJ+(7=ICH%-<W!)*B/D!D(7IXNN=BRML1
MD3[@U].,@%=;'(&N /BK.ZTXFBR NA%'25N0 ]=Y'MD&RIJECH7''BGTU0=M
M10JVHV8G;YKWOT5XUQ>:\%M\@=*U>[^BX_70^:,5[W'[ 3(/:E_4GQ^P$R#V
MI?-6(ZK,\6ACM&7;@+3=2LCQA&0YA'Q73C]9K,&, GXKC#&ZEJ6M(RUVY*[T
M[M6SE)KQ_8W2=6C9>SF;'.LKZ3*1LUMIWM.[3E5?!>9Z4X&X.,+07YK:NR#)
MR6M)66X"JNRK=!]G4>GQ6;(BRNU#V4A?)L#T*;3VR.>G,L;0#XA7W&M*^:D8
M^ 9V6?MU:^ALSNVR#GP6O)Y)S/C'AXMZ^HU34L@:Z,C<;*##7MC)<0"517BX
M.=*YX.Q.53"MG=(7:NXOF>7R7I]GQ<21K_7QK<>A*X2U987.!R#T5'#4AX._
M>7;$CF ZAA>;'7VS\-?<98WDC.%:4O$U7'&UHE>1X*DGA<[("CAKX<*2V7XZ
M3UL^MFR\U$T?:%SFE/BN=0\[RN>1R&5F*:>>7N-Y>2UMEM3Q/ Z4;$KT<==O
M+Y9S&GX9FKJL-B>Q[&;=Y>@^L^KTS8<ZBX8)4:ABAI;8TM&' #=5YJ-<CG$Y
MQR7MXFSZ\'DO_C7VQH%.T.<O/O2G,_MF,!+00=EJ+15S32AH]E4WI,HG2NBE
M V:W<KEY.4\3#V27ZD1B/)(QE47%U/)13X#R0X96JL;&-&<<@J#C8/J:]NGV
M=..2\'?+Z_BZ^,C35DSLMUN('(96FX;9+62ALC"UAZKA:;+VCVG3X+1UL,UN
MH<TP(</@L26+Y.H]!X8IJ.@9K>YH=S5A?;G3S4Q;%("<87BM7<[N[0&N(&/
MKO8YKG-<&LE)+#CHN_'5>#RWVK5FTOK'/.XR5 ?PK(R9[LDY6_H:4QTL9/,C
M=3!!F,$C==N>7#'DU-PU/#<F2:C@%>F6]Y@HV1N.X4IM(R1V<;A=C1M( '1;
M]9$BHO,1EHGANZ\LN]BK99GEL3B,E>UB %N@A+ZGJ:!MA<NO'K7->#VCAVL9
M7"1T3ODO1:2WS-@&IAV"VC;;H;J&,J-)VH.D$+G_  <_^.T\O7^5Y7Q!;*U]
M62R)Q;E4G$5DK)J8-[-VX7K]8^5F03LHS&.JW=_<!9].>?QOC>OUYUP+PAV
M;+.P$D=5KKS:HF4Q<V-H('@K[NTX#6X&%&N,@EIG9\$G=:ZGQFN#!BX2,(P
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MM:,D@]$$.IN,\;SV<9<%)I*PU4+FG+7@<E#959 QL!SRF6[4^OD+ 0"I3_\
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MMF:**L?I>3UY[+2UD1,9'0\PL!?;>ZBJO7*,:2WP6^7#J-S42U#GED;28P<
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MJ8HX@USL#Q5M35D(@<UK\Y6%I*C6WO. \U<6F9KR1K!W6;XT]OJU$<<<D\S
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M*F#Z!8[X@IQ=LO*K-QZ9#B?N^:V5OXJH)\ S-#DP7Y<<[)V[O:7&&N@F +'
MKJ[+O94L"&%I3.Q9OD+I&WQ)3G8:1E9$*6DA<-F#]PH4UH@F:0^-I!^"NS@<
M@C.?RJZ,17\%6VJ),D0W^"H:ST=VUP/J\1#OB%ZD]C>NR:YC -FA6&X\(N?H
M[K&9-.!I\EEZWA"O@<>T9G_XKZ:<QKL@M&%!J+?!*3JB:?V5-?*=99GL<YKH
MW9'^55WT=H.['?)?4-9PS1SEV88QGX*@K>!J5Q);I!_=1J/!:>(M.S'?):"Q
M&0U#62-/9?$+TMG!L43MH@X)M18"R33'3@8Z@+GU^-R:I+S96S/HVT+>\\;J
M?0<,5=+I?4-RT;\E=V[%/50F9N=!ZK;4E72UKS&0W..6%F='HKN&Z^G<!$X:
M2W;?9:@!K#J:.:R/$=N]1::RG.AK-SA6G"5[BN5(V,N!>!DK4Z8O*^BA<YW:
M.Y!! U'">&N[-V20$\M^K&!^ZZS\9S'#"3&%U 1I*@XC8I1E/+4FDH%:Y=(S
MNN24.P4(61^(Y?)8.F=_ZH8?C_5;B<_4R$]0L-2@'B)A^/\ 52_A_J?Z6"76
M> MSL%X3!*USSYKZ,X\I&5%B:'<].R^<J^G-%(_5W=RO'Y9KZ/\ S7$PG8$)
MT<V.955'5['?8)PJ6N. 5YI\>[J[%OVH\>:<R7XJG]9^*Z1U&_-:35TR7;FG
M]L?%5;)ACFNC)@=LK-VL6IW;'Q*42GQ45CP5T&_)3UI+$F"4M?E6+;A@  JF
MP[H%UB9MWSA;FK[R_%Y'7ES<!R:9GN)RY4AE+'=PDI_K+\\EK6<E6CPYP*JZ
MN!Y*[LJR!WDDE6UVP6+:8I:@3,(T$I6RSXP2ILL@YEHPN3)&2/P,*\6KN0D&
MMIRXJWIY'21X400ZRT-ZK36RQ2/I@_!W7IXCAUY,9@TWKD<K:C<9P%#H+%ZK
M5B6)O=<0%N9K!(\:0W3XX2PVN>$-C$>L-/-=^>7E[\BQHF=E;B!MLJJ?=Y\U
M>SL,-(6D8V5')N?W7;GX\O5]C&I7[(PARUKGAJ$J,*:N&I$J,)JX1"$833 A
M" FF (/) 0>2:F!WLJTX''][N_YXJK?["M>" 1=BX\CC^JS:WR];?]U'DJT'
MO%3JEXCI&E^PTJHCJ8WO(:X%<ZTE=4AY%)G;/1+S"@B5/(JKJ3N<*VJ!L565
M#-RI1 <\MW7%TQ<=)4A[5%E;B0$<EEJ,'Z6,NM;0T9(RO A.]CGD$AP=U7TK
MQA1LJZ*0.Z X7SU>[<:>KD')NH[JPOXE4C164^)"-6%'CMT]//J:X!JK8NUA
M>"Q[L*SCJII&AN"5TLB<=V+6.LEA:TEP[O@IEK?+<Z[F0SP)4"AM53.X.<TZ
M2KZVVZ6FJR]K2&X7+J1WG=KTZQ&&@MY[/[3 W5JRL?5T0[0[ =%C+/53&&1C
MVG"TUO>6T_>&V%G(Q;5+5_;%,;L<IU=O.2-PFY!  YKG'6O._2+2%TYF:-@.
M:P48R['5>S<6T;9[5(< R>'[+Q\QEE5(P\VE=>7"NY(;'A%!&9)OW7*8GD%:
MV:')!73F(U5A@Q@86]ML>E@V65L<7L[+:4;,, 6X.NZI.+8M=O>M 6E5G$$1
MDM[]MUUY9KR>I;IV4=NSE/N$1,I#1G!W4.0#HNDC%JKJP=141L9/1659&YH!
M(YKC1C7)H RY<>Y]:Y5<K2'<DL8R2K6JIL'ENJXM+7D'HN%CI#VL=S"XS,?G
M<KH'$#JN;]3DD6P4<HIY0]W):_A.!U;=Z:1@V#PL4YGB5LN%+U!:]#G%N6G*
MU&=SX]CXLD,-N;'D; ?[*?Z,W-]:;GF2O*+SQN+C*(P01L%ZEZ*G=I)$X[95
M8>\L'='DBGYR?J_HEC&6 _!)3^U+^K^B$.([^5D..\:H2>@*V2Q''L$TI9H!
M.Q6N/TJEMDKGM+&'?"A5%#,V4LD.SD6-D]+-F1FV.JG7ZM<\A[&#NA>C6,9.
MJ@-+4N\,J4PNE E9LX;+C4RFI=@CO$J9;Z:6.0,+<@^*U+!;V83L>UQZK5/E
M?/3EA.^%74T;HX6DL  ":+I!3S8>X!>>?J5YOQ/8)WUSI&L)R[.P59##44LA
M'9R;?Y5[-!64E5G#8W'XA%8RF9#J]7BR3[H7>=,/)'R3U3"V1KAC;<*EJ)V4
M<KF.('3=>TOLU+6/8US6QZ_="\N],'"#+33MJJ21[G.?C"G73KPIV541<,[Y
M5W9H(ZB9AQU'->4PW6OB!:V'./%7-LXGNU.X%E+RQ_SDL6[#?KZAX2@BAIFY
M(SYK1.BA?[6"OF:V^D:^1$-]6V\UI*7TCW,@=O"&_NN5C;W!])%CNX^:X"-S
M3AJ\RMWI J)" ]H'[K;V.^FL:"X-6<%V8&S1ELHR"LGQ#PE'4Q2"D8&O=U6T
MUM<S)V4"NNL%-3O>YS=3>05]_5)SKPVOMU?9*ES9'#2#C92Z"O8QP=N7^*MK
M_=?I:IE9H;H&X<J"FCCIVEX.H ]5SO\ T8[\>'5S/=WB/+2<A6O#7&$-*0VJ
MR?FL>Z1LCB<[%<:B".?(:_2[X+CU_P!&N\\"3Z0KY6U<K9+9*&L&Y"P#N)+]
M"[ >_'Z2KRH;54LPTQF1O^;=7-LJ8)VXJ:>)I_2ISY&._!]9.GXHOY]F5S3\
M05=V^_\ $4N-=2,>2MZJGI6=Z-D>/)0)*Z)@(:UH(\%+Y6N? TMGO%T:6FJJ
M&D#_ )XJ;4\2O8YX$G>6"%SD>2#D#/0KB:H:G$O)S\5S_EUVOA>A\/U<M=("
MYXQE7TIPTCGA8W@EXE@U!Q]KHM5VGM G*S>M<_X_5P[?1)A$KM>X4.I)[0D)
MT4N=ESM:D.<W4['Q5M2,^JP%!CCR-2L;;WY0.B<Q;5M::3+LD*7>X@VA>T>"
METT8AAS@94.YR:Z5^5Z)'&UB.':5PNU0[&Q6#]+C,\2;_P"&%[!P["SUB5V!
MDKR?TQC_ -1$CW%ZN/QYNOU@Z2,-F!'BMU:Y VF:3T7GE/,&5 #SC=>B6&&&
M>B;WUJIR?=;PUM(^/<Y"P-9B24O:T[KTEW#T%2'9>4D7"%&X8=(1CX*3\3I@
M*-A WRIVGN\EN&<)T+/^J?DNG\+T1&TI^2:SZO/G G(;S4.I'=.K"])?PG1D
M;2GY*MK^$*1L3G=L[..6%FUJ3'D=S8-9PJLN8#WANM%Q10MI)7"-Q<LUH+LE
MW135!.Z7.RXN9@\R@ 8W*J+"US%E; <\GM7T3P_6LJ*&)P/)H"^:H<,<' [@
MY7L7HRN#JB@TN.^?%1J/1^S:[O*+<>]3OQR *>US@"$RH:[U1^1XJ:Z1\[<0
M[7BIU#\RJVN#9"KWC&,17.4CJY430#NKKGC:^CPAUUA(Z/"]\803E>"^BMH?
M< 3R:\+W5[\$XY(LB-62'5LL?QE6F"A?D^T"%J*F3F3T7F/I(N'U(8TC()"*
M\VF?KE>3[RYY"Y.<<GXI-16Y)CE=UU*:4W)1E62'THPE_9-RG!,@?$ 24]K
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M*:3LC>.4@RH[ANI+]\K@Y0<B,J3P[$[Z0:0.JBNYYZ+2<(PL?5-)\4CS>?\
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MJF]TAG@PT8(.<JX)ZM3*H/DIRW2.2S?K?$ZC+P2>M4<M/@[;+I8NS;*ZD>
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M.7&U6Q6[;?\ V3C;\!7L<7P3G1!=9RGLS3X!'W=/)<NR.=ME>U,+=R1NJQ^
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MSTDEW.)J3_\ L0RDM,3<+%OM,>.Y&[Y)T5F/Y6'/DI?K4Y;7^(HZO<M:$-J
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MD,A04J?73>[7UL<?9 I$R/4>.6I&2#]T8<(&^"9@9U>N^$.,A_</1=9?C2Y
MZZL*F*=;2AJ>V-J5>\GL[QIHW9.:$NH#?Q#NI6XUK*3=,[!'N-=2U:#MI2=E
MK<M?R>^*E.NY7\__T$.Q0N[ CIO506R4BJ-_&3R@DV&BRJ\2D4; G>?_(JU5
M-^!R[B2$J?^6_.R'&$JU#N[A#'[?/+'E,-,X8!/%@^_];:8 1JQWYP56#IK+
MM?7M4@UU8<N[^^;SG JZI:@PTCP,.)],=NKM=!I>RNBE>3 ].Y?SU.2]Y2JK
M==8^696#:/DG/[Y"LR:SE^W<GR%2VF\\; KT'.P2I%MJJ[7*:N?R\NG8-856
M=_L3\HWP#8J*-H^.1995T&5DX716]A4.S@%AZ#PVSWH.7G3Y0K8_[KFHHG?V
MABU?+D0:2R//0=5)&A6GTG]7594%9&L9X%)QK6-IGLL_A@]*L!$JS+ZCBW\2
M8U$83[.42M!66;$;J7*3B<8G>@HN. FN;^RH]4CX4N<)<WM==?7N>D':$VR[
M!94@2<YF[Y#BDE;[<JDN[.W@1^$-/,N4Q;"DF['\"*2(JXL\R S#TLT6_>SK
M5#;.?%7E:F;_TF&U25Q;TVOO"(B6K;Q1B$&3TWB&5&JAM-M5>I,"F[)XMB2>
MA$(438Z=<F6JOHZMFBYI.75;7;2\D],LWG\;7]M8W[TB1^-E.#'QR9QTMN'Y
M0S^HD]\M$PND^4GF436P2%"#7Y$F?#)Y+LIA#4LO#JN:MQ]XL-A!BV[=AHPI
M()IGOC+H*XT+2,NH5[9SD:_W0+.;;,Y!XNU4Y/1AR[."VVJ#O?&)&NV?\3M1
MYG*&// E"+P>3F876#V2FLDJ_GJ/I?ZZDY\3L^F*@4J/E_Y;2(SI-VZ_C'DA
MAB&YRG)F]DL/1GJCQ:H=>S_:<6Z,BS7XD;0H#_NKZF;['$1G#>C8B0NG)/7B
MCT4&&N_-[302*F*2(IUSAB)GY9-GJ)EQ"6IF:#B)FJ=[)[2M((7*PF"JNY%V
MUDJ^73V[YYGNKZ\,M%4_!0D$ :S.$VWZ(5UT_:1*EJ2;E/ZUARQ#OA"8NR,O
M19@53^E:V8>%A,QKSZ3GL8J@JH@O3".)B&7E[T-+4N)UHP/4_5DYY'>^!/J(
MT+Q8"#&J^]S32!;]R B1:.EC*>/\!;*C7=Z*;W]QZG _LG5V\8HL/+SL=MQ]
M76>4%\U-.RS.?(7]0"AWS6PEQQ^]#N9OS=<*CGZ?:Z)N62$RUY^UB!N"OENK
M<H)G'L2NZ&$^B,5_U1J]'6,>6EQ5L6AL:_>TY#5CJVK*'&?IX/O!GZMN1B<A
MXA?]$S3B8CG=3^7XT!5/6R>:UB_#)1LISD%XV<I^EQJ)8.H"UQ3ZWN**>)+=
M0Z10.^*]ZB2LH-UY)$NY\_"J_6A]F*')2ZDNXY,K*_$GAD^:G!R"=9 #09PH
MVOH2<#L8ZK*HJQJD*@C=^N0Z(V.F!-[7D&5EC2GO>QS?!J/M88V8XN!=:T_Z
MZBH+F8@8L;&Q/\#.>J3YM#4="-N\=/8\?C=#]>?:?F$U-H9)(%GR U.AC_MT
M.L^M.@CYM9F(IOM@]4HTETC#0304K!@<HJSE^HLR0E]V6K J)<^;2@(?CF^F
M\QZ(5/Z6DJ AETHAE_,*<==*>KGF87PC@V$XZ^SO7@N$;[+?BF_#5QEJ]%*D
MATG./$UB&6_>$LZ[4J.]1HZ2Y;UN^<'VNZ&X&C8J5YYN,"4MUY2AOR#OZ]([
M78EGU 9Q)M-Z[D6>?FK+1J?"(K>YA'D9NJ%XW",# U:WT;:33X&5DQ N\CPK
M#5M.<CYIB6WW[4<S5SM]IU8RP%V-O%@UJL;+Z[W%=[@WBKLF2GF+//E)E+*3
MXW\:/U=[,MA'>\^MLT-S#*MB\3K6V,_(2.J4IQ+^"\9O=^$5/[LK_YYYD.^W
M].>99(NJ/N2/Q_ M(="3C)"47AAWNV:"JY$0-1TA>B+;/,SNNIK%EC=+NX;0
M=P)BHWLS-?MI;I7?F#ZB=]#0,1\#L]],?=$7B)Z]V$)XU92Y&9^7R^W -%=_
MY?=-P>X8N%O7MK'Y97419K)O/BXEVG13/W)^F$)N0393$RUSFOS9HK8T?1RE
M_=9Y)34ADYE>4YAG1U$CLU6OBR,V-W)$4X73TQJ6L9"%V<2X-:1*;G\HU%].
M0%Z"TUN DN)6A+9GH^2UXM0;Q5^-)3^X-O6EC7.". ?'MM:%"#QW.8XN+)T(
M:I[1(+]3&QQS730YT,X\@9R#AJ\@*?7/05& ?#S_X@./2A&Q*=6S\.2M#/Z#
MR^>@/&']2\#U'%4&ZT@Z)9$]4$FJ$/N;:X=$ 8^33H#+@95 +O2<A;]54TH_
MNUS FO^'YX-9 /R\=53*.&,LXMCA/@<I G?TVP?_8_X=V>EP=.$NUA#SQ]H1
ML+Y2*+?PQSH]Z@R%7*4VCB=3@7M4,I^#"H  ];#U/V6<00<QBT[U*#JSLCCA
M^([%WE8-_RV"!3^AWC*)[!TSH2[ R=^T>K&I50<GNC5KP8MXDZ:K[Q$\X7#@
MQI&$X^B"'F!2\0X#S =,U6K!$XA9<=+8P+RD)UKNU"-)O<-(#3S-KJ#?$"<Z
M17X-N@%!)2[/*TE[$ (Z.7"(VZL&Z3MQFZ:8Q1?>_8><'K,VR6>:<-29=/"$
M[=::KK0GFAR1DHSIH0_Z= ZBK8.=\OC3*BY^ 6&>//1Y&<!?^#3H[868+TP2
M=R!W;%(C/&L;\C^N#WI4_ZK!JL33,(7JK6Q/%;DDCM+=RMIA/?MN$7G=D2>9
M3G\/OJ_<7C"D$(F9$R2/M!FHLHB=%I^C#)8*SH<&;FZ=M*^UJ\-BO^T_V@8$
M=7/@G],;J%ZYG0=V'.DG*3N,Z.^'HLI$7FZ:_/ +N?U5P;;1] <.0V^^K3X"
M.(D#[:MP=N0.X](V1ZH""C,G-"PK=9S/]I*H? Y:56_#)N7S[>O@@BCLAWQX
M?F9MH#I7SD'* QN,>%NB]C$0![_MD \?O<)?,H!R7M$^\#S"H5<U@6"H+']_
MR2O>IU*(>A&FW$9=Y]!\Q0](IPD(0Z9M-(T82QM]+< E)FGYN]/ZY1R,)Y14
MM#E,<_B8+_B?,#97*4/QVUIG'.EGRFTL@)/+Q )$#;Z/M8,EGZ3IT/:/Q!+:
M./X(&@'! #+F&Q"QM ?^J/XDL]#/95]9&PC(8"SP_5;_:=>VXF+L,6# _>?#
M@# H2>H,@FP*4W^/W=RGQP4]!C+E!KPQC 7F+3K0]X9IW*>G:9;IW\&D[B@,
MH%<5$PK2E&NI9GS;*HI\W%F8J-H_,GSVF#MYCJ+Q4@+]AD/X/;I7FL/48=%#
M0"+!A0'<:EM@* S; R07%:T*\)"% 60(]W XA!1K>6:P;3[7.0!+!]ZX0>PI
M"U<6 L@Z5QYWUBSYN1\9T)-A ^O.0>-!,C8Z]QS=(RU_1W0,,[3 3G4#V'-H
M_)!GY2,[2:#D>H=I'0//%;$M6Q?Y">11U1*JEVUX,W7^.SOE@..6P:CH6\N9
MKBNWD[T\%LOD6!NY8D/Q]26%\N54TFXZ%+RL,OQ1[9K>X?%"W^F=NI!TN 5"
M22P/,%%F(9PD6\0G.<>!DPY%2"H["[+YV[N>C]<,)MC'H\^N!K+C#OG.0=2P
MSB^\K20@NB:B+OV!U?Q:N]K95<^3JD/A/8I(+>Y.Z%X%_589_[0_L)2=1,>S
M]&0(=LK8MU9F7?R $Q$OCQJBU-TG,>):&.4:P^<W%-&WH _#U M0X2= L\ 2
M =RDG6+O"=4P5N&DWC!U>LKZW.F3S#R$>W/FW1"&L3.-WR-8+0YB%46W7H+W
MZ(],\KZ[1VK1;L%AJ:T''E'JW4GG(".$P^(O=0%I;B1YU:C<Y0BT1F:+>=$3
MB*:QW^+]VXA=5^F'J-%NM!7$AI9)I]E 7J-D3@@!3)NJ_1=?9NM3C?(Y@=T[
M.5Y"3M?MY9,3NV$^W'I/=V]47T@;>YWT3<A]JF<#Y2=VG'^1>_4(XU-X=*?P
M3+^1C;AFP/PI11_=*NDH6.U+\JF<!#:&.']_N4!T"F[(CR85W @=;0PE:O;!
M?(0XL7&NB@JX1^3M>6'Z#7/Q8:NJ@(%0DYA"OMZ"W@])A>]F;H >=TW2'-4Q
M-Z/ :U7E',$;(533?C?W]:;JYDP^O^@.*M*)T&9\JT#N$@PY'09B]7ULVRVG
M/W; =*UAB!>N:J"MT^D6+'#Z(8;/9AIBVOCY9H/<F$=!O_:U,,TB&+4ZQS=_
M7)#L@Y%#90^;T/$DXQ7?Y<'%,A)Y+-(V8;'Q&(,+T@%BXKGTAL.6OVS3PI\M
MYL%<<E<M6H#?&62C;3S6Q7R2S\UE^47-^%Z;L83>>'"1:-FXS;20P[_0R]!Z
M@/=Q<Y@=?]GX<<FR\>2?_04 3,RBQ&0#DZ4A\*/N9T8]$;J(&TRC4V;XHY,.
M6]-@9FN;_[$((2MP.IPS$=$+BDI/N=I9^!L[:**GF1:34:85?&W3T>XBY\B8
M[0(CNL@$8UOY)E+L\((%T"[.#T'1.LUZ/YB "H81VU>;- >&GA48;*2'LN@C
M!<V .GD0&W/)*BR^%)9>>'2C8$XH\%^X"N%V*AVJU=LQ4FTV_EW[-Q"!H=;C
M>H YLRY,T&P>@ ?U/\S(.8"YZ%:ZKS&[IW><?X&/ON^2-7ES0;F&GGLI:[;Q
MS#_F5*L?&YX5>B.T=Q_FN'1EU!(1ECA"2C&I,WK\]1\_3E!R#,((C:? ;&36
MN8?KIZS0+9:D[1'_K'6=@[K.-$>#^0+(V@"DK.-[6RUQ]E<R<.,\4T=& ^<V
MS4EF$;%X$K?G3,;V M\L^@-]$]WJ D#0(N7OI!;0)74#.M2P61A/073N!D?J
M#G D_.F/O([#2V"W6P )D@8V!^/]3H3C1"!#HJ_JK:[MX%A"1!<]$3)-;/^!
M3'J'EXE_L+0DYC'&\I_/$]$7KNF[/+!8$AM,0:@W%M(LF[TE=BP, \SX)?-;
M([FC[]W)[UBN\TV_DIG+66F-L-&10D&B[NK3UQ(V]<MZKC?D_FN+XG9O8"BX
MQUZ'L/XWS] Z@4GWI.CVV(]6JAEBM=GBPQ:4GC(R\7@)9348MKCRNJ'@'.E_
M^FK9'EO*^IEP!R^>K80PVR#V"]C::.CDB[&MM->W+/!16T:;.\%DN2ND9QEK
MIR_%?J)RTP/VE-'%K;[S2?F<]10A:::KGW/\<^B0&GMB-&$+:@=9$7.LXVFT
M@=SR'-WS<-CW1UD=G]SY6@AM#^Y]"A8 .EJ%_KG4=PZ*9%G83/58>+\-B%2!
M8#)KW9LQO3;]/>08'^ <(S\')9]DEOG!MS2!P= AR%OH;E#8) 4;AZ31@SYL
M!+5K3M#0R'V^\L1T(SH4/TZ@V_$E;98EO#L'G;I21)R#-/:(A28BA>#&6!*S
M0H)@$G1SI\IAQ)6[6?94Z'.P].EP)A%T?"VNAS*-TL6>"F( 2-1G^(G9J?;\
M60!+!P!EEHK^LL.K9J5A $C]W%_]@+L 2%I/G,@_(QS0<PZ:8)RG.!6,'?$5
M&QPD?K7JG],>+'=_/DZP)D?V5/#1:E4:+5?)J= ,#9R;O(!25HHA@=N6'3JD
MPC@B)T?:>&B2M[7^_ Z?RD3:W(&PU)-#1VWG:_.*9'2JSRZ%*_\[PEY"7?@7
M7;R$X@3H,HH+]/]*)"@N,-G?9 56M (KDT"4+X'_,^KX/[DL7O^QPW_W.<:\
M#I5+J XNL#$)$/C_)E*6?+ B%UCI?/J_ %!+ P04    " "+,8I97VWOG\O9
M  !K+ $ $0   &<Y,34X,SEG.#9A,#$N:G!G[+P'6%--MS\:0! 14'H1E2H=
MI(0.*E5 0!)ZE1(@A"20A"Z""BI(4:I4I00(57H710$%0>G2>U6:- 6!&U!\
M]2W?^<XYW_W?YW\?!I,]LV:M]5NS9LW:>R8^>_?#[@C@I(:JNBJ  %\$" 0
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MY/T5Q/-=;B^<+RP!_J!3[5<)OF>>([3[K;T))=IO[_$#*-)^..P)_@/&5T<
M@'A\G>(>@!% L/MA=QY ?LD6:0VQ5-("$.XN "CW6P!;OSVYW7Z /X"<E)3T
M&"GYL6/D5,?)CE/1G2 G/T''2$-#1T/#2$6^7WY<_KX04!P_3D%)<9*2\B0M
M)24E[=X7)>UW$:I_1\'N<P 5*=[X)T0$[ !"*@(B*H+=0?Q R79?$5S 6TE,
ML%]^N)$(0$!XA)CD*.DQLN,$?^XD ! 2'72>!! <(2 B/$)(?)2$E)B(7 S?
M245TA(U:A/B2KA4-N\M-41+:A\D%BAR<=* 7UF+BJ%MM2D>YPL%+H\LV:"!]
M2N'M<\H1>K8J=:D8"89V_3'(YR+_EQVNXRNJW)%I <51KSHG5K$E]5V3:P9V
M;G>BTTL;NJ?6)=4,[=WOQF24-?9,;U !" GQUA[9M^DH"3%PWP0V$>HC> M<
MV&F(16\^I-VSX 6H;4F,TWH4=2M<"4QG@Q9?YB+9,^#H.6!=.]Z(5 9;%7T)
M#&3LIPG_; 'W'R;L]@'(B?8QJ0 7 &OD,<\J63:;E?PO>=Y9&007"4N1W$FP
MJWDQU&&[Q&@TNGK!L[_VH^-V5&$#O='[J:1+G6P^]\G/%[7E6W%&SU-Q/WX=
M'I?*?\$A(M2"Y7CL,_D'[ENUWIZY;/&)Q>7!#LR/BI<S/NN']7Z@N6"7';M)
M]+B"K>/I4<:UP)-63Z"G9'VYN("#,9TFE[?UMD+;G037W_F<J')\G-_)<C'[
MO>=)\T69>QLNJVX?[LG8:Y^ZVYNUL<U[32QG@[3$>AST>3,+@F0_'O>>_,9"
M(&_^W!JZDB?MTIWFUDKM^5-;.UWL"QDYAKJWW+9"4\0',TI,U;G$ZQ--3HMW
MR#B=&AQ?&/RT_0ZELGV5AJY]5(9ZFH(C+&72A3.R\\2</U/> TWM872PC'SR
M4/>6.T^,JZ^.JNXS-2&,LO?6#<?*< UHC*NQD^B]_D7BUDWPUPQD6U]BZYR?
MG$AD^)%NS03.A4VA4[YM-]P7LZ&<Z0]]C8ZH8&0O<:/C<[P;VWRG?6CO;SYG
MYWL2NK-!N5U36YF7%AX7O_G F23K_F51I5!_1/_K3:%UGF=#><QF?;PN1*J;
M_NI+C[7,U;F !8^3IANTKMA($%6$/L9L4V1LF 2;7RO))8][S?4NZ83=_ XH
M3IUW]_V:7KBQC]I'$FZ=TKX<FT^NP/NGBYPT$T[-;"7U>/6?_NC[*BU#ERL6
MV2T4!59*A(J9(A5ZE!S1-1>,%T*"[28N]<BXO&;L'Q#B"J]KI'B&Z[WT=+[O
MG7$CW#M<OZQ=U^7Z2[6W2P].+(Q^/L8;KD%E;T\TH;9UU3*NJ7#F54'8FBA1
M"Q)F-K?M)UW7[-<+3KR0"MN)TW"Z_&AQ)"8<^[CC*2H''DM7L4$2;6 R+>YW
MI6I&.BM5YH*Z=[]=3Q6TOZ:L9H1ID]Y[%S 7#BX,MVD,"IO5N:TV! *+1[H]
M4XA^=CY^]?:+X9L[O+QQUT:L2<7J\N\F:L,I*Y^N _-]$/ <5P2Q?T%[,Y'Y
MMW1?-ONR)ZNI"QE,6T>43=9G.! -BYM"_=NUZ>&)D5'76:X[><D+V$4;L(P7
MAU]VD7U<A:F:Y3_&J\X9KN&[VU;36=M@:/IJSO.1Z]A89;73?:A-XIPZ'.D*
M1]?L C3[BC[M AAK%-NG33MD? ):!\:FI-M'Y.47!A:QLUL7,@N]&GC*\NUI
M?(#W-^^ *3=>Y,/#%'+G^S]A=P$C0WXRJI<(A>HWCCDPT7W$:^O?+N&B?'L.
M5)1=/KP<D##8[V6I<VH5(](7.'QT<&MG=6T7$&R1:OE^]A&%*/F=9SX9WL#!
MKZ%GW@T8<6!--./7@\WG1<IZ$"F2"S:[@'AW6868#HW6J(=&L$3(*<NJ#N>*
M-*FGQ=+)+V=J5T,VU?6\.8+,AV)V :<5\$-Q$;FPI/,MSO++[-KP5F#@+N"6
M[T0/FZMV>H_!YQ[IZF@IZ<K ]9IG/3SWQ":XSE#UFJ$6UB_@F1>W[GYG;M\%
M-.KD[0(&KNA\H]D%G*O06-9*"C:_+!GCUR,G7F3O/?TUO7_GZ$;;8-MGYL&&
M;Y<I*"_D&+ANOX,J3)2K05PTJV8NZ.^4#J_=L[.9+,T2G5L=!/-1.ON -W5L
M-BJV!':\[:<$E<*=10K%"@<VEV<@>4_[36&<%S\P3]TIZ7]<$MGS;6IMTA7S
MK<D,Q?,F/;L@P5T^IB3:8*JJ8Z"Q9&C']WFV9]1:4IJ$G:MCT2G3E.C>R.-F
M:E]41?I-AC\.Q->57^E.-32O'=?)A]/<#13)7WG\57P7\)L[9.U5:ZKNO:[W
M?G0\H=NBW:T8(8Q<%%CU4(-4X[UAN>^-P#]Y0^Z'-TC$O#_:WMGT)YQF=(@H
M0]>ZAGR;M N-^[AM7B&5LYHT1;BEY/[P):YC&+P+$!U^$D;NS1]J/I3^>#FY
MZZS/E;?U#0B.I.X)Z:1DYYSRXV9O?-OAL/<ABDW-,T^E*SAENY 5!:L?=@'0
M#4F[!F&&TPQLSVD>WGN/$7O0 NS_D$U>E8^9:S@GJ0>TJ9;J[A/UB:.JR F;
M\FG=483>DQ4*?CUL^'3SW=H&?YJK90%F+K.Z,#TAU<I%L/C=3'H9R1:LMP;B
M.Y[1X[MPAGOGV"X@PJSHJ= U=$AD8J'YI@&-_"Y =C74_3,X]+&+RS4?40Z7
M-2, MWE5X(8OA.ID<:MA<D;FGCOR?0]BH_@&WC7!0OE=7E/<VJ\;&B'&0FB+
MS8V%4T9;/E6)9;,BGK,G+R^); C6XLY^R9VM[2G:!<@-/+R7&\[%S[SFN]O^
M\J,$\[."-7YFYK&WGVXQ+U=DK);Z2.R@CHNMES-8CU6?:!&_>:%I?0=5U6FJ
ML@LP%EVN(8+DS4E;I(8\>U20WKB)V6K,""M"KLR\FUDK";U0!.?*#=D%.&4^
MK1JD'&C[VF]9H-&3"GG#%!JQ28XZ3=T!MM$91$[AR#<(B,XR2W.T(3):S+?H
M^;,]\LEZ69_%;*=7],V(;V,S-GR&+ZE\\ B#KB[EPN9A(91;FL?MB\Q:JA*F
MI(=;%C15'"?+%UPP!.41%">/['ST!9[;<5_3%17):WC:Y4'Q])C@$<9= /!2
M;>(23[)7#M"HG\CD<^]Z-0+ZL&Q@N'62J?>=,W+&I<_D$G&)^&G*^=HN39;Q
MFB]KVPD?EBP_WHA 9I''?9"$0Q1B\+E"(U_VQ,E*Z(MR$ND70^E:=M=D5%\4
M?;V0=$M)<WX=>6+5Y:6?,Z<>R?PX;&-G@\=](KZ/>0YGRS1H;N4_6WKL;%QQ
M*R45NXS/9^TGD![FI*%W*5GF-^&E=ZUM*K-R$J.>-=2T#V>0F&[[%QOD,IXA
M6E W]M5ISO<LN)D4[UYIT9'\8#AE?,&MRYA6Z,;]&V=?I72%;SXRZC:8=>:L
MN?GJE3?G+N!VQPR/>$E^[CO$%*F0[2N_\8JJ6DFT_B>!ZZ8;'S[)PO,[G6%\
MKV$LW8G8J!BS'F3_3D3'-KN*EDO"Z-ELZ]E= "%PI]!N*MJ/1$$A"4BH'CN@
MOQR@8G5K(>GS+#FG;;'F/;?0[49O]R<0F['QFM BZKDL9U8B[S-C"^X(V(V@
M8UU'^Q,N7[!O?$_P[?V(<_9%H@!H-.;]BV?QB=>8Z_TD;&9]*(8U5ZXNNK$1
M?5I[5GALP&+I*S/\3'>1(X]BF4*:[UA9^B[ XMVW%=1+4U_0A673C@OY]CN>
M%40%GZ_<L)K:!>QVU'W4(=]L[$S"3R2ZD+(Q$);2+^[MZTHT[_IF,% I[B+!
M@Y$V$O<MEI9%S([O-IPAW[=Y$)\!*"=\IWNR^*R*S!9,C_*E %^F8EY?EU&K
M\FT;Q@_[A7?L*G698*D>;$M>(%&RY.EHIFS&1K%^N\9#Q]@OB>KX>Q>8+XF_
M(!]]R@'Z6&NS>!=@0F49H?G!2(3'2DX^N?U"=L7K8YS8)Q[<@.O4ZEQ\1V_A
M12*CDXYQAD<1O> ,5]=0YWP(BI[N#/MFL#K\L7<7D(0P@J'GU';XO9!K^%O>
M.\ESB4$VY2N^NYT9W;ZV.[US"AD?)+?SMOOQ.0CQ6'>K1D=M5787X-NVS; )
M!'_#KZVXQ1UF(6+\K)>$?3/$WW X?*>J=@%W AL_(;_U^"ZU.?-RK6=_,WQV
MMJ!VQ7P7\%*Y]O7P5WR:&$T9 6G.&W[)]]E1W06TN.\"*&A\'W[G47G!&=.7
MOVRQ=0# ]9.'@3#<TK&VWGOQL^0.K/:+0\S74_B%-?Q-W(SLLD_6+H!NT?=
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M(2.CX6&F9^;Y;Y?]5S(2?B"^_<LK&5\!6 #?7[CXR^L<"'Z\;Q'?JWH20$A
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MOZ1U4PU2_9FU:"RO9F@832G2%<+96<*-D3;T(1 +IOO RL%/N?#)\K?\'O@
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M!X0S0T>OC;H.GBNJ3$B.J461=D)!&*'DX)%9H&P04! TI:W%7"5_9CQ6FE?
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MB<Q03=DYH>4<42TJLF<2 >)-2J;[E:(T3''@[+MLX=1QV+5'UA[BPXFJ_N9
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M684D;L(N)\1XMW-1B\0]C=\X2Q)K<=O@MG,"M9WSZD_<!<5(@D@F=>^>ZIQ
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M+TV<R7C<B'P5SZ-*$FC'ANLB"!1"?P%S-BL(5%H&$#K+Q-)X)1Z-=\O0N\X
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MU7KN]RL[[.L*=Q(LI+1T)AU?UL3ZNWPU85)IR/]P>%>2JCO/E(*"7)7DFW<
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M?*VQ8"((8=O52=)V9AOBNNW[T X.6Z[;42=5QP,E16 O:';L(;.NA7XJ4Y>
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M!40+8*._J JT08ZC\0AD1IW.5U9@(59H)U=61933 <4R-0VF6J\ DA%:P@#
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MPDADP>A[\F:PU%6.C&XH29J=ZV;.*2?A9LZP89OV$?LE<A6 71AXUL="3"%
MV%1W/A*:PGAY^D^J/<,!@/Q1$A%F@'JDIM/TM4V>_U+=!7^'1<-/G\,8\LNI
M/S!GC"+6Q'BT(,\"VZWMI8LY8-*]-:\V^U@973!*0R3"PO=^HL=%.N=WPQZO
MIV0*%?7!]8K<[AUY.[%T2]P+Y,%I$V?'Y2740[7A'EDA6',Q%OEE@V?G:^J
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M8K#6VYV2C]Q,9)S)8?HCCPM&JY%]2C>_<F%LFTF1G5(,S51TZ:J9ZI,],$B
M'V-S8.,BTQ^6M6F>NFRD2V4S[I$L9H&^];H<4+RN)(##6_G>'2%ZT>B-I?'=
M =;HREA1[LB&?&F%YNUA BZ4_6&Z=%2]K<Z=^C1M\[^G#[";:WKMHV+S-\.2
ME=E_L;\P^WC_8=ASQ[&CSVGFEZ'.JJ+-,:[J9V3NV],WRM1\?DY-US%+7XP'
MFN58W515 (&8/2)J)'OJD_1-5,ZYF:?+>L?*2_N^NV_W(<@GXD'%NN'-S$^3
MFQ;;(U8A(32J#U-P5:S7P\P>%_O2RD)I=G5,>TE]<S%_?[!X1F?LG#%>]:<X
M-G.BU<?7HJLE=<K7?LW2?+_J&?,*AR?%_<F^3FW::?\XD*X0>))B8U.&'5F9
M%><$(RH_7'Z Z""*$SGW3Z,).3;H\G4Z*DQ!5HF%L*X'/=17+-U$J"ZG&+,&
MIWJ"-6O9*)+3YD2'ZQYAJ>Z"C^@7Y5?D,1@+BODRS(HO,<E'GW@SQF^7K33&
M[5@)!/JPMR?_P"V=,PMF$D"WKJFLW[8/>NUJ8NQ=M*'4*&9->=[J?T6CKJZY
MO)5M>J)X\</D26:#M7G>36F'DQM^/[F;MW,,KCR.A,65_4M?41SU^/ID?\N_
M+V8(&9^'RE%'>$R#>_(KRKS4_&TQQ;^8HN[-;M[D<D>N>@V+U))]P?]FY_(T
M=Q$(]O9!W38A4>IN Q#3^,PG0)W:P\"()E*?JI]TGU5]GX_7N?(6XMU^)\T/
M+ZW[43.W(K@R#.PKF%>SL)F3,YTKN0'WBTV]LVCM_C;F6?&O,BY;>GFY6SS)
MN.^5*24(KY'9D(CIJHC!!OM;,$GJF_S@88\@RKJ>T[NM!PU,=X'Y9>$_$K_(
MK5N'VJR?,A]!Y L:TMMJEY9V&_G=&EUL@H^NB7U5&JK+OC]QU=3U"&8%U^R
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M >.74ACUL,T%]7W\G$^9L$%WP0/<G?> T<:E6["'CMS,?0_98MA0?VT&C!P
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M@@9VD9\P-B8C-8HE@WARR>>J;+YO,PQ3>)23D:F'N<N;;[N?9UVQ7>B_M?+
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M+7P\L$L7O"X/D9Q@BB/O;*YD"ZS1.DR$,OI]N,M666/ZI*[LR'COE)?)<KJ
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M-]<1 ]QIP"LUF(I'/@(U)P/S&<.?ZX>V<6GCF,_@8"&]6M!+9,D78PSWEB*
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ML,Z,V,8;7J2Z!@AD\?_CL(!C$B6++"-7HB_@43G<$X^709QR%TD<+H/+H$E
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MNS/HR![=3CBK+0)_X!EV0=!>YB%AWJWM#"C);GVG/\#U^;O#,@@?0I8&C0)
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MY98H9N>"@>\N,H"FN248ZH\.V&O;75=("?L@>H 98 .X 3[@"&$'(P7( 4J
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MD'TA^T+VA>P+^0\+H?KCU08PI+L*;R"OFNKV(* )D)&0DI&2D)'MOB>4@NH
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M0^_JNM95)0FE%Z9%N&9!. ,W0P01#PS0#^G"6E3+'QK8SM5>/^UQS.BM2L>
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M=XDEYQ;&;>I76HW(O!'.8,.H0%_=66U4&<((XD]E%00&<Y7<Z[S8^_!R]_V
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M'H6_%P#R<XOX%\,J_S0;D*_1/SO@W_<XH/]MD;\"KD'ZK^U9H6K(W\EU\H>
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MR<STH= ;X$!55"EPH!1($B@-$I-(M QX<),8V']#EZ- FF-2%\M%:Q9=(G%
M+V!6)R:_2_,..$ +=O* $]3 C%JO) ]B#@T-J:H.X ,V&.KJ<1#=( 0.BF%5
M8/7 VRD01($JZAR#[BHDA"3Z1(%2XOI$F9D.<YGDERO0#,0T>:!Y@R/<$@H
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M1A(N^TLDE7>\I8Q.AAF[BLUC/X]Y?>AHDV?A5.7<OHY+Z\J94$943B/-8Y8
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MUX7N]DJN$2;/&G[HYSE@W;9DL+<X>JC8&(>ME&6.X28]EJ "ZE<[4PH3Q)S
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M  [<RGB./[VO5P!D%>A7H ;^*4)_EXX1Y:@AVBX^=1?9KK_]N';^6S]R9\1
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M\,)R1: M2A\J2$OJJ8,<7G?[R:*1@_X,E66!641OIZ/]SO.V,87<6^V3M$)
MKAW-2 ^"MF$T-NR:-07-UY@[AXAJLJ6S,KU?H!<9^SE/CZ9_O48T!%?@A\4_
MJ7Z=N7<:53R_]!L ^3[[/OU"Z<,)VX5(>$.UTQWH/(Q0'8WQ;KP%*>@5L?'#
M2K N['_WH<[_/A=L,1P"U/27F%QT%*V8L#=+)9(M#7IG[PQS;\M2M.LL! BM
M(J94C-ZNOJ#OSLO(KXFQW&]/2V(Q[;'RBCH,'6[H.-;-5C0W1\D"4(]E9@0E
M$)5%8-A&A4Y)7/[HP]\3@7"!'.Z8T(!8ATI) ?DDGKJ)ZL,CL$N(BZ!I;%O?
M<B";%FC#*/]M!RT*1B\Z$^(;+)S_B1F+00I3>)FR23X)6PQC.G8$IKBH5G<2
MV<)BG*)-)O;_!739F;;2;O.\E3_322PH>;25316+L9<O@:.$<]+2LX.UWL&>
M4CGQ&Y#R:+[G7'.PKPF3A6@UK4$C\/2N689;7M\O>_\*]?&A81%K\:E^"VWL
M$8VY'P:%$699V7*1_COR3)Y5N,HA>CH1M4MJV#K5 I16-4*KLZ6FN8+H4@AR
MHTCT5^X:&K;9VI@LO8\!W-54G*7]A C+EJ86,AR_9SLI+DUZC<6/H\ 1R:%]
MQNS6K^C2/9Q2^1YEU=Q=0@,:I4&&VYQQ[(PX,> NV)GP)>'W9(WDY_"3AS"1
M [6<$8O"AA^MC_=V=*JT;-@>/;+H!.[7,9S9H)ZI6[;/;T5:,,"$\;-4JY[-
MYIIBR:!.P2;8\=K@A8PG^;2VQ\.MEEG2""PK*OBHZIMA79#;=B_U9G\Z2-.&
M$U.#M)W2HX@(@:4VY5D[$<F_!&K-MU9L5=0UF9,K^*0DMF"5\FNBJ&-2+UD;
M:OEM'K7UPRHQN<ZR1?),^N2S7JT3#3/L7=1QU],2W<WFIIF-<K=%=^#/G7V?
MH;@IL)$UH=UF> Q@O<3KBS<?6,&.@Y@74 VO+9^4I7EU8!!X,'I0"3KM DZ8
MQ'\\!$ C6@[LXZ=7G"+1?L:O_+B(JE(6!A\>SF9HD\CBGV:58.$,6?NF>,CV
MU[@I)HG:50G%R(W)V8<7$4V'(?30'NW<X9TA,EOU$+RX[TTK7U(XC$NNVE_C
M"K4E@$?,WO,-W,_12_@4,5>X+.A8U6;9D;]#E%S=E.SMN\]9M7: +-]<FU*"
MO,:$NC%NZ_544BZ9XE/=O7W][_4_FWQ^IKN($ZJQ+5)._%HD0?/#_%*CGL,O
M(,L8-<J*"07Q<Q,'O,O"351?C5=IHFF'@;9?UL-MESY4_T2($SJ994]3C+8$
MH^7@6P_3!R6E?!NKQT\+HXOYQ),HN%M,UI5.IV4 -=YB"VF*XBB93>-,LCQZ
MNJ"$LJ*U[W8?E 4X5 #[N*\0IG"G]GT?U,7&H!=5ES2P9Q,T0(.LIXIE''0#
M[/A:C&TZ0CN.4J,1BWJTKCCJ"R<?ZW=Q@>&!IOS&N_P%'_RV1=72T30>B(?T
M8VZ>9(*@LB@J=5!U,PJ]..*?U'RDF',U^TI%2V_ *@M2TI*0?$T(&A[E_M/F
M50TYB_>"U%]V%[S$R/H\[()]H7.W[W97FM1T]:EJ!D2W9*4 NM:AO#^HT"UL
M7O2/2AACT#*5"= W!5NCMO8:HQFBBW8NXH?;E75Q/22-;GI83M/'BRAKHS4V
M716@,7)65^VF]0IP7\<#E\Y)"ZFD.&MPAR\#_6$R?9B8*4B[^I/4F_M<[9>#
MPVO0=5(<8-@>+.0,R#]2!! I[A\;4-#LH$JW<I^2VM(0.CRX5=9475FYJ,OA
M#X4C0(MYO/&+C4?6]$Z$2G:!B]-JMX?P_>*T(>##$=M)52Z=-'?1JKHT#]K4
MRH-!QZPZ587=,74N82S7!FQ>$<U>7453S#?IV)","2"(."B8KP/@K'9?GR(V
M$%*$K@"YQ^:W.+'_7)3.((6@59/8X&!0MY"6=2T%%!"=]I9-TF+9#O+D]EY*
M'/$*$8HJ?O8$\$GAY"["_^.R7>A,Y%->ICG^E(\U:H)+;6JNNH?J.&@/I(2@
M;(RH3$- 3GY6YNTXE=2*D<?!4_G2SIDP=Q/N37=*% [;S&955>#]>996G2U-
M\-8[\*9KP3C-?9.]8Q#O @O&&-OL.R]"5X.%_: 2"MQW_ 6R? BH=WTNV6=!
M$YTZ$0AYN$&\:J2=+U==WIT[?"VHD3G:/J73@^@(7R3;/_CQJKN.4@,)B!^.
MI96#[-_/D6"$:!?5#Q!3P!48.UF":B46C#]2AP>&,C]G<1@/YBZL05$ JP['
M:3@H.;80&_T&@!8+AFE)M>:^\2REP':.CA?%-0/20M(P*ZFPW]X!/@QW65W1
MQ89\<#]2NI7/N_"03>PI*6A@FQ KR$Z,['.)A$; >!-+,&VQJL1_OKFY!S*+
MW80(LI*G&C%M?(WBG6WZD<G-[BJ\P]&B] ,'/;+-:FI)387SQSY\DQNG,&EL
M]-8X>*[ Z\ZSB"QS"HPR0B5^=*.<:6JCBMA!$P!:4Y]]-_7_ZM7X9C54RX>.
M=*1H3/6#BA8%R"W_7@7";R'GI_91W%?HF[)F?(*JD4^YN*OQY9EQ#EVFU1Z/
MC_)GN]QWGR7-39( A]])B>$Y7'^VY<T"]<-PA$[15&#',D*4"X!09ST]4.7)
MK_P-8)2>XUU M_^ $+(@X!]U;Y!5?%2%R?"%K&5G7V=*[(0>$?1\U4I[5; "
MA0-!9UZ(LQ0)H:"YWT?0-B:A 5]L]2_N9\ID,JT8!;LXEH<2]3!L&A2+@WTR
M@FC W@W1XN/";?;L^91Q8;$&=9QK4EVBY&^[4)R?A"\L<B1J/AQ/MMF*I#M8
MR!KS%E75="[(];+&^\)Y1P',+$D4_$R6_J@2)8)5&*1 9P&D5&\;72_"L4UG
M6C.LH5 %.[!HG;>F$4Y2FF>"B%%& G7#J1^Z9?YO5V7VK>RHF(X]=A7]Y]/2
MB 61'5&TX> +N_*SCM.2S)1&Q^$7\^1/ZMFS@([Q?06==<;Y"2E\7^U1)^H3
M$J -B]OV_0T>B3:LCODS@VD9;K-,K#:8*[K>XRZ9C=)/[K_SV]&.@[.96(EZ
MENWH3J8& X :YLD3;]WM.]5ZBU_;'$U(KT?:N0!UTF $TQ\^)E5VVN]HSK(]
MZ'0Q7K1#;!@[B4EMLS%FUN8[TSNN&'X)_E9'X-@]>-3?)E:X]3[K2SSCQ^BF
MB%^$J7I.=,6)GQ_OB!"&/E\.B>SI%Q[5O/UC]9G[OI9EMK?$EI%.\Q(-0_%W
MQ?%6K./$.MJI"IYB6/TJL6! RTR4E+AJ2-[[S=GN1*U\IDWUMAU6)Z/C%*+,
MSL'A*8=L*3V6QL_"+*]7O?;'@H.K2#%@8RXEQHZ"$B12;AI<VJ^_<-R:_>(K
MI?D"7'W<2VS+[=)>]N6!8/SIII'"V&\ 9D<F*-#D?7GE<GRL;OB&Q\S11-4O
M2V%U:+./R/8S%O30Y$7[-PH#HBC2:7<_D)R7'*D)\>&=B&'+++!3G7H[WCV,
M2>NS_KE#$XXZZF@S)462R1>.*^B?.FUY+DZ0A_H1!(\VK$9U,OM2$O6:83QK
M[^R DH*UD5]NEYP\P+NG0,*2B?+TK1+YJ/+1_5RV):]'V+S[*NO+^>XQ#&)8
M1L!=^('0?-C,T2^[[\Z/H04[V3,4 RM6+[Y"HKF'JPX#&\1JER0L$2DG.K.2
MJZ-E+W,RW]8TG+@S'B?\\JS:&IL4@4I"A!3QK/;%0U;DN#\5%L/E9LMKLB(+
M&EZ\M)97*"%YZS"\FA6CE5<2EY3UD*9]@3BK?W75VBADY^<IN>1W#\\4U0ZN
MD#A?3KGTLN96:G^AL.5D4M#AN8(2^:>H!YH-QZ]ADPZ91B:.KI[C!;NO\_KK
MHIZ<BG1\_X)@?%MD5.6T7JP_Z;R AZ>Z-IL]HE&NK2S.ABJX\.A4NSA79@;T
MQ&;"G78B-W98\C'%$MFF4Z>6)4TDOT48R=AI\,=C%E(H95RQU[AE0B\U2OD[
M3O4*58A4CY[H@R<T]0[U[=.6SBT[ZD8)4I2'Y\_J7+>XN'EJ@)8,O+9AH<-$
M2V63J4:(1^7"FC:M_2P^G]55!OJTM-=2#BI7) X)MC,'AVI2ZMR!9PEC;^&2
MZHA),\\TW5^G,XOXV4/CKKG5TG-B=O8I^-WCU0@R[0>+-/1+3828Y3O98U5,
M 2DT5DKS]%9,WB+/V]<ZMW<LE@29P_*]"YZISJRRFCOJ#K=O$TM]=PF=QW6J
M/[OECTAVF=XY'KP[-2YH!F1SOOB4F_5,5JD]\7&*WVJ2TR'9?7G9YTP1?KV,
M43J!M6R'YXNF=M)5L .RZNU8S586YKJ&+,H24CT*<4+)1PGO&PP3397<*-2P
M8WLBQD!RIE\O(GE;QJOG-Z 2+W5C:5T!F$&]VNSC2V(=%Q&^O(86B%K%T_9!
M)6.7WJ2. P5^!69P/+I"5#AXB_5,U\0D<Y3;&7+Q%C5YI]*#R;2FLDWVN>TK
M]D?L[U CN;HGQP[O?9K*\&)C]5D];2U1*6;+&X4/JJD)2U<;D2*J[:S(&!5G
M:J*P-V('I=C5NH0DDZ/[[8P'J^@()QLFJ$]H4H<C?TIMM;;A/\NWHC41\:8-
M=M[1?5S$=.]\(%)AC717)?1[RE$R@XJNM@[#@.A:>+Z$AINP><WRZ7:80+U'
M?E!.Z<S#A*2^X00CE@A5&#0+V\XJ1=L> 9U+2AW4-LO%9KOUQ"#=H6/R/*-\
M<+1'Y=O.D,!WAR2GE,GM7=TEAGO^MV58LO7@V>F ^AT)KNH18I[@![,3*![D
M/K!'M?NI]MY4O,P;=K\!$G9'DVN#BH]&G2IY/LFT)[1%HJ@*&2IBU8G!@U'\
MOT9'F>O-F@%,H)Q<\)SJI>;'X/&,$?719PD<O.E@DPZUP8%JC&#!WX#I[H5U
M*T?F1S;I]IXGISWRHH-A\=Y.1Q*QP.#[@I&PPGQXYHFBHU5=2J5?#,7HRVI+
M,DOF< ?CNDY*=9"&\'3^JC,??7F=A8T;L- Y[EM6I4R6YZS_UZU^2I#AD*$L
MS!Q!DR"&Y>*&WP6I0L! 4[&H9,?5;C6B<&MXW%3[(($#7^&[TU[@K5K^]L"$
M'T.R=Z=>T$H#'UH-:8O:B"Y $VJA"7>RG&R;.D#2$G>S@],GJ&)"CJ.IW,7(
M8X34.A5T]*RIM"9?E37*DE?'CC9+@0F]@O4&U5JIMV=NVVFDO1MV4#8U]L\T
M[%J76U:?II*>0L>BBU[>.PI]:35.5QP9\:[\V1,1WP*[:G%II4FST^P%)HVJ
MUXYVY0$TYIPX1\_/Y-^7;4RYVC;MD/LG.27*V@=6-ISP1I$N%X/UB[+#3-NK
M_=UI['>47G]]/J.$X\3Q.J8U[]5@5_:;;<^4'U+NPG>#9>&?EM"]V;,EC[QS
M'*R.((2DT1DECG[-T]V+YD,6&PQA[H^.2F55"]!?W4_;G5J+6!6?#79,@[1F
M[[="&]7RHPMGR#!"IVHL+>6]6HC!VZ[G]="QU-RTM+1/A5QX2?M#!)X*NC#$
MV48JJK&COC8G9["R&ES?8ON^4)\H)5HA86UH9$S1X4Y7=,-3$%ZN06VSJU/,
M4QVL^=A^P"/[Z4;5+<K/G +FI$V"3.799!%]=3KS]-2.+Q;?P9WN$SIS#YW*
M5PM;VJ,_LI<@&0M'62[G8:A 5.+829[I]2?OG[O79NE.F\]MBM)Z&Z8['"ZE
MHR^?9ZAA]GI:O959K?F*$(F1@#=XE)5/*F\0<'+PI?A2=,>8%[R)_W1;7FM'
MES(O$+O1PB/)\#!(F3L\;(RZNK"X05@(!SA0"9X^/JT']>4<D34&I=FLEXN)
M-M-FSA<41N;VJ DR!N )>8?UY3>J$%7!*R/<D\SL@8'3PV4:'69%)CI86C2\
M7<</OXM+61*I3LV9SOVXBZ/LD3I9POU#RB;8G]]?';]"0)U+QS1US7YN,>#7
MZ)1);IC*"+Q$0(]YJ8F>)W?<:DNH+GBE#^/=J+SD:?+Z8R+M'4:FB/'!]][0
MF&0C(?G&2J5E] ZXNOJOGWE!&JY\%D<Z30B"UCRHRLQ"08)YUN)>"K#0<6;C
M6^I _:J"$[KH-AA[N J:LO\TW\?[98&E,?RT);. [="1"D.0@4)@CYC_!WGR
MCOI!>''\U(FR#:T[FS U(6FDV*P\N:X,@+"W[*E-+6RY2U_^H<M3>HX-,-P2
M4V[-MTG[8%6CK>] WC:Z*.FTCY0$A _-SX3/M$D\P-U?F W('!WCZ-+)?[0Y
ML]#Q!:OL5WRKVAEDBB4NZI6UW?0WB#.Z6Y5.*E<?AJ1S;B@_F>DG8>407<IA
M6F^I5$?:_G%@(+%/]!EALIZHX/Z,TL\JD[3E^N>YPZ-.^\\=>G=0+O@P%3,H
M^V.U!T>+ ,7PL<:@V+K#<0X;%_)J-Y@E5Q%LF4BHWX47K6"+OS821*:E/WF7
M%NTGJ\^0UM0'V@ <J'VGUEJE./9;K];OGQX%!#ZF5V*&+::%*[6>"IKQZ3X_
M,@$Z$-UN^ (T9M.(27AB;GY?HJV(C[P\*_L'SVG"M'1V97W,01=&7*O^^_M#
M=RT4>@6-6#X(YV?E63@&I&[:@EAR8 S>N2OSQD05_9D5$M.D&AL@>L_4E'!*
M,4-D.3N3=[%P%M9>L/=/9#D"UV_%$0M\ 8NS[H7Y0(.(!(,:)EN&8QHQK17U
M-AQ,(EW):Q24AK2<G< _J,1R<*SVTI^[V&A.L-IS*V'-Z*1#Q%^IKRH^IS<1
M-!C^88:-&MA=4%($;31Y%X)F2XNTL"I3!TQ(;__%\*O[F7SYU\V>$Y;N MJ:
MQD5%.H)I1^HY\B94EE'FU@8RUE;L*:Y=!4L]T3K)][T):0^]I8^TN6M-\2W!
MJD3!0<0.&OT6&<T#KTA=_5>GS&WBQXZEM(Z_+(;[PYZ<"=:/R,J*Y'QV)&68
M(W@_E18VE.5KXSBWE845;3L</?%*3:JCIL]]1G:75S>R?XOU"=G&JKV]U?[,
M?@C\2>W<QI;]3M*R&0E&?)%HO@5+SCT#1\?C.*&O)\J5_+5RP=%8.N^X6B9&
MG>P'(!VJ^#WZS;Z#32"VD;%%Y]!9$J\.FGE-3+!.D2'V_<!R\/+2NVJ/XE(R
M*XE1'%8+.\9X:\?%VO&*Y=5/"D:(-U^VUF^M3GG@J3U;C*A+(-?/R:[N^[EH
M%327?:A:9$L0- D$U-1$86#EY&V5#EMX=>_/M+N*?&%X5'06F9==-?)#V6I^
MRY8E0]31OY98]NZ1M&K\6AQ[)(\<DTR!J7+QA5HYHC9$SVW'#Z7< (>N50US
M2U56FC9IJ\]N%XN0ISC;F2O;SL5QN$WB4=S+$FW=-Y'T=3[Y&P.PX>F'-J7&
M*,NE404+N0PCWZ:]@U88.AT&4W!7YL,! QB2JX2O3IZHJ4G?Y?4*&S;L:X]=
M3II/[GP;RO.?O2R)96QG==>^"9-&XX5K'7_\FQ^/:)I^.O\&#&TB^/M6/]08
MGM.E $HW8/CH^'1Q/BGGQM*F:3RM^%J#X>CQVN2Q,<62E^^+&"07D_C-[+7<
M0P0V-\A@!6MZ1W*Z\-G#=ASEE,;M_/5/H3JC6S^++-C>561T!X;FY[BR_P:
MWQ>W.GR3NRO:(,7/7>"C$[493^R41PEKFQ=P57^PZ&$VR?+(52N%;U'B2^1T
MO$)]Y3M_:\)7..>E1*WZX]Z:M^HW1^1)3^=7JRQL'21'XO#?J")8SHQ1ZUU9
M*I2?W^LEU^<,,,0U:L;%P\-@5%$)#94FZ=@0'"M.+MD1WUCF=1('%I^0?A^4
M8./>U[$)3\!#R&S6G^$JX!GEQ5=(4;8FG!1>?M5#B;#89H'#KEB(4)!7--0T
M6&I!RDW?3.6K)31RQO<B;'@9H\YNK^7@^;=\LF)BOC?M=-\#G?M'%-FF4RU3
MFY8.S:*6Z^LDU?1L"""L&:DCFP_2S4+T\]VMTE\E2?%-N%W(@2>S.=M,8#O/
MX><;[=(-5FI$YM.SL@G%R=4UVV^6[/>TGWA^_8%5&><TVO+!O$^VI<<X)V7F
M>VN2U-I>2X2R=2CK<X&"]TRFPJ5]1&I;].7ZN55S+ZO4(1[RV:0SV)H9&"LU
M!_H6)I^FLT=PE16ZY*<X@-)80T^I#0XAT/WMH3QGL%9\(2?%DM^.5G%RK5S!
MT[R$20YT7QO619MC_VU$*6_[VOVE5F$6FQ6G*EGC[;-$4AZ45L*7WWDB#',J
MNM2[4,M([<(=Q)85A8;V:-="OYDG#WE+IU 2Z3VAL!:J_>26M$@:GG"K)B'$
MJ"@G_H=40\5R^),H;OHRYL$?K6Z9L%!I6V^^"7TOC>(XJZ",&I.FE<^(&KW$
MIS]I:SFD:<7G7+8IA^K(]$EI/\^XELUK%O,B@L8:4/"^:TUI.P9T=WDU0#1G
M NF+MHW\IM:>-&ND,>L5).UV&%FL84F]^17HE@]6K>,28>7MO&-M$M2XDOL]
MH#BV-I/YCL&/XH3L$7Q%'?3<D'9F! F0;K][R0KTWG8N3-DVHB^!V95W*9RE
M1/U %>'I_>HK \DWE"\X#F'P=_Q'+_/?C$$:W6;<A>7S"^'D&YNXHZKUP4+3
M#D+?;V<VJ(VWW2/8]$R[P* @%G@VM1(L_TQLE:__08!?_UO)J385VU=59$O:
M%YOWMM1261V<33[A,>CNSNEZ:?(OH;A$>FJWZ)7:!^IA4C(?\P762;^5RLEW
M5!*#P=^8!3KTJ$A(J/[]5J2:G985[+FLPDG.:00I2Z]5G7:YJJ8B6K^/EGV3
M=IISE/Y:(O16P:_QN">?O(65<6(7LK7%]77@]Z),6%)TL?GN=@EU)V>B/7_U
M]_MRE=R_4D1"/)+WMR=GA!51+U:8#LYY1-:N7OK &6-9T^,5'>-YY1YU]$(2
MKTLKJ^O,V-P)NS]Y[_GMN; 93ST#[IW^)'T:/3K[@)B:B0[HV'9/ES!HM\-#
M(*R?18._5-<E#@H54!9D3EH+HXWDL]0&"JFX/V,N.O0)PI)_XCE^._*N'OE\
MV5Q+88)%\NR'&DI256,;[:5PS2#[RGBV?+@T@6+\1\?N@,D5RH2A'X[Q(M;M
MI-21G [V@61INJ2TT0<>A2Y"/?0NYOE=N+R=4J(HLN2LCW#]M1W3W+2*-06,
M=XPY_(WM]H L*X^^".HCONKHZP_PWZIB=5V3F9<NM/ RZS6%9OO+I193'PRP
M?D]-#HH98K1]L*)^YL3JH4&V^G[B^#:E?5J8J1"+3629WT%;?;5]C=%PE0RS
MN?ZX;'@4^$Y);=^YDD"^K.E>I$;]Z-1I@,STM,TG3AY!HC-,J]@(+NW76UI.
MW'WY92TF?79$UC:HE6UV^R\WSIWV3UZZ4AY:G[U -&!(M],5!;]^I^\,873:
M_ V8R26[=:0,WDXC3;MM1_SAW/$W(/&%,+]'=$2$/0D@,DR0TW\86(\R#()O
M&CSN[,]/6>M]"3/+%FVD"OU)=60;;@7A;F2L%&#5=RV:5;5^Q99E]7XN1:BU
M2\E<1Q!.,=R8SZ*I/L#C\9P6:D[S<6OQ18?9"VL?JJY>]]E:+7* ,T2<$D<C
MIO*(.J^J4CBZ%Z65SW( EIGK+WTWFQ7U'6=U_&W8PI(BJAZUX!.LV;7Q$)^T
MWP#R+>U4B&99&4].6T"SK%,?+.*=AV *[\]X/#*I1@SX?HO=MW+UB0)2];&A
M]L6.9WF??5@O&EZ'[6FE3+ 1_) [>5F LN1"'L^:0_5P'+PK8,Q'@N(>&-GO
MD)&D+C-S.Z5X:^A<3:7]R\PR86O'RL':_&\ N^W*+^^?'4.G'JL]@>2Z';<\
MV#J7V:DV8[:/A]]:ZHJ'U6L6MVRU"F-DGKU>^]70L?IY^&?U8>?;L*$#+$)Y
MK,7H@+8<$['L3.+<0@?5\1&Y7;N-N\^P1@5@4(:0K,0G*$Y[R[<R4"F(X!_6
M5'IIC+@3+)AA.JE]C/%M.1]KM!AA>(F=77H)09%APUBW/>R*G)Y6>Q313A&.
MN8EQM_EGK9"%I1J%[$P]-:H-K%$VC\&:*$ =(25YME5$0H(Z\T'*BV!T!7OD
MF+G859LL0>!>X"2-HS.KO]'S#2=?^!SOGOZ;U1COD%(!FB;<XCQVP<R\ZK$Q
MB8470.N%@&^UI^U,2Z4]\[RDR?UJC"GY"O;@O!%SU)GJ)]./JIXG38K +-;2
MT8;C-,M[N(/>5_$'G&HN.XZZV"98@,!@0BN^5^(8WW*(:N]85UKGO3'TL_YA
MW?$TMW _Q#*,&WZD_BP@FKSYZIO%%@E+HD#[Y2W:*/^$+9+UP(]'@-P2)L4U
MY2ZAVNC=/=5[!N Y&ON\T!U!/-7@KFJ@T)RAA[LY:_NM+]2 [?LV.Y3X:G&<
M=;*)%E6JDGZT;^V%YS1IK4?CI*8\6X \&$:^#2+ ,\+(R(<+\N3I@@PI#Q-8
ML*"O^B)M]<VXP\_&])BMDJ=%5;HBMW;L4>10E;PX8&08OBT6W11YF['/9A$(
M?6]9BG<$-5F@\ZQ.D)]O<D4?3;)_%[T&++,(=32B6@2WUL-_[K26=V*P$ZLA
MO'+9 891T*G(9_>* #L/[L'5(6Q)OV_2H3S2AWCYHUR3V#"+94C*U3X<Q%?D
MJA$0Q9&<\E';ITL3HG_:W0'D70;/8?G(X_>5F31Y:U11)2>!BU!],6K(9IQ1
MN%?NCQSSL3C?KRVK^2(8GZBI;5HM*5_!:.R;;V\NC KRJ\<5L^BYSVT2MU?Z
MDQN]>=2EBR4#Y3TOIDR3>S=*RC)#"1M/0I8S12ZO/A^Z'1@]QC)"3U:/1$"+
M8)D;.Y608V;_MIJ22J^92<(B(7#PW-*!XN0W8$5J)Z$N?ML?9$:\9=1:0RD_
MVD,FBHV*KM6993!%)GP7Y!"F,;D*'<;.PEZKN_\;0%]G7B6<J!@JYFW00NQI
M<)]W3ZH4D.S@KS:=\VF@E[:+.B;#I8"TN* P[NM8ZO+11O>Q!X(!HL;/B(T9
M5"<WJB;/F.$'7V.,=^:UW!!(S^[7-%F9'>;9WM5^V:OV$F;O5QS#"%S, CW/
M=?K*4_L>U/D;$!+GL2+S1I%U\>-92[)#\$8R>8A7Q:C<$BG?/6'4KA>6<+E>
M0TUMLN?DTRV)E> L7Y$8X)$!J6K^BLH,+DQ*[$FN,D1=@ZMIQ7T57C$BGP_=
MQ@5WU-KZZH>O+K/HD6-C)=^E;'-F3W4OLNVNTNJE>ZFEO0/Y$HF)4-M@^Z[
M,T]C-4=1)SP*WD["UAX+/R-LSL@ ,P8G-J/WA?(QZ]+9,]YSX4=GROBD0<XU
MR?VE9N^=X_8S_95(/D\RY1KCJ<=50(82IK3@2EEK> ]YGZP]B[Y_#XOM@Z\+
M+CO=[]O;VWDJ#6AL!5&B"(83$\<G$.MP(8@G:G:D$@"55W/J$:0",<$6DP@.
MM^%XG7A!G%/+X<%-Y:;I:H -P)@IKF@A+7FE7*?6OMZQ8429O\]B)JEMG%$.
MATL[RW:R@52DW#K:- W,?P-:+/=#>'JI&WERI3W"HNW+Q[2W8S4&:B;B)VD:
M60;F\?7Y,!N&L>RT[U!:6O3T0@M'J\)J8##'-[P81HGZWXV28>>B@OJ%=MS<
M^6&T5LK0 9&8S^;[=_-8S9>HK?>U"M8G(4KK*S:K5.@-4=1)2V]&5U8V/\T6
M.N/WW(N*812@B2!=A'R:.I=6)5]C#XFNY@7_8E=T>D6]@@PH//IQRA8@G3HY
M)<O#OP_Q03KK2:)=^:A.MD^B-TG?$N4HS016N5TQ*QI>H-,*9D9I#V5LZ%N[
MU0?J'J&3R.W*R./VU4;I!U11'D>FE;>74%XZJ2:&\(1'O4QV\+/H%=&4E;8W
M$>_:T?&+'Q\B&E=13=(?THO]SBQKI3L7@#DQ&73J"RA.R:B8S#$Y):LRZ;50
MT4Y&=1DEQ@4"(LXQCVMH9X8X.#,J-IX;E$!AF:CU22N3S(4OL.DC/R_7!6=2
MZ2Z1B_5[ED(Z[/-J5 4_,9SN1#3HUA%%,*WJ"O&78O\*MW-[MBHV,,#!@2^[
MB%8YK,L&/O\>MA"1#10(%#22L7+O V 61=30FE,N% .X[7)K9=\6%U=VO5!#
M3;I['U&GD23TP)_W.,6WEA<#"FE2?-Q?_Q012ES6(+>\H:.SGL[W#LB;3]/E
M\A@!6S#8(F'.%3Q3F;!$'F9F\^_2_[*VA11.8?;,MC-;/N%A""?B-6(9?!_L
M46+..$48Q#2Q2S9 L8;$=+GVXL,P?6:6(1X/HU$ZH904]S1M$N\#&2#SIZQA
M$6:9KJ?GM-C2#>;2.8Q%K":=]R/X2)B+=7G8<&7=LT,V+=#*7$B?'N2]D%("
M:NG$#WW,M08+O#1?S$)YY=.%#60NCNWIMCZN+9!X]NQQ9'3;EVU;N%.E1EHA
MO+%H7T:7T>4;P06_6[LN,J_$&LJ"ULQ108C]X,G-H6<(4'<A[J2.WX7E>F$,
MEQIGX?X 08?!'BISI=E'->1JL&&4D'NBK-8W)@(R;@X">,5/4,HDCR0]?/B?
M?,KFWD\8[V+V"2B-*'7JM51FC 1>#?![X )V)C&SJNG_X.L]@Z( FG91<$D2
M121'!20C6;(BDG-8EAP$A"4N+#DH01#)+%&B9%C8);/D*%GBLF006#*2,X@>
MO_=\=<^YM^XY?[KFQ]34U-1T]]/33_>@T[SUEGDHQ<4-9"%GB47?F%*4#G:B
MXW;@T7QV@<9+346U1'/FAZ%*52C7>3N'^6Z%!N]V";G1V,1"SQD-*8ZF2HZK
M<&@"YTOQPD]TV1:M\'RP'' 4?\S$YVR20'(^K)'A+,+9."AU[?,0_@'48[C,
MSB%5 9?W!)>(U[)+J*;%12RR(I;PX=*C<+759KW*IVY1D,I HF,%N-HX;*X$
M 2.$:%/G_/Q"/#"0&\79F-65B,N7[L/#R.XK=MPV0RO/WLVK9MMRX!BW77ZB
MP*WDXD;A"-D!#I+D^96XI!A(4IB+K7E1,P$R30.>,&D)O/K]*$SQUNC"HH\J
M_WF6H?:4!XWD=;F9/_U;PT#@PP'+Z%QG2WB)M*/Y+A,!833#/!XE!M<2ZCRC
M;V@53"I$D[[*= ?*;U@IUU0#V<Z,A\UZ<SS3/J^W@TXZ@"\"*O4-WPX0M*]2
MK<*1@7A)6";J^-Q<27;^*)R'PY6I9-:L=N>\6Y(LIIZRF'ZC/BTF-TX$8P*P
M MJHCZFC)F7*_2;0*^LJ"0WAM&JCV0CH'57*F$:9\>S8+@)>7R:B((3Z-=(^
MU0';3E$Y2APH!X.WRZ/DW5*&<\D@78,9I2^91..PF;!>-2I/8XI3T_HKT_#@
M8-+$=SF%SW3$EX(5;>F3R8@%E1AU&&T.%R;H8VU)TN[P&4N.)$*.//<'1#G
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MY =7X\/Y9\@\?"O28DL8FL1P"&%4J]*5%G=!JH1#AFKC;+A;&<[LRI) 8Q0
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MH+M4WOO5(]&>^$7X+X^>'3@OAXN[E,^3EB/Q%T-/)G5EO%ZXX<J;%S@;J(Y
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MVVF=A$'\(_=&I:3:.Y!4;1[UQP^3T]]^'@7#UUXT0#_U=E5\&GQY]].I?N3
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MX!B37NAZ1^8LPULGTJ9F[!SQI^ G-J7DB:Q"(#ZL2MJ0#MD3F9PA>16^++V
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M/7U72,12?03*SL-%5U#J'?)HGK%A,;1HAOR!9'92_JR]?X"?^.:KDKFRQC\
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MQ7XD<V' _@ Z*5[YOU+.^[#-*_;KI#ZH^U:X2H0B2_0T4H_)3[=@?MM8M$O
MT?>A;E:;&<!]T_KL&E><WWWQ+B/='*>Z8-Z]W>"J6R#^YK>="_"J4OB8Z(/T
MW6PJ]#)J8G R?F]+5QKSXZ4NEXN=F;35S<E5\66'N<E2?IBQ@*A=I_$0CC;^
MEUO*#$N9@)S<TH[$WBQ T*S0?(FQ;.V:DP)#-E'+ 5T[]S>EB/>$U73PP_AD
M=6/&WW:6;LXI4N))P>IS/%^OO.046^@IM4F60A?=VS/>OT+/Z,>&'AO$_:AR
M/F0HTJ;YF;\%XPDB '>QT?R,6PO@/WP04O(DX!H9% 0\VB=\_C9!,IT_2,U7
M!</=IY\X$S'X*SU5;:EO?IX+8Y";H9GWIA;\DUOT4;H3@._SW:N]IBRW/)/B
MHYC=5127T#+1)\@OHY(=C;<P@^Z'N$6;-](^],'F"H[EVRZ&\SF'X_IDT*R)
M*2'FPV=?#6[OBI: VN>D,I;B:P'I"YKFNQ9;![ZXM<&OQG]K['5\^G!NW7!=
M53MSZN-QHB^%K>DM'"=$EX7S4->)6\E<D+HTOK?I:QU(Q0^>WO'%]6M/7J1_
MQQ_ ^YG\GQU"Y\,I*][M34X]0#4F&YTD8\O)]$=>0=^BMBZ><BHG5^5)F=GD
MEOE+;_#M;]OV*L_F;G]M/]_\F'[SFL5]=ZB"50I"V^R//573Y;Y,I9G@&KBF
MZ=+J)&'ZS0[W&3Q-=Z)/C0I")7[U'/%;YP\@6^;M]>[ZST\[?P"GI=8%%_Y-
MTE9CVT6'Q+&+-Z%(-VW*Y9]O$]Y()*]='MU^LF;AK6-AP0 D@#!50KOA3,0D
M)-CT<=[#<Q6EL4A*%1Y+5)QEU1%;V6\T,$59DH559PJU<$YJ.AM@Y4UM4^I"
M4F;K3"3C#U9)P<5'N+L/&@$SMVD5L90)S/:\U\#T2!R#+ 7:E*:?+S'VGT!;
M:)[,%X1X^R@ACJDGUJPI3)4[K5E<[6Z75ZXC9]S%Q;5:,&7QR@08WV26B$-L
M+*/IHM;L*J=G4F7%KC5'<' )FF/*!+I+IF?2IE2O>K]\0CY83)C6H NB)? X
M I-I:5L+E=N0->X6EI4]\_^5A)B\RI@&XH>/5OMO)QCDCA)CB3] C-@X "P#
MV',&)&]P UYN16U_+:;0$F ,$"J)PVG?_)P ]^9?2]?J4 $P/IW.W,J6H8+9
M:L7D+FC+F>SQHLZGJ6SC2S-W&B-\3U?A\L^^PJH%NB.TI@7=S_IO/QDE?)"9
M&M'RL+&!BK8YCJF"7QDS2'(G!$O"R@3*9%JA3GJ$M0T'1/WX6\#=5O^ME=JP
MB((!I14)D):%32XY,D\R[U<MZ@75&/EHD_*S)X?4!$$8(-+,+CWMH2*!P8FM
M/ ESY5THQU)4]]BQQ$(DB\$J89J$)W>5-SHNT=OEBPW14V_#2<=;4WN97PL$
MB_S:E/8Y<=Z:X:H*F1.%C3U:M-!^U .OSX:BDX $7QRQ)Y=KWK]B0VTX6NB<
MI+"E"7EX(%F;D:&.4'E]!I;7XR21S(9)&I\.%3(G?>JR^ID7FTA^64AR=7[3
MW(L0\UT^B;-SC0A7Z3)X) N'J9#,<M"Z)_@V%&/[+'^F;:+&MO62!^EY%-+7
M46C:$KFQ$N3KP<I7.+U8;!02S*7G@MD#%#+7-2R+,W*392DHA/;")7F$;UW3
M$Y9WOK5[<W>2$P<_WI(@;U3E>D7Z@3;SEINKRF!:$2,F^Z?Z(>%9J#]L.G-M
M8K>5RS2,/SYW=4=NTVUJP2K<A&$V]!7:M2D/%!*#&MQNG<-(:Q=ID>WS: 1"
M[3]O"=?^4I9$3,X]U,91;]-,?(&^TC]6.3(F]&BF#_7G"Y'A2=7^NNM(CT%U
M6=,A,"FHK3H&FNR=]7; 7<P&9LX5QWR!Q5=+Y=!@<),9MCKLO9)B<4A>4E]Q
MHY;[*U'.7"H^B@::J!J/<&[N=Z\WJ[I !0ATCYTNMGSVX:Y@]N5?AM<V00+V
M8$B5!]5:/3+ +8R"MFJ"-Y.0\"426UX'K(TU[W8)PR@<5%2A='\#B$R$SS$K
M;"'0S@:ZH*9':I-"D8':L!]U>RR9CZU3)1-M(S\+!4JQ"P@/=D7E,Z'V+@YY
MSEKE:6FV/8\DD5\''<]!U-W/!(9AM5,]N'Y+_(F>DV\R2@)\=[X-G>E+IT[J
MC3[=(/?>DD@Q<2PMLI-.%AFU1Z\737_0U$-M3O+_ ; QC4E>@K0D$OP;INWR
M"]TJIB.+@645&^7>1:*;2_[@#8:9Z<SUQ@'E00TL(AY9*F.K:53RC*#1RZDM
M.M3Z'O*,PXM"H+!Y/5\D$.NOU.W_O05J'V#L%4&C,M3Q^ESX^9Z[$S,H<!D:
M<F6:2&O;],MCDR!<$ E(G%9*7$NKK^=FP[1:RU_WVU)3"<:^JRAQE^76]<_5
M;$C@!,?9=YDRX*TG9:YN%Z'X,3,N3N636%@XWF'.V)'@4$YUG^XKHRMY8;E_
M '4/=EB(N5&_I!+UR?/%.']/@F?D^U[GAW5R6W/+2.&BL;V3<1[N,L<%5A$(
MF=). .!_S=%F*<H9\&%68^"MWE&*[K^B%\9JPQX(E=9U7-FGN0YDI=^7&H%_
MK=&[%7;EHWKJ(\O]T:8P!6EC!!H)6^?2':]$82FM?PTS'1,W8NDB>8S77:SM
ME1";R$0<R,0D%LX?4]DR7DLA.D@G+L_M*<_*S(]>W4XDUSLT?""92&Z;*E*0
MLC80;E65Z'KT2(>\/R0<JKYM ,!,3)F9;EKWK$*\SY^4<AA.;IJA.RN?M>ND
M&/XF&KX5]R#=6\"@4TP:LV:#MWVMQ? C2DP"D_/*UNN((C:P/YE;Y1.!*9&$
M&JGVUOO\!\&4EL-+65CB0>06)[-GJ_@A631NC?)/]02^4"7NW9&G-\(#8<Y9
M8<N7$Y P5_GA\A=DTZPQ2F6.%:4KE]&[^=CS1!@%&-VPD\5C?^4V">;/#8]@
MB/X5;&=VB<],-U7"L['^CBO$8LIK<>2?GL9!_*2**BWF /(/0\1YIF:<L]_@
MK.#\X%OD5\'$M,9 7/&%*&WE<35-IQ!DKR*:P;]H^$X4KQ\Q/5[TR=E:Q[I4
M)FKG-553/!&T%VYR'WL4/O;-=+TG3%/+;G!,:)C'Q=VO2H59KU[YNUFS*[[U
M/J?!,VPG<^ZB@E!9^["Q)^&-DLTCZTSO1)ICPQ8]0[>[R W^_<+)'0UO*AG[
M.]0"W%Q>P0=..14QM=\&\RR?=,9[WHS\55P9"J$S-$TD.!QY4-I[:2'&OQ(5
M-F31L[!"VL;0MW4;N AQ6EUG(DFW*4$@!$J(@L.F*84)&3[,N+1ZIB0C%FC-
M56((1,CXS7;G:0#<;%I!EF5>WUC-<5-FA2"%=,*'1!#3R0.CS@Q<\:/XMN#9
M=^15 B)][S[R?IRK4=@7PPJH6IUIW1UVVJ+C%THH>,Z)-GUC9I#HK>7U;>OE
MY1Y!3$7,W2.%R/ ;!7*?3L..T$^._88_$Z%.-*^KI#T1T)PZ7\(D2L-?ZBYS
M'_N5^5&5)3C^IQN-HT&BT%A11XHG&#+?-I X'Y-D6PZ\Y+<'EMMN'4MO34FV
M^ACKP[3>".1?#PNF-R1W]%+-4Z:OS./ DA&KN,0?T/:^W01&*7O/Q)W$VD:[
ME(MW+0;/SZT05\BMYG6-OU:G6_65_>[=IM/@US!P;=KV@_*%LJQAA1]R^<5]
M$(>XLEXT=^SW%_\#4-H ,8(_]?VNG+L3_&6O\3.C?32FVE'@P8,ND<X\MWT6
MQ]\:'ATD7IUL;$@IU"_2A"#874VU76Q,2R\A]14?_-G ]A] W_&,.UQX4V@A
MBBAO$QH[CLVQUI:818#\$/\'\&R]R>.-^@"=53%F:!T+W^_@<2%6&E03U]IG
MS:*"Z-BH@.[B^@3),FWW=VLE:SCXL8..7\%"/1Y;527-"H:C$S)(MTQS&=]N
M9Q&=#S&*]JZ2F_Y1[RO1KS=HV,I=1,_[Q?=BWN2K1R3!6QK?_ %,%(OPL?V@
M'MXACDV!JYX:MGP]?2DN81ZO8;9#$9C54W,EQOQ4P_P/()?0Y<H)SS=T.C1X
M)BMAL2OA??KW*70C7%(CVI%T\,3BF*$2?7 97]G4O[-,#,#%KY61!.^;Y?82
M<M49=K0X#NJ&V /!=!-U*2H");<C1+&M59*O1PSI:!8/AZVO\MZ'>SY2\CV-
MQ&U:MK]YT%IZY+NS$FI(<X=P*(A2W68:)"5.K17RR]@$30$"+&Q ;-^AX5S;
M<_35[E3#0X%MBZ];S79V[;U?OR9,ZVDJ:7S=G"/N'F4I;90S8O+**FC41>VC
M'R8!F]!1DR\-5+V8SN;S'2EI4^$Q5D0Z0L\,6\*KU!]SOJ!FA6LT9940*=23
M\?[.L-U;3"KR'6@$E+*5.FP]KB/?9-1G.+6S^)!!PT'*44*:'/=@EB;*K$3D
MB5^FK]#/X5VGO?E8XWG.#1ZO]UCLS]4XLDK["N*0(*T-)?^$]XG&]EQ/;O@N
M4*C+Q"JV:G\LWL;17<FZ%",&J=K\P/8RM;LR&SEB=ZP+PR$@'<E']57<+(N
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MCM&3)?,['Y7BF5^ZO@T:HI&CK0LF1B3S@+=Y)#EN7:ROXQY[XK>YBM.3J2?
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MM+5+Z:5:.(^$ST(.X25H7%SAHR@M2.H9J?/EPB0WPMUPA+;$5=.>V;M=3VF
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M_XS'A;D9O5+9[Q)N?YW7GH)9B8A42N$NPGE91#X*7][4NOKK$V$$W@"U;[6
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M.XS7%P]IQ*B.<+3!6*0ZQI9*>-ACNHSG@,FIMOEYYJ+!ATR9ZW7X%+\1Y1]
M&NIKA56AY;%?_ T#?D"_;RC]%B)8S_LKG4KXB+ZXV'!;#HW/V02*YE>QPP ^
MHJKED\X !R1$RKY*ID6?X3#!E6Y"):6>ZE)13D3Y_V'NK8/B>J)\\<'= D-P
M2( @ P0/[D[P&5P#! 8=W"4X!$^0$ ($9X AZ.#!W0<)[NZ: (&\?'?W]VJW
MZNUNU>_5>_7^.;>J[^GNVWWOZ?,Y79_3M\B]KA[B#&DJWIK@E("UB%SBSRH
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M^-V%IJ<M@C-.R?W3I8>>13X%H7C+N?Q1X$?.TA691!F/+?C"D,M9?\J*)Z>
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M)=>/LNG^O@MNM,'X-\;[,:*QN5CLO%VH,)H:X?0G_#1/=/T4]Z$FKS>7OY'
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MY3&3!XDG:#3=,ST_Z>HK@ONI5-;6+FIQT#;X6X=5ESCMG:YG!'8=&?Q83;W
M>3\[[DI2AJQ0*(%W@P1)$/_BL&TLYDY^-1AO 9D#/.L.MJ 4K;&=U@._FG,D
M,(%3&7ODCA+-E;<>0]TDL*B:'3(Y'$:>LPT #E; <95MURS5NUBCS)&[3G$-
MD^8W<6Y<=*D_W<OTB*1+F5KQ,+D"7>P8:HZVK&>9DQS"M$WM\^/RO56H07[<
M=.Z(HJIF?88;7*2"'PZ[@UN+AZHKIE]Y>(?5];MG\N4O@>>3HA<*-.OK:2/U
M#@;O(WA;[Z9:J(9H,J?,-G-V64DQ53I3#30%D,].J'^64@@T?#::?6TVUMTU
M\1DB)<N5=]%O3:UCZQ]N@&&,[CRY>5Q>5SFQQ"'_90[-I"+VBJH_ZIHFX1#G
MAK19/=?6GL*Y/W7O>3W/]Q]O'\EO7T9Y:?W,K_IM%^QXXEAR0_T]XE%]_8O>
MPV[Y'P#U:M;'(.<??P TPDF_E+>*BUK&\".\94*V%J37&9/U4HX->Q=0J:N:
M&^JA0X,:A+RIU#/V<]W:^ZKQ3_AK3/9M5LQXE/%O4[@1Z;3?RO&N@^2'>O7[
M8W#?9W!15'X4_)D7V135H#[PEG&X[;U2PZ:Z\D-@O.-=?"-6<X>\CQ?!\+W>
MU,Q/>-^PC&V'/965<?Q<D>ZTL/UG9CJZ.4]N4:.:P&D/^<7=AGF.O#(>_NI,
M\;B4EDBC]UD;%5F:)Z\D5R$%K&;4AN5&*RAUJH?B]3=(&D'D@G]TNB!=>&)Y
MZ4AZ-#+_O=$1=\G'=N5&NM3"E*;)T [^)]SFNZ);%Z%1O)]PN\JCL.5V5S!K
M4*+)8:;*5"963:L=JV1#RB#Z9T2<7/:.7UCL'+^)73133%]SE;*$U^.>M& D
MA[. C+N1N:PPJKW\SB;7.!S",[@6E;Y;2U@DFH^OIJ_A5ED<!^Q"X-1(E@W6
M%6^^S[E=*HDR^_U!YX7-Z '#$J,#M:R$Y'<@Y97_3=]D_7Q7<WI.2PABSDIP
M* VP(?7M=7)]&;-OO.M:97Q^MQMX24^"TQ9H^H1?"\WX;?17V'B;$:_'U^17
M"!$=E*+^_A+LN/W:2"7RM=$"G11(@+&C7Y'X2FQ=5[B^)V :$8EP(GH29,O9
M9_\E*[*N/O^QS:FB G= 7TJXJ?W;4!N.IHX^MO]G+45[RX1&(XC4MYL7Q=R.
M&,IP2G)EZH^JR-FA>044E0.3S2C:I@AGV)?*[3P<XO=2(OIU3]RW^*+4WK:&
MG:<"C2ALSI: N:/:9R)XQ7S]M(9_ -J6OA5MVIQH@[)1#KYOI5KX(<F3W622
MBS#]B35..ANF3E86W4MF=\AHE(B2\8Q?O.MR:I4&E0DY;4:=M42:S3E_48NZ
M/[!VIY(Y$0>,HLHK27QVQXO^O<55A*$&L9R79FICURO81\W!G-;X$1U2K=M+
MKN6^).J$]B&UE,XCC/RU5?JGVE=7:^+X/_*LE?<^UU566+. K-VXQGCU7NM4
M P3>-5FEIZ6V>(0.;#MC03'I$O5>6_$IBRS<%$G2\:9:N^"/:.*@05I)'*!Q
M"%NS8CQXI-+J% EP:CP3W+&@I,;9UX<IFTA-!29SBA>F>T7P4H:W4JIL0)Y2
MLT]M[$0VNX)W<7]#U-&/P#7^'J+#%SO)KW0A<F$\.='%V"R\EB34C"/ZVH9L
M4K!?>-T^JK'/UIXU&O254".*=Z /8(#V+AY^1?<\7&+;Y%DW[@THK89$9V5+
MX4WNOQ)VHTK;I ]G_P"^DQ8>0W)!&5]N.HX,.4,B_9]?YOSP^P9.N0$GM(M4
M2/^>_@/H0V*^2\)9JBL7:9VV.Z[\L>F9.(QM4'[>*IW69 1FB0&(=C6G4M,_
M);%?MQ*LD? TP/>/B@? D.9!+C5X$39X)N?Z--3OU>]GMP+TL5'C24"/-Z6=
MKB)&@B?;"Z\DZ,HME)'9D:H<Q1UK<'R_@5V0>S%\0>YT 1]1P!1D67GEM^"+
M9=!4ZM:)I:%?D2(:7:IO4_E!^:4I!87[YD%QYNR0>X,B2\F-]J3Z#01%,_3>
M;I*5L0;.\4*Z)FX6;**4:E%3/4BP>;>);]\3HX+Q\6P\C!7L:>C".)WVI63&
MD >'EXXG^# D2I+@F\<?P'#N.<Y6>T?1X]?R343G=].0WYVW+ZLYI,M<F_S*
M]_T>!9X_$U$DTR:5*V6ZDE' ^HLFDL4^8H*),<_D;/SRX)SH)'*5_-55A#QH
M_9U8>Z7FDS/=&W!<25(RM'].W_DWTNI'3(88W$\,T(__G$'T0BZ/Z8J=,R8&
M-W1;NQ$C/CX/_HS)-Q_]A<Y_0X/V*W&>'LG0!+?]6/KQRSR]M0 95R)O%RA?
ML"FJF\3YF&CH79Z60ZMVYU_Z)C/R;ZA^Y4,K!$YDX 8=T'3?D9WH"FYF9*<@
M\YM*C@F?$6.N19: WS(=/_-OO<W<-+'9/4A3IN/[(;'NGGG7D$-'>2T02QTR
M*ZG?%+.VQ".4K+E.YPJ[P7J_';?&#S4/2?WHX];4DS)49L]&A*9I%;/>-'/L
MV$:]*=5K727DG,L0_YBC7J^_O[ 3E6X)3.@S/Q-)7S<WVA]Y&H=D/$KZQ:GE
M"8=!3QA$+W15K'V3V!P*>FSS1-RS*ZYFZ\99)A[3(@)FUYE2<0@H$ '6S[E"
MA,:P*T2^C&H:E!@E,&4WZ83CN$)&3N'&:Z9*>&;L[BQ0_W2R":0X,>Q2.V=9
M9"J4L2Z$50BY/M4827 \B1 SI#MO?%0?WY^2"+B3ID?.H?T</N@]7[7Q.7#D
M'E,]4%T8=(>U+;?50->3?ZJF ?=+6[OW,S0]#M5R7R]X'*N%HR;]HE'"V?>Z
M\,1YS_.]?5)_]Y=\=S:H/P#G_:O!DD?4A+][77S*V--/M0T:4A9ANYM+S>GM
M**Y7U!%N:O*Q_16PO"^6=IRSXM[N?)&).;X';Y[(G*T%QHT ";T,'<+;Z+ND
M&L^,9 <Y2R4.B,19^S;V#SHE%]M,D[#4$W.]$ W4>YGJA;[+=2_EYNOG70"2
MD!KL\T9;!WTNA3?(U\>J^UJ.#9GGJ!_Z:?3%7^N0L)V6)R)KUO"<9+<^_LI=
M9JK^.+:7 K:*UO8%>5>J&-:2,&2[6HZ)7D&@RZ"W6Z1@96EQ(7=@ =8N1F1]
M\@[.*RK._2&0A3QHWW[3D:24U^!9PT&Y4 ""K.\62>B,ID'K61C81[_62F<-
M$M)0$#P[_1@J6<X1PP+V>MJR!+GHV@NH1D()RJ!(=8H,C5'8*3;:Y5[A1R!,
MB[PP)@SMS$0&V0/;ZLW1&>60915P_[W^9F:VB36E_OR)!8&OO=FI1AAG@5:N
MH2]WOU"2%92.]/WP./-T!AL*7VEQ&S.A;0>_N1EEPAK^TB.79\TM$;PX!?TQ
M3]N_%Z56"01#JI^B+M"ZRH8 #B >?A1**E5EGHJ(YYFGYT.BFGC=J2]K]->N
MK%9!HD;:I&K;A,]&$;,E'U\@%@6S$*+?O*,88#6&W!<HX1W3.?J3 88@BO2&
MAIR(I].B>?=JXZ]W5$E3I>&/<FPOA5M^V%592BY^_G;21RD>Q%7O'N<S*27A
MUAIY($)W"Z+IP^B@5O+S6Q*L%_,N&HO"&5]A1)OTYB RZQ@6C/>4J;LK#*!H
MY?6"8=',9J^]J'HIG%=85M8P.ZFJ^6N1.8G%RYCB?!AS)>+><<M27/Z\ZSIT
M='X P)G9MPHF+,Z66#%1F'4'0=]X7/9U4#[%7VPH:I@1RU%ACEB?)T 93R84
MVL!]9.H[.ZP$<]RJM.FYGM1'.[Z'T>753L^9% =)3%^ PS^T$$P4++C/)L8E
M)D1I&N-IF)M;*=N7-N.',05);6Z((2(E^QK&,>RIE9D[K@,ZGN;Q)6*>\4;Q
M;O@ 8%G9K0?'JK"$MI-Y5B@U%YK[WO&,P/+>CF!2/-]:SM/*J&A?0DX?#08,
MCK(NBD6GQ&F(1SN_\0ZL@$][F*Y6X0 GO6EKEV"V&T/3;8A2\/+=F8;1=N_4
M&2ZT>BGSE_[AL^8P:1.&YE-!2UBC6 ?)A\WEFVF'H%='EOA*"?/KG@8\ T9[
MQT0X(F8*#D+_*Z1:=8/W_R'5O7]%JH.,1C<RTEL+$D$IMUBB]KMIN$?A"?3*
MOYDO]#Z,*\8[)USRE:0")X?F@G3K7A2FJM:NIR$QB6)8U.-[1UW<90R7%+*C
M;;B\8&+Z7^*&5"P824 ZZ3Z\[5+$9-UDZP5IF7>5ZPKUB37Y*"U"^'*J0(>Q
M0KYP-%H?+MC3"*2NN9S7NIA?7C(V3]N2AL($%?,U2&!Z.G(6Q!"Q7!G5VZ&(
M.U#9MN!7?G>-I@>?"]V&ZZ-]6M*FBO])EKM05:Q14N*%$$A:RHWIUT/DH1LO
M0V3J1LWH%%P&#^!O-N&HQ&/-]>GRXB94=3C/II1]0LY>[H)! YT7"(+$#TPR
M]#@VH;CF&S&E4L:=MECF])&7X"HHP?V:X-WCD^8]/N7.7_,A?ML>;/8LS*QJ
MB AQRI8,?]8?-WUKG!D?#0Q\2E4<3*/M1/7]!$)&R!6>'%-A-H?_96HDAC?S
MCE.5 0=>,[ VL+2YUG34W&=N[-%531L >.LV)-2TV^O1;APZC7MK9I_-T+%S
MQ9[9U??XQ0DK/L2TAKU:3F!B+>]:F8U]\UUJD]<K.+M#0*R-?4A]Q_/F/"_9
M?L4XCH*/.$HWC0'X0Z$QT?GXY#EHV\:[](LRCPY$WM,UG8$YB=DM <KI^HXO
M2GD0ML"W)X_R!V<5\0<.N/O9R0F[.>\MVA(210-DS[=-7UA!O6^.+X>L*EJB
MCM"!P\8<SP)BK1>TOB&>M8=<I*+0@_02XW@* ]_ME-)V#NKSG1!B#<O5G*MK
M0( 2X[3;^T,T^Z0J#$A%GTO3DK_8J8?JQWH=L&6?CW)]2I 1^EHH<XVA36>,
M.<_P];<6S*$QZ1/\2Y#W+JP_1X_(+)Y84RNU5 )&R<>EZ4W+3- :'M:6R/2E
M/Z(;(@H[C-3EERPG*(F1J)_B97R^AGCR"C,:Z?JWGGF'DKM[O"@];W6_#C4+
M'E7((U-=^4O!JS3)$03:RC5L3B6;1)"NCN%]$L23"_XNI=$YQ;/G_)AV92*H
M!"^J9HL\%/XMUG#61K+Q<JA^1KONW8H 6PE'5&UB(= ":[1IN>SXR+HD(,@.
M^TQ_BS\V<^Y; H+ZM5!R+G&DGAN]DKXH0X<'<]:2YV#7^K2%O O/.P0FQOI0
MIH-"($KB"24EN,^0(&<V56"PJ\:_=.W=10;244EUR*HRZLGZ0%?+,P_NC+B
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MD]^*RCOKN_@]X''I^*1?Y4'/7=M">@U5F1' O !(SZRKRN=3BW/P56S[]1\
M,(G."_P(C:KU5UCU_P.(^[=+]V_4;3'-\+Z YZE%KO\\<NE@[^T398E/.-*&
ME3BDDSGP"O&%H!BIYB-R?56??&?)UY'C1#AI1VUT?!OMZH])0HE1YW7DUW)W
M0]D9<E.!*49 .MB47.F!ON@@:2L20:KXTC^J(<>LKEIHY)S5#NE IJ<**NP/
M(/<AS0<>E:?"G=1VB/K#-ZKW8QR>9VVP6A<26V%$EFX?/+1PS0(O%=Y&45+)
M5[<05!J4T2RHW.<3J2\FCSNL+^S3,Z0%$+)(M)Y'CF3EV+L(>OS4]* >I%*8
MN<OZZ996IP&/4$*Q;P7,%:&>+!CV:QN2W+X4G7F*O93 HJ,K(IH:IG5I'OM:
MI>!M<,?O%-O_P=A;1T79]N&B@TA(BC0,("7*.(0X=$B7-$.G0P_=*24APA *
M(A+2,,#07=(E,72']- E);#U?;]O[WW6.?N<\\^SUKV>_Y[UK/N^KON*G\_+
M1RJXQ?$WJ]%O3"0Y%4OAKW^5V:RQ_[:X5P7+C-_8XW;W"DU*!1-SJ^EK060\
MHGW,S+N7B^AV;#Z$%IRNR[XNY7(SC29/' W5FA>9-H:(T*LQKTP?&A$(ZV>6
M3\HN-.)*!\?:S2%+W*OXKQ26/5?:Q!6FE(P=N>D0^K9&)FH1(7NS$+ 6YHN:
M*3V,:SN,QO_%W/[^ ;-[Z!YLMA9CX=&ACA;&!TZ^-*LCB6P6?I);,;YHT/>@
M@V$5#=\N*JBV]1H7FXOUEC,>?J_WE.63[N+T&^<SA@@8<G5<?;Q13B@3Q=$\
M-"*62XY,E$1R_C@Z1[^4N94N7\X]/:FQN1_CA=1-TNS08JN*:W4+!ECW^;(:
MV(*YS=:J(PB>%X@W''!YN<A3(.#X0P;.C0U26]L%N>'RUF@QH\L[0%-!<Z/J
M_ $EJHZ@$O]^K>V1[NPV9A?ZL8U_^_[^>L?--1G8BQ,"M4@\T4++3)W#..8K
MY9$/:I3Y#AG'$%$0V_H7L9I3W;;S*Y7T35<E?I5,$$1>UM,?STFO6FP2<EFU
MC$3RE*8-S+N-#MY\FH'/N&39[W8_.%07AC<RY=,K/3->%!9K+-_5=,"[_VF2
M7_XI\PQ'(GTBNZ<:=E95V5$(]#NR8#9Y\RDNWT]D)!)&^YU6LG<SY._\^I 8
M>E4\6<V_]E$"L6(Y\-'J7B'!,IQ[XN@.0,?JVS/(^N<UVFB.]!?_]6=%_/&&
M.X#YUPNUM1;:"8G%J-:CM,O2>M1_*5.U9'?!O_P(M"/><XD>#VR7>)P/[A7O
MPMWU=QRE2*8YDU_+QWJ'_1F'UT-3+6Y='?#3,%T^9*Q.VSYRUZL8+V2MHL:*
M>*VN+H^]D!YW,==H(R3[2%?I#O"(^@W>?O2CW2(6N T1T5.KVI'QJRRSRW4_
M'EY,(O@1\CTE<) 7ANARC$J@KA^,:913VEE-M/9IKVQJD\P@I-@]8/%[(2?W
M(D2JP.([B.JY:\'SXKSDWO//UY?&256X*]G8TV45SJ[X?\ ]8+GJ79R%* E5
MKCMN7N*NZ*.*W@.J1(VGV'&UM%,/I\/I(QK%SQSDOMJ7!R^) B]1UPQQJI3%
MG[E$*<C.;9M1MO:CP,#YVCW/'JWFZ\7??E.O%=\=:+SY)0!WIGS5WK7X+5 T
MCW"X)*Z>\E?X^&!:I_5L@Y2:7A!Y\\T3_CS6N#ELEQO8+4@,G"/U.Z+Q9X/*
MQX2T33%R7+F7U=\LC<J^N"QK5!SU/R_N+7\O5=6;6;3N>#$_ZHLRJY:SX'#I
M^X6*]0DJZ(D ELA,,4S2=#9V+&3X[FGU+$A-^N"8?YSLIEQ8Z?\4<6.9""^?
MR2 TETM21FQ?;H>=#-N^/+<]T^"O!,WL>HI^'KEV-0(*@C*.Q3ARSA<&O/SB
M.<EF!ISB92;GLYR=:-AG3!+*_WRU$B<L"RF"&?%"74Y!"Y:F="02"?8PWAK_
MD1S^2#K<>UUS2@,\N3\7/5+#JKI7YX2E#*OHA8BI&!J'-]>)@O6?OY#T^8!>
MJ/DRWYR="=+HSD8T-&15- E[A0PCL0R=C?*$W;TJ!"TO%M*A$RG&AU-JK/@L
M6MUXLN70/#OV<GY<Q>JVN7C6>!STN%>#0E;:P2.B."5,C>;UCPHS:T^EB0@5
M17WGO *S_4'!66],(WK[\JL>^X$@1US>RT6!6J^LYT2P/NDS%3R?PCV?=+GS
M"%'!:]TL>@_>MOVO=21(,:3#(S67[.)WRY+7K%V4A?J@ CN+,!37W$\UZ/ ^
MAHO22)E551B/:W5O5,?*Z^5^8/)6C0/5Y]&FYDV.^>+(" TM[?$N4U;,$Y*\
M(70C<J9@W$USN]]+\#9^?U;I0$-O P&*.Y H'1+[(%>IU& (Y!%J&^6=&:($
M1G'F=[B%>-NQQ7=:VXIR2_N/*MJ[=YI?NP5EU@P09:'X]^80?&%\R,@N> )X
M1L0ED1+/@I+:8$9Y(^'%B"K=+J?!?L+O+X9$%2(3GB.[QU5;;TJC=KAZFB+N
M"1HKJ7"KST'U_.L3=!WQ&"CE"> 1F<,*9H7Q^_'+#Q4-KY(B)^?UF;_L>M)_
M!QFH@#7XMJ6-=Z26%7N@;$VS[ E?$LI^JK_:[F=R$-Z.:5B%Q[)?VJP=UT/.
MG90;)V39I5>)MNB<<S[J/RDJ^98B[T(NYTK-N)X7(S9K%[+PTP073X:&R1N9
M.Q8[NRDT5Y[@<V2HDI6QMJ3F/VHA\%; N9;)S'_233E:-'6__< _^0X0M_1Z
MTV)W#DTDR3U>6C]K8\>>+K>A@5[P,8FQ"JVK:5_8]Z018I<#[;HU#*@0DIXY
MD2P_$XNO('A28[1&Y/I.MIK!: )Z--9Y#LF<%A0T\O75';&C!3)N>P,%UQ7.
M($G6VO)0I;U&52, IG[<LZ'A0RC&Q&AD)9H,353L=8DCJVV(9'O?U@3))S29
MT0<'4/;'C];5"/:2#(.L:KHT*.8L7%+D79EBBW;U3_=34[XDK@]O6,7EBL]>
M<7T<L>^6^W$.3,]?K)^HY$]54^_O4YYUJW5IWYMS@*K+7(GM'XF4U9OR;R1Q
M1J;N?DXO8E-[6:*,+!X_$5RKL_28XGBM(1XR0?$(F$1DZ1$_2O W+\^)E,"(
MS$=%:_W'(27\M%EB9^.O]I*+G<4GD1]RC)C!,(*/>S8F,#M](K82A\=,3PKO
M  ;^:=J[B^RK:3O%\RBC:8$O=X 8CQ1ODU*FGN'?_2&H0YVB"-G:]PFDJ-KM
ME![Y)^O9V$&!K*!\9=4G-*3$_1#Z'_G9IWI]@<4Z0N9Y!\Y3+F&!?3(\@9T"
M6+!3WD:&';>-*'EB'@XNW0$&;G> %V?<W+G@[1?DN2'NOI7=RZX%S3JS>@=Y
M11G]&VN02=8\:V3=ZZ6U"JV1#='SP:UW5I9@5LFSR>R?>1 P?3,T3HNADU:J
M:&_O:F''-:I&3K-L!:7;0PR:VQ%[0X'5<S59O%L+6-HQB"R3?<U&O(!)](\;
MY1&!3[)*[T0K391"5;?Z;AX_A?S"8FY;41>8%$5VXV-<D6KEN&D]5]6,**9,
M3FF7VQ+YG=9"U^%:I\[T7P_5!B3^9;]*:ACZ?5,&3[*KS3O !FE?P ?Y&VG=
MI):(V-479'&1,;PT=,:? 0&8FU Q85 \.<7]M1!!E6] 9!9G.[X7X*'_N/!U
M5G;#E+"/G14@-7Q?D,!J64$01.K;>[*H@'<B4[">K=3C5 #O/!;+_F7D2JW3
M,JQLJ/)<-2:&E(8-9R3*.^^V9&5Q+<'[S6.Q/4?_?HZG::/=&&4Q" .YZZ3"
M _$?A>"&9$F%[F7L*DMK^"IXH3DW(JO4>_0H(MJ'F37&L;Q#Q5!#T(7+I\^X
M#%W)(-4#"EIO'28$0LD^QUG82%@_15$N*4L;ZLR&*UVD+I4YH_+&7*2!,?ZE
M@=X\R@BE.*%!//9E4M_N&3VCGR;\8276GU1FG[ R>6UKV0^YU%LUV.)S7H>P
MN1&IS.)SJC"\U@3R[GE5@3B1/X,;,Q[3;#+:N"+FJF(@]*FW9_MN%VR)2C&L
M])M+%,=RHBF[7&EYQP-A[F4U+["%*6=8\43*'JXSQ:IV]GO);#/N=22H@=@F
M:7(RPY-[]\J!H8E3E ^;NT+D/N/TYK5T7W>>:@HX>5W+=Y$G%U;(7$UC\"9A
MGD4E_#8E$^0#9&P_7-?'+-!*I.Z'*QM4?%IDB<4OJO/S^"9(-(BA;SZ.6I3D
M]?E=L(I10*MXN\C7\K]L?&,J2L0((+>>KN!:"\ 1/$H540OV:5EZYM&?W>(B
M.&U76$O4S^\ AG8=[.$<4PVY0T*L-,9)Y\Y\M,0V6Y3T&D3!<VSP2-KOG-Q<
MQF()-+96^??W/JV5?+6L_D3<02(O6V3?0)#RGN9 NWIZW8.M(++5VAL[(ES#
MI:^T7-[0=*G_IV%LT7(-IN3E!(5J'F_5RV@+G(#N31QB"1]0BE#W X,IT((8
M>_F$"O.R@">6]&=A%?;75W;>#*PU4GN#F@I9]O9P_%YL((KQ2^.'*L:X%Y.,
MSKIFT,Y+?L@>Q[06^<5,+PUV%G+*?S>6/O6>[VLS1VX;QM.NR7:PJ6)DVLV)
M)TE3\9%2GYS>\LJNAH?O8R'\_W.1&3?/WN">8UH!7N%[7]]CTFW ,=A/7IKV
M]WCVC\#LVO/$.T"[[L3K#>9]4\X[@+S<'6#P$>FUTA62BT9L /PLA)S=4 M*
MS(-K'1ZZ4?9B4YYCXDNND65E+3,>H>XZI^0=P+C(5:!&#H\G9.QG,GA=P_+[
MZR=$Y'(F\R1%FISZ-+_3/V0'"1F<3$EB=982BT^X4/71I\^#Z,EG>8JIH\#7
M,H-L)<G(Y<0YO4/CM>3Q8K6P(5N]Y5SGMZJZ\M%@6I1[7"_-90HPV5U9]5A5
MF+.#O.TLT= US^6QTB*5'B=+*CEY:- JL[)&X*NFI5K)_S!.]D[O4OZ]J9@G
M$G_X)M/LV#J!% ZQHSA:X[*EO#_!(&M)V8#T0_](49:-K9!)+*->=3> ,:I=
MN&3K&?8PB:%*+<^9B[%@\4XT+M0E;(I_\B2"4NWCW*^H)NTIC@=ADU0;-UD9
M' )[E()Y]:QX(<A1.GS"_&,_Z<JZ;!L#(U>EP2/#)#&^,M8/T^<X9V?/!D6]
MKYG]$Z>C[X&F>U[CG.4^OI<NZH,S]$-'77+KG859WL/HL/@!9/FHMF+S\N9T
MY9CA2AY-I(=A=E!49^_4R\''E3;3)1X4JK:V-CWU]M4SA]#^!C?@].[IX$=O
M8,D14T1(LQ[^K*JW>F_[K)S 6\!90Y$L*VU:#+9X5VV;MLMC9U0^;[$M*Z_P
M"W3H5%B)FDU^E+Q0=H;=MOO:)^S"8>VQY/&4!:(.4H)9D+MVM'.TJZJKSCZE
M/\58\B1%><QOHD9D^2?U'C(;F[FU6LI2QXW5K 8W.I[9PI]<;H9]Z_8M:;%F
M)%M4]BYAZH+M=B=TAQWT].& >U-U&CTB/*\6EG4.K1CB4-U:6LGO#4]7J&G9
MTNK,@92-@157LFFG527TJ=I!SE'D/Q XJ"ZBEW'\&E=ZWXU[4^CFS8A\0.53
MLS$T-$,:%E R,AD9T?OW)?O_^:<?X6G?EWFE<0.[:I%8U<1AFC0M6KU]*7<6
M<4UCS#Y8=@> .=6[Q\4HE_['FU3RUYO4LR1R8NJZ$%@V^)OCV)38[F.,QM^T
MRDO=R1O$YH8#X]O>WR%?A6*$^D-_2>S8S(H>86)[G^4J_Z X<)/[>8]$9#UH
MZ%?J&D4.C*W(CU',R+EI3!U.W\S0;[-2$Q$SSP3A&_/R;=B!B(YJAJL>%(\4
M6^7>6R(1,RH.Q^7]1G18M5E28,8P+U*G;YN?X/F1E7^%+"T[S!D(PM*]]X&R
M/9,@K/]=V)M2NPZC<WEE4-;52C[!KSH?I"AD#\P1DM4IA3;T*"@66W:<7\U*
MCME_G_EG:P.6V#S3!_S!CA7=T8^,XO(,NJ^Z;.>1C4F/1)-Z15+=1D"<YA9'
M<3\IJ[\"^3'WYJ-+4@A[O&_]=73TS=S><]T!V/T<XJ4.H/TT6R1R_A/.!>T
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MVOW$;!E3^'E#TXH<7M1O*$4 )80(I2HPYL@$W8_-3='NQM.[C]J41<%+$8S
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MA,[;FDN3$1<<TR.P;\>5@%^2H48G)+"S;.*$O'E@X2(0(9["?X"JC9@TH#I
MZ5Q@FGG[D:3L!O[0CB[]L&* >E%0>R:P4,-<E!-'UYTS6$UKNY5;8]?TK/</
MZ#:F_F5ST^9?.-VZ$[]/B$%R[Z*O0P[?JNW4)KG+&*50 H1$#\N@4&E5>=]=
M2U.*'XE?DY<E9295Z2@?G"D>0;OI^U%D.F5 WRZ>I2($I7&J<]W4];A.;^3P
MMC\90WAJ*@D ZO)=O2' <*>VI==<S#GGE#($Q?S2^E0^3XO<,,>R"?G2S(\R
M3[*O][N1DM^NZZ#!Y,<KDL(/J$MM\:Z^:F-ZUTAQ\O9MO"I!XHYGX14"/9S9
ML^7-RT0?HT'W@ZKJ4< G=/V,#WHX<THX#;8XTU?(*S: E+4?PYPG!GN!Z5 @
MT(C'^5ZEU\?P $QN#T(JO%1,>$7=HTU';/#QVNFZ79<I1:4]K$+*O&0A7\P;
MBDWXQ:FA!ZHE^NJ$MGTK O"VK-\\^_U"D-")E&?LBQ+X/-W/W]9M=!O1J6MY
M=,WUK&*4:O%'!AKSMNO%+S.7<H E(Y+ 9U&9>(Q(:P8=NB\S]U7=%J*)4 $U
MF/X97MI>7=HI<_6U4[WY92,A0AP'^#.#T7, T#FY898-(>H_@>USAH!BS['Y
MX(44PZ=/.EJ0=$-102$/'_K@(__6CYDR':&N_BM5$/]'H7"SEYB>VS=F4_BK
M5)C]3Z7"MRG@I!5R#OF?\7+D[<G$/_%RRK-66/:M2O;P#%.<UN<JL5P4+8YD
M(X/$\;^X/NWQZO@T>.(1M2*A\N0Z ['8<_-X'B+G&B(P-TE?_VC^E^[-YQ97
MWYQ#W670UYQ9_+5!B\B5QAZ" MYSL.K6\\A0)G?R>KO>2%XO8M7U(L['/0OW
M]T/^+,\E[[\^_BL1YJ8\W_^ZG#:FPYDR_<UVWD?O&8I7U7D*W*?ETKC X\WI
MI<+9H?YC.1UZL_-JK7@%21.\8L1JLT59\HD\ P>>;^;LZ,.9A-HW3/"'RH"'
M%/II ?@FDP@E.B\5U2W0NZ"\PZR2_9!2=_*F!XOW*?9#O"1UFPC2EK5%\O)=
M)]0/H2N2T5+CO *$+(^KHXFW4/\1JO4V'#<>5K#@RU+2SR%!.=.O>,E2_0BF
MRM#B]% _JYBNH;CX(TZO^;)'&U6.HM:$]&:P%]_1$:[>!I.\&Y4&UBERJC!/
M9I&@]H8S,979$&$8_87WX;')YZVCI*0]&O&N$) _KX0S_.V#PGXBAV/^,SNQ
MN;+>[Z)^5(9=P)8,]8WNGT#O%=4TU?;#FVSG[?:B3%A+I8%:/<3GU=[XBXKW
M<].[UH(&5:.*SM5&MIVDL CD?-C68'!HMIQH65F/RGWZ#CUTW=IA2FK3,:+%
M0%F4OW:L=S-6UQGH6J$Q8Y7O"1S=6ZRM5PNC%-\_:714*[>V)[H/) VQ[:=^
MF^.'+$%9.(K@#]VK&%-[.@%YU(R8-NQAG.#GB1#ALA'<;B\(#NYJ^R8R_""?
M6[QU=( Q+[_0#!R3G4B/:)&;_P,0-P2 HJLAU,7S!;1:Y!^"%I:SN,8F2OSW
MHIYXN1ZJ(<A5-8E!S^6&R?(!?+U<)^+(-=M&_1I#?2P,M9DS18E/,@M+S/^]
MV^5_Q[4LAV^;_UX OR:(;ONW-NNI#M\=0/>"^_E>_IE[:WNSNKN)X9P\9CLP
M3.UJW/^#X!U@8^,6,F>%9\K>]?5L?JD[[TIJBGAV:];GI"JZ5/YK_$GK\R6]
MU<A4.@5;*$]3%4-NP#.GW?21*^_Y0U4#@AF&3_H5<@3^T;?5_KW="FT=2HTO
M+IE"KF!;2</#2*T_SU_&AVKQUI<[&T';K[;6S1.,;G3]J<=@%8;\PDPAM5L)
M@^D1RQDLM\W^/RP^,FDLX3CYW@'*UD^W=Q/ZY:4/=6HKZ+E%F4+\/UR=G3Q.
MO"5RUN'7=]T'MJ1[6?";LA[JW#S4]X]M$Y<^V]G@?9DM*K)<8C$:G@%=PCD]
M0.-\[?W]T%/"ZECB_B7I5&ERX[::3KW(-MYN?8#(J9BET/)O2CS8I+HO4XAG
M*XY_SS8Y*1YL'I6 U*#!W+MR6(B=459HNWC:7;W;LN!0K?P2L%["KK^C>4O/
M^!"4JNH%TG=Q7DC0^3@[O>%'/_*H^'$T*K[_HGNM&A'?K"O<FJP($@1 S%&W
MWXI]G8XXC,/CYGI,$OY>'4LM7UG%M4!VM<ZRR\^# R(LAK^5)6Z49JY>+,G(
MTJE[O#X9*5(.E2=8]NZ3"1=Z-G3PID!&_5004Y\WIS03O<%C*::T;>%:!=]A
MSK)-< M/?*,S;R&42@3J48.TYXQK0[EF>P3]VG>EEC<<;9?SZ'I?:0-([N6M
MH$G<XI+MF@6]A%Y]%\:1VB75>T?2VROT(!S5\RP6HM)6P$C1H0MRQA=<1FZF
M%K'YP>"IWE@\$SY.4!?&B2C:&9X!$AWIG?L=KY9>Q  >W?-Y#'BDA>-/8 9C
M ]MB?N;A-8'XV$C-G$49WX<7#7R-;R^E;:_E8J!4RX@R+Z&;@XH9H5L4VMQ(
M) U_?/<$'+ZZ [Q<Y(NE@+CLA**U <)@W8GNOCG"8=3^!QMW*?S(*',>LH<\
MY%ADV/]?&856AXR%E.P[P%ZI@HG3G-/YF]+?+QGY;AB&?X]Q'":>:8D7G',G
M!F:7GF>IK8 P>3>2^T:8^MJO\=]LG!W7"^U:&VJ,PT7]=$WR$'1Y/SW7S?.J
MQ[0D>"IQ[%A],G3%[5;0!B/RL02[?V<$AX09!.A\G")H5F-7CTX0?2B_.<ZP
MH.NNW^W<0"& I<7L..%>$Z7/MOCKWGIZ>A2=ZVN'-G7[T.7B+S=SA.5HXW:A
MX#WF!0(2LN8,!7\_02S'&<R@MBJ7HY#N5V.NX[W4XM-/Q?E6K$ /P];.:-3R
M8=-2K=/^MUO62V[YM80_"Y.7R7\6S]5VU#[MA9Y" SO+M>\ F@>NP_:W>447
M272E&.-]DX/.U>WAV@#7VAYHIM-MN3L>=!OQ"J.A[<'Y08&%53-:E0%ZKWF+
M*B"0_OATO^NB*=;9%(H.M(J=I^Y/B[ZMOY4^^>\ZXECXTDI&MJLVT1,-U5(#
MOHU@[?RJ2C<VA8SU=/-K[;_(+LQ/K61-: [?L<BI5^VSRY[?<#>DT*8XC2$.
M#O[F1PFCIU@?BJ2.9F)/Q,//=H'' DO%&D.U4,LYGY\(\ F*'S8_F.8@H$:"
M(2PG#*-?YLOK5I'%4XX-@XI@\M7]Z6%=^G*T/-PZH&6!@9@M=W\A9E"/O7ER
MTB$G)@&R?Z8<*:A?5$+I/KFUOM!@54=MY@VB?9-?7%2S8!ZN*ZZPN-"9@9-O
M^[$)V1*/7EWI-:08/_/ZD/KBN%=O 06/8 LKMZM6))9%!^<XT> QKFODVM;[
M?WP#:WK0O1[S.4(V)5S["_ZFH\ZZ7%J2'\B, Y.:3BV</H/EG6,ITHE8=0$^
MWA*_U/",>FI. HLE 1NZJ\\_PQACI[%F/^=P,:@P?%(9N19I.;.)Y?&\PJB(
M"]>'*4KEG3UK:E:=\=?1<?JPMF/5\^!GRQ>NN;/IY:?NH8U#FQ;.=70&!!^,
M^U$"(3+'CT@$,0V^(W7HGMJ=>R$O[4#;)?NE[A4/IV"..C?M1ZS+.9THJU]7
MG8P?XBFJ$W^=.-@X^Z7%'9-032P.BH%L!F9-)@6FB!E\D=$UA#\2%I!;UZ.'
MD\YN!WJ[5=7$S0<'B_H?NP.0@WR6<::<\#>X@E:.V$;"'L9R/9"6BVXAE!N0
M[[LZ7,,X@ Z>G3*?1/YQK;Y\,2?E2Z(]TL7%DY!OSYB.$'@\X'Y(ODE+&*]F
M94DU2RVU^M13^:B=I-KD6P$2E9\;X>R6(@RR1A75C'?WF9PL-M* ;).>,3>C
M!TFPL/L<,(WVB1XO29RX8&TN/<WW/1'IN;-'TVDKC7RUXA/;KA)HF]1-8!P%
M9UZZ'8/A=AO*73:S#DLEUZPHBW6/E!+D@E60A%H%.\,7:28MS*ZI&*@NE_/B
M)%R<W>HY+V.@R :4 .3 H@/.7W6(JIYU9 F[MB2.[VQD\^;L@H\OL(<HKGEH
M58R=N9;;^:9$[; WZ"C]<HIS)866:#AXR$"(W)T.@ML\A1,G4_J@7"FUW5/F
M(XTN-)CH'J7R,77]#@:^"@.2W6MJ*OJ= M2GAP^BP[T /H937ZQ*<A[A+\UW
MCXS.,^H^$I$/]*E]/6URWPDO_D"SZBSID7</(:O<B^)((.GSYU'"DG\K<R_N
M #%>4]CZ;TMC+\9U]B*NZ0,&<NIKF'8=SKD2V.R, \M4_MXM$V$^QFCH!-YL
M_E_RL=#_YF-!.XX]S0[_Q P(/+\U(V(O_XG*4FSC/GCLMA!W+!8EYG=@PTG/
M!U3=!&A_BCC8:9^JUZS(PWN Z])[7D26@+ :)"14]:;5+Q]RS:3XW#.+?$W>
MQ9JBIBY*$;X4D%\BZ%3X6Y9RBHVDH&1E?HWJFK*\T4=PF82"ENPA\-L_FM!S
MMP I'=EP:P"/5#EH$#+8GY7Z$SQ_2=D]*N#;QW%/KC5?JOG1)2R\_BMB/A92
M:#56AH[G^W7<N-LCW.'2I-W%YF?;MP+[J '==9S5I7SZLJQ?[I"$2D(J:'\6
M8%2L@&C4G'A!M1$_GQBU'5",0.+U*/W\<4\[2QC?Z(<H=G]Q53Q9]>" AH/,
M0A%2 #=**[%9Y2TRW?,@STW/7Q=:$\6RUQ;J.A>%>,P;',:3F$)-W<F$-JZ#
M">D$+Y1%7R$/U,M;"E\[0B6'965ZE\+C[DD0L\9]<.04PWQAM,&W+EYMD]*C
M4W0,Z$U =O3/F _H5*HZ^X*3;Y$QG)%1?V6Q[#;6"4'.;D<FO2SX8Z&MJ([P
MTR-= <%U8B@9110GI&[XO:K;+A1' V[@99'H0DLPO\]&D@FM/\$/=J;!0UKC
M;X2X_0P59Z>4#]E8!H*\5YH#D+?IZU+HT.A[ZMI8T9P7(/VX);UU[,HQ)&%E
M^S<A6B@V03H! 1(KUC7;E90SY\)20SU8H\E9BS6+(,O;.?TX*&I*5. [LOI[
MD#J4G/,+/F=41 :ET6%0U->/0D *B+:V#6NA]EM_ L+W/=IL6/T]Z#HOSKK>
MMJWW13VL[^16:?"C./_:"I#_F<G2Q%1J>/M;*B&,+O1LYV_"TZJ(]@Y0U".[
MGE;U$'Q\!R XD\!97ZCL:9CAO0-4_X,O!7;J6V-\K2V#_%<=Y0*@&V[WYL8[
M;L^VC9-$;BT<W_8?2!P?7MT!YC"UV@WITSV0IG"<<,(:O?8-5YT^]S<+M)\L
MO]X;?S1"%03XY5JW.@5Z8UBI]QOW:*/\=X4H'9(Y)SYY.<-WRF]+SS/\.+GA
M!W<,URS=@V/HI5G$RH_V-K5CEX_AOCM612.AP7ZNSE]T]8T]X(9I1=I+JWT
MTJ@>MG&]LZ_Q!W):AGG1S=&TXB/)=NC Q0-H2VG*3,)1>0Q['8[M:)?T?4?X
MS,\:]@#LY,GF5.\G=(WKDT"2%Q5]'L1^TN$OJM[I3/:E!=T!>&K@7Q6P33;<
M@4^T=%4\B6A[</0I]]ZM3!-$6U)*T^ #_:24%9W@Y>&;B[F*QC86CRJ=M[)N
ML@*],!42VT**SYC(K%A8L<. >^37K=!;\E;V5HE)L3L $RW43(49^U?4U)!D
M_[!VH!K'$25*MW3X:/E\VYO6KLNX$\?*:4(/U%H RJAI?02?SKP#K!O?/C9]
MHZ]J0],BO*M[EMW:2;BKS/$+EQMR^]>S$* Q'Z8M1F&[P9"-Z3L]Z8O)[? 4
M+CKEMC$%QU/$[[D(8JBU]+8.4LG)F1U_;.(XVBZ0VE7N)N"_^@1+%T9V*B5[
M\3!!7'O(@:.[Z:*4%X+K<I.G]_^<[=H#7BWB[U'@AXT<>*6@$9,IQ@@LG_5M
M5(5)F@'-IM=0VZP8LMQ8I";U2:JBTEXLP'FB6L7#H_GTDQM1_6^+$GAX_AW@
M'6,L\&LD(V%\P9/X*7H5Q9@U#R_"U[D3M9**ZEXDU(SK2$N+/4LV7'7?%9<=
M+MR6/5:10B(S"Y<)VWF1L:[Z/#Q840BH^6W+!']P;!2UX]QGK.6B-^,)+_IG
M,*O@OL>6;EL+FM<6/[\)#<&$!#'5=@;;IS\$;3LLKNHVD22[PGG?FEKL-'OQ
M]M(_L _HX+/$C'0SFH[AN'(+"&*>MT3<)R5Q>R4*%E;BH"E9.6JBRF"3MP*;
MJU^^QOUTOFSMA*#:@_R>=Y@0F5E(<M9E+Q/9_)$ B7!REU=[,Q7"(2_O-D./
M,/*G>(3/I:EI.,<N:O5&7E //(LR2-G'Z!$YM&'J*TQP:MKP'RHN*N!OE>L#
MBFI%Z]]!ZQ(>,!(4%6D4F;#'%W\ F[>!7*Y2!$O0/UYQ!0(L?6X$"Q!VW4I3
M9(U]3O.VJ0,J%,US UZQVB3O0QU7_8O2ZZ/3\>1ZW#+>G-+[#!)Q#>^&;9[;
M;4#'QSJ9?9B#+' @)/XZ9OIQ!D-1)-!-C7%-77$:VX'9>=\V^YX"O6N9:EA:
M\GT?2N*"(F12GG7,=ZIT?+WGSY,"V%U(8Y:_"#]T]>',4H5 I1MK^9//+8X/
MWBP6C_]PX/$ B<RH[88-6_)>EI/#HB,B+U>GLR:Y?BT)%1;$[)L+=E,I+'A@
MD/EZ<UEIB$B)[Z50LP[=I,E)66@Q6.O% UST%.$X3"290&#=]?^]VO2_CZ:E
MFJ7]+M,+Y5'JK[_F;J;_G(L/\(\RMG9NMC]>*%T59JC[?>YO18]=_\L+WGX[
MY_+0PUA:^'DU$DRJD>JT2@RZ'21M%TG?UZ*"];E\S=^!B>HHR#=[9'1#0'QE
ML?K?GQ?/&N +$4#$PDN.?*MC\9;N +D+-=\OGK$BY#\+92>HQS3=_RZCD2<
MJ1=B-^K&11 T8O<9@I17P7CW+[ZU6[]3#+D#Z)OTP=S?069<8[1MK^KM!N9T
M-J(W:8U%/%KL;!7]<]?Q]**1%ZZ%L7;9;>#'WA=YQ-;:KZ;JG,XBH %L/Q+?
ME:U9NG(^KQ3/'"4(P3KLGZG64%3BN22L5XH?!;?U_F% I>?J@62_/^=Z>Y@X
MS*'>VI'^_'LM6G6I.76CHGM$B2AX&[:XGC35"37M+"EDRO*J]PND3%['"'FN
M7$DU8"-':T,7*5OP0&//79"DE'9UC$K5]AK:[K)&SS1@#4@<%TQAF-A?[C#4
M'6AT!V"^+"UZVEHIOT^XSM4=>P=X(=86H"]]DYB^W,24T'!I+2/;5TU00//W
MZHABV54G9K:%CH9PG74EL<7EY[?9X/VB"1=UH9Y&-[[8C<A$#>%T[W?EU2VU
M$E![D=X@@ZPR.YIMEG0\&=KY0S'D)[KZ:IQ!=UAP>S%&>QI&2F)#+#Y$.3Q#
M;W0,P"Y4GSGSCED/2PX,.M&SK8[UWF9-XB+%?FJOO(W<QBA:./8=M_=WRXPJ
M&RPL>FM$&7:J\S3)T+E,N&"J(2HR"P,T6\&KWC+3J6J&:L 8A.9"YVK6++$9
MT(STS?' NB549&N^1UAS$R$59W#&=J(;]> ;6&S1B\FUZ#3YX8CKR+QW8DA+
M.-U%J(D: T_3'4!I80?##253;$8_4-C\1FN2/,K[O9U8F.ZI+?-,=?VPD6N-
MIX#MXHA\E:7K&?OP6I$;1MF+;&4CVP6#+&--/$4]%$E-STAY8"EKR?",8364
M$(&+2[5*3Q_D.>(JR,8M."$0R@X1TR9:9+P%&!,0ZZOW)]NRYPFY2?;= <[4
M57E&2+JCK^]5UL.Z+6!>?I\<8S4?S!@F[;DK2QD;7/G!. D):T6 F:=?<:NS
MV4B$P=[PQRG6<OA<3N5R)0U1OMMZ0VOA(D6)3P_*I76-1#);Q-/'U7*:( C1
M*O(]_,G(.MNURP)1X8KRH_==Y!^4:U:9K@UK%^0A](6AMGT']!]W9<?3'7=Y
M&N1J$8K,\%'M,>VR2" ^'A"'IL8NV!-1D]I3?L1SJ\P5X983-A>[ES%(QHF@
M J['7( %=YYEZ%V]6:E/IS'T<(U\[%[_W2YJFC7 \BHK9[/1BQEB\9KH-?%W
MF+,_#^IAMS#OM^O$93-SC>_I$0204+>?18DVMGC(.I8/P<6MNCW_F;SE']@=
MZMEQ$].R/OJ/41WUOR%J8KN, UF3MY=+*==).S<A3BL2"1?6VM$8W_([P('(
MB6R R_3Y^;\H>EVRD8$&7?6/9_TI[Y=7G@3U83FIG((\C:F6!C1ZQ_)2WR;K
MT)*ZM.^7\40Z2;1=-_.(B!Z-4#?H1*]R&M&'IEI<%EV%R4BHSN^_R4?#?\+I
M\* @B_+@LPA0;$%):?JC*VLJY0WA@NP9S_?=KRP]AW@WJMFR AED^)0V>"_=
M?,/*A%V;SF+JU 7& A59<]<J^PP\P@:ZPU::^6[[]4/1 ;W9DX2K.^%,9+9#
M%&$69 \?^E+@(&#A&9!XF L-6Y8V_XZ8GRF'"XT;=+  E3!,M4%\J<]%7:,U
M"!(#BEKWV1'+TF?!B;"RQ96+6U4]2H^K^U/4B1S:>R"8=5"L%SE!7!126JW%
M1C_5.ZS4H2@[15_Q_3>!Q$\(+2=J86\L=Y4A7:L9M^*"V%-T%:5WG6&J9W-Y
M4BQ/_$*!@;(!#7H?BEPWVME_./1:(^1%^>]:-W<S+Y7^.+I9ZEJW4"!5:S_5
MS321E;9E\5Q,Q\B:7[;C*VCXD>&66?),8A77)\FP]#R&Y:K<1DW(((S5W*F>
M&'8IM<HFN_>^OK_M>*+'V=IS_M18;L$FG#8<H*M$8&!+PV[O(+3V3->#JJ3)
MZ,/]@+$7)$H'VU=7405N?( >0N_1[RMU[?,9;_I45!C$#6D (NED,(D]<'B
M>O65D+W\F51,EP:9+!D93D)]L:T;XMZJ2D!M#W1>V%ZBSP,#V%]HS*,>3LM3
M7[3S4.1O [$>/E_MHRG]QAI?"C-JQP>)^'(+[OZ<\PH!.$+X1%V"CIN9F\G\
MHQ""!,@9\4RY..7%G&;"^2JJ2)9/E0FD"?.5&*52U:BHW4E9+8X)N+9!WJJ6
M=&F1\7V2Y*15+ <5N^(ZH^S&7F/L;UM=Q3#XJ-]D@@&^SI>LB!V1WU/IZ@3;
MQ '2R(S([N4'.G//BARKN(HA%8 ']&YKR5]-$K;U:)L:P^P]R ;/&$FH4T>-
M<M.C\M(FN$CA-:$9[ ,!#AYY66E#!7XSK.5]KX5]5W/AN";.U<@B9D2*X@)'
M(4T?)Z$6V'CR:M8;8TI.R!<$M7.H=M9W)!O0.U\SL\BCU[P"=8DYL&;(W1P0
M<Q!<0_P3-5I'^:N7EP&9OE(+$'"4XO4F$SJ#Z<U(E<[$BRB[2KZR&?P_YP2*
M04QE-/Q0C2.K?.*Y-:DSCL^$\6)6G33DY1##,#=VEQN3J7-Q<8+5P&,;6F(M
M\OR2\W=E2<<Z8<:O1P;)#7 9??I_VG#V(P?L\RJ=W4R#ZV&3$$UI8T<8T #X
MF^GDM;'2@@;0X6SAG:4RF^US9S"#THGO1T/](NM<2^DY&JM7_3GDDX;;G.9\
MXKIUA_X?R?-SKK3UNX\2\R':68V--O?-?8I)4*>1IAI05KI-DEROC<(DD=JM
M36['H7K9\8DS%SGTHN"]>LKS+7/!X.7&/FD0T@[$DC98Z,8XA.T_$4"E:P!S
MSZG1%"_'O"_<0ZYONSCZV.CM"Z3X!6B3B;\6UOH.&K+,1F6-Q2(=[(,B5DN;
M=34TQ[7'I].W%U)=W::0=&>>X[QHO'UZI08AFK=%P29>A5^-U1S?::D\\2):
M+BEY>ADC\SJ]9"CNI.J3<>'&[CWC[WIA,C*I@I8VII;[6VR=7X%XT UJI5F,
M G.Z\!?@E (>WFQX<V@3L2VW(.,9S(XE;J6TCW#XH!KR<1Y\>C@N+O[K20)>
MW7./DJ+R%KP^S4N1CI%/D"VW<7Y^P34++DC*B88IE)50?Z%ZNE?#\T7%D<EA
M?VWW0OWW9S/CKAW&.GU/7IBON1WH0[9?.[-5>1"LRP4]^+X.97C\_R1/*%'8
MD4[]'6[&K)A"&7T'F%C-.EZ<90/7]./-F.2.<(/WOF$[?+V0&KZQ$Y=+_NB;
M? =8;.:H:'_K*H#]2S=ER,7WZ\54KJ>.6\'<"J94Y@XPT+%S!W J6KCO-D?3
M]QZNC*M@Y&4 _DYZ\5YPNW]G@#"ONCS&Q?8Y$.5.Y8.-Y;\65+<S$09A(&2;
M[UOCR'N@'8"*&=T_,$W0L9Y5GC4&UAVNP&MZ1$P_:J_^GD!_24JA4FQZ?;-X
M5B[6DJ2UH[3L7-4B57#@=648>=Q?4S.CU42#81C[7HC\<0T&!>/*!\="$M(G
ME.]+EB2N^2E-46@U\>:YDLJZ>W[)_O1Y(JUE%)4'/:C6^H)KX=6E+X:,63W]
M*.IP# *KY!DDW485A&X03(5W01.8-'_2[V%2+/6)42&*SD_BXO>,G^W%B3]F
M/,<-1A1!)WV\?!.H,EYZ9*',;PJ728GRDLN3,%02Q&F7C!.Z!C9+XJNB&4PW
MQ<[32'KF)YD]E[G&*"1_2)^)JO]H,:(9IT;8O#[69YB5W?E:ANGX1O="53-%
M+FFL3##!6;B@QZ9IFC/HNO;9BMAP?M=9X%3?;_D3@QVKTO?KP[,@O5*GV-5-
MOPS[F*LB'*\S'.N__#-BBV!SN[4SQ1-TA5[ZB?.+_>,U-G5/0-21A]=%<,![
MF,0AD0G\)H"4J?N*Y>DHNM&EE^;5/'8(2O)G)-'J)[6--#QV2GB;&%6:!QNE
M_<Q36L:N1H1;.K5XS::BTD_V^,S;B3<ZU9 $&C%G 4'&=^"^0M84, +N$NV^
M5;W-=3JFML!O]3D#QT%V(TD@Z3QF%<EWVJ=F'X*-J6*R)9B=DX68"*RW=K0/
M'*>!;.E%<FVB3UT[N2D08:/OZ<N\,T]G$0F"VXU!Z%J:(2&0";V#J%GE[[)R
MS45;*Y][5INB?M S+U\E:_-1@:9CZ:UPM!K1UU^;BU1SA;"W2^IF[BOF^0V:
M@X3I[([H"?C7L\=QE4V.?!/BPWE;V1]&HR_.CL(4MEG>5]C#55<_QI6WK*L
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MF_Y$H:,C7,<X.[--2]7(04A60U[.4'O91-7;("5J@KT;%7^T2B;"(3&H,&]
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MR2HAZ@;L8V(UM7A12"O:K/,).-HGP##7\,5#H^\]VX:WANX^'ENOZDQQ9:=
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M,)"K2;/-&ZD\97!X:\V4K*DVT(&HY+"LG5A*!#$FE@MZ>$F2\1)=23KC-YF
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M\4%%G-QYO6:W3RN\S7X&0T0$6&S:H:K5#P[#K9Z/K$=O8YZPE=WG5DIG+%6
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MPF*O55'25O>2;DI Y_M\/$\%DLBW4;KEL+Q$O,!SG#PC^%M"60P2UM$\:?S
ML*1^;/76+Y_F?/ 89IG(K]E0*_R"ACRFH'G#N&8R=EK<X[(JER%DN!)][)5I
MFBAZ*'CQ.V+Y2\SCPEXY0ZX6];U\+(%!@9Q$I&WQN<OVARRT1]_B0@XTVM%4
M!)GU\-03GW]6E-<U%)?EL8BQ^^JQGSA>/7>/69=K^.,J$]7CS9S0IF%@>04[
M5F*;\,X@/;EWN7N%2M<[WZR6EH2X+%0:"N$229_#3=[-CN(J:3YM/S%M*Z$S
M;?",60E2+]QKG<:S$E@HM)YK,^1"9A81ZX [W\LT[,I4Y6-0"C4(-_/0VV2*
MCD&=7XP%ZW'U<'V ;X%>^!)/W<<BMZHWGH '_I@_K=A1P8<>^)8-<,QN6[-Z
MPA?_V.!@_;,Z@>"??9IY8 $M%P'K(F=O7?]5L)!U)/WV>N1N[*V!AS!7GO5O
MP(?WXBI:9%7[=\-Y#P0WJ$+BYE%]].YZ,U\R"2>^FODTX&T%0RACWG43E$3X
MQ494>ND;KK^:>,_2^MW:3\W&,J Z-6L?V+C$([CPBK5Y]O)C-UJ2%04Q6"KQ
MK4>]2(]_S@D8SV9G]43:QO-Q3]%;S772Q:71FN7(=^_FJ%Z0HDYXO[!ZKRI1
M7\\S_!UHN$_U>(3.B'^ *Q;R(X3]$O:1]]SI.F>UD+G,@]R*E:OX5)_Q*::2
MP5,ZK%2W^K0DP6#"]0QOLB^0+OHPV=J@19?24'AMK5K/S5>"PQY7N++I-Y'S
MZ,3F%%4E=UW4C*JJQ04=S_UT-YE7\Z0N46,&O]I.1HC1232I4*DFDFZRW_EJ
M'9QZ%V.H?^>3 DN]TY+6DM0"2TG52"DQ9VJ)07X$@.WB!F9B$'EV<03_?,+]
MJ1^0(C8OB-CF,&::R_CY#C:%DP_1"\]]J):I7W(JA^ILD$0?.%V2P[*4:",)
MOWL9+U00\,JW'$/>DF]_$*3[/$$<Q>87+(%$EUN29_\A@AB#TG;;W&D)J)\4
MH[.)&M?U'.EP;NP0LU=#8KUUWRY=^!FA(U<OYFH4=?<BUU [0*!?=T&F78^8
ML+WW35D (-V\(*7'U.Y+\$^)"@_^=13,8Q5T"K4& 9%TSC"9RKQ/'E(.HYF$
MEMU!H7$A*+":%G1_Y\,!)JY(!1TCQ2PR [\^[6I"O@:[-Y3BYK<=8"+2AT^
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M>JM^EMJOGVSD"O.FQ4.KL\4)1$:E9^RNS"B0/U@W^UEFP%%G7551+?,G+X#
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MQ$73WY2#E?4+:\'?O6WLCE\Q&*A,)$VW;VT(&;&NL2UFOGBF:V%1%U75.X6
M#+F3Z9#N>E-BFLPY8AE^W 2/M/>IS64H:@U'Y10  =CD[,T>>4<K&1-\I6F,
MR4*9\A_EZ5VX)11=$YUO%WX#&) LOY7$ITY,C/&=H#LL8.Y-VUI**SY?G]O-
M7-@?C3095U/QHE#_^C >.<N'*NVV);3[XXW73?GF>.UG7FC&(0"/U] QV1W5
M9@&TEATNMAWLE(>N!8] B:;F[7THK')V[T;D^F!Z3DBW,<EQKAY)37]5!W.7
ML^_OU!&1*7GF+E/Y4H[K8>X73?Y/8>Q_6!8Q[/X+TSYXC9Z[/YSWWS'X:XT6
MB0UNOOUG#?-W-=]DX7+_N:UY7[UMSN97BK%\^@RN>GWA]*N>H!UI,X_FT,$0
M%6GL7T/IV[E5SS R6J,]4P9:=3JJ<O)BD;]WJ&T/ [E=Q\#J*@!1#@?WL9H/
MP9U.308N-7;6^AJJS$+LDU5"UUR9)?G2;A:25?76>N@JO=_%M@@7Q8ID RF]
MQ.&CX4)8R<ZMW#%"48UNN>\\AK]N6FOKDVG&*^#:DV:R1%",H;J5"3#">]:C
MC*_+_7R\ Y,=._1K^*M4NO9@0VY]Z%./5YPZ\IGJ1P##3CM:/5GRE\OMF#0S
M],L_G.9U94PG')C%D@P?W'RY\^OV^C<@JJU,+YR6-OMOK[,WK$5_86U(EG.M
MAK;"]&1WZ_ .Y,>+DRYB<P>DO-R9-\#);E*,$_% +[ J\(5!M+S<[;QOG@E"
M6R=3%7,:%QAA &*O/?_L(G.6T6&KH?LUN"[7V,L72R(A"^8$).9>B LN(6^9
M,A31FE;JK[X2^Q$"_>0XGX_05>7RO3<64Q%F.3%SCO^I4*(#V(4___PL+7/?
MU((Y]B/O1KH7V_0PYWS^5F2NY8;,3_*"+\1//0 @\(7;0^R,9,^5&X9+]$]=
MUB++,OMW]]C1M%P;>?#;]Z9=.)(&-U=67I3PW1A7D^@13YFH^-K=_."F5R<I
M=&)JFQ;E&9/G^)4/@P C3VSW.,3@IQ4FO/6@ Z,B-++0P;P:;K*H"_KMEF-U
M;VG:"7>@<^JFY^ZWR=#YX)_;>DP%HD)=)!IR<T,F)<\1U!'=U:*\GP7%BP^N
M2!74)9_WV7F-$#UKFT38M#[3A)Y-<8#@:;2^GCRXHY&K"!!&X^K^^VDD*%!%
M#<%4/:;Y1)E6Y3@(<<UBP5"[S**H)D-&Q_6@J+*<]X-'FC>!B)!\)9&Y*(D4
M@L+3A2[^6<A[T2C)'T?_JS&]X.&J>W&IN_)7MZCW*%\F,,V)9U-PN?$DRN*&
MPXB2L;ER<(U\Y0N_IKDNUE2_JY,8=JW2$N1+)$F(PD;EJY^45%=>UEQMS\RQ
MS]RI?TEWD]NWLJMOMY-#L\ )1=+3JQL34PH=BS==AV,:M$\+P&]AIST-KGWJ
MWMX9KU*+W,>AV>;\KUI8V.O&Z 4&!O+2Y190F0AJW#"SD<8D/^.N%UB4%W%X
MZ\'K]CXGW129>1,T-ON\E,(A/RY>_,8$QVA9_YC+7JUW?OYB@KRU5=L? #"F
MY?W?2.4_VTO.-<G%_>>8>"OPWV/B_VX0_QO@^J^@^'K&W^8]+B&0XOQA)W2L
MY$4MOH?2$$=MHQ*$"(4V,[_*65(ZB*0\Z%D*+CE*$JOXJ_6EUS26KFDT@IZL
M P(X(P-%=>_/7\/?(X^JF/=6#'1K(7F"ZS&00B@5^$AK@PUJ:F=(M*M&<,@:
M%<8YE_P@.F^XHG*+L]167&K)EDE4IM=GZH\)/\D!WVU_D.F22ND: <=7_094
M[[.GUP^QN29=.6ZBULQ7[:671:$&1T%WC#>MU"%)R$&!H#AL3>M3Y9!^,'XW
M/QZ#<J;MAN0+;.MCB7:P.BK_AW:PU(MVY1PPOJ:U$JK6&SKFOP-3P3WKOI5"
M9]H.U[!<+$77(VU>8Y?PP-+$8!G\P\AS)J0GD._*_ KUDQ*21D? I,5"ZHC%
M TG)? K,@\G)+N(?,3A7)<I:- V^[:=Z4=K(A<I<%[CQSVL$3^ML>>^>ZX?R
M+XF/:-M4D F@)-V4F!5'C,Q-!ZLS"D*&!7!$@_7BVF2<NC8(A8?Y^UG-DUYA
M%TYIL+#21CW$K;9=0!2F@U<O1,<,%'"$4-E02ZUQ03Z9<#*6_-!UMH0B_3BX
M)-UE]1O#C?C)[J<_1G&8"K0(>FW"JOU^O/E 2?KUQ>?]_'!NFL#J:DNY]IV1
MU2W"6HN>I!1+7;UE'^/Q9EWJAE'R;_4BN!#;3UK/QWLQ+(F[8@E)/WUKWB'#
M]EV/O3=9:?+_1?>N_,T5+$M%N:=#5:.#VAB(36S7DE3+D1;)5"<9?2^O@5$
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M#U $-!R! "JWYI!3,* <*I?"R$T@RB 808*(""@(,5&Y$3P05 BH7")"(&A
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M<$J_PP'0[*7DJW1>^!?E I&UI+N7?8.49+%/$9#]A%(6P>6LJA3F?\X&_S\
M76+]#5!+ 0(4 Q0    ( (LQBEG)R#&WE"@  ,7\ 0 1              "
M 0    !A;'5R+3(P,C0P.3,P+GAS9%!+ 0(4 Q0    ( (LQBED,E!!ZQA4
M ,U# 0 5              "  <,H  !A;'5R+3(P,C0P.3,P7V-A;"YX;6Q0
M2P$"% ,4    " "+,8I9[ %O06JC  "\, H %0              @ &\/@
M86QU<BTR,#(T,#DS,%]D968N>&UL4$L! A0#%     @ BS&*6;9],3/LX@
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M  X              ( !PI," &0Y,34X,SED<S$N:'1M4$L! A0#%     @
MBS&*67\T(P?G,   ED\  !$              ( !=, ) &<Y,34X,SEG,#%A
M,#,N:G!G4$L! A0#%     @ BS&*63*,3HJT90$ ,]<! !$
M ( !BO$) &<Y,34X,SEG.#%A,#$N:G!G4$L! A0#%     @ BS&*6;)\QQ7X
ME@  OMX  !$              ( !;5<+ &<Y,34X,SEG.#)A,#$N:G!G4$L!
M A0#%     @ BS&*63)(!.(;JP$ DP0" !$              ( !E.X+ &<Y
M,34X,SEG.#-A,#$N:G!G4$L! A0#%     @ BS&*63+)"Z7?W0$ SRH" !$
M             ( !WID- &<Y,34X,SEG.#-A,#(N:G!G4$L! A0#%     @
MBS&*65]M[Y_+V0  :RP! !$              ( !['</ &<Y,34X,SEG.#9A
M,#$N:G!G4$L! A0#%     @ BS&*6;./O$<4' ( 69$" !$
M ( !YE$0 &<Y,34X,SEG.#=A,#$N:G!G4$L%!@     /  \ Q0,  "EN$@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>d915839ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alur="http://www.allurion.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alur-20240930.xsd" xlink:type="simple"/>
    <context id="P01_01_2024To09_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn08_01_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="P02_15_2023To02_15_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_29_2024To08_29_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtApril012013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:OtherCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:OtherCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCCommonStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesCCommonStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesBPreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PublicWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EarnOutSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDTwoPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesDThreePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_DoNotExpireMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:DoNotExpireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_StockOptionPlan2020MemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersDMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ESsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CLsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShippingAndHandlingMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alur:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ESsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CLsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchasePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandNineteenTermLoanAndSuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ShippingAndHandlingMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EarliestTaxYearMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LatestTaxYearTwoThousandFortyTwoMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">alur:LatestTaxYearTwoThousandFortyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_EarliestTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LatestTaxYearMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alur:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:LegacyAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_FortressTermLoanMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:PipeSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoAdditionalSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoSharesAndBackstopShareLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:NewAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:HVLTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:GaurContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorContributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RSUForfeitureAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_01_2023_MinimumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:NewAllurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RtwAndFortressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthSponsorSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SideLetterTerminationSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:LegacyAllurionEquityholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ComputeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:PipeSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:SponsorSupportAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alur:ComputeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BusinessCombinationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-01</instant>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="P06_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:UntilMarch312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:FromApril12024ToJune302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:FromJuly12024ToSeptember302024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:OnOctober12024AndThereafterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-29</instant>
        </period>
    </context>
    <context id="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="P02_01_2023To08_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="PAsOn05_02_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="PAsOn05_02_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-02</instant>
        </period>
    </context>
    <context id="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:SideLetterHolderBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:HVLBridgeNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:BackstopAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommitmentSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:LnmpJpbcInvestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:KkgEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:RemusGroupManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alur:HunterVenturesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-15</startDate>
            <endDate>2023-02-15</endDate>
        </period>
    </context>
    <context id="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:BenoitChardonConsultingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:TerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="P06_01_2022To12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P02_01_2023To02_28_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-14</instant>
        </period>
    </context>
    <context id="PAsOn04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-14</instant>
        </period>
    </context>
    <context id="PAsOn04_14_2024_MaximumMembersrtRangeAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-14</instant>
        </period>
    </context>
    <context id="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-14</startDate>
            <endDate>2024-04-14</endDate>
        </period>
    </context>
    <context id="P04_14_2024To04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-14</startDate>
            <endDate>2024-04-14</endDate>
        </period>
    </context>
    <context id="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="P04_16_2024To04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteAgreementWithRtwMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-16</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alur:BenoitChardonConsultingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2023To10_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alur:ComputersAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember152022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune042022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJanuary172017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtAugust032017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtSeptember082017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune192018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJune252019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtJuly012024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtDecember012014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">alur:WarrantsIssuedAtMarch302021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_EarnOutSharesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_ConvertibleNotesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesCPreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:LegacyAllurionOtherCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alur:LegacyAllurionSeriesD1PreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:DerivativeLiabilitySuccessFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:LegacyAllurionCommonStockWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PIPEConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedTwoThousandTwentyOneTermLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">alur:RunwayGrowthCreditFundIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">alur:ScenarioPlanFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_GBsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ESsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ITsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CLsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyOneConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FRsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ESsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_GBsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:EarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alur:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingAndPipeConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:TwoThousandNineteenTermLoanAndSuccessFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:ChardanEquityFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ChefPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">alur:ComputeHealthAcquisitionCorprationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RTWParticipationInPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">alur:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">currency:TRY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_AUsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_ITsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:FourCountriesIncludedWithinAllOtherCountriesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:EachCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemablePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2024To06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="PAsOn04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:ConvertibleNoteAgreementWithRtwMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="PAsOn04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:NotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-16</instant>
        </period>
    </context>
    <context id="P01_01_2024To04_16_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">alur:FortressTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:FortressCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-04-16</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="P12_30_2026To12_30_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-12-30</startDate>
            <endDate>2026-12-30</endDate>
        </period>
    </context>
    <context id="P12_30_2026To12_30_2026_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-12-30</startDate>
            <endDate>2026-12-30</endDate>
        </period>
    </context>
    <context id="P12_31_2026To12_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-12-31</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2027To01_01_2027_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-01-01</endDate>
        </period>
    </context>
    <context id="P01_01_2027To01_01_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-01-01</endDate>
        </period>
    </context>
    <context id="P01_02_2027To01_02_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-01-02</startDate>
            <endDate>2027-01-02</endDate>
        </period>
    </context>
    <context id="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-17</instant>
        </period>
    </context>
    <context id="P06_28_2024To06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-28</startDate>
            <endDate>2024-06-28</endDate>
        </period>
    </context>
    <context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWithRTWMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="PAsOn07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingWarrantsAndShareOverallotmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="PAsOn07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-05</startDate>
            <endDate>2024-07-05</endDate>
        </period>
    </context>
    <context id="PAsOn07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-05</instant>
        </period>
    </context>
    <context id="P04_01_2024To04_30_2024_NatickAndHudsonMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alur:NatickAndHudsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="P08_29_2024To08_29_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="PAsOn08_29_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="PAsOn10_30_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:AmendedAndRestatedRtwSideLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alur:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">alur:RestructuringPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-06</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:BasePubcoAndBackstopShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PubcoShareLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alur:StockOptionPlan2020And2023StockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:PublicOfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alur:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:TermLoanDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:PreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">alur:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RevenueInterestFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:PipeConversionDerivativeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:EarnOutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alur:RtwConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alur:SuccessFeeDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">alur:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001964979</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Country">
        <measure>alur:Country</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Days">
        <measure>alur:Days</measure>
    </unit>
    <unit id="Unit_Employees">
        <measure>alur:Employees</measure>
    </unit>
    <unit id="Unit_TradingDay">
        <measure>alur:TradingDay</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2024To09_30_2024" id="ixv-39978">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To09_30_2024" id="hidden127678485">0001964979</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2024To09_30_2024" id="hidden127678532">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden127678533">MA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2024To09_30_2024" id="ixv-47345">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2024To09_30_2024" id="ixv-47346">ALLURION TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2024To09_30_2024" id="ixv-47347">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2024To09_30_2024" id="ixv-47348">3841</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2024To09_30_2024" id="ixv-47349">92-2182207</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2024To09_30_2024" id="ixv-47350">11 Huron Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2024To09_30_2024" id="ixv-47351">Natick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2024To09_30_2024" id="ixv-47352">01760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2024To09_30_2024" id="ixv-47353">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2024To09_30_2024" id="ixv-47354">647-4000</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47355">Shantanu Gaur</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47356">11 Huron Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47357">Natick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47358">01760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47359">508</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2024To09_30_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-47360">647-4000</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2024To09_30_2024" id="ixv-47361">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2024To09_30_2024" id="ixv-47362">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2024To09_30_2024" id="ixv-47363">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2024To09_30_2024" id="ixv-47364">false</dei:EntityExTransitionPeriod>
    <us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2023" id="hidden127681918">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2022" id="hidden127681919">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn09_30_2024" id="hidden127682685">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2023" id="hidden127682686">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P01_01_2022To12_31_2022" id="hidden127680782">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P01_01_2023To12_31_2023" id="hidden127680783">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P01_01_2023To09_30_2023" id="hidden127680849">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P01_01_2024To09_30_2024" id="hidden127680850">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P07_01_2023To09_30_2023" id="hidden127681126">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="P07_01_2024To09_30_2024" id="hidden127681127">http://fasb.org/us-gaap/2024#FairValueAdjustmentOfWarrants</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn09_30_2024_MinimumMembersrtRangeAxis"
      id="hidden127680941">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn03_31_2024_MinimumMembersrtRangeAxis"
      id="hidden127682050">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="hidden127680787"
      unitRef="Unit_shares">0.5</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="hidden127682683"
      unitRef="Unit_shares">0.5</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="hidden127682954"
      unitRef="Unit_USD">895000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      id="hidden127682733">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47385"
      unitRef="Unit_USD">38037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47386"
      unitRef="Unit_USD">7685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47387"
      unitRef="Unit_USD">12671000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47388"
      unitRef="Unit_USD">741000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47389"
      unitRef="Unit_USD">18194000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47390"
      unitRef="Unit_USD">29346000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47391"
      unitRef="Unit_USD">6171000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47392"
      unitRef="Unit_USD">3865000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47393"
      unitRef="Unit_USD">2414000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47394"
      unitRef="Unit_USD">2487000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47395"
      unitRef="Unit_USD">64816000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47396"
      unitRef="Unit_USD">43383000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47397"
      unitRef="Unit_USD">3381000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47398"
      unitRef="Unit_USD">2382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47399"
      unitRef="Unit_USD">3010000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47400"
      unitRef="Unit_USD">2899000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47401"
      unitRef="Unit_USD">505000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47402"
      unitRef="Unit_USD">2706000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47403"
      unitRef="Unit_USD">71712000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47404"
      unitRef="Unit_USD">51370000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47405"
      unitRef="Unit_USD">10379000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47406"
      unitRef="Unit_USD">5809000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47407"
      unitRef="Unit_USD">38643000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47408"
      unitRef="Unit_USD">53360000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47409"
      unitRef="Unit_USD">908000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47410"
      unitRef="Unit_USD">905000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47411"
      unitRef="Unit_USD">15495000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47412"
      unitRef="Unit_USD">15793000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47413"
      unitRef="Unit_USD">65425000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47414"
      unitRef="Unit_USD">75867000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47415"
      unitRef="Unit_USD">3103000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-47416"
      unitRef="Unit_USD">5943000</us-gaap:WarrantsAndRightsOutstanding>
    <alur:RevenueInterestFinancingLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47417"
      unitRef="Unit_USD">36200000</alur:RevenueInterestFinancingLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47418"
      unitRef="Unit_USD">23990000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47419"
      unitRef="Unit_USD">2306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47420"
      unitRef="Unit_USD">2163000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023_ScenarioPreviouslyReportedMembersrtRestatementAxis"
      decimals="-3"
      id="ixv-47421"
      unitRef="Unit_USD">8335000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47422"
      unitRef="Unit_USD">2551000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47423"
      unitRef="Unit_USD">142199000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47424"
      unitRef="Unit_USD">83684000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-47425"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      id="ixv-47426"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47427"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47428"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47429"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47430"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47431"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47432"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47433"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47434"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47435"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47436"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47437"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47438"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47439"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47440"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47441"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47442"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47443"
      unitRef="Unit_shares">27079856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-47444"
      unitRef="Unit_shares">27079856</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47445"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47446"
      unitRef="Unit_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47447"
      unitRef="Unit_USD">143007000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47448"
      unitRef="Unit_USD">99875000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47449"
      unitRef="Unit_USD">-700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47450"
      unitRef="Unit_USD">-212799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47451"
      unitRef="Unit_USD">-132192000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47452"
      unitRef="Unit_USD">-70487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47453"
      unitRef="Unit_USD">-32314000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47454"
      unitRef="Unit_USD">71712000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47455"
      unitRef="Unit_USD">51370000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47456"
      unitRef="Unit_USD">53467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47457"
      unitRef="Unit_USD">64211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47458"
      unitRef="Unit_USD">11970000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47459"
      unitRef="Unit_USD">13485000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47460"
      unitRef="Unit_USD">41497000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47461"
      unitRef="Unit_USD">50726000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47462"
      unitRef="Unit_USD">46857000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47463"
      unitRef="Unit_USD">50405000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47464"
      unitRef="Unit_USD">27694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47465"
      unitRef="Unit_USD">16966000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47466"
      unitRef="Unit_USD">46024000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47467"
      unitRef="Unit_USD">15365000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47468"
      unitRef="Unit_USD">120575000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47469"
      unitRef="Unit_USD">82736000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47470"
      unitRef="Unit_USD">-79078000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47471"
      unitRef="Unit_USD">-32010000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47472"
      unitRef="Unit_USD">10566000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47473"
      unitRef="Unit_USD">4426000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47474"
      unitRef="Unit_USD">-8364000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47475"
      unitRef="Unit_USD">821000</us-gaap:FairValueAdjustmentOfWarrants>
    <alur:ChangesInFairValueOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47476"
      unitRef="Unit_USD">3751000</alur:ChangesInFairValueOfDebt>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47477"
      unitRef="Unit_USD">-2192000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47478"
      unitRef="Unit_USD">29050000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47479"
      unitRef="Unit_USD">-17598000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47480"
      unitRef="Unit_USD">-3929000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47481"
      unitRef="Unit_USD">-643000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47482"
      unitRef="Unit_USD">-344000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47483"
      unitRef="Unit_USD">-1265000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47484"
      unitRef="Unit_USD">-5591000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47485"
      unitRef="Unit_USD">-80343000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47486"
      unitRef="Unit_USD">-37601000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47487"
      unitRef="Unit_USD">264000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47488"
      unitRef="Unit_USD">143000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47489"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47490"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47491"
      unitRef="Unit_USD">1697000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47492"
      unitRef="Unit_USD">2907000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47493"
      unitRef="Unit_USD">-82304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47494"
      unitRef="Unit_USD">-40651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-47495"
      unitRef="Unit_USD_per_Share">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-47496"
      unitRef="Unit_USD_per_Share">-2.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-47497"
      unitRef="Unit_USD_per_Share">-1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-47498"
      unitRef="Unit_USD_per_Share">-1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47499"
      unitRef="Unit_shares">35581656</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-47500"
      unitRef="Unit_shares">35581656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47501"
      unitRef="Unit_shares">26918484</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-47502"
      unitRef="Unit_shares">26918484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47503"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47504"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47505"
      unitRef="Unit_USD">-700000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47506"
      unitRef="Unit_USD">-81307000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47507"
      unitRef="Unit_USD">-37744000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47508"
      unitRef="Unit_shares">26807365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47509"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47510"
      unitRef="Unit_USD">99282000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47511"
      unitRef="Unit_USD">-94448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-47512"
      unitRef="Unit_USD">4837000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47513"
      unitRef="Unit_shares">128567</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47514"
      unitRef="Unit_USD">128000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47515"
      unitRef="Unit_USD">128000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47516"
      unitRef="Unit_USD">437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47517"
      unitRef="Unit_USD">437000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47518"
      unitRef="Unit_shares">5611</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47519"
      unitRef="Unit_USD">24000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47520"
      unitRef="Unit_USD">24000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47521"
      unitRef="Unit_shares">1028</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47522"
      unitRef="Unit_USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2022To12_31_2022_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47523"
      unitRef="Unit_USD">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47524"
      unitRef="Unit_shares">137285</alur:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47525"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47526"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47527"
      unitRef="Unit_shares">27079856</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47528"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47529"
      unitRef="Unit_USD">99875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47530"
      unitRef="Unit_USD">-132192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47531"
      unitRef="Unit_USD">-32314000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47532"
      unitRef="Unit_shares">298562</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47533"
      unitRef="Unit_USD">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47534"
      unitRef="Unit_USD">145000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47535"
      unitRef="Unit_shares">8530</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47536"
      unitRef="Unit_USD">89000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47537"
      unitRef="Unit_USD">89000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47538"
      unitRef="Unit_shares">492</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47539"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_SeriesA1ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-47540"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47541"
      unitRef="Unit_shares">13735872</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47542"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47543"
      unitRef="Unit_USD">58572000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47544"
      unitRef="Unit_USD">58573000</us-gaap:StockIssuedDuringPeriodValueOther>
    <alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47545"
      unitRef="Unit_USD">-13762000</alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger>
    <alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47546"
      unitRef="Unit_USD">-13762000</alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47547"
      unitRef="Unit_shares">918412</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47548"
      unitRef="Unit_shares">3301222</alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47549"
      unitRef="Unit_USD">1000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47550"
      unitRef="Unit_USD">25569000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47551"
      unitRef="Unit_USD">25570000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47552"
      unitRef="Unit_USD">-53040000</alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities>
    <alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47553"
      unitRef="Unit_USD">-53040000</alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47554"
      unitRef="Unit_USD">929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47555"
      unitRef="Unit_USD">929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47556"
      unitRef="Unit_shares">2287696</alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability>
    <alur:StockIssuedDuringPeriodValueDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47557"
      unitRef="Unit_USD">16098000</alur:StockIssuedDuringPeriodValueDerecognitionOfLiability>
    <alur:StockIssuedDuringPeriodValueDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47558"
      unitRef="Unit_USD">16098000</alur:StockIssuedDuringPeriodValueDerecognitionOfLiability>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47559"
      unitRef="Unit_shares">21943</alur:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47560"
      unitRef="Unit_USD">46000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47561"
      unitRef="Unit_USD">46000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47562"
      unitRef="Unit_USD">8357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47563"
      unitRef="Unit_USD">8357000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares
      contextRef="P01_01_2023To12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47564"
      unitRef="Unit_shares">35511</alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingShares>
    <alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47565"
      unitRef="Unit_USD">123000</alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount>
    <alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47566"
      unitRef="Unit_USD">123000</alur:IssuanceOfCommonStockForCommitmentSharesForEquityLineFinancingAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47567"
      unitRef="Unit_USD">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47568"
      unitRef="Unit_USD">-700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47569"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47570"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47571"
      unitRef="Unit_shares">47688096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47572"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47573"
      unitRef="Unit_USD">143007000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47574"
      unitRef="Unit_USD">-700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-47575"
      unitRef="Unit_USD">-212799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47576"
      unitRef="Unit_USD">-70487000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47577"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47578"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <alur:NonCashLeaseExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47579"
      unitRef="Unit_USD">824000</alur:NonCashLeaseExpense>
    <alur:NonCashLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47580"
      unitRef="Unit_USD">1104000</alur:NonCashLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47581"
      unitRef="Unit_USD">746000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47582"
      unitRef="Unit_USD">895000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47583"
      unitRef="Unit_USD">8357000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47584"
      unitRef="Unit_USD">437000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47585"
      unitRef="Unit_USD">12675000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47586"
      unitRef="Unit_USD">436000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47587"
      unitRef="Unit_USD">180000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47588"
      unitRef="Unit_USD">113000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47589"
      unitRef="Unit_USD">1399000</us-gaap:InventoryWriteDown>
    <alur:ChangeInFairValueOfWarrantLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47590"
      unitRef="Unit_USD">-8364000</alur:ChangeInFairValueOfWarrantLiabilities>
    <alur:ChangeInFairValueOfWarrantLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47591"
      unitRef="Unit_USD">820000</alur:ChangeInFairValueOfWarrantLiabilities>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47592"
      unitRef="Unit_USD">-1730000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47593"
      unitRef="Unit_USD">-19000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <alur:FairValueAdjustmentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47594"
      unitRef="Unit_USD">3751000</alur:FairValueAdjustmentOfDebt>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47595"
      unitRef="Unit_USD">-2192000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47596"
      unitRef="Unit_USD">29050000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:InterestPaidOnDebtRecordedAtFairValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47597"
      unitRef="Unit_USD">1092000</alur:InterestPaidOnDebtRecordedAtFairValue>
    <alur:NonCashInterestExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47598"
      unitRef="Unit_USD">2083000</alur:NonCashInterestExpense>
    <alur:NonCashInterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47599"
      unitRef="Unit_USD">953000</alur:NonCashInterestExpense>
    <alur:NonCashTerminationOfConvertibleNoteSideLetters
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47600"
      unitRef="Unit_USD">16098000</alur:NonCashTerminationOfConvertibleNoteSideLetters>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47601"
      unitRef="Unit_USD">-3929000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <alur:NonCashIssuanceOfCommonStockForCommitmentShares
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47602"
      unitRef="Unit_USD">123000</alur:NonCashIssuanceOfCommonStockForCommitmentShares>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47603"
      unitRef="Unit_USD">1210000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47604"
      unitRef="Unit_USD">1318000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47605"
      unitRef="Unit_USD">22817000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47606"
      unitRef="Unit_USD">3705000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47607"
      unitRef="Unit_USD">1150000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47608"
      unitRef="Unit_USD">-285000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47609"
      unitRef="Unit_USD">577000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47610"
      unitRef="Unit_USD">-789000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47611"
      unitRef="Unit_USD">-733000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47612"
      unitRef="Unit_USD">4664000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47613"
      unitRef="Unit_USD">3324000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47614"
      unitRef="Unit_USD">1057000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47615"
      unitRef="Unit_USD">8165000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47616"
      unitRef="Unit_USD">-63982000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47617"
      unitRef="Unit_USD">-46981000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47618"
      unitRef="Unit_USD">1606000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47619"
      unitRef="Unit_USD">1550000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47620"
      unitRef="Unit_USD">-1606000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47621"
      unitRef="Unit_USD">-1550000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47622"
      unitRef="Unit_USD">28700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47623"
      unitRef="Unit_USD">1103000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47624"
      unitRef="Unit_USD">59780000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47625"
      unitRef="Unit_USD">29850000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47626"
      unitRef="Unit_USD">3450000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47627"
      unitRef="Unit_USD">262000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <alur:ProceedsFromBusinessCombinationNetOfTransactionCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47628"
      unitRef="Unit_USD">61652000</alur:ProceedsFromBusinessCombinationNetOfTransactionCosts>
    <alur:ProceedsFromRevenueInterestFinancing
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47629"
      unitRef="Unit_USD">40000000</alur:ProceedsFromRevenueInterestFinancing>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis"
      decimals="-3"
      id="ixv-47630"
      unitRef="Unit_USD">57659000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To12_31_2023_FortressTermLoanMemberusgaapShortTermDebtTypeAxis"
      decimals="-3"
      id="ixv-47631"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47632"
      unitRef="Unit_USD">2500000</us-gaap:RepaymentsOfNotesPayable>
    <alur:ProceedsFromOptionAndWarrantExercises
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47633"
      unitRef="Unit_USD">213000</alur:ProceedsFromOptionAndWarrantExercises>
    <alur:ProceedsFromOptionAndWarrantExercises
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47634"
      unitRef="Unit_USD">132000</alur:ProceedsFromOptionAndWarrantExercises>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47635"
      unitRef="Unit_USD">10750000</us-gaap:RepaymentsOfConvertibleDebt>
    <alur:PaymentOfDeferredFinancingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47636"
      unitRef="Unit_USD">286000</alur:PaymentOfDeferredFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47637"
      unitRef="Unit_USD">95986000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47638"
      unitRef="Unit_USD">30537000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47639"
      unitRef="Unit_USD">30398000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47640"
      unitRef="Unit_USD">-17994000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47641"
      unitRef="Unit_USD">8023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-47642"
      unitRef="Unit_USD">26017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47643"
      unitRef="Unit_USD">38421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47644"
      unitRef="Unit_USD">8023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47645"
      unitRef="Unit_USD">8035000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47646"
      unitRef="Unit_USD">3476000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47647"
      unitRef="Unit_USD">134000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47648"
      unitRef="Unit_USD">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <alur:IssuanceOfWarrantsInConnectionWithFinancing
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47649"
      unitRef="Unit_USD">834000</alur:IssuanceOfWarrantsInConnectionWithFinancing>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47650"
      unitRef="Unit_USD">580000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47651"
      unitRef="Unit_USD">1919000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <alur:RecognitionOfAssumedWarrantLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47652"
      unitRef="Unit_USD">13762000</alur:RecognitionOfAssumedWarrantLiability>
    <alur:RecognitionOfEarnOutLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47653"
      unitRef="Unit_USD">53040000</alur:RecognitionOfEarnOutLiabilities>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47654"
      unitRef="Unit_USD">25569000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47655"
      unitRef="Unit_USD">-700000</alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16276">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left"&gt;Organization and Basis of Presentation &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Allurion Technologies, Inc. (&#x201c;Allurion&#x201d; or the &#x201c;Company&#x201d;) is a &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;vertically &lt;/div&gt;integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion Balloon. The Allurion Balloon is the world&#x2019;s first and only swallowable, procedure-less intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement or removal. Allurion sells the Allurion Balloon and related hardware accessories through distributors or directly to health care providers. The Company currently also provides, free of charge, artificial intelligence (&#x201c;AI&#x201d;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#x201c;VCS&#x201d;) and, collectively with the Allurion Balloon referred to as the &#x201c;Allurion Program&#x201d;. Allurion currently markets the Allurion Program in over 50 countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, Hong Kong, the United Kingdom, Italy, Spain, Australia and Mexico. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#x201c;Legacy Allurion&#x201d;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.), entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#x201c;Business Combination Agreement&#x201d;) with Compute Health Acquisition Corp. (&#x201c;CPUH&#x201d; or &#x201c;Compute Health&#x201d;), Compute Health Corp. (&#x201c;Merger Sub I&#x201d;) and Compute Health LLC (&#x201c;Merger Sub II&#x201d; and, together with Merger Sub I, the &#x201c;Merger Subs&#x201d;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#x201c;Closing Date&#x201d;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#x201c;CPUH Merger&#x201d;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#x201c;CPUH Merger Effective Time&#x201d;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#x201c;Intermediate Merger&#x201d; and the time at which the Intermediate Merger became effective, the &#x201c;Intermediate Merger Effective Time&#x201d;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#x201c;Final Merger&#x201d; and, collectively with the CPUH Merger and the Intermediate Merger, the &#x201c;Mergers&#x201d;, and together with all other transactions contemplated by the Business Combination Agreement, the &#x201c;Business Combination&#x201d;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#x201c;Final Merger Effective Time&#x201d;). Allurion shares began trading on the New York Stock Exchange (&#x201c;NYSE&#x201d;) under the ticker symbol &#x201c;ALUR&#x201d; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#x2019;s business operations continued as our business operations. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America. Under this method of accounting, Compute Health was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes and Legacy Allurion was the accounting &#x201c;acquirer&#x201d;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of &lt;/div&gt;  &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#x2019;s common stock, $0.0001 par value per share (&#x201c;Allurion Common Stock&#x201d; or the &#x201c;Company&#x2019;s Common Stock&#x201d;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#x2019;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the &#x201c;Exchange Ratio&#x201d;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the consolidated financial statements have changed. Refer to Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;for further discussion regarding the closing of the Business Combination with Compute Health. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Unless otherwise indicated, references to the &#x201c;Company&#x201d;, &#x201c;our&#x201d;, and &#x201c;Allurion&#x201d; refer to the consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#x201c;Legacy Allurion&#x201d; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company&#x2019;s equity structure has been restated in prior periods to reflect the number of shares of the Allurion Common Stock, $0.0001 par value per share, issued to Legacy Allurion stockholders. As such, the shares and corresponding capital amounts presented in the consolidated balance sheet and consolidated statement of redeemable convertible preferred stock and stockholders&#x2019; deficit have been retroactively restated as shares reflecting the Exchange Ratio established in the Business Combination. All then-existing Legacy Allurion redeemable convertible preferred stock and Legacy Allurion convertible preferred stock were converted into shares of Allurion Common Stock at the closing of the Business Combination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The consolidated financial statements include Allurion; and its consolidated subsidiaries, Allurion France SAS, and Allurion Middle East, LLC, which were both incorporated in 2017; Allurion Hong Kong Ltd., which was incorporated in 2019; Allurion UK Ltd., which was incorporated in 2021; Allurion Italy, Srl, Allurion Spain, Srl, Allurion Australia Pty Ltd. and Allurion Mexico S. de R.L de C.V, which were incorporated in 2022; and Allurion Technologies, LLC, which was incorporated in 2023. The Company&#x2019;s operations are located in Europe, the Middle East, Africa, Latin America, Canada and the Asia-Pacific region, and it operates in one business segment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. Gains (losses) from remeasurement of $0.1&#160;million and $(0.7) million for the years ended December&#160;31, 2023 and 2022, respectively, are recorded in the statements of operations and comprehensive loss within other expense, net. The Company translates the foreign functional currency financial &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;statements &lt;/div&gt;to U.S.&#160;dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;equity transactions. The effects of foreign currency translation adjustments were immaterial for the years ended December&#160;31, 2023 and 2022. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has incurred recurring losses since inception and anticipates net losses and negative operating cash flows for the near future and may be unable to remain in compliance with certain financial covenants required under the Fortress Term Loan. Through December&#160;31, 2023, the Company has funded its operations primarily with proceeds from the sale of its convertible preferred stock, issuance of convertible notes, issuance of term loans and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including net losses of $80.6&#160;million and $37.7&#160;million and cash outflows from operating activities of $64.0&#160;million and $47.0&#160;million for the years ended December&#160;31, 2023 and 2022, respectively. As of &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;December&#160;&lt;/div&gt;31, 2023, the Company had an accumulated deficit of $212.8&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Based on the Company&#x2019;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations and debt service payments, and the potential of being unable to remain in compliance with certain financial covenants under the Fortress Term Loan, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Due to the substantial doubt about the Company&#x2019;s ability to continue operating as a going concern for twelve months from the issuance date of these financial statements and the liquidity and revenue covenant clauses within the Fortress Term Loan, the amounts due as of December&#160;31, 2023, have been classified as current liabilities in the consolidated financial statements. The lender under the Fortress Term Loan has not invoked the material adverse change clause and the Company has met the liquidity covenant as of the date of issuance of these financial statements. &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <alur:NumberOfCountriesInWhichEntityMarketsTheProgram
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47656"
      unitRef="Unit_Country">50</alur:NumberOfCountriesInWhichEntityMarketsTheProgram>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-47657"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <alur:BusinessCombinationCommonStockExchangeRatio
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-47658"
      unitRef="Unit_pure">0.978</alur:BusinessCombinationCommonStockExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47659"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47660"
      unitRef="Unit_USD">100000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47661"
      unitRef="Unit_USD">-700000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47663"
      unitRef="Unit_USD">-80600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47664"
      unitRef="Unit_USD">-37700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47665"
      unitRef="Unit_USD">-64000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47666"
      unitRef="Unit_USD">-47000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-47667"
      unitRef="Unit_USD">-212800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16356">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reclassification of Prior Year Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;consolidated statement of &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;operations &lt;/div&gt;and comprehensive loss for the year ended December&#160;31, 2022 to present the change in fair value of derivative liabilities as part of Other income (expense), net, and to present the change in fair value of warrants as its own line item. The change in fair value of derivative liabilities was a separate line item in prior years and the change in fair value of warrants was part of Other income (expense), net in prior years. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk of Concentration of Credit, Significant Customers and Significant Suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue for the years ended December&#160;31, 2023 and 2022 or accounts receivable, net balance as of December&#160;31, 2023 and 2022. The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts&#160;Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer C&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#x2019;s operating results, financial condition and cash flows and damage its customer relationships. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2022, the Company adopted ASC 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) asset and a current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; lease liability as applicable, in the consolidated balance sheets if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having an original term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will either renew or not cancel the lease. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#x2019;s incremental borrowing rate. The &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company&#x2019;s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of the lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into contracts that contain both lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Non&lt;/div&gt;-lease&lt;/div&gt; components include costs that do not provide a right to use a leased asset but instead provide a service, such as maintenance costs. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash consists of amounts held in bank savings and checking accounts. Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds. The Company&#x2019;s restricted cash consists of cash that the Company is contractually obligated to maintain and deposits of cash collateral held in accordance with the terms of various corporate credit cards. Restricted cash is included within other long-term assets on the consolidated balance sheets. A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash included in &lt;div style="-sec-ix-hidden:hidden127681918;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127681919;display:inline;"&gt;other long-term assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents and restricted cash shown in the statement of cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company operates in a single operating and reportable segment. Operating segments are defined as components of an enterprise for which discrete financial information is available and is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) in order to make decisions regarding resource allocation and performance assessment. The Company has determined that its CODM is its Chief Executive Officer. The Company&#x2019;s CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since the Company operates as one operating segment, all required financial segment information can be found in the consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s products include the Allurion Balloon and related accessories. See Note 4, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;below&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;for financial information about sales in geographic areas. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying value of the Company&#x2019;s financial instruments such as cash and cash equivalents, accounts payable, and accrued expenses approximate their fair values due to their short-term maturity. The carrying value of the Company&#x2019;s term loan approximates its fair value as the interest rate and other terms are that which are currently available to the Company. The Company&#x2019;s &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;assets and liabilities recorded at fair value have been categorized based upon a fair value hierarchy, which is distinguished between observable and unobservable inputs in accordance with authoritative accounting guidance: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 inputs: Other than quoted prices included in Level&#160;1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that the observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventories, which include the costs of material, labor, and overhead, are stated at the lower of cost or net realizable value, with cost generally computed using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-in,&lt;/div&gt; first out method. Estimated losses from obsolete and slow-moving inventories are recorded to reduce inventory values to their estimated net realizable value and are charged to cost of sales. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in a recovery in carrying value. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment include computers, laboratory equipment, machinery, and leasehold improvements. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated on a straight-line basis over the shorter of the estimated life or the lease term. Expenditures for repairs and maintenance are expensed as incurred. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Internal-Use&lt;/div&gt; Software &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Software development costs consist of certain consulting costs and compensation expenses for employees who devote time to the development projects of our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software, as well as certain upgrades and enhancements that are expected to result in enhanced functionality. The Company amortizes these development costs over the estimated useful life, which is determined based on our best estimate of the useful life of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software after considering factors such as continuous developments in the technology, obsolescence, and anticipated life of the service offering before significant upgrades. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined the amount of internal software costs to be capitalized based on the amount of time spent by our developers on projects in the application stage of development. There is judgment in estimating the time allocated to a particular project in the application stage. A significant change in the time spent on each project could have a material impact on the amount capitalized and related amortization expense in subsequent periods. As of December&#160;31, 2023 and 2022, capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software was immaterial. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt Issuance Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company defers costs directly associated with acquiring third-party financing. Fees incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. Fees incurred in connection with a modification are deferred and amortized as a component of interest expense over the remaining life of the loan if due to the creditor. Third-party fees incurred in connection with a &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;modification &lt;/div&gt;are expensed as incurred. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the Business Combination. The Company deferred offering costs classified as a long-term asset until the closing or termination of the transaction. At the closing of the Business Combination, these costs were recorded in stockholders&#x2019; deficit as a reduction of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital. Deferred offering costs are included in other long-term assets. As of December&#160;31, 2023 and 2022, there were zero and $2.3&#160;million of deferred offering costs recorded within other long-term assets on the consolidated balance sheet, respectively. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;480-10,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;ASC&#160;480-10&#x201d;),&lt;/div&gt; then in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40&#x201d;).&lt;/div&gt; Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;480-10,&lt;/div&gt; warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or are warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;480-10,&lt;/div&gt; the Company assesses the requirements under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40&lt;/div&gt; or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its convertible instruments and other contracts, including warrants, to determine if those contracts or embedded components of those contracts are required to be accounted for as derivatives, either in whole or in part. If an embedded derivative is bifurcated from a debt host contract, changes in the fair value of the bifurcated derivative are recorded in the accompanying consolidated statements of operations. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the convertible notes issued between February 2023 and August 2023 (the &#x201c;2023 Convertible Notes&#x201d;) under the fair value option (&#x201c;FVO&#x201d;) election of ASC Topic 825, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 825&#x201d;). The convertible notes accounted for under the FVO election were each debt host financial instruments containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the convertible notes were &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recorded as a component of Other (expense) income in the consolidated statements of operations. As a result of electing the FVO, direct costs and fees related to the 2023 Convertible Notes were expensed as incurred. The convertible notes issued in 2020, 2021 and 2022 are accounted for as disclosed in Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt;. In connection with the closing of the Business Combination on August&#160;1, 2023, a portion of the 2023 convertible notes was repaid, with the remaining balance converted to shares of our Common Stock. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, certain holders of Legacy Allurion common &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;stock &lt;/div&gt;and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive up to 9,000,000 additional shares of Allurion Common Stock (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Shares&#x201d;) upon the achievement of certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; targets. The contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration contains a settlement provision that in the event of a change in control, the number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares issued may vary. This settlement provision precludes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liability from being indexed to the Company&#x2019;s Common Stock as a change in control event is not an input into the pricing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; forward or option on equity shares. As such, it is classified as a liability under ASC 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 480&#x201d;). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration is remeasured on a quarterly basis over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; period with changes in the estimated fair value of the contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration recorded in Other (expense) income in the consolidated statements of operations, and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration may materially impact or cause volatility in our operating results. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company entered into a revenue interest financing agreement, dated as of February&#160;9, 2023 (the &#x201c;Revenue Interest Financing Agreement&#x201d;) with certain entities that have engaged RTW Investments, LP as investment manager (collectively, &#x201c;RTW&#x201d;), under which the Company received $40.0&#160;million upfront (the &#x201c;Revenue Interest Financing&#x201d;). In exchange, the Company is obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for the Revenue Interest Financing Agreement under the fair value option election of ASC 825. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument that contains embedded features. The embedded features include requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events, a change in royalty rates upon the occurrence of certain contingent events, and the Company&#x2019;s ability to prepay the Revenue Interest Financing. As the Company has elected the FVO, these embedded features would not meet the criteria for bifurcation and separate accounting as the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis on each reporting period date. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Company entering in the Revenue Interest Financing, the Company and RTW entered into the RTW side letter under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE (as &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;defined in Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;below) subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by the PIPE subscription (the &#x201c;PIPE Conversion Option&#x201d;). The Company accounts for the PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 815&#x201d;). The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other (expense) income in the consolidated statements of operations. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are unsecured and are carried at net realizable value, including an allowance for doubtful accounts. Trade credit is generally extended on a short-term basis; trade receivables do not bear interest, although a finance charge may be applied to such receivables that are past due. The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors that may affect a customer&#x2019;s ability to pay, such as historical expense, credit quality, &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;the &lt;/div&gt;age of the account receivable balances, and current economic conditions. Amounts determined to be uncollectible are charged or written off against the allowance. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes activity in the allowance for doubtful accounts: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2023&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2022&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at beginning of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for uncollectible accounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,675&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Uncollectible accounts written off&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at end of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,671&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2014-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;&lt;/div&gt;(&#x201c;Topic 606&#x201d; or &#x201c;ASC 606&#x201d;). In general, the Company&#x2019;s sales contracts fall under its standard sales agreement whereby control transfers to the customer upon shipment, satisfying the performance obligations of the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue when control of its products is transferred to customers at an amount that reflects the consideration it expects to receive in exchange for those products. The Company&#x2019;s revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a good or service to the customer, meaning that such customer has the ability to use and obtain the benefit of the good or service. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has provided customers purchasing the Allurion Balloon with an implied license for access to its VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#x2019;s contracts. Further, the customer contracts and related purchase orders do not include nor specify rights or obligations associated with the VCS software. Based on this assessment, the Company determined the implied license to be immaterial in the context of the contract with customers purchasing the Allurion Balloon, and as such did not allocate any value to the implied VCS license. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company generates revenue from sales of its Allurion Balloon to distributors and health care providers. Customers &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;typically &lt;/div&gt;purchase the Allurion Balloon, including the gastric balloon and related accessories together, although customers can purchase the gastric balloon and its accessories separately. Therefore, each component of the Allurion Balloon and accessories represents a distinct performance obligation and is separately identifiable. In arrangements with multiple performance obligations, the transaction price is allocated to each performance obligation using the relative standalone selling price. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account internally approved pricing guidelines and market conditions. Revenue is generally recognized upon shipment of the product because at that point, the customer obtains control of the product and has the ability to direct the use and obtain the benefit of the product. Components of the Allurion Balloon are typically shipped to the customer together, resulting in the performance obligations in the contract being satisfied at the same time. Components shipped separately are recognized upon shipment at their relative standalone selling price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue at the transaction price, which reflects the consideration it believes it is entitled to receive. Transaction price includes estimates of variable consideration for promotions and prompt pay discounts, which are recorded as a reduction of transaction price in the period the related product revenue is recognized. The Company may also make payments to customers for marketing programs. Payments to customers for a distinct good or service that reasonably estimate the fair value of the distinct benefit received, such as marketing programs, are recorded as a marketing expense on the consolidated statement of operations and comprehensive loss. Shipping and logistics costs inclusive of these payments to customers and other costs included in sales and marketing expense for the years ended December&#160;31, 2023 and 2022 were $3.3&#160;million and $3.6&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses incremental costs of obtaining a contract, such as sales commissions, when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company&#x2019;s consolidated statement of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the sales tax practical expedient; therefore, sales and other taxes assessed by a governmental authority that are collected concurrently with revenue-producing activities are excluded from the transaction price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the significant financing component practical expedient, which allows management to not assess whether the contract has a significant financing component in circumstances where, at contract inception, the expected contract duration is less than one year. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Warranty &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company does not provide general rights of return of products sold to its customers. However, the Company does provide for rights of exchange to its distributors and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;end-use&lt;/div&gt; customers for products that fail to conform to the Company&#x2019;s specifications for a limited time following delivery. These performance specifications include that the Allurion Balloon (i)&#160;is successfully filled upon initial placement when used according to the instructions for use provided by the Company and/or (ii)&#160;remains in the patient&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;body &lt;/div&gt;for 90 days or more once placed. Customers may exchange product within 30 calendar days if they discover product nonconformities through a reasonable inspection and within 30 calendar days after discovery of any hidden or latent product nonconformities that could not have been discovered by a reasonable inspection. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These instances of nonconformity have been immaterial, and the Company&#x2019;s management expects instances of nonconformity to be extremely rare. &lt;/div&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist of costs associated with performing research and development activities, including salaries and benefits, stock-based compensation, product development costs, materials and supplies, clinical trial activities, depreciation of equipment, and contract and other outside services. Payments for activities that are provided by outside vendors are based upon the terms of the individual arrangements with each vendor. Costs of certain of these activities are expensed based upon an evaluation of the progress to completion of specific tasks and actual costs incurred, using information provided to the Company by its vendors. As payments for these activities may differ from the pattern of costs actually incurred, additional costs are reflected in the consolidated financial statements as prepaid or accrued research and development expenses. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advertising and Marketing Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses advertising and marketing costs as incurred. Advertising and marketing expenses are included in sales and marketing operating expenses. Advertising and marketing costs for the years ended December&#160;31, 2023 and 2022 were $10.8&#160;million and $16.0&#160;million, respectively. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intellectual Property Prosecution Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company incurs registration and prosecution costs related to its intellectual property. The related costs are expensed as incurred and are classified as a component of general and administrative expenses. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for net operating loss and tax credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines whether a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company has not identified any uncertain tax positions for which reserves would be required. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method to compute basic and diluted net loss per share attributable to common stockholders, when shares meet the definition of participating securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2023 and 2022. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders less the cumulative undeclared dividend by the weighted average number of common shares outstanding for the period. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The holders of the Legacy Allurion Series D convertible preferred stock were contractually entitled to receive a cumulative dividend, whether or not declared, and therefore, Legacy Allurion Series D convertible preferred stocks were participating securities. The holders of all other redeemable and convertible preferred stock were not entitled to cumulative dividends. The preferred equity holders were also not contractually required to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination with Compute Health, the Company&#x2019;s equity in previous periods has been retroactively adjusted to the earliest period presented to reflect the equivalent number of shares of Allurion Common Stock issued to the Company&#x2019;s stockholders in connection with the Business Combination. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Business Combination. See Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;, for details of the Business Combination. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes compensation expense for awards based on the grant-date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The Company accounts for awards issued to nonemployees under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2018-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation-Stock Compensation (&#x201c;Topic 718&#x201d;): Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;&lt;/div&gt;, with the measurement date for nonemployee awards being the date of grant. The fair value of stock options is calculated using the Black-Scholes option-pricing model. The fair value of Restricted Stock Units (&#x201c;RSUs&#x201d;) is based on the fair market value of common stock at the date of grant. The Company records forfeitures as they occur. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, comprehensive loss consists of net loss and other comprehensive loss, which includes changes in the fair value attributable to instrument-specific credit risk related to the Revenue Interest Financing with RTW. There were no differences between net loss and comprehensive loss presented in the statements of operations and comprehensive loss for the year ended December&#160;31, 2022. &lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses: &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Measurement &lt;/div&gt;of Credit Losses on Financial Instruments (Topic 326)&lt;/div&gt;&lt;/div&gt;. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets such as available for sale debt securities, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; effective January 1, 2023 under the prospective transition approach. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt;, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The Company does not expect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; to have a material impact on its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/div&gt;&lt;/div&gt; which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;, which require public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2023To12_31_2023" id="ixv-16365"> &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. &lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="P01_01_2023To12_31_2023" id="ixv-16371"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reclassification of Prior Year Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustments have been made to the &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;  &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;consolidated statement of &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;operations &lt;/div&gt;and comprehensive loss for the year ended December&#160;31, 2022 to present the change in fair value of derivative liabilities as part of Other income (expense), net, and to present the change in fair value of warrants as its own line item. The change in fair value of derivative liabilities was a separate line item in prior years and the change in fair value of warrants was part of Other income (expense), net in prior years. &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2023To12_31_2023" id="ixv-16396"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk of Concentration of Credit, Significant Customers and Significant Suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue for the years ended December&#160;31, 2023 and 2022 or accounts receivable, net balance as of December&#160;31, 2023 and 2022. The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts&#160;Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer C&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#x2019;s operating results, financial condition and cash flows and damage its customer relationships. &lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47670"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-47671"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-47672"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47673"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-47674">The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts&#160;Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer C&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47675"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      id="ixv-47676"
      unitRef="Unit_pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47677"
      unitRef="Unit_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerCMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      id="ixv-47678"
      unitRef="Unit_pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersDMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-47679"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16547"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2022, the Company adopted ASC 842, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 842&#x201d;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) asset and a current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; lease liability as applicable, in the consolidated balance sheets if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having an original term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will either renew or not cancel the lease. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company&#x2019;s incremental borrowing rate. The &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company&#x2019;s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of the lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received or initial direct costs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company enters into contracts that contain both lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-lease&lt;/div&gt; components. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Non&lt;/div&gt;-lease&lt;/div&gt; components include costs that do not provide a right to use a leased asset but instead provide a service, such as maintenance costs. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-16586"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash consists of amounts held in bank savings and checking accounts. Cash equivalents include all highly liquid investments maturing within 90 days from the date of purchase. Cash equivalents consist of money market funds. The Company&#x2019;s restricted cash consists of cash that the Company is contractually obligated to maintain and deposits of cash collateral held in accordance with the terms of various corporate credit cards. Restricted cash is included within other long-term assets on the consolidated balance sheets. A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash included in &lt;div style="-sec-ix-hidden:hidden127681918;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127681919;display:inline;"&gt;other long-term assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents and restricted cash shown in the statement of cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <alur:ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-47682">A reconciliation of the amounts of cash and cash equivalents and restricted cash in the consolidated balance sheets to the amount in the consolidated statements of cash flows is as follows (in thousands): &lt;div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,037&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted cash included in &lt;div style="-sec-ix-hidden:hidden127681918;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127681919;display:inline;"&gt;other long-term assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;384&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;338&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents and restricted cash shown in the statement of cash flows&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,421&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </alur:ReconciliationOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47683"
      unitRef="Unit_USD">38037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47684"
      unitRef="Unit_USD">7685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47685"
      unitRef="Unit_USD">384000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47686"
      unitRef="Unit_USD">338000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47687"
      unitRef="Unit_USD">38421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47688"
      unitRef="Unit_USD">8023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16687"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company operates in a single operating and reportable segment. Operating segments are defined as components of an enterprise for which discrete financial information is available and is regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) in order to make decisions regarding resource allocation and performance assessment. The Company has determined that its CODM is its Chief Executive Officer. The Company&#x2019;s CODM reviews financial information presented on a regular basis at the consolidated level for purposes of allocating resources and evaluating financial performance. Since the Company operates as one operating segment, all required financial segment information can be found in the consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s products include the Allurion Balloon and related accessories. See Note 4, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;below&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;for financial information about sales in geographic areas. &lt;/div&gt; </us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16698"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying value of the Company&#x2019;s financial instruments such as cash and cash equivalents, accounts payable, and accrued expenses approximate their fair values due to their short-term maturity. The carrying value of the Company&#x2019;s term loan approximates its fair value as the interest rate and other terms are that which are currently available to the Company. The Company&#x2019;s &lt;/div&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;assets and liabilities recorded at fair value have been categorized based upon a fair value hierarchy, which is distinguished between observable and unobservable inputs in accordance with authoritative accounting guidance: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;1 inputs: Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;2 inputs: Other than quoted prices included in Level&#160;1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Level&#160;3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that the observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16733"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventories, which include the costs of material, labor, and overhead, are stated at the lower of cost or net realizable value, with cost generally computed using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;first-in,&lt;/div&gt; first out method. Estimated losses from obsolete and slow-moving inventories are recorded to reduce inventory values to their estimated net realizable value and are charged to cost of sales. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in a recovery in carrying value. &lt;/div&gt; </us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16740"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment include computers, laboratory equipment, machinery, and leasehold improvements. Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated on a straight-line basis over the shorter of the estimated life or the lease term. Expenditures for repairs and maintenance are expensed as incurred. &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InternalUseSoftwarePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-16746"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Internal-Use&lt;/div&gt; Software &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Software development costs consist of certain consulting costs and compensation expenses for employees who devote time to the development projects of our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software, as well as certain upgrades and enhancements that are expected to result in enhanced functionality. The Company amortizes these development costs over the estimated useful life, which is determined based on our best estimate of the useful life of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software after considering factors such as continuous developments in the technology, obsolescence, and anticipated life of the service offering before significant upgrades. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determined the amount of internal software costs to be capitalized based on the amount of time spent by our developers on projects in the application stage of development. There is judgment in estimating the time allocated to a particular project in the application stage. A significant change in the time spent on each project could have a material impact on the amount capitalized and related amortization expense in subsequent periods. As of December&#160;31, 2023 and 2022, capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;internal-use&lt;/div&gt; software was immaterial. &lt;/div&gt; </us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16757"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <alur:DebtIssuanceCostsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16781"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt Issuance Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company defers costs directly associated with acquiring third-party financing. Fees incurred to issue debt are generally deferred and amortized as a component of interest expense over the estimated term of the related debt using the effective interest rate method. Fees incurred in connection with a modification are deferred and amortized as a component of interest expense over the remaining life of the loan if due to the creditor. Third-party fees incurred in connection with a &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;modification &lt;/div&gt;are expensed as incurred. &lt;/div&gt; </alur:DebtIssuanceCostsPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16788"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Deferred Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Deferred offering costs include certain legal, accounting, consulting and other third-party fees incurred directly related to the Business Combination. The Company deferred offering costs classified as a long-term asset until the closing or termination of the transaction. At the closing of the Business Combination, these costs were recorded in stockholders&#x2019; deficit as a reduction of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital. Deferred offering costs are included in other long-term assets. As of December&#160;31, 2023 and 2022, there were zero and $2.3&#160;million of deferred offering costs recorded within other long-term assets on the consolidated balance sheet, respectively. &lt;/div&gt; </us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2023_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="0"
      id="ixv-47692"
      unitRef="Unit_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2022_OtherNoncurrentAssetsMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      id="ixv-47693"
      unitRef="Unit_USD">2300000</us-gaap:DeferredOfferingCosts>
    <alur:WarrantsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16795"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines the accounting classification of warrants it issues, as either liability or equity classified, by first assessing whether the warrants meet liability classification in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;480-10,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(&#x201c;ASC&#160;480-10&#x201d;),&lt;/div&gt; then in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40&#x201d;).&lt;/div&gt; Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;480-10,&lt;/div&gt; warrants are considered liability classified if the warrants are mandatorily redeemable, obligate the Company to settle the warrants or the underlying shares by paying cash or other assets, or are warrants that must or may require settlement by issuing a variable number of shares. If warrants do not meet liability classification under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASC&#160;480-10,&lt;/div&gt; the Company assesses the requirements under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; which states that contracts that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40,&lt;/div&gt; and in order to conclude equity classification, the Company also assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;815-40&lt;/div&gt; or other applicable GAAP. After all relevant assessments, the Company concludes whether the warrants are classified as liability or equity. Liability classified warrants require fair value accounting at issuance and subsequent to initial issuance, with all changes in fair value after the issuance date recorded in the consolidated statements of operations. Equity classified warrants only require fair value accounting at issuance with no changes recognized subsequent to the issuance date. &lt;/div&gt; </alur:WarrantsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16814"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluates its convertible instruments and other contracts, including warrants, to determine if those contracts or embedded components of those contracts are required to be accounted for as derivatives, either in whole or in part. If an embedded derivative is bifurcated from a debt host contract, changes in the fair value of the bifurcated derivative are recorded in the accompanying consolidated statements of operations. &lt;/div&gt; </us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16820"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the convertible notes issued between February 2023 and August 2023 (the &#x201c;2023 Convertible Notes&#x201d;) under the fair value option (&#x201c;FVO&#x201d;) election of ASC Topic 825, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 825&#x201d;). The convertible notes accounted for under the FVO election were each debt host financial instruments containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the convertible notes were &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;recorded as a component of Other (expense) income in the consolidated statements of operations. As a result of electing the FVO, direct costs and fees related to the 2023 Convertible Notes were expensed as incurred. The convertible notes issued in 2020, 2021 and 2022 are accounted for as disclosed in Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt;. In connection with the closing of the Business Combination on August&#160;1, 2023, a portion of the 2023 convertible notes was repaid, with the remaining balance converted to shares of our Common Stock. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <alur:EarnoutLiabilityPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16848"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, certain holders of Legacy Allurion common &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;stock &lt;/div&gt;and Legacy Allurion preferred stock and holders of vested options, warrants and restricted stock units exercisable or convertible into Legacy Allurion capital stock received the contingent right to receive up to 9,000,000 additional shares of Allurion Common Stock (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Shares&#x201d;) upon the achievement of certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; targets. The contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration contains a settlement provision that in the event of a change in control, the number of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares issued may vary. This settlement provision precludes the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liability from being indexed to the Company&#x2019;s Common Stock as a change in control event is not an input into the pricing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; forward or option on equity shares. As such, it is classified as a liability under ASC 480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 480&#x201d;). &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration is remeasured on a quarterly basis over the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; period with changes in the estimated fair value of the contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration recorded in Other (expense) income in the consolidated statements of operations, and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; consideration may materially impact or cause volatility in our operating results. &lt;/div&gt; </alur:EarnoutLiabilityPolicyTextBlock>
    <alur:BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable
      contextRef="P08_01_2023To08_01_2023_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-47696"
      unitRef="Unit_shares">9000000</alur:BusinessCombinationContingentConsiderationNumberOfAdditionalSharesReceivable>
    <alur:RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16870"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company entered into a revenue interest financing agreement, dated as of February&#160;9, 2023 (the &#x201c;Revenue Interest Financing Agreement&#x201d;) with certain entities that have engaged RTW Investments, LP as investment manager (collectively, &#x201c;RTW&#x201d;), under which the Company received $40.0&#160;million upfront (the &#x201c;Revenue Interest Financing&#x201d;). In exchange, the Company is obligated to remit to RTW certain revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounts for the Revenue Interest Financing Agreement under the fair value option election of ASC 825. The Revenue Interest Financing Agreement accounted for under the FVO election is a debt host financial instrument that contains embedded features. The embedded features include requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events, a change in royalty rates upon the occurrence of certain contingent events, and the Company&#x2019;s ability to prepay the Revenue Interest Financing. As the Company has elected the FVO, these embedded features would not meet the criteria for bifurcation and separate accounting as the entire financial instrument is initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis on each reporting period date. Changes in the estimated fair value of the Revenue Interest Financing Agreement are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the Revenue Interest Financing are expensed as incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Company entering in the Revenue Interest Financing, the Company and RTW entered into the RTW side letter under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE (as &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;defined in Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;below) subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by the PIPE subscription (the &#x201c;PIPE Conversion Option&#x201d;). The Company accounts for the PIPE Conversion Option as a freestanding financial instrument that qualifies for derivative liability accounting in accordance with ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 815&#x201d;). The PIPE Conversion Option is initially measured at its fair value within Other liabilities on the consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. Subsequent changes in fair value of the derivative liability are recognized as a gain or loss as a component of Other (expense) income in the consolidated statements of operations. &lt;/div&gt;</alur:RevenueInterestFinancingAndPipeConversionOptionPolicyTextBlock>
    <alur:ProceedsFromRevenueInterestFinancing
      contextRef="P08_01_2023To08_01_2023_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47697"
      unitRef="Unit_USD">40000000</alur:ProceedsFromRevenueInterestFinancing>
    <alur:PercentageOfAnnualNetSales
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-47698"
      unitRef="Unit_pure">0.06</alur:PercentageOfAnnualNetSales>
    <alur:RemittanceOfRevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-47699"
      unitRef="Unit_pure">0.10</alur:RemittanceOfRevenueInterestPaymentsPercentage>
    <us-gaap:RevenuesNetOfInterestExpense
      contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47700"
      unitRef="Unit_USD">7500000</us-gaap:RevenuesNetOfInterestExpense>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-16903"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accounts receivable are unsecured and are carried at net realizable value, including an allowance for doubtful accounts. Trade credit is generally extended on a short-term basis; trade receivables do not bear interest, although a finance charge may be applied to such receivables that are past due. The allowance for doubtful accounts is based on the Company&#x2019;s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors that may affect a customer&#x2019;s ability to pay, such as historical expense, credit quality, &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;the &lt;/div&gt;age of the account receivable balances, and current economic conditions. Amounts determined to be uncollectible are charged or written off against the allowance. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes activity in the allowance for doubtful accounts: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2023&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2022&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at beginning of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for uncollectible accounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,675&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Uncollectible accounts written off&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at end of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,671&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-16910"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes activity in the allowance for doubtful accounts: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2023&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2009;&#x2003;2022&#x2003;&#x2009;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at beginning of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provision for uncollectible accounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,675&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Uncollectible accounts written off&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance at end of period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,671&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47703"
      unitRef="Unit_USD">741000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-47704"
      unitRef="Unit_USD">354000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47705"
      unitRef="Unit_USD">12675000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47706"
      unitRef="Unit_USD">436000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47707"
      unitRef="Unit_USD">745000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47708"
      unitRef="Unit_USD">49000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47709"
      unitRef="Unit_USD">12671000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47710"
      unitRef="Unit_USD">741000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17015"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2014-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;&lt;/div&gt;(&#x201c;Topic 606&#x201d; or &#x201c;ASC 606&#x201d;). In general, the Company&#x2019;s sales contracts fall under its standard sales agreement whereby control transfers to the customer upon shipment, satisfying the performance obligations of the contract. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue when control of its products is transferred to customers at an amount that reflects the consideration it expects to receive in exchange for those products. The Company&#x2019;s revenue recognition process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue as performance obligations are satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. Performance obligations are considered satisfied once the Company has transferred control of a good or service to the customer, meaning that such customer has the ability to use and obtain the benefit of the good or service. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has provided customers purchasing the Allurion Balloon with an implied license for access to its VCS software. This implied software license was given to customers for no additional consideration and was not negotiated as part of the customer&#x2019;s contracts. Further, the customer contracts and related purchase orders do not include nor specify rights or obligations associated with the VCS software. Based on this assessment, the Company determined the implied license to be immaterial in the context of the contract with customers purchasing the Allurion Balloon, and as such did not allocate any value to the implied VCS license. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company generates revenue from sales of its Allurion Balloon to distributors and health care providers. Customers &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;typically &lt;/div&gt;purchase the Allurion Balloon, including the gastric balloon and related accessories together, although customers can purchase the gastric balloon and its accessories separately. Therefore, each component of the Allurion Balloon and accessories represents a distinct performance obligation and is separately identifiable. In arrangements with multiple performance obligations, the transaction price is allocated to each performance obligation using the relative standalone selling price. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account internally approved pricing guidelines and market conditions. Revenue is generally recognized upon shipment of the product because at that point, the customer obtains control of the product and has the ability to direct the use and obtain the benefit of the product. Components of the Allurion Balloon are typically shipped to the customer together, resulting in the performance obligations in the contract being satisfied at the same time. Components shipped separately are recognized upon shipment at their relative standalone selling price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue at the transaction price, which reflects the consideration it believes it is entitled to receive. Transaction price includes estimates of variable consideration for promotions and prompt pay discounts, which are recorded as a reduction of transaction price in the period the related product revenue is recognized. The Company may also make payments to customers for marketing programs. Payments to customers for a distinct good or service that reasonably estimate the fair value of the distinct benefit received, such as marketing programs, are recorded as a marketing expense on the consolidated statement of operations and comprehensive loss. Shipping and logistics costs inclusive of these payments to customers and other costs included in sales and marketing expense for the years ended December&#160;31, 2023 and 2022 were $3.3&#160;million and $3.6&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses incremental costs of obtaining a contract, such as sales commissions, when incurred because the amortization period would have been one year or less. These costs are recorded within sales and marketing expenses in the Company&#x2019;s consolidated statement of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the sales tax practical expedient; therefore, sales and other taxes assessed by a governmental authority that are collected concurrently with revenue-producing activities are excluded from the transaction price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the significant financing component practical expedient, which allows management to not assess whether the contract has a significant financing component in circumstances where, at contract inception, the expected contract duration is less than one year. &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To12_31_2023_ShippingAndHandlingMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-47712"
      unitRef="Unit_USD">3300000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2022To12_31_2022_ShippingAndHandlingMembersrtProductOrServiceAxis"
      decimals="-5"
      id="ixv-47713"
      unitRef="Unit_USD">3600000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:StandardProductWarrantyPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17049"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Warranty &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company does not provide general rights of return of products sold to its customers. However, the Company does provide for rights of exchange to its distributors and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;end-use&lt;/div&gt; customers for products that fail to conform to the Company&#x2019;s specifications for a limited time following delivery. These performance specifications include that the Allurion Balloon (i)&#160;is successfully filled upon initial placement when used according to the instructions for use provided by the Company and/or (ii)&#160;remains in the patient&#x2019;s &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;body &lt;/div&gt;for 90 days or more once placed. Customers may exchange product within 30 calendar days if they discover product nonconformities through a reasonable inspection and within 30 calendar days after discovery of any hidden or latent product nonconformities that could not have been discovered by a reasonable inspection. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These instances of nonconformity have been immaterial, and the Company&#x2019;s management expects instances of nonconformity to be extremely rare. &lt;/div&gt; </us-gaap:StandardProductWarrantyPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17076"> &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist of costs associated with performing research and development activities, including salaries and benefits, stock-based compensation, product development costs, materials and supplies, clinical trial activities, depreciation of equipment, and contract and other outside services. Payments for activities that are provided by outside vendors are based upon the terms of the individual arrangements with each vendor. Costs of certain of these activities are expensed based upon an evaluation of the progress to completion of specific tasks and actual costs incurred, using information provided to the Company by its vendors. As payments for these activities may differ from the pattern of costs actually incurred, additional costs are reflected in the consolidated financial statements as prepaid or accrued research and development expenses. &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17082"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advertising and Marketing Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses advertising and marketing costs as incurred. Advertising and marketing expenses are included in sales and marketing operating expenses. Advertising and marketing costs for the years ended December&#160;31, 2023 and 2022 were $10.8&#160;million and $16.0&#160;million, respectively. &lt;/div&gt; </us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47715"
      unitRef="Unit_USD">10800000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47716"
      unitRef="Unit_USD">16000000</us-gaap:MarketingAndAdvertisingExpense>
    <alur:IntellectualPropertyProsecutionCostsPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17088"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Intellectual Property Prosecution Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company incurs registration and prosecution costs related to its intellectual property. The related costs are expensed as incurred and are classified as a component of general and administrative expenses. &lt;/div&gt; </alur:IntellectualPropertyProsecutionCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17094"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s consolidated financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for net operating loss and tax credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines whether a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. As of December&#160;31, 2023 and 2022, the Company has not identified any uncertain tax positions for which reserves would be required. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47717"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47718"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17101"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company applies the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method to compute basic and diluted net loss per share attributable to common stockholders, when shares meet the definition of participating securities. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;two-class&lt;/div&gt; method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (loss) for the period had been distributed. The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2023 and 2022. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders less the cumulative undeclared dividend by the weighted average number of common shares outstanding for the period. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The holders of the Legacy Allurion Series D convertible preferred stock were contractually entitled to receive a cumulative dividend, whether or not declared, and therefore, Legacy Allurion Series D convertible preferred stocks were participating securities. The holders of all other redeemable and convertible preferred stock were not entitled to cumulative dividends. The preferred equity holders were also not contractually required to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination with Compute Health, the Company&#x2019;s equity in previous periods has been retroactively adjusted to the earliest period presented to reflect the equivalent number of shares of Allurion Common Stock issued to the Company&#x2019;s stockholders in connection with the Business Combination. As a result, net loss per share was also retrospectively adjusted for periods ended prior to the Business Combination. See Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;, for details of the Business Combination. &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2023To12_31_2023" id="ixv-17133"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes compensation expense for awards based on the grant-date fair value of stock-based awards on a straight-line basis over the period during which an award holder provides service in exchange for the award. The Company accounts for awards issued to nonemployees under ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2018-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation-Stock Compensation (&#x201c;Topic 718&#x201d;): Improvements to Nonemployee Share-Based Payment Accounting&lt;/div&gt;&lt;/div&gt;, with the measurement date for nonemployee awards being the date of grant. The fair value of stock options is calculated using the Black-Scholes option-pricing model. The fair value of Restricted Stock Units (&#x201c;RSUs&#x201d;) is based on the fair market value of common stock at the date of grant. The Company records forfeitures as they occur. &lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17142"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the year ended December&#160;31, 2023, comprehensive loss consists of net loss and other comprehensive loss, which includes changes in the fair value attributable to instrument-specific credit risk related to the Revenue Interest Financing with RTW. There were no differences between net loss and comprehensive loss presented in the statements of operations and comprehensive loss for the year ended December&#160;31, 2022. &lt;/div&gt; </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17148"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses: &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Measurement &lt;/div&gt;of Credit Losses on Financial Instruments (Topic 326)&lt;/div&gt;&lt;/div&gt;. The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets such as available for sale debt securities, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; effective January 1, 2023 under the prospective transition approach. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2016-13&lt;/div&gt; did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt;, which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The Company does not expect the adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; to have a material impact on its consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/div&gt;&lt;/div&gt; which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;, which require public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-47720">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-47721">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="PAsOn12_31_2023_AccountingStandardsUpdate201613MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-47722">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17200">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As discussed in Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Basis of Presentation&lt;/div&gt;&lt;/div&gt;, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately 0.9780, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Allurion Common Stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio (&#x201c;Rollover Option&#x201d;), (d) each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#x201c;Rollover Warrant&#x201d;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#x201c;Sponsor&#x201d;) to CPUH, which balance was $3.7&#160;million at the time of the Business Combination (the &#x201c;Sponsor Loan Excess&#x201d;), was converted into 525,568 shares of Allurion Common Stock (the &#x201c;Sponsor Loan Equity Issuance&#x201d;). For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive 1.420455 &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;shares of Allurion Common Stock. Additionally, the Company assumed 13,206,922 outstanding public warrants to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company incurred approximately $22.7&#160;million of transaction costs, consisting of legal and other professional fees, $15.2&#160;million of which were recorded to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital as a reduction of proceeds, $2.5&#160;million of which were recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $5.0&#160;million of which were recorded as an expense in general and administrative expenses on the consolidated statement of operations and comprehensive loss. Of the $5.0&#160;million recorded as expense, $3.6&#160;million relates to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $1.2&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; CPUH trust (net of redemptions)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; PIPE Investors&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross Proceeds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net proceeds from the Business Combination (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: warrant liabilities assumed (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: repayment of note assumed in the Business Combination (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accrued transaction costs at December&#160;31, 2023 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business Combination, net of transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The Net proceeds from the Business Combination, less the repayment of note assumed in the Business Combination, less the accrued transaction costs at December&#160;31, 2023 are presented net in the consolidated statements of stockholders deficit within line &#x201c;Reverse recapitalization, net of transaction costs (Note 3)&#x201d;. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The warrant liabilities assumed are presented separately from the &#x201c;Reverse recapitalization, net of transaction costs (Note 3)&#x201d; line within the consolidated statements of stockholders deficit. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Equityholders (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,897,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Stockholders (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issued to PIPE Investors (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,386,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to RTW and Fortress (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,900,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to convertible note holders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301,222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Sponsor Shares (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,262,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Side Letter Termination Shares (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;387,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of Common Stock immediately after Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,301,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Consists of Legacy Allurion common stock and Legacy Allurion preferred stockholders, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Contributed &lt;/div&gt;Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#x201c;Reverse recapitalization, net of transaction costs&#x201d; line, which is less the Gaur Contributed Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#x201c;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#x201d; line. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;PIPE Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023 (the &#x201c;PIPE Subscription Agreements&#x201d;), with certain accredited investors and qualified institutional buyers (the &#x201c;PIPE Investors&#x201d;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of 5,386,695 shares of Allurion Common Stock at a purchase price of $7.04 per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $37.9&#160;million, following the CPUH Merger Effective Time (the &#x201c;PIPE Investment&#x201d;). &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement with RTW. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million (the &#x201c;Investment Amount&#x201d;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Additionally, in connection with the Company entering in the Revenue Interest Financing, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#x201c;RTW Side Letter&#x201d;) on February&#160;9, 2023 under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE subscription into an additional revenue interest financing by forfeiting a number of shares of Allurion common stock acquired by its PIPE Investment. Refer to Note 9, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing, Side Letter, and PIPE Conversion Option&lt;/div&gt;&lt;/div&gt; below for further discussion on the Revenue Interest Financing. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#x201c;Amended and Restated RTW Side Letter&#x201d;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued 250,000 shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fortress Credit Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#x201c;Fortress Term Loan&#x201d;) pursuant to a credit agreement and guaranty, dated as of August&#160;1, 2023 (the &#x201c;Fortress Credit Agreement&#x201d;), with Fortress Credit Corp. (&#x201c;Fortress&#x201d;), as administrative agent for the lenders party thereto from time to time (the &#x201c;Lenders&#x201d;). Under the terms of the Fortress Term Loan, we borrowed $60.0&#160;million which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement, Allurion issued an aggregate of 950,000 shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;for further discussion on the Fortress Term Loan. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Backstop Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#x201c;Backstop Purchasers&#x201d;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#x201c;HVL&#x201d;) entered into the backstop agreement (the &#x201c;Backstop Agreement&#x201d;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing (a)&#160;each Backstop Purchaser purchased $2&#160;million of the aggregate principal amount outstanding of HVL&#x2019;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $2&#160;million each and (d)&#160;Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further discussion around the Backstop Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;HVL Termination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#x201c;HVL Termination Agreement&#x201d;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#x2019;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL 387,696 shares of Allurion Common Stock. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further discussion regarding the HVL Termination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gaur Contribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#x201c;Gaur Trust&#x201d;) and Allurion entered into a contribution agreement (the &#x201c;Gaur Contribution Agreement&#x201d;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, 79,232 shares of Allurion Common Stock (the &#x201c;Gaur Trust Contributed Shares&#x201d;). The Gaur Trust&#x2019;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RSU Forfeiture Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, Krishna Gupta, a member of our Board of Directors, entered into a letter agreement with Legacy Allurion (the &#x201c;RSU Forfeiture Agreement&#x201d;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit 79,232 restricted stock units of Allurion (the &#x201c;Forfeited RSUs&#x201d;). The Forfeited RSUs were terminated and cancelled without consideration therefore immediately following the closing of the Business Combination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Contribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#x201c;Sponsor Contribution Agreement&#x201d;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, 161,379 shares of Compute Health Class&#160;A Common Stock (&#x201c;Sponsor Contributed Shares&#x201d;). The Sponsor&#x2019;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Allurion entered into a support agreement (the &#x201c;Sponsor Support Agreement&#x201d;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the Sponsor&#x2019;s 21,442,500 shares of Compute Health Class&#160;B Common Stock, and all 12,833,333 of the Sponsor&#x2019;s warrants to purchase shares of Class&#160;A Common Stock, into 2,088,327 shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement (the &#x201c;Additional Class&#160;B Holders&#x201d;) recapitalized his or her 30,000 shares of Compute Health Class&#160;B Common Stock into 21,120 shares of Compute Health Class&#160;A Common Stock (the &#x201c;CPUH Recapitalization&#x201d;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of 1.420455 (the &#x201c;CPUH Exchange Ratio&#x201d;). &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion of Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $21.8&#160;million were converted into 3,301,222 shares of Allurion Common Stock with a corresponding recognition of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital (&#x201c;APIC&#x201d;) of $25.6&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further information on the Company&#x2019;s convertible notes. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Public Warrants and Warrant Amendment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company assumed 13,206,922 outstanding Public Warrants (defined below) to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $13.8&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-share&lt;/div&gt; settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capital Stock and Stockholders&#x2019; Deficit&lt;/div&gt;&lt;/div&gt; and Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt; for further information on the Public Warrants and Warrant Amendment. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the shares price achieves certain targets. The Company accounts for the potential issuance of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares as a contingent consideration arrangement, which was initially valued and recorded at $53.0&#160;million. See Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt; for further information on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liabilities. &lt;/div&gt; </us-gaap:BusinessCombinationDisclosureTextBlock>
    <alur:BusinessCombinationCommonStockExchangeRatio
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-47724"
      unitRef="Unit_pure">0.978</alur:BusinessCombinationCommonStockExchangeRatio>
    <alur:SponsorLoanExcessAmount
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47725"
      unitRef="Unit_USD">3700000</alur:SponsorLoanExcessAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47726"
      unitRef="Unit_shares">525568</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47727"
      unitRef="Unit_shares">1.420455</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-47730"
      unitRef="Unit_shares">13206922</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P08_01_2023To08_01_2023"
      decimals="INF"
      id="ixv-47731"
      unitRef="Unit_shares">18759838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47732"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-47733"
      unitRef="Unit_USD">22700000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-47734"
      unitRef="Unit_USD">15200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47735"
      unitRef="Unit_USD">2500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-47736"
      unitRef="Unit_USD">5000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P08_01_2023To08_01_2023"
      decimals="-5"
      id="ixv-47737"
      unitRef="Unit_USD">5000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <alur:BusinessCombinationOneTimeInsurancePayment
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-47738"
      unitRef="Unit_USD">3600000</alur:BusinessCombinationOneTimeInsurancePayment>
    <alur:DirectCostsAndFees
      contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47739"
      unitRef="Unit_USD">1200000</alur:DirectCostsAndFees>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17237"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows and the consolidated statement of changes in equity: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; CPUH trust (net of redemptions)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; PIPE Investors&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross Proceeds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net proceeds from the Business Combination (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: warrant liabilities assumed (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: repayment of note assumed in the Business Combination (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accrued transaction costs at December&#160;31, 2023 (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business Combination, net of transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The Net proceeds from the Business Combination, less the repayment of note assumed in the Business Combination, less the accrued transaction costs at December&#160;31, 2023 are presented net in the consolidated statements of stockholders deficit within line &#x201c;Reverse recapitalization, net of transaction costs (Note 3)&#x201d;. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The warrant liabilities assumed are presented separately from the &#x201c;Reverse recapitalization, net of transaction costs (Note 3)&#x201d; line within the consolidated statements of stockholders deficit. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-47740"
      unitRef="Unit_USD">38395000</alur:GrossProceedsFromBusinessCombination>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-47741"
      unitRef="Unit_USD">37922000</alur:GrossProceedsFromBusinessCombination>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47742"
      unitRef="Unit_USD">76317000</alur:GrossProceedsFromBusinessCombination>
    <alur:BusinessCombinationTransactionCostPaid
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47743"
      unitRef="Unit_USD">14665000</alur:BusinessCombinationTransactionCostPaid>
    <alur:NetProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47744"
      unitRef="Unit_USD">61652000</alur:NetProceedsFromBusinessCombination>
    <alur:WarrantLiabilitiesAssumed
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47745"
      unitRef="Unit_USD">-13762000</alur:WarrantLiabilitiesAssumed>
    <alur:RepaymentOfNoteAssumedInBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47746"
      unitRef="Unit_USD">-2500000</alur:RepaymentOfNoteAssumedInBusinessCombination>
    <alur:BusinessAcquisitionAccruedTransactionCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47747"
      unitRef="Unit_USD">-580000</alur:BusinessAcquisitionAccruedTransactionCosts>
    <alur:BusinessCombinationNetOfTransactionCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47748"
      unitRef="Unit_USD">44810000</alur:BusinessCombinationNetOfTransactionCosts>
    <alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding contextRef="P01_01_2023To12_31_2023" id="ixv-17361"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Equityholders (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,897,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Stockholders (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issued to PIPE Investors (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,386,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to RTW and Fortress (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,900,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to convertible note holders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301,222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Sponsor Shares (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,262,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Side Letter Termination Shares (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;387,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of Common Stock immediately after Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,301,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Consists of Legacy Allurion common stock and Legacy Allurion preferred stockholders, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Contributed &lt;/div&gt;Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#x201c;Reverse recapitalization, net of transaction costs&#x201d; line, which is less the Gaur Contributed Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the consolidated statements of redeemable convertible preferred stock and stockholders deficit on the &#x201c;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#x201d; line. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47749"
      unitRef="Unit_shares">27897387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47750"
      unitRef="Unit_shares">5165698</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47751"
      unitRef="Unit_shares">5386695</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47752"
      unitRef="Unit_shares">1900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47753"
      unitRef="Unit_shares">3301222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47754"
      unitRef="Unit_shares">3262711</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47755"
      unitRef="Unit_shares">387696</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023"
      decimals="INF"
      id="ixv-47756"
      unitRef="Unit_shares">47301409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-47758"
      unitRef="Unit_shares">5386695</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-47759"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-47760"
      unitRef="Unit_USD">37900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <alur:ProceedsFromRevenueInterestFinancing
      contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47761"
      unitRef="Unit_USD">40000000</alur:ProceedsFromRevenueInterestFinancing>
    <alur:PercentageOfAnnualNetSales
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47762"
      unitRef="Unit_pure">0.06</alur:PercentageOfAnnualNetSales>
    <alur:RemittanceOfRevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47763"
      unitRef="Unit_pure">0.10</alur:RemittanceOfRevenueInterestPaymentsPercentage>
    <alur:ConversionOfPipeSubscriptionToRevenueInterestFinance
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-47764"
      unitRef="Unit_USD">7500000</alur:ConversionOfPipeSubscriptionToRevenueInterestFinance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47765"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47766"
      unitRef="Unit_USD">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47767"
      unitRef="Unit_shares">950000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-47769"
      unitRef="Unit_USD">2000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-47770"
      unitRef="Unit_USD">2000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-47771"
      unitRef="Unit_shares">700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47772"
      unitRef="Unit_shares">387696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alur:ContributionOfCapitalByJointVenturePartner
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47773"
      unitRef="Unit_shares">79232</alur:ContributionOfCapitalByJointVenturePartner>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47774"
      unitRef="Unit_shares">79232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <alur:ContributionOfCapitalByJointVenturePartner
      contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47775"
      unitRef="Unit_shares">161379</alur:ContributionOfCapitalByJointVenturePartner>
    <alur:RecapitalizationOfCommonStock
      contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47778"
      unitRef="Unit_shares">21442500</alur:RecapitalizationOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47779"
      unitRef="Unit_shares">12833333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47780"
      unitRef="Unit_shares">2088327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:RecapitalizationOfAdditionalShares
      contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47781"
      unitRef="Unit_shares">30000</alur:RecapitalizationOfAdditionalShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-47782"
      unitRef="Unit_shares">21120</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-47783"
      unitRef="Unit_shares">1.420455</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-47784"
      unitRef="Unit_USD">21800000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-47785"
      unitRef="Unit_shares">3301222</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-47786"
      unitRef="Unit_USD">25600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-47787"
      unitRef="Unit_shares">13206922</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P08_01_2023To08_01_2023"
      decimals="INF"
      id="ixv-47788"
      unitRef="Unit_shares">18759838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-47789"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-47790"
      unitRef="Unit_USD">13800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-47791"
      unitRef="Unit_USD">53000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17604">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue by geographic region is based on the country in which our customer is domiciled and is summarized by geographic area as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Spain&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,852&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Chile&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,078&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There is currently no revenue generated in the United States. For the year ended December&#160;31, 2023, $13.3&#160;million of revenue was generated in four countries included within All other countries in the table above, representing approximately 25% of Total Revenues, with each country responsible for approximately &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;5%-9%&lt;/div&gt; of the total. The remaining revenue was generated by sales in 55 other countries included within All other countries. For the year ended December&#160;31, 2022, $16.0&#160;million of revenue was generated in four countries included within All other countries, representing approximately 25% of Total Revenues, with each country responsible for approximately &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;6%-7%&lt;/div&gt; of the total. Remaining revenue was generated by sales in 50 other countries included within All other countries. &lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17613"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue by geographic region is based on the country in which our customer is domiciled and is summarized by geographic area as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,569&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,032&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,494&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Spain&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,852&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Chile&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,078&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42,240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,467&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47792"
      unitRef="Unit_USD">5569000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47793"
      unitRef="Unit_USD">6032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47794"
      unitRef="Unit_USD">5494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47795"
      unitRef="Unit_USD">4079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_ESsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47796"
      unitRef="Unit_USD">4618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ESsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47797"
      unitRef="Unit_USD">6852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_CLsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47798"
      unitRef="Unit_USD">2708000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_CLsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47799"
      unitRef="Unit_USD">5008000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47800"
      unitRef="Unit_USD">35078000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47801"
      unitRef="Unit_USD">42240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47802"
      unitRef="Unit_USD">53467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-47803"
      unitRef="Unit_USD">64211000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2023To12_31_2023_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-47805"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47806"
      unitRef="Unit_USD">13300000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-47807"
      unitRef="Unit_Country">4</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47808"
      unitRef="Unit_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47809"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47810"
      unitRef="Unit_pure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P01_01_2023To12_31_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-47811"
      unitRef="Unit_Country">55</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47812"
      unitRef="Unit_USD">16000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      id="ixv-47813"
      unitRef="Unit_Country">4</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47814"
      unitRef="Unit_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47815"
      unitRef="Unit_pure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-47816"
      unitRef="Unit_pure">0.07</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P01_01_2022To12_31_2022_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-47817"
      unitRef="Unit_Country">50</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17759">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,556&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Inventory&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory is stated net of less than $0.1&#160;million and zero for the provision of excess and obsolete inventory as of December&#160;31, 2023 and 2022, respectively. &lt;/div&gt; </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17768"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,096&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,556&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Inventory&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,865&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47818"
      unitRef="Unit_USD">3427000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47819"
      unitRef="Unit_USD">2096000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47820"
      unitRef="Unit_USD">967000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47821"
      unitRef="Unit_USD">213000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47822"
      unitRef="Unit_USD">1777000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47823"
      unitRef="Unit_USD">1556000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47824"
      unitRef="Unit_USD">6171000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47825"
      unitRef="Unit_USD">3865000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-47826"
      unitRef="Unit_USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2022"
      decimals="-6"
      id="ixv-47827"
      unitRef="Unit_USD">0</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17875">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td style="width:22%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates Useful Life&lt;br/&gt; (in Years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and purchased software&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Shorter&#160;of&#160;useful&#160;life&lt;br/&gt; or lease term&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;at cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Less accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Construction in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense was $0.7&#160;million and $0.9&#160;million for the years ended &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;December&#160;&lt;/div&gt;31, 2023 and 2022, respectively, recorded as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sales and marketing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total depreciation and amortization expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-hidden:hidden127682954;display:inline;"&gt;875&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-17884"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td style="width:22%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimates Useful Life&lt;br/&gt; (in Years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and purchased software&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;575&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;Shorter&#160;of&#160;useful&#160;life&lt;br/&gt; or lease term&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,822&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;251&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Machinery and equipment&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,002&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;at cost&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Less accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Construction in progress&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;583&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;net&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,382&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-47828">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47829"
      unitRef="Unit_USD">618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47830"
      unitRef="Unit_USD">575000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47831"
      unitRef="Unit_USD">1943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47832"
      unitRef="Unit_USD">1822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-47833">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47834"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47835"
      unitRef="Unit_USD">251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"
      id="ixv-47836">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis"
      id="ixv-47837">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47838"
      unitRef="Unit_USD">2893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-47839"
      unitRef="Unit_USD">2002000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47840"
      unitRef="Unit_USD">5745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47841"
      unitRef="Unit_USD">4650000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47842"
      unitRef="Unit_USD">3559000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47843"
      unitRef="Unit_USD">2851000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <alur:ConstructionInProgress
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47844"
      unitRef="Unit_USD">1195000</alur:ConstructionInProgress>
    <alur:ConstructionInProgress
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47845"
      unitRef="Unit_USD">583000</alur:ConstructionInProgress>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47846"
      unitRef="Unit_USD">3381000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47847"
      unitRef="Unit_USD">2382000</us-gaap:PropertyPlantAndEquipmentNet>
    <alur:ScheduleOfDepreciationExpenseTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18110"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense was $0.7&#160;million and $0.9&#160;million for the years ended &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;December&#160;&lt;/div&gt;31, 2023 and 2022, respectively, recorded as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;367&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sales and marketing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total depreciation and amortization expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;746&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="-sec-ix-hidden:hidden127682954;display:inline;"&gt;875&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </alur:ScheduleOfDepreciationExpenseTableTextBlock>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47848"
      unitRef="Unit_USD">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-47849"
      unitRef="Unit_USD">900000</us-gaap:Depreciation>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47850"
      unitRef="Unit_USD">367000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47851"
      unitRef="Unit_USD">568000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47852"
      unitRef="Unit_USD">179000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47853"
      unitRef="Unit_USD">90000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47854"
      unitRef="Unit_USD">138000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47855"
      unitRef="Unit_USD">160000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47856"
      unitRef="Unit_USD">62000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2022To12_31_2022_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-47857"
      unitRef="Unit_USD">57000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-47858"
      unitRef="Unit_USD">746000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18240">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accrued Expenses and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses and other current liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distributor fees and marketing reimbursements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trials and R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued selling and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;481&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued warranty&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued restructuring&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with strategic initiatives implemented during the period ended December&#160;31, 2023, the Company&#x2019;s management approved and initiated plans to reduce its cost structure. The Company recorded $1.0&#160;million of restructuring charges during the year ended December&#160;31, 2023, of which $0.4&#160;million has been paid as of December&#160;31, 2023. The restructuring charges are included in operating expenses in the statement of operations. Substantially all of this charge represents the severance cost of terminated employees. &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18249"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses and other current liabilities consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Distributor fees and marketing reimbursements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,453&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trials and R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;228&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued selling and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;481&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,105&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued warranty&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued restructuring&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,641&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <alur:DistributorFeesAndMarketingReimbursements
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47859"
      unitRef="Unit_USD">2834000</alur:DistributorFeesAndMarketingReimbursements>
    <alur:DistributorFeesAndMarketingReimbursements
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47860"
      unitRef="Unit_USD">6348000</alur:DistributorFeesAndMarketingReimbursements>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47861"
      unitRef="Unit_USD">1687000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47862"
      unitRef="Unit_USD">3453000</us-gaap:WorkersCompensationLiabilityCurrent>
    <alur:AccruedClinicalTrialsAndResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47863"
      unitRef="Unit_USD">3694000</alur:AccruedClinicalTrialsAndResearchAndDevelopment>
    <alur:AccruedClinicalTrialsAndResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47864"
      unitRef="Unit_USD">228000</alur:AccruedClinicalTrialsAndResearchAndDevelopment>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47865"
      unitRef="Unit_USD">1110000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47866"
      unitRef="Unit_USD">481000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47867"
      unitRef="Unit_USD">1505000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47868"
      unitRef="Unit_USD">2105000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47869"
      unitRef="Unit_USD">489000</us-gaap:InterestPayableCurrent>
    <us-gaap:StandardProductWarrantyAccrualCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47870"
      unitRef="Unit_USD">44000</us-gaap:StandardProductWarrantyAccrualCurrent>
    <us-gaap:StandardProductWarrantyAccrualCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47871"
      unitRef="Unit_USD">48000</us-gaap:StandardProductWarrantyAccrualCurrent>
    <alur:AccruedRestructuringCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47872"
      unitRef="Unit_USD">655000</alur:AccruedRestructuringCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47873"
      unitRef="Unit_USD">3966000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47874"
      unitRef="Unit_USD">2641000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47875"
      unitRef="Unit_USD">15495000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47876"
      unitRef="Unit_USD">15793000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47877"
      unitRef="Unit_USD">1000000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-47878"
      unitRef="Unit_USD">400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18422">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s third-party debt consisted of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fortress Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2021 Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amounts of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus: Accretion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of long-term debt, net of discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53,360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: unamortized deferred financing costs and debt discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,605&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term debt, net of current portion and discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the fair value for the Company&#x2019;s Fortress Term Loan and 2021 Term Loan approximated the respective carrying amounts. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Term Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2021, the Company entered into a loan and security agreement (as amended, the &#x201c;2021 Term Loan&#x201d; and the &#x201c;2021 Term Loan Agreement&#x201d;) with Runway Growth Credit Fund, Inc. (&#x201c;Runway&#x201d;) that provided initial cash proceeds of $15.0&#160;million, all of which was drawn down in March 2021 and provided for additional borrowings of up to $10.0&#160;million, in $5.0&#160;million increments, based upon the achievement of certain revenue thresholds within specified time periods, as defined in the 2021 Term Loan Agreement. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2021, the 2021 Term Loan Agreement was amended (the &#x201c;Amendment&#x201d;) to extend the maturity date of the 2021 Term Loan to December 30, 2025 and provide for an additional $20.0&#160;million of borrowings, of which $15.0&#160;million (the &#x201c;Term C Loan&#x201d;) was available based upon the achievement of certain revenue thresholds within specified time periods as defined in 2021 Term Loan Agreement as amended. The agreement provided for equal monthly principal payments to commence on December 30, 2024 such that the borrowed principal amounts would be repaid in full on December&#160;30, 2025. However, if certain revenue thresholds were achieved prior to April&#160;15, 2023, the borrowed principal amounts would be repaid in full on December&#160;30, 2025. The revenue thresholds were achieved in June 2022. In connection with the 2021 Term Loan, the Company paid issuance costs of $0.7&#160;million which were amortized over the remaining life of the loan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2021, the Company issued warrants exercisable for 132,979 shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $0.3&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheet as of December&#160;31, 2023 and 2022 (see Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for 130,053 shares of Allurion Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and financial covenant. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things: (1)&#160;change the interest rate to the higher of the prime rate or 3.25% &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;plus &lt;/div&gt;&lt;/div&gt;the applicable margin of 6.44186%, (2) extend the maturity date of its outstanding term loans from December&#160;30, 2025 to December 30, 2026, and (3)&#160;increase additional borrowing up to $15.0&#160;million (the &#x201c;Term D Loan&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During June through September of 2022, the Company drew an additional $15.0&#160;million of the Term C Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. In connection with the Term C Loan under the 2021 Term Loan, the Company paid issuance costs of $0.3&#160;million, which were amortized over the remaining life of the loan. Upon the additional $15.0&#160;million draw on the Term C Loan, warrants exercisable for 44,220 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; preferred stock were issued. In 2022, the Company recorded a warrant liability of $0.4&#160;million in connection with the Term C Loan on the consolidated balance sheets. In September 2022, in connection with the amendment of the 2021 Term Loan, the Company committed to issue warrants exercisable for an additional 44,220 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; preferred stock if the Company drew on the entire Term D Loan. The fair value of these warrants was determined to be $0.4&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of December&#160;31, 2023 and 2022 (see Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;). Upon the closing of the Business Combination, the warrants exercisable for 88,440 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; preferred stock were converted into warrants exercisable for 90,476 shares of Allurion Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During October through December of 2022, the Company drew an additional $15.0&#160;million of the Term D Loan based upon the achievement of certain revenue thresholds under the amended and restated provisions of the 2021 Term Loan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $58.0&#160;million, consisting of $55.0&#160;million repayment of principal, a $1.1&#160;million prepayment fee, and a $1.6&#160;million final payment fee. The prepayment fee was calculated as 2% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as 3% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $0.1&#160;million. The Company recorded a $3.9&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the year ended December&#160;31, 2023 related to the 2021 Term Loan was $5.0&#160;million, consisting of $4.7&#160;million of contractual interest, $0.1&#160;million amortization of debt discount, $0.1&#160;million &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;amortization &lt;/div&gt;of warrant, and $0.1&#160;million term loan accretion. Interest expense for the year ended December&#160;31, &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;2022 was $4.3&#160;million, consisting of $3.8&#160;million of contractual interest, $0.2&#160;million amortization of debt discount, $0.1&#160;million amortization of warrant, and $0.2&#160;million term loan accretion.&#x2003; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fortress Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $60&#160;million. The Fortress Term Loan has a maturity date of June 30, 2027 and accrues interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest is payable in arrears on a monthly basis. An exit payment equal to 3.0% of the Fortress Term Loan (the &#x201c;Exit Fee&#x201d;) is due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee. The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $2.5&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#x201c;Fortress Amendment&#x201d;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $12.5&#160;million to $33.5&#160;million until March&#160;31, 2024, $23.5&#160;million from April&#160;1, 2024 to June 30, 2024, $16.9&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $12.5&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provides that at any time after March&#160;31, 2024, each lender will have the right to convert a portion of the outstanding principal amount, not to exceed the lender&#x2019;s proportionate share of a maximum of $20.0&#160;million in aggregate outstanding principal amount, into shares of Common Stock of the Company at a conversion price based on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; volume weighted average price (&#x201c;VWAP&#x201d;) of the Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#x2019;s conversion right (the &#x201c;Fortress Conversion Option&#x201d;). As part of the Fortress Amendment, the Company prepaid $20.0&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $3.1&#160;million of fees were incurred and considered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in-kind&lt;/div&gt;&lt;/div&gt; and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees will be amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470. In connection with the modification and related prepayment, the Company wrote off $0.8&#160;million of the unamortized debt issuance costs which was recorded within Interest expense on the consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Fortress Credit Agreement contains certain financial reporting and other covenants, including the maintenance of a minimum liquidity amount and maintenance of minimum product revenues over trailing twelve-month periods. Upon the occurrence of an event of default, the Lenders may declare all outstanding obligations immediately due and payable as well as increase the interest rate 3.0% above the rate that is otherwise applicable. The Company has determined that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern (see Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Basis of Presentation&lt;/div&gt;&lt;/div&gt;) and there is a risk that it may not meet its covenants under the Fortress Term Loan in the future. Therefore, the amounts due as of December&#160;31, 2023 have been classified as a current liability in the consolidated financial statements. The Company is in compliance with all covenants as of December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of 3% which will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#x201c;Term Loan Derivative Liability&#x201d;) that is required to be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-remeasured&lt;/div&gt; at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;derivative was determined to be immaterial. The fair value of the Term Loan Derivative Liability was $1.9&#160;million as of December&#160;31, 2023, with a corresponding recognition of Other income (expense), net in the consolidated statement of operations. The Company classified the Term Loan Derivative Liability as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-current&lt;/div&gt; liability within Other liabilities on the balance sheet as of December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense from August&#160;1, 2023 through December&#160;31, 2023 related to the Fortress Term Loan was $4.1&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;million&lt;/div&gt;, consisting of $3.8&#160;million of contractual interest, $0.2&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. The average interest rate of the Fortress Term Loan during the year ended December&#160;31, 2023 was 14.94%. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Scheduled future maturities of the Fortress Term Loan for years subsequent to December&#160;31, 2023 are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2021, the Company entered into a convertible note agreement with an investor for gross proceeds of $2.0&#160;million with a stated interest rate of 5.0% per annum (the &#x201c;2021 Convertible Notes&#x201d;) and a maturity date 36 months from the date of issuance unless previously converted pursuant to their terms of the agreement. No issuance costs were incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#x201c;deSPAC&#x201d;) transaction, closing of a qualified financing, or closing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-qualified&lt;/div&gt; financing, all of the outstanding principal and interest would automatically convert into common shares or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $600.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2021 Convertible Notes was $0.1&#160;million, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate 133,617 shares of Allurion Common Stock with a corresponding recognition of APIC of $2.2&#160;million, and are no longer outstanding. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2022 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In January 2022, the Company entered into a convertible note agreement with investors for gross proceeds of $1.1&#160;million with a stated interest rate of 5.0% per annum (the &#x201c;2022 Convertible Notes&#x201d;). The 2022 Convertible Notes mature 36 months from the issuance date unless previously converted pursuant to their terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible notes. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the years ended December&#160;31, 2023 and 2022 related to the 2022 Convertible Notes was less than $0.1&#160;million and $0.2&#160;million, respectively, consisting entirely of contractual interest. Interest expense &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;related to the 2022 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate 83,216 shares of Allurion Common Stock with a corresponding recognition of APIC of $1.2&#160;million, and are no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of the 2023 Convertible Notes to certain investors for gross proceeds of $28.7&#160;million, with a stated interest rate of 7.0% per annum. The 2023 Convertible Notes provided that they would mature on December 31, 2026 unless previously converted pursuant to the terms of their agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $217.3&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. Additionally, the 2023 Convertible Notes provide that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into common shares or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $260.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the year ended December&#160;31, 2023 related to the 2023 Convertible Notes was $0.5&#160;million, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the consolidated statement of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023 the Company entered into termination agreements (the &#x201c;Termination Agreements&#x201d;) with respect to side letters entered into with certain holders of Legacy Allurion Convertible Notes. With respect to the Termination Agreement with one of the side letter holders (the &#x201c;Side Letter Holder&#x201d;), the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under the 2023 Convertible Note (the &#x201c;Side Letter Holder Bridge Note&#x201d;), including by way of (a)&#160;a $2&#160;million payment in cash by the Company to the Side Letter Holder on May&#160;2, 2023, $1.5&#160;million of which is deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $0.5&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $6&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the Side Letter Holder Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the Side Letter Holder Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, under the Termination Agreement executed with the Side Letter Holder, the Company agreed to issue to the Side Letter Holder a number of shares of Allurion Common Stock (&#x201c;PubCo Additional Shares&#x201d;) &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;equal to (a)&#160;the outstanding principal and accrued interest under the Side Letter Holder Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $5.00, plus (b) 300,000 shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the PubCo Additional Shares are issued. A $3.4&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the consolidated balance sheet and the related expense recorded through Other income (expense) on the consolidated statement of operations and comprehensive loss for the year ended December&#160;31, 2023. On August&#160;1, 2023, upon closing of the Business Combination, the Side Letter Holder was issued 387,696 PubCo Additional Shares with a corresponding recognition of APIC of $2.7&#160;million, and the liability is no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further on May&#160;2, 2023, RTW and Fortress (the &#x201c;Backstop Purchasers&#x201d;) entered into the Backstop Agreement with the Company, Legacy Allurion and the Side Letter Holder. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any Side Letter Holder Bridge Notes remain outstanding prior to the consummation of the Business Combination, such Backstop Purchaser will, at the closing of the Business Combination, purchase up to $2.0&#160;million of the Side Letter Holder Bridge Notes from the Side Letter Holder in exchange for shares of Allurion Common Stock (the &#x201c;Base PubCo Shares&#x201d;, &#x201c;Backstop Shares&#x201d; and &#x201c;Conditional Additional PubCo Shares&#x201d;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability is initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares are issued. A $3.3&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the consolidated balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and the Backstop Agreement, the Backstop Purchasers were each issued 950,000 shares of Allurion Common Stock with a corresponding recognition of APIC of $13.4&#160;million, and the liability is no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $6.3&#160;million of the Side Letter Holder Bridge Note, leaving a principal balance of $6.3&#160;million. Each Backstop Purchaser then purchased $2.0&#160;million principal amount of the outstanding portion of the Side Letter Holder Bridge Note, Allurion canceled the existing Side Letter Holder Bridge Note and issued a new convertible note to the Side Letter Holder for the remaining balance together with all unpaid interest accrued since the date of issuance of $2.7&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $2.0&#160;million each and Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate 3,084,389 shares of Allurion Common Stock with a corresponding recognition of APIC of $22.2&#160;million, and are no longer outstanding. &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18431"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s third-party debt consisted of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fortress Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2021 Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amounts of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;58,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus: Accretion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of long-term debt, net of discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53,360&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: unamortized deferred financing costs and debt discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,605&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,853&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term debt, net of current portion and discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-47879"
      unitRef="Unit_USD">43100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-47880"
      unitRef="Unit_USD">55000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-47881"
      unitRef="Unit_USD">3103000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47882"
      unitRef="Unit_USD">43100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47883"
      unitRef="Unit_USD">58103000</us-gaap:DebtInstrumentCarryingAmount>
    <alur:LoanAccretion
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47884"
      unitRef="Unit_USD">148000</alur:LoanAccretion>
    <alur:LoanAccretion
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47885"
      unitRef="Unit_USD">213000</alur:LoanAccretion>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47886"
      unitRef="Unit_USD">38643000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47887"
      unitRef="Unit_USD">53360000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-47888"
      unitRef="Unit_USD">-4605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47889"
      unitRef="Unit_USD">-1853000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-47890"
      unitRef="Unit_USD">3103000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P03_01_2021To03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47891"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromLinesOfCredit>
    <alur:AdditionalBorrowings
      contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47892"
      unitRef="Unit_USD">10000000</alur:AdditionalBorrowings>
    <alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds
      contextRef="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47893"
      unitRef="Unit_USD">5000000</alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      id="ixv-47895">2025-12-30</us-gaap:LineOfCreditFacilityExpirationDate1>
    <alur:AdditionalBorrowings
      contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47896"
      unitRef="Unit_USD">20000000</alur:AdditionalBorrowings>
    <alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds
      contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47897"
      unitRef="Unit_USD">15000000</alur:BorrowingCapacityAvailableBasedUponAchievementOfCertainRevenueThresholds>
    <us-gaap:LineOfCreditFacilityDateOfFirstRequiredPayment1
      contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      id="ixv-47898">2024-12-30</us-gaap:LineOfCreditFacilityDateOfFirstRequiredPayment1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47899"
      unitRef="Unit_USD">700000</us-gaap:DeferredFinanceCostsGross>
    <alur:ExercisableWarrantsIssuedAsConsideration
      contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47900"
      unitRef="Unit_shares">132979</alur:ExercisableWarrantsIssuedAsConsideration>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47901"
      unitRef="Unit_USD">300000</alur:FairValueOfTheWarrants>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47902"
      unitRef="Unit_USD">300000</alur:FairValueOfTheWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47903"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="P01_01_2023To12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      id="ixv-18637">change the interest rate to the higher of the prime rate or 3.25% plus the applicable margin of 6.44186%,</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-47904"
      unitRef="Unit_pure">0.0325</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="7"
      id="ixv-47905"
      unitRef="Unit_pure">0.0644186</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      id="ixv-47906">2026-12-30</us-gaap:LineOfCreditFacilityExpirationDate1>
    <alur:AdditionalBorrowings
      contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47907"
      unitRef="Unit_USD">15000000</alur:AdditionalBorrowings>
    <alur:AdditionalBorrowings
      contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47908"
      unitRef="Unit_USD">15000000</alur:AdditionalBorrowings>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47909"
      unitRef="Unit_USD">300000</us-gaap:DeferredFinanceCostsGross>
    <alur:AdditionalBorrowings
      contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47910"
      unitRef="Unit_USD">15000000</alur:AdditionalBorrowings>
    <alur:ExercisableWarrantsIssuedAsConsideration
      contextRef="P06_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47911"
      unitRef="Unit_shares">44220</alur:ExercisableWarrantsIssuedAsConsideration>
    <alur:WarrantLiability
      contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47912"
      unitRef="Unit_USD">400000</alur:WarrantLiability>
    <alur:ExercisableWarrantsIssuedAsConsideration
      contextRef="P09_01_2022To09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47913"
      unitRef="Unit_shares">44220</alur:ExercisableWarrantsIssuedAsConsideration>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47914"
      unitRef="Unit_USD">400000</alur:FairValueOfTheWarrants>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_ScenarioPreviouslyReportedMembersrtRestatementAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47915"
      unitRef="Unit_USD">400000</alur:FairValueOfTheWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47916"
      unitRef="Unit_shares">88440</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-47917"
      unitRef="Unit_shares">90476</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:AdditionalBorrowings
      contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47918"
      unitRef="Unit_USD">15000000</alur:AdditionalBorrowings>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47919"
      unitRef="Unit_USD">58000000</us-gaap:RepaymentsOfLinesOfCredit>
    <alur:RepaymentOfPrincipal
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47920"
      unitRef="Unit_USD">55000000</alur:RepaymentOfPrincipal>
    <alur:PrepaymentFee
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47921"
      unitRef="Unit_USD">1100000</alur:PrepaymentFee>
    <alur:FinalPaymentFee
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47922"
      unitRef="Unit_USD">1600000</alur:FinalPaymentFee>
    <alur:PrepaymentFeePercentage
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-47923"
      unitRef="Unit_pure">0.02</alur:PrepaymentFeePercentage>
    <alur:FinalPaymentFeePercentage
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-47924"
      unitRef="Unit_pure">0.03</alur:FinalPaymentFeePercentage>
    <alur:OriginalFinalPayment
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47925"
      unitRef="Unit_USD">100000</alur:OriginalFinalPayment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47926"
      unitRef="Unit_USD">-3900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47927"
      unitRef="Unit_USD">5000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47928"
      unitRef="Unit_USD">4700000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47929"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:AmortizationOfTheWarrant
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47930"
      unitRef="Unit_USD">100000</alur:AmortizationOfTheWarrant>
    <alur:TermLoanAccretion
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47931"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47934"
      unitRef="Unit_USD">4300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47935"
      unitRef="Unit_USD">3800000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47936"
      unitRef="Unit_USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:AmortizationOfTheWarrant
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47937"
      unitRef="Unit_USD">100000</alur:AmortizationOfTheWarrant>
    <alur:TermLoanAccretion
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47938"
      unitRef="Unit_USD">200000</alur:TermLoanAccretion>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-6"
      id="ixv-47939"
      unitRef="Unit_USD">60000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis"
      id="ixv-47940">The Fortress Term Loan has a maturity date of June 30, 2027 and accrues interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest is payable in arrears on a monthly basis. An exit payment equal to 3.0% of the Fortress Term Loan (the &#x201c;Exit Fee&#x201d;) is due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      id="ixv-47941">2027-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-47942"
      unitRef="Unit_pure">0.0644</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-47943"
      unitRef="Unit_pure">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <alur:DebtInstrumentExitPaymentPercentage
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-47944"
      unitRef="Unit_pure">0.03</alur:DebtInstrumentExitPaymentPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47945"
      unitRef="Unit_USD">2500000</us-gaap:DeferredFinanceCostsGross>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47946"
      unitRef="Unit_USD">12500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-47947"
      unitRef="Unit_USD">33500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-47948"
      unitRef="Unit_USD">23500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-47949"
      unitRef="Unit_USD">16900000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-47950"
      unitRef="Unit_USD">12500000</alur:MinimumLiquidityAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-47951"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47952"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47953"
      unitRef="Unit_USD">3100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47954"
      unitRef="Unit_USD">800000</us-gaap:DeferredFinanceCostsNet>
    <alur:DebtInstrumentInterestRateIncreaseEventOfDefault
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-47955"
      unitRef="Unit_pure">0.03</alur:DebtInstrumentInterestRateIncreaseEventOfDefault>
    <alur:DebtInstrumentDefaultInterestRate
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-47956"
      unitRef="Unit_pure">0.03</alur:DebtInstrumentDefaultInterestRate>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47959"
      unitRef="Unit_USD">1900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:InterestExpenseDebt
      contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47960"
      unitRef="Unit_USD">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47961"
      unitRef="Unit_USD">3800000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47962"
      unitRef="Unit_USD">200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:TermLoanAccretion
      contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-47963"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P08_01_2023To12_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-47964"
      unitRef="Unit_pure">0.1494</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18702"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Scheduled future maturities of the Fortress Term Loan for years subsequent to December&#160;31, 2023 are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;December&#160;31, 2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-47965"
      unitRef="Unit_USD">8979000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-47966"
      unitRef="Unit_USD">34121000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-47967"
      unitRef="Unit_USD">43100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47968"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47969"
      unitRef="Unit_pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-47970">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47971"
      unitRef="Unit_USD">0</us-gaap:DeferredFinanceCostsNet>
    <alur:ConversionDividedByCappedConversionPrice
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47972"
      unitRef="Unit_USD">600000000</alur:ConversionDividedByCappedConversionPrice>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47973"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47974"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47975"
      unitRef="Unit_shares">133617</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47976"
      unitRef="Unit_USD">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47977"
      unitRef="Unit_USD">1100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47978"
      unitRef="Unit_pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-47979">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47980"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47981"
      unitRef="Unit_USD">200000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47982"
      unitRef="Unit_shares">83216</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47983"
      unitRef="Unit_USD">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47984"
      unitRef="Unit_USD">28700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-47985"
      unitRef="Unit_pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-47986">2026-12-31</us-gaap:DebtInstrumentMaturityDate>
    <alur:ConversionDividedByDiscountedCappedConversionPrice
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47987"
      unitRef="Unit_USD">217300000</alur:ConversionDividedByDiscountedCappedConversionPrice>
    <alur:CappedPrice
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47988"
      unitRef="Unit_USD">260000000</alur:CappedPrice>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To12_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47989"
      unitRef="Unit_USD">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-47990"
      unitRef="Unit_USD">2000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-47991"
      unitRef="Unit_USD">2000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47992"
      unitRef="Unit_USD">1500000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <alur:RepaymentOfPrincipal
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47993"
      unitRef="Unit_USD">500000</alur:RepaymentOfPrincipal>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_MinimumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-47994"
      unitRef="Unit_USD">6000000</us-gaap:RepaymentsOfConvertibleDebt>
    <alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities
      contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-47997"
      unitRef="Unit_USD">5</alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-47998"
      unitRef="Unit_shares">300000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <alur:DeferredLiabilityForIssuanceOfAdditionalShares
      contextRef="PAsOn05_02_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-47999"
      unitRef="Unit_USD">3400000</alur:DeferredLiabilityForIssuanceOfAdditionalShares>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-48000"
      unitRef="Unit_shares">387696</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48001"
      unitRef="Unit_USD">2700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48002"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <alur:DeferredLiabilityForIssuanceOfAdditionalShares
      contextRef="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48003"
      unitRef="Unit_USD">3300000</alur:DeferredLiabilityForIssuanceOfAdditionalShares>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-48004"
      unitRef="Unit_shares">950000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48005"
      unitRef="Unit_USD">13400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48006"
      unitRef="Unit_USD">6300000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48007"
      unitRef="Unit_USD">6300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48008"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_SideLetterHolderBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48009"
      unitRef="Unit_USD">2700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48010"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-48011"
      unitRef="Unit_shares">700000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-48012"
      unitRef="Unit_shares">3084389</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-48013"
      unitRef="Unit_USD">22200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18817">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Interest Financing, Side Letter, and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;1&lt;/div&gt;, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of 260% of the Investment Amount (the &#x201c;Hard Cap&#x201d;). In addition, prior to December&#160;31, 2025, the Company may prepay a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-specified&lt;/div&gt; payment amount (the &#x201c;Prepayment Amount&#x201d;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to 165% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;separate &lt;/div&gt;accounting. The Revenue Interest Financing is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other (expense) income in the consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. For the year ended December&#160;31, 2023, the Company recorded a $3.4&#160;million gain and a $0.7&#160;million loss through the consolidated statements of operations and other comprehensive loss, respectively. In connection with the issuance of the Investment Amount, we paid $1.2&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election. As of December&#160;31, 2023, the Company has made $1.1&#160;million in royalty payments to RTW. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Concurrently and in connection with the Revenue Interest Financing and PIPE Subscription Agreement (as discussed in Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;), on February&#160;9, 2023, Legacy Allurion entered into the RTW Side Letter with RTW, subsequently amended on May&#160;2, 2023. The Amended and Restated RTW Side Letter amended and restated the existing RTW Side Letter in its entirety, in order to reflect that any conditional additional shares issuable to RTW would be calculated net of any Backstop Shares issuable to RTW under the Backstop Agreement. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;for discussion around the additional shares issued to RTW in connection with the Amended and Restated RTW Side Letter and Backstop Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $7.04 for the average of 20 trading days within any 30 trading day period (&#x201c;Stock Price Drop&#x201d;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $10.00 per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $7.5&#160;million of its initial PIPE subscription into additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE subscription. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $3.3&#160;million within Other liabilities on the consolidated balance sheet with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;income &lt;/div&gt;(expense). &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s Revenue Interest Financing consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amounts of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Royalty payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Change in fair value of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term Revenue Interest Financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock>
    <alur:RevenuesInterestFinancingLiability
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48014"
      unitRef="Unit_USD">40000000</alur:RevenuesInterestFinancingLiability>
    <alur:PercentageOfAnnualNetSales
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-48015"
      unitRef="Unit_pure">0.06</alur:PercentageOfAnnualNetSales>
    <alur:RemittanceOfRevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-48016"
      unitRef="Unit_pure">0.10</alur:RemittanceOfRevenueInterestPaymentsPercentage>
    <alur:CashPaymentsPercentage
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48019"
      unitRef="Unit_pure">1</alur:CashPaymentsPercentage>
    <alur:RevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48020"
      unitRef="Unit_pure">2.40</alur:RevenueInterestPaymentsPercentage>
    <alur:CashPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48021"
      unitRef="Unit_pure">2.40</alur:CashPaymentsPercentage>
    <alur:RevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-48022"
      unitRef="Unit_pure">2.60</alur:RevenueInterestPaymentsPercentage>
    <alur:PrePaymentsPercentage
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-48023"
      unitRef="Unit_pure">1.65</alur:PrePaymentsPercentage>
    <alur:ChangesInFairValueOfRevenueInterestFinancing
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48024"
      unitRef="Unit_USD">3400000</alur:ChangesInFairValueOfRevenueInterestFinancing>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48025"
      unitRef="Unit_USD">-700000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48026"
      unitRef="Unit_USD">1200000</us-gaap:DeferredFinanceCostsGross>
    <alur:RoyaltyPayments
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48027"
      unitRef="Unit_USD">1100000</alur:RoyaltyPayments>
    <alur:VolumeWeightedAveragePricePerShare
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-48028"
      unitRef="Unit_USD_per_Share">7.04</alur:VolumeWeightedAveragePricePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-48029"
      unitRef="Unit_Days">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-48030"
      unitRef="Unit_Days">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:SharePrice
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-48031"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <alur:ConversionOfPipeSubscriptionToRevenueInterestFinance
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48032"
      unitRef="Unit_USD">7500000</alur:ConversionOfPipeSubscriptionToRevenueInterestFinance>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48033"
      unitRef="Unit_USD">3300000</us-gaap:DebtInstrumentFairValue>
    <alur:ComponentsOfRevenueInterestFinancingTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18873"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s Revenue Interest Financing consist of the following (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amounts of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Royalty payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Change in fair value of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,708&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term Revenue Interest Financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </alur:ComponentsOfRevenueInterestFinancingTableTextBlock>
    <alur:RevenuesInterestFinancingLiability
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48035"
      unitRef="Unit_USD">40000000</alur:RevenuesInterestFinancingLiability>
    <alur:RevenueInterestFinancingLiabilityPrincipalAmountOfDebt
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48036"
      unitRef="Unit_USD">40000000</alur:RevenueInterestFinancingLiabilityPrincipalAmountOfDebt>
    <alur:RoyaltyPayments
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48037"
      unitRef="Unit_USD">1092000</alur:RoyaltyPayments>
    <alur:ChangeInFairValueOfDebt
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48038"
      unitRef="Unit_USD">2708000</alur:ChangeInFairValueOfDebt>
    <alur:RevenueInterestFinancingLiabilityNoncurrent
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-48039"
      unitRef="Unit_USD">36200000</alur:RevenueInterestFinancingLiabilityNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18959">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present the fair value hierarchy for assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term Loan Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:58%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Common Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series B Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derivative Liability-Success Fee&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Public Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of the Business Combination on August&#160;1, 2023, the &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Company &lt;/div&gt;recorded a liability for Public Warrants to purchase the Company&#x2019;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as of December&#160;31, 2023 of $0.45, which is a Level&#160;1 input. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legacy Allurion Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has classified the warrants within Level&#160;3 of the hierarchy as the fair value is derived &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;using &lt;/div&gt;the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (level 3) inputs. See table below for the assumptions used in the pricing model: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:36%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock warrants (as converted to Common)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31,&#160;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7.25&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;8.71&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series B Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Common Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;1.02&lt;div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;-&#160;1.10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;4.6&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;4.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;3.88&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;3.92&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;8.2&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;9.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Expected dividend yield for all calculations is 0.00%. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the changes in fair value for the years ended December&#160;31, 2023 and 2022 of the warrant liabilities valued using Level&#160;3 inputs: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680782;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680783;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(720&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;172&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(548&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2019 Term Loan Success Fee Derivative Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The derivative liability for the success fee associated with Legacy Allurion&#x2019;s November 2019 loan and security agreement with Western Alliance Bank (the &#x201c;2019 Term Loan&#x201d; and such fee, the &#x201c;Success Fee&#x201d;) was recorded at fair value as of December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within four years from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measured&lt;/div&gt; at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the notes, using the share price at conversion ($7.04 per share). Upon the conversion of the notes, the convertible note liability was derecognized. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;PubCo Additional Shares Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The PubCo Additional Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;just &lt;/div&gt;prior to the close of the Business Combination, using the number of shares issued at the close of the Business Combination of 387,696 and an estimated price of shares at settlement of $7.04. Upon the issuance of shares, the PubCo Additional Shares liability was derecognized. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Base PubCo Shares and Backstop Shares Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Base PubCo Shares and Backstop Shares liability was initially recorded at fair value as of May&#160;2, 2023 and revalued as of August&#160;1, 2023, just prior to the close of the Business Combination, using the number of shares for each Backstop Purchaser at the close of the Business Combination of 950,000 and an estimated price of shares at settlement of $7.04. Upon the issuance of shares, the Base PubCo Shares and Backstop Shares liability was derecognized. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Revenue Interest Financing was accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of December&#160;31, 2023 using a discounted cash flow (&#x201c;DCF&#x201d;) method under the income approach utilizing future revenue projections and a discount rate of 24.4%. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method using the number of shares convertible of 1,065,341 and the following assumptions: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon the closing of the Business Combination, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Common &lt;/div&gt;Stock, with the change in fair value recognized in Change in the fair value of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liabilities in the consolidated statement of operations. The estimated fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; shares was determined using a Monte Carlo Simulation Method using the following assumptions at the valuation date: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Term Loan Derivative Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Term Loan Derivative Liability associated with the Fortress Term Loan was recorded at fair value as of December&#160;31, 2023 using a DCF model that includes default interest payments expected to be made based on future revenue projections and cash flow assumptions and a discount rate of 24.4%. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, PubCo Additional Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; liability, and Term Loan Derivative Liability categorized with Level&#160;3 inputs for the years ended December&#160;31, 2023 and 2022 were as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:41%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, PubCo &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;Additional &lt;/div&gt;Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; liability, and Term Loan Derivative Liability at each period is recorded as a component of Other (expense) income in the consolidated statements of operations, with the exception of the change in fair value associated with the change in credit risk related to the Revenue Interest Financing which is recorded as a component of other comprehensive loss. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Assets and Liabilities Not Carried at Fair Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Fortress term loan is carried at amortized cost. The fair value of the Fortress term loan was estimated to be $43.2&#160;million on December&#160;31, 2023. The fair value was determined using a discounted cash flow approach. We classified the fair value disclosures for the Fortress Term Loan within level 3 of the fair value hierarchy because the fair value is derived using a significant unobservable input, which includes a discount rate. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-18968">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present the fair value hierarchy for assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term Loan Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:58%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,925&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Common Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series B Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;303&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derivative Liability-Success Fee&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock Warrant Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,551&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-48040"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-48041"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48042"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48043"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48044"
      unitRef="Unit_USD">821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48045"
      unitRef="Unit_USD">821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48046"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48047"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48048"
      unitRef="Unit_USD">36200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48049"
      unitRef="Unit_USD">36200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48050"
      unitRef="Unit_USD">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48051"
      unitRef="Unit_USD">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48052"
      unitRef="Unit_USD">23990000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48053"
      unitRef="Unit_USD">23990000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48054"
      unitRef="Unit_USD">1895000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48055"
      unitRef="Unit_USD">1895000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48056"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48057"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48058"
      unitRef="Unit_USD">74463000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48059"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48060"
      unitRef="Unit_USD">68520000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-48062"
      unitRef="Unit_USD">4925000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-48063"
      unitRef="Unit_USD">4925000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48064"
      unitRef="Unit_USD">4925000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48065"
      unitRef="Unit_USD">4925000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48066"
      unitRef="Unit_USD">340000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCCommonStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48067"
      unitRef="Unit_USD">340000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48068"
      unitRef="Unit_USD">303000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesBPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48069"
      unitRef="Unit_USD">303000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48070"
      unitRef="Unit_USD">82000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesA1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48071"
      unitRef="Unit_USD">82000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48072"
      unitRef="Unit_USD">255000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48073"
      unitRef="Unit_USD">255000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48074"
      unitRef="Unit_USD">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesCPreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48075"
      unitRef="Unit_USD">684000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48076"
      unitRef="Unit_USD">180000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48077"
      unitRef="Unit_USD">180000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48078"
      unitRef="Unit_USD">707000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionSeriesD1PreferredStockWarrantLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48079"
      unitRef="Unit_USD">707000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48080"
      unitRef="Unit_USD">2551000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-48081"
      unitRef="Unit_USD">2551000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      id="ixv-48082"
      unitRef="Unit_USD_per_Share">0.45</us-gaap:SharePrice>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-19818">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has classified the warrants within Level&#160;3 of the hierarchy as the fair value is derived &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;using &lt;/div&gt;the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (level 3) inputs. See table below for the assumptions used in the pricing model: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:36%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock warrants (as converted to Common)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31,&#160;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;7.25&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;8.71&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.42&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series B Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.38&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.91&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Common Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series C Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.58&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other Common Stock Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;1.02&lt;div style="color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;-&#160;1.10&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;4.6&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;4.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Rollover warrants)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;3.88&lt;/div&gt;-&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;3.92&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;8.2&lt;/div&gt;&#160;-&#160;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;9.7&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48084"
      unitRef="Unit_pure">0.0388</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48085"
      unitRef="Unit_pure">6.73</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48086"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48087"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48088">P7Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48089"
      unitRef="Unit_pure">0.0395</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48090"
      unitRef="Unit_pure">1.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48091"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48092"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48093">P3Y8M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48094"
      unitRef="Unit_pure">0.0388</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48095"
      unitRef="Unit_pure">12.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48096"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48097"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48098">P7Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48099">P8Y8M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48100"
      unitRef="Unit_pure">0.0442</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48101"
      unitRef="Unit_pure">1.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48102"
      unitRef="Unit_pure">6.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48103"
      unitRef="Unit_pure">0.69</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesA1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48104">P0Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48105"
      unitRef="Unit_pure">0.0441</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48106"
      unitRef="Unit_pure">2.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48107"
      unitRef="Unit_pure">6.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48108"
      unitRef="Unit_pure">0.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesBPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48109">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48110"
      unitRef="Unit_pure">0.0411</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48111"
      unitRef="Unit_pure">0.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48112"
      unitRef="Unit_pure">4.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48113"
      unitRef="Unit_pure">0.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCCommonStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48114">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48115"
      unitRef="Unit_pure">0.0392</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48116"
      unitRef="Unit_pure">6.58</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48117"
      unitRef="Unit_pure">7.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48118"
      unitRef="Unit_pure">0.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48119">P8Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-48120"
      unitRef="Unit_pure">0.0399</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48121"
      unitRef="Unit_pure">1.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48122"
      unitRef="Unit_pure">1.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48123"
      unitRef="Unit_pure">4.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="0"
      id="ixv-48124"
      unitRef="Unit_pure">63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48125">P4Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_OtherCommonStockWarrantsMemberusgaapStatementEquityComponentsAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48126">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48127"
      unitRef="Unit_pure">3.88</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48128"
      unitRef="Unit_pure">3.92</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48129"
      unitRef="Unit_pure">11.87</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48130"
      unitRef="Unit_pure">11.31</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="0"
      id="ixv-48131"
      unitRef="Unit_pure">63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48132">P8Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-48133">P9Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48134"
      unitRef="Unit_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-48135"
      unitRef="Unit_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-20150">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the changes in fair value for the years ended December&#160;31, 2023 and 2022 of the warrant liabilities valued using Level&#160;3 inputs: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:48%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;741&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680782;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;365&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680783;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(720&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;172&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(548&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48136"
      unitRef="Unit_USD">510000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48137"
      unitRef="Unit_USD">231000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-48138"
      unitRef="Unit_USD">741000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48139"
      unitRef="Unit_USD">834000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48140"
      unitRef="Unit_USD">834000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48141"
      unitRef="Unit_USD">456000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48142"
      unitRef="Unit_USD">365000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48143"
      unitRef="Unit_USD">821000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2022To12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48144"
      unitRef="Unit_USD">-23000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48145"
      unitRef="Unit_USD">-23000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48146"
      unitRef="Unit_USD">1777000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48147"
      unitRef="Unit_USD">596000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48148"
      unitRef="Unit_USD">2373000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48149"
      unitRef="Unit_USD">-720000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48150"
      unitRef="Unit_USD">172000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48151"
      unitRef="Unit_USD">-548000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48152"
      unitRef="Unit_USD">-75000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48153"
      unitRef="Unit_USD">-75000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48154"
      unitRef="Unit_USD">-340000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48155"
      unitRef="Unit_USD">-589000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48156"
      unitRef="Unit_USD">-929000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48157"
      unitRef="Unit_USD">642000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48158"
      unitRef="Unit_USD">179000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48159"
      unitRef="Unit_USD">821000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <alur:FairValueAssumptionsOfLiquidityEventTerm
      contextRef="P01_01_2023To12_31_2023_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis"
      id="ixv-48161">P4Y</alur:FairValueAssumptionsOfLiquidityEventTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-48162"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alur:FairValueOfEstimatedNumberOfShares
      contextRef="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="0"
      id="ixv-48163"
      unitRef="Unit_shares">387696</alur:FairValueOfEstimatedNumberOfShares>
    <alur:FairValueOfEstimatedPriceOfShares
      contextRef="P08_01_2023To08_01_2023_PubcoAdditionalSharesLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="2"
      id="ixv-48164"
      unitRef="Unit_USD_per_Share">7.04</alur:FairValueOfEstimatedPriceOfShares>
    <alur:FairValueOfEstimatedNumberOfShares
      contextRef="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="0"
      id="ixv-48165"
      unitRef="Unit_shares">950000</alur:FairValueOfEstimatedNumberOfShares>
    <alur:FairValueOfEstimatedPriceOfShares
      contextRef="P08_01_2023To08_01_2023_BasePubcoSharesAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="2"
      id="ixv-48166"
      unitRef="Unit_USD_per_Share">7.04</alur:FairValueOfEstimatedPriceOfShares>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="1"
      id="ixv-48167"
      unitRef="Unit_pure">24.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      id="ixv-20430">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method using the number of shares convertible of 1,065,341 and the following assumptions: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <alur:FairValueOfEstimatedNumberOfShares
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-48168"
      unitRef="Unit_shares">1065341</alur:FairValueOfEstimatedNumberOfShares>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-48169"
      unitRef="Unit_USD_per_Share">3.74</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-48170"
      unitRef="Unit_pure">0.0446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      id="ixv-48171">P1Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-48172"
      unitRef="Unit_pure">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      id="ixv-20502">The estimated fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; shares was determined using a Monte Carlo Simulation Method using the following assumptions at the valuation date: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-48173"
      unitRef="Unit_USD_per_Share">3.74</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-48174"
      unitRef="Unit_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      id="ixv-48175">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-48176"
      unitRef="Unit_pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="1"
      id="ixv-48177"
      unitRef="Unit_pure">24.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      id="ixv-20554">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, PubCo Additional Shares liability, Base PubCo Shares and Backstop Shares liability, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; liability, and Term Loan Derivative Liability categorized with Level&#160;3 inputs for the years ended December&#160;31, 2023 and 2022 were as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:41%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January 1, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;133,609&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,408&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29,050&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(17,147&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(11,842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48178"
      unitRef="Unit_USD">159000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48179"
      unitRef="Unit_USD">159000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48180"
      unitRef="Unit_USD">19000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48181"
      unitRef="Unit_USD">19000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48182"
      unitRef="Unit_USD">178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48183"
      unitRef="Unit_USD">178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48184"
      unitRef="Unit_USD">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48185"
      unitRef="Unit_USD">3370000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48186"
      unitRef="Unit_USD">3264000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48187"
      unitRef="Unit_USD">40000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48188"
      unitRef="Unit_USD">3340000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48189"
      unitRef="Unit_USD">53040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48190"
      unitRef="Unit_USD">1895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48191"
      unitRef="Unit_USD">133609000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48192"
      unitRef="Unit_USD">-164000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48193"
      unitRef="Unit_USD">3751000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48194"
      unitRef="Unit_USD">-642000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48195"
      unitRef="Unit_USD">10106000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48196"
      unitRef="Unit_USD">-3408000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48197"
      unitRef="Unit_USD">2260000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48198"
      unitRef="Unit_USD">-29050000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48199"
      unitRef="Unit_USD">-17147000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48200"
      unitRef="Unit_USD">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48201"
      unitRef="Unit_USD">700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48202"
      unitRef="Unit_USD">10750000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48203"
      unitRef="Unit_USD">1092000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48204"
      unitRef="Unit_USD">11842000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48205"
      unitRef="Unit_USD">-21701000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48206"
      unitRef="Unit_USD">-2728000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48207"
      unitRef="Unit_USD">-13370000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48208"
      unitRef="Unit_USD">-37799000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48209"
      unitRef="Unit_USD">14000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48210"
      unitRef="Unit_USD">36200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48211"
      unitRef="Unit_USD">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48212"
      unitRef="Unit_USD">23990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-48213"
      unitRef="Unit_USD">1895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-48214"
      unitRef="Unit_USD">67699000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-48216"
      unitRef="Unit_USD">43200000</us-gaap:LineOfCredit>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21288">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of net loss before income taxes are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between the effective tax rate and the statutory federal income tax rate for the years ended &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;D&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;m&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;b&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;e&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;r&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;31, 2023 and 2022 is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income taxes, net of federal income tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effective tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. federal and state net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,051&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;start-up&lt;/div&gt; and research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,868&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,918&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Bad debt reserve&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other deferred tax liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded income tax expense of $0.3&#160;million during the year ended December&#160;31, 2023 due to foreign operating income. The Company recorded $0.1&#160;million of income tax expense during the year ended December&#160;31, 2022. The Company maintains a valuation allowance for the full amount of the net United States deferred tax assets, as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased for the years ended December&#160;31, 2023 and 2022 by approximately $24.5&#160;million and $10.9&#160;million, respectively, due to an increase in deferred tax assets having a full valuation allowance primarily due to the operating losses incurred, capitalized research and development expenses and tax credits generated. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had $132.2&#160;million and $131.7&#160;million of federal and state NOL carryforwards, respectively. Of the federal NOL carryforwards, $12.8&#160;million expire between 2030 and 2037 and $119.5&#160;million do not expire. The state NOL carryforwards expire between 2030 and 2042. As of December&#160;31, 2023, the Company had $1.5&#160;million and $0.9&#160;million of federal and state research and development tax credits, which expire beginning in 2031 and 2028, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Changes to the Company&#x2019;s valuation allowance are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions charged to net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Realization of the future tax benefits from these assets is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company&#x2019;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss and research and development credit carryforwards that could be used annually to offset future taxable income. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company&#x2019;s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#x2019;s ability to utilize net operating loss and research and development credit carryforwards in the future. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to US federal income tax, state income tax in Massachusetts, and income tax in certain foreign jurisdictions. The Company&#x2019;s historical income taxes in foreign jurisdictions have been immaterial to the consolidated financial statements. The Company is not currently under examination by the Internal Revenue Service (&#x201c;IRS&#x201d;) or any other jurisdictions for any tax years; however, all tax years since inception remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the U.S. IRS or other authorities if they have, or will be, used in a future period. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the unremitted earnings of the Company&#x2019;s foreign subsidiaries are immaterial. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interpretive guidance on the accounting for global intangible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;low-taxed&lt;/div&gt; income (&#x201c;GILTI&#x201d;) states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred as a period expense. The Company made the accounting policy election to recognize GILTI as a period expense. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023 and 2022, the Company has not recorded a tax liability for any uncertain tax positions. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. There are no accrued interest and penalties as of December&#160;31, 2023 and 2022. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21297"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of net loss before income taxes are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;&#x2003;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(81,259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;916&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Loss before income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,343&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,601&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48217"
      unitRef="Unit_USD">-81259000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48218"
      unitRef="Unit_USD">-38267000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48219"
      unitRef="Unit_USD">916000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48220"
      unitRef="Unit_USD">666000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48221"
      unitRef="Unit_USD">-80343000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48222"
      unitRef="Unit_USD">-37601000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21391"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The reconciliation between the effective tax rate and the statutory federal income tax rate for the years ended &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;D&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;c&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;e&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;m&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;b&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;/div&gt;e&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;r&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;31, 2023 and 2022 is as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State income taxes, net of federal income tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value of financial instruments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(30.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Non-deductible&lt;/div&gt; expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Effective tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48223"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48224"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48225"
      unitRef="Unit_pure">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48226"
      unitRef="Unit_pure">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48227"
      unitRef="Unit_pure">0.03</alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments>
    <alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48228"
      unitRef="Unit_pure">0</alur:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfFinancialInstruments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48229"
      unitRef="Unit_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48230"
      unitRef="Unit_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48231"
      unitRef="Unit_pure">-0.305</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48232"
      unitRef="Unit_pure">-0.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48233"
      unitRef="Unit_pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48234"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48235"
      unitRef="Unit_pure">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48236"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48237"
      unitRef="Unit_pure">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      id="ixv-48238"
      unitRef="Unit_pure">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21579">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of the Company&#x2019;s deferred tax assets are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;U.S. federal and state net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;25,051&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;start-up&lt;/div&gt; and research and development expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,868&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development tax credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,275&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,780&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,918&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;659&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Bad debt reserve&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other temporary differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;994&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34,276&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(57,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Right of use asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(623&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other deferred tax liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(792&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48239"
      unitRef="Unit_USD">36092000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48240"
      unitRef="Unit_USD">25051000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48241"
      unitRef="Unit_USD">10868000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48242"
      unitRef="Unit_USD">5377000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48243"
      unitRef="Unit_USD">2275000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48244"
      unitRef="Unit_USD">1780000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48245"
      unitRef="Unit_USD">3918000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <alur:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48246"
      unitRef="Unit_USD">659000</alur:DeferredTaxAssetsLeaseLiabilities>
    <alur:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48247"
      unitRef="Unit_USD">838000</alur:DeferredTaxAssetsLeaseLiabilities>
    <alur:DeferredTaxAssetsDepreciation
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48248"
      unitRef="Unit_USD">203000</alur:DeferredTaxAssetsDepreciation>
    <alur:DeferredTaxAssetsDepreciation
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48249"
      unitRef="Unit_USD">236000</alur:DeferredTaxAssetsDepreciation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48250"
      unitRef="Unit_USD">3461000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48251"
      unitRef="Unit_USD">2145000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48252"
      unitRef="Unit_USD">994000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48253"
      unitRef="Unit_USD">59621000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48254"
      unitRef="Unit_USD">34276000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48255"
      unitRef="Unit_USD">57985000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48256"
      unitRef="Unit_USD">33484000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48257"
      unitRef="Unit_USD">1636000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48258"
      unitRef="Unit_USD">792000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48259"
      unitRef="Unit_USD">623000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48260"
      unitRef="Unit_USD">792000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48261"
      unitRef="Unit_USD">1013000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48262"
      unitRef="Unit_USD">1636000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48263"
      unitRef="Unit_USD">792000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48264"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48265"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-48267"
      unitRef="Unit_USD">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-48268"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-5"
      id="ixv-48269"
      unitRef="Unit_USD">24500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      id="ixv-48270"
      unitRef="Unit_USD">10900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-48271"
      unitRef="Unit_USD">132200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-48272"
      unitRef="Unit_USD">131700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ExpireBetweenTwoThousandThirtyAndTwoThousandThirtySevenMemberusgaapTaxPeriodAxis"
      decimals="-5"
      id="ixv-48273"
      unitRef="Unit_USD">12800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_EarliestTaxYearMemberusgaapTaxPeriodAxis"
      id="ixv-48274">2030</alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod>
    <alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_LatestTaxYearMemberusgaapTaxPeriodAxis"
      id="ixv-48275">2037</alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_DoNotExpireMemberusgaapTaxPeriodAxis"
      decimals="-5"
      id="ixv-48276"
      unitRef="Unit_USD">119500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_EarliestTaxYearMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-48277">2030</alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod>
    <alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_LatestTaxYearTwoThousandFortyTwoMemberusgaapTaxPeriodAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-48278">2042</alur:DeferredTaxAssetsOperatingLossCarryForwardExpirationPeriod>
    <alur:TaxCreditCarryForwardsResearchAndDevelopment
      contextRef="PAsOn12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-48279"
      unitRef="Unit_USD">1500000</alur:TaxCreditCarryForwardsResearchAndDevelopment>
    <alur:TaxCreditCarryForwardsResearchAndDevelopment
      contextRef="PAsOn12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-48280"
      unitRef="Unit_USD">900000</alur:TaxCreditCarryForwardsResearchAndDevelopment>
    <alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear
      contextRef="P01_01_2023To12_31_2023_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-48281">2031</alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear>
    <alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear
      contextRef="P01_01_2023To12_31_2023_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-48282">2028</alur:TaxCreditCarryForwardsResearchAndDevelopmentExpirationYear>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21865"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Changes to the Company&#x2019;s valuation allowance are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Beginning balances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22,579&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Additions charged to net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,501&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Ending balances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,985&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48283"
      unitRef="Unit_USD">33484000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      id="ixv-48284"
      unitRef="Unit_USD">22579000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48285"
      unitRef="Unit_USD">24501000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48286"
      unitRef="Unit_USD">10905000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48287"
      unitRef="Unit_USD">57985000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48288"
      unitRef="Unit_USD">33484000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48290"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48291"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48292"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48293"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-21985">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Capital Stock and Stockholders&#x2019; Deficit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Allurion certificate of incorporation authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of December&#160;31, 2023, no shares of Allurion preferred stock were outstanding. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legacy Allurion Preferred Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Legacy Allurion preferred stock was retroactively adjusted, converted into common stock at the Exchange Ratio, and reclassified to permanent equity as a result of the reverse recapitalization. As of December&#160;31, 2023, there is no Legacy Allurion preferred stock authorized, issued, or outstanding. The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&lt;br/&gt; Authorized (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&lt;br/&gt; Issued&#160;and&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,276,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,276,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,513,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,486,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series B Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,298,929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,245,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series C Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,113,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,927,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,684,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;842,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,614&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-2&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,644,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,644,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-3&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,498,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,498,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,029,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,921,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors, and the Legacy Allurion common stockholders were entitled to elect four members of the Board of Directors. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividend Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All Legacy Allurion preferred stock participated in dividends with Legacy Allurion common stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;as-converted&lt;/div&gt; basis when declared by the Board of Directors. The Legacy Allurion preferred stockholders were entitled to receive dividends, when and if declared, on a pro rata pari passu basis according to the number of shares of Legacy Allurion common stock held by such holder. The Legacy Allurion Series D preferred stockholders were also entitled to a cumulative dividend that accrues at the rate of 6% per annum. The dividend accrued on a daily basis from and including the issuance date of such shares, whether or not declared. Through the date of the Business Combination, no dividends had been declared. &lt;/div&gt; &lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Preference &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the event of any voluntary or involuntary liquidation, dissolution, or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;winding-up&lt;/div&gt; of Legacy Allurion, before any payment were to be made to the holders of common stock, the holders of shares of Legacy Allurion &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;preferred stock then outstanding were entitled to be paid out of the funds and assets available for distribution to Legacy Allurion&#x2019;s stockholders, on a pari passu basis, an amount per share equal to (i)&#160;the Legacy Allurion Series A, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1,&lt;/div&gt; Series B and Series C preferred stock, a per share liquidation preference equal to $1.092, $2.850, $3.563 and $4.935, respectively, plus any accruing dividends accrued but unpaid, whether or not declared and (ii)&#160;the Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1,&lt;/div&gt; Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-2,&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-3&lt;/div&gt; preferred stock, a per share liquidation preference equal to $17.809, $9.338, and $15.137, respectively, plus any accruing dividends accrued but unpaid, whether or not declared provided, that, if Legacy Allurion achieved a revenue milestone of $65.0&#160;million in a trailing twelve month period (the &#x201c;Milestone&#x201d;), then in lieu of the foregoing, the holders of the Legacy Allurion Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1,&lt;/div&gt; Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-2,&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-3&lt;/div&gt; Preferred Stock were entitled to receive an amount per share equal to $11.8725, $6.2256 and $10.0916, respectively, plus any accruing dividends accrued but unpaid, whether or not declared (collectively, the &#x201c;Preferred Stock Preference&#x201d;). After payment of the Preferred Stock Preference, the funds and assets available for distribution to Legacy Allurion&#x2019;s stockholders, if any, would be initially distributed on a pro rata basis to the holders of common stock in Legacy Allurion in proportion to the number of shares of common stock held at an amount per share equal to 150% of the Original Issue Price of the Legacy Allurion Series A Preferred Stock ($1.092), plus any dividends declared but unpaid thereon (the &#x201c;First Catchup Amount&#x201d;). Any remaining funds and assets available for distribution to Legacy Allurion stockholders, if any, after the First Catchup Amount would then be distributed on a pro rata basis to the holders of common stock and preferred stock in proportion to the number of shares of common stock or preferred stock held. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series&#x2019; applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The holders of Legacy Allurion Series A, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1,&lt;/div&gt; Series B, Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1,&lt;/div&gt; Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-2,&lt;/div&gt; and Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-3&lt;/div&gt; preferred stock were not entitled to any redemption rights, other than those under their liquidation rights discussed above. Upon the election of the holders of a majority of shares of the Legacy Allurion Series C preferred stock, up to 50% of the outstanding shares of Legacy Allurion Series C preferred stock were redeemable at a price equal to 1.5 times the original issuance price, plus all declared, but unpaid dividends thereon, on a pro rata basis in an equal semiannual portion, after January&#160;17, 2022. The Legacy Allurion Series C contingent redemption upon a deemed liquidation event resulted in mezzanine equity classification (outside of permanent equity) on the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Allurion certificate of incorporation authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of December&#160;31, 2023 and 2022, 47,688,096 and 27,079,856 shares of common stock were outstanding, respectively, after retrospectively adjusting for the effect of the reverse recapitalization. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company&#x2019;s securities as of December&#160;31, 2023, is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase preferred stock (as converted to warrants to purchase common stock)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,693,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrants to Purchase Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of December&#160;31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td style="width:38%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying Equity Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12/1/2014&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3/30/2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9/15/2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/4/2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1/17/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8/3/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9/8/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/19/2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/25/2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying Equity Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4/1/2013&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;16,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series B Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;60,768&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series C Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;436,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In Compute Health&#x2019;s initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class&#160;A Common Stock, $0.0001 par value, of Compute Health (&#x201c;Class A Common Stock&#x201d;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127680787;display:inline;"&gt;one-half&lt;/div&gt;&lt;/div&gt; of a redeemable warrant (each a &#x201c;Public Warrant&#x201d;) that entitled the holders the right to purchase one share of Class&#160;A Common Stock of CPUH at a price of $11.50 per share. On July&#160;26, 2023, Compute Health&#x2019;s Public Warrant holders approved an amendment (the &#x201c;Warrant Amendment&#x201d;) to the warrant agreement that governed all Compute Health&#x2019;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 1.420455 shares of the Company&#x2019;s Common Stock, par value $0.0001 per share, at an exercise price of $8.10 per share and each Compute Health Public Warrant was exchanged for 0.6125 Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may redeem the outstanding Public Warrants for cash at a price of $0.01 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#x2019;s Common Stock equals or exceeds $12.67 per share of any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; trading period ending on the third trading day prior to the date on which notice of redemption is given. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $0.10 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#x2019;s Common Stock equals or exceeds $7.04 per share of any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#x201c;Redemption Fair Market Value&#x201d;) of the shares of the Company&#x2019;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#x2019;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of December&#160;31, 2023, the Company has not redeemed any of the outstanding Public Warrants. As of December&#160;31, 2023, there were 13,206,922 outstanding Public Warrants exercisable for 18,759,838 shares of Allurion Common Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Chardan Equity Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) and a Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;), each with Chardan Capital Markets (&#x201c;Chardan&#x201d;) related to a &#x201c;ChEF,&#x201d; Chardan&#x2019;s committed equity facility (the &#x201c;Chardan Equity Facility&#x201d;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of the Company&#x2019;s Common Stock, and (ii) 9,482,468 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#x201c;Exchange Cap&#x201d;). In consideration for Chardan&#x2019;s entry into the Purchase Agreement, Allurion agreed to issue to Chardan 35,511 shares of Allurion Common Stock (the &#x201c;Commitment Shares&#x201d;). The Company recorded $0.1&#160;million to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital and $0.1&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1&#160;million related to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable&lt;/div&gt; structuring fee (the &#x201c;Structuring Fee&#x201d;) immediately following commencement. As of December&#160;31, 2023, the Company had not sold any shares of Common Stock to Chardan in connection with the Purchase Agreement. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48294"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48295"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-48296">The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts):
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&lt;br/&gt; Authorized (1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&lt;br/&gt; Issued&#160;and&lt;br/&gt; Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,276,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,276,786&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,542&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,513,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,486,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,842&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series B Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,298,929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,245,515&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,253&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series C Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,113,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,927,446&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,684,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;842,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,614&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-2&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,644,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,644,616&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-3&lt;/div&gt; Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,498,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,498,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21,029,888&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,921,042&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,216&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company&#x2019;s securities as of December&#160;31, 2023, is as follows:
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase preferred stock (as converted to warrants to purchase common stock)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public warrants to purchase common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,693,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48297"
      unitRef="Unit_shares">2276786</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48298"
      unitRef="Unit_shares">2276786</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48299"
      unitRef="Unit_USD">1542000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48300"
      unitRef="Unit_shares">1513028</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48301"
      unitRef="Unit_shares">1486048</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48302"
      unitRef="Unit_USD">2842000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48303"
      unitRef="Unit_shares">2298929</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48304"
      unitRef="Unit_shares">2245515</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48305"
      unitRef="Unit_USD">5253000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48306"
      unitRef="Unit_shares">8113616</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48307"
      unitRef="Unit_shares">7927446</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48308"
      unitRef="Unit_USD">39122000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48309"
      unitRef="Unit_shares">1684565</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48310"
      unitRef="Unit_shares">842283</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48311"
      unitRef="Unit_USD">9614000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48312"
      unitRef="Unit_shares">3644616</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48313"
      unitRef="Unit_shares">3644616</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48314"
      unitRef="Unit_USD">24054000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-48315"
      unitRef="Unit_shares">1498348</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48316"
      unitRef="Unit_shares">1498348</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48317"
      unitRef="Unit_USD">14789000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      decimals="0"
      id="ixv-48318"
      unitRef="Unit_shares">21029888</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-48319"
      unitRef="Unit_shares">19921042</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      decimals="-3"
      id="ixv-48320"
      unitRef="Unit_USD">97216000</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockVotingRights
      contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      id="ixv-48321">The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors</us-gaap:PreferredStockVotingRights>
    <us-gaap:CommonStockVotingRights
      contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      id="ixv-48322">common stockholders were entitled to elect four members of the Board of Directors.</us-gaap:CommonStockVotingRights>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="P01_01_2023To12_31_2023_SeriesDPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-48323"
      unitRef="Unit_pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStockCash
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-48324"
      unitRef="Unit_USD">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48327"
      unitRef="Unit_USD_per_Share">1.092</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48328"
      unitRef="Unit_USD_per_Share">2.85</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48329"
      unitRef="Unit_USD_per_Share">3.563</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48330"
      unitRef="Unit_USD_per_Share">4.935</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48331"
      unitRef="Unit_USD_per_Share">17.809</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48332"
      unitRef="Unit_USD_per_Share">9.338</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48333"
      unitRef="Unit_USD_per_Share">15.137</us-gaap:PreferredStockLiquidationPreference>
    <alur:RevenueRecognitionMilestoneMethodOfRecognizedRevenue
      contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-48334"
      unitRef="Unit_USD">65000000</alur:RevenueRecognitionMilestoneMethodOfRecognizedRevenue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-48335"
      unitRef="Unit_USD_per_Share">11.8725</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDTwoPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-48336"
      unitRef="Unit_USD_per_Share">6.2256</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesDThreePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-48337"
      unitRef="Unit_USD_per_Share">10.0916</us-gaap:PreferredStockParOrStatedValuePerShare>
    <alur:PercentageOfSharesOfCommonStockHeld
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      decimals="2"
      id="ixv-48338"
      unitRef="Unit_pure">1.50</alur:PercentageOfSharesOfCommonStockHeld>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="3"
      id="ixv-48339"
      unitRef="Unit_USD_per_Share">1.092</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConversionBasis
      contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis"
      id="ixv-48340">Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series&#x2019; applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock.</us-gaap:PreferredStockConversionBasis>
    <alur:PercentageOfPreferredStockRedeemableShares
      contextRef="PAsOn12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_MaximumMembersrtRangeAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48341"
      unitRef="Unit_pure">0.50</alur:PercentageOfPreferredStockRedeemableShares>
    <alur:PreferredStockRedemptionValueToPrice
      contextRef="P01_01_2023To12_31_2023_LegacyAllurionMemberdeiLegalEntityAxis_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="1"
      id="ixv-48342"
      unitRef="Unit_pure">1.5</alur:PreferredStockRedemptionValueToPrice>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48343"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48344"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-48345"
      unitRef="Unit_shares">27079856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48348"
      unitRef="Unit_shares">3886038</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      id="ixv-48349"
      unitRef="Unit_shares">643635</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48350"
      unitRef="Unit_shares">138857</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48351"
      unitRef="Unit_shares">264801</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_PublicWarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48352"
      unitRef="Unit_shares">18759838</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_EarnOutSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48353"
      unitRef="Unit_shares">9000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48354"
      unitRef="Unit_shares">32693169</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-48355">As of December&#160;31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td style="width:38%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying Equity Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;12/1/2014&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;3/30/2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9/15/2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/4/2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;1/17/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;8/3/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;9/8/2017&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/19/2018&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;6/25/2019&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying Equity Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4/1/2013&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;A-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;16,557&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series B Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;60,768&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series C Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; Preferred Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;4.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Common stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;436,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-48356"
      unitRef="Unit_shares">403658</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48357">P0Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48358"
      unitRef="Unit_shares">44272</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48359"
      unitRef="Unit_USD_per_Share">2.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48360">P7Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48361"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48362"
      unitRef="Unit_USD_per_Share">6.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48363">P8Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48364"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48365"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48366">P8Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48367"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48368"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48369">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48370"
      unitRef="Unit_shares">73349</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48371"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48372">P3Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48373"
      unitRef="Unit_shares">9779</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48374"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48375">P3Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48376"
      unitRef="Unit_shares">28764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48377"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48378">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48379"
      unitRef="Unit_shares">17977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48380"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48381">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48382"
      unitRef="Unit_shares">8988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48383"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48384"
      unitRef="Unit_shares">403658</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48385">P0Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48386"
      unitRef="Unit_shares">16557</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_SeriesAOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtApril012013MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48387"
      unitRef="Unit_USD_per_Share">1.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48388">P1Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48389"
      unitRef="Unit_shares">60768</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48390"
      unitRef="Unit_USD_per_Share">2.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48391">P8Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48392"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48393"
      unitRef="Unit_USD_per_Share">6.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48394">P9Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48395"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48396"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48397">P9Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48398"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_SeriesDOnePreferredStockMemberusgaapStatementClassOfStockAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48399"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48400">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48401"
      unitRef="Unit_shares">73349</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48402"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48403">P4Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48404"
      unitRef="Unit_shares">9779</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48405"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48406">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48407"
      unitRef="Unit_shares">28764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48408"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48409">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48410"
      unitRef="Unit_shares">17977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48411"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-48412">P6Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-48413"
      unitRef="Unit_shares">8988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-48414"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-48415"
      unitRef="Unit_shares">436711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      id="ixv-48417"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2023To12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-48418"
      unitRef="Unit_shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-48419"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48420"
      unitRef="Unit_shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-48421"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="6"
      id="ixv-48422"
      unitRef="Unit_shares">1.420455</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="4"
      id="ixv-48423"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-48424"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="PAsOn12_31_2023_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-48425"
      unitRef="Unit_shares">0.6125</us-gaap:ClassOfWarrantOrRightUnissued>
    <alur:WarrantsRedumptionPricePerShare
      contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48426"
      unitRef="Unit_USD_per_Share">0.01</alur:WarrantsRedumptionPricePerShare>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48427"
      unitRef="Unit_USD_per_Share">12.67</us-gaap:SharePrice>
    <alur:WarrantsRedumptionPricePerShare
      contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48428"
      unitRef="Unit_USD_per_Share">0.1</alur:WarrantsRedumptionPricePerShare>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-48429"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-48430"
      unitRef="Unit_USD">13206922</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To12_31_2023_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-48431"
      unitRef="Unit_shares">18759838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-48432"
      unitRef="Unit_USD">100000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48433"
      unitRef="Unit_shares">9482468</us-gaap:CommonStockSharesOutstanding>
    <alur:PercentageOfCommonStockSharesOutstanding
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-48434"
      unitRef="Unit_pure">0.1999</alur:PercentageOfCommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-48435"
      unitRef="Unit_USD">35511</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48436"
      unitRef="Unit_USD">100000</us-gaap:AdditionalPaidInCapital>
    <alur:ExpenseOfIssuanceOfCommitmentShares
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48437"
      unitRef="Unit_USD">100000</alur:ExpenseOfIssuanceOfCommitmentShares>
    <alur:StructuringFeePayable
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48438"
      unitRef="Unit_USD">100000</alur:StructuringFeePayable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2023To12_31_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-48439"
      unitRef="Unit_shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23058">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share was calculated as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,607&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cumulative undeclared dividends to participating securities (Legacy Series D convertible preferred stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(82,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40,651&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted weighted-average common stock outstanding&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,581,656&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,918,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,301,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase preferred stock (as converted to warrants to purchase common stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;297,854&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares of Common Stock issued upon the exercise of Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible notes (as converted to common stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,693,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,325,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23067"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share was calculated as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(80,607&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,744&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cumulative undeclared dividends to participating securities (Legacy Series D convertible preferred stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,907&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(82,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(40,651&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted weighted-average common stock outstanding&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35,581,656&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,918,484&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted (1)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48440"
      unitRef="Unit_USD">-80607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48441"
      unitRef="Unit_USD">-37744000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48442"
      unitRef="Unit_USD">1697000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48443"
      unitRef="Unit_USD">2907000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48444"
      unitRef="Unit_USD">-82304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48445"
      unitRef="Unit_USD">-40651000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-48446"
      unitRef="Unit_shares">35581656</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-48447"
      unitRef="Unit_shares">26918484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="Fact_127680424"
      unitRef="Unit_USD_per_Share">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="Fact_127680422"
      unitRef="Unit_USD_per_Share">-2.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="Fact_127680425"
      unitRef="Unit_USD_per_Share">-1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="Fact_127680423"
      unitRef="Unit_USD_per_Share">-1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-48452">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,301,960&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase preferred stock (as converted to warrants to purchase common stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;297,854&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;264,801&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;138,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares of Common Stock issued upon the exercise of Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible notes (as converted to common stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;171,256&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,693,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,325,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48453"
      unitRef="Unit_shares">3886038</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48454"
      unitRef="Unit_shares">4301960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48455"
      unitRef="Unit_shares">643635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48456"
      unitRef="Unit_shares">1415104</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48457"
      unitRef="Unit_shares">138857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_WarrantsToPurchasePreferredStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48458"
      unitRef="Unit_shares">297854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48459"
      unitRef="Unit_shares">264801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48460"
      unitRef="Unit_shares">138857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48461"
      unitRef="Unit_shares">18759838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48462"
      unitRef="Unit_shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-48463"
      unitRef="Unit_shares">171256</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-48464"
      unitRef="Unit_shares">32693169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      id="ixv-48465"
      unitRef="Unit_shares">6325031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23390">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s 2010 Stock Option Plan (the &#x201c;2010 Plan&#x201d;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#x2019;s Common Stock. On December&#160;11, 2020, the Company&#x2019;s Board of Directors adopted the 2020 Stock Option Plan (the &#x201c;2020 Plan&#x201d;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#x2019;s Common Stock. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#x201c;2023 Plan&#x201d;), which provides for the award of stock options (both incentive and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-qualified),&lt;/div&gt; stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. A total of 7,822,700 shares of Allurion Common Stock were initially reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by 5% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the Compensation Committee. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, 4,529,673 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2022, 5,717,072 options and RSUs were issued and outstanding under the 2010 Plan and 2020 Plan. The stock options generally vest over a four-year period and expire 10 years from the date of grant. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Stock-based compensation expense included in the consolidated statement of operations and comprehensive loss was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general, and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the year ended December&#160;31, 2023: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;option)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,301,968&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(375,051&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(298,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Exercisable at December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,735,884&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock compensation expense related to stock option awards during the year ended December&#160;31, 2023 was $2.7&#160;million. As of December&#160;31, 2023, there was approximately $2.5&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2020 Plan, which is expected to be recognized over a weighted-average vesting term of 2.1 years. The weighted average grant-date fair value of the stock option awards granted during the years ended December&#160;31, 2023 and 2022 was $3.98 and $2.36 per option, respectively. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#x2019;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies which are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted- average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees&lt;/div&gt; is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions used in the Black-Scholes option-pricing model are as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2002;&#x2003;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2022, the Company issued RSUs under the 2020 Plan to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Basis of Presentation &lt;/div&gt;&lt;/div&gt;and Note 3&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;, Business Combination &lt;/div&gt;&lt;/div&gt;above for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, 62.5% of the RSUs awarded vested. Thereafter, the remaining 37.5% of the RSUs vest monthly over a period of two years. In October 2023, the Company issued additional RSUs to Board of Director members with annual vesting over three years. All RSUs are subject to forfeiture if the grantee&#x2019;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the year ended December&#160;31, 2023: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&lt;br/&gt; Date&#160;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;226,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(918,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;December 31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock compensation expense related to RSUs for the year ended December&#160;31, 2023 was $5.7&#160;million. As of December&#160;31, 2023, there were $1.7&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of 2.0 years. The weighted average grant-date fair value of time-vested restricted stock units granted during the years ended December&#160;31, 2023 and 2022 was $4.32 and $4.51 per share, respectively. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#x201c;2023 ESPP&#x201d;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#x2019;s Common Stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#x2019;s payroll deductions under the 2023 ESPP are limited to 15% of the employee&#x2019;s compensation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A total of 1,422,309 shares of the Company&#x2019;s Common Stock were initially reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 ESPP will automatically increase each January&#160;1, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) 1,600,000 shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of December&#160;31, 2023, no shares have been issued under the 2023 ESPP. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48467"
      unitRef="Unit_shares">7822700</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance
      contextRef="P01_01_2023To12_31_2023_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48468"
      unitRef="Unit_pure">0.05</alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan
      contextRef="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48469"
      unitRef="Unit_shares">4529673</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan
      contextRef="PAsOn12_31_2022_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48470"
      unitRef="Unit_shares">5717072</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      id="ixv-48471">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2023To12_31_2023_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      id="ixv-48472">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23423"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Stock-based compensation expense included in the consolidated statement of operations and comprehensive loss was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:70%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general, and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,198&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-48473"
      unitRef="Unit_USD">32000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-48474"
      unitRef="Unit_USD">8198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-48475"
      unitRef="Unit_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-48476"
      unitRef="Unit_USD">127000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-48477"
      unitRef="Unit_USD">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48478"
      unitRef="Unit_USD">8357000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48479"
      unitRef="Unit_USD">437000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23532"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the year ended December&#160;31, 2023: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:59%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;option)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,301,968&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,437&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257,683&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(375,051&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(298,562&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Exercisable at December&#160;31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,735,884&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,812&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48480"
      unitRef="Unit_shares">4301968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48481"
      unitRef="Unit_USD_per_Share">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2022To12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-48482">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-48483"
      unitRef="Unit_USD">9437000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48484"
      unitRef="Unit_shares">257683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48485"
      unitRef="Unit_USD_per_Share">5.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48486"
      unitRef="Unit_shares">375051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48487"
      unitRef="Unit_USD_per_Share">2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48488"
      unitRef="Unit_shares">298562</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48489"
      unitRef="Unit_USD_per_Share">1.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48490"
      unitRef="Unit_shares">3886038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48491"
      unitRef="Unit_USD_per_Share">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-48492">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-48493"
      unitRef="Unit_USD">5565000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-48494"
      unitRef="Unit_shares">2735884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48495"
      unitRef="Unit_USD_per_Share">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-48496">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-48497"
      unitRef="Unit_USD">4812000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-48498"
      unitRef="Unit_USD">2700000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2023_StockOptionPlan2020MemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-48499"
      unitRef="Unit_USD">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-48500">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-48501"
      unitRef="Unit_USD_per_Share">3.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-48502"
      unitRef="Unit_USD_per_Share">2.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-23794"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions used in the Black-Scholes option-pricing model are as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:69%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2023&#x2003;&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2003;&#x2002;2022&#x2002;&#x2003;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48504"
      unitRef="Unit_pure">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      id="ixv-48505"
      unitRef="Unit_pure">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-48506"
      unitRef="Unit_pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      id="ixv-48507"
      unitRef="Unit_pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-48508">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022" id="ixv-48509">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2023To12_31_2023_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="3"
      id="ixv-48510"
      unitRef="Unit_pure">0.625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="3"
      id="ixv-48511"
      unitRef="Unit_pure">0.375</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-48512">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P10_01_2023To10_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-48513">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-48514">The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the year ended December&#160;31, 2023: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Grant&lt;br/&gt; Date&#160;Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,415,104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;226,175&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(79,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(918,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;December 31, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48515"
      unitRef="Unit_shares">1415104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48516"
      unitRef="Unit_USD_per_Share">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48517"
      unitRef="Unit_shares">226175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48518"
      unitRef="Unit_USD_per_Share">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48519"
      unitRef="Unit_shares">79232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48520"
      unitRef="Unit_USD_per_Share">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48521"
      unitRef="Unit_shares">918412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48522"
      unitRef="Unit_USD_per_Share">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48523"
      unitRef="Unit_shares">643635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48524"
      unitRef="Unit_USD_per_Share">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-48525"
      unitRef="Unit_USD">5700000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-48526"
      unitRef="Unit_USD">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2023To12_31_2023" id="ixv-48527">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-48528"
      unitRef="Unit_USD_per_Share">4.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_TimeVestedRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-48529"
      unitRef="Unit_USD_per_Share">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <alur:PercentageOfPriceLowerOfFairValueMarketValue
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48531"
      unitRef="Unit_pure">0.85</alur:PercentageOfPriceLowerOfFairValueMarketValue>
    <alur:PercentageOfEmployeesCompensationToPayrollDeductions
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48532"
      unitRef="Unit_pure">0.15</alur:PercentageOfEmployeesCompensationToPayrollDeductions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48533"
      unitRef="Unit_shares">1422309</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alur:PercentageOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-48534"
      unitRef="Unit_pure">0.01</alur:PercentageOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48535"
      unitRef="Unit_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-48536"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24032">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contribution. During the years ended December&#160;31, 2023 and 2022, the Company&#x2019;s matching contributions to the plan were $0.1&#160;million. &lt;/div&gt; </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-48537"
      unitRef="Unit_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2023To12_31_2023_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-48538"
      unitRef="Unit_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24043">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases. As a result of these amendments, the leases in Natick and Hudson will now expire between June 2024 and March 2028, and additional operating lease assets obtained in exchange for lease obligations were $0.9&#160;million. As of December&#160;31, 2023, the Company was a party to seven different leases for office, manufacturing, and laboratory space under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; office leases in three cities. These leases total approximately 51,000 square feet and will expire between June 2024 and March 2028. The Company has a right to extend certain of these leases for periods between &lt;div style="-sec-ix-hidden:hidden127682050;display:inline;"&gt;three&lt;/div&gt; and five years. The Company also holds immaterial leases related to vehicles and office equipment. Under its leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of ROU assets and lease liabilities are included in the consolidated balance sheets. The short-term portion of the Company&#x2019;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the consolidated balance sh&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;e&lt;/div&gt;ets. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Aggregate Lease Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Other pertinent lease information is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;918&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows paid for amounts in the measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Future commitments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreements are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(908&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average remaining lease terms and discount rates related to our leases were as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not received any material product liability claims. While product defects and adverse patient reactions associated with the Allurion Balloon have occurred, and are expected to continue to occur, the Company does not have a history of product defects or adverse patient reactions that the Company&#x2019;s management believes would give rise to a material product liability claim. Furthermore, the Company has obtained insurance related to potential product liability claims. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation and Claims &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of December&#160;31, 2023 and 2022, the Company has not recorded accruals for potential losses related to any existing or pending litigation or claims as the Company&#x2019;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="P01_01_2023To12_31_2023" id="ixv-48539">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.</us-gaap:LesseeOperatingLeaseDescription>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48540">2024-06</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P02_01_2023To02_28_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48541">2024-06</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48542">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48543">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis"
      decimals="-5"
      id="ixv-48544"
      unitRef="Unit_USD">900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:AreaOfLand
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48545"
      unitRef="Unit_sqft">51000</us-gaap:AreaOfLand>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P08_01_2023To08_31_2023_MinimumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48546">2024-06</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-48547">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="P01_01_2023To12_31_2023" id="ixv-24059">The Company has a right to extend certain of these leases for periods between three and five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="P01_01_2023To12_31_2023" id="ixv-48548">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      id="ixv-48549">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24084"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Other pertinent lease information is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;918&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows paid for amounts in the measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,084&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease assets obtained in exchange for lease obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,677&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48550"
      unitRef="Unit_USD">1123000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48551"
      unitRef="Unit_USD">918000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48552"
      unitRef="Unit_USD">12000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48553"
      unitRef="Unit_USD">14000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48554"
      unitRef="Unit_USD">187000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48555"
      unitRef="Unit_USD">191000</us-gaap:VariableLeaseCost>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48556"
      unitRef="Unit_USD">1084000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48557"
      unitRef="Unit_USD">807000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-48558"
      unitRef="Unit_USD">936000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      id="ixv-48559"
      unitRef="Unit_USD">1677000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24167"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Future commitments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreements are as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,114&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(563&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(908&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48560"
      unitRef="Unit_USD">1173000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48561"
      unitRef="Unit_USD">1114000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48562"
      unitRef="Unit_USD">737000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48563"
      unitRef="Unit_USD">645000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48564"
      unitRef="Unit_USD">108000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48565"
      unitRef="Unit_USD">3777000</alur:OperatingLeaseAndFinanceLeaseLiabilityPaymentsDue>
    <alur:OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48566"
      unitRef="Unit_USD">563000</alur:OperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <alur:OperatingAndFinanceLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48567"
      unitRef="Unit_USD">3214000</alur:OperatingAndFinanceLeaseLiability>
    <alur:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48568"
      unitRef="Unit_USD">908000</alur:OperatingAndFinanceLeaseLiabilityCurrent>
    <alur:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48569"
      unitRef="Unit_USD">2306000</alur:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24280"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average remaining lease terms and discount rates related to our leases were as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:85%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-48570">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022" id="ixv-48571">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-48572"
      unitRef="Unit_pure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      id="ixv-48573"
      unitRef="Unit_pure">0.095</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      id="ixv-48574"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48575"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24346">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Geographic Information &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,282&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-lived assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Refer to Note 4, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt; for information on revenue by geography. &lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24355"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,999&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,282&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-lived assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,281&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-48576"
      unitRef="Unit_USD">5381000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2022_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-48577"
      unitRef="Unit_USD">3999000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-48578"
      unitRef="Unit_USD">1010000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2022_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-48579"
      unitRef="Unit_USD">1282000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48580"
      unitRef="Unit_USD">6391000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48581"
      unitRef="Unit_USD">5281000</us-gaap:NoncurrentAssets>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2023To12_31_2023" id="ixv-24464">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Related-party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Lease Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#x2019;s then-Trade Marketing Director was the signor of this lease for LNMP JPBS Invest. Additionally, the Company&#x2019;s Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $0.1&#160;million per year. The lease commenced August 1, 2022 and was to end on July 31, 2025. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;arm&#x2019;s-length.&lt;/div&gt; This lease was terminated in February 2024. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#x201c;KKG Enterprises&#x201d;) and Remus Group Management, LLC (&#x201c;Remus Group Management&#x201d;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $0.2&#160;million to KKG Enterprises and $0.3&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on June 20, 2023. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Convertible Note with Hunter Ventures Limited &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;15, 2023, Allurion sold $13&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than 5% of our outstanding Common Stock). Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for additional information regarding the 2023 Convertible Notes. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Consulting Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, Allurion France, a French soci&#xe9;t&#xe9; par actions simplifi&#xe9;e and wholly-owned subsidiary of Allurion, entered into a new corporate officer agreement with the Company&#x2019;s Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#xe9;t&#xe9; &#xe0; responsabilit&#xe9; limit&#xe9;e which is solely owned by Mr.&#160;Chardon (&#x201c;BCC&#x201d;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The new corporate officer agreement provided that BCC would receive base consulting fees of &#x20ac;28,333.33 per month and additional &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on December 12, 2023 by virtue of the termination agreement described below. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Termination Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;12, 2023, Allurion France, a French soci&#xe9;t&#xe9; par actions simplifi&#xe9;e and wholly-owned subsidiary of Allurion, entered into a termination agreement with the Company&#x2019;s Chief Commercial Officer, Benoit Chardon and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC will resign from its duties as managing director of Allurion France effective December&#160;31, 2023 and Allurion France will pay BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion France will pay BCC a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;lump-sum&lt;/div&gt; termination fee of $0.2&#160;million. &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-48582"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeasePayments>
    <alur:OperatingLeaseCommencementDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-48583">2022-08-01</alur:OperatingLeaseCommencementDate>
    <alur:OperatingLeaseEndDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-48584">2025-07-31</alur:OperatingLeaseEndDate>
    <alur:LesseeOperatingLeaseTerminatedDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-48585">2024-02</alur:LesseeOperatingLeaseTerminatedDate>
    <alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-48586"
      unitRef="Unit_USD">200000</alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination>
    <alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-48587"
      unitRef="Unit_USD">300000</alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination>
    <alur:AgreementsTerminationDate
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      id="ixv-48588">2023-06-20</alur:AgreementsTerminationDate>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-48589"
      unitRef="Unit_USD">13000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <alur:PercentageOfOutstandingCapitalStock
      contextRef="P02_15_2023To02_15_2023"
      decimals="2"
      id="ixv-48590"
      unitRef="Unit_pure">0.05</alur:PercentageOfOutstandingCapitalStock>
    <alur:RelatedPartyTransactionConsultingFees
      contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-48591"
      unitRef="Unit_EUR">28333.33</alur:RelatedPartyTransactionConsultingFees>
    <alur:AgreementsTerminationDate
      contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      id="ixv-48594">2023-12-12</alur:AgreementsTerminationDate>
    <alur:RelatedPartyTransactionTerminationFees
      contextRef="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-48595"
      unitRef="Unit_USD">200000</alur:RelatedPartyTransactionTerminationFees>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48596"
      unitRef="Unit_USD">28654000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48597"
      unitRef="Unit_USD">38037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48598"
      unitRef="Unit_USD">8243000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48599"
      unitRef="Unit_USD">12671000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48600"
      unitRef="Unit_USD">9935000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48601"
      unitRef="Unit_USD">18194000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48602"
      unitRef="Unit_USD">4568000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48603"
      unitRef="Unit_USD">6171000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48604"
      unitRef="Unit_USD">1672000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48605"
      unitRef="Unit_USD">2414000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48606"
      unitRef="Unit_USD">44829000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48607"
      unitRef="Unit_USD">64816000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48608"
      unitRef="Unit_USD">3080000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48609"
      unitRef="Unit_USD">3381000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48610"
      unitRef="Unit_USD">2283000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48611"
      unitRef="Unit_USD">3010000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48612"
      unitRef="Unit_USD">507000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48613"
      unitRef="Unit_USD">505000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48614"
      unitRef="Unit_USD">50699000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48615"
      unitRef="Unit_USD">71712000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48616"
      unitRef="Unit_USD">10393000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48617"
      unitRef="Unit_USD">10379000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48618"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48619"
      unitRef="Unit_USD">38643000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48620"
      unitRef="Unit_USD">878000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48621"
      unitRef="Unit_USD">908000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48622"
      unitRef="Unit_USD">7973000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48623"
      unitRef="Unit_USD">15495000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48624"
      unitRef="Unit_USD">19244000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48625"
      unitRef="Unit_USD">65425000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48626"
      unitRef="Unit_USD">7381000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48627"
      unitRef="Unit_USD">6765000</us-gaap:WarrantsAndRightsOutstanding>
    <alur:RevenueInterestFinancingLiabilityNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48628"
      unitRef="Unit_USD">38500000</alur:RevenueInterestFinancingLiabilityNoncurrent>
    <alur:RevenueInterestFinancingLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48629"
      unitRef="Unit_USD">36200000</alur:RevenueInterestFinancingLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48630"
      unitRef="Unit_USD">1850000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48631"
      unitRef="Unit_USD">23990000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48632"
      unitRef="Unit_USD">36090000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48633"
      unitRef="Unit_USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48634"
      unitRef="Unit_USD">1578000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48635"
      unitRef="Unit_USD">2306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48636"
      unitRef="Unit_USD">9867000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48637"
      unitRef="Unit_USD">7513000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48638"
      unitRef="Unit_USD">114510000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48639"
      unitRef="Unit_USD">142199000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2024"
      id="ixv-48640"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-48641"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48642"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48643"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48644"
      unitRef="Unit_shares">100000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48645"
      unitRef="Unit_shares">100000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48646"
      unitRef="Unit_shares">2260159</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48647"
      unitRef="Unit_shares">2260159</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48648"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48649"
      unitRef="Unit_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48650"
      unitRef="Unit_USD">979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48651"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48652"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48653"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48654"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48655"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48656"
      unitRef="Unit_shares">64369381</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-48657"
      unitRef="Unit_shares">64369381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48658"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-48659"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48660"
      unitRef="Unit_USD">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48661"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48662"
      unitRef="Unit_USD">150692000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48663"
      unitRef="Unit_USD">143007000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48664"
      unitRef="Unit_USD">2890000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48665"
      unitRef="Unit_USD">-700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48666"
      unitRef="Unit_USD">-218379000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48667"
      unitRef="Unit_USD">-212799000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48668"
      unitRef="Unit_USD">-64790000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48669"
      unitRef="Unit_USD">-70487000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48670"
      unitRef="Unit_USD">50699000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48671"
      unitRef="Unit_USD">71712000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48672"
      unitRef="Unit_USD">5367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48673"
      unitRef="Unit_USD">18200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48674"
      unitRef="Unit_USD">26519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48675"
      unitRef="Unit_USD">45232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48676"
      unitRef="Unit_USD">2256000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48677"
      unitRef="Unit_USD">4232000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48678"
      unitRef="Unit_USD">7549000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48679"
      unitRef="Unit_USD">10165000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48680"
      unitRef="Unit_USD">3111000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48681"
      unitRef="Unit_USD">13968000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48682"
      unitRef="Unit_USD">18970000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48683"
      unitRef="Unit_USD">35067000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48684"
      unitRef="Unit_USD">5197000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48685"
      unitRef="Unit_USD">13989000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48686"
      unitRef="Unit_USD">18060000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48687"
      unitRef="Unit_USD">36127000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48688"
      unitRef="Unit_USD">3212000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48689"
      unitRef="Unit_USD">7191000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48690"
      unitRef="Unit_USD">13247000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48691"
      unitRef="Unit_USD">21623000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48692"
      unitRef="Unit_USD">7043000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48693"
      unitRef="Unit_USD">18942000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48694"
      unitRef="Unit_USD">20746000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48695"
      unitRef="Unit_USD">30657000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48696"
      unitRef="Unit_USD">15452000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48697"
      unitRef="Unit_USD">40122000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48698"
      unitRef="Unit_USD">52053000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48699"
      unitRef="Unit_USD">88407000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48700"
      unitRef="Unit_USD">-12341000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48701"
      unitRef="Unit_USD">-26154000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48702"
      unitRef="Unit_USD">-33083000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48703"
      unitRef="Unit_USD">-53340000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48704"
      unitRef="Unit_USD">2586000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48705"
      unitRef="Unit_USD">2264000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48706"
      unitRef="Unit_USD">7331000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48707"
      unitRef="Unit_USD">-9703000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48708"
      unitRef="Unit_USD">-3868000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48709"
      unitRef="Unit_USD">-14210000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48710"
      unitRef="Unit_USD">-2189000</us-gaap:FairValueAdjustmentOfWarrants>
    <alur:ChangesInFairValueOfDebt
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48711"
      unitRef="Unit_USD">-1790000</alur:ChangesInFairValueOfDebt>
    <alur:ChangesInFairValueOfDebt
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48712"
      unitRef="Unit_USD">6008000</alur:ChangesInFairValueOfDebt>
    <alur:ChangesInFairValueOfDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48713"
      unitRef="Unit_USD">-10020000</alur:ChangesInFairValueOfDebt>
    <alur:ChangesInFairValueOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48714"
      unitRef="Unit_USD">3751000</alur:ChangesInFairValueOfDebt>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48715"
      unitRef="Unit_USD">-11104000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48716"
      unitRef="Unit_USD">-2040000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48717"
      unitRef="Unit_USD">-9608000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48718"
      unitRef="Unit_USD">-2040000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48719"
      unitRef="Unit_USD">2260000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48720"
      unitRef="Unit_USD">24330000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48721"
      unitRef="Unit_USD">22140000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48722"
      unitRef="Unit_USD">24330000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48723"
      unitRef="Unit_USD">-3929000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48724"
      unitRef="Unit_USD">-8713000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48725"
      unitRef="Unit_USD">-3929000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48726"
      unitRef="Unit_USD">-9466000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48727"
      unitRef="Unit_USD">-17598000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48728"
      unitRef="Unit_USD">757000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48729"
      unitRef="Unit_USD">389000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48730"
      unitRef="Unit_USD">1928000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48731"
      unitRef="Unit_USD">133000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48732"
      unitRef="Unit_USD">3406000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48733"
      unitRef="Unit_USD">4558000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48734"
      unitRef="Unit_USD">27713000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48735"
      unitRef="Unit_USD">-7997000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48736"
      unitRef="Unit_USD">-8935000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48737"
      unitRef="Unit_USD">-21596000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48738"
      unitRef="Unit_USD">-5370000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48739"
      unitRef="Unit_USD">-61337000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48740"
      unitRef="Unit_USD">69000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48741"
      unitRef="Unit_USD">34000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48742"
      unitRef="Unit_USD">210000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48743"
      unitRef="Unit_USD">90000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48744"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48745"
      unitRef="Unit_USD">-21630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48746"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48747"
      unitRef="Unit_USD">-61427000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48748"
      unitRef="Unit_USD">255000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48749"
      unitRef="Unit_USD">1697000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48750"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48751"
      unitRef="Unit_USD">-21885000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48752"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48753"
      unitRef="Unit_USD">-63124000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2024To09_30_2024"
      decimals="2"
      id="ixv-48754"
      unitRef="Unit_USD_per_Share">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="2"
      id="ixv-48755"
      unitRef="Unit_USD_per_Share">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      id="ixv-48756"
      unitRef="Unit_USD_per_Share">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      id="ixv-48757"
      unitRef="Unit_USD_per_Share">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-48758"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-48759"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-48760"
      unitRef="Unit_USD_per_Share">-2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-48761"
      unitRef="Unit_USD_per_Share">-2</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2024To09_30_2024"
      decimals="0"
      id="ixv-48762"
      unitRef="Unit_shares">64086265</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="0"
      id="ixv-48763"
      unitRef="Unit_shares">64086265</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      id="ixv-48764"
      unitRef="Unit_shares">40335457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      id="ixv-48765"
      unitRef="Unit_shares">40335457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To09_30_2024"
      decimals="0"
      id="ixv-48766"
      unitRef="Unit_shares">53310214</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="0"
      id="ixv-48767"
      unitRef="Unit_shares">53310214</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      id="ixv-48768"
      unitRef="Unit_shares">31558538</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      id="ixv-48769"
      unitRef="Unit_shares">31558538</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48770"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48771"
      unitRef="Unit_USD">-21630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48772"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48773"
      unitRef="Unit_USD">-61427000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P07_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48774"
      unitRef="Unit_USD">5800000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingDueMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48775"
      unitRef="Unit_USD">600000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48776"
      unitRef="Unit_USD">3070000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-48777"
      unitRef="Unit_USD">2990000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48778"
      unitRef="Unit_USD">-134000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48779"
      unitRef="Unit_USD">-21630000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48780"
      unitRef="Unit_USD">-1990000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48781"
      unitRef="Unit_USD">-61427000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48782"
      unitRef="Unit_shares">27079856</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48783"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48784"
      unitRef="Unit_USD">99875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48785"
      unitRef="Unit_USD">-132192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48786"
      unitRef="Unit_USD">-32314000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48787"
      unitRef="Unit_shares">15376</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48788"
      unitRef="Unit_USD">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-48789"
      unitRef="Unit_USD">20000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2023To03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48790"
      unitRef="Unit_shares">3554</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48791"
      unitRef="Unit_USD">29000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-48792"
      unitRef="Unit_USD">29000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48793"
      unitRef="Unit_USD">409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-48794"
      unitRef="Unit_USD">409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48795"
      unitRef="Unit_USD">-17801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To03_31_2023"
      decimals="-3"
      id="ixv-48796"
      unitRef="Unit_USD">-17801000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48797"
      unitRef="Unit_shares">27098786</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48798"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48799"
      unitRef="Unit_USD">100333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48800"
      unitRef="Unit_USD">-149993000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2023"
      decimals="-3"
      id="ixv-48801"
      unitRef="Unit_USD">-49657000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48802"
      unitRef="Unit_shares">27626</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48803"
      unitRef="Unit_USD">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      id="ixv-48804"
      unitRef="Unit_USD">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P04_01_2023To06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48805"
      unitRef="Unit_shares">492</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48806"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      id="ixv-48807"
      unitRef="Unit_USD">6000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2023To06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48808"
      unitRef="Unit_USD">401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      id="ixv-48809"
      unitRef="Unit_USD">401000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2023To06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48810"
      unitRef="Unit_USD">-21996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2023To06_30_2023"
      decimals="-3"
      id="ixv-48811"
      unitRef="Unit_USD">-21996000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48812"
      unitRef="Unit_shares">27126904</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48813"
      unitRef="Unit_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48814"
      unitRef="Unit_USD">100768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48815"
      unitRef="Unit_USD">-171989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      id="ixv-48816"
      unitRef="Unit_USD">-71218000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48817"
      unitRef="Unit_shares">77214</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48818"
      unitRef="Unit_USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48819"
      unitRef="Unit_USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48820"
      unitRef="Unit_shares">4976</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48821"
      unitRef="Unit_USD">60000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48822"
      unitRef="Unit_USD">60000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48823"
      unitRef="Unit_shares">13735872</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48824"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48825"
      unitRef="Unit_USD">58572000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48826"
      unitRef="Unit_USD">58573000</us-gaap:StockIssuedDuringPeriodValueOther>
    <alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48827"
      unitRef="Unit_USD">-13762000</alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger>
    <alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48828"
      unitRef="Unit_USD">-13762000</alur:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilitiesInConnectionMerger>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48829"
      unitRef="Unit_shares">906551</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48830"
      unitRef="Unit_shares">3301222</alur:IssuanceOfSharesCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48831"
      unitRef="Unit_USD">1000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48832"
      unitRef="Unit_USD">25569000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48833"
      unitRef="Unit_USD">25570000</alur:IssuanceOfSharesValueCommonStockForConversionOfConvertibleNotes>
    <alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48834"
      unitRef="Unit_USD">-53040000</alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities>
    <alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48835"
      unitRef="Unit_USD">-53040000</alur:AdjustmentsToAdditionalPaidInCapitalRecognitionOfEarnOutLiabilities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48836"
      unitRef="Unit_USD">929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48837"
      unitRef="Unit_USD">929000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48838"
      unitRef="Unit_shares">2287696</alur:StockIssuedDuringPeriodSharesDerecognitionOfLiability>
    <alur:StockIssuedDuringPeriodValueDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48839"
      unitRef="Unit_USD">16098000</alur:StockIssuedDuringPeriodValueDerecognitionOfLiability>
    <alur:StockIssuedDuringPeriodValueDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48840"
      unitRef="Unit_USD">16098000</alur:StockIssuedDuringPeriodValueDerecognitionOfLiability>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="P07_01_2023To09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48841"
      unitRef="Unit_shares">20506</alur:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48842"
      unitRef="Unit_USD">42000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48843"
      unitRef="Unit_USD">42000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2023To09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48844"
      unitRef="Unit_USD">5539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48845"
      unitRef="Unit_USD">5539000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48846"
      unitRef="Unit_USD">-21630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48847"
      unitRef="Unit_USD">-21630000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48848"
      unitRef="Unit_shares">47460941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48849"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48850"
      unitRef="Unit_USD">140858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48851"
      unitRef="Unit_USD">-193619000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      id="ixv-48852"
      unitRef="Unit_USD">-52756000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48853"
      unitRef="Unit_shares">47688096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48854"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48855"
      unitRef="Unit_USD">143007000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48856"
      unitRef="Unit_USD">-700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48857"
      unitRef="Unit_USD">-212799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48858"
      unitRef="Unit_USD">-70487000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48859"
      unitRef="Unit_shares">4646</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48860"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-48861"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48862"
      unitRef="Unit_shares">142</alur:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48863"
      unitRef="Unit_shares">143234</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48864"
      unitRef="Unit_USD">378000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-48865"
      unitRef="Unit_USD">378000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2024To03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48866"
      unitRef="Unit_shares">62619</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48867"
      unitRef="Unit_USD">552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-48868"
      unitRef="Unit_USD">552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2024To03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48869"
      unitRef="Unit_USD">-2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-48870"
      unitRef="Unit_USD">-2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48871"
      unitRef="Unit_USD">5586000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To03_31_2024"
      decimals="-3"
      id="ixv-48872"
      unitRef="Unit_USD">5586000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48873"
      unitRef="Unit_shares">47898737</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48874"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48875"
      unitRef="Unit_USD">143946000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48876"
      unitRef="Unit_USD">-2900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48877"
      unitRef="Unit_USD">-207213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2024"
      decimals="-3"
      id="ixv-48878"
      unitRef="Unit_USD">-66162000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48879"
      unitRef="Unit_shares">11491</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48880"
      unitRef="Unit_USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2024To06_30_2024"
      decimals="-3"
      id="ixv-48881"
      unitRef="Unit_USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48882"
      unitRef="Unit_shares">62619</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsShares
      contextRef="P04_01_2024To06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48883"
      unitRef="Unit_shares">142</alur:IssuanceOfCommonStockForExerciseOfWarrantsShares>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48884"
      unitRef="Unit_USD">1000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount
      contextRef="P04_01_2024To06_30_2024"
      decimals="-3"
      id="ixv-48885"
      unitRef="Unit_USD">1000</alur:IssuanceOfCommonStockForExerciseOfWarrantsAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2024To06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48886"
      unitRef="Unit_USD">805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2024To06_30_2024"
      decimals="-3"
      id="ixv-48887"
      unitRef="Unit_USD">805000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2024To06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48888"
      unitRef="Unit_USD">-3080000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2024To06_30_2024"
      decimals="-3"
      id="ixv-48889"
      unitRef="Unit_USD">-3080000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2024To06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48890"
      unitRef="Unit_USD">-2162000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2024To06_30_2024"
      decimals="-3"
      id="ixv-48891"
      unitRef="Unit_USD">-2162000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48892"
      unitRef="Unit_shares">47972989</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48893"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48894"
      unitRef="Unit_USD">144768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48895"
      unitRef="Unit_USD">-5980000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48896"
      unitRef="Unit_USD">-209375000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2024"
      decimals="-3"
      id="ixv-48897"
      unitRef="Unit_USD">-70582000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48898"
      unitRef="Unit_shares">62619</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48899"
      unitRef="Unit_USD">860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48900"
      unitRef="Unit_USD">860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <alur:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48901"
      unitRef="Unit_shares">2260159</alur:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P07_01_2024To09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48902"
      unitRef="Unit_USD">979000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48903"
      unitRef="Unit_shares">16333773</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_01_2024To09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48904"
      unitRef="Unit_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_01_2024To09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48905"
      unitRef="Unit_USD">5064000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48906"
      unitRef="Unit_USD">5066000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2024To09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48907"
      unitRef="Unit_USD">8870000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48908"
      unitRef="Unit_USD">8870000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48909"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48910"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-48911"
      unitRef="Unit_shares">2260159</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2024_RedeemablePreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-48912"
      unitRef="Unit_USD">979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-48913"
      unitRef="Unit_shares">64369381</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48914"
      unitRef="Unit_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48915"
      unitRef="Unit_USD">150692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48916"
      unitRef="Unit_USD">2890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-48917"
      unitRef="Unit_USD">-218379000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48918"
      unitRef="Unit_USD">-64790000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48919"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48920"
      unitRef="Unit_USD">-61427000</us-gaap:NetIncomeLoss>
    <alur:NonCashLeaseExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48921"
      unitRef="Unit_USD">561000</alur:NonCashLeaseExpense>
    <alur:NonCashLeaseExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48922"
      unitRef="Unit_USD">618000</alur:NonCashLeaseExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48923"
      unitRef="Unit_USD">778000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48924"
      unitRef="Unit_USD">558000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48925"
      unitRef="Unit_USD">2217000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48926"
      unitRef="Unit_USD">6349000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48927"
      unitRef="Unit_USD">1065000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48928"
      unitRef="Unit_USD">4953000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48929"
      unitRef="Unit_USD">29000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48930"
      unitRef="Unit_USD">-253000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48931"
      unitRef="Unit_USD">1052000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48932"
      unitRef="Unit_USD">743000</us-gaap:InventoryWriteDown>
    <alur:ChangeInFairValueOfWarrantLiabilities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48933"
      unitRef="Unit_USD">-14210000</alur:ChangeInFairValueOfWarrantLiabilities>
    <alur:ChangeInFairValueOfWarrantLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48934"
      unitRef="Unit_USD">-2189000</alur:ChangeInFairValueOfWarrantLiabilities>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48935"
      unitRef="Unit_USD">1895000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48936"
      unitRef="Unit_USD">165000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48937"
      unitRef="Unit_USD">-9608000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48938"
      unitRef="Unit_USD">-2040000</alur:ChangesInFairValueOfRevenueInterestFinancingAndPipeConversionOption>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48939"
      unitRef="Unit_USD">22140000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:FairValueAdjustmentOfEarnOutLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48940"
      unitRef="Unit_USD">24330000</alur:FairValueAdjustmentOfEarnOutLiabilities>
    <alur:InterestPaidOnDebtRecordedAtFairValue
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48941"
      unitRef="Unit_USD">2458000</alur:InterestPaidOnDebtRecordedAtFairValue>
    <alur:FairValueAdjustmentOfDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48942"
      unitRef="Unit_USD">-10020000</alur:FairValueAdjustmentOfDebt>
    <alur:FairValueAdjustmentOfDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48943"
      unitRef="Unit_USD">-10020000</alur:FairValueAdjustmentOfDebt>
    <alur:FairValueAdjustmentOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48944"
      unitRef="Unit_USD">3751000</alur:FairValueAdjustmentOfDebt>
    <alur:FairValueAdjustmentOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48945"
      unitRef="Unit_USD">3751000</alur:FairValueAdjustmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48946"
      unitRef="Unit_USD">1357000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48947"
      unitRef="Unit_USD">1210000</us-gaap:AmortizationOfFinancingCosts>
    <alur:NonCashInterestExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48948"
      unitRef="Unit_USD">1464000</alur:NonCashInterestExpense>
    <alur:NonCashInterestExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48949"
      unitRef="Unit_USD">1117000</alur:NonCashInterestExpense>
    <alur:NonCashTerminationOfConvertibleNoteSideLetters
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48950"
      unitRef="Unit_USD">16098000</alur:NonCashTerminationOfConvertibleNoteSideLetters>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48951"
      unitRef="Unit_USD">-3929000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48952"
      unitRef="Unit_USD">-8713000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <alur:AmortizationOfIssuanceCostsAssociatedWithWarrants
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48953"
      unitRef="Unit_USD">942000</alur:AmortizationOfIssuanceCostsAssociatedWithWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48954"
      unitRef="Unit_USD">-7199000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48955"
      unitRef="Unit_USD">3883000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48956"
      unitRef="Unit_USD">-551000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48957"
      unitRef="Unit_USD">899000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48958"
      unitRef="Unit_USD">-747000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48959"
      unitRef="Unit_USD">-409000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48960"
      unitRef="Unit_USD">-593000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48961"
      unitRef="Unit_USD">-617000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48962"
      unitRef="Unit_USD">-578000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48963"
      unitRef="Unit_USD">3492000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48964"
      unitRef="Unit_USD">-7777000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48965"
      unitRef="Unit_USD">4879000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48966"
      unitRef="Unit_USD">-29026000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48967"
      unitRef="Unit_USD">-43111000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48968"
      unitRef="Unit_USD">611000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48969"
      unitRef="Unit_USD">1208000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48970"
      unitRef="Unit_USD">-611000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48971"
      unitRef="Unit_USD">-1208000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48972"
      unitRef="Unit_USD">48000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48973"
      unitRef="Unit_USD">28700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48974"
      unitRef="Unit_USD">59780000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <alur:ProceedsFromBusinessCombinationNetOfTransactionCosts
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48975"
      unitRef="Unit_USD">62078000</alur:ProceedsFromBusinessCombinationNetOfTransactionCosts>
    <alur:ProceedsFromRevenueInterestFinancing
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48976"
      unitRef="Unit_USD">40000000</alur:ProceedsFromRevenueInterestFinancing>
    <alur:ProceedsFromOptionAndWarrantExercises
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48977"
      unitRef="Unit_USD">26000</alur:ProceedsFromOptionAndWarrantExercises>
    <alur:ProceedsFromOptionAndWarrantExercises
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48978"
      unitRef="Unit_USD">195000</alur:ProceedsFromOptionAndWarrantExercises>
    <alur:ProceedsFromEquityLineFinancing
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48979"
      unitRef="Unit_USD">378000</alur:ProceedsFromEquityLineFinancing>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48980"
      unitRef="Unit_USD">10750000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48981"
      unitRef="Unit_USD">2685000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48982"
      unitRef="Unit_USD">18249000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48983"
      unitRef="Unit_USD">1357000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48984"
      unitRef="Unit_USD">3450000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapShortTermDebtTypeAxis"
      decimals="-3"
      id="ixv-48985"
      unitRef="Unit_USD">57659000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48986"
      unitRef="Unit_USD">2500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapShortTermDebtTypeAxis"
      decimals="-3"
      id="ixv-48987"
      unitRef="Unit_USD">47720000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48988"
      unitRef="Unit_USD">20261000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48989"
      unitRef="Unit_USD">116394000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48990"
      unitRef="Unit_USD">-9376000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48991"
      unitRef="Unit_USD">72075000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-48992"
      unitRef="Unit_USD">38421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-48993"
      unitRef="Unit_USD">8023000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-48994"
      unitRef="Unit_USD">29045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      id="ixv-48995"
      unitRef="Unit_USD">80098000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48996"
      unitRef="Unit_USD">2672000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48997"
      unitRef="Unit_USD">5022000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-48998"
      unitRef="Unit_USD">270000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-48999"
      unitRef="Unit_USD">1004000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49000"
      unitRef="Unit_USD">1006000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <alur:RecognitionOfAssumedWarrantLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49001"
      unitRef="Unit_USD">13762000</alur:RecognitionOfAssumedWarrantLiability>
    <alur:RecognitionOfEarnOutLiabilities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49002"
      unitRef="Unit_USD">53040000</alur:RecognitionOfEarnOutLiabilities>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49003"
      unitRef="Unit_USD">25569000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49004"
      unitRef="Unit_USD">600000</alur:ChangeInFairValueOfRevenueInterestFinancingThroughOci>
    <alur:ChangeInFairValueOfRtwConvertibleNotesThroughOci
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49005"
      unitRef="Unit_USD">2990000</alur:ChangeInFairValueOfRtwConvertibleNotesThroughOci>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49006"
      unitRef="Unit_USD">28654000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49007"
      unitRef="Unit_USD">38037000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49008"
      unitRef="Unit_USD">391000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49009"
      unitRef="Unit_USD">384000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49010"
      unitRef="Unit_USD">29045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49011"
      unitRef="Unit_USD">38421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29665">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td id="fin915839_13" style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Organization and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Organization &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Allurion Technologies, Inc. (&#x201c;Allurion&#x201d; or the &#x201c;Company&#x201d;) is a vertically integrated medical device company that is developing, manufacturing, and commercializing innovative weight loss experiences centered around its Allurion&lt;div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"&gt;&#x2122;&lt;/div&gt; Balloon. The Allurion Balloon is the world&#x2019;s first and only swallowable, procedureless&lt;div style="font-size:75%; vertical-align:top;display:inline;font-size:8.3px"&gt;&#x2122;&lt;/div&gt; intragastric balloon for weight loss that does not require surgery, endoscopy, or anesthesia for placement. Allurion sells the Allurion Balloon and connected scale through distributors or directly to health care providers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company also offers tiered access to artificial intelligence (&#x201c;AI&#x201d;)-powered remote patient monitoring tools, a mobile app for patients and a clinic dashboard for providers, referred to as the Allurion Virtual Care Suite (&#x201c;VCS&#x201d;) and, collectively with the Allurion Balloon, referred to as the &#x201c;Allurion Program&#x201d;. The base tier of the VCS is free of charge to those purchasing the Allurion Balloon, as well as customers looking for a weight-loss management platform for patients utilizing other weight loss treatments, including anti-obesity medications and bariatric surgery. More full-scale versions of the VCS are available to health care providers on an upgrade basis. Allurion currently markets the Allurion Program in over 50 countries, and the Company operates subsidiaries in the United States, France, the United Arab Emirates, the United Kingdom, Italy, Spain, Australia and Mexico. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Business Combination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Allurion Technologies Opco, Inc. (formerly Allurion Technologies, Inc., &#x201c;Legacy Allurion&#x201d;) and Allurion Technologies, Inc. (formerly Allurion Technologies Holdings, Inc.) entered into the Business Combination Agreement (as subsequently amended on May&#160;2, 2023, the &#x201c;Business Combination Agreement&#x201d;) with Compute Health Acquisition Corp. (&#x201c;CPUH&#x201d; or &#x201c;Compute Health&#x201d;), Compute Health Corp. (&#x201c;Merger Sub I&#x201d;) and Compute Health LLC (&#x201c;Merger Sub II&#x201d; and, together with Merger Sub I, the &#x201c;Merger Subs&#x201d;). Pursuant to the Business Combination Agreement, on August&#160;1, 2023 (the &#x201c;Closing Date&#x201d;), the Mergers (as defined below) were consummated in three steps: (a)&#160;Compute Health merged with and into Allurion (the &#x201c;CPUH Merger&#x201d;), with Allurion surviving the CPUH Merger as a publicly listed entity (the time at which the CPUH Merger became effective, the &#x201c;CPUH Merger Effective Time&#x201d;) and becoming the sole owner of the Merger Subs; (b)&#160;three hours following the consummation of the CPUH Merger, Merger Sub I merged with and into Legacy Allurion (the &#x201c;Intermediate Merger&#x201d; and the time at which the Intermediate Merger became effective, the &#x201c;Intermediate Merger Effective Time&#x201d;), with Legacy Allurion surviving the Intermediate Merger and becoming a direct, wholly-owned subsidiary of Allurion; and (c)&#160;thereafter, Legacy Allurion merged with and into Merger Sub II (the &#x201c;Final Merger&#x201d; and, collectively with the CPUH Merger and the Intermediate Merger, the &#x201c;Mergers&#x201d;, and together with all other transactions contemplated by the Business Combination Agreement, the &#x201c;Business Combination&#x201d;), with Merger Sub II surviving the Final Merger and remaining a direct, wholly-owned subsidiary of Allurion (the time at which the Final Merger became effective, the &#x201c;Final Merger Effective Time&#x201d;). Shares of Allurion&#x2019;s Common Stock (defined below) began trading on the New York Stock Exchange (&#x201c;NYSE&#x201d;) under the ticker symbol &#x201c;ALUR&#x201d; on August&#160;2, 2023. Upon completion of the Business Combination, Legacy Allurion&#x2019;s business operations continued as our business operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination was accounted for as a reverse capitalization in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Under this method of accounting, Compute Health was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes and Legacy Allurion was the accounting &#x201c;acquirer&#x201d;. Accordingly, the Business Combination was treated as the equivalent of Legacy Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. As a result of the reverse recapitalization, the assets and liabilities of the Company are presented at their historical carrying values, and the assets and liabilities of Compute Health are recognized on the acquisition date and measured on the basis of the net proceeds from the capital transaction, with no goodwill or other intangible assets recorded. This determination is primarily based on the fact that, immediately following the Business Combination, Legacy Allurion stockholders had a majority of the voting power of Allurion, Legacy Allurion controlled the majority of the board seats of Allurion, and Legacy Allurion senior management comprised all of the senior management of &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Allurion. The equity structure has been restated in all comparative periods up to the Closing Date to reflect the number of shares of the Company&#x2019;s common stock, $0.0001 par value per share (&#x201c;Common Stock,&#x201d; &#x201c;Allurion Common Stock&#x201d; or the &#x201c;Company&#x2019;s Common Stock&#x201d;), issued to Legacy Allurion stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Allurion&#x2019;s convertible preferred stock and Legacy Allurion common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of approximately 0.9780 (the &#x201c;Exchange Ratio&#x201d;) established in the Business Combination. As a result of this retrospective application, certain prior period balances within the condensed consolidated financial statements have changed. Refer to Note&#160;3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt; for further discussion regarding the closing of the Business Combination with &lt;div style="display:inline;"&gt;Compute &lt;/div&gt;Health. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Unless otherwise indicated, references in this prospectus to the &#x201c;Company&#x201d;, &#x201c;our&#x201d;, and &#x201c;Allurion&#x201d; refer to the condensed consolidated operations of Allurion Technologies, Inc. and its subsidiaries. References to CPUH and Compute Health refer to Compute Health Acquisition Corp. and its subsidiaries prior to the consummation of the Business Combination and references to &#x201c;Legacy Allurion&#x201d; refer to Allurion Technologies, Inc. prior to the consummation of the Business Combination. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to the applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;), and Accounting Standards Update (&#x201c;ASU&#x201d;), of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). They should be read in conjunction with our audited financial statements as of and for the year ended December&#160;31, 2023 included in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K,&lt;/div&gt; as amended (&#x201c;Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K&#x201d;).&lt;/div&gt; The financial statements as of September&#160;30, 2024 and for the three and nine months ended September&#160;30, 2024 and 2023 presented in this report are unaudited; however, in the opinion of management, such financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Our foreign operations are subject to exchange rate fluctuations and foreign currency transaction costs. The functional currency for all of our foreign subsidiaries is the United States dollar except Allurion Australia Pty Ltd., which uses the Australian dollar. When remeasuring from a local currency to the functional currency, assets and liabilities are remeasured into U.S. dollars at exchange rates in effect at the balance sheet dates and results of operations transacted in local currency are remeasured into U.S. dollars using average exchange rates for the period presented. A gain from remeasurement of less than $0.1&#160;million and a loss from remeasurement of s$0.3&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, and a gain from remeasurement of $0.4&#160;million and loss from remeasurement of $0.3&#160;million for the three months ended September&#160;30, 2024 and 2023, respectively, are recorded in the statements of operations within Other income, net. The Company translates the foreign functional currency financial statements to U.S. dollars for Allurion Australia Pty Ltd. using the exchange rates at the balance sheet date for assets and liabilities, the period average exchange rates for revenues and expenses, and the historical exchange rates for equity transactions. The effects of foreign currency translation adjustments were immaterial for the three and nine months ended September&#160;30, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated whether there are certain events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the interim condensed consolidated financial statements are issued. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has incurred recurring losses since inception, anticipates net losses and negative operating cash flows for the near future, and may be unable to remain in compliance with certain financial covenants required under its credit facilities. Through September&#160;30, 2024, the Company has funded its operations primarily with proceeds from the sale of its Common Stock, convertible preferred stock, issuance of convertible notes, issuance of term loans, and funds received upon consummation of the Business Combination. The Company has incurred recurring losses and cash outflows from operating activities since its inception, including losses from operations of $33.1&#160;million and $53.3&#160;million and cash outflows from operating activities of $29.0&#160;million and $43.1&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively. As of September&#160;30, 2024, the Company had an accumulated deficit of $218.4&#160;million. The Company expects to continue to generate significant operating losses for the foreseeable future. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Based on the Company&#x2019;s recurring losses from operations incurred since inception, its expectation of continuing operating losses for the foreseeable future, the potential need to raise additional capital to finance its future operations, and the potential of being unable to remain in compliance with certain financial covenants under its credit facilities, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these condensed consolidated financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <alur:NumberOfCountriesInWhichEntityMarketsTheProgram
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49012"
      unitRef="Unit_Country">50</alur:NumberOfCountriesInWhichEntityMarketsTheProgram>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49015"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <alur:BusinessCombinationCommonStockExchangeRatio
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-49016"
      unitRef="Unit_pure">0.978</alur:BusinessCombinationCommonStockExchangeRatio>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-49017"
      unitRef="Unit_USD">100000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49018"
      unitRef="Unit_USD">-300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49019"
      unitRef="Unit_USD">400000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49020"
      unitRef="Unit_USD">-300000</us-gaap:TranslationAdjustmentFunctionalToReportingCurrencyGainLossReclassifiedToEarningsNetOfTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49022"
      unitRef="Unit_USD">-33100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49023"
      unitRef="Unit_USD">-53300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49024"
      unitRef="Unit_USD">-29000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49025"
      unitRef="Unit_USD">-43100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2024"
      decimals="-5"
      id="ixv-49026"
      unitRef="Unit_USD">-218400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29740">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There have been no significant changes, except as described below, to the significant accounting policies disclosed in Note 2 of the &#x201c;Notes to Consolidated Financial Statements&#x201d; to the consolidated audited financial statements as of and for the year ended December&#160;31, 2023 included in our Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-K.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RTW Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the RTW Convertible Notes (defined below) under the fair value option (&#x201c;FVO&#x201d;) election of ASC Topic 825, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 825&#x201d;). The RTW Convertible Notes accounted for under the FVO election was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the RTW Convertible Notes were recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the RTW Convertible Notes were expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Reclassification of Prior Year Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustment has been made to the condensed consolidated balance sheet as of December&#160;31, 2023, to present the Legacy Allurion common stock warrant liabilities as part of the Warrant liabilities line item. These amounts were part of the Other liabilities line item in prior years. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Mezzanine Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Mezzanine equity represents the Series A Preferred Stock (defined below) issued by the Company. The shares of Series A Preferred Stock are redeemable at a determinable price on a fixed date, which results in mezzanine equity classification (outside of permanent equity) on the Company&#x2019;s consolidated balance sheet. Refer to Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock and Stockholder&#x2019;s Deficit,&lt;/div&gt;&lt;/div&gt; for additional information regarding the Series A Preferred Stock. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk of Concentration of Credit, Significant Customers and Significant Suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue for the three and nine months ended September&#160;30, 2024 and 2023 or accounts receivable, net balance as of September&#160;30, 2024 and December&#160;31, 2023. The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:41%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#x2019;s operating results, financial condition and cash flows and damage its customer relationships. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity, &lt;/div&gt;&lt;/div&gt;which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; effective January 1, 2024 under the modified retrospective method of transition approach. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; did not have an impact on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt;, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2024To09_30_2024" id="ixv-29751">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ from those estimates. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29756">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RTW Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company accounted for the RTW Convertible Notes (defined below) under the fair value option (&#x201c;FVO&#x201d;) election of ASC Topic 825, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 825&#x201d;). The RTW Convertible Notes accounted for under the FVO election was a debt host financial instrument containing embedded features wherein the entire financial instrument was initially measured at its issue-date estimated fair value and then subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in the estimated fair value of the RTW Convertible Notes were recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. As a result of electing the FVO, direct costs and fees related to the RTW Convertible Notes were expensed as incurred. &lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="P01_01_2024To09_30_2024" id="ixv-29779">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Reclassification of Prior Year Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Adjustment has been made to the condensed consolidated balance sheet as of December&#160;31, 2023, to present the Legacy Allurion common stock warrant liabilities as part of the Warrant liabilities line item. These amounts were part of the Other liabilities line item in prior years. &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <alur:MezzanineEquityPolicyTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29784">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Mezzanine Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Mezzanine equity represents the Series A Preferred Stock (defined below) issued by the Company. The shares of Series A Preferred Stock are redeemable at a determinable price on a fixed date, which results in mezzanine equity classification (outside of permanent equity) on the Company&#x2019;s consolidated balance sheet. Refer to Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock and Stockholder&#x2019;s Deficit,&lt;/div&gt;&lt;/div&gt; for additional information regarding the Series A Preferred Stock. &lt;/div&gt;</alur:MezzanineEquityPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2024To09_30_2024" id="ixv-29791">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Risk of Concentration of Credit, Significant Customers and Significant Suppliers &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable, net. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue for the three and nine months ended September&#160;30, 2024 and 2023 or accounts receivable, net balance as of September&#160;30, 2024 and December&#160;31, 2023. The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:41%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company relies on third parties for the supply of parts and components for its products as well as third-party logistics providers. In instances where these parties fail to perform their obligations, the Company may be unable to find alternative suppliers of parts and components to satisfactorily deliver its products to its customers on time, if at all, which could have a material adverse effect on the Company&#x2019;s operating results, financial condition and cash flows and damage its customer relationships. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49028"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49029"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To09_30_2023_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49030"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-49031"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis"
      decimals="2"
      id="ixv-49032"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2024To09_30_2024_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CustomersMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49033"
      unitRef="Unit_pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-49034">The following table presents customers that represent 10% or more of the Company&#x2019;s total revenue and accounts receivable, net: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:41%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&#160;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer A&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Customer B&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;N/A&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2024To09_30_2024_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49035"
      unitRef="Unit_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49036"
      unitRef="Unit_pure">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To09_30_2023_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49037"
      unitRef="Unit_pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      id="ixv-49038"
      unitRef="Unit_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To12_31_2023_AccountsReceivableMemberusgaapConcentrationRiskByBenchmarkAxis_CustomerAMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      id="ixv-49039"
      unitRef="Unit_pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_CustomerBMembersrtMajorCustomersAxis_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49040"
      unitRef="Unit_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29954">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt with Conversion and Other Options and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity, &lt;/div&gt;&lt;/div&gt;which simplifies the accounting for convertible instruments. The guidance removes certain accounting models which separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; effective January 1, 2024 under the modified retrospective method of transition approach. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2020-06&lt;/div&gt; did not have an impact on the Company&#x2019;s condensed consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-07,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt;, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December&#160;15, 2023, and interim periods within fiscal periods beginning after December&#160;15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. This ASU is effective for fiscal years beginning after December&#160;15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-49041">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-49042">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="PAsOn09_30_2024_AccountingStandardsUpdate202006MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis"
      id="ixv-49043">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-29997">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As discussed in Note 1, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Basis of Presentation&lt;/div&gt;&lt;/div&gt;, on August&#160;1, 2023 the Company consummated the Business Combination with Compute Health pursuant to the Business Combination Agreement. The Business Combination was accounted for as a reverse capitalization in accordance with U.S. GAAP. Under this method of accounting, Compute Health, which was the legal acquirer, was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Allurion issuing stock for the net assets of Compute Health, accompanied by a recapitalization. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon the closing of the Business Combination, (a)&#160;holders of Legacy Allurion common stock received shares of Allurion Common Stock in an amount determined by application of the Exchange Ratio of approximately 0.9780, (b) each then-outstanding share of Legacy Allurion preferred stock was converted into the right to receive shares of Allurion Common Stock equal to the number of shares of Legacy Allurion common stock that would be issued upon conversion of such outstanding share of Legacy Allurion preferred stock based on the applicable conversion ratio multiplied by the Exchange Ratio, (c)&#160;each then-outstanding and unexercised Legacy Allurion option was converted into a new Allurion option on the same terms and conditions as were applicable to such Legacy Allurion option based on the Exchange Ratio, (d)&#160;each then-outstanding Legacy Allurion warrant was converted into a new Allurion warrant based on the Exchange Ratio (&#x201c;Rollover Warrant&#x201d;), (e) each then-outstanding Legacy Allurion restricted stock unit was converted into a rollover restricted stock unit based on the Exchange Ratio, and (f)&#160;certain amounts of loans made by Compute Health Sponsor LLC (the &#x201c;Sponsor&#x201d;) to CPUH, which balance was $3.7&#160;million at the time of the Business Combination, were converted into 525,568 shares of Allurion Common Stock. For periods prior to the Business Combination, the reported share and per share amounts have been retroactively converted by applying the Exchange Ratio. The consolidated assets, liabilities, and results of operations prior to the Business Combination are those of Legacy Allurion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further, upon the closing of the Business Combination, each then-outstanding share of Compute Health Class&#160;A common stock was canceled and extinguished and was converted into the right to receive 1.420455 shares of Allurion Common Stock. Additionally, the Company assumed 13,206,922 outstanding public warrants to purchase an aggregate 18,759,838&#160;shares of Allurion Common Stock at $8.10 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company incurred approximately $22.7&#160;million of transaction costs, consisting of legal and other professional fees, of which $15.2&#160;million was recorded to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital as a reduction of proceeds, $2.5&#160;million was recorded as debt issuance costs in connection with the Fortress Term Loan (as defined below), and $5.0&#160;million was recorded as an expense in general and administrative expenses on the condensed consolidated statement of operations and comprehensive &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;loss. Of the $5.0&#160;million recorded as general and administrative expenses, $3.6&#160;million relates to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; insurance payment related to any potential matters that might arise from the period prior to the Business Combination, and as such is not capitalized as an asset. An additional $1.2&#160;million relates to direct costs and fees incurred as part of the Revenue Interest Financing with RTW (as defined below). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; CPUH trust (net of redemptions)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; PIPE Investors&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross Proceeds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net proceeds from the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: warrant liabilities assumed&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: repayment of note assumed in the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accrued transaction costs at December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business Combination, net of transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Equityholders (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,897,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Stockholders (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issued to PIPE Investors (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,386,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to RTW and Fortress (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,900,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to convertible note holders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301,222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Sponsor Shares (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,262,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Side Letter Termination Shares (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;387,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of Common Stock immediately after Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,301,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#x201c;Reverse recapitalization, net of transaction costs&#x201d; line, which is less the Gaur Trust Contributed Shares. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#x201c;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#x201d; line. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;PIPE Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution of the Business Combination Agreement, Allurion and Compute Health entered into subscription agreements, each dated February&#160;9, 2023, with certain accredited investors and &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;qualified institutional buyers (the &#x201c;PIPE Investors&#x201d;), pursuant to which, upon the terms and subject to the conditions set forth therein, the PIPE Investors, among other things, purchased an aggregate of 5,386,695 shares of Allurion Common Stock at a purchase price of $7.04 per share (other than as set forth in the Amended and Restated RTW Side Letter, as defined below), for an aggregate purchase price of $37.9&#160;million, following the CPUH Merger Effective Time (the &#x201c;PIPE Investment&#x201d;). &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue Interest Financing Agreement, Side Letter and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, concurrently with the execution of the Business Combination Agreement, the Company entered into the Revenue Interest Financing Agreement (the &#x201c;Revenue Interest Financing Agreement&#x201d;) with certain entities that engaged RTW Investments, LP (together with its affiliates, &#x201c;RTW&#x201d;) as investment manager. Pursuant to the Revenue Interest Financing Agreement, at the closing of the Business Combination, RTW paid Allurion an aggregate of $40.0&#160;million (the &#x201c;Investment Amount&#x201d;). In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. The Revenue Interest Financing Agreement was amended pursuant to the RIFA Amendment (as defined below) on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries. Refer to Note 9, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing, Side Letter, and PIPE Conversion Option&lt;/div&gt;&lt;/div&gt; below for further discussion on the Revenue Interest Financing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Additionally, in connection with the Company entering into the Revenue Interest Financing Agreement, the Company, Compute Health, Legacy Allurion, Merger Sub II and RTW entered into a side letter (the &#x201c;RTW Side Letter&#x201d;) on February&#160;9, 2023 under which RTW may elect to convert up to $7.5&#160;million of its initial PIPE Investment into an additional revenue interest financing by forfeiting a number of shares of Allurion Common Stock acquired by its PIPE Investment. Refer to Note 9, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue Interest Financing, Side Letter, and PIPE Conversion Option&lt;/div&gt;&lt;/div&gt; below for further discussion on the Revenue Interest Financing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, the parties amended and restated the RTW Side Letter (as amended, the &#x201c;Amended and Restated RTW Side Letter&#x201d;), in connection with the Backstop Agreement (defined below), pursuant to which, among other things, Allurion issued 250,000 shares of Allurion Common Stock to RTW immediately prior to the Intermediate Merger Effective Time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of Common Stock of the Company representing $7.5&#160;million in consideration for the New RIFA (as defined below). Refer to Note 19, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent Events&lt;/div&gt;&lt;/div&gt;, below for further discussion on the RTW conversion. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fortress Credit Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company entered into a term loan facility (the &#x201c;Fortress Term Loan&#x201d;) pursuant to a Credit Agreement and Guaranty, dated as of August&#160;1, 2023 (the &#x201c;Fortress Credit Agreement&#x201d;), with Fortress Credit Corp. (&#x201c;Fortress&#x201d;), as administrative agent for the lenders party thereto from time to time (the &#x201c;Lenders&#x201d;). Under the terms of the Fortress Term Loan, we borrowed $60.0&#160;million, which was used to repay the outstanding principal, accrued and unpaid interest, and other obligations with respect to the 2021 Term Loan (as defined below). Additionally, per the terms of the Fortress Term Loan and Backstop Agreement (as defined below), Allurion issued an aggregate of 950,000 shares of Allurion Common Stock to an affiliate of Fortress pursuant to a subscription agreement between Allurion and such affiliate. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;for further discussion on the Fortress Term Loan. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Backstop Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, CFIP2 ALLE LLC, an affiliate of Fortress Credit Corp., and RTW (collectively, the &#x201c;Backstop Purchasers&#x201d;), Legacy Allurion, Allurion and Hunter Ventures Limited (&#x201c;HVL&#x201d;) entered into the backstop agreement (the &#x201c;Backstop Agreement&#x201d;). Pursuant to the Backstop Agreement, immediately prior to the Intermediate Merger Closing, (a)&#160;each Backstop Purchaser purchased $2&#160;million of the aggregate principal amount outstanding of HVL&#x2019;s Legacy Allurion convertible note issued in February 2023, (b) Allurion canceled the existing HVL Legacy Allurion Convertible Note and issued a new Allurion Convertible Note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance thereof, (c)&#160;Allurion issued new Allurion Convertible Notes to each Backstop Purchaser with an issuance date of August&#160;1, 2023 and an original principal amount of $2&#160;million each and (d)&#160;Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further discussion around the Backstop Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;HVL Termination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, HVL and Legacy Allurion entered into a letter agreement (the &#x201c;HVL Termination Agreement&#x201d;), terminating the side letter agreement entered into between Legacy Allurion and HVL in connection with the issuance of HVL&#x2019;s Legacy Allurion convertible note on February&#160;15, 2023. Pursuant to the HVL Termination Agreement, among other things, at the closing of the Business Combination, upon the terms and subject to the conditions set forth therein, Allurion issued to HVL 387,696 shares of Allurion Common Stock. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further discussion regarding the HVL Termination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Gaur Contribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, Shantanu K. Gaur and Neha Gaur, trustees of The Shantanu K. Gaur Revocable Trust of 2021 (the &#x201c;Gaur Trust&#x201d;) and Allurion entered into a contribution agreement (the &#x201c;Gaur Contribution Agreement&#x201d;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Gaur Trust contributed to Allurion, as a contribution of capital, 79,232 shares of Allurion Common Stock (the &#x201c;Gaur Trust Contributed Shares&#x201d;). The Gaur Trust&#x2019;s contribution of the Gaur Trust Contributed Shares was effective immediately following the consummation of the Business Combination and the issuance of shares of Allurion Common Stock to the Gaur Trust pursuant to the terms of the Business Combination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RSU Forfeiture Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, Krishna Gupta, a member of the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d; or &#x201c;Board of Directors&#x201d;), entered into a letter agreement with Legacy Allurion (the &#x201c;RSU Forfeiture Agreement&#x201d;), pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, Mr.&#160;Gupta agreed to forfeit 79,232 restricted stock units of Allurion (the &#x201c;Forfeited RSUs&#x201d;). The Forfeited RSUs were terminated and cancelled without consideration therefor immediately following the closing of the Business Combination Agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Sponsor Contribution Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023, the Sponsor and Compute Health entered into a letter agreement (the &#x201c;Sponsor Contribution Agreement&#x201d;) pursuant to which, among other things, upon the terms and subject to the conditions set forth therein, the Sponsor agreed to contribute to Compute Health, as a contribution of capital, 161,379 shares of Compute Health Class&#160;A Common Stock (&#x201c;Sponsor Contributed Shares&#x201d;). The Sponsor&#x2019;s contribution of the Sponsor Contributed Shares was made immediately following the CPUH Recapitalization (defined below) and immediately prior to the CPUH Merger Effective Time. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Allurion entered into a support agreement (the &#x201c;Sponsor Support Agreement&#x201d;), pursuant to which immediately prior to the CPUH Merger Effective time, (a)&#160;the Sponsor recapitalized each of &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the Sponsor&#x2019;s 21,442,500 shares of Compute Health Class&#160;B Common Stock, and all 12,833,333 of the Sponsor&#x2019;s warrants to purchase shares of Class&#160;A Common Stock, into 2,088,327 shares of Compute Health Class&#160;A Common Stock and (b)&#160;the additional Class&#160;B Holders set forth on Schedule I of the Sponsor Support Agreement recapitalized his or her 30,000 shares of Compute Health Class&#160;B Common Stock into 21,120 shares of Compute Health Class&#160;A Common Stock (the &#x201c;CPUH Recapitalization&#x201d;). Subsequently, at the CPUH Merger Effective Time, each such share of Compute Health Class&#160;A Common Stock was converted into shares of Allurion Common Stock at an exchange ratio of 1.420455 (the &#x201c;CPUH Exchange Ratio&#x201d;). &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Conversion of Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, outstanding Legacy Allurion Convertible Notes with an aggregate principal amount together with accrued but unpaid interest of approximately $21.8&#160;million were converted into 3,301,222 shares of Allurion Common Stock with a corresponding recognition of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital (&#x201c;APIC&#x201d;) of $25.6&#160;million provided for under the terms of such Legacy Allurion Convertible Notes, and are no longer outstanding. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for further information on the Company&#x2019;s convertible notes. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Public Warrants and Warrant Amendment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company assumed 13,206,922 outstanding public warrants (the &#x201c;Public Warrants&#x201d;) to purchase an aggregate 18,759,838 shares of Allurion Common Stock at $8.10 per share following the Warrant Amendment (defined below). The total value of the liability associated with the Public Warrants was $13.8&#160;million measured at fair value based on the public warrant quoted price. The Company concluded the warrants met the definition of a liability based on the settlement provision that allows the warrant holders to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;net-share&lt;/div&gt; settle their warrants in the event of a failed registration statement within 60 days of the Business Combination or any time a registration is not effective. As such, they have been classified as a liability on the balance sheet. See Note 12, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redeemable Convertible Preferred Stock and Stockholders Deficit&lt;/div&gt;&lt;/div&gt; and Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt; for further information on the Public Warrants and Warrant Amendment. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, Legacy Allurion equity holders are entitled to receive additional shares of Allurion Common Stock if the share price achieves certain targets (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#x201c;Earn-Out&lt;/div&gt; Shares&#x201d;). The Company accounts for the potential issuance of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares as a contingent consideration arrangement, which was initially valued and recorded at $53.0&#160;million. See Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt; for further information on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liabilities. &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <alur:BusinessCombinationCommonStockExchangeRatio
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-49045"
      unitRef="Unit_pure">0.978</alur:BusinessCombinationCommonStockExchangeRatio>
    <alur:SponsorLoanExcessAmount
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49046"
      unitRef="Unit_USD">3700000</alur:SponsorLoanExcessAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49047"
      unitRef="Unit_shares">525568</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49048"
      unitRef="Unit_shares">1.420455</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49049"
      unitRef="Unit_shares">13206922</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P08_01_2023To08_01_2023"
      decimals="INF"
      id="ixv-49050"
      unitRef="Unit_shares">18759838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49051"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-49052"
      unitRef="Unit_USD">22700000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-49053"
      unitRef="Unit_USD">15200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49054"
      unitRef="Unit_USD">2500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-49055"
      unitRef="Unit_USD">5000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="P08_01_2023To08_01_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      id="ixv-49058"
      unitRef="Unit_USD">5000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <alur:BusinessCombinationOneTimeInsurancePayment
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-49059"
      unitRef="Unit_USD">3600000</alur:BusinessCombinationOneTimeInsurancePayment>
    <alur:DirectCostsAndFees
      contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49060"
      unitRef="Unit_USD">1200000</alur:DirectCostsAndFees>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30031">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows and the condensed consolidated statement of changes in equity: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; CPUH trust (net of redemptions)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,395&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash &#x2013; PIPE Investors&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gross Proceeds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;76,317&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: transaction costs paid&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(14,665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net proceeds from the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;61,652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: warrant liabilities assumed&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: repayment of note assumed in the Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: accrued transaction costs at December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Business Combination, net of transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-49061"
      unitRef="Unit_USD">38395000</alur:GrossProceedsFromBusinessCombination>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      id="ixv-49062"
      unitRef="Unit_USD">37922000</alur:GrossProceedsFromBusinessCombination>
    <alur:GrossProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49063"
      unitRef="Unit_USD">76317000</alur:GrossProceedsFromBusinessCombination>
    <alur:BusinessCombinationTransactionCostPaid
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49064"
      unitRef="Unit_USD">14665000</alur:BusinessCombinationTransactionCostPaid>
    <alur:NetProceedsFromBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49065"
      unitRef="Unit_USD">61652000</alur:NetProceedsFromBusinessCombination>
    <alur:WarrantLiabilitiesAssumed
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49066"
      unitRef="Unit_USD">-13762000</alur:WarrantLiabilitiesAssumed>
    <alur:RepaymentOfNoteAssumedInBusinessCombination
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49067"
      unitRef="Unit_USD">-2500000</alur:RepaymentOfNoteAssumedInBusinessCombination>
    <alur:BusinessAcquisitionAccruedTransactionCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49068"
      unitRef="Unit_USD">-580000</alur:BusinessAcquisitionAccruedTransactionCosts>
    <alur:BusinessCombinationNetOfTransactionCosts
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-49069"
      unitRef="Unit_USD">44810000</alur:BusinessCombinationNetOfTransactionCosts>
    <alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding contextRef="P01_01_2024To09_30_2024" id="ixv-30144">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Allurion Common Stock outstanding immediately following the consummation of the Business Combination was as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:78%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Equityholders (1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,897,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Stockholders (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares Issued to PIPE Investors (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,386,695&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to RTW and Fortress (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,900,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares issued to convertible note holders&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,301,222&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;CPUH Sponsor Shares (2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,262,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Side Letter Termination Shares (3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;387,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of Common Stock immediately after Business Combination&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;47,301,409&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Consists of Legacy Allurion common stock and Legacy Allurion preferred stock, plus the issuance of common stock in connection with the vesting of RSUs at closing, less the Gaur Trust Contributed Shares (as defined below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The CPUH Stockholders shares, PIPE shares, and CPUH Sponsor shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#x201c;Reverse recapitalization, net of transaction costs&#x201d; line, which is less the Gaur Trust Contributed Shares. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;The shares issued to RTW and Fortress and the Side Letter Termination shares are presented combined within the condensed consolidated statements of stockholders deficit on the &#x201c;Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and additional RTW and Fortress shares and issuance of related shares&#x201d; line. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfBusinessCombinationSharesCommonStockOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_LegacyAllurionEquityholdersMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49070"
      unitRef="Unit_shares">27897387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ComputeHealthMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49071"
      unitRef="Unit_shares">5165698</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_PipeInvestorsMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49072"
      unitRef="Unit_shares">5386695</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_RtwAndFortressMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49073"
      unitRef="Unit_shares">1900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ConvertibleNoteHoldersMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49074"
      unitRef="Unit_shares">3301222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_ComputeHealthSponsorSharesMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49075"
      unitRef="Unit_shares">3262711</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023_SideLetterTerminationSharesMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49076"
      unitRef="Unit_shares">387696</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn08_01_2023"
      decimals="INF"
      id="ixv-49077"
      unitRef="Unit_shares">47301409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-49080"
      unitRef="Unit_shares">5386695</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-49081"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P08_01_2023To08_01_2023_PipeSubscriptionAgreementsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-49082"
      unitRef="Unit_USD">37900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <alur:ProceedsFromRevenueInterestFinancing
      contextRef="P08_01_2023To08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49083"
      unitRef="Unit_USD">40000000</alur:ProceedsFromRevenueInterestFinancing>
    <alur:PercentageOfAnnualNetSales
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-49084"
      unitRef="Unit_pure">0.06</alur:PercentageOfAnnualNetSales>
    <alur:RemittanceOfRevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_NewAllurionMemberdeiLegalEntityAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-49085"
      unitRef="Unit_pure">0.10</alur:RemittanceOfRevenueInterestPaymentsPercentage>
    <alur:ConversionOfPipeInvestmentToRevenueInterestFinance
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49086"
      unitRef="Unit_USD">7500000</alur:ConversionOfPipeInvestmentToRevenueInterestFinance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49087"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alur:NumberOfSurrenderSharesOfCommonStock
      contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-49088"
      unitRef="Unit_shares">749998</alur:NumberOfSurrenderSharesOfCommonStock>
    <alur:SurrenderCommonStockValue
      contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-49089"
      unitRef="Unit_USD">7500000</alur:SurrenderCommonStockValue>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis_TermLoanFacilityMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49090"
      unitRef="Unit_USD">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49091"
      unitRef="Unit_shares">950000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-49093"
      unitRef="Unit_USD">2000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-49094"
      unitRef="Unit_USD">2000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49095"
      unitRef="Unit_shares">700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_HVLTerminationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49096"
      unitRef="Unit_shares">387696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <alur:ContributionOfCapitalByJointVenturePartner
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_GaurContributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49097"
      unitRef="Unit_shares">79232</alur:ContributionOfCapitalByJointVenturePartner>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P08_01_2023To08_01_2023_RSUForfeitureAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49098"
      unitRef="Unit_shares">79232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <alur:ContributionOfCapitalByJointVenturePartner
      contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_SponsorContributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49099"
      unitRef="Unit_shares">161379</alur:ContributionOfCapitalByJointVenturePartner>
    <alur:RecapitalizationOfCommonStock
      contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49102"
      unitRef="Unit_shares">21442500</alur:RecapitalizationOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49103"
      unitRef="Unit_shares">12833333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49104"
      unitRef="Unit_shares">2088327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:RecapitalizationOfAdditionalShares
      contextRef="PAsOn08_01_2023_CommonClassBMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49105"
      unitRef="Unit_shares">30000</alur:RecapitalizationOfAdditionalShares>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthMemberdeiLegalEntityAxis_SponsorSupportAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49106"
      unitRef="Unit_shares">21120</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P08_01_2023To08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49107"
      unitRef="Unit_shares">1.420455</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="PAsOn08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49108"
      unitRef="Unit_USD">21800000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-49109"
      unitRef="Unit_shares">3301222</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49110"
      unitRef="Unit_USD">25600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49111"
      unitRef="Unit_shares">13206922</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P08_01_2023To08_01_2023"
      decimals="INF"
      id="ixv-49112"
      unitRef="Unit_shares">18759838</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn08_01_2023_BusinessCombinationAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantAmendmentMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49113"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn08_01_2023_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="-5"
      id="ixv-49114"
      unitRef="Unit_USD">13800000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="PAsOn08_01_2023"
      decimals="-5"
      id="ixv-49115"
      unitRef="Unit_USD">53000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30385">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Australia&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Italy&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;511&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Chile&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,956&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All Other Countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,367&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three months ended September&#160;30, 2024, $1.8&#160;million of revenue was generated in five countries included within All Other Countries in the table above, representing approximately 34% of Total Revenues, with each country responsible for approximately 5% to 8% of the total. Remaining revenue was generated by sales in 36 other countries included within All Other Countries. For the three months ended September&#160;30, 2023, $5.9&#160;million of revenue was generated in five countries included within All Other Countries, representing approximately 33% of Total Revenues, with each country responsible for approximately 5% to 7% of the total. Remaining revenue was generated by sales in 45 other countries included within All Other Countries. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Spain&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All Other Countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,980&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the nine months ended September&#160;30, 2024, $7.2&#160;million of revenue was generated in five countries included within All Other Countries in the table above, representing approximately 27% of Total Revenues, with each country responsible for approximately 4% to 8% of the total. Remaining revenue was generated by sales in 49 other countries included within All Other Countries. For the nine months ended September&#160;30, 2023, $11.1&#160;million of revenue was generated in five countries included within All Other Countries, representing approximately 25% of Total Revenues, with each country responsible for approximately 4% to 7% of the total. Remaining revenue was generated by sales in 58&#160;other countries included within All Other Countries. No revenue was generated in the United States for the three and nine months ended September&#160;30, 2024. &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30394">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Revenue by geographic region is based on the country in which our customer is located and is summarized by geographic area as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Australia&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;543&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Italy&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;511&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;626&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Chile&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,956&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All Other Countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,347&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,122&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,367&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:74%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Spain&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,534&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,431&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,423&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Turkey&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,573&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All Other Countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,980&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,143&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Revenues&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;26,519&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;45,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49116"
      unitRef="Unit_USD">966000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49117"
      unitRef="Unit_USD">3517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024_AUsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49118"
      unitRef="Unit_USD">543000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_AUsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49119"
      unitRef="Unit_USD">979000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024_ITsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49120"
      unitRef="Unit_USD">511000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_ITsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49121"
      unitRef="Unit_USD">626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_CLsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49122"
      unitRef="Unit_USD">1956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49123"
      unitRef="Unit_USD">3347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49124"
      unitRef="Unit_USD">11122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49125"
      unitRef="Unit_USD">5367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49126"
      unitRef="Unit_USD">18200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49128"
      unitRef="Unit_USD">1800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P07_01_2024To09_30_2024"
      decimals="INF"
      id="ixv-49129"
      unitRef="Unit_Country">5</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49130"
      unitRef="Unit_pure">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49131"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49132"
      unitRef="Unit_pure">0.08</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P07_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-49133"
      unitRef="Unit_Country">36</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49134"
      unitRef="Unit_USD">5900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P07_01_2023To09_30_2023"
      decimals="INF"
      id="ixv-49135"
      unitRef="Unit_Country">5</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49136"
      unitRef="Unit_pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49137"
      unitRef="Unit_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P07_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49138"
      unitRef="Unit_pure">0.07</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P07_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-49139"
      unitRef="Unit_Country">45</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_ESsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49140"
      unitRef="Unit_USD">3001000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_ESsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49141"
      unitRef="Unit_USD">3715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_GBsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49142"
      unitRef="Unit_USD">2534000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_GBsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49143"
      unitRef="Unit_USD">3456000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49144"
      unitRef="Unit_USD">2431000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49145"
      unitRef="Unit_USD">4423000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49146"
      unitRef="Unit_USD">1573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_TRYsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49147"
      unitRef="Unit_USD">5495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49148"
      unitRef="Unit_USD">16980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49149"
      unitRef="Unit_USD">28143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49150"
      unitRef="Unit_USD">26519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49151"
      unitRef="Unit_USD">45232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49152"
      unitRef="Unit_USD">7200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P01_01_2024To09_30_2024"
      decimals="INF"
      id="ixv-49153"
      unitRef="Unit_Country">5</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49154"
      unitRef="Unit_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49155"
      unitRef="Unit_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2024To09_30_2024_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49156"
      unitRef="Unit_pure">0.08</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P01_01_2024To09_30_2024_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-49157"
      unitRef="Unit_Country">49</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49158"
      unitRef="Unit_USD">11100000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <alur:NumberOfCountriesGenerateRevenue
      contextRef="P01_01_2023To09_30_2023"
      decimals="INF"
      id="ixv-49159"
      unitRef="Unit_Country">5</alur:NumberOfCountriesGenerateRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To09_30_2023_FourCountriesIncludedWithinAllOtherCountriesMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49160"
      unitRef="Unit_pure">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MinimumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49161"
      unitRef="Unit_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2023To09_30_2023_EachCountryMembersrtStatementGeographicalAxis_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_MaximumMembersrtRangeAxis_RevenueFromContractWithCustomerMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      id="ixv-49162"
      unitRef="Unit_pure">0.07</us-gaap:ConcentrationRiskPercentage1>
    <alur:NumberOfCountriesGenerateRevenueBySales
      contextRef="P01_01_2023To09_30_2023_AllOtherCountriesMembersrtStatementGeographicalAxis"
      decimals="INF"
      id="ixv-49163"
      unitRef="Unit_Country">58</alur:NumberOfCountriesGenerateRevenueBySales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P07_01_2024To09_30_2024_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49164"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="P01_01_2024To09_30_2024_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-49165"
      unitRef="Unit_USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30668">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,748&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory is stated net of $0.7&#160;million and less than $0.1&#160;million for the provision for excess and obsolete inventory as of September&#160;30, 2024 and December&#160;31, 2023, respectively. &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30677">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Inventory consists of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,748&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Work in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,005&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;967&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Raw materials&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Inventory&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,568&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,171&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49166"
      unitRef="Unit_USD">2748000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49167"
      unitRef="Unit_USD">3427000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49168"
      unitRef="Unit_USD">1005000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49169"
      unitRef="Unit_USD">967000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49170"
      unitRef="Unit_USD">815000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49171"
      unitRef="Unit_USD">1777000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49172"
      unitRef="Unit_USD">4568000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49173"
      unitRef="Unit_USD">6171000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn09_30_2024"
      decimals="-5"
      id="ixv-49174"
      unitRef="Unit_USD">700000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="PAsOn12_31_2023_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49175"
      unitRef="Unit_USD">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30790">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated Useful Life&lt;br/&gt; (in Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and purchased software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;Shorter&#160;of&#160;useful&#160;life&lt;br/&gt; or lease term&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Machinery and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,507&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;at cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,359&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(4,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense was $0.2&#160;million for each of the three months ended September&#160;30, 2024 and 2023, and $0.8&#160;million and $0.6&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, recorded as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sales and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total depreciation and amortization expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;558&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-30799">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated Useful Life&lt;br/&gt; (in Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computers and purchased software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;618&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;Shorter&#160;of&#160;useful&#160;life&lt;br/&gt; or lease term&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;291&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Machinery and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,507&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,893&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;at cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,359&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,745&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(4,169&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(3,559&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in progress&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,195&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&#x2014;net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,080&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-49176">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2024_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49177"
      unitRef="Unit_USD">618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputersAndPurchasedSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49178"
      unitRef="Unit_USD">618000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49179"
      unitRef="Unit_USD">1943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49180"
      unitRef="Unit_USD">1943000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="ixv-49181">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49182"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49183"
      unitRef="Unit_USD">291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis"
      id="ixv-49184">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis"
      id="ixv-49185">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2024_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49186"
      unitRef="Unit_USD">3507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_MachineryAndEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-49187"
      unitRef="Unit_USD">2893000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49188"
      unitRef="Unit_USD">6359000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49189"
      unitRef="Unit_USD">5745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49190"
      unitRef="Unit_USD">4169000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49191"
      unitRef="Unit_USD">3559000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <alur:ConstructionInProgress
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49192"
      unitRef="Unit_USD">890000</alur:ConstructionInProgress>
    <alur:ConstructionInProgress
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49193"
      unitRef="Unit_USD">1195000</alur:ConstructionInProgress>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49194"
      unitRef="Unit_USD">3080000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49195"
      unitRef="Unit_USD">3381000</us-gaap:PropertyPlantAndEquipmentNet>
    <alur:ScheduleOfDepreciationExpenseTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31050">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation expense was $0.2&#160;million for each of the three months ended September&#160;30, 2024 and 2023, and $0.8&#160;million and $0.6&#160;million for the nine months ended September&#160;30, 2024 and 2023, respectively, recorded as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:60%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;433&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;280&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;63&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sales and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total depreciation and amortization expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;558&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfDepreciationExpenseTableTextBlock>
    <us-gaap:Depreciation
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49196"
      unitRef="Unit_USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P07_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49197"
      unitRef="Unit_USD">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49198"
      unitRef="Unit_USD">800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2023To09_30_2023"
      decimals="-5"
      id="ixv-49199"
      unitRef="Unit_USD">600000</us-gaap:Depreciation>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49200"
      unitRef="Unit_USD">119000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49201"
      unitRef="Unit_USD">63000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49202"
      unitRef="Unit_USD">433000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49203"
      unitRef="Unit_USD">280000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49204"
      unitRef="Unit_USD">63000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49205"
      unitRef="Unit_USD">48000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49206"
      unitRef="Unit_USD">161000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49207"
      unitRef="Unit_USD">131000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49208"
      unitRef="Unit_USD">19000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49209"
      unitRef="Unit_USD">34000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49210"
      unitRef="Unit_USD">104000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49211"
      unitRef="Unit_USD">104000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49212"
      unitRef="Unit_USD">14000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49213"
      unitRef="Unit_USD">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49214"
      unitRef="Unit_USD">80000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023_SellingAndMarketingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49215"
      unitRef="Unit_USD">43000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49216"
      unitRef="Unit_USD">215000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49217"
      unitRef="Unit_USD">160000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49218"
      unitRef="Unit_USD">778000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49219"
      unitRef="Unit_USD">558000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31256">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accrued Expenses and Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketing reimbursement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trials and R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued selling and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued warranty&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued restructuring&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with strategic initiatives implemented during the year ended December&#160;31, 2023, the Company&#x2019;s management approved and initiated plans to reduce its cost structure. During the nine months ended September&#160;30, 2024, the Company recorded less than $0.1&#160;million in restructuring charges and paid $0.7&#160;million in restructuring charges. No restructuring charges were incurred or paid during the three months ended September&#160;30, 2024. &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31265">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses and other current liabilities consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Marketing reimbursement&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,733&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,687&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trials and R&amp;amp;D&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;81&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued selling and marketing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;592&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;493&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,505&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued warranty&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued restructuring&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,128&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,966&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15,495&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <alur:DistributorFeesAndMarketingReimbursements
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49220"
      unitRef="Unit_USD">930000</alur:DistributorFeesAndMarketingReimbursements>
    <alur:DistributorFeesAndMarketingReimbursements
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49221"
      unitRef="Unit_USD">2834000</alur:DistributorFeesAndMarketingReimbursements>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49222"
      unitRef="Unit_USD">1733000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49223"
      unitRef="Unit_USD">1687000</us-gaap:WorkersCompensationLiabilityCurrent>
    <alur:AccruedClinicalTrialsAndResearchAndDevelopment
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49224"
      unitRef="Unit_USD">81000</alur:AccruedClinicalTrialsAndResearchAndDevelopment>
    <alur:AccruedClinicalTrialsAndResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49225"
      unitRef="Unit_USD">3694000</alur:AccruedClinicalTrialsAndResearchAndDevelopment>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49226"
      unitRef="Unit_USD">592000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49227"
      unitRef="Unit_USD">1110000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49228"
      unitRef="Unit_USD">493000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49229"
      unitRef="Unit_USD">1505000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:StandardProductWarrantyAccrualCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49230"
      unitRef="Unit_USD">16000</us-gaap:StandardProductWarrantyAccrualCurrent>
    <us-gaap:StandardProductWarrantyAccrualCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49231"
      unitRef="Unit_USD">44000</us-gaap:StandardProductWarrantyAccrualCurrent>
    <alur:AccruedRestructuringCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49232"
      unitRef="Unit_USD">655000</alur:AccruedRestructuringCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49233"
      unitRef="Unit_USD">4128000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49234"
      unitRef="Unit_USD">3966000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49235"
      unitRef="Unit_USD">7973000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49236"
      unitRef="Unit_USD">15495000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:RestructuringCharges
      contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49237"
      unitRef="Unit_USD">100000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49238"
      unitRef="Unit_USD">700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="P07_01_2024To09_30_2024"
      decimals="INF"
      id="ixv-49239"
      unitRef="Unit_USD">0</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="P07_01_2024To09_30_2024"
      decimals="INF"
      id="ixv-49240"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31430">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s third-party debt consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fortress Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RTW Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amount of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus: Accretion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of long-term debt, net of discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: unamortized deferred financing costs and debt discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,605&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term debt, net of current portion and discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the fair value for the Company&#x2019;s Fortress Term Loan approximated the carrying amount. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Term Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2021, the Company entered into a loan and security agreement (as amended, the &#x201c;2021 Term Loan&#x201d; and the &#x201c;2021 Term Loan Agreement&#x201d;) with Runway Growth Credit Fund, Inc. (&#x201c;Runway&#x201d;) that provided for borrowings up to $25.0&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2021, the 2021 Term Loan Agreement was amended (the &#x201c;Amendment&#x201d;) to extend the maturity date of the 2021 Term Loan to December 30, 2025 and provide for an additional $20.0&#160;million of borrowings. In December 2021, the Company issued warrants exercisable for 132,979 shares of Legacy Allurion Series C preferred stock as consideration for the Amendment and the draw down related to the 2021 Term Loan Agreement. The fair value of these warrants was determined to be $0.3&#160;million upon issuance and are classified as a warrant liability on the condensed consolidated balance sheet as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;). Upon the closing of the Business Combination, these warrants were converted into warrants exercisable for 130,053 shares of Allurion Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2022, the 2021 Term Loan Agreement was amended to revise definitional terms for certain milestone events, the final payment amount and certain financial covenants. In September 2022, the 2021 Term Loan Agreement was further amended to, among other things, increase additional borrowing up to $15.0&#160;million. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;During June through December of 2022, the Company drew an additional $30.0&#160;million of the 2021 Term Loan and warrants exercisable for 88,440 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; preferred stock were issued. The fair value of these warrants was determined to be $0.8&#160;million upon issuance and are classified as a warrant liability on the consolidated balance sheets as of September&#160;30, 2024 and December&#160;31, 2023 (see Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;). Upon the closing of the Business Combination, the warrants exercisable for 88,440 shares of Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;D-1&lt;/div&gt; preferred stock were converted into warrants exercisable for 90,476 shares of Allurion Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, the 2021 Term Loan was paid off using the proceeds from the Fortress Term Loan (see below). The total payoff amount was $58.0&#160;million, consisting of $55.0&#160;million repayment of principal, a &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;$1.1&#160;million prepayment fee, and a $1.6&#160;million final payment fee. The prepayment fee was calculated as 2% of the outstanding principal balance as of August&#160;1, 2023. The final payment fee was calculated as the 3% of the outstanding principal balance as of August&#160;1, 2023 less the original final payment of $0.1&#160;million. The Company recorded a $3.9&#160;million loss on extinguishment of debt in connection with the 2021 Term Loan repayment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the three months ended September&#160;30, 2023 related to the 2021 Term Loan was $0.8&#160;million, consisting of $0.7&#160;million of contractual interest, and $0.1&#160;million of amortization of the debt discount, amortization of warrant, and term loan accretion. Interest expense for the nine months ended September&#160;30, 2023 related to the 2021 Term Loan was $5.0&#160;million, consisting of $4.7&#160;million of contractual interest, $0.1&#160;million amortization of the debt discount, $0.1&#160;million of amortization of the warrant, and $0.1&#160;million of term loan accretion. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fortress Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, the Company entered into the Fortress Term Loan pursuant to the Fortress Credit Agreement with Fortress that provided gross proceeds of $60&#160;million. The Fortress Term Loan had a maturity date of June 30, 2027 and accrued interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to 3.0% of the Fortress Term Loan (the &#x201c;Exit Fee&#x201d;) due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee. The Exit Fee is treated as additional interest expense and is accreted over the life of the loan using the effective interest method. Proceeds of the Fortress Term Loan were used, in part, to repay all amounts outstanding under the 2021 Term Loan. In connection with the issuance of the Fortress Term Loan, the Company paid issuance costs of $2.5&#160;million, which were recorded as a debt discount and will be amortized over the remaining life of the loan. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;29, 2023, the Company entered into an amendment to the Fortress Credit Agreement (the &#x201c;Fortress Amendment&#x201d;). The Fortress Amendment waived the December&#160;31, 2023 minimum revenue covenant under the Fortress Credit Agreement and modified the minimum liquidity covenant by increasing the minimum liquidity amount from $12.5&#160;million to $33.5&#160;million until March&#160;31, 2024, $23.5&#160;million from April&#160;1, 2024 to June&#160;30, 2024, $16.9&#160;million from July&#160;1, 2024 to September&#160;30, 2024 and $12.5&#160;million on October&#160;1, 2024 and thereafter. The Fortress Amendment also provided that at any time after March&#160;31, 2024, each lender had the right to convert a portion of the outstanding principal amount, not to exceed the lender&#x2019;s proportionate share of a maximum of $20.0&#160;million in aggregate outstanding principal amount, into shares of Allurion Common Stock at a conversion price based on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; volume weighted average price (&#x201c;VWAP&#x201d;) of Allurion Common Stock on the NYSE ending on the trading day immediately preceding the date of exercise of the lender&#x2019;s conversion right. As part of the Fortress Amendment, the Company prepaid $20.0&#160;million of the principal outstanding under the Fortress Credit Agreement. Additionally, $3.1&#160;million of fees were incurred and considered &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in-kind&lt;/div&gt;&lt;/div&gt; and capitalized as an additional debt discount and added to the outstanding principal amount of the loans under the Fortress Amendment. The fees were amortized through interest expense over the remaining life of the loan. The Fortress Amendment was accounted for as a modification under ASC 470, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt;. In connection with the modification and related prepayment, the Company wrote off $0.8&#160;million of the unamortized debt issuance costs, which was recorded within interest expense on the condensed consolidated statement of operations for the year ended December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assessed the terms and features of the Fortress Credit Agreement in order to identify any potential embedded features that would require bifurcation or any beneficial conversion features. The terms and features assessed include, under certain circumstances, a default interest rate of 3% that will apply to all outstanding obligations during the occurrence and continuance of an event of default. In accordance with ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 815&#x201d;), the Company concluded that this feature is not clearly and closely related to the host instrument and represents an embedded derivative (the &#x201c;Term Loan Derivative Liability&#x201d;) that is required to be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measured&lt;/div&gt; at fair value on a quarterly basis. At the inception of the Fortress Term Loan, the fair value of the embedded derivative was determined to be immaterial. The Term Loan Derivative Liability was &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;fair valued to zero in connection with the repayment of the Fortress Term Loan, with a corresponding $2.0&#160;million gain recorded in &lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127682733;display:inline;"&gt;other income, net&lt;/div&gt;&lt;/div&gt; in the condensed consolidated statement of operations for the three and nine months ended September&#160;30, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;16, 2024, the Company repaid all outstanding obligations under the Fortress Term Loan with proceeds from the Amended Note Purchase Agreement (as defined below) with RTW. The total payoff amount was $48.0&#160;million, consisting of $43.1&#160;million repayment of principal, a $2.7&#160;million prepayment fee, a $1.3&#160;million exit fee, $0.6&#160;million of other fees paid directly to Fortress, and $0.3&#160;million of accrued interest. The Company recorded an $8.7&#160;million loss on extinguishment of debt in connection with the Fortress Term Loan repayment in the condensed consolidated statement of operations for nine months ended September&#160;30, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the three and nine months ended September&#160;30, 2023 related to the Fortress Term Loan was $1.7&#160;million, consisting of $1.5&#160;million of contractual interest, $0.1&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. The average interest rate during the three months ended September&#160;30, 2023 was 14.94%. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for the nine months ended September&#160;30, 2024 related to the Fortress Term Loan was $2.3&#160;million, consisting of $1.9&#160;million of contractual interest, $0.3&#160;million amortization of the debt discount, and term loan accretion of $0.1&#160;million. There was no interest expense for the three months ended September&#160;30, 2024 due to the extinguishment of the Fortress Term Loan on April&#160;16, 2024. The average interest rate through April&#160;16, 2024 was 14.94%. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2021, the Company entered into a convertible note agreement with investors for gross proceeds of $2.0&#160;million with a stated interest rate of 5.0% per annum (the &#x201c;2021 Convertible Notes&#x201d;) and a maturity date 36 months from the date of issuance unless previously converted pursuant to their terms of the agreement. No issuance costs were incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2021 Convertible Notes provided that, effective upon either a Special Purpose Acquisition Company (i.e. &#x201c;deSPAC&#x201d;) transaction, closing of a qualified financing, or closing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-qualified&lt;/div&gt; financing, all of the outstanding principal and interest would automatically convert into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing in an amount equal to the balance of the 2021 Convertible Notes on the date of conversion divided by the capped conversion price, which is calculated by dividing $600.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2021 Convertible Notes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2021 Convertible Notes was less than $0.1&#160;million and $0.1&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2021 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2021 Convertible Notes were converted into an aggregate 133,617 shares of Allurion Common Stock with a corresponding recognition of APIC of $2.2&#160;million, and are no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2022 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In January 2022, the Company entered into a convertible note purchase agreement with investors for gross proceeds of $1.1&#160;million with a stated interest rate of 5.0% per annum (the &#x201c;2022 Convertible Notes&#x201d;). The 2022 Convertible Notes were to mature 36 months from the issuance date unless previously converted pursuant to the terms of the agreement. Issuance costs were de minimis. The 2022 Convertible Notes had the same terms as the 2021 Convertible Notes. &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2022 Convertible Notes was less than $0.1&#160;million, consisting entirely of contractual interest. Interest expense related to the 2022 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. On August&#160;1, 2023, in connection with the closing of the Business Combination, the outstanding 2022 Convertible Notes were converted into an aggregate 83,216 shares of Allurion Common Stock with a corresponding recognition of APIC of $1.2&#160;million, and are no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Between February and August 2023, the Company entered into a convertible note purchase agreement, and related side letters, for the sale of convertible notes (the &#x201c;2023 Convertible Notes&#x201d;) to certain investors for gross proceeds of $28.7&#160;million, with a stated interest rate of 7.0% per annum. The 2023 Convertible Notes provided that they would mature on December 31, 2026 unless previously converted pursuant to the terms of the note purchase agreement. The 2023 Convertible Notes also provided that, effective upon a deSPAC transaction, all of the outstanding principal and interest would automatically convert into a number of shares of Legacy Allurion common stock equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the discounted capped conversion price, which is calculated by dividing $217.3&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Additionally, the 2023 Convertible Notes provided that, effective upon the closing of a qualified financing, holders of the 2023 Convertible Notes could optionally accelerate repayment of the principal and interest of the 2023 Convertible Notes or convert all of the outstanding principal and interest into shares of Legacy Allurion common stock or shares of the same class or series of capital stock issued in the qualified financing equal to the balance of the 2023 Convertible Notes on the date of conversion divided by the greater of the capped price or the discounted price. The capped price is calculated by dividing $260.0&#160;million by the fully diluted capitalization of the Company immediately prior to the conversion of the 2023 Convertible Notes, and the discounted price is calculated as 85% of the cash price of the same class or series of capital stock issued in the qualified financing. The 2023 Convertible Notes are accounted for under the fair FVO election of ASC 825 as the notes contain embedded derivatives, including the automatic conversion upon a deSPAC transaction prior to the deSPAC deadline, voluntary conversion upon a qualified financing, automatic repayment upon a sale event, and conversion rate adjustment, which would require bifurcation and separate accounting. These convertible notes are initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Interest expense for each of the three and nine months ended September&#160;30, 2023 related to the 2023 Convertible Notes was $0.1&#160;million and $0.5&#160;million, respectively, consisting entirely of contractual interest. Interest expense related to the 2023 Convertible Notes is recorded within Interest expense on the condensed consolidated statement of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;2, 2023 the Company entered into termination agreements (the &#x201c;Termination Agreements&#x201d;) with respect to side letters entered into with certain holders of the 2023 Convertible Notes. With respect to the Termination Agreement with HVL, the Company had the right to prepay, in one or more transactions, all or a portion of the outstanding principal amount, plus accrued interest, under such holder&#x2019;s 2023 Convertible Note (the &#x201c;HVL Bridge Note&#x201d;), including by way of (a)&#160;a $2&#160;million payment in cash by the Company to HVL on May&#160;2, 2023, $1.5&#160;million of which was deemed a prepayment penalty and recorded as other expense on the income statement, with the remaining $0.5&#160;million recorded as a reduction of the principal amount, (b)&#160;immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement, an additional payment of at least $6&#160;million, up to the then-outstanding principal amount, plus accrued interest, under the HVL Bridge Note by way of (i)&#160;payment in cash by the Company and/or (ii)&#160;the sale and transfer of all or any portion of the HVL Bridge Note, equivalent in value to the portion of the additional payment to be repaid pursuant to this clause (b)(ii), to any person or persons designated in writing by the Company. The Termination Agreements were accounted for as a modification of debt and the modified &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;convertible notes continued to be accounted for under the FVO with any change in fair value recognized in other expense on the income statement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, under the Termination Agreement executed with HVL, the Company agreed to issue to HVL a number of shares of Allurion Common Stock (&#x201c;PubCo Additional Shares&#x201d;) equal to (a)&#160;the outstanding principal and accrued interest under the HVL Bridge Note immediately prior to the consummation of the transactions contemplated by the Business Combination Agreement (after giving effect to the payment of the repayments) divided by $5.00, plus (b) 300,000 shares of Allurion Common Stock. The PubCo Additional Shares were accounted for as a freestanding financing liability. The liability for the PubCo Additional Shares was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period, with changes in fair value reflected in earnings until the PubCo Additional Shares were issued. A $3.4&#160;million liability was recorded at issuance for the PubCo Additional Shares as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, HVL was issued 387,696 PubCo Additional Shares with a corresponding recognition of APIC of $2.7&#160;million, and the liability is no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Further on May&#160;2, 2023, RTW and Fortress as the Backstop Purchasers entered into the Backstop Agreement with the Company, Legacy Allurion and HVL. Pursuant to the Backstop Agreement, each Backstop Purchaser agreed that to the extent any HVL Bridge Notes remained outstanding prior to the consummation of the Business Combination, such Backstop Purchaser would, at the closing of the Business Combination, purchase up to $2.0&#160;million of the HVL Bridge Notes from HVL in exchange for shares of Allurion Common Stock (the &#x201c;Base PubCo Shares&#x201d;, &#x201c;Backstop Shares&#x201d; and &#x201c;Conditional Additional PubCo Shares&#x201d;). The Base PubCo Shares and Backstop Shares were accounted for as a freestanding financing liability. The Base PubCo Shares and Backstop Shares liability was initially measured at its issue-date estimated fair value and subsequently remeasured at fair value at each reporting period with changes in fair value reflected in earnings until the Base PubCo Shares and Backstop Shares were issued. A $3.3&#160;million liability was recorded at issuance for the Base PubCo Shares and Backstop Shares liability as Other liabilities on the balance sheet. On August&#160;1, 2023, upon closing of the Business Combination, per the terms of the Fortress Term Loan, the Amended and Restated RTW Side Letter and Backstop Agreement, the Backstop Purchasers were each issued 950,000 shares of Allurion Common Stock with a corresponding recognition of APIC of $13.4&#160;million, and the liability is no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;1, 2023, immediately prior to the closing of the Business Combination, the Company repaid $6.3&#160;million of the HVL Bridge Note, leaving a principal balance of $6.3&#160;million. Each Backstop Purchaser then purchased $2.0&#160;million principal amount of the outstanding portion of the HVL Bridge Note, Allurion canceled the existing HVL Bridge Note and issued a new convertible note to HVL for the remaining balance together with all unpaid interest accrued since the date of issuance of $2.7&#160;million, Allurion issued convertible notes to each Backstop Purchaser with an issuance date of the Closing Date (August 1, 2023) and an original principal amount of $2.0&#160;million each, and Allurion issued 700,000 shares of Allurion Common Stock to each Backstop Purchaser. Additionally, the outstanding 2023 Convertible Notes were converted into an aggregate 3,084,389 shares of Allurion Common Stock with a corresponding recognition of APIC of $22.2&#160;million, and are no longer outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;RTW Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On April&#160;14, 2024, the Company entered into a note purchase agreement (the &#x201c;Original Note Purchase Agreement&#x201d;) with RTW as agent for the purchasers (the &#x201c;Purchasers&#x201d;) party thereto from time to time (RTW in such capacity, the &#x201c;Principal Purchaser&#x201d;), and Acquiom Agency Services LLC (&#x201c;Acquiom&#x201d;) as collateral agent for the Purchasers. Subsequently, on April&#160;16, 2024, the Company, the Principal Purchaser, the Purchasers, and Acquiom entered into the First Amendment to the Original Note Purchase Agreement (the Original Note Purchase Agreement as amended, the &#x201c;Amended Note Purchase Agreement&#x201d;). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Amended Note Purchase Agreement, the Company issued and sold $48.0&#160;million of convertible senior secured notes (the &#x201c;RTW Convertible Notes&#x201d;). The RTW Convertible Notes bear interest at an &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;annual rate of 6%, which interest is paid quarterly in cash or, at the Company&#x2019;s option, in kind for the first three years. The RTW Convertible Notes will mature on April 16, 2031 unless previously converted pursuant to the terms of the Amended Note Purchase Agreement. The RTW Convertible Notes are convertible into shares of Allurion Common Stock, at a Purchaser&#x2019;s election at any time after the earliest of (i)&#160;the date on which Stockholder Approval (as defined below) is obtained, (ii)&#160;December&#160;31, 2025, (iii) the date of a Fundamental Change Company Notice (as defined in the Amended Note Purchase Agreement), and (iv)&#160;the Make-Whole Fundamental Change Effective Date (as defined in the Amended Note Purchase Agreement), subject to certain terms and limitations in the Amended Note Purchase Agreement, based on a conversion rate of 617.2840 shares of common stock per $1,000 principal amount of Notes (equivalent to a conversion price of approximately $1.62 per share, which represents a 35% premium to the lowest price per share in an equity financing for capital raising purposes ending on the date on which the Company has raised aggregate gross offering proceeds of at least $15,000,000 (the &#x201c;Next Equity Financing&#x201d;). On July&#160;1, 2024, we consummated the Public Offering, as described elsewhere in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;10-Q,&lt;/div&gt; which constituted a Next Equity Financing. The Amended Note Purchase Agreement provides that unless and until requisite approval of the Company&#x2019;s stockholders is obtained (&#x201c;Stockholder Approval&#x201d;), the Company will not deliver Allurion Common Stock upon conversion of the RTW Convertible Notes in excess of 1% of the number of shares of Allurion Common Stock outstanding as of April&#160;14, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The RTW Convertible Notes are accounted for under the FVO election of ASC 825 as the notes contain embedded derivatives, including the conversion upon Stockholder Approval, the conversion upon a Fundamental Change Company Notice, the conversion upon a Make-Whole Fundamental Change, redemption upon the event of default, and redemption upon a Fundamental Change, which would require bifurcation and separate accounting. The RTW Convertible Notes were initially measured at their issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes at issuance was $49.1&#160;million, with a corresponding $1.1&#160;million loss recognized in Other income, net in the condensed consolidated statement of operations. In connection with the issuance of the RTW Convertible Notes and RIFA Amendment (as defined below), we incurred $1.4&#160;million in issuance costs, which were directly expensed through general and administrative expense due to the FVO election of the RTW Convertible Notes and Revenue Interest Financing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three months ended September&#160;30, 2024, the Company recorded gains of $1.8&#160;million and $3.1&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded gains of $10.0&#160;million and $3.0&#160;million through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Amended Note Purchase Agreement contains financial maintenance covenants, which require (i)&#160;the Company maintain not less than $12,500,000 in unrestricted cash in controlled accounts in the U.S. at all times, (ii)&#160;the Company to receive minimum trailing twelve-month consolidated revenue at amounts designated in the Amended Note Purchase Agreement, tested quarterly beginning with the twelve-month period ending March&#160;31, 2025, and (iii)&#160;the Company&#x2019;s and its subsidiaries&#x2019; consolidated business operations outside the United States to be profitable for the trailing three-month period, tested quarterly beginning with the three-month period ending December&#160;31, 2025. The Company is in compliance with the covenants in the Amended Note Purchase Agreement as of September&#160;30, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company elected paid in kind interest for the three and nine months ended September&#160;30, 2024 related to the RTW Convertible Notes. &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31439">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the Company&#x2019;s third-party debt consist of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fortress Term Loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RTW Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total principal amount of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,320&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,230&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Plus: Accretion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of long-term debt, net of discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(38,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: unamortized deferred financing costs and debt discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,605&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term debt, net of current portion and discounts&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-3"
      id="ixv-49241"
      unitRef="Unit_USD">43100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-3"
      id="ixv-49242"
      unitRef="Unit_USD">49320000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49243"
      unitRef="Unit_USD">49320000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49244"
      unitRef="Unit_USD">43100000</us-gaap:DebtInstrumentCarryingAmount>
    <alur:ChangeInFairValueOfDebt
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49245"
      unitRef="Unit_USD">13230000</alur:ChangeInFairValueOfDebt>
    <alur:LoanAccretion
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49246"
      unitRef="Unit_USD">148000</alur:LoanAccretion>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49247"
      unitRef="Unit_USD">38643000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49248"
      unitRef="Unit_USD">-4605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49249"
      unitRef="Unit_USD">36090000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn03_31_2021_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49250"
      unitRef="Unit_USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      id="ixv-49251">2025-12-30</us-gaap:LineOfCreditFacilityExpirationDate1>
    <alur:AdditionalBorrowings
      contextRef="PAsOn12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49252"
      unitRef="Unit_USD">20000000</alur:AdditionalBorrowings>
    <alur:ExercisableWarrantsIssuedAsConsideration
      contextRef="P12_01_2021To12_31_2021_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_LegacyAllurionSeriesCPreferredStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49253"
      unitRef="Unit_shares">132979</alur:ExercisableWarrantsIssuedAsConsideration>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49254"
      unitRef="Unit_USD">300000</alur:FairValueOfTheWarrants>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49255"
      unitRef="Unit_USD">300000</alur:FairValueOfTheWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49256"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:AdditionalBorrowings
      contextRef="PAsOn09_30_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49257"
      unitRef="Unit_USD">15000000</alur:AdditionalBorrowings>
    <alur:AdditionalBorrowings
      contextRef="PAsOn12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49258"
      unitRef="Unit_USD">30000000</alur:AdditionalBorrowings>
    <alur:ExercisableWarrantsIssuedAsConsideration
      contextRef="P06_01_2022To12_31_2022_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermCLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49259"
      unitRef="Unit_shares">88440</alur:ExercisableWarrantsIssuedAsConsideration>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn09_30_2024_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49260"
      unitRef="Unit_USD">800000</alur:FairValueOfTheWarrants>
    <alur:FairValueOfTheWarrants
      contextRef="PAsOn12_31_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49261"
      unitRef="Unit_USD">800000</alur:FairValueOfTheWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_SeriesD1PreferredStockMemberusgaapStatementClassOfStockAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49262"
      unitRef="Unit_shares">88440</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn08_01_2023_AmendedTwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_CommonStockMemberusgaapStatementClassOfStockAxis_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TermDLoanMemberusgaapCreditFacilityAxis"
      decimals="INF"
      id="ixv-49263"
      unitRef="Unit_shares">90476</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49264"
      unitRef="Unit_USD">58000000</us-gaap:RepaymentsOfLinesOfCredit>
    <alur:RepaymentOfPrincipal
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49265"
      unitRef="Unit_USD">55000000</alur:RepaymentOfPrincipal>
    <alur:PrepaymentFee
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49266"
      unitRef="Unit_USD">1100000</alur:PrepaymentFee>
    <alur:FinalPaymentFee
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49267"
      unitRef="Unit_USD">1600000</alur:FinalPaymentFee>
    <alur:PrepaymentFeePercentage
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-49268"
      unitRef="Unit_pure">0.02</alur:PrepaymentFeePercentage>
    <alur:FinalPaymentFeePercentage
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-49269"
      unitRef="Unit_pure">0.03</alur:FinalPaymentFeePercentage>
    <alur:OriginalFinalPayment
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49270"
      unitRef="Unit_USD">100000</alur:OriginalFinalPayment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P08_01_2023To08_01_2023_RunwayGrowthCreditFundIncMemberusgaapLineOfCreditFacilityAxis_TwoThousandTwentyOneTermLoanAgreementMemberusgaapDebtInstrumentAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49271"
      unitRef="Unit_USD">-3900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49272"
      unitRef="Unit_USD">800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49273"
      unitRef="Unit_USD">700000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49274"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49275"
      unitRef="Unit_USD">5000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49276"
      unitRef="Unit_USD">4700000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49277"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:AmortizationOfTheWarrant
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49278"
      unitRef="Unit_USD">100000</alur:AmortizationOfTheWarrant>
    <alur:TermLoanAccretion
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyOneTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49279"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-6"
      id="ixv-49280"
      unitRef="Unit_USD">60000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis"
      id="ixv-49281">The Fortress Term Loan had a maturity date of June 30, 2027 and accrued interest per annum at a rate of 6.44% plus the greater of (i)&#160;the Wall Street Journal Prime Rate and (ii) 3.0%, which interest was payable in arrears on a monthly basis. The Fortress Term Loan provided for an exit payment equal to 3.0% of the Fortress Term Loan (the &#x201c;Exit Fee&#x201d;) due upon prepayment or the maturity date of the Fortress Term Loan, in addition to any early prepayment fee.</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      id="ixv-49282">2027-06-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P08_01_2023To08_31_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-49283"
      unitRef="Unit_pure">0.0644</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-49284"
      unitRef="Unit_pure">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <alur:DebtInstrumentExitPaymentPercentage
      contextRef="P08_01_2023To08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="3"
      id="ixv-49285"
      unitRef="Unit_pure">0.03</alur:DebtInstrumentExitPaymentPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49286"
      unitRef="Unit_USD">2500000</us-gaap:DeferredFinanceCostsGross>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49287"
      unitRef="Unit_USD">12500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_UntilMarch312024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-49288"
      unitRef="Unit_USD">33500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromApril12024ToJune302024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-49289"
      unitRef="Unit_USD">23500000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_FromJuly12024ToSeptember302024MembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-49290"
      unitRef="Unit_USD">16900000</alur:MinimumLiquidityAmount>
    <alur:MinimumLiquidityAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_OnOctober12024AndThereafterMembersrtStatementScenarioAxis"
      decimals="-5"
      id="ixv-49291"
      unitRef="Unit_USD">12500000</alur:MinimumLiquidityAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_29_2023_CommonStockMemberusgaapStatementClassOfStockAxis_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49292"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49293"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49294"
      unitRef="Unit_USD">3100000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_29_2023_FortressAmendmentMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49295"
      unitRef="Unit_USD">800000</us-gaap:DeferredFinanceCostsNet>
    <alur:DebtInstrumentDefaultInterestRate
      contextRef="PAsOn08_01_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-49296"
      unitRef="Unit_pure">0.03</alur:DebtInstrumentDefaultInterestRate>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="PAsOn09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-6"
      id="ixv-49297"
      unitRef="Unit_USD">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49298"
      unitRef="Unit_USD">2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49299"
      unitRef="Unit_USD">48000000</us-gaap:RepaymentsOfLinesOfCredit>
    <alur:RepaymentOfPrincipal
      contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49300"
      unitRef="Unit_USD">43100000</alur:RepaymentOfPrincipal>
    <alur:PrepaymentFee
      contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49301"
      unitRef="Unit_USD">2700000</alur:PrepaymentFee>
    <alur:DebtInstrumentExitFee
      contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49302"
      unitRef="Unit_USD">1300000</alur:DebtInstrumentExitFee>
    <us-gaap:PaymentsForFees
      contextRef="P04_16_2024To04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49303"
      unitRef="Unit_USD">600000</us-gaap:PaymentsForFees>
    <us-gaap:InterestReceivable
      contextRef="PAsOn04_16_2024_FortressTermLoanMemberusgaapCreditFacilityAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49304"
      unitRef="Unit_USD">300000</us-gaap:InterestReceivable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2024To09_30_2024_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49305"
      unitRef="Unit_USD">-8700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49306"
      unitRef="Unit_USD">1700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49307"
      unitRef="Unit_USD">1700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49308"
      unitRef="Unit_USD">1500000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49309"
      unitRef="Unit_USD">1500000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49310"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49311"
      unitRef="Unit_USD">100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:TermLoanAccretion
      contextRef="P01_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49312"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <alur:TermLoanAccretion
      contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49313"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P07_01_2023To09_30_2023_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-49314"
      unitRef="Unit_pure">0.1494</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49315"
      unitRef="Unit_USD">2300000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49316"
      unitRef="Unit_USD">1900000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49317"
      unitRef="Unit_USD">300000</us-gaap:AmortizationOfDebtDiscountPremium>
    <alur:TermLoanAccretion
      contextRef="P01_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-49318"
      unitRef="Unit_USD">100000</alur:TermLoanAccretion>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2024To09_30_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="-6"
      id="ixv-49319"
      unitRef="Unit_USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="P01_01_2024To04_16_2024_FortressCreditAgreementMemberusgaapDebtInstrumentAxis_FortressTermLoanMemberusgaapCreditFacilityAxis"
      decimals="4"
      id="ixv-49320"
      unitRef="Unit_pure">0.1494</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49321"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49322"
      unitRef="Unit_pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-49323">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49324"
      unitRef="Unit_USD">0</us-gaap:DeferredFinanceCostsNet>
    <alur:ConversionDividedByCappedConversionPrice
      contextRef="P12_01_2021To12_31_2021_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49325"
      unitRef="Unit_USD">600000000</alur:ConversionDividedByCappedConversionPrice>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49326"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49327"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49328"
      unitRef="Unit_shares">133617</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49329"
      unitRef="Unit_USD">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49330"
      unitRef="Unit_USD">1100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49331"
      unitRef="Unit_pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="P01_01_2022To01_31_2022_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-49332">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49333"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49334"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49335"
      unitRef="Unit_shares">83216</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyTwoConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49336"
      unitRef="Unit_USD">1200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49337"
      unitRef="Unit_USD">28700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49338"
      unitRef="Unit_pure">0.07</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyOneConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-49339">2026-12-31</us-gaap:DebtInstrumentMaturityDate>
    <alur:ConversionDividedByDiscountedCappedConversionPrice
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49340"
      unitRef="Unit_USD">217300000</alur:ConversionDividedByDiscountedCappedConversionPrice>
    <alur:CappedPrice
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49341"
      unitRef="Unit_USD">260000000</alur:CappedPrice>
    <alur:PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice
      contextRef="P02_01_2023To08_31_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49342"
      unitRef="Unit_pure">0.85</alur:PercentageOfConversionDiscountedPriceIsCalculatedOfCashPrice>
    <us-gaap:InterestExpenseDebt
      contextRef="P07_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49343"
      unitRef="Unit_USD">100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="P01_01_2023To09_30_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49344"
      unitRef="Unit_USD">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-49345"
      unitRef="Unit_USD">2000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49346"
      unitRef="Unit_USD">1500000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <alur:RepaymentOfPrincipal
      contextRef="P08_01_2023To08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49347"
      unitRef="Unit_USD">500000</alur:RepaymentOfPrincipal>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-49348"
      unitRef="Unit_USD">6000000</us-gaap:RepaymentsOfConvertibleDebt>
    <alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49349"
      unitRef="Unit_USD">5</alur:DebtInstrumentConvertiblePriceForCalculatingEquitySecurities>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49350"
      unitRef="Unit_shares">300000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <alur:DeferredLiabilityForIssuanceOfAdditionalShares
      contextRef="PAsOn05_02_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49351"
      unitRef="Unit_USD">3400000</alur:DeferredLiabilityForIssuanceOfAdditionalShares>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49352"
      unitRef="Unit_shares">387696</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49353"
      unitRef="Unit_USD">2700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P05_02_2023To05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-49354"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <alur:DeferredLiabilityForIssuanceOfAdditionalShares
      contextRef="PAsOn05_02_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49355"
      unitRef="Unit_USD">3300000</alur:DeferredLiabilityForIssuanceOfAdditionalShares>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49356"
      unitRef="Unit_shares">950000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementClassOfStockAxis_FortressTermLoanMemberusgaapCreditFacilityAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49357"
      unitRef="Unit_USD">13400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49358"
      unitRef="Unit_USD">6300000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49359"
      unitRef="Unit_USD">6300000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49360"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_HVLBridgeNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49361"
      unitRef="Unit_USD">2700000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49362"
      unitRef="Unit_USD">2000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_BackstopAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49363"
      unitRef="Unit_shares">700000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49364"
      unitRef="Unit_shares">3084389</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="P08_01_2023To08_01_2023_CommonStockMemberusgaapStatementClassOfStockAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      id="ixv-49365"
      unitRef="Unit_USD">22200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49366"
      unitRef="Unit_USD">48000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-49367"
      unitRef="Unit_pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="P04_14_2024To04_14_2024_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      id="ixv-49368">2031-04-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      id="ixv-49369"
      unitRef="Unit_pure">617.284</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <alur:DebtInstrumentPrincipalAmountForConversionIntoCommonStock
      contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-49370"
      unitRef="Unit_USD">1000</alur:DebtInstrumentPrincipalAmountForConversionIntoCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-49371"
      unitRef="Unit_USD_per_Share">1.62</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <alur:DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger
      contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      id="ixv-49372"
      unitRef="Unit_pure">0.35</alur:DebtInstrumentConvertiblePremiumPercentageOfStockPriceTrigger>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      id="ixv-49373"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromConvertibleDebt>
    <alur:DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding
      contextRef="P04_14_2024To04_14_2024_CommonStockMemberusgaapStatementClassOfStockAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="INF"
      id="ixv-49374"
      unitRef="Unit_pure">0.01</alur:DebInstrumentConvertibleMaximumLimitationPercentageOfSharesOfCommonStockOutstanding>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49375"
      unitRef="Unit_USD">49100000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49376"
      unitRef="Unit_USD">1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49377"
      unitRef="Unit_USD">1400000</us-gaap:DeferredFinanceCostsGross>
    <alur:ChangesInFairValueOfRevenueInterestFinancing
      contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49378"
      unitRef="Unit_USD">1800000</alur:ChangesInFairValueOfRevenueInterestFinancing>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P07_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49379"
      unitRef="Unit_USD">3100000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <alur:ChangesInFairValueOfRevenueInterestFinancing
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49380"
      unitRef="Unit_USD">10000000</alur:ChangesInFairValueOfRevenueInterestFinancing>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      id="ixv-49381"
      unitRef="Unit_USD">3000000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <alur:UnrestrictedCash
      contextRef="PAsOn04_14_2024_MaximumMembersrtRangeAxis_NotePurchaseAgreementMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49382"
      unitRef="Unit_USD">12500000</alur:UnrestrictedCash>
    <alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31789">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Interest Financing, Side Letter, and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;9, 2023, Legacy Allurion entered into the Revenue Interest Financing Agreement. Pursuant to the Revenue Interest Financing, at the closing of the Business Combination, RTW paid Allurion an aggregate of &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;$40.0&#160;million Investment Amount. In exchange for the Investment Amount, Allurion will remit revenue interest payments on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries at a rate up to 6.0% of annual net sales prior to December&#160;31, 2026. On or after January&#160;1, 2027, the Company will remit revenue interest payments at a rate up to 10.0% of annual net sales, and it will continue to make revenue interest payments to RTW until December&#160;31, 2030. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;If RTW has not received aggregate revenue interest payments equal to at least 100% of the Investment Amount by December&#160;31, 2027, the Company must make a cash payment in an amount sufficient to catch RTW up to 100% of the Investment Amount. If RTW has not received revenue interest payments equal to at least 240% of the Investment Amount by December&#160;31, 2030, the Company must make a cash payment in an amount sufficient to catch RTW up to 240% of the Investment Amount. In any event, RTW shall not receive aggregated revenue interest payments in excess of 260% of the Investment Amount (the &#x201c;Hard Cap&#x201d;). In addition, prior to December&#160;31, 2025, the Company may prepay a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;pre-specified&lt;/div&gt; payment amount (the &#x201c;Prepayment Amount&#x201d;) and terminate the Revenue Interest Financing Agreement. The Prepayment Amount shall be an amount equal to 165% of the Investment Amount less the sum of all revenue interest payments made to RTW prior to such date of prepayment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Revenue Interest Financing is accounted for under the FVO election of ASC 825 as the Revenue Interest Financing contains embedded derivatives, including the requirements to settle the Revenue Interest Financing prior to maturity upon the occurrence of certain contingent events and our ability to prepay the Revenue Interest Financing, which would require bifurcation and separate accounting. The Revenue Interest Financing was initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. Changes in fair value are recorded as a component of Other income (expense) in the condensed consolidated statements of operations. A portion of the estimated change in fair value must be reported in other comprehensive loss to the extent that it is attributable to instrument-specific credit risk. In connection with the issuance of the Investment Amount, we paid $1.2&#160;million in issuance costs in August 2023, which were directly expensed through general and administrative expense due to the FVO election. As of September&#160;30, 2024, the Company has made $3.6&#160;million in royalty payments to RTW. Refer to Note 10, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;, for additional information regarding the changes in fair value of the Revenue Interest Financing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Concurrently, and in connection with the Amended Note Purchase Agreement, the Revenue Interest Financing Agreement was amended pursuant to the Omnibus Amendment (the &#x201c;RIFA Amendment&#x201d;) by and among the Company, Allurion Opco, Allurion Australia Pty Ltd, a proprietary limited company organized under the laws of Australia and a wholly-owned subsidiary of the Company, the Original RIFA Investors (as defined therein) and RTW, on April&#160;14, 2024. The RIFA Amendment, among other things, increased the rate of revenue interest payments to be paid to RTW on all current and future products, digital solutions and services developed, imported, manufactured, marketed, offered for sale, promoted, sold, tested or otherwise distributed by Allurion and its subsidiaries for net sales less than or equal to $100&#160;million prior to December&#160;31, 2026 from 6% to 12% and increased the rate on net sales in less than or equal to $100&#160;million on or after January&#160;1, 2027 from 10% to 12%. Additionally, the Prepayment Amount was modified such that, prior to March&#160;31, 2026, the Company is entitled to settle the Revenue Interest Financing for a prepayment amount that would allow the investors to yield a 20% internal rate of return. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Company entering into the Revenue Interest Financing, if, at any time beginning 12 months and ending 24 months following the closing of the Mergers, the VWAP per share of Allurion Common Stock is less than $7.04 for the average of 20 trading days within any 30 trading day period (&#x201c;Stock Price Drop&#x201d;); and the absolute value of the percentage decrease of such Stock Price Drop measured from a reference price of $10.00 per share of Allurion Common Stock is greater than the absolute value of the percentage decrease in the VWAP of a comparable publicly traded peer index as defined in the Amended and Restated RTW Side Letter over the same time period, then RTW may elect to convert up to $7.5&#160;million of its initial PIPE Investment into &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;additional revenue interest financing to be added to the Investment Amount by forfeiting a number of shares of Allurion Common Stock acquired in the PIPE Investment. Such additions to the Investment Amount would result in proportional increases to the minimum aggregate revenue interest payments described above. The PIPE Conversion Option is accounted for as a derivative under ASC 815. The PIPE Conversion Option was initially measured at its issue-date estimated fair value of $3.3&#160;million within Other liabilities on the condensed consolidated balance sheets with corresponding recognition of expense at inception as there is no right received by the Company that meets the definition of an asset and the transaction did not involve a distribution or a dividend. The PIPE Conversion Option liability is subsequently remeasured at its estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The RIFA Amendment was accounted for as a modification with the change in fair value of the PIPE Conversion Option treated as an exchange between the Company and RTW as part of the RIFA Amendment. As such, the Revenue Interest Financing and PIPE Conversion Option were remeasured as of April&#160;16, 2024 just prior to the RIFA Amendment, to $33.0&#160;million and $6.6&#160;million, respectively. The Revenue Interest Financing and PIPE Conversion Option were subsequently remeasured as of April&#160;16, 2024 under the terms of the RIFA Amendment, to $39.0&#160;million and $4.6&#160;million, respectively. As of September&#160;30, 2024, the fair value of the Revenue Interest Financing and PIPE Conversion Option were $38.5&#160;million and $9.9&#160;million, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the three months ended September&#160;30, 2024, the Company recorded a $6.7&#160;million loss and a $5.8&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. For the nine months ended September&#160;30, 2024, the Company recorded a $5.4&#160;million loss and a $0.6&#160;million gain on the Revenue Interest Financing through the condensed consolidated statements of operations and other comprehensive income (loss), respectively. The changes in fair value were recorded in the Changes in fair value of Revenue Interest Financing and PIPE Conversion Option in the condensed consolidated statement of operations. &lt;/div&gt;</alur:RevenueInterestFinancingSideLetterAndPIPEConversionOptionTextBlock>
    <alur:RevenuesInterestFinancingLiability
      contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49385"
      unitRef="Unit_USD">40000000</alur:RevenuesInterestFinancingLiability>
    <alur:PercentageOfAnnualNetSales
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-49386"
      unitRef="Unit_pure">0.06</alur:PercentageOfAnnualNetSales>
    <alur:RemittanceOfRevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="3"
      id="ixv-49387"
      unitRef="Unit_pure">0.10</alur:RemittanceOfRevenueInterestPaymentsPercentage>
    <alur:RevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-49388"
      unitRef="Unit_pure">1</alur:RevenueInterestPaymentsPercentage>
    <alur:CashPaymentsPercentage
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanOneMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49389"
      unitRef="Unit_pure">1</alur:CashPaymentsPercentage>
    <alur:RevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49390"
      unitRef="Unit_pure">2.40</alur:RevenueInterestPaymentsPercentage>
    <alur:CashPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_ScenarioPlanTwoMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49391"
      unitRef="Unit_pure">2.40</alur:CashPaymentsPercentage>
    <alur:RevenueInterestPaymentsPercentage
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-49392"
      unitRef="Unit_pure">2.60</alur:RevenueInterestPaymentsPercentage>
    <alur:PrePaymentsPercentage
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-49393"
      unitRef="Unit_pure">1.65</alur:PrePaymentsPercentage>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="PAsOn08_01_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49394"
      unitRef="Unit_USD">1200000</us-gaap:DeferredFinanceCostsGross>
    <alur:RoyaltyPayments
      contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49395"
      unitRef="Unit_USD">3600000</alur:RoyaltyPayments>
    <alur:SalesRevenueNet
      contextRef="P12_30_2026To12_30_2026_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-6"
      id="ixv-49396"
      unitRef="Unit_USD">100000000</alur:SalesRevenueNet>
    <alur:PercentageOfNetSales
      contextRef="P12_30_2026To12_30_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49397"
      unitRef="Unit_pure">0.06</alur:PercentageOfNetSales>
    <alur:PercentageOfNetSales
      contextRef="P12_31_2026To12_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49398"
      unitRef="Unit_pure">0.12</alur:PercentageOfNetSales>
    <alur:IncreaseInSalesRevenueNet
      contextRef="P01_01_2027To01_01_2027_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="-6"
      id="ixv-49399"
      unitRef="Unit_USD">100000000</alur:IncreaseInSalesRevenueNet>
    <alur:PercentageOfIncreaseInNetSales
      contextRef="P01_01_2027To01_01_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49400"
      unitRef="Unit_pure">0.10</alur:PercentageOfIncreaseInNetSales>
    <alur:PercentageOfIncreaseInNetSales
      contextRef="P01_02_2027To01_02_2027_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49401"
      unitRef="Unit_pure">0.12</alur:PercentageOfIncreaseInNetSales>
    <alur:PercentageOfInternalRateOfReturn
      contextRef="PAsOn03_31_2026_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis_ScenarioForecastMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49402"
      unitRef="Unit_pure">0.20</alur:PercentageOfInternalRateOfReturn>
    <alur:VolumeWeightedAveragePricePerShare
      contextRef="PAsOn02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-49403"
      unitRef="Unit_USD_per_Share">7.04</alur:VolumeWeightedAveragePricePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P02_09_2023To02_09_2023_MinimumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49404"
      unitRef="Unit_Days">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="P02_09_2023To02_09_2023_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49405"
      unitRef="Unit_Days">30</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:SharePrice
      contextRef="PAsOn02_09_2023_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-49406"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <alur:ConversionOfPipeInvestmentToRevenueInterestFinance
      contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49407"
      unitRef="Unit_USD">7500000</alur:ConversionOfPipeInvestmentToRevenueInterestFinance>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn08_01_2023_PIPEConversionOptionMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49410"
      unitRef="Unit_USD">3300000</us-gaap:DebtInstrumentFairValue>
    <alur:RevenueInterestFinancingAgreementRemeasuredValue
      contextRef="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49411"
      unitRef="Unit_USD">33000000</alur:RevenueInterestFinancingAgreementRemeasuredValue>
    <alur:PipeConversionOptionRemeasuredValue
      contextRef="PAsOn04_16_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49412"
      unitRef="Unit_USD">6600000</alur:PipeConversionOptionRemeasuredValue>
    <alur:RevenueInterestFinancingAgreementRemeasuredValue
      contextRef="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49413"
      unitRef="Unit_USD">39000000</alur:RevenueInterestFinancingAgreementRemeasuredValue>
    <alur:PipeConversionOptionRemeasuredValue
      contextRef="PAsOn04_17_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49414"
      unitRef="Unit_USD">4600000</alur:PipeConversionOptionRemeasuredValue>
    <alur:FairValueOfRevenueInterestFinancingAgreements
      contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49415"
      unitRef="Unit_USD">38500000</alur:FairValueOfRevenueInterestFinancingAgreements>
    <alur:FairValueOfPipeConversionOption
      contextRef="PAsOn09_30_2024_RevenueInterestFinancingAgreementAmendmentMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49416"
      unitRef="Unit_USD">9900000</alur:FairValueOfPipeConversionOption>
    <alur:ChangesInFairValueOfRevenueInterestFinancing
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49417"
      unitRef="Unit_USD">6700000</alur:ChangesInFairValueOfRevenueInterestFinancing>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49418"
      unitRef="Unit_USD">5800000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <alur:ChangesInFairValueOfRevenueInterestFinancing
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49419"
      unitRef="Unit_USD">5400000</alur:ChangesInFairValueOfRevenueInterestFinancing>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49420"
      unitRef="Unit_USD">600000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31846">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present the fair value hierarchy for the Company&#x2019;s assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of September&#160;30, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Offering Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RTW Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term Loan Derivative Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Public Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result of the Business Combination on August&#160;1, 2023, the Company recorded a liability for Public Warrants to purchase the Company&#x2019;s Common Stock. The Public Warrants are traded on the NYSE and are recorded at fair value using the closing price as September&#160;30, 2024 of $0.04, which is a Level&#160;1 input. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legacy Allurion Warrants, Public Offering Warrants, and Private Placement Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), and Private Placement Warrants (defined below) within Level&#160;3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, and Private Placement Warrants: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value&#160;of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy&#160;Allurion&#160;Series&#160;C&#160;Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30,&#160;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.65%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Other Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.59%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3.65%&#160;-&lt;/div&gt;&lt;br/&gt; 3.71%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;6.5&#160;-&#160;7.96&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Offering Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.58%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.58%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value&#160;of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series&#160;C Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31,&#160;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Other Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;7.25&#160;-&#160;8.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Expected dividend yield for all calculations is 0.00%. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the changes in fair value for the three and nine months ended September&#160;30, 2024 and 2023 of the warrant liabilities valued using Level&#160;3 inputs: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:37%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&#160;Offering&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&#160;Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127681126;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at issuance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,827&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127681127;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div&gt;&lt;/div&gt;&lt;div&gt; &lt;div style="line-height:normal;display: inline;"&gt;  &lt;/div&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&#160;Offering&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&#160;Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680849;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(647&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,827&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680850;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(587&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;2019 Term Loan Success Fee Derivative Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The derivative liability for the success fee associated with Legacy Allurion&#x2019;s November 2019 loan and security agreement with Western Alliance Bank (the &#x201c;2019 Term Loan&#x201d; and such fee, the &#x201c;Success Fee&#x201d;) was recorded at fair value as of September&#160;30, 2024 and December&#160;31, 2023 using the following assumptions: weighted-average probability for the likelihood of a change in control or liquidity event within four years from the initial valuation date of the derivative liability and a market-based discount rate that will increase or decrease each period based on changes in the probability in the future cash flows. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;2023 Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The 2023 Convertible Notes were accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;re-measured&lt;/div&gt; at estimated fair value on a recurring basis at each reporting period date. The fair value was measured as of August&#160;1, 2023, just prior to the conversion of the 2023 Convertible Notes, using the share price at conversion ($7.04 per share). Upon the conversion of the 2023 Convertible Notes, the convertible note liability was derecognized. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Revenue Interest Financing and PIPE Conversion Option &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Revenue Interest Financing is accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently remeasured at estimated fair value on a recurring basis at each reporting period date. The fair value of the Revenue Interest Financing was remeasured as of September&#160;30, 2024 and December&#160;31, 2023 using a discounted cash flow (&#x201c;DCF&#x201d;) method under the income approach utilizing future revenue projections and a discount rate of 23.5% and 24.4%, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method (&#x201c;MCSM&#x201d;) using the number of shares convertible of 1,065,341 and the following assumptions: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon the closing of the Business Combination, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares were accounted for as a liability because the triggering events that determine the number of shares to be earned included events that were not indexed to Allurion Common Stock, with the change in fair value recognized in Change in the fair value of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;earn-out&lt;/div&gt; liabilities in the consolidated statement of operations. The estimated fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares was determined using a MCSM with the following assumptions at each valuation date: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Term Loan Derivative Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Term Loan derivative liability associated with the Fortress Term Loan was derecognized during the second quarter of 2024 as the Fortress Term Loan was repaid on April&#160;16, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RTW Convertible Notes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The RTW Convertible Notes are accounted for using the FVO election. Under the FVO election, the financial instrument is initially measured at its issue-date estimated fair value and subsequently measured at estimated fair value on a recurring basis at each reporting period date. The fair value of the RTW Convertible Notes was remeasured as of September&#160;30, 2024 using a DCF method under the income approach with a MCSM applied to determine the simulated stock price at each payment date and event that may trigger conversion of the RTW Convertible Notes. The fair value was measured using the $48.0&#160;million principal amount of the RTW Convertible Notes and the following assumptions: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; liability, Term Loan Derivative liability, RTW Convertible Notes, PubCo Share liability, Base PubCo and Backstop Share liability, and Warrant Overallotment Liability categorized with Level&#160;3 inputs for the three and nine months ended September&#160;30, 2024 and 2023 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:29%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RTW&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,305&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(599&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,704&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,790&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131,714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,581&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:26%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RTW&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,590&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The change in fair value of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; liability, Term Loan Derivative liability, RTW Convertible &lt;div style="display:inline;"&gt;Not&lt;/div&gt;es, Pubco Share liability, and Base PubCo and Backstop Share liability at each period is recorded as a component of Other income (expense) in the condensed consolidated statements of operations, with the exception of the changes in fair value associated with the change in credit risk related to the Revenue Interest Financing and RTW Convertible Notes, which is recorded as a component of other comprehensive loss. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-31855">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following tables present the fair value hierarchy for the Company&#x2019;s assets and liabilities that are measured at fair value at issuance date and on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of September&#160;30, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Offering Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RTW Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt; margin-top:0pt; margin-bottom:0pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:51%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="16" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurement as of December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;Carrying&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash equivalents&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Money market funds&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;30,582&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Common Stock Warrant Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue Interest Financing&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PIPE Conversion Option&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term Loan Derivative Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Success Fee Derivative Liability&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total Liabilities&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,463&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,943&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;68,520&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-49421"
      unitRef="Unit_USD">23749000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-49422"
      unitRef="Unit_USD">23749000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49423"
      unitRef="Unit_USD">23749000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49424"
      unitRef="Unit_USD">23749000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49425"
      unitRef="Unit_USD">71000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49426"
      unitRef="Unit_USD">71000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49427"
      unitRef="Unit_USD">531000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49428"
      unitRef="Unit_USD">531000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49429"
      unitRef="Unit_USD">5970000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49430"
      unitRef="Unit_USD">5970000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49431"
      unitRef="Unit_USD">810000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49432"
      unitRef="Unit_USD">810000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49433"
      unitRef="Unit_USD">38500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49434"
      unitRef="Unit_USD">38500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49435"
      unitRef="Unit_USD">9850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49436"
      unitRef="Unit_USD">9850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49437"
      unitRef="Unit_USD">1850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49438"
      unitRef="Unit_USD">1850000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49439"
      unitRef="Unit_USD">36090000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RtwConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49440"
      unitRef="Unit_USD">36090000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49441"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49442"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49443"
      unitRef="Unit_USD">93686000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49444"
      unitRef="Unit_USD">531000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49445"
      unitRef="Unit_USD">93155000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-49447"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      id="ixv-49448"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49449"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49450"
      unitRef="Unit_USD">30582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49451"
      unitRef="Unit_USD">821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_LegacyAllurionCommonStockWarrantLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49452"
      unitRef="Unit_USD">821000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49453"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PublicWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49454"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49455"
      unitRef="Unit_USD">36200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_RevenueInterestFinancingMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49456"
      unitRef="Unit_USD">36200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49457"
      unitRef="Unit_USD">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_PIPEConversionOptionMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49458"
      unitRef="Unit_USD">5600000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49459"
      unitRef="Unit_USD">23990000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49460"
      unitRef="Unit_USD">23990000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49461"
      unitRef="Unit_USD">1895000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49462"
      unitRef="Unit_USD">1895000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49463"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_DerivativeLiabilitySuccessFeeMemberusgaapFairValueByLiabilityClassAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49464"
      unitRef="Unit_USD">14000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_CarryingReportedAmountFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49465"
      unitRef="Unit_USD">74463000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49466"
      unitRef="Unit_USD">5943000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      id="ixv-49467"
      unitRef="Unit_USD">68520000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      id="ixv-49468"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:SharePrice>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-32743"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has classified the Legacy Allurion Common Stock Warrants, Public Offering Warrants (defined below), and Private Placement Warrants (defined below) within Level&#160;3 of the hierarchy as the fair value is derived using the Black-Scholes option pricing model, which uses a combination of observable (Level 2) and unobservable (Level 3) inputs. See table below for the assumptions used in the pricing model of the Legacy Allurion Common Stock Warrants, Public Offering Warrants, and Private Placement Warrants: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value&#160;of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy&#160;Allurion&#160;Series&#160;C&#160;Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30,&#160;2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.65%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Other Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.59%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;3.65%&#160;-&lt;/div&gt;&lt;br/&gt; 3.71%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;br/&gt; &#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;6.5&#160;-&#160;7.96&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Offering Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.58%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;September&#160;30, 2024&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.58%&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Measurement&#160;Date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;br/&gt; Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Fair&lt;br/&gt; Value&#160;of&lt;br/&gt; Underlying&#160;Share&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&lt;br/&gt; Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected&#160;Life&lt;br/&gt; (Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Series&#160;C Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31,&#160;2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.25&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion Other Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.95&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legacy Allurion &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;D-1&lt;/div&gt; Preferred Stock warrants (as converted to Common)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;December&#160;31, 2023&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;7.25&#160;-&#160;8.71&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49470"
      unitRef="Unit_pure">0.0365</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49471"
      unitRef="Unit_pure">6.73</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49472"
      unitRef="Unit_pure">0.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49473"
      unitRef="Unit_pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49474">P6Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49475"
      unitRef="Unit_pure">0.0359</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49476"
      unitRef="Unit_pure">1.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49477"
      unitRef="Unit_pure">0.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49478"
      unitRef="Unit_pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49479">P2Y11M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49480"
      unitRef="Unit_pure">0.0365</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49481"
      unitRef="Unit_pure">0.0371</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49482"
      unitRef="Unit_pure">12.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49483"
      unitRef="Unit_pure">0.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49484"
      unitRef="Unit_pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49485">P6Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49486">P7Y11M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49487"
      unitRef="Unit_pure">0.0358</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49488"
      unitRef="Unit_pure">1.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49489"
      unitRef="Unit_pure">0.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49490"
      unitRef="Unit_pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49491">P4Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49492"
      unitRef="Unit_pure">0.0358</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49493"
      unitRef="Unit_pure">1.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49494"
      unitRef="Unit_pure">0.61</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49495"
      unitRef="Unit_pure">0.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49496">P4Y9M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49497"
      unitRef="Unit_pure">0.0388</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49498"
      unitRef="Unit_pure">6.73</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49499"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49500"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesCPreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49501">P7Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49502"
      unitRef="Unit_pure">0.0395</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49503"
      unitRef="Unit_pure">1.05</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49504"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49505"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionOtherCommonStockMemberusgaapStatementEquityComponentsAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49506">P3Y8M8D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="4"
      id="ixv-49507"
      unitRef="Unit_pure">0.0388</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49508"
      unitRef="Unit_pure">12.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49509"
      unitRef="Unit_pure">3.74</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputPriceVolatilityMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49510"
      unitRef="Unit_pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49511">P7Y3M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_LegacyAllurionSeriesD1PreferredStockWarrantsMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      id="ixv-49512">P8Y8M15D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2023_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49513"
      unitRef="Unit_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn09_30_2024_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_MeasurementInputExpectedDividendRateMemberusgaapMeasurementInputTypeAxis_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      id="ixv-49514"
      unitRef="Unit_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-33103"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table reconciles the changes in fair value for the three and nine months ended September&#160;30, 2024 and 2023 of the warrant liabilities valued using Level&#160;3 inputs: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:37%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&#160;Offering&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&#160;Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,679&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,351&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,030&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127681126;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(555&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,126&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;35&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at issuance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,827&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127681127;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,121&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div&gt;&lt;/div&gt;&lt;div&gt; &lt;div style="line-height:normal;display: inline;"&gt;  &lt;/div&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Preferred&#160;Stock&#160;Warrants&lt;br/&gt; (as&#160;converted&#160;to&#160;Common)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Common&#160;Stock&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public&#160;Offering&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&#160;Placement&lt;br/&gt; Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,777&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,373&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680849;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(647&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise of warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(589&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(929&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;715&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;922&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;179&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;821&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value at issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,670&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14,827&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="-sec-ix-hidden:hidden127680850;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(587&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(163&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(7,187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,797&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,970&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49515"
      unitRef="Unit_USD">2679000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49516"
      unitRef="Unit_USD">1351000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023"
      decimals="-3"
      id="ixv-49517"
      unitRef="Unit_USD">4030000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49518"
      unitRef="Unit_USD">-1571000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49519"
      unitRef="Unit_USD">-555000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49520"
      unitRef="Unit_USD">-2126000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49521"
      unitRef="Unit_USD">-53000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49522"
      unitRef="Unit_USD">0</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49523"
      unitRef="Unit_USD">-53000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49524"
      unitRef="Unit_USD">-340000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49525"
      unitRef="Unit_USD">-589000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49526"
      unitRef="Unit_USD">-929000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49527"
      unitRef="Unit_USD">715000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49528"
      unitRef="Unit_USD">207000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      id="ixv-49529"
      unitRef="Unit_USD">922000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49530"
      unitRef="Unit_USD">110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49531"
      unitRef="Unit_USD">35000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024"
      decimals="-3"
      id="ixv-49532"
      unitRef="Unit_USD">145000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49533"
      unitRef="Unit_USD">13157000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49534"
      unitRef="Unit_USD">1670000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49535"
      unitRef="Unit_USD">14827000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49536"
      unitRef="Unit_USD">-55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49537"
      unitRef="Unit_USD">-19000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49538"
      unitRef="Unit_USD">-7187000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49539"
      unitRef="Unit_USD">-860000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49540"
      unitRef="Unit_USD">-8121000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49541"
      unitRef="Unit_USD">55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49542"
      unitRef="Unit_USD">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49543"
      unitRef="Unit_USD">5970000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49544"
      unitRef="Unit_USD">810000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49545"
      unitRef="Unit_USD">6851000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49546"
      unitRef="Unit_USD">1777000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49547"
      unitRef="Unit_USD">596000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-49548"
      unitRef="Unit_USD">2373000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49549"
      unitRef="Unit_USD">-647000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49550"
      unitRef="Unit_USD">200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49551"
      unitRef="Unit_USD">-447000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49552"
      unitRef="Unit_USD">-75000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49553"
      unitRef="Unit_USD">-75000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExerciseOfWarrants>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49554"
      unitRef="Unit_USD">-340000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49555"
      unitRef="Unit_USD">-589000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49556"
      unitRef="Unit_USD">-929000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49557"
      unitRef="Unit_USD">715000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49558"
      unitRef="Unit_USD">207000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      id="ixv-49559"
      unitRef="Unit_USD">922000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49560"
      unitRef="Unit_USD">642000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49561"
      unitRef="Unit_USD">179000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-49562"
      unitRef="Unit_USD">821000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49563"
      unitRef="Unit_USD">13157000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49564"
      unitRef="Unit_USD">1670000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49565"
      unitRef="Unit_USD">14827000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49566"
      unitRef="Unit_USD">-587000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49567"
      unitRef="Unit_USD">-163000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49568"
      unitRef="Unit_USD">-7187000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49569"
      unitRef="Unit_USD">-860000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49570"
      unitRef="Unit_USD">-8797000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PreferredStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49571"
      unitRef="Unit_USD">55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_CommonStockWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-49572"
      unitRef="Unit_USD">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicOfferingWarrantsMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49573"
      unitRef="Unit_USD">5970000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PrivatePlacementWarrantsMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-49574"
      unitRef="Unit_USD">810000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49575"
      unitRef="Unit_USD">6851000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <alur:FairValueAssumptionsOfLiquidityEventTerm
      contextRef="P01_01_2024To09_30_2024_TwoThousandNineteenTermLoanAndSuccessFeeMemberusgaapDebtInstrumentAxis"
      id="ixv-49576">P4Y</alur:FairValueAssumptionsOfLiquidityEventTerm>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="PAsOn08_01_2023_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49577"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn09_30_2024_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="1"
      id="ixv-49578"
      unitRef="Unit_pure">23.5</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn12_31_2023_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="1"
      id="ixv-49579"
      unitRef="Unit_pure">24.4</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      id="ixv-34051">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of the PIPE Conversion Option was accounted for as a derivative under ASC 815. The instrument is measured using a Monte Carlo Simulation Method (&#x201c;MCSM&#x201d;) using the number of shares convertible of 1,065,341 and the following assumptions: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;130.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;82.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <alur:FairValueOfEstimatedNumberOfShares
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="0"
      id="ixv-49580"
      unitRef="Unit_shares">1065341</alur:FairValueOfEstimatedNumberOfShares>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49581"
      unitRef="Unit_USD_per_Share">0.61</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49582"
      unitRef="Unit_USD_per_Share">3.74</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-49583"
      unitRef="Unit_pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="4"
      id="ixv-49584"
      unitRef="Unit_pure">0.0446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      id="ixv-49585">P0Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      id="ixv-49586">P1Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To09_30_2024_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49587"
      unitRef="Unit_pure">1.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_RevenueInterestFinancingAndPipeConversionOptionMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49588"
      unitRef="Unit_pure">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      id="ixv-34146">The estimated fair value of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares was determined using a MCSM with the following assumptions at each valuation date: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:14%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;87.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49590"
      unitRef="Unit_USD_per_Share">0.61</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49591"
      unitRef="Unit_USD_per_Share">3.74</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49592"
      unitRef="Unit_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49593"
      unitRef="Unit_pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      id="ixv-49594">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      id="ixv-49595">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49596"
      unitRef="Unit_pure">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49597"
      unitRef="Unit_pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-49598">The fair value was measured using the $48.0&#160;million principal amount of the RTW Convertible Notes and the following assumptions: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:18%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;90.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      id="ixv-49599"
      unitRef="Unit_USD">48000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="2"
      id="ixv-49600"
      unitRef="Unit_USD_per_Share">0.61</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49601"
      unitRef="Unit_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      id="ixv-49602">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To09_30_2024_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="3"
      id="ixv-49603"
      unitRef="Unit_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      id="ixv-34291">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The changes in the fair values of the Success Fee derivative liability, 2023 Convertible Notes, Revenue Interest Financing, PIPE Conversion Option, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-out&lt;/div&gt; liability, Term Loan Derivative liability, RTW Convertible Notes, PubCo Share liability, Base PubCo and Backstop Share liability, and Warrant Overallotment Liability categorized with Level&#160;3 inputs for the three and nine months ended September&#160;30, 2024 and 2023 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:29%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RTW&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,327&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,305&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,150&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;105,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,008&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(599&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,065&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,357&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; June&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,450&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,950&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89,524&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,704&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,790&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,054&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,070&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(8,870&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,404&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;178&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,340&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,264&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131,714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(166&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,751&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,400&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,330&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(642&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,106&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(12,581&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Derecognition of liability to equity&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,701&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,728&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(13,370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(37,799&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,440&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;28,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70,762&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:26%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Success&lt;br/&gt; Fee&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue&lt;br/&gt; Interest&lt;br/&gt; Financing&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PIPE&lt;br/&gt; Conversion&lt;br/&gt; Derivative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt;&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Term&lt;br/&gt; Loan&lt;br/&gt; Derivative&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RTW&lt;br/&gt; Convertible&lt;br/&gt; Notes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PubCo&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Base&lt;br/&gt; PubCo&#160;&amp;amp;&lt;br/&gt; Backstop&lt;br/&gt; Share&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; January&#160;1, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,200&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value upon issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;49,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,358&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(22,140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,895&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(10,020&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(24,447&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in fair value &#x2013; OCI&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(600&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,990&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,590&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Repayments of debt&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,458&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Balance &#x2013; September&#160;30, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;38,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,850&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;36,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49605"
      unitRef="Unit_USD">213000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49606"
      unitRef="Unit_USD">16793000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49607"
      unitRef="Unit_USD">3327000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49608"
      unitRef="Unit_USD">3305000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49609"
      unitRef="Unit_USD">23638000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49610"
      unitRef="Unit_USD">9150000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49611"
      unitRef="Unit_USD">40000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49612"
      unitRef="Unit_USD">3340000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49613"
      unitRef="Unit_USD">53040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49614"
      unitRef="Unit_USD">105530000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49615"
      unitRef="Unit_USD">-201000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49616"
      unitRef="Unit_USD">6008000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49617"
      unitRef="Unit_USD">-3400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49618"
      unitRef="Unit_USD">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49619"
      unitRef="Unit_USD">-24330000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49620"
      unitRef="Unit_USD">-599000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49621"
      unitRef="Unit_USD">10065000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49622"
      unitRef="Unit_USD">-10357000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49623"
      unitRef="Unit_USD">-10250000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49624"
      unitRef="Unit_USD">-10250000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49625"
      unitRef="Unit_USD">-21701000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49626"
      unitRef="Unit_USD">-2728000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49627"
      unitRef="Unit_USD">-13370000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P07_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49628"
      unitRef="Unit_USD">-37799000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49629"
      unitRef="Unit_USD">12000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49630"
      unitRef="Unit_USD">36600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49631"
      unitRef="Unit_USD">5440000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49632"
      unitRef="Unit_USD">28710000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49633"
      unitRef="Unit_USD">70762000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49634"
      unitRef="Unit_USD">14000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49635"
      unitRef="Unit_USD">39000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49636"
      unitRef="Unit_USD">5450000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49637"
      unitRef="Unit_USD">4110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49638"
      unitRef="Unit_USD">40950000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49639"
      unitRef="Unit_USD">89524000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49640"
      unitRef="Unit_USD">6704000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49641"
      unitRef="Unit_USD">4400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49642"
      unitRef="Unit_USD">-2260000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49643"
      unitRef="Unit_USD">-1790000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49644"
      unitRef="Unit_USD">7054000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49645"
      unitRef="Unit_USD">-5800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49646"
      unitRef="Unit_USD">-3070000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49647"
      unitRef="Unit_USD">-8870000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49648"
      unitRef="Unit_USD">-1404000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P07_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49649"
      unitRef="Unit_USD">-1404000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49650"
      unitRef="Unit_USD">14000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49651"
      unitRef="Unit_USD">38500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49652"
      unitRef="Unit_USD">9850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49653"
      unitRef="Unit_USD">1850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49654"
      unitRef="Unit_USD">36090000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49655"
      unitRef="Unit_USD">86304000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49656"
      unitRef="Unit_USD">178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49657"
      unitRef="Unit_USD">178000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49658"
      unitRef="Unit_USD">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49659"
      unitRef="Unit_USD">40000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49660"
      unitRef="Unit_USD">3340000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49661"
      unitRef="Unit_USD">53040000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49662"
      unitRef="Unit_USD">3370000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49663"
      unitRef="Unit_USD">3264000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49664"
      unitRef="Unit_USD">131714000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49665"
      unitRef="Unit_USD">-166000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49666"
      unitRef="Unit_USD">3751000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49667"
      unitRef="Unit_USD">-3400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49668"
      unitRef="Unit_USD">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49669"
      unitRef="Unit_USD">-24330000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49670"
      unitRef="Unit_USD">-642000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49671"
      unitRef="Unit_USD">10106000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49672"
      unitRef="Unit_USD">-12581000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49673"
      unitRef="Unit_USD">-10750000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49674"
      unitRef="Unit_USD">-10750000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49675"
      unitRef="Unit_USD">-21701000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_PubcoShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49676"
      unitRef="Unit_USD">-2728000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_BasePubcoAndBackstopShareLiabilityMemberusgaapFairValueByLiabilityClassAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49677"
      unitRef="Unit_USD">-13370000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability
      contextRef="P01_01_2023To09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49678"
      unitRef="Unit_USD">-37799000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49679"
      unitRef="Unit_USD">12000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49680"
      unitRef="Unit_USD">36600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49681"
      unitRef="Unit_USD">5440000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49682"
      unitRef="Unit_USD">28710000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49683"
      unitRef="Unit_USD">70762000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49685"
      unitRef="Unit_USD">14000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49686"
      unitRef="Unit_USD">36200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49687"
      unitRef="Unit_USD">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49688"
      unitRef="Unit_USD">23990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49689"
      unitRef="Unit_USD">1895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2023_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49690"
      unitRef="Unit_USD">67699000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49691"
      unitRef="Unit_USD">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49692"
      unitRef="Unit_USD">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49693"
      unitRef="Unit_USD">5358000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49694"
      unitRef="Unit_USD">4250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49695"
      unitRef="Unit_USD">-22140000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49696"
      unitRef="Unit_USD">-1895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49697"
      unitRef="Unit_USD">-10020000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49698"
      unitRef="Unit_USD">-24447000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49699"
      unitRef="Unit_USD">-600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49700"
      unitRef="Unit_USD">-2990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49701"
      unitRef="Unit_USD">-3590000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49702"
      unitRef="Unit_USD">-2458000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt
      contextRef="P01_01_2024To09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49703"
      unitRef="Unit_USD">-2458000</alur:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityRepaymentOfDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_SuccessFeeDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49704"
      unitRef="Unit_USD">14000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RevenueInterestFinancingMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49705"
      unitRef="Unit_USD">38500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PipeConversionDerivativeMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49706"
      unitRef="Unit_USD">9850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_EarnOutLiabilityMemberusgaapDebtInstrumentAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49707"
      unitRef="Unit_USD">1850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_TermLoanDerivativeLiabilityMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      id="ixv-49708"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis_RtwConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      id="ixv-49709"
      unitRef="Unit_USD">36090000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn09_30_2024_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      id="ixv-49710"
      unitRef="Unit_USD">86304000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-36041">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded income tax expense of $0.1&#160;million and $0.2&#160;million for the three and nine months ended September&#160;30, 2024, respectively, representing effective tax rates of (0.8%) and (3.9%), respectively. The Company recorded income tax expense for the three and nine months ended September&#160;30, 2023 of less than $0.1&#160;million and $0.1&#160;million, respectively, representing effective tax rates of (0.2%) and (0.1%), respectively. The tax expense recorded relates to the earnings of the Company&#x2019;s profitable foreign subsidiaries. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2024 and 2023, the Company maintained a full valuation allowance against its net deferred tax assets as the Company has incurred significant operating losses since inception and has concluded that its net deferred tax asset is not &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;more-likely-than-not&lt;/div&gt; realizable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2024 and 2023, the Company has not recorded tax reserves for any uncertain tax provisions. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49711"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-49712"
      unitRef="Unit_USD">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2024To09_30_2024"
      decimals="3"
      id="ixv-49713"
      unitRef="Unit_pure">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To09_30_2024"
      decimals="3"
      id="ixv-49714"
      unitRef="Unit_pure">-0.039</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P07_01_2023To09_30_2023_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49715"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49716"
      unitRef="Unit_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P07_01_2023To09_30_2023"
      decimals="3"
      id="ixv-49717"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To09_30_2023"
      decimals="3"
      id="ixv-49718"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-49719"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn09_30_2023"
      decimals="-3"
      id="ixv-49720"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <alur:RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-36055">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Redeemable Convertible Preferred Stock and Stockholders&#x2019; Deficit &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;28, 2024, the Company entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) with RTW, pursuant to which the Company agreed to sell to RTW 2,260,159 shares of a newly created series of preferred stock, the Series A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-voting&lt;/div&gt; convertible preferred stock, par value $0.0001 per share (&#x201c;Series A Preferred Stock&#x201d;), and 2,260,159 private placement warrants (&#x201c;Private Placement Warrants&#x201d;) to purchase common stock, equal to the per share Public Offering (defined below) price for the shares of common stock and Public Offering Warrants (defined below) in the Public Offering (the &#x201c;Private Placement&#x201d;). The Private Placement closed on July&#160;1, 2024 with net proceeds received of $2.5&#160;million after deducting offering costs of $0.2&#160;million. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Private Placement Warrants met the definition of a derivative under ASC 815. The gross proceeds from the Private Placement were first allocated to the Private Placement Warrants based on its issue-date estimated fair value of $1.7&#160;million. The Private Placement Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The remaining gross proceeds of $1.0&#160;million were allocated to the Series A Preferred Stock. Of the $0.2&#160;million in offering costs, $0.1&#160;million was recorded against the Series A Preferred Stock as a reduction of proceeds and $0.1&#160;million was expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Allurion Certificate of Incorporation authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of September&#160;30, 2024, 2,260,159 shares of Allurion Series A Preferred Stock were outstanding. The rights and preferences of the Series A Preferred Shares are as follows: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Series A Preferred Stockholders have no voting rights. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividend Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Series A Preferred Stock participates in dividends with Common Stock on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;as-converted&lt;/div&gt; basis when declared by the Board of Directors. No dividends were declared through September&#160;30, 2024. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Preference &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the event of any voluntary or involuntary liquidation, dissolution, or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;winding-up&lt;/div&gt; of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder&#x2019;s Series A&#160;Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each share of Series A Preferred Stock is convertible after the date that the Company&#x2019;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#x201c;Series A Stockholder Approval&#x201d;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;(ii)&#160;pre-funded&lt;/div&gt; conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.&lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each share of Series A&#160;Preferred Stock outstanding on December&#160;31, 2026 (the &#x201c;Redemption Date&#x201d;) shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the &#x201c;Redemption Price&#x201d;). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Allurion Certificate of Incorporation authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of September&#160;30, 2024 and December&#160;31, 2023, 64,369,381 and 47,688,096 shares of Common Stock were outstanding, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;28, 2024, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with Jefferies LLC and TD Securities (USA) LLC, as representative of the several underwriters (the &#x201c;Underwriters&#x201d;), pursuant to which the Company agreed to issue and sell 14,406,508 shares of the Company&#x2019;s Common Stock and warrants (&#x201c;Public Offering Warrants&#x201d;) to purchase up to 14,406,508 shares of the Company&#x2019;s Common Stock at an offering price of $1.20 per share and accompanying warrant (the &#x201c;Public Offering&#x201d;). The Public Offering closed on July&#160;1, 2024 with net proceeds received of $15.2&#160;million after deducting underwriting discounts of $1.0&#160;million and offering costs of $1.0&#160;million. The Underwriters fully exercised their option for additional Public Offering Warrants, with 2,160,976 additional Public Offering Warrants issued at closing, for a total of 16,567,484 Public Offering Warrants. Further, the Underwriters exercised a portion of the option with respect to the Common Stock (the &#x201c;Share Overallotment&#x201d;) on July&#160;5, 2024 for net proceeds of $2.2&#160;million, which resulted in the issuance of 1,927,265 shares of the Company&#x2019;s Common Stock at an offering price of $1.20 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Public Offering Warrants met the definition of a derivative under ASC 815 and the Share Overallotment met the requirements for equity classification under ASC 815. The $17.4&#160;million in net proceeds from the Public Offering and exercise of the Share Overallotment were first allocated to the Public Offering Warrants based on their issue-date estimated fair value of $13.2&#160;million. The Public Offering Warrants are subsequently remeasured at their estimated fair value on a recurring basis at each reporting period date, with a gain or loss recognized within Other income (expense). The $0.8&#160;million offerings costs allocated to the Public Offering Warrants were expensed as general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. The remaining net proceeds of $5.1&#160;million were allocated to Common Stock and APIC. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company&#x2019;s securities as of September&#160;30, 2024, is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,108,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;530,778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,231,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares of Common Stock issued upon the exercise of Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260,159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;479,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,369,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Warrants to Purchase Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of September&#160;30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock. &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td style="width:36%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying&#160;Equity&#160;Instrument&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common&#160;Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;7/1/2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;18,827,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,231,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td style="width:34%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying&#160;Equity&#160;Instrument&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In Compute Health&#x2019;s initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class&#160;A Common Stock, $0.0001 par value, of Compute Health (&#x201c;Class A Common Stock&#x201d;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden127682683;display:inline;"&gt;one-half&lt;/div&gt;&lt;/div&gt; of a redeemable warrant (each a &#x201c;Public Warrant&#x201d;) that entitled the holder to purchase one share of Class&#160;A Common Stock of CPUH at a price of $11.50 per share. On July&#160;26, 2023, Compute Health&#x2019;s Public Warrant holders approved an amendment (the &#x201c;Warrant Amendment&#x201d;) to the warrant agreement that governed all Compute Health&#x2019;s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 1.420455 shares of the Company&#x2019;s Common Stock at an exercise price of $8.10 per share and each whole Compute Health Public Warrant was exchanged for 0.6125 Allurion Public Warrants in the Business Combination. The Public Warrants will expire August&#160;1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may redeem the outstanding Public Warrants for cash at a price of $0.01 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price the Company&#x2019;s Common Stock equals or exceeds $12.67 per share of any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; trading period ending on the third trading day prior to the date on which notice of redemption is given. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $0.10 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company&#x2019;s Common Stock equals or exceeds $7.04 per share of any &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;30-day&lt;/div&gt; trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the &#x201c;Redemption Fair Market Value&#x201d;) of the shares of the Company&#x2019;s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company&#x2019;s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of September&#160;30, 2024, the Company has not redeemed any of the outstanding Public Warrants. As of September&#160;30, 2024, there were 13,206,720 outstanding Public Warrants exercisable for 18,759,554 shares of Allurion Common Stock. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Chardan Equity Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;18, 2023, we entered into a ChEF Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) and a Registration Rights Agreement, each with Chardan Capital Markets (&#x201c;Chardan&#x201d;) related to a &#x201c;ChEF,&#x201d; Chardan&#x2019;s committed equity facility (the &#x201c;Chardan Equity Facility&#x201d;). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000&#160;in aggregate gross purchase price of newly issued shares of the Company&#x2019;s Common Stock, and (ii) 9,482,468 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the &#x201c;Exchange Cap&#x201d;). In consideration for Chardan&#x2019;s entry into the Purchase Agreement, Allurion issued to Chardan 35,511 shares of Allurion Common Stock (the &#x201c;Commitment Shares&#x201d;). The Company recorded $0.1&#160;million to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;paid-in&lt;/div&gt; capital and $0.1&#160;million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1&#160;million related to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-refundable&lt;/div&gt; structuring fee immediately following commencement. As of September&#160;30, 2024, the Company had sold 143,234&#160;shares of Common Stock to Chardan at a purchase price of $0.4&#160;million in connection with the Purchase Agreement. &lt;/div&gt; </alur:RedeemableConvertiblePreferredStockAndStockholdersDeficitTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49721"
      unitRef="Unit_shares">2260159</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49722"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      id="ixv-49723"
      unitRef="Unit_shares">2260159</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49724"
      unitRef="Unit_USD">2500000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2024To07_01_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49725"
      unitRef="Unit_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-49727"
      unitRef="Unit_USD">1700000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-49728"
      unitRef="Unit_USD">1000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-49729"
      unitRef="Unit_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <alur:ReductionInProceedsFromOffering
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-49730"
      unitRef="Unit_USD">100000</alur:ReductionInProceedsFromOffering>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapSubsidiarySaleOfStockAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-49731"
      unitRef="Unit_USD">100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49732"
      unitRef="Unit_shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49733"
      unitRef="Unit_shares">2260159</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockVotingRights
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-49734">no</us-gaap:PreferredStockVotingRights>
    <us-gaap:DividendsPreferredStockCash
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-49735"
      unitRef="Unit_USD">0</us-gaap:DividendsPreferredStockCash>
    <alur:PreferredStockLiquidationPreferenceBasis
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-36103">In the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the Company, payment shall be made to the holders of shares of Series A Preferred Stock on a pari passu basis with all holders of Common Stock. Each Series A Preferred Stock holder shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of Common Stock would receive if such holder&#x2019;s Series A&#160;Convertible Preferred Stock were fully converted to Common Stock plus an additional amount equal to any dividends declared but unpaid to such share.</alur:PreferredStockLiquidationPreferenceBasis>
    <us-gaap:PreferredStockConversionBasis
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-36109">Each share of Series A Preferred Stock is convertible after the date that the Company&#x2019;s stockholders approve the conversion of the Series A&#160;Preferred Stock into shares of Common Stock in accordance with the listing rules of the NYSE (the &#x201c;Series A Stockholder Approval&#x201d;). Upon the Series A Stockholder Approval, each share of Series A&#160;Preferred Stock then outstanding shall automatically convert into (i)&#160;a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events, and (ii)&#160;pre-funded conversion warrants in the form agreed by the holder and the Company, exercisable for a number of shares of Common Stock equal to the number of Series A Preferred Stock outstanding at the time of conversion, adjustable for certain dilutive events.</us-gaap:PreferredStockConversionBasis>
    <alur:PreferredStockRedemptionBasis
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-49736">Each share of Series A&#160;Preferred Stock outstanding on December&#160;31, 2026 (the &#x201c;Redemption Date&#x201d;) shall be automatically redeemed by the Company for cash at a redemption price equal to the volume-weighted average price per share of the Common Stock on the NYSE during the twenty consecutive trading day period ending and including the trading day immediately preceding the Redemption Date (the &#x201c;Redemption Price&#x201d;). The Series A Preferred Stock is redeemable at a determinable price (the Redemption Price) on a fixed date (the Redemption Date), which results in mezzanine equity classification (outside of permanent equity) on the Company&#x2019;s consolidated balance sheet.</alur:PreferredStockRedemptionBasis>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49738"
      unitRef="Unit_shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49739"
      unitRef="Unit_shares">64369381</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-49740"
      unitRef="Unit_shares">47688096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_28_2024To06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49741"
      unitRef="Unit_shares">14406508</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49742"
      unitRef="Unit_shares">14406508</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn06_28_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-49743"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:SaleOfStockPricePerShare>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49744"
      unitRef="Unit_USD">15200000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <alur:UnderwritingDiscounts
      contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49745"
      unitRef="Unit_USD">1000000</alur:UnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49746"
      unitRef="Unit_USD">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49747"
      unitRef="Unit_shares">2160976</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P07_01_2024To07_01_2024_PublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49748"
      unitRef="Unit_shares">16567484</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49749"
      unitRef="Unit_USD">2200000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P07_05_2024To07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49750"
      unitRef="Unit_shares">1927265</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn07_05_2024_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      id="ixv-49751"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49752"
      unitRef="Unit_USD">17400000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="PAsOn07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49753"
      unitRef="Unit_USD">13200000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P07_01_2024To07_01_2024_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49754"
      unitRef="Unit_USD">800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_01_2024To07_01_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49755"
      unitRef="Unit_USD">5100000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <alur:NetProceedsFromIssuanceOrSaleOfEquity
      contextRef="P07_01_2024To07_01_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_PublicOfferingWarrantsAndShareOverallotmentMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      id="ixv-49756"
      unitRef="Unit_USD">5100000</alur:NetProceedsFromIssuanceOrSaleOfEquity>
    <alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-36137">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of shares of Common Stock that have been reserved for issuance upon the potential conversion or exercise, as applicable, of the Company&#x2019;s securities as of September&#160;30, 2024, is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,108,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;530,778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase Common Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,231,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares of Common Stock issued upon the exercise of Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260,159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;479,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,369,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49757"
      unitRef="Unit_shares">7108316</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      id="ixv-49758"
      unitRef="Unit_shares">530778</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49759"
      unitRef="Unit_shares">19231301</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49760"
      unitRef="Unit_shares">18759554</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49761"
      unitRef="Unit_shares">2260159</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_EarnOutSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49762"
      unitRef="Unit_shares">9000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_ConvertibleNotesMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-49763"
      unitRef="Unit_shares">479196</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49764"
      unitRef="Unit_shares">57369304</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-49765">As of September&#160;30, 2024, there were 403,658 Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified. &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Public Offering and Private Placement, we issued the Public Offering Warrants and Private Placement Warrants. As of September&#160;30, 2024, there were 16,567,484 Public Offering Warrants and 2,260,159 Private Placement Warrants outstanding to purchase Common Stock. &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td style="width:36%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying&#160;Equity&#160;Instrument&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common&#160;Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;7/1/2024&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;18,827,643&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,231,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td style="width:34%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td colspan="18" style="BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style=" BORDER-BOTTOM:1.00pt solid #000000;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issuance&#160;Date&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;br/&gt; Contractual&#160;Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Underlying&#160;Equity&#160;Instrument&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance Sheet&lt;br/&gt; Classification&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&#160;Issuable&lt;br/&gt; Upon Exercise&lt;br/&gt; of Warrant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&#160;Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;12/1/2014&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;44,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.44&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;3/30/2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;7.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;130,053&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/15/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/4/2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;45,238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;12.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;1/17/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;73,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;8/3/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Equity&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,779&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;9/8/2017&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;28,764&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/19/2018&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;17,977&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;6/25/2019&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Common Stock&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Liability&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;8,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.05&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;403,658&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49766"
      unitRef="Unit_shares">403658</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49768"
      unitRef="Unit_shares">16567484</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49769"
      unitRef="Unit_shares">2260159</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49770">P0Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49771"
      unitRef="Unit_shares">44272</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49772"
      unitRef="Unit_USD_per_Share">2.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49773">P6Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49774"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49775"
      unitRef="Unit_USD_per_Share">6.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49776">P8Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49777"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49778"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49779">P7Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49780"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49781"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49782">P2Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49783"
      unitRef="Unit_shares">73349</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49784"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49785">P2Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49786"
      unitRef="Unit_shares">9779</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49787"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49788">P2Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49789"
      unitRef="Unit_shares">28764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49790"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49791">P3Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49792"
      unitRef="Unit_shares">17977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49793"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49794">P4Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49795"
      unitRef="Unit_shares">8988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49796"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49797">P4Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49798"
      unitRef="Unit_shares">18827643</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJuly012024MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49799"
      unitRef="Unit_USD_per_Share">1.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2024"
      decimals="0"
      id="ixv-49800"
      unitRef="Unit_shares">19231301</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49801">P0Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49802"
      unitRef="Unit_shares">44272</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtDecember012014MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49803"
      unitRef="Unit_USD_per_Share">2.44</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49804">P7Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49805"
      unitRef="Unit_shares">130053</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtMarch302021MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49806"
      unitRef="Unit_USD_per_Share">6.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49807">P8Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49808"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember152022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49809"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49810">P8Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49811"
      unitRef="Unit_shares">45238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune042022MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49812"
      unitRef="Unit_USD_per_Share">12.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49813">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49814"
      unitRef="Unit_shares">73349</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJanuary172017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49815"
      unitRef="Unit_USD_per_Share">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49816">P3Y7M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49817"
      unitRef="Unit_shares">9779</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtAugust032017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49818"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49819">P3Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49820"
      unitRef="Unit_shares">28764</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtSeptember082017MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49821"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49822">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49823"
      unitRef="Unit_shares">17977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune192018MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49824"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      id="ixv-49825">P5Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      id="ixv-49826"
      unitRef="Unit_shares">8988</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2023_CommonStockMemberusgaapStatementEquityComponentsAxis_WarrantsIssuedAtJune252019MemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      id="ixv-49827"
      unitRef="Unit_USD_per_Share">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-49828"
      unitRef="Unit_shares">403658</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-49829"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2024To09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49830"
      unitRef="Unit_shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49831"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2024To09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-49832"
      unitRef="Unit_shares">1</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49833"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn09_30_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="6"
      id="ixv-49834"
      unitRef="Unit_shares">1.420455</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2024"
      decimals="2"
      id="ixv-49835"
      unitRef="Unit_USD_per_Share">8.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="PAsOn09_30_2024_ComputeHealthAcquisitionCorprationMemberusgaapBusinessAcquisitionAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="4"
      id="ixv-49836"
      unitRef="Unit_shares">0.6125</us-gaap:ClassOfWarrantOrRightUnissued>
    <alur:WarrantsRedumptionPricePerShare
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49837"
      unitRef="Unit_USD_per_Share">0.01</alur:WarrantsRedumptionPricePerShare>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanThreeMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49838"
      unitRef="Unit_USD_per_Share">12.67</us-gaap:SharePrice>
    <alur:WarrantsRedumptionPricePerShare
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49839"
      unitRef="Unit_USD_per_Share">0.1</alur:WarrantsRedumptionPricePerShare>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis_ScenarioPlanFourMembersrtStatementScenarioAxis"
      decimals="2"
      id="ixv-49840"
      unitRef="Unit_USD_per_Share">7.04</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49841"
      unitRef="Unit_USD">13206720</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2024To09_30_2024_PublicWarrantMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      id="ixv-49842"
      unitRef="Unit_shares">18759554</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="0"
      id="ixv-49843"
      unitRef="Unit_USD">100000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-49844"
      unitRef="Unit_shares">9482468</us-gaap:CommonStockSharesOutstanding>
    <alur:PercentageOfCommonStockSharesOutstanding
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="4"
      id="ixv-49845"
      unitRef="Unit_pure">0.1999</alur:PercentageOfCommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis_CommitmentSharesMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-49846"
      unitRef="Unit_USD">35511</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49847"
      unitRef="Unit_USD">100000</us-gaap:AdditionalPaidInCapital>
    <alur:ExpenseOfIssuanceOfCommitmentShares
      contextRef="P12_18_2023To12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49848"
      unitRef="Unit_USD">100000</alur:ExpenseOfIssuanceOfCommitmentShares>
    <alur:StructuringFeePayable
      contextRef="PAsOn12_18_2023_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49849"
      unitRef="Unit_USD">100000</alur:StructuringFeePayable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-49850"
      unitRef="Unit_shares">143234</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="P01_01_2024To09_30_2024_ChardanEquityFacilityMemberusgaapCreditFacilityAxis_ChefPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-49851"
      unitRef="Unit_USD">400000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-36905">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Basic and diluted net loss per share was calculated as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:54%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61,427&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cumulative undeclared preferred dividends to participating securities (Legacy Series&#160;D convertible preferred stock)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(255&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to common shareholders&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9,004&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(21,885&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,580&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,124&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic and diluted weighted-average common stock outstanding&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;64,086,265&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;40,335,457&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;53,310,214&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,558,538&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per share, basic and diluted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.14&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding options to purchase Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,108,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,270,229&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Restricted Stock Units&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;530,778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;429,321&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Series A Preferred Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,260,159&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Warrants to purchase Common Stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;19,231,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;404,988&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Shares of Common Stock issued upon the exercise of Public Warrants&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18,759,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Earn-Out&lt;/div&gt; Shares&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Notes&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;479,196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;57,369,304&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,864,376&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49852"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49853"
      unitRef="Unit_USD">-21630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49854"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49855"
      unitRef="Unit_USD">-61427000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49856"
      unitRef="Unit_USD">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49857"
      unitRef="Unit_USD">255000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49858"
      unitRef="Unit_USD">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49859"
      unitRef="Unit_USD">1697000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49860"
      unitRef="Unit_USD">-9004000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49861"
      unitRef="Unit_USD">-21885000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49862"
      unitRef="Unit_USD">-5580000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49863"
      unitRef="Unit_USD">-63124000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2024To09_30_2024"
      decimals="0"
      id="ixv-49864"
      unitRef="Unit_shares">64086265</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="0"
      id="ixv-49865"
      unitRef="Unit_shares">64086265</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      id="ixv-49866"
      unitRef="Unit_shares">40335457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="0"
      id="ixv-49867"
      unitRef="Unit_shares">40335457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To09_30_2024"
      decimals="0"
      id="ixv-49868"
      unitRef="Unit_shares">53310214</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="0"
      id="ixv-49869"
      unitRef="Unit_shares">53310214</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      id="ixv-49870"
      unitRef="Unit_shares">31558538</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      id="ixv-49871"
      unitRef="Unit_shares">31558538</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49872"
      unitRef="Unit_USD_per_Share">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49873"
      unitRef="Unit_USD_per_Share">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49874"
      unitRef="Unit_USD_per_Share">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49875"
      unitRef="Unit_USD_per_Share">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49876"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49877"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49878"
      unitRef="Unit_USD_per_Share">-2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49879"
      unitRef="Unit_USD_per_Share">-2</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49880"
      unitRef="Unit_shares">7108316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_OutstandingOptionsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49881"
      unitRef="Unit_shares">4270229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49882"
      unitRef="Unit_shares">530778</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49883"
      unitRef="Unit_shares">429321</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-49884"
      unitRef="Unit_shares">2260159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      id="ixv-49885"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49886"
      unitRef="Unit_shares">19231301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_WarrantsToPurchaseCommonStockMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49887"
      unitRef="Unit_shares">404988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49888"
      unitRef="Unit_shares">18759554</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_SharesOfCommonStockIssuedUponTheExerciseOfPublicWarrantsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49889"
      unitRef="Unit_shares">18759838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49890"
      unitRef="Unit_shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_EarnOutSharesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49891"
      unitRef="Unit_shares">9000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49892"
      unitRef="Unit_shares">479196</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023_ConvertibleNotesMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-49893"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To09_30_2024"
      decimals="0"
      id="ixv-49894"
      unitRef="Unit_shares">57369304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To09_30_2023"
      decimals="0"
      id="ixv-49895"
      unitRef="Unit_shares">32864376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-37381">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s 2010 Stock Incentive Plan (the &#x201c;2010 Plan&#x201d;) provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#x2019;s Common Stock. On December&#160;11, 2020, the Company&#x2019;s Board of Directors adopted the Amended and Restated 2020 Stock Option and Grant Plan (the &#x201c;2020 Plan&#x201d;), which provided for the grant of qualified incentive stock options, nonqualified stock options, and other awards to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants to purchase the Company&#x2019;s Common Stock. Each stock option from the 2010 Plan and the 2020 Plan that was outstanding immediately prior to the Business Combination, whether vested or unvested, was cancelled and exchanged for a stock option to purchase Allurion Common Stock based on the Exchange Ratio. The per share exercise price for each stock option was divided by the Exchange Ratio. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company adopted the 2023 Stock Option and Incentive Plan (the &#x201c;2023 Plan&#x201d;), which provides for the award of stock options (both incentive and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-qualified),&lt;/div&gt; stock appreciation rights, restricted stock units, restricted stock awards, cash-based awards, and dividend equivalent rights. As of September&#160;30, 2024, a total of 8,174,364&#160;shares of Allurion Common Stock are reserved for issuance under the 2023 Plan. The 2023 Plan provides that the number of shares reserved for issuance under the 2023 Plan will automatically increase each January&#160;1, beginning January&#160;1, 2024 and ending January&#160;1, 2033, by 5% of the number of fully diluted outstanding shares of Allurion Common Stock as of the immediately preceding December&#160;31 or such lesser amount as determined by the Board and the compensation committee. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2024,&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;7,639,094 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. As of December&#160;31, 2023, 4,529,673 options and RSUs were issued and outstanding under the 2010 Plan, 2020 Plan, and 2023 Plan. The stock options generally vest over a four-year period and expire 10 years from the date of grant. &lt;/div&gt; &lt;div&gt;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Stock-based compensation expense included in the condensed consolidated statement of operations was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the nine months ended September&#160;30, 2024: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;option)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding&#x2014;January 1, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,686,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(447,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,137&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding&#x2014;September 30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,108,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at September&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,872,814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock compensation expense related to stock option awards during the three and nine months ended September&#160;30, 2024 was $0.6&#160;million and $1.4&#160;million, respectively. As of September&#160;30, 2024, there was approximately $5.6&#160;million of unrecognized compensation costs related to unvested stock options granted under the 2010 Plan, 2020 Plan, and 2023 Plan, which is expected to be recognized over a weighted-average vesting term of 3.0 years. The weighted average grant-date fair value of the stock option awards granted during the nine months ended September&#160;30, 2024 was $1.30 per option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the table below. Expected volatility for the Company&#x2019;s Common Stock was determined based on an average of the historical volatility of a peer group of public companies that are similar to the Company. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The expected term of options granted to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-employees&lt;/div&gt; is the remaining contractual term of the award. The assumed dividend yield is based upon the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the option is based upon the U.S. Treasury yield curve in effect at the time of grant. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2022, the Company issued RSUs to a member of the Board of Directors with vesting subject to both a performance-based closing condition dependent on the successful Business Combination with Compute Health and time-based vesting conditions. See Note 3, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt; for information about the closing of the Business Combination with Compute Health. Upon the satisfaction of the closing condition, 62.5% of the RSUs awarded vested. Thereafter, the remaining 37.5% of the RSUs vest monthly over a period of two years. All RSUs are subject to forfeiture if the grantee&#x2019;s continuous service relationship as a member of the Board of Directors terminates prior to vesting. In October 2023 and March 2024, the Company issued RSUs to its Board of Director members that vest in equal installments over three years, subject to continued service as a director through each vesting date. &lt;/div&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended September&#160;30, 2024: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;75,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(187,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;September 30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;530,778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Total stock compensation expense related to RSUs for the three and nine months ended September&#160;30, 2024 was $0.2&#160;million and $0.8&#160;million, respectively. As of September&#160;30, 2024, there were $1.0&#160;million of unrecognized compensation costs related to nonvested RSUs granted under the 2020 Plan and 2023 Plan, which is expected to be recognized over a remaining weighted-average vesting term of 1.6 years. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the closing of the Business Combination, the Company adopted the 2023 Employee Stock Purchase Plan (the &#x201c;2023 ESPP&#x201d;). Under the 2023 ESPP plan, substantially all employees may voluntarily enroll to purchase the Company&#x2019;s Common Stock through payroll deductions at a price equal to 85% of the lower of the fair market values of the stock as of the beginning or end of the offering period. An employee&#x2019;s payroll deductions under the 2023 ESPP are limited to 15% of the employee&#x2019;s compensation. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A total of 2,226,122 shares of the Company&#x2019;s Common Stock are reserved and authorized for issuance under the 2023 ESPP. In addition, the number of shares of Common Stock available for issuance under the 2023 &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;ESPP will automatically increase each January&#160;1, beginning on January&#160;1, 2024 and each January thereafter, by the lesser of (i) 1% of the fully diluted outstanding shares of our Common Stock as of the immediately preceding December&#160;31, (ii) 1,600,000 shares of our Common Stock, or (iii)&#160;such lesser number of shares determined by the administrator of the 2023 ESPP. As of September&#160;30, 2024, no shares have been issued under the 2023 ESPP. &lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49896"
      unitRef="Unit_shares">8174364</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance
      contextRef="P01_01_2024To09_30_2024_StockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49897"
      unitRef="Unit_pure">0.05</alur:IncreaseDecreaseInPercentageOfNumberOfSharesReservedForFutureIssuance>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan
      contextRef="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-49898"
      unitRef="Unit_shares">7639094</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan
      contextRef="PAsOn12_31_2023_StockOptionPlan2020StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-49899"
      unitRef="Unit_shares">4529673</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsusIssuedAndExercisableUnderThePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      id="ixv-49900">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      id="ixv-49901">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-37421"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Stock-based compensation expense included in the condensed consolidated statement of operations was as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2024&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2002;2023&#x2002;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cost of revenue&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Selling, general and administrative&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,109&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,235&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;56&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;84&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,217&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49902"
      unitRef="Unit_USD">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49903"
      unitRef="Unit_USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To09_30_2024_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49904"
      unitRef="Unit_USD">24000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_CostOfSalesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49905"
      unitRef="Unit_USD">31000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49906"
      unitRef="Unit_USD">791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49907"
      unitRef="Unit_USD">5477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To09_30_2024_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49908"
      unitRef="Unit_USD">2109000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_SellingGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49909"
      unitRef="Unit_USD">6235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49910"
      unitRef="Unit_USD">56000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49911"
      unitRef="Unit_USD">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To09_30_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49912"
      unitRef="Unit_USD">84000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-49913"
      unitRef="Unit_USD">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49914"
      unitRef="Unit_USD">860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49915"
      unitRef="Unit_USD">5539000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49916"
      unitRef="Unit_USD">2217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49917"
      unitRef="Unit_USD">6349000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-37611"> &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the option activity under the 2010 Plan, 2020 Plan, and the 2023 Plan during the nine months ended September&#160;30, 2024: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:50%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;option)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding&#x2014;January 1, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,886,038&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,686,059&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(447,644&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(16,137&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding&#x2014;September 30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,108,316&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.28&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable at September&#160;30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,872,814&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49918"
      unitRef="Unit_shares">3886038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49919"
      unitRef="Unit_USD_per_Share">2.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2023To12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-49920">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      id="ixv-49921"
      unitRef="Unit_USD">5565000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-49922"
      unitRef="Unit_shares">3686059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49923"
      unitRef="Unit_USD_per_Share">1.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-49924"
      unitRef="Unit_shares">447644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49925"
      unitRef="Unit_USD_per_Share">2.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-49926"
      unitRef="Unit_shares">16137</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49927"
      unitRef="Unit_USD_per_Share">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49928"
      unitRef="Unit_shares">7108316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49929"
      unitRef="Unit_USD_per_Share">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-49930">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49931"
      unitRef="Unit_shares">2872814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49932"
      unitRef="Unit_USD_per_Share">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTenStockOptionPlanTwoThousandAndTwentyStockOptionPlanTwoThousandAndTwentyThreeStockOptionAndIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-49933">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-49934"
      unitRef="Unit_USD">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-49935"
      unitRef="Unit_USD">1400000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      id="ixv-49936"
      unitRef="Unit_USD">5600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2024To09_30_2024_StockOptionPlan2020StockOptionPlanAnd2023StockOptionPlanMemberusgaapPlanNameAxis"
      id="ixv-49937">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To09_30_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-49938"
      unitRef="Unit_USD_per_Share">1.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-37873"> &lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The assumptions used in the Black Scholes option-pricing model for the nine months ended September&#160;30, 2024 and 2023 are as follows: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.36&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49940"
      unitRef="Unit_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49941"
      unitRef="Unit_pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To09_30_2024"
      decimals="4"
      id="ixv-49942"
      unitRef="Unit_pure">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To09_30_2023"
      decimals="4"
      id="ixv-49943"
      unitRef="Unit_pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To09_30_2024"
      decimals="2"
      id="ixv-49944"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To09_30_2023"
      decimals="2"
      id="ixv-49945"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2024To09_30_2024" id="ixv-49946">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To09_30_2023" id="ixv-49947">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2024To09_30_2024_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      decimals="3"
      id="ixv-49948"
      unitRef="Unit_pure">0.625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      decimals="3"
      id="ixv-49949"
      unitRef="Unit_pure">0.375</alur:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRemainingVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-49950">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To09_30_2024_BoardOfDirectorsChairmanMembersrtTitleOfIndividualAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-49951">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-37959"> &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the restricted stock unit activity under the 2020 Plan and 2023 Plan during the three months ended September&#160;30, 2024: &lt;/div&gt; &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of RSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&lt;br/&gt; Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(per&#160;share)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;January 1, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;643,635&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;75,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.61&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancellations and forfeitures&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Vested&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(187,857&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.51&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Outstanding&#x2014;September 30, 2024&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;530,778&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49952"
      unitRef="Unit_shares">643635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49953"
      unitRef="Unit_USD_per_Share">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49954"
      unitRef="Unit_shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49955"
      unitRef="Unit_USD_per_Share">2.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49956"
      unitRef="Unit_shares">187857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49957"
      unitRef="Unit_USD_per_Share">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49958"
      unitRef="Unit_shares">530778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_StockOptionPlan2020And2023StockOptionPlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49959"
      unitRef="Unit_USD_per_Share">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="P07_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-49960"
      unitRef="Unit_USD">200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To09_30_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-49961"
      unitRef="Unit_USD">800000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2024"
      decimals="-5"
      id="ixv-49962"
      unitRef="Unit_USD">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2024To09_30_2024" id="ixv-49963">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <alur:PercentageOfPriceLowerOfFairValueMarketValue
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49964"
      unitRef="Unit_pure">0.85</alur:PercentageOfPriceLowerOfFairValueMarketValue>
    <alur:PercentageOfEmployeesCompensationToPayrollDeductions
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49965"
      unitRef="Unit_pure">0.15</alur:PercentageOfEmployeesCompensationToPayrollDeductions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49966"
      unitRef="Unit_shares">2226122</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <alur:PercentageOfDilutedSharesOutstanding
      contextRef="P01_01_2024To09_30_2024_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-49967"
      unitRef="Unit_pure">0.01</alur:PercentageOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis_TwoThousandAndTwentyThreeEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="0"
      id="ixv-49968"
      unitRef="Unit_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38112">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has a 401(k) retirement plan that covers eligible U.S. employees. Eligible employees may elect to contribute up to the maximum limits, as set by the Internal Revenue Service, of their eligible compensation. The Company may elect to make a discretionary contribution or match a discretionary percentage of employee contributions. During each of the three and nine months ended September&#160;30, 2024 and 2023, the Company&#x2019;s matching contributions to the plan were less than $0.1&#160;million. &lt;/div&gt; </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2023To09_30_2023_MaximumMembersrtRangeAxis"
      decimals="INF"
      id="ixv-49969"
      unitRef="Unit_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-49970"
      unitRef="Unit_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38123">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;With respect to contracts involving the use of assets, if the Company has the right to direct the use of the asset and obtain substantially all economic benefits from the use of an asset, it accounts for the service contract as a lease. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases. As a result of these amendments, the leases in Natick and Hudson will now expire between March 2025 and March 2028, and additional operating lease assets obtained in exchange for lease obligations were $0.9&#160;million. In April 2024, the Company executed an amendment to one of its leases in Natick, Massachusetts. The amendment was accounted for as a modification of the existing lease agreement, with impacts to the lease term, lease payments, and related lease liability for the lease. As a r&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;es&lt;/div&gt;ult of this amendment, the lease in Natick will now expire in March 2025 and additional operating lease assets obtained in exchange for lease obligations were less than $0.1&#160;million. In February 2024, the Company terminated one of its leases in Paris, France. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of September&#160;30, 2024, the Company was a party to six different leases for office, manufacturing, and laboratory space under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; office leases in three cities. These leases total approximately 51,000 square feet and will expire between March 2025 and March 2028. The Company has a right to extend certain of these leases for periods between &lt;div style="-sec-ix-hidden:hidden127680941;display:inline;"&gt;three&lt;/div&gt; and five years. Under its real property leases, the Company pays base rent and a proportional share of operating expenses. Such operating expenses are subject to annual adjustment and are accounted for as variable payments in the period in which they are incurred. The Company also holds immaterial leases related to vehicles and office equipment. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and lease liabilities are included in the condensed co&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;ns&lt;/div&gt;olidated balance sheets. The short-term portion of the Company&#x2019;s operating lease liability is recorded as part of Accrued expenses and other current liabilities on the condensed consolidated balance sheets. &lt;/div&gt; &lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt; &lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Aggregate Lease Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Other pertinent lease information for the three and nine months ended September&#160;30, 2024 and 2023 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows paid for amounts in the &lt;br/&gt; measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;826&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease assets obtained in exchange &lt;br/&gt; for lease obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Future commitments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreements as of September&#160;30, 2024 are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,044&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;646&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(878&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average remaining lease terms and discount rates related to our leases were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted -average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Product Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has not received any material product liability claims. Notwithstanding this, the Company has obtained insurance related to potential product liability claims. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Litigation and Claims &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, the validity or scope of its intellectual property rights, employee-related matters, securities class actions, or adverse patient reactions. Additionally, during the normal course of business, the Company may be a party to legal claims that may not be covered by insurance. As of September&#160;30, 2024 and December&#160;31, 2023, the Company has not recorded accruals for probable losses related to any existing or pending litigation or claims as the Company&#x2019;s management has determined that there are no matters where a potential loss is probable and reasonably estimable. The Company does not believe that any existing or pending claims would have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;French Regulatory Decision &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;6, 2024, it was announced that the Agence Nationale de S&#xe9;curit&#xe9; du M&#xe9;dicament (&#x201c;ANSM&#x201d;), the French regulatory authority, has suspended sales of the Allurion Balloon in France, and the Company withdrew the device from the French market. The Company has implemented a remediation plan to reduce certain risks associated with the advertising, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;follow-up&lt;/div&gt; program, and adverse events for the Allurion Balloon. For the three and nine months ended September&#160;30, 2024, the Company recognized a reduction to revenues of $1.2&#160;million for customer returns of the Allurion Balloon. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;NYSE Continued Listing Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;12, 2024, we received a letter from the NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#x2019;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;trading-day&lt;/div&gt; period ending on the last trading day of that month. In the event that at the expiration of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;six-month&lt;/div&gt; cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;trading-day&lt;/div&gt; period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;29, 2024, we received written notice from the NYSE that we are not in compliance with the con&lt;div style="display:inline;"&gt;tinu&lt;/div&gt;ed listing standard set forth in Section&#160;802.01B of the NYSE&#x2019;s Listed Company Manual because the average market capitalization of the Company was less than $50.0&#160;million over the consecutive 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;trading-day&lt;/div&gt; period ended August&#160;29, 2024 and the Company&#x2019;s last reported stockholders&#x2019; equity as of August&#160;29, 2024 was less than $50.0&#160;million. In accordance with applicable NYSE procedures, we submitted a plan to the NYSE outlining measures designed to regain compliance with the continued listing standard within 18 months of receipt the written notice. If the NYSE accepts our plan, the NYSE will review the Company on a quarterly basis to confirm compliance with the plan. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="P01_01_2024To09_30_2024" id="ixv-49971">In February 2023 and August 2023, the Company executed amendments to three of its leases in Natick, Massachusetts and its Hudson, Massachusetts lease, respectively. The amendments were accounted for as a modification of the existing lease agreements, with impacts to the lease term, lease payments, and related lease liability for each of the four leases.</us-gaap:LesseeOperatingLeaseDescription>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P08_01_2023To08_31_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-49972">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P02_01_2023To02_28_2023_MaximumMembersrtRangeAxis_NatickAndHudsonMembersrtStatementGeographicalAxis"
      id="ixv-49973">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023_NatickAndHudsonMembersrtStatementGeographicalAxis"
      decimals="-5"
      id="ixv-49974"
      unitRef="Unit_USD">900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2024To04_30_2024_NatickAndHudsonMembersrtStatementGeographicalAxis"
      decimals="-5"
      id="ixv-49975"
      unitRef="Unit_USD">100000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:AreaOfLand
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-49976"
      unitRef="Unit_sqft">51000</us-gaap:AreaOfLand>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P01_01_2024To09_30_2024_MinimumMembersrtRangeAxis"
      id="ixv-49977">2025-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <alur:LesseeOperatingLeaseExpirationPeriod
      contextRef="P01_01_2024To09_30_2024_MaximumMembersrtRangeAxis"
      id="ixv-49978">2028-03</alur:LesseeOperatingLeaseExpirationPeriod>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="P01_01_2024To09_30_2024" id="ixv-38141">The Company has a right to extend certain of these leases for periods between three and five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="P01_01_2024To09_30_2024" id="ixv-49979">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="PAsOn09_30_2024_MaximumMembersrtRangeAxis"
      id="ixv-49980">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38169">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Other pertinent lease information for the three and nine months ended September&#160;30, 2024 and 2023 is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:72%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Nine Months&lt;br/&gt; Ended&lt;br/&gt; September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;259&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;285&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;794&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;23&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;59&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;52&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows paid for amounts in the &lt;br/&gt; measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;271&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;284&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;826&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;815&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease assets obtained in exchange &lt;br/&gt; for lease obligations&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfOtherPertinentLeaseInformationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49982"
      unitRef="Unit_USD">259000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49983"
      unitRef="Unit_USD">285000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49984"
      unitRef="Unit_USD">794000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49985"
      unitRef="Unit_USD">834000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49986"
      unitRef="Unit_USD">3000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49987"
      unitRef="Unit_USD">5000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49988"
      unitRef="Unit_USD">23000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49989"
      unitRef="Unit_USD">17000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49990"
      unitRef="Unit_USD">59000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49991"
      unitRef="Unit_USD">52000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49992"
      unitRef="Unit_USD">194000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49993"
      unitRef="Unit_USD">211000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49994"
      unitRef="Unit_USD">271000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49995"
      unitRef="Unit_USD">284000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49996"
      unitRef="Unit_USD">826000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49997"
      unitRef="Unit_USD">815000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P07_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-49998"
      unitRef="Unit_USD">62000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2024To09_30_2024"
      decimals="-3"
      id="ixv-49999"
      unitRef="Unit_USD">15000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To09_30_2023"
      decimals="-3"
      id="ixv-50000"
      unitRef="Unit_USD">936000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38326">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Future commitments under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreements as of September&#160;30, 2024 are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:87%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;273&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,044&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;646&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2028&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,456&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(878&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,578&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50001"
      unitRef="Unit_USD">273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50002"
      unitRef="Unit_USD">1044000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50003"
      unitRef="Unit_USD">739000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50004"
      unitRef="Unit_USD">646000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <alur:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50005"
      unitRef="Unit_USD">108000</alur:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50006"
      unitRef="Unit_USD">2810000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50007"
      unitRef="Unit_USD">354000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50008"
      unitRef="Unit_USD">2456000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50009"
      unitRef="Unit_USD">878000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50010"
      unitRef="Unit_USD">1578000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38439">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average remaining lease terms and discount rates related to our leases were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:15%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted -average remaining lease term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</alur:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRatesRelatedLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2024" id="ixv-50011">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn06_30_2023" id="ixv-50012">P3Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2024"
      decimals="3"
      id="ixv-50013"
      unitRef="Unit_pure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn06_30_2023"
      decimals="3"
      id="ixv-50014"
      unitRef="Unit_pure">0.099</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn09_30_2024"
      decimals="INF"
      id="ixv-50015"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-50016"
      unitRef="Unit_USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <alur:IncreaseDecreaseInRevenuesForCustomerReturns
      contextRef="P01_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-50018"
      unitRef="Unit_USD">1200000</alur:IncreaseDecreaseInRevenuesForCustomerReturns>
    <alur:IncreaseDecreaseInRevenuesForCustomerReturns
      contextRef="P07_01_2024To09_30_2024"
      decimals="-5"
      id="ixv-50019"
      unitRef="Unit_USD">1200000</alur:IncreaseDecreaseInRevenuesForCustomerReturns>
    <alur:StockExchangeListingRequirementsDescription contextRef="P01_01_2024To09_30_2024" id="ixv-38522">On August&#160;12, 2024, we received a letter from the NYSE notifying us that, as of August&#160;8, 2024, for the last 30 consecutive business days, the average closing price of the Company&#x2019;s common stock was less than $1.00 per share, the minimum average closing bid price required by the continued listing requirements of Rule 802.01C of the NYSE Listed Company Manual. A company can regain compliance with the minimum share price requirement at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, the company has (i)&#160;a closing share price of at least $1.00 and (ii)&#160;an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. In the event that at the expiration of the six-month cure period, both a $1.00 closing share price on the last trading day of the cure period and a $1.00 average closing share price over the 30 trading-day period ending on the last trading day of the cure period are not attained, the NYSE will commence suspension and delisting procedures. We intend to monitor the closing bid price of our Common Stock and may, if appropriate, consider available options to regain compliance with the NYSE minimum share price requirement.</alur:StockExchangeListingRequirementsDescription>
    <alur:AverageMarketCapitalizationAmount
      contextRef="P08_29_2024To08_29_2024_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-50020"
      unitRef="Unit_USD">50000000</alur:AverageMarketCapitalizationAmount>
    <alur:NumberOfConsecutiveTradingDay
      contextRef="P08_29_2024To08_29_2024"
      decimals="INF"
      id="ixv-50021"
      unitRef="Unit_TradingDay">30</alur:NumberOfConsecutiveTradingDay>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn08_29_2024_MaximumMembersrtRangeAxis"
      decimals="-5"
      id="ixv-50022"
      unitRef="Unit_USD">50000000</us-gaap:StockholdersEquity>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38531">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Geographic Information &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-lived assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Refer to Note 4, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue&lt;/div&gt;&lt;/div&gt; for information on revenue by geography. &lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38540">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Long-lived assets, consisting of property and equipment, net and ROU assets by geography were as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;United States&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;France&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,010&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;All other countries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-lived assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,363&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn09_30_2024_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-50023"
      unitRef="Unit_USD">4690000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023_USsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-50024"
      unitRef="Unit_USD">5381000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn09_30_2024_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-50025"
      unitRef="Unit_USD">673000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023_FRsrtStatementGeographicalAxis"
      decimals="-3"
      id="ixv-50026"
      unitRef="Unit_USD">1010000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn09_30_2024"
      decimals="-3"
      id="ixv-50027"
      unitRef="Unit_USD">5363000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-50028"
      unitRef="Unit_USD">6391000</us-gaap:NoncurrentAssets>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38644">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Related-party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Lease Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2022, the Company entered into an operating lease agreement for additional office space in Paris, France with LNMP JPBC Invest. The Company&#x2019;s then-Trade Marketing Director was the signor of this lease for &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;LNMP JPBS Invest. Additionally, the Company&#x2019;s former Chief Commercial Officer is also a partner of LNMP JPBC Invest. The lease agreement included lease payments of approximately $0.1&#160;million per year. The term of the lease was August 1, 2022 through July 31, 2025. The Company concluded that the commercial terms of the lease agreement were competitive, at the current market rate and conducted at &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;arm&#x2019;s-length.&lt;/div&gt; This lease was terminated in February 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Consulting Agreements with KKG Enterprises, LLC and Remus Group Management, LLC &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC (&#x201c;KKG Enterprises&#x201d;) and Remus Group Management, LLC (&#x201c;Remus Group Management&#x201d;) to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination. These agreements were tied to Allurion Board-related work by Krishna Gupta, who is a director of Allurion, CEO of Remus Group Management, principal at KKG Enterprises, and affiliated with Romulus Capital, a stockholder of Allurion. The agreements included payments of $0.2&#160;million to KKG Enterprises and $0.3&#160;million to Remus Group Management as board compensation to Krishna Gupta. These agreements were terminated on June 20, 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Note with Hunter Ventures Limited &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On February&#160;15, 2023, Allurion sold $13&#160;million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta (a director of Allurion; in addition, entities affiliated with him hold more than 5% of our outstanding common stock). Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt; for additional information regarding the 2023 Convertible Notes. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Consulting Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, Allurion France, a French soci&#xe9;t&#xe9; par actions simplifi&#xe9;e and wholly-owned subsidiary of Allurion (&#x201c;Allurion France&#x201d;), entered into a corporate officer agreement with the Company&#x2019;s then-Chief Commercial Officer and Benoit Chardon Consulting, a French soci&#xe9;t&#xe9; &#xe0; responsabilit&#xe9; limit&#xe9;e solely owned by Mr.&#160;Chardon (&#x201c;BCC&#x201d;), pursuant to which BCC agreed to serve as Managing Director of Allurion France. The corporate officer agreement provided that BCC would receive base consulting fees of &#x20ac;28,333.33 per month and additional variable compensation subject to the incentive plan terms issued annually by Allurion and conditional on meeting Allurion France and personal performance attainment defined each year by Allurion. This agreement was terminated on December 12, 2023 by virtue of the termination agreement described below, effective December&#160;31, 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Termination Agreement with Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;12, 2023, Allurion France entered into a termination agreement with the Company&#x2019;s Chief Commercial Officer, Benoit Chardon, and BCC. Pursuant to the termination agreement, the parties agreed to terminate the corporate officer agreement as of December&#160;31, 2023 and BCC resigned from its duties as managing director of Allurion France effective December&#160;31, 2023. Allurion paid BCC all amounts due to it under the corporate officer agreement through December&#160;31, 2023. In addition, Allurion paid BCC a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;lump-sum&lt;/div&gt; termination fee of $0.2&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Note Agreement with RTW &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Amended Note Purchase Agreement, on April&#160;16, 2024, we issued and sold $48&#160;million aggregate principal amount of convertible notes to RTW. RTW holds more than 5% of our outstanding Common Stock, has the right to designate an independent director nominee to be elected by our stockholders, is entitled to designate one representative to serve as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;non-voting&lt;/div&gt; observer on our Board, and had the right to approve an &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;additional director nominee for election In September 2024, we expanded our Board and appointed a new director in satisfaction of certain of these obligations to RTW as set forth in the Amended Note Purchase Agreement. Refer to Note 8, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt&lt;/div&gt;&lt;/div&gt;, for additional information regarding the RTW Convertible Notes. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RTW Participation in Public Offering &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Public Offering, the Company issued and sold 239,842 shares of Common Stock and accompanying warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $0.3&#160;million. The Public Offering closed on July&#160;1, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Private Placement with RTW &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On June&#160;28, 2024, pursuant to the Subscription Agreement, the Company agreed to sell to RTW 2,260,159 shares of Series A Preferred Stock, and 2,260,159 Private Placement Warrants, for an aggregate purchase price of approximately $2.7&#160;million. The Private Placement closed on July&#160;1, 2024. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-50031"
      unitRef="Unit_USD">100000</us-gaap:OperatingLeasePayments>
    <alur:OperatingLeaseStartDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-50032">2022-08-01</alur:OperatingLeaseStartDate>
    <alur:OperatingLeaseEndDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-50033">2025-07-31</alur:OperatingLeaseEndDate>
    <alur:LesseeOperatingLeaseTerminatedDate
      contextRef="P08_01_2022To08_31_2022_LnmpJpbcInvestMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      id="ixv-50034">2024-02</alur:LesseeOperatingLeaseTerminatedDate>
    <alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_KkgEnterprisesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-50035"
      unitRef="Unit_USD">200000</alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination>
    <alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis_RemusGroupManagementMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      id="ixv-50036"
      unitRef="Unit_USD">300000</alur:PaymentsOfAdvisoryServicesRelatedToBusinessCombination>
    <alur:AgreementsTerminationDate
      contextRef="P01_01_2023To03_31_2023_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      id="ixv-50037">2023-06-20</alur:AgreementsTerminationDate>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="P02_15_2023To02_15_2023_HunterVenturesLimitedMembersrtCounterpartyNameAxis_TwoThousandTwentyThreeConvertibleNotesMemberusgaapDebtInstrumentAxis"
      decimals="-6"
      id="ixv-50038"
      unitRef="Unit_USD">13000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <alur:PercentageOfOutstandingCapitalStock
      contextRef="P02_15_2023To02_15_2023"
      decimals="2"
      id="ixv-50039"
      unitRef="Unit_pure">0.05</alur:PercentageOfOutstandingCapitalStock>
    <alur:RelatedPartyTransactionConsultingFees
      contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-50040"
      unitRef="Unit_EUR">28333.33</alur:RelatedPartyTransactionConsultingFees>
    <alur:AgreementsTerminationDate
      contextRef="P09_01_2023To09_30_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementsMemberusgaapTypeOfArrangementAxis"
      id="ixv-50041">2023-12-12</alur:AgreementsTerminationDate>
    <alur:RelatedPartyTransactionTerminationFees
      contextRef="P12_12_2023To12_12_2023_BenoitChardonConsultingMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TerminationAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-50042"
      unitRef="Unit_USD">200000</alur:RelatedPartyTransactionTerminationFees>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis"
      decimals="-6"
      id="ixv-50043"
      unitRef="Unit_USD">48000000</us-gaap:DebtInstrumentFaceAmount>
    <alur:PercentageOfOutstandingCommonStock
      contextRef="P04_16_2024To04_16_2024_ConvertibleNoteAgreementWithRtwMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      id="ixv-50044"
      unitRef="Unit_pure">0.05</alur:PercentageOfOutstandingCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-50047"
      unitRef="Unit_shares">239842</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <alur:AggregatePurchasePriceFromOffering
      contextRef="P01_01_2024To09_30_2024_RTWParticipationInPublicOfferingMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-50048"
      unitRef="Unit_USD">300000</alur:AggregatePurchasePriceFromOffering>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-50049"
      unitRef="Unit_shares">2260159</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      id="ixv-50050"
      unitRef="Unit_shares">2260159</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <alur:AggregatePurchasePriceFromOffering
      contextRef="P06_28_2024To06_28_2024_PrivatePlacementWithRTWMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      id="ixv-50051"
      unitRef="Unit_USD">2700000</alur:AggregatePurchasePriceFromOffering>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To09_30_2024" id="ixv-38730">
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;RTW PIPE Conversion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;22, 2024, funds affiliated with RTW provided notice to the Company of their election under the Amended and Restated RTW Side Letter, to surrender 749,998 shares of Common Stock of the Company representing $7.5&#160;million in consideration for an additional Revenue Interest Financing Agreement. Accordingly, on October&#160;30, 2024, the Company and the funds affiliated with RTW entered into the additional Revenue Interest Financing Agreement (the &#x201c;New RIFA&#x201d;). The New RIFA has substantially identical terms and conditions as the RIFA Amendment, except that the amount of financing provided under the New RIFA is equal to the conversion amount of $7.5&#160;million. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restructuring Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;6, 2024, the Company&#x2019;s board of directors approved a restructuring plan to reduce operating costs and better align its workforce with the needs of its business. The majority of the restructuring is expected to be completed in the fourth quarter of 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Under the restructuring plan, the Company is reducing its workforce by approximately 113 roles (approximately 50%). In connection with the restructuring, the Company estimates that it will incur &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;one-time&lt;/div&gt; aggregate restructuring charges of approximately $3.5&#160;million, which will be recorded primarily in the fourth quarter of 2024, related to severance payments and other employee-related costs. The cash payments related to the personnel-related restructuring will be paid primarily during the first quarter of 2025. The charges that the Company expects to incur in connection with the workforce reduction are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the workforce reduction. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <alur:NumberOfSurrenderSharesOfCommonStock
      contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-50052"
      unitRef="Unit_shares">749998</alur:NumberOfSurrenderSharesOfCommonStock>
    <alur:SurrenderCommonStockValue
      contextRef="P10_22_2024To10_22_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-50053"
      unitRef="Unit_USD">7500000</alur:SurrenderCommonStockValue>
    <alur:ConversionOfPipeInvestmentToRevenueInterestFinance
      contextRef="PAsOn10_30_2024_AmendedAndRestatedRtwSideLetterMemberusgaapDebtInstrumentAxis_RevenueInterestFinancingAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-50054"
      unitRef="Unit_USD">7500000</alur:ConversionOfPipeInvestmentToRevenueInterestFinance>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-50055"
      unitRef="Unit_Employees">113</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-50056"
      unitRef="Unit_pure">0.50</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCosts
      contextRef="P11_06_2024To11_06_2024_RestructuringPlanMemberusgaapRestructuringPlanAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      id="ixv-50057"
      unitRef="Unit_USD">3500000</us-gaap:RestructuringCosts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_127680422"
          xlink:label="Fact_127680422"
          xlink:type="locator"/>
        <link:footnote id="FN_485645" xlink:label="FN_485645" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The weighted-average common shares and thus net loss per share calculations and potentially dilutive security amounts for all periods prior to the Business Combination have been retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization. See Note 3 for further information.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_127680422"
          xlink:to="FN_485645"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_127680423"
          xlink:label="Fact_127680423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_127680423"
          xlink:to="FN_485645"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_127680424"
          xlink:label="Fact_127680424"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_127680424"
          xlink:to="FN_485645"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_127680425"
          xlink:label="Fact_127680425"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_127680425"
          xlink:to="FN_485645"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
